abstract
involv
j
freedman
laboratori
medicin
st
michael
hospit
toronto
canada
thing
alway
seem
need
commit
examin
much
relev
evid
possibl
even
threaten
interpret
use
critic
approach
sourc
especi
seem
confirm
convent
wisdom
struggl
overcom
person
bia
last
least
resolut
refus
believ
someth
mere
wish
true
talk
review
histori
blood
transfus
ancient
modern
time
focus
canadian
contribut
field
highlight
august
luminari
chang
way
practic
transfus
medicin
today
discuss
success
failur
learn
histori
medicin
fact
histori
human
up
down
brave
aspir
truth
final
pathet
failur
bone
marrow
cultur
histori
field
garrison
g
sher
canadian
blood
servic
ottawa
canada
canadian
blood
servic
celebr
anniversari
much
chang
last
year
organ
serv
canadian
patient
differ
environ
creat
maintain
core
focu
blood
blood
product
acquisit
deliveri
today
canadian
blood
servic
also
play
leadership
role
nation
system
organ
tissu
donat
transplant
conduct
support
research
innov
continu
enabl
stem
cell
transplant
one
constant
work
bring
scientif
knowledg
bear
essenti
challeng
relat
transfus
transplant
medicin
scienc
canada
canadian
blood
servic
approach
knowledg
mobil
innov
research
develop
creat
converg
essenti
expertis
rang
educ
engin
benchwork
busi
data
discoveri
model
essenti
engin
move
canada
blood
system
crisi
contamin
blood
confid
canadian
express
blood
system
today
futur
hold
transfus
transplant
practic
chang
technolog
innov
upon
us
polit
fiscal
demograph
trend
drive
innov
pose
new
challeng
privat
sector
competit
raw
materi
form
commerci
plasma
collector
new
realiti
like
intern
peer
canadian
blood
servic
relentlessli
pursu
transform
requir
adapt
chang
context
maintain
secur
suppli
blood
blood
product
remain
relev
gener
busi
donor
deliv
dividend
fund
govern
taxpay
know
tradit
paradigm
oper
think
must
constantli
evolv
ensur
best
abl
meet
patient
requir
rapidli
chang
environ
meet
need
tomorrow
popul
necessit
collabor
learn
new
way
take
advantag
new
opportun
continu
critic
advanc
transfus
transplant
knowledg
practic
canada
import
histori
guid
shape
work
rich
legaci
achiev
mani
year
upon
futur
success
built
innov
futur
ensur
find
better
answer
tomorrow
continu
provid
secur
system
life
essenti
transfus
transplant
reliabl
access
sustain
canadian
jn
fesser
patholog
queen
elizabeth
hospit
charlottetown
pe
canada
nation
advisori
committe
blood
blood
product
nac
group
made
predominantli
physician
expert
transfus
medicin
across
canada
serv
provid
advic
util
manag
transfus
medicin
practic
provincialterritori
ministri
health
via
canadian
blood
servic
provincialterritori
blood
liaison
committe
cb
pt
blc
cb
pt
blc
function
major
forum
formal
commun
cb
funder
committe
compos
provinci
territori
blood
repres
individu
within
provincialterritori
ministri
given
primari
respons
interact
provinceterritori
cb
select
repres
cb
execut
senior
manag
team
request
cb
pt
blc
nac
undertak
initi
includ
develop
recommend
blood
componentproduct
use
guidanc
statement
establish
uniform
transfus
medicin
practic
develop
plan
direct
action
difficult
circumst
recent
initi
includ
updat
nation
plan
manag
shortag
labil
blood
compon
releas
recommend
util
cmv
seroneg
compon
irradi
compon
neg
red
blood
cell
rbc
unit
provid
guidanc
statement
around
test
manag
prenat
patient
discrep
weak
inconclus
serolog
rhd
test
result
upcom
initi
includ
develop
posit
statement
factor
xiii
util
autolog
blood
collect
platelet
use
consider
given
abo
rh
group
h
g
de
montreal
universitair
de
mcgill
montreal
de
la
et
de
servic
sociaux
quebec
canada
consultatif
nation
de
transfusionnel
ccnmt
transfus
medicin
tm
advisori
committe
director
biovigil
medic
biolog
direct
de
la
biovigil
et
de
la
biologi
dbbm
quebec
ministri
health
social
servic
de
la
et
de
servic
sociaux
msss
membership
consist
eight
vote
member
five
physician
two
transfus
safeti
offic
dbbm
director
plu
member
includ
repres
blood
supplier
quebec
mandat
review
studi
discuss
aspect
transfus
practic
blood
componentproduct
util
make
recommend
dbbm
concern
blood
product
avail
quebec
hospit
addit
remov
indic
transfus
standard
guidelin
applic
quebec
hospit
aspect
tm
committe
consid
pertin
develop
tm
recommend
quebec
hospit
recommend
dbbm
concern
addit
remov
blood
product
made
follow
initi
review
product
nation
institut
excel
health
social
servic
institut
nation
dexcel
en
et
en
servic
sociaux
inesss
inesss
review
process
includ
scientif
committe
among
other
ccnmt
repres
seven
major
issu
address
ccnmt
recommend
dbbm
inesss
review
plasma
protein
product
ppp
submiss
ccnmt
support
recommend
made
inesss
recommend
dbbm
review
inesss
pathogen
reduct
technolog
interceptmc
blood
system
plasma
platelet
inesss
recommend
technolog
introduc
quebec
blood
system
present
time
ccnmt
endors
recommend
collabor
inesss
develop
implement
guidelin
optim
use
intraven
subcutan
immunoglobulin
ivig
scig
neurolog
guidelin
document
avail
http
discuss
concern
dissemin
implement
standard
ivigscig
transfus
request
form
provinc
collabor
associ
hematologist
oncologist
quebec
associ
de
et
oncologu
du
prepar
posit
paper
futur
tm
submit
msss
particular
posit
paper
advoc
increas
number
tm
physician
provinc
enhanc
role
transfus
safeti
offic
establish
provinci
blood
coordin
offic
survey
platelet
usag
provinc
major
find
need
facilit
transfer
platelet
unit
quebec
hospit
work
group
establish
address
issu
promot
patient
blood
manag
strategi
ccnmt
continu
support
two
pilot
project
one
preoper
anemia
second
late
cord
clamp
collabor
nation
advisori
committe
blood
blood
product
nac
complet
posit
paper
recommend
irradi
blood
compon
canada
topic
discuss
updat
confer
present
g
blood
servic
medicin
patholog
univers
alberta
edmonton
canada
sinc
dramat
chang
basic
blood
bank
test
donor
patient
test
antigen
type
revolution
monoclon
antisera
patient
antigen
type
routin
avail
adjunct
antibodi
identif
addit
avail
monoclon
antisera
allow
routin
phenotyp
chronic
transfus
patient
well
mani
donor
provid
potenti
match
red
cell
antigen
abo
rhd
stay
troubl
vs
get
troubl
approach
transfus
antigen
type
patient
set
posit
dat
meant
dri
match
sometim
augment
even
replac
complex
time
consum
auto
method
find
safest
donor
unit
transfus
genotyp
predict
phenotyp
extens
strategi
allow
antigen
predict
donor
unit
match
even
patient
recent
chronic
transfus
antibodi
identif
method
also
evolv
becom
specif
clinic
signific
antibodi
sensit
techniqu
gel
card
solid
phase
plate
antibodi
identif
easili
interpret
tube
method
amen
autom
develop
comput
assist
allow
rapid
safe
compat
assess
without
need
physic
mix
patient
donor
blood
open
possibl
match
locat
remot
blood
transfus
lab
includ
er
also
distant
commun
immunohematolog
expertis
limit
recent
remot
review
antibodi
investig
panel
cloud
storag
avail
antigen
panel
emerg
like
alter
strategi
pre
transfus
test
next
gener
sequenc
rapidli
evolv
tool
like
significantli
impact
transfus
medicin
test
rapid
comprehens
econom
mean
predict
donor
red
cell
antigen
extend
phenotyp
match
patient
donor
feasibl
fulli
type
donor
unit
may
repres
major
unit
blood
bank
shelv
devin
g
blood
servic
vancouv
blood
servic
ottawa
canada
excit
time
transfus
medicin
canada
new
approach
new
product
horizon
approach
innov
us
countri
histor
time
give
us
level
comfort
consid
implement
option
product
describ
yet
receiv
regulatori
approv
either
manufactur
canadian
blood
servic
remain
research
realm
major
safeti
improv
consider
implement
pathogen
inactiv
technolog
one
technolog
current
licens
use
plasma
canada
other
anticip
licens
soon
technolog
current
global
marketplac
clinic
trial
use
treat
finish
product
one
except
treat
whole
blood
unit
work
underway
determin
appropri
path
adopt
pathogen
inactiv
technolog
canada
platelet
research
offer
interest
suit
opportun
canadian
hospit
addit
ongo
discours
canadian
blood
servic
hospit
serv
around
manag
platelet
inventori
reduc
wastag
last
august
implement
outdat
platelet
product
enhanc
bacteri
cultur
protocol
provid
safer
product
activ
reduc
platelet
wastag
across
system
two
import
area
focu
platelet
product
use
platelet
addit
solut
pa
replac
much
plasma
platelet
concentr
chang
storag
condit
platelet
room
temperatur
platelet
given
activ
bleed
patient
use
pa
reduc
total
plasma
content
therebi
decreas
antibodi
titr
provid
addit
nutrient
store
platelet
platelet
may
better
product
bleed
patient
permit
storag
beyond
current
day
benefit
could
make
platelet
attract
product
smaller
remot
hospit
unpredict
platelet
demand
continu
revamp
rare
blood
program
hope
expand
avail
product
thaw
abil
conduct
extens
genet
analysi
blood
group
trauma
medicin
excit
recent
studi
use
leukoreduc
whole
blood
canadian
blood
servic
also
look
start
clinic
studi
canada
product
trauma
plan
surgeri
perhap
return
us
better
version
day
compon
therapi
renew
interest
plasma
militari
civilian
medicin
canadian
blood
servic
investig
possibl
bring
system
produc
plasma
canada
product
would
permit
prepar
plasma
immedi
use
improv
manag
ab
plasma
trauma
protocol
would
also
mean
end
convent
plasma
bag
broken
shipment
thaw
last
least
improv
canada
posit
suffici
drug
high
prioriti
canadian
blood
servic
end
increas
amount
plasma
collect
manufactur
immun
globulin
product
continu
work
assist
system
appropri
use
drug
laboratori
medicin
molecular
diagnost
sunnybrook
health
scienc
centr
laboratori
medicin
pathobiolog
univers
toronto
toronto
canada
goal
transfus
commun
provid
high
qualiti
transfus
care
tradit
defin
get
right
sampl
get
right
test
result
right
equip
get
right
bag
high
safeti
standard
wast
inventori
get
right
unit
right
patient
howev
key
initi
entir
process
ensur
right
decis
transfus
made
focu
transfus
medicin
educ
clinician
current
state
transfus
medicin
knowledg
show
need
improv
technolog
advanc
novel
approach
teach
transfus
medicin
develop
session
review
exampl
publish
transfus
medicin
educ
experi
well
highlight
innov
method
platform
teach
transfus
clinician
data
evalu
effect
approach
chang
transfus
behaviour
also
present
wall
divis
haematologyoncolog
hospit
sick
children
toronto
canada
field
hematopoiet
stem
cell
transplant
seem
reach
comfort
approach
treatment
malign
disordersrec
advanc
cellular
therapi
bring
transform
chang
strategi
first
success
gener
cell
treat
b
cell
malign
becom
commerci
avail
therapi
place
new
requir
clinic
cellular
laboratori
servic
clinic
laboratorycellular
therapi
program
coordin
collect
raw
cellular
materi
manufactur
commerci
manufactur
site
manufactur
product
receiv
back
program
product
store
releas
clinic
use
eye
health
canada
cellular
therapi
program
respons
collect
storag
releas
manufactur
product
carri
full
respons
sourc
establish
initi
relat
deriv
cell
use
manufactur
product
expect
parti
cell
select
specif
hla
express
engin
cell
bypass
host
immun
system
cellular
therapi
product
target
rang
malign
infecti
diseas
develop
reach
clinic
near
futur
cell
pharmaci
requir
manag
immun
effector
cell
clinic
new
role
cellular
therapi
laboratori
talk
discuss
clinic
practic
new
therapi
focu
blood
bankcellular
therapi
laboratori
requir
abl
support
excit
new
product
c
pool
medic
divis
south
african
nation
blood
servic
johannesburg
south
africa
collect
blood
compon
apheresi
part
modern
blood
product
servic
provis
patient
need
apheresi
technolog
use
collect
platelet
red
cell
plasma
donor
set
collect
reduct
replac
platelet
red
cell
plasma
haematopoiet
stem
cell
granulocyt
clinic
set
word
apheresi
deriv
greek
mean
take
away
take
away
object
talk
includ
overview
advantag
patient
blood
establish
apheresi
collect
whole
blood
collect
gener
consider
apheresi
servic
term
legisl
regulatori
complianc
patient
guid
demand
apheresi
blood
product
standard
set
fiscal
oversight
technolog
partnership
donor
elig
apheresi
platelet
collect
apheresi
plasma
collect
apheresi
red
cell
collect
concurr
collect
eg
apheresi
platelet
plasma
recruit
select
gener
donor
elig
apheresi
collect
includ
consider
total
blood
volum
weight
proxi
determin
collect
safeti
blood
count
relev
product
collect
frequenc
apheresi
singl
concurr
donat
donor
elig
platelet
apheresi
collect
platelet
count
monitor
red
cell
plasma
loss
time
educ
surveil
use
antiplatelet
medic
donor
elig
plasma
collect
includ
gender
total
protein
assess
period
serum
protein
electrophoresi
assess
period
physic
examin
donor
elig
red
cell
collect
includ
threshold
haemoglobin
haematocrit
doubl
red
cell
collect
specif
height
weight
haemoglobin
consider
recruit
select
apheresi
donor
includ
analysi
relev
apheresi
product
demand
success
convers
whole
blood
donor
apheresi
donat
appropri
inform
consent
educ
time
commit
potenti
advers
event
h
az
delta
roeselar
roeselar
medicin
sanquin
blood
suppli
amsterdam
netherland
az
delta
roeselar
roeselar
belgium
apheresi
procedur
one
blood
compon
obtain
machin
process
whole
blood
return
residu
compon
blood
donor
end
process
side
effect
procedur
origin
collect
blood
process
blood
return
compon
type
frequenc
sever
advers
event
depend
sever
factor
eg
condit
donor
type
number
procedur
perform
way
venou
access
side
effect
exclus
relat
apheresi
procedur
also
appear
whole
blood
donat
although
overal
morbid
apheresi
donat
low
side
effect
import
impact
return
rate
donor
donor
center
mani
side
effect
apheresi
relat
venou
access
adequ
venou
access
need
good
draw
return
flow
donor
machin
peripher
venipunctur
caus
local
problem
hematoma
bruis
burn
pain
due
peripher
nerv
injuri
also
thrombosi
phlebiti
use
central
venou
cathet
lead
pneumothorax
infect
air
embol
hemorrhag
arrhythmia
overreact
bodi
certain
trigger
eg
stress
pain
dehydr
lead
reaction
sever
hypotens
bradycardia
event
experienc
unpleas
neg
effect
return
rate
donor
hemodynam
chang
apheresi
procedur
also
lead
hypovolemia
especi
smaller
donor
hypotens
furthermor
enhanc
use
ace
inhibitor
blood
pressur
lower
drug
donor
apheresi
procedur
solut
ad
donor
blood
enter
apheresi
devic
anticoagul
anticoagul
achiev
bind
ioniz
calcium
citrat
complet
resolv
plasma
therefor
return
compon
donor
depend
procedur
less
citrat
plasma
result
ioniz
solubl
calcium
concentr
donor
less
reduc
therefor
like
mild
symptom
hypocalcemia
due
citrat
infus
frequent
occur
especi
plasma
return
long
term
effect
citrat
publish
well
frequent
plateletapheresi
donor
show
signific
osteoporosi
especi
metabol
activ
lumbar
spine
karin
amrein
besid
chelat
calcium
citrat
also
magnesium
bound
result
signific
drop
magnesium
level
rare
side
effect
apheresi
procedur
hemolysi
air
embol
hematopoiet
stem
cell
donor
mobil
medic
filgrastim
plerixafor
medic
side
effect
sometim
confus
apheresi
caus
event
low
ferritin
level
apheresi
donor
spotlight
although
erythrocyt
collect
plateletplasmapheresi
procedur
loss
mg
iron
per
apheresi
procedur
normal
due
loss
apheresi
dispos
test
tube
therefor
rel
high
level
anemia
frequent
apheresi
donor
observ
despit
normal
hemoglobin
valu
time
donat
b
p
v
k
h
cancer
center
calmett
hospit
phnom
penh
cambodia
medicin
sanquin
blood
suppli
amsterdam
netherland
cambodia
south
east
asia
becam
independ
franc
road
difficult
civil
war
lead
genocid
econom
destruct
massacr
intellectu
million
death
situat
end
januari
leav
healthcar
limit
nine
physician
surviv
sinc
countri
experienc
signific
consist
econom
growth
cambodian
flagship
hospit
calmett
hospit
modern
enorm
last
decad
nation
blood
transfus
center
nbtc
start
role
collect
process
store
distribut
blood
compon
cambodian
hospit
free
charg
cambodian
red
cross
particip
donor
recruit
educ
program
technic
support
despit
effort
shortag
blood
suppli
forc
reli
whole
blood
collect
famili
donor
apheresi
avail
nbtc
apheresi
start
calmett
hospit
donat
mc
devic
haemonet
train
han
vrielink
first
apheresi
procedur
leukoreduct
cml
patient
leukostasi
sinc
patient
treat
leukoreduct
hand
leukapheresi
combin
hyperhydr
cytoreduct
medic
show
better
outcom
term
acut
mortal
rate
compar
patient
receiv
leukapheresi
follow
asfa
guidelin
tpe
also
approv
eighteen
patient
sever
myasthenia
gravi
guillain
syndrom
treat
plasma
exchang
igg
much
expens
compar
tpe
limit
resourc
tpe
significantli
improv
surviv
rate
compar
patient
receiv
tpe
die
cobe
spectra
terumo
bct
donat
prof
yoshihisa
kodera
aichi
medic
univers
japan
behalf
asia
pacif
blood
marrow
transplant
group
sinc
platelet
collect
apheresi
approv
activ
bleed
case
sever
thrombocytopenia
eg
pregnanc
append
subdur
bleed
ureter
stone
hematuria
acut
intestin
occlus
sinc
plateletapheresi
procedur
famili
donor
perform
patient
appli
dual
needl
procedur
approxim
min
averag
platelet
ml
collect
side
effect
plateletapheresi
seen
shortli
collect
leukoreduc
platelet
initi
near
futur
apheresi
collect
hpc
autolog
allogen
transplant
patient
start
nation
cancer
center
ncc
calmett
hospit
challeng
technic
problem
apheresi
equip
lack
apheresi
applic
awar
among
colleagu
mani
physician
convinc
apheresi
help
patient
despit
indic
prefer
basic
support
care
steroid
rather
apheresi
howev
strong
commit
hematologist
team
ncc
calmett
hospit
apheresi
consid
technolog
choic
save
life
perform
follow
asfa
guidelin
proper
indic
howev
two
apheresi
machin
one
countri
suffici
apheresi
sustain
success
respons
need
machin
human
resourc
capac
need
k
medicin
st
michael
hospit
univers
toronto
medicin
st
michael
hospit
univers
toronto
toronto
canada
simul
first
introduc
healthcar
enhanc
train
modal
augment
tradit
educ
method
healthcar
simul
techniqu
serv
replic
real
experi
fulli
interact
manner
strength
simul
practic
occur
nonpunit
environ
without
pose
threat
patient
safeti
ideal
simul
case
consist
rare
scenario
practic
real
patient
furthermor
sbme
facilit
train
provid
opportun
particip
reflect
upon
perform
discuss
skill
structur
debrief
benefit
without
challeng
relat
cost
time
train
requir
success
implement
simul
use
transfus
medicin
although
adopt
slow
commonli
use
enhanc
transfus
educ
assess
among
nurs
medic
traine
recent
medic
educ
sbme
gain
popular
among
staff
physician
nurs
field
transfus
medicin
clinic
situat
commonli
use
transfus
simul
includ
administr
blood
compon
manag
transfus
reaction
manag
massiv
hemorrhag
healthcar
simul
wide
adopt
applic
broaden
matur
within
transfus
medicin
educ
method
includ
vast
array
option
focus
procedur
skill
eg
rapid
infus
use
team
train
use
manikin
eg
resuscit
bleed
trauma
patient
improv
integr
standard
patient
train
evalu
modul
enabl
traine
practic
import
skill
consent
blood
product
administr
navig
ethic
dilemma
relat
transfus
recent
simul
gain
popular
qualiti
improv
intervent
test
modal
specif
ppid
technolog
simul
offer
uniqu
approach
test
new
exist
process
without
impact
patient
move
simul
actual
situ
clinic
environ
repres
excit
shift
toward
blend
sbme
qualiti
improv
ultim
improv
patient
outcom
discuss
two
local
studi
util
situ
simul
identifi
evalu
latent
safeti
threat
relat
massiv
hemorrhag
protocol
within
trauma
bay
oper
room
find
inform
chang
local
department
institut
level
futur
simul
transfus
medicin
seek
enhanc
educ
opportun
simultan
evalu
improv
patient
outcom
smith
qualiti
regulatori
affair
new
zealand
blood
servic
auckland
new
zealand
present
person
reflect
year
qualiti
manag
blood
industri
australia
nz
time
regul
qualiti
system
think
evolv
significantli
implement
qualiti
system
easi
focu
detail
complianc
without
step
back
consid
biggest
risk
challeng
lie
present
highlight
wisdom
hindsight
area
present
particular
challeng
resourc
qualiti
team
adequ
level
staff
skill
crucial
consid
task
team
level
support
team
need
provid
organis
team
like
requir
train
area
audit
root
caus
analysi
risk
analysi
etc
may
also
need
specif
technic
train
area
calibr
structur
team
need
consid
especi
wide
geograph
spread
unless
busi
activ
educ
qualiti
may
difficult
achiev
desir
level
regulatori
complianc
encourag
depart
take
respons
qualiti
complianc
qualiti
within
provid
extra
support
concept
difficult
eg
mani
peopl
find
valid
chang
control
challeng
thing
black
white
yet
staff
typic
want
black
white
answer
risk
underpin
everyth
regul
take
approach
year
ago
import
establish
organis
risk
manag
polici
procedur
well
standard
methodolog
risk
assess
encourag
staff
think
level
risk
everyth
appli
appropri
control
document
quickli
becom
unmanag
care
plan
manag
peopl
tend
creat
document
without
think
ongo
burden
mainten
process
map
identif
critic
control
point
key
determin
exactli
document
requir
use
risk
assess
identifi
appropri
control
qualiti
need
develop
effect
interfac
respons
procur
supplier
manag
supplier
may
alway
understand
gmp
constraint
custom
work
procur
staff
may
fulli
appreci
risk
involv
sourc
critic
product
inform
technolog
larg
complex
area
well
understood
mani
outsid
profess
also
challeng
get
requir
level
gmp
complianc
depart
provid
therefor
anoth
import
interfac
qualiti
team
although
highli
benefici
certain
function
comput
system
necessarili
answer
problem
easi
underestim
amount
work
involv
specifi
implement
valid
far
possibl
help
engag
regul
ensur
flow
inform
regul
educ
role
new
blood
industri
may
requir
train
manufactur
blood
compon
educ
risk
involv
blood
manufactur
ongo
process
la
bust
africa
societi
blood
transfus
afsbt
cape
town
south
africa
background
size
structur
qualiti
depart
blood
transfus
servic
tailor
suit
organis
qualiti
manag
lead
team
dedic
profession
guid
organis
toward
object
suppli
qualiti
product
servic
achiev
accredit
certif
individu
must
adequ
author
carri
qualiti
respons
must
report
top
execut
independ
line
function
discuss
appoint
staff
qualiti
depart
import
select
candid
appropri
qualif
experi
desir
person
attribut
includ
good
organis
skill
meticul
diplomaci
strong
ethic
valu
conflict
resolut
abil
qualiti
personnel
undergo
ongo
train
remain
current
train
formal
certif
diploma
cours
inform
short
cours
internet
topic
train
could
includ
qualiti
principl
five
whi
pareto
analysi
seven
tool
qualiti
six
sigma
etc
document
principl
audit
techniqu
risk
manag
qualiti
indic
train
job
manag
skill
also
benefici
could
includ
project
manag
commun
techniqu
time
manag
personnel
also
encourag
research
appropri
qualiti
topic
conduct
train
session
depart
ongo
develop
qualiti
personnel
includ
exposur
organis
system
learn
network
congress
attend
regular
compet
assess
feedback
success
plan
within
depart
import
qualiti
depart
achiev
accredit
regulatori
complianc
teamwork
requir
support
depart
garner
appoint
qualiti
ambassador
champion
technic
depart
region
zone
qualiti
depart
also
understand
need
depart
serv
aim
keep
qualiti
system
simpl
overli
impos
routin
workload
conclus
qualiti
crucial
blood
transfus
due
natur
work
product
infus
directli
vein
human
patient
effect
qualiti
manag
system
provid
strong
foundat
rest
organis
qualiti
depart
support
top
manag
need
develop
cultur
employe
think
act
qualiti
daili
basi
employe
feel
part
overal
qualiti
team
pervad
qualiti
cultur
lead
continu
improv
contribut
sustain
organis
vuk
qualiti
manag
croatian
institut
transfus
medicin
zagreb
croatia
accord
mani
characterist
featur
transfus
medicin
specif
area
medic
scienc
particular
posit
also
entail
great
respons
transfus
servic
provid
access
safe
transfus
therapi
despit
tremend
progress
term
qualiti
safeti
transfus
medicin
fact
activ
transfus
chain
take
place
without
problem
risk
still
present
biolog
origin
blood
product
may
caus
infect
transfus
reaction
complex
process
larg
number
particip
transfus
chain
facilit
occurr
error
reason
import
ensur
proper
function
activ
entir
process
transfus
medicin
vein
vein
monitor
differ
control
mechan
qualiti
manag
system
haemovigil
significantli
contribut
safeti
qualiti
transfus
medicin
system
role
prevent
thing
go
badli
happen
allow
prevent
mitig
damag
correct
rapid
respons
best
approach
manag
qualiti
problem
prevent
approach
comprehens
risk
manag
educ
definit
critic
control
point
perman
qualiti
monitor
vigil
audit
identif
opportun
etc
blood
bank
qualiti
problem
often
manifest
blood
product
possibl
caus
includ
biolog
origin
blood
product
human
error
suboptim
plan
organ
work
poor
qualiti
materi
equip
use
product
realiz
hospit
transfus
unit
problem
commonli
relat
test
particularli
error
phase
select
issu
blood
compon
transfus
problem
transfus
medicin
relat
clinic
transfus
practic
activ
directli
jurisdict
blood
transfus
servic
bt
howev
bt
affect
hospit
transfus
committe
educ
clinic
staff
even
maximum
commit
qualiti
product
servic
alway
line
custom
requir
expect
therefor
custom
complaint
valuabl
sourc
inform
servic
provid
manufactur
solv
problem
led
complaint
give
custom
sens
trust
collabor
solv
problem
import
follow
standard
protocol
clearli
defin
respons
prescrib
sequenc
activ
use
appropri
problem
solv
tool
ensur
adequ
inform
within
outsid
institut
qualiti
problem
complaint
resolv
time
manner
procedur
must
document
traceabl
order
carri
appropri
correct
action
make
effect
necessari
carri
root
caus
analysi
problem
analyz
risk
problem
associ
particular
product
materi
equip
impact
product
investig
includ
assess
need
product
recal
ultim
goal
activ
continu
qualiti
improv
b
custer
abstract
avail
al
riyami
pc
ligthart
immunohematolog
sanquin
blood
suppli
amsterdam
netherland
antigen
kell
blood
group
system
express
singl
pass
glycoprotein
encod
kel
gene
kell
blood
group
antigen
either
high
antigen
low
frequenc
antigen
ethnic
popul
k
antigen
frequenc
around
caucasian
popul
approxim
peopl
african
descent
almost
case
underli
genet
variat
singl
nucleotid
polymorph
caus
amino
acid
chang
kell
glycoprotein
influenc
glycosyl
express
level
genotyp
allel
therefor
quit
easi
done
larg
scale
antibodi
kell
antigen
report
caus
sever
immedi
delay
transfus
reaction
pregnanc
kell
antibodi
may
caus
sever
form
haemolyt
diseas
foetu
newborn
make
intra
uterin
transfus
foetu
necessari
explain
fact
kell
antibodi
suppress
develop
prolifer
red
cell
precursor
bone
marrow
mani
mutat
kel
allel
identifi
either
caus
low
express
kell
antigen
k
mod
phenotyp
express
kell
antigen
k
null
phenotyp
presenc
allel
caus
discrep
phenotyp
genotyp
kell
express
complex
xk
protein
impair
express
xk
also
lead
low
kell
express
furthermor
link
kell
protein
protein
describ
protein
part
membran
complex
also
membran
structur
carri
gerbich
antigen
present
antigen
gerbich
blood
group
system
express
two
differ
singl
pass
glycoprotein
encod
one
gene
gypc
presenc
two
differ
start
codon
caus
transcript
two
differ
protein
glycophorin
c
gpc
shorter
glycophorin
gpd
antigen
express
either
gpc
gpd
other
express
absenc
antigen
caus
gpc
exon
delet
presenc
lsa
caus
exon
rearrang
absenc
high
frequent
antigen
gepl
geat
geti
express
low
frequent
antigen
wb
ana
dha
gei
caus
point
mutat
gypc
gene
genotyp
gene
rearrang
lsa
phenotyp
difficult
wherea
genotyp
antigen
much
easier
antibodi
describ
clinic
signific
patient
patient
advers
reaction
seen
case
incompat
transfus
respons
posit
dat
newborn
correl
sever
hdfn
report
abl
suppress
erythroid
progenitor
cell
growth
seen
kell
antibodi
besid
role
gpc
gpd
structur
red
blood
cell
recent
also
role
regul
function
adhes
protein
bcam
carri
lutheran
antigen
propos
c
gassner
molecular
diagnost
research
develop
blood
transfus
servic
zurich
src
switzerland
mn
second
blood
group
system
discov
landstein
levin
procsocexpbiol
ny
first
antibodi
describ
year
later
walsh
natur
levin
procsocexpbiol
ny
defin
basic
two
coupl
antithet
public
antigen
n
mn
blood
group
system
mn
ss
encod
gypa
gypa
gypb
gypb
respect
gype
complet
tandemli
organ
locu
chromosom
despit
homolog
gene
specif
point
mutat
especi
affect
account
pronounc
differ
length
transmembran
peptid
gpa
gpb
contribut
bare
detect
express
gpe
respect
addit
antigen
mn
probabl
rh
complex
approach
understand
systemat
group
antigen
need
distinct
domin
low
recess
high
frequenc
antigen
lfa
hfa
b
consider
genet
origin
gypab
c
descript
molecular
event
causal
variat
instanc
mur
like
origin
ectop
unequ
gene
convers
event
gypb
recipi
gypa
donor
due
hybrid
charact
allel
lack
b
name
gyp
gyp
mur
result
gyp
hybrid
gene
activ
come
gypa
express
mur
antigen
lfa
preval
caucasian
black
african
hfa
certain
east
asian
popul
cours
molecular
event
rare
happen
relev
evolut
might
origin
affect
singl
individu
origin
identifi
swiss
two
new
lfa
sta
allel
gyp
type
g
type
h
first
describ
repeat
observ
among
caucasian
duplic
gyp
hybrid
gene
clearli
distinguish
formerli
known
type
f
accord
within
intron
becam
appar
due
seroposit
genotyp
gypa
n
neg
meyer
brit
j
hematol
also
recent
observ
individu
australia
canada
lfa
sara
describ
gypa
variant
missens
point
mutat
term
gypa
allel
level
mcbean
transfus
australian
german
lfa
kipp
encod
allel
gyp
appar
origin
mechan
compar
gyp
mur
though
involv
smaller
part
gypa
lopez
transfus
scharberg
gassner
unpublish
observ
hfa
jenu
newest
mn
antigen
obtain
isbt
number
yet
antithet
mur
word
gyp
mur
homozyg
individu
neg
jenu
antibodi
may
therefor
like
expect
peopl
east
asia
highest
probabl
gyp
mur
homozygos
lopez
transfus
black
african
recent
report
detail
molecular
natur
preval
gypb
delet
haplotyp
contribut
reduc
risk
malaria
invas
leffler
scienc
plu
independ
research
develop
genotyp
assay
delet
underli
result
phenotyp
may
soon
allow
target
unambigu
molecular
approach
toward
last
mn
frontier
molecular
u
neg
detect
gassner
confer
j
hamilton
immunohematolog
refer
laboratori
american
red
michigan
region
detroit
mi
unit
state
kidd
blood
group
system
origin
describ
three
antigen
system
jka
jkb
defin
two
codomin
autosom
allel
complex
system
expand
molecular
analysi
jk
protein
kidd
system
antigen
product
urea
transport
gene
chromosom
glycoprotein
transmembran
domain
intracellular
termini
jka
jkb
antigen
result
chang
exon
result
substitut
fourth
extern
loop
two
antithet
allel
result
three
common
phenotyp
jk
jk
ab
jk
red
cell
phenotyp
express
high
preval
antigen
red
cell
caucasian
asian
jk
ab
jk
jk
phenotyp
occur
popul
individu
african
descent
larg
jk
jk
lack
jka
red
cell
antigen
unaffect
proteolyt
enzym
sulfhydryl
compound
snp
jk
jk
allel
encod
weak
partial
jka
jkb
antigen
common
jk
identifi
caucasian
asian
chines
weak
jka
antigen
produc
sever
allel
produc
partial
antigen
determin
product
appar
jkajkb
alloantibodi
immun
person
five
jk
two
jk
current
recogn
jk
found
person
african
descent
lack
antigen
identifi
jk
phenotyp
rare
phenotyp
gener
result
inherit
two
recess
silenc
allel
greater
frequenc
polynesian
finnish
popul
polynesian
jk
allel
caus
mutat
delet
exon
finn
jk
allel
encod
substitut
null
allel
recogn
found
individu
multipl
ethnic
background
rare
jk
phenotyp
associ
domin
inherit
pattern
jk
molecular
basi
recent
report
delet
zinc
domain
gene
chromosom
kidd
glycoprotein
urea
transport
molecul
kidney
red
cell
renal
function
import
regul
urea
part
urin
concentr
erythrocyt
jk
protein
insur
structur
stabil
red
cell
pass
kidney
jk
individu
decreas
urin
concentr
abil
littl
clinic
sequela
resist
jk
red
cell
lysi
urea
exploit
simpl
test
identifi
rare
phenotyp
kidd
system
antibodi
immun
antibodi
caus
immedi
delay
clearanc
jk
red
cell
produc
immun
jk
individu
clinic
signific
kidd
antigen
detect
fetal
red
cell
week
gestat
howev
hemolyt
diseas
fetu
newborn
due
jk
antibodi
includ
gener
mild
jk
antigen
may
role
renal
transplant
acut
graft
reject
simultan
appear
jk
antibodi
sever
year
transplant
report
especi
donor
specif
hla
antibodi
present
routin
practic
red
cell
phenotyp
jka
jkb
antigen
identif
straightforward
presenc
weak
partial
antigen
silenc
allel
add
complex
interpret
routin
test
mr
looney
medicin
univers
california
san
francisco
san
francisco
unit
state
blood
transfus
uncommonli
associ
develop
respiratori
complic
includ
acut
lung
injuri
trali
circulatori
overload
taco
trali
lead
caus
mortal
mani
countri
associ
longer
stay
intens
care
unit
hospit
taco
common
complic
also
associ
substanti
hospit
morbid
adjud
case
trali
taco
challeng
pulmonari
edema
state
diagnost
test
distinguish
hydrostat
permeabl
pulmonari
edema
gener
avail
addit
trali
taco
may
case
anoth
challeng
diagnosi
trali
case
major
risk
factor
acut
respiratori
distress
syndrom
ard
present
possibl
trali
present
format
use
highlight
key
featur
trali
possibl
trali
taco
use
transfus
medicin
profession
adjud
case
hypoxemia
c
blood
transfus
laboratori
divis
hematolog
univers
health
networkunivers
toronto
toronto
canada
endem
area
global
burden
malaria
anemia
converg
togeth
upon
children
sever
malari
anemia
sma
account
disproportion
demand
limit
red
blood
cell
rbc
suppli
attribut
morbid
mortal
manifest
sever
malaria
remain
high
improv
outcom
hing
part
timeli
suffici
safeti
transfus
support
pathogenesi
sma
complex
depreci
kinet
toward
hemoglobin
level
gl
occur
acut
insidi
relat
parasit
burden
host
respons
beyond
mere
hemolysi
parasit
erythrocyt
mechan
bystand
erythrocyt
loss
broaden
erythrophagocytosi
toxic
dyserythropoiesi
ineffect
erythropoiesi
figur
promin
lend
insight
parallel
hyperhemolysi
syndrom
involuntarili
undertransfus
children
sma
countri
lic
differ
numer
way
adult
countri
hic
deliber
renounc
transfus
despit
advantag
physiolog
power
adapt
anemia
critic
reduct
oxygen
carri
capac
illustr
hierarch
impact
organ
anoxia
termin
cardiorespiratori
event
irrevers
neurocognit
impair
survivor
resourc
permit
dynam
restor
oxygen
deliveri
transfus
particularli
observ
sma
trigger
transfus
much
lower
odd
correspond
lactic
acidosi
much
higher
hic
question
best
hemotherapi
approach
sma
sever
anemia
lic
remain
dosag
pace
administr
compon
prepar
match
option
fundament
concern
transcend
relat
storag
durat
sma
problem
rbc
breakdown
persist
global
scourg
ultim
drive
face
mandat
bank
deliv
rbc
suppli
gain
otherwis
lose
e
fan
abstract
avail
pisacka
refer
laboratori
immunohaematolog
institut
haematolog
blood
transfus
pragu
czech
republ
rhd
antigen
abo
system
antigen
clinic
signific
blood
group
antigen
reflect
high
immunogen
potenti
caus
haemolyt
transfus
reaction
htr
sever
haemolyt
diseas
newborn
hdn
thu
correct
determin
antigen
essenti
safe
transfus
strategi
adequ
indic
immunoglobulin
prophylact
administr
rhd
determin
challeng
start
case
histori
fatal
hdn
htr
mother
transfus
blood
husband
subsequ
find
antibodi
react
abo
compat
rbc
serum
afflict
woman
lead
hypothesi
mother
lack
antigen
present
father
fetal
rbc
product
od
correspond
antibodi
respons
hdn
htr
proven
correct
effort
describ
origin
causal
antigen
coincid
next
year
anim
immun
experi
develop
similarli
react
antibodi
inject
rhesu
monkey
rbc
rabbit
guinea
pig
also
anoth
public
htr
abo
compat
blood
transfus
patient
antibodi
appar
ident
specif
first
challeng
era
name
bit
erron
human
antibodi
defin
antigen
rhesu
year
later
anim
antibodi
got
name
lw
meanwhil
complex
rh
group
antigen
increas
aim
explain
sever
genet
model
suggest
singl
gene
three
gene
c
e
final
two
locu
model
year
later
disclos
molecular
analysi
accur
one
begin
serolog
determin
rhd
done
human
first
direct
agglutin
igm
later
also
coomb
test
igg
challeng
time
weak
antigen
term
du
obsolet
use
antigen
neg
direct
agglutin
posit
coomb
test
weaken
antigen
could
caus
indirectli
posit
effect
c
tran
directli
mutat
rhd
gene
usual
point
mutat
code
amino
acid
transmembran
intracellular
part
polypeptid
date
allel
extrem
weaken
antigen
call
del
serolog
detect
adsorptionelut
test
date
allel
multipl
genet
mechan
next
challeng
reveal
sixti
observ
qualit
variant
partial
antigen
first
case
detect
develop
posit
individu
immun
part
protein
miss
epitop
mosaic
mutual
reactiv
individu
differ
partial
antigen
establish
basi
classif
increas
character
partial
acceler
dramat
develop
mous
hybridoma
techniqu
product
numer
differ
monoclon
accord
pattern
reactiv
differ
partial
ds
two
intern
workshop
number
epitop
reach
dna
techniqu
subsequ
allow
refin
discrimin
partial
type
date
number
describ
variant
antigen
sure
higher
isbt
congress
work
parti
meet
increas
could
anticip
ng
bring
new
inform
data
come
larg
asian
african
popul
polymorph
complex
rhd
whole
rh
system
grow
ff
depart
red
cross
blood
servic
nstob
clementinenhau
spring
germani
background
number
known
rh
allel
steadili
increas
inform
allel
dispers
among
mani
public
nucleotid
databas
entri
result
descript
known
allel
novel
occur
due
failur
identifi
prior
descript
aim
overview
aim
exemplifi
possibl
pitfal
allel
descript
give
overview
publicli
access
allel
list
present
human
rhesusbas
possibl
inform
sourc
rhd
method
pitfal
allel
descript
exemplifi
incid
identifi
human
rhesusbas
descript
statist
analysi
base
statist
modul
human
rhesusbas
result
automat
data
extract
limit
nucleotid
databas
entri
contain
error
includ
submiss
artefact
produc
high
throughput
sequenc
effort
possibl
secondari
inform
resourc
includ
allel
list
isbt
erythrogen
wwwerythrogenecom
blood
group
mutat
databas
regrett
shutdown
oct
cover
blood
group
system
human
rhesusbas
focus
rhd
current
feb
rhd
allel
list
human
rhesusbas
erythrogen
list
isbt
isbt
allel
name
numer
combin
number
name
indic
weaken
del
allel
exampl
weak
type
denot
rhd
rhd
weak
type
human
rhesusbas
web
resourc
tri
collat
molecular
serolog
inform
data
base
public
nucleotid
sequenc
databas
entri
scan
isbt
allel
list
data
entri
nucleotid
databas
sequenc
check
versu
standard
sequenc
identifi
error
ensur
high
qualiti
enter
record
still
data
qualiti
limit
primari
inform
serolog
inform
avail
allel
describ
weak
partial
neg
del
multipl
assign
possibl
preval
mechan
singl
missens
mutat
n
follow
multipl
missens
mutat
hybrid
allel
number
allel
describ
per
year
prior
median
culmin
allel
remain
median
thereaft
summaryconclus
web
resourc
import
aid
quickli
find
inform
rh
allel
high
qualiti
data
maintain
without
manual
check
data
entri
may
present
bottleneck
rhd
human
rhesusbas
tri
collat
data
molecular
structur
serolog
inform
number
allel
describ
per
year
remain
almost
constant
indic
allel
divers
left
discov
yet
laboratori
medicin
divis
children
nation
health
system
pediatr
depart
georg
washington
univers
washington
dc
unit
state
pregnant
patient
impact
blood
type
presenc
red
blood
cell
antibodi
influenc
cours
pregnanc
health
fetu
newborn
infant
throughout
histori
hemolyt
diseas
fetu
newborn
hdfn
play
fundament
role
discoveri
blood
group
antibodi
cognat
antigen
note
advent
rh
immunoglobulin
technolog
advanc
diagnosi
treatment
hdfn
provid
critic
tool
need
support
mother
affect
pregnanc
knowledg
blood
type
refin
explos
understand
blood
group
gene
particularli
rh
blood
group
genom
blood
group
type
improv
ultrasound
technolog
transfus
medicin
progress
advanc
field
care
women
potenti
affect
pregnanc
never
robust
despit
risk
fetu
signific
prevent
strategi
matern
alloimmun
deserv
continu
attent
e
b
medicin
univers
hospit
cologn
cologn
germani
epidemiolog
prevent
medicin
monash
univers
melbourn
australia
bacteri
safeti
cellular
prepar
includ
blood
product
stem
cell
prepar
still
present
challeng
physician
manufactur
regul
although
mani
new
approach
enhanc
microbi
safeti
cellular
product
last
decad
establish
method
microbiolog
control
still
need
fulli
adapt
special
circumst
cellular
prepar
experi
transfus
medicin
regard
microbi
safeti
blood
compon
alreadi
demonstr
varieti
problem
risk
factor
develop
new
strategi
microbi
safeti
special
attent
given
strategi
recommend
prevent
detect
bacteri
contamin
platelet
concentr
far
none
target
strategi
rapid
detect
pathogen
reduct
becom
routin
implement
worldwid
part
least
develop
requir
new
technolog
implement
routin
laboratori
set
whole
differ
problem
result
classic
microbiolog
control
method
still
repres
gold
standard
factor
includ
short
nontradit
lot
size
cellular
product
drive
need
rapid
microbiolog
method
signific
chang
regulatori
requir
made
recent
revis
chapter
european
pharmacopeia
fda
make
chang
requir
address
need
therapi
side
coin
standard
condit
requir
extens
valid
base
concept
correspond
author
conclus
lesson
microbi
safeti
platelet
concentr
enabl
us
understand
detect
reduct
bacteria
repres
difficult
challeng
comparison
virus
cellular
product
differ
formul
may
present
differ
challeng
recent
regulatori
chang
demonstr
get
closer
goal
shift
tradit
view
steril
evalu
identifi
inactiv
anyth
everyth
new
think
microbiolog
control
e
b
e
j
c
nanni
nation
transplant
centr
cnt
italian
nation
institut
health
rome
itali
bethesda
silver
spring
md
transfus
medicin
mayo
clinic
rochest
mn
unit
state
refer
laboratori
banc
de
sang
teixit
bst
barcelona
spain
unit
state
de
sang
teixit
bst
transplant
organ
ocatt
barcelona
spain
orthopaed
sport
medicin
univers
washington
school
medicin
seattl
wa
unit
state
background
blood
compon
cornea
hematopoiet
progenitor
cell
hpc
kidney
gamet
improv
often
save
live
group
term
medic
product
human
origin
mpho
sinc
requir
human
donor
share
exposur
risk
breach
ethic
safeti
standard
exampl
risk
diseas
transmiss
lesson
learn
advers
occurr
ao
associ
product
share
wide
possibl
order
maxim
donor
recipi
safeti
aim
notifi
librari
wwwnotifylibraryorg
joint
global
initi
world
health
organ
italian
nation
transplant
centr
cnt
support
share
publish
vigil
inform
teach
purpos
greater
public
transpar
clinic
use
mpho
set
transplant
transfus
assist
reproduct
method
sinc
ao
identifi
primarili
literatur
review
associ
mpho
collect
analyz
dedic
editori
group
intern
expert
notifi
librari
categori
occurr
analyz
includ
transmit
infect
malign
donor
reaction
clinic
complic
incid
order
facilit
structur
databas
search
case
classifi
accord
ao
type
harm
recipi
harm
donor
harm
fetu
offspr
risk
harm
mpho
type
organ
blood
cell
tissu
etc
taxonomi
expert
review
case
identifi
alert
signal
latenc
frequenc
method
confirm
imput
blood
expert
join
editori
group
sinc
haemovigil
record
also
incorpor
databas
result
notifi
librari
contain
refer
link
didact
case
organ
bloodblood
product
cell
tissu
reproduct
tissu
cell
deriv
medicin
product
report
ao
associ
bloodblood
product
relat
red
blood
cell
transfus
platelet
plasma
whole
blood
granulocyt
remaind
specifi
blood
report
classifi
harm
recipi
report
immunolog
natur
includ
delay
hemolyt
transfus
reaction
dhtr
acut
hemolyt
transfus
reaction
ahtr
delay
serolog
transfus
reaction
dstr
transfus
relat
acut
lung
injuri
trali
allerg
reaction
whitak
immunohematolog
case
infect
transmiss
bacteri
viral
parasit
fungal
prion
record
ao
associ
hpc
marrow
apheresi
cord
blood
sourc
specifi
classifi
harm
recipi
harm
donor
risk
harm
summaryconclus
conclus
notifi
librari
import
resourc
collect
descript
ao
transplant
transfus
assist
reproduct
librari
aim
support
clinician
compet
author
potenti
donor
recipi
better
understand
reduc
risk
associ
donat
clinic
applic
mpho
sipp
abstract
avail
georgieff
pediatricsneonatolog
univers
minnesota
medic
center
st
paul
unit
state
brain
undergo
rapid
growth
develop
late
fetal
neonat
life
develop
brain
consum
bodi
total
oxygen
consumpt
much
purpos
neuron
growth
differenti
synaptogenesi
fetal
brain
thu
highli
depend
substrat
support
rate
oxygen
consumpt
atp
gener
among
substrat
iron
critic
incorpor
cytochrom
mediat
electron
transport
iron
necessari
neuron
energi
demand
also
synthesi
neurotransmitt
eg
dopamin
serotonin
myelin
recent
data
show
iron
also
regul
fetal
neonat
neuron
gene
express
epigenet
modif
chromatin
multipl
gestat
earli
postnat
condit
place
newborn
risk
total
bodi
brain
iron
defici
includ
sever
matern
iron
defici
hypertens
diabet
mellitu
smoke
postnat
condit
includ
prematur
birth
phlebotomi
induc
anemia
restrict
transfus
practic
rapid
growth
condit
neg
iron
balanc
fetu
neonat
priorit
iron
red
cell
hemoglobin
synthesi
expens
organ
includ
brain
reduct
brain
iron
concentr
measur
iron
defici
neonat
iron
defici
neonat
demonstr
poor
recognit
memori
find
continu
year
accompani
plan
difficulti
late
childhood
model
degre
iron
defici
demonstr
profound
effect
myelin
dopaminerg
neurotransmiss
neuron
structur
function
structur
function
deficit
includ
alter
cerebr
metabol
includ
reduct
glutamaterg
neurotransmiss
alter
cerebr
phospholipid
indic
abnorm
myelin
structur
abnorm
includ
reduc
dendrit
arbor
smaller
synapt
spine
head
accompani
loss
electr
potenti
hippocampu
area
brain
serv
recognit
memori
process
genet
model
neuron
specif
iron
defici
mice
demonstr
critic
period
iron
hippocamp
neuron
develop
late
fetal
earli
neonat
life
failur
provid
adequ
neuron
iron
critic
period
result
larg
scale
alter
synapt
plastic
gene
express
persist
adulthood
spite
iron
replet
critic
period
import
defin
critic
period
human
talk
discuss
role
iron
brain
develop
earli
life
brain
function
review
clinic
condit
lead
compromis
fetal
neonat
iron
statu
neurodevelopment
consequ
across
lifespan
h
e
l
k
k
g
k
c
h
clinic
immunolog
copenhagen
univers
hospit
copenhagen
clinic
immunolog
hospit
clinic
immunolog
aalborg
univers
hospit
aalborg
clinic
immunolog
odens
univers
hospit
odens
denmark
medic
epidemiolog
biostatist
karolinska
institutet
stockholm
sweden
epidemiolog
research
staten
serum
institut
copenhagen
clinic
immunolog
aarhu
univers
hospit
aarhu
denmark
background
preval
iron
deplet
high
among
women
donat
blood
frequent
littl
known
possibl
consequ
iron
deplet
studi
popul
indic
iron
defici
anemia
associ
increas
risk
low
birth
weight
well
advers
pregnanc
outcom
prompt
concern
iron
defici
induc
frequent
blood
donat
might
impair
subsequ
fetal
growth
far
address
recent
canadian
studi
report
associ
donat
intens
risk
low
birth
weight
g
offspr
aim
valid
expand
canadian
observ
use
scandinavian
donat
transfus
databas
scandat
nation
regist
assess
whether
donat
intens
affect
birth
weight
singleton
born
term
gestat
week
later
nullipar
femal
donor
denmark
method
identifi
first
live
singleton
birth
danish
women
complet
inform
gestat
age
birth
weight
child
sex
parent
age
matern
smoke
statu
pregnanc
parent
educ
length
annual
incom
linear
regress
analysi
appli
birth
weight
outcom
number
donat
year
prior
pregnanc
explanatori
variabl
confound
variabl
describ
similar
analys
perform
compar
follow
group
high
intens
donor
donat
year
prior
pregnanc
low
intens
donor
donat
year
prior
pregnanc
donat
histori
pregnanc
lastli
patern
donat
intens
use
evalu
whether
intern
healthi
donor
effect
affect
observ
associ
women
analys
result
identifi
women
low
intens
donor
high
intens
donor
respect
gener
femal
blood
donor
older
less
like
smoke
pregnanc
longer
educ
femal
low
intens
donor
gave
birth
larger
babi
g
g
p
high
intens
donor
g
p
adjust
linear
regress
analysi
consid
donat
intens
year
pregnanc
offspr
birth
weight
decreas
g
confid
interv
ci
g
per
donat
per
year
similar
estim
observ
donat
intens
year
correspondingli
adjust
analys
high
donat
activ
result
g
ci
g
lower
birth
weight
compar
low
intens
activ
similar
adjust
linear
regress
analysi
high
intens
patern
donor
donat
year
prior
pregnanc
effect
subsequ
birth
weight
compar
low
intens
patern
donor
donat
year
prior
pregnanc
regress
coeffici
g
ci
p
n
conclus
high
donat
intens
invers
associ
birth
weight
singleton
born
term
nullipar
women
recommend
premenopaus
femal
blood
donor
screen
iron
defici
moreov
paramount
import
find
confirm
cohort
g
c
van
k
hospitali
de
de
montreal
hospit
research
institut
clinic
evalu
scienc
blood
servic
outcom
registri
network
ottawa
canada
background
iron
defici
common
problem
women
child
bear
age
known
associ
advers
matern
newborn
outcom
repeat
blood
donat
deplet
iron
store
decreas
hemoglobin
level
howev
clinic
impact
iatrogen
iron
defici
due
blood
donat
unknown
addit
investig
advers
outcom
associ
blood
donat
requir
aim
object
studi
assess
associ
repeat
blood
donat
femal
donor
age
associ
risk
matern
neonat
outcom
method
undertook
longitudin
cohort
studi
femal
deliv
live
stillbirth
infant
ontario
canada
januari
march
use
data
better
outcom
registri
network
canadian
blood
servic
institut
clinic
evalu
scienc
woman
first
pregnanc
within
studi
time
frame
includ
analysi
women
year
year
age
time
deliveri
exclud
multipl
birth
pregnanc
record
femal
donor
made
whole
blood
donat
januari
septemb
obtain
canadian
blood
servic
data
variou
sourc
combin
use
probabilist
linkag
primari
outcom
diagnosi
small
gestat
age
neonat
secondari
outcom
preterm
birth
stillbirth
apgar
min
cord
ph
neonat
death
matern
transfus
infect
gestat
hypertens
gestat
diabet
placent
abrupt
matern
death
regress
model
evalu
effect
repeat
donat
time
interv
donat
outcom
develop
model
adjust
matern
age
deliveri
matern
bmi
matern
alcohol
drug
use
smoke
matern
diabet
hypertens
use
assist
reproduct
technolog
matern
depriv
quintil
ethnic
concentr
quintil
pariti
time
sinc
previou
deliveri
result
women
deliv
live
stillbirth
infant
januari
march
women
whole
blood
donor
mean
donat
studi
period
mean
matern
age
time
deliveri
donor
yr
yr
respect
small
gestat
age
occur
neonat
born
born
donor
preterm
birth
rate
among
donor
respect
adjust
odd
ratio
risk
age
neonat
ci
addit
donat
proxim
donat
concept
effect
risk
sga
secondari
analys
ongo
summaryconclus
evid
repeat
blood
donat
may
result
anemia
femal
donor
preliminari
data
suggest
associ
repeat
blood
donat
prior
pregnanc
risk
small
gestat
age
neonat
confirm
find
jurisdict
although
possibl
result
healthi
donor
effect
find
reassur
femal
donor
well
clinic
blood
organ
stakehold
seek
inform
polici
decis
c
e
mh
kr
ks
ob
hm
c
h
lw
h
immunolog
copenhagen
univers
hospit
rigshospitalet
copenhagen
immunolog
aalborg
univers
hospit
aalborg
immunolog
nastv
sygehust
nastv
immunolog
odens
univers
hospit
odens
immunolog
aarhu
univers
hospit
aarhu
research
staten
serum
institut
copenhagen
univers
hospit
rigshospitalet
copenhagen
denmark
background
recent
research
suggest
associ
level
circul
ferritin
depress
sever
studi
shown
increas
preval
depress
disord
patient
iron
defici
anemia
howev
find
inconsist
larg
studi
possibl
associ
need
blood
donor
increas
risk
iron
deplet
imper
potenti
link
depress
symptom
explor
aim
investig
associ
iron
defici
id
depress
symptom
blood
donor
clarifi
id
associ
specif
depress
symptom
method
cohort
studi
includ
women
enrol
danish
blood
donor
studi
depress
symptom
data
collect
use
major
depress
inventori
mdi
mood
questionnair
assess
presenc
depress
symptom
valid
gener
danish
popul
experi
depress
symptom
defin
mdi
score
rang
data
antidepress
prescript
demograph
lifestyl
factor
collect
use
questionnair
nation
popul
regist
id
defin
ferritin
level
ngml
particip
mean
corpuscular
volum
mcv
examin
fl
indic
low
iron
ferritin
level
measur
thaw
plasma
sampl
use
commerci
assay
autom
system
ortho
vitro
mcv
measur
whole
blood
sampl
use
sheath
flow
direct
current
sysmex
descript
statist
multivari
linear
logist
cox
regress
analys
perform
analys
adjust
age
bodi
mass
index
smoke
habit
alcohol
consumpt
cox
regress
analys
also
adjust
number
blood
donat
sinc
iron
measur
result
id
found
n
n
classifi
depress
id
women
higher
mdi
score
median
interquartil
rang
iqr
compar
women
normal
ferritin
level
p
ferritin
mcv
neg
correl
mdi
score
ferritin
ngml
regress
coeffici
rc
p
mcv
fl
rc
p
id
women
increas
odd
depress
symptom
compar
women
odd
ratio
confid
interv
ci
similar
risk
found
women
low
mcv
ci
howev
mcv
independ
predictor
depress
symptom
ferritin
level
includ
model
p
among
particip
depress
symptom
domin
symptom
feel
lack
energi
strength
id
women
increas
odd
experienc
particular
symptom
ci
id
statist
significantli
associ
particular
symptom
final
id
women
statist
insignificantli
increas
hazard
subsequ
use
antidepress
hazard
ratio
ci
summaryconclus
low
ferritin
level
associ
increas
depress
symptom
larg
popul
femal
blood
donor
observ
symptom
pattern
possibl
classif
depress
symptom
studi
mimic
natur
effect
low
ferritin
level
studi
need
clarifi
id
part
underli
pathophysiolog
mechan
depress
dr
innov
canadian
blood
servic
univers
toronto
toronto
canada
year
sinc
first
report
haemolyt
anaemia
emerg
sinc
initi
observ
intraven
penicillin
result
immun
haemolyt
anaemia
patient
receiv
develop
haemolyt
anaemia
similar
warm
autoimmun
haemolyt
anaemia
case
patient
haemolysi
expand
greatli
includ
myriad
differ
drug
inde
well
drug
describ
caus
haemolysi
histori
immun
haemolyt
anaemia
subdivid
two
differ
chapter
penicillin
methyldopa
chapter
cephalothin
cefotetan
chapter
review
two
chapter
histori
immun
haemolyt
anaemia
dissect
includ
differ
mechan
haemolysi
propos
includ
hapten
drug
adsorpt
autoimmun
mechan
biochem
immunolog
mechan
immun
haemolyt
anaemia
discuss
well
import
consider
approach
laboratori
investig
condit
blood
bank
refer
laboratori
approach
use
drug
metabolit
well
hypothesi
nonspecif
drug
adsorpt
occur
prevent
present
object
review
provid
understand
type
immun
haemolyt
anaemia
differenti
laboratori
biochemistri
immunolog
underli
condit
tn
e
v
j
moh
biolog
laboratori
french
establish
blood
ile
de
franc
site
pari
franc
biolog
laboratori
french
establish
blood
ile
de
franc
site
tenon
pari
franc
immun
hemolyt
anemia
diiha
rare
underdiagnos
condit
two
patient
suspect
immun
hemolyt
anemia
iha
due
imatinib
iomeprol
respect
patient
man
gastrointestin
stromal
tumor
gist
metastat
liver
treat
imatinib
mg
twice
daili
initi
dose
mg
daili
develop
anemia
hb
gl
evid
hemolysi
imatinib
inhibitor
tyrosin
kinas
indic
treatment
chronic
myeloid
leukemia
cml
metastat
gist
first
case
ha
previous
report
patient
cml
antibodi
immunoglobulin
igg
detect
sole
drug
adsorpt
method
patient
woman
histori
recurr
ovarian
cancer
develop
hemorrag
shock
associ
sever
iha
hb
gl
underw
computer
tomographi
scan
abdomen
receiv
infus
iomeprol
iomeprol
nonion
contrast
medium
cm
wide
use
diagnost
imag
procedur
aim
studi
support
clinic
diagnosi
diiha
laboratori
studi
includ
direct
indirect
antiglobulin
test
dat
iat
drug
antibodi
investig
perform
incub
patient
serum
adsorb
serum
eluat
presenc
drug
random
normal
donor
red
blood
cell
rbc
previous
treat
drug
ie
immun
complex
method
determin
immunoglobulin
class
reactiv
antibodi
test
repeat
incub
patient
serum
dithiotreitol
dtt
drug
test
includ
imatinib
iomeprol
iodixanol
anoth
wide
use
nonion
cm
patient
neg
dat
unexpect
rbc
antibodi
detect
iat
patient
serum
without
vitro
addit
drug
weakli
reactiv
antibodi
direct
normal
donor
rbc
demonstr
patient
serum
tube
gel
test
presenc
imatinib
patient
posit
dat
evid
warm
autoantibodi
patient
serum
iggigm
antibodi
direct
untreat
random
normal
donor
rbc
presenc
iomeprol
demonstr
patient
adsorb
serum
titer
eluat
evid
patient
serum
eluat
pool
normal
sera
react
presenc
drug
two
case
two
patient
ha
demonstr
antibodi
describ
exampl
dat
neg
ha
associ
imatinib
report
first
time
antibodi
could
detect
immun
complex
method
patient
metastat
gist
patient
patient
appear
iggigm
antibodi
show
iodixanol
iomeprol
commonli
use
diagnost
imag
consid
whenev
patient
undergo
variou
radiograph
procedur
develop
hemolyt
anemia
andor
posit
dat
n
l
et
innov
de
et
de
cellul
souch
canada
background
immunotherapeut
strategi
emerg
novel
therapeut
approach
multipl
myeloma
sever
monoclon
antibodi
mab
advanc
stage
clinic
develop
daratumumab
dara
mab
current
use
treatment
patient
refractori
multipl
myeloma
promis
blood
sampl
patient
treat
dara
demonstr
panreact
red
blood
cell
rbc
panel
test
due
express
rbc
complic
identif
clinic
signific
alloantibodi
shown
treatment
rbc
dithiothreitol
dtt
allow
elimin
howev
treatment
also
elimin
antigen
clinic
import
thu
treatment
dtt
imperfect
solut
problem
whose
incid
increas
aim
find
adapt
method
applic
therapeut
antibodi
counter
interfer
test
without
affect
detect
antibodi
interest
method
two
approach
evalu
panel
rbc
mous
neutral
antibodi
prior
serolog
test
deplet
dara
plasma
sampl
adsorpt
daudi
cell
prior
serolog
test
method
outcom
evalu
flow
cytometri
gel
card
result
flow
cytometri
analysi
reveal
rbc
panel
monoclon
mous
result
signific
reduct
dara
bind
signal
fold
reduct
mean
fluoresc
intens
mfi
howev
gel
liss
result
show
signific
reduct
interfer
plasma
dara
patient
daudi
cell
result
signific
reduct
dara
bind
signal
fold
reduct
mfi
flow
cytometri
associ
absenc
interfer
gel
liss
assay
summaryconclus
incub
plasma
patient
daudi
cell
effici
overcom
interfer
induc
latter
serolog
test
e
lazarova
v
pede
emond
muylaert
p
vandekerckhov
v
compernol
blood
servic
belgian
red
mechelen
belgium
background
daratumumab
alreadi
use
monotherapi
adult
patient
relaps
refractori
multipl
myeloma
recent
receiv
extend
approv
second
line
therapi
eu
medic
howev
interfer
routin
blood
bank
test
direct
bind
express
reagent
red
blood
cell
rbc
rbc
number
differ
method
exist
elimin
bypass
effect
reagent
rbc
cord
rbc
rbc
transfus
guid
patient
phenotyp
genotyp
neutral
unfortun
consensu
best
method
combin
method
use
follow
transfus
polici
implement
belgian
red
cross
flander
region
rbc
genotyp
clinic
signific
antigen
provid
patient
start
afterward
demand
blood
select
basi
extend
donor
phenotyp
patient
genet
predict
phenotyp
aim
aim
analyz
year
implement
transfus
polici
effici
safe
adequ
increas
demand
transfus
immun
therapi
set
method
studi
period
novemb
till
novemb
patient
molecular
rbc
type
perform
veryfi
kit
rh
system
c
c
e
e
cw
allel
detect
furthermor
blood
group
kell
kidd
duffi
allel
b
fyx
fynul
mutat
mn
allel
n
uvar
uvar
ny
test
regular
blood
group
donor
continu
phenotyp
kell
k
k
duffi
fya
fyb
kidd
jka
jkb
mn
system
result
total
patient
rbc
molecular
type
perform
patient
enrol
treatment
genotyp
rbc
genotyp
averag
phenotyp
activ
donor
result
phenotyp
blood
group
rbc
phenotyp
blood
group
rbc
avail
distribut
abl
address
actual
blood
transfus
need
patient
total
unit
select
blood
bank
laboratori
transfus
total
patient
advers
transfus
event
report
one
patient
present
rare
blood
group
antigen
combin
posit
ccee
k
fyb
jka
jkb
n
result
complet
phenotyp
combin
incid
total
donat
success
transfus
patient
summaryconclus
select
rbc
support
transfus
decis
alreadi
common
practic
complex
clinic
situat
panreact
eg
hemolyt
anemia
patient
receiv
daratumumab
could
success
manag
manner
approach
avoid
time
labor
consum
serolog
techniqu
elimin
delay
issu
rbc
unit
prevent
futur
daratumumab
becom
wide
use
avail
conveni
laboratori
test
cross
match
rbc
may
becom
critic
adequ
blood
suppli
cl
whitham
j
white
rowley
uk
nation
extern
qualiti
assess
servic
uk
neqa
btlp
watford
unit
kingdom
background
uk
transfus
laboratori
manag
tlm
must
compli
legisl
iso
accredit
standard
uk
transfus
laboratori
collabor
uk
tlc
standard
deliv
comprehens
train
compet
assess
staff
transfus
laboratori
increas
workload
retir
experienc
staff
add
pressur
task
addit
chang
patholog
servic
deliveri
model
necessit
train
assess
staff
area
blood
scienc
littl
background
transfus
resourc
restraint
contribut
laboratori
error
report
seriou
hazard
transfus
shot
error
eqa
tact
introduc
support
tlm
provid
continu
monitor
knowledg
base
compet
tact
avail
complement
exist
practic
compet
scheme
eqa
multipl
variat
standard
test
scenario
gener
use
control
randomis
logic
rule
automat
assess
sampl
accept
abod
antibodi
screen
ab
identif
abid
compon
issu
base
bsh
guidanc
tlm
particip
staff
educ
process
identifi
train
need
amend
result
accommod
local
polici
local
audit
reason
eg
unfamiliar
tact
typograph
error
aim
aim
determin
area
bm
train
may
requir
tact
particip
monitor
tlm
compar
tact
eqa
shot
data
method
tact
data
examin
determin
error
rate
complex
extent
manageri
review
complex
assess
element
uninterpret
abo
andor
group
situat
abo
specif
blood
inappropri
addit
specif
requir
red
cell
result
overal
assess
element
incorrect
review
underw
tlm
review
amend
reduc
overal
error
rate
incorrect
particip
score
abo
amend
tlm
correct
request
accept
abid
ab
compon
select
error
rate
assess
element
categoris
complex
simpl
abo
group
complex
cf
simpl
type
cf
red
cell
compon
select
cf
summaryconclus
complex
element
gener
higher
error
rate
greatest
complex
compon
select
support
shot
eqa
find
shot
data
includ
incorrect
blood
compon
case
specif
requir
met
origin
laboratori
eqa
exercis
laboratori
issu
abo
specif
blood
emerg
complet
bsh
recommend
test
tlm
error
review
rate
encourag
demonstr
tact
potenti
educ
train
well
monitor
compet
tact
updat
accommod
misspel
posit
neg
influenc
amend
rate
ab
amend
sampl
accept
error
may
reflect
local
polici
differ
nation
guidanc
plan
investig
reason
amend
continu
develop
tact
monitor
address
issu
highlight
eqa
shot
data
g
de
montreal
hematolog
medicin
univers
montreal
montreal
canada
hematopoiet
stem
progenitor
cell
hspc
transplant
commonli
use
stem
cur
therapi
medicin
consider
fraction
patient
find
suitabl
unrel
match
donor
patient
umbil
cord
blood
cb
repres
highli
promis
sourc
hspc
broader
avail
cb
transplant
mostli
limit
low
cell
number
associ
high
transplant
relat
mortal
trm
identifi
small
molecul
enabl
ex
vivo
expans
hspc
term
repopul
abil
associ
cultur
system
allow
small
cultur
volum
reduc
cost
labor
approv
clinic
applic
phase
iii
clinic
trial
test
safeti
efficaci
expand
cb
ecb
adult
transplant
singl
ecb
pt
ecb
necb
pt
median
day
neutrophil
respect
ecb
recipi
compar
determin
recipi
peripher
bone
hspsc
hospit
reduc
day
compar
cd
transplant
full
donor
chimer
achiev
cell
subset
expans
protocol
enabl
util
smaller
better
match
cb
patient
receiv
singl
cb
instead
doubl
cb
median
follow
month
rang
trm
grade
acut
gvhd
mild
chronic
gvhd
preliminari
data
thu
suggest
ecb
provid
clinic
benefit
beyond
faster
engraft
better
hla
match
low
trm
transcriptom
analys
indic
cb
cell
respond
enhanc
gene
implic
immunomodulatori
activ
antigen
present
cell
activ
cytolyt
effector
respons
phenotyp
analys
ecb
uncov
notic
expans
dendrit
cell
progenitor
cell
select
differenti
either
function
myeloid
plasmacytoid
dendrit
cell
capabl
stimul
allogen
cell
prolifer
cytotox
natur
killer
nk
cell
leukem
blast
glucocorticoid
suppress
expans
dendrit
cell
also
compromis
capac
expand
hspc
suggest
immunomodulatori
effect
critic
immun
effector
cell
hspc
activ
preliminari
observ
therefor
suggest
ecb
enabl
rapid
sustain
engraft
hspc
innat
immun
cell
might
provid
approach
immunotherapi
refractori
leukemia
j
kurtzberg
carolina
cord
blood
bank
durham
unit
state
cord
blood
cell
work
paracrin
trophic
mechan
help
endogen
cell
heal
brain
tissu
damag
diseas
injuri
learn
observ
made
use
unrel
donor
umbil
cord
blood
transplant
myeloabl
chemotherapi
treat
children
certain
inherit
metabol
diseas
cord
blood
therapi
develop
treat
children
acquir
brain
injuri
like
hypox
ischem
encephalopathi
cerebr
palsi
autism
result
preclin
ind
enabl
studi
present
provid
inform
safeti
potenti
mechan
action
cord
blood
cell
set
data
earli
phase
human
clinic
trial
safeti
efficaci
diseas
present
speaker
session
k
institut
research
educ
transfus
medicin
tehran
islam
republ
iran
high
institut
research
educ
transfus
medicin
faculti
medic
scienc
tarbiat
modar
univers
tehran
iran
islam
republ
iran
background
npi
recogn
potent
growth
factor
caus
cell
prolifer
human
embryon
stem
cell
matur
lymphoid
cell
howev
possibl
prolif
effect
hematopoiet
stem
cell
hsc
remain
unknown
mani
previou
studi
shown
role
sympathet
nervou
system
regul
bm
microenviron
innerv
npi
releas
fiber
hsc
microenviron
suggest
evid
direct
link
nervou
hematopoiet
system
involv
npi
hematopoiesi
aim
aim
studi
evalu
support
role
neuropeptid
expans
cord
blood
hematopoiet
stem
cell
cytokin
supplement
addit
retain
abil
differenti
method
cell
isol
mononuclear
cell
mnc
cord
blood
express
receptor
cord
blood
cell
studi
pcr
ex
vivo
cultur
perform
two
condit
one
cytokin
control
group
differ
concentr
npi
addit
cytokin
prolifer
respons
follow
npi
treatment
studi
flow
cytometri
mnc
cell
cell
calcul
abil
expand
cell
format
coloni
short
term
long
term
cultur
examin
via
cfu
assay
statist
analysi
perform
pair
sampl
use
ibm
spss
consid
statist
signific
result
detect
express
transcript
cell
pcr
describ
hsc
far
ex
vivo
expans
day
result
signific
increas
number
mnc
cell
cell
treat
npi
effect
observ
highest
expans
fold
chang
npi
concentr
npi
elev
number
mnc
expand
also
cell
respect
cultur
hematopoiet
stem
cell
retain
abil
differenti
variou
blood
cell
formul
coloni
short
term
long
term
cultur
cfu
assay
show
number
coloni
cell
control
group
freshli
cell
per
seed
cell
respect
expans
fold
cfc
significantli
higher
group
comparison
control
group
result
assay
shown
capac
differenti
cultur
preserv
expand
cell
summaryconclus
studi
highlight
support
role
neuropeptid
expans
hematopoiet
stem
cell
retain
potenti
differenti
variou
cell
lineag
cultur
period
cytokin
supplement
md
x
w
n
innov
canadian
blood
servic
laboratori
medicin
univers
british
columbia
vancouv
canada
background
lymphocyt
occupi
central
role
cellular
immun
respons
donor
tissu
pathogenesi
autoimmun
diseas
effect
kill
cancer
cell
consequ
signific
often
expens
pharmacolog
tool
develop
either
suppress
enhanc
cell
respons
previou
work
laboratori
demonstr
allogen
leukocyt
could
use
induc
tolerogen
state
vitro
vivo
surprisingli
polym
graft
cell
also
exert
potent
persist
system
immunomodul
subsequ
studi
identifi
absencepres
polym
gener
uniqu
pattern
extracellular
microrna
mirna
could
purifi
use
achiev
effect
vitro
vivo
aim
use
bioreactor
manufactur
approach
laboratori
develop
two
mirna
base
therapeut
cocktail
either
induc
toler
toler
agent
enhanc
inflamm
inflammatori
agent
mechanist
agent
significantli
alter
ratio
regulatori
cell
treg
proinflammatori
effector
cell
teff
method
immunomodulatori
activ
examin
mous
human
context
use
vitro
mix
lymphocyt
reaction
mlr
model
assess
vivo
use
nod
mous
model
type
diabet
cell
depend
autoimmun
diseas
model
proinflammatori
effect
experiment
examin
use
vitro
cancer
kill
model
result
vitro
dramat
increas
treg
teff
ratio
prevent
alloprolifer
immunolog
normal
mice
vivo
studi
demonstr
give
rise
highli
persist
day
singl
dose
tolerogen
state
prevent
inflammatori
respons
transfer
allogen
leukocyt
clinic
relev
singl
treatment
nod
mice
autoimmun
murin
model
give
rise
type
diabet
result
significantli
decreas
level
multipl
teff
subset
correspond
increas
multipl
tolerogen
cell
subset
lead
dramat
increas
treg
teff
ratio
mice
treat
mice
rel
untreat
anim
consequ
immunomodul
incid
decreas
islet
histolog
better
maintain
efficaci
examin
rel
etanercept
solubl
receptor
found
equal
superior
etanercept
modul
cell
prolifer
subsequ
allogen
challeng
contrast
dramat
decreas
treg
teff
ratio
ie
proinflammatori
mlr
model
moreov
human
pbmc
pretreat
hr
demonstr
signific
increas
effect
measur
cancer
cell
prolifer
assay
summaryconclus
studi
provid
signific
new
insight
potenti
util
therapeut
approach
modul
system
immun
respons
creat
either
tolerogen
proinflammatori
environ
cost
effect
therapeut
mirna
approach
may
broad
clinic
relev
treat
diseas
divers
graft
reject
autoimmun
disord
cancer
therapi
p
meybohm
k
zacharowski
univers
hospit
frankfurt
frankfurt
main
germani
world
popul
anem
seriou
medic
econom
consequ
red
blood
cell
transfus
mainstay
correct
anemia
also
one
top
five
overus
procedur
carri
risk
cost
burden
patient
blood
manag
pbm
multidisciplinari
approach
manag
anemia
minim
iatrogen
blood
loss
har
toler
anemia
effort
improv
patient
outcom
despit
resolut
world
health
organ
endors
pbm
current
guidelin
includ
recommend
use
diagnostictherapeut
resourc
provid
better
health
care
mani
hospit
yet
implement
pbm
routin
clinic
practic
propos
simpl
measur
enabl
hospit
reduc
anemia
red
blood
cell
transfus
surgic
medic
patient
comprehens
bundl
pbm
compon
encompass
differ
pbm
measur
provid
divid
bundl
block
act
work
templat
develop
institut
individu
pbm
practic
hospit
begin
program
tri
improv
alreadi
exist
program
stepwis
select
feasibl
measur
facilit
implement
pbm
manner
pbm
repres
new
qualiti
safeti
standard
ref
meybohm
p
et
al
transfus
medicin
review
g
l
sport
health
scienc
nurs
midwiferi
paramedicin
usc
australia
sippi
down
emerg
medicin
sunshin
coast
hospit
health
servic
birtinya
australia
background
recent
year
randomis
control
trial
rct
publish
find
compar
patient
outcom
associ
liber
versu
restrict
transfus
strategi
rct
evid
challeng
assumpt
gener
earlier
observ
studi
guidelin
base
rct
promot
restrict
transfus
practic
except
specif
patient
group
insuffici
evid
make
recommend
adult
studi
enrol
patient
across
broad
age
rang
studi
focuss
patient
age
year
patient
age
year
highest
consum
red
cell
aim
examin
evid
regard
restrict
liber
transfus
strategi
older
adult
examin
pathophysiolog
chang
associ
age
may
impact
toler
anaemia
transfus
outcom
method
prefer
report
item
systemat
review
prisma
guidelin
use
first
identifi
rct
focuss
transfus
evid
adult
age
year
three
rct
met
condit
inclus
criteria
widen
incorpor
addit
studi
mean
patient
age
least
year
identifi
rct
compar
liber
versu
restrict
transfus
strategi
subject
literatur
relat
pathophysiolog
age
examin
factor
impact
circul
oxygen
transport
result
total
nine
rct
mean
patient
age
rang
year
includ
evid
rct
support
liber
transfus
strategi
older
adult
respect
mortal
cardiac
outcom
infect
risk
hospit
length
stay
equivoc
restrict
liber
transfus
strategi
public
find
transfus
requir
cardiac
surgeri
tric
iii
studi
report
includ
analysi
older
patient
releas
found
restrict
strategi
risk
patient
liber
strategi
includ
older
patient
differ
hb
threshold
note
studi
liber
hb
threshold
rct
restrict
patient
age
rang
gl
tric
iii
howev
appli
lower
liber
threshold
gl
gl
icu
patient
pathophysiolog
chang
age
occur
cellular
system
level
neg
impact
rate
oxygen
deliveri
rel
haemoglobin
level
summaryconclus
recent
rct
provid
valuabl
new
inform
challeng
observ
studi
evid
regard
associ
blood
transfus
infect
length
stay
howev
find
rct
regard
transfus
outcom
older
adult
conflict
differ
rct
hb
trigger
complic
interpret
consequ
infer
term
liber
restrict
transfus
paper
critic
analys
differ
studi
approach
outcom
intent
highlight
challeng
need
consid
address
pathophysiolog
chang
may
explain
differ
outcom
associ
variou
hb
trigger
use
rct
avenu
research
discuss
particularli
context
inform
pbm
guidelin
develop
older
adult
largest
cohort
blood
recipi
mm
h
van
p
k
e
red
cross
blood
transfus
servic
hessen
frankfurt
germani
practic
belgian
red
cross
mechelen
belgium
anaesthesiolog
intens
care
medicin
pain
therapi
univers
hospit
frankfurt
germani
blood
allianc
amsterdam
netherland
background
patient
blood
manag
pbm
comprehens
initi
qualiti
manag
focuss
improv
patient
outcom
diagnos
treat
preoper
periop
anaemia
implement
blood
save
measur
throughout
cours
diagnosi
treatment
transfus
patient
follow
accept
transfus
trigger
aim
intern
consensu
confer
icc
pbm
initi
order
evalu
current
evid
regard
three
differ
topic
pbm
firstli
red
blood
cell
concentr
rbc
transfus
trigger
avail
differ
periop
clinic
set
evid
qualiti
differ
indic
variabl
rang
evid
avail
evid
secondli
periop
anaemia
uniformli
accept
periop
risk
factor
definit
diagnosi
treatment
still
matter
debat
thirdli
pbm
measur
uniformli
implement
differ
countri
even
within
one
singl
countri
icc
pbm
took
place
frankfurtmain
germani
april
togeth
partner
australia
canada
intern
scientif
group
european
blood
allianc
eba
aabb
formerli
known
associ
american
blood
bank
intern
societi
blood
transfus
isbt
french
sft
italian
simti
german
dgti
scientif
societi
blood
transfus
activ
methodolog
pbm
icc
defin
accord
world
health
organ
definit
pbm
systemat
approach
optim
manag
patient
transfus
blood
product
qualiti
effect
patient
care
identifi
avail
scientif
evid
scientif
committe
sc
phrase
differ
pico
popul
intervent
comparison
outcom
question
accord
three
chosen
topic
preoper
anaemia
rbc
transfus
trigger
implement
pbm
centr
practic
cebap
carri
systemat
literatur
review
develop
search
strategi
four
differ
biomed
databas
pubm
embas
cochran
librari
transfus
evid
librari
cebap
screen
approx
paper
includ
relev
paper
within
three
pbm
topic
conclus
well
qualiti
evid
use
grade
methodolog
present
frankfurt
consensu
confer
sc
transpar
framework
accord
grade
approach
use
three
multidisciplinari
expert
panel
formul
recommend
compil
consensu
statement
result
consensu
statement
support
evid
present
lectur
comprehens
summari
consensu
statement
publish
later
conclus
first
intern
consensu
confer
three
chosen
pbm
topic
perform
use
intern
accept
systemat
rigor
methodolog
utmost
import
clinician
perform
haemotherapi
follow
updat
evid
close
possibl
order
perform
effect
medic
treatment
cr
product
safeti
polici
unit
australian
red
cross
blood
servic
perth
australia
director
blood
system
research
institut
san
francisco
unit
state
work
parti
transfus
transmit
infecti
diseas
respons
evalu
advocaci
way
increas
blood
safeti
world
order
reduc
frequenc
ttid
accomplish
review
gather
analyz
relev
data
develop
coordin
intern
studi
publish
scientif
report
propos
guidanc
procedur
advoc
blood
safeti
technolog
region
take
account
differ
region
epidemiolog
resourc
wp
membership
bring
togeth
scientif
expert
compani
repres
member
lead
institut
field
blood
safeti
infecti
diseas
member
categor
follow
group
individu
member
institut
liaison
corpor
member
honorari
member
observ
invit
guest
attend
discret
organis
committe
oc
full
member
includ
corpor
member
countri
activ
coordin
oc
coordin
oc
compris
five
individu
activ
member
elect
membership
current
year
term
compris
individu
corpor
member
repres
treasurersecretari
oc
meet
quarterli
basi
consid
financi
membership
function
issu
partli
coordin
particip
full
wp
meet
annual
isbt
congress
last
meet
occur
region
congress
copenhagen
present
five
sg
bacteria
parasit
surveil
risk
assess
polici
srap
transmiss
spongiform
encephalopathi
tse
virolog
one
coordin
appoint
oc
coordin
activ
includ
conven
regular
teleconfer
progress
sg
specif
project
publish
find
develop
content
annual
meet
current
sg
project
includ
intern
survey
impact
parasit
infect
optimis
hiv
risk
model
msm
deferr
criteria
review
hbv
vaccin
breakthrough
develop
frozen
panel
bacteri
strain
rbc
studi
effect
room
temperatur
exposur
qualiti
safeti
thaw
plasma
b
surveil
canadian
blood
servic
ottawa
canada
health
polici
scienc
blood
system
research
institut
san
francisco
unit
state
background
srap
isbt
transfus
transmit
infecti
diseas
ttid
work
parti
focus
research
methodolog
use
surveil
popul
data
assess
infecti
diseas
risk
implic
polici
aim
describ
surveil
risk
assess
relat
polici
describ
current
work
srap
subgroup
method
current
member
subgroup
srap
meet
teleconfer
least
time
per
year
well
annual
ttid
work
parti
meet
srap
member
also
particip
project
specif
team
commun
teleconfer
email
result
surveil
data
donor
patient
gener
popul
fundament
quantit
risk
assess
polici
formul
quantit
risk
assess
aim
estim
accur
possibl
probabl
event
occur
releas
infecti
unit
blood
inventori
srap
team
current
evalu
mathemat
model
predict
hiv
risk
reduc
deferr
period
sex
year
uncertainti
predict
consequ
relat
assumpt
requir
construct
model
well
qualiti
data
model
base
deferr
period
chang
england
canada
year
observ
model
valid
compar
predict
incid
actual
incid
furthermor
team
modifi
model
predict
risk
shorter
deferr
period
strategi
altern
risk
question
eg
ask
msm
histori
remov
msm
criteria
plasma
product
quarantin
retest
use
pathogen
reduct
technolog
anoth
srap
team
collect
data
better
assess
durat
transient
hepat
b
viru
hbv
antigenemia
data
symptomat
patient
avail
donor
gener
asymptomat
cours
infect
may
differ
hbv
infect
period
time
hepat
b
surfac
antigen
assay
nat
would
identifi
infect
resolv
indic
would
neg
estim
risk
hepat
b
blood
donor
import
estim
mani
transient
antigenemia
case
occur
otherwis
risk
underestim
third
team
collabor
ttid
parasitolog
evalu
decis
make
process
five
develop
countri
relat
blood
donor
polici
intend
reduc
malaria
risk
gain
insight
potenti
benefit
use
abo
decis
make
framework
assess
carri
countri
compar
framework
would
requir
fourth
team
collabor
ttid
transmiss
spongiform
encephalopathi
form
evalu
vcjd
polici
differ
countri
summari
srap
cover
rang
infecti
diseas
risk
work
collabor
focu
srap
methodolog
mathemat
model
risk
applic
surveil
risk
assess
polici
formul
c
blood
servic
ottawa
canada
london
unit
kingdom
bacteria
subgroup
bs
isbt
work
parti
transfus
transmit
infecti
diseas
undertak
activ
focus
enhanc
blood
safeti
dissemin
knowledg
new
develop
eg
bacteri
test
pathogen
inactiv
technolog
bs
two
coordin
activ
member
meet
quarterli
basi
discuss
project
led
group
activ
individu
member
potenti
public
particip
isbt
congress
sinc
march
member
bs
met
time
discuss
differ
ongo
activ
current
bs
coordin
studi
aim
gener
repositori
bacteri
strain
red
blood
cell
rbc
endors
world
health
organ
standard
bacteri
strain
use
growth
kinet
studi
valid
detect
pathogen
inactiv
technolog
rbc
frozen
stock
six
candid
bacteria
shown
abil
prolifer
rbc
prepar
ehrlich
institut
ship
particip
laboratori
throughout
globe
studi
perform
second
studi
coordin
bs
focus
determin
effect
safeti
thaw
plasma
upon
room
temperatur
excurs
initi
involv
three
organ
canadian
blood
servic
canada
nhsbt
england
studi
aim
provid
evid
support
individu
exposur
thaw
plasma
room
temperatur
min
storag
qualiti
bacteri
growth
experi
undertaken
three
organ
public
bacteria
subgroup
includ
survey
bacteri
test
platelet
concentr
latin
america
enlarg
repositori
bacteri
strain
platelet
compon
publish
isbt
journal
present
two
ongo
public
initi
confer
proceed
summari
present
given
isbt
copenhagen
congress
ttid
meet
publish
isbt
scienc
seri
three
sequenti
review
key
bacteri
issu
bacteri
cultur
detect
method
rapid
test
techniqu
pathogen
inactiv
publish
vox
sanguini
bs
meet
person
isbt
toronto
meet
present
session
includ
updat
current
studi
repositori
strain
rbc
effect
room
temperatur
exposur
thaw
plasma
present
consider
session
includ
propos
increas
platelet
safeti
food
drug
administr
us
review
cultur
method
detect
bacteri
contamin
platelet
product
updat
pathogen
inactiv
technolog
rapid
method
bacteri
detect
e
john
hopkin
univers
school
medicin
baltimor
unit
state
hospit
blood
bank
sao
paulo
brazil
blood
research
review
us
food
drug
administr
silver
spring
md
unit
state
background
transfus
transmit
parasit
remain
neglect
despit
low
percept
risk
impact
exce
mani
major
transfus
transmit
virus
particularli
countri
robust
measur
contend
viral
risk
alreadi
place
publish
data
transfus
transmit
parasit
ttp
babesia
babesiosi
plasmodium
malaria
trypanosoma
cruzi
chaga
diseas
leishmania
leishmaniasi
limit
compar
transfus
transmit
virus
bacteria
activ
strive
fill
void
aim
parasit
subgroup
intern
societi
blood
transfus
isbt
work
parti
infecti
diseas
ttid
compris
approxim
member
overseen
three
subgroup
strive
research
relat
ttp
conduct
review
current
practic
polici
regular
updat
innov
develop
mitig
risk
ttp
subgroup
conduct
quarterli
call
review
progress
brainstorm
new
idea
frequent
commun
guid
individu
member
relat
ongo
project
addit
updat
subgroup
activ
conduct
annual
biannual
isbt
congress
method
project
conduct
past
year
includ
pilot
serosurvey
babesia
microti
chines
blood
donor
complet
intern
parasit
survey
compar
practic
major
ttp
evalu
cruzi
mitig
countri
occasion
subgroup
member
collabor
subgroup
project
share
interest
eg
investig
malaria
polici
formul
countri
srap
subgroup
result
progress
date
individu
project
follow
total
blood
donor
heilongjiang
provinc
screen
antibodi
b
microti
indirect
fluoresc
antibodi
test
ifat
donor
ifat
posit
titer
posit
titer
find
suggest
b
microti
present
merit
investig
molecular
surveil
linkag
import
futur
research
endeavor
manuscript
detail
find
collabor
effort
review
vox
sanguini
global
survey
complet
ttp
countri
particip
europ
america
africa
asia
pacif
manuscript
detail
find
review
vox
sanguini
result
highlight
challeng
surround
mitig
ttp
wide
region
variat
practic
inform
epidemiolog
individu
ttp
survey
mitig
practic
contend
transfus
transmit
cruzi
countri
pilot
distribut
select
isbt
member
countri
addit
research
activ
continu
administr
oversight
subgroup
coupl
grow
membership
summari
parasit
subgroup
continu
activ
ongo
project
grow
interest
work
reflect
view
author
constru
repres
fda
view
polici
j
georgsen
l
espensen
depart
clinic
immunolog
south
danish
transfus
servic
tissu
center
odens
c
denmark
background
correct
ident
control
donor
patient
pivot
collect
transfus
respect
half
centuri
uniqu
nation
person
identif
number
pin
use
identif
donor
patient
nordic
countri
last
decad
identif
process
becom
electron
howev
patient
pin
either
avail
exist
consequ
replac
pin
need
orer
wristband
often
cover
barcod
pin
thu
avail
scan
aim
describ
use
pin
replac
pin
pro
con
regard
nation
replac
pin
describ
newli
implement
system
electron
ident
control
transfus
orer
environ
patient
wristband
cover
method
procedur
regard
collect
transfus
regist
use
blood
establish
comput
system
bec
ab
stockholm
nation
pin
uniqu
ten
digit
number
alloc
minut
birth
nation
popul
regist
kept
unchang
forev
first
six
digit
show
dob
last
four
hold
inform
regard
centuri
birth
gender
modulu
check
digit
togeth
electron
imag
fingerprint
pin
identifi
donor
collect
pin
connect
isbt
donat
inform
number
din
transfus
datamatrix
bar
code
scan
wrist
band
pin
embed
isbt
data
structur
thereaft
din
product
code
scan
bar
code
label
blood
compon
onlin
check
bec
give
clinician
go
stop
messag
regard
transfus
patient
brought
unconsci
reason
incap
small
children
psychiatr
patient
retard
person
foreign
need
replac
pin
hospit
system
dob
known
appear
first
six
digit
wherea
inform
regard
centuri
birth
gender
embed
last
four
alphanumer
charact
two
charact
letter
distinguish
normal
pin
dob
known
number
automat
gener
still
two
letter
inform
gender
last
four
charact
orer
wristband
often
cover
thu
avail
scan
alloc
uniqu
identifi
orser
scan
patient
room
start
procedur
possibl
transfus
multipl
compon
scan
din
compon
code
unit
assum
one
patient
per
orer
end
procedur
patient
scan
room
result
conclus
uniqu
nation
pin
region
system
replac
pin
made
implement
electron
identif
easi
develop
increas
safeti
level
save
consider
resourc
transfus
chain
l
brigg
inform
servic
versitiblood
center
wisconsin
milwauke
unit
state
background
abil
locat
provid
need
blood
product
remain
critic
pillar
patient
care
need
precis
match
rare
uncommon
blood
product
critic
ill
frequent
transfus
patient
call
technolog
better
enabl
gather
storag
readi
access
blood
product
locat
key
attribut
hla
antigen
type
aim
describ
use
rfid
technolog
use
isbt
data
standard
coupl
internet
thing
iot
cloud
servic
emerg
data
sharingtransmiss
standard
better
enabl
industri
find
get
right
product
right
patient
right
time
method
isbt
establish
data
standard
proven
solid
foundat
ensur
blood
bank
understand
blood
product
key
inform
coupl
standard
rfid
higher
densiti
data
storag
transmiss
technolog
rel
low
cost
cloud
internet
thing
iot
option
longer
limit
eye
readabl
label
barcod
limit
system
system
data
exchang
find
blood
product
new
world
blood
product
track
trace
open
eas
data
gather
share
also
enabl
greater
data
analyt
product
need
well
potenti
faster
transfer
movement
blood
product
across
wider
geographi
result
better
visibl
transpar
inform
locat
predict
blood
product
need
better
ensur
get
right
product
right
patient
right
time
summaryconclus
better
visibl
transpar
inform
locat
predict
blood
product
need
better
ensur
get
right
product
right
patient
right
time
lam
blood
servic
group
health
scienc
author
singapor
singapor
background
technolog
develop
cost
reduct
rfid
year
make
possibl
har
use
fragil
blood
product
manag
fluid
inventori
movement
secur
blood
patient
safeti
possibl
applic
potenti
benefit
blood
suppli
chain
wide
studi
blood
transfus
industri
adapt
use
slow
singapor
intend
implement
use
rfid
manag
nation
blood
inventori
enhanc
blood
transfus
safeti
aim
outlin
potenti
applic
object
rfid
blood
suppli
chain
explain
use
gap
analysi
valu
stream
map
tool
identif
area
improv
rfid
address
highlight
variou
practic
point
concern
address
use
rfid
blood
suppli
chain
base
use
singapor
experi
method
rfid
nation
blood
programm
one
key
initi
toward
smart
healthcar
singapor
har
technolog
increas
blood
patient
safeti
effect
manag
nation
blood
suppli
increas
staff
product
order
ensur
effect
use
rfid
complement
exist
blood
bank
comput
system
hospit
laboratori
patient
medic
record
inform
system
gap
analysi
valu
stream
map
studi
conduct
identifi
area
improv
exist
process
workflow
busi
propos
fund
requir
put
variou
accept
result
mani
practic
consider
rais
process
delay
project
actualis
includ
impact
current
process
equip
extend
use
rfid
fund
need
cost
alloc
type
rfid
hardwar
use
type
network
infrastructur
scope
rfid
tag
data
captur
mode
data
exchang
rfid
exist
system
rfid
system
secur
integr
scope
applic
softwar
critic
concern
ensur
variou
includ
leadership
oper
personnel
blood
servic
hospit
summaryconclus
experi
good
chang
manag
plan
rfid
project
commun
earli
stage
plan
continu
updat
progress
instrument
smooth
implement
achiev
full
benefit
rfid
blood
suppli
chain
lc
harrington
entomolog
cornel
univers
ithaca
unit
state
pathogen
pose
consider
risk
global
safeti
blood
product
overview
biolog
exposur
risk
transmiss
dynam
vector
born
pathogen
greatest
risk
suppli
blood
product
present
agent
includ
virus
dengu
chikungunya
yellow
fever
zika
well
parasit
public
health
import
malaria
babesia
bacteri
pathogen
role
vector
recent
spread
viral
diseas
impact
transfus
may
happen
present
addit
futur
strategi
entomologist
consid
vector
born
diseas
control
e
trust
centr
human
genet
univers
oxford
oxford
trust
sanger
institut
hinxton
unit
kingdom
plasmodium
parasit
caus
malaria
widespread
tropic
region
thousand
year
still
lead
larg
number
case
death
today
due
sever
histor
preval
malari
diseas
driven
spread
genet
resist
variant
human
popul
character
resist
mutat
offer
distinct
window
pathogen
mechan
diseas
interact
natur
evolutionari
select
clinic
symptom
malaria
occur
blood
stage
infect
polymorph
affect
red
blood
cell
structur
function
strong
candid
malaria
resist
inde
sever
shown
play
role
malaria
suscept
howev
identifi
candid
gene
studi
reli
heavili
prior
expect
knowledg
associ
studi
gwa
larg
number
individu
provid
altern
avenu
search
human
genom
variat
associ
suscept
malaria
enabl
novel
discoveri
well
elucid
protect
effect
previous
report
loci
present
result
gwa
carri
malaria
genom
epidemiolog
network
malariagen
involv
sever
malaria
case
popul
control
countri
africa
analysi
data
replic
associ
sever
loci
includ
sickl
cell
variant
hbb
blood
group
variant
abo
also
identifi
novel
associ
particular
identifi
variat
associ
protect
sever
malaria
near
glycophorin
gene
cluster
encod
red
blood
cell
protein
gypa
gypb
serv
receptor
parasit
invas
also
determin
mn
blood
group
system
investig
copi
number
variat
locu
find
associ
explain
complex
structur
variant
involv
loss
gypb
gain
two
hybrid
gene
show
structur
variant
correspond
dantu
ne
blood
group
variant
primarili
present
east
african
popul
reach
much
higher
frequenc
previous
report
survey
dantu
moreov
frequenc
variat
across
popul
haplotyp
structur
suggest
variant
recent
select
contrast
frequent
gypb
delet
variant
show
evid
associ
sever
malaria
follow
function
work
understand
hybrid
receptor
contribut
protect
malaria
absenc
receptor
appar
may
yield
new
insight
process
parasit
invas
gwa
conduct
malariagen
largest
studi
infecti
diseas
date
reveal
new
associ
dantu
blood
group
variant
malaria
suscept
find
reinforc
import
red
blood
cell
blood
group
polymorph
specif
resist
sever
malaria
intriguingli
abo
gypagypb
also
show
signal
diversifi
select
rais
question
current
resist
malaria
may
relat
select
pattern
driver
genet
divers
loci
b
mcmorran
john
curtin
school
medic
research
australian
nation
univers
canberra
australia
malaria
infecti
diseas
caus
protozoan
parasit
plasmodium
threaten
live
billion
peopl
nineti
countri
despit
control
effort
span
sever
decad
still
fatal
annual
surviv
malari
infect
major
driver
evolutionari
histori
human
mani
host
respons
mechan
determin
individu
abil
surviv
infect
remain
poorli
understood
laboratori
discov
novel
protect
mechan
malaria
involv
platelet
seemingli
innocu
agent
bloodstream
function
hemostasi
understood
mediat
rang
immunolog
function
import
determin
host
respons
mani
type
infect
malaria
platelet
appear
differ
oppos
role
depend
context
sever
infect
one
hand
platelet
implic
advers
cerebr
malaria
sever
diseas
manifest
microvascular
occlus
develop
brain
lead
inflammatori
foci
brain
swell
caus
coma
often
death
platelet
adher
cerebr
endothelium
mediat
accumul
infect
erythrocyt
brain
postul
outcom
increas
sever
even
mediat
diseas
clinic
one
earliest
sign
infect
induc
thrombocytopenia
consid
advers
prognost
marker
malaria
howev
underli
caus
thrombocytopenia
various
attribut
system
platelet
activ
clearanc
vascular
pool
recent
observ
laboratori
indic
signific
role
red
blood
cell
observ
anim
model
malaria
clinic
infect
hand
platelet
bind
infect
red
cell
peripheri
activ
releas
cytokin
turn
bind
duffi
antigen
red
cell
intern
enter
parasit
food
vacuol
destroy
kill
parasit
kill
malari
parasit
observ
vitro
parasit
cultur
system
mous
model
diseas
recent
studi
laboratori
observ
occurr
platelet
parasit
kill
human
malaria
evid
signific
contribut
host
abil
control
infect
understand
interact
platelet
malaria
mani
infecti
diseas
improv
immens
past
decad
continu
acceler
knowledg
certain
lead
excit
insight
host
respons
mechan
infecti
diseas
provid
novel
intervent
therapeut
tool
ha
doughti
medic
depart
nh
blood
transplant
birmingham
unit
kingdom
emerg
transfus
prepared
increasingli
recognis
import
element
healthcar
respons
mass
casualti
event
mce
plan
design
support
integr
respons
blood
servic
hospit
alert
earli
follow
event
lesson
identifi
manchest
recent
incid
incorpor
wider
uk
plan
revis
transfus
guidanc
hospit
guidanc
inform
global
experi
civilian
mce
chang
trend
trauma
care
plan
assum
trauma
care
optimis
across
trauma
network
exist
trauma
network
provid
valuabl
forum
polici
plan
educ
exercis
transfus
team
servic
encourag
particip
exercis
level
local
cross
border
event
current
evid
suggest
modest
number
patient
hospitalis
follow
mce
requir
transfus
past
experi
suggest
may
approxim
mean
demand
consist
calcul
red
cell
unit
within
first
hr
howev
small
number
critic
injur
may
requir
access
massiv
transfus
haemostat
resuscit
blood
use
day
one
may
ongo
requir
due
revis
surgeri
demand
plan
one
aspect
transfus
emerg
prepared
commun
logist
respons
key
enabl
equal
effort
must
address
patient
identif
organis
transfus
staff
laboratori
manag
facil
receiv
larg
number
patient
may
consid
transfus
staff
red
cell
thaw
plasma
within
emerg
depart
forward
transfus
triag
enabl
best
use
compon
laboratori
resourc
mani
blood
servic
report
meet
initi
demand
blood
exist
stock
howev
care
commun
donor
commun
essenti
manag
control
replenish
stock
stock
manag
mce
consid
compon
type
blood
group
similar
principl
may
appli
proactiv
build
stock
part
plan
mass
gather
sport
entertain
event
prepar
inform
sound
busi
continu
principl
oper
system
suffici
resili
accommod
surg
clinic
demand
donat
transfus
tradit
import
element
major
incid
plan
howev
transfus
commun
encourag
plan
mce
share
oper
experi
work
togeth
mutual
support
f
f
imperi
colleg
healthcar
nh
trust
nh
blood
transplant
london
unit
kingdom
background
st
mari
hospit
open
door
major
trauma
centr
octob
rank
best
countri
nh
england
assess
servic
major
trauma
centr
cover
london
one
london
four
major
trauma
center
hospit
stood
major
incid
first
westminst
bridg
involv
vehicl
attack
stab
singl
perpetr
second
incid
involv
vehicl
attack
london
bridg
borough
market
stab
multipl
attack
third
incid
involv
fire
residenti
tower
block
grenfel
tower
fourth
involv
bomb
train
parson
green
tube
station
aim
share
experi
learn
cope
differ
type
major
incid
short
period
time
describ
cope
strategi
transfus
trauma
centr
perspect
method
review
experi
report
debrief
major
incid
result
despit
major
trauma
centr
well
prepar
train
cope
differ
type
major
incid
identifi
differ
shortcom
incid
first
incid
secur
patient
perpetr
identifi
issu
debrief
london
bridg
incid
occur
saturday
night
mani
manag
site
limit
staff
grenfel
tower
fire
incid
highlight
import
safeguard
paediatr
patient
famili
miss
difficulti
identifi
famili
member
also
discov
patient
sent
inappropri
hospit
london
ambul
servic
incid
result
patient
treat
centr
lead
delay
correct
manag
patient
addit
experienc
problem
sampl
label
one
incid
despit
train
fourth
incid
stood
earli
injuri
sustain
minor
incid
order
extra
blood
compon
expect
signific
number
victim
materialis
impact
wastag
figur
redistribut
across
site
prove
difficult
due
road
closur
incid
also
sister
site
stood
receiv
patient
physiolog
psycholog
impact
four
major
incid
short
period
differ
clinic
team
could
overestim
summaryconclus
matter
much
prepar
train
carri
incid
highlight
differ
shortcom
need
depend
type
time
day
occur
subsequ
wastag
blood
compon
inevit
order
minimis
wastag
would
accept
l
c
c
j
van
b
p
j
matter
australian
red
cross
blood
servic
west
melbourn
servic
research
australian
red
cross
blood
servic
brisban
australia
background
victoria
australia
reduct
demand
red
blood
cell
rbc
unit
sinc
reflect
nation
intern
declin
demand
rbc
contrast
demand
group
rhd
neg
rbc
increas
increas
approxim
unit
unit
unit
account
rbc
neg
issu
contrast
australian
donor
popul
time
period
wastag
rhd
neg
unit
declin
partli
due
nation
blood
blood
product
wastag
reduct
strategi
order
conserv
stock
ensur
avail
rhd
neg
unit
patient
altern
australian
red
cross
blood
servic
develop
guidelin
appropri
use
group
rhd
neg
rbc
unit
endors
nation
blood
transfus
committe
help
understand
increas
demand
rhd
neg
blood
matter
audit
use
compar
guidelin
aim
document
use
rhd
neg
rbc
unit
issu
health
servic
compar
guidelin
method
audit
circul
victorian
particip
health
servic
tasmania
australian
capit
territori
northern
territori
audit
includ
question
determin
align
rhd
neg
use
guidelin
question
includ
patient
gender
age
abo
rhd
group
known
time
issu
specif
antibodi
phenotyp
requir
transfus
urgenc
health
servic
identifi
primari
reason
rhd
neg
unit
select
patient
algorithm
develop
determin
align
rhd
neg
unit
guidelin
mandatori
recommend
accept
indic
use
result
preliminari
data
show
rhd
neg
unit
transfus
larg
varianc
guidelin
rang
mean
similarli
number
rhd
neg
unit
transfus
avoid
vari
wide
rang
mean
discard
rate
consist
low
across
report
health
servic
rang
mean
data
highlight
issu
result
noncompli
often
uniqu
individu
health
servic
exampl
region
hub
receiv
larg
number
rotat
stock
satellit
site
short
expiri
result
high
use
avoid
routin
transfus
rhd
neg
unit
patient
known
non
blood
group
result
hold
full
abo
inventori
strategi
reduc
wastag
summaryconclus
initi
data
show
improv
requir
meet
guidelin
increas
understand
rhd
neg
unit
use
identifi
theme
noncompli
strategi
implement
reduc
inappropri
demand
better
reflect
true
need
ensur
avail
patient
altern
blood
matter
provid
individu
report
card
health
servic
includ
recommend
improv
practic
al
k
l
k
blood
bank
ministri
health
muscat
oman
british
columbia
coastal
health
author
blood
servic
coastal
health
author
univers
british
columbia
vancouv
canada
background
group
ab
plasma
scarc
approxim
north
american
donor
group
ab
grow
use
part
due
massiv
transfus
protocol
mtp
bleed
patient
pose
challeng
key
qualiti
indic
kqi
appropri
usag
current
exist
aid
benchmark
qualiti
improv
aim
hypothes
institut
transfus
disproportion
high
amount
ab
plasma
patient
assess
ab
plasma
appropri
index
abai
could
mitig
inappropri
match
plasma
transfus
qualiti
improv
initi
mtp
process
method
data
ab
plasma
unit
collect
retrospect
period
januari
februari
hospit
british
columbia
bc
canada
bc
provinci
blood
coordin
offic
ab
plasma
util
analyz
disposit
statu
transfus
expir
discard
transfus
unit
recipi
blood
group
abai
calcul
kqi
ab
plasma
util
defin
ratio
ab
plasma
transfus
ab
patient
unknown
blood
group
compar
ab
plasma
util
includ
expireddiscard
unit
abai
closest
ideal
institut
data
ab
plasma
unit
collect
retrospect
period
data
collect
includ
disposit
ab
plasma
unit
includ
specif
indic
ab
plasma
transfus
includ
usag
mtp
usag
prevent
expiri
plasmapheresi
result
total
number
transfus
discard
expir
ab
plasma
unit
bc
studi
period
unit
unit
unit
respect
overal
abai
provinc
bc
abai
institut
place
median
assess
bc
hospit
rang
institut
audit
period
ab
plasma
unit
transfus
patient
prevent
expiri
mtp
activ
thu
implement
thaw
bank
first
mtp
cooler
instead
ab
bank
begin
juli
base
retrospect
assess
project
decreas
ab
plasma
util
chang
juli
exclud
unit
use
plasmapheresi
unit
ab
plasma
use
compar
unit
period
previou
year
plasmapheresi
exclud
appropri
use
account
unit
chang
period
observ
usag
ab
plasma
patient
unit
prevent
expiri
due
thaw
anoth
patient
stat
use
unknown
abo
group
incorrect
use
exclud
plasmapheresi
abai
period
previou
year
chang
period
summaryconclus
abai
novel
kqi
indic
inappropri
ab
plasma
usag
target
qualiti
improv
led
use
thaw
plasma
mtp
effect
reduc
inappropri
ab
plasma
usag
p
langi
van
k
van
den
technolog
assess
donor
studi
medic
affair
technolog
assess
sanquin
amsterdam
netherland
background
western
blood
transfus
practic
current
chang
due
variou
driver
adopt
blood
manag
polici
ongo
technolog
develop
new
therapeut
option
netherland
result
diminish
trend
red
blood
cell
fresh
frozen
plasma
yet
increas
use
plasma
protein
medicin
purpos
steadi
trend
platelet
uncertain
trend
continu
futur
therefor
import
blood
bank
manag
anticip
futur
demand
blood
product
sake
medium
long
term
decis
make
support
decis
make
employ
scenario
develop
use
mani
sector
financ
transport
also
appli
blood
transfus
therefor
mix
qualit
quantit
method
approach
appli
order
explor
topic
systemat
yet
exploratori
manner
aim
studi
aim
prepar
list
highli
probabl
medium
long
term
scenario
detail
specif
organiz
implic
medium
term
scenario
dutch
nation
blood
bank
sanquin
use
mix
qualit
quantit
approach
method
literatur
search
discuss
held
regard
select
method
could
support
adapt
scenario
develop
blood
transfus
netherland
result
combin
qualit
quantit
method
integr
four
step
approach
develop
interview
variou
expert
blood
transfus
netherland
manner
simultan
extens
literatur
review
databas
gray
literatur
within
literatur
review
histor
develop
blood
usag
variou
innov
would
impact
futur
demand
blood
product
dutch
context
explor
conduct
quantif
histor
blood
use
netherland
use
prior
data
estim
per
patient
group
organ
expert
elicit
workshop
estim
chang
blood
use
per
patient
group
construct
variou
medium
long
term
scenario
develop
organiz
model
test
sensit
analys
appli
probabilist
map
summaryconclus
first
step
ongo
research
nearli
complet
expect
aforement
approach
ultim
result
creation
medium
long
term
scenario
organiz
implic
therein
approach
contribut
toward
adapt
polici
recommend
support
dutch
nation
blood
bank
sanquin
un
forese
futur
j
finnish
red
cross
blood
servic
helsinki
finland
vasovag
reaction
vvr
repres
major
report
donor
advers
reaction
among
whole
blood
apheresi
donor
rate
vvr
loss
conscious
whole
blood
donor
variat
intern
donor
hemovigil
report
vvr
without
loss
conscious
report
vvr
rate
apheresi
donor
remark
lower
among
whole
blood
donor
incid
vvr
strongli
associ
donor
charact
young
age
femal
sex
small
estim
blood
volum
donat
first
time
risk
factor
type
vvr
besid
unpleas
experi
harm
risk
trauma
occur
vvr
induc
reduc
donor
return
rate
extra
work
collect
staff
three
main
categori
method
effect
prevent
reduc
vvr
physiolog
intervent
psycholog
approach
donor
select
physiolog
intervent
donor
select
base
blood
establish
environ
familiar
theori
method
medic
base
clinic
intervent
theoret
model
cover
chang
blood
volum
chang
fluid
balanc
nervou
mechan
activ
stabil
effect
blood
loss
physiolog
intervent
effect
prevent
reduc
vvr
water
isoton
drink
load
appli
muscl
tension
donat
caffein
consumpt
psycholog
approach
effect
prevent
reduc
donor
vvr
shorter
histori
smaller
number
donor
research
public
physiolog
intervent
approach
scientif
evid
prevent
reduc
vvr
fear
anxieti
assess
reduct
activ
donor
particip
donat
process
distract
social
support
even
appli
muscl
tension
discov
studi
physiolog
method
also
shown
effect
psycholog
approach
donor
select
criteria
take
account
risk
vvr
includ
limit
donor
weight
age
estim
blood
volum
well
take
account
donor
previou
donat
experi
especi
advers
reaction
import
donor
care
donor
comprehend
blood
establish
year
ago
still
challeng
implement
data
scientif
evid
vvr
prevent
reduct
daili
life
collect
center
donor
contact
need
practic
easi
use
model
tool
combin
physiolog
psycholog
prevent
method
feasibl
implement
daili
donor
contact
also
need
research
focu
activ
role
collect
staff
prevent
vrr
part
donor
care
reflect
gener
trend
person
individu
demand
everi
custom
servic
situat
effect
new
approach
reduc
vvr
might
discov
context
genuin
encount
might
includ
target
evid
base
method
easi
implement
h
r
blood
servic
ottawa
citi
canada
system
inc
scottsdal
arizona
unit
state
background
gener
donor
popul
age
mani
countri
upper
age
limit
whole
blood
wb
donat
variabl
recent
studi
evalu
safeti
donat
older
individu
aim
assess
contribut
older
donor
make
blood
suppli
countri
permit
donat
individu
age
compar
deferr
vasovag
reaction
rate
donor
age
vs
year
method
best
member
upper
age
limit
wb
donat
canada
canadian
blood
servic
new
zealand
new
zealand
blood
servic
englandnorthern
wale
nation
health
servic
blood
transplant
usa
american
red
cross
blood
system
inc
carter
blood
care
bloodwork
northwest
ucla
memori
blood
center
upper
age
limit
australian
red
cross
blood
servic
provid
data
donor
donat
deferr
rate
vasovag
reaction
donor
age
donor
includ
deferr
reaction
rate
sinc
differ
characterist
compris
variabl
proport
countri
donor
base
comparison
age
group
within
countri
thu
control
variabl
deferr
donor
reaction
definit
data
captur
countri
result
donor
account
new
zealand
usa
wb
donor
new
zealand
usa
wb
donat
donat
frequenc
higher
year
old
vs
donat
per
donor
p
countri
countri
deferr
rate
male
higher
male
year
old
hemoglobin
vital
sign
perform
donor
histori
vs
p
similar
femal
donor
vs
p
male
femal
countri
lower
vasovag
reaction
rate
among
year
old
donor
odd
ratio
vs
year
old
rang
englandnorthern
wale
usa
upper
confid
interv
ci
vasovag
reaction
loss
conscious
loc
rare
countri
per
femal
per
male
vs
year
old
rang
canada
usa
upper
ci
number
small
meaning
analysi
new
zealand
loc
reaction
older
donor
ci
summaryconclus
data
donat
close
donor
age
demonstr
donor
donat
frequent
similar
femal
slightli
higher
male
deferr
rate
lower
vasovag
reaction
rate
compar
year
old
loc
reaction
rare
donor
countri
lower
donor
compar
year
old
healthi
older
individu
may
continu
safe
donat
make
substanti
contribut
blood
suppli
past
arbitrari
age
limit
c
c
n
c
p
j
du
sang
rhone
alp
auvergn
grenobl
alp
grenobl
du
sang
rhone
alp
auvergn
lyon
du
sang
la
plain
franc
background
prevent
faint
reaction
fr
associ
whole
blood
donat
import
issu
donor
safeti
donor
retent
evas
studi
prospect
random
trial
involv
blood
donor
demonstr
muscl
tens
time
donat
could
reduc
incid
earli
fr
donat
drink
ml
isoton
solut
could
reduc
incid
delay
fr
well
tired
morand
transfus
aim
part
evas
studi
analysi
risk
factor
delay
fr
male
femal
blood
donor
perform
method
data
pertain
put
fr
risk
factor
prospect
collect
odd
ratio
determin
univari
analysi
follow
multivari
analysi
mean
backward
stepwis
elimin
condit
logist
regress
model
result
faint
reaction
occur
n
n
male
femal
donor
respect
expect
femal
versu
male
gender
associ
increas
fr
univari
analysi
odd
ratio
p
femal
donor
multivari
analysi
reveal
student
risk
factor
close
link
age
p
donat
work
hour
without
profession
activ
versu
donat
work
hour
p
p
p
respect
stress
p
high
hemoglobin
hg
level
per
ml
hb
increas
p
reduc
physic
statu
per
reduc
grade
scale
p
fr
risk
factor
male
donor
first
donat
odd
ratio
p
stress
p
donat
mobil
site
vs
fix
site
p
high
hemoglobin
hb
level
per
ml
hb
increas
p
pain
time
venipunctur
p
donat
p
independ
fr
risk
factor
risk
factor
associ
versu
delay
fr
examin
femal
donor
n
n
respect
low
number
delay
fr
n
prevent
similar
analysi
male
donor
physic
statu
stress
pain
donat
donat
mobil
site
risk
factor
associ
fr
high
hemoglobin
level
blood
donat
work
hour
without
profession
activ
risk
factor
associ
delay
faint
reaction
student
risk
factor
delay
faint
reaction
lastli
fr
occurr
associ
higher
frequenc
delay
fr
delay
fr
among
femal
donor
fr
ic
delay
fr
among
male
donor
fr
ic
summaryconclus
result
confirm
previous
identifi
risk
factor
femal
gender
young
age
strongli
associ
model
student
statu
stress
pain
donat
highlight
less
know
risk
factor
high
hemoglobin
level
risk
factor
differ
significantli
depend
donor
gender
well
faint
reaction
occur
find
could
pave
way
implement
person
risk
prevent
strategi
h
kamel
bravo
townsend
medic
affair
blood
system
scottsdal
unit
state
background
mechan
underli
advers
event
ae
blood
donor
thought
includ
psycholog
stress
instrument
give
blood
ie
fear
needl
pain
sight
blood
direct
effect
remov
ml
whole
blood
orthostat
effect
superimpos
hypovolem
state
donat
aim
determin
preval
bradycardia
puls
bpm
tachycardia
puls
bpm
ae
start
variou
period
donat
process
method
donor
present
wb
donat
us
blood
bank
analyz
ae
presenc
bradycardia
tachycardia
record
donor
ae
form
vital
sign
monitor
donor
experienc
ae
rate
bradycardia
tachycardia
calcul
base
period
donat
event
occur
period
screen
registr
min
needl
remov
min
needl
remov
onsit
min
needl
remov
offsit
donor
estim
blood
volum
ebv
sex
age
experi
donat
without
needl
characterist
describ
group
result
identifi
ae
syncop
event
percent
start
period
respect
bradycardia
report
tachycardia
report
ae
bradycardia
occur
mostli
among
male
needl
incomplet
collect
among
older
donor
tachycardia
occur
mostli
among
femal
complet
collect
among
yo
ebv
shown
significantli
lower
among
observ
tachycardia
ml
ci
compar
bradycardia
ci
summaryconclus
find
support
hypothesi
syncop
ae
occur
process
blood
donat
neural
mediat
reflex
reaction
name
sympathet
withdraw
andor
increas
vagal
tone
bradycardia
occur
blood
donat
either
donor
hypovolem
state
ambul
driven
primarili
orthostat
central
hypovolemia
tachycardia
vari
strategi
mitig
vasovag
event
throughout
cours
donat
distract
fluid
replac
continu
promot
k
kumar
n
marwaha
sachdev
transfus
medicin
pgimer
chandigarh
india
background
studi
conduct
associ
vvr
vasovag
reaction
variou
factor
like
age
gender
weight
blood
pressur
predon
water
intak
effect
orthostat
hypotens
post
donat
pauciti
data
compar
effect
salt
load
immedi
delay
vvr
separ
also
compar
distribut
immedi
delay
vvr
variou
group
base
gender
age
weight
bmi
donat
statu
percentag
blood
volum
withdrawn
aim
studi
effect
salt
load
vvr
colleg
go
student
came
voluntari
blood
donat
method
young
year
voluntari
blood
donor
random
control
group
test
group
donor
control
group
given
ml
sweeten
limewat
donor
test
group
given
gm
salt
mixtur
donor
observ
immedi
vvr
ivvr
campsit
telephon
follow
h
delay
vvr
dvvr
result
vvr
present
studi
ivvr
dvvr
reaction
rate
vvr
less
test
group
compar
control
group
decreas
dvvr
statist
signific
decreas
ivvr
signific
group
femal
gender
signific
risk
factor
howev
test
group
femal
signific
decreas
ivvr
dvvr
compar
control
group
femal
first
time
donor
ftd
tend
higher
reaction
repeat
donor
rd
salt
load
affect
incid
vvr
ftd
first
time
donat
independ
risk
factor
test
group
rd
signific
reduct
dvvr
mild
decreas
ivvr
overal
donor
weight
rang
kg
reaction
compar
higher
weigh
donor
differ
seen
test
vs
control
group
analyz
weight
trend
decreas
occurr
vvr
observ
bmi
donor
increas
increas
percentag
vvr
obes
donor
bmi
kgsq
compar
donor
bmi
rang
kgsq
donor
higher
blood
volum
withdrawn
vvr
decreas
trend
test
group
reach
statist
signific
summaryconclus
overal
reaction
rate
vvr
less
salt
load
young
whole
blood
donor
decreas
dvvr
statist
signific
l
l
c
e
l
j
f
p
r
develop
laboratori
nh
blood
transplant
cambridg
blood
transplant
health
nh
trust
uk
institut
queen
mari
univers
london
london
blood
transplant
bristol
haematolog
univers
cambridg
cambridg
unit
kingdom
background
earli
resuscit
trauma
patient
blood
compon
becom
increasingli
widespread
whole
blood
wb
use
routin
militari
use
reduc
significantli
due
introduct
blood
compon
renew
interest
administ
whole
blood
wb
resuscit
bleed
trauma
patient
owe
evid
studi
proppr
trial
suggest
red
cell
plasma
platelet
may
improv
patient
outcom
aim
wb
day
depend
jurisdict
establish
decad
ago
base
viabil
red
cell
howev
plasma
qualiti
wb
storag
establish
examin
studi
method
wb
prepar
use
standard
uk
process
compar
wb
process
use
leucocyt
deplet
filter
wbplt
wb
held
day
alongsid
standard
red
cell
sagm
never
frozen
liquid
plasma
lp
thrombin
gener
coagul
factor
assay
use
assess
plasma
wbplt
compar
lp
understand
effect
store
plasma
alongsid
red
cell
thromboelastographi
perform
wbplt
well
plasma
separ
lp
contact
activ
assess
statist
compar
coagul
factor
level
subsequ
day
day
wbplt
lp
day
result
whilst
certain
coagul
factor
remain
unaffect
storag
platelet
andor
red
cell
eg
fibrinogen
other
vari
depend
type
cell
store
time
notabl
fv
activ
lost
significantli
storag
wbplt
statist
differ
lp
day
iuml
vs
iuml
respect
free
protein
antigen
also
reduc
wbplt
significantli
differ
lp
free
protein
activ
decreas
dramat
three
arm
day
level
detect
wbplt
margin
higher
lp
significantli
differ
lp
day
fviii
activ
aptt
result
wbplt
significantli
higher
lp
day
level
fviii
fv
fvii
remain
averag
iuml
day
wbplt
thrombin
gener
potenti
plasma
remain
rel
stabl
day
group
contact
activ
demonstr
lp
unit
day
unit
wbplt
summaryconclus
data
suggest
term
plasma
qualiti
shelf
life
day
less
may
appropri
day
wb
data
use
propos
uk
trial
use
treatment
major
haemorrhag
data
platelet
function
wbplt
need
inform
hh
medicin
univers
iceland
bank
landspitali
nation
univers
hospit
iceland
reykjavik
iceland
background
revis
guidelin
patient
blood
manag
pbm
publish
iceland
propos
restrict
red
blood
cell
rbc
transfus
threshold
gl
patient
chronic
anemia
gl
patient
bone
marrow
suppress
anemia
frequent
complic
chronic
lymphocyt
leukemia
cll
rbc
transfus
commonli
use
support
treatment
iceland
blood
compon
provid
singl
blood
bank
facilit
studi
blood
compon
util
aim
investig
transfus
practic
cll
year
period
emphasi
hemoglobin
transfus
trigger
method
retrospect
investig
util
registri
iceland
cll
patient
includ
cll
patient
diagnos
iceland
period
medic
record
review
inform
symptom
laboratori
test
treatment
surviv
data
obtain
nation
registri
transfus
data
retriev
blood
bank
inform
system
comparison
transfus
trigger
period
split
two
b
result
total
patient
male
femal
diagnos
cll
studi
period
total
patient
receiv
rbc
transfus
march
median
time
cll
diagnosi
first
transfus
year
rang
year
total
number
rbc
unit
transfus
vari
wide
rang
median
unit
number
transfus
episod
rang
median
per
patient
patient
n
transfus
episod
cll
case
transfus
episod
higher
age
diagnosi
associ
higher
number
rbc
transfus
p
patient
rai
stage
diagnosi
like
receiv
transfus
patient
lower
rai
stage
stage
p
stage
p
well
patient
receiv
chemotherapi
p
data
hemoglobin
hb
transfus
trigger
first
rbc
transfus
avail
case
mean
hb
trigger
ci
latter
period
significantli
lower
mean
hb
threshold
earlier
period
ci
p
group
stratifi
accord
presenc
absenc
confirm
bone
marrow
infiltr
differ
hb
trigger
signific
group
without
involv
hb
gl
latter
period
ci
compar
gl
earlier
period
ci
p
median
time
cll
diagnosi
transfus
significantli
longer
second
period
year
ci
year
compar
first
period
year
ci
year
p
summaryconclus
cll
patient
requir
rbc
transfus
cours
studi
older
patient
higher
rai
stage
need
chemotherapi
likeli
receiv
rbc
transfus
public
pbm
guidelin
hb
transfus
trigger
drop
significantli
patient
without
bone
marrow
infiltr
time
first
rbc
transfus
increas
pa
g
g
h
michael
hospit
toronto
blood
servic
toronto
canada
background
immun
thrombocytopenia
itp
autoimmun
diseas
character
reduct
platelet
count
lead
sever
bleed
potenti
fatal
intracrani
hemorrhag
major
itp
patient
possess
autoantibodi
mediat
platelet
destruct
spleen
macrophag
phagocytosi
intraven
inject
pool
human
serum
immunoglobulin
ivig
use
treatment
itp
decad
howev
ivig
replac
therapi
signific
interest
due
ivig
high
cost
theoret
risk
diseas
transmiss
demand
blood
donor
previous
demonstr
monoclon
antibodi
hyaluron
acid
receptor
success
treat
murin
itp
lower
dose
ivig
unknown
mechan
express
leukocyt
includ
macrophag
hypothes
increas
platelet
count
interf
macrophag
phagocytosi
aim
studi
aim
determin
whether
antibodi
increas
platelet
count
mice
inhibit
macrophag
phagocytosi
method
three
differ
antibodi
test
inhibit
macrophag
phagocytosi
platelet
platelet
opson
one
five
differ
antibodi
differ
igg
subtyp
role
receptor
interact
antibodi
evalu
deglycosyl
f
ab
fragment
gener
antibodi
final
method
also
test
use
erythrocyt
phagocyt
target
determin
whether
could
inhibit
phagocytosi
erythrocyt
similar
manner
result
demonstr
macrophag
phagocytosi
platelet
complet
inhibit
antibodi
inhibit
phagocytosi
manner
near
complet
inhibit
use
monoclon
antibodi
murin
platelet
mous
subtyp
found
inhibit
phagocytosi
opson
therapeut
antibodi
subtyp
match
put
receptor
bind
result
suggest
inhibit
phagocytosi
platelet
fc
block
remov
receptor
interact
fc
deglycosyl
gener
f
ab
fragment
led
complet
loss
therapeut
activ
addit
inhibit
macrophag
phagocytosi
murin
erythrocyt
also
depend
upon
igg
subtyp
presenc
igg
fc
suggest
antibodi
inhibit
phagocytosi
erythrocyt
mechan
summaryconclus
antibodi
constitut
potent
inhibitor
macrophag
phagocytosi
platelet
erythrocyt
manner
depend
upon
fc
portion
igg
subtyp
result
suggest
import
implic
igg
subtyp
monoclon
antibodi
therapeut
efficaci
whether
subtyp
may
explain
failur
therapeut
antibodi
remain
explor
j
f
k
c
h
l
j
institut
medic
scienc
colleg
medicin
taipei
medic
univers
taipei
taiwan
republ
china
de
pharmacologi
cliniqu
licend
coen
center
lill
univers
lill
inserm
chu
de
lill
lill
franc
institut
biomed
materi
tissu
engin
colleg
biomed
engin
taipei
medic
univers
microbiolog
immunolog
school
medicin
colleg
medicin
taipei
medic
univers
phd
program
biomed
engin
colleg
biomed
engin
taipei
medic
univers
taipei
taiwan
republ
china
background
one
promis
clinic
develop
human
platelet
lysat
hpl
regen
medicin
potenti
use
diseas
modifi
treatment
neurolog
disord
scientif
ration
support
therapeut
approach
platelet
rich
multipl
neurotroph
molecul
includ
growth
factor
pdgf
vegf
bdnf
etc
neurotransmitt
challeng
creat
therapeut
strategi
appli
complex
organ
like
brain
lie
need
ensur
optim
qualiti
safeti
profil
safe
administr
either
intracerebroventricular
icv
intranas
rout
recent
develop
chou
et
al
biomateri
platelet
lysat
brain
administr
free
fibrinogen
avoid
fibrin
deposit
devoid
thrombogen
proteolyt
inflammatori
activ
allogen
sourc
hppl
also
subject
viru
reduct
treatment
aim
develop
neuroprotect
hpl
enrich
multipl
neurotroph
growth
factor
deplet
plasma
protein
includ
fibrinogen
safeti
profil
compat
brain
administr
diseas
modifi
strategi
parkinson
diseas
pd
method
apheresi
platelet
concentr
centrifug
elimin
plasma
platelet
pellet
suspend
pb
subject
three
cycl
centrifug
platelet
lysat
supernat
subject
min
sd
treatment
tnbptriton
use
planova
vitro
thrombogen
proteolyt
inflammatori
activ
assess
thrombin
gener
assay
zymuphen
prothrombinas
assay
procoagul
clot
time
assay
inflammatori
marker
access
microglia
cell
model
neuroprotect
effect
assess
vitro
use
luhm
cell
model
expos
mpp
neurotoxin
b
vivo
use
mice
expos
mptp
neurotoxin
result
result
decreas
total
protein
content
modif
neurotroph
growth
factor
content
elimin
thrombogen
proteolyt
activ
inactiv
log
hcv
furthermor
hppl
stimul
releas
inflammatori
marker
eg
ino
microgli
cell
cultur
could
restrict
express
upon
lp
exposur
provid
strong
neuroprotect
activ
luhm
vitro
administr
mice
induc
diffus
platelet
deriv
growth
factor
pdgf
olfactori
bulb
striatum
cortex
brain
area
protect
express
tyrosin
hydroxylas
th
dopaminerg
neuron
substantia
nigra
par
compacta
striatum
inflammatori
base
express
microglia
sd
treatment
step
shown
inactiv
log
hcv
step
log
hcv
reduct
differ
viral
inactiv
step
still
preserv
neuroprotect
vitro
summaryconclus
appear
feasibl
develop
platelet
lysat
prepar
potenti
biotherapi
treatment
neurodegen
disord
central
nervou
system
pd
k
k
k
h
h
c
clinic
immunolog
aarhu
univers
hospit
aarhu
clinic
immunolog
naestv
hospit
naestv
epidemiolog
research
staten
serum
institut
haematolog
clinic
immunolog
copenhagen
univers
hospit
rigshospitalet
copenhagen
denmark
background
combin
oral
contracept
oc
use
women
age
year
denmark
oc
offer
conveni
effect
revers
fertil
regul
fundament
side
effect
venou
thromboembol
includ
deep
vein
thrombosi
pulmonari
embol
potenti
seriou
side
effect
myocardi
infarct
ischem
stroke
studi
investig
metabol
proinflammatori
haemostat
effect
estrogen
progestin
contain
oc
platelet
play
import
role
pathogenesi
venou
thromboembol
howev
impact
oc
blood
platelet
level
remain
unknown
aim
aim
studi
examin
impact
oc
level
blood
platelet
larg
cohort
blood
donor
method
blood
platelet
level
women
danish
blood
donor
studi
give
blood
capit
central
danish
region
measur
autom
haematolog
analys
donat
particip
complet
standard
questionnair
lifestyl
factor
state
use
contracept
childbirth
menopaus
statu
type
oc
oc
exposur
period
identifi
atc
code
danish
nation
prescript
registri
associ
oc
blood
platelet
level
explor
repeat
measur
mix
model
analysi
analys
adjust
age
time
sinc
previou
donat
perform
result
present
coeffici
confid
interv
ci
result
total
femal
particip
fill
oc
prescript
studi
period
intermitt
oc
user
continu
oc
user
among
user
user
gener
oc
respect
blood
platelet
level
higher
among
oc
user
compar
coeffici
billion
thrombocytesl
ci
differ
increas
compar
oc
continu
user
vs
coeffici
ci
although
differ
oc
intermitt
user
vs
coeffici
ci
oc
user
vs
differ
oc
type
effect
blood
platelet
level
summaryconclus
oc
user
higher
level
blood
platelet
find
import
help
understand
effect
oc
risk
thromboembol
mechan
oc
blood
platelet
need
investig
find
underscor
blood
donor
cohort
feasibl
studi
health
properti
healthi
person
r
j
develop
australian
red
cross
blood
servic
kelvin
grove
medicin
univers
queensland
queensland
critic
care
research
group
princ
charl
hospit
chermsid
health
queensland
univers
technolog
brisban
health
command
australian
defenc
forc
canberra
australia
background
platelet
concentr
requir
treatment
thrombot
haemostat
disord
platelet
maintain
vascular
integr
mediat
coagul
contribut
immun
respons
despit
therapeut
benefit
platelet
transfus
induc
immun
modul
trim
subsequ
immunosuppress
chang
immun
respons
increas
patient
risk
advers
event
infect
failur
tumour
growth
mortal
trim
describ
clinic
experiment
model
definit
mechan
immun
modul
provid
use
establish
vitro
transfus
model
project
aim
characteris
monocyt
dendrit
cell
neutrophil
immun
profil
associ
underli
infect
aim
use
establish
vitro
transfus
model
monocyt
dendrit
cell
neutrophil
immun
respons
aim
investig
respons
platelet
supernatantsaim
determin
whether
respons
alter
presenc
lipopolysaccharid
lp
model
underli
bacteri
infectionaim
determin
whether
respons
alter
increas
concentr
lpsaim
investig
whether
platelet
storag
durat
impact
immunomodul
observ
method
monocyt
dendrit
cell
neutrophil
cytokin
product
investig
follow
exposur
platelet
supernat
establish
vitro
model
fresh
whole
blood
cultur
rpmi
media
day
day
day
pool
platelet
supernat
unit
pool
time
point
final
dilut
model
one
unit
transfus
model
differ
level
underli
infect
lp
use
protein
transport
inhibitor
contain
brefeldin
ad
facilit
detect
intracellular
cytokin
via
flow
cytometri
statist
differ
match
control
lp
determin
p
use
analysi
varianc
anova
anova
tukey
result
absenc
lp
stimul
platelet
supernat
significantli
modul
monocyt
dendrit
cell
neutrophil
cytokin
product
ie
aim
model
underli
infect
ie
lp
platelet
supernat
suppress
monocyt
tnf
dendrit
cell
cytokin
product
ie
aim
compar
higher
level
underli
infect
lower
level
underli
infect
ie
vs
lp
modul
monocyt
tnf
cytokin
product
evid
ie
aim
increas
platelet
storag
durat
significantli
impact
monocyt
dendrit
cell
respons
observ
studi
ie
aim
neutrophil
cytokin
product
limit
detect
differ
observ
vitro
transfus
model
summaryconclus
togeth
data
provid
evid
underli
infect
induc
chang
patient
monocyt
dendrit
cell
immun
profil
modifi
presenc
platelet
supernat
also
evid
level
underli
infect
modul
immun
profil
may
contribut
poor
patient
outcom
includ
increas
risk
infect
r
cardigan
abstract
avail
k
r
medicin
medic
faculti
medicin
univers
medicin
greifswald
greifswald
medicin
medic
faculti
tuebingen
medicin
medic
faculti
germani
background
bacteri
contamin
major
problem
platelet
transfus
sinc
platelet
concentr
pc
routin
store
room
temperatur
rt
cold
storag
pc
potenti
approach
overcom
risk
chill
platelet
shown
poorer
recoveri
surviv
compar
rt
store
platelet
hypothes
residu
plasma
content
platelet
storag
media
influenc
storag
lesion
recoveri
cold
store
platelet
aim
evalu
impact
differ
residu
plasma
proport
platelet
storag
media
cold
storag
pc
platelet
function
surviv
method
apheresi
pc
apc
collect
healthi
volunt
resuspend
plasma
platelet
addit
solut
pa
ssp
maco
pharma
franc
final
plasma
concentr
respect
apc
store
either
rt
constant
agit
recoveri
surviv
transfus
platelet
assess
appli
nodscid
mous
model
min
inject
adhes
spread
abil
analys
collagen
fibrinogen
coat
surfac
result
platelet
store
alway
show
impair
surviv
compar
store
rt
compar
surviv
curv
found
plasma
content
compar
plasma
regardless
storag
temperatur
platelet
store
pa
low
plasma
concentr
clear
mous
circul
faster
compar
store
plasma
especi
plt
surviv
h
vs
p
vs
respect
hand
platelet
storag
preserv
hemostat
function
better
current
standard
care
cell
adher
collagen
fibrinogen
compar
platelet
store
howev
effect
disappear
plasma
reduc
suggest
excess
reduct
plasma
volum
lower
impair
plt
adhes
function
especi
summaryconclus
plasma
factor
seem
major
impact
cold
lesion
although
excess
reduct
plasma
impair
platelet
function
surviv
platelet
concentr
store
pa
inferior
store
plasma
room
temperatur
well
chowdhri
patel
agraw
transfus
medicin
indraprastha
apollo
hospit
new
delhi
india
background
shortag
sdp
singl
donor
platelet
altern
group
sdp
use
albeit
risk
acut
haemolyt
transfus
reaction
ahtr
high
titr
group
donor
andor
platelet
addit
solut
pa
overcom
risk
ahtrallerg
reaction
propos
prolong
shelf
life
sdp
day
aim
compar
variou
haematolog
biochem
paramet
pa
store
sdp
unit
sdp
store
plasma
day
assess
feasibl
use
pa
obtain
low
titr
sdp
unit
utilis
across
group
method
prospect
studi
perform
june
januari
clearanc
institut
ethic
committe
studi
group
includ
donor
b
group
whose
sdp
prepar
ratio
pa
ssp
macopharma
plasma
control
group
includ
donor
ab
group
whose
sdp
store
plasma
sdp
group
compar
visual
appear
swirl
arteri
blood
ga
analysi
abg
platelet
indic
day
steril
test
group
assess
day
pearson
test
use
analys
correl
ph
platelet
indic
day
group
group
sdp
titr
compar
modif
sdp
pa
high
titr
titr
group
result
studi
group
compris
donor
control
group
consist
donor
paramet
compar
bicarbon
level
reach
statist
signific
higher
level
control
group
day
p
though
mean
ph
higher
studi
group
compar
control
group
day
p
reach
signific
day
ph
significantli
well
maintain
studi
group
compar
control
group
p
mean
increas
mean
platelet
volum
mpv
day
compar
day
significantli
higher
control
group
p
compar
studi
group
potassium
higher
control
group
compar
studi
group
day
statist
signific
mean
decreas
mean
platelet
compon
concentr
mpc
day
day
higher
control
group
compar
studi
group
statist
signific
none
remain
paramet
pearson
correl
reach
statist
signific
bacteri
growth
seen
group
studi
group
median
antibodi
titr
group
sdp
n
prior
pa
addit
reduc
significantli
p
high
n
titter
n
group
signific
titr
reduct
note
p
summaryconclus
vitro
characterist
platelet
store
pa
maintain
qualiti
per
standard
till
day
storag
use
pa
sdp
elimin
need
platelet
therebi
help
maintain
better
inventori
e
pryzdial
f
lee
depart
patholog
laboratori
medicin
univers
british
columbia
vancouv
canada
background
cardiovascular
diseas
lead
caus
death
worldwid
major
contributor
blood
clot
ie
thrombi
block
normal
blood
flow
thrombi
compris
larg
fibrin
provid
structur
support
clot
current
ie
thrombolyt
drug
design
base
natur
occur
proteas
tissu
plasminogen
activ
tpa
activ
plasminogen
pg
plasmin
enzym
respons
cleav
dissolv
fibrin
howev
tpa
activ
enzym
must
given
high
dose
overcom
rapid
clearanc
therefor
work
bodi
thrombu
site
caus
bleed
patient
treat
thrombosi
may
improv
instead
acceler
intrins
tpa
use
therapi
local
clot
discov
plasmin
cleav
convert
essenti
coagul
cofactor
factor
va
fva
fibrinolysi
cofactor
capabl
acceler
pg
activ
associ
anion
phospholipid
apl
local
clot
complex
sequenti
cleavag
fva
plasmin
dissoci
heavi
fvah
light
subunit
fval
caus
loss
coagul
activ
aim
goal
determin
simplest
combin
fragment
acceler
tpa
provid
safer
therapeut
altern
method
correl
fragment
fva
follow
plasmin
cleavag
acquisit
tpa
cofactor
activ
chromogen
assay
use
measur
plasmin
product
either
intact
fva
incub
tpa
pg
sampl
taken
time
measur
plasmin
gener
fragment
remain
bound
apl
separ
differenti
centrifug
fragment
sampl
concomitantli
analyz
polyacrylamid
gel
electrophoresi
western
blot
correl
fragment
tpa
cofactor
activ
addit
autoradiographi
use
assess
direct
bind
fva
fragment
pg
result
cleavag
fva
plasmin
prior
incub
tpa
pg
significantli
acceler
pg
activ
demonstr
proteolyt
modul
plasmin
confer
tpa
cofactor
activ
enhanc
observ
presenc
anion
phospholipid
apl
interestingli
separ
fragment
fragment
bound
al
enhanc
plasmin
gener
tpa
howev
kda
fragment
shown
directli
bind
pg
suggest
fragment
enhanc
tpa
cofactor
activ
addit
mechan
summaryconclus
addit
understand
physiolog
fibrinolysi
extens
work
treatment
thrombot
diseas
stroke
heart
attack
thrombolysi
requir
restor
blood
flow
sinc
fval
contain
high
site
apl
apl
must
present
effici
convers
fva
function
nascent
tpa
cofactor
function
would
local
exclus
clot
gener
recombin
fibrinolyt
fragment
fval
toward
approach
dissolv
clot
reduc
side
effect
associ
therapeut
tpa
p
b
z
k
innov
canadian
blood
servic
laboratori
medicin
univers
british
columbia
vancouv
innov
canadian
blood
servic
edmonton
innov
canadian
blood
servic
ottawa
canada
background
requir
canadian
standard
red
blood
cell
concentr
rcc
produc
canadian
blood
servic
held
destruct
qualiti
test
day
storag
one
day
expiri
result
loss
rcc
per
year
inventori
aim
present
pilot
concept
would
potenti
elimin
need
discard
rcc
qualiti
control
qc
test
use
aliquot
remov
rcc
time
product
store
separ
test
expiri
techniqu
would
also
enabl
increas
sampl
size
better
understand
donor
variat
without
neg
impact
inventori
method
rectangular
r
shape
capac
ml
ml
ml
compar
length
width
ratio
design
weld
modif
standard
rcc
storag
bag
macopharma
lill
franc
rcc
produc
use
method
three
size
fill
syring
rcc
volum
ml
ml
ml
respect
n
per
arm
test
potenti
impact
air
air
bubbl
ml
size
ad
via
syring
n
per
arm
mother
unit
mu
correspond
fill
store
expiri
assess
red
blood
cell
rbc
qualiti
day
storag
includ
rbc
count
hematocrit
hemoglobin
hemolysi
harbo
method
ph
glucos
lactat
supernat
potassium
result
rbc
count
hematocrit
hemoglobin
level
statist
differ
higher
compar
respect
mu
hemolysi
develop
lowest
middl
volum
rang
test
three
size
smallest
chang
mu
ml
rcc
find
align
potassium
level
show
differ
mm
compar
mu
metabol
activ
measur
also
show
similar
trend
effect
ph
use
ml
configur
addit
ml
air
bubbl
signific
effect
measur
compar
air
order
challeng
system
rcc
n
held
room
temperatur
h
prior
fill
subsequ
storag
mu
expect
qualiti
markedli
decreas
increas
glucos
consumpt
higher
potassium
releas
hemolysi
develop
howev
ml
reflect
lower
qualiti
small
margin
regular
rcc
summaryconclus
present
data
present
concept
shape
rcc
fill
volum
exhibit
similar
storag
featur
compar
respect
rcc
mu
concept
valid
blood
product
set
implement
separ
sampl
method
would
avoid
loss
rcc
qc
test
evan
mcintyr
c
difranco
goldman
canadian
blood
servic
ottawa
canada
background
platelet
concentr
pc
routin
screen
bacteri
contamin
autom
bactalert
cultur
system
sinc
august
pc
extend
day
improv
bacteri
test
algorithm
includ
cultur
perform
h
post
collect
vs
h
inocul
one
aerob
cultur
bottl
one
anaerob
cultur
bottl
buffi
coat
bc
pool
singl
apheresi
unit
screen
doubl
apheresi
three
aerob
bottl
one
anaerob
bottl
quarantin
period
contamin
pc
neg
screen
result
may
found
report
transfus
reaction
qualiti
control
qc
test
outdat
pc
aim
summar
bacteri
screen
result
pc
obtain
sinc
august
method
august
decemb
bc
pool
apheresi
unit
screen
routin
test
addit
outdat
pc
includ
apheresi
unit
bc
pool
posit
result
classifi
confirm
posit
bacterium
isol
initi
confirmatori
cultur
bacterium
isol
initi
pc
cultur
associ
implic
pc
unavail
fals
posit
bacteria
isol
initi
confirmatori
cultur
unconfirm
posit
bacteria
present
initi
cultur
confirmatori
test
pc
avail
confirm
initi
result
test
neg
fals
neg
unit
miss
routin
screen
captur
qc
test
outdat
pc
implic
septic
transfus
reaction
result
three
cultur
result
categor
confirm
posit
routin
screen
bc
pool
apheresi
unit
respect
bacteria
isol
bc
pool
includ
propionibacterium
acn
streptococcu
spp
coagulas
neg
staphylococcu
con
staphylococcu
aureu
diphtheroid
bacillu
seven
confirm
posit
involv
initi
cultur
pc
pool
confirmatori
test
associ
rbc
unit
contamin
p
acn
confirm
posit
cultur
obtain
apheresi
pc
identifi
p
acn
streptococcu
viridan
con
fals
posit
result
account
bc
pool
apheresi
unit
test
respect
unconfirm
posit
yield
rate
correspondingli
bc
apheresi
pc
outdat
pc
one
bc
pool
confirm
contamin
con
one
septic
transfus
reaction
involv
bc
pool
contamin
staphylococcu
epidermidi
report
approxim
rate
transfus
reaction
summaryconclus
compar
result
confirm
posit
cultur
present
herein
pc
prior
august
screen
pc
demonstr
enhanc
detect
contamin
product
detect
contamin
pc
increas
approxim
aerob
bacteria
apheresi
unit
bc
pool
cultur
anaerob
organ
includ
detect
contamin
pool
apheresi
unit
increas
approxim
respect
result
indic
improv
sensit
current
pc
screen
protocol
longer
observ
period
necessari
quantifi
residu
safeti
risk
f
g
qualif
affair
canada
background
bacteri
detect
platelet
plt
introduc
hq
plt
product
plt
whole
blood
apheresi
despit
hq
receiv
report
septic
reaction
fatal
product
transfus
aureu
pyogen
improv
process
need
aim
reduc
risk
advers
reaction
due
contamin
plt
improv
process
bacteri
detect
achiev
increas
time
sampl
increas
volum
sampl
delay
issu
plt
method
februari
novemb
ml
sampl
h
collect
plt
inocul
aerob
bottl
bpa
incub
classic
durham
nc
plt
issu
incub
start
novemb
octob
ml
taken
least
h
collect
ml
inocul
bpa
ml
place
newli
introduc
bpn
platelet
issu
incub
start
sinc
octob
time
sampl
increas
h
h
incub
period
bactalert
ad
issu
plt
also
extend
plt
day
health
canada
approv
result
true
posit
rate
tpr
plt
transfus
cultur
becam
posit
advers
reaction
observ
staphylococcu
epidermidi
tpr
eight
intercept
two
transfus
staphylococcu
propionibacterium
sp
gave
advers
reaction
nine
posit
anaerob
bottl
propionibacterium
sp
staphylococcu
staphylococcu
saccharolyticu
strict
anaerob
one
breakthrough
infect
due
bacillu
report
octob
decemb
tpr
five
transfus
propionibacterium
sp
advers
reaction
mean
time
detect
day
posit
bpn
breakthrough
infect
report
close
product
cultur
exclud
propionibacterium
case
tpr
use
two
bottl
aerob
anaerob
caus
increas
fals
posit
rate
fpr
fals
signal
read
instrument
cultur
neg
use
bpa
fpr
use
bpa
bpn
increas
fpr
summaryconclus
increas
sampl
volum
time
sampl
time
issu
increas
true
posit
rate
cultur
consequ
reduc
risk
advers
reaction
due
bacteri
contamin
plt
increas
delay
sampl
issu
requir
adopt
longer
shelf
life
k
k
u
h
e
manag
donor
screen
german
red
cross
frankfurt
manag
german
red
cross
plauen
donor
screen
german
red
cross
ulm
donor
screen
german
red
cross
plauen
german
red
cross
ulm
german
red
cross
frankfurt
germani
background
bacteri
contamin
blood
compon
still
major
challeng
transfus
medicin
especi
platelet
concentr
store
room
temperatur
improv
blood
safeti
maximum
shelf
life
reduc
germani
platelet
day
addit
rapid
bacteri
screen
method
develop
nat
bactiflow
implement
gener
bacteria
screen
h
h
blood
donat
aim
implement
bacteria
screen
system
bactiflow
platelet
maximum
pool
size
platelet
compon
per
pool
platelet
releas
without
bacteri
test
day
h
blood
donat
sampl
platelet
concentr
collect
pool
test
bacteria
contamin
shelf
life
screen
platelet
neg
test
result
extend
day
method
platelet
releas
product
without
delay
platelet
transfus
h
blood
donat
test
bacteri
contamin
bactiflow
system
analyt
sensit
method
app
cfu
bactiflow
method
abl
detect
transfus
relev
bacteria
strain
spike
platelet
concentr
cfubag
storag
h
room
temperatur
result
may
januari
platelet
screen
bacteri
contamin
total
platelet
identifi
bacteri
contamin
klebsiella
pneumonia
staphylococcu
epidermidi
escherichia
coli
staphylococcu
aureu
growth
kinet
demonstr
rapid
bacteria
grow
summaryconclus
compar
cultur
method
bacteri
rapid
detect
method
like
bactiflow
nat
character
high
clinic
effici
rate
bacteri
contamin
platelet
concentr
could
identifi
discard
releas
platelet
compon
recal
describ
cultur
method
concept
necessari
introduct
rapid
bacteri
screen
method
lead
improv
suppli
hospit
platelet
concentr
extend
shelf
life
day
addit
increas
blood
safeti
therefor
blood
donor
servic
perform
voluntari
basi
test
strategi
screen
avail
platelet
concentr
day
onward
bacteri
contamin
major
step
improv
blood
safeti
l
j
rojo
g
j
director
bank
nation
blood
transfus
center
mexico
mexico
background
chaga
diseas
american
trypanosomiasi
diseas
caus
parasit
trypanosoma
cruzi
found
mainli
latin
america
transmit
human
princip
contact
infect
insect
fece
call
vector
transmiss
blood
transfus
infect
second
transmiss
mechan
vector
due
process
urban
latin
america
intensifi
second
half
twentieth
centuri
increas
popul
movement
modifi
epidemiolog
profil
diseas
becom
global
risk
due
particular
blood
donat
migrat
peopl
endem
area
area
triatomin
exist
mexican
offici
standard
dispos
human
blood
compon
therapeut
purpos
state
infecti
seroreact
screen
mandatori
donat
whole
blood
unit
includ
cruzi
howev
transmiss
infect
prevent
select
blood
donor
likewis
difficult
establish
confirmatori
diagnosi
asymptomat
mild
clinic
manifest
import
standard
serolog
test
demonstr
antibodi
cruzi
aim
determin
seropreval
reactiv
trypanosoma
cruzi
detect
antibodi
blood
donor
mexico
studi
period
method
present
work
observ
multicent
longitudin
retrospect
prolect
studi
demonstr
behavior
seropreval
reactiv
cruzi
blood
donor
differ
blood
bank
health
system
mexico
monthli
serolog
report
blood
donor
organ
analyz
descript
statist
sent
nation
blood
transfus
center
cnt
blood
bank
n
health
system
mexico
report
includ
number
donor
studi
cruzi
detect
sero
reactiv
cruzi
well
repeatedli
reactiv
result
causal
agent
test
use
reagent
strip
immunoenzymat
assay
complement
fixat
indirect
hemagglutin
direct
agglutin
indirect
immunofluoresc
result
cnt
receiv
serolog
report
reactiv
detect
cruzi
serolog
studi
repeatedli
reactiv
increas
percentag
applic
reactiv
test
cruzi
blood
donor
decreas
reactiv
seropreval
studi
period
observ
identifi
state
michoacan
colima
guerrero
nayarit
tamaulipa
five
feder
entiti
highest
seropreval
reactiv
cruzi
summaryconclus
transmiss
form
cruzi
call
urban
chaga
transfusionaltranspl
challeng
countri
condit
screen
coverag
blood
donor
transmiss
via
vector
cruzi
remain
mexico
import
howev
blood
transfus
remain
transmiss
risk
due
migrat
countri
emerg
case
geograph
area
vector
detect
therefor
import
alway
consid
transfus
histori
risk
factor
transmiss
cruzi
blood
bank
opportun
field
creat
effect
clinic
care
algorithm
reactiv
blood
donor
cruzi
implement
nationwid
across
sector
c
c
w
g
surveil
collabor
corpor
secretariat
canadian
blood
servic
ottawa
canada
red
cross
blood
servic
perth
australia
transfus
microbiolog
refer
laboratori
nation
health
servic
blood
transplant
london
unit
kingdom
de
qualif
biologiqu
de
don
etabliss
francai
du
sang
poitier
franc
affair
american
red
cross
rockvil
unit
state
affair
microbiolog
canada
biolog
evalu
research
food
drug
administr
silver
spring
unit
state
background
malaria
parasit
infect
caus
cyclic
fever
endem
africa
mani
part
world
countri
transfus
transmiss
risk
blood
donor
born
spent
time
endem
area
risk
address
select
test
donor
deferr
polici
vari
countri
allianc
blood
oper
risk
base
decis
make
framework
recommend
rang
assess
consid
determin
polici
aim
compar
type
assess
use
formul
malaria
polici
england
franc
australia
canada
usa
recommend
framework
method
key
relev
element
framework
identifi
intervent
safeti
threat
avail
threat
donor
impact
financi
implic
risk
commun
stakehold
relat
regulatori
aspect
decis
analyz
two
key
area
separ
decis
implement
select
test
select
donor
criteria
decis
detail
assess
inform
consid
compar
compon
framework
concern
level
key
consider
framework
rate
result
three
countri
implement
select
test
strategi
franc
england
australia
franc
safeti
risk
key
wherea
risk
alreadi
address
deferr
blood
compon
restrict
england
australia
suffici
blood
suppli
assess
highli
import
countri
societ
donor
concern
consid
main
tradeoff
accept
high
oper
impact
cost
exchang
reduc
donor
deferralfresh
compon
loss
franc
increas
safeti
screen
criteria
decis
select
analysi
franc
born
live
endem
countri
first
year
life
england
criteria
accept
donor
return
travel
month
ago
franc
australia
donor
would
test
travel
within
last
year
australia
year
deferr
travel
papua
new
guinea
canada
perman
deferr
donor
malaria
histori
usa
year
deferr
donor
malaria
histori
risk
involv
isol
transfus
transmiss
case
near
miss
canada
australia
franc
case
per
year
usa
england
shorter
period
travel
test
countri
social
concern
assess
high
franc
australia
politicalregulatori
influenc
high
franc
australia
canada
suffici
key
consider
canada
usa
donor
impact
import
decis
vari
countri
gener
involv
accept
moder
oper
impact
address
perceiv
safeti
risk
politicalregulatori
concern
summaryconclus
assess
inform
consid
countri
gener
consist
object
framework
data
support
quantifi
risk
assess
safeti
oper
feasibl
greatest
weight
decis
risk
well
defin
contextu
factor
social
polit
concern
greater
weight
stakehold
concern
health
econom
carri
proport
less
weight
decis
current
expect
would
requir
greater
attent
vuk
qualiti
manag
croatian
institut
transfus
medicin
zagreb
croatia
data
manag
healthcar
system
increasingli
import
challeng
given
role
transfus
medicin
differ
area
medic
scienc
public
health
signific
data
dispos
goe
beyond
use
manag
transfus
servic
huge
amount
differ
data
gener
blood
establish
daili
base
data
differ
accord
sourc
signific
purpos
valu
data
larg
depend
use
inform
technolog
enabl
collect
larg
amount
data
differ
sourc
nowaday
common
data
devic
analyz
sourc
transfer
central
system
addit
automat
data
transfer
avail
manual
entri
oper
therefor
essenti
ensur
accuraci
reliabl
procedur
applic
scan
technolog
data
entri
verif
optic
charact
recognit
ocr
intellig
charact
recognit
icr
redesign
data
entri
form
exampl
reduc
risk
error
addit
benefit
use
comput
technolog
abil
combin
individu
data
order
increas
valu
softwar
develop
commerci
applic
local
nation
level
nation
blood
bank
softwar
addit
contribut
integr
data
comparison
intern
level
extrem
import
system
properli
valid
addit
varieti
specif
requir
relat
qualiti
safeti
vein
vein
traceabl
utmost
import
data
serv
import
resourc
staff
train
organ
increasingli
perceiv
need
document
retain
knowledg
use
educ
tool
effici
data
manag
also
result
save
result
select
optim
strategi
better
alloc
resourc
although
qualiti
integr
activ
data
crucial
import
qualiti
manag
system
qm
exampl
includ
data
relat
audit
inspect
deviat
advers
event
reaction
product
recal
complaint
manag
qualiti
control
materi
equip
product
servic
data
relat
process
productservic
realiz
qualiti
improv
one
fundament
object
qm
extent
object
achiev
larg
depend
data
avail
way
use
select
improv
strategi
collect
data
import
role
benchmark
compar
data
institut
possibl
detect
compar
strength
weak
well
opportun
improv
benchmark
close
relat
defin
key
perform
indic
correct
interpret
data
prerequisit
make
right
decis
therefor
import
data
high
qualiti
compar
data
relat
qm
function
effect
part
period
report
use
manag
review
also
inform
employe
p
strenger
execut
offic
intern
plasma
fraction
associ
amsterdam
netherland
product
van
plasma
deriv
medicin
product
pdmp
intraven
immunoglobulin
coagul
factor
albumin
great
number
hereditari
acquir
diseas
disord
human
plasma
sourc
materi
manufactur
human
plasma
rich
biolog
substanc
plasma
protein
isol
plasma
concentr
therapeut
plasma
protein
product
requir
regulatori
author
product
medicin
product
take
place
good
manufactur
practic
gmp
condit
start
sourc
materi
product
pdmp
obtain
process
gmp
condit
establish
respons
suppli
sourc
materi
place
facil
train
personnel
subject
qualiti
assur
qa
program
compli
principl
gmpgmp
good
practic
gp
blood
establish
propos
council
europ
adopt
european
union
requir
qualiti
safeti
guidanc
qa
system
blood
establish
requir
qa
system
defin
collect
process
qualiti
control
blood
blood
compon
pdmp
requir
impli
exist
nation
structur
independ
manufactur
complianc
process
qualiti
assur
biolog
product
ie
control
start
materi
product
process
final
product
strict
adher
principl
gmp
gp
sinc
put
blood
compon
model
list
essenti
medicin
blood
establish
need
compli
gmp
gp
product
blood
compon
qa
system
base
gmp
principl
impli
activ
oper
qualiti
assur
system
cover
activ
blood
establish
qualiti
blood
plasma
depend
collect
prepar
test
storag
transport
qualiti
plasma
manufactur
influenc
rang
qualiti
safeti
pdmp
blood
establish
wish
suppli
recov
sourc
plasma
manufactur
qualiti
agreement
accord
agre
standard
manufactur
sign
suppli
plasma
manufactur
requir
import
sinc
impact
cost
organ
oversight
includ
author
vigil
traceabl
inspect
blood
establish
wish
start
collect
sourc
plasma
manufactur
pdmp
mean
plasmapheresi
mode
oper
differ
gener
gmp
requir
also
requir
blood
compon
unfortun
guid
council
europ
gener
gmp
requir
defin
collect
sourc
plasma
suffici
address
might
interest
review
light
possibl
introduct
less
stringent
transfus
transmit
infect
tti
test
criteria
take
account
safeti
measur
taken
manufactur
process
pdmp
c
seidl
german
red
cross
blood
donor
servic
frankfurt
main
germani
background
audit
system
import
element
qualiti
manag
system
cover
part
oper
blood
establish
verifi
complianc
standard
regulatori
requir
serv
ideal
valuabl
tool
evalu
facil
qualiti
oper
system
aim
includ
risk
assess
qualiti
indic
process
product
implement
necessari
correctiveprevent
action
measur
assist
continu
qualiti
improv
ensur
safeti
qualiti
blood
blood
compon
eubi
european
blood
inspect
system
initi
public
health
programm
director
gener
sant
european
commiss
bring
togeth
regul
compet
author
manufactur
blood
establish
jointli
develop
criteria
standard
aim
assist
blood
establish
need
optimis
qualiti
system
process
prepar
regulatori
inspect
compet
author
method
standard
criteria
inspect
blood
establish
publish
eubi
manual
eubi
guid
structur
eubi
guid
follow
critic
aspect
qualiti
manag
address
order
achiev
goodbest
practic
qualiti
relat
critic
point
criterion
descript
exampl
evid
refer
relev
intern
standard
good
manufactur
practic
gmp
standard
pharmaceut
inspect
scheme
pic
good
practic
guidelin
gpg
council
europeedqm
relat
eu
direct
base
guid
risk
base
approach
audit
trail
includ
risk
assess
manag
easili
develop
systemat
fashion
cover
relev
activ
blood
establish
result
global
survey
carri
isbt
work
parti
qualiti
manag
indic
blood
establish
need
improv
system
audit
continu
improv
need
substanti
modif
improv
system
addit
strongli
regard
tool
prepar
qualiti
system
requir
regulatori
inspect
compris
besid
nation
legisl
includ
eu
direct
requir
set
gmp
pic
council
europ
consider
number
blood
establish
also
compli
regul
cover
tissu
cell
two
third
blood
establish
addit
compli
audit
perform
third
parti
subcontractor
institut
particular
focu
address
improv
made
document
handl
organis
personnel
job
descript
organogram
summaryconclus
self
inspect
continu
improv
import
element
establish
maintain
suffici
qualiti
manag
system
blood
establish
assess
risk
manag
implement
regulatori
requir
la
bust
africa
societi
blood
transfus
afsbt
cape
town
south
africa
background
global
survey
carri
isbt
qualiti
work
parti
indic
particip
blood
servic
fulli
integr
qualiti
manag
system
qm
area
identifi
requir
improv
document
intern
audit
handl
organis
personnel
job
descript
organogram
qualiti
awar
develop
countri
less
advanc
mani
initi
stage
qm
implement
discuss
develop
countri
often
limit
human
resourc
especi
regard
train
skill
personnel
poor
infrastructur
logist
lack
essenti
equip
regular
suppli
inadequ
govern
support
challeng
achiev
effect
qualiti
system
spite
obstacl
africa
societi
blood
transfus
afsbt
develop
accredit
programm
allow
countri
certifi
basic
intermedi
level
step
attain
full
accredit
step
accredit
assess
done
afsbt
standard
develop
conjunct
american
associ
blood
bank
aabb
team
intern
expert
standard
recent
revis
updat
accredit
process
begin
train
afsbt
standard
follow
baselin
assess
identifi
place
still
need
develop
action
plan
drawn
complet
prior
perform
progress
assess
order
formal
accredit
certif
assess
carri
step
assist
countri
prepar
accredit
afsbt
conduct
addit
train
rang
topic
well
manag
issu
team
forti
afsbt
educ
assessor
train
conduct
train
assess
addit
small
group
mentor
train
provid
coach
mentorship
websit
afsbt
provid
inform
qualiti
assist
countri
establish
qm
gener
sop
post
aspect
blood
transfus
chain
countri
use
exampl
gener
document
guidelin
also
provid
develop
organogram
job
descript
perform
risk
manag
draft
emerg
plan
guidelin
process
draft
conclus
approach
use
afsbt
extend
develop
countri
beyond
africa
enhanc
qualiti
awar
establish
effect
qm
accredit
programm
enabl
countri
start
basic
level
progress
rate
suit
circumst
lay
strong
foundat
futur
growth
major
challeng
assist
develop
countri
relat
sourc
adequ
fund
enhanc
human
resourc
capac
blood
servic
laboratori
medicin
univ
british
columbia
vancouv
canada
pathogen
inactiv
technolog
pi
use
blood
product
transfus
us
decad
mani
jurisdict
adopt
pi
either
fulli
part
treatment
blood
product
although
technolog
avail
treatment
either
platelet
concentr
plasma
yet
seen
consist
adopt
blood
safeti
technolog
present
review
statu
pathogen
inactiv
technolog
includ
hurdl
face
move
routin
use
discuss
gap
exist
understand
overcom
hurdl
numer
studi
support
effect
pi
kill
pathogen
although
differ
kill
effici
exist
among
differ
technolog
develop
date
underli
mechan
pi
kill
pathogen
human
blood
cell
plasma
protein
treat
product
also
affect
extent
process
extent
damag
vari
exact
process
type
cell
damag
platelet
appar
laboratori
analys
unclear
whether
matter
routin
clinic
use
platelet
studi
conduct
support
product
licensur
well
recent
clinic
trial
show
shorten
intertransfus
interv
concomit
increas
use
platelet
cours
treatment
increas
risk
signific
bleed
may
simpli
reflect
tradeoff
circul
resid
time
increas
safeti
transmiss
agent
use
technolog
current
formul
hurdl
adopt
pi
relat
either
fund
model
detail
process
well
concern
impact
pi
clinic
manag
patient
jurisdict
mandat
pi
treatment
plasma
platelet
fund
avail
howev
other
effort
seek
cost
offset
divert
resourc
pi
treatment
necessari
may
includ
optim
number
platelet
plasma
unit
treat
togeth
eg
treat
doubl
buffi
coat
pool
cessat
bacteri
test
certain
donor
screen
test
offset
current
configur
pi
technolog
system
limit
concentr
cell
maximum
volum
treat
intern
standard
around
exampl
platelet
concentr
finish
product
adapt
pi
jurisdict
complic
blood
oper
current
guard
band
around
platelet
concentrationvolum
mean
product
treat
kind
issu
eventu
get
sort
may
slow
implement
adopt
pi
technolog
jurisdict
clinic
trial
assess
safeti
efficaci
product
normal
conduct
stabl
patient
hypoprolif
thrombocytopenia
patient
receiv
prophylact
platelet
transfus
thalassemia
patient
receiv
chronic
rbc
support
concern
remain
possibl
addit
loss
efficaci
type
compon
given
trauma
patient
small
retrospect
studi
seem
support
concern
rigor
studi
remain
conduct
trauma
patient
receiv
larg
amount
blood
product
short
time
pi
remain
import
addit
blood
safeti
practic
addit
research
bring
comfort
gener
approach
n
j
van
c
j
van
der
j
van
rood
center
clinic
transfus
research
sanquin
research
clinic
epidemiolog
leiden
univers
medic
center
transplant
reaction
patient
trip
hemovigil
biovigil
offic
leiden
hematolog
haga
teach
hospit
hagu
donor
affair
sanquin
blood
bank
transfus
medicin
sanquin
blood
suppli
amsterdam
netherland
background
netherland
switch
progress
use
fresh
frozen
plasma
ffp
solventdeterg
treat
pool
plasma
expect
result
nation
switch
reduct
risk
trali
allerg
reaction
well
viral
prion
transmiss
despit
smaller
volum
unit
compar
ffp
unit
ml
vs
ml
number
transfus
plasma
unit
expect
remain
consist
patient
transfus
surgic
set
plasma
often
order
per
unit
rise
patient
treat
plasma
exchang
eg
ttphu
specif
plasma
volum
transfus
aim
compar
clinic
use
effect
safeti
plasma
transfus
netherland
period
surround
transit
method
collect
diagnost
data
transfus
episod
involv
plasma
transfus
six
dutch
hospit
along
nation
blood
bank
data
unit
distribut
dutch
hospit
nation
hemovigil
data
transfus
reaction
report
blood
product
transfus
period
stratifi
patient
hospit
type
ward
diagnost
code
compar
use
plasmarbc
unit
ratio
f
patient
receiv
ffp
vs
calcul
odd
ratio
or
compar
ffp
report
plasma
transfus
reaction
result
six
particip
hospit
collect
data
transfus
episod
involv
plasma
transfus
togeth
episod
involv
transfus
plasma
unit
ffp
rbc
unit
platelet
unit
code
uniqu
diagnost
code
transfus
episod
group
treat
ward
analysi
perform
three
subcohort
cardiothorac
surgeri
cardiolog
episod
gener
surgeri
gynecolog
transfus
episod
group
diagnosi
analysi
perform
addit
three
subcohort
cabg
valv
replac
maze
procedur
aneurysm
partu
cardiothorac
patient
mean
plasmarbc
unit
ratio
f
slightli
higher
ffp
cardiothorac
patient
fsd
fffp
fsd
fffp
confid
interv
ci
chang
observ
patient
group
nation
hemovigil
data
suggest
associ
reduc
risk
allerg
reaction
odd
ratio
p
febril
transfus
reaction
fnhtr
p
compar
ffp
summaryconclus
switch
ffp
netherland
lead
substanti
chang
clinic
use
effect
despit
differ
volum
two
product
though
plasmarbc
unit
ratio
increas
slightli
cardiothorac
patient
sd
plasma
associ
fewer
allerg
reaction
fnhtr
l
l
develop
australian
red
cross
blood
servic
core
facil
univers
technolog
sydney
medic
school
sydney
australia
background
altern
rt
storag
platelet
interest
increas
safeti
profil
compon
may
facilit
extens
platelet
pathogen
inactiv
pi
reduc
risk
pathogen
transmiss
separ
investig
ultraviolet
c
uvc
shown
two
storag
modal
differenti
affect
aspect
platelet
qualiti
aim
aim
studi
determin
impact
combin
vitro
platelet
qualiti
platelet
storag
method
pool
split
design
use
gener
platelet
four
studi
arm
rt
cold
n
arm
day
platelet
left
untreat
use
theraflex
system
macopharma
one
unit
pair
store
rt
refriger
vitro
qualiti
function
test
day
data
analys
use
anova
assess
combin
effect
treatment
storag
p
consid
signific
result
combin
treatment
reduc
platelet
glycolyt
metabol
pi
treatment
acceler
glucos
consumpt
compar
untreat
rt
platelet
whilst
cold
storag
opposit
effect
platelet
glucos
consumpt
rate
equival
cold
platelet
similar
result
observ
lactat
product
whilst
impair
hypoton
shock
respons
hsr
compar
rt
control
combin
pi
treatment
result
complet
abrog
respons
day
combin
pi
treatment
also
led
increas
externalis
phosphatidylserin
bind
activ
gpiibiiia
receptor
bind
level
seen
individu
treatment
aggreg
respons
adp
collagen
enhanc
platelet
compar
rt
group
primarili
mediat
rather
pi
treatment
summaryconclus
platelet
reduc
acceler
glycolyt
metabol
howev
combin
pi
result
addit
phenotyp
function
chang
compar
treatment
individu
work
requir
understand
whether
impact
chang
would
affect
clinic
efficaci
h
l
immunologytransfus
medicin
karolinska
univers
clinic
scienc
intervent
technolog
karolinska
institutet
stockholm
sweden
background
three
year
ago
karolinska
univers
hospit
switch
autom
product
buffi
coat
platelet
bcp
via
orbisac
product
system
terumo
bct
enhanc
bacteri
detect
system
ebd
pall
combin
irradi
safeti
measur
manual
product
bcp
combin
pathogen
inactiv
intercept
blood
system
intercept
ceru
corp
improv
safeti
bcp
cut
cost
howev
saw
potenti
improv
sinc
frequent
product
error
fluctuat
qualiti
wast
time
money
aim
aim
evalu
product
process
consecut
year
underw
differ
stage
develop
method
compar
blood
compon
qualiti
yearli
qualiti
control
n
safeti
product
cost
year
automatedebd
year
manualintercept
implement
year
manualintercept
undergo
improv
year
manualintercept
result
blood
compon
qualiti
implement
new
product
procedur
decreas
bcp
volum
ml
ml
compar
year
platelet
count
concomitantli
decreas
due
concentr
bcp
allow
bcp
fit
within
intercept
volum
limit
optimis
year
platelet
count
increas
render
total
platelet
count
decreas
mean
count
remain
unchang
optimis
finish
sd
decreas
demonstr
stabl
product
mirror
volum
chang
ml
fluctuat
manual
procedur
reflect
scrap
rate
year
stabilis
procedur
scrap
rate
reduc
even
lower
year
qualiti
plasma
rbc
remain
unaffect
throughout
entir
period
safeti
switch
product
system
allow
ratio
complet
safeti
measur
increas
ebd
b
intercept
optimis
reach
explain
shorter
overal
product
time
use
irradi
decreas
correspondingli
two
case
bacteri
sepsi
occur
last
month
preced
intercept
implement
wherea
case
observ
sinc
product
cost
chang
product
system
decreas
total
cost
year
optimis
cost
reduc
total
reduct
decreas
optimis
mainli
consequ
reduc
labour
cost
stabl
product
year
also
elimin
previou
need
extra
qualiti
control
implement
therebi
contribut
reduc
cost
summaryconclus
intercept
implement
greatli
improv
safeti
bcp
combin
manual
bcp
product
cost
per
unit
reduc
optimis
product
procedur
standardis
product
achiev
reduc
cost
qualiti
blood
compon
still
agreement
edqm
guidelin
although
admittedli
platelet
count
lower
switch
process
benefit
manual
process
detail
meticul
control
autom
process
show
proper
optimis
manual
process
give
bcp
less
fluctuat
content
autom
process
also
show
cut
cost
c
r
v
n
c
l
r
transfus
medicin
immunohaematolog
frankfurtmain
univers
frankfurt
frankfurt
germani
univers
izmir
turkey
cagliari
cagliari
torino
san
luigi
gonzaga
hospit
torino
itali
corpor
concord
unit
state
background
thalassemia
major
outcom
markedli
improv
chronic
red
blood
cell
rbc
transfus
combin
iron
chelat
therapi
treatment
carri
high
lifetim
risk
transfus
transmit
infect
blood
system
rbc
ceru
corpor
concord
ca
investig
devic
use
ex
vivo
prepar
rbc
compon
transfus
intercept
amustalin
glutathion
gsh
treatment
result
broad
spectrum
inactiv
virus
bacteria
protozoa
donor
leukocyt
prior
studi
use
first
gener
intercept
rbc
low
titer
antibodi
specif
adduct
detect
two
subject
multipl
studi
transfus
intercept
process
reformul
decreas
treatment
adduct
current
process
develop
aim
assess
use
rbc
screen
reagent
gel
column
assay
random
control
studi
evalu
intercept
rbc
thalassemia
major
patient
sparc
studi
method
rbc
screen
confirmatori
panel
gener
treatment
select
rbc
concentr
use
condit
similar
either
first
gener
intercept
process
high
adduct
mm
mm
gsh
current
process
low
adduct
mm
mm
gsh
left
untreat
control
adduct
assess
flow
cytometri
gel
column
agglutin
igg
lisscoomb
biorad
use
plasma
rbc
volum
accord
manufactur
recommend
rbc
screen
panel
previous
identifi
natur
occur
antibodi
intercept
rbc
gener
hospit
chronic
transfus
patient
subsequ
screen
panel
gel
column
assay
use
prior
transfus
episod
sparc
random
control
crossov
studi
evalu
intercept
rbc
thalassemia
major
subject
result
screen
gener
hospit
patient
chronic
transfus
patient
previous
expos
intercept
rbc
reveal
patient
respect
natur
occur
low
titer
igm
andor
igg
isotyp
antibodi
intercept
rbc
either
acridin
specif
sera
react
low
adduct
rbc
sparc
studi
subject
transfus
intercept
control
rbc
studi
product
hospit
orbassano
cagliari
itali
n
izmir
turkey
n
mean
subject
age
year
male
age
year
rbc
alloantibodi
subject
receiv
mean
rang
unit
test
control
rbc
transfus
episod
period
mean
transfus
interv
test
control
day
treatment
emerg
rbc
alloantibodi
antibodi
detect
time
studi
summaryconclus
describ
rbc
screen
panel
sensit
specif
reagent
detect
antibodi
intercept
rbc
thalassemia
major
patient
chronic
transfus
regimen
multipl
transfus
intercept
rbc
evok
antibodi
j
g
e
n
j
develop
australian
red
cross
blood
servic
care
research
group
princ
charl
hospit
medicin
univers
queensland
health
queensland
univers
technolog
brisban
australia
background
transfus
platelet
concentr
pc
therapi
use
control
prevent
bleed
cancer
haematolog
surgic
trauma
patient
howev
transfus
pc
associ
advers
outcom
transfus
relat
acut
lung
injuri
infect
mortal
pc
store
routin
room
temperatur
either
day
depend
countri
period
routin
storag
storag
lesion
includ
solubl
factor
protein
lipid
microparticl
develop
pc
may
contribut
advers
outcom
associ
transfus
absenc
randomis
control
trial
studi
possibl
associ
anim
model
crucial
improv
understand
aim
investig
whether
storag
durat
transfus
pc
contribut
reduc
respiratori
function
sheep
infect
model
method
standard
buffi
coat
pool
pc
n
obtain
australian
red
cross
blood
servic
pc
store
routin
either
day
n
supernat
sn
collect
pool
form
pool
pool
pool
pool
min
min
aliquot
frozen
sheep
n
anaesthet
mechan
ventil
oxygen
instrument
h
baselin
period
sheep
infus
h
period
lipopolysaccharid
lp
model
bacteri
infect
h
sheep
transfus
vv
either
n
n
n
h
period
follow
transfus
sheep
monitor
h
euthanis
underw
throughout
experi
arteri
blood
ga
sampl
collect
min
interv
use
measur
arteri
partial
pressur
oxygen
autom
analys
result
use
calcul
inspir
level
measur
respiratori
function
ratio
sheep
averag
across
baselin
pc
transfus
time
period
ratio
across
three
group
sheep
analys
anova
bonferroni
group
p
result
three
group
sheep
result
decreas
ratio
compar
baselin
p
p
p
group
respect
decreas
ratio
transfus
depend
upon
storag
durat
pc
evid
group
p
p
respect
summaryconclus
data
suggest
increas
storag
durat
transfus
pc
associ
reduc
respiratori
function
analys
eg
histolog
lung
section
requir
demonstr
whether
decreas
ratio
associ
develop
lung
injuri
data
also
implic
solubl
factor
present
pc
caus
agent
subsequ
studi
plan
identifi
agent
e
n
j
van
der
transfus
research
sanquin
research
univers
medic
center
leiden
univers
medic
centr
rotterdam
rotterdam
medic
center
amsterdam
research
leiden
netherland
background
one
main
goal
therapi
critic
care
medicin
obtain
adequ
tissu
oxygen
global
oxygen
deliveri
assess
monitor
cardiac
output
arteri
oxygen
content
cellular
oxygen
clinic
assess
yet
protoporphyrin
state
lifetim
techniqu
measur
mitochondri
oxygen
tension
vivo
may
earli
indic
oxygen
demand
cell
might
promis
new
monitor
cellular
compart
measur
obtain
optic
properti
protoporphyrin
ix
techniqu
valid
vivo
variou
tissu
anim
model
well
healthi
volunt
healthi
volunt
averag
valu
mmhg
aim
determin
feasibl
variabl
measur
critic
ill
patient
anaemia
method
prospect
includ
critic
ill
patient
admit
mix
intens
care
leiden
univers
medic
center
anaemia
red
cell
transfus
plan
multipl
predefin
moment
red
cell
transfus
assess
anterior
chest
wall
measur
perform
use
comet
monitor
photon
healthcar
utrecht
netherland
skin
prime
h
ala
contain
patch
alacar
photonam
wedel
germani
induct
mitochondri
ppix
report
valu
mean
consecut
measur
time
point
furthermor
hemodynam
paramet
arteri
venou
blood
sampl
determin
along
measur
result
measur
obtain
particip
like
due
excess
chlorhexidin
measur
site
measur
ratio
despit
sever
critic
ill
assess
via
apach
iv
score
rang
median
transfus
mmhg
interquartil
rang
overal
median
transfus
mmhg
iqr
mmhg
standard
deviat
measur
mmhg
first
hour
transfus
gradual
increas
mmhg
h
mmhg
h
two
patient
haemoglobin
concentr
gdl
median
increas
iqr
iqr
mmhg
transfus
patient
higher
haemoglobin
concentr
transfus
median
chang
iqr
vs
iqr
mmhg
p
median
heart
frequenc
chang
iqr
transfus
iqr
beat
per
minut
overal
transfus
likewis
mean
arteri
pressur
iqr
vs
iqr
mmhg
central
venou
pressur
iqr
vs
iqr
mmhg
central
venou
oxygen
satur
iqr
vs
iqr
gap
iqr
vs
iqr
kpa
show
chang
expect
summaryconclus
feasibl
measur
mitochondri
oxygen
tension
critic
ill
patient
measur
seem
reliabl
first
h
patch
remov
interestingli
higher
critic
ill
patient
seen
healthi
volunt
jg
van
der
f
le
h
c
j
van
rood
center
clinic
transfus
research
cctr
sanquin
blood
suppli
leiden
univers
medic
center
clinic
epidemiolog
medic
statist
care
leiden
univers
medic
center
leiden
netherland
background
intens
care
unit
percent
patient
receiv
red
blood
cell
transfus
random
trial
consist
shown
transfus
critic
ill
patient
hemoglobin
concentr
gdl
posit
effect
outcom
patient
compar
postpon
transfus
patient
hemoglobin
drop
gdl
controversi
remain
regard
translat
grade
evid
individu
critic
ill
patient
guidelin
advis
higher
hemoglobin
transfus
trigger
critic
ill
patient
ischem
heart
diseas
sepsi
traumat
brain
injuri
advic
creat
consider
undesir
transfus
practic
variat
aim
enabl
predict
possibl
effect
red
cell
transfus
organ
function
critic
ill
patient
take
account
relev
patient
characterist
hemoglobin
concentr
gdl
method
extract
data
hemoglobin
concentr
gdl
subsequ
transfus
decis
yesno
sequenti
organ
function
assess
sofa
score
correspond
clinic
variabl
electron
health
record
patient
admit
intens
care
unit
leiden
univers
medic
center
netherland
novemb
may
base
literatur
clinic
reason
select
characterist
might
modifi
andor
confound
associ
transfus
sofa
score
characterist
along
interact
term
transfus
yesno
enter
linear
regress
model
patient
sofa
score
depend
variabl
next
estim
effect
transfus
sofa
score
decis
moment
calcul
differ
predict
sofa
predict
sofa
score
without
transfus
result
cohort
compris
icu
admiss
critic
ill
patient
hemoglobin
valu
gdl
subsequ
red
cell
transfus
proport
patient
receiv
transfus
decreas
increas
hemoglobin
valu
hemoglobin
level
gdl
gdl
gdl
respect
mean
differ
sofa
score
without
transfus
adjust
measur
confound
confid
interv
strata
hemoglobin
valu
gdl
gdl
gdl
estim
effect
transfus
sofa
score
respect
summaryconclus
result
show
red
cell
transfus
associ
improv
organ
function
score
major
critic
patient
hemoglobin
valu
gdl
extern
valid
model
help
decid
whether
transfus
critic
ill
patient
anemia
r
e
z
epidemiolog
prevent
medicin
monash
univers
develop
australian
red
cross
blood
servic
box
hill
hospit
melbourn
monash
health
care
diseas
group
australasian
leukaemia
lymphoma
group
new
zealand
intens
care
research
centr
melbourn
australia
background
massiv
obstetr
haemorrhag
moh
defin
blood
loss
ml
pregnanc
puerperium
rise
incid
sever
develop
world
dilut
coagulopathi
thrombocytopenia
hyperfibrinogenaemia
perpetu
bleed
requir
prompt
correct
order
reduc
mortal
morbid
aim
better
defin
current
moh
transfus
manag
clinic
outcom
includ
differ
caus
moh
method
perform
cohort
studi
women
receiv
massiv
transfus
moh
use
australian
new
zealand
massiv
transfus
registri
moh
defin
week
gestat
requir
red
blood
cell
rbc
unit
within
h
caus
bleed
identifi
use
intern
classif
diseas
code
system
result
patient
australian
new
zealand
hospit
met
inclus
criteria
mode
deliveri
vagin
caesarean
section
emerg
elect
percent
occur
outsid
usual
work
hour
defin
weekend
well
weekday
six
patient
report
develop
amniot
fluid
embol
bleed
caus
includ
obstetr
trauma
n
uterin
atonyabnorm
forc
labour
n
placenta
praevia
n
type
morbidli
adher
placenta
n
caus
n
major
one
patient
document
caus
median
platelet
count
aptt
inr
upper
limit
normal
respect
h
caus
patient
placenta
praevia
type
morbidli
adher
placenta
highest
median
first
fibrinogen
level
gl
iqr
gl
iqr
respect
women
prolong
nadir
apttinr
nadir
platelet
count
respect
receiv
fresh
frozen
plasma
ffp
platelet
women
nadir
fibrinogen
gl
receiv
cryoprecipit
receiv
unit
median
ffp
rbc
ratio
iqr
h
h
respect
intens
care
unit
icu
admiss
andor
hysterectomi
occur
case
respect
analysi
emerg
caesarean
section
ci
placenta
praevia
ci
case
rbc
unit
transfus
first
cryoprecipit
unit
ci
found
independ
associ
increas
risk
hysterectomi
initi
inr
valu
ci
compar
inr
protect
icu
admiss
three
death
includ
one
due
amniot
fluid
embol
matern
mortal
ratio
mmr
therefor
per
women
summaryconclus
studi
one
largest
cohort
moh
describ
date
uterin
atoni
abnorm
adher
placenta
obstetr
trauma
common
caus
moh
ffp
platelet
like
transfus
cryoprecipit
patient
abnorm
haemostasi
paramet
moh
result
mortal
signific
morbid
includ
hysterectomi
associ
emerg
caesarean
section
placenta
praevia
later
administr
cryoprecipit
van
den
c
k
de
j
j
van
der
clinic
transfus
research
sanquin
research
clinic
epidemiolog
obstetr
leiden
univers
medic
center
leiden
obstetr
univers
medic
center
utrecht
utrecht
hematolog
erasmu
medic
center
rotterdam
thrombosi
hemostasi
leiden
univers
medic
center
leiden
netherland
background
postpartum
haemorrhag
major
caus
matern
morbid
incid
seem
increas
data
chang
coagul
paramet
cours
postpartum
haemorrhag
per
categoris
amount
blood
loss
limit
order
determin
optim
valu
initi
treatment
crucial
analys
pattern
coagul
paramet
chang
relat
blood
loss
identifi
women
diverg
pattern
increas
risk
sever
matern
outcom
aim
aim
studi
describ
chang
coagul
paramet
includ
fibrinogen
cours
postpartum
haemorrhag
per
categoris
amount
blood
loss
compar
level
coagul
paramet
earli
postpartum
haemorrhag
women
without
composit
sever
matern
outcom
method
nationwid
retrospect
cohort
studi
hospit
netherland
women
postpartum
haemorrhag
blood
loss
exceed
ml
within
first
h
childbirth
receiv
least
four
unit
red
cell
fresh
frozen
plasma
platelet
addit
red
cell
studi
women
coagul
paramet
avail
amount
blood
loss
time
blood
sampl
categoris
group
ml
ml
ml
ml
ml
ml
ml
ml
refer
categori
coagul
paramet
alloc
categori
repres
amount
blood
loss
sampl
main
outcom
measur
haemoglobin
haematocrit
platelet
count
fibrinogen
activ
partial
thromboplastin
time
aptt
prothrombin
time
pt
per
categoris
amount
blood
loss
postpartum
haemorrhag
composit
endpoint
matern
morbid
emerg
peripartum
hysterectomi
ligat
uterin
arteri
emerg
sutur
arteri
embol
admiss
intens
care
unit
mortal
result
women
cohort
averag
year
age
gave
birth
median
gestat
age
week
deliv
caesarean
section
uterin
atoni
primari
case
bleed
case
women
develop
composit
endpoint
sever
matern
morbid
mortal
haemoglobin
fibrinogen
show
decreas
trend
litr
blood
loss
level
stabil
gdl
gl
respect
rise
blood
loss
platelet
count
decreas
aptt
increas
pt
remain
unchang
low
level
fibrinogen
gl
prolong
aptt
earli
cours
bleed
l
blood
loss
associ
composit
outcom
women
develop
composit
outcom
matern
morbid
mortal
reach
fibrinogen
valu
gl
sporad
blood
loss
litr
summaryconclus
result
support
notion
fibrinogen
aptt
promis
candid
guid
target
haemostat
treatment
earli
phase
sever
postpartum
haemorrhag
l
k
toronto
medicin
michael
hospit
toronto
canada
medicin
st
michael
hospit
toronto
canada
background
massiv
transfus
protocol
mtp
wide
implement
rapidli
deliv
blood
product
bleed
trauma
patient
everi
minut
delay
blood
product
administr
associ
increas
mortal
improv
deliveri
therefor
critic
step
improv
patient
outcom
use
situ
simul
iss
novel
prospect
iter
approach
identifi
improv
upon
latent
safeti
threat
lst
impact
deliveri
actual
trauma
resuscit
aim
reduc
time
blood
deliveri
bleed
trauma
patient
use
iss
method
project
consist
twelv
iss
session
trauma
center
toronto
canada
situ
simul
mtp
activ
evalu
use
particip
human
factor
expert
observ
iss
session
three
major
lst
identifi
issu
mtp
activ
vari
transport
rout
porter
blood
bank
trauma
room
inadequ
priorit
blood
product
administr
process
improv
issu
test
subsequ
iss
session
implement
refin
made
impact
project
measur
retrospect
chart
review
januari
septemb
actual
trauma
patient
requir
mtp
case
categor
tempor
whether
occur
iss
qi
project
demograph
clinic
blood
bank
time
stamp
extract
medic
chart
trauma
blood
bank
registri
primari
outcom
product
administr
mtp
activ
result
case
review
met
inclus
criteria
prior
iss
qi
project
group
similar
demograph
data
trauma
characterist
injuri
sever
score
mean
deliveri
mtp
activ
decreas
min
sd
min
sd
min
sd
overal
rel
reduct
achiev
deliveri
follow
qi
intervent
p
summaryconclus
comprehens
qi
project
associ
reduct
deliveri
trauma
patient
situ
simul
repres
novel
approach
identif
lst
improv
relat
mtp
trauma
patient
methodolog
consid
part
qi
process
test
optim
mtp
blood
deliveri
bleed
trauma
patient
h
govern
servic
hospit
post
graduat
medic
institut
comsat
institut
inform
technolog
islamabad
pakistan
surveil
canadian
blood
servic
ottawa
canada
background
donor
health
assess
questionnair
dhaq
key
tool
blood
donor
select
reduc
risk
transfus
transmiss
infect
tti
ensur
safeti
donor
recipi
potenti
donor
must
answer
questionnair
accept
defer
basi
respons
standard
uniform
simpl
unambigu
cultur
accept
easi
complet
dhaq
ensur
collect
inform
potenti
donor
donat
use
throughout
countri
design
pilot
valid
implement
dhaq
respons
nation
blood
transfus
servic
bt
countri
redesign
questionnair
took
place
america
result
develop
new
uniform
donor
histori
questionnair
udhq
aabb
task
forc
format
fulli
base
cognit
scienc
principl
facilit
attent
comprehens
memori
bt
pakistan
consist
unorgan
isol
poorli
complet
unregul
blood
establish
own
public
privat
organ
ngo
sector
blood
centr
throughout
pakistan
develop
dhaq
without
follow
proper
standard
guidelin
nt
questionnair
perform
document
behavior
screen
govern
pakistan
initi
process
restructur
bt
follow
recommend
central
model
establish
safe
blood
transfus
programm
sbtp
first
phase
project
complet
construct
new
region
blood
centr
gradat
hospit
blood
bank
rbc
process
operation
phase
ii
start
propos
expans
scope
coverag
phase
concept
uncov
area
next
step
central
develop
udhq
requir
proper
uniform
donor
histori
assess
vital
part
transfus
safeti
nation
dhaq
base
cognit
scienc
principl
test
donor
comprehens
accept
need
hour
pakistan
ensur
blood
establish
adopt
uniform
behavior
screen
protocol
aim
highlight
need
uniform
donor
histori
questionnair
pakistan
methodolog
order
gain
understand
divers
dhaq
donor
criteria
current
place
throughout
pakistan
blood
transfus
centr
visit
dhaq
collect
question
ask
histori
take
process
observ
also
record
result
total
dhaq
collect
blood
transfus
servic
throughout
countri
dhaq
use
set
two
use
set
blood
transfus
servic
four
questionnair
english
languag
urdu
lowest
number
question
ask
questionnair
ten
highest
dhaq
uniqu
design
number
arrang
question
conclus
situat
analysi
first
step
develop
new
standard
uniform
dhaq
expect
prevent
tti
improv
transfus
safeti
countri
v
magutu
human
patholog
univers
nairobi
nairobi
kenya
malaria
one
common
transmiss
infect
transfus
pose
signific
challeng
blood
safeti
malaria
control
africa
diseas
endem
major
healthi
adult
live
region
degre
immun
diseas
asymptomat
parasitaemia
shown
exist
subset
popul
form
donor
pool
area
malaria
lead
caus
death
particular
aspect
malaria
control
blood
safeti
complic
inadequ
blood
suppli
result
mani
african
countri
includ
kenya
yet
adopt
world
health
organ
recommend
defer
donor
risk
malaria
exposur
anoth
recommend
poor
uptak
african
transfus
servic
screen
donat
blood
malaria
although
infecti
agent
readili
identifi
screen
assay
avail
differ
perform
characterist
resourc
logist
requir
may
advers
impact
blood
suppli
malaria
endem
area
introduc
routin
diagnost
test
use
kenyan
clinic
practic
microscop
examin
thick
blood
smear
rapid
malaria
antigen
detect
kit
may
suitabl
term
feasibl
sensit
detect
parasitaemia
asymptomat
donor
malaria
kenya
nation
blood
transfus
servic
recommend
use
prophylact
transfus
approach
attempt
safeguard
blood
suppli
allow
retent
unit
possibl
contain
parasit
theoret
prevent
transfus
transmit
malaria
circumv
sticki
issu
test
select
screen
document
antimalari
use
sulfadoxinepyrimethamin
sp
drug
current
reserv
prophylaxi
pregnanc
infanc
due
widespread
resist
efficaci
manag
ttm
therefor
question
altern
anecdot
evid
suggest
clinician
kenya
opt
presumpt
treatment
use
artemisinin
combin
therapi
act
instead
sp
kenyan
govern
implement
use
act
first
line
treatment
malaria
nation
polici
guid
use
reserv
laboratori
confirm
case
curb
rise
antimalari
resist
also
due
cost
artemisinin
combin
therapi
use
act
ttm
prophylaxi
therefor
contrari
polici
howev
lack
effect
altern
prophylact
option
signific
challeng
prophylaxi
realli
necessari
major
limit
prevent
ttm
kenya
actual
incid
known
recent
preval
studi
demonstr
signific
differ
preval
malaria
kenyan
blood
donor
compar
gener
popul
given
document
reduct
risk
malaria
infect
kenya
differenti
evid
base
polici
address
risk
ttm
kenya
weigh
feasibl
sustain
individu
control
measur
must
consid
b
z
l
b
el
center
diseas
control
bethesda
md
unit
state
nation
de
la
transfus
sanguin
pari
franc
system
research
institut
san
francisco
center
diseas
control
atlanta
ga
san
francisco
unit
state
background
previou
profici
test
studi
reveal
defici
viral
marker
screen
mani
african
blood
center
laboratori
recent
year
nation
intern
program
made
substanti
invest
format
nation
blood
transfus
servic
nbt
sever
african
countri
howev
unclear
whether
invest
improv
profici
test
viral
marker
aim
perform
contemporari
multin
profici
test
larg
sampl
african
blood
center
laboratori
compar
perform
accord
nbt
statu
nbt
vs
lab
accord
locat
lab
within
outsid
hospit
method
seven
african
countri
vari
level
extern
invest
nbt
includ
nbt
center
includ
laboratori
countri
chosen
randomli
stratif
number
blood
unit
collect
per
year
blind
panel
contain
pedigre
plasma
sampl
includ
posit
hbsag
well
pedigre
neg
ship
frozen
particip
laboratori
laboratori
perform
routin
test
algorithm
screen
hiv
hepat
b
c
virus
hbv
hcv
report
result
coordin
center
along
data
laboratori
test
algorithm
result
analyz
viral
marker
accord
sensit
specif
overal
perform
percent
correct
result
differ
test
gener
estim
equat
gee
result
seven
countri
particip
within
studi
time
frame
total
panel
ship
countri
laboratori
confirm
receipt
panel
return
laboratori
result
least
one
viral
marker
lab
report
hiv
sensit
lab
miss
posit
lab
miss
posit
lab
report
hbv
sensit
miss
posit
miss
posit
miss
posit
lab
report
hcv
sensit
lab
miss
posit
lab
miss
posit
lab
miss
posit
overal
specif
better
sensit
virus
sensit
significantli
p
higher
three
virus
nbt
vs
lab
howev
use
rapid
test
common
lab
also
associ
poor
sensit
p
lower
therefor
probabl
account
much
effect
better
profici
also
associ
higher
proport
donor
report
accredit
statu
particip
eqa
program
summaryconclus
profici
hiv
test
improv
sinc
previou
studi
profici
hbv
hcv
test
remain
poor
overal
larg
variat
lab
poor
profici
strongli
associ
statu
use
rapid
test
specif
remedi
measur
recommend
assess
provid
lab
poor
profici
v
p
abdallahi
p
g
oumar
rakoto
h
c
agent
institut
nation
de
la
transfus
sanguin
pari
franc
blood
center
nouakchott
mauritania
blood
center
bujumbura
burundi
blood
center
kinshasa
democrat
republ
congo
blood
center
bamako
mali
blood
center
antananarivo
madagascar
blood
center
niamey
niger
faculti
medicin
biomed
scienc
univers
cameroon
background
result
blood
screen
viral
infect
remain
issu
due
impact
blood
suppli
especi
countri
need
blood
alway
cover
blood
collect
aim
order
find
strategi
abus
discard
donat
studi
focus
hiv
hcv
conduct
estim
frequenc
reaction
observ
blood
screen
routin
seven
african
countri
method
total
blood
donat
test
hcv
hiv
collect
seven
african
countri
investig
burundi
cameroon
democrat
republ
congo
madagascar
mali
mauritania
niger
sampl
test
hcv
accord
countri
screen
rapid
test
rt
gen
enzym
immunoassay
eia
gen
eia
hiv
screen
rt
gen
eia
gen
eia
sampl
report
posit
hcv
n
hiv
n
investig
agab
assay
monolisa
hcvagab
ultra
genscreen
hivagab
biorad
immunoblot
ib
hcv
innogenet
geeniu
hiv
biorad
molecular
investig
confirm
infect
result
rate
hcv
reactiv
sampl
rt
significantli
lower
eia
vs
p
convers
provid
reactiv
result
eia
vs
gen
gen
assay
p
hcv
initi
reactiv
sampl
avail
retest
monolisa
reactiv
irrespect
type
assay
use
screen
test
posit
hiv
initi
reactiv
sampl
retest
genscreen
reactiv
signific
differ
accord
assay
use
screen
rt
eia
p
thirti
eight
avail
supplement
investig
ib
rna
neg
ib
indetermin
rna
neg
sampl
posit
neg
test
overal
repeatedli
posit
sampl
confirm
hiv
posit
account
retest
sampl
summaryconclus
hcv
hiv
reactiv
confirm
highli
sensit
eia
initi
reactiv
donat
respect
independ
type
primari
screen
assay
use
hcv
frequent
hiv
rapid
test
confirmatori
test
increas
rate
hiv
unconfirm
reactiv
find
underlin
need
confirmatori
strategi
avoid
blood
wastag
reevalu
viral
infect
preval
african
blood
donor
may
overestim
r
r
g
uj
clinic
immunolog
transfus
medicin
justu
liebig
univers
giessen
transfus
medicin
eberhard
karl
univers
tuebingen
biolog
chemistri
freseniu
hochschul
idstein
germani
background
immun
thrombocytopenia
itp
result
autoimmun
platelet
antigen
result
autoantibodi
aab
consid
repres
major
mechan
thrombocytopenia
itp
induc
platelet
clearanc
circul
sever
line
evid
demonstr
aab
glycoprotein
gp
iibiiia
ibix
predomin
itp
patient
diseas
sever
treatment
respons
rate
specif
therapeut
associ
aab
pattern
gp
v
immun
target
thrombocytopenia
never
studi
systemat
itp
aim
studi
presenc
v
antibodi
itp
predict
potenti
clinic
relev
method
patient
suspect
diagnosi
primari
itp
includ
met
clinic
inclus
criteria
presenc
gp
gp
ibix
gp
aab
investig
monoclon
antibodi
immobil
platelet
antigen
maipa
assay
patient
autolog
platelet
direct
maipa
serum
indirect
maipa
serum
igg
fraction
test
surfac
plasmon
reson
spr
technolog
presenc
v
aab
clearanc
human
platelet
circul
presenc
v
aab
studi
nodscid
mous
model
result
qualifi
patient
three
gp
specif
could
test
aab
detect
patient
v
aab
either
alon
togeth
specif
free
v
aab
detect
patient
indirect
maipa
spr
avid
aab
detect
method
n
significantli
higher
avid
aab
detect
spr
n
p
nodscid
mous
model
igg
prepar
type
v
aab
elimin
human
platelet
detect
differ
group
mean
platelet
surviv
min
rang
versu
rang
compar
platelet
clearanc
also
obtain
monoclon
antibodi
gp
v
summaryconclus
v
often
detect
platelet
itp
patient
studi
import
implic
develop
laboratori
test
guidanc
clinic
decis
make
comparison
maipa
spr
reveal
free
aab
may
frequent
report
sinc
aab
appear
escap
detect
standard
laboratori
method
low
affin
v
induc
platelet
clearanc
predict
diseas
sever
andor
tailor
itp
therapi
restrict
previous
postul
differ
iibiiia
ibix
prospect
studi
requir
understand
impact
differ
platelet
aab
clinic
cours
itp
k
c
c
k
k
g
j
b
hospit
north
norway
pharma
arctic
univers
north
norway
norway
red
cross
frankfurt
germani
univers
hospit
oslo
norway
univers
hospit
stockholm
sweden
univers
hospit
aalborg
denmark
region
laboratori
lund
sweden
amsterdam
univers
medic
center
leiden
netherland
background
preclin
studi
tiller
et
al
transfus
show
passiv
administr
antibodi
patern
platelet
antigen
induc
antibodi
mediat
immun
suppress
ami
prevent
clinic
complic
fetal
neonat
alloimmun
thrombocytopenia
fnait
mice
goal
larg
european
collabor
studi
profnait
develop
monitor
efficaci
well
safeti
hyperimmun
igg
naitgam
manufactur
femal
donor
prevent
postpartum
fnait
subsequ
pregnanc
aim
aim
part
profnait
project
collect
enough
plasma
manufactur
two
conform
lot
hyperimmun
igg
make
sure
collect
plasma
best
possibl
composit
regard
safeti
efficaci
method
donor
includ
hyperimmun
donor
program
either
identifi
screen
exist
donor
center
diagnos
patient
organ
naitbabi
naitbabiesorg
result
europ
total
femal
potenti
donor
identifi
germani
norway
sweden
major
donor
fnait
mother
n
refer
program
doctor
rest
potenti
donor
identifi
screen
neg
donor
german
red
cross
us
total
femal
plasma
donor
year
previou
pregnanc
screen
antibodi
ten
high
titer
donor
identifi
median
rang
antibodi
level
group
high
titer
donor
iuml
iuml
addit
total
women
fnait
mother
throughout
us
volunt
donat
howev
long
distanc
plasma
center
limit
number
donat
volunt
henc
us
opposit
europ
major
plasma
collect
screen
donor
among
donor
investig
one
identifi
antibodi
antibodi
donor
exclud
program
final
pool
donor
current
select
naitgam
product
n
none
antibodi
igg
andor
igg
final
pool
low
level
titer
detect
wherea
igg
titer
respect
glycosyl
profil
investig
differ
sialyl
fucosyl
pattern
isol
donor
identifi
screen
compar
isol
refer
donor
fnait
mother
howev
find
decreas
fucosyl
total
igg
hyperimmun
donor
compar
healthi
popul
final
identifi
decreas
galactosyl
isol
screen
group
compar
refer
group
summaryconclus
identifi
qualifi
posit
donor
success
includ
naitgam
donor
program
togeth
collect
l
l
high
titer
plasma
us
eu
donor
respect
q
f
j
g
r
z
blood
center
shanghai
china
school
medicin
mount
sinai
new
york
unit
state
quje
central
blood
station
quje
china
background
phagocyt
activ
accompani
erythrophagocytosi
thought
result
proinflammatori
cytokin
releas
two
differ
mechan
senesc
erythrocyt
clearanc
describ
phagocytosi
age
rbc
monocyt
mechan
term
unopson
opson
phagocytos
control
regulatori
protein
signal
pathway
immunoglobulin
g
igg
gamma
receptor
signal
pathway
respect
receptor
express
phagocyt
inhibit
phagocytosi
bound
erythrocyt
membran
low
express
age
rbc
subsequ
reduc
eat
signal
caus
rbc
clear
monocyt
age
rbc
also
form
band
cluster
subsequ
bind
antibodi
andor
complement
phagocytosi
rbc
induc
follow
ligat
receptor
nlr
famili
pyrin
protein
inflammasom
well
character
inflammasom
involv
control
activ
matur
secret
proinflammatori
cytokin
interleukin
il
aim
work
plan
disclos
whether
phagocytosi
age
rbc
would
activ
inflammasom
whether
suppress
activ
inhibitor
could
regul
erythrophagocytosi
method
cell
cultur
without
inhibitor
rbc
rhmod
sampl
use
low
express
rbc
treat
rbc
mark
rbc
erythrophagocytosi
determin
monocyt
monolay
assay
mma
live
cell
imag
system
proinflammatori
cytokin
express
determin
cytometr
bead
array
activ
inflammasom
test
digit
pcr
immunoblot
result
rbc
exhibit
highest
clearanc
rate
express
rhmod
rbc
lower
rbc
phagocytosi
rate
rhmod
rbc
much
lower
rbc
inflammasom
inhibitor
exist
cultur
system
phagocytosi
rate
test
rbc
downregul
addit
untreat
rbc
rbc
rbc
rhmod
rbc
could
trigger
activ
inflammasom
produc
proinflammatori
cytokin
tumor
necrosi
factor
also
could
decreas
inflammasom
inhibitor
summaryconclus
inflammasom
activ
age
rbc
clearanc
unopson
opson
pathway
phagocytosi
rate
age
rbc
decreas
inflammasom
inhibitor
rbc
clearanc
rate
show
posit
correl
express
proinflammatori
cytokin
downregul
addit
untreat
rbc
rbc
rbc
rhmod
rbc
could
trigger
activ
inflammasom
produc
proinflammatori
cytokin
tumor
necrosi
factor
also
could
decreas
inflammasom
inhibitor
sm
meindert
g
baker
van
wijk
b
beuger
j
geissler
van
den
berg
r
van
bruggen
depart
blood
cell
research
sanquin
research
landstein
laboratori
amsterdam
netherland
background
neutrophil
innat
immun
cell
first
respond
tissu
injuri
infect
particularli
well
known
function
nonetheless
neutrophil
versatil
cell
numer
function
includ
innat
adapt
immun
regul
increas
evid
indic
neutrophil
contribut
adapt
immun
influenc
antigen
specif
respons
certain
condit
neutrophil
shown
upregul
moreov
depend
condit
neutrophil
exhibit
antigen
present
function
aim
project
investig
antigen
present
capac
neutrophil
red
blood
cell
phagocytosi
method
measur
neutrophil
produc
burst
follow
rbc
phagocytosi
use
amplex
red
assay
dihydrorhodamin
assay
nitroblu
tetrazolium
assay
costimulatori
molecul
express
measur
use
flow
cytometri
western
blot
qpcr
addit
tetanu
toxoid
specif
cell
prolifer
assay
use
explor
capac
neutrophil
stimul
cell
prolifer
rbc
uptak
result
studi
show
neutrophil
express
costimulatori
molecul
follow
rbc
phagocytosi
follow
rbc
uptak
found
respiratori
burst
could
measur
neutrophil
acquir
antigen
present
cell
apc
characterist
tetanu
toxoid
model
neutrophil
proven
illicit
cell
respons
summaryconclus
rbc
uptak
neutrophil
induc
apc
phenotyp
neutrophil
find
could
suggest
neutrophil
play
unexpect
role
rbc
alloimmun
kuosmanen
toivonen
k
haimila
k
sulin
korhonen
sareneva
sainio
finnish
red
cross
blood
servic
helsinki
finland
background
fetal
rhd
test
week
gestat
target
routin
antenat
prophylaxi
raadp
week
women
carri
fetu
offer
rhd
neg
mother
finland
sinc
postnat
prophylaxi
still
administ
base
serolog
determin
newborn
rhd
statu
aim
aim
studi
assess
accuraci
fetal
rhd
test
week
gestat
evalu
whether
rhd
test
newborn
made
redund
method
prospect
cohort
studi
involv
matern
care
center
deliveri
hospit
finland
februari
decemb
fetal
rhd
genotyp
use
fetal
dna
matern
plasma
perform
polymeras
chain
reaction
central
set
result
systemat
compar
serolog
newborn
rhd
type
result
fetal
rhd
screen
women
three
twelv
result
report
deliveri
hospit
result
mostli
serolog
neg
rhd
variant
carri
fetu
result
report
unclear
due
rhd
variant
carri
mother
summaryconclus
data
first
year
fetal
rhd
test
finland
indic
mother
get
fals
neg
result
mean
fetal
rhd
test
result
use
target
postnat
prophylaxi
would
given
postnat
prophylaxi
although
give
birth
rhd
posit
child
rate
less
achiev
serolog
rhd
determin
newborn
report
high
accur
fetal
rhd
screen
test
allow
discontinu
newborn
test
without
risk
ca
h
e
g
g
r
g
develop
red
cross
blood
servic
fetal
medicin
mater
health
servic
brisban
australia
background
clinic
need
prenat
test
nipt
accur
assess
fetal
blood
group
antigen
statu
women
alloimmunis
atyp
blood
group
antigen
nipt
predict
blood
group
antigen
aris
singl
nucleotid
variat
snv
problemat
cf
dna
matern
plasma
domin
mother
genotyp
droplet
digit
pcr
ddpcr
permit
detect
rare
event
complex
sampl
partit
reaction
thousand
minimis
competit
effect
aim
establish
suitabl
ddpcr
platform
nipt
assess
fetal
blood
group
statu
antigen
aris
snv
method
droplet
digit
pcr
assay
develop
detect
snv
give
rise
red
cell
antigen
k
rhe
rhc
platelet
antigen
assay
design
encod
use
alleleid
softwar
publish
primer
probe
sequenc
use
rhc
rhe
cffdna
control
marker
sri
hypermethyl
genom
dna
plasma
cfdna
characteris
sampl
use
optimis
reaction
ddpcr
platform
alloimmunis
pregnant
women
enrol
inform
consent
blood
sampl
collect
edta
streck
bct
tube
current
sampl
subject
ga
rang
week
provid
fetal
n
rhe
n
rhc
n
n
assess
cfdna
prepar
matern
plasma
use
qiagen
protocol
ddpcr
ad
reaction
replic
cord
blood
phenotyp
amniocyt
genotyp
use
evalu
test
accuraci
result
optimis
demonstr
ddpcr
assay
could
perform
use
thermal
cycl
protocol
primer
probe
concentr
nm
nm
respect
detect
hypermethyl
bstui
digest
perform
directli
ddpcr
reaction
h
prior
amplif
contrast
h
use
pcr
case
test
six
show
fetal
signal
predict
k
antigen
fetal
detect
earli
ga
one
case
use
streck
bct
permit
fetal
fraction
estim
rhe
rhc
assay
fetal
signal
detect
earli
week
gestat
respect
second
sampl
concord
initi
find
use
control
marker
hypermethyl
sri
test
confirm
cffdna
present
case
correl
cord
blood
phenotyp
amniocyt
genotyp
current
avail
case
three
three
rhe
one
rhc
one
match
assay
predict
summaryconclus
studi
provid
ddpcr
reliabl
detect
cffdna
signal
detect
signal
earlier
gestat
compar
real
time
pcr
technolog
system
capac
run
assay
use
pcr
protocol
reduc
run
time
sampl
manipul
univers
fetal
dna
control
marker
assay
highlight
potenti
scalabl
practic
nich
area
refer
laboratori
test
mother
babi
children
theme
south
australian
health
medic
research
institut
research
institut
univers
adelaid
neonat
medicin
women
children
hospit
north
adelaid
australia
background
increas
uncertainti
potenti
benefit
harm
volum
expans
paediatr
adult
critic
care
set
feast
studi
found
increas
mortal
critic
ill
children
randomis
receiv
fluid
bolu
therapi
addit
increas
number
report
advers
effect
associ
rbc
transfus
neonat
includ
necrotis
enterocol
preterm
infant
week
gestat
particular
consid
vulner
volum
shift
chang
blood
pressur
due
uniqu
physiolog
potenti
neg
impact
volum
expans
may
effect
need
care
examin
aim
seri
review
studi
discuss
attende
method
advers
effect
red
blood
cell
transfus
neonat
systemat
review
intraven
fluid
bolus
benefici
neonat
suspect
haemodynam
compromis
structur
literatur
review
intern
observ
studi
characteris
current
practic
around
use
volum
expans
neonat
neobolu
studi
result
evid
support
use
fluid
bolu
therapi
late
preterm
term
infant
sign
haemodynam
compromis
without
evid
acut
haemorrhag
fluid
bolu
therapi
may
marker
ill
sever
clear
clinic
benefit
may
associ
advers
clinic
event
signific
differ
rang
harm
outcom
neonat
expos
restrict
liber
rbc
transfus
practic
found
howev
risk
bia
identifi
studi
lack
consist
report
definit
event
limit
conclus
review
neonat
receiv
bolu
elig
patient
day
neonat
unit
across
australia
canada
europ
new
zealand
usa
preval
type
fluid
bolu
therapi
vari
centr
admit
neonat
per
day
pool
preval
rate
confid
interv
summaryconclus
clear
need
prospect
trial
neonat
evalu
use
volum
expans
blood
product
crystalloid
result
top
ettno
await
may
provid
addit
insight
potenti
benefit
harm
commonli
use
therapi
neonat
need
address
r
r
g
transfus
medicin
paediatr
govern
medic
colleg
hospit
chandigarh
chandigarh
india
background
convent
pack
red
blood
cell
rbc
transfus
volum
given
neonat
mlkg
mlkg
weight
base
formula
underestim
volum
prbc
requir
achiev
target
haemoglobin
hb
hematocrit
hct
preterm
neonat
aim
studi
done
compar
rise
hct
transfus
prbc
volum
calcul
either
base
bodi
weight
use
formula
consid
hct
bag
hct
preterm
neonat
method
prospect
studi
includ
total
preterm
neonat
requir
transfus
first
time
week
gestat
age
neonat
random
use
block
random
receiv
either
group
mlkg
pack
red
blood
cell
transfus
group
transfus
base
formula
group
b
volum
prbc
ml
desir
hct
initi
hcthct
bag
x
blood
volum
neonat
ml
maximum
volum
blood
given
babi
group
b
exceed
beyond
mlkg
primari
outcom
interest
rise
hematocrit
h
transfus
secondari
outcom
effect
transfus
short
term
hemodynam
transfus
effect
neonat
morbid
term
retinopathi
prematur
dysplasia
intraventricular
hemorrhag
periventricular
leukomalacia
necrot
enterocol
death
result
mean
birth
weight
mean
gestat
age
gram
week
mean
apgar
score
min
respect
baselin
variabl
birth
weight
gestat
age
apgar
score
matern
anemia
compar
group
two
group
similar
sick
level
mean
snap
score
score
neonat
acut
physiolog
compar
group
vs
p
sampl
loss
group
b
vs
p
hematocrit
bag
compar
group
vs
p
mean
volum
pack
rbc
group
ml
wherea
group
b
ml
p
total
number
donor
babi
expos
day
transfus
also
compar
two
group
two
group
hemodynam
compar
hr
rr
requir
mode
ventil
blood
pressur
hematocrit
valu
prior
transfus
post
transfus
group
receiv
transfus
per
formula
group
b
statist
signific
chang
hr
post
transfus
hematocrit
vs
p
need
decreas
group
b
secondari
outcom
rop
bpd
ivh
pvl
nec
death
also
compar
two
group
babi
group
group
b
die
summaryconclus
post
transfus
rise
hct
patient
group
b
signific
compar
group
need
decreas
group
b
despit
transfus
volum
blood
r
mb
van
c
ro
ge
wh
health
develop
center
pediatr
child
health
makerer
univers
colleg
health
scienc
kampala
uganda
global
health
emma
children
hospit
academ
medic
centr
univers
amsterdam
amsterdam
netherland
white
center
pediatr
infecti
diseas
global
health
indiana
univers
school
medicin
indiana
unit
state
health
develop
center
makerer
univers
colleg
health
scienc
kampala
uganda
patholog
transfus
harvard
universitymassachusett
gener
hospit
boston
unit
state
background
blood
transfus
common
emerg
treatment
children
sever
anaemia
save
million
children
africa
howev
belief
percept
transfus
recipi
region
well
document
yet
may
influenc
behaviour
aim
describ
local
percept
paediatr
blood
transfus
uganda
method
qualit
studi
base
interview
children
transfus
sever
anaemia
six
focu
group
discuss
commun
member
conduct
three
region
buganda
busoga
bunyoro
uganda
octob
novemb
themat
analysi
support
atlasti
softwar
use
code
organ
track
segment
data
result
commun
member
alik
held
blood
transfus
high
regard
valu
howev
strong
reserv
transfus
widespread
fear
misconcept
commun
member
fear
hiv
transmiss
child
question
use
blood
health
worker
routin
drew
person
treatment
concern
potenti
foul
play
malici
health
worker
other
suspici
child
may
transfus
blood
anim
could
result
child
behaviour
becom
wild
major
awar
blood
group
incompat
perceiv
fatal
believ
blood
donor
could
stronger
recipi
reason
latter
child
sick
report
frequent
discourag
peopl
claim
children
got
transfus
would
alway
requir
blood
transfus
time
got
sick
challeng
regard
access
transfus
servic
report
includ
distant
inaccess
hospit
scarciti
blood
hospit
especi
group
blood
well
tabl
cost
concern
besid
belief
receiv
blood
child
fed
belief
minim
howev
care
practic
includ
avoid
rain
bath
warm
water
avoid
heat
sun
fire
common
report
passion
summaryconclus
commun
member
children
sever
anaemia
uganda
regard
blood
transfus
highli
howev
safeti
concern
hiv
transmiss
blood
incompat
plu
knowledg
gap
commun
result
suspicion
blood
scarciti
coupl
poor
access
major
challeng
blood
transfus
uganda
risk
live
mani
children
im
r
van
der
de
e
leiden
univers
medic
center
transfus
research
sanquin
research
epidemiolog
transfus
research
blood
transfus
leiden
univers
medic
center
leiden
diagnost
sanquin
research
amsterdam
netherland
background
neonat
hemolyt
diseas
fetu
newborn
hdfn
due
red
cell
alloimmun
often
requir
red
blood
cell
transfus
treat
late
anemia
first
month
life
aim
aim
quantifi
need
postnat
red
cell
transfus
neonat
treat
intrauterin
transfus
design
risk
model
predict
late
anemia
method
observ
studi
data
collect
medic
record
term
neonat
week
gestat
hdfn
due
matern
red
cell
alloimmun
admit
leiden
univers
medic
center
lumc
januari
decemb
treatment
postnat
red
cell
transfus
number
transfus
number
day
birth
first
transfus
given
record
well
test
result
concern
potenti
risk
factor
result
neonat
treat
one
intrauterin
transfus
receiv
postnat
transfus
compar
neonat
treat
intrauterin
transfus
p
median
number
postnat
transfus
per
neonat
slightli
higher
group
treat
intrauterin
transfus
iqr
compar
iqr
intrauterin
transfus
group
p
median
time
birth
transfus
day
intrauterin
transfus
group
compar
day
without
intrauterin
transfus
p
multivari
predict
model
treatment
intrauterin
transfus
p
treatment
exchang
transfus
p
strongest
predictor
postnat
transfus
summaryconclus
treatment
intrauterin
transfus
strongli
associ
increas
risk
late
anemia
postnat
transfus
children
hdfn
exchang
transfus
strongli
associ
lower
risk
postnat
transfus
c
g
h
n
j
r
g
du
pediatr
chu
center
chu
montreal
canada
background
given
recent
result
mani
random
control
trial
advoc
restrict
approach
transfus
therapi
transfus
practic
target
hemoglobin
level
gl
increasingli
follow
pediatr
intens
care
unit
picu
chu
hospit
chusj
adher
strictli
recommend
one
lowest
proport
transfus
critic
ill
children
north
america
consequ
hypothes
chusj
larg
proport
picu
survivor
anem
picu
discharg
aim
determin
incid
anemia
picu
discharg
method
retrospect
cohort
studi
consecut
picu
survivor
tertiari
care
pediatr
hospit
patient
characterist
last
hemoglobin
level
prior
picu
discharg
collect
use
electron
medic
record
databas
intellispac
critic
care
anesthesia
philip
medic
system
royal
philip
electron
netherland
hb
level
measur
part
complet
blood
count
anemia
defin
per
canadian
blood
servic
cb
diagnost
criteria
result
januari
januari
patient
admit
chusj
picu
surviv
picu
discharg
includ
studi
children
nt
receiv
red
blood
cell
transfus
picu
stay
overal
survivor
found
anem
prior
picu
discharg
proport
anem
children
vari
age
n
infant
day
age
hb
gl
infant
age
day
month
hb
gl
infant
age
month
hb
gl
infant
age
month
hb
gl
children
age
month
year
hb
gl
children
age
year
hb
gl
children
year
old
hb
gl
p
annual
overal
proport
anem
children
remain
stabl
year
summaryconclus
larg
proport
picu
survivor
anem
picu
discharg
could
result
adher
restrict
transfus
threshold
consequ
anemia
children
unknown
need
investig
specif
paramount
determin
impact
anemia
neurodevelop
children
year
age
c
univers
hospit
compani
sun
ii
di
napoli
itali
napoli
itali
blood
donor
usual
toler
donat
well
advers
reaction
variabl
sever
may
occur
end
blood
collect
advers
reaction
divid
local
reaction
system
reaction
local
reaction
occur
relat
venou
access
ie
hematoma
due
extravas
vein
pain
hyperemia
swell
may
develop
site
extravas
howev
also
trauma
subcutan
nerv
end
final
phlebiti
thrombophleb
rare
contrast
system
reaction
divid
mild
sever
event
relat
vasovag
reaction
trigger
pain
venipunctur
anxieti
undergo
donat
system
reaction
becom
clinic
evid
appear
pallor
sweat
gastrointestin
disord
hypotens
bradycardia
syncop
variabl
sever
may
may
complic
onset
muscl
spasm
accompani
vomit
loss
sphincter
control
system
reaction
occur
also
apheresi
procedur
requir
use
anticoagul
acd
compound
caus
hypocalcaemia
chelat
lower
concentr
calcium
ion
lead
episod
paraesthesia
lip
oral
caviti
limb
symptom
resolv
interrupt
apheresi
procedur
well
administr
calcium
glucon
sever
rare
clinic
condit
may
includ
complex
ventricular
arrhythmia
convuls
death
thu
medic
doctor
involv
blood
donat
must
train
prevent
treat
advers
event
townsend
corpor
medic
affair
blood
system
scottsdal
unit
state
routin
phlebotomi
whether
whole
blood
apheresi
collect
larg
calib
needl
insert
antecubit
space
although
target
vein
interest
superfici
locat
within
fossa
deeper
structur
risk
struck
advanc
needl
includ
arteri
nerv
muscl
tendon
needl
need
caus
direct
injuri
underli
structur
order
produc
pain
secondari
inflamm
irrit
structur
may
also
induc
pain
involv
deeper
structur
within
fossa
may
result
unusu
rare
advers
event
sometim
devast
consequ
object
session
describ
common
advers
event
secondari
needl
insert
describ
rare
advers
event
includ
rate
typic
present
provid
insight
particip
hemovigil
program
may
assist
identif
needl
relat
advers
event
h
vrielink
see
abstract
r
e
r
c
practition
ijsselland
hospit
capel
ad
ijssel
netherland
practition
hemovigil
uz
leuven
leuven
belgium
transfus
practition
great
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
matter
transfus
nurs
depart
health
human
servic
australian
red
cross
blood
servic
victoria
australia
background
disast
natur
industri
accid
terror
plan
involv
coordin
multidisciplinari
approach
defin
document
specif
task
respons
requir
deal
situat
healthcar
provid
must
plan
unexpect
event
might
affect
servic
plan
ensur
appropri
blood
compon
locat
administ
time
safe
manner
requir
treatment
need
ongo
suppli
avail
disast
plan
event
could
influenc
blood
suppli
undertaken
highest
level
govern
right
individu
laboratori
small
hospit
includ
transfus
practition
tp
expert
knowledg
transfus
chain
provid
valuabl
input
plan
implement
review
disast
plan
aim
describ
role
tp
may
undertak
multidisciplinarymultimod
team
plan
implement
review
disast
plan
method
context
tp
primari
role
promot
safe
appropri
use
blood
within
hospit
includ
extraordinari
event
internalextern
disast
role
could
localis
across
whole
health
servic
broader
includ
liaison
blood
provid
govern
plan
includ
respons
intern
extern
event
includ
variat
role
respons
relat
tp
would
normal
consid
part
respons
team
unless
work
howev
import
role
ensur
plan
develop
understood
plan
event
tp
provid
valuabl
insight
inform
import
mandatori
patient
safeti
issu
guidelinesstandard
requir
set
patient
identif
logist
movementstoragehandl
commun
channel
promot
implement
plan
key
role
tp
educ
includ
dedic
session
simul
expect
laboratori
disast
blood
would
provid
ideal
simul
would
involv
associ
staff
nursinglaboratorymed
play
test
scenario
tp
assist
staff
understand
outcom
session
address
issu
might
aris
peopl
may
think
disast
someth
occur
outsid
health
servic
disast
intern
failur
system
fire
laboratori
cut
usual
blood
supplier
affect
abil
laboratori
provid
appropri
blood
patient
tp
along
laboratori
staff
advoc
type
scenario
includ
disast
plan
may
includ
liaison
health
servic
blood
supplier
result
summaryconclus
transfus
practition
role
plan
disast
tp
skill
bring
togeth
knowledg
enabl
knowledg
convert
practic
also
play
key
role
collect
inform
evalu
disast
plan
collabor
broader
team
ensur
safe
appropri
use
avail
blood
suppli
time
l
c
l
de
matter
depart
health
human
servic
victoria
australian
red
cross
blood
servic
melbourn
australia
stock
manag
scheme
nation
health
servic
blood
transplant
london
unit
kingdom
region
blood
coordin
network
toronto
canada
background
blood
blood
compon
lifesav
howev
suppli
limit
reli
dedic
donor
countri
product
limit
must
use
appropri
store
handl
correctli
prevent
wast
transfus
blood
identifi
one
therapi
much
inappropri
transfus
practition
tp
includ
known
transfus
nurs
transfus
safeti
offic
haemovigil
offic
patient
blood
manag
pbm
coordin
key
aspect
role
drive
influenc
clinic
blood
manag
activ
help
align
practic
intern
recognis
guidelin
standard
includ
minimis
wast
wast
includ
inappropriateov
use
along
compon
wast
due
handl
storag
error
inadequ
inventori
manag
aim
describ
tp
role
strategi
use
minimis
blood
wastag
context
tp
play
fundament
role
within
multidisciplinari
team
implement
support
review
practic
minimis
blood
wast
assist
provid
safe
transfus
practic
use
audit
measur
report
inappropri
use
often
facilit
implement
strategi
minimis
strategi
includ
restrict
transfus
practic
appropri
patient
group
use
singl
unit
transfus
stabl
nonbleed
patient
promot
pbm
strategi
anaemia
manag
minimis
transfus
surgic
set
encourag
practic
group
hold
rather
crossmatch
help
reduc
inventori
stock
hold
discourag
use
product
educ
support
use
establish
maximum
surgic
blood
order
schedul
tp
work
close
laboratori
staff
often
act
liaison
laboratori
clinic
area
support
practic
minimis
potenti
wast
promot
import
cold
chain
manag
time
return
compon
use
laboratori
practic
regular
inventori
review
use
electron
decis
make
order
tool
electron
crossmatch
minimis
potenti
wast
tp
play
key
role
help
broader
clinic
commun
understand
process
import
hub
spoke
principl
use
blood
manag
movement
tpor
equival
work
close
laboratori
educ
audit
practic
result
unit
kingdom
uk
blood
stock
manag
scheme
canadian
choos
wise
promot
utilis
best
practic
recommend
australian
blood
wastag
reduct
strategi
focu
optimis
appropri
blood
use
minimis
potenti
wast
multidisciplinari
intervent
produc
mani
tool
resourc
assist
laboratori
health
servic
measur
monitor
activ
minimis
wast
reduc
wast
laboratori
staff
tp
collabor
reduc
red
cell
wast
victoria
australia
uk
seen
wastag
rate
stabilis
summari
minimis
unnecessari
blood
wast
essenti
sustain
blood
suppli
requir
team
approach
tp
play
activ
crucial
role
implement
support
strategi
across
clinic
spectrum
howel
ontrac
program
st
michael
hospit
toronto
canada
ontrac
program
success
patient
blood
manag
pbm
network
ontario
canada
fund
ontario
ministri
health
long
term
care
form
program
pbm
coordin
hospit
site
across
provinc
hospit
includ
teach
commun
hospit
coordin
interact
physician
nurs
staff
patient
promot
patient
blood
manag
altern
allogen
transfus
target
procedur
includ
knee
hip
surgeri
cardiac
surgeri
gynecolog
procedur
mani
procedur
follow
transfus
rate
decreas
markedli
sinc
onset
exampl
mean
provinci
transfus
rate
knee
surgeri
onset
accompani
lower
stay
infect
rate
program
enhanc
patient
safeti
satisfact
whilst
time
cost
effect
n
gleadal
abstract
avail
c
j
j
p
h
clinic
transfus
medicin
immunogenet
ulm
german
red
cross
blood
servic
hessen
institut
transfus
medicin
ulm
univers
ulm
transfus
medicin
immunolog
heidelberg
univers
medic
faculti
mannheim
german
red
cross
blood
servic
hessen
mannheim
germani
background
preemptiv
extend
phenotyp
blood
donor
time
consum
expens
next
gener
sequenc
ng
techniqu
enabl
investig
mani
genet
loci
polymorph
larg
number
individu
parallel
ng
well
establish
human
leukocyt
antigen
hla
stem
cell
donor
may
also
use
type
blood
donor
aim
develop
amplicon
base
target
sequenc
panel
parallel
type
donor
miseq
system
illumina
method
primer
pair
design
amplif
genom
region
encompass
polymorph
site
blood
group
system
mn
kel
fy
jk
lu
yt
co
di
sc
lw
jr
lan
vel
addit
two
sequenc
within
exon
exon
respect
rhce
gene
includ
order
screen
rhce
variant
multiplex
polymeras
chain
reaction
pcr
gener
contain
primer
pair
second
pcr
result
amplicon
extend
indic
donor
identif
adapt
data
analysi
rbioconductor
pipelin
use
programm
call
blood
group
defin
base
specifi
posit
target
sequenc
report
genotyp
well
predict
phenotyp
result
dna
sampl
type
parallel
total
pcr
amplicon
first
level
sequenc
process
final
reaction
fail
result
low
coverag
ie
number
final
amplicon
use
data
analysi
data
analysi
number
amplicon
requir
reliabl
allel
call
set
typic
run
howev
coverag
rang
amplicon
sampl
type
earlier
taqman
genotyp
assay
compar
result
discrep
allel
call
found
discrep
result
due
poor
amplif
sequenc
gene
requir
adjust
primer
concentr
primari
multiplex
pcr
addit
lu
fy
yt
allel
fals
due
coverag
near
discrep
vel
genotyp
discrep
yt
genotyp
found
correctli
type
new
ng
method
discrep
fy
genotyp
shown
sanger
sequenc
caus
new
allel
recognis
ng
type
fals
fy
taqman
method
summaryconclus
type
blood
donor
parallel
one
run
possibl
use
illumina
techniqu
newli
develop
test
panel
found
suitabl
reliabl
cost
effect
present
setup
panel
test
frequent
allel
eg
system
mn
kel
fy
jk
also
screen
rare
allel
null
allel
eg
system
vel
jr
lan
easili
customis
addit
new
allel
remov
unwant
allel
w
h
j
j
l
c
brigham
women
hospit
medic
school
york
blood
center
new
york
unit
state
background
abo
type
recipi
donor
import
optim
transfus
transplant
outcom
although
serolog
abo
type
highli
reliabl
limit
discord
forward
revers
type
especi
weak
antigen
abo
subtyp
hybrid
enzym
activ
addit
live
solid
organ
stem
cell
donor
evalu
often
involv
buccal
swab
dna
isol
thu
prevent
upfront
serolog
abo
type
combin
dna
base
genotyp
solut
ssp
sequenc
etc
use
help
resolv
serolog
abo
discord
well
screen
transplant
donor
abo
method
requir
interpret
subject
matter
expert
aim
sought
develop
target
abo
next
gener
sequenc
ng
assay
along
companion
interpret
softwar
autom
data
process
abo
type
known
abo
allel
method
target
long
rang
pcr
base
dna
enrich
abo
gene
achiev
evalu
seri
pcr
primer
combin
use
blood
buccal
swab
isol
dna
pcr
product
run
agaros
gel
agil
bioanalyz
determin
product
size
qualiti
promis
pcr
product
underw
illumina
trusight
ng
librari
prepar
sequenc
use
illumina
miseq
previous
creat
curat
allel
databas
http
bloodantigenscom
custom
bloodtyp
interpret
softwar
determin
blood
group
whole
genom
sequenc
data
improv
previou
effort
curat
abo
allel
ad
ng
sequenc
read
base
cistran
phase
bloodtyp
softwar
determin
full
abo
allel
haplotyp
result
pcr
primer
evalu
show
reproduc
pcr
product
span
abo
exon
blood
sampl
buccal
swab
yield
good
qualiti
ng
data
exon
encod
major
abo
specif
includ
abo
subtyp
ax
weak
antigen
aweak
ael
hybrid
allel
cisab
b
verifi
abo
ng
assay
combin
blood
buccal
swab
sampl
test
found
concord
serolog
abo
type
sanger
sequenc
weak
subtyp
hybrid
allel
sampl
found
case
target
abo
ng
result
could
fulli
resolv
cistran
phase
genotyp
allow
unambigu
allel
determin
interpret
softwar
summaryconclus
target
abo
ng
base
assay
develop
optim
blood
buccal
swab
isol
dna
companion
interpret
softwar
autom
ng
abo
analysi
develop
correctli
determin
abo
type
compar
serolog
sanger
sequenc
assay
softwar
interpret
repres
new
improv
standard
dna
base
abo
test
allow
abo
type
blood
sampl
avail
resolut
weak
subtyp
hybrid
abo
allel
w
g
refer
laboratori
bloodcent
wisconsin
patholog
medic
colleg
wisconsin
research
institut
versitibloodcent
wisconsin
milwauke
unit
state
background
high
throughput
genotyp
revolution
routin
access
antigen
neg
donor
red
blood
cell
unit
develop
larg
donor
databas
present
uniqu
opportun
map
genet
variat
red
blood
cell
antigen
time
locat
rare
pocket
antigen
neg
donor
guid
locat
mobil
fix
donat
site
aim
data
mine
larg
genotyp
donor
databas
provid
analyt
common
rare
donor
region
method
donor
red
blood
cell
genotyp
via
molecular
type
januari
decemb
collat
data
pertain
donor
address
age
gender
ethnic
date
donat
genotyp
antigen
distanc
donat
site
socioeconom
statu
cite
barrier
donat
minor
appli
geoloc
data
visual
donor
assess
factor
affect
local
donor
data
categor
age
ethnic
visual
sum
donor
zip
code
identifi
local
region
trend
rare
blood
donor
includ
poverti
index
educ
percent
individu
live
resid
year
data
visual
map
microsoft
excel
map
creat
bing
map
donor
extract
popul
data
superimpos
geograph
map
zip
code
result
year
donor
genotyp
age
group
frequent
donor
percent
donor
male
frequenc
abo
group
follow
expect
rel
incid
b
ab
caucasian
repres
largest
ethnic
group
follow
african
american
hispan
asian
nativ
american
donor
report
address
center
wisconsin
address
identifi
donor
everi
us
state
european
countri
rare
donor
frequenc
younger
donor
cluster
within
specif
us
zip
code
high
volum
african
american
hispan
minor
surround
caucasian
donor
rare
minor
donor
gave
averag
unit
compar
unit
rare
caucasian
donor
median
household
incom
rare
donor
common
donor
equival
howev
educ
length
occup
home
differ
rare
donor
regardless
ethnic
averag
high
school
educ
common
donor
averag
colleg
educ
rare
donor
averag
occupi
home
year
compar
year
common
donor
summaryconclus
larg
metropolitan
us
citi
tend
toward
ethnic
segreg
popul
mani
african
american
hispan
young
rare
donor
repres
minor
donor
live
defin
zip
code
surround
predomin
older
caucasian
recruit
donor
enrich
inventori
rare
blood
type
tailor
particular
zip
code
focu
recruit
retain
young
donor
j
van
h
n
van
ce
van
der
technolog
assess
sanquin
research
amsterdam
healthcar
oper
improv
research
oper
research
univers
twent
ensched
immunohematolog
sanquin
research
laboratori
academ
medic
center
univers
amsterdam
amsterdam
netherland
background
red
blood
cell
alloimmun
one
import
advers
event
may
occur
result
antigen
incompat
blood
transfus
alloimmun
reduc
match
donor
transfus
recipi
larg
number
antigen
current
prevent
match
strategi
appli
patient
group
includ
limit
number
antigen
howev
ultim
ambit
might
find
extens
match
red
blood
cell
unit
transfus
recipi
select
extens
type
unit
inventori
requir
entir
donor
popul
type
larg
number
antigen
one
way
achiev
genotyp
entir
donor
popul
might
becom
afford
near
futur
aim
goal
studi
investig
proport
alloimmun
prevent
depend
size
inventori
donor
popul
comprehens
genotyp
method
multipl
inventori
size
match
strategi
popul
likelihood
extens
type
red
blood
cell
unit
avail
inventori
quantifi
likelihood
depend
antigen
distribut
donor
patient
popul
match
strategi
appli
moreov
base
exist
literatur
immunogen
specif
antigen
differ
popul
proport
alloimmun
event
prevent
comput
result
inventori
size
small
hospit
unit
larg
hospit
unit
academ
hospit
unit
distribut
center
unit
match
strategi
differ
antigen
ie
abo
rh
kell
duffi
kidd
ss
result
obtain
mathemat
model
demonstr
european
patient
popul
european
donor
popul
proport
alloimmun
prevent
equal
stock
stock
stock
stock
african
patient
european
donor
popul
proport
respect
increas
proport
african
donor
limit
effect
decreas
alloimmun
event
summaryconclus
donor
becom
fulli
genotyp
allow
identif
rare
donor
also
enabl
extens
prevent
match
transfus
recipi
much
bigger
scale
current
anticip
impli
alloimmun
reduc
substanti
prevent
problem
pregnanc
subsequ
transfus
sauleda
transfus
safeti
laboratori
banc
de
sang
teixit
barcelona
spain
blood
safeti
reli
sever
action
differ
natur
combin
throughout
donor
select
screen
product
blood
compon
conceptu
technic
complex
action
increas
dramat
cumul
year
implement
modifi
elimin
measur
almost
imposs
partial
due
strong
regul
blood
donat
also
regul
concern
sometim
beyond
evid
risk
blood
safeti
might
increas
donor
deferr
men
sex
men
msm
place
decad
mani
countri
aim
reduc
residu
risk
infecti
diseas
ttid
name
perman
deferr
replac
temporari
deferr
countri
length
deferr
variabl
month
year
perman
temporari
msm
deferr
polici
controversi
debat
spain
one
countri
appli
gender
neutral
deferr
base
sexual
risk
practic
month
spain
also
one
western
european
countri
highest
preval
case
per
inhabit
annual
reflect
high
preval
incid
blood
donor
mandatori
screen
marker
among
other
hbsag
hcv
rna
latter
implement
hiv
rna
hbv
dna
mandatori
law
recommend
transfus
safeti
scientif
committe
spanish
ministri
health
blood
donat
present
hcvhivhbv
nat
screen
routin
either
individu
nat
minipool
donat
spanish
surveil
nat
group
report
posit
donor
window
phase
equal
donat
screen
region
data
catalonia
show
window
phase
donat
sever
posit
donor
intercept
annual
per
donat
male
regular
donor
msm
practic
fact
posit
donor
donat
blood
center
rather
mobil
unit
short
time
elaps
sinc
previou
elig
donat
suggest
current
select
criteria
limit
effect
safeti
regard
hiv
infect
reli
mainli
nat
serolog
screen
inde
demonstr
spanish
hemovigil
system
last
transmiss
document
back
two
recipi
infect
hiv
window
phase
donat
miss
first
gener
nat
improv
sensit
design
nat
system
minim
risk
fals
neg
result
due
low
viral
load
mutat
sequenc
correctli
address
hiv
residu
risk
spain
howev
ttdi
might
still
pose
threat
blood
safeti
recent
outbreak
hepat
viru
europ
link
msm
practic
controversi
debat
therefor
still
open
tj
van
de
w
van
k
van
den
e
schim
van
der
h
infect
sanquin
infecti
diseas
research
public
health
servic
amsterdam
donor
studi
sanquin
infect
immun
institut
academ
medic
centr
amsterdam
netherland
background
deferr
men
sex
men
msm
blood
donat
highli
debat
aim
assist
defin
msm
donor
deferr
polici
investig
suitabl
msm
donat
blood
hypothes
msm
behavior
pose
low
threat
blood
safeti
infect
pressur
compar
male
donor
method
compar
antibodi
preval
sexual
transfus
transmiss
infect
tti
among
msm
amsterdam
cohort
studi
repeat
male
blood
donor
msm
classifi
lr
hr
base
sexual
behavior
elig
use
dutch
donor
deferr
criteria
perman
exclus
infect
pressur
defin
number
infect
give
class
infect
hbv
hcv
syphili
doubl
weight
class
b
infect
cmv
hev
parvoviru
given
singl
weight
result
repeat
donor
lower
median
infect
pressur
elig
elig
versu
iqr
p
low
infect
pressur
infect
pressur
found
donor
elig
elig
preval
class
infect
differ
donor
msm
significantli
higher
elig
msm
recent
acquir
class
infect
detect
compar
blood
donor
cmv
preval
msm
group
p
preval
increas
higher
level
risk
behavior
summaryconclus
infect
pressur
correl
sexual
risk
behavior
msm
although
might
form
low
threat
blood
safeti
regard
class
infect
high
seropreval
human
herp
virus
may
repres
sexual
might
compromis
blood
safeti
warrant
investig
g
k
c
uk
blood
transfus
tissu
transplant
servic
profession
advisori
committe
jpac
sheffield
epidemiolog
unit
nh
blood
transplant
epidemiolog
unit
public
health
england
london
nephrolog
transplant
leed
teach
hospit
nation
health
servic
trust
leed
unit
kingdom
background
uk
depart
health
ask
advisori
committe
task
ensur
safeti
blood
tissu
organ
uk
sabto
review
donor
select
guidelin
men
sex
men
commerci
sex
worker
higher
risk
sexual
partner
skin
pierc
inject
drug
use
endoscopi
blood
tissu
stem
cell
donor
exposur
behaviour
associ
potenti
increas
risk
acquir
blood
born
infect
exampl
hepat
b
viru
hbv
sabto
set
donor
select
work
group
review
criteria
report
back
recommend
whether
still
appropri
proportion
aim
review
use
evid
base
approach
make
recommend
donor
select
base
sole
risk
transmiss
blood
born
infect
donat
rather
previou
risk
behaviour
donor
sabto
donor
select
work
group
use
allianc
blood
oper
risk
decis
make
framework
abo
rbdmf
guid
review
process
method
work
group
consid
avail
data
infect
risk
rate
infect
donor
current
test
window
period
inform
complianc
current
criteria
toler
risk
transmiss
defin
greater
predict
current
model
predict
undetect
infect
blood
suppli
hbv
hcv
hiv
syphili
model
rang
select
criteria
framework
use
assign
toler
work
group
includ
sabto
member
expert
scientist
clinician
key
stakehold
group
repres
patient
group
disproportion
affect
criteria
review
process
start
open
meet
describ
plan
process
allow
feedback
interest
parti
includ
result
rang
recommend
made
sabto
uk
depart
health
recommend
relat
sexual
partner
accept
possibl
reduc
deferr
current
place
pierc
inject
drug
use
endoscopi
legal
requir
blood
safeti
regul
take
account
risk
assess
ethic
societ
consider
sabto
recommend
reduc
select
criteria
msm
commerci
sex
worker
higher
risk
sexual
partner
month
sinc
last
sex
commun
strategi
put
place
ensur
interest
parti
awar
announc
summaryconclus
abo
rdmf
use
support
recent
donor
select
criteria
review
prove
use
ensur
assess
carri
logic
manner
essenti
area
stakehold
particip
commun
ethic
societ
consider
consid
framework
also
use
assess
toler
risk
new
donor
select
criteria
implement
novemb
across
england
scotland
wale
k
c
epidemiolog
unit
public
health
england
public
health
analyt
branch
depart
health
social
care
epidemiolog
unit
nh
blood
transplant
london
unit
kingdom
background
uk
advisori
committe
safeti
blood
tissu
organ
sabto
report
review
donor
select
guidelin
recommend
select
criteria
donor
high
risk
sexual
behaviour
hrsb
reduc
risk
detect
hiv
window
period
wp
infect
donat
test
hiv
residu
risk
deferr
model
review
addit
risk
consid
due
donor
adher
guidelin
ie
methodolog
similar
use
assess
risk
chang
deferr
men
sex
men
msm
lifetim
aim
uk
advisori
committe
safeti
blood
tissu
organ
sabto
report
review
donor
select
guidelin
recommend
select
criteria
donor
high
risk
sexual
behaviour
hrsb
reduc
risk
detect
hiv
window
period
wp
infect
donat
test
hiv
residu
risk
deferr
model
review
addit
risk
consid
due
donor
adher
guidelin
ie
methodolog
similar
use
assess
risk
chang
deferr
men
sex
men
msm
lifetim
method
number
donat
compliant
hrsb
donor
current
deferr
estim
appli
weight
respons
uk
blood
donor
survey
number
donat
test
uk
hiv
risk
calcul
observ
person
year
multipli
window
period
day
deferr
gener
popul
sexual
behaviour
data
use
determin
number
donat
hrsb
hrsb
donor
ie
addit
number
compliant
remain
number
remain
number
donor
hrsb
increas
proport
increas
compliant
observ
hiv
incid
avid
test
use
calcul
hiv
risk
among
hrsb
donor
upper
bound
confid
interv
incid
use
estim
risk
group
hrsb
donor
differ
hiv
risk
ad
current
valu
across
donat
give
overal
risk
reason
deferr
result
increas
hrsb
donor
expect
follow
implement
deferr
rang
zero
msm
worst
case
chang
detect
due
low
number
hiv
risk
estim
per
million
donat
test
month
deferr
hrsb
donor
deferr
scenario
would
remain
unchang
increas
almost
per
million
donat
test
mostli
due
msm
summaryconclus
implement
deferr
donor
hrsb
could
impact
hiv
risk
uk
even
worst
case
risk
per
million
donat
consid
toler
standpoint
agre
sabto
donor
select
work
group
chang
made
novemb
jo
b
z
k
van
den
servic
south
african
nation
blood
servic
mpumalanga
zone
south
africa
health
polici
research
blood
system
research
institut
san
francisco
unit
state
therapeut
transfus
south
african
nation
blood
servic
eastern
cape
south
africa
background
donor
select
play
crucial
role
ensur
blood
safeti
sinc
emerg
hiv
epidem
select
strategi
focuss
prevent
window
period
infect
defer
donor
engag
recent
high
risk
behaviour
strategi
use
includ
donor
educ
direct
indirect
question
donor
regard
risk
behaviour
use
approach
wide
accept
often
precautionari
measur
evid
efficaci
practic
limit
aim
studi
evalu
impact
blood
safeti
use
script
interview
conduct
donor
elig
assess
south
africa
method
conduct
implement
evalu
studi
determin
impact
use
script
interview
high
risk
deferr
hrd
recent
acquir
hiv
rah
infect
among
accept
blood
donor
compar
two
period
unscript
period
novemb
april
implement
interview
script
script
period
june
novemb
test
use
statist
signific
assess
multivari
model
develop
determin
odd
ratio
separ
outcom
hrd
rah
adjust
covari
includ
sex
age
race
collect
zone
donat
histori
result
donor
present
two
period
made
script
period
odd
hrd
time
greater
script
period
ci
femal
donor
ci
lower
odd
hrd
male
donor
zone
lower
odd
hrd
compar
egoli
zone
lowest
odd
ci
separ
model
evalu
odd
rah
infect
show
odd
rah
time
lower
ci
script
period
odd
rah
higher
among
femal
ci
compar
male
among
black
ci
colour
ci
donor
compar
white
donor
signific
differ
collect
zone
evid
summaryconclus
use
script
result
increas
odd
hrd
concomit
reduct
rah
infect
lower
odd
hrd
yet
almost
doubl
odd
rah
among
femal
might
indic
differ
societ
standard
regard
sexual
behaviour
also
willing
declar
behaviour
other
interview
addit
sexual
dispar
south
africa
sa
contribut
lack
knowledg
among
femal
potenti
high
risk
behaviour
sexual
partner
signific
greater
odd
rah
among
black
colour
donor
parallel
hiv
infect
trend
among
gener
popul
sa
geograph
certain
area
predominantli
greater
rural
popul
demonstr
lower
odd
hrd
greater
odd
rah
infect
reason
differ
like
includ
differ
also
potenti
differ
oper
consider
potenti
unmeasur
confound
factor
exclud
studi
found
improv
blood
safeti
implement
script
donor
interview
h
blood
bank
uganda
blood
transfus
servic
kampala
uganda
montreal
montreal
canada
achiev
univers
health
coverag
includ
essenti
servic
coverag
target
unit
nation
sustain
develop
goal
index
essenti
health
servic
coverag
indic
includ
proport
facil
access
essenti
medicin
includ
blood
blood
compon
world
health
organ
estim
least
donat
per
popul
requir
adequ
fulfil
countri
blood
transfus
requir
accord
global
statu
report
blood
safeti
avail
gdb
median
whole
blood
wb
donat
rate
high
incom
countri
hic
popul
low
incom
countri
lmiclic
respect
order
achiev
donat
goal
provid
safe
blood
encourag
among
thing
coordin
blood
collect
process
system
ministri
health
collect
blood
voluntari
donor
vnrd
test
blood
donat
hiv
hepat
b
c
virus
hbv
hcv
manner
accord
gdb
respond
countri
indic
unit
countri
ministri
health
blood
servic
countri
africa
receiv
fund
extern
sourc
support
servic
gdb
also
report
countri
africa
still
collect
blood
suppli
vnrd
depend
familyreplac
donor
frd
major
blood
suppli
respect
test
hiv
hbv
hcv
gdb
report
countri
polici
screen
donat
hiv
hbv
hcv
spite
polici
countri
report
abl
test
unit
collect
lic
report
test
perform
qualiti
assur
manner
sever
lic
perform
test
use
rapid
diagnost
test
low
sensit
pathogen
reduct
pr
plasma
platelet
clinic
use
hic
lic
lmic
pr
wb
shown
ghana
reduc
risk
malaria
infecti
agent
common
lic
test
current
perform
respect
compon
product
gdb
report
wb
donat
collect
hic
versu
lic
separ
compon
spite
recommend
argu
complet
convers
lic
blood
suppli
wb
compon
alway
best
option
uganda
blood
transfus
servic
ubt
spite
lic
achiev
goal
albeit
aid
presid
emerg
plan
aid
relief
pepfar
ubt
organ
ugandan
ministri
health
whose
mandat
provid
blood
free
charg
ugandan
hospit
patient
ubt
collect
blood
exclus
vnrd
donat
repeat
donor
donat
test
serolog
hiv
hbv
hcv
total
blood
donat
approxim
per
ugandan
talk
step
taken
ubt
achiev
success
discuss
along
challeng
liclmic
face
strive
continu
improv
blood
safeti
suffici
includ
discuss
vnrd
versu
frd
potenti
role
pr
technolog
optim
mix
wb
versu
compon
r
n
r
k
blood
transplant
london
blood
transplant
cambridg
blood
transplant
newcastl
univers
nh
foundat
trust
blood
transplant
manchest
newcastl
upon
tyne
hospit
nh
foundat
trust
newcastl
univers
hospit
nh
foundat
trust
blood
transplant
oxford
unit
kingdom
background
tradit
approach
collect
compar
data
blood
utilis
support
clinic
benchmark
labori
involv
obtain
inform
multipl
electron
system
andor
manual
clinic
record
big
data
refer
collect
extrem
larg
data
set
difficult
process
use
tradit
databas
softwar
techniqu
electron
health
record
develop
patholog
informat
support
collect
larg
data
set
link
analys
support
qualiti
improv
initi
transfus
medicin
aim
aim
feasibl
studi
determin
larg
amount
data
three
nh
trust
could
collect
merg
allow
transfus
practic
benchmark
method
clinic
laboratori
transfus
data
patient
discharg
three
nh
trust
manchest
oxford
newcastl
financi
year
gather
patient
administr
system
laboratori
inform
manag
system
haemonet
blood
track
avail
two
trust
data
upload
along
variou
refer
data
tabl
data
warehous
use
analyt
busi
intellig
softwar
structur
queri
languag
data
link
made
gener
output
relev
transfus
practic
result
patient
spell
dataset
compon
transfus
across
three
trust
benchmark
result
includ
number
blood
compon
transfus
per
bed
day
paramet
use
enhanc
compar
blood
usag
hospit
rather
number
compon
issu
hospit
blood
servic
number
compon
transfus
given
time
red
cell
utilis
bed
day
trust
platelet
utilis
bed
day
inform
blood
compon
use
show
overal
rbc
unit
transfus
recipi
group
exclud
patient
unknown
blank
abod
group
rate
drop
data
one
trust
show
emerg
transfus
rbc
transfus
recipi
unknown
abod
group
detail
inform
blood
use
analys
accord
diagnost
procedur
healthcar
resourc
group
hrg
code
provid
inform
focu
patient
blood
manag
effort
exampl
one
trust
found
cardiac
platelet
usag
total
platelet
use
higher
two
trust
challeng
data
manag
remain
includ
varianc
data
format
hospit
inform
system
howev
compar
tradit
approach
collect
blood
utilis
inform
increment
benefit
time
effort
staff
resourc
summaryconclus
comprehens
compar
data
blood
usag
includ
standardis
denomin
data
hospit
bed
day
allow
direct
comparison
transfus
practic
hospit
individu
clinic
servic
allow
identif
target
qualiti
improv
initi
addit
insight
blood
use
might
also
support
demand
plan
blood
servic
allow
accur
predict
blood
use
adjust
blood
collect
activ
use
big
data
first
step
develop
machin
learn
improv
transfus
practic
v
administr
post
graduat
institut
medic
educ
research
chandigarh
india
chandigarh
famili
welfar
govern
himach
pradesh
nahan
medicin
gynecolog
post
graduat
institut
medic
educ
research
chandigarh
india
chandigarh
india
background
arbitrari
excess
requisit
blood
elect
surgeri
common
practic
lead
wastag
blood
safe
side
surgeon
request
pack
red
blood
cell
prbc
requir
elect
surgeri
maximum
surgic
blood
order
schedul
msbo
evid
base
method
allow
effici
use
blood
stock
optim
util
blood
bank
resourc
reduc
blood
wastag
studi
undertaken
tertiari
care
teach
hospit
india
determin
msbo
certain
elect
surgeri
around
surgeri
perform
institut
annual
aim
studi
blood
requisit
util
pattern
nine
elect
surgic
procedur
three
surgic
depart
surgeri
orthoped
gynecolog
determin
msbo
method
patient
undergo
nine
elect
surgeri
hysterectomi
ah
vagin
hysterectomi
vh
exploratori
elg
exploratori
el
whippl
procedur
wp
frey
procedur
fp
splenectomi
total
hip
replac
thr
total
knee
replac
tkr
june
august
includ
prospect
studi
data
blood
requisit
issuanc
transfus
return
within
h
patient
collect
prospect
patient
record
oper
room
blood
bank
descript
analysi
perform
determin
ct
ratio
transfus
probabl
transfus
index
ti
msbo
surgic
procedur
altogeth
studi
approv
institut
review
committe
result
total
patient
underw
surgeri
studi
period
femal
mean
age
patient
year
sd
total
prbc
unit
request
issu
blood
bank
mean
prbc
unit
request
per
surgeri
max
splenectomi
min
vh
unit
issu
transfus
patient
maximum
tkr
patient
receiv
transfus
wherea
splenectomi
patient
transfus
unit
return
blood
bank
within
h
statist
signific
differ
p
hemoglobin
patient
transfus
gdl
gdl
total
perform
ct
ratio
surgeri
max
splenectomi
min
ah
overal
transfus
probabl
max
tkr
min
splenectomi
ti
max
tkr
min
splenectomi
msbo
elect
surgeri
follow
ah
vh
elg
el
wp
fp
splenectomi
thr
tkr
summaryconclus
studi
show
msbo
nine
elect
surgeri
less
one
much
lower
actual
prbc
requisit
sent
elect
surgeri
keep
view
larg
volum
surgeri
institut
implement
msbo
would
huge
benefit
term
effici
use
blood
blood
bank
resourc
studi
provid
evid
formul
msbo
base
blood
util
polici
institut
level
l
w
l
manag
coordin
manag
ontario
region
blood
coordin
hamilton
kingston
gener
hospit
kingston
canada
background
ontario
ministri
health
care
mohltc
immun
globulin
advisori
panel
igap
examin
differ
screen
methodolog
ig
sever
reason
ig
util
cost
continu
growconcern
sustain
growtha
complianc
audit
demonstr
need
improv
appropri
ig
utilizationth
need
patient
reassess
therapi
determin
treatment
dosag
continu
achiev
expect
clinic
responseth
expertis
screen
request
across
specialti
avail
everi
hospitalan
ig
audit
conduct
indic
ontario
ivig
use
unapprov
condit
igap
prefer
except
access
program
eap
model
current
use
drug
due
avail
ig
hospit
issu
ig
familiar
physician
neurolog
select
immun
globulin
screen
pilot
igsp
provinci
champion
identifi
will
support
aim
object
igsp
reduc
inappropri
use
wastag
ig
ensur
minimum
effect
dose
administ
improv
patient
outcom
ensur
treatment
effect
gain
understand
increas
util
ig
rais
awar
ig
use
cost
ensur
dose
correct
obes
patient
develop
screen
model
may
expand
specialti
method
eap
electron
request
technolog
avail
pilot
fax
system
develop
fill
gap
pilot
ran
may
januari
ig
neurolog
request
initi
screen
igsp
assessor
pharmacist
order
approv
within
h
guidelin
met
request
forward
anonym
neurologist
review
approv
reject
urgent
process
develop
critic
patient
appeal
process
avail
renew
also
requir
outcom
questionnair
complet
submit
new
request
ensur
treatment
continu
effect
minim
effect
dose
appli
result
hospit
submit
request
repres
patient
eleven
request
reject
request
approv
request
dose
adjust
pilot
potenti
conserv
g
ig
cost
save
complianc
assess
determin
igsp
approv
dose
actual
dose
administ
hospit
final
cost
save
complianc
rate
appli
along
eap
cost
summaryconclus
pilot
partial
success
provid
uniform
expert
screen
inappropri
request
deni
adjust
awar
ig
treatment
cost
increas
patient
outcom
monitor
cost
save
realiz
manual
process
tediou
unsustain
ig
screen
model
posit
effect
patient
outcom
util
requisit
technolog
must
avail
support
raouf
r
sharma
blood
bank
dubai
health
author
dubai
unit
arab
emir
background
increas
blood
donor
recruit
retent
key
import
transfus
servic
cope
increas
demand
blood
compon
presenc
stringent
donor
elig
criteria
qualiti
requir
blood
collect
build
nation
sustain
voluntari
non
remuner
blood
donat
program
among
dubai
nation
agenda
aim
improv
blood
donor
recruit
retent
dubai
blood
donat
center
conduct
custom
satisfact
survey
evalu
exist
servic
develop
initi
base
voic
custom
need
except
integr
plan
implement
initi
method
dubai
blood
donat
center
introduc
smart
mobil
applic
dammi
septemb
avail
appl
android
system
applic
allow
intend
donor
read
blood
donat
process
journey
educ
materi
benefit
blood
donat
elig
criteria
onlin
donor
histori
questionnair
avail
arab
english
languag
donor
answer
questionnair
submit
blood
center
gener
barcod
donor
also
regist
detail
case
will
donat
emerg
get
notif
dubai
blood
bank
applic
evalu
initi
select
key
perform
indic
evalu
effect
effici
qualiti
servic
result
donor
use
smart
applic
insid
center
donor
load
dammi
applic
smart
phone
fill
donor
histori
questionnair
registr
servic
deliveri
time
reduc
min
min
wait
time
educ
materi
fill
questionnair
reduc
min
min
incid
report
due
document
error
registr
procedur
reduc
blood
donor
notif
infecti
diseas
accord
fda
guidanc
improv
complianc
custom
happi
survey
shown
custom
satisfact
speed
servic
improv
profession
staff
improv
servic
inform
improv
access
inform
summaryconclus
smart
mobil
applic
improv
custom
satisfact
servic
make
educ
materi
avail
mobil
phone
read
care
give
opportun
blood
donor
fill
donor
questionnair
onlin
home
offic
confidenti
process
shorten
servic
time
make
blood
donat
procedur
shorter
conveni
blood
donor
encourag
retent
smart
applic
allow
public
regist
inform
donat
case
emerg
disast
allow
blood
bank
wide
data
base
peopl
will
donat
locat
blood
group
dubai
blood
bank
proceed
phase
two
applic
featur
improv
servic
mc
medicin
univers
queensland
brisban
health
command
australian
defenc
forc
canberra
australia
platelet
essenti
haemostasi
platelet
shorter
shelf
life
day
blood
compon
day
red
cell
month
fresh
frozen
plasma
outer
metropolitan
hospit
rural
hospit
deploy
militari
hospit
usual
justifi
maintain
platelet
unit
would
inevit
wast
resourc
high
demand
elsewher
respons
netherland
militari
blood
bank
built
earlier
us
navi
research
refin
process
freez
use
dimethylsulfoxid
cryopreserv
store
year
reconstitut
plasma
platelet
use
militari
oper
experi
cryopreserv
platelet
unit
transfus
patient
afghanistan
suggest
safe
effect
treat
activ
bleed
noorman
et
al
although
comparison
platelet
whole
blood
made
also
sever
instanc
civilian
practic
abil
transfus
platelet
judg
outweigh
unquantifi
risk
associ
cryopreserv
product
includ
poland
czech
republ
franc
unit
state
howev
extens
preclin
assess
one
phase
human
studi
cryopreserv
platelet
perform
date
one
clinic
trial
involv
bleed
patient
publish
us
studi
khuri
et
al
randomis
patient
cryopreserv
platelet
treatment
bleed
cardiac
surgeri
advers
effect
observ
patient
receiv
cryopreserv
platelet
blood
loss
cryopreserv
platelet
significantli
less
despit
lower
platelet
increment
tendenc
toward
decreas
platelet
surviv
uniformli
encourag
evid
base
insuffici
justifi
regulatori
approv
sever
intern
trial
group
seek
address
defici
includ
czech
militari
us
depart
defensedartmouth
univers
australian
red
cross
blood
servic
australian
defenc
forc
commenc
clinic
trial
program
cryopreserv
vs
liquid
platelet
trial
clip
design
evalu
effect
safeti
cryopreserv
platelet
comparison
platelet
australian
pilot
trial
ceas
enrol
decemb
new
zealand
variant
protocol
due
run
australian
pilot
cardiac
surgic
patient
randomis
transfus
platelet
studi
group
baselin
advers
event
attribut
platelet
transfus
medic
complic
might
relat
cryopreserv
platelet
transfus
also
common
cardiac
surgeri
fever
infect
acut
respiratori
distress
syndrom
deep
venou
thrombosi
present
similar
proport
two
trial
group
signific
trend
superior
sever
outcom
includ
blood
loss
requir
red
cell
transfus
need
return
oper
theatr
bleed
result
justifi
progress
definit
phase
iii
trial
l
l
j
f
r
k
l
c
r
p
behalf
best
develop
australian
red
cross
blood
servic
alexandria
australia
school
medicin
dartmouth
lebanon
system
research
institut
denver
unit
state
develop
innov
scottish
nation
blood
transfus
servic
edinburgh
unit
kingdom
compon
develop
new
zealand
blood
servic
auckland
new
zealand
blood
bank
leiden
netherland
scienc
laboratori
research
develop
innov
test
scottish
nation
blood
transfus
servic
edinburgh
unit
kingdom
excel
safer
transfus
best
collabor
lebanon
unit
state
background
cryopreserv
platelet
manufactur
mani
blood
centr
global
effort
improv
storag
logist
andor
support
militari
deploy
howev
process
method
particularli
volum
type
solut
use
resuspend
thaw
platelet
vari
among
countri
plasma
salin
variou
platelet
addit
solut
pa
shown
support
platelet
recoveri
separ
studi
appropri
resuspens
solut
remain
defin
plasma
provid
advantag
coagul
factor
fibrinogen
addit
support
coagul
bleed
patient
use
base
solut
provid
advantag
improv
safeti
standardis
composit
hypothesis
inclus
glucos
would
support
extend
storag
follow
thaw
intern
studi
particip
australia
au
new
zealand
nzl
scotland
sct
unit
state
america
usa
perform
compar
qualiti
platelet
resuspend
differ
solut
aim
determin
suitabl
three
differ
solut
resuspens
cryopreserv
platelet
intern
context
method
pool
split
design
use
cryopreserv
dmso
resuspend
thaw
apheresi
platelet
solut
salin
usa
plasma
au
nzl
sct
intersol
intersol
mm
glucos
n
arm
per
site
vitro
qualiti
function
test
site
use
protocol
prior
freez
immedi
thaw
h
store
collat
data
analys
use
anova
assess
combin
effect
resuspens
solut
countri
result
platelet
content
vari
among
countri
au
x
nzl
x
sct
x
usa
x
due
platelet
content
rather
resuspens
solut
result
mean
platelet
recoveri
immedi
thaw
similar
among
site
intersol
intersol
glucos
although
use
pa
reduc
platelet
loss
h
storag
compar
plasma
resuspens
solut
lead
differ
platelet
activ
marker
includ
phosphatidylserin
thromboelastographi
teg
paramet
includ
maximum
amplitud
similar
among
three
resuspens
solut
minor
differ
qualiti
paramet
detect
among
product
site
may
due
variat
donor
product
techniqu
andor
vitro
measur
summaryconclus
although
intern
manufactur
cryopreserv
platelet
differ
composit
differ
slight
may
consequ
interestingli
resuspens
solut
substanti
influenc
platelet
recoveri
activ
function
even
h
storag
studi
demonstr
fluid
test
suitabl
resuspens
cryopreserv
platelet
glucos
improv
storag
allow
thaw
platelet
flexibl
adjust
volum
andor
composit
support
differ
patient
logist
requir
n
p
develop
unit
region
clinic
immunolog
transfus
medicin
karolinska
univers
hospit
karolinska
institutet
stockholm
sweden
background
due
risk
replic
contamin
pathogen
platelet
store
maximum
day
prolong
day
use
pathogen
inactiv
pi
technolog
intercept
blood
system
even
use
pathogen
reduct
technolog
day
still
short
storag
time
caus
logist
suppli
problem
cryopreserv
platelet
cpp
could
altern
meet
demand
well
function
backup
stock
crisi
situat
howev
activ
lysi
platelet
result
secret
biolog
respons
modifi
brm
consist
cytokin
biomolecul
brm
thought
activ
autocrin
paracrin
pathway
influenc
key
cellular
function
donor
recipi
cell
aim
aim
studi
investig
impact
cryopreserv
brm
releas
cryopreserv
affect
platelet
treat
intercept
blood
system
regard
addit
correl
brm
releas
platelet
surfac
marker
also
investig
method
platelet
concentr
plasma
platelet
addit
solut
spss
prepar
buffi
coat
technolog
twelv
unit
treat
intercept
blood
system
unit
use
non
control
unit
cryopreserv
brm
concentr
analys
cryopreserv
white
blood
cell
wbc
brm
well
brm
rant
vegf
investig
correl
analysi
also
made
brm
platelet
surfac
marker
assess
flow
cytometri
activ
conform
gpiibiiia
measur
bind
well
platelet
mitochondria
transmembran
potenti
measur
bind
result
concentr
brm
increas
significantli
p
cryopreserv
except
cpp
significantli
lower
increas
rant
increas
pgml
cryopreserv
pgml
cryopreserv
control
cpp
increas
pgml
cryopreserv
pgml
cryopreserv
weak
correl
r
found
platelet
surfac
marker
strong
correl
r
found
brm
p
well
bind
except
weak
correl
r
found
spontan
bind
brm
wherea
also
strong
correl
bind
sever
brm
summaryconclus
cryopreserv
result
increas
accumul
brm
gener
similar
degre
control
cpp
brm
accumul
correl
chang
platelet
surfac
marker
cpp
may
reduc
patient
safeti
risk
upon
transfus
howev
clinic
relev
find
need
evalu
c
c
l
h
institut
biomed
materi
tissu
engin
colleg
biomed
engin
institut
translat
medicin
taipei
medic
univers
radiat
oncolog
graduat
institut
biomed
materi
tissu
engin
colleg
biomed
engin
taipei
medic
univers
hospit
taipei
medic
univers
taipei
taiwan
republ
china
oncolog
colleg
medicin
univers
saskatchewan
saskatchewan
canada
background
increasingli
evid
platelet
plt
abund
anucl
cell
circul
blood
play
detriment
role
cancer
progress
membran
glycoprotein
present
plt
target
interact
coagul
factor
tumor
cancer
cell
surfac
marker
lead
detriment
cell
activ
loop
culmin
tumor
platelet
aggreg
platelet
degranul
releas
content
support
scientif
rational
trojan
hors
strategi
use
platelet
novel
physiolog
base
smart
target
drug
deliveri
system
tdd
achiev
goal
requir
develop
load
plt
storag
procedur
ensur
meaning
drug
load
capac
b
mainten
platelet
function
c
storag
suitabl
drug
releas
kinet
tumor
aim
develop
procedur
manufactur
frozen
plt
target
drug
deliveri
treatment
cancer
method
platelet
concentr
pc
obtain
volunt
donor
taipei
blood
center
guandu
taiwan
pc
centrifug
pellet
plt
pellet
resuspend
dox
platelet
addit
solut
pa
mixtur
incub
h
encapsul
dox
pd
pd
pellet
suspend
dimethyl
sulfoxid
dmso
frozen
fpd
use
fpd
thaw
min
resuspend
pa
follow
centrifug
remov
excess
dmso
entrap
dox
pd
fpd
observ
deconvolut
microscopi
presenc
plt
surfac
marker
determin
western
blot
function
assess
thromboelastographi
teg
dox
entrap
effici
ee
vitro
releas
dox
pd
fpd
pa
ph
control
group
pb
ph
breast
cancer
cell
cultur
condit
medium
examin
hplc
fluoresc
detect
nm
human
breast
lung
colon
cancer
cell
treat
variou
concentr
pd
fpd
free
dox
plt
frozen
plt
control
h
analyz
assay
determin
viabil
result
deconvolut
microscopi
show
similar
dox
entrap
pd
freez
dox
encapsul
effici
approxim
pd
fpd
respect
western
blot
show
marker
express
pd
fpd
teg
assay
maximum
amplitud
fpd
similar
plt
pd
dox
releas
effici
acid
ph
mimick
tumor
cancer
cell
condit
medium
contain
tissu
factor
microvesicl
cell
viabil
affect
pd
fpd
effici
free
dox
significantli
liposom
dox
summaryconclus
data
support
rational
feasibl
use
cryopreserv
platelet
target
deliv
platform
agent
translat
applic
l
l
develop
australian
red
cross
blood
servic
core
facil
univers
technolog
sydney
medic
school
univers
sydney
sydney
australia
background
convent
storag
platelet
limit
day
modif
storag
includ
cryopreserv
pathogen
inactiv
pi
may
facilit
extens
improv
product
safeti
cryopreserv
pi
shown
individu
although
differenti
alter
abund
conform
glycosyl
profil
platelet
adhes
aggreg
receptor
gpiibiiia
given
pivot
role
glycoprotein
mediat
platelet
function
import
establish
combin
effect
storag
modal
aim
aim
studi
determin
effect
platelet
prior
cryopreserv
focuss
impact
combin
treatment
platelet
glycoprotein
method
two
deriv
platelet
unit
pool
split
form
match
pair
n
one
unit
remain
untreat
uvc
pathogen
inactiv
theraflex
system
accord
manufactur
instruct
macopharma
cryopreserv
use
dimethylsulfoxid
resuspend
unit
plasma
thaw
platelet
sampl
test
immedi
follow
thaw
h
storag
abund
conform
respect
gpiibiiia
respect
amount
surfac
bound
fibrinogen
rest
condit
measur
flow
cytometri
exposur
specif
glycan
residu
measur
use
follow
lectin
sambucu
nigra
sna
sialic
acid
ricinu
communi
agglutinin
rca
galactos
succinyl
wheat
germ
agglutinin
swga
statist
comparison
perform
use
pair
result
recoveri
platelet
significantli
lower
untreat
platelet
p
declin
storag
abund
gpiibiiia
platelet
similar
untreat
platelet
p
p
respect
howev
reduc
bind
indic
chang
conform
platelet
immedi
follow
thaw
p
membran
h
storag
although
recoveri
lower
platelet
p
p
respect
bind
platelet
higher
untreat
platelet
p
increas
subsequ
storag
p
indic
greater
platelet
activ
bind
correl
increas
fibrinogen
bind
r
p
platelet
bound
fibrinogen
follow
storag
p
lectin
bind
includ
bind
sna
sialic
acid
residu
reduc
platelet
compar
untreat
platelet
immedi
thaw
p
lectin
howev
recov
storag
group
similar
h
summaryconclus
prior
cryopreserv
alter
platelet
phenotyp
increas
abund
activ
gpiibiiia
fibrinogen
bind
may
enhanc
aggreg
cryopreserv
platelet
howev
loss
desialyl
platelet
protein
could
lead
rapid
clearanc
cryopreserv
platelet
bisht
haemovigil
programm
india
nation
institut
biolog
ministri
health
famili
welfar
noida
india
background
object
haemovigil
programm
india
hvpi
nation
level
launch
decemb
nation
institut
biolog
nib
ministri
health
famili
welfar
govern
india
nation
coordin
centr
hvpi
key
object
outlin
hvpi
monitor
transfus
reaction
ii
creat
awar
amongst
health
care
profession
iii
gener
evid
base
recommend
iv
advis
central
drug
standard
control
organ
cdsco
safeti
relat
regulatori
decis
v
commun
find
key
stakehold
vi
creat
nation
intern
linkag
implement
haemovigil
programm
india
main
characterist
programm
accord
guidelin
advers
event
report
learn
system
confidenti
report
maintain
independ
punish
author
data
review
expert
intent
improv
process
system
make
particip
respons
recommend
sinc
nation
programm
first
type
india
one
challeng
dissemin
awar
programm
achiev
cme
workshop
newslett
next
major
challeng
softwar
facilit
collect
collat
data
trrf
variou
enrol
centr
transmit
data
hvpi
challeng
overcom
develop
indigen
softwar
facilit
onlin
report
centr
initi
simplifi
one
page
transfus
reaction
report
form
trrf
introduc
encourag
report
well
structur
committe
defin
role
respons
provid
oversight
programm
come
first
report
analysi
transfus
reaction
report
januari
april
key
recommend
blood
safeti
analysi
transfus
reaction
report
found
review
process
restrain
due
inadequ
inform
improv
qualiti
data
detail
trrf
introduc
onlin
report
new
format
initi
may
look
success
recipi
haemovigil
programm
nation
blood
donor
vigil
programm
launch
report
reaction
via
softwar
initi
june
signific
outcom
programm
steadi
increas
number
centr
report
hvpi
sinc
launch
programm
reflect
increas
confid
programm
report
sensit
data
outreach
transfus
medicin
commun
clinician
one
object
programm
creat
intern
linkag
direct
nib
taken
leap
collabor
royal
govern
bhutan
nib
offici
undertaken
visit
bhutan
novemb
regard
cme
haemovigil
establish
haemovigil
system
bhutan
cell
hvpi
develop
dedic
softwar
bhutan
offici
hand
last
day
cme
bhutan
initi
haemovigil
program
countri
pilot
phase
wef
identifi
centr
india
member
intern
haemovigil
network
ihn
conclus
haemovigil
programm
india
envisag
protect
promot
public
health
ensur
safe
blood
transfus
practic
countri
p
n
van
der
l
f
j
p
j
product
collect
blood
transfus
center
luxembourg
red
cross
luxembourg
luxembourg
background
methylen
blue
mb
one
wide
use
method
plasma
inactiv
consid
safe
effect
howev
observ
french
haemovigil
data
rais
question
increas
rate
allerg
reaction
plasma
recipi
decad
ago
aim
retrospect
review
reaction
addit
data
last
year
aim
aim
retrospect
review
reaction
addit
data
last
year
method
haemovigil
report
afssap
later
ansm
consid
along
ef
rate
advers
reaction
along
confid
interv
time
trend
comput
result
period
rate
allergi
mb
plasma
higher
unit
compar
type
plasma
unit
rate
allerg
reaction
grade
high
imput
decreas
time
mb
plasma
unit
maintain
type
plasma
unit
achiev
level
unit
unit
respect
allerg
reaction
grade
imput
addit
confid
interv
reaction
type
plasma
overlap
entir
observ
period
statist
differ
period
number
allerg
reaction
type
plasma
grade
imput
significantli
increas
compar
previou
year
unit
unit
unit
unit
unit
respect
summaryconclus
report
bia
could
taken
place
result
strengthen
biolog
explor
allerg
reaction
mb
plasma
bia
case
would
invalid
compar
mb
group
mb
plasma
exclus
produc
apheresi
franc
result
allergi
whole
blood
plasma
saadah
n
et
al
br
j
haematol
updat
french
data
confirm
previou
conclus
identifi
istar
databas
either
conclus
longer
evid
point
consid
mb
plasma
respons
greater
number
allergi
flesland
c
espinosa
report
learn
system
unit
norwegian
director
health
oslo
norway
background
norwegian
haemovigil
system
use
haemovigil
definit
transfus
reaction
incorpor
correct
trali
definit
adopt
june
transfus
reaction
report
clinician
blood
bank
blood
bank
necessari
laboratori
analys
forward
report
haemovigil
system
use
internet
base
form
report
select
list
symptom
list
transfus
reaction
isbt
definit
shown
form
help
report
two
option
definit
suitabl
unclassifi
complic
transfus
uct
local
ca
nt
conclud
haemovigil
system
report
valid
least
one
medic
specialist
transfus
medicin
includ
check
classif
definit
aim
aim
studi
see
extent
report
transfus
reaction
classifi
use
current
use
definit
compar
year
period
character
transfus
reaction
report
fit
definit
method
transfus
reaction
report
norwegian
haemovigil
system
analys
data
compar
alreadi
publish
data
http
result
report
classifi
uct
ca
nt
conclud
mean
total
report
fit
definit
report
classifi
utc
six
ca
nt
conclud
mean
total
report
fit
definit
patient
transfus
reaction
classifi
utcca
nt
conclud
age
distribut
other
femal
vs
rel
reaction
death
unclassifi
group
otherwis
sever
patient
unclassifi
transfus
reaction
recov
complet
outcom
last
three
unknown
time
report
imput
weaker
unclassifi
group
none
imput
definit
two
imput
probabl
patient
utcca
nt
conclud
record
total
symptom
averag
symptom
nauseavomit
tachycardia
chill
rigor
respiratori
distress
increas
blood
pressur
chest
pain
dizzi
headach
addit
nine
symptom
experienc
one
patient
patient
symptom
averag
summaryconclus
evalu
report
transfus
medicin
specialist
haemovigil
system
transfus
reaction
classifi
utcca
nt
conclud
use
definit
unclassifi
reaction
mostli
mild
reaction
patient
recov
complet
imput
low
opinion
current
definit
transfus
reaction
work
well
j
j
h
j
k
k
laboratori
medicin
hallym
univers
colleg
medicin
human
blood
safeti
surveil
korea
center
diseas
control
prevent
laboratori
medicin
seoul
nation
univers
colleg
medicin
seoul
republ
korea
background
set
oper
nation
haemovigil
system
support
korean
ministri
health
welfar
mohw
independ
oper
korean
societi
blood
transfus
ksbt
sinc
aim
intend
report
year
oper
result
korean
haemovigil
system
method
start
develop
korean
haemovigil
system
research
fund
korean
center
diseas
control
prevent
defin
scope
report
event
develop
report
form
next
year
pilot
studi
made
homepag
korean
haemovigil
system
institut
particip
report
voluntarili
develop
report
system
data
collect
websit
sinc
includ
particip
haemovigil
system
checklist
blood
manag
fee
newli
creat
revis
categori
transfus
reaction
updat
report
form
hold
explanatori
meet
particip
organ
everi
year
result
nation
haemovigil
system
formal
launch
support
korean
mohw
independ
oper
ksbt
although
korean
haemovigil
system
voluntari
report
system
particip
includ
accredit
checklist
korea
institut
healthcar
accredit
assess
certif
laboratori
excel
korean
laboratori
medicin
foundat
particip
also
requir
institut
receiv
blood
manag
fee
requir
dramat
increas
number
particip
institut
advers
event
includ
transfus
reaction
incid
report
haemovigil
system
year
oper
includ
year
pilot
studi
total
advers
event
report
overal
transfus
reaction
report
febril
transfus
reaction
allerg
reaction
frequent
report
advers
reaction
case
acut
lung
injuri
case
acut
hemolyt
transfus
reaction
case
delay
hemolyt
transfus
reaction
case
delay
serolog
transfus
reaction
report
circulatori
overload
dyspnea
hypotens
reaction
newli
categor
case
report
respect
report
incid
near
miss
incid
without
advers
reaction
incid
lead
advers
reaction
half
incid
occur
relat
blood
sampl
occur
transfus
ward
occur
perform
test
blood
bank
summaryconclus
set
success
oper
nation
haemovigil
system
year
includ
pilot
studi
particip
institut
increas
consider
account
transfus
korea
expect
data
haemovigil
support
develop
blood
safeti
strategi
korea
j
medicin
mcmaster
univers
hamilton
laboratori
medicin
pathobiolog
univers
toronto
health
scienc
centr
toronto
canada
background
error
remain
major
caus
advers
transfus
event
data
seriou
hazard
transfus
report
error
account
report
error
occur
variou
point
along
transfus
chain
accur
patient
registr
key
first
step
howev
data
pertain
registr
error
limit
frequenc
pattern
impact
patient
registr
error
remain
unclear
requir
studi
aim
provid
descript
overview
patient
registr
error
affect
transfus
medicin
servic
academ
hospit
ontario
canada
highlight
clinic
impact
patient
registr
error
illustr
case
method
patient
registr
error
impact
transfus
medicin
servic
academ
hospit
sunnybrook
health
scienc
toronto
ontario
canada
review
illustr
case
investig
summar
result
year
period
total
patient
registr
error
impact
blood
bank
detect
blood
bank
technologist
nurs
patient
physician
other
respect
major
registr
error
discoveri
occur
time
sampl
receipt
unit
request
n
error
detect
time
bedsid
check
common
error
duplic
patient
record
wrong
name
spell
name
order
registr
wrong
hospit
identifi
total
six
error
reach
patient
one
case
patient
histor
antibodi
match
jka
two
case
error
led
delay
surgeri
case
male
sickl
cell
diseas
admit
ontario
hospit
acut
pain
crisi
red
blood
cell
rbc
phenotyp
jka
jkb
known
regist
nation
sickl
cell
registri
histori
mandat
extend
match
rh
duffi
kidd
rbc
transfus
per
local
polici
admiss
erron
regist
first
last
name
revers
order
assign
new
medic
record
number
error
led
lack
patient
histori
hospit
nation
registri
level
detect
screen
receiv
two
rbc
unit
match
rh
antigen
unit
unit
fya
registr
error
serendipit
identifi
clinic
staff
prior
transfus
requir
acut
chest
syndrom
lead
signific
delay
procur
appropri
match
product
discharg
hospit
three
day
later
without
detect
new
alloantibodi
format
summaryconclus
patient
registr
error
common
detect
laboratori
clinic
staff
pose
seriou
harm
patient
accur
patient
registr
key
compon
safe
transfus
practic
r
l
r
c
blood
transplant
london
unit
kingdom
hospit
capel
ad
ijssel
netherland
australian
red
cross
blood
servic
melbourn
australia
ormond
street
hospit
children
nh
foundat
trust
london
unit
kingdom
children
women
hospit
vancouv
canada
backgroundaim
transfus
practition
tp
term
describ
healthcar
profession
hcp
whose
key
role
drive
influenc
clinic
blood
manag
safeti
activ
includ
patient
blood
manag
pbm
initi
common
aim
support
safe
appropri
care
patient
isbt
clinic
work
parti
cwp
establish
tp
forum
tpf
support
role
develop
across
member
countri
time
becom
clear
signific
variat
staff
group
fill
role
understand
variat
survey
undertaken
aim
survey
gain
understand
countri
tp
role
equival
differ
tp
role
across
isbt
member
countri
role
place
challengesbarri
adoptiondevelop
tp
role
resourc
isbt
tp
forum
steer
committe
tpfsc
could
develop
support
role
method
survey
develop
tpfsc
input
cwp
chair
member
two
cycl
review
undertaken
agre
question
check
function
format
use
survey
distribut
isbt
offic
isbt
member
promot
via
newslett
social
media
respond
ask
cascad
survey
resultsdiscuss
five
hundr
respons
receiv
differ
countri
tp
role
exist
countri
countri
tp
role
eight
indic
know
note
conflict
respons
receiv
within
countri
perhap
highlight
differ
role
understand
role
tp
role
mani
differ
titl
commonli
report
titl
tp
follow
haemovigil
offic
transfus
safeti
nurs
overal
differ
job
titl
indic
respond
tp
indic
tp
spent
time
anoth
role
main
report
activ
tp
role
polici
procedur
develop
follow
educ
hospit
transfus
committe
involv
audit
activ
fewer
tp
involv
blood
manufactur
develop
work
associ
websit
research
respond
countri
indic
tp
role
main
barrier
financi
follow
lack
support
role
eight
respond
indic
previous
tp
role
longer
place
due
varieti
reason
lack
support
role
nationalorganis
cutback
prioriti
within
transfus
medicin
percent
respond
awar
tpf
prior
survey
support
develop
tool
support
educ
audit
specif
train
tp
regionaln
campaign
programm
support
safe
appropri
blood
use
report
respond
report
nation
guidelin
transfus
summaryconclus
survey
provid
insight
tp
function
provid
tpfsc
valuabl
inform
develop
tool
support
develop
role
l
gomez
j
de
canada
background
administr
blood
product
therapi
frequent
use
within
number
clinic
context
signific
impact
healthcar
system
transfus
affect
peopl
health
statu
also
well
social
relat
within
medic
set
addit
blood
product
also
rais
ethic
legal
issu
kleinman
starr
research
focus
perspect
patient
receiv
blood
transfus
famili
aim
explor
studi
fortin
transfus
document
factor
symbol
associ
blood
relat
patient
profession
amongst
health
profession
seem
influenc
decis
administ
transfus
experi
receiv
blood
transfus
aim
enhanc
studi
precis
observ
role
sociocultur
biomed
environ
process
experi
blood
transfus
procedur
occur
purpos
character
represent
patient
famili
attribut
blood
transfus
well
perspect
regard
blood
transfus
procedur
method
undertook
qualit
trial
base
upon
ethnograph
fieldwork
consist
interview
children
adult
approach
famili
popul
includ
patient
follow
medic
requir
administr
blood
product
famili
provid
attent
paid
acquir
cohort
repres
sociocultur
divers
montreal
blood
transfus
receiv
divid
two
categori
requir
medic
care
first
group
enrol
patient
receiv
multipl
blood
transfus
result
chronic
condit
basi
exampl
sickl
cell
diseas
patient
second
group
receiv
blood
transfus
shorter
term
context
intens
care
unit
admiss
data
collect
underw
themat
analysi
three
level
individu
horizont
transvers
result
found
varieti
idea
ambigu
surround
blood
transfer
mean
valu
respond
believ
blood
donor
carri
contain
individu
characterist
context
surround
blood
transfus
therapeut
cours
also
affect
transfus
patient
famili
respond
disagre
current
anonym
blood
donat
system
would
prefer
donat
blood
children
sever
doctor
state
take
account
symbol
aspect
blood
parent
patient
prescrib
transfus
summaryconclus
better
knowledg
sociocultur
relat
aspect
blood
transfus
plural
clinic
context
might
provid
preciou
inform
physician
nurs
ethnographi
help
better
understand
impact
medic
procedur
like
transfus
differ
popul
daili
live
peopl
see
need
sensit
caregiv
realiti
parent
ideat
pertain
blood
transfus
kay
clinic
govern
darl
down
hospit
health
servic
toowoomba
australia
background
darl
down
hospit
health
servic
ddhh
major
referr
centr
central
western
queensland
cover
squar
kilometr
facil
servic
peopl
seven
site
provid
birth
servic
four
host
queensland
patholog
laboratori
five
site
hold
emerg
neg
red
cell
late
transfus
nurs
tn
employ
cover
ddhh
time
standardis
central
coordin
activitiesresourc
relat
blood
manag
aim
implement
rural
region
blood
manag
practic
measur
understand
current
practic
issu
relat
blood
managementincreas
awar
safe
appropri
blood
managementincreas
staff
confid
complianc
procedurespractic
across
ddhh
method
tn
visit
site
gather
inform
current
practic
challeng
face
staff
around
blood
manag
includ
suggest
improv
polici
procedur
review
updat
align
nation
standardsguidelin
audit
undertaken
four
key
site
measur
practic
complianc
polici
result
challeng
express
relat
access
inform
bloodblood
product
support
medic
specialist
transfus
medicinehaematologist
educ
program
anoth
challeng
lack
familiar
experi
infrequ
transfus
administ
strategi
use
address
challeng
includ
develop
one
stop
blood
shop
intranet
page
provid
link
blood
manag
resourcescommenc
educ
target
workshop
initi
two
workshop
plan
howev
due
demand
given
year
across
ddhh
site
workshop
request
continu
within
outsid
ddhh
staff
becom
awar
tn
role
valu
educationestablish
close
work
relationship
withbetween
laboratori
site
connect
pharmacist
gener
practition
network
consum
group
prove
key
compon
promot
blood
managementlink
tn
state
nation
network
support
inform
sharingcommenc
obstetr
patient
blood
manag
clinic
practic
improv
project
partnership
australian
red
cross
blood
servic
address
iron
defici
anaemia
consequ
strategi
particip
express
increas
knowledg
feel
confid
blood
manag
know
access
resourc
one
key
site
reduc
red
cell
use
significantli
separ
separ
use
singl
unit
transfus
increas
transfus
incid
give
two
unit
transfus
reduc
timefram
summaryconclus
tn
posit
cover
larg
number
site
distanc
establish
dedic
posit
enabl
ddhh
provid
staff
increas
knowledg
increas
patient
safeti
reduc
blood
use
increas
complianc
polici
staff
knowledg
confid
compet
blood
manag
blood
safeti
ongo
work
engag
necessari
maintain
practic
also
continu
make
improv
futur
k
l
c
b
j
van
j
matter
australian
red
cross
blood
servic
melbourn
servic
research
australian
red
cross
blood
servic
brisban
australia
background
subcutan
immunoglobulin
scig
form
treatment
patient
primari
immunodefici
pid
allow
outsid
hospit
set
signific
evid
demonstr
effect
improv
trough
level
immunoglobulin
subsequ
increas
health
relat
qualiti
life
patient
report
increas
complianc
treatment
reduct
overal
cost
care
scig
approv
use
australia
treatment
patient
pid
secondari
immunodefici
health
servic
must
appli
approv
treatment
site
howev
uptak
slow
state
australia
increas
uptak
victorian
govern
offer
health
servic
scig
program
accept
blood
matter
employ
project
nurs
novemb
support
assist
develop
program
aim
assist
support
health
servic
implement
scig
program
across
victoria
method
project
nurs
role
includ
identifi
site
elig
patientspromot
benefit
scig
site
clinician
patientsidentifi
reduc
barrier
program
developmentprovid
educ
scig
assist
train
trainer
educ
modelprovid
tool
resourc
easili
access
central
repositori
result
date
health
servic
approv
administ
scig
six
site
establish
program
seven
develop
program
estim
site
patient
potenti
elig
receiv
scig
howev
individu
assess
requir
health
servic
level
determin
patient
interest
capabl
undertak
quarter
one
patient
elig
diagnosi
scig
record
receiv
scig
increas
februari
import
link
establish
auspip
victorian
pid
advocaci
support
group
interact
strengthen
throughout
project
health
servic
report
posit
feedback
patient
receiv
scig
particularli
relat
choic
therapi
tailor
treatment
around
life
rather
life
around
treatment
financi
barrier
identifi
health
servic
without
cost
associ
develop
program
equip
consum
reduc
fund
current
receiv
intraven
immunoglobulin
treatment
admiss
comprehens
work
plan
develop
outlin
site
visit
support
promot
scig
uptak
develop
tool
key
perform
indic
initi
inform
resourc
made
avail
blood
matter
websit
http
summaryconclus
given
infanc
project
still
consider
work
done
emb
scig
program
across
victoria
initi
feedback
patient
receiv
scig
posit
formal
evalu
respons
treatment
incorpor
project
anticip
patient
becom
awar
treatment
option
may
help
drive
uptak
strategi
need
develop
assist
site
perceivedr
financi
barrier
uptak
c
l
n
sinai
hospit
toronto
canada
medicin
servic
mlt
msc
mount
sinai
hospit
toronto
canada
background
red
blood
cell
rbc
transfus
may
request
patient
iron
defici
anemia
hemoglobin
concentr
perceiv
low
inclus
ferritin
level
rbc
transfus
decis
support
may
prompt
clinician
request
iron
supplement
ferritin
concentr
low
instead
rbc
transfus
help
identifi
clinic
servic
request
rbc
transfus
iron
defici
direct
educ
initi
aim
aim
studi
determin
frequenc
measur
ferritin
level
prior
transfus
frequenc
rbc
transfus
iron
defici
follow
implement
computer
decis
support
exclud
patient
requir
massiv
transfus
protocol
rbc
exchang
transfus
method
retrospect
studi
tertiari
care
affili
center
data
rbc
unit
transfus
serum
ferritin
level
extract
august
juli
decis
support
rbc
transfus
implement
includ
patient
ferritin
level
avail
within
h
rbc
transfus
ferritin
valu
level
consid
diagnost
iron
defici
result
interv
rbc
unit
transfus
patient
ferritin
level
avail
patient
unit
transfus
patient
ferritin
level
rbc
unit
request
patient
emerg
room
gener
medicin
preoper
unit
outpati
depart
icu
pregnanc
oncolog
servic
hemoglobin
hgb
rang
prior
rbc
transfus
follow
patient
hgb
gl
patient
hgb
gl
patient
hbg
gl
patient
hgb
gl
main
indic
cite
major
transfus
low
hgb
bleed
summaryconclus
investig
iron
defici
occur
frequent
rbc
transfus
request
sever
servic
transfus
rbc
instead
iron
iron
defici
futur
modif
decis
support
includ
prompt
check
iron
indic
prior
rbc
transfus
educ
regard
patient
blood
manag
warrant
base
find
r
tocchetti
transfus
medicin
sa
patholog
adelaid
australia
blood
suppli
chain
includ
storag
transport
blood
blood
product
donor
collectionprocess
centr
transfus
servic
laboratori
hospit
transfus
event
occur
blood
suppli
chain
requir
strict
mainten
correct
temperatur
mainten
correct
temperatur
blood
blood
product
blood
suppli
chain
refer
blood
cold
chain
chain
vital
import
factor
mainten
blood
cell
viabil
preserv
cell
function
prevent
bacteri
contamin
complianc
ensur
avail
safe
effect
blood
blood
product
lead
unsaf
blood
blood
product
wastag
preciou
resourc
correct
temperatur
achiev
use
combin
dedic
valid
blood
refriger
equip
transport
contain
blood
refriger
freezer
special
equip
ideal
treat
critic
medic
devic
correctli
specifi
valid
qualifi
maintain
specif
use
blood
storag
importantli
blood
refriger
equip
must
continu
temperatur
record
devic
alarm
system
blood
transport
box
similarli
special
must
also
specifi
valid
qualifi
blood
transport
common
also
possibl
temperatur
environ
transport
period
requir
importantli
facilit
correct
use
blood
refriger
equip
transport
box
train
staff
maintain
process
qualiti
system
must
exist
throughout
everi
link
blood
cold
chain
donor
patient
train
must
level
link
blood
cold
chain
qualiti
system
must
includ
regular
audit
system
test
advent
central
donor
collectionprocess
centr
decentr
site
transfus
perform
blood
suppli
cold
chain
ever
import
effect
blood
cold
chain
import
part
strategi
promot
univers
access
safe
blood
blood
product
transfus
matter
recipi
blood
cold
chain
achiev
technolog
appropri
storag
transport
equip
afford
access
level
health
care
system
blood
suppli
chain
blood
cold
chain
appear
simpl
uncompl
complex
process
involv
mani
import
step
mani
peopl
like
process
chain
strong
weakest
link
failur
link
result
collaps
chain
critic
import
establish
cultur
peopl
involv
blood
suppli
chain
cultur
centr
safe
effect
blood
blood
product
avail
patient
yazer
abstract
avail
h
blood
bank
uganda
blood
transfus
servic
kampala
uganda
montreal
montreal
canada
blood
transfus
critic
compon
health
care
system
high
incom
countri
hic
major
red
blood
cell
rbc
rare
whole
blood
wb
transfus
prescrib
patient
complex
surgic
procedur
trauma
cancer
low
incom
countri
lic
rbc
wb
transfus
given
patient
usual
children
year
old
malaria
women
obstetr
haemorrhag
trauma
one
could
argu
everi
rbc
wb
transfus
set
emerg
transfus
ie
administ
transfus
would
result
within
short
time
period
signific
advers
effect
patient
clinic
cours
need
transfus
major
set
hic
predict
blood
shortag
rare
true
emerg
transfus
less
common
hic
lic
occur
blood
necessari
respond
emerg
avail
contrast
major
request
rbc
wb
transfus
lic
true
emerg
blood
suppli
mostli
level
would
consid
state
sever
shortag
hic
order
manag
doubl
impact
limit
blood
suppli
frequent
emerg
need
rbcwb
transfus
often
given
much
stricter
indic
liclmic
hic
eg
recommend
rbcwb
transfus
children
lic
acut
anemia
indic
transfus
given
children
hemoglobin
hb
level
gl
symptomat
usual
hb
level
gl
spite
restrict
children
lic
die
lack
blood
recent
studi
shown
acut
ill
children
sever
anemia
transfus
significantli
increas
risk
die
bmc
versu
transfus
bmc
hematolog
versu
likewis
estim
africa
ssa
approxim
women
haemorrhag
die
due
lack
blood
bjog
altern
studi
lic
shown
rbcwb
transfus
given
without
appropri
indic
issu
deserv
scientif
evalu
issu
deserv
studi
includ
inventori
manag
blood
wastag
blood
supplier
hospit
level
exampl
blood
supplier
level
includ
improv
blood
donor
select
procedur
decreas
underweight
collect
ensur
suppli
safe
small
volum
unit
neonat
paediatr
patient
hospit
level
exampl
includ
coordin
inventori
blood
use
among
differ
sector
within
given
institut
decreas
wastag
blood
sent
ward
theatr
transfus
approach
ensur
best
use
limit
blood
suppli
lic
includ
better
commun
collabor
blood
supplier
user
effect
nation
blood
transfus
committe
implement
patient
blood
manag
strategi
eg
late
cord
blood
clamp
correct
iron
defici
pregnanc
prior
elect
surgeri
massiv
transfus
protocol
includ
earli
use
tranexamin
acid
traumat
obstetr
haemorrhag
present
focu
strategi
respond
emerg
requir
rbcwb
transfus
presenc
limit
blood
avail
particularli
ssa
aa
pourfathollah
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
iranian
blood
transfus
organ
tehran
iran
islam
republ
iran
sinc
iran
locat
thalassemia
belt
prevent
treatment
thalassemia
major
one
prioriti
nation
health
govern
countri
current
patient
thalassemia
major
iran
provid
constant
compat
safe
adequ
blood
blood
product
thalassemia
patient
prevent
treatment
thalassemia
major
one
prioriti
nation
health
govern
countri
nation
thalassemia
prevent
plan
start
consid
number
new
patient
prove
one
success
plan
develop
countri
preval
alloimmun
among
iranian
thalassemia
patient
decreas
iran
howev
rate
consider
low
compar
countri
although
strategi
reduc
risk
rbc
alloimmun
find
compat
rbc
unit
patient
thalassemia
remain
big
challeng
ibto
provid
constant
compat
safe
adequ
blood
blood
product
thalassemia
patient
also
leukoreduct
appli
thalassemia
patient
refer
subsidiari
clinic
center
throughout
countri
provid
health
servic
patient
accord
protocol
set
iranian
ministri
health
part
mitig
strategi
manag
alloimmun
ibto
recommend
perform
match
protocol
k
antigen
kell
system
preval
rh
alloantibodi
patient
thalassemia
like
c
e
rh
system
secondli
person
medicin
give
appropri
transfus
format
alloantibodi
prevent
sever
complic
find
compat
rbc
unit
lastli
perform
screen
programm
find
donor
phenotyp
antigen
may
help
make
pool
donor
express
immunogen
rbc
antigen
kell
rh
antigen
n
k
h
r
k
k
z
z
e
epidemiolog
prevent
medicin
monash
univers
medic
centr
monash
health
health
econom
monash
univers
melbourn
australia
background
beta
thalassaemia
major
inherit
disord
haemoglobin
requir
red
blood
cell
rbc
transfus
therapi
inform
requir
understand
true
cost
support
part
overal
manag
new
treatment
develop
condit
howev
current
australian
intern
data
avail
determin
true
cost
transfus
requir
comprehens
investig
complex
rang
activ
requir
provid
rbc
support
specif
patient
cohort
variou
factor
influenc
cost
eg
inpatientoutpati
set
includ
laboratori
clinic
govern
activ
input
requir
deliv
servic
aim
accur
determin
total
cost
rbc
transfus
support
adult
thalassaemia
patient
monash
medic
centr
mmc
thalassaemia
treatment
centr
melbourn
australia
method
cost
td
abc
studi
clinic
laboratori
administr
process
rbc
transfus
adult
thalassaemia
patient
mmc
perform
detail
process
map
develop
everi
procedur
undertaken
month
march
direct
indirect
cost
personnel
consum
equip
clinic
test
procedur
calcul
includ
cost
govern
manag
consequ
transfus
complic
detail
process
map
correspond
flowchart
develop
provid
descript
entir
transfus
pathway
includ
phlebotomi
laboratori
procedur
patient
day
admiss
rbc
administr
treatment
process
directli
relat
transfus
direct
observ
verifi
process
map
time
process
conduct
expert
opinion
obtain
process
unabl
time
activ
resourc
staff
equip
consum
overhead
includ
cost
sensit
analysi
perform
result
complet
process
map
includ
prescript
sampl
collect
laboratori
activ
includ
inventori
manag
administr
rbc
transfus
iron
chelat
patient
receiv
deferasirox
desferrioxamin
receiv
process
step
staff
consum
requir
provid
rbc
transfus
adult
patient
averag
rbc
per
admiss
thalassaemia
major
month
includ
frequenc
direct
indirect
overhead
cost
contribut
unit
cost
aud
ci
summaryconclus
td
abc
method
provid
accur
measur
cost
transfus
unit
rbc
patient
beta
thalassaemia
major
consid
staff
time
equip
consum
resourc
cost
transfus
unit
rbc
set
doubl
publish
manufactur
cost
rbc
unit
studi
also
provid
detail
process
map
cost
method
adapt
cost
studi
blood
compon
hospit
set
patient
group
includ
chronic
transfus
patient
popul
myelodysplasia
detail
cost
data
determin
part
studi
valuabl
clinician
hospit
manag
govern
blood
servic
patient
broader
commun
research
support
celgen
celgen
role
studi
design
analys
data
abstract
prepar
h
c
laboratori
medicin
pathobiolog
univers
toronto
toronto
british
columbia
vancouv
medicin
program
univers
health
network
toronto
canada
background
red
blood
cell
rbc
alloimmun
occur
often
patient
hemoglobinopathi
propens
sickl
cell
diseas
scd
especi
pronounc
owe
inflammatori
milieu
rbc
transfus
indic
differ
donor
base
versu
host
antigen
profil
address
prophylact
match
episod
transfus
scd
associ
higher
rate
alloimmun
hemolysi
per
rbc
unit
compar
patient
chronic
transfus
regimen
whether
patient
thalassemia
intermedia
ti
share
similar
alloimmun
risk
episod
rbc
transfus
unknown
ti
includ
clinic
sever
trait
major
hemoglobin
h
diseas
hhd
affect
patient
ti
requir
transfus
birth
may
requir
episod
ill
chronic
basi
later
life
treat
complic
aim
primari
object
studi
evalu
frequenc
rbc
alloimmun
patient
hhd
receiv
episod
rbc
transfus
method
retrospect
review
ti
patient
follow
red
blood
cell
disord
clinic
januari
septemb
conduct
academ
institut
toronto
canada
patient
andor
mutat
result
ti
phenotyp
mutat
result
hhd
includ
review
patient
exclud
studi
inform
regard
transfus
histori
frequenc
antibodi
investig
result
age
first
transfus
collect
chronic
transfus
defin
receiv
one
unit
rbc
per
month
least
month
transfus
institut
thalassemia
match
rhd
result
patient
ti
hhd
review
studi
patient
femal
addit
transfus
administ
institut
patient
also
receiv
transfus
institut
forti
patient
receiv
episod
transfus
median
interquartil
rang
iqr
rbc
unit
mean
unit
transfus
institut
patient
receiv
chronic
transfus
median
iqr
unit
mean
unit
transfus
institut
mean
age
chronic
transfus
initi
year
old
rbc
antibodi
detect
patient
patient
multipl
antibodi
frequenc
rbc
alloimmun
patient
receiv
episod
transfus
n
compar
n
chronic
transfus
p
antibodi
detect
specif
target
rhce
antigen
summaryconclus
despit
limit
exposur
rbc
unit
patient
ti
receiv
episod
rbc
transfus
increas
risk
alloimmun
specif
rh
antigen
provis
unit
patient
may
mitig
risk
sm
j
j
de
k
van
b
j
r
van
e
van
der
k
f
van
den
blood
cell
research
sanquin
research
landstein
laboratori
pediatr
hematolog
immunolog
infecti
diseas
emma
children
hospit
academ
medic
center
univers
amsterdam
hematolog
clinic
epidemiolog
biostatist
bioinformat
academ
medic
center
univers
amsterdam
amsterdam
hematolog
erasmu
mc
univers
medic
center
rotterdam
hematolog
haga
hospit
hagu
netherland
du
sang
ile
de
franc
inserm
univers
pari
henri
mondor
center
sickl
cell
diseas
henri
mondor
franc
experiment
immunohematolog
plasma
protein
sanquin
research
landstein
laboratori
amsterdam
netherland
background
virtual
sickl
cell
diseas
scd
patient
reli
blood
transfus
main
treatment
strategi
howev
frequent
blood
transfus
pose
risk
alloimmun
sever
complic
lead
blood
transfus
reaction
potenti
lethal
delay
hemolyt
transfus
reaction
dhtr
patient
develop
alloantibodi
repeat
transfus
appear
alloimmun
patient
respond
repres
genet
distinct
group
prone
rbc
sensit
averag
patient
alloimmun
patient
remain
toler
despit
high
transfus
exposur
promis
strategi
reduc
alloimmun
scd
prophylact
match
order
reduc
cost
make
logist
feasibl
strategi
reserv
scd
patient
risk
develop
alloantibodi
predict
patient
turn
respond
identif
genet
biomark
alloimmun
necessari
aim
aim
studi
evalu
whether
snp
gene
previous
associ
alloimmun
graft
reject
autoimmun
diseas
associ
rbc
alloimmun
cohort
scd
patient
method
studi
dna
sampl
cohort
transfus
scd
patient
combin
franc
netherland
case
posit
histori
alloimmun
receiv
rbc
unit
control
neg
histori
alloimmun
receiv
rbc
unit
singl
nucleotid
polymorph
snp
copi
number
variat
gene
cluster
studi
multiplex
probe
amplif
assay
addit
genotyp
snp
gene
use
next
gener
sequenc
ng
frequenc
compar
use
logist
regress
patient
includ
control
case
result
open
read
frame
gene
strongli
associ
decreas
risk
ci
associ
persist
includ
control
exposur
unit
ci
appear
even
stronger
exclud
case
rh
k
antibodi
ci
genotyp
analysi
select
snp
use
ng
addit
snp
pick
statist
analysi
current
perform
genotyp
snp
summaryconclus
conclus
scd
patient
polymorph
threefold
lower
risk
rbc
compar
patient
without
mutat
protect
effect
strongest
exposur
antigen
immunogen
rh
k
antigen
next
come
week
expect
find
polymorph
associ
alloimmun
scd
g
j
w
refer
laboratori
research
institut
servic
versitibloodcent
wisconsin
patholog
medic
colleg
wisconsin
hospit
milwauke
unit
state
background
minor
blood
group
antigen
inform
red
cell
unit
provid
valuabl
inform
hospit
alloimmun
patient
transfus
regulatori
label
exorbitantli
expens
meet
demand
access
unlicens
histor
phenotyp
red
cell
genotyp
result
provid
option
confirm
statu
specif
unit
howev
histor
antigen
inform
provid
pack
slip
cumbersom
unit
shipment
need
set
asid
document
transfer
refer
creat
electron
access
program
queri
blood
center
central
databas
histor
phenotyp
red
cell
genotyp
screen
result
find
unit
local
inventori
aim
provid
hospit
search
engin
queri
blood
center
central
databas
red
cell
phenotyp
genotyp
identifi
histor
unit
local
inventori
method
electron
queri
develop
mimic
process
use
phenotyp
unit
hospit
oper
scan
isbt
unit
number
barcod
set
blood
unit
local
inventori
design
field
select
desir
criteria
list
along
number
unit
requir
queri
electron
sent
blood
center
report
back
unit
id
match
search
criteria
search
criteria
met
queri
perform
addit
unit
criteria
relax
order
electron
push
blood
center
use
isbt
unit
number
blood
establish
comput
system
identifi
red
cell
phenotyp
genotyp
inform
link
donor
pattern
match
use
determin
genotyp
inform
satisfi
full
request
argument
complet
unit
queri
search
list
oldest
unit
first
number
unit
requir
satisfi
match
unit
display
oper
result
facil
locat
mile
away
blood
center
hospit
bed
rang
blood
bank
inventori
hold
least
unit
search
criteria
rang
type
among
common
rh
mn
kell
duffi
kidd
antigen
approxim
blood
donor
unit
leav
blood
center
phenotyp
red
cell
genotyp
includ
rh
mn
kell
duffi
kidd
common
antigen
year
end
search
found
unit
among
unit
scan
success
search
correl
frequenc
percent
successparti
success
rate
singl
antigen
rang
e
k
c
jkb
fya
jka
n
fyb
successparti
success
rate
addit
attribut
respect
summaryconclus
access
histor
phenotyp
red
cell
genotyp
inform
blood
center
provid
valuabl
inform
significantli
reduc
confirmatori
phenotyp
process
provid
data
unit
hospit
inventori
limit
ship
delay
blood
blood
provid
e
di
angelantonio
public
health
primari
care
univers
cambridg
cambridg
unit
kingdom
everi
year
europ
approxim
million
blood
donor
donat
million
unit
blood
product
transfus
hospit
stay
includ
procedur
past
year
effort
blood
transfus
mainli
focus
improv
viral
safeti
establish
better
use
blood
product
patient
benefit
although
effort
must
maintain
also
need
develop
plan
ensur
blood
suppli
adequ
maintain
donor
health
use
randomis
trial
robust
methodolog
assess
key
question
time
interv
blood
donat
personalis
risk
anaemia
iron
defici
reduc
optim
approach
haemoglobin
test
allow
donat
address
first
question
describ
result
interv
trial
open
randomis
pragmat
trial
determin
whether
blood
safe
accept
collect
donor
frequent
present
practic
england
similar
interv
current
custom
countri
donor
age
year
internet
access
includ
equal
number
men
women
recruit
routin
donor
session
static
donat
centr
june
june
men
randomli
assign
standard
vs
vs
interv
women
assign
standard
vs
vs
interv
primari
endpoint
number
blood
donat
made
key
secondari
endpoint
donor
qualiti
life
assess
short
address
second
question
describ
result
compar
studi
comparison
differ
approach
measur
haemoglobin
level
blood
donor
haemoglobin
level
measur
use
gravimetr
copper
sulphat
test
strategi
wherebi
haemoglobin
level
previou
donat
use
predict
like
haemoglobin
level
current
donat
test
capillari
blood
two
spectrometri
strategi
well
venou
sampl
analys
gold
standard
autom
cell
counter
primari
outcom
combin
sensit
specif
test
strategi
detect
haemoglobin
level
beneath
minimum
threshold
find
studi
provid
evid
develop
personalis
approach
blood
donat
improv
donor
safeti
minimis
risk
iron
defici
townsend
h
kamel
bravo
corpor
medic
affair
blood
system
scottsdal
unit
state
background
allerg
reaction
donor
well
recogn
describ
hemovigil
system
local
allerg
reaction
includ
rash
itch
site
skin
disinfect
applic
adhes
bandag
gener
allerg
reaction
gar
may
express
widespread
rash
hive
itch
swell
face
neck
throat
wheez
extrem
case
anaphylaxi
sever
allerg
reaction
associ
ethylen
oxid
steril
apheresi
kit
hydroxyethyl
starch
use
granulocyt
collect
rariti
reaction
rate
publish
daurat
report
rate
gar
per
system
allerg
event
among
apheresi
platelet
collect
none
wb
collect
transfus
aim
determin
rate
gar
system
method
analyz
allogen
apheresi
wb
collect
gar
identifi
base
sign
symptom
gener
rashhiv
itch
report
staff
andor
medic
director
classif
allerg
system
consist
aabbihnisbt
definit
record
review
perform
case
assess
appropri
classif
base
record
observ
sign
manag
staff
outsid
medic
care
donor
deferr
due
advers
event
donat
inform
includ
type
apheresi
collect
devic
use
report
rate
gar
calcul
per
wb
apheresi
collect
ac
overal
stratifi
base
procedur
type
vs
collect
includ
plasma
platelet
procedur
result
twelv
gar
among
ac
rate
per
none
among
wb
collect
identifi
analysi
period
seven
event
associ
collect
n
rate
per
five
per
associ
platelet
platelet
combin
apheresi
collect
system
event
associ
plasma
plasma
combin
apheresi
collect
n
wb
collect
n
event
donor
defer
ac
two
event
requir
outsid
medic
care
case
report
use
requir
case
resolv
spontan
sever
symptom
rang
hive
bodi
extrem
swollen
lip
throat
tight
troubl
swallowingthroat
tightnesschest
tight
summaryconclus
gar
rare
concern
safeti
may
dictat
donor
suffer
reaction
may
need
defer
futur
autom
donat
rate
system
allerg
reaction
system
significantli
differ
separ
manufactur
type
collect
vs
platelet
combin
rate
system
compar
report
daurat
howev
data
includ
apheresi
platelet
collect
includ
apheresi
collect
rate
rare
reaction
subject
limit
small
number
event
w
de
k
van
den
studi
sanquin
vumc
amsterdam
netherland
background
whole
blood
donat
involv
risk
bodi
iron
store
deplet
loss
haemoglobin
hb
hb
level
though
accur
reflect
donor
true
iron
statu
altern
marker
bodi
iron
store
like
zinc
protoporphyrin
zpp
ferritin
present
opportun
supplement
replac
hb
measur
loss
iron
everi
donat
world
health
organis
alreadi
advis
monitor
ferritin
level
donor
combin
hb
zpp
andor
ferritin
predict
marker
potenti
donor
deferr
could
advantag
term
donor
health
effici
term
blood
bank
practic
aim
aim
estim
compar
predict
valu
ferritin
zpp
hb
individu
combin
deferr
subsequ
donat
method
studi
popul
consist
repeat
donor
donor
observ
cohort
studi
among
repeat
donor
aim
gain
insight
genet
determin
hb
level
iron
defici
select
subset
donor
made
least
one
follow
donat
attempt
particip
studi
whole
blood
donor
age
construct
logist
regress
predict
model
use
predictor
hb
zzp
ferritin
primari
predictor
interest
deferr
previou
donat
age
bmi
donat
histori
prior
studi
period
season
donat
addit
predictor
interest
deferr
next
donat
use
outcom
analys
stratifi
sex
wald
statist
nagelkerk
area
curv
auc
present
predict
model
predict
model
intern
valid
result
total
male
femal
donor
includ
studi
popul
mean
ferritin
level
mean
zpp
level
male
femal
respect
odd
ratio
confid
interv
ci
zpp
observ
men
women
ci
ci
ferritin
observ
men
women
respect
intern
valid
area
curv
auc
zpp
ferritin
hb
estim
next
backward
select
procedur
zpp
deem
signific
predictor
final
model
built
signific
secondari
predictor
previou
donat
histori
age
auc
final
model
hb
ferritin
previou
donat
histori
age
improv
men
women
summaryconclus
hb
ferritin
demonstr
higher
predict
valu
subsequ
low
hb
deferr
zpp
ad
previou
donat
histori
age
predictor
improv
predict
valu
model
addit
outcom
like
subsequ
hb
level
also
consid
evalu
valu
ferritin
zpp
potenti
practic
predictor
daili
blood
bank
set
br
j
e
g
g
b
c
w
affair
american
red
cross
rockvil
affair
american
red
cross
gaithersburg
unit
state
background
singl
donor
platelet
sdp
donor
transit
plateletpheresi
donat
histori
whole
blood
wb
doubl
red
cell
apheresi
donat
drc
recruit
often
follow
identif
high
platelet
count
marker
associ
iron
deplet
id
allow
donat
frequenc
per
year
estim
red
cell
loss
ml
per
donat
sdp
donor
may
risk
id
unrecogn
id
could
advers
impact
donor
uncorrect
id
could
lead
donor
loss
increas
deferr
follow
higher
minimum
hemoglobin
male
donor
requir
us
fda
final
rule
ultim
impact
sdp
suppli
aim
evalu
impact
donat
return
behavior
pilot
ferritin
test
program
provid
donor
low
ferritin
test
result
method
test
control
subject
male
sdp
donor
may
wb
drc
donat
consid
risk
id
base
fingerstick
hemoglobin
gdl
start
march
test
subject
mail
letter
report
low
ferritin
result
ngml
recommend
iron
supplement
lf
letter
annual
rate
donat
low
hemoglobin
deferr
summar
receipt
lf
letter
test
subject
compar
intervent
estim
develop
control
sdp
donor
final
rule
implement
may
differ
mean
test
control
group
test
use
analysi
varianc
anova
approxim
lf
letter
test
subject
sent
final
rule
implement
elig
group
requir
sdp
procedur
minimum
respect
period
electron
survey
test
donor
inquir
iron
supplement
practic
result
test
n
control
n
donor
sdp
donat
rate
prior
evalu
intervent
vs
annual
respect
f
p
receipt
lf
letter
annual
donat
rate
test
donor
declin
declin
donat
rate
much
sharper
control
fall
failur
return
test
subject
receiv
lf
letter
control
follow
final
rule
implement
p
proport
visit
result
low
hemoglobin
deferr
increas
test
donor
control
donor
test
donor
report
take
supplement
iron
receiv
lf
letter
take
iron
report
initi
iron
supplement
follow
letter
summaryconclus
data
suggest
mani
donor
respons
notif
low
ferritin
attend
messag
iron
supplement
test
subject
also
subject
final
rule
higher
hemoglobin
requir
experienc
declin
donat
rate
less
half
larg
control
donor
failur
return
twice
high
control
ferritin
test
potenti
benefit
donor
health
stabl
blood
suppli
analys
need
assess
impact
donor
behavior
implement
ferritin
test
program
r
j
g
g
g
j
j
immunolog
transfus
medicin
uppsala
univers
hospit
uppsala
sweden
red
cross
blood
servic
helsinki
finland
blood
transfus
societi
pari
franc
nation
blood
centr
rome
itali
director
qualiti
medicin
health
care
strasbourg
franc
drug
administr
silver
spring
md
unit
state
red
cross
blood
servic
kelvin
grove
qld
australia
background
european
committe
partial
agreement
blood
transfus
council
europ
coe
appoint
work
group
wg
address
plasma
suppli
manag
psm
wg
psm
task
gather
data
support
revis
guid
prepar
use
qualiti
assur
blood
compon
coe
guid
current
ed
http
registeredqmeufreepub
previou
survey
literatur
review
indic
wide
practic
variat
pauciti
support
evid
aim
defin
rang
current
practic
obtain
oper
donor
safeti
data
wg
psm
conduct
survey
blood
establish
be
perform
plasmapheresi
collect
plasma
fraction
pff
method
survey
cover
elig
criteria
medic
assess
donor
collect
volum
frequenc
blood
test
manag
red
cell
loss
donor
panel
demograph
captur
record
advers
event
equip
use
staff
qualif
supervis
site
requir
product
measur
key
perform
indic
use
limit
pilot
util
questionnair
survey
took
place
septemb
decemb
survey
submit
be
via
repres
member
state
ms
observ
relev
profession
network
result
preliminari
analysi
survey
data
focus
comparison
plasmapheresi
practic
recommend
coe
guid
respons
countri
includ
respond
countri
report
collect
pff
plasmapheresi
respons
coe
ms
respons
countri
outsid
coe
respond
report
total
plasmapheresi
collect
last
fiscal
year
guid
allow
annual
collect
volum
exclud
anticoagul
report
stringent
allow
larger
volum
align
guid
allow
plasmapheresi
procedur
per
year
report
stringent
allow
larger
number
align
mean
number
annual
donat
per
donor
respond
stringent
number
procedur
among
respond
allow
procedur
per
year
mean
number
per
donor
number
guid
allow
maximum
collect
ml
exclud
anticoagul
report
stringent
allow
larger
volum
depend
donor
size
align
overal
advers
event
rate
per
collect
report
respond
rang
wide
report
less
summaryconclus
collect
pff
plasmapheresi
common
among
ms
coe
contribut
suppli
pff
practic
vari
wide
alway
align
recommend
guid
analysi
survey
data
yield
correl
collect
practic
outcom
relev
donor
safeti
plasma
avail
incorpor
recommend
plasmapheresi
guid
anticip
advanc
progress
toward
robust
suppli
pff
safeguard
donor
health
p
mali
blood
transfus
centr
slovenia
c
l
societi
blood
transfus
cameroon
societi
blood
transfus
cairo
egypt
societi
blood
transfus
cap
town
south
africa
societi
blood
transfus
zimbabw
background
despit
improv
blood
safeti
indic
african
countri
latest
survey
report
cumul
transfus
transmit
infect
median
seropreval
reach
area
transfus
advers
event
found
patient
african
blood
servic
still
run
daili
activ
without
qualiti
manag
system
place
africa
societi
blood
transfus
afsbt
profession
bodi
creat
mission
advoc
highest
ethic
profession
standard
skill
blood
transfus
across
african
contin
enabl
safe
univers
access
sustain
nation
blood
programm
particip
countri
strateg
object
includ
develop
support
implement
afsbt
accredit
programm
endors
oper
standard
highest
qualiti
practic
blood
transfus
take
cogniz
dispar
state
develop
blood
servic
africa
afsbt
accredit
programm
programm
establish
provid
blood
servic
virtual
stage
blood
safeti
develop
step
step
accreditationcertif
mechan
differ
common
none
approach
step
certif
provid
facil
meet
minimum
basic
qualiti
oper
requir
step
certif
recognit
meet
intermedi
qualiti
oper
requir
step
correspond
full
accredit
qualiti
oper
requir
intern
standard
met
programm
base
local
relev
standard
prepar
review
biannual
expert
field
establish
africa
societi
blood
transfus
afsbt
collabor
aabb
outcom
sinc
total
blood
servic
countri
enrol
process
certif
accredit
among
countri
afsbt
assessor
conduct
assess
among
baselin
initi
progress
formal
assess
led
aabb
assessor
two
countri
accredit
step
facil
got
certifi
step
challeng
despit
rise
interest
afsbt
accredit
program
afsbt
face
limit
fund
run
program
extern
fund
support
run
qualiti
cultur
qualiti
system
staff
capac
build
still
reinforc
african
blood
servic
prior
formal
assess
continu
improv
blood
transfus
field
dictat
regular
revis
standard
match
new
technolog
intern
regul
emerg
blood
transfus
associ
risk
michel
abstract
avail
r
f
k
u
clinic
transfus
medicin
center
clinic
transfus
medicin
giessen
giessen
germani
background
immun
thrombocytopenia
itp
bleed
diseas
caus
autoantibodi
aab
direct
platelet
plt
glycoprotein
recent
platelet
clearanc
via
receptor
recogn
glycan
chang
platelet
surfac
propos
new
mechan
itp
mice
aim
studi
investig
impact
aab
itp
patient
glycan
pattern
megakaryocyt
mk
platelet
analyz
subsequ
effect
surviv
vivo
method
mk
differenti
hematopoiet
stem
cell
cultiv
thrombopoietin
mk
plt
incub
modif
glycan
pattern
assess
flow
cytometri
use
two
lectin
ricinu
communi
agglutinin
rca
erythrina
cristag
lectin
ecl
impact
glycan
pattern
modif
surviv
human
platelet
analyz
use
nodscid
mous
model
result
incub
differ
pattern
glycan
modif
observ
platelet
surfac
sera
induc
high
ecl
bind
sera
show
decreas
rca
bind
interestingli
subgroup
abl
chang
glycan
pattern
mk
surfac
fold
increas
compar
control
inject
aab
acceler
clearanc
human
plt
circul
vivo
destruct
human
plt
larg
reduc
neuraminidas
inhibitor
prevent
glycan
chang
plt
surfac
plt
surviv
h
vs
summari
conclus
result
indic
aab
itp
patient
abl
induc
chang
glycan
pattern
mk
plt
surfac
mechan
modif
glycan
pattern
seem
contribut
platelet
destruct
well
interfer
plt
product
mk
r
medicin
pathobiolog
univers
toronto
medicin
st
michael
hospit
divis
hematolog
univers
toronto
blood
servic
toronto
canada
background
immun
thrombocytopenia
itp
autoimmun
disord
caus
thrombocytopenia
decreas
platelet
level
primarili
due
presenc
antiplatelet
antibodi
therapi
treatment
antibodi
factor
rbc
proven
amelior
itp
come
limit
product
limit
quantiti
alway
carri
theoret
risk
transfer
emerg
pathogen
limit
essenti
elimin
replac
recombin
antibodi
order
achiev
import
first
elucid
mechan
action
amelior
itp
antibodi
glycophorin
associ
protein
present
rbc
use
wide
model
effect
mice
past
work
shown
abl
amelior
itp
success
vivo
inhibit
platelet
phagocytosi
vitro
howev
also
associ
anemia
observ
also
decreas
bodi
temperatur
mice
indic
undesir
inflammatori
activ
aim
determin
whether
effect
requir
amelior
itp
potenti
help
determin
characterist
therapeut
rbc
antibodi
anoth
antibodi
test
method
test
therapeut
efficaci
potenti
side
effect
murin
model
itp
well
test
abil
induc
vitro
phagocytosi
result
demonstr
increas
platelet
count
passiv
itp
consist
across
variou
mous
strain
alway
induc
anemia
lead
decreas
bodi
temperatur
similar
therapeut
rbc
antibodi
murin
model
itp
induc
phagocytosi
rbc
bound
rbc
inhibit
phagocytosi
macrophag
summari
conclus
may
possibl
use
inhibit
platelet
phagocytosi
vitro
predictor
determin
abil
antibodi
amelior
itp
vivo
anemia
inflammatori
activ
may
requir
itp
amelior
antibodi
character
rbc
antibodi
requir
solidifi
current
conclus
well
elucid
mechan
action
itp
q
z
research
depart
jiangsu
provinc
blood
center
medic
mycolog
institut
dermatolog
chines
academi
medic
scienc
peke
union
medic
colleg
nanj
china
background
becom
increasingli
clear
platelet
play
role
initi
modul
inflammatori
immun
respons
infect
autophagi
process
maintain
cellular
homeostasi
metabol
also
key
regul
immun
demonstr
canon
autophagi
could
constitut
present
rest
platelet
induc
upon
platelet
activ
aim
clarifi
whether
candida
albican
could
influenc
autophagi
human
platelet
determin
underli
mechan
method
human
platelet
challeng
c
albican
presenc
absenc
chloroquin
cq
vitro
h
western
blot
use
analyz
accumul
protein
level
serv
load
control
calcofluor
white
cfw
use
tool
analyz
local
c
albican
cfw
use
stain
c
albican
make
exhibit
fluoresc
expos
ultraviolet
light
antibodi
use
detect
express
distribut
imag
collect
laser
scan
confoc
microscop
result
found
level
accumul
increas
platelet
treatment
lysosom
inhibitor
cq
h
indic
basal
autophagi
level
accumul
decreas
platelet
challeng
c
albican
presenc
cq
h
compar
cell
incub
cq
alon
receptor
cargo
destin
degrad
autophagi
abl
bind
ubiquitin
use
target
autophagosom
clear
ubiquitin
protein
found
level
significantli
increas
treatment
c
albican
presenc
absenc
cq
immunofluoresc
assay
also
prove
find
fluoresc
enhanc
wrap
around
c
albican
summari
conclus
data
suggest
c
albican
may
inhibit
autophagi
flux
platelet
underli
mechan
c
albican
influenc
autophagi
platelet
role
autophag
adaptor
protect
c
albican
infect
need
studi
blood
servic
ottawa
michael
hospit
toronto
toronto
canada
background
red
blood
cell
rbc
alloimmun
seriou
complic
transfus
pregnanc
caus
hemolyt
diseas
fetu
newborn
hdfn
polyclon
use
prevent
hdfn
mechan
refer
immun
suppress
ami
although
therapi
highli
success
mechan
remain
poorli
understood
major
theori
behind
ami
base
upon
erythrocyt
clearanc
epitop
mask
immunolog
deviat
recent
antigen
ag
loss
also
known
ag
modul
propos
potenti
mechan
ami
kel
immunoprophylaxi
model
receptor
andor
complement
requir
hand
recent
demonstr
model
system
immunoglobulin
g
fc
glycan
essenti
ami
presenc
fc
glycan
consid
import
receptor
complement
function
howev
relev
predictor
ami
effect
impact
antibodi
glycosyl
process
assess
aim
aim
present
work
studi
abil
wild
type
deglycosyl
antibodi
specif
differ
portion
experiment
ag
induc
ami
activ
ii
rbc
clearanc
iii
ag
modul
determin
relat
exist
ami
activ
one
mechan
method
transgen
hod
mice
possess
erythrocyt
express
antigen
compos
hen
egg
lysozym
hel
sequenc
ovalbumin
ova
human
duffi
transmembran
protein
hod
label
fluoresc
dye
transfus
mice
h
select
antibodi
administ
mice
bled
h
percentag
circul
level
surviv
rbc
assess
flow
cytometri
igm
igg
antibodi
respons
measur
elisa
transfus
result
antibodi
specif
differ
portion
induc
ami
independ
abil
clear
rbc
strikingli
howev
antibodi
abl
fulli
inhibit
igm
respons
induc
signific
earli
deglycosyl
variant
monoclon
antibodi
abl
induc
ami
loss
ag
even
though
unabl
promot
rbc
clearanc
compar
antibodi
respons
rbc
clearanc
demonstr
ami
induc
antibodi
correl
abil
caus
erythrocyt
clearanc
summari
conclus
ag
loss
highli
relat
ami
induct
rbc
clearanc
dispens
requir
ami
find
demonstr
good
predictor
ami
activ
hod
model
nation
de
pour
le
group
sanguin
institut
nation
de
la
transfus
sanguin
inserm
pari
diderot
dexcel
pari
franc
rh
blood
group
system
high
clinic
relev
alloantibodi
known
involv
hemolyt
transfus
reaction
hdfn
rh
one
two
complex
system
mn
first
reason
complex
lie
fact
rh
encod
two
gene
rhd
rhce
second
reason
atyp
orient
gene
facilit
materi
exchang
meiosi
major
molecular
background
origin
rh
complex
gene
convers
mechan
howev
mani
molecular
event
delet
insert
splice
variant
point
mutat
also
report
give
rise
larg
number
rhd
rhce
variant
gene
alter
may
result
loss
weak
express
one
sever
exist
epitop
andor
product
new
epitop
note
rare
rh
variant
may
origin
alter
anoth
gene
rhag
rhnull
regul
type
rhmod
two
paralog
rhd
rhce
gene
exon
encod
rhd
rhce
protein
respect
rh
current
compris
antigen
antigen
among
antigen
encod
rhce
rhd
gene
eg
g
antigen
complex
antigen
lie
great
number
phenotyp
variant
weak
partial
phenotyp
even
greater
number
allel
variant
today
weak
del
exclud
partial
phenotyp
report
blood
requir
partial
usual
problem
challeng
patient
andor
complex
rhce
protein
much
challeng
transfus
medicin
mani
variant
correspond
rare
blood
type
today
rhce
allel
report
clinic
signific
rhce
allel
mainli
encount
peopl
african
descent
rhce
cear
rhce
ceek
rhce
cebi
rhce
cesm
code
rare
type
rh
rhce
ce
also
call
rhce
code
rare
type
rh
rhce
includ
rn
haplotyp
encod
rare
type
rh
rhce
cejal
encod
rare
rh
type
rhce
cecf
encod
rare
rh
type
rhce
ceag
encod
rare
rh
type
rhce
cemo
encod
rare
rh
type
rhce
ceti
encod
partial
c
partial
e
report
lack
antigen
today
anoth
degre
complex
due
fact
previou
rare
rhce
variant
code
partial
e
partial
c
potenti
develop
usual
mutual
compat
made
rhce
cear
rhce
ceek
rhce
cebi
rhce
cesm
call
made
rhce
ce
call
unfortun
rhce
variant
specif
name
call
confus
addit
mutual
compat
depend
encod
allel
also
case
make
thing
even
complex
anoth
complex
rh
system
resid
inde
rhce
variant
may
express
epitop
eg
rhce
cecf
rhce
cehar
convers
eg
express
c
diva
rhd
hybrid
allel
result
time
unexplain
rh
reactiv
occur
molecular
alter
observ
sequenc
correspond
gene
second
gene
haplotyp
need
investig
v
apheresi
rabin
medic
center
petah
tikva
blood
group
refer
laboratori
magen
david
adom
nation
blood
servic
ramat
gan
israel
red
blood
cell
rbc
transfus
one
common
medic
procedur
perform
amongst
hospit
patient
develop
countri
rare
blood
type
defin
isbt
work
parti
wp
absenc
high
frequenc
hf
antigen
multipl
common
blood
group
antigen
found
less
individu
nevertheless
certain
blood
type
extrem
rare
around
globe
rh
null
ko
k
u
neg
other
differ
preval
amongst
divers
popul
pp
jr
vel
neg
yt
rare
blood
type
usual
discov
serum
react
screen
panel
reagent
cell
presenc
neg
auto
control
encount
patient
rare
blood
type
antibodi
hf
antigen
rare
combin
multipl
common
antibodi
requir
blood
elect
procedur
especi
emerg
situat
pose
signific
challeng
involv
care
identif
provis
rare
blood
unitsa
rare
blood
type
especi
presenc
antibodi
confirm
refer
laboratori
experienc
technologist
uniqu
resourc
rare
rbc
sera
fluid
technolog
enzym
treat
cell
inhibit
test
molecular
test
other
knowledg
rare
blood
type
clinic
signific
amongst
local
ethnic
group
follow
identif
hf
antibodi
rare
combin
common
antibodi
commun
clinic
team
essenti
verifi
necess
transfus
time
rbc
provis
requir
rare
rbc
unit
provid
suppli
liquid
rbc
unit
may
avail
blood
center
thaw
unit
local
nation
frozen
inventori
call
known
rare
blood
donor
donat
screen
index
case
famili
anoth
target
popul
rare
blood
unavail
local
nation
clinic
decis
made
best
avail
therapeut
option
compat
blood
attain
nation
intern
contact
intern
rare
donor
panel
irdp
andor
direct
contact
member
isbt
work
parti
rare
blood
despit
differ
donor
criteria
test
requir
languag
barrier
work
hour
holiday
mutual
goal
suppli
rare
blood
patient
need
result
coordin
chain
effort
commun
local
andor
intern
enabl
time
provis
rare
rbc
around
globe
ml
olsson
burnouf
taipei
medic
univers
taipei
citi
taiwan
republ
china
scientif
evid
demonstr
human
platelet
lysat
hpl
substitut
fetal
bovin
serum
fb
cell
therapi
field
valuabl
clinic
compliant
supplement
growth
media
vitro
propag
human
cell
mesenchym
stromal
cell
msc
hpl
contain
plethora
growth
factor
releas
platelet
well
addit
nutrient
promot
agent
origin
plasma
platelet
clinic
advantag
hpl
applic
encompass
avoid
risk
zoonot
infect
associ
materi
anim
origin
fb
addit
scientif
studi
identifi
ex
vivo
expans
msc
differ
tissu
sourc
may
actual
effici
medium
supplement
vv
hpl
fb
cell
prolifer
stronger
cell
popul
doubl
time
shorter
size
increas
addit
use
hpl
maintain
clonogen
immunophenotyp
vitro
trilineag
differenti
capac
vitro
cell
immunosuppress
properti
expand
msc
thu
increas
number
protocol
expans
human
cell
like
reli
use
hpl
supplement
especi
regul
recommend
avoid
fb
impli
continu
increas
need
defin
implement
product
manufactur
method
ensur
hpl
qualiti
safeti
consist
hpl
prepar
manufactur
blood
establish
commerci
supplier
use
expir
platelet
concentr
origin
collect
transfus
purpos
reach
expiri
date
platelet
concentr
devot
hpl
product
frozen
store
platelet
concentr
subject
sever
freez
thaw
cycl
eg
cycl
induc
platelet
lysi
pool
pool
either
directli
clarifi
centrifugationfiltr
may
undergo
treatment
clot
remov
fibrinogen
prior
steril
filtrat
dispens
freez
storag
main
variabl
hpl
manufactur
method
includ
collect
procedur
platelet
concentr
whole
blood
apheresi
use
platelet
addit
solut
impli
dilut
plasma
nutrient
pool
size
current
donat
may
pool
improv
standard
depend
upon
jurisdict
implement
pathogen
inactiv
treatment
perform
blood
establish
enhanc
safeti
platelet
concentr
transfus
remov
fibrinogen
avoid
gelat
growth
medium
cell
cultur
impact
process
altern
may
cell
propag
need
understand
regardless
variat
manufactur
process
done
condit
compli
gmp
whenif
hpl
use
cell
expans
subsequ
transplant
patient
develop
hpl
manufactur
technolog
expect
aim
improv
product
standard
viru
safeti
addit
intern
consensu
regul
qualiti
control
safeti
criteria
hpl
prepar
increasingli
need
use
cell
therapi
tissu
engin
regen
medicin
expand
cs
medicin
patholog
univers
minnesota
minneapoli
unit
state
georg
univers
hospit
nh
foundat
trust
london
unit
kingdom
background
autolog
plasma
aprp
poorli
regul
blood
compon
often
produc
patient
bedsid
use
indic
chronic
acut
orthoped
injuri
wound
rheumatolog
diseas
platelet
contain
growth
factor
cytokin
thought
play
role
reduc
inflamm
aid
heal
process
aprp
made
use
small
centrifug
cartridg
deliv
uneven
platelet
enrich
thu
consist
qualiti
aprp
question
lower
yield
prp
may
decreas
efficaci
blood
compon
held
stringent
standard
regard
safeti
efficaci
content
sinc
prp
autolog
product
similar
standard
appli
lack
standard
highli
heterogen
natur
prp
make
difficult
develop
evid
use
guidelin
isol
qualiti
control
qc
measur
impos
process
could
help
clinician
develop
consist
efficaci
approach
aim
knowledg
publish
report
qc
protocol
prp
develop
survey
better
understand
prp
usag
qc
measur
taken
hospit
use
prp
method
survey
design
assess
aprp
manufactur
usag
qualiti
control
qc
measur
taken
prior
use
survey
develop
input
content
expert
survey
sent
member
best
isbt
survey
respond
encourag
forward
survey
colleagu
thu
true
denomin
unknown
total
complet
partial
complet
survey
receiv
result
respons
came
countri
came
unit
state
respond
report
aprp
use
hospit
aprp
use
predominantli
outpati
though
hospit
also
use
aprp
set
hospit
aprp
use
md
howev
hospit
md
use
aprp
aprp
use
orthoped
woundincis
repair
rheumatolog
indic
us
aprp
manufactur
outsid
blood
bank
outsid
us
aprp
isol
blood
bank
personnel
nearli
aprp
manufactur
done
qualiti
control
qc
measur
howev
respond
assess
final
product
prior
releas
qc
measur
includ
platelet
count
measur
enrich
platelet
fraction
cultur
product
infecti
serolog
test
case
aprp
fail
qc
could
still
use
pend
md
approv
hospit
conduct
qc
final
aprp
test
done
blood
bank
summari
conclus
prp
use
hospit
throughout
world
wide
varieti
indic
blood
bank
involv
manufactur
countri
us
aprp
made
outsid
blood
bank
qualiti
control
aprp
product
final
product
done
hospit
improv
consist
efficaci
prp
stringent
qc
measur
need
place
mb
koh
cell
therapi
facil
blood
servic
group
health
scienc
author
singapor
singapor
central
role
orchestr
platelet
inflamm
well
understand
platelet
rich
growth
factor
cytokin
result
manufactur
novel
platelet
deriv
product
eventu
clinic
therapeut
platelet
deriv
product
includ
human
platelet
lysat
hpl
extens
use
ancillari
materi
support
mesenchym
stromal
cell
growthprolifer
cell
therapi
platelet
rich
plasma
prp
wide
use
orthopaed
often
via
direct
inject
joint
product
current
often
manufactur
blood
bank
evolv
new
role
beyond
tradit
product
standard
blood
compon
increasingli
adopt
activ
role
support
cellular
therapi
demand
platelet
base
product
also
result
larg
scale
commerci
manufactur
variou
compani
potenti
altern
foetal
bovin
serum
cell
cultur
hand
point
care
devic
develop
transform
field
prp
clinic
use
central
product
one
made
within
individu
clinic
centr
inevit
issu
variabl
consist
scienc
platelet
physiolog
well
understood
less
specif
mechan
action
inject
clinic
partli
initi
lack
rigour
run
robust
clinic
trial
addit
signific
variat
individualis
product
includ
select
donor
platelet
fresh
vs
frozen
pool
vs
apheres
product
methodolog
characteris
final
product
includ
potenc
made
interpret
clinic
efficaci
difficult
said
increas
evid
suggest
clinic
effect
although
much
remain
anecdot
blood
deriv
compon
regul
sometim
class
togeth
red
cell
blood
compon
transfus
howev
experiment
natur
use
well
use
cell
cultur
open
new
issu
standard
regulatori
framework
k
l
j
ml
laboratori
medicin
lund
univers
immunolog
transfus
medicin
labmedicin
region
lund
sweden
background
first
describ
mann
et
al
lancet
men
women
express
xga
erythrocyt
due
skew
gender
distribut
xg
becam
first
blood
group
system
assign
specif
chromosom
x
chromosom
underli
gene
pbdx
known
xg
identifi
elli
et
al
nat
genet
molecular
basi
xga
antigen
remain
undefin
xg
partli
resid
region
sex
chromosom
first
three
exon
lie
remain
seven
exist
x
chromosom
thu
xg
disrupt
chromosom
produc
function
protein
x
chromosom
aim
use
integr
bioinformat
approach
aim
establish
genet
basi
underli
xg
vs
xg
phenotyp
hypothes
xga
express
transcript
regul
singl
snp
within
xg
region
potenti
disrupt
erythroid
transcript
factor
bind
site
method
calcul
xga
allel
frequenc
differ
popul
compil
histor
data
comparison
made
frequenc
multipl
variant
xg
region
found
genom
project
express
quantit
trait
loci
eqtl
analyz
gtex
portal
http
gtexportalorg
transcript
factor
bind
site
analysi
made
jaspar
http
jaspargeneregnet
blood
sampl
blood
donor
anonym
gender
phenotyp
xga
genom
dna
mrna
isol
genotyp
candid
snp
xg
transcript
quantif
perform
pcr
function
detect
snp
ascertain
electrophoret
mobil
shift
assay
emsa
luciferas
report
assay
result
among
investig
variant
xg
region
locat
kb
upstream
transcript
start
site
identifi
snp
strongest
correl
expect
distribut
furthermor
identifi
eqtl
signific
impact
xg
transcript
level
whole
blood
p
jaspar
analysi
identifi
bind
motif
disrupt
find
corrobor
snp
genotyp
femal
xg
sampl
n
homozyg
xg
sampl
regardless
gender
carri
least
one
copi
major
allel
g
male
xg
sampl
identifi
n
carri
least
one
c
allel
sampl
accompani
g
allel
presum
chromosom
oppos
xg
individu
xg
donor
mrna
level
suggest
disrupt
motif
prevent
transcript
xg
strong
bind
nuclear
extract
observ
emsa
use
biotinyl
oligonucleotid
probe
c
addit
result
supershift
final
luciferas
report
assay
determin
motif
import
transcript
show
robust
posit
respons
vector
contain
basal
express
substitut
summari
conclus
xg
phenotyp
depend
intact
bind
motif
kb
upstream
xg
transcript
start
site
xg
phenotyp
due
impair
transcript
turn
follow
disrupt
site
locu
solv
longstand
conundrum
combin
bioinformat
molecular
approach
genotyp
predict
xga
statu
blood
donor
transfus
recipi
possibl
v
karamat
r
p
r
n
blood
group
refer
laboratori
biotechnolog
centr
nh
blood
transplant
bristol
cell
immunohaematolog
nh
blood
transplant
liverpool
laboratori
tamesid
gener
hospit
laboratori
manchest
univers
foundat
trust
manchest
unit
kingdom
background
antigen
yt
blood
group
system
locat
acetylcholinesteras
ach
glycoprotein
ach
highli
conserv
enzym
crucial
cholinerg
neurotransmiss
synapt
junction
whilst
erythroid
isoform
hydrophob
membran
enzym
unknown
function
isoform
encod
singl
gene
ach
locat
sinc
discoveri
yt
system
compris
two
antithet
antigen
yta
ytb
third
antigen
yteg
describ
aim
present
serolog
genet
evid
two
novel
high
frequenc
hfa
yt
antigen
discov
complex
antibodi
investig
two
unrel
pregnant
patient
first
case
sampl
pregnant
woman
famili
investig
patient
histori
transfus
previou
pregnanc
known
present
plasma
togeth
addit
unidentifi
antibodi
hfa
second
case
pregnant
sickl
cell
diseas
patient
present
complex
mixtur
antibodi
requir
extens
serolog
molecular
investig
identifi
multipl
antibodi
includ
one
novel
hfa
yt
blood
group
system
method
serolog
investig
perform
standard
iat
liss
tube
gel
techniqu
enzym
treat
chemic
modifi
cell
utilis
includ
papain
trypsin
chymotrypsin
pronas
dtt
treat
cell
plasma
inhibit
studi
complet
solubl
recombin
yt
sryt
protein
eluat
prepar
jk
cell
isol
antibodi
interest
genom
dna
patient
famili
member
isol
whole
blood
code
exon
erythroid
ach
isoform
amplifi
pcr
analys
sanger
sequenc
impact
identifi
mutat
ach
structur
studi
molecular
dynam
calcul
result
confirm
present
plasma
react
iat
untreat
papain
treat
cell
plasma
react
weak
moder
strength
untreat
jk
cell
except
autolog
cell
cell
patient
brother
neg
reactiv
papain
treat
jk
cell
much
weaker
plasma
inhibit
studi
use
sryt
show
complet
inhibit
jk
cell
wherea
jk
cell
remain
posit
due
cell
yt
yteg
yt
cell
cell
posit
patient
plasma
eluat
respect
ach
sequenc
confirm
yt
aa
novel
homozyg
mutat
exon
reveal
encod
chang
ach
test
famili
sampl
reveal
patient
mother
four
sibl
heterozyg
yt
ab
parent
two
sibl
heterozyg
whilst
one
sibl
compat
brother
homozyg
although
unit
red
cell
compat
brother
avail
time
deliveri
transfus
requir
healthi
newborn
posit
dat
clinic
sign
hdfn
detect
eluat
prepar
newborn
cell
babi
subsequ
shown
yt
aa
heterozyg
second
case
plasma
react
antigen
match
fy
cell
liss
iat
reactiv
variabl
cell
show
papain
resist
other
show
weaken
reactiv
papain
test
serolog
pictur
indic
possibl
least
two
antibodi
antibodi
suspect
result
enzym
studi
subsequ
antibodi
success
inhibit
solubl
recombin
yt
protein
cell
yt
yteg
sequenc
ach
confirm
yt
aa
identifi
novel
homozyg
mutat
exon
encod
chang
ach
identif
antibodi
lead
larger
scale
inhibit
studi
solubl
recombin
yt
protein
enabl
identif
underli
alloantibodi
includ
despit
elucid
novel
antibodi
complex
mixtur
least
one
antibodi
specif
remain
unresolv
shown
mutual
incompat
case
molecular
dynam
calcul
suggest
amino
acid
chang
locat
peripher
loop
ach
although
may
affect
ach
conform
unlik
affect
enzymat
activ
summaryconclus
present
evid
two
new
hfa
yt
blood
group
system
lack
antigen
result
homozyg
mutat
case
also
demonstr
difficulti
encount
investig
complex
antibodi
mixtur
multipli
transfus
patient
highlight
effect
use
solubl
recombin
blood
group
protein
circumst
e
ml
clinic
immunolog
transfus
medicin
labmedicin
region
laboratori
medicin
lund
univers
lund
sweden
background
for
group
system
describ
much
remain
investig
regard
genet
immunohematolog
characterist
well
clinic
import
whilst
gene
result
glycosphingolipid
express
human
erythrocyt
phenotyp
rare
popul
test
far
convers
howev
plasma
appear
common
individu
aim
aim
studi
character
new
blood
group
system
genet
b
select
princip
interest
allel
variant
studi
c
test
presenc
plasma
donor
differ
abo
group
gain
insight
antibodi
method
recent
report
databas
erythrogen
wwwerythrogenecom
util
probe
genet
variat
also
screen
swedish
blood
donor
three
princip
import
snp
select
sampl
analyz
transcript
level
examin
extract
mrna
peripher
blood
two
individu
homozyg
two
control
transfect
cell
perform
examin
effect
antigen
express
plasma
enzym
activ
assay
three
differ
test
outcom
analys
flow
cytometri
screen
plasma
donor
differ
abo
group
done
use
human
ovin
canin
red
blood
cell
rbc
well
kodecyt
rbc
artifici
upload
forssman
pentasaccharid
result
identifi
allel
erythrogen
four
previous
list
blood
group
allel
isbt
eight
potenti
null
allel
observ
base
three
differ
nonsens
mutat
common
present
european
donor
four
healthi
swedish
donor
found
homozyg
truncat
fs
synthas
prematur
first
descript
human
transcript
readili
detect
mrna
prepar
sampl
appar
quantit
differ
note
rare
mutat
alter
codon
found
individu
african
descent
investig
induc
phenotyp
contrast
mutat
result
synthesi
human
plasma
well
supernat
protein
express
system
show
enzymat
activ
contrast
canin
plasma
test
indic
solubl
human
may
present
function
form
plasma
plasma
test
posit
test
human
rbc
none
n
n
group
came
posit
howev
test
posit
kodecyt
upload
high
concentr
forssman
structur
interestingli
lower
titer
score
note
plasma
test
summari
conclus
extend
knowledg
variant
allel
characterist
antibodi
newest
carbohydr
blood
group
system
for
frequenc
antibodi
reactiv
may
suggest
respons
find
blood
donor
indic
dispens
human
r
p
experiment
transfus
medicin
dresden
transfus
medicin
immunolog
medic
faculti
mannheim
heidelberg
mannheim
germani
background
abo
blood
group
system
unequivoc
import
clinic
transfus
medicin
furthermor
abo
implic
develop
number
human
diseas
abo
antigen
confin
rbc
wide
express
varieti
human
cell
tissu
aberr
b
oligosaccharid
express
level
common
mani
case
explain
report
genet
variat
respect
glycosyltransferas
aim
role
mirna
regul
blood
group
antigen
erythropoiesi
address
far
microrna
small
noncod
rna
bind
untransl
region
utr
target
mrna
result
translat
repress
mrna
degrad
show
directli
target
glycosyltransferas
b
mrna
method
distinct
complementari
approach
includ
gene
array
analysi
overexpress
glycosyltransferas
specif
mirna
primari
hematopoiet
stem
cell
hsc
identifi
directli
target
glycosyltransferas
b
use
microrna
target
predict
tool
also
identifi
potenti
target
gene
therefor
treat
hsc
inhibitor
analyz
blood
group
express
flow
cytometri
gel
method
result
express
level
found
invers
correl
amount
blood
group
antigen
interestingli
alreadi
case
hematopoiet
stem
cell
hsc
remain
stabil
matur
red
blood
cell
rbc
overexpress
hsc
lead
signific
reduct
number
blood
group
antigen
per
rbc
effect
enhanc
simultan
target
transcript
factor
render
incap
bind
promot
abo
gene
therebi
downregul
blood
group
antigen
express
approach
inhibitor
mithramycin
reveal
similar
result
summari
conclus
express
chang
mirna
may
account
rare
case
weak
ab
phenotyp
explain
genet
variat
may
play
import
role
disappear
glycan
antigen
carcinogenesi
c
le
van
n
nation
de
pour
le
group
sanguin
institut
nation
de
la
transfus
sanguin
inserm
pari
diderot
dexcel
nation
de
la
transfus
sanguin
pari
de
de
montpelli
nation
de
la
recherch
scientifiqu
de
montpelli
montpelli
franc
background
augustin
blood
group
system
consist
two
antigen
abbrevi
ata
locat
equilibr
nucleosid
transport
null
phenotyp
aug
result
homozyg
splice
site
mutat
gene
c
ata
red
blood
cell
rbc
antigen
date
individu
neg
phenotyp
african
origin
team
recent
shown
lack
human
aug
phenotyp
associ
ectop
calcif
suggest
import
factor
regul
bone
metabol
aim
given
absenc
red
cell
individu
analyz
properti
rbc
well
erythroid
differenti
potenti
hematopoiet
progenitor
method
rbc
deform
osmoscan
data
determin
laser
diffract
analysi
ecktacytometri
use
optic
rotat
cell
analys
lorca
rr
mechatron
hoorn
netherland
vitro
erythropoiesi
perform
phase
briefli
isol
peripher
blood
progenitor
patient
well
healthi
donor
expand
day
presenc
cytokin
scf
differenti
presenc
erythropoietin
scf
erythropoietin
densiti
cellsml
result
haematolog
properti
individu
show
abnorm
assess
ccmh
reticulocyt
count
hb
level
howev
rbc
display
macrocytosi
fl
abnorm
morpholog
character
presenc
anisopoikilocytosistarget
cell
addit
patient
exhibit
hyperhydr
rbc
rheolog
experi
show
alter
deform
one
patient
furthermor
upon
erythroid
differenti
progenitor
donor
n
detect
decreas
level
prolifer
delay
erythroblast
matur
interestingli
differenti
reticulocyt
show
increas
volum
compar
control
reticulocyt
consist
macrocytosi
observ
individu
assess
whether
phenotyp
alter
due
chang
nucleosid
transport
evalu
effect
exogen
adenosin
erythroid
differenti
healthi
progenitor
notabl
exogen
adenosin
attenu
progenitor
cell
prolifer
differenti
progenitor
reticulocyt
stage
acceler
moreov
differenti
reticulocyt
exhibit
increas
volum
suggest
macrocytosi
observ
patient
may
due
higher
intracellular
adenosin
level
intriguingli
effect
specif
adenosin
neither
guanosin
uridin
cytidin
affect
erythroid
commit
differenti
healthi
hsc
summari
conclus
studi
null
phenotyp
blood
group
system
promot
understand
role
protein
carri
antigen
erythroid
differenti
process
matur
rbc
physiolog
result
strongli
suggest
signific
role
adenosin
transport
erythroid
differenti
macrocytosi
patient
c
c
le
van
nation
de
pour
le
group
sanguin
institut
nation
de
la
transfus
sanguin
inserm
pari
diderot
dexcel
imagin
pari
descart
inserm
pari
diderot
institut
nation
de
la
transfus
sanguin
pari
franc
background
augustin
blood
group
system
consist
two
antigen
locat
equilibr
nucleosid
transport
note
provision
antigen
c
recent
propos
null
phenotyp
aug
result
homozygos
splice
site
mutat
gene
g
c
ata
red
blood
cell
rbc
antigen
molecular
basi
rare
phenotyp
specif
encount
peopl
african
descent
correspond
homozyg
mutat
exon
predict
caus
amino
acid
chang
aim
investig
antibodi
antigen
unknown
specif
proband
caucasian
ancestri
method
antibodi
identif
rbc
type
perform
iat
exom
sequenc
data
analysi
perform
genom
dna
express
level
analyz
flow
cytometri
western
blot
test
result
alloantibodi
rbc
antigen
detect
femal
patient
group
e
one
pregnanc
rbc
transfus
antibodi
found
prior
gastric
surgeri
effort
toward
determin
specif
antibodi
unsuccess
identifi
gene
respons
rare
blood
phenotyp
proband
implement
sequenc
ng
approach
use
sequenc
we
variant
filter
strategi
use
hous
softwar
packag
polyweb
led
identif
homozyg
missens
variat
gene
encod
protein
proband
homozyg
allel
g
g
variant
report
frequenc
exom
aggreg
consortium
exac
databas
variant
howev
report
homozyg
state
g
mutat
predict
nonpathogen
polyphen
sift
tool
suggest
probabl
caus
null
augustin
phenotyp
character
augustin
phenotyp
proband
perform
crossmatch
test
use
antisera
proband
rbc
reactiv
confirm
presenc
rbc
proband
eluat
react
standard
aug
rbc
aug
rbc
confirm
antibodi
direct
protein
addit
flow
cytometri
immunoblot
analys
indic
express
level
proband
rbc
significantli
decreas
approxim
suggest
mutat
probabl
affect
express
rbc
surfac
summari
conclus
case
provid
illustr
exampl
benefit
genom
method
resolv
complex
case
immunohematolog
serolog
molecular
studi
provid
evid
novel
antigen
augustin
blood
group
system
sinc
system
current
compris
three
antigen
suggest
provision
assign
name
ayma
proband
name
new
antigen
describ
subject
agreement
isbt
work
parti
red
cell
immunogenet
blood
group
terminolog
j
cid
lozano
apheresi
cellular
therapi
unit
depart
hemotherapi
hemostasi
hospit
barcelona
spain
autom
blood
compon
prepar
bcp
whole
blood
wb
collect
help
optim
bcp
process
increasingli
widespread
implement
present
summar
qualiti
blood
compon
obtain
new
autom
devic
develop
qualiti
blood
compon
obtain
new
autom
devic
report
avail
literatur
show
blood
compon
obtain
new
devic
met
european
standard
import
point
compar
platelet
concentr
obtain
manual
method
autom
bcp
improv
consist
final
platelet
product
conclus
complet
autom
bcp
wb
collect
still
develop
repres
huge
chang
paradigm
aw
n
r
n
j
q
mip
investig
behalf
best
laboratori
medicin
vancouv
coastal
health
author
laboratori
medicin
univers
british
columbia
vancouv
centr
transfus
research
mcmaster
univers
hamilton
innov
canadian
blood
servic
medicin
patholog
univers
alberta
edmonton
canada
medicin
nhsbt
oxford
unit
kingdom
background
recent
public
shown
vitro
qualit
differ
red
blood
cell
rbc
unit
process
whole
blood
wb
depend
method
process
differ
blood
product
factor
hold
process
leukoreduct
centrifug
speed
materi
use
lead
differ
qualiti
marker
hemolysi
residu
plasma
clinic
inform
emerg
regard
variabl
patient
outcom
depend
differ
type
rbc
product
transfus
essenti
understand
differ
process
method
may
contribut
differ
qualiti
characterist
aim
collect
inform
key
blood
manufactur
differ
countri
regard
detail
wb
process
produc
rbc
qualiti
paramet
use
test
rbc
part
routin
qualiti
control
test
method
survey
develop
submit
data
redcap
databas
store
secur
server
refin
perform
pilot
data
collect
three
particip
site
blood
center
repres
differ
jurisdict
approach
particip
provid
uniqu
login
survey
complet
result
januari
data
nine
blood
oper
eight
countri
australia
canada
franc
germani
netherland
norway
sweden
unit
kingdom
collect
two
primari
method
rbc
process
tat
method
produc
rbc
plasma
use
six
blood
oper
bat
addit
produc
buffi
coat
platelet
use
eight
blood
oper
six
oper
use
method
three
favor
bat
process
blood
oper
survey
norway
util
reveo
system
jurisdict
survey
univers
leukoreduc
blood
product
use
cpd
anticoagul
sagm
addit
solut
except
german
red
cross
paggsm
canada
netherland
norway
sweden
activ
cool
whole
blood
process
process
paramet
demonstr
variabl
amongst
respond
includ
length
hold
process
donor
hemoglobin
limit
accept
collect
weight
concentr
anticoagul
collect
set
time
leukoreduct
centrifug
speed
extract
devic
rbc
shelf
life
jurisdict
day
except
germani
red
cross
day
netherland
norway
unit
kingdom
day
canada
unit
kingdom
higher
centrifug
speed
record
tat
method
compar
bat
method
qualiti
marker
test
also
differ
unit
volum
hematocrit
hemolysi
residu
white
blood
cell
wbc
concentr
common
marker
test
jurisdict
survey
unit
volum
bat
method
similar
though
canada
higher
hematocrit
significantli
lower
hemolysi
mean
differ
ci
trend
lower
residu
wbc
concentr
bat
process
across
jurisdict
compar
tat
summari
conclus
method
paramet
wb
process
rbc
differ
amongst
blood
produc
worldwid
qualiti
differ
bat
tat
method
may
import
understand
evalu
emerg
clinic
data
blood
therapeut
biolog
studi
need
elucid
effect
differ
clinic
outcom
associ
variat
wb
process
potenti
harmon
method
ja
r
j
electr
comput
engin
ryerson
univers
biomed
engin
scienc
technolog
ibest
physic
ryerson
univers
toronto
innov
canadian
blood
servic
edmonton
research
institut
ltri
sinai
health
system
toronto
laboratori
medicin
patholog
univers
alberta
edmonton
canada
background
rbc
transfus
red
cell
concentr
rcc
unit
produc
separ
rbc
donat
blood
suspend
preserv
solut
storag
characterist
biconcav
exhibit
regular
function
rbc
term
smooth
disc
gradual
lost
follow
sequenc
format
membran
crenat
crenat
disc
spicul
format
result
bud
vesicl
crenat
discoid
loss
cell
membran
intracellular
content
central
pallor
crenat
spheroid
complet
loss
biconcav
adopt
spheric
shape
crenat
sphere
complet
loss
spicul
smooth
sphere
convent
morpholog
indic
mi
labori
inher
subject
use
rel
small
data
set
analysi
potenti
applic
imag
flow
cytometri
ifc
branch
flow
cytometri
captur
imag
cell
flow
suspens
character
rbc
morpholog
recent
publish
techniqu
rapidli
captur
character
ten
thousand
rbc
imag
minut
overcom
limit
outlin
light
microscopi
allow
robust
statist
analysi
aim
studi
includ
valid
ifc
techniqu
light
microscopi
use
mi
method
use
ifc
techniqu
investig
effect
storag
durat
donor
variabl
tempor
behaviour
morpholog
distribut
method
laboratori
canadian
blood
servic
edmonton
ca
ibest
st
michael
hospit
toronto
ca
carri
light
microscopi
ifc
techniqu
respect
morpholog
character
lr
sagm
top
bottom
rcc
unit
femal
male
donor
storag
rcc
unit
share
two
facil
mean
mi
measur
calcul
use
triplic
measur
weekli
h
basi
expir
week
ifc
dataset
morpholog
class
use
trend
analysi
base
donor
variabl
result
strong
correl
exhibit
mi
obtain
techniqu
bland
altman
plot
data
show
mean
differ
ifc
light
microscopi
unit
attribut
current
limit
ifc
techniqu
captur
smooth
sphere
morpholog
found
higher
amount
variat
trend
exhibit
infrequ
donor
donat
yr
found
sharper
tempor
chang
morpholog
distribut
younger
femal
donor
yr
week
storag
summari
conclus
mi
comparison
studi
provid
confid
abil
ifc
techniqu
morpholog
character
rbc
similar
precis
convent
method
work
ifc
techniqu
requir
particularli
captur
smooth
sphere
imag
order
reduc
overestim
ifc
techniqu
show
promis
demonstr
effect
donor
variabl
morpholog
distribut
rcc
unit
k
f
r
develop
australian
red
cross
blood
servic
kelvin
grove
health
school
biomed
scienc
queensland
univers
technolog
brisban
australia
background
pack
red
blood
cell
prbc
transfus
associ
modul
recipi
immun
respons
contribut
increas
rate
infect
higher
patient
mortal
longer
hospit
stay
howev
mechan
behind
modul
larg
unknown
interleukin
il
import
mediat
inflammatori
respons
involv
sever
cellular
process
includ
prolifer
differenti
apoptosi
matur
releas
depend
inflammasom
activ
inflammasom
import
innat
immun
multiprotein
activ
pathogen
damag
signal
particul
matter
trigger
proteolyt
cascad
cleav
form
matur
regul
mani
biolog
activ
protein
lipid
enzym
prbc
could
modul
inflammasom
specif
assess
potenti
prbc
transfus
modul
process
involv
depend
inflamm
includ
inflammasom
activ
aim
investig
whether
solubl
factor
prbc
modul
inflammasom
activ
method
prbc
obtain
process
depart
australian
red
cross
blood
servic
day
routin
storag
aliquot
asept
remov
unit
centrifug
g
min
obtain
supernat
develop
model
transfus
concurr
infect
briefli
monocyt
isol
healthi
volunt
cultur
h
without
stimul
stimul
lipopolysaccharid
lp
lp
lp
lp
atp
inflammasom
activ
assess
quantif
via
cytometr
bead
array
via
elisa
cultur
supernat
macrophag
migrat
inhibitori
factor
mif
also
quantifi
lp
alon
use
compar
treatment
treatment
pair
n
p
consid
signific
result
detect
regardless
storag
durat
mif
known
modul
inflammasom
activ
detect
monocyt
cultur
model
limit
detect
unstimul
monocyt
expect
exposur
lp
alon
lp
atp
result
releas
cultur
monocyt
level
significantli
increas
model
concurr
infect
lp
transfus
demonstr
solubl
mediat
present
prbc
augment
matur
releas
indic
modul
inflammasom
addit
signific
increas
model
concurr
infect
transfus
provid
evid
modul
inflammasom
activ
summari
conclus
inflammasom
play
critic
role
regul
inflamm
diseas
cancer
provid
first
evid
solubl
mediat
present
prbc
modul
inflamm
immun
respons
activ
inflammasom
pathway
releas
like
modul
inflammasom
activ
inflamm
mediat
multitud
factor
includ
reactiv
oxygen
speci
ro
microparticl
mif
signal
characteris
blood
transfus
modul
inflammasom
activ
warrant
ms
j
k
j
j
care
research
group
faculti
medicin
univers
queensland
develop
australian
red
cross
blood
servic
brisban
australia
background
ex
vivo
storag
pack
red
blood
cell
prbc
accumul
biochem
function
chang
associ
advers
transfus
outcom
microparticl
submicron
particl
form
cellular
stress
activ
particl
postul
potenti
mediat
advers
transfus
outcom
interact
cell
disrupt
immun
thrombosi
process
store
prbc
constitu
red
blood
cell
cytokin
microparticl
lipid
bound
iron
activ
recipi
endotheli
immun
cell
potenti
alter
circul
bioactiv
microparticl
popul
aim
studi
aim
detect
chang
microparticl
concentr
store
prbc
circul
whole
blood
use
novel
vitro
vascular
flow
model
method
whole
blood
dilut
pb
simul
recipi
blood
prbc
unit
ad
recipi
blood
dilut
simul
transfus
prbc
transfus
experi
perform
prbc
unit
day
old
fresh
day
old
store
lipopolysaccharid
lp
combin
recipi
blood
final
concentr
ngml
simul
endotoxaemia
nine
replic
conduct
treatment
blood
mixtur
transfus
prbc
transfus
lp
perfus
endothelialis
vascular
model
h
microparticl
concentr
cytokin
concentr
perfus
measur
use
flow
cytometri
nanoparticl
track
analysi
result
store
prbc
transfus
increas
microparticl
format
compar
fresh
prbc
transfus
flow
cytometri
vs
p
nanoparticl
track
analysi
vs
p
prbc
transfus
lp
treatment
led
differ
microparticl
cytokin
respons
summari
conclus
perfus
prbc
whole
blood
endothelialis
vascular
model
led
increas
microparticl
format
acknowledg
australian
govern
fund
australian
red
cross
blood
servic
provis
blood
blood
product
servic
australian
commun
project
partial
fund
princ
charl
hospit
foundat
bate
public
health
liverpool
school
tropic
medicin
liverpool
unit
kingdom
aim
present
provid
overview
challeng
success
associ
differ
donor
base
model
africa
ssa
inform
deriv
multipl
sourc
includ
primari
data
publish
literatur
consult
person
experi
blood
suppli
inadequ
meet
global
need
avail
access
highli
inequit
incom
countri
lmic
global
blood
suppli
world
popul
peopl
compar
countri
use
conserv
target
blood
donat
popul
shortfal
blood
ssa
exclud
south
africa
million
unit
three
type
blood
donor
recognis
ssa
voluntari
donor
vnrd
familyreplac
donor
frd
paidprofession
donor
vnrd
donat
blood
without
coercion
payment
cash
kind
frd
donat
blood
respons
need
famili
member
friend
either
advanc
transfus
replac
blood
use
paid
donor
receiv
money
donat
emerg
wherev
demand
blood
exce
suppli
situat
pertain
across
much
ssa
mani
countri
ssa
struggl
achiev
goal
ensur
donor
vnrd
exampl
countri
africa
account
region
popul
blood
vnrd
outreach
servic
recruit
vnrd
one
costliest
compon
blood
system
unafford
mani
poorer
ssa
countri
henc
relianc
mani
countri
sustain
inadequ
frd
system
although
ssa
countri
manag
set
nationwid
vnrd
system
other
run
hybrid
system
vnrd
recruit
larg
citi
frd
less
access
peripher
rural
area
safest
type
donor
one
unpaid
donat
regularli
irrespect
whether
origin
vnrd
frd
better
avail
qualiti
health
review
infect
screen
test
ssa
increas
focu
convert
frd
repeat
voluntari
donor
advantag
frd
requir
expens
outreach
recruit
servic
alreadi
overcom
initi
barrier
donat
blood
furthermor
evid
frd
often
perceiv
voluntari
donor
express
main
reason
donat
altruism
wish
save
live
donat
blood
famili
commun
member
summaryconclus
paradigm
shift
requir
increas
blood
donat
ssa
prevent
mani
needless
death
pregnant
women
children
result
critic
chronic
blood
shortag
involv
new
focu
encourag
retain
repeat
donor
includ
origin
frd
motiv
messag
cultur
sensit
focus
donat
famili
commun
badawi
hematolog
king
abdulaziz
univers
jeddah
saudi
arabia
despit
signific
advanc
transfus
medicin
field
maintain
adequ
safe
blood
suppli
remain
challeng
area
world
data
world
health
organ
reveal
mani
develop
countri
continu
low
rate
blood
collect
per
capita
mani
suffer
chronic
shortag
blood
compon
effect
way
improv
statu
transfus
servic
variou
countri
establish
effect
blood
system
variou
model
system
exist
includ
nation
blood
system
blood
center
hybrid
two
model
current
saudi
arabia
continu
oper
model
blood
collect
process
center
affili
almost
individu
hospit
given
high
number
sector
hospit
belong
challeng
face
commun
collabor
among
blood
center
includ
geograph
proxim
build
nation
blood
system
expect
result
posit
outcom
mani
aspect
includ
donor
recruit
effort
strategi
standard
polici
process
effect
util
resourc
suppli
hybrid
model
propos
suitabl
approach
countri
recruit
effort
manag
financi
resourc
creation
polici
standard
establish
nation
level
time
blood
collect
process
test
storag
may
perform
multipl
satellit
site
allow
easier
access
minim
transport
difficulti
step
taken
toward
achiev
goal
kingdom
df
w
servic
director
ethiopian
nation
blood
bank
servic
system
manag
addi
ababa
univers
addi
ababa
ethiopia
background
access
safe
adequ
blood
transfus
challeng
worldwid
even
critic
sub
saharan
africa
accord
world
health
organ
recommend
order
meet
nation
basic
blood
need
number
blood
donor
nation
total
popul
contrari
recommend
ethiopia
less
popul
donat
blood
aim
studi
aim
identifi
first
time
voluntari
blood
donor
return
rate
return
determin
ethiopian
nation
blood
bank
servic
enbb
method
evalu
return
rate
secondari
data
review
first
time
voluntari
blood
donor
done
investig
return
determin
facil
base
unmatch
case
control
studi
design
implement
case
first
time
voluntari
blood
donor
return
donat
within
two
year
sinc
index
donat
wherea
control
nt
return
structur
question
use
collect
data
randomli
select
sampl
enbb
donor
record
telephon
interview
march
logist
regress
analysi
implement
assess
relev
determin
result
first
time
voluntari
blood
donor
return
rate
among
first
time
voluntari
blood
donor
return
within
two
year
period
index
donat
make
return
rate
per
two
year
first
time
voluntari
blood
donor
return
determin
total
case
control
particip
studi
first
time
voluntari
blood
donor
return
found
like
determin
posit
perceiv
donat
capabl
aor
ci
larger
volum
blood
donat
aor
ci
furthermor
compar
donor
donat
blood
reason
self
interest
donat
altruism
time
like
return
aor
ci
summari
conclus
studi
find
show
less
half
first
time
voluntari
blood
donor
return
success
blood
donat
order
increas
donor
return
rate
recommend
time
schedul
mobil
campaign
blood
collect
site
also
increas
number
fix
donat
site
make
donat
servic
conveni
avail
return
first
time
voluntari
blood
donor
found
posit
associ
altruism
perceiv
donat
capabl
donat
larger
blood
volum
therefor
work
promot
market
servic
enbb
could
sensit
commun
altruism
regular
blood
donat
addit
make
donor
awar
requir
screen
procedur
benefit
donat
blood
could
avoid
feel
perceiv
incap
enhanc
urg
donat
blood
regularli
jd
c
r
p
medicin
chennai
medicin
oncolog
miot
intern
hospit
medicin
ramachandra
medic
colleg
hospit
chennai
medicin
vinayaka
mission
medic
colleg
hospit
salem
india
background
world
health
organis
fact
sheet
blood
safeti
avail
state
countri
collect
blood
suppli
familyreplac
paid
donor
nation
aid
control
organis
state
blood
bank
india
oper
privat
sector
depend
replac
donat
main
sourc
blood
suppli
studi
analys
challeng
voluntari
blood
donat
among
replac
famili
blood
donor
india
aim
understand
challeng
face
toward
voluntari
blood
donat
look
possibl
convert
motiv
replacementfamili
blood
donor
repeat
regular
voluntari
blood
donor
method
studi
conduct
april
decemb
major
corpor
medic
colleg
hospit
tamilnadu
india
motiv
replac
famili
donor
interview
use
standard
questionnair
question
includ
donat
blood
patient
voluntarili
blood
camp
awar
continu
need
blood
hospit
will
regular
voluntari
blood
donor
reason
donat
blood
expos
blood
donat
camp
work
place
colleg
day
awar
blood
donat
camp
place
donat
blood
come
donat
result
total
replac
famili
donor
interview
standard
questionnair
studi
among
replac
donor
male
femal
first
time
donor
donor
donat
time
donor
donat
time
vari
interv
time
replac
donor
awar
need
blood
never
expos
blood
donat
either
educ
work
place
opportun
donat
blood
though
awar
blood
donat
summari
conclus
lack
awar
toward
voluntari
blood
donat
stand
import
caus
decreas
voluntari
blood
donat
develop
countri
knowledg
access
blood
camp
place
donat
blood
second
biggest
challeng
face
donor
otherwis
will
donat
blood
healthi
adult
neither
access
blood
camp
awar
place
donat
blood
donor
attach
big
educ
institut
park
industri
get
awar
opportun
donat
blood
healthi
common
popul
like
farmer
peopl
run
small
scale
busi
pizza
deliveri
boy
awar
need
blood
catchment
popul
get
first
idea
blood
donat
mostli
replac
famili
donat
system
adopt
motiv
replac
donor
toward
repeat
voluntari
donat
proper
counsel
would
improv
voluntari
blood
donat
develop
world
r
imperio
lima
h
borg
da
silva
r
fonseca
cassado
j
alvarez
mosig
depart
immunolog
univers
paulo
sao
paulo
brazil
spleen
particularli
shape
maintain
blood
homeostasi
microanatom
spleen
divid
white
pulp
red
pulp
rp
separ
margin
zone
mz
rp
mz
complex
macrophag
network
distinct
origin
function
contribut
complimentari
way
control
infect
properli
execut
function
provid
larg
varieti
receptor
prr
recogn
molecular
pattern
pamp
molecular
pattern
damp
margin
metallophil
macrophag
margin
zone
macrophag
cell
great
abil
intern
pathogen
viru
bacteria
local
adjac
splenic
area
favor
rapid
contact
macrophag
cell
adapt
immun
inde
consid
import
bridg
innat
adapt
immun
rp
macrophag
play
import
role
uptak
apoptot
cell
oxid
ldl
senesc
red
blood
cell
circul
venou
cord
sinus
render
splenic
rp
bloodstream
slow
pace
characterist
allow
filter
function
spleen
favor
elimin
aberr
red
blood
cell
also
import
iron
homeostasi
convers
iron
homeostasi
seem
control
develop
beyond
task
maintain
blood
homeostasi
steadi
state
condit
contribut
control
infect
malaria
bacteri
viral
infect
well
induct
innat
adapt
immun
interestingli
proport
rp
phagocyt
exhibit
strong
label
phenotyp
share
dendrit
cell
popul
particip
earli
clearanc
plasmodium
parasit
sharpli
declin
parasitemia
peak
slow
turnov
rate
possibl
undergo
cell
death
ingest
rbc
due
toxic
effect
hemozoin
note
mani
cell
scatter
rp
popul
interact
cell
acut
immun
respons
plasmodium
infect
involv
control
excess
immun
respons
suggest
studi
autoimmun
syndrom
similar
particip
infecti
diseas
remain
establish
sever
aspect
splenic
shape
splenic
structur
andor
microenviron
develop
splenomegali
typic
infect
character
profound
chang
splenic
microarchitectur
includ
remodel
rp
given
splenic
expect
play
promin
role
recruit
differ
cell
type
acut
immun
respons
convers
splenic
structur
microenviron
seem
play
pivot
role
home
function
instanc
arrang
sinusoid
endotheli
cell
insid
rp
hamper
circul
age
andor
rbc
facilit
trap
insid
rp
posterior
phagocytosi
studi
address
role
one
subset
special
focu
recogn
help
elimin
pathogen
turn
splenic
microarchitectur
microenviron
influenc
macrophag
function
surviv
differ
phase
infect
acut
chronic
pathogen
clearanc
wa
c
k
van
den
test
sanb
durban
test
sanb
johanessburg
sanb
port
elizabeth
south
africa
background
hepat
b
hbv
endem
south
africa
sa
popul
expos
even
though
vaccin
prevent
diseas
remain
one
main
caus
liver
relat
diseas
april
sa
introduc
univers
hepat
b
vaccin
newborn
part
expand
programm
immunis
infant
vaccin
becam
elig
donat
blood
age
aim
compar
hbv
rate
first
time
blood
donor
year
age
determin
whether
introduct
univers
hbv
vaccin
translat
decreas
observ
hbv
rate
among
blood
donor
method
donat
screen
hbsag
abbott
prism
hbv
dna
procleix
tigri
holog
ultrio
assay
use
ultrio
plu
assay
improv
hbv
sensit
hbv
posit
rate
analys
age
gender
popul
group
first
time
donat
probabl
probabl
vaccin
signific
determin
use
chi
squar
statist
result
donat
first
time
donor
year
age
test
hbv
posit
confirm
posit
nat
yield
ny
hbv
four
serolog
yield
hbv
hbv
rate
decreas
p
hbv
rate
decreas
male
p
femal
p
insignific
decreas
hbv
rate
white
donor
p
fold
signific
decreas
black
p
colour
donor
p
occult
hbv
infect
obi
account
ny
p
vaccin
breakthrough
first
time
donor
year
old
hbv
ny
attribut
vaccin
breakthrough
p
hbv
posit
donor
also
hiv
posit
summari
conclus
hbv
rate
first
time
blood
donor
year
age
decreas
significantli
probabl
probabl
vaccin
decreas
hbv
rate
male
donor
greater
femal
donor
could
indic
program
higher
impact
male
donor
reason
yet
appar
decreas
slightli
greater
white
donor
compar
black
colour
donor
howev
insignific
due
small
sampl
size
increas
vaccin
breakthrough
observ
donor
probabl
vaccin
obi
decreas
donor
even
sensit
assay
obi
use
work
area
requir
includ
perform
titr
test
hbsag
hbv
dna
neg
donor
conclud
declin
hbv
rate
young
blood
donor
relat
implement
univers
hbv
vaccin
sa
p
v
q
x
j
de
agent
transmiss
par
le
sang
int
pari
de
qualif
biologiqu
de
don
etabliss
du
sang
et
de
vigil
etabliss
du
sang
et
grand
est
nanci
de
maladi
infectieus
publiqu
franc
nation
etabliss
du
sang
franc
background
franc
risk
transmiss
hiv
infect
blood
reduc
implement
nucleic
acid
test
nat
pool
individu
test
nevertheless
two
situat
lead
result
even
highli
sensit
polymorph
genom
region
target
assay
donat
collect
earli
phase
infect
aim
report
first
case
blood
donat
identifi
eclips
phase
test
neg
method
blood
donat
current
screen
hiv
antibodi
ab
prism
abbott
hiv
rna
ultrio
procleix
grifol
lod
uiml
upon
seroconvers
repeat
donor
repositori
sampl
donat
retest
roch
coba
taqman
assay
lod
uiml
result
august
male
repeat
donor
without
declar
risk
factor
screen
posit
hiv
ab
rna
donat
n
vl
uiml
subtyp
b
donat
test
neg
ultrio
march
posit
retest
coba
taqman
vl
quantif
limit
uiml
sequenc
ident
donat
control
sampl
collect
two
week
donat
n
confirm
strain
ident
addit
sequenc
strain
show
mismatch
primersprob
use
ultrio
target
sequenc
studi
allow
identifi
recipi
blood
compon
donat
red
blood
cell
residu
volum
plasma
rvp
ml
transfus
bone
marrow
transplant
recipi
die
diseas
six
day
transfus
sampl
gather
five
day
test
neg
hiv
rna
platelet
rvp
ml
pool
donat
inactiv
amotosalenuva
transfus
woman
acut
myeloblast
leukaemia
hiv
ab
neg
seven
month
transfus
rule
transmiss
lastli
plasma
yield
donat
fraction
measur
withdraw
product
initi
given
efficaci
pathogen
inactiv
low
level
viremia
summari
conclus
case
underlin
result
remain
except
demonstr
risk
contamin
donat
due
earli
hiv
infect
phase
go
undetect
real
report
agreement
hiv
residu
risk
estim
franc
million
donat
one
donat
everi
year
absenc
detect
hiv
rna
red
blood
cell
recipi
formal
exclud
transmiss
given
earli
death
lastli
absenc
transmiss
platelet
recipi
could
due
low
viral
inoculum
ml
rvp
x
uiml
ui
andor
efficaci
viral
inactiv
use
pool
platelet
case
also
highlight
addit
valu
systemat
donat
archiv
year
franc
lookback
studi
k
b
r
servic
nh
blood
transplant
infect
servic
public
health
england
london
unit
kingdom
background
februari
english
blood
servic
introduc
partial
hev
rna
screen
blood
donor
order
minimis
risk
hev
infect
certain
group
vulner
patient
initi
predict
donor
pool
would
test
number
rais
significantli
order
meet
need
hospit
inventori
april
extend
univers
screen
accord
recommend
made
uk
advisori
committe
safeti
blood
tissu
organ
sabto
follow
introduct
univers
screen
donor
stem
cell
tissu
organ
octob
aim
describ
incid
acut
hev
infect
english
blood
donor
popul
sinc
implement
univers
screen
method
donor
screen
pool
sampl
use
roch
coba
mpx
taqscreen
reactiv
pool
resolv
singl
donat
confirm
procleix
hev
assay
hev
rna
confirm
posit
sampl
test
wantai
igg
igm
assay
fortress
diagnost
viral
load
permit
strain
sequenc
genotyp
sub
genotyp
assign
base
partial
open
read
frame
sequenc
result
partial
screen
period
nhsbt
screen
donor
observ
posit
rate
april
decemb
donor
screen
donor
sampl
found
initi
reactiv
sampl
test
posit
second
assay
refer
laboratori
mani
sampl
viral
load
low
allow
sequenc
date
strain
sequenc
belong
genotyp
distribut
follow
clade
sub
genotyp
clade
sub
genotyp
first
phase
follow
introduct
screen
sequenti
monitor
hev
rna
igg
igm
perform
donor
reinstat
panel
serolog
compat
differ
stage
acut
hev
infect
pick
initi
seroneg
seroconvers
demonstr
donor
bar
one
whole
blood
donor
seroneg
found
viraem
return
year
later
hev
igg
undetect
presenc
hev
rna
confirm
plasma
pack
possibl
antibodi
level
peak
declin
period
observ
donor
test
serial
sampl
reactiv
therefor
true
infect
summari
conclus
hev
rna
preval
blood
donor
declin
compar
period
around
keep
hev
activ
observ
gener
uk
popul
public
health
england
data
vari
period
sub
genotyp
distribut
genotyp
viru
clade
continu
predomin
clade
also
mimick
distribut
seen
clinic
case
present
commun
continu
monitor
chang
epidemiolog
clinic
impact
infect
vulner
group
help
inform
blood
tissu
cell
organ
safeti
strategi
k
r
servic
nh
blood
transplant
infect
servic
public
health
england
london
unit
kingdom
background
partial
blood
donor
screen
hev
rna
implement
uk
blood
servic
univers
screen
april
order
monitor
nat
perform
collect
data
inform
donor
reinstat
criteria
follow
donor
test
hev
rna
igg
igm
whole
blood
donor
defer
month
apheresi
donor
could
return
panel
hev
rna
becam
undetect
igg
samplecut
ratio
greater
criterion
later
modifi
relax
aim
describ
small
subset
prospect
data
collect
blood
donor
found
hev
viraem
time
donat
longitudin
hev
igg
valu
monitor
document
seroconvers
trend
antibodi
level
time
method
screen
perform
use
pool
sampl
roch
assay
pool
reactiv
resolv
singl
donat
undergo
individu
nat
hev
grifol
diagnost
solut
mikrogen
diagnostik
assay
serolog
perform
use
hev
igg
igm
assay
fortress
diagnost
follow
sampl
test
individu
nat
procleix
amplicub
assay
return
donor
longitudin
serolog
perform
sampl
test
month
initi
hev
rna
posit
pick
donat
result
donor
screen
confirm
hev
rna
posit
case
posit
rate
donor
longest
follow
time
month
donor
seroneg
pick
demonstr
seroconvers
hev
rna
screen
result
follow
seroconvers
donor
maintain
good
level
hev
igg
samplecut
ratio
rang
small
number
donor
differ
serolog
pattern
longitudin
follow
reveal
variat
abil
sustain
level
specif
igg
five
donor
clear
declin
level
two
went
lose
detect
hev
antibodi
signific
drop
igg
level
rang
seen
month
four
donor
document
two
donor
month
one
donor
seroneg
pick
return
donat
year
later
possibl
donor
reach
peak
antibodi
level
went
becam
undetect
time
interv
summari
conclus
unclear
donor
signific
declin
hev
igg
level
observ
period
longest
interv
month
sampl
obtain
interv
test
sampl
collect
purpos
apheresi
donor
sampl
taken
donor
return
donat
donor
report
overt
acut
hepatit
ill
post
index
donat
symptomat
diseas
alon
account
strength
durat
specif
antibodi
respons
viral
host
factor
may
play
role
observ
may
signific
futur
blood
safeti
strategi
plan
understand
host
respons
hev
explor
tinmouth
j
b
l
van
de
j
van
der
van
c
clinic
transfus
research
sanquin
research
clinic
epidemiolog
leiden
univers
medic
center
leiden
transfus
medicin
sanquin
blood
bank
amsterdam
hematolog
univers
medic
center
groningen
groningen
hematolog
erasmu
den
ho
cancer
center
rotterdam
donor
affair
sanquin
blood
bank
amsterdam
netherland
background
patient
defin
refractori
platelet
transfus
one
hour
correct
count
increment
two
subsequ
transfus
random
platelet
concentr
patient
may
benefit
platelet
transfus
match
antigen
larg
panel
donor
patient
receiv
product
either
partial
match
contain
four
feasibl
taken
account
aim
aim
evalu
donor
program
quantifi
efficaci
partial
mismatch
platelet
transfus
mean
transfus
method
cohort
studi
perform
among
recipi
platelet
netherland
number
avail
donor
per
patient
determin
ethnic
background
patient
five
less
donor
compar
random
sampl
patient
least
donor
sinc
ethnic
regist
netherland
use
haplostat
estim
like
ethnic
background
next
select
first
transfus
exposit
new
mismatch
mismatch
transfus
compar
match
transfus
use
mix
model
linear
regress
adjust
within
patient
variat
next
subgroup
analys
perform
patient
posit
neg
screen
necessarili
known
upon
request
first
product
lastli
effect
investig
result
studi
period
patient
receiv
total
transfus
septemb
donor
regist
median
interquartil
rang
match
donor
avail
per
patient
patient
five
less
donor
avail
patient
estim
caucasian
african
american
random
sampl
patient
median
donor
iqr
like
ethnic
accord
haplostat
caucasian
nativ
american
hispan
avail
first
transfus
uniqu
mismatch
transfus
averag
match
transfus
refer
interv
decreas
confid
interv
ci
transfus
patient
posit
screen
decreas
mismatch
transfus
regardless
antibodi
specif
wherea
patient
neg
screen
degre
influenc
condit
decreas
ci
major
mismatch
transfus
summari
conclus
platelet
support
could
offer
major
refractori
patient
number
patient
ethnic
minor
disproport
larg
group
patient
less
five
donor
platelet
concentr
yield
highest
partial
match
transfus
still
result
increment
larger
would
recommend
divers
donor
popul
order
meet
patient
need
j
p
van
p
van
der
j
ten
sanquin
amsterdam
leiden
netherland
system
research
institut
san
francisco
unit
state
amsterdam
netherland
tromso
norway
univers
medic
center
leiden
netherland
background
platelet
transfus
elicit
alloimmun
respons
lead
alloantibodi
format
polymorph
residu
hla
class
ultim
result
platelet
transfus
refractori
howev
unknown
risk
alloimmun
caus
white
blood
cell
remain
leukoreduct
alloimmun
even
induc
platelet
aim
studi
first
investig
capac
platelet
induc
alloimmun
subsequ
determin
effect
storag
pathogen
reduct
alloimmun
platelet
transfus
method
platelet
either
isol
untreat
pathogen
reduc
platelet
concentr
store
routin
blood
bank
condit
freshli
isol
subsequ
incub
dendrit
cell
h
dc
harvest
platelet
intern
determin
use
confoc
microscopi
quantifi
imag
flow
cytometri
addit
present
peptid
hla
class
ii
determin
use
mass
spectrometri
immunoprecipit
hla
class
iipeptid
complex
altern
dc
subsequ
incub
human
platelet
antigen
cell
product
measur
determin
cell
respons
effect
pathogen
reduct
alloimmun
investig
vivo
patient
n
random
receiv
either
untreat
n
mirasol
pathogen
reduc
n
platelet
transfus
part
prepar
trial
weekli
blood
sampl
presenc
hla
class
class
ii
antibodi
determin
use
luminex
assay
patient
analyz
accord
per
protocol
analysi
result
allogen
platelet
phagocytos
peptid
present
dendrit
cell
dc
furthermor
dc
induc
cell
respons
altogeth
indic
abil
induc
alloimmun
phagocytosi
store
platelet
enhanc
compar
fresh
platelet
apoptosi
accompani
phosphatidylserin
exposur
seem
instrument
increas
phagocytosi
mirasol
pathogen
reduct
enhanc
phagocytosi
platelet
enrol
patient
hla
class
hla
class
ii
posit
patient
differ
observ
antibodi
titer
broad
immun
receiv
either
untreat
pathogen
reduc
platelet
concentr
patient
antibodi
neg
enrol
develop
class
antibodi
receiv
pathogen
reduc
platelet
concentr
compar
receiv
untreat
pc
p
appar
differ
antibodi
titer
panel
reactiv
observ
receiv
untreat
vs
pathogen
reduc
platelet
hla
class
ii
antibodi
format
similar
studi
arm
p
summari
conclus
studi
show
capac
platelet
induc
alloimmun
respons
moreov
apoptosi
platelet
identifi
potenti
risk
factor
alloimmun
platelet
transfus
furthermor
vivo
platelet
concentr
treat
mirasol
pathogen
reduct
enhanc
hla
class
alloimmun
may
due
enhanc
apoptosi
pathogen
reduct
r
chandrabhan
dara
r
sharma
h
bhardwaj
v
tak
transfus
medicin
manip
hospit
jaipur
jaipur
india
background
platelet
due
short
shelf
life
alway
remain
limit
suppli
platelet
often
transfus
across
abo
blood
group
abo
major
compat
essenti
requisit
red
cell
transfus
platelet
transfus
evid
publish
literatur
transfus
efficaci
abo
incompat
platelet
transfus
inferior
compar
compat
transfus
howev
studi
involv
cancer
hematolog
transplant
recipi
aim
assess
respons
plt
transfus
cohort
recipi
studi
relationship
abo
compat
plt
count
increment
plt
transfus
method
studi
conduct
observ
studi
primarili
recipi
determin
efficaci
compat
versu
abo
incompat
platelet
transfus
data
collect
recipi
receiv
platelet
transfus
period
august
juli
collect
variabl
gender
age
time
transfus
height
weight
diagnosi
abo
group
number
platelet
unit
transfus
type
platelet
unit
transfus
platelet
count
abo
group
volum
platelet
platelet
count
time
correct
count
increment
cci
absolut
platelet
count
increment
api
calcul
compar
versu
incompat
platelet
transfus
model
model
appli
potenti
explanatori
variabl
interest
p
valu
less
consid
signific
result
total
platelet
unit
random
donor
platelet
singl
donor
platelet
transfus
recipi
transfus
episod
studi
period
total
platelet
unit
includ
final
analysi
exclud
median
age
patient
year
male
contribut
compat
statu
plt
transfus
includ
abo
ident
minor
incompat
abo
major
incompat
transfus
median
api
abo
minor
incompat
transfus
median
api
valu
transfus
median
api
valu
p
median
cci
ident
transfus
minor
incompat
transfus
versu
incompat
transfus
p
limit
first
observ
studi
lack
random
analys
chang
platelet
count
use
api
cci
rather
clinic
criteria
bleed
length
hospit
stay
andor
mortal
sinc
data
initi
collect
plan
qualiti
improv
studi
monitor
count
increment
transfus
formal
sampl
size
calcul
perform
summari
conclus
platelet
transfus
lead
higher
absolut
increment
compar
platelet
transfus
base
median
api
respect
compar
abo
compat
versu
abo
major
incompat
platelet
transfus
signific
differ
observ
median
cci
e
j
c
hospit
north
norway
pharma
norway
red
cross
frankfurt
germani
region
laboratori
lund
sweden
univers
hospit
oslo
norway
background
larg
european
collabor
studi
profnait
process
develop
hyperimmun
igg
naitgam
prevent
immun
fetal
neonat
alloimmun
thrombocytopenia
fnait
posit
children
born
neg
women
abil
naitgam
elimin
posit
platelet
transfus
neg
healthi
individu
test
phase
trial
tradit
vivo
monitor
surviv
transfus
platelet
carri
measur
platelet
label
procedur
requir
signific
manipul
platelet
question
platelet
compar
platelet
henc
establish
valid
high
sensit
method
studi
surviv
transfus
platelet
would
allow
measur
true
platelet
surviv
kinet
use
clinic
set
aim
aim
establish
optim
valid
high
sensit
flow
cytometr
method
allow
detect
minor
amount
transfus
platelet
establish
method
use
profnait
phase
phase
clinic
trial
measur
vivo
platelet
surviv
method
establish
flow
cytometr
assay
base
method
publish
vetlesen
et
al
transfus
use
mismatch
donor
recipi
standard
qualiti
control
sampl
prepar
ad
small
amount
hla
hla
posit
platelet
differ
batch
platelet
rich
plasma
prp
hla
hla
neg
donor
total
platelet
flow
rate
collect
isol
beckman
coulter
dot
plot
target
popul
hla
hla
posit
platelet
identifi
dot
plot
use
fitc
conjug
monoclon
antibodi
one
lamda
inc
paramet
valid
select
lower
limit
detect
lloq
calibr
curv
accuraci
precis
robust
result
posit
platelet
exhibit
strong
signal
allow
discrimin
posit
platelet
among
neg
platelet
valid
confirm
accept
criteria
accuraci
precis
within
respect
lloq
linear
lloq
summari
conclus
success
establish
high
sensit
method
measur
natur
clearanc
transfus
platelet
method
valid
accord
ema
guidelin
fulfil
requir
good
laboratori
practic
glp
r
goel
laboratori
medicin
patholog
pediatr
new
hospit
weill
cornel
medic
colleg
new
york
unit
state
pediatricneonat
transfus
blood
manag
practic
remain
rel
understudi
underrepres
area
transfus
medicin
despit
highli
transfus
popul
still
nearli
two
decad
centuri
major
clinic
practic
continu
extrapol
result
adult
studi
appli
neonat
children
remain
critic
need
compel
tangibl
opportun
neonat
pediatr
popul
fill
identifi
gap
knowledg
also
eventu
dissemin
research
result
directli
applic
vulner
popul
thu
ensur
translat
integr
evid
routin
practic
pediatr
neonat
transfus
medicin
transfus
red
blood
cell
rbc
platelet
plasma
critic
therapi
pediatr
popul
rang
intrauterin
transfus
transfus
preterm
neonat
neonat
intens
care
unit
nicu
treat
critic
ill
child
pediatr
intens
care
unit
picu
extracorpor
membran
oxygen
childadolescentyoung
adult
need
solid
organ
hematopoiet
cell
transplant
involv
clinic
care
neonat
pediatr
patient
recogn
signific
physiolog
adapt
intrins
transit
fetu
neonat
childhood
adolesc
context
therapi
administ
import
consider
treat
patient
includ
pair
chang
bodi
weight
blood
plasma
volum
develop
renal
hepat
hematolog
immun
system
addit
effect
toxic
environment
factor
development
evolv
neonat
child
big
data
ptm
may
answer
problem
identifi
nhlbi
seminar
small
sampl
size
difficulti
get
irb
approv
consent
difficulti
rct
neonat
children
due
slow
enrol
thu
remain
underpow
studi
variou
outcom
altern
util
larg
databas
registri
allow
retrospect
well
longitudin
analys
employ
robust
statist
tool
attract
feasibl
option
appropri
acknowledg
multipl
inher
limit
studi
design
nation
repres
databas
eg
kid
ped
nsqip
phi
neonat
databas
key
potenti
treasur
trove
robust
tool
may
help
answer
vital
ptm
question
p
spinella
h
nh
blood
transplant
imperi
colleg
london
unit
kingdom
haemovigil
collect
inform
advers
outcom
transfus
reaction
error
part
decis
transfus
also
take
account
clinic
situat
transfus
threshold
possibl
altern
inform
advers
outcom
aid
develop
transfus
guidelin
optim
patient
blood
manag
neonat
children
consid
distinct
group
assess
transfus
advers
outcom
sever
countri
haemovigil
scheme
identifi
paediatr
patient
includ
netherland
trip
uk
seriou
hazard
transfus
scheme
shot
provid
separ
analysi
paediatr
report
sinc
paediatr
report
year
shot
total
commonli
incorrect
blood
compon
transfus
includ
failur
provid
correct
specif
requir
mani
specif
sourc
error
paediatr
transfus
lead
disproportion
report
particularli
neonat
mani
countri
provid
special
compon
may
incorrectli
selectedrequest
laboratoryclinician
neonat
compat
test
includ
matern
blood
groupserolog
increas
chanc
laboratori
error
administr
blood
compon
neonat
small
children
requir
specif
give
set
pump
sourc
technic
error
miscalcul
prescript
transfus
volum
inexperienc
staff
result
signific
transfus
error
commun
share
care
centr
lead
miss
special
requir
irradi
focu
paediatr
transfus
educ
import
laboratori
clinic
staff
although
preterm
neonat
vulner
recipi
like
suscept
transfus
reaction
cardiac
overload
taco
rel
fewer
report
acut
transfus
reaction
shot
group
possibl
due
subtl
sign
research
contribut
understand
potenti
advers
transfus
reaction
neonat
children
eg
transfus
associ
necrotis
enterocol
tanec
acut
lung
injuri
trali
taco
uk
prospect
observ
studi
shown
cardiorespiratori
chang
follow
neonat
red
cell
transfus
number
patient
paediatr
intens
care
taco
shown
vari
significantli
depend
diagnost
criteria
use
de
cloedt
et
al
transfus
http
studi
emphasis
need
clinic
awar
paediatr
transfus
reaction
research
true
incid
develop
appropri
definit
age
group
report
shot
also
highlight
specif
area
risk
complex
specialis
situat
includ
fatal
transfus
associ
graft
vs
host
diseas
follow
intrauterin
transfus
matern
blood
shot
report
morbid
delay
neonat
exchang
transfus
unusu
high
supernat
potassium
level
red
cell
unit
donor
mutat
increas
potassium
leakag
cold
storag
shot
report
bawazir
et
al
transfus
lesson
learn
incorpor
recommend
recent
british
societi
haematolog
fetal
neonat
paediatr
transfus
guidelin
new
et
al
b
j
haem
b
dykstra
j
valdez
c
peter
l
beaulieu
j
thon
platelet
biogenesi
cambridg
unit
state
platelet
princip
blood
cell
respons
clot
format
blood
vessel
repair
site
activ
bleed
platelet
transfus
unit
platelet
per
ml
present
deriv
exclus
human
volunt
mount
demand
exce
suppli
develop
scalabl
human
induc
pluripot
stem
cell
hipsc
platelet
hipsc
line
meet
clinic
need
establish
serum
megakaryocyt
differenti
process
feng
et
al
stem
cell
report
sinc
identifi
primari
backup
hipsc
line
gener
megakaryocyt
platelet
begin
translat
megakaryocyt
differenti
protocol
industri
scale
bioreactor
increas
overal
yield
decreas
platelet
unit
cost
result
platelet
express
relev
biomark
size
ploidi
flow
cytometri
morpholog
ultrastructur
microscopi
growth
factor
cytokin
chemokin
composit
luminex
array
increas
overal
platelet
yield
develop
millifluid
platelet
bioreactor
expos
megakaryocyt
physiolog
shear
stress
flow
blood
thon
et
al
blood
sinc
begun
industri
manufactur
devic
thermoplast
scale
platelet
bioreactor
support
larger
volum
defin
pressur
shear
forc
trigger
platelet
product
improv
separationconcentr
platelet
progenitor
cell
begun
autom
bioreactor
oper
function
platelet
rest
express
activ
biomark
upon
agonist
exposur
vitro
studi
present
extend
mice
platelet
product
pois
becom
among
first
stem
tissu
engin
platform
advanc
clinic
use
repres
major
first
step
toward
sustain
blood
system
mt
rondina
molecular
medicin
univers
utah
salt
lake
citi
unit
state
platelet
one
eukaryot
cell
live
function
without
nucleu
anucl
platelet
long
categor
simpl
cell
inherit
predict
fix
hemostat
toolset
parent
megakaryocyt
emerg
evid
howev
demonstr
platelet
far
dynam
complex
previous
consid
well
accept
platelet
regul
critic
involv
develop
progress
evolut
numer
human
diseas
includ
arthriti
atherosclerosi
cancer
diabet
inflammatori
syndrom
new
role
platelet
emerg
parallel
appreci
anucl
cell
possess
complex
molecular
machineri
govern
behavior
machineri
includ
extens
repertoir
mrna
rna
ncrna
use
emerg
technolog
ribosom
footprint
profil
transcript
translat
landscap
human
platelet
health
diseas
coupl
vitro
vivo
valid
function
determin
novel
role
previous
unknown
protein
platelet
megakaryocyt
discov
lectur
discuss
inflammatori
stressor
alter
regul
gene
express
platelet
megakaryocyt
function
respons
follow
k
medicin
st
michael
hospit
univers
toronto
st
michael
hospit
univers
toronto
toronto
canada
platelet
refractori
refer
lack
appropri
platelet
increment
follow
transfus
platelet
platelet
refractori
associ
increas
bleed
increas
health
resourc
util
case
refractori
due
factor
splenomegali
infect
medic
bleed
among
other
less
case
platelet
refractori
thought
caus
alloimmun
hla
class
andor
hpa
antigen
present
platelet
surfac
alloimmun
platelet
refractori
manag
provis
match
platelet
transfus
method
hla
select
well
platelet
crossmatch
avail
usual
lead
improv
post
transfus
increment
howev
none
method
shown
affect
clinic
signific
outcom
furthermor
method
gener
expens
well
time
resourc
intens
prevent
alloimmun
refractori
therefor
goal
product
recipi
factor
play
role
pathogenesi
alloimmun
refractori
appear
dose
respons
relationship
alloimmun
patient
refractori
murin
model
alloimmun
occur
effici
platelet
product
contain
platelet
white
cell
mhc
molecul
free
platelet
associ
platelet
product
taken
re
allow
antigen
present
cell
stimul
recipi
immun
respons
produc
igg
antibodi
igg
antibodi
effect
bind
donor
platelet
caus
prematur
destruct
furthermor
enhanc
immun
donor
mhc
class
molecul
direct
allorecognit
donor
antigen
present
cell
necessari
mean
reduc
number
donor
white
cell
platelet
product
result
less
robust
immun
respons
recipi
therefor
surpris
multipl
studi
shown
leukoreduct
significantli
reduc
rate
alloimmun
alloimmun
platelet
refractori
recent
studi
involv
canin
model
leukoreduct
combin
mirasol
pathogen
reduct
technolog
result
signific
reduct
alloimmun
suggest
alloimmun
effect
prevent
mechan
salutari
effect
prt
yet
elucid
g
h
epidemiolog
biostatist
karolinska
institutet
cardiolog
stockholm
sweden
epidemiolog
research
staten
serum
institut
hematolog
rigshospitalet
copenhagen
denmark
background
sever
recent
studi
investig
whether
differ
characterist
blood
donor
demograph
variabl
pariti
statu
affect
surviv
transfus
patient
howev
result
variabl
least
two
studi
find
patient
transfus
unit
femal
donor
increas
mortal
larger
studi
unabl
replic
effect
aim
recogn
methodolog
inconsist
problem
miss
data
previou
studi
investig
effect
blood
donor
sex
pariti
surviv
transfus
patient
use
data
scandinavian
donat
transfus
scandat
databas
nationwid
complet
data
sweden
denmark
method
set
retrospect
cohort
studi
patient
transfus
sweden
denmark
patient
follow
mortal
start
first
transfus
period
effect
number
transfus
femal
donor
parou
femal
donor
risk
death
estim
separ
model
use
cox
regress
time
depend
covari
adjust
made
total
number
transfus
use
flexibl
method
key
confound
factor
also
investig
risk
addit
transfus
relat
sex
contribut
donor
adjust
donor
hemoglobin
concentr
result
total
patient
includ
among
observ
death
neither
number
unit
femal
donor
hazard
ratio
hr
confid
interv
ci
number
unit
previous
pregnant
donor
hr
ci
associ
recipi
mortal
analys
restrict
male
recipi
younger
year
yield
virtual
ident
result
hr
ci
conspicu
pattern
emerg
number
unit
femal
donor
previous
pregnant
donor
categor
patient
receiv
unit
previous
pregnant
donor
ident
risk
death
hr
ci
patient
receiv
unit
analys
mortal
show
virtual
ident
result
wider
confid
interv
account
fewer
death
analysi
risk
blood
unit
femal
donor
result
higher
risk
need
addit
unit
hr
ci
adjust
donor
hemoglobin
concentr
remov
associ
hr
ci
indic
blood
unit
femal
donor
poorer
efficaci
account
lower
hemoglobin
concentr
conclus
analysi
donor
demograph
pariti
statu
outcom
transfus
patient
find
effect
mortal
overal
select
implic
previou
studi
due
complet
data
larg
sampl
size
result
provid
reassur
transfus
medicin
commun
ra
transfus
research
sanquin
research
epidemiolog
leiden
univers
medic
center
leiden
netherland
first
discuss
effect
sex
donor
surviv
transfus
recipi
appear
literatur
late
report
transfus
reaction
associ
ie
leukocyt
agglutin
antibodi
publish
soon
shown
common
among
donor
ie
donor
sever
previou
pregnanc
acut
lung
injuri
trali
report
main
transfus
reaction
associ
subsequ
research
confirm
role
plasma
rich
blood
product
femal
donor
etiolog
trali
corollari
plasma
femal
donor
also
shown
associ
increas
mortal
especi
pulmonari
caus
howev
modern
red
blood
cell
contain
littl
plasma
possibl
associ
femal
blood
donor
increas
incid
trali
shown
immeasur
weak
therefor
came
somewhat
surpris
observ
associ
sex
donor
mortal
transfus
recipi
associ
especi
strong
young
male
recipi
red
blood
cell
femal
donor
hazard
ratio
hr
confid
interv
ci
subsequ
sever
group
confirm
increas
mortal
male
recipi
femal
blood
product
pool
hr
studi
ci
meanwhil
also
perform
confirm
studi
show
two
thing
first
associ
transfus
femal
donor
increas
mortal
limit
male
recipi
year
age
femal
donor
previou
pregnanc
second
ignor
two
import
effect
modifi
result
dilut
effect
point
near
undetect
recipi
year
age
differ
cumul
mortal
recipi
singl
transfus
male
donor
donor
ci
male
recipi
neg
control
group
ie
femal
recipi
show
relev
differ
ci
altern
neg
control
group
ie
male
recipi
never
pregnant
femal
donor
differ
cumul
mortal
ci
interpol
hr
male
recipi
year
age
transfus
donor
ci
neg
control
group
ie
femal
recipi
ci
altern
neg
control
group
ie
male
recipi
transfus
never
pregnant
femal
donor
hr
ci
conclus
popul
might
seem
like
littl
effect
sex
donor
surviv
transfus
recipi
could
explain
rel
contribut
male
year
age
popul
transfus
recipi
previous
pregnant
donor
popul
femal
donor
biolog
mechan
still
need
elucid
could
lead
contribut
explan
potenti
includ
product
prepar
storag
time
j
r
x
g
j
molecular
genet
univers
colorado
denver
aurora
eastlak
avenu
e
suit
bloodwork
northwest
seattl
medic
institut
univers
pittsburgh
pittsburgh
intern
atlanta
unit
state
rockcrest
avenu
center
blood
research
victoria
canada
system
research
institut
san
francisco
rockcrest
avenu
blood
system
research
institut
seattl
nation
heart
lung
blood
institut
recipi
epidemiolog
donor
evalu
studi
iii
program
red
iii
unit
state
background
background
spontan
hemolysi
one
gold
standard
determin
storag
qualiti
pack
red
blood
cell
rbc
per
food
drug
administr
criteria
transfus
recipi
rbc
also
expos
oxid
osmot
stressor
may
aggrav
hemolysi
impact
transfus
efficaci
safeti
compromis
vasodil
promot
septic
complic
light
consider
nation
heart
lung
blood
institut
recipi
epidemiolog
donor
evalu
studi
iii
program
launch
red
blood
studi
one
aim
studi
defin
genet
metabolom
base
differ
rbc
storag
stabil
aim
aim
identifi
small
molecul
marker
oxid
osmot
hemolysi
donor
character
extrem
valu
spontan
oxid
osmot
hemolysi
method
method
high
throughput
hemolysi
assay
develop
use
evalu
store
rbc
sampl
african
american
asian
white
hispan
blood
donor
geograph
divers
region
unit
state
rbc
sampl
store
day
either
addit
solut
evalu
storag
osmot
oxid
hemolysi
six
hundr
donor
show
extrem
spontan
oxid
osmot
hemolysi
recal
second
donat
store
sampl
evalu
spontan
stress
hemolysi
storag
day
aliquot
process
metabolom
store
serial
sampl
recal
donor
select
untarget
metabolom
analys
via
liquid
spectrometri
univers
colorado
denver
result
result
untarget
metabolom
lipidom
analys
confirm
expand
upon
previous
identifi
small
molecul
marker
metabol
age
store
pack
rbc
quantit
marker
includ
hypoxanthin
lactat
reduc
glutathion
spike
stabl
intern
standard
identifi
rang
predict
oxid
osmot
hemolysi
unsupervis
data
analysi
compound
discover
identifi
total
featur
put
metabolit
preliminari
statist
analys
data
reveal
candid
small
molecul
marker
oxid
osmot
hemolysi
basi
donor
gender
age
ethnic
addit
solut
high
oxid
hemolyz
character
significantli
higher
level
adenosin
triphosph
well
reduc
oxid
glutathion
test
time
point
p
anova
summari
conclus
summari
unbal
homeostasi
axi
atpglutathion
ratio
significantli
correl
propens
oxid
hemolysi
ongo
mechanist
analys
includ
linkag
detail
genet
data
donor
expand
relev
observ
find
report
nm
r
r
j
j
mcmaster
univers
hamilton
actuari
scienc
univers
waterloo
waterloo
centr
transfus
research
mcmaster
univers
centr
transfus
research
mcmaster
univers
hamilton
innov
canadian
blood
servic
edmonton
canada
background
conflict
report
associ
blood
donor
sex
andor
age
mortal
transfus
recipi
canadian
studi
found
recipi
mortal
increas
exposur
red
blood
cell
rbc
femal
donor
younger
donor
analysi
scandinavian
countri
found
associ
aim
analys
data
larg
transfus
registri
explor
associ
donor
characterist
sex
age
mortal
transfus
adult
method
exploratori
retrospect
analysi
use
clinic
transfus
registri
data
adult
transfus
linkag
donor
sex
age
inform
blood
supplier
cox
regress
model
use
control
risk
variabl
confound
variabl
either
covari
use
stratif
variabl
either
fix
time
depend
fix
covari
includ
recipi
age
sex
abo
group
time
depend
covari
includ
exposur
intervent
hospit
exposur
base
method
blood
process
exposur
fresh
rbc
store
day
fix
stratif
variabl
includ
diagnosi
fiscal
year
admiss
time
depend
stratif
variabl
includ
cumul
number
rbc
transfus
hemoglobin
creatinin
exposur
abo
rbc
exposur
platelet
exposur
plasma
time
depend
variabl
updat
model
new
inform
becam
avail
seri
model
fit
explor
recipi
outcom
donor
sex
exposur
femal
male
donor
age
exposur
year
year
exposur
donorrecipi
rbc
transfus
donor
age
one
model
exposur
model
defin
mutual
exclus
categori
outcom
mortal
result
patient
receiv
rbc
unit
patient
diagnost
categori
cardiovascular
neoplasm
injuri
gastrointestin
transfus
rbc
unit
came
male
donor
median
age
donor
year
risk
death
increas
femal
expos
male
rbc
hazard
ratio
hr
ci
p
male
expos
femal
rbc
hr
ci
p
risk
death
femal
recipi
expos
rbc
donor
year
differ
compar
exclus
exposur
donor
year
age
hr
ci
p
howev
risk
death
male
expos
rbc
donor
year
higher
compar
exclus
exposur
rbc
donor
year
hr
ci
p
interact
term
indic
differ
male
femal
recipi
p
interact
remov
model
hr
male
femal
recipi
expos
rbc
donor
year
ci
p
final
model
includ
rbc
exposur
donor
age
show
variabl
associ
increas
mortal
sex
mismatch
hr
ci
p
donor
year
hr
ci
p
summari
conclus
donorrecipi
sex
mismatch
rbc
transfus
transfus
rbc
donor
year
associ
increas
recipi
mortal
find
statist
signific
increas
risk
mortal
exposur
femal
rbc
significantli
increas
risk
observ
femal
expos
male
rbc
f
nhsbtouh
oxford
behaviour
chang
ucl
london
unit
kingdom
background
audit
feedback
f
defin
summari
clinic
perform
healthcar
provid
specifi
time
period
wide
use
qualiti
improv
strategi
transfus
practic
howev
effect
f
modest
highli
variabl
evid
continu
use
blood
outsid
recommend
rais
question
regard
efficaci
current
transfus
f
strategi
improv
aim
affiniti
develop
evalu
audit
feedback
intervent
increas
transfus
practic
research
programm
funder
nihr
aim
appli
behaviour
theori
evid
relat
f
develop
evalu
two
feedback
intervent
within
nhsbt
nation
compar
audit
nca
programm
blood
transfus
method
affiniti
programm
describ
four
interrel
workstream
intervent
analysi
exist
feedback
report
identifi
discrep
content
format
current
nca
feedback
report
f
theori
evid
b
observ
hospit
meet
transfus
feedback
discuss
plu
interview
base
behaviour
theori
staff
role
identifi
barriersenabl
hospit
respond
feedbacktwo
link
trial
embed
nca
evalu
effect
two
enhanc
intervent
standard
nca
practic
trial
audit
surgic
patient
blood
manag
trial
use
transfus
haematolog
primari
outcom
whether
transfus
categoris
necessari
binari
measur
measur
patient
level
base
nca
audit
dataparallel
process
evalu
investig
intervent
fidel
howwhi
intervent
achiev
observ
outcomesexplor
generalis
affiniti
find
nation
audit
programm
beyond
transfus
result
current
feedback
report
found
make
limit
use
behaviour
chang
techniqu
feedback
characterist
like
increas
effect
eg
action
plan
multipl
modal
compar
intervent
enhanc
content
therefor
develop
includ
specif
guidanc
group
prepar
feedback
report
hospit
staff
includ
contenthospit
respons
feedback
found
vari
wide
term
extent
localis
plan
depend
upon
support
infrastructur
role
clariti
feedback
often
reach
key
individu
involv
transfus
amend
local
use
intervent
enhanc
therefor
design
consist
practic
tool
support
dissemin
plan
strateg
eg
action
plan
around
local
respons
feedback
plu
telephon
support
encourag
engag
tool
transfus
staffrecruit
nation
cluster
trial
good
nearli
hospit
england
particip
nation
audit
surgeri
haematolog
eg
cluster
data
patient
surgeri
analysi
outcom
current
underway
summari
conclus
affiniti
describ
pragmat
research
programm
enhanc
test
effect
f
strategi
use
rigour
randomis
trial
design
provid
framework
implement
research
address
often
poor
slow
uptak
research
patient
blood
manag
practic
f
karim
patholog
laboratori
medicin
aga
khan
univers
hospit
karachi
pakistan
background
order
blood
compon
one
critic
step
transfus
safeti
facilit
physician
order
blood
compon
aid
decis
make
comput
physician
order
entri
system
cpoe
use
worldwid
system
help
physician
make
appropri
request
avoid
unnecessari
transfus
aim
improv
blood
compon
order
practic
develop
countri
introduc
comput
physician
order
entri
system
method
qualiti
project
initi
blood
bank
aga
khan
univers
hospit
karachi
pakistan
pdsa
plan
studi
act
use
methodolog
tool
plan
phase
audit
conduct
one
thousand
randomli
select
blood
compon
order
order
review
complet
legibl
defici
identifi
audit
note
team
compris
transfus
medicin
consult
blood
bank
manag
inform
technolog
personnel
formul
phase
cpoe
design
multipl
meet
stakehold
clinic
decis
support
option
promot
evid
base
transfus
practic
incorpor
indic
transfus
base
british
committe
standard
hematolog
bcsh
guidelin
cpoe
link
laboratori
inform
system
medic
health
record
inform
treat
physician
clinic
diagnosi
lab
result
automat
captur
system
project
first
pilot
medic
unit
februari
feedback
taken
blood
bank
minor
issu
rectifi
cpoe
valid
gradual
implement
area
hospit
implement
awar
creat
present
given
use
cpoe
gradual
shift
made
manual
request
onlin
order
juli
project
complet
success
implement
across
hospit
studi
phase
post
audit
blood
compon
order
done
march
novemb
evalu
blood
order
practic
act
cpoe
use
continu
result
plan
phase
audit
complet
legibl
order
poor
type
number
blood
compon
mention
slip
inform
miss
order
includ
primari
consult
name
n
order
physician
name
n
clinic
diagnosi
n
reason
transfus
miss
n
blood
order
identifi
defici
cpoe
care
design
implement
post
cpoe
implement
audit
total
blood
compon
order
review
pack
red
cell
n
platelet
n
ffp
n
cryoprecipit
n
blood
order
gave
complet
inform
clinic
diagnosi
treat
physician
order
physician
name
reason
transfus
select
provid
list
n
order
summari
conclus
cpoe
clinic
decis
support
success
implement
institut
improv
order
practic
promot
transfus
practic
develop
cpoe
significantli
improv
qualiti
order
term
legibl
complet
step
forward
enhanc
transfus
safeti
develop
countri
c
w
c
l
p
w
k
j
e
n
r
e
j
laboratori
medicin
molecular
diagnost
sunnybrook
health
scienc
centr
toronto
toronto
innov
canadian
blood
servic
region
blood
coordin
network
ottawa
hospit
ottawa
blood
servic
toronto
canada
background
transfus
common
procedur
administ
hospit
prescrib
physician
almost
everi
specialti
optim
method
postgradu
transfus
medicin
tm
educ
yet
determin
transfus
camp
novel
approach
tm
educ
central
curriculum
postgradu
traine
variou
specialti
deliv
local
multipl
univers
aim
evalu
transfus
camp
educ
program
postgradu
traine
attitud
knowledg
acquisit
behaviour
method
transfus
camp
establish
univers
toronto
central
local
tm
educ
curriculum
deliv
five
day
across
academ
year
target
audienc
specialti
base
postgradu
traine
start
collabor
canadian
blood
servic
transfus
camp
expand
canadian
unit
kingdom
univers
site
didact
lectur
given
toronto
webcast
five
site
remot
record
later
view
remain
two
site
learn
seminar
deliv
local
faculti
site
knowledg
assess
use
valid
multipl
choic
question
exam
conduct
camp
attitud
impact
transfus
behaviour
collect
traine
survey
result
academ
year
postgradu
traine
attend
least
one
day
attend
least
day
attend
least
day
attend
least
day
attend
day
day
averag
traine
attend
rang
traine
differ
specialti
program
repres
top
specialti
anesthesia
hematolog
patholog
critic
care
medicin
obstetr
averag
score
exam
n
compar
averag
score
n
p
mean
differ
ci
traine
wrote
exam
improv
score
chang
wors
score
improv
score
also
seen
site
end
transfus
camp
rate
abil
obtain
consent
goodveri
good
excel
rate
overal
abil
manag
transfus
relat
patient
issu
goodveri
goodexcel
rate
tm
knowledg
extrem
import
provid
patient
care
final
evalu
survey
transfus
camp
n
respond
indic
transfus
camp
impact
clinic
practic
exampl
includ
minim
unnecessari
transfus
transfus
one
unit
time
consid
furosemid
prevent
taco
alway
give
vitamin
k
warfarin
revers
obtain
transfus
consent
manag
transfus
reaction
respond
indic
would
recommend
transfus
camp
colleagu
summari
conclus
transfus
camp
novel
approach
deliveri
high
qualiti
tm
educ
postgradu
traine
exampl
scalabl
intervent
expand
addit
univers
site
transfus
camp
demonstr
modest
increas
tm
knowledg
foster
posit
attitud
toward
tm
enabl
posit
impact
transfus
practic
c
b
j
b
polici
educ
australian
red
cross
blood
servic
west
melbourn
polici
educ
australian
red
cross
blood
servic
adelaid
polici
educ
australian
red
cross
blood
servic
sydney
polici
educ
australian
red
cross
blood
servic
brisban
australia
background
earli
postgradu
train
critic
period
influenc
junior
doctor
current
futur
clinic
transfus
practic
within
australian
blood
sector
multipl
provid
onlin
educ
support
best
transfus
practic
relev
use
resourc
junior
doctor
unknown
littl
understood
australian
junior
doctor
exist
transfus
knowledg
applic
patient
care
aim
understand
junior
doctor
transfus
practic
support
educ
prefer
determin
develop
practic
support
tool
implement
evalu
util
tool
method
studi
conduct
two
phase
april
march
particip
voluntari
phase
involv
focu
group
session
six
hospit
transcript
audio
record
analys
use
themat
analysi
find
consid
develop
suit
transfus
practic
support
tool
present
transfus
orient
pack
pack
address
prioriti
transfus
topic
identifi
junior
doctor
print
onlin
format
tool
includ
practic
advic
prescrib
transfus
lanyard
card
infograph
patient
blood
manag
pbm
transfus
checklist
transfus
practic
flow
chart
advers
event
recognit
manag
lanyard
card
poster
phase
survey
junior
doctor
respons
tool
provid
orient
five
hospit
result
junior
doctor
particip
focu
group
prioriti
abl
practis
safe
appropri
confid
prefer
format
transfus
learn
includ
educ
print
tool
eg
lanyard
card
one
app
cover
essenti
aspect
transfus
practic
advers
event
manag
practic
transfus
prescrib
topic
import
infograph
promot
understand
pbm
least
valu
item
survey
respond
found
transfus
practic
support
tool
use
assist
everyday
practic
particularli
transfus
overview
poster
three
lanyard
card
major
respond
would
recommend
use
tool
complement
clinic
practic
junior
doctor
report
support
tool
impact
practic
learn
someth
new
feel
reassur
transfus
knowledg
summari
conclus
need
improv
educ
ensur
best
transfus
practic
australian
junior
doctor
want
immedi
practic
reliabl
transfus
inform
credibl
sourc
support
practic
safe
confid
educ
need
driven
real
time
patient
manag
transfus
practic
support
tool
develop
user
input
assess
junior
doctor
high
accept
seen
valuabl
easi
use
met
expect
simpl
comprehens
authorit
practic
support
tool
predict
intern
intak
transfus
orient
pack
modifi
result
studi
provid
hospit
across
australia
promot
avail
resourc
tool
provid
blood
sector
import
may
translat
institut
intern
h
k
r
n
univers
vermont
health
network
univers
vermont
burlington
unit
state
montreal
montreal
laboratori
medicin
pathobiolog
st
michael
hospit
toronto
alberta
edmonton
canada
women
hospit
harvard
univers
boston
unit
state
innov
canadian
blood
servic
ottawa
medicin
laboratori
medicin
pathobiolog
institut
health
polici
manag
evalu
mount
sinai
hospit
canadian
blood
servic
toronto
canada
background
intern
collabor
transfus
medicin
guidelin
ictmg
establish
evid
base
transfus
medicin
guidelin
optim
transfus
care
intent
intern
group
increas
credibl
guidelin
develop
transfus
medicin
use
wide
collabor
effort
leverag
consist
methodolog
enabl
time
creation
transfus
medicin
guidelin
ictmg
consist
hematologist
hematopathologist
methodologist
countri
addit
publish
guidelin
facilit
guidelin
dissemin
ictmg
creat
websit
podcast
guidelin
aim
aim
assess
determin
impact
icmtg
guidelin
platelet
transfus
patient
hypoprolif
thrombocytopenia
well
impact
ictmg
websit
podcast
modal
dissemin
guidelin
recommend
method
ictmg
assembl
expert
panel
conduct
systemat
review
develop
recommend
platelet
transfus
patient
hypoprolif
thrombocytopenia
includ
recommend
prophylact
platelet
transfus
trigger
platelet
dose
use
apheresi
compar
whole
blood
deriv
platelet
use
abo
compat
platelet
need
rh
immun
globulin
patient
patient
rhd
neg
receiv
rhd
posit
platelet
manag
platelet
refractori
ictmg
partner
aabb
produc
podcast
platelet
transfus
platelet
unplug
sticki
truth
guidelin
develop
aabb
complement
guidelin
develop
ictmg
min
podcast
divid
three
segment
enhanc
use
guidelin
podcast
made
avail
ictmgorg
podcast
also
post
aabborg
ictmg
develop
powerpoint
present
method
guidelin
develop
summari
recommend
aid
implement
guidelin
user
podcast
download
websit
access
guidelin
citat
monitor
assess
guidelin
dissemin
result
platelet
guidelin
publish
guidelin
cite
articl
read
podcast
access
occas
octob
januari
ictmg
websit
aabb
websit
receiv
page
view
podcast
includ
podcast
platelet
transfus
ictmgorg
receiv
page
view
april
januari
visit
educ
resourc
page
contain
guidelin
present
page
view
predominantli
canadian
site
also
includ
unit
state
australia
unit
kingdom
india
netherland
brazil
itali
philippin
countri
summari
conclus
dissemin
guidelin
use
web
tool
podcast
appear
effect
circul
guidelin
inform
futur
studi
need
determin
whether
modal
improv
implement
guidelin
recommend
l
h
school
tropic
medicin
liverpool
unit
kingdom
clinic
immunolog
copenhagen
univers
hospit
copenhagen
denmark
ghana
shortag
blood
transfus
year
round
deficit
annual
nation
requir
unit
voluntari
nonremuner
blood
donor
vnrbd
uncommon
contribut
donat
blood
repeat
donat
constitut
donat
vnrbd
southern
area
blood
centr
nation
blood
servic
ghana
aim
identifi
percept
blood
blood
donat
motiv
deterr
blood
donat
intent
return
donat
blood
among
vnrbd
famili
replac
blood
donor
frd
recommend
intervent
increas
repeat
donat
among
first
time
donor
method
survey
first
time
vnrbd
select
sabc
conduct
questionnair
design
determinepercept
motiv
deterr
blood
donat
intent
return
donat
among
first
time
donor
use
data
collect
june
result
person
accept
respond
complet
survey
respond
age
year
median
year
interquartil
rang
year
respond
year
male
singl
christian
employ
least
basic
educ
live
parentsfamili
vnrbd
younger
median
year
interquartil
rang
year
frd
median
year
interquartil
rang
year
factor
posit
predict
intent
return
donat
conveni
access
donat
session
ci
p
ghana
need
blood
ci
p
make
one
feel
good
himselfherself
ci
p
smsemail
remind
ci
p
tv
radio
newspap
advertis
ci
p
n
van
dyke
c
gemelli
thijsen
n
van
dyke
davison
clinic
servic
research
australian
red
cross
blood
servic
melbourn
australia
background
temporari
deferr
neg
impact
donor
retent
research
found
type
deferr
donor
statu
durat
deferr
predictor
donor
return
post
deferr
howev
aspect
amen
intervent
area
requir
investig
donor
level
knowledg
regard
deferr
emot
respons
temporarili
defer
anecdot
evid
australian
red
cross
blood
servic
blood
servic
blood
collect
staff
involv
appli
deferr
suggest
donor
display
feel
anger
disappoint
reject
receiv
deferr
mani
unclear
reason
deferr
howev
lack
inform
donor
perspect
poor
knowledg
neg
reaction
receiv
deferr
present
associ
intent
may
possibl
develop
tailor
strategi
improv
donor
retent
aim
aim
studi
investig
donor
knowledg
deferr
emot
reaction
receiv
deferr
identifi
whether
aspect
impact
intent
method
survey
sent
donor
recent
receiv
temporari
deferr
telephon
call
within
donat
centr
attend
donat
survey
focus
inform
receiv
time
deferr
donor
understand
deferr
degre
donor
experienc
number
emot
intent
result
total
donor
complet
survey
respons
rate
donor
receiv
deferr
telephon
call
attend
donat
centr
donat
compar
defer
via
telephon
donor
defer
attend
donat
appoint
less
satisfi
quantiti
qualiti
inform
receiv
deferr
felt
less
knowledg
defer
donor
studi
could
correctli
identifi
current
inelig
donat
report
current
elig
report
unsur
emot
respons
impact
neg
intent
return
key
emot
includ
anger
sad
disappoint
neg
emot
report
strongli
donor
defer
centr
donor
defer
via
telephon
report
higher
level
calm
summari
conclus
studi
provid
insight
assist
blood
collect
agenc
develop
potenti
strategi
prevent
futur
laps
donor
temporarili
defer
donat
would
benefici
increas
number
donor
notifi
inelig
prior
attend
donat
centr
ensur
donor
understand
reason
defer
time
deferr
elig
return
also
appear
import
studi
find
demonstr
impact
emot
experienc
receiv
deferr
intent
develop
evalu
strategi
address
emot
time
deferr
worth
consider
en
l
j
develop
nation
blood
servic
ghana
accra
ghana
school
tropic
medicin
liverpool
unit
kingdom
blood
servic
ghana
accra
ghana
background
blood
donat
rate
african
countri
gener
low
ghana
abl
meet
blood
requir
leav
deficit
blood
collect
per
popul
nation
blood
servic
ghana
nbsg
appli
best
access
strategi
increas
blood
collect
voluntari
unpaid
blood
donor
vubd
nbsg
institut
strategi
within
catchment
area
southern
area
blood
centr
sabc
increas
blood
collect
vubd
analysi
donor
recruit
activ
inform
develop
strategi
aim
boost
perform
donor
servic
staff
key
compon
strategi
includ
format
perman
mobil
blood
collect
team
zone
catchment
area
set
target
team
aim
analyz
effect
strategi
increas
voluntari
unpaid
blood
donat
use
data
blood
collect
sabc
method
base
blood
need
four
blood
collect
team
form
team
compris
minimum
six
member
includ
blood
donor
recruit
offic
bdro
donor
care
nurs
assist
orderli
driver
catchment
area
divid
four
zone
base
popul
organ
donor
panel
educ
religi
institut
workplac
organ
group
distanc
blood
centr
team
assign
zone
given
blood
collect
target
meet
bdro
encourag
stop
concentr
activ
weekend
day
util
weekday
educ
talk
blood
donat
activ
zone
base
target
group
calendar
activ
school
holiday
exam
religi
activ
festiv
blood
collect
team
also
increas
number
blood
collect
session
educ
institut
analysi
trend
total
blood
collect
percentag
blood
collect
vubd
versu
famili
replac
donor
frd
pre
post
implement
conduct
result
prior
implement
mobil
session
conduct
implement
mobil
blood
donat
session
increas
blood
collect
increas
prior
implement
compar
increas
show
gradual
increas
compar
sharp
increas
right
implement
blood
collect
vubd
alway
lower
collect
frd
implement
two
year
implement
collect
vubd
higher
collect
frd
respect
summari
conclus
find
show
blood
collect
sabc
percentag
blood
collect
vubd
implement
strategi
significantli
higher
compar
implement
em
hui
g
e
studi
sanquin
blood
suppli
amsterdam
netherland
medic
scienc
anton
de
kom
univers
blo
bank
rode
krui
paramaribo
surinam
consult
servic
sanquin
blood
suppli
amsterdam
netherland
background
choic
becom
donor
person
influenc
extern
factor
eg
open
time
person
factor
eg
attitud
toward
donat
procedur
surinam
need
recruit
new
donor
high
part
collabor
twin
project
capac
build
surinam
red
cross
blood
bank
sanquin
netherland
main
author
visit
blood
bank
paramaribo
train
staff
improv
donor
recruit
perform
retent
research
aim
assess
willing
donat
blood
key
barrier
motiv
gener
popul
surinam
furthermor
compar
aspect
attitud
exist
blood
donor
method
two
studi
develop
donor
satisfact
survey
n
blood
donor
donor
motiv
survey
n
gener
popul
donor
sampl
recruit
among
donor
attempt
donat
paramaribo
nickeri
two
week
window
fill
questionnair
locat
sampl
recruit
onlin
use
snowbal
sampl
among
exist
donor
particip
ask
rate
extent
agre
motiv
reason
becom
donor
likert
scale
attitud
toward
blood
donat
rate
bipolar
scale
well
intent
donat
come
year
likert
scale
sampl
ask
rate
much
donat
barrier
stop
becom
donor
prefer
method
commun
would
result
donat
attitud
significantli
neg
among
especi
thought
donat
repuls
unpleas
annoy
scari
indic
inform
procedur
better
use
social
media
abil
donat
togeth
famili
friend
might
motiv
donat
furthermor
ask
religi
leader
relat
higher
donat
willing
donor
like
believ
donat
good
health
right
thing
wherea
like
say
would
donat
show
other
good
person
howev
indic
thought
donat
might
good
health
show
higher
donat
intent
donat
barrier
among
could
cluster
three
main
type
barrier
relat
fear
lack
knowledg
health
concern
knowledg
eg
procedur
posit
wherea
fear
eg
needl
neg
impact
donat
intent
would
prefer
recruit
via
whatsapp
social
media
summari
conclus
futur
recruit
campaign
surinam
could
benefit
involv
religi
leader
better
use
social
media
whatsapp
email
also
focu
educ
aspect
regard
whole
procedur
consequ
addit
appeal
help
peopl
furthermor
intervent
aim
help
peopl
cope
certain
fear
needl
advers
reaction
pain
could
benefit
donor
recruit
retent
e
p
studi
sanquin
blood
suppli
scienc
vrije
universiteit
amsterdam
netherland
background
variou
studi
examin
stop
reason
blood
donor
mostli
use
survey
design
studi
provid
import
input
develop
effect
retent
strategi
best
knowledg
social
media
data
use
data
sourc
research
retent
analysi
social
media
data
supplement
current
knowledg
stop
motiv
add
exist
databas
donor
data
base
cohort
studi
eg
donor
insight
danish
blood
donor
studi
benefit
social
media
provid
inform
donor
think
present
blood
bank
particip
research
social
media
commun
goe
beyond
factual
campaign
inform
often
entail
posit
neg
opinion
experi
larg
scale
use
social
media
million
activ
facebook
user
netherland
alon
make
social
media
import
context
tool
blood
bank
learn
influenc
donor
gener
public
think
feel
behav
regard
blood
donat
hundr
thousand
social
media
messag
provid
blood
bank
big
data
sourc
rich
inform
donor
motiv
behavior
aim
studi
explor
actor
commun
blood
donat
social
media
platform
focus
motiv
relat
stop
blood
donat
appear
onlin
messag
facebook
twitter
besid
also
focus
dissatisfact
anger
disappoint
around
blood
bank
blood
donat
unfavor
experi
method
onlin
messag
januari
decemb
collect
social
media
monitor
tool
coosto
appli
search
string
relat
blood
donat
blood
bank
content
analysi
dutch
post
relat
blood
donat
facebook
twitter
perform
find
relev
messag
dataset
messag
cluster
categori
includ
actor
topic
associ
keyword
measur
visual
result
final
dataset
contain
messag
blood
donat
blood
bank
contain
word
relat
stop
either
voluntarili
involuntarili
dissatisfact
ie
anger
disappoint
stop
reason
categor
physic
reaction
medic
reason
pregnanc
travel
lifestyl
eg
lack
time
open
wait
time
sexual
risk
behavior
blood
bank
polici
stop
involuntarili
associ
strongli
medic
reason
sexual
risk
behavior
stop
voluntarili
associ
strongli
top
manag
salari
medic
reason
post
includ
anger
associ
strongli
sexual
risk
behavior
post
includ
disappoint
strongli
medic
reason
summari
conclus
studi
give
insight
promin
stop
motiv
dissatisfact
regard
blood
donat
blood
bank
social
media
messag
often
discuss
stop
motiv
social
media
differ
obtain
survey
research
result
may
indic
social
desir
select
bia
play
role
survey
research
combin
data
sourc
includ
social
media
data
observ
survey
studi
may
paint
fuller
pictur
stop
motiv
blood
donor
futur
g
vidarsson
experiment
immunohematolog
sanquin
research
amsterdam
netherland
alloimmun
diseas
blood
cell
occur
pregnanc
blood
transfus
antibodi
form
target
foreign
cell
tissu
destruct
myeloid
cell
igg
particular
pregnanc
antibodi
human
platelet
red
cell
antigen
rbc
caus
anaemia
thrombocytopenia
develop
foetu
peculiar
featur
mani
antibodi
especi
clinic
import
antigen
antibodi
titer
correl
well
diseas
sever
true
antibodi
induc
pregnanc
transfus
work
laboratori
other
shown
antigen
cell
type
mani
case
induc
immun
respons
character
alter
glycosyl
stabl
time
also
found
year
induct
irrespect
intermitt
boost
event
chang
particular
low
level
also
increas
galactosyl
seri
biochem
analysi
other
found
featur
affect
bind
low
level
boost
addit
high
galactos
elev
galactos
increas
bind
well
result
increas
downstream
complement
activ
degre
chang
also
agreement
level
anemia
seen
exampl
pregnanc
affect
thrombocytopenia
pregnanc
affect
agreement
clinic
import
rbc
antigen
newer
show
alter
glycosyl
work
collect
show
transfus
medicin
featur
extrem
import
culmin
elev
diseas
patholog
provid
evid
base
platform
screen
antibodi
patient
risk
r
kapur
lund
univers
lund
sweden
circulatori
overload
taco
frequent
pulmonari
complic
transfus
second
lead
caus
fatal
report
food
drug
administr
taco
character
new
worsen
hydrostat
pulmonari
edema
occur
within
h
blood
transfus
result
respiratori
distress
taco
underdiagnos
underreport
increas
incid
mix
intens
care
unit
popul
make
taco
independ
risk
factor
morbid
mortal
retrospect
cohort
studi
patient
diagnos
taco
identifi
cardiac
failur
renal
failur
degre
posit
fluid
balanc
risk
factor
taco
bosboom
et
al
transfus
anoth
studi
prospect
enrol
patient
taco
found
congest
heart
failur
cardiomegali
chest
diuret
use
elev
blood
pressur
chronic
kidney
diseas
acut
kidney
injuri
plasma
transfus
emerg
surgeri
risk
factor
associ
taco
roubinian
et
al
crit
care
med
retrospect
review
taco
case
also
identifi
congest
heart
failur
renal
dysfunct
common
featur
taco
addit
age
year
lieberman
et
al
transfu
med
rev
studi
also
describ
frequent
suboptim
fluid
manag
inappropri
infus
practic
rapid
infus
rate
unfortun
pathophysiolog
taco
poorli
understood
hypothes
pathophysiolog
taco
may
gener
reflect
model
first
hit
taco
may
repres
poor
adapt
volum
overload
transfus
recipi
support
identif
cardiovascular
renal
risk
factor
onset
taco
second
hit
may
subsequ
convey
transfus
blood
product
interestingli
recent
found
degre
posit
fluid
balanc
associ
less
develop
taco
develop
circulatori
overload
absenc
transfus
bosboom
et
al
transfus
may
due
increas
pressur
blood
product
stimul
fluid
extravascular
space
intravascular
space
contribut
effect
circul
volum
altern
may
indic
factor
transfus
blood
product
besid
transfus
volum
could
perhap
play
role
develop
taco
factor
may
possibl
contribut
inflamm
capillari
leakag
interest
interleukin
il
level
describ
increas
taco
patient
roubinian
et
al
transfus
secret
known
requir
specif
stimul
microbi
product
specif
antibodi
could
therefor
hypothes
factor
transfus
blood
product
may
perhap
respons
effect
obtain
insight
taco
pathophysiolog
howev
import
assess
valid
potenti
biomark
taco
addit
develop
current
unavail
model
provid
use
tool
dissect
pathophysiolog
mechan
collect
aid
improv
diagnost
approach
shed
light
possibl
therapeut
intervent
c
f
j
l
h
j
transfus
laboratori
divis
hematolog
univers
health
networkunivers
toronto
transfus
laboratori
univers
health
network
transfus
laboratori
univers
health
networkunivers
toronto
transfus
laboratori
divis
hematolog
sunnybrook
health
scienc
centreunivers
toronto
munk
cardiac
centr
univers
health
networkunivers
toronto
toronto
canada
background
transfus
associ
circulatori
overload
taco
common
assum
revers
diuret
howev
often
sever
nevertheless
rise
rank
commonest
caus
death
extent
taco
mortal
reflect
direct
effect
injuri
driver
select
sick
passeng
known
fundament
whether
associ
mortal
rate
differ
taco
compar
reaction
unknown
aim
consecut
report
transfus
reaction
tr
sought
determin
whether
taco
vs
reaction
ntr
exhibit
higher
proport
death
discharg
whether
time
death
occur
sooner
method
hemovigil
databas
adult
healthcar
institut
compris
site
transfus
total
componentsyear
consecut
tr
outpati
inpati
retrospect
analyz
final
diagnosi
taco
possibl
definit
disturb
vs
ntr
tr
includ
one
follow
unrel
allerg
febril
serolog
hemolyt
dyspnea
acut
lung
injuri
bacteri
contamin
citrat
toxic
cold
product
otherwis
specifi
vital
statu
discharg
dead
aliv
compar
taco
vs
ntr
among
deced
interv
character
result
use
applic
summari
statist
proport
fisher
exact
test
comparison
median
interquartil
rang
iqr
distribut
ns
defin
p
review
earli
death
defin
death
within
day
tr
also
undertaken
result
year
tr
assess
median
patient
age
year
male
femal
vital
statu
discharg
record
tr
case
taco
tr
leav
ntr
higher
proport
taco
case
die
versu
ntr
p
among
tr
death
discharg
time
tr
death
similar
day
taco
day
ntr
p
ns
furthermor
similar
proport
die
within
day
taco
ntr
p
ns
taco
case
death
within
day
taco
deem
singularli
attribut
case
thought
contribut
part
andor
acceler
demis
four
versu
inevit
death
two
intracrani
hemorrhag
metastat
termin
cancer
none
death
occur
within
h
rather
day
amid
intervent
locat
death
medic
surgic
summari
conclus
patient
taco
exhibit
higher
mortal
rate
ntr
although
time
demis
proport
die
within
three
day
similar
taco
contribut
part
exclus
death
earli
deced
untransfus
cohort
match
casemix
morbid
would
serv
valuabl
compar
better
distinguish
caus
effect
although
neither
typic
immedi
fatal
taco
persist
import
form
harm
may
prognost
transfus
recipi
r
j
l
k
blood
center
shanghai
first
affili
hospit
anhui
medic
univers
fei
china
background
research
indic
system
pulmonari
inflamm
coagulopathi
import
charact
transfus
rel
lung
injuri
trali
red
blood
cell
microparticl
rmp
accumul
store
red
blood
cell
concentr
rbc
inflammatori
coagul
potenti
littl
known
rmp
play
role
develop
trali
hypothes
rmp
improv
intrins
pathway
blood
coagul
induc
human
pulmonari
microvascular
endotheli
cell
hmvec
activ
damag
may
contribut
trali
aim
investig
effect
red
cell
microparticl
thrombin
gener
hmvec
activ
damag
method
rmp
obtain
day
store
rbc
amount
mp
count
use
flow
cytometr
nanoparticl
track
analysi
rmp
promot
thrombin
gener
intrins
pathway
blood
coagul
assay
calibr
autom
thrombogram
assay
cat
activ
partial
thromboplastin
time
aptt
respect
express
releas
cytokin
endotheli
cell
determin
flow
cytometr
analysi
hmvec
damag
determin
incub
lipopolysaccharid
lp
treat
endotheli
cell
rmp
activ
nadph
oxidas
neutrophil
inhibit
apocynin
treatment
result
microparticl
store
rbc
heterogen
vesicl
popul
diamet
nm
rmp
major
remaind
platelet
leukocyt
microparticl
rmp
improv
thrombin
gener
dose
depend
manner
aptt
shorten
ad
rmp
mp
deplet
plasma
deplet
microparticl
day
store
rbc
supernat
either
filtrat
g
centrifug
reduc
amount
rmp
meanwhil
decreas
promot
thrombin
gener
abil
rbc
supernat
significantli
express
adhes
molecul
hmvec
increas
significantli
incub
endotheli
cell
rmp
h
continu
increas
h
incub
meanwhil
rmp
induc
endotheli
cell
releas
inflammatori
cytokin
h
incub
rmp
abl
induc
lp
activ
hmvec
damag
prevent
inhibit
pmn
respiratori
burst
apocynin
summari
conclus
rmp
store
rbc
may
improv
system
coagulopathi
induc
pulmonari
endotheli
cell
activ
prime
lp
treat
hmvec
damag
rel
onset
trali
role
rmp
implic
onset
trali
need
explor
c
h
clinic
immunolog
aarhu
univers
hospit
aarhu
clinic
immunolog
copenhagen
univers
hospit
copenhagen
denmark
emerg
infecti
diseas
eid
special
group
infect
defin
increas
incid
human
last
two
decad
either
new
infect
known
infect
introduc
new
popul
eid
pose
threat
blood
safeti
pathogen
asymptomat
phase
present
blood
surviv
blood
process
storag
establish
clinic
relev
infect
recipi
threat
patient
may
exagger
fact
mani
transfus
patient
immunocompromis
sinc
hiv
epidem
world
experienc
mani
emerg
infect
eg
variabl
diseas
sever
acut
respiratori
syndrom
sar
west
nile
viru
infect
chikungunya
viru
infect
dengu
viru
infect
zika
viru
infect
ebola
viru
infect
babesiosi
infect
staphylococcu
aureu
mrsa
number
new
threat
increas
due
popul
growth
global
extens
exchang
peopl
good
within
countri
lead
effect
spread
transmit
infect
spread
diseas
facilit
climat
chang
subsequ
introduct
vector
new
area
fortun
tool
recogn
handl
eid
improv
newli
develop
screen
test
eg
zika
viru
babesia
microti
better
surveil
recognit
eid
pose
threat
blood
suppli
face
challeng
choos
correct
intervent
may
includ
spectrum
intervent
screen
eg
travel
deferr
test
pathogen
pathogen
inactiv
paramount
import
decis
base
risk
assess
use
avail
knowledg
diseas
eg
travel
pattern
appropri
tool
european
risk
assess
tool
eufrat
must
mitig
risk
recipi
time
avoid
take
unnecessari
often
costli
measur
howev
sever
featur
newli
discov
pathogen
epidem
often
known
moreov
also
inher
challeng
intervent
deferr
risk
donor
may
thought
cheap
intervent
temporarili
defer
donor
decreas
donor
return
rate
littl
focu
accumul
cost
associ
deferr
base
evid
screen
donat
pathogen
costli
take
time
implement
may
avail
pathogen
inactiv
pi
may
soon
avail
treatment
plasma
platelet
compon
also
red
blood
cell
compon
howev
pi
costli
still
need
larger
studi
assess
qualiti
pi
treat
compon
especi
use
area
low
infecti
pressur
present
includ
review
new
threat
blood
suppli
dilemma
pose
requir
reduc
residu
risk
neglig
level
context
ever
grow
demand
effici
howev
blood
bank
potenti
provid
new
knowledg
eid
use
access
larg
percentag
popul
w
b
scienc
engin
stanford
univers
palo
alto
support
offic
american
red
cross
gaithersburg
polici
scienc
blood
system
research
institut
laboratori
medicin
univers
california
san
francisco
san
francisco
unit
state
background
spread
zika
viru
zikv
throughout
america
prompt
unit
state
fda
requir
individu
donat
nucleic
acid
test
unit
donat
blood
us
state
territori
econom
consequ
screen
blood
suppli
zikv
systemat
evalu
aim
assess
effect
univers
us
state
separ
puerto
rico
pr
first
year
implement
compar
altern
screen
option
method
polici
evalu
microsimul
model
captur
expect
lifetim
health
consequ
cost
accru
period
advers
health
event
experienc
transfus
recipi
sexual
partner
infant
born
recipi
sexual
partner
captur
us
pr
compar
univers
univers
mp
nat
unit
transfus
women
age
pr
also
consid
strategi
state
consid
strategi
target
donor
base
resid
travel
area
known
local
transmiss
result
preliminarili
zikv
screen
estim
number
pr
year
symptomat
case
case
syndrom
case
congenit
zika
syndrom
screen
us
state
estim
number
symptomat
case
case
syndrom
case
congenit
zika
syndrom
estim
annual
cost
screen
puerto
rico
million
state
compar
screen
ratio
per
qali
pr
million
per
qali
state
district
columbia
compar
potenti
intervent
exclus
use
increment
ratio
million
per
addit
qali
gain
pr
billion
per
addit
qali
gain
state
district
columbia
million
per
qualiti
adjust
life
year
qali
use
high
mosquito
season
pr
per
addit
qali
gain
intervent
state
howev
use
exclus
area
experienc
known
local
transmiss
lowest
ratio
state
million
per
qali
summari
conclus
first
year
screen
us
state
district
columbia
compar
screen
pr
million
per
qali
compar
intervent
includ
season
test
use
moreov
period
lower
zikv
preval
intervent
less
report
p
g
b
v
g
j
l
test
solut
temp
system
research
institut
san
francisco
state
center
diseas
control
fort
collin
unit
state
de
sangr
servicio
mutuo
san
juan
puerto
rico
molecular
system
inc
pleasanton
unit
state
background
us
territori
puerto
rico
pr
began
screen
blood
donat
zika
viru
zikv
rna
use
nucleic
acid
amplif
technolog
nat
april
result
fda
guidanc
analys
index
donat
posit
donor
use
assess
viral
serolog
dynam
earli
stage
zikv
infect
estim
incid
infect
pr
popul
aim
analyz
blood
donat
puerto
rico
zikv
epidem
order
assess
viral
serolog
dynam
earli
infect
estim
incid
puerto
rican
popul
method
individu
donat
id
aliquot
plasma
volunt
blood
donor
screen
presenc
zikv
use
nat
roch
zika
reactiv
sampl
test
confirm
infect
estim
viral
load
vl
identifi
antibodi
monoclon
antibodi
captur
mac
zikv
igm
igg
elisa
simul
minipool
mp
test
zika
discrimin
detect
vs
donat
stage
accord
vl
zikv
igm
reactiv
cours
puerto
rico
epidem
novel
analyt
process
use
estim
nat
detect
period
time
igm
seroconvers
acut
infect
donor
first
viral
load
index
donat
rna
doubl
time
acut
infect
macaqu
h
standard
error
h
use
first
date
infect
donor
date
use
evalu
durat
nat
detect
time
igm
seroconvers
base
result
sampl
collect
day
donat
nat
detect
period
yield
donor
use
project
number
infect
incid
zikv
pr
result
april
decemb
donat
pr
screen
ct
presenc
zikv
confirm
infect
nat
donat
detect
decemb
index
donat
test
significantli
higher
vl
mean
x
vs
x
intern
unitsml
higher
proport
simul
result
vs
respect
donat
distribut
stage
infect
proport
nat
reactiv
donat
detect
donat
increas
significantli
epidem
season
evolv
mean
durat
estim
ci
day
time
initi
estim
ci
day
appli
nat
detect
period
nat
yield
data
result
estim
ci
zikv
infect
season
incid
ci
pr
summari
conclus
character
earli
zikv
infect
dynam
import
blood
safeti
consider
sinc
infect
util
mp
vs
id
nat
screen
like
correl
vl
serolog
stage
infect
find
also
import
implic
diagnost
test
public
health
surveil
epidemiolog
includ
estim
pr
popul
infect
outbreak
g
p
j
orlando
r
j
system
research
institut
san
francisco
intern
rockvil
test
solut
temp
de
sangr
de
servicio
mutuo
puerto
rico
ft
lauderdal
molecular
system
pleasanton
inc
jefflinnen
hologiccom
san
diego
unit
state
patholog
univers
british
columbia
univers
british
columbia
victoria
canada
background
zika
viru
zikv
associ
sever
neurolog
consequ
fetus
adult
potenti
transfus
transmiss
tt
prompt
amplif
test
nat
screen
plasma
us
blood
donor
rna
persist
report
whole
blood
wb
long
clearanc
viremia
plasma
character
dynam
zikv
persist
follow
acut
infect
need
inform
donor
nat
diagnost
test
polici
understand
natur
histori
zikv
infect
aim
sought
character
dynam
infect
estim
durat
rna
serolog
persist
prospect
studi
zikv
rna
blood
donor
method
donor
identifi
investig
zikv
nat
screen
confirm
zika
quantit
serolog
enrol
longitudin
assess
viral
serolog
persist
clinic
outcom
plasma
rbc
obtain
index
donat
blood
urin
saliva
semen
collect
prospect
week
year
follow
index
donat
detail
symptom
questionnair
administ
visit
blood
compart
bodi
fluid
sampl
test
zikv
rna
calibr
intern
standard
plasma
urin
wb
also
test
donor
natdiagnost
assay
grifol
zika
procleixholog
aptima
replic
plasma
urin
wb
plasma
sampl
test
igm
igg
dengu
viru
denv
igg
antibodi
result
durat
detect
zikv
rna
assaysampl
type
rel
estim
date
infect
deriv
viral
load
index
donat
rna
doubl
time
viremia
macaqu
infect
studi
calcul
test
enrol
donor
plasma
viremia
detect
day
ci
wherea
viral
rna
persist
day
ci
day
ci
respect
test
grifol
nat
assay
replic
plasma
detect
posit
result
extend
day
ci
wb
posit
result
day
ci
urin
saliva
reactiv
ci
day
ci
respect
zikv
igm
persist
day
ci
follow
index
donat
reduct
zikv
rna
igm
persist
observ
dengu
igg
seroposit
donor
donor
identifi
acut
stage
infect
develop
multipl
symptom
week
index
donat
compar
donor
detect
summari
conclus
zikv
rna
persist
sever
month
follow
clearanc
plasma
bodi
fluid
highli
sensit
nat
test
extend
period
detect
compart
perform
replic
test
higher
rate
incid
zikv
symptom
observ
previous
report
persist
zikv
rna
rbc
unknown
implic
blood
screen
current
reli
plasma
test
infect
studi
progress
wb
test
may
valu
extend
detect
acut
infect
diagnost
monitor
pregnant
women
sexual
partner
g
k
van
l
k
j
p
system
research
institut
san
francisco
nation
primat
research
center
patholog
microbiolog
immunolog
univers
california
davi
test
solut
temp
unit
state
background
demonstr
zika
viru
zikv
tt
led
rapid
introduct
sensit
individu
donat
id
nucleic
acid
amplif
test
nat
us
howev
follow
resolut
recent
epidem
america
import
question
remain
concern
effici
nat
zikv
infect
particular
whether
donor
screen
safe
switch
routin
minipool
mp
trigger
autochthon
outbreak
identifi
similar
well
establish
nat
screen
algorithm
west
nile
viru
aim
defin
minim
infecti
dose
zikv
tt
use
murin
macaqu
model
method
use
suscept
cell
line
immunodefici
mice
immunocompet
rhesu
macaqu
transfus
model
calcul
infect
zikv
use
acut
infect
human
macaqu
plasma
sampl
perform
titrat
studi
produc
dilut
panel
use
uninfect
macaqu
plasma
diluent
zikv
rna
reactiveseroneg
plasma
sampl
two
deriv
nat
human
one
acut
infect
macaqu
intraven
inocula
serostatu
input
plasma
character
elisa
assay
igm
igg
zikv
dengu
viru
well
neutral
assay
infect
monitor
zikv
specif
result
use
zikv
amplifi
tissu
cultur
titrat
cell
line
mice
one
infecti
unit
correspond
viral
rna
copi
comparison
use
rna
reactiveseroneg
plasma
one
infecti
unit
correspond
viral
rna
copi
mice
significantli
sensit
infect
vitro
cultur
macaqu
observ
variabl
infect
zikv
seroneg
plasma
plasma
zikv
rna
reactiv
brazilian
blood
donor
infect
macaqu
dose
rang
rna
copi
perform
back
titrat
equat
dose
unit
pfu
infect
tissu
cultur
second
plasma
zikv
rna
reactiv
puerto
rican
blood
donor
infect
macaqu
dose
rna
copi
approxim
pfu
final
macaqu
plasma
collect
day
one
macaqu
infect
brazilian
plasma
infecti
dose
rna
copi
copi
pfu
interestingli
kinet
viral
load
develop
anim
low
dose
infect
consider
retard
compar
macaqu
infect
high
pfu
zikv
dose
summari
conclus
use
tissu
cultur
amplifi
zikv
found
similar
ratio
infect
rna
report
virus
also
line
viral
system
found
uncultur
viru
donor
experiment
infect
anim
significantli
infecti
low
immunodefici
mice
prove
sensit
model
detect
infecti
zikv
found
relev
macaqu
model
plasma
transfus
rna
copi
requir
infect
current
test
seroposit
plasma
macaqu
demonstr
effect
specif
antibodi
tt
h
medicin
pathobiolog
univers
toronto
innov
canadian
blood
servic
medicin
st
michael
hospit
univers
toronto
toronto
canada
thrombocytopenia
includ
alloimmun
thrombocytopenia
platelet
destruct
mediat
antibodi
opson
although
platelet
clearanc
may
also
involv
pathogenesi
major
target
antigen
platelet
surfac
glycoprotein
gp
iibiiia
integrin
gpib
complex
earlier
studi
dr
nieswandt
group
demonstr
thrombocytopenia
occur
manner
wherea
antibodi
need
antibodi
fc
portion
induc
platelet
clearanc
subsequ
found
thrombocytopenia
resist
intraven
igg
ivig
treatment
consist
sever
clinic
studi
also
found
itp
patient
antibodi
irrespect
presenc
antibodi
time
resist
steroid
therapi
recent
found
antibodi
induc
platelet
activ
sialidas
transloc
platelet
desialyl
mice
lead
platelet
clearanc
liver
significantli
differ
classic
macrophag
phagocytosi
mechan
importantli
sialidas
inhibitor
amelior
thrombocytopenia
mice
anim
data
partial
confirm
human
itp
patient
interestingli
matern
platelet
activ
lead
thrombosi
placenta
murin
model
fetal
neonat
alloimmun
thrombocytopenia
fnait
integrin
antibodi
may
integrin
angiogen
vessel
trophoblast
lead
intracrani
hemorrhag
placent
patholog
intrauterin
growth
restrict
miscarriag
present
discuss
signific
studi
implic
diagnosi
therapi
itp
fnait
uj
sach
institut
clinic
immunolog
transfus
medicin
justu
liebig
univers
giessen
germani
background
identif
platelet
antibodi
gener
consid
pivot
diagnosi
fetalmatern
alloimmun
thrombocytopenia
fnait
thrombocytopenia
ditp
platelet
transfus
refractori
ptr
relev
platelet
serolog
diagnos
immun
thrombocytopenia
itp
contrast
often
question
isbt
issu
guidanc
far
aim
review
aim
analyz
relev
platelet
serolog
establish
diagnosi
thrombocytopenia
guid
therapeut
andor
prophylact
strategi
thrombocytopen
patient
method
current
literatur
avail
guidelin
review
platelet
serolog
test
method
characterist
clinic
util
fnait
ditp
itp
result
fnait
identif
antibodi
specif
gener
consid
relev
respect
current
subsequ
pregnanc
also
consid
partial
relev
treatment
affect
newborn
sensit
specif
method
avail
rigor
control
extern
qualiti
assess
eqa
scheme
genotyp
famili
member
insuffici
establish
diagnosi
andor
guid
clinic
decis
whether
antibodi
antibodi
titrat
use
diagnost
current
discuss
ditp
relev
serolog
test
less
clear
avail
test
lack
standard
sensit
specif
well
defin
establish
eqa
scheme
could
identifi
posit
test
result
specif
drug
may
clinic
relev
especi
patient
multipl
drug
therapi
clinic
relev
neg
test
result
well
establish
itp
clear
evid
clinic
util
antibodi
test
avail
assay
highli
specif
lack
sensit
surprisingli
specif
eqa
scheme
identifi
posit
test
result
use
sinc
addit
extens
test
exclud
disord
may
becom
unnecessari
may
also
shorten
time
treatment
patient
neg
test
result
clinic
valu
preliminari
evid
indic
autoantibodi
may
relev
predict
diseas
sever
andor
select
appropri
treatment
option
conclus
fnait
itp
robust
specif
test
method
avail
test
result
contribut
substanti
initi
diagnosi
facilit
clinic
guidanc
fnait
famili
itp
patient
substanti
evid
identifi
platelet
serolog
disregard
itp
guidelin
ditp
test
evid
clinic
util
robust
specif
test
method
overal
profession
accept
may
benefit
better
standard
exchang
l
l
l
al
g
cell
refer
laboratori
servic
canadian
blood
servic
winnipeg
canada
blood
bank
muscat
oman
servic
canadian
blood
servic
alberta
edmonton
affair
innov
sherbrook
sherbrook
affair
innov
quebec
citi
canada
background
intern
societi
blood
transfus
platelet
immunolog
workshop
interest
exercis
organ
perform
refer
laboratori
world
promot
share
expertis
knowledg
particular
concern
platelet
immunolog
aim
aim
intern
societi
blood
transfus
platelet
immunolog
workshop
compar
sensit
specif
commerci
avail
method
detect
human
platelet
antigen
hpa
antibodi
current
use
particip
laboratori
particular
emphasi
prepar
platelet
monoclon
antibodi
immobil
platelet
antigen
maipa
monoclon
antibodi
moab
antibodi
detect
role
antibodi
fnait
survey
also
perform
identifi
common
practic
subject
discuss
role
platelet
refer
laboratori
fetal
neonat
alloimmun
thrombocytopenia
fnait
manag
method
laboratori
countri
particip
set
seven
serumplasma
sampl
antibodi
identif
eight
dna
sampl
genotyp
sent
case
studi
section
addit
three
exercis
one
use
commerci
kit
one
platelet
prepar
detect
antibodi
one
test
four
moab
antibodi
detect
provid
particip
critic
reagent
materi
three
exercis
provid
includ
paklx
kit
four
moab
final
survey
fnait
case
analysi
report
laboratori
answer
survey
result
particip
great
success
categori
among
particip
laboratori
submit
data
particip
case
resolut
exercis
serolog
genotyp
genotyp
hpa
system
propos
genotyp
exercis
complet
particip
sixteen
laboratori
genotyp
propos
hpa
system
laboratori
particip
exercis
platelet
prepar
protocol
antibodi
detect
particip
exercis
detect
use
differ
monoclon
antibodi
wide
variat
reactiv
observ
among
laboratori
use
maipa
techniqu
twenti
twenti
eight
laboratori
particip
antibodi
detect
commerci
kit
exercis
less
variat
observ
lab
use
commerci
reagent
particip
survey
also
good
particip
answer
survey
laboratori
manag
fnait
case
detail
exercis
depict
discuss
summaryconclus
detect
hpa
antibodi
hpa
genotyp
well
perform
particip
laboratori
workshop
identifi
two
specif
area
room
need
improv
prepar
platelet
detect
alloantibodi
identif
antibodi
survey
find
suggest
wide
variat
laboratori
practic
respect
antibodi
monitor
fnait
affect
pregnanc
practic
relat
antibodi
quantif
recommend
work
parti
technic
aspect
overcom
problem
fnait
laboratori
manag
help
p
j
newman
blood
research
institut
bloodcent
wisconsin
milwauke
unit
state
human
platelet
alloantigen
hpa
resid
function
import
platelet
membran
glycoprotein
caus
singl
nucleotid
polymorph
gene
encod
antibodi
form
hpa
respons
sever
clinic
import
alloimmun
bleed
disord
includ
fetal
neonat
alloimmun
thrombocytopenia
posttransfus
purpura
alloantigen
system
also
known
polymorph
frequent
implic
hpa
among
white
singl
amino
acid
polymorph
within
integrin
subunit
respons
gener
alloantigen
epitop
platelet
like
bear
alloantigen
rel
rare
popul
difficult
obtain
purpos
transfus
therapi
diagnost
test
use
cluster
regularli
interspac
short
palindrom
repeatscrispr
associ
protein
technolog
transform
induc
pluripot
stem
cell
ipsc
allotyp
megakaryocyt
progenitor
deriv
cell
express
alloantigen
epitop
report
diagnost
ncii
restrict
enzym
digest
dna
sequenc
western
blot
analysi
use
human
matern
alloantisera
ip
cell
line
express
hpa
similarli
gener
applic
technolog
genet
edit
hpa
hold
great
potenti
product
design
platelet
diagnost
investig
ultim
therapeut
use
starr
program
scienc
journal
boston
univers
colleg
commun
boston
unit
state
histori
blood
histori
resourc
one
origin
human
bodi
sure
govern
suppli
demand
well
technolog
stori
blood
one
great
saga
histori
medicin
centuri
peopl
work
understand
heal
power
blood
marshal
resourc
divid
use
compon
maintain
safe
reliabl
suppli
way
blood
bear
strang
strike
analog
oil
although
oil
sure
transmit
infect
talk
trace
epic
histori
blood
first
experi
transfus
creation
blood
bank
manag
blood
suppli
great
war
also
discuss
tragedi
hepat
aid
relat
blood
plasma
suppli
public
health
offici
learn
address
talk
lead
subsequ
discuss
current
effort
ensur
safeti
blood
conserv
preciou
resourc
w
dzik
blood
transfus
servic
massachusett
gener
hospit
boston
unit
state
year
follow
pioneer
work
jame
blundel
scientif
technic
advanc
enrich
field
transfus
medicin
made
essenti
part
healthcar
worldwid
abil
blood
transfus
sustain
life
oxygen
deliveri
common
foundat
profess
lectur
examin
respons
insuffici
tissu
oxygen
highlight
role
factor
iron
model
tumor
hypoxia
use
analog
current
global
threat
human
threat
summar
germ
gun
steal
singl
common
upstream
caus
behind
three
great
challeng
repres
today
press
healthcar
issu
solut
complet
within
human
control
clear
understand
import
hold
key
global
well
centuri
c
smit
f
consult
zuidhorn
netherland
communic
diseas
control
health
laboratori
offic
eastern
mediterranean
region
cairo
egypt
background
essenti
medicin
em
defin
medicin
product
satisfi
need
major
popul
therefor
avail
time
adequ
amount
appropri
dosag
form
assur
qualiti
afford
blood
transfus
essenti
compon
system
contribut
save
million
live
everi
year
improv
life
expect
qualiti
life
patient
support
complex
medic
surgic
procedur
recognit
blood
blood
product
whole
blood
red
blood
cell
platelet
fresh
plasma
medicin
product
ad
model
list
essenti
medicin
effect
blood
regul
crucial
manag
product
em
aim
requir
countri
put
place
appropri
regulatori
framework
legisl
regul
etc
function
regulatori
author
howev
numer
situat
particularli
less
develop
world
prerequisit
bare
implement
method
exist
legisl
member
state
eastern
mediterranean
region
collect
analys
relev
appropri
prepar
use
blood
blood
product
well
use
associ
substanc
relev
medic
devic
literatur
search
done
match
combin
regulatori
system
regulatori
framework
legisl
regul
product
use
blood
blood
product
result
almost
exclus
refer
respect
nation
intern
legisl
recommend
aid
eu
direct
use
refer
result
varieti
formal
legisl
regulatori
document
issu
put
forc
govern
countri
egypt
till
pakistan
sindh
less
detail
descript
regulatori
author
oper
establish
specif
requir
howev
none
legisl
compli
eu
recommend
format
content
support
effect
regulatori
oversight
order
promot
enhanc
qualiti
safeti
avail
blood
blood
product
summari
conclus
ministri
health
provid
effect
leadership
govern
develop
nation
blood
system
fulli
integr
nation
system
essenti
function
nation
blood
system
includ
appropri
regulatori
framework
legisl
regul
instrument
administ
regulatori
bodi
document
spell
principl
boundari
standard
set
organ
blood
system
ensur
adequ
suppli
blood
blood
product
safe
clinic
transfus
structur
nation
blood
system
depend
organ
level
develop
system
howev
critic
activ
within
nation
blood
system
coordin
nation
promot
uniform
standard
consist
staff
compet
qualiti
safeti
blood
blood
product
best
transfus
practic
key
formul
appropri
regulatori
framework
administ
regulatori
author
respons
regul
chain
prepar
use
product
abstract
withdrawn
abstract
withdrawn
f
clinic
patholog
far
eastern
memori
hospit
societi
blood
transfus
new
taipei
citi
taiwan
republ
china
background
regular
inspect
blood
establish
undertaken
triennial
sinc
ensur
good
practic
donor
recruit
blood
compon
process
distribut
fulfil
medic
need
patent
need
blood
transfus
taiwan
societi
blood
transfus
tsbt
author
inspect
depart
medic
affair
sinc
taiwan
food
drug
administr
tfda
sinc
aim
compar
perform
blood
establish
introduct
european
blood
inspect
system
eubi
pharmaceut
inspect
convent
scheme
pic
method
task
forc
call
tsbt
formul
checklist
base
upon
donor
elig
standard
requir
blood
establish
taiwan
requir
pic
eubi
blood
center
blood
station
select
mobil
donat
vehicl
inspect
accord
checklist
checklist
cover
rang
servic
qualiti
manag
personnel
facil
equip
document
donor
manag
compon
process
storag
distribut
audit
laboratori
test
complaint
recal
educ
train
occup
safeti
inspector
must
train
advanc
tsbt
get
consensu
result
major
critic
unconform
event
found
compar
inspect
number
unconform
event
decreas
event
inspect
common
unconform
event
facil
andor
equip
follow
human
resourc
manag
document
compar
common
unconform
chang
human
resourc
manag
follow
facil
andor
equip
screen
blood
donor
summari
conclus
blood
program
achiev
annual
donat
rate
per
thousand
popul
fulfil
transfus
need
healthcar
organ
howev
tri
introduc
requir
standard
ensur
transfus
qualiti
safeti
regular
system
inspect
unconform
remain
decreas
taalbi
us
depart
energi
nation
nuclear
secur
administr
washington
dc
unit
state
background
common
applic
radioact
materi
irradi
blood
compon
prevent
transfus
associ
graft
vs
host
diseas
histor
common
method
prevent
diseas
applic
gamma
radiat
irradi
contain
howev
technolog
irradi
ultraviolet
pathogen
reduct
becom
increasingli
avail
us
commerci
market
aim
radioact
materi
play
critic
role
medic
industri
commerci
applic
technolog
advanc
case
blood
irradi
led
increas
avail
altern
irradi
part
mission
protect
reduc
elimin
radioact
materi
dnn
offic
radiolog
secur
or
within
offic
global
materi
secur
lead
effort
reduc
need
sourc
support
viabl
altern
technolog
replac
common
devic
use
sourc
result
perman
risk
reduct
elimin
radioact
materi
method
or
current
engag
effort
domest
intern
exchang
inform
statu
technolog
invest
encourag
improv
technolog
possibl
understand
reduc
obstacl
prevent
implement
promot
transit
altern
technolog
feasibl
program
voluntari
aim
find
mutual
benefici
solut
maintain
improv
intend
end
result
also
achiev
perman
risk
reduct
result
or
partner
commerci
license
unit
state
choos
replac
irradi
irradi
voluntari
cesium
irradi
replac
program
cirp
cirp
qualifi
site
receiv
fund
toward
purchas
new
irradi
addit
or
remov
dispos
base
irradi
sourc
recoveri
project
cost
site
given
lack
commerci
disposit
option
sourc
or
continu
work
mani
site
around
unit
state
replac
irradi
cirp
develop
broader
partnership
model
engag
region
intern
or
explor
partnership
altern
technolog
interest
countri
exist
radiolog
secur
cooper
activ
or
support
sever
bilater
multilater
engag
share
experi
among
oper
use
consid
altern
technolog
blood
irradi
addit
or
priorit
cooper
relev
industri
stakehold
includ
ngo
intern
organ
support
technic
exchang
among
oper
summari
conclus
interest
altern
technolog
blood
irradi
grown
around
world
seen
part
multilater
endors
polit
statement
demonstr
interest
radiolog
secur
mission
or
uniqu
role
facilit
integr
nation
secur
health
consider
support
need
blood
bank
commun
p
djordjev
blood
transfus
institut
ni
ni
serbia
background
latest
law
transfusiolog
medicin
pass
april
serbia
establish
nation
blood
transfus
servic
line
european
transfus
guidelin
recommend
aim
servic
divid
author
blood
transfus
servic
blood
bank
author
blood
transfus
servic
independ
institut
deal
collect
test
process
blood
well
distribut
blood
blood
bank
blood
bank
part
clinic
hospit
center
method
literatur
law
transfusiolog
medicin
data
transfus
servic
result
implement
law
began
gradual
take
territori
smaller
transfus
center
plan
januari
collect
test
blood
process
continu
perform
author
blood
transfus
institut
instead
far
blood
establish
differ
degre
direct
indirect
cost
data
manag
equip
materi
staff
support
function
facil
advantag
new
organ
primarili
increas
safeti
blood
uniform
qualiti
safeti
throughout
countri
also
expect
better
distribut
blood
elimin
blood
shortag
part
countri
occur
due
weaker
respons
donor
season
charact
econom
term
lower
total
cost
per
unit
blood
expect
due
central
procur
equip
test
well
depend
cost
central
model
good
opportun
optim
procur
process
gain
low
price
consum
central
enabl
better
manag
personnel
train
accord
standard
need
servic
addit
better
economi
increas
invest
research
work
field
rais
qualiti
safeti
blood
expect
central
inform
system
facilit
easier
administr
donor
easier
nation
plan
quick
respons
shortcom
individu
blood
compon
also
help
allevi
correct
geograph
differ
respons
blood
donor
central
distribut
throughout
countri
allow
avail
blood
compon
hospit
elimin
occurr
local
defici
blood
compon
risk
accumul
unnecessari
amount
blood
compon
obsolesc
due
fear
shortag
reduc
summari
conclus
author
blood
transfus
servic
oblig
improv
good
transfus
practic
staff
train
qualiti
improv
monitor
monitor
analyz
trend
need
well
creat
nation
polici
c
goh
j
liew
h
wongso
h
chong
lam
blood
servic
group
health
scienc
author
singapor
singapor
background
blood
servic
group
bsg
singapor
secur
nation
blood
suppli
ensur
patient
singapor
access
adequ
safe
blood
bsg
provid
autom
post
donat
call
back
line
call
back
line
ad
measur
provis
safe
blood
call
backlin
donor
feel
donat
blood
given
patient
ii
forgotten
declar
relev
inform
may
compromis
blood
safeti
andor
iii
develop
infect
symptom
first
two
week
follow
blood
donat
allow
bsg
reduc
risk
transfus
transmit
infect
tti
mandatori
infecti
diseas
test
may
cover
detect
time
test
call
back
line
autom
octob
allow
donor
provid
key
inform
voic
prompt
guidanc
unsuit
use
blood
donat
without
need
speak
oper
speak
oper
option
call
back
line
oper
sync
open
hour
hsa
blood
bank
answer
donor
gener
enquiri
current
data
reveal
donor
call
multipl
time
call
back
line
impli
low
line
effect
import
improv
line
ensur
possibl
case
call
back
miss
aim
identifi
possibl
root
caus
low
line
effect
enhanc
donor
experi
call
back
line
method
busi
process
map
use
identifi
possibl
factor
may
contribut
low
line
effect
statist
analysi
data
record
may
juli
perform
use
sigmaxl
softwar
phone
survey
conduct
understand
issu
donor
face
result
possibl
root
caus
identifi
coverag
avail
option
ii
oper
busi
iii
call
back
case
go
wrong
depart
iv
inform
ask
v
abrupt
line
cut
first
caus
applic
speak
oper
option
iv
v
applic
donat
call
back
option
call
log
data
month
period
reveal
donor
use
call
back
line
gener
enquiri
purpos
enquir
inform
pertain
donat
call
back
donor
advis
call
use
donat
call
back
option
result
low
line
effect
phone
survey
reveal
donor
tri
multipl
time
reach
oper
also
show
donor
made
repeat
call
could
rememb
donat
date
prompt
donor
unsur
detail
regist
thu
make
multipl
call
reason
contribut
low
line
effect
summari
conclus
although
major
call
made
regard
donat
call
back
purpos
call
back
line
better
explain
donor
card
pass
donat
call
back
line
flow
also
redesign
make
access
meet
need
donor
skov
j
h
thue
j
clinic
immunolog
rheumatolog
gastroenterolog
microbiolog
odens
univers
hospit
odens
denmark
background
fecal
microbiota
transplant
fmt
becom
highli
recommend
treatment
recurr
clostridium
difficil
infect
addit
fmt
current
investig
therapeut
option
variou
autoimmun
diseas
consequ
rise
demand
easi
rapid
access
high
qualiti
fmt
current
intern
standard
recommend
regard
recruit
select
screen
fece
donor
avail
likewis
standard
recommend
regard
product
storag
distribut
fmt
establish
furthermor
european
legal
framework
concern
donat
human
fece
exist
aim
aim
establish
stool
bank
odens
univers
hospit
denmark
collabor
involv
tissu
transplant
servic
depart
clinic
immunolog
depart
medic
gastroenterolog
depart
rheumatolog
depart
clinic
microbiolog
fulfil
demand
fmt
treatment
recurr
clostridium
difficil
infect
region
southern
denmark
research
fmt
therapeut
option
variou
autoimmun
diseas
aim
recruit
minimum
six
fece
donor
per
year
method
qualiti
manag
system
stool
bank
well
system
traceabl
fmt
develop
use
alreadi
exist
qualiti
manag
system
qualiwar
laboratori
inform
system
prosang
tissu
transplant
servic
depart
clinic
immunolog
screen
strategi
potenti
fece
donor
determin
elig
unpaid
volunt
fece
donor
recruit
present
blood
donor
corp
advertis
donor
wait
area
blood
bank
result
within
less
year
stool
bank
establish
standard
oper
procedur
equip
registr
compet
personnel
involv
stool
bank
handl
qualiti
manag
system
traceabl
fmt
donor
patient
ensur
use
laboratori
inform
system
howev
new
tissu
modul
develop
part
prosang
implement
found
newer
version
suitabl
handl
fece
donat
four
donor
recruit
donat
stool
time
donor
shown
interest
donat
far
use
research
purpos
addit
five
patient
suffer
recurr
clostridium
difficil
infect
success
treat
fmt
summari
conclus
larger
difficulti
establish
stool
bank
due
lack
regulatori
aspect
legisl
formal
aspect
establish
central
stool
bank
collabor
effort
alreadi
exist
tissu
transplant
servic
sever
advantag
process
donat
transplant
handl
personnel
experi
work
gmp
standard
well
regul
tissu
donat
patient
treat
fmt
high
qualiti
popul
donor
full
traceabl
product
ensur
possibl
safeti
issu
address
end
cost
effect
use
system
alreadi
place
consider
abstract
withdrawn
cs
booth
j
lancut
allard
haematolog
royal
london
hospit
london
uk
london
unit
kingdom
background
hospit
transfus
servic
depend
inform
technolog
system
maximis
transfus
safeti
automat
transfer
group
antibodi
screen
g
result
analys
patient
electron
record
amelior
risk
human
error
transcript
result
check
histor
group
provid
protect
wrong
blood
tube
special
requir
identifi
support
electron
crossmatch
without
need
serolog
crossmatch
major
patient
without
red
cell
antibodi
electron
track
use
remot
fridg
support
readi
avail
blood
near
clinic
area
may
hit
organis
across
world
includ
uk
nation
health
servic
london
trust
within
min
detect
viru
entir
network
elect
taken
protect
spread
leav
four
hospit
without
access
variou
system
major
incid
declar
total
last
day
aim
aim
draw
learn
point
manag
futur
downtim
method
reflect
debrief
follow
event
involv
patholog
manag
transfus
scientist
transfus
clinician
result
transfus
laboratori
handl
g
sampl
per
year
vast
increas
manual
workload
patient
need
two
separ
sampl
confirm
g
result
everi
unit
red
cell
crossmatch
manual
clinician
initi
sent
addit
sampl
patient
might
need
blood
case
lab
staff
need
check
clinic
team
establish
urgenc
request
result
telephon
enquiri
deal
doctor
enter
lab
encroach
upon
time
need
undertak
addit
serolog
test
meticul
paper
record
compon
issu
kept
maintain
traceabl
remot
fridg
could
longer
use
stock
return
lab
increas
number
experienc
transfus
scientist
need
challeng
attack
occur
start
weekend
altern
mean
order
stock
nation
blood
servic
negoti
onlin
order
system
unavail
ongo
activ
discuss
hospit
manag
transfus
consult
senior
patholog
scientist
anaesthetist
surgeon
led
agre
approach
toward
maintain
patient
safeti
elect
surgeri
cancel
major
trauma
initi
divert
accid
emerg
soon
routin
outpati
transfus
defer
wherev
feasibl
clinic
haematologist
work
laboratori
team
vet
request
provid
advic
clinic
team
regular
meet
teleconfer
commun
via
whatsapp
kept
involv
updat
restor
network
electron
record
downtim
rebuilt
summari
conclus
hospit
specif
major
incid
polici
downtim
transfus
set
role
respons
design
lead
staff
defin
line
commun
identifi
expertis
distribut
addit
staf
need
met
agre
criteria
cancel
elect
surgeri
prioriti
given
restor
laboratori
system
remot
fridg
forward
plan
extend
nation
blood
servic
support
nation
recommend
e
krstova
krajnc
b
bizjak
k
perbil
center
transfus
medicin
univers
hospit
maribor
maribor
slovenia
background
pneumat
tube
system
major
develop
laboratori
practic
commonli
use
hospit
transport
blood
sampl
diagnost
laboratori
blood
centr
blood
sampl
deliv
human
courier
recent
consid
use
pt
transport
blood
sampl
decid
valid
proton
pt
compar
routin
immunohematolog
coagul
test
result
sampl
integr
sampl
transport
either
manual
pt
aim
goal
evalu
impact
pneumat
tube
system
pt
compar
transport
sampl
method
pair
edta
citrat
blood
sampl
collect
randomli
select
patient
valid
perform
within
two
day
first
day
recoveri
depart
second
day
depart
laboratori
diagnost
sampl
four
differ
seri
sent
day
three
immunohematolog
test
abo
blood
group
indirect
coomb
test
conduct
day
sampl
five
differ
seri
sent
seven
coagul
test
bc
xp
siemen
conduct
prothrombin
time
pt
intern
normal
ratio
inr
thrombin
time
tt
activ
partial
thromboplastin
time
aptt
platelet
count
pltc
platelet
aggreg
test
hart
biolog
accept
criteria
determin
follow
contain
blood
sampl
transport
anoth
locat
must
remain
close
result
immunohematolog
test
result
must
ident
transport
result
haemostat
examin
result
transport
vari
due
biolog
variabl
result
result
immunohematolog
test
follow
transport
ident
one
prior
send
sampl
addit
transport
sampl
visibl
sign
haemolysi
statist
analysi
coagul
test
perform
highest
variabl
rate
note
thrombin
time
test
summari
conclus
pt
investig
studi
accept
reliabl
sampl
deliveri
routin
immunohematolog
coagul
laboratori
test
tube
show
sign
congest
overturn
stand
open
tube
also
visibl
sign
haemolysi
w
e
manag
german
red
cross
frankfurt
german
red
cross
kassel
german
red
cross
frankfurt
germani
background
prevent
graft
versu
host
diseas
gvhd
especi
immunosuppress
patient
blood
compon
radioact
irradi
dose
gray
gy
therebi
inactiv
nearli
residu
leucocyt
success
irradi
control
indic
switch
color
red
black
unfortun
color
chang
alreadi
occur
lower
irradi
dose
therefor
indic
guarante
effici
irradi
gy
moreov
adhes
strength
indic
use
reliabl
color
chang
process
import
sinc
potenti
loss
indic
miss
legibl
irradi
would
prohibit
secur
respect
blood
compon
success
irradi
aim
includ
electron
data
manag
system
irradi
blood
compon
method
newli
design
irradi
indic
previous
use
indic
test
parallel
differ
irradi
dose
gy
step
gy
second
studi
part
stick
strength
new
indic
test
routin
condit
differ
blood
compon
pack
red
cell
platelet
result
irradi
indic
test
irradi
gy
replic
n
figur
show
indic
statutori
irradi
gy
success
irradi
procedur
new
indic
indic
scannabl
barcod
ok
well
notion
bestrahlt
becom
visibl
irradi
minimum
irradi
dose
gy
contrast
indic
chang
color
red
black
hold
alreadi
clear
dose
gy
moreov
indic
test
routin
condit
appli
irradi
gy
barcod
reliabl
visibl
scannabl
time
without
except
summari
conclus
indic
improv
blood
safeti
monitor
irradi
dose
blood
compon
scannabl
barcod
appear
minimum
dose
gy
therebi
guarante
effici
irradi
irradi
process
barcod
could
scan
result
ad
electron
data
set
store
respect
blood
compon
could
addit
inform
concern
blood
compon
independ
indic
final
indic
store
room
temperatur
thu
facilit
handl
new
indic
document
technolog
describ
line
request
complet
monitor
strategi
product
step
concern
blood
compon
therefor
importantli
contribut
fulfil
good
manufactur
practic
w
e
manag
german
red
cross
frankfurt
german
red
cross
kassel
german
red
cross
frankfurt
germani
background
usual
blood
donor
sampl
label
donat
side
venipunctur
case
unsuccess
venipunctur
sampl
tube
might
necessari
blood
donor
servic
hess
two
donor
donat
blood
side
side
separ
tabl
middl
two
bed
mix
failur
donat
occur
approxim
time
per
year
identifi
laboratori
blood
group
aim
sampl
tube
greiner
bio
one
use
pilot
studi
exclud
mix
failur
blood
donat
side
therefor
code
label
sampl
tube
manufactur
tube
method
tube
scan
blood
donat
side
fill
merg
togeth
blood
donat
number
sampl
bag
laboratori
number
donor
number
donat
number
precod
sampl
tube
number
handl
laboratori
inform
system
test
test
result
transfer
blood
donat
program
inlog
edg
blood
result
total
three
first
time
donor
three
differ
precod
sampl
tube
per
donat
six
multipl
time
donor
two
differ
precod
sampl
tube
test
pilot
studi
sampl
tube
scan
electron
merg
togeth
blood
donat
number
test
instrument
preanalyt
decapp
sarstedt
beckman
coulter
hamilton
pool
instrument
roch
coba
abbott
prism
beckman
coulter
instrument
abl
without
specif
oo
test
data
transfer
li
blood
donat
programm
addit
possibl
without
failur
summari
conclus
pilot
studi
demonstr
introduct
sampl
tube
alphanumer
feasibl
abl
improv
blood
safeti
order
prevent
sampl
mix
up
blood
donat
side
use
sampl
tube
reduc
electron
devic
blood
donat
side
optim
scan
sampl
tube
laboratori
barcod
label
exactli
place
final
sampl
tube
link
blood
donat
bag
immedi
fill
sampl
tube
use
sampl
tube
reduc
risk
manual
failur
improv
laboratori
test
autom
screen
instrument
therefor
blood
donor
servic
hess
implement
sampl
tube
donat
b
c
g
b
blood
servic
brampton
blood
servic
edmonton
blood
servic
calgari
canada
background
juli
implement
autom
suppli
chain
electron
donor
questionnair
option
question
regard
donor
ethnic
group
ad
perman
donor
clinic
site
question
answer
appear
medic
questionnair
question
read
follow
option
question
ethnic
background
use
help
us
identifi
rare
blood
group
will
provid
inform
busi
intellig
warehous
report
develop
gather
data
respons
use
select
donor
addit
phenotyp
genotyp
test
aim
donor
ethnic
inform
support
identif
rare
blood
group
phenotyp
improv
frozen
inventori
decreas
turn
around
time
fill
request
red
cell
unit
complex
antigen
phenotyp
effici
direct
test
resourc
phenotyp
genotyp
method
phenotypegenotyp
algorithm
develop
select
test
donor
sampl
base
ethnic
donor
follow
ethnic
test
arab
anwj
antigen
asian
ena
gy
jr
south
asian
b
latin
american
ge
black
aborigin
donor
sampl
sent
genotyp
result
respons
rate
ethnic
question
donor
respond
total
donor
littl
chang
respons
rate
donor
respond
total
new
donor
ethnic
divers
donor
follow
ethnic
aborigin
arab
asian
black
latin
american
south
asian
white
two
rare
donor
identifi
test
use
ethnic
donor
report
donor
one
posit
ror
fy
b
b
identifi
decemb
donor
two
posit
fy
b
jk
b
identifi
novemb
addit
ethnic
donor
report
import
tool
fill
urgent
demand
request
request
red
cell
unit
group
rh
posit
pregnant
sickl
cell
patient
ethnic
donor
report
provid
list
black
donor
sampl
phenotyp
antigen
reduc
test
time
requir
find
match
unit
summari
conclus
identifi
rare
donor
ethnic
question
success
strategi
improv
frozen
rare
phenotyp
inventori
provid
red
cell
unit
complex
phenotyp
time
manner
ethnic
donor
report
effect
tool
reduc
test
time
requir
fill
demand
request
statist
difficult
antigen
combin
c
l
n
medicin
servic
mlt
sinai
hospit
toronto
canada
msc
mount
sinai
hospit
toronto
canada
background
decis
support
intend
optim
clinic
practic
decis
support
associ
variabl
effect
clinic
practic
howev
develop
computer
decis
support
red
blood
cell
rbc
transfus
tertiari
care
center
emphas
rbc
transfus
trigger
accord
indic
preemptiv
use
diuret
transfus
one
unit
time
advis
medic
feedback
indic
list
aim
studi
aim
assess
effect
decis
support
rbc
util
character
transfus
practic
accord
clinic
servic
method
retrospect
determin
effect
decis
support
rbc
use
one
year
prior
one
year
implement
tertiari
care
univers
affili
centr
collect
follow
data
follow
implement
clinic
servic
request
rbc
transfus
hemoglobin
concentr
prior
rbc
transfus
whether
post
transfus
complet
blood
count
cbc
avail
administr
unit
whether
practition
transfus
accord
criteria
exclud
patient
requir
massiv
transfus
protocol
rbc
exchang
transfus
result
decis
support
implement
mid
juli
review
data
juli
juli
august
juli
unit
transfus
year
decis
support
implement
unit
transfus
year
implement
reduct
usag
rbc
unit
rbc
unit
transfus
unit
transfus
one
unit
time
unit
transfus
two
unit
time
unit
transfus
three
unit
time
unit
unit
use
patient
icu
unit
use
preoper
unit
emerg
room
unit
oncolog
unit
unit
gener
intern
medicin
servic
unit
pregnanc
unit
unit
cardiolog
unit
outpati
clinic
unit
transfus
one
time
icu
unit
preoper
clinic
unit
gener
intern
medicin
servic
unit
emerg
room
unit
oncolog
unit
unit
pregnanc
unit
unit
cardiolog
unit
unit
outpati
clinic
rbc
unit
transfus
hemoglobin
hgb
concentr
less
gl
unit
transfus
hgb
gl
unit
transfus
pretransfus
hgb
valu
summari
conclus
sinc
implement
decis
support
rbc
usag
decreas
character
rbc
transfus
accord
servic
hemoglobin
concentr
abl
identifi
clinic
unit
intervent
could
institut
reduc
rbc
use
ongo
assess
determin
whether
reduct
rbc
usag
maintain
subsequ
year
g
sato
vicin
pti
ltd
sydney
australia
na
singapor
singapor
background
blood
bank
perform
rfid
evalu
evalu
rfid
tag
equip
program
rfid
tag
fail
read
quickli
unabl
track
bulk
accur
tag
fail
read
centrifug
process
encod
blood
inform
corrupt
post
radiat
encod
inform
match
encod
inform
prior
radiat
due
failur
test
discontinu
aim
differ
form
rfid
tag
pjm
rfid
tag
attach
blood
product
subject
variou
process
read
specifi
distanc
reader
includ
speed
bulk
read
capac
pjm
rfid
tag
whilst
check
accuraci
integr
data
store
tag
method
total
blood
bag
fill
tap
water
affix
pjm
rfid
tag
uppermost
posit
base
label
blood
bag
repres
unit
follow
test
red
blood
cell
rbc
platelet
plt
fresh
frozen
plasma
ffp
buffi
coat
bc
data
encod
onto
pjm
rfid
tag
use
isbt
data
structur
blood
compon
pjm
rfid
tag
subject
follow
standard
treatment
condit
specifi
durat
centrifug
irradi
refriger
result
pjm
rfid
tag
success
read
temperatur
specifi
follow
test
blood
bag
subject
centrifug
min
plt
bag
ffp
bag
subject
second
round
centrifug
min
bc
bag
subject
normal
radiat
exposur
gy
subsequ
refriger
day
rbc
bag
subject
doubl
radiat
exposur
gy
subsequ
refriger
day
plt
bag
subject
doubl
dose
radiat
gy
read
distanc
irradi
pjm
rfid
tag
measur
pjm
rfid
desktop
reader
within
specifi
rang
ffp
bag
rapid
frozen
frozen
h
follow
day
week
week
summari
conclus
pjm
rfid
solut
meet
requir
object
outlin
vox
sanguini
rfid
guidelin
provid
bulk
read
unaffect
centrifug
irradi
refriger
base
test
result
show
pjm
rfid
tag
could
read
throughout
test
f
c
l
imperi
colleg
healthcar
nh
trust
stock
manag
scheme
nh
blood
transplant
transfus
imperi
colleg
healthcar
nh
trust
london
unit
kingdom
background
nh
huge
financi
pressur
recent
year
provid
effect
clinic
care
limit
resourc
blood
compon
wastag
import
financi
issu
hospit
implement
patient
blood
manag
pbm
increas
focu
use
blood
compon
appropri
minim
inappropri
use
aid
cost
save
larg
nh
trust
hous
specialti
known
high
user
blood
compon
look
caus
extent
blood
wastag
within
blood
transfus
laboratori
implement
intervent
minim
wastag
without
compromis
patient
care
whilst
follow
uk
guidelin
aim
ensur
blood
stock
order
stock
manag
undertaken
aim
prevent
wastag
without
compromis
clinic
care
method
review
order
blood
compon
regular
usag
via
blood
stock
manag
scheme
vanesa
systemto
ensur
order
peer
group
reviewedto
provid
train
across
trust
appropri
order
blood
compon
correctli
minim
time
expiri
wastag
result
compar
data
week
implement
chang
data
month
previou
year
show
total
fall
rbc
stock
equat
reduct
unit
averag
daili
stock
hold
reduct
stock
equat
save
one
save
revis
daili
stock
order
base
inform
vanesa
previou
year
data
result
reduct
timex
unit
averag
unit
unit
monthli
potenti
save
equat
excess
per
month
summari
conclus
first
year
expect
potenti
save
cost
save
per
year
f
f
l
l
transfus
imperi
colleg
healthcar
nh
trust
nh
blood
transplant
london
unit
kingdom
background
joint
ukbt
profession
advisori
committe
chang
notif
june
advis
blood
could
return
fridg
min
rather
min
provid
twice
previous
min
also
advis
rbc
unit
must
refriger
h
outing
establish
author
min
rule
rbc
unit
fridg
min
could
collect
transfus
within
h
return
fridg
provid
transfus
complet
within
h
risk
bacteri
prolifer
increas
rbc
unit
remov
fridg
min
return
h
fulli
cool
remov
second
time
min
transfus
aim
want
assess
much
blood
save
implement
rule
identifi
cost
monetari
term
method
flowchart
manag
blood
outing
devis
ensur
unit
check
return
fridg
unit
return
second
third
time
check
refriger
h
outing
qualifi
return
fridg
unit
return
satellit
fridg
quarantin
remot
use
electron
blood
track
implement
full
chang
control
retrospect
audit
mani
unit
could
save
june
decemb
estim
impact
chang
result
reduct
cold
chain
wastag
safe
made
extend
min
rule
min
simpl
system
ensur
quarantin
unit
h
outing
unless
immin
transfus
identifi
rbc
unit
prevent
wast
result
save
summari
conclus
rule
implement
nation
save
nh
would
signific
b
pasko
c
darrel
h
kurbaj
moham
k
obrien
patholog
beth
israel
deaco
medic
center
boston
unit
state
background
joint
commiss
accredit
healthcar
requir
blood
avail
patient
undergo
procedur
might
requir
intraop
transfus
major
patient
undergo
procedur
elig
electron
crossmatch
ecm
pack
red
blood
cell
prbc
unit
elig
ecm
patient
must
two
concord
sampl
prior
surgeri
ecm
unit
readili
avail
sent
oper
room
without
delay
compromis
patient
care
thu
preoper
crossmatch
storag
prbc
patient
elig
ecm
creat
unnecessari
wast
blood
bank
hospit
resourc
includ
technologist
time
prbc
storag
time
dollar
mind
septemb
institut
implement
new
protocol
handl
preoper
request
prbc
patient
elig
ecm
protocol
specifi
blood
crossmatch
surgeri
ecm
elig
patient
prior
order
requir
unit
thu
blood
prepar
aim
goal
studi
evalu
effect
new
blood
bank
program
preoper
patient
might
requir
intraop
prbc
transfus
defin
effect
reduct
total
prbc
unit
unnecessarili
crossmatch
issu
return
blood
bank
method
systemat
retrospect
review
procedur
requir
least
type
screen
prior
surgeri
perform
januari
march
prior
implement
prbc
program
analysi
review
number
ecm
unit
prepar
store
surgeri
across
multipl
surgic
disciplin
includ
cardiothorac
vascular
neurosurgeri
obgyn
urolog
transplant
orthoped
surgeri
evalu
total
number
patient
prbc
unit
crossmatch
issu
return
transfus
analysi
use
crossmatch
unit
due
known
plan
decreas
total
unit
crossmatch
variabl
number
patient
issu
return
transfus
result
significantli
fewer
patient
elig
ecm
crossmatch
follow
implement
program
januari
march
compar
prior
year
patient
elig
ecm
crossmatch
vs
p
number
total
patient
elig
ecm
unchang
period
vs
p
significantli
fewer
prbc
crossmatch
januari
march
januari
march
ecm
elig
patient
unit
vs
unit
p
decreas
total
prbc
unit
issu
return
transfus
januari
march
compar
time
period
statist
signific
differ
issu
unit
vs
unit
p
return
vs
p
transfus
unit
vs
unit
p
summari
conclus
implement
ecm
program
result
significantli
fewer
patient
requir
crossmatch
crossmatch
ecm
unit
proven
effici
manag
preoper
ecm
elig
sampl
without
compromis
patient
care
sharifi
pourfathollah
k
sham
asanjan
ali
balazadeh
asadi
high
institut
research
educ
transfus
medicin
tehran
islam
republ
background
wast
manag
one
import
prioriti
transfus
organ
wastag
reduct
blood
blood
product
blood
transfus
organ
lead
huge
save
optim
use
health
resourc
aim
studi
aim
evalu
manag
blood
blood
product
wastag
three
year
period
iranian
blood
transfus
organ
method
studi
conduct
blood
transfus
organ
iran
year
firstli
order
manag
avoid
wast
blood
blood
product
instruct
develop
contain
main
caus
wastag
control
workshop
instruct
train
head
quarter
wastag
reduct
blood
blood
product
deputi
blood
distribut
author
provinc
monitor
wastag
rate
product
blood
compon
correct
action
monitor
monthli
provinc
reduc
expir
product
store
inventori
reduc
day
consumpt
maximum
admiss
volum
day
consumpt
tariff
blood
blood
product
develop
cost
blood
blood
product
paid
health
center
blood
transfus
organ
equip
compon
product
servic
calibr
blood
blood
product
transfer
low
consumpt
center
high
consumpt
center
result
amount
wast
reduc
product
product
year
therefor
wast
reduc
use
aforement
method
amount
wast
decreas
unit
year
unit
year
equal
save
rial
iranian
currenc
summari
conclus
accord
find
essenti
improv
wastag
manag
process
includ
monthli
monitor
wastag
surplu
movement
blood
product
continu
train
staff
equip
monitor
chuhriiev
zhytomyr
region
blood
centr
zhytomyr
ukrain
background
time
access
suffici
quantiti
safe
blood
product
assur
qualiti
effect
oper
region
blood
servic
optim
clinic
use
blood
compon
significantli
affect
reinforc
healthcar
system
countri
annual
european
director
qualiti
medicin
healthcar
edqm
conduct
assess
eu
countri
donor
blood
sever
section
use
rel
intens
valu
form
indic
per
popul
specif
weight
structur
per
donor
per
blood
compon
transfus
aim
aim
creat
system
macro
assess
state
transfus
medicin
region
ukrain
method
criteria
macro
assess
determin
delphi
method
rank
region
carri
rank
evalu
method
result
macro
assess
criteria
final
valu
blood
center
oper
divid
two
block
first
block
popul
procur
consist
five
criteria
number
donor
number
red
blood
cell
unit
apheresi
platelet
unit
apu
issu
hospit
amount
plasma
suitabl
fraction
criteria
calcul
per
popul
second
block
oper
effici
consist
criteria
two
area
staff
product
donor
donat
apu
amount
donor
blood
procur
worker
effici
equip
util
amount
plasma
apu
per
devic
apheresi
sum
point
criterion
rank
region
defin
first
block
popul
procur
second
block
oper
effici
basi
result
two
block
rank
blood
servic
region
defin
nation
level
summari
conclus
macro
assess
blood
servic
oper
allow
identifi
problem
area
oper
level
popul
procur
blood
compon
usag
effect
main
resourc
region
blood
center
ensur
coordin
develop
organis
measur
achiev
econom
effici
nation
blood
servic
w
clinic
diagnost
raritan
unit
state
clinic
diagnost
turnhout
belgium
background
evalu
select
new
immunohematolog
test
instrument
laboratori
often
challeng
way
manufactur
product
provid
inform
instrument
often
inform
base
decis
center
state
throughput
instrument
throughput
often
state
term
test
column
profil
per
hour
clear
understand
inform
difficult
achiev
util
comparison
instrument
capabl
usual
common
import
criteria
evalu
turnaround
time
tat
deliveri
accur
time
result
critic
provid
transfus
therapi
aim
studi
design
evalu
ih
instrument
tat
perspect
mix
test
profil
typic
laboratori
speed
deliveri
result
consist
perform
util
standard
workload
laboratori
method
three
instrument
evalu
ortho
vision
ov
ortho
vision
max
ovm
four
workload
protocol
wlp
vari
volum
repres
workflow
protocol
test
analyz
load
pattern
time
test
type
tat
test
profil
includ
blood
group
bg
rhk
phenotyp
rhk
antibodi
screen
ab
major
crossmatch
xm
antibodi
identif
abid
direct
antiglobulin
test
dat
follow
wlp
evalu
test
bg
rhk
ab
xm
bg
ab
rhk
ab
xm
abid
rhk
ab
dat
result
complet
test
min
tat
rang
min
ov
min
tat
rang
min
ovm
min
tat
rang
min
complet
test
min
tat
rang
min
ov
min
tat
rang
min
ovm
min
tat
rang
min
complet
test
min
tat
rang
min
ov
min
tat
rang
min
ovm
min
tat
rang
min
complet
test
min
tat
rang
min
ov
min
tat
rang
min
ovm
min
tat
rang
min
summari
conclus
evalu
instrument
perform
determin
best
fit
laboratori
challeng
studi
demonstr
import
use
workload
arriv
load
tat
determin
capabl
manag
workload
laboratori
situat
compar
instrument
ortho
vision
platform
instrument
demonstr
capabl
routin
consist
provid
shorter
tat
compar
addit
demonstr
ovm
workload
concentr
shorter
arriv
time
provid
improv
tat
ts
w
clinic
diagnost
raritan
unit
state
clinic
diagnost
turnhout
belgium
background
evalu
need
new
immunohematolog
instrument
necessari
consid
workload
volum
mixtur
test
profil
time
arriv
within
laboratori
frequenc
urgent
sampl
complex
patient
test
evalu
criteria
permit
laboratori
identifi
ih
system
select
mani
instrument
would
need
manag
workload
often
done
base
throughput
number
alway
accur
reflect
true
need
aim
studi
design
evalu
mani
ih
instrument
would
necessari
would
effect
succeed
routin
complet
workload
variou
test
profil
typic
laboratori
well
meet
turnaround
time
expect
method
instrument
evalu
grifol
erytra
ge
system
ortho
vision
max
vision
system
three
comparison
scenario
evalu
turnaround
time
tat
instrument
first
evalu
current
practic
use
three
instrument
one
perform
test
sampl
specif
classif
routin
urgent
surgeri
load
timescan
time
result
captur
sampl
erytra
system
parallel
comparison
instrument
second
scenario
kept
load
base
arriv
urgenc
requir
optim
spread
workload
without
regard
uniqu
sampl
classif
ov
third
scenario
ran
workload
respect
sampl
arriv
time
ovm
addit
stat
sampl
tat
evalu
ge
ov
instrument
result
follow
result
tat
found
total
sampl
scenario
sampl
tat
rang
min
test
min
sampl
tat
rang
min
test
min
sampl
tat
rang
min
test
min
sampl
tat
rang
min
test
min
sampl
tat
rang
min
test
min
sampl
tat
rang
min
test
min
scenario
sampl
across
instrument
analyz
follow
result
sampl
tat
rang
min
test
min
ov
sampl
tat
rang
min
test
min
sampl
tat
rang
min
test
min
scenario
sampl
ov
tat
rang
min
test
min
stat
ge
sampl
tat
rang
min
test
min
sampl
tat
rang
min
test
min
instrument
sampl
tat
rang
min
test
min
summari
conclus
evalu
instrument
perform
determin
multipl
instrument
system
perform
manag
workload
meet
result
deliveri
time
accomplish
proper
comparison
studi
demonstr
import
use
workload
arriv
load
tat
determin
capabl
manag
workload
laboratori
signific
reduct
consist
predict
tat
achiev
seen
comparison
ortho
vision
max
system
versu
grifol
erytra
yay
e
unal
b
eser
erciy
univers
erciy
univers
kayseri
turkey
background
turkish
guidelin
nation
prepar
use
qualiti
assur
blood
blood
compon
updat
report
donor
donat
bloodblood
compon
first
time
donor
histori
pregnanc
transfus
histori
sinc
last
blood
donat
screen
erythrocyt
antibodi
aim
intern
studi
report
posit
rate
antibodi
screen
blood
donor
around
studi
advis
nation
guidelin
donor
carri
characterist
began
screen
antibodi
june
result
cost
analysi
month
studi
period
examin
method
june
januari
volunt
blood
donor
donat
first
time
pregnanc
transfus
stori
sinc
last
blood
donat
erciy
univers
blood
center
screen
triplet
cell
antibodi
scan
devic
donor
result
june
januari
total
peopl
donat
blood
blood
product
donor
blood
donor
first
time
donor
femal
donor
pregnant
donor
within
studi
period
total
first
donat
pregnanc
antibodi
screen
test
perform
test
chi
squar
p
show
posit
antibodi
screen
donor
posit
donor
antibodi
detect
total
cost
spent
antibodi
screen
donor
period
euro
unit
test
cost
x
total
number
test
euro
studi
test
cost
calcul
region
blood
center
period
time
calcul
annual
cost
test
approxim
euro
addit
cost
cover
sgk
way
charg
anywher
erythrocyt
suspens
year
period
blood
center
prepar
erythrocyt
suspens
outsid
red
crescent
well
increas
cost
bag
test
add
neg
impact
final
cost
summari
conclus
specul
order
reduc
cost
test
found
rate
volunt
donor
group
donor
specimen
consid
donor
pool
singl
pool
cell
instead
test
cell
consid
strategi
reduc
annual
cost
turkey
estim
million
unit
blood
donat
per
year
half
donat
first
donat
hb
othman
z
khalid
w
wan
mohd
saman
patholog
diagnost
research
laboratori
univers
teknolog
mara
sungai
buloh
malaysia
background
polici
releas
blood
immedi
spin
crossmatch
electron
crossmatch
ec
blood
recipi
neg
antibodi
screen
practis
worldwid
practic
save
time
cost
well
expedit
releas
blood
patient
grow
clinic
servic
new
tertiari
care
centr
blood
request
becom
frequent
aim
evalu
possibl
implement
type
screen
ts
immedi
spin
crossmatch
polici
recipi
neg
centr
method
cross
section
studi
done
transfus
medicin
unit
uitm
medic
specialist
centr
august
januari
retrospect
analysi
perform
retriev
data
pretransfus
test
perform
studi
period
current
practic
includ
standard
pretransfus
test
ie
blood
group
type
three
cell
panel
test
full
crossmatch
procedur
c
anti
human
phase
prior
releas
blood
result
standard
crossmatch
perform
patient
neg
crossmatch
found
incompat
ahg
phase
common
reason
incompat
due
posit
direct
coomb
test
dct
blood
unit
crossmatch
extend
dct
perform
determin
specif
dct
reaction
incompat
also
detect
one
crossmatch
blood
unit
test
neg
dct
like
reason
incompat
presenc
alloantibodi
toward
low
incid
antigen
howev
investig
perform
compat
blood
obtain
follow
subsequ
crossmatch
blood
unit
two
crossmatch
mix
field
reaction
could
due
fibrin
format
sampl
storag
centr
blood
collect
centr
thu
direct
access
donor
inform
blood
process
blood
blood
product
come
local
nation
blood
centr
nbc
kuala
lumpur
malaysia
current
dct
posit
blood
unit
return
back
nbc
manag
signific
number
crossmatch
incompat
due
posit
dct
blood
unit
implement
new
polici
centr
unfavour
tend
miss
reaction
ahg
phase
omit
routin
procedur
blood
releas
ec
made
possibl
institut
softwar
valid
safeti
element
especi
assign
compat
blood
neg
prevent
releas
abo
incompat
blood
exist
basic
blood
bank
inform
system
fit
safeti
criteria
need
polici
still
assign
abo
compat
blood
unit
manual
system
summari
conclus
transfus
medicin
unit
healthcar
facil
respons
safeti
blood
issu
recipi
incompat
ahg
crossmatch
detect
among
neg
recipi
conclud
readi
ts
crossmatch
polici
even
though
emin
cost
effect
standard
crossmatch
phase
still
relev
centr
adher
current
practic
suffici
technic
infrastructur
support
avail
centr
addit
suffici
screen
cell
panel
relev
local
popul
need
develop
clinic
signific
antibodi
detect
abstract
withdrawn
abstract
withdrawn
l
de
l
k
b
region
blood
coordin
network
sunnybrook
health
care
scienc
centr
toronto
health
scienc
centr
london
michael
hospit
health
network
toronto
health
partner
mississauga
health
oshawa
gener
hospit
kingston
canada
background
report
royal
commiss
inquiri
blood
system
canada
krever
inquiri
releas
novemb
transfus
safeti
offic
tso
role
establish
enhanc
safeti
qualiti
blood
transfus
canada
respons
royal
commiss
recommend
tso
fundament
role
improv
patient
safeti
aspect
transfus
practic
posit
come
sever
respons
encompass
follow
area
technic
clinic
util
manag
qualiti
risk
profession
educ
research
guid
assist
healthcar
profession
transit
role
tso
advantag
howev
limit
resourc
date
aim
tso
resourc
manual
develop
provid
conveni
access
resourc
audit
tool
educ
tool
algorithm
monograph
checklist
guidelin
facil
without
tso
place
facil
open
new
tso
posit
method
clinic
project
safeti
nurs
provinci
blood
coordin
network
visit
variou
larg
healthcar
institut
inform
collect
observ
discuss
tso
daili
activ
respons
tso
institut
identifi
minim
guidanc
limit
resourc
assist
transit
role
acknowledg
tso
might
come
divers
background
healthcar
could
contribut
limit
understand
clinic
technic
terminolog
gap
commun
experienc
tso
six
larg
provinci
healthcar
institut
close
involv
develop
resourc
result
transfus
safeti
offic
resourc
manual
deliv
detail
inform
regard
role
respons
tso
expect
time
commit
resourc
provid
inform
follow
tso
job
descriptionabbrevi
glossari
termscommitte
organizationsus
linksinvestig
report
transfus
reactionsrecallswithdrawalsproduct
administr
guidelin
monograph
equip
use
infus
blood
wordpress
featur
use
monitor
amount
user
download
sinc
releas
transfus
safeti
offic
resourc
manual
march
ontario
region
blood
coordin
network
orbcon
websit
recent
report
februari
display
user
download
sinc
releas
resourc
manual
summari
conclus
transfus
safeti
offic
resourc
manual
develop
refer
guid
medic
laboratori
technologist
regist
nurs
healthcar
profession
appoint
tso
role
also
intend
util
hospit
formal
tso
posit
deleg
respons
staff
transfus
safeti
offic
resourc
manual
provid
help
inform
assist
educ
transfus
safeti
advers
event
investig
report
product
administr
guidelin
monograph
link
inform
equip
use
infus
blood
resourc
manual
serv
use
refer
tool
assist
healthcar
profession
transit
tso
role
region
blood
coordin
network
orbcon
sunnybrook
health
scienc
centr
toronto
region
blood
coordin
network
orbcon
ottawa
hospit
research
institut
ottawa
region
blood
coordin
network
orbcon
mcmaster
univers
hamilton
canada
background
ontario
region
blood
coordin
network
orbcon
creat
provid
organ
integr
approach
blood
manag
ontario
one
orbcon
strateg
goal
develop
high
qualiti
relev
transfus
medicin
educ
resourc
collabor
transfus
medicin
expert
help
facilit
adopt
best
practic
improv
patient
safeti
first
step
increas
physician
engag
transfus
medicin
educ
resourc
orbcon
evalu
util
content
access
resourc
ensur
educ
need
met
encourag
user
adopt
evid
base
practic
chang
orbcon
access
inform
resourc
provid
necessari
pathway
reach
common
purpos
ensur
patient
get
right
product
right
time
right
purpos
aim
aim
project
determin
need
gap
current
educ
resourc
ensur
futur
develop
transfus
medicin
resourc
address
educ
need
method
educ
need
assess
undertaken
qualit
analysi
use
question
survey
creat
use
softwar
call
survey
distribut
ontario
hospit
transfus
servic
n
via
email
transfus
medicin
medic
director
transfus
committe
chairperson
specif
clinic
scenario
includ
mean
determin
gap
transfus
medicin
knowledg
amongst
intend
target
audienc
result
total
respons
receiv
small
commun
academ
hospit
set
repres
respons
respect
staff
physician
account
respond
classifi
repres
profession
lectur
laboratori
director
transfus
safeti
offic
mandat
transfus
medicin
compet
enforc
hospit
common
motiv
choos
cme
increas
knowledg
follow
reassur
current
practic
consist
standard
practic
adopt
new
practic
respond
ask
consid
target
clinic
situat
scenario
regard
routin
dose
intraven
immunoglobulin
plasma
prothrombin
complex
concentr
albumin
summari
conclus
despit
low
respons
rate
need
assess
provid
insight
gap
avail
requir
order
remain
current
maintain
compet
transfus
medicin
orbcon
continu
collabor
blood
compon
product
provid
current
relev
resourc
learner
unabl
assess
nt
know
need
know
given
topic
specialti
therefor
order
provid
content
current
relev
servic
receiv
address
need
encourag
knowledg
translat
best
practic
ensur
patient
receiv
best
care
use
right
product
right
time
right
purpos
f
coria
gimenez
l
lazo
polop
l
scalercio
veloso
c
gamba
kuperman
centro
region
de
hemoterapia
hospit
garrahan
ciudad
autonoma
de
bueno
air
argentina
background
umbil
cord
blood
ucb
sourc
hematopoiet
progenitor
cell
hpc
transplant
gmp
regul
standard
requir
train
personnel
perform
procur
sinc
relat
program
launch
pediatr
hospit
aim
famili
child
condit
allogen
hpc
transplant
constitut
therapeut
altern
ucb
collect
offer
famili
staff
later
program
open
institut
becom
nationwid
new
tool
develop
appropri
train
healthcar
profession
involv
collect
ship
aim
aim
present
differ
tool
develop
train
healthcar
profession
ucb
collect
techniqu
relat
program
method
retrospect
descript
studi
descript
purpos
three
period
defin
initi
stage
n
ucb
collect
b
expans
stage
n
ucb
collect
c
improv
stage
n
ucb
collect
result
initi
stage
program
open
patient
hospit
collect
made
near
matern
ucb
bank
staff
follow
sop
mean
collectionsyear
sinc
allow
enrol
patient
nationwid
becam
necessari
organ
collect
distant
center
expans
stage
mean
ucb
collectionsyear
collect
done
facil
cover
provinc
countri
new
tool
train
healthcar
profession
implement
lectur
support
powerpoint
present
written
instruct
hand
traine
cover
collect
techniqu
ship
instruct
mainli
perform
train
via
phone
call
case
design
personnel
matern
obstetrician
midwif
nurs
surgic
technician
blood
bank
technician
come
center
receiv
train
travel
center
purpos
improv
stage
mean
ucb
collectionsyear
cover
provinc
use
hospit
telemedicin
servic
standard
form
guid
distanc
train
allow
us
improv
fulfil
sop
among
new
cord
blood
bank
staff
final
made
train
video
use
birth
simul
mamanatali
creat
realist
scenario
video
show
ucb
collect
techniqu
detail
min
length
summari
conclus
achiev
nationwid
network
profession
abl
provid
ucb
relat
program
use
new
tool
train
distant
collect
facil
increas
patient
access
healthcar
especi
underserv
area
distant
procur
done
santa
cruz
km
process
facil
use
telemedicin
servic
highli
motiv
traine
remot
size
facil
without
chanc
travel
video
access
thorough
hospit
campu
regist
health
care
profession
request
train
receiv
certif
standard
assess
complet
train
effort
seek
continu
improv
techniqu
guarante
adequ
cell
dose
futur
use
transplant
program
allow
allogen
hpc
transplant
children
countri
abstract
withdrawn
w
wan
alkamar
othman
n
mohd
medic
dental
institut
amdi
univers
sain
malaysia
kepala
bata
medicin
unit
depart
haematolog
hospit
univers
sain
malaysia
kubang
kerian
malaysia
background
blood
transfus
one
common
therapi
prescrib
clinician
despit
injudici
unsaf
transfus
contribut
lead
caus
morbid
mortal
global
jeopardi
qualiti
care
caus
wastag
blood
product
resourc
therefor
vital
clinician
mainli
postgradu
resid
possess
knowledg
clinic
transfus
current
level
knowledg
among
postgradu
resid
hospit
univers
sain
malaysia
husm
yet
known
aim
studi
clinic
transfus
knowledg
level
among
postgradu
resid
within
depart
anaesthesiolog
intens
care
accid
emerg
obstetr
gynaecolog
gener
surgeri
gener
medicin
hospit
univers
sain
malaysia
husm
demograph
factor
associ
method
studi
use
valid
question
distribut
particip
five
depart
husm
valid
assess
tool
consist
six
demograph
survey
question
clinic
transfus
knowledg
total
score
score
categoris
poor
knowledg
level
score
categoris
good
knowledg
level
statist
analysi
perform
use
statist
packag
social
scienc
spss
program
version
first
object
demograph
factor
second
object
knowledg
level
analys
use
descript
analysi
third
object
associ
demograph
factor
knowledg
level
analys
use
simpl
logist
regress
variabl
simpl
logist
regress
p
valu
analyz
use
multipl
logist
regress
p
valu
set
statist
signific
result
major
particip
depart
accid
emerg
base
postgradu
year
year
account
major
particip
mean
sd
age
year
number
male
femal
particip
gender
nearli
balanc
respect
formal
train
attend
particip
mean
sd
work
experi
year
question
platelet
transfus
prophylaxi
procedur
correctli
answer
highest
percentag
particip
highest
percentag
particip
wrongli
answer
question
report
transfus
reaction
mean
score
sd
total
particip
obtain
poor
knowledg
level
signific
associ
found
demograph
factor
depart
gender
age
postgradu
year
work
experi
formal
train
knowledg
level
summari
conclus
gener
major
particip
poor
knowledg
level
clinic
transfus
result
consist
knowledg
base
studi
howev
signific
associ
found
demograph
factor
knowledg
level
thu
blood
transfus
servic
focu
collabor
respect
clinic
depart
conduct
continu
medic
educ
cme
session
special
base
train
improv
knowledg
clinic
transfus
among
postgradu
resid
factor
awar
attitud
might
associ
poor
knowledg
consid
test
well
intervent
studi
done
similar
group
particip
test
impact
educ
method
clinic
transfus
knowledg
freir
knight
iccbba
san
bernardino
unit
state
background
earli
cours
first
gulf
war
blood
unit
dispatch
mani
countri
combat
zone
lack
uniqu
identif
common
product
descript
duplic
donat
number
highli
variabl
label
design
differ
languag
caus
confus
increas
risk
error
associ
blood
transfus
strategi
improv
transfus
safeti
intern
task
member
isbt
aabb
american
red
cross
depart
defens
health
industri
manufactur
ask
design
intern
standard
code
label
system
consequ
isbt
standard
first
publish
world
health
assembl
approv
resolut
affirm
urgent
need
implement
global
consist
code
system
human
cell
tissu
organ
aim
understand
extent
adopt
intern
standard
code
label
countri
differ
categori
human
develop
past
year
method
iccbba
intern
databas
use
gener
list
countri
facil
regist
use
isbt
purpos
abstract
countri
categor
use
classif
accord
human
develop
index
hdi
unit
nation
develop
programm
high
hdi
high
hdi
medium
hdi
low
hdi
result
isbt
standard
adopt
facil
countri
across
categori
human
develop
present
facil
countri
world
adopt
standard
blood
transfus
servic
total
collect
center
transfus
world
regist
use
isbt
howev
data
show
signific
dispar
number
facil
per
categori
high
hdi
high
hdi
medium
hdi
low
hdi
trend
also
reflect
data
correspond
percentag
countri
facil
adopt
isbt
categori
high
hdi
high
hdi
medium
hdi
low
hdi
summari
conclus
year
first
public
isbt
standard
vision
intern
standard
code
label
blood
transfus
becom
realiti
predominantli
countri
assess
high
human
develop
unequ
adopt
standard
amongst
differ
categori
human
develop
minim
adopt
categori
rais
question
whether
necessari
develop
new
strategi
make
chang
trend
year
come
intern
cooper
nation
intern
polici
increas
support
softwar
develop
label
manufactur
well
use
emerg
technolog
field
inform
technolog
healthcar
may
creat
necessari
opportun
attain
global
standard
decis
improv
safeti
blood
transfus
everyon
bhatti
b
hermundstad
llohn
immunolog
transfus
medicin
akershu
univers
hospit
norway
background
environment
monitor
blood
bank
describ
regul
guidelin
environment
monitor
done
area
includ
accept
criteria
howev
clearli
defin
actual
regul
guidelin
council
europ
guid
prepar
use
qualiti
assur
blood
compon
pic
guid
good
manufactur
practic
medicin
product
nation
regul
base
interact
colleagu
norway
told
us
practic
environment
monitor
differ
nation
guidelin
unclear
aim
aim
studi
see
environment
monitor
perform
follow
blood
bank
norway
method
survey
sent
blood
bank
norway
follow
aspect
method
use
accept
criteria
accept
criteria
chosen
area
monitor
often
result
follow
rule
visitor
blood
compon
lab
result
two
method
use
norway
agar
plate
place
surfac
get
sampl
coloni
form
unit
cfu
calcul
incub
cmeasur
atp
given
surfac
area
measur
rel
light
unit
rlu
method
give
hygien
statu
surfac
area
blood
bank
use
hygiena
system
sure
plu
use
agar
plate
mainli
hygicult
tpc
orion
diagnostica
major
use
agar
plate
cfu
per
accept
limit
rest
accept
limit
cfu
per
case
techniqu
less
rlu
per
accept
criteria
blood
bank
follow
instruct
distribut
choos
accept
limit
other
establish
accept
criteria
validational
blood
bank
monitor
product
donat
area
major
monitor
storag
room
also
monitor
immunohematolog
lab
monitor
time
per
year
monitor
time
per
yearal
blood
bank
written
standard
oper
procedur
follow
result
correct
measur
taken
result
fail
accept
criteriath
major
allow
visitor
compon
lab
use
shoe
cover
lab
coat
blood
bank
special
requir
enter
use
adhes
doormat
reduc
dirt
product
room
summari
conclus
concret
requir
hygien
control
given
avail
guidelinescultiv
method
atp
base
method
usedaccept
criteria
vari
widelyfrequ
monitor
variesdiffer
rule
visitor
compon
labal
blood
bank
written
procedur
good
routinesour
survey
show
great
desir
establish
nation
recommend
andor
guidelin
environment
monitor
verma
p
negi
j
singh
singh
khan
transfus
medicin
max
super
special
hospit
vaishali
ghaziabad
india
background
blood
donor
counsel
confidenti
dialogu
blood
donor
train
counsellor
issu
relat
donor
health
donat
process
may
provid
blood
donat
worldwid
million
blood
donat
collect
annual
estim
million
unit
discard
due
presenc
marker
transfus
transmit
infect
tti
includ
hiv
hepat
b
hbv
hepat
c
hcv
syphili
scale
discard
deferr
underlin
import
public
health
inform
donor
educ
counsel
enabl
prospect
donor
may
unsuit
donat
blood
stage
donat
process
howev
mani
nation
blood
transfus
servic
recogn
import
blood
donor
counsel
aim
main
aim
case
studi
highlight
import
blood
donor
counsel
need
establish
counsel
system
individu
accept
blood
donor
method
studi
conduct
depart
transfus
medicin
retrospect
analyz
counsel
method
period
year
januari
decemb
total
blood
donor
counsel
done
four
stage
blood
donat
process
first
stage
inform
individu
regist
blood
donat
second
counsel
confidenti
interview
medic
histori
third
stage
counsel
blood
donat
last
stage
counsel
blood
donat
result
donor
confirm
posit
tti
test
result
turn
counsel
donor
provid
inform
mode
infect
transmiss
possibl
implic
donor
health
treatment
opportun
prevent
transmiss
need
inform
contact
might
risk
infect
test
treat
earli
possibl
strict
confidenti
person
inform
donor
test
result
ensur
time
seven
hiv
reactiv
blood
donor
refer
integr
counsel
test
centr
ictc
blood
donor
refer
sti
clinic
hepat
b
hepat
c
reactiv
donor
refer
gastroenterolog
depart
donor
also
inform
donat
blood
discard
defer
blood
donat
perman
summari
conclus
train
blood
donor
counsel
provid
staff
interact
prospect
current
blood
donor
includ
nurs
phlebotomist
doctor
donor
recruit
staff
laboratori
technician
volunt
purpos
train
blood
donor
counsel
provid
staff
necessari
knowledg
skill
conduct
counsel
effect
benefit
blood
transfus
servic
wider
health
system
implement
blood
donor
counsel
contribut
continuum
care
health
system
play
import
role
prevent
transmiss
infect
contribut
contain
epidem
reduc
diseas
burden
nation
health
system
ha
n
control
depart
nation
blood
transfus
servic
cairo
egypt
background
health
care
associ
infect
worldwid
problem
occur
across
point
health
care
deliveri
thu
fundament
infect
control
need
employ
regardless
constraint
resourc
support
fundament
essenti
protect
donor
patient
client
health
care
provid
exposur
infecti
microorgan
morbid
mortal
associ
agent
aim
implement
infect
control
standard
egyptian
blood
transfus
servic
ensur
prevent
control
associ
infectionsto
minim
occup
hazard
associ
deliveri
health
careto
promot
sound
infect
control
practic
focus
inject
safeti
safe
blood
transfus
method
infect
control
team
develop
action
plan
implement
infect
control
program
egyptian
nation
blood
transfus
servic
includ
maintain
appropri
infrastructur
ensur
avail
suppli
establish
effect
infect
control
practic
improv
occup
health
manag
system
develop
surveil
nosocomi
infect
train
health
care
provid
plan
review
updat
annual
infect
control
team
initi
formul
infect
control
standard
oper
procedur
distribut
one
central
region
blood
transfus
center
refer
egyptian
nation
infect
prevent
control
guidelin
polici
health
care
servic
well
american
associ
blood
bank
standard
standard
includ
infect
control
practic
concern
hand
hygien
wast
manag
person
protect
equip
safe
inject
prevent
needlestick
sharp
injuri
environment
clean
prophylaxi
asept
techniqu
reprocess
instrument
surveil
nosocomi
infect
face
emerg
ill
laboratori
work
instruct
dentistri
work
instruct
infect
control
team
provid
initi
train
guidanc
total
individu
includ
infect
control
offic
head
differ
depart
health
care
provid
nation
region
blood
center
period
assess
supervis
monitor
train
health
care
provid
well
annual
evalu
infect
control
program
perform
result
improv
infrastructur
regard
construct
hand
wash
basin
establish
central
steril
servic
area
reprocess
instrument
ensur
high
standard
decontamin
introduct
new
suppli
infect
control
dispos
apron
dispos
tourniquet
vaccin
coverag
health
care
provid
hepat
b
train
major
health
care
provid
statist
evalu
implement
infect
control
program
increas
increas
complianc
health
care
provid
infect
control
standard
summari
conclus
infect
control
necessari
compon
safe
high
qualiti
blood
suppli
infect
control
program
commit
prevent
advers
outcom
health
care
associ
infect
also
contribut
qualit
improv
blood
transfus
servic
w
h
z
center
zhejiang
provinc
hangzhou
china
manag
blood
center
zhejiang
provinc
hangzhou
china
background
edit
guid
prepar
use
qualiti
assur
blood
compon
releas
public
council
europ
novemb
edit
guid
contain
updat
comprehens
systemat
inform
relat
prepar
use
qualiti
assur
blood
compon
field
blood
transfus
blood
donat
law
peopl
republ
china
took
effect
sinc
ministri
health
moh
peopl
republ
china
develop
standard
relat
blood
transfus
drib
drab
construct
standard
system
china
still
infanc
aim
aim
studi
compar
differ
guid
prepar
use
qualiti
assur
blood
compon
publish
council
europ
standard
china
assess
statu
standard
system
relat
blood
transfus
china
method
march
chines
version
copyright
agreement
sign
freseniu
kabi
ag
edqm
may
year
freseniu
kabi
ag
author
blood
center
zhejiang
provinc
complet
work
translat
public
china
like
differ
guid
prepar
use
qualiti
assur
blood
compon
standard
relat
blood
transfus
china
estim
result
edit
guid
provid
standard
qualiti
safeti
collect
test
process
storag
distribut
use
human
blood
blood
compon
separ
three
section
first
section
entitl
good
practic
guidelin
contain
updat
version
good
practic
guidelin
fulli
reflect
recent
chang
good
manufactur
practic
relev
blood
establish
second
section
entitl
principl
encompass
background
inform
consid
form
polici
decis
thu
provid
third
section
entitl
standard
state
must
done
china
end
although
standard
issu
field
blood
transfus
basic
standard
system
cover
process
blood
collect
use
main
differ
follow
system
standard
method
ii
statist
process
control
iii
maneuver
integr
iv
social
econom
evalu
v
uniform
data
process
system
summari
conclus
develop
health
standard
system
chines
characterist
urgent
take
sever
effect
measur
china
includ
design
system
plan
coordin
learn
advanc
experi
adequ
educ
g
e
hospit
research
institut
ottawa
hospit
ottawa
canada
background
patient
blood
manag
pbm
multidisciplinari
approach
minim
patient
exposur
risk
associ
anemia
transfus
blood
product
patient
undergo
liver
resect
preoper
anemia
consist
associ
increas
risk
blood
transfus
increas
length
hospit
increas
risk
major
morbid
inferior
overal
surviv
addit
indic
anemia
periop
blood
transfus
may
associ
wors
oncolog
outcom
patient
undergo
resect
primari
metastat
malign
aim
object
work
identifi
miss
opportun
offer
preoper
blood
manag
patient
undergo
liver
resect
oncolog
indic
method
retrospect
review
medic
chart
conduct
patient
underw
liver
resect
oncolog
indic
one
tertiari
academ
hospit
includ
result
three
hundr
patient
underw
liver
resect
oncolog
indic
januari
may
median
time
surgic
consent
surgeri
day
time
consent
patient
recent
within
week
complet
blood
count
cbc
recent
test
blood
ferritin
vitamin
patient
patient
cbc
blood
ferritin
test
vitamin
test
time
consent
anemia
present
patient
patient
receiv
least
one
red
blood
cell
transfus
anemia
associ
increas
risk
transfus
p
summari
conclus
work
demonstr
patient
undergo
oncolog
liver
surgeri
one
tertiari
academ
hospit
adequ
cbc
ferritin
vitamin
level
avail
time
consent
identifi
lack
time
anemia
screen
may
repres
import
opportun
improv
applic
patient
blood
manag
intervent
popul
data
use
inform
valid
pbm
strategi
patient
requir
liver
resect
centr
r
e
g
blood
transplant
birmingham
blood
transplant
liverpool
unit
kingdom
background
provis
rare
phenotyp
may
requir
intern
collabor
nh
blood
transplant
nhsbt
uk
receiv
averag
nine
enquiri
per
month
potenti
provis
rare
red
cell
phenotyp
enquiri
origin
uk
abroad
nation
improv
initi
led
establish
central
databas
nation
request
provis
present
data
first
three
year
aim
provid
overview
demand
suppli
rare
red
cell
phenotyp
identifi
common
phenotyp
request
method
retrospect
review
perform
enquiri
nhsbt
rare
phenotyp
log
januari
decemb
enquiri
log
nhsbt
nation
frozen
blood
bank
nfbb
clinic
staff
intern
blood
group
refer
laboratori
result
nhsbt
receiv
total
enquiri
could
fulfil
enquiri
period
differ
countri
outsid
uk
order
gener
total
enquiri
enquiri
made
differ
phenotyp
commonest
enquiri
red
cell
enquiri
red
cell
enquiri
red
cell
enquiri
follow
r
r
countri
outsid
uk
commonest
enquiri
still
red
cell
one
two
enquiri
receiv
follow
phenotyp
dr
co
mcleod
mkmk
nhsbt
could
provid
red
cell
case
phenotyp
could
suppli
often
due
patient
specif
combin
antibodi
order
gener
order
fulfil
thaw
frozen
red
cell
liquid
unit
stock
donor
remaind
combin
three
red
cell
export
nhsbt
air
separ
order
differ
countri
outsid
uk
summari
conclus
request
rare
phenotyp
account
consider
proport
red
cell
demand
work
provid
overview
potenti
actual
suppli
use
inform
futur
plan
nhsbt
potenti
fulfil
major
request
rare
phenotyp
order
gener
enquiri
major
rare
blood
provid
thaw
unit
nfbb
limit
clinic
option
howev
order
fulfil
liquid
unit
provid
call
specif
donor
nhsbt
achiev
develop
maintain
loyal
pool
rare
blood
donor
manag
document
procedur
sn
nahirniak
h
blain
h
gerg
laboratori
medicin
patholog
alberta
health
servic
univers
alberta
edmonton
canada
background
canada
approxim
gener
popul
group
rh
neg
neg
request
nation
blood
supplier
neg
red
cell
rbc
approach
march
due
concern
regard
shortag
canada
nation
advisori
committe
blood
blood
product
nac
post
posit
paper
util
inventori
manag
group
rh
neg
red
cell
help
narrow
suppli
demand
gap
edmonton
zone
transfus
servic
largest
transfus
servic
countri
transfus
rbc
per
month
huge
impact
avail
nation
inventori
rbc
local
polici
alreadi
restrict
neg
unmatch
rbc
femal
age
year
unclear
area
improv
aim
improv
neg
red
cell
util
understand
possibl
inappropri
use
occur
method
number
nega
rbc
non
group
individu
extract
sunquest
laboratori
inform
system
two
time
period
one
prior
posit
paper
januari
juli
one
januari
number
rbc
broken
appropri
accord
nac
categori
mandatori
intrauterin
transfus
emerg
transfus
femal
childbear
potenti
gener
accept
non
neg
infant
less
year
age
group
specif
unit
avail
non
neg
patient
requir
phenotyp
match
antigen
neg
unit
group
specif
unit
unavail
like
unaccept
neg
male
femal
year
without
requir
larg
volum
transfus
unit
non
neg
patient
unit
close
expiri
plu
two
categori
confirmatori
blood
group
accept
inventori
stock
practic
like
unaccept
result
total
neg
rbc
transfus
neg
individu
categori
categori
categori
categori
categori
total
mandatori
accept
unaccept
rate
nac
paper
total
non
rbc
transfus
categori
categori
categori
categori
categori
mandatori
accept
unaccept
increas
categori
due
remot
alloc
provis
irradi
stock
unit
highest
proport
increas
summari
conclus
despit
consist
mandatori
plu
gener
accept
improv
like
unaccept
categori
identifi
still
signific
proport
inappropri
util
need
address
secondari
inventori
stock
practic
explicitli
discuss
nac
paper
impact
inventori
manag
remot
alloc
satellit
blood
fridg
rural
hospit
facil
need
discuss
develop
recommend
due
geographi
lessen
impact
limit
resourc
j
j
l
clsucalgari
medicin
calgari
lab
servic
calgari
canada
background
supplement
intraven
immun
globulin
ivig
enter
challeng
phase
consid
continu
annual
growth
limit
plasma
resourc
uptrend
cost
drive
health
author
come
plan
ensur
vigil
appropri
use
product
alberta
one
highest
ivig
user
canada
approach
issu
requir
robust
patient
data
registri
inform
system
manag
monitor
ivig
util
effect
aim
establish
structur
ivig
util
program
comprehens
databas
record
patient
demograph
multipl
clinic
laboratori
paramet
well
defin
clinic
categori
addit
essenti
report
system
capac
trend
recognit
reliabl
paramet
indic
enhanc
effici
patient
medic
manag
product
dispens
time
manner
method
patient
clinic
diagnos
regist
three
categori
primari
secondari
specif
diagnosi
allow
extract
precis
clinic
data
requir
patient
also
alloc
three
set
inpati
outpati
facilit
approv
process
product
dispens
period
clinic
mandat
local
nation
guidelin
ivig
util
data
use
rank
multipl
clinic
disciplin
total
ivig
usag
number
patient
disciplin
specif
diagnost
entiti
well
averag
ivig
usagepati
differ
set
also
develop
ivig
util
index
averag
disciplin
specif
annual
ivig
usag
patientmean
annual
ivig
usag
patient
compar
ivig
util
among
specif
disciplin
region
nation
level
unbias
reliabl
manner
data
regist
patient
receiv
ivig
demonstr
meaning
quarterli
trend
differ
clinic
disciplin
result
total
activ
patient
regist
ivig
databas
inpati
outpati
patient
account
respect
adult
neurolog
immun
defici
patient
pid
sid
account
major
regist
patient
respect
hematolog
patient
defici
rank
third
place
total
g
total
region
ivig
usag
neurolog
g
immun
defici
g
hematolog
g
itp
top
hematolog
indic
among
inpati
case
review
collabor
clinic
disciplin
case
label
appropri
ivig
util
index
calcul
disciplin
pleas
see
method
section
index
neurolog
immun
defici
hematolog
group
respect
summari
conclus
consist
reliabl
monitor
ivig
util
implement
clinic
ivig
guidelin
requir
robust
databas
inform
system
consid
fact
ivig
util
cz
consid
appropri
estim
save
potenti
multipl
measur
ivig
calcul
restrict
clinic
approv
process
exceed
current
annual
ivig
util
ivig
util
index
could
reliabl
indic
monitor
ivig
usag
major
clinic
disciplin
region
nation
level
l
w
l
j
c
j
medicin
laboratori
conserv
lakeridg
health
oshawa
medicin
program
uhn
medicin
program
sunnybrook
health
scienc
toronto
canada
background
prospect
audit
approv
paa
shown
result
decreas
transfus
rate
reduc
healthcar
cost
incid
transfus
reaction
appli
restrict
rbc
transfus
guidelin
prophylact
transfus
hgb
gl
singl
unit
transfus
inpati
strong
evid
base
support
practic
howev
efficaci
paa
question
aim
determin
initi
success
sustain
physician
revert
histor
order
practic
need
ongo
technologist
intervent
determin
effect
paa
use
hospit
establish
transfus
guidelin
tg
rbc
transfus
rate
first
year
screen
method
hospit
tg
larg
commun
site
institut
implement
paa
medic
laboratori
technologist
mlt
use
guidelin
implement
identifi
inappropri
transfus
order
indic
dose
process
phase
gradual
januari
juli
initi
weekday
inpati
transfus
simultan
widespread
educ
physician
nurs
technologist
perform
three
year
mlt
paa
retrospect
examin
annual
total
rbc
transfus
annual
transfus
mortal
rate
compar
hospit
baselin
year
includ
comparison
screen
phase
gradual
first
month
retrospect
audit
conduct
octob
determin
often
technologist
screen
alter
transfus
order
compar
audit
transfus
rate
oncolog
outpati
paa
implement
serv
control
result
first
year
screen
total
rbc
transfus
decreas
unit
compar
baselin
inpati
transfus
reduc
progress
reduct
subsequ
year
culmin
inpati
reduct
baselin
chang
overal
hospit
mortal
rate
throughout
period
week
pilot
audit
unit
order
inpati
unit
deem
outsid
hospit
guidelin
transfus
one
month
audit
octob
identifi
unit
deem
inappropri
total
inpati
rbc
order
demonstr
need
technologist
intervent
significantli
decreas
time
summari
conclus
efficaci
paa
decreas
transfus
rate
sustain
fact
becom
progress
less
interestingli
parallel
improv
seen
patient
popul
subject
paa
suggest
presenc
social
contagion
improv
transfus
practic
nonetheless
appear
ongo
benefit
continu
paa
inpati
rbc
order
still
deem
inappropri
upon
review
adopt
maintain
process
hospit
demonstr
sustain
continu
improv
rbc
util
transfus
practic
w
l
de
e
h
l
region
blood
coordin
network
ottawa
hospit
research
institut
ottawa
region
blood
coordin
network
mcmaster
univers
hamilton
region
blood
coordin
network
sunnybrook
hospit
toronto
canada
background
region
network
fund
ministri
health
care
mohltc
support
provinci
util
strategi
ontario
canada
time
ontario
hospit
transfus
servic
ontario
larg
geograph
area
one
million
popul
approxim
million
aim
ontario
region
blood
coordin
network
orbcon
establish
three
region
offic
provid
provinci
coverag
allow
region
specif
issu
address
goal
improv
commun
within
provinc
allow
identif
issu
concern
relat
blood
util
method
initi
staf
full
time
equival
fte
fte
ad
five
prioriti
goal
identifi
blood
util
educ
inventori
manag
commun
qualiti
improv
contact
first
establish
transfus
medicin
laboratori
hospit
annual
visit
schedul
collabor
blood
supplier
canadian
blood
servic
initi
focu
improv
blood
inventori
manag
standard
stock
decis
minim
wastag
educ
resourc
program
event
provid
encourag
standard
best
practic
healthcar
profession
involv
blood
transfus
audit
tool
creat
support
audit
blood
componentsproduct
safe
transfus
practic
provinci
scale
orbcon
facilit
develop
provinci
qualiti
improv
plan
qip
improv
use
red
blood
cell
rbc
ontario
result
initi
improv
inventori
manag
blood
ontario
hospit
includ
inventori
calcul
redistribut
program
benchmark
ontario
annual
rbc
outdat
reduc
unit
unit
annual
averag
provinci
platelet
outdat
rate
fell
time
period
audit
rbc
plasma
platelet
bedsid
transfus
check
improv
understand
appropri
use
product
help
accredit
complianc
increas
use
practic
wide
use
orbcon
bloodi
easi
seri
tool
distribut
past
month
provid
standard
guidanc
transfus
practic
earli
adopt
ontario
transfus
qip
report
improv
per
cent
singl
unit
rbc
transfus
baselin
summari
conclus
eleven
year
period
establish
orbcon
proven
coordin
region
network
model
effect
sustain
within
geographi
larg
divers
ontario
network
model
facilit
connect
remot
clinic
technic
hospit
staff
larger
centr
promot
share
inform
collabor
come
decad
orbcon
continu
work
healthcar
profession
ensur
patient
ontario
receiv
best
safest
possibl
care
come
transfus
blood
blood
product
l
lu
w
hong
shenzhen
blood
center
shenzhen
china
background
common
problem
blood
center
china
encount
first
season
insuffici
blood
suppli
china
blood
donat
mode
primari
way
collect
blood
strongli
affect
weather
condit
especi
cold
weather
high
temperatur
continu
typhoon
second
due
uncertainti
clinic
blood
use
throughout
year
could
time
inventori
blood
certain
type
goe
lower
ideal
amount
shenzhen
ever
sinc
voluntari
blood
donat
start
street
voluntari
blood
donat
main
mode
blood
collect
collect
blood
donat
supplementari
aim
solv
problem
season
insuffici
blood
suppli
shortag
certain
blood
type
explor
method
strategi
consist
follow
two
part
carri
seri
blood
donat
activ
winter
organ
red
action
summer
hold
thousand
chaoshang
blood
donat
blood
donat
month
angel
white
relat
activ
past
five
year
center
succeed
avoid
insuffici
blood
suppli
often
happen
winter
summer
carri
holiday
blood
collect
mode
make
best
use
holiday
throughout
year
includ
statutori
holiday
weekend
principl
plan
focu
open
motiv
forc
emphas
key
blood
donat
station
orderli
organ
uninterrupt
connect
volunt
staff
goal
improv
blood
inventori
within
day
remit
within
week
fulli
recov
within
week
blood
stock
goe
shortag
certain
blood
type
occur
also
strive
keep
daili
inventori
red
blood
cell
adequ
clinic
use
day
throughout
year
result
winter
event
red
action
shenzhen
lion
club
center
take
place
decemb
year
run
month
edit
event
number
blood
donat
help
club
reach
total
six
element
success
red
action
strong
organiz
structur
special
plan
servic
awar
attent
public
advanc
commun
inherit
good
intent
behind
blood
donat
first
thousand
chaoshang
blood
donat
launch
summer
end
peopl
particip
blood
donat
event
set
new
record
volum
donat
blood
via
collect
blood
donat
shenzhen
unbalanc
inventori
blood
type
case
februari
inventori
type
blood
effect
recov
within
week
reach
optim
volum
week
case
three
consecut
typhoon
septemb
led
shortag
red
blood
cell
type
howev
effici
recov
inventori
within
week
reach
optim
inventori
week
achiev
goal
maintain
daili
blood
inventori
suffici
clinic
use
day
throughout
whole
year
summari
conclus
event
red
action
thousand
chaoshang
blood
donat
show
systemat
social
linkag
voluntari
blood
donat
shenzhen
establish
sum
blood
donat
weekend
usual
bigger
sum
weekday
mean
weekend
holiday
critic
time
enhanc
blood
inventori
effici
f
j
c
c
qualif
servic
hospit
inventori
manag
canada
background
improv
safeti
platelet
plt
hq
modifi
process
bacteri
detect
octob
hq
introduc
h
delay
collect
sampl
plt
h
delay
incub
releas
plt
health
canada
approv
shelf
life
day
plt
octob
delay
sampl
h
plt
day
shelf
life
h
delay
ad
time
differ
manipul
inher
process
sampl
inocul
document
start
incub
ad
challeng
maintain
good
custom
servic
aim
establish
thorough
streamlin
workflow
laboratori
team
order
put
platelet
inventori
without
impair
remain
shelf
life
rsl
plt
give
time
hospit
transfus
method
plt
collect
day
week
fix
mobil
site
either
apheresi
whole
blood
time
collect
rang
pm
three
team
involv
process
bacteri
detect
laboratori
assist
la
product
lab
sampl
plt
laboratori
technician
regulatori
test
laboratori
inocul
result
report
la
label
depart
issu
plt
close
monitor
activ
perform
supervisor
streamlin
oper
delay
collect
readi
issu
plt
rsl
plt
sent
hospit
expiri
rate
hospit
monitor
result
laboratori
oper
monday
saturday
pm
plt
collect
saturday
thursday
sampl
inocul
monday
saturday
plt
collect
friday
sampl
inocul
monday
depend
inocul
time
plt
issu
day
inocul
morn
howev
plt
collect
thursday
late
day
issu
monday
morn
plt
collect
saturday
wednesday
readi
issu
h
collect
plt
collect
thursday
friday
mean
time
h
novemb
day
rsl
day
rsl
day
rsl
day
rsl
would
expir
day
sinc
decemb
rsl
day
rsl
day
rsl
day
rsl
day
rsl
would
expir
day
expiri
rate
hospit
data
period
summari
conclus
improv
safeti
plt
rais
sampl
time
h
ad
period
h
issu
plt
posit
impact
rsl
rsl
day
compar
furthermor
expiri
rate
reduc
hospit
e
g
w
j
monitor
evalu
busi
strategi
divis
blood
transfus
center
divis
gener
rwanda
biomed
center
kigali
rwanda
background
access
medic
product
mainli
hinder
failur
deliv
need
medicin
remot
area
due
challeng
environ
lack
adequ
transport
commun
short
shelf
life
product
suffici
suppli
chain
infrastructur
rwanda
partnership
ziplin
intern
inc
start
deliv
blood
product
health
facil
remot
area
use
drone
last
month
overcom
countri
challeng
topographi
bid
shorten
turnaround
time
order
receiv
blood
product
aim
aim
project
assess
drone
technolog
help
maxim
blood
blood
product
util
minim
blood
shortag
expiri
blood
suppli
chain
system
end
improv
patient
health
outcom
method
drone
deploy
rwanda
capac
serv
health
facil
within
kilomet
drone
port
project
start
one
drone
port
set
southern
provinc
muhanga
district
capabl
serv
health
facil
area
order
process
simpl
cheaper
quicker
one
health
facil
need
blood
product
lab
technician
send
whatsapp
messag
log
ziplin
order
websit
drone
also
known
zip
readi
go
ziplin
send
confirm
messag
zip
within
minut
destin
lab
technician
receiv
text
messag
drone
drop
packag
parachut
return
home
base
return
rwanda
ministri
health
pay
ziplin
fix
servic
fee
base
rate
plu
addit
bonu
base
perform
success
deliveri
end
month
result
project
launch
octob
one
year
implement
health
facil
current
order
receiv
blood
product
drone
system
blood
unit
deliv
health
facil
use
drone
system
health
facil
receiv
order
product
within
min
emerg
order
h
order
expiri
blood
product
estim
project
reduc
less
blood
product
commonli
use
short
shelf
life
platelet
plasma
reach
patient
need
time
increasingli
use
save
live
annual
health
facil
satisfact
blood
deliveri
demand
versu
suppli
risen
around
health
facil
use
drone
system
summari
conclus
drone
ziplin
abl
deliv
blood
product
health
facil
within
minut
receiv
request
move
demand
drone
deliveri
help
health
facil
store
less
blood
unlimit
access
suppli
need
need
promis
result
encourag
govern
rwanda
extend
project
cover
health
facil
kivipuro
h
sareneva
hospit
relat
depart
finnish
red
cross
blood
servic
helsinki
finland
background
finnish
red
cross
blood
servic
frcb
nationwid
blood
servic
provid
finland
respons
collect
test
process
distribut
blood
product
hospit
health
care
provid
recent
year
demand
blood
product
especi
rbc
decreas
finland
howev
time
usag
rhd
neg
neg
rbc
slightli
increas
approxim
percent
finnish
popul
neg
current
averag
demand
neg
rbc
challeng
blood
servic
ensur
adequ
suppli
avail
requir
aim
aim
studi
identifi
analyz
chang
usag
neg
rbc
method
analyz
hospit
transfus
data
data
includ
patient
blood
type
product
blood
type
compon
age
transfus
deliveri
inform
hospit
depart
inform
data
analyz
use
qlikview
busi
intellig
system
result
past
year
increas
demand
neg
rbc
compar
blood
type
observ
frcbc
studi
neg
rbc
product
transfus
approxim
transfus
neg
patient
howev
proport
indic
decreas
trend
neg
rbc
transfus
posit
patient
data
show
neg
rbc
transfus
emerg
ward
intens
care
unit
time
number
emerg
transfus
slightli
increas
rbcx
treatment
sickl
cell
patient
start
finland
begin
due
peopl
african
origin
rbc
use
blood
exchang
neg
howev
proport
neg
rbc
issu
patient
suffer
hemoglobinopathi
deliv
neg
rbc
median
age
neg
rbc
transfus
quit
high
clear
peak
usag
day
seem
neg
rbc
often
transfus
prevent
time
expiri
situat
abo
ident
product
would
avail
howev
smaller
hospit
locat
far
frcbc
need
suffici
target
inventori
neg
rbc
ensur
avail
product
emerg
situat
summari
conclus
detail
inform
constant
follow
usag
neg
rbc
util
frcb
ensur
suppli
neg
rbc
futur
draw
guidelin
prevent
overus
neg
rbcsbi
plan
phenotyp
strategi
blood
donor
across
abo
groupsbi
educ
hospit
customersbi
commun
hospit
via
custom
meet
newslett
etc
sent
frcb
j
j
p
gener
intern
medicin
depart
medicin
univers
toronto
region
blood
coordin
network
laboratori
medicin
molecular
diagnost
sunnybrook
health
scienc
centr
laboratori
medicin
pathobiolog
univers
toronto
toronto
canada
background
restrict
transfus
strategi
shown
equival
liber
transfus
strategi
term
mortal
morbid
outcom
major
clinic
trial
although
patient
blood
manag
program
reduc
transfus
rate
improv
patient
outcom
program
univers
appli
recent
provinc
wide
audit
frozen
plasma
fp
red
blood
cell
rbc
use
ontario
show
high
rate
inappropri
transfus
aim
primari
aim
compar
transfus
rate
rbc
fp
across
ontario
commun
hospit
activ
treatment
bed
secondari
aim
identifi
clinic
hospit
factor
may
account
differ
method
studi
retrospect
review
transfus
data
ontario
commun
hospit
rbc
fp
transfus
issu
data
acquir
canadian
blood
servic
data
warehous
acut
inpati
bed
day
annual
averag
number
activ
adult
treatment
bed
obtain
ministri
health
long
term
care
ontario
annual
transfus
rate
report
fp
rbc
unit
transfus
per
acut
inpati
day
aipd
use
descript
statist
trend
transfus
rate
time
determin
use
gener
linear
regress
poisson
distribut
rate
blood
compon
use
correl
size
hospit
use
linear
regress
final
rate
rbc
transfus
correl
rate
fp
transfus
use
linear
regress
result
decreas
rate
rbc
fp
use
time
p
fp
p
rbc
wide
rang
variat
amongst
hospit
averag
number
fp
unit
transfus
unit
per
aipd
respect
averag
number
rbc
unit
transfus
unit
per
aipd
respect
larger
hospit
associ
significantli
higher
fp
transfus
rate
p
year
howev
correl
rbc
transfus
rate
size
hospit
high
rbc
transfus
rate
associ
high
fp
transfus
rate
fiscal
year
p
year
summari
conclus
may
cultur
differ
differ
institut
contribut
variat
transfus
rate
across
ontario
commun
hospit
character
transfus
practic
understand
institut
cultur
surround
blood
compon
use
hope
lead
qualiti
improv
qi
initi
aim
creat
better
guidelin
educ
transfus
order
entri
system
data
serv
baselin
highlight
site
practic
qi
initi
may
benefici
potenti
replic
jurisdict
borg
sousa
p
cstlisboa
ipst
lisboa
portug
background
portugues
institut
blood
transplant
ipst
ip
respons
ensur
regul
transfus
medicin
transplant
activ
nation
level
concern
donat
collect
analysi
process
preserv
storag
distribut
blood
compon
organ
tissu
cell
human
origin
high
standard
qualiti
safeti
ipstip
collect
approxim
nation
whole
blood
donat
wb
tree
blood
center
locat
north
center
south
portug
lisbon
south
region
blood
center
cst
lisboa
collect
unit
wb
nearli
nation
collect
issu
accord
demand
consequ
depend
cst
lisboa
carri
blood
collect
analyt
studi
process
storag
distribut
blood
compon
nation
health
system
public
privat
hospit
protocol
establish
cst
lisboa
hospit
allow
return
blood
compon
within
day
expir
shelf
life
aim
identifi
cst
lisbon
custom
highest
red
blood
cell
concentr
rbc
return
rate
accord
aborh
blood
group
evalu
neg
impact
stock
manag
rbc
wastag
method
cst
lisbon
custom
consist
hospit
clinic
public
n
privat
n
wide
rang
dimens
small
clinic
larg
tertiari
care
hospit
data
obtain
informat
system
asi
analyz
per
type
custom
public
versu
privat
blood
group
wastag
accord
rbc
return
rate
custom
group
class
result
rbc
issu
hospit
return
global
wastag
rate
expir
shelf
life
first
class
return
rate
zero
client
rate
rang
return
return
rate
total
rbc
wastag
ab
rh
rh
ab
rbc
inventori
never
issu
point
return
rbc
public
hospit
discard
expir
ab
rh
rh
ab
discard
rbc
return
privat
hospit
ab
rh
rh
rh
public
institut
transfus
total
rb
demand
return
rate
higher
privat
hospit
highest
return
rate
reach
privat
return
rate
first
time
client
summari
conclus
clear
differ
return
rate
privat
public
custom
wastag
rbc
shelf
life
return
highli
influenc
return
rbc
polici
b
h
medicin
institut
nation
health
insur
servic
ilsan
hospit
goyang
medicin
sever
hospit
yonsei
univers
colleg
medicin
seoul
republ
korea
background
red
blood
cell
rbc
transfus
process
patient
periop
bleed
transfus
caus
advers
event
maximum
surgic
blood
order
schedul
msbo
use
rbc
product
prepar
elect
surgeri
aim
aim
investig
recent
statu
rbc
usag
elect
surgeri
suggest
univers
applic
guidelin
regard
amount
rbc
unit
variou
surgic
procedur
base
repres
nationwid
cohort
data
method
analyz
number
rbc
unit
use
hospit
patient
underw
surgic
procedur
use
nation
health
insur
sampl
cohort
data
includ
total
case
select
oper
result
rbc
unit
use
case
total
rbc
unit
transfus
averag
unit
per
patient
overal
averag
unit
per
case
receiv
rbc
transfus
addit
rbc
unit
transfus
femal
rbc
unit
transfus
patient
age
older
rbc
unit
use
often
orthoped
surgeri
follow
gener
surgeri
vascular
surgeri
number
oper
perform
cohort
increas
averag
rbc
unit
use
per
oper
also
increas
unit
unit
summari
conclus
continu
transfus
manag
need
effici
util
blood
period
revis
polici
regard
use
blood
product
nationwid
studi
could
suggest
practic
guidelin
applic
variou
elect
surgic
oper
bonheur
children
hospit
patholog
univers
tennesse
health
scienc
center
memphi
unit
state
background
platelet
inventori
manag
histor
present
challeng
hospit
transfus
servic
due
short
compon
intern
commun
mechan
achiev
platelet
expir
exist
time
unit
state
platelet
norm
fda
recent
approv
bacteri
detect
safeti
measur
allow
platelet
expir
perform
test
platelet
pgd
test
verax
biomed
inc
describ
numer
us
hospit
knowledg
descript
implement
pediatr
institut
pediatr
platelet
inventori
manag
complex
due
major
transfus
aliquot
repres
small
fraction
platelet
unit
aim
describ
implement
pgd
test
le
bonheur
children
hospit
pediatr
hospit
level
trauma
center
memphi
tennesse
given
hospit
tradit
high
rate
platelet
expir
implement
seen
opportun
improv
inventori
manag
method
data
gather
period
platelet
receiv
januari
septemb
descript
statist
regard
platelet
transfus
expir
compar
period
includ
platelet
receiv
octob
januari
platelet
product
consist
entir
apheresi
unit
unit
consid
expir
reach
outdat
prior
transfus
access
aliquot
prepar
reason
wastag
includ
among
outdat
unit
unit
return
blood
center
transfer
anoth
hospit
includ
analysi
result
period
receiv
apheresi
platelet
unit
unit
expir
prior
use
platelet
unit
receiv
transfus
full
aliquot
prepar
unit
unit
wast
reason
period
receiv
apheresi
platelet
unit
unit
expir
prior
use
period
unit
transfus
full
aliquot
prepar
unit
unit
wast
reason
period
platelet
unit
pgd
test
unit
test
unit
test
twice
total
test
estim
spent
test
test
unit
use
transfus
repres
approxim
save
addit
outdat
unit
provid
addit
day
platelet
stock
estim
amount
addit
cost
avoid
summari
conclus
describ
success
implement
pgd
test
achiev
outdat
apheresi
platelet
pediatr
hospit
period
demonstr
decreas
platelet
expir
allow
addit
platelet
unit
use
transfus
estim
total
save
improv
made
logist
pgd
test
achiev
greater
effici
experi
serv
model
pediatr
institut
estim
impact
pgd
test
inventori
manag
hand
implement
result
increas
platelet
avail
also
decreas
cost
improv
patient
safeti
hm
c
p
c
medicin
dalhousi
univers
hematopatholog
blood
transfus
servic
queen
elizabeth
ii
health
scienc
center
capit
district
health
author
inform
system
manag
laboratori
depart
izaak
walton
killam
hospit
halifax
canada
background
definit
childbear
age
import
guid
transfus
therapi
instanc
current
nation
intern
guidelin
recommend
transfus
blood
femal
childbear
potenti
standard
care
although
age
limit
defin
childbear
potenti
univers
defin
static
menopaus
determin
natur
physiolog
limit
guidelin
defin
age
younger
other
defin
age
even
cutoff
limit
aim
studi
conduct
evalu
kinet
childbear
age
major
tertiari
matern
hospit
iwk
provinc
nova
scotia
canada
examin
dynam
pattern
trend
relat
childbear
age
may
aris
chang
societi
ie
delay
childbear
inform
childbear
age
static
dynam
method
retrospect
analysi
data
year
age
discharg
deliv
postpartum
patient
januari
decemb
conduct
data
queri
laboratori
inform
system
li
iwk
hospit
locat
halifax
nova
scotia
variabl
includ
qualiti
assur
dataset
data
plot
heat
map
proport
age
deliveri
tabl
chart
analyz
statist
mean
minimum
maximum
age
discharg
standard
deviat
year
result
total
patient
includ
studi
studi
period
mean
age
discharg
deliveri
increas
gradual
year
year
maximum
age
discharg
rang
year
maximum
age
discharg
show
pattern
higher
recent
year
notic
maximum
age
women
deliveri
year
younger
rang
year
howev
beyond
maximum
age
higher
rang
year
total
number
women
age
year
older
deliveri
annual
rate
women
age
year
older
deliveri
rang
mean
minimum
age
deliveri
chang
year
well
earlier
year
minimum
age
year
compar
recent
year
minimum
age
deliveri
year
standard
deviat
age
discharg
year
rang
mean
summari
conclus
data
reveal
recent
trend
increas
age
women
time
deliveri
even
though
guidelin
consid
cutoff
age
limit
year
childbear
age
gradual
increas
maximum
age
women
deliveri
may
indic
need
cutoff
futur
j
molecular
laboratori
american
red
cross
rare
donor
program
american
rare
donor
program
refer
laboratori
american
red
cross
philadelphia
unit
state
background
american
rare
donor
program
facilit
meet
rare
blood
request
amongst
member
american
red
cross
center
american
red
cross
use
rbc
genotyp
african
american
aa
ethnic
minor
blood
donor
aid
identif
donor
unit
lack
multipl
rare
blood
group
antigen
aim
examin
request
red
cell
unit
rare
antigen
phenotyp
common
individu
african
descent
determin
frequenc
genotyp
donor
pool
american
red
cross
compar
expect
ethnic
popul
frequenc
data
method
period
distinct
request
made
american
rare
donor
program
phenotyp
rare
red
cell
unit
request
phenotyp
could
identifi
via
rbc
genotyp
phenotyp
k
antigen
neg
c
e
k
antigen
neg
lack
fya
fyb
lack
jkb
lack
one
antigen
neg
phenotyp
includ
jsa
kpa
doa
cw
phenotyp
frequenc
predict
base
report
frequenc
caucasian
black
reid
et
al
blood
group
antigen
factsbook
compar
frequenc
identifi
rbc
genotyp
nearli
primarili
aa
blood
donor
rarefind
script
agena
bioscienc
use
talli
specif
predict
phenotyp
entir
cohort
well
subset
donor
lack
c
e
k
comparison
includ
abo
rhd
result
phenotyp
common
black
case
occurr
rate
request
phenotyp
roughli
doubl
cohort
compar
full
cohort
genotyp
donor
frequenc
rang
low
fy
jk
high
fy
black
ten
rare
phenotyp
predict
found
less
caucasian
phenotyp
highest
frequenc
caucasian
fy
jk
four
type
predict
found
black
fy
without
fyb
jkb
cw
antigen
summari
conclus
red
blood
cell
rare
phenotyp
base
neg
statu
combin
common
antigen
blood
group
system
rh
k
fy
jk
mn
describ
request
american
rare
donor
program
often
phenotyp
found
black
phenotyp
exceedingli
rare
caucasian
rbc
genotyp
aa
donor
aid
identif
rare
donor
data
show
still
challeng
meet
need
alloimmun
african
american
patient
even
american
red
cross
screen
donor
sinc
test
donor
preferenti
higher
number
donor
rare
phenotyp
identifi
p
robillard
gregoir
montreal
canada
background
age
popul
develop
countri
made
blood
banker
predict
increas
blood
util
decad
ago
howev
mani
experienc
declin
demand
red
blood
cell
rbc
data
compon
like
platelet
plt
plasma
lack
popul
level
aim
describ
recent
trend
epidemiolog
blood
compon
transfus
provinc
quebec
canada
popul
million
method
quebec
blood
bank
computer
softwar
manag
umbrella
quebec
health
ministri
qhm
allow
central
extract
transfus
data
hq
sole
blood
supplier
provinc
data
transfus
year
extract
qhm
match
hq
databas
product
calcul
age
product
transfus
popul
denomin
extract
censu
data
publish
institut
de
la
statistiqu
du
sa
softwar
use
conduct
descript
analys
rate
present
per
inhabit
result
number
rbc
transfus
steadili
declin
unit
rate
rate
declin
period
femal
male
rate
rbc
transfus
declin
significantli
age
group
except
pediatr
popul
plt
transfus
continu
declin
period
increas
rate
rate
femal
male
differ
present
age
group
plasma
transfus
rate
declin
declin
present
age
group
gender
summari
conclus
despit
alreadi
low
rbc
transfus
rate
compar
intern
figur
uk
franc
netherland
demand
rbc
continu
decreas
seem
signific
chang
transfus
practic
floor
transfus
rate
appear
reach
demand
plt
plasma
also
declin
year
except
blip
plt
w
j
p
r
region
blood
coordin
network
health
scienc
centr
toronto
canada
background
retrospect
audit
conduct
ontario
region
blood
coordin
network
orbcon
platelet
order
particip
ontario
hospit
januari
april
ontario
hospit
invit
particip
audit
aim
primari
outcom
audit
appropri
platelet
transfus
particip
site
ontario
secondari
outcom
includ
percent
appropri
type
transfus
prophylact
prophylact
therapeut
bleed
patient
locat
medic
servic
method
data
collect
retrospect
train
materi
provid
design
individu
collect
data
site
ensur
uniform
definit
data
collect
includ
patient
demograph
age
sex
use
medic
anticoagul
pre
post
platelet
transfus
count
order
respons
physician
specialti
locat
transfus
indic
transfus
prophylact
prophylact
prior
procedur
therapeut
bleed
platelet
dose
order
physician
dose
administ
bleed
defin
minor
grade
bleed
major
bleed
grade
appropri
criteria
base
modifi
version
publish
etchel
et
al
vox
sang
adjud
perform
duplic
independ
either
comput
algorithm
one
human
adjud
two
individu
adjud
comput
algorithm
could
adjud
transfus
comput
algorithm
develop
use
excel
formula
order
use
techniqu
discrep
review
resolv
consensu
categor
variabl
summar
frequenc
percentag
continu
variabl
mean
standard
deviat
sd
median
rang
iqr
data
skew
agreement
adjud
assess
use
kappa
statist
result
total
hospit
site
voluntarili
particip
audit
captur
provinci
platelet
transfus
activ
total
order
order
use
excel
formula
preliminari
data
analysi
order
show
primari
indic
order
platelet
order
prophylaxi
bleed
plan
procedur
order
therapeut
current
bleed
order
prophylaxi
invas
procedur
summari
conclus
use
autom
adjud
techniqu
significantli
reduc
amount
time
need
manual
adjud
audit
order
howev
techniqu
could
use
order
manual
adjud
current
complet
remain
platelet
order
could
excel
formula
detail
audit
result
follow
shirmohammadi
lab
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
islam
republ
iran
shiraz
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
islam
republ
iran
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
iran
islam
republ
iran
english
languag
teach
ahvaz
branch
islam
azad
univers
ahvaz
islam
republ
iran
background
blood
transfus
play
vital
role
disast
blood
donor
manag
disast
save
blood
suppli
reduc
unnecessari
blood
donat
blood
discard
well
prevent
occur
blood
suppli
shortag
far
blood
transfus
servic
fbt
second
common
blood
donat
iran
aim
determin
effect
kermanshah
earthquak
blood
donat
suppli
safeti
method
blood
donat
rate
seroposit
transfus
transmit
infect
tti
demograph
characterist
donor
compar
two
similar
period
period
nov
period
nov
far
blood
transfus
servic
fbt
result
analyz
use
spss
softwar
result
overli
donor
admit
fbt
first
period
includ
first
time
laps
regular
respect
donor
defer
donat
second
period
donor
admit
defer
femal
donor
significantli
increas
earthquak
similarli
first
time
donor
increas
moreov
temporari
perman
deferr
increas
respect
five
blood
donor
per
confirm
tti
earthquak
period
comparison
one
blood
donor
per
posit
tti
previou
period
summari
conclus
find
show
natur
disast
great
effect
donor
recruit
provid
blood
suppli
safeti
blood
may
threaten
admiss
inappropri
donor
strict
donor
select
criteria
algorithm
disast
recommend
guarante
blood
safeti
well
educ
program
donor
counsel
first
time
donor
becom
laps
repeat
blood
donor
highli
recommend
h
siti
maryuningsih
mega
blood
centr
indonesian
red
cross
indonesian
red
cross
lumajang
east
java
provinc
blood
servic
committe
ministri
health
republ
indonesia
jakarta
blood
center
indonesian
red
cross
lumajang
district
indonesia
background
blood
transport
play
key
role
blood
safeti
efficaci
uncontrol
blood
temperatur
handl
transport
caus
damag
blood
cell
impact
patient
treatment
establish
hospit
blood
bank
everi
hospit
mandat
ministri
health
moh
decre
effici
need
blood
hospit
limit
lumajang
small
district
east
java
provinc
popul
delay
blood
distribut
transfus
uncertain
qualiti
blood
receiv
complain
five
among
six
hospit
obtain
blood
lumajang
blood
centr
bc
aim
evalu
impact
innov
blood
transport
system
decreas
hospit
complaint
blood
distribut
method
retrospect
observ
data
blood
servic
complaint
hospit
result
blood
distribut
lumajang
bc
hospit
involv
patient
famili
practic
caus
hospit
complaint
delay
blood
distribut
uncertain
qualiti
blood
receiv
problem
impact
delay
patient
treatment
lengthen
treatment
period
lumajang
bc
introduc
blood
transport
system
use
motorcycl
equip
simpl
cool
box
hospit
complaint
delay
distribut
decreas
complaint
uncertain
qualiti
blood
receiv
still
remain
moh
decre
insist
everi
hospit
set
hospit
blood
bank
hbb
function
store
prepar
blood
transfus
lumajang
district
hospit
set
hbb
howev
five
hospit
set
hbb
effici
limit
blood
need
unit
per
hospit
per
day
situat
forc
lumajang
bc
improv
blood
transport
system
set
blood
jek
transport
system
system
involv
train
bc
staff
handl
monitor
blood
temperatur
transport
use
special
design
motorcycl
equip
standard
blood
cool
box
temperatur
monitor
blood
jek
blood
blood
compon
reach
hospit
time
good
condit
term
jek
inspir
gojek
motorcycl
transport
method
popular
indonesia
last
year
solv
traffic
jam
problem
hospit
complain
blood
distribut
qualiti
significantli
decreas
afterward
blood
jek
system
win
public
servic
innov
contest
provinci
level
summari
conclus
uncontrol
blood
temperatur
handl
transport
impact
patient
treatment
establish
hbb
effici
blood
need
low
blood
jek
standard
blood
transport
system
decreas
hospit
complain
blood
distribut
small
district
area
v
e
e
l
center
mother
teresa
tirana
albania
background
frequenc
thalassemia
carrier
countri
sinc
import
step
taken
albania
improv
treatment
thalassemia
patient
educ
gener
popul
prevent
last
year
notic
increas
blood
demand
thalassemia
patient
match
need
becom
challeng
blood
servic
yearli
blood
suppli
goe
cover
need
thalassemia
patient
aim
evalu
age
distribut
thalassemia
patient
regularli
transfus
tirana
blood
demand
accord
age
group
method
analyz
retrospect
data
age
distribut
blood
use
thalassemia
patient
transfus
nbtc
data
extract
regist
nbtc
tirana
divid
thalassemia
patient
age
group
year
old
yo
order
observ
age
distribut
blood
demand
well
overal
life
expect
new
infant
born
last
ten
year
result
total
number
thalassemia
patient
regularli
transfus
nbtc
femal
male
accord
age
group
patient
respect
age
group
yo
yo
yo
yo
lack
patient
yo
decreas
number
patient
age
group
yo
compar
yo
group
demonstr
low
life
expect
thalassemia
patient
countri
import
mention
patient
yo
treat
center
also
observ
blood
need
increas
significantli
age
averag
blood
usepati
accord
age
group
unitspatientyear
respect
age
group
yo
yo
yo
yo
constant
increas
blood
demand
thalassemia
patient
grow
base
data
calcul
everi
ten
year
increas
blood
demand
thalassemia
patient
popul
signific
decreas
new
infant
born
last
ten
year
compar
previou
decad
summari
conclus
improv
treatment
thalassemia
patient
blood
compon
also
chelat
therapi
servic
implement
sinc
significantli
increas
life
expect
popul
patient
constantli
increas
way
blood
demand
decreas
new
infant
born
last
decad
demonstr
posit
influenc
prevent
awar
campaign
still
import
step
need
taken
complet
control
new
infant
born
prevent
strategi
base
awar
educ
also
screen
genet
counsel
prenat
diagnosi
urgent
need
order
control
disord
affect
proport
popul
strain
resourc
avail
blood
medicin
product
special
servic
j
kelley
f
martinez
laboratori
medicin
univers
texa
md
anderson
cancer
center
houston
unit
state
background
patient
blood
manag
pbm
program
reli
metric
analyz
transfus
practic
optim
resourc
util
metric
suggest
certif
organ
joint
commiss
aabb
often
benchmark
institut
use
guid
develop
medic
practic
financi
decis
exampl
suggest
metric
includ
crossmatch
transfus
ratio
respons
transfus
patient
outcom
data
relat
length
stay
hospit
acquir
infect
well
commonli
follow
metric
blood
usag
depart
monitor
transfus
reaction
aim
aim
appli
suggest
metric
certif
standard
data
institut
comprehens
cancer
center
unit
state
provid
benchmark
compar
verifi
util
less
wide
follow
metric
method
extract
two
year
data
laboratori
inform
system
cerner
millennium
kansa
mo
electron
health
record
epic
system
verona
wi
use
sap
busi
intellig
tool
microsoft
accessexcel
analyz
transfus
practic
patient
outcom
guid
develop
perform
improv
initi
pbm
program
activ
approv
institut
qualiti
improv
advisori
board
result
analyz
data
transfus
blood
product
patient
periop
crossmatch
transfus
ratio
hemoglobin
level
patient
receiv
rbc
transfus
increas
averag
gdl
unit
gdl
unit
platelet
level
increas
averag
follow
dose
protim
pt
decreas
per
unit
thaw
plasma
transfus
fibrinogen
increas
averag
mgdl
per
unit
cryoprecipit
transfus
term
length
inpati
stay
lo
patient
averag
day
per
admiss
transfus
patient
averag
lo
day
patient
receiv
transfus
averag
day
lo
compar
rate
hospit
acquir
infect
transfus
found
patient
hospit
acquir
ha
infect
also
transfus
admiss
howev
transfus
patient
develop
ha
infect
transfus
patient
ha
infect
case
due
organ
could
potenti
associ
transfus
donor
exposur
summari
conclus
mani
metric
suggest
accredit
organ
may
less
inform
measur
appropri
util
blood
product
may
appli
specif
popul
oncolog
patient
exampl
high
rate
transfus
patient
ha
infect
may
reflect
transfus
ha
infect
correl
patient
sever
exposur
health
care
system
rather
caus
link
two
variabl
similarli
length
stay
transfus
use
independ
reflect
sever
rather
relationship
two
variabl
howev
widespread
metric
also
includ
pbm
standard
transfus
usag
servic
line
track
advers
event
eg
suspect
transfus
reaction
may
guid
perform
improv
effort
addit
work
need
see
suggest
metric
report
influenc
practic
l
w
l
region
blood
coordin
network
ottawa
region
blood
coordin
network
hamilton
region
blood
coordin
network
ontario
toronto
health
partner
credit
valley
hospit
mississauga
health
care
oakvil
trafalgar
memori
hospit
oakvil
canada
background
provinci
outdat
rate
rbc
ontario
sinc
decreas
unit
unit
ontario
region
blood
coordin
network
orbcon
introduc
redistribut
toolkit
compon
hospit
choic
use
valid
ship
contain
provid
either
orbcon
canadian
blood
servic
cb
orbcon
partner
factor
concentr
redistribut
program
fcrp
creat
provinci
monitor
redistribut
program
factor
concentr
product
plasma
protein
product
cb
announc
would
phase
ship
contain
use
ship
blood
new
ship
contain
would
avail
use
hospit
program
jeopardi
valid
ship
contain
readili
hospit
aim
ensur
provinci
redistribut
program
continu
valid
contain
avail
hospit
ship
blood
patient
transfer
one
facil
anoth
method
provinci
work
group
review
process
ship
contain
evalu
document
use
ship
compon
product
perform
environment
scan
equip
avail
ice
gel
pack
courier
system
blood
supplier
support
provinci
program
ship
contain
valid
two
hospit
partner
ensur
contain
perform
accept
standard
result
valid
result
ship
contain
set
tone
updat
process
procedur
eighti
hospit
respond
report
access
freezer
provid
temperatur
survey
identifi
freezer
temperatur
ice
pack
help
develop
pack
configur
valid
test
result
valid
ship
contain
review
accept
time
transit
establish
provinci
redistribut
toolkit
updat
includ
oper
procedur
ship
blood
compon
product
report
near
expir
blood
product
ship
form
memorandum
understand
mou
implement
ontario
hospit
ship
blood
compon
product
orbconfcrp
ensur
commit
program
standard
requir
ship
blood
compon
product
transfer
rbc
hospit
increas
unit
approxim
transfer
unit
identifi
redistribut
averag
annual
cost
save
million
averag
vial
plasma
protein
product
redistribut
within
provinc
averag
cost
save
million
per
year
summari
conclus
loss
readili
avail
valid
ship
contain
transfer
hospit
redistribut
send
product
patient
would
signific
loss
save
product
money
provinc
revis
redistribut
program
valid
ship
contain
maintain
orbcon
fcrp
ensur
program
continu
provid
save
abstract
withdrawn
g
c
c
j
c
donat
french
blood
servic
pari
donat
french
blood
servic
besancon
donat
french
blood
servic
lill
depart
suppli
laboratori
french
blood
servic
pari
franc
background
granulocyt
transfus
except
less
product
patient
per
year
patient
concern
sever
bacteri
fungal
infect
therapeut
effici
difficult
evalu
accord
sever
hematolog
diseas
chemotherapi
aplasia
granulocyt
short
life
span
appoint
collect
donor
must
perform
short
delay
clinician
request
aim
provid
apheresi
granulocyt
concentr
agc
throughout
french
territori
nation
support
blood
donor
center
pari
area
ensur
secur
process
donor
safeti
compli
timelin
ensur
qualiti
product
volum
ml
granulocyt
count
ensur
dispon
product
short
delay
h
end
collect
method
french
blood
servic
ef
public
nation
organ
provid
nation
blood
donor
databas
nation
donor
voluntari
unrel
ef
call
donor
previous
inform
identifi
specif
code
facilit
convoc
emerg
regulatori
requir
age
maximum
frequenc
month
donat
interv
donat
week
minimum
weight
kg
adequ
venou
access
manag
collect
process
perform
accord
nation
procedur
prescript
donor
select
criteria
safeti
instruct
stimul
corticoid
heparin
use
collect
process
apheresi
devic
harmon
ef
give
expert
transfus
advic
assist
prescrib
guidanc
indic
qualiti
risk
specif
blood
product
inform
concern
donor
risk
given
inform
consent
obtain
discuss
consensu
physician
charg
patient
daili
follow
patient
transfus
need
accord
clinic
evolut
done
suppli
transport
logist
major
import
manag
transport
variou
site
within
region
transfus
site
et
daili
challeng
result
last
two
year
donat
collect
donor
donor
given
agc
patient
pediatr
receiv
agc
patient
treatment
clinician
request
hospit
mean
unit
transfus
median
four
patient
chronic
granulomatosi
diseas
cgd
other
patient
sever
neutropenia
absolut
neutrophil
count
cell
per
occur
acut
leukemia
immun
defici
idiopath
aplasia
patient
sever
infect
cellul
perin
other
fungal
infect
digest
infect
agc
qualiti
defin
mean
pnn
per
product
summari
conclus
administr
healthi
donor
author
franc
use
corticoid
question
despit
lack
scientif
evid
real
clinic
effect
request
hematologist
persist
sinc
ef
launch
studi
order
prepar
granulocyt
whole
blood
prepar
nhsbt
studi
still
go
abstract
withdrawn
j
w
health
afghanistan
ministri
health
aatm
afghanistan
countri
chapter
kabul
afghanistan
health
arizona
state
univers
phoenix
unit
state
background
year
strife
blood
suppli
afghanistan
limit
lack
central
coordin
less
optim
qualiti
aim
earli
afghanistan
nation
blood
safeti
transfus
servic
anbst
establish
respons
blood
bank
transfus
servic
nationwid
previous
exist
infrastructur
necessari
develop
entir
organ
process
object
provid
safe
qualiti
adequ
blood
equit
manner
peopl
resid
afghanistan
qualiti
nation
blood
servic
compliant
intern
standard
method
capabl
director
appoint
support
provid
parliament
nato
forc
us
canadian
embassi
relationship
extern
expert
establish
polici
establish
infrastructur
strengthen
capabl
staff
acquir
train
standard
oper
procedur
develop
test
improv
qualiti
system
establish
thirti
train
held
blood
center
staff
four
formal
train
held
physician
nurs
andor
midwiv
laboratori
technician
donor
recruit
program
establish
seven
region
center
establish
new
facil
construct
staff
establish
kabul
central
blood
bank
technic
staff
seven
kabul
hospit
branch
region
blood
bank
three
medic
offic
base
kabul
medic
offic
pharmacist
formal
train
transfus
first
time
afghanistan
blood
safeti
histori
blood
collect
drive
held
insid
nato
compound
canadian
embassi
good
advocaci
promot
voluntari
blood
collect
drive
creat
insid
outsid
countri
blood
safeti
servic
result
standard
donor
histori
form
creat
qa
program
establish
elisa
test
infecti
agent
introduc
blood
safeti
servic
promot
expos
conduct
blood
collect
drive
afghan
presid
offic
prior
establish
anbst
unit
whole
blood
collect
unit
whole
blood
collect
thu
sinc
anbst
format
blood
collect
increas
increas
summari
conclus
despit
consider
difficulti
effect
nation
blood
system
establish
afghanistan
function
success
illustr
huge
increas
blood
collect
capabl
staff
r
niyibizi
gitega
region
blood
transfus
center
burundi
ministri
health
gitega
burundi
background
burundi
east
african
low
incom
countri
popul
current
close
eleven
million
high
densiti
inhabit
per
squar
kilomet
avail
suffici
good
qualiti
blood
compon
remain
public
health
issu
look
upon
burden
malaria
malnutrit
gynecolog
obstetr
complic
within
nation
context
sinc
establish
nation
blood
transfus
center
locat
capit
bujumbura
sole
compet
institut
collect
deliv
blood
product
hospit
throughout
countri
caus
mani
challeng
four
region
blood
transfus
center
creat
within
framework
decentr
transfus
servic
aim
aim
studi
assess
impact
transfus
servic
decentr
blood
suppli
burundi
method
retrospect
studi
done
use
nation
region
blood
transfus
center
report
statist
analysi
perform
volum
blood
suppli
result
blood
unit
collect
nation
blood
transfus
center
sinc
transfus
servic
effect
decentr
total
volum
blood
unit
collect
steadili
grew
moment
contribut
region
blood
transfus
center
total
whole
blood
collect
rais
summari
conclus
establish
four
region
blood
transfus
center
signific
posit
impact
blood
suppli
burundi
inde
number
blood
unit
collect
increas
twofold
six
year
side
decentr
transfus
servic
improv
proxim
blood
center
facilit
organ
mobil
blood
collect
suppli
blood
compon
provinci
rural
hospit
allow
consequ
mitig
time
resourc
wastag
j
pajk
transfus
center
gener
hospit
celj
celj
slovenia
background
twenti
year
ago
gener
hospit
celj
ghc
constitut
hospit
transfus
committe
htc
help
blood
transfus
servic
introduc
guidelin
recommend
ration
use
blood
compon
drug
autolog
blood
transfus
collect
evalu
data
untoward
reaction
patient
blood
donor
haemovigil
aim
period
mani
chang
introduc
field
extens
preoper
orthopaed
surgeri
neurolog
treatment
interest
influenc
chang
use
blood
compon
drug
ffp
last
seven
year
method
use
blood
compon
drug
ffp
period
gener
hospit
celj
ghc
bed
present
data
collect
inform
system
datec
analys
excel
result
last
seven
year
use
red
cell
concentr
rcc
ffp
decreas
use
platelet
plt
human
albumin
ha
gammaglobulin
ggl
increas
usag
rcc
unit
plt
unit
ffp
unit
ration
despit
activ
htc
four
time
year
peak
usag
rcc
unit
unit
plt
unit
ffp
unit
ha
g
ggl
g
result
present
tabl
graph
summari
conclus
larg
number
patient
treat
ghc
due
seriou
intern
diseas
surgeri
oper
analys
exemplari
cooper
transfusiologist
clinician
regular
activ
htc
everi
three
month
consid
guidelin
recommend
optim
use
blood
compon
drug
use
blood
compon
decreas
use
rbc
diminish
ffp
slight
increas
use
plt
hand
use
ha
ggl
increas
ha
ggl
activ
role
hospit
transfus
committe
htc
period
succeed
introduc
restrict
safe
transfus
therapi
blood
compon
ghc
even
ration
use
drug
ffp
expect
futur
jalali
shirmohammadi
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
research
institut
research
center
thalassemia
hemoglobinopathi
ahvaz
jundishapur
univers
medic
scienc
ahvaz
transfus
research
center
high
institut
research
educ
transfus
medicin
shiraz
bank
hospit
ahwaz
treatment
affair
shahid
beheshti
univers
medic
scienc
tehran
islam
republ
iran
background
need
blood
perpetu
need
disast
elev
becom
vital
donor
recruit
situat
need
highli
experi
expertis
provid
adequ
safe
blood
suppli
disast
need
blood
refer
blood
transfus
blood
donat
increas
balanc
necessari
avoid
reduc
blood
suppli
blood
collect
real
need
wast
resourc
aim
recogn
studi
peopl
refer
disast
mobil
fix
collect
center
compar
period
previou
year
help
us
analyz
donor
manag
retent
disast
situat
manag
blood
suppli
disast
method
cross
section
descript
studi
survey
blood
donor
refer
fix
mobil
center
far
provinc
blood
transfus
servic
fpbt
day
kermanshah
disast
novemb
compar
day
last
year
demograph
donat
profil
extract
databas
analyz
statist
softwar
result
blood
donat
refer
mobil
collect
center
temporari
perman
deferr
earthquak
increas
two
time
comparison
time
previou
year
vs
vs
vs
respect
temporari
perman
deferr
rate
mobil
center
earthquak
significantli
reduc
comparison
last
year
vs
particip
femal
blood
donor
disast
increas
five
time
last
year
vs
donat
prefer
donat
blood
fix
blood
center
wherea
number
male
blood
donor
show
increas
vs
donat
confidenti
unit
exclus
cue
earthquak
half
last
year
vs
donor
plasma
platelet
apheresi
show
great
growth
earthquak
time
previou
year
donor
vs
summari
conclus
accord
result
fpbt
good
respons
disast
especi
femal
blood
donor
show
good
sympathi
kermanshah
peopl
increas
blood
donor
disast
give
us
good
opportun
becom
laps
regular
donor
safeti
blood
suppli
must
sacrif
quantiti
blood
donat
surveil
train
mobil
collect
center
must
appli
j
g
c
blood
collect
blood
center
guangzhou
china
background
ultim
function
transfus
servic
support
local
health
system
ration
assess
transfus
servic
countri
region
base
develop
local
health
system
clinic
blood
need
talk
develop
china
health
system
inevit
mention
new
round
health
system
reform
launch
china
determin
direct
overal
pattern
china
health
care
system
similar
system
reform
carri
around
world
new
round
health
system
reform
china
aim
break
situat
health
resourc
larg
citi
especi
tertiari
public
hospit
perspect
health
medic
system
reform
would
china
blood
transfus
servic
match
public
answer
question
yet
aim
evalu
develop
blood
transfus
servic
mainland
china
context
health
care
system
reform
provid
refer
china
health
system
reform
blood
transfus
servic
method
base
data
nation
survey
blood
collect
suppli
institut
juli
total
blood
collect
whole
blood
donat
per
popul
suppli
demand
relationship
analyz
administr
region
level
area
rel
health
resourc
compar
dimens
total
blood
collect
human
resourc
result
variat
total
blood
collect
volum
provinc
mainland
china
wide
highest
point
beij
thousand
unit
lowest
point
locat
qinghai
provinc
thousand
unit
provinci
capit
collect
blood
volum
nationwid
citi
collect
remain
whole
blood
donat
rate
per
popul
among
provinc
mainland
china
rang
overal
whole
blood
donat
rate
per
popul
central
western
area
lower
eastern
coast
provinc
donat
blood
volum
per
popul
concentr
ml
blood
volum
per
inpati
ml
regardless
develop
transfus
servic
phd
phd
recruit
provinci
blood
establish
rest
phd
scatter
central
blood
station
ten
time
lower
blood
center
group
summari
conclus
context
china
health
reform
imbal
develop
insuffici
suppli
blood
transfus
servic
among
region
restrict
achiev
goal
therefor
china
blood
transfus
servic
urgent
need
redeploy
nation
level
accord
extent
develop
polici
prioriti
given
area
imbal
human
resourc
solv
creativ
measur
promot
sink
technolog
manag
experi
break
extrem
uneven
develop
differ
area
l
n
f
blood
servic
turkish
red
crescent
biochemistri
yildirim
beyazit
univers
ankara
turkey
background
eu
domain
classifi
donor
accord
donat
domain
creat
seri
detail
definit
donor
type
donat
type
domain
definit
also
indic
paramet
use
dataset
descript
detail
extens
eu
definit
return
laps
donor
term
ad
turkish
red
crescent
trc
donor
definit
base
domain
trc
blood
bank
inform
manag
system
contain
inform
million
activ
person
aim
studi
analyz
classif
trc
donor
due
domain
method
analyz
donor
donat
due
definit
domain
averag
unit
blood
donat
per
capita
donor
blood
donat
collect
peopl
blood
donat
collect
peopl
observ
peopl
regist
system
even
nt
donat
also
seen
donor
donat
blood
record
highest
blood
donat
number
singl
donor
unit
donor
young
peopl
age
year
donor
femal
rate
femal
donor
risen
result
trc
donor
base
definit
domain
newli
regist
donor
blood
donor
newli
regist
donor
donor
analyz
seen
averag
donat
blood
could
nt
donat
blood
due
deferr
reason
first
time
donor
rate
first
time
blood
donor
regular
donor
donat
collect
regular
blood
donor
ratio
year
rate
regular
donor
growth
exceed
laps
donor
donor
databas
silent
donor
inact
donor
approxim
donor
databas
inact
donor
addit
silent
donor
sens
blood
donor
recruit
plan
action
project
inact
donor
chang
inact
silent
donor
regular
donor
minimum
unit
addit
blood
collect
per
year
two
type
donor
age
seem
stop
give
blood
first
object
project
prepar
reach
regain
donor
return
donor
someon
made
least
two
donat
donor
made
one
donat
within
last
month
interv
last
last
donat
month
donor
return
donor
summari
conclus
result
classif
analysi
blood
donor
system
seem
abl
increas
number
blood
donat
collect
regular
blood
donor
h
k
k
laboratori
medicin
seoul
nation
univers
colleg
medicin
laboratori
medicin
kangdong
sacr
heart
hospit
laboratori
medicin
korea
univers
anam
hospit
seoul
republ
korea
background
frequent
period
blood
suppli
shortag
occur
especi
group
red
blood
cell
rbc
blood
center
korea
howev
imbal
exist
abo
blood
group
distribut
blood
donat
b
ab
gener
korean
popul
b
ab
korea
group
rbc
frequent
use
univers
rbc
abo
blood
group
recipi
strictli
adher
select
blood
compon
transfus
rbc
actual
use
biolog
epidemiolog
factor
blood
donat
may
need
addit
focus
group
aim
studi
investig
group
rbc
use
end
blood
suppli
chain
possibl
relat
differ
among
abo
blood
group
distribut
highli
blood
use
diseas
korean
popul
method
top
diseas
categori
use
rbc
platelet
plasma
compon
identifi
nation
databas
provid
korean
health
insur
review
assess
servic
januari
june
blood
compon
util
accord
abo
blood
group
analyz
diseas
categori
three
major
tertiari
hospit
korea
januari
decemb
result
data
rbc
patient
platelet
apheresi
platelet
count
random
donor
platelet
patient
plasma
compon
patient
analyz
group
rbc
usag
increas
compar
blood
donat
rate
group
p
group
b
ab
rbc
usag
reduc
respect
compar
respect
rate
blood
donat
group
ab
platelet
plasma
compon
usag
increas
respect
compar
respect
rate
blood
donat
p
abo
distribut
patient
transfus
rbc
platelet
plasma
compon
statist
differ
blood
donat
summari
conclus
differ
abo
group
distribut
blood
donat
rbc
util
small
insuffici
account
low
inventori
level
group
rbc
korean
blood
center
may
possibl
stockpil
group
rbc
hospit
may
caus
undesir
unnecessari
inventori
shift
rbc
blood
center
hospit
blood
bank
enhanc
hospit
blood
inventori
statu
monitor
capabl
implement
revis
nation
surveil
system
plan
enabl
investig
issu
l
c
w
clinic
laboratori
offic
r
team
pingtung
christian
hospit
pingtung
taiwan
republ
china
background
wastag
blood
compon
essenti
issu
face
hospit
worldwid
mani
blood
bank
adopt
rule
complianc
aabb
requir
accept
rbc
unit
outsid
blood
bank
min
extent
caus
blood
product
wastag
identifi
multipl
monitor
address
caus
wastag
implement
aim
aim
establish
patient
blood
manag
pbm
program
base
electron
data
captur
order
monitor
blood
compon
wast
region
health
care
hospit
method
multipl
monitor
process
includ
singl
blood
transfer
improv
transport
via
electron
inform
system
print
digit
specifi
patient
messag
blood
bag
compon
identif
modal
educ
outreach
nurs
staff
implement
begin
impact
reduc
blood
compon
wastag
monitor
process
implement
compar
wastag
rate
cost
result
made
crucial
chang
computer
physician
order
entri
cpoe
system
physician
order
two
blood
bag
deliveri
system
show
singl
blood
transfer
avoid
transport
staff
confus
error
take
blood
bag
overal
wastag
rate
blood
compon
percentag
number
decreas
p
multipl
monitor
process
implement
cost
wastag
approxim
net
cost
save
reduc
wast
estim
summari
conclus
multipl
monitor
process
electron
data
captur
prompt
signific
impact
reduc
blood
wastag
result
enhanc
qualiti
safeti
blood
transfus
servic
reduc
incid
transfus
reaction
abstract
withdrawn
nr
k
belfast
citi
hospit
northern
ireland
transfus
servic
northern
ireland
blood
transfus
servic
belfast
unit
kingdom
background
recent
benchmark
data
associ
blood
oper
indic
wide
variat
issu
platelet
compon
differ
popul
variat
attrit
northern
ireland
blood
transfus
servic
detail
data
collect
perform
apheresi
compon
donat
whole
blood
deriv
platelet
compon
manufactur
detail
analysi
attrit
compon
present
fate
everi
compon
issu
hospit
region
track
multipl
dose
abo
cross
group
aim
analys
current
platelet
provis
northern
ireland
match
demand
aim
implement
platelet
strategi
region
method
donat
apheresi
whole
blood
platelet
compon
nibt
analys
month
period
donor
detail
abo
group
manufactur
attrit
data
collect
match
clinic
need
requir
specialti
attrit
donat
unit
platelet
result
donat
platelet
analys
wast
cross
group
donor
recipi
group
individu
specialti
destin
identifi
haematolog
highest
user
transfus
multipl
dose
within
h
period
perform
transfus
common
reason
identifi
vascular
surgic
procedur
complianc
region
nation
guidelin
address
direct
comparison
hospit
trust
practic
summari
conclus
final
conclus
report
recommend
improv
inventori
manag
product
effici
collect
compon
manufactur
improv
necessari
reduc
donor
base
cost
contain
measur
like
impact
patient
demograph
increas
haematolog
cancer
diagnos
intens
treatment
protocol
led
develop
region
platelet
strategi
northern
ireland
l
weifeng
profession
manag
depart
guangzhou
blood
center
guangzhou
china
background
blood
donat
popul
increas
transfus
safeti
effect
protect
due
blood
donat
law
republ
china
promulg
sinc
oct
special
blood
donat
popul
one
job
object
blood
center
need
carri
safe
time
clinic
blood
suppli
strategi
order
ensur
clinic
ration
scientif
use
blood
aim
retrospect
analysi
clinic
blood
suppli
guangzhou
blood
center
grasp
overal
level
clinic
use
blood
guangzhou
promot
ration
scientif
use
blood
method
data
clinic
blood
suppli
guangzhou
blood
center
collect
whole
blood
blood
compon
erythrocyt
plasma
platelet
cryoprecipit
statist
object
result
guangzhou
blood
center
suppli
u
blood
product
clinic
use
past
five
year
whole
blood
u
account
blood
compon
u
account
includ
erythrocyt
u
account
plasma
u
account
platelet
u
account
cryoprecipit
u
account
summari
conclus
amount
blood
suppli
speed
growth
rate
increas
year
year
blood
compon
transfus
popular
hospit
ration
scientif
use
blood
partial
reliev
suppli
pressur
ensur
transfus
safeti
abstract
withdrawn
abstract
withdrawn
p
c
medic
research
regulatori
affair
rwanda
biomed
center
biomed
center
rwanda
nation
center
blood
transfus
medic
research
center
nation
center
blood
transfus
rwanda
biomed
center
kigali
rwanda
background
medic
advanc
enabl
access
qualiti
servic
patient
especi
critic
healthcar
need
promis
innov
approach
revolution
improv
diseas
prevent
diagnosi
care
treatment
transfus
scienc
contribut
save
live
made
tremend
progress
achiev
safer
transfus
aim
zero
transfus
risk
transfus
therapi
therefor
constitut
intervent
especi
emerg
mainli
due
technolog
improv
techniqu
sound
regulatori
polici
technic
expertis
health
profession
remark
progress
mainli
led
develop
countri
specif
emphas
need
rare
immedi
accommod
set
need
especi
africa
particularli
disturb
africa
left
behind
technolog
transfer
basic
knowledg
skill
necessari
ensur
transfus
sadli
despit
expos
burden
transmitt
diseas
like
hivaid
hepatitis
notwithstand
barrier
african
countri
set
enabl
research
clinic
environ
effect
adopt
transfus
medicin
tailor
respect
context
low
absent
invest
transfus
medicin
research
develop
rare
probabl
undertaken
accommod
african
context
regrett
key
african
research
challeng
concern
transfus
safeti
algorithm
risk
mitig
transfus
safeti
monitor
gap
lack
blood
research
data
transfus
shortag
blood
cell
product
access
afford
standard
infrastructur
capac
adequ
blood
bank
stem
cell
collect
process
preserv
transfus
etc
given
challeng
rwanda
envis
implement
model
achiev
conduc
medic
research
environ
eg
clinic
trial
capac
build
eg
human
resourc
health
innov
approach
blood
cell
product
suppli
especi
remot
area
use
drone
deliv
servic
aim
paper
emphasis
analysi
newli
combin
model
reflect
blood
safeti
suppli
research
bssr
incorpor
intervent
adopt
sinc
includ
drone
blood
deliveri
method
comprehens
analysi
transfus
medicin
practic
regulatori
aspect
eg
post
transfusiontranspl
monitor
safeti
compar
model
contrast
drone
empow
blood
deliveri
servic
suppli
medic
research
analysi
compon
research
result
benefit
challeng
lesson
learnt
prior
qualiti
flexibl
cost
supplier
reliabl
innov
respons
deliveri
lead
time
product
divers
asset
manag
approach
model
best
fit
best
practic
set
challeng
opportun
best
practic
invest
clinic
research
promot
technolog
biomedicin
includ
transfus
scienc
summari
conclus
paper
underlin
achiev
challeng
opportun
well
best
practic
drawn
boldli
implement
model
priorit
blood
safeti
suppli
research
bssr
framework
achiev
transfus
medicin
rwanda
avail
model
resourc
limit
countri
blood
transfus
servic
transfus
servic
nepal
red
cross
societi
kathmandu
nepal
background
blood
transfus
servic
start
nepal
start
collect
per
year
unit
sinc
establish
blood
servic
nepal
red
cross
societi
respons
manag
blood
blood
product
needi
blood
centr
district
across
countri
nationwid
total
unit
collect
unit
blood
blood
compon
suppli
year
increas
demand
treatment
technolog
avail
countri
though
appropri
donor
follow
system
countri
mani
school
colleg
univers
club
corpor
offic
donat
year
motiv
awar
talk
program
instead
one
time
organ
start
donat
two
three
time
year
also
everi
religi
group
also
start
organ
donat
camp
increas
new
organ
easi
fulfil
demand
countri
start
storag
centr
hospit
less
number
blood
discard
save
unnecessari
transport
blood
blood
product
rel
aim
motiv
awar
program
realiz
blood
donor
import
blood
donat
becam
easi
manag
blood
demand
throughout
countri
hospit
stock
manag
hospit
start
come
receiv
blood
blood
product
help
maintain
qualiti
cold
chain
time
transfer
product
destin
manag
suffici
blood
avail
blood
center
regular
blood
collect
center
also
establish
help
donor
organ
cooper
collabor
nrc
blood
center
nationwid
manag
suppli
blood
needi
per
demand
method
maintain
list
blood
donor
group
organ
regular
motiv
awar
program
record
data
updat
donor
organ
volunt
blood
donor
blood
unit
commun
regular
updat
hospit
collabor
stakehold
media
support
result
blood
blood
compon
well
manag
suppli
accord
demand
awar
motiv
help
peopl
understand
use
need
blood
individu
blood
donor
volunt
motiv
support
blood
donat
cooper
coordin
differ
stakehold
help
blood
manag
without
difficulti
countri
summari
conclus
summari
conclus
individu
blood
donor
volunt
motiv
support
blood
donat
blood
manag
properli
cooper
coordin
differ
stakehold
build
blood
manag
without
difficulti
countri
key
word
motiv
awar
blood
donor
organ
demand
sa
ali
ali
h
mansoori
laboratori
patel
hospit
karachi
pakistan
background
wastag
blood
product
may
atroci
outcom
health
care
system
improv
overal
health
care
system
emerg
focu
limit
cost
avoid
practic
may
lead
wastag
blood
product
time
call
adopt
practic
minim
wastag
prize
blood
unit
almost
zero
aim
determin
wastag
rate
blood
product
form
return
blood
product
multidisciplinari
institut
identifi
reason
return
blood
product
allow
time
method
retrospect
audit
conduct
section
blood
bank
dec
design
determin
rate
product
return
blood
bank
dispatch
part
institut
program
reason
return
key
personnel
area
involv
identifi
result
blood
compon
wast
studi
durat
return
pack
red
cell
specifi
time
contribut
n
n
blood
product
return
within
min
taken
back
inventori
major
product
return
oper
room
n
n
case
nurs
physician
oblivi
accept
durat
keep
blood
product
control
temperatur
total
patient
order
multipl
unit
time
anticip
excess
bleed
procedur
n
patient
apprehens
n
unavail
proper
intraven
access
n
identifi
key
reason
behind
delay
transfus
summari
conclus
wastag
blood
form
return
product
found
signific
plan
formul
import
step
toward
hemovigil
order
reduc
wastag
form
small
group
educ
session
flyer
new
blood
bag
tag
transport
box
label
min
rule
messag
plan
analyz
affect
outcom
effort
j
van
van
n
van
technolog
assess
sanquin
research
amsterdam
healthcar
oper
improv
research
oper
research
univers
twent
ensched
studi
sanquin
research
amsterdam
netherland
background
challeng
face
blood
transfus
servic
becom
complex
chang
continu
due
introduct
new
technolog
increas
custom
expect
one
expect
abil
select
extens
type
red
blood
cell
unit
directli
stock
current
unit
issu
accord
principl
irrespect
specif
type
kind
polici
might
result
shortag
rare
unit
shortag
avoid
retain
rarer
blood
unit
longer
stock
might
hand
lead
increas
wastag
age
rariti
unit
requir
aim
object
research
develop
match
strategi
balanc
qualiti
match
red
blood
cell
age
unit
issu
method
due
specif
match
restrict
red
blood
cell
unit
tradit
perish
inventori
alloc
model
appli
therefor
develop
integ
linear
program
model
optim
alloc
inventori
introduc
new
perform
measur
indic
qualiti
match
base
decis
unit
issu
given
demand
balanc
rariti
age
blood
product
stock
simul
perform
valid
perform
match
strategi
use
histor
blood
type
request
dutch
hospit
result
simul
perform
new
issu
polici
appli
differ
rang
set
includ
variat
stock
size
prioriti
age
versu
rariti
number
decis
moment
per
day
simul
show
appli
new
issu
polici
number
exact
match
increas
whilst
retain
suppli
level
summari
conclus
new
issu
polici
high
percentag
request
fulfil
exactli
match
rbc
unit
combin
signific
reduct
percentag
outdat
unit
low
proport
match
product
avail
stock
request
current
unit
issu
select
manual
complex
demand
abo
rhd
met
approach
like
becom
inventori
type
rbc
far
complex
human
manag
result
addit
effort
meet
request
complex
rbc
unit
might
avoid
appli
advanc
issu
polici
appli
simul
rs
tabao
omar
lyon
p
chai
j
godfroy
wong
laboratori
medicin
khoo
teck
puat
hospit
singapor
singapor
background
khoo
teck
puat
hospit
acut
care
region
hospit
cater
healthcar
need
northern
singapor
depart
laboratori
medicin
blood
bank
issu
blood
product
year
period
year
unit
pack
cell
unit
fresh
frozen
plasma
unit
cryoprecipit
unit
platelet
discard
accord
nation
polici
percent
directli
attribut
breach
cold
chain
element
blood
blood
product
transport
within
hospit
cours
investig
wastag
surreptiti
follow
issu
product
receiv
locat
observ
product
handl
observ
mani
receiv
locat
adopt
materi
practic
result
increas
risk
product
spoilag
aim
aim
project
prevent
unnecessari
wastag
blood
product
maintain
cold
chain
transport
product
within
hospit
method
cooler
box
use
studi
first
valid
intact
expir
blood
product
store
cooler
box
maximum
time
appropri
temperatur
maintain
given
ratio
blood
product
ice
pack
typic
condit
ward
environ
determin
temperatur
measur
perform
use
nation
institut
scienc
technolog
nist
thermomet
trial
previous
valid
cooler
box
use
transport
blood
product
cooler
box
kept
ward
transfus
end
unus
blood
product
remain
provid
cooler
box
return
blood
bank
use
blood
product
pack
also
return
provid
cooler
box
storag
return
blood
bank
steril
test
perform
pack
verifi
condit
cooler
box
maintain
blood
product
integr
throughout
time
blood
product
control
environ
blood
bank
result
blood
product
return
within
accept
temperatur
blood
product
discard
due
breach
temperatur
control
steril
test
result
total
transfus
unit
neg
two
unit
later
inocul
known
microorgan
posit
control
rule
fals
neg
result
januari
octob
blood
product
wastag
due
breach
temperatur
control
implement
process
improv
novemb
blood
wastag
due
breach
temperatur
control
novemb
februari
summari
conclus
blood
valuabl
resourc
wastag
minimis
mainten
cold
chain
requir
collabor
involv
multipl
stakehold
includ
laboratori
staff
nurs
porter
cooper
abl
maintain
cold
chain
blood
product
transport
within
hospit
campu
reduc
blood
wastag
jt
g
develop
canadian
blood
servic
engin
dalhousi
univers
halifax
nova
scotia
medicin
patholog
univers
alberta
edmonton
ab
servic
canadian
blood
servic
edmonton
alberta
canada
background
patient
complex
red
cell
antibodi
profil
antibodi
high
preval
antigen
limit
option
blood
transfus
requir
thu
mani
countri
establish
rare
blood
program
screen
donor
rare
phenotyp
registri
record
inform
donor
identifi
blood
agenc
may
also
collect
freez
store
rare
blood
unit
provid
either
autolog
allogen
transfus
frozen
blood
howev
expens
frozen
unit
cost
time
fresh
unit
aim
canadian
blood
servic
cb
maintain
rare
blood
program
servic
demand
rare
blood
canada
outsid
program
includ
process
screen
donor
regist
individu
rare
phenotyp
store
fresh
frozen
inventori
anecdot
evid
frozen
inventori
level
optim
configur
object
studi
evalu
use
analyt
method
combin
discret
event
simul
rare
blood
inventori
canada
identifi
oper
set
ensur
demand
rare
unit
met
effici
method
approach
employ
first
phase
analysi
suppli
demand
undertaken
identifi
minimum
screen
rate
necessari
ensur
stabl
suppli
rare
phenotyp
estim
minimum
phenotyp
rare
stock
frozen
unit
necessari
minimum
level
identifi
simul
model
employ
evalu
stochast
version
rare
blood
network
varieti
inventori
level
result
minimum
rare
donor
popul
size
calcul
compar
estim
screen
donor
popul
cb
rare
phenotyp
combin
manag
cb
number
known
donor
less
minimum
number
donor
need
ensur
stabl
flow
product
analyt
result
suggest
number
identifi
donor
must
increas
total
exploit
differenti
retent
rate
rare
turnoveryear
regular
blood
donor
turnoveryear
possibl
build
rare
donor
registri
requir
year
depend
screen
rate
adopt
incom
donor
simul
execut
differ
phenotyp
frequenc
experi
measur
delay
patient
request
rare
phenotyp
blood
fill
request
experi
assum
either
unit
apiec
blood
result
show
hold
unit
apiec
improv
patient
access
rare
blood
almost
phenotyp
frequenc
howev
hold
unit
apiec
associ
statist
signific
decreas
patient
delay
exampl
consid
phenotyp
neg
e
c
antigen
rh
group
occur
individu
hold
frozen
inventori
result
averag
day
fulfil
patient
request
blood
unit
apiec
held
access
time
decreas
day
signific
decreas
delay
could
detect
increas
frozen
inventori
summari
conclus
level
frozen
blood
need
buffer
fluctuat
suppli
demand
rare
blood
larg
inventori
unlik
improv
access
easili
collect
rare
phenotyp
model
suggest
modest
amount
frozen
inventori
combin
increas
screen
provid
greatest
chanc
ensur
patient
complex
serolog
access
red
blood
cell
need
h
r
blood
transfus
center
univers
oradea
transfus
societi
karl
landstein
oradea
babe
bolyai
univers
cluj
napoca
cluj
napoca
medicin
univers
oradea
oradea
romania
background
transfus
therapi
repres
chain
specif
event
hospit
level
order
minim
transfus
risk
includ
immunolog
one
aim
abo
rh
minor
erythrocyt
system
immunolog
assay
one
major
pillar
transfus
safeti
cover
method
studi
done
blood
donor
repres
total
pool
donor
bihor
counti
level
select
area
oradea
salonta
beiu
upon
specif
criteria
ethnic
consanguin
reason
data
collect
donor
file
respect
confidenti
rule
case
approach
common
skeleton
area
blood
donor
number
gender
age
oab
rh
system
rh
phenotyp
minor
erythrocyt
group
k
result
ratio
oab
group
found
oab
system
b
ab
rh
system
posit
b
ab
neg
b
ab
oradea
area
group
rh
posit
identifi
phenotyp
seldom
rh
neg
phenotyp
seldom
group
rh
posit
rh
neg
phenotyp
b
group
rh
posit
phenotyp
seldom
rh
neg
phenotyp
seldom
ab
group
rh
posit
phenotyp
seldom
rh
neg
phenotyp
salonta
area
group
rh
posit
phenotyp
seldom
kel
rh
neg
phenotyp
b
group
rh
posit
phenotyp
seldom
rh
neg
phenotyp
seldom
ab
group
rh
posit
phenotyp
seldom
kel
rh
neg
phenotyp
area
group
rh
posit
phenotyp
seldom
rh
neg
phenotyp
seldom
group
rh
posit
phenotyp
seldom
kel
rh
neg
phenotyp
seldom
b
group
rh
posit
phenotyp
seldom
rh
neg
phenotyp
ab
group
rh
posit
phenotyp
seldom
rh
neg
phenotyp
summari
conclus
import
studi
prove
heterogen
blood
donor
categori
accord
demograph
ethnic
behavior
characterist
blood
system
sometim
challeng
transfus
compat
necess
extend
model
cover
entir
pool
blood
donor
nation
chart
regard
popul
featur
profession
approach
way
minim
immunolog
transfus
risk
base
nation
data
organ
nation
regist
rare
blood
group
l
mei
zhee
c
sze
sze
l
salli
blood
servic
group
health
scienc
author
singapor
singapor
background
singapor
donor
popul
compris
differ
ethnic
group
name
chines
malay
indian
ethnic
origin
import
knowledg
frequenc
red
cell
phenotyp
donor
popul
order
suppli
compat
red
blood
cell
rbc
patient
multipl
alloantibodi
prevent
develop
transfus
reaction
ensur
blood
safeti
aim
studi
frequenc
rbc
phenotyp
blood
donor
popul
method
mass
phenotyp
perform
regular
donor
made
donat
last
year
phenotyp
rhesu
antigen
c
e
c
e
done
use
beckman
coulter
blood
group
analys
base
haemagglutin
follow
detect
rbc
antigen
jka
jkb
donor
sampl
test
neg
jka
andor
jkb
antigen
test
fya
fyb
antigen
subsequ
fya
andor
fyb
antigen
neg
sampl
screen
antigen
antigen
type
jka
jkb
fya
fyb
perform
analys
use
gel
column
techniqu
retrospect
rbc
phenotyp
data
januari
decemb
analys
phenotyp
frequenc
express
percentag
result
regular
donor
consist
chines
malay
indian
ethnic
origin
studi
donor
select
kidd
jka
jkb
duffi
fya
fyb
mnss
antigen
type
respect
blood
group
highest
preval
blood
group
ab
lowest
preval
among
ethnic
rhd
posit
rate
rhd
neg
rate
common
phenotyp
rhd
posit
donor
cdecd
common
ethnic
group
rr
cdecd
common
phenotyp
rhd
neg
donor
preval
indian
follow
ethnic
origin
malay
chines
cdecd
common
chines
compar
ethnic
cdecd
phenotyp
found
donor
preval
chines
malay
indian
ethnic
origin
fy
jk
b
commonest
phenotyp
duffi
kidd
system
ethnic
rare
jk
phenotyp
found
donor
none
fy
phenotyp
found
studi
popul
mnss
system
preval
phenotyp
ethnic
phenotyp
frequent
indian
donor
show
lower
express
chines
malay
ethnic
origin
summari
conclus
differ
rbc
phenotyp
frequenc
observ
differ
ethnic
group
singapor
blood
donor
popul
knowledg
allow
us
maintain
suffici
stock
rbc
allow
provis
compat
rbc
patient
multipl
alloantibodi
readili
inform
also
allow
us
work
donor
recruit
recruit
blood
donor
specif
ethnic
group
less
common
red
cell
phenotyp
abstract
withdrawn
z
andjelkov
blood
donor
test
depart
blood
transfus
institut
ni
ni
serbia
background
irregular
antibodi
screen
aborhd
group
blood
donor
part
mandatori
test
perform
routin
institut
possibl
mistak
sampl
identif
interpret
result
well
mistak
perform
test
could
prevent
test
autom
system
laboratori
usa
fulli
autom
instrument
abo
rh
group
antibodi
screen
identif
aim
hous
evalu
autom
system
aborhd
group
irregular
antibodi
screen
blood
donor
blood
transfus
institut
ni
method
evalu
period
total
sampl
aborhd
group
direct
revers
type
sampl
sampl
previous
known
antibodi
presenc
irregular
antibodi
screen
test
sampl
test
miti
system
ortho
usa
use
micropl
method
aborhd
group
tube
test
method
antibodi
screen
identif
parallel
result
aborhd
group
sampl
show
complet
concord
micropl
result
result
rhd
posit
b
rhd
posit
rhd
posit
ab
rhd
posit
rhd
neg
rhd
neg
b
rhd
neg
two
antibodi
screen
method
sampl
neg
sampl
show
posit
result
antibodi
specif
posit
sampl
anti
c
anti
e
anti
c
anti
anti
fya
one
case
result
observ
system
due
nonspecif
reason
summaryconclus
system
good
correl
routin
method
micropl
method
aborhd
group
tube
method
antibodi
screen
identif
use
fulli
autom
system
blood
donor
test
reduc
chanc
human
error
increas
safeti
blood
transfus
j
arva
p
korkalainen
finnish
red
cross
blood
servic
helsinki
finland
background
donor
hemoglobin
hb
must
test
prior
blood
donat
low
hb
lead
reason
donor
deferr
mani
extern
factor
associ
low
hb
known
studi
conduct
concern
effect
analyt
variat
donor
hb
measur
deferr
aim
aim
studi
investig
effect
analyt
variat
chb
measur
method
blood
donor
hb
deferr
rate
method
effect
donor
age
season
daili
distribut
donat
variat
hemocu
hb
cuvett
donor
capillari
hb
chb
measur
deferr
analyz
million
donor
visit
nation
blood
establish
furthermor
approxim
million
chb
measur
year
includ
analys
correl
measur
chb
valu
hb
deferr
rate
result
statist
signific
correl
mean
annual
chb
measur
hb
deferr
rate
observ
women
men
season
donat
strongest
explanatori
factor
monthli
variat
chb
explain
variat
women
men
respect
variat
hemocu
cuvett
explain
monthli
variat
women
men
monthli
chang
donor
age
distribut
explain
monthli
variat
women
men
summaryconclus
small
clinic
set
neglig
analyt
variat
hb
measur
method
signific
consequ
use
hb
screen
blood
donor
minim
use
method
analyt
variat
control
kept
low
possibl
r
l
h
j
j
r
develop
laboratori
nh
blood
transplant
cambridg
unit
kingdom
affair
sysmex
kobe
japan
haematolog
univers
cambridg
cambridg
unit
kingdom
background
european
guidelin
requir
ongo
monitor
residu
white
blood
cell
rwbc
leucodeplet
ld
blood
compon
residu
red
blood
cell
rrbc
mani
countri
monitor
rwbc
use
flow
cytometri
bd
leucocount
assay
sinc
level
low
reliabl
enumer
standard
haematolog
analys
current
wide
accept
method
accur
consist
measur
level
rrbc
blood
compon
haematolog
analys
sysmex
develop
novel
algorithm
design
quantit
level
rwbc
rrbc
process
compon
provision
term
blood
bank
mode
bb
mode
aim
investig
whether
bb
mode
algorithm
measur
sysmex
analys
capabl
accur
reproduc
quantit
residu
wbc
rbc
method
whole
blood
use
spike
wbc
leucodeplet
platelet
plasma
red
cell
concentr
rcc
variou
dilut
rang
n
spike
compon
test
parallel
use
either
leucocount
assay
bb
mode
also
measur
level
rrbc
approx
present
compon
unit
plasma
n
platelet
n
routin
product
also
test
residu
cell
contamin
result
result
spike
wbc
platelet
plasma
rcc
show
good
correl
level
observ
expect
rwbc
rang
dilut
test
either
flow
cytometri
bb
mode
compar
expect
valu
gener
estim
mean
rwbc
use
leucocount
assay
whilst
bb
mode
tend
estim
rwbc
count
mean
bb
mode
data
use
spike
platelet
plasma
compon
show
littl
carryov
sampl
repeat
test
show
good
degre
conform
cv
valu
standard
deviat
rwbc
rrbc
analys
sampl
routin
product
contain
low
level
wbc
ld
compon
also
assay
flow
cytometri
bb
mode
unit
routin
product
ld
fail
mean
cv
leucocount
bb
mode
apheresi
platelet
rcc
respect
data
dilut
rrbc
platelet
plasma
compon
also
show
good
correl
estim
actual
valu
measur
bb
softwar
residu
red
cell
count
manufactur
compon
show
plasma
compon
low
level
rrbc
howev
expect
platelet
compon
show
larger
degre
variat
rrbc
contamin
low
level
apheresi
platelet
n
compar
produc
pool
buffi
coat
n
summaryconclus
bb
mode
softwar
capabl
accur
reproduc
measur
level
residu
white
red
blood
cell
process
blood
compon
order
evalu
softwar
assess
routin
work
environ
warrant
quantifi
benefit
replac
flow
cytometri
may
bring
blood
servic
blood
manag
program
program
anesthesiolog
pain
medicin
ottawa
hospit
ottawa
canada
background
patient
preoper
type
screen
test
done
prior
primari
total
knee
arthroplasti
tka
ottawa
hospit
toh
requir
blood
transfus
associ
surgeri
test
expens
cost
toh
annual
tka
procedur
alon
choos
wise
canada
campaign
recommend
elimin
test
surgic
procedur
routin
requir
blood
transfus
preoper
test
previous
order
toh
patient
schedul
primari
tka
despit
low
blood
transfus
rate
order
strategi
implement
toh
unit
pau
limit
test
tka
patient
risk
requir
blood
transfus
therefor
reduc
unnecessari
test
strategi
involv
use
point
care
hemoglobin
test
devic
poc
hgb
test
order
follow
five
criteria
identifi
preoper
assess
poc
hgb
level
gl
histori
coagulopathi
bleed
diathesi
known
alloantibodi
increas
risk
develop
alloantibodi
angina
patient
weight
kg
aim
main
purpos
studi
assess
whether
order
criteria
use
appropri
order
preoper
test
determin
impact
rate
tka
procedur
method
studi
design
retrospect
chart
review
patient
receiv
primari
tka
result
patient
popul
predominantli
femal
mean
age
patient
year
howev
well
year
age
studi
sampl
repres
slightli
obes
popul
kg
patient
otherwis
rel
healthi
small
percentag
demonstr
symptomat
ischem
heart
diseas
bleed
risk
averag
poc
hgb
level
gl
preoper
test
order
total
patient
wherea
patient
test
order
test
deem
appropri
order
wherebi
consid
unnecessari
accord
criteria
test
order
seven
high
risk
case
none
miss
case
requir
blood
transfus
otherwis
one
patient
requir
receiv
red
cell
transfus
pau
staff
use
poc
hgb
devic
assess
criteria
case
summaryconclus
overal
preoper
test
reduc
although
reduct
test
observ
use
poc
hgb
devic
order
criteria
often
use
support
decis
make
lack
adher
order
strategi
result
signific
number
unnecessari
test
order
addit
small
number
oversight
appli
appropri
criteria
appear
effect
assess
tool
guid
order
tka
procedur
ultim
reduc
cost
associ
test
approxim
cost
save
nearli
attribut
reduc
test
studi
ongo
educ
coach
requir
improv
staff
engag
adher
new
order
strategi
manag
ontario
region
blood
coordin
hamilton
medicin
sunnybrook
health
scienc
centr
project
coordin
tm
physician
manag
ontario
region
blood
coordin
toronto
canada
background
ontario
transfus
qualiti
improv
plan
otqip
committe
struck
drive
transfus
qualiti
improv
initi
forward
provinci
level
committe
plan
work
support
ontario
region
blood
coordin
network
orbcon
program
fund
ontario
ministri
health
care
mohltc
orbcon
canadian
blood
servic
cb
facilit
mani
transfus
laboratori
improv
surround
optim
inventori
level
redistribut
reduc
wastag
therefor
committe
turn
focu
transfus
order
practic
committe
consist
broad
rang
transfus
stakehold
across
provinc
orbcon
ontario
nurs
transfus
coordin
ontrac
cb
hospit
administr
qualiti
risk
repres
transfus
safeti
offic
transfus
laboratori
nurs
medic
expert
transfus
recipi
aim
otqip
committe
object
facilit
transfus
qualiti
improv
initi
hospit
level
provinc
wide
committe
aim
connect
qualiti
transfus
organ
rais
profil
adopt
otqip
method
committe
priorit
red
blood
cell
rbc
util
wide
use
addit
orbcon
rbc
audit
survey
demonstr
need
improv
order
practic
plan
call
screen
rbc
order
technologist
accord
transfus
guidelin
ensur
pretransfus
hemoglobin
less
gl
order
one
unit
time
qip
util
health
qualiti
ontario
hqo
model
align
current
hospit
model
committe
work
group
collabor
choos
wise
canada
cwc
canadian
societi
transfus
medicin
cstm
ontario
hospit
associ
oha
support
toolkit
develop
contain
institut
qip
narr
templatean
institut
qip
templateclin
practic
recommendationsan
order
set
templat
blood
componentsa
sop
prospect
screen
mltsaddit
support
document
inform
document
physician
nurs
onlin
educ
tool
technologist
screen
tool
hospit
track
baselin
data
audit
result
subsequ
develop
result
inform
survey
reveal
ontario
hospit
interest
implement
improv
initi
subsequ
survey
reveal
plan
adopt
otqip
alreadi
adopt
portion
plan
toolkit
download
time
cwc
websit
includ
cstm
hit
time
orbcon
websit
sinc
launch
initi
data
tool
shown
improv
transfus
order
pretransfus
hemoglobin
less
gl
singl
unit
transfus
hospit
enter
tool
next
focu
promot
educ
summaryconclus
facilit
practic
improv
develop
standard
templat
instruct
educ
tool
transfus
qualiti
improv
assist
hospit
practition
qualiti
improv
initi
provinci
approach
allow
aggreg
hospit
data
comparison
analys
j
p
luxconsultran
nbcred
cross
luxembourg
luxembourg
luxembourg
background
prepar
safe
effect
blood
compon
complex
activ
requir
strict
organ
measur
ensur
qualiti
gener
principl
qualiti
manag
qm
blood
establish
set
eu
council
europ
other
qualiti
manag
system
qm
nowaday
mandatori
law
mani
jurisdict
aim
compli
rule
regul
invest
be
necessari
implement
effect
qm
reflect
gmp
iso
expens
initi
invest
run
cost
mainli
relat
specif
tool
qm
addit
staff
put
placemaintain
qm
qm
caus
expens
also
gener
substanti
save
well
establish
maintain
qm
net
gain
substanti
higher
expens
balanc
almost
certainli
posit
method
retrospect
analysi
cost
save
relat
qm
undertaken
nation
blood
centerluxembourg
red
cross
expens
major
activ
easili
quantifi
account
system
hand
cost
qm
often
compart
qualiti
activ
share
connect
activ
similarli
save
alway
delin
directli
attribut
qm
case
well
found
ration
estim
use
come
order
magnitud
save
result
initi
cost
start
organ
structur
qm
rather
moder
eur
expens
posit
acquisit
electron
document
system
includ
applic
document
control
staff
train
softwar
manag
equip
instrument
includ
calibr
analyt
scale
precis
thermomet
run
cost
somewhat
euryear
includ
addit
dedic
staff
pharmacist
lab
technician
reagent
consum
use
qc
hand
save
substanti
weight
cost
far
full
implement
qm
certif
accord
substanti
save
achiev
ad
total
nbc
budget
refer
year
proper
qm
start
stepwis
biggest
save
made
relat
outdat
blood
compon
mainli
pack
red
blood
cell
rbc
fulli
establish
qm
product
differ
product
variou
origin
effici
qm
intervent
train
capa
came
low
cost
signific
ad
valu
summaryconclus
although
data
present
recent
lesson
conclus
nbc
luxembourg
still
valid
confront
cost
save
qm
conclud
qualiti
pay
qm
especi
demonstr
present
case
annual
budget
verifi
save
qm
intervent
e
kyeyun
amar
el
r
depart
blood
transfus
servic
kampala
uganda
transfus
servic
blutspend
srk
schweiz
bern
switzerland
background
whole
blood
wb
donor
collect
session
need
transport
appropri
set
order
minim
transport
relat
degrad
cellular
viabil
plasma
qualiti
prevent
relat
advers
effect
recipi
mani
guidelin
agre
transport
temperatur
whole
blood
held
collect
process
h
uk
guidelin
indic
maximum
level
transport
process
guidelin
defin
maximum
level
recommend
maximum
durat
h
date
period
monitor
temperatur
whole
blood
transport
collect
site
blood
process
center
perform
uganda
blood
transfus
servic
ubt
aim
perform
inspect
transport
temperatur
whole
blood
two
collect
site
provid
data
insight
optim
qualiti
assur
ubt
provid
guidelin
improv
standard
oper
procedur
sop
proper
handl
oper
level
order
maintain
integr
labil
blood
product
method
use
infrar
thermomet
superfici
temperatur
unit
wb
taken
two
separ
collect
session
transport
arriv
bag
cool
prior
transport
collect
venu
accord
standard
procedur
use
case
transport
direct
collect
site
process
center
case
bag
collect
site
transfer
close
blood
center
store
refriger
overnight
temperatur
follow
day
bag
put
cool
box
transport
process
center
kampala
result
transport
site
directli
process
center
nakasero
kampala
show
follow
measur
departur
mean
sd
mean
sd
arriv
transport
site
intermedi
storag
blood
centr
show
follow
measur
mean
sd
departur
mean
sd
arriv
transport
follow
day
process
center
show
mean
sd
departur
mean
sd
arriv
summaryconclus
result
show
temperatur
site
could
use
product
prp
provid
minimum
temperatur
drop
effort
employ
cool
transport
blood
collect
site
intend
prp
process
sinc
maxim
storag
temperatur
platelet
temperatur
drop
accept
level
whole
blood
red
blood
cell
concentr
process
prp
process
adequ
overnight
storag
take
place
effort
employ
cool
transport
blood
collect
site
maximum
minimum
strict
control
temperatur
monitor
institut
qualiti
manag
system
ubt
necessari
order
maintain
integr
product
basu
basu
reddi
transfus
medicin
tata
medic
center
kolkata
india
background
autom
immunohematolog
sever
advantag
like
decreas
human
error
sampl
identif
prevent
transcript
error
improv
object
reproduc
data
retriev
reduc
howev
discrep
result
must
cautious
review
interpret
ensur
patient
safeti
report
near
miss
event
blood
group
patient
use
autom
aim
report
event
emphas
need
follow
sop
manufactur
instruct
method
autom
immunohematolog
platform
ortho
vision
recent
instal
us
use
blood
group
antibodi
screen
donor
patient
blood
group
threshold
valu
forward
reaction
revers
reaction
set
machin
give
alarm
alert
user
discrep
result
requir
review
case
blood
group
repeat
tube
alarm
also
given
machin
whenev
abnorm
blood
sampl
reagent
card
mani
cell
cell
calibr
index
meniscu
problem
fib
alarm
given
machin
find
fibrin
entangl
case
alert
protocol
review
imag
refer
sop
repeat
test
manual
result
forward
abo
group
patient
perform
ortho
vision
show
group
b
fibrin
alarm
fib
anti
column
sever
time
earlier
note
fib
alarm
antibodi
screen
test
repeat
biovu
antibodi
screen
neg
henc
oper
presum
fib
alarm
anti
due
fibrin
strand
fals
posit
due
fibrin
interpret
test
rh
neg
manufactur
instruct
state
case
fib
alarm
test
repeat
use
salin
wash
red
cell
advis
use
pack
red
cell
button
avoid
buffi
coat
plasma
layer
standard
oper
procedur
sop
also
mention
addit
requir
test
repeat
tube
method
case
oper
assum
posit
band
anti
column
due
fibrin
group
interpret
b
neg
weak
test
perform
next
morn
imag
review
note
agglutin
band
along
irregular
blood
group
repeat
tube
techniqu
wash
red
cell
salin
blood
group
b
posit
b
neg
summaryconclus
henc
suggest
case
machin
alarm
intern
sop
must
follow
result
imag
care
review
addit
also
emphas
manufactur
instruct
must
adher
ensur
error
free
result
wilson
g
desnoy
b
whittemor
p
pelleti
hematolog
mcgill
univers
health
centr
canada
background
blood
bank
sampl
accept
criteria
three
site
indic
differ
polici
impact
rate
sampl
reject
site
requir
patient
full
name
uniqu
number
sampl
paper
form
sampl
initi
form
sign
person
collect
sampl
one
adult
site
addit
requir
reject
wbit
rate
adult
site
accept
sampl
encourag
attent
bedsid
label
reject
sampl
due
transcript
error
name
number
less
wbit
pediatr
site
requir
wit
sign
patient
check
match
sampl
form
lowest
reject
rate
lowest
wbit
rate
sampl
thought
due
part
pediatr
set
parent
wit
aim
merg
site
onto
one
polici
recogn
extra
requir
two
stringent
site
provid
indic
laboratori
recogn
protocol
follow
reduc
risk
accept
wbit
sampl
mandatori
wit
attest
blood
bank
sampl
implement
across
site
fall
match
complet
initi
sampl
accept
aim
analysi
determin
impact
wbit
detect
ii
wbit
rate
sampl
method
wbit
rate
primari
qualiti
indic
sampl
indic
noncompli
protocol
could
time
like
wbit
dzik
vox
sanguini
type
sampl
implement
detect
possibl
wbit
event
obtain
accur
rate
wbit
blood
bank
comput
system
configur
blood
type
reject
sampl
could
enter
without
impact
patient
record
remain
access
comparison
histor
new
patient
record
result
implement
wbit
found
found
accept
sampl
dramat
reduct
compar
anoth
found
reject
sampl
provid
truer
rate
sampl
total
wbit
found
high
risk
reject
sampl
patient
idsignatur
mismatch
tube
versu
form
miss
incomplet
name
number
miss
initialssignatur
samplewit
attest
averag
high
risk
sampl
reject
sampl
carri
time
higher
risk
wbit
summaryconclus
maxim
wbit
detect
type
sampl
high
yield
result
support
strict
enforc
sampl
accept
polici
supervisor
phlebotomist
take
proven
wbit
event
serious
report
reject
sampl
foster
cultur
safeti
blood
bank
uniqu
abil
serv
watch
guard
seriou
error
alert
lab
sampl
drawn
time
allow
train
prevent
action
appropri
implement
patient
safeti
requir
high
surveil
detect
possibl
wbit
electron
patient
identif
system
becom
standard
practic
b
n
b
f
f
etabliss
du
sang
ef
la
control
etabliss
du
sang
ef
nant
control
etabliss
du
sang
ef
boi
guillaum
control
etabliss
du
sang
ef
toulous
control
etabliss
du
sang
ef
pari
control
etabliss
du
sang
ef
lill
control
etabliss
du
sang
ef
control
etabliss
du
sang
ef
nanci
control
etabliss
du
sang
ef
st
etienn
control
etabliss
du
sang
ef
bordeaux
control
etabliss
du
sang
ef
renn
control
etabliss
du
sang
ef
tour
control
etabliss
du
sang
ef
marseil
franc
background
etabliss
francai
du
sang
ef
uniqu
blood
transfus
oper
franc
french
depart
region
establish
charg
collect
prepar
qualiti
control
distribut
issu
blood
product
product
facil
associ
qualiti
control
laboratori
n
whose
respons
ensur
conform
blood
product
nation
guidelin
current
commerci
avail
profici
test
scheme
pt
qc
blood
compon
initi
pt
interlaboratori
comparison
within
ef
qc
laboratori
order
guaranti
standard
product
qualiti
supervis
conform
statu
nation
aim
primari
object
determin
product
process
storag
ship
organ
data
collect
statist
analysi
specif
pt
sampl
biolog
characterist
match
blood
compon
specif
thereaft
scheme
would
becom
main
driver
indic
analyt
standard
site
method
qc
laboratori
contribut
program
follow
annual
agenda
specif
qc
site
design
prepar
sampl
use
scheme
sampl
issu
blood
compon
desir
paramet
set
adjust
valu
valid
reproduc
stabil
organ
laboratori
send
sampl
particip
collect
data
instruct
given
proceed
analysi
given
timelin
data
analysi
follow
iso
standard
inspect
paramet
hemoglobin
hematocrit
hemolysi
residu
leukocyt
rcc
pc
platelet
count
pc
total
protein
plasma
factor
viii
fibrinogen
plasma
residu
protein
content
wash
blood
compon
organ
laboratori
charg
final
report
follow
standard
templat
paramet
real
valu
consensu
valu
particip
result
valu
bia
consid
laboratori
must
implement
action
result
sinc
implement
measur
number
pt
paramet
ilcv
stand
interlaboratori
cv
hemoglobin
pt
sinc
ilcv
bia
hematocrit
pt
sinc
ilcv
bia
hemolysi
pt
sinc
ilcv
bia
residu
leucocyt
rcc
pc
pt
sinc
ilcv
bia
platelet
count
pt
sinc
ilcv
bia
total
protein
pt
sinc
ilcv
bia
residu
protein
wash
rcc
pc
pt
sinc
ilcv
bia
factor
viii
pt
sinc
ilcv
bia
fibrinogen
pt
sinc
ilcv
bia
summaryconclus
profici
test
interlaboratori
comparison
demonstr
use
standard
analyt
method
ensur
qc
laboratori
result
accur
reliabl
compar
wherev
produc
ef
abstract
withdrawn
abstract
withdrawn
mi
puppo
oknaian
v
abatemarco
kuperman
centro
region
de
hemoterapia
hospit
nacion
de
pediatria
prof
dr
juan
p
garrahan
caba
argentina
background
qualiti
system
blood
bank
provid
guidanc
implement
procedur
assur
complianc
current
good
manufactur
practic
set
incorpor
new
technolog
valid
want
autom
blood
donor
immunohematolog
laboratori
decreas
human
error
risk
link
step
test
perform
guarante
reliabl
traceabl
element
contribut
test
process
plan
valid
protocol
evalu
neo
galileo
fulli
autom
workstat
immunohaematolog
determin
aim
valid
purpos
verifi
devic
correct
perform
produc
document
evid
provid
high
level
assur
part
relat
autoanalyz
use
work
correctli
provid
reliabl
result
also
necessari
ensur
complianc
accuraci
safeti
standard
know
regard
neo
galileo
prevent
mainten
calibr
method
autoanalyz
set
three
technician
receiv
train
instrument
basic
oper
mainten
calibr
valid
carri
evalu
concord
result
blood
donor
sampl
group
phenotyp
extend
phenotyp
irregular
antibodi
screen
identif
perform
autom
micropl
techniqu
gel
card
system
use
total
sampl
test
abod
group
antibodi
screen
phenotyp
extend
phenotyp
frozen
donor
plasma
sampl
known
irregular
antibodi
test
antibodi
identif
test
process
accord
protocol
parallel
neo
galileo
micropl
routin
method
gel
card
system
result
user
staff
receiv
train
carri
work
routin
instrument
valid
show
neo
galileo
good
perform
sampl
process
term
qualiti
result
process
time
traceabl
safeti
reduct
human
error
found
concord
result
abod
group
antibodi
screen
extend
phenotyp
sampl
method
eight
sampl
irregular
antibodi
process
antibodi
identif
concord
two
antibodi
clinic
signific
detect
micropl
techniqu
three
sampl
gel
techniqu
identifi
one
antibodi
sampl
result
micropl
techniqu
two
sampl
undetermin
gel
techniqu
indentifi
anti
one
anti
lea
one
sampl
anti
lea
anti
lub
detect
enzym
result
micropl
techniqu
conclus
gel
neg
summaryconclus
technic
user
train
use
prevent
mainten
equip
calibr
valid
process
allow
us
verifi
neo
galileo
devic
design
autom
process
blood
sampl
concord
group
phenotyp
irregular
antibodi
detect
test
regard
identif
irregular
antibodi
observ
neo
provid
greater
potenc
sensit
reaction
discrep
result
associ
antibodi
clinic
signific
abstract
withdrawn
abstract
withdrawn
e
r
k
j
j
ryerson
univers
biomed
engin
scienc
technolog
toronto
innov
canadian
blood
servic
medicin
patholog
univers
alberta
edmonton
canada
background
annual
million
red
cell
concentr
rcc
unit
use
meet
transfus
demand
rcc
unit
produc
separ
includ
leukoreduct
rbc
donat
whole
blood
suspens
preserv
fluid
bag
store
refriger
environ
use
six
week
biochem
biomechan
chang
commonli
refer
rbc
storag
lesion
known
occur
storag
rcc
unit
chang
lower
efficaci
rbc
primari
function
oxygen
transport
deliveri
furthermor
deleteri
effect
increas
proport
storag
durat
correl
increas
morbid
rbc
storag
lesion
caus
deregul
affin
hemoglobin
oxygen
result
increas
oxygen
satur
rbc
undergo
irrevers
degrad
result
cell
term
spheroechinocyt
highlight
characterist
spheric
morpholog
storag
lesion
progress
function
storag
well
document
howev
techniqu
use
studi
advers
event
must
irrevers
destroy
steril
rcc
unit
gain
sampl
access
render
unfit
transfus
aim
present
novel
techniqu
acquir
rcc
unit
use
photoacoust
pa
technolog
pa
effect
optic
phenomenon
well
suit
acquisit
achiev
deeper
penetr
depth
optic
techniqu
furthermor
current
pa
technolog
incorpor
oximetri
produc
map
imag
platform
method
use
vevo
pa
system
develop
setup
acquir
rcc
unit
compar
measur
convent
invas
techniqu
blood
ga
analysi
bga
seven
lr
sagm
topbottom
rcc
unit
measur
techniqu
throughout
storag
lifetim
alongsid
pa
bga
measur
measur
rel
spheroechinocyt
popul
percentag
rspp
use
imag
flow
cytometri
ifc
techniqu
result
correl
measur
pa
bga
less
rise
also
compar
rise
spheroechinocyt
popul
use
ifc
techniqu
tempor
chang
rspp
unit
yield
correl
except
outlier
whose
uncharacterist
high
initi
result
plateau
correl
poorli
rspp
summaryconclus
experiment
evid
suggest
consist
small
discrep
measur
pa
bga
method
attribut
brief
exposur
extern
environ
sampl
extract
bga
measur
result
show
strong
evid
accuraci
precis
pa
approach
acquir
correl
suggest
tempor
chang
could
use
infer
approxim
chang
morpholog
pa
techniqu
present
studi
could
potenti
provid
clinician
storag
lesion
assess
prior
use
rcc
unit
transfus
j
thilakavathi
blood
servic
group
health
scienc
author
singapor
singapor
background
nation
supplier
blood
blood
product
hospit
singapor
blood
servic
group
bsg
health
scienc
author
singapor
ensur
good
qualiti
system
back
establish
intern
standard
adopt
facil
lack
formal
assess
structur
document
correctiveprevent
action
taken
henc
comprehens
assess
framework
develop
inspect
facil
aim
aim
follow
ensur
good
qualiti
system
place
hospitalsto
educ
hospit
staff
requir
standard
blood
bank
transfus
servicesto
ensur
necessari
correct
prevent
action
takento
provid
hospit
offici
audit
report
investigationsto
appris
hospit
transfus
committe
find
action
takento
provid
trend
analysi
hospit
perform
method
audit
checklist
base
intern
standard
adopt
set
audit
document
guid
auditor
conduct
report
audit
develop
audit
report
correct
prevent
action
templat
also
craft
team
senior
bsg
staff
train
conduct
hospit
assess
biennial
schedul
develop
inspect
variou
hospit
team
bsg
auditor
educ
hospit
staff
standard
requir
concurr
perform
audit
summari
audit
find
share
facil
end
inspect
audit
report
sent
hospit
correctiveprevent
action
hospit
given
month
respond
thereaft
action
taken
verifi
endors
hospit
supervisor
lead
auditor
qualiti
manag
group
director
bsg
action
requir
lead
auditor
would
follow
hospit
correct
action
satisfactori
report
would
endors
copi
sent
hospit
result
audit
report
provid
hospit
staff
manag
insight
laps
necessari
correctiveprevent
action
requir
establish
good
qualiti
system
structur
report
system
also
prevent
disput
parti
audit
team
provid
audit
summari
end
inspect
ensur
hospit
staff
accept
nonconform
identifi
framework
assist
bsg
analysi
variou
nonconform
observ
fourteen
hospit
inspect
allow
parti
work
synergi
establish
good
qualiti
system
trend
analysi
base
framework
show
hospit
reduct
number
nonconform
record
inspect
suggest
assess
framework
correct
measur
put
place
effect
summaryconclus
bsg
comprehens
assess
framework
provid
structur
inspect
hospit
provid
valuabl
inform
improv
blood
bank
transfus
servic
robust
assess
framework
place
good
qualiti
system
establish
assur
bsg
hospit
blood
blood
product
qualiti
extend
patient
c
c
v
bint
servic
group
patient
servic
scienc
author
singapor
singapor
background
laboratori
suppli
ie
test
kit
reagent
manag
manual
laboratori
staff
involv
staff
verbal
inform
manag
whenev
suppli
run
low
near
expiri
order
deliveri
new
suppli
manag
sole
email
manag
henc
commun
limit
peopl
involv
lead
inform
dissemin
effect
new
suppli
requir
label
quarantin
qualiti
control
qc
done
track
use
document
multipl
duplic
data
document
sometim
difficult
locat
sent
review
differ
staff
coupl
delay
releas
suppli
quarantin
qc
frequent
incomplet
document
result
occasion
repeat
qc
time
wastag
electron
databas
thu
develop
utilis
suppli
inventori
manag
aim
manag
laboratori
suppli
effici
effect
reduc
time
manpow
requir
digitis
method
analysi
valu
stream
map
vsm
use
identifi
hotspot
area
improv
current
process
time
taken
paper
document
measur
base
current
practic
compar
new
digitis
process
anova
test
use
determin
overal
time
save
statist
signific
result
overal
time
spent
document
manag
lab
suppli
inventori
signific
reduct
per
reagent
p
summaryconclus
digit
databas
incorpor
laboratori
standard
oper
procedur
sop
januari
differ
type
document
gener
entri
inform
variou
need
eg
list
expir
reagent
expect
deliveri
date
qc
form
less
resourc
requir
inventori
manag
focus
routin
sampl
new
test
valid
inform
databas
access
staff
empow
transpar
system
also
facilit
effici
effect
dissemin
inform
within
laboratori
staff
staff
would
also
ownership
inventori
also
inculc
stronger
sens
respons
introduct
new
system
challeng
entir
databas
build
scratch
staff
train
use
new
system
actual
implement
sop
new
inventori
manag
system
flexibl
potenti
custom
laboratori
futur
n
u
w
h
health
ajk
blood
transfus
author
ajk
muzaffarabad
blood
transfus
author
ministri
nation
health
servic
islamabad
pakistan
background
state
azad
jammu
kashmir
ajk
popul
million
lie
north
east
pakistan
state
administr
divid
three
divis
ten
district
healthcar
coverag
state
remain
inadequ
blood
transfus
servic
integr
compon
health
polici
ajk
servic
provid
public
sector
hospit
ever
increas
number
ngo
sector
blood
bank
mani
cater
need
thalassaemia
patient
one
key
issu
blood
transfus
servic
ajk
weak
regul
govern
system
govern
ajk
pass
act
regul
blood
system
recent
implement
act
start
earnest
aim
implement
ajk
transfus
safe
blood
act
xvi
method
ajk
blood
transfus
author
bta
made
announc
newspap
registr
blood
bank
howev
poor
respons
receiv
registr
octob
ajk
author
approach
islamabad
blood
transfus
author
assist
support
regul
blood
transfus
servic
state
ibta
coordin
ajk
bta
share
develop
test
technic
tool
coordin
plan
conduct
blood
bank
inspect
three
phase
phase
includ
district
mirpur
bhimber
kotli
sudhanoti
inspect
conduct
novemb
detail
report
prepar
share
doh
novemb
ajk
bta
conduct
inspect
remain
six
district
two
phase
phase
ii
district
muzaffarabad
jhelum
valley
neelum
valley
novemb
phase
iii
district
bagh
poonch
have
decemb
blood
bank
identifi
inform
unplan
map
conduct
assist
local
contact
addit
snowbal
sampl
exercis
also
appli
purpos
result
inspect
visit
blood
bank
inspect
number
blood
bank
found
much
higher
anticip
figur
highlight
regulatori
control
whole
standard
servic
deliveri
found
extrem
poor
unsaf
except
five
blood
bank
none
blood
bank
man
qualifi
pathologistsblood
transfus
offic
privat
sector
blood
bank
mostli
run
unqualifi
technician
even
remot
familiar
basic
concept
blood
safeti
blood
bank
visit
six
blood
bank
fulfil
minimum
criteria
grant
licens
one
year
five
centr
map
blood
bank
oper
seek
bta
assist
start
blood
bank
one
blood
bank
close
bta
recommend
remain
blood
bank
place
probat
inform
defici
remedi
action
soon
summaryconclus
inspect
report
prepar
submit
depart
health
includ
recommend
adopt
earnest
significantli
improv
blood
safeti
standard
gener
public
confid
health
care
system
ajk
abstract
withdrawn
n
diaz
g
el
medic
affair
sanquin
utrecht
medic
affair
sanquin
leiden
medic
affair
sanquin
eindhoven
nationa
bureau
voor
en
biovigilanti
leiden
netherland
background
netherland
increas
number
blood
donor
treat
medic
devic
contain
materi
deriv
anim
sourc
biomateri
accord
current
intern
guidelin
donor
perman
defer
aim
aim
studi
assess
potenti
risk
biomateri
blood
bank
sanquin
practic
base
literatur
method
literatur
review
conduct
gener
overview
biomateri
regul
intern
organ
regul
donor
implant
biomateri
next
survey
conduct
among
blood
donor
reject
biomateri
pubm
search
perform
keyword
link
medic
devic
contain
materi
deriv
anim
sourc
overview
european
dutch
legal
framework
made
includ
data
current
polici
european
european
blood
bank
organ
result
retriev
articl
relev
question
none
articl
report
transmiss
virus
andor
prion
accord
european
legisl
safeti
biomateri
proven
conform
class
iii
regim
prion
risk
strictli
monitor
accord
european
guidelin
european
countri
differ
polici
regard
donor
biomateri
rang
full
accept
deferr
countri
accept
blood
donor
treat
specif
brand
biomateri
summaryconclus
base
safeti
regul
absenc
report
transmiss
donor
treat
biomateri
europ
accept
blood
donor
thu
increas
pool
potenti
donor
polici
regard
biomateri
differ
substanti
among
blood
bank
world
j
van
f
k
van
den
w
de
p
van
studi
sanquin
amsterdam
erasmusmc
rotterdam
netherland
background
repeat
blood
donat
lead
lower
haemoglobin
hb
level
time
trajectori
hb
valu
subject
select
effect
exampl
due
donor
becom
demotiv
reject
becom
import
monitor
precis
cours
repeat
blood
donat
bring
probabl
hb
level
donat
end
data
iron
store
indic
zinc
protoporphyrin
zpp
could
prove
essenti
aim
primari
aim
studi
determin
whether
predict
futur
hb
level
use
current
hb
level
improv
take
zpp
level
account
whether
zpp
use
effect
earli
detect
donor
prone
reject
due
low
hb
valu
method
use
data
zpp
iron
netherland
cohort
studi
oct
oct
consist
approxim
whole
blood
donor
new
repeat
donor
identifi
current
zpp
level
primari
predictor
use
previou
hb
level
age
previou
zpp
level
day
time
donat
previou
donat
histori
bmi
blood
volum
blood
count
secondari
predictor
sinc
donor
repeat
measur
use
linear
mix
model
investig
associ
futur
hb
level
zpp
includ
predictor
sinc
rang
zpp
show
larg
variat
popul
variabl
zpp
reflect
margin
chang
predictor
variabl
result
total
femal
donor
mean
age
year
mean
zpp
mean
hb
mean
donat
studi
period
male
donor
studi
mean
age
year
mean
zpp
mean
hb
mean
donat
zpp
show
statist
signific
associ
p
subsequ
hb
level
femal
size
associ
quit
small
regress
coeffici
confid
interv
true
male
signific
p
size
associ
even
smaller
blood
volum
age
women
signific
secondari
predictor
variabl
blood
volum
age
donat
interv
men
stratifi
women
premenopaus
women
show
highli
signific
associ
zpp
p
compar
postmenopaus
women
p
case
size
effect
estim
rather
small
respect
summaryconclus
although
zpp
donat
histori
seem
predict
subsequ
hb
level
men
women
donor
size
predict
estim
small
zpp
may
effect
iron
defici
marker
daili
blood
bank
set
predict
subsequ
hb
level
blood
donor
j
r
medicin
hospit
queen
elizabeth
kota
kinabalu
sabah
medicin
advanc
medicin
dental
institut
usm
cluster
advanc
medicin
dental
institut
usm
penang
malaysia
background
blood
donat
vital
meet
patient
need
blood
blood
product
howev
reduct
haemoglobin
haematocrit
blood
volum
follow
blood
donat
might
affect
cardiorespiratori
fit
level
aim
determin
effect
blood
donat
level
cardiorespiratori
fit
measur
predict
maximum
oxygen
uptak
max
method
total
male
blood
donor
involv
cross
section
studi
particip
poor
averag
excel
fit
group
multistag
shuttl
run
fit
test
protocol
use
measur
cardiorespiratori
fit
level
test
perform
h
ml
whole
blood
donat
simultan
haemoglobin
haematocrit
assess
h
immedi
h
donat
result
median
baselin
predict
max
mlkgmin
poor
averag
excel
fit
group
respect
cardiorespiratori
fit
level
slightli
reduc
h
blood
donat
poor
averag
excel
fit
group
respect
howev
reduct
statist
signific
excel
fit
group
p
haemoglobin
haematocrit
significantli
reduc
group
h
donat
haemoglobin
reduc
p
p
p
poor
averag
excel
fit
group
respect
haematocrit
reduc
p
p
p
poor
averag
excel
fit
group
respect
spearman
correl
analysi
reveal
signific
relationship
haemoglobin
chang
predict
max
chang
group
poor
fit
level
group
rs
averag
fit
level
rs
excel
fit
level
group
rs
summaryconclus
cardiorespiratori
fit
level
slightli
reduc
h
follow
ml
whole
blood
donat
concomit
signific
haemoglobin
haematocrit
reduct
howev
signific
relationship
chang
haemoglobin
cardiorespiratori
fit
blood
donat
p
b
c
k
b
health
primari
care
univers
cambridg
cambridg
unit
kingdom
univers
queensland
brisban
australia
mcgill
univers
montreal
canada
background
blood
donor
recruit
remain
import
worldwid
challeng
due
chang
popul
demograph
shift
demand
blood
variou
cognit
model
help
predict
donat
intent
though
import
affect
deterr
becom
increasingli
clear
aim
studi
aim
identifi
specif
fear
affect
blood
donat
intent
explor
rel
import
determin
attitud
mediat
relat
method
n
donor
n
live
respond
questionnair
assess
medic
fear
psychosoci
factor
relat
donat
intent
includ
theori
plan
behaviour
tpb
construct
anticip
regret
facilit
factor
examin
rel
import
factor
context
blood
donat
question
also
ask
medic
activ
also
involv
salient
needl
blood
stimuli
includ
flu
vaccin
dental
examin
result
signific
effect
medic
fear
p
attitud
p
well
decreas
donat
intent
p
propos
mediat
attitud
posit
associ
intent
p
p
respect
path
signific
bootstrap
analys
conduct
confirm
signific
indirect
effect
mediat
ci
attitud
ci
higher
fear
lower
intent
donat
result
reduc
attitud
donat
final
medic
fear
intent
becam
control
attitud
suggest
full
mediat
p
varianc
donat
intent
account
propos
mediat
predictor
donat
intent
includ
anticip
regret
standard
p
past
experi
standard
p
facilit
factor
standard
p
underlin
import
medic
fear
blood
donat
context
medic
fear
associ
attitud
intent
dental
examin
flu
vaccin
summaryconclus
medic
fear
especi
fear
play
key
role
predict
donat
attitud
intent
mediat
pathway
shed
light
novel
way
interven
especi
address
donor
muon
c
caeiro
j
gome
lobo
centro
de
sangu
e
da
de
coimbra
coimbra
portug
background
portug
low
haemoglobin
common
caus
deferr
among
whole
blood
donor
gdl
women
gdl
men
frequent
donor
often
iron
defici
anemia
one
way
prevent
prolong
interv
donat
determin
optim
interv
donat
blood
donor
essenti
prevent
donor
low
haemoglobin
nation
guidelin
recommend
interv
donat
month
men
month
woman
howev
month
interv
donat
permit
aim
determin
optim
interv
donat
whole
blood
donor
order
recommend
whole
blood
donat
interv
polici
review
committe
method
region
blood
establish
maintain
databas
record
keep
track
donor
includ
result
donor
haemoglobin
determin
present
haemoglobin
measur
use
instrument
lyse
red
cell
convert
haemoglobin
azidemethaemoglobin
quantifi
amount
present
use
spectrophotometri
data
concern
year
whole
blood
donor
haemoglobin
determin
analys
accord
gender
interv
donat
conduct
r
softwar
r
develop
core
team
result
region
blood
establish
databas
show
donor
present
along
ten
year
activ
low
haemoglobin
determin
present
event
donat
donor
analys
femal
n
haemoglobin
percentag
exclus
due
low
hemoglobin
analys
accord
interv
donat
month
n
mean
gdl
month
n
mean
gdl
month
n
mean
gdl
month
n
mean
gdl
month
n
mean
gdl
male
n
haemoglobin
determin
percentag
exclus
due
low
hemoglobin
analys
accord
interv
donat
month
n
mean
gdl
month
n
mean
gdl
month
n
mean
gdl
month
n
mean
gdl
month
n
mean
gdl
summaryconclus
find
show
blood
establish
higher
percentag
exclus
due
low
haemoglobin
femal
donor
male
donor
interv
donat
higher
percentag
exclus
due
low
haemoglobin
found
donor
interv
donat
less
month
femal
donor
much
relev
reach
recommend
need
major
focu
prevent
femal
invit
donat
interv
donat
less
month
avoid
low
haemoglobin
exclus
machado
b
delgado
f
bischoff
teixeira
ramalho
c
monteiro
c
neve
c
vaz
c
koch
transfus
medicin
blood
bank
centro
hospitalar
porto
portug
background
elig
criteria
blood
donor
dynam
time
upper
age
limit
differ
among
countri
mainli
relat
maintain
balanc
evid
safeti
donat
elderli
contribut
blood
suppli
accord
legisl
center
remov
upper
age
limit
donat
chang
obtain
moment
studi
aim
evalu
blood
donat
repeat
older
donor
impact
blood
suppli
use
experi
acquir
center
year
time
method
retrospect
studi
perform
includ
repeat
blood
donat
januari
decemb
center
patient
divid
group
accord
age
year
year
consid
advers
reaction
vasovag
syncop
convuls
lipothymia
nausea
vomit
data
regard
venipunctur
difficulti
prolong
donat
time
also
account
statist
signific
set
p
result
popul
demograph
compar
literatur
includ
donor
year
older
mean
age
year
subgroup
year
year
mean
age
year
year
respect
total
donat
donat
came
donor
older
year
correspond
donat
studi
period
associ
age
group
venipunctur
difficulti
prolong
donat
time
found
p
p
respect
regard
advers
reaction
statist
signific
associ
p
favor
safeti
group
year
old
advers
reaction
report
one
occur
group
summaryconclus
accord
center
experi
blood
donat
older
repeat
blood
donor
posit
impact
contribut
blood
suppli
may
also
safe
continu
nonetheless
data
necessari
sustain
result
optim
decis
extrem
upper
age
limit
b
f
e
british
columbia
blood
servic
vancouv
blood
servic
regina
blood
servic
calgari
canada
background
medic
enquiri
process
enabl
blood
center
physician
assess
elig
donor
medic
condit
cover
donor
screen
manual
donor
temporarili
defer
process
previou
work
demonstr
immedi
loss
accept
donor
subject
deferr
accept
donor
fail
return
donat
enquiri
requir
inform
donor
physician
may
complet
immedi
telephon
histor
evid
suggest
occur
obtain
real
time
donor
accept
cb
physician
telephon
donor
remain
clinic
would
avoid
temporari
deferr
accept
donor
allow
immedi
blood
donat
aim
pilot
studi
undertaken
determin
feasibl
real
time
verbal
vme
process
singl
provinc
canada
first
object
document
exclus
use
vme
process
whole
blood
donor
clinic
week
period
secondari
object
document
absolut
number
accept
donor
retain
vme
process
compar
histor
data
model
number
donor
donat
could
save
nation
implement
process
method
use
exist
work
instruct
clinic
staff
direct
exclus
use
verbal
process
me
studi
period
clinic
nurs
use
central
telephon
number
contact
physician
respond
within
min
donor
remain
clinic
inform
provid
physician
determin
whether
donor
accept
defer
inform
requir
donor
physician
document
me
includ
deferr
sent
per
standard
practic
medic
offic
blood
center
physician
signatur
data
collect
altern
process
follow
physician
call
return
within
min
result
total
donor
attend
whole
blood
clinic
alberta
studi
period
medic
enquiri
requir
lower
nation
rate
complet
verbal
requir
input
donor
physician
temporarili
defer
protocol
violat
occur
requir
donor
physician
input
could
done
verbal
input
donor
physician
requir
overal
lower
histor
rate
accept
rate
donor
exclus
use
vme
process
would
result
addit
immedi
donat
possibl
addit
donat
annual
summaryconclus
pilot
studi
demonstr
feasibl
adopt
vme
process
singl
provinc
increas
vme
rate
nation
could
result
immedi
retent
annual
whole
blood
donat
overal
rate
medic
enquiri
studi
much
lower
suggest
histor
data
reduc
potenti
benefit
intervent
ml
w
b
e
medicin
univers
paulo
preto
brazil
system
research
institut
san
francisco
california
san
francisco
system
research
institut
san
francisco
california
unit
state
america
paulo
preto
brazil
background
blood
donat
determin
vari
across
countri
due
differ
tradit
cultur
religion
level
educ
brazil
preval
blood
donor
adequ
howev
studi
evalu
blood
donat
determin
associ
factor
among
individu
never
donat
blood
aim
investig
psychosoci
sociodemograph
role
attitud
donor
larg
repres
sampl
user
healthcar
servic
brazilian
municip
method
conduct
survey
use
stratifi
random
sampl
primari
healthcar
user
group
primari
healthcar
facil
strata
accord
geograph
area
paulo
social
vulner
index
ipv
drew
sampl
interview
strata
base
region
popul
size
number
total
patient
visit
facil
per
month
particip
answer
question
lifetim
donat
profil
frequenc
donat
never
donat
unabl
donat
attitud
regard
blood
donat
among
intent
donat
futur
never
thought
donat
health
good
regular
poor
knowledg
regard
blood
donat
religi
belief
fear
blood
donat
peer
group
household
close
friend
knowledg
regard
blood
donat
estim
use
blood
donat
knowledg
questionnair
religi
belief
investig
duke
univers
religi
index
durel
measur
three
dimens
organiz
religios
religios
intrins
religios
assess
fear
blood
inject
vasovag
reaction
blood
inject
fear
scale
bif
appli
instrument
use
previous
valid
studi
sampl
sociodemograph
variabl
consid
sex
age
socioeconom
statu
educ
level
data
includ
structur
equat
model
attitud
regard
blood
donat
consid
depend
variabl
central
construct
structur
model
evalu
use
polychor
correl
matrix
weigh
least
squar
mean
varianc
adjust
method
fit
model
analyz
consid
good
fit
indic
signific
causal
path
assess
use
z
test
consid
signific
level
result
primari
healthcar
user
agre
particip
never
donat
blood
includ
studi
femal
mean
year
fit
structur
model
adequ
varianc
explain
model
variabl
show
signific
influenc
attitud
regard
blood
donat
age
socioeconom
statu
knowledg
fear
p
older
individu
lower
socio
econom
level
lower
knowledg
donat
process
report
fear
blood
fear
inject
fear
vasovag
reaction
like
neg
attitud
toward
blood
donat
summaryconclus
result
present
studi
may
use
understand
multifactori
determin
blood
donat
among
find
provid
guidanc
futur
recruit
campaign
focus
individu
never
donat
blood
may
expand
knowledg
regard
determin
blood
donat
popul
b
c
f
f
l
r
et
bretagn
ef
renn
investig
cliniqu
chu
de
la
collect
et
ef
ivri
sur
sein
depart
ef
la
plain
product
collect
depart
ef
la
plain
cnr
claud
bernard
lyon
villeurbann
person
blood
compon
ef
la
plain
franc
background
cardiovascular
diseas
risk
popul
blood
donor
lower
european
gener
popul
howev
acut
coronari
syndrom
occasion
report
blood
donor
decompens
cardiovascular
diseas
prevent
perman
deferr
criteria
select
blood
donor
defin
french
health
author
agreement
european
direct
cardiovascular
risk
factor
includ
select
criteria
aim
aim
estim
preval
cardiovascular
risk
factor
among
blood
donor
assess
impact
blood
suppli
variou
risk
factor
combin
donor
deferr
method
nationwid
epidemiolog
studi
perform
mobil
blood
drive
blood
center
march
april
survey
period
last
two
day
randomli
select
whole
blood
donat
two
week
apheresi
characterist
donor
sex
age
blood
pressur
bodi
mass
index
bmi
regular
exercis
tobacco
use
alcohol
drink
diabet
ongo
therapi
medic
histori
famili
cardiovascular
histori
donat
number
type
previou
year
collect
donor
candid
could
includ
except
consent
particip
higher
rate
men
women
studi
differ
usual
observ
relat
two
fact
one
hand
high
particip
rate
scarciti
apheresi
donor
firstli
recruit
hand
plasma
apheresi
done
almost
exclus
therapeut
use
subsequ
collect
men
order
prevent
trali
result
among
candid
defer
donat
done
miss
data
distribut
follow
plasma
platelet
apheresi
miss
data
among
blood
donor
whose
gender
report
men
women
men
older
yo
women
older
yo
donor
bmi
smoker
hypertens
diabet
famili
cardiovascular
background
around
half
donor
younger
least
one
risk
factor
associ
two
risk
factor
rare
smoke
diabet
hypertens
diabet
associ
three
risk
factor
rare
smoke
hypertens
diabet
hypertens
diabet
famili
histori
smoke
diabet
famili
histori
smoke
hypertens
famili
histori
combin
sex
age
donor
risk
factor
men
older
yo
women
older
yo
impact
donor
deferr
variou
risk
factor
combin
current
assess
summaryconclus
blood
donor
least
one
cardiovascular
risk
factor
frequent
repres
half
donor
younger
donor
high
cardiovascular
risk
rare
rais
question
deferr
avoid
potenti
cardiovascular
advers
effect
donat
b
intern
affair
recruit
canada
background
demand
therapi
increas
sharpli
around
globe
result
increas
focu
recruit
sourc
plasma
donor
thousand
quebec
need
product
treat
immun
defici
diseas
hemophilia
collect
plasma
manufactur
medic
thu
key
issu
part
strateg
plan
sinc
work
increas
immunoglobulin
ivig
human
plasma
volum
plasma
collect
local
sent
fraction
abl
meet
need
ivig
aim
want
gradual
increas
proport
immunoglobulin
deriv
plasma
organ
aim
increas
collect
plasma
fraction
order
achiev
target
l
purpos
present
share
journey
get
learn
differ
strategi
tactic
approach
develop
order
reinvent
model
method
accomplish
goal
two
obstacl
overcom
regard
plasma
collect
high
cost
collect
abil
recruit
larg
number
voluntari
donor
without
affect
overal
avail
blood
suppli
order
deal
challeng
recruit
donor
achiev
competit
cost
collect
plasma
creat
first
collect
center
intend
exclus
collect
plasma
fraction
first
plasmavi
plasma
donor
loung
open
novemb
first
pilot
set
ground
develop
network
plasma
center
includ
four
new
model
need
us
revisit
everi
aspect
brand
spirit
center
layout
donat
process
flow
staff
hire
profil
donor
recruit
manag
retent
strategi
volunt
employe
role
result
went
l
collect
immunoglobulin
rate
averag
donat
per
donor
per
year
reach
donor
give
time
summaryconclus
becam
clear
earli
journey
would
keep
challeng
us
key
success
would
reli
human
capit
abil
engag
commun
capac
collabor
team
innov
tri
new
idea
measur
evalu
implement
ongo
basi
blood
centr
blood
transfus
servic
nation
blood
centr
colombo
sri
lanka
background
sri
lanka
receiv
award
best
transfus
servic
among
develop
countri
intern
isbt
congress
voluntari
non
remuner
donor
play
key
role
effici
transfus
practic
cur
health
care
servic
order
maintain
donor
pool
suppli
increas
demand
patient
duti
creat
awar
encourag
younger
gener
potenti
blood
donor
futur
aim
aim
assess
knowledg
awar
attitud
potenti
futur
blood
donor
colombo
sri
lanka
method
cross
section
descript
studi
conduct
among
tamil
speak
high
schooler
never
donat
three
differ
school
colombo
sri
lanka
data
collect
structur
questionnair
statist
analys
spss
softwar
microsoft
excel
result
among
student
femal
male
mean
age
year
know
blood
group
interest
becom
blood
donor
futur
common
motiv
factor
identifi
help
other
famili
memberfriend
donor
would
like
blood
test
donat
analys
knowledg
basic
criteria
blood
donat
either
wrong
awar
minim
age
requir
haemoglobin
level
minimum
bodi
weight
requir
awar
peopl
chronic
ill
commerci
sexual
worker
donat
consid
menstruat
deferr
criteria
commonest
misconcept
gain
bodi
weight
acquir
infect
diseas
interest
learn
blood
donat
prefer
educ
mass
media
newspap
leaflet
prefer
includ
chapter
blood
donat
routin
curriculum
summaryconclus
major
studi
popul
show
interest
donat
blood
futur
unawar
blood
group
basic
knowledg
blood
donat
found
poor
student
awar
certain
absolut
deferr
criteria
sinc
major
show
interest
learn
blood
donat
fals
belief
misconcept
educ
prefer
medium
inclus
chapter
curriculum
could
help
elimin
common
misconcept
younger
gener
would
increas
number
donor
improv
qualiti
transfus
servic
sri
lanka
cg
k
n
de
manag
blood
center
colombo
sri
lanka
background
nation
blood
transfus
servic
sri
lanka
central
coordin
system
blood
bank
blood
requir
fulfil
voluntari
non
remuner
blood
donor
accord
global
data
gradual
declin
voluntari
non
remuner
blood
donat
throughout
past
decad
becom
challeng
transfus
servic
recruit
low
risk
donor
increas
life
expect
rate
accid
special
surgeri
increas
rate
blood
usag
becom
global
need
studi
blood
donat
promot
blood
donat
among
individu
accord
prevail
research
act
blood
donat
influenc
factor
includ
altruism
social
behavior
social
pressur
level
knowledg
blood
donat
etc
identif
characterist
essenti
develop
strategi
motiv
recruit
retain
blood
donor
aim
determin
factor
motiv
first
time
donor
donat
bloodto
determin
factor
motiv
regular
donor
continu
blood
donationto
assess
knowledg
awar
attitud
blood
donat
among
blood
donor
method
descript
cross
section
studi
carri
use
sampl
donor
visit
blood
donat
campaign
colombo
district
blood
donat
data
collect
use
self
administ
questionnair
pretest
valid
differ
set
result
blood
donor
first
time
donor
first
time
donor
note
blood
donat
social
respons
regular
blood
donor
admit
first
time
donor
regular
donor
consid
blood
donat
religi
act
peer
pressur
motiv
factor
first
time
door
contrast
regular
donor
blood
donor
awar
accept
gap
blood
donat
awar
donor
awar
minimum
requir
bodi
weight
donat
blood
awar
correct
bodi
weight
donat
blood
donor
awar
age
limit
donat
blood
donor
respond
incorrectli
respond
question
donor
wish
receiv
certif
blood
donat
favor
token
appreci
favor
free
health
check
mention
prioriti
govern
clinic
blood
donor
donor
deni
obtain
gift
note
appreci
none
particip
admit
obtain
payment
blood
donat
summaryconclus
donat
blood
consid
social
respons
major
regular
first
time
donor
consider
amount
donor
categori
consid
blood
donat
religi
act
first
time
donor
peer
pressur
signific
motiv
factor
contrari
regular
donor
major
accept
donat
blood
social
respons
religi
duti
thu
requir
motiv
new
donor
adopt
behavior
motiv
strategi
would
effect
offer
certif
token
appreci
recruit
retent
donor
papadogiannaki
p
kanel
e
lydaki
stagaki
j
liapi
nikoloudi
bolonaki
k
fountouli
transfus
medicin
univers
hospit
heraklion
heraklion
greec
background
accord
latest
revis
world
health
organ
guidelin
lower
level
hemoglobin
hb
requir
diagnosi
polycythemia
vera
pv
incur
diseas
earli
diagnosi
lead
effect
manag
relat
symptom
better
surviv
therefor
lower
upper
limit
current
hb
refer
interv
could
increas
number
patient
assess
pv
howev
possibl
lead
exclus
signific
number
blood
donor
aim
purpos
studi
screen
assess
volunt
blood
donor
level
hb
upper
limit
blood
donat
depart
univers
hospit
heraklion
period
method
period
volunt
blood
donor
examin
total
number
donor
criteria
assess
hemoglobin
gdl
men
gdl
women
hematocrit
men
women
assess
includ
record
risk
factor
erythremia
smoke
live
high
altitud
snore
famili
histori
symptom
like
dizzi
headach
tinnitu
hypertens
facial
erythema
etc
ii
blood
examin
liver
kidney
function
vitamin
ferritin
erythropoietin
epo
level
iii
mutat
epo
level
low
base
result
blood
donor
either
exclud
perman
refer
haematologist
low
epo
ii
exclud
temporarili
eg
refer
sleep
specialist
snore
etc
iii
free
donat
blood
result
total
volunt
examin
risk
factor
erythremia
risk
factor
risk
factor
unremark
medic
histori
seven
donor
erythremia
symptom
laboratori
evalu
remark
wherea
low
level
epo
blood
donor
examin
mutat
one
found
posit
remain
blood
donor
refer
examin
function
similar
mutat
eg
exon
mutat
possibl
bone
marrow
biopsi
exclud
blood
donat
perman
blood
donor
high
level
hemoglobin
consid
secondari
eg
smoke
abl
continu
donat
blood
remain
exclud
temporarili
refer
pneumologist
internist
evalu
import
note
blood
donor
nt
care
result
laboratori
test
nt
cooper
investig
summaryconclus
accord
studi
found
blood
donor
high
hemoglobin
low
level
epo
need
investig
order
determin
presenc
myeloprolif
diseas
detect
mutat
one
donor
establish
signific
benefit
consult
blood
donat
depart
earli
diagnosi
myeloprolif
diseas
also
recruit
import
number
blood
donor
benign
secondari
erythremia
blood
donat
n
van
k
b
c
k
servic
research
australian
red
cross
blood
servic
melbourn
psycholog
univers
queensland
st
lucia
australia
background
increas
volum
plasma
collect
key
prioriti
australian
red
cross
blood
servic
blood
servic
order
address
grow
demand
immunoglobulin
incent
one
possibl
approach
address
problem
remain
commit
voluntari
system
recent
literatur
review
incent
blood
donat
chell
et
al
transfus
howev
conclud
degre
incent
succeed
attract
facilit
repeat
high
frequenc
donat
unclear
moreov
known
introduct
incent
encourag
donat
would
view
australian
context
aim
aim
studi
explor
australian
donor
percept
use
incent
promot
donor
recruit
retent
method
survey
donor
conduct
onlin
via
telephon
research
compani
central
focu
perceiv
effect
incent
along
impact
introduct
view
blood
servic
item
assess
knowledg
regard
domest
sourc
plasma
intent
donat
whole
blood
plasma
futur
sever
psycholog
scale
relev
incent
blood
donat
result
attitud
incent
blood
donat
mainli
posit
donor
donor
slightli
posit
group
rate
time
work
incent
would
encourag
donat
health
check
incent
would
posit
affect
view
blood
servic
mileston
plaqu
certif
incent
current
offer
blood
servic
assess
studi
posit
view
donor
although
attitud
incent
intent
gener
posit
associ
donor
magnitud
associ
typic
small
p
p
perhap
unexpectedli
higher
percentag
donor
correctli
believ
australia
demand
plasma
higher
current
suppli
howev
donor
knowledg
regard
plasma
suppli
significantli
associ
intent
donat
plasma
summaryconclus
perhap
contrari
expect
australian
blood
donor
hold
mostli
favour
attitud
toward
wide
rang
incent
case
hold
posit
view
result
may
reflect
chang
norm
societi
offer
incent
behaviour
mani
behaviour
incentiv
previous
result
accept
incent
even
behaviour
born
altruism
benevol
blood
blood
product
donat
social
accept
result
studi
provid
provision
support
introduct
incent
blood
donat
voluntari
set
facilit
recruit
new
donor
retent
exist
donor
howev
rigor
trial
includ
examin
actual
return
behaviour
requir
determin
whether
approach
effect
prior
implement
n
g
blood
centr
blood
transfus
servic
nation
blood
centr
colombo
sri
lanka
background
platelet
apheresi
introduc
sri
lanka
late
nineti
sinc
platelet
apheresi
donor
registri
maintain
nation
blood
transfus
servic
record
around
donor
increas
demand
hla
match
platelet
concern
toward
reduc
donor
exposur
paediatr
patient
pool
platelet
indic
apheresi
platelet
import
creat
awar
increas
number
platelet
apheresi
donor
popul
whole
blood
donor
aim
aim
assess
knowledg
awar
attitud
voluntari
non
remuner
whole
blood
donor
toward
platelet
apheresi
donat
method
cross
section
descript
studi
conduct
among
whole
blood
donor
mobil
donat
campaign
colombo
sri
lanka
data
collect
structur
questionnair
statist
analys
spss
softwar
microsoft
excel
result
among
donor
male
femal
mean
age
year
among
regular
donor
awar
apheresi
donat
first
time
donor
awar
donor
previous
knew
apheresi
would
like
donat
apheresi
platelet
among
one
awar
would
like
willing
help
other
religi
factor
common
reason
interest
seen
among
donor
learn
patient
requir
apheresi
platelet
avail
donat
centr
close
expect
receiv
special
felicit
transfus
servic
found
common
motiv
factor
misconcept
lose
weight
follow
apheresi
donat
side
effect
fear
weight
gain
acquir
infect
diseas
show
interest
toward
learn
platelet
apheresi
prefer
educ
medic
staff
summaryconclus
male
predomin
notic
among
studi
popul
popul
awar
platelet
apheresi
fair
number
regular
donor
knowledg
compar
first
time
donor
commonest
misconcept
lose
weight
believ
learn
patient
need
platelet
would
motiv
becom
apheresi
donor
sinc
major
interest
learn
would
benefici
transfus
servic
encourag
medic
staff
educ
whole
blood
donor
platelet
apheresi
donat
abstract
withdrawn
mangwana
blood
transfus
servic
sri
balaji
action
medic
institut
new
delhi
india
background
spite
precaut
improv
method
detect
transfus
transmit
infect
tti
like
nucleic
acid
test
blood
donat
though
small
residu
risk
transfus
recipi
suscept
receiv
contamin
blood
blood
donat
made
within
window
period
proper
screen
select
blood
donor
crucial
factor
reduc
risk
transmiss
viral
diseas
upgrad
overal
safeti
donat
blood
inventori
care
select
donor
import
pragmat
risk
manag
strategi
ensur
blood
safeti
aim
studi
focus
msm
idu
western
countri
indian
studi
best
knowledg
report
sexual
behaviour
among
blood
donor
blood
safeti
fill
knowledg
gap
observ
studi
undertaken
determin
preval
trend
behaviour
explor
possibl
improv
donor
screen
procedur
import
educ
gener
popul
implement
blood
donor
reduc
risk
tti
method
studi
undertaken
two
part
first
part
retrospect
data
donor
attend
blood
transfus
servic
tertiari
care
centr
collat
analyz
donor
routin
given
bilingu
educ
materi
along
donor
form
advis
read
fill
form
understand
risk
behaviour
statist
analysi
done
use
student
test
second
part
onlin
survey
conduct
assess
preval
awar
among
donor
survey
data
compil
analyz
result
total
donor
report
blood
donat
potenti
donor
defer
deferr
incid
due
behaviour
increas
year
p
valu
major
donor
male
donor
repeat
donor
incid
deferr
highest
less
year
age
nearli
deferr
less
year
age
survey
center
question
donor
behaviour
center
specif
question
sex
histori
seroreact
donor
first
part
studi
respond
found
donor
give
posit
histori
behaviour
counsel
summaryconclus
almost
sex
educ
india
lack
knowledg
direct
implic
blood
safeti
gener
popul
complet
honest
blood
donor
screen
new
insight
studi
offer
convent
indirect
questionnair
identifi
potenti
infecti
donor
direct
question
though
lead
increas
rate
deferr
effect
optim
cost
health
care
servic
maintain
highest
level
transfus
safeti
new
solut
need
devis
deal
potenti
riski
sexual
behaviour
review
frequent
deferr
criteria
sexual
behaviour
chang
diseas
epidemiolog
deferr
polici
would
never
effect
without
donor
complianc
effort
also
need
educ
gener
popul
understand
potenti
risk
behaviour
transfus
safeti
promot
deferr
confidenti
unit
exclus
abstract
withdrawn
k
r
transfus
medicin
faculti
medicin
siriraj
hospit
mahidol
univers
clinic
microscopi
faculti
alli
health
scienc
chulalongkorn
univers
bangkok
thailand
background
thalassemia
hemoglobinopathi
common
inherit
red
blood
cell
abnorm
caus
public
health
socioeconom
problem
thailand
preval
rate
thalassemia
carrier
thai
rang
vari
region
region
thalassemia
trait
individu
asymptomat
becom
blood
donor
signific
thalassemia
trait
condit
blood
donor
impact
blood
donat
transfus
outcom
concern
aim
studi
aim
determin
preval
characterist
retent
blood
donor
thalassemia
trait
method
prospect
blood
donor
randomli
recruit
depart
transfus
medicin
siriraj
hospit
mahidol
univers
bangkok
august
decemb
total
blood
donor
inform
consent
thalassemia
diagnosi
whole
blood
collect
process
use
standard
procedur
donor
reaction
routin
vigil
hematolog
paramet
thalassemia
diagnost
perform
blood
diagnosi
thalassemia
determin
analysi
use
hplc
variant
hemoglobin
test
system
hercul
ca
hemoglobin
type
multiplex
blood
donor
characterist
data
includ
sex
age
blood
group
number
previou
donat
domicil
retriev
blood
donor
inform
system
return
rate
blood
donor
defin
second
attempt
donat
within
month
deferr
rate
due
low
hemoglobin
subsequ
donat
defin
attempt
donat
within
month
defer
due
hemoglobin
less
gdl
result
preval
rate
thalassemia
trait
blood
donor
hemoglobin
e
relat
disord
alpha
thalassemia
trait
significantli
higher
proport
male
gender
found
thalassemia
trait
blood
donor
vs
p
signific
differ
age
proport
donor
number
previou
donat
blood
group
domicil
region
donor
thalassemia
trait
normal
blood
donor
three
vasovag
reaction
record
one
thalassemia
trait
donor
two
normal
donor
month
follow
return
rate
donor
thalassemia
trait
significantli
differ
return
rate
normal
donor
vs
p
deferr
rate
due
low
hemoglobin
subsequ
donat
also
significantli
differ
two
group
vs
p
summaryconclus
high
preval
rate
thalassemia
trait
thai
blood
donor
except
higher
proport
male
gender
thalassemia
trait
group
significantli
differ
characterist
two
group
moreov
return
rate
deferr
rate
due
low
hemoglobin
subsequ
donat
significantli
differ
blood
donor
thalassemia
trait
normal
blood
donor
nhat
le
pham
thi
nhu
b
van
tran
hoang
le
truong
nguyen
cho
ray
blood
transfus
centr
cho
ray
hospit
ho
chi
minh
citi
viet
nam
background
cho
ray
blood
transfus
center
cho
ray
btc
one
five
standard
blood
transfus
center
vietnam
cho
ray
btc
import
role
collect
distribut
safe
blood
compon
provinci
hospit
south
east
vietnam
increas
qualiti
blood
blood
compon
product
well
use
blood
product
effect
clinic
implement
plan
reduc
paid
famili
donat
strategi
educ
encourag
voluntari
blood
donor
donat
ml
blood
instead
standard
ml
collect
ml
blood
fraction
least
differ
blood
compon
close
system
could
subsequ
distribut
differ
patient
first
period
implement
strategi
experienc
challeng
howev
success
appli
year
commun
consid
import
key
lead
success
voluntari
blood
donat
campaign
includ
numer
activ
propagand
campaign
voluntari
blood
donat
commit
govern
present
mean
benefit
blood
donat
consult
connect
blood
donor
pre
post
blood
aim
aim
studi
evalu
impact
strategi
chang
blood
donat
resourc
educ
well
encourag
blood
donor
ml
volum
blood
donat
cho
ray
blood
transfus
center
method
studi
conduct
cho
ray
btc
cho
ray
hospit
ho
chi
minh
citi
vietnam
firstli
propos
provinci
voluntari
blood
donat
campaign
board
approv
secondli
organ
numer
activ
present
mean
benefit
donat
ml
blood
potenti
voluntari
blood
donor
prior
day
collect
thirdli
offer
consult
voluntari
blood
donor
fix
mobil
site
prior
collect
fourthli
establish
good
relationship
blood
donor
result
ml
blood
donat
total
blood
collect
ratio
continu
increas
addit
ratio
regular
donor
amount
collect
blood
also
increas
year
collect
unit
blood
retain
donat
importantli
reduc
paid
famili
donor
still
paid
donat
famili
donat
howev
ratio
paid
donat
famili
donat
therefor
ensur
qualiti
blood
donat
sourc
contribut
safeti
blood
transfus
summaryconclus
data
show
result
conclud
commun
key
import
factor
lead
success
voluntari
blood
donat
campaign
n
g
blood
centr
blood
transfus
servic
nation
blood
centr
colombo
sri
lanka
background
adequ
stabl
suppli
blood
voluntari
non
remuner
blood
donor
support
nation
blood
transfus
servic
sri
lanka
fulfil
demand
increas
number
patient
reli
blood
transfus
blood
donat
campaign
organis
provid
enorm
support
nobl
servic
time
analysi
knowledg
concern
toward
blood
donat
would
ensur
transfus
servic
address
make
necessari
chang
obtain
contribut
aim
aim
assess
knowledg
attitud
concern
mobil
blood
donat
campaign
organis
toward
blood
donat
method
cross
section
descript
studi
conduct
among
mobil
blood
donat
campaign
organis
colombo
sri
lanka
data
collect
structur
questionnair
statist
analys
spss
softwar
microsoft
excel
result
among
particip
male
femal
research
popul
organis
less
five
mobil
organis
mobil
among
motiv
factor
would
like
help
commun
religi
reason
memori
belov
person
celebr
life
event
analys
awar
toward
basic
criteria
donat
blood
awar
minim
age
requir
knew
minimum
weight
haemoglobin
level
respect
analys
knowledg
donor
select
criteria
sri
lanka
score
score
less
mani
wrong
menstruat
femal
deferr
period
histori
travel
abroad
concern
express
inadequ
number
staff
equip
alloc
mobil
campaign
gener
public
knowledg
blood
donat
poor
organis
inadequ
knowledg
concern
complaint
interest
learn
get
educ
prefer
attend
talk
discuss
conduct
transfus
servic
handout
prefer
mass
media
summaryconclus
around
half
studi
popul
good
knowledg
basic
criteria
donor
select
criteria
blood
donat
still
number
need
knowledg
updat
around
half
research
popul
concern
complaint
common
concern
inadequ
number
staff
equip
show
interest
learn
blood
donat
organis
educ
programm
prefer
transfus
servic
would
improv
qualiti
output
mobil
blood
donat
campaign
yg
l
develop
center
defenc
univers
colleg
health
scienc
safeti
nation
blood
bank
servic
ethiopia
addi
ababa
ethiopia
background
though
world
health
organ
recommend
voluntari
none
remuner
blood
donat
percentag
blood
collect
voluntari
blood
donor
averag
annual
blood
collect
rate
low
ethiopia
around
total
popul
ethiopia
health
worker
expect
practic
blood
donat
creat
good
imag
public
crucial
meet
demand
safe
blood
studi
blood
donat
practic
may
improv
success
implement
blood
donat
program
ethiopia
aim
object
studi
ass
practic
blood
donat
among
health
profession
addi
ababa
govern
hospit
ethiopia
method
institut
base
studi
deploy
februari
juli
aggreg
health
worker
includ
studi
use
simpl
random
sampl
techniqu
government
hospit
data
collect
use
pre
test
structur
questionnair
via
method
descript
summari
statist
employ
bivari
multipl
logist
regress
comput
odd
ratio
confid
interv
calcul
determin
level
signific
result
total
particip
includ
final
analysi
respons
rate
among
particip
practic
blood
donat
age
year
aor
ci
health
profession
knowledg
blood
donat
aor
ci
health
profession
attitud
toward
blood
donat
aor
ci
presenc
famili
member
rel
receiv
blood
aor
ci
significantli
independ
associ
blood
donat
behavior
health
profession
summaryconclus
blood
donat
practic
health
profession
studi
found
low
compar
studi
conduct
develop
countri
health
profession
knowledg
attitud
age
presenc
famili
member
rel
receiv
blood
independ
associ
blood
donat
practic
thu
awar
creat
health
profession
improv
blood
donat
practic
ho
blood
transfus
univers
ilorin
blood
transfus
univers
ilorin
teach
hospit
univers
ilorin
ilorin
ilorin
nigeria
background
haemoglobin
concentr
haematolog
paramet
routin
done
order
determin
donor
fit
therefor
possibl
donor
non
symptomat
derang
haematolog
paramet
recruit
blood
donat
repeat
blood
donat
may
lead
deplet
iron
store
may
reflect
red
cell
indic
even
haemoglobin
concentr
still
normal
aim
determin
haematolog
paramet
male
blood
donor
effect
regular
blood
donat
paramet
compar
paramet
regular
first
time
donor
method
hospit
base
cross
section
studi
involv
male
donor
age
year
conduct
blood
bank
univers
ilorin
teach
hospit
ilorin
purpos
sampl
method
employ
select
age
match
regular
first
time
male
blood
donor
consent
donor
found
fit
donat
haemoglobin
concentr
gdl
screen
neg
hbsag
hcv
hiv
antibodi
recruit
studi
full
blood
count
fbc
determin
sysmex
sysmex
japan
accord
manufactur
instruct
result
mean
age
regular
first
time
donor
year
year
respect
p
one
donor
polycythaemia
hb
conc
gdl
forti
four
neutropaenia
absolut
neutrophil
count
one
donor
neutrophilia
four
thrombocytopaenia
platelet
count
thrombocytosi
platelet
count
twenti
four
low
mcv
five
high
mcv
eighti
two
low
mch
low
mchc
proport
donor
low
mch
significantli
higher
among
regular
donor
first
time
donor
versu
p
valu
signific
differ
regular
first
time
donor
number
low
mcv
versu
p
valu
low
mchc
versu
p
valu
mean
valu
haemoglobin
concentr
mch
mchc
significantli
higher
among
first
time
regular
donor
versu
p
versu
p
versu
p
respect
signific
differ
regular
first
time
donor
mean
valu
paramet
summaryconclus
low
red
cell
indic
neutropaenia
common
haematolog
abnorm
obtain
among
male
blood
donor
studi
regular
donor
lower
mean
valu
haemoglobin
concentr
mch
mchc
significantli
higher
proport
low
mch
compar
first
time
donor
recommend
full
blood
count
conduct
routin
first
time
donor
annual
regular
blood
donor
follow
serum
ferritin
order
determin
iron
statu
prescrib
possibl
intervent
low
red
cell
indic
abstract
withdrawn
n
r
univers
teach
hospit
maharajgunj
health
diseas
studi
shankhamul
kathmandu
nepal
background
way
compens
extens
blood
loss
blood
transfus
blood
donat
healthi
individu
use
purpos
therefor
activ
public
particip
essenti
blood
bank
liais
societi
motiv
public
blood
donat
besid
confirm
blood
safe
transfus
blood
bank
keep
record
donor
demand
met
time
aim
develop
countri
like
nepal
struggl
meet
demand
blood
due
sever
reason
lack
awar
gender
bias
ethnic
issu
unfit
donor
etc
paramet
may
chang
time
major
demograph
alter
requir
wide
correl
view
blood
donor
term
gender
ethnic
variat
blood
type
incid
tti
donor
method
retrospect
studi
data
volunt
blood
donor
visit
blood
bank
tribhuvan
univers
teach
hospit
kathmandu
collect
use
collect
data
project
number
age
distribut
donor
ii
blood
type
variat
iii
ethnic
variat
iv
correl
studi
ethnic
blood
type
variat
v
evid
tti
correl
ethnic
blood
type
spss
use
data
input
analysi
result
data
show
male
donor
femal
proport
respect
male
femal
popul
donor
within
age
group
year
brahmin
chhetri
newar
major
contributor
blood
donat
proport
respect
muslim
thakali
yadav
among
least
contributor
blood
donat
posit
common
blood
type
newar
chhetri
ethnic
proport
respect
posit
common
one
brahmin
donor
ab
neg
indic
least
common
blood
type
among
donor
studi
among
tti
hcv
common
gurung
lama
respect
follow
newar
despit
lower
number
popul
gurung
lama
ethnic
higher
incid
hcv
contrast
although
chhetri
brahmin
hold
major
popul
donor
incid
tti
donor
ethnic
low
ethnic
henc
data
warn
analysi
etiolog
higher
incid
hcv
gurung
lama
hcv
common
tti
observ
donor
posit
blood
group
blood
group
incid
tti
less
obviou
correl
observ
tti
ethnic
blood
type
summaryconclus
analysi
show
popul
age
group
motiv
blood
donat
strong
associ
ethnic
blood
group
blood
donat
incid
tti
q
zhou
blood
collect
beij
red
cross
blood
center
beij
china
background
china
offici
cancel
famili
member
donat
feb
order
improv
effici
apheresi
platelet
donor
recruit
increas
rate
platelet
donat
cope
collect
platelet
better
motiv
donor
devot
love
need
effect
innov
engag
activ
aim
understand
posit
effect
doubl
happi
activ
cope
apheresi
platelet
collect
understand
demograph
characterist
apheresi
platelet
donor
prefer
channel
know
activ
method
apheresi
platelet
donat
doubl
happi
activ
refer
two
donat
apheresi
platelet
extra
gift
reward
activ
collect
organ
activ
questionnair
fill
apheresi
platelet
donor
activ
analyz
demograph
factor
feedback
activ
inform
valid
questionnair
summar
horizont
analysi
evalu
result
dose
apheresi
platelet
collect
increas
significantli
period
last
year
activ
growth
donat
two
time
apheresi
platelet
donat
increas
activ
signific
increas
apheresi
platelet
donor
give
continu
apheresi
platelet
donat
amount
apheresi
platelet
dose
collect
increas
significantli
reach
expect
goal
amount
doubl
dose
donat
increas
significantli
summaryconclus
apheresi
platelet
donat
doubl
happi
activ
signific
posit
effect
cope
declin
apheresi
platelet
suppli
apheresi
platelet
collect
obviou
effect
increas
donat
apheresi
platelet
volum
stimul
apheresi
platelet
donor
term
mobil
apheresi
platelet
donor
activ
public
strategi
taken
accord
demograph
characterist
includ
sm
notif
phone
call
recruit
u
institut
biochemistri
biotechnolog
pma
arid
agricultur
univers
patholog
blood
bank
rawalpindi
institut
cardiolog
social
scienc
pma
arid
agricultur
univers
rawalpindi
blood
transfus
program
pakistan
biotechnolog
islam
intern
univers
islamabad
pakistan
background
volunt
behavior
social
base
happen
differ
rate
variou
geograph
area
variou
barrier
may
continu
exist
commun
like
concern
famili
member
friend
religi
ethnic
believ
influenc
potenti
voluntari
donor
increas
educ
health
safeti
concern
may
prove
effect
aim
understand
motiv
factor
behind
blood
donat
activ
respons
famili
blood
donat
actto
find
link
blood
donat
behaviour
volunt
activ
univers
student
method
studi
conduct
two
famou
univers
pakistan
ie
univers
islamabad
pma
arid
agricultur
univers
rawalpindi
univers
total
student
also
member
blood
donor
societi
randomli
select
face
face
interview
conduct
collect
data
collect
quantit
data
analyz
spss
result
major
age
group
studi
popul
year
n
respond
belong
provinc
pakistan
major
punjab
provinc
n
result
gener
questionnair
motiv
factor
respons
famili
show
respond
mother
illiter
becam
voluntari
donor
due
convinc
friend
student
tell
parent
voluntari
activ
question
ask
interview
told
parent
volunt
act
repli
due
fear
restrict
particip
also
involv
routin
emerg
volunt
activ
studi
popul
particip
donat
blood
replac
donat
particip
donat
blood
time
percent
respond
repli
religi
restrict
regard
donat
blood
voluntarili
repli
patient
receiv
blood
donor
differ
religion
state
blood
transfus
relationship
human
summaryconclus
studi
suggest
percept
toward
voluntari
blood
donat
could
influenc
larg
extent
variabl
barrier
voluntari
blood
donat
exist
predominantli
illiter
rural
commun
countri
young
gener
pakistan
altruist
natur
requir
educ
stimul
motiv
nation
level
especi
illiter
peopl
societi
increas
number
voluntari
blood
donat
also
need
make
blood
transfus
system
transpar
pakistan
sokolowski
l
gulinski
k
olbromski
blood
center
poznan
poznan
poland
background
blood
servic
poland
base
voluntari
donat
region
blood
donor
centr
poznan
well
region
centr
entiti
author
collect
process
store
distribut
blood
compon
hospit
region
activ
also
respons
provid
suffici
amount
blood
compon
henc
critic
introduc
suitabl
measur
increas
number
donor
aim
aim
survey
analys
common
reason
resign
donat
blood
subsequ
modifi
current
market
strategi
region
blood
centr
poland
method
survey
carri
septemb
group
donor
peopl
never
donat
blood
ask
question
regard
factor
influenc
decis
resign
donat
result
reason
resign
donat
blood
medic
reason
lack
time
lack
opportun
factor
influenc
decis
donat
blood
lack
remuner
common
belief
donat
blood
harm
blood
wast
blood
trade
final
fear
infect
side
effect
summaryconclus
donor
mention
medic
reason
key
reason
resign
donat
blood
vital
ensur
constant
avail
well
design
concis
educ
materi
regard
criteria
donor
must
meet
donat
blood
hard
copi
premis
articl
infograph
download
etc
websit
user
friendli
interfac
abil
contact
receiv
support
staff
especi
survey
regard
donor
percept
actual
medic
condit
lack
time
second
import
factor
influenc
decis
donat
blood
process
blood
collect
must
optimis
assur
shortest
time
necessari
spent
donor
give
blood
time
effect
commun
regard
numer
opportun
donat
blood
essenti
www
social
media
etc
creat
imag
full
access
polici
final
survey
show
often
occur
fals
belief
regard
blood
center
wast
blood
trade
potenti
harm
effect
donat
blood
etc
influenc
donor
henc
vital
keep
current
polici
regard
transpar
function
blood
donor
centr
well
continu
develop
variou
educ
activ
regard
donat
blood
donor
blood
safeti
qualifi
criteria
etc
l
h
heier
immunolog
transfus
medicin
univers
hospit
oslo
oslo
norway
background
compar
western
countri
norway
rel
blood
donor
norway
cellular
blood
compon
erythrocyt
thrombocyt
concentr
experi
increas
deficit
plasma
product
correspondingli
increas
import
plasma
product
paid
donor
continent
europ
need
inform
blood
donor
revers
imbal
product
use
blood
product
aim
previou
studi
indic
voluntari
blood
donor
recruit
often
social
class
class
oslo
averag
incom
level
consider
higher
western
eastern
part
citi
pilot
studi
suggest
howev
higher
frequenc
blood
donor
among
peopl
eastern
western
part
want
test
larger
cohort
also
ask
reason
becom
voluntari
blood
donor
method
blood
bank
oslo
ca
activ
blood
donor
ca
unit
whole
blood
per
month
collect
site
use
anonym
survey
collect
inform
gender
age
donat
site
current
address
recent
migrat
number
donat
week
period
answer
obtain
inhabit
citi
oslo
citi
region
compar
use
partial
regress
analysi
result
present
demograph
data
blood
donor
donat
site
report
blood
bank
young
men
compar
young
women
frequenc
blood
donor
oslo
estim
per
inhabit
slightli
higher
nation
averag
eastern
part
per
blood
donor
significantli
less
compar
western
area
p
citi
area
neighbour
donat
site
averag
donor
frequenc
per
distant
area
per
donor
p
summaryconclus
hypothesi
blood
donor
low
incom
eastern
area
support
studi
instead
found
signific
effect
blood
donor
frequenc
compar
area
near
donat
site
distant
area
conclud
easi
access
donat
site
main
determin
blood
donor
recruit
line
previou
find
practic
obstacl
eg
park
open
hour
often
import
donor
return
probabl
motiv
donat
misj
et
al
vox
sang
increas
donat
frequenc
oslo
seem
reason
consid
open
anoth
donat
site
area
distant
today
center
van
schalkwyk
gever
promot
public
relat
western
provinc
blood
transfus
servic
wpbt
cape
town
south
africa
background
research
shown
onlin
video
outperform
onlin
advertis
format
build
brand
awar
drive
purchas
decis
recognis
youth
hold
futur
safe
sustain
blood
suppli
hand
western
provinc
blood
transfus
servic
wpbt
south
africa
launch
youthtub
competit
aim
object
competit
drive
brand
engag
promot
blood
donat
provid
platform
young
aspir
filmmak
show
talent
creat
short
film
promot
blood
donat
method
success
south
african
youtub
grant
hind
ann
hirsch
invit
youth
creat
short
film
min
promot
blood
donat
detail
brief
competit
c
found
youthtub
tab
wpbt
websit
entri
categori
individu
school
learner
individu
tertiari
learner
competit
deadlin
month
entri
review
finalist
chosen
per
categori
finalist
video
upload
wpbt
websit
public
encourag
vote
favourit
within
month
vote
vet
winner
announc
invit
poster
sent
secondari
tertiari
institut
detail
competit
well
film
school
around
cape
town
text
messag
sent
youth
blood
donor
addit
promot
competit
done
quarterli
youth
newslett
social
media
radio
advertis
prize
includ
camera
equip
categori
winner
spot
prize
voter
result
individu
school
learner
entri
receiv
individu
tertiari
student
entri
receiv
number
video
view
number
vote
receiv
campaign
cost
approxim
facebook
reach
number
impress
facebook
number
youtub
view
summaryconclus
campaign
met
object
set
number
entri
video
view
vote
receiv
facebook
reach
impress
youtub
view
illustr
public
engag
wpbt
brand
campaign
grown
blood
donat
promot
fantast
final
video
much
longer
lifespan
competit
prize
also
help
winner
passion
filmmak
l
k
olbromski
blood
center
poznan
poznan
poland
background
poland
blood
servic
base
voluntari
blood
donat
unit
authoris
collect
process
storag
distribut
blood
blood
compon
treatment
region
blood
centr
militari
blood
centr
blood
centr
ministri
interior
affair
region
blood
centr
one
largest
centr
poland
throughout
countri
nation
blood
centr
nck
nation
coordin
activ
concern
blood
donat
separ
blood
compon
manag
blood
suppli
nck
specif
task
includ
among
other
suggest
solut
ensur
republ
poland
blood
blood
compon
blood
product
well
carri
task
relat
health
programm
field
blood
donat
blood
therapi
decemb
initi
nck
loyalti
program
financ
ministri
health
everi
drop
valuabl
implement
framework
health
polici
programm
entitl
ensur
republ
poland
blood
compon
year
aim
program
encourag
current
potenti
blood
donor
promot
social
posit
attitud
behaviour
collect
stamp
loyalti
card
exchang
donat
blood
compon
blood
donor
opportun
choos
symbol
reward
relat
promot
idea
voluntari
blood
donat
aim
analysi
effect
implement
loyalti
programm
everi
drop
valuabl
region
blood
centr
method
survey
involv
group
blood
donor
randomli
select
user
loyalti
program
fill
anonym
questionnair
result
survey
analys
take
account
follow
index
csi
custom
satisfact
index
custom
satisfact
index
sum
point
award
custom
categorynumb
categori
retent
rate
rr
mainten
rate
number
blood
donor
regist
donat
blood
given
periodnumb
donor
donat
blood
previou
period
result
decemb
januari
total
number
donor
sign
loyalti
program
mention
period
number
donat
particip
programm
total
user
loyalti
program
donor
donat
blood
oncein
analys
group
women
menin
analys
group
peopl
age
analys
group
donor
sign
loyalti
programm
obtain
inform
loyalti
program
visit
region
blood
center
custom
satisfact
rate
retent
rate
blood
donor
summaryconclus
implement
loyalti
program
brought
expect
result
prove
effect
promot
idea
voluntari
blood
donationin
order
increas
evalu
index
addit
form
inform
donor
possibl
particip
loyalti
programm
social
network
site
onlin
advertis
appliedwhen
analys
posit
effect
loyalti
scheme
note
use
tool
correl
voluntari
donat
blood
individu
element
manag
within
blood
collect
system
e
przybylska
k
olbromski
blood
center
poznan
poznan
poland
background
woodstock
festiv
poland
biggest
music
mass
event
take
place
everi
year
summer
kostrzyn
poland
attend
peopl
differ
subcultur
attract
approxim
peopl
variou
age
group
young
matur
particip
festiv
accompani
variou
event
cultur
one
theatric
perform
danc
workshop
tutor
person
develop
well
event
organ
differ
religi
group
also
opportun
donat
blood
blood
collect
festiv
high
import
level
blood
centr
summer
rel
low
event
make
possibl
promot
donat
blood
educ
wider
group
current
potenti
donor
aim
aim
analysi
estim
viru
safeti
blood
collect
woodstock
festiv
method
analysi
base
data
comput
system
bank
krwi
asseco
regard
first
time
repeat
donor
donat
blood
woodstock
festiv
poland
year
focus
particularli
donor
confirm
posit
viru
result
result
year
total
number
donor
donat
blood
area
activ
blood
centr
donat
blood
woodstock
festiv
account
total
number
donor
averag
number
donat
per
event
follow
posit
confirm
test
result
record
summaryconclus
number
donor
donat
blood
woodstock
festiv
count
total
number
donationsth
averag
number
donat
per
one
event
significantli
restock
blood
suppli
time
summer
holidaysth
infect
donor
first
time
donor
henc
conclus
first
time
donor
possess
knowledg
regard
donat
blood
mean
potenti
viru
infectionfurth
educ
activ
wider
scale
regard
respons
donat
blood
must
carri
outgrow
number
repeat
regular
donor
observ
show
awar
respons
donor
increasingalthough
particip
event
gener
mistakenli
perceiv
group
increas
risk
appli
thorough
method
medic
qualif
verif
donor
use
mean
viru
test
serolog
nat
method
allow
conclud
blood
collect
event
safe
recipientsfor
mani
repeat
donor
give
blood
woodstock
festiv
event
occas
year
decid
give
blood
time
prove
possibl
combin
entertain
help
need
v
compon
depart
russian
research
institut
hematolog
transfusiolog
servic
organ
depart
russian
research
institut
hematolog
transfusiolog
transfus
depart
russian
research
institut
hematolog
transfusiolog
laboratori
russian
research
institut
hematolog
transfusiolog
russian
feder
background
voluntari
donat
blood
blood
compon
basi
blood
servic
obtain
safe
effect
blood
product
government
program
blood
servic
develop
aim
develop
donat
system
creation
common
inform
base
blood
blood
compon
donat
technic
blood
servic
establish
implement
russian
feder
aim
aim
work
studi
dynam
indic
voluntari
donat
blood
blood
compon
blood
servic
establish
russian
feder
method
indic
activ
blood
servic
establish
russian
feder
sector
statist
observ
period
calcul
indic
character
level
develop
voluntari
donat
blood
blood
compon
analyz
data
present
accord
administr
divis
russian
feder
feder
district
fd
result
period
proport
voluntari
donor
blood
servic
establish
russian
feder
increas
reach
proport
voluntari
donor
siberian
volga
southern
fd
vari
region
russian
feder
voluntari
blood
donat
recent
year
progress
increas
number
voluntari
plasma
donor
percentag
plasma
donat
voluntari
donor
increas
greatest
number
voluntari
plasma
donat
observ
volga
siberian
central
fd
period
volum
blood
collect
voluntari
donor
increas
blood
collect
mobil
unit
blood
servic
establish
central
volga
siberian
fd
collect
largest
volum
donat
blood
proport
donor
variou
action
held
recruit
blood
donor
retain
regular
donor
blood
blood
compon
public
institut
organ
play
import
role
activ
purpos
educ
inform
program
creat
media
channel
social
network
use
summaryconclus
posit
chang
indic
blood
donat
voluntari
donor
blood
plasma
russian
feder
percentag
voluntari
donor
increas
percentag
voluntari
plasma
donat
volum
blood
collect
voluntari
donor
l
espensen
ei
lund
k
titlestad
klinisk
immunologisk
afdel
odens
universitetshospit
odens
c
denmark
background
computer
donor
questionnair
place
sinc
implement
reduc
number
cancel
donat
initi
accept
approx
per
quarter
approx
per
quarter
deferr
initi
accept
focu
involv
staff
utensil
blood
bank
number
donor
also
defer
donor
interview
fill
donor
questionnair
nt
fulfil
current
donor
select
criteria
number
follow
regular
basi
howev
import
donor
donat
voluntari
basi
defer
blood
bank
alreadi
spend
time
show
without
get
donat
could
lead
loss
donor
sever
studi
show
defer
donor
less
like
return
furthermor
staff
spent
time
look
questionnair
talk
donor
defer
abl
educ
donor
select
criteria
facilit
import
know
actual
number
deferr
reason
deferr
aim
aim
studi
assess
number
deferralsth
reason
deferralway
reduc
deferr
rate
method
donor
data
store
blood
bank
system
csam
prosang
stockholm
data
donor
questionnair
withdrawn
databas
gener
report
reason
deferr
data
includ
result
result
divid
whole
blood
donor
plasma
donor
select
criteria
differ
total
whole
blood
donor
show
defer
reason
mainli
medicin
defer
donor
deferr
quarantin
due
travel
defer
donor
deferr
diseas
oper
defer
donor
deferr
minor
deferr
rate
due
dentist
examin
deferr
tattoo
deferr
pierc
deferr
minor
reason
total
plasma
donor
show
defer
reason
mainli
medicin
defer
donor
deferr
diseas
oper
defer
donor
deferr
less
often
found
deferr
quarantin
due
travel
deferr
tattoo
deferr
acupunctur
deferr
pierc
deferr
minor
reason
summaryconclus
conclus
result
show
donor
deferr
criteria
could
improv
regard
drug
administr
travel
diseas
oper
blood
bank
could
benefit
better
inform
blood
bank
websit
order
save
time
staff
prevent
donor
wast
time
show
donat
defer
k
bank
gener
hospit
mandalay
laboratori
gener
hospit
pakokku
myanmar
background
donor
select
critic
blood
transfus
safeti
unnecessari
deferr
also
import
blood
adequaci
anemia
one
major
caus
temporari
donor
deferr
prevent
treatabl
iron
defici
world
widespread
nutrit
disord
especi
develop
countri
moreov
myanmar
high
preval
import
haemoglobinopathi
alpha
thalassaemia
hb
e
beta
thalassaemia
copper
sulfat
method
use
screen
blood
donor
haemoglobin
measur
blood
bank
gener
hospit
mandalay
howev
detect
etiolog
anemia
investig
etiolog
benefit
blood
donor
prompt
correct
iron
defici
proper
guidanc
haemoglobinopathi
prompt
current
studi
aim
determin
preval
etiolog
anemia
defer
blood
donor
aim
aim
current
studi
determin
actual
preval
anemia
blood
donor
defer
copper
sulfat
techniqu
haemoglobin
estim
etiolog
anemia
defer
blood
donor
regard
iron
defici
anemia
haemoglobinopathi
method
studi
done
blood
bank
gener
hospit
mandalay
myanmar
studi
includ
prospect
blood
donor
defer
copper
sulfat
techniqu
haemoglobin
estim
haemoglobin
estim
compar
autom
screen
method
blood
sampl
haemoglobin
level
less
target
valu
test
etiolog
anemia
g
male
g
femal
serum
ferritin
estim
done
chemiluminesc
immunoassay
identif
abnorm
haemoglobin
verifi
quantit
hemoglobin
electrophoresi
result
among
potenti
blood
donor
fit
donat
defer
preval
anemia
among
total
defer
donor
fifti
eight
initi
defer
donor
present
normal
hemoglobin
level
autom
method
male
femal
ratio
anemia
donor
among
actual
anem
donor
iron
defici
anemia
identifi
hb
e
trait
beta
thalassemia
trait
alpha
thalassemia
hb
e
beta
iron
defici
anemia
common
male
femal
howev
haemoglobinopathi
common
femal
summaryconclus
rate
temporari
defer
donor
anemia
high
discrep
observ
copper
sulfat
method
autom
screen
method
suggest
need
standard
constant
control
haemoglobin
screen
method
iron
defici
anemia
still
major
caus
anemia
follow
haemoglobinopathi
blood
donor
popul
preval
hb
e
slight
lower
gener
popul
preval
beta
thalassemia
trait
higher
gener
popul
wherea
alpha
thalassemia
trait
lower
recogn
type
anemia
provid
guid
futur
develop
programm
improv
blood
donor
health
promot
donor
recruit
achiev
blood
safeti
ultim
goal
abstract
withdrawn
abstract
withdrawn
l
pan
w
hu
blood
center
zhejiang
provinc
zhejiang
provinci
key
laboratori
blood
safeti
research
hangzhou
china
background
data
blood
donor
zhejiang
provinc
china
retrospect
analyz
proport
repeat
donor
global
proport
repeat
donor
meet
increas
demand
blood
clinic
use
necessari
increas
proport
repeat
donor
aim
establish
highli
reliabl
index
system
investig
evalu
behavior
intent
repeat
blood
donat
relat
influenc
factor
system
use
analyz
factor
affect
blood
donat
develop
strategi
first
blood
donor
recal
method
base
theori
plan
behavior
evalu
index
system
framework
behavior
intent
repeat
blood
donat
relat
influenc
factor
form
literatur
research
open
discuss
focu
group
expert
consult
evalu
index
system
carri
delphi
method
total
expert
scholar
select
carri
comprehens
evalu
aspect
attitud
cognit
behavior
control
subject
norm
identifi
screen
evalu
index
assign
weight
result
posit
coeffici
expert
consult
degre
author
expert
cr
determin
two
factor
expert
basi
judgment
point
point
practic
experi
intuit
express
coeffici
judgment
ca
expert
familiar
subject
point
point
familiar
unfamiliar
express
coeffici
familiar
cs
studi
expert
author
coeffici
index
system
cr
expert
author
consid
high
result
credibl
coordin
coeffici
expert
consult
analyz
test
p
statist
signific
expert
evalu
opinion
well
coordin
primari
indic
attitud
p
primari
indic
subject
behavior
criterion
p
primari
indic
perceptu
behavior
control
p
secondari
indic
preliminari
system
indic
develop
studi
final
credibl
effect
secondari
indic
obtain
summaryconclus
evalu
index
system
establish
studi
reliabl
use
tool
evalu
motiv
repeat
blood
donor
work
support
scienc
research
foundat
zhejiang
provinc
k
fuxian
z
yue
li
f
qing
l
haifeng
zhejiang
blood
center
hangzhou
china
background
retent
regular
blood
donor
basi
blood
safeti
strengthen
construct
regular
blood
donor
team
explor
scientif
concept
effect
oper
mode
voluntari
blood
donor
challeng
task
blood
center
staff
understand
composit
blood
donor
help
defin
key
popul
recruit
futur
direct
work
nation
plan
aim
aim
studi
analyz
platelet
apheresi
donor
hangzhou
statu
quo
construct
platelet
apheresi
donor
team
discuss
improv
strategi
order
provid
scientif
basi
construct
platelet
apheresi
donor
team
nation
plan
method
distribut
sex
age
blood
type
educ
background
number
donat
platelet
apheresi
donor
hangzhou
studi
data
analyz
spss
statist
softwar
result
number
amount
platelet
apheresi
donat
increas
respect
number
regular
platelet
apheresi
donor
number
regular
platelet
apheresi
donat
increas
significantli
p
amount
blood
donat
regular
platelet
apheresi
donor
account
total
amount
blood
increas
compar
proport
new
regular
platelet
apheresi
donat
increas
p
number
regular
apheresi
donor
type
type
b
type
ab
type
male
femal
highest
educ
degre
univers
degre
account
donor
donor
year
old
group
show
descend
group
show
ascend
trend
number
donat
regular
apheresi
donor
donat
year
decreas
number
donat
regular
apheresi
donor
donat
twice
year
account
largest
number
donat
three
five
time
year
account
number
regular
apheresi
donor
donat
ten
time
year
year
increas
donat
increas
donor
six
nine
time
year
increas
respect
summaryconclus
although
construct
platelet
apheresi
donor
achiev
remark
result
great
room
improv
develop
accur
recruit
retent
mainten
target
group
import
healthi
sustain
develop
construct
platelet
apheresi
donor
dm
f
blood
bank
colombian
red
cross
de
escuela
de
medicina
ciencia
de
la
salud
universidad
del
rosario
blood
bank
colombian
red
cross
para
alternativa
la
fuat
dc
colombia
background
low
hemoglobin
level
one
main
caus
donor
deferr
aim
identifi
proport
repetit
altruist
blood
donor
defer
exclus
due
low
hemoglobin
time
select
method
consid
repetit
altruist
donor
import
input
blood
bank
popul
defin
person
made
two
donat
last
day
includ
whole
blood
plateletpheresi
erythropheresi
total
number
regist
donat
select
well
total
number
defer
donor
regist
softwar
tharsi
subsequ
repetit
defer
donor
select
hemoglobin
lower
gdl
women
gdl
men
mean
uniqu
identif
number
cut
point
hemoglobin
use
appli
resid
studi
popul
masl
comparison
popul
student
test
test
use
use
sigmastat
softwar
result
repetit
donor
contribut
donat
total
receiv
men
abund
period
analyz
repetit
donor
made
averag
donat
rang
howev
made
donat
men
within
group
donor
donat
men
p
identifi
episod
deferr
low
hemoglobin
repetit
donor
women
occur
donor
p
popul
peopl
least
one
previou
donat
last
year
remain
donor
least
one
donat
low
hb
deferr
period
studi
total
donat
collect
correspond
whole
blood
plateletpheresi
erythropheresi
defer
donat
correspond
low
hemoglobin
frequent
exclus
women
men
time
p
donor
repetit
one
base
data
obtain
estim
repetit
donor
analysi
bank
five
time
less
like
defer
low
hemoglobin
compar
first
time
donor
summaryconclus
although
popul
repetit
donor
blood
bank
period
analyz
repres
peopl
frequenc
defer
low
hemoglobin
total
donor
popul
per
donat
deduc
donor
one
greatest
impact
caus
deferr
therefor
data
suggest
repetit
donat
seem
caus
appear
low
hb
reflect
deferr
eventu
loss
valuabl
repetit
altruist
donor
bajpaye
depart
transfus
medicin
blood
bank
aiim
jodhpur
india
background
year
world
health
assembl
resolut
establish
effici
nation
blood
transfus
servic
base
voluntari
non
remuner
donat
vnrd
countri
still
face
deficit
safe
blood
patient
nation
blood
polici
formul
first
object
provid
safe
adequ
quantiti
blood
compon
recommend
action
plan
achiev
object
monitor
blood
transfus
servic
achiev
goal
vnrbd
even
though
number
outdoor
voluntari
blood
donat
camp
markedli
increas
region
actual
collect
blood
guarante
provis
safe
blood
patient
well
donor
safeti
drive
forc
behind
camp
equal
import
aim
aim
studi
assess
qualiti
safeti
aspect
vbdc
actual
statu
donor
screen
donor
select
method
follow
outdoor
blood
donat
camp
object
understand
current
barrier
collect
safe
blood
without
compromis
donor
safeti
method
studi
period
march
februari
wit
voluntari
blood
donat
camp
variou
region
jodhpur
district
outdoor
blood
donat
camp
two
indoor
camp
insid
blood
bank
nation
aid
control
organ
naco
india
central
drug
standard
control
organ
cdsco
india
given
guidelin
defin
minimum
basic
standard
follow
outdoor
voluntari
blood
donat
camp
evalu
camp
track
complianc
five
paramet
safeti
hygien
handl
biomed
wast
donor
hemoglobin
screen
complet
donor
questionnair
consent
form
post
donat
care
role
incent
voluntari
blood
donat
also
made
small
documentari
mega
blood
donat
drive
common
practic
countri
result
region
outdoor
blood
donat
camp
organ
local
commun
cast
base
organ
local
leader
camp
conduct
educ
institut
offic
noncompli
observ
privat
standalon
blood
bank
five
paramet
state
govern
blood
bank
noncompli
associ
individu
paramet
vari
number
blood
unit
collect
camp
variou
particip
blood
bank
vari
also
increas
wastag
unit
due
outdat
drive
forc
behind
camp
also
non
altruist
summaryconclus
mega
blood
donat
camp
donor
screen
post
donat
care
serious
compromis
need
urgent
attent
nation
health
polici
maker
nation
blood
polici
defin
paper
still
need
implement
even
year
format
mechan
evalu
adher
guidelin
regular
strict
monitor
blood
bank
licens
author
sj
h
z
comsat
institut
inform
technolog
ciit
govern
servic
hospit
post
graduat
medic
institut
islamabad
pakistan
background
voluntari
blood
donat
vnrbd
consid
safest
transfus
pakistan
concept
voluntari
donat
rare
continu
increas
blood
demand
met
mostli
replac
blood
donor
arrang
famili
recipi
current
practic
replac
system
pressur
attend
recipi
provid
blood
donor
transfus
creat
huge
risk
blood
safeti
danger
multipl
donat
famili
member
recipi
day
arrang
paid
donor
instig
blood
bank
staff
pilferag
blood
exclud
pakistan
one
signatori
world
health
organ
resolut
reach
vnrbd
govern
pakistan
govern
germani
spend
huge
budget
technic
servic
blood
transfus
system
pakistan
around
privat
blood
donor
organ
current
promot
collect
voluntari
donat
pakistan
despit
variou
effort
govern
privat
organ
signific
increas
voluntari
blood
donat
studi
done
dig
reason
low
rate
vnrbd
pakistan
aim
document
knowledg
attitud
practic
among
popul
elig
donationto
help
polici
maker
set
strategi
promot
vnrbd
method
studi
conduct
januari
decemb
individu
respond
questionnair
respond
resid
district
across
pakistan
data
collect
visit
sever
blood
camp
univers
data
analysi
perform
use
r
result
total
particip
donat
blood
least
non
donor
none
donor
regular
voluntari
donor
donat
blood
friend
famili
replac
transfus
survey
taken
femal
male
particip
donat
least
femal
male
common
reason
opportun
lack
awar
fear
donat
respond
thought
blood
screen
pakistan
sure
will
becom
regular
donor
sure
particip
awar
basic
question
apart
volum
blood
donat
time
answer
correctli
summaryconclus
studi
highli
endors
elig
blood
donor
less
awar
process
import
donat
blood
femal
popul
need
target
blood
donor
campaign
awar
blood
donat
ad
curricula
high
school
graduat
level
opportun
creat
elig
blood
donor
commun
form
blood
camp
mat
h
moham
f
abdul
medic
dental
institut
kepala
bata
pulau
pinang
darah
negara
kuala
lumpur
transfus
unit
hospit
sultanah
nur
zahirah
kuala
terengganu
terengganu
malaysia
background
increment
blood
util
reduct
blood
collect
lead
blood
suppli
shortag
worldwid
problem
includ
malaysia
note
terengganu
record
lowest
blood
donat
rate
among
state
malaysia
five
consecut
year
still
lag
far
behind
despit
increment
yearli
usag
blood
aim
determin
knowledg
attitud
score
toward
blood
donat
associ
among
donor
resid
kuala
terengganu
hospit
sultanah
nur
zahirah
hsnz
method
studi
use
questionnair
includ
demograph
data
knowledg
attitud
section
three
hundr
twenti
particip
donor
resid
kuala
terengganu
attend
hsnz
select
use
systemat
random
sampl
result
percent
particip
heard
blood
donat
social
media
anoth
heard
televis
radio
gener
particip
good
knowledg
toward
blood
donat
mean
score
possibl
attitud
particip
good
attitud
mean
score
possibl
howev
signific
associ
found
knowledg
score
attitud
score
p
major
particip
agre
statement
want
blood
given
religion
follow
statement
want
blood
given
race
statement
donat
fear
needl
blood
donat
pain
agre
particip
summaryconclus
particip
record
good
mean
knowledg
score
mean
attitud
score
pertain
blood
donat
could
explain
knowledg
share
internet
social
media
provid
everi
individu
age
group
differ
sociodemograph
background
open
access
platform
howev
knowledg
popul
mean
follow
posit
attitud
also
explain
lowest
blood
donat
rate
record
previous
situat
could
mask
myth
fals
belief
regard
blood
donat
alway
spread
around
without
intent
correct
gain
knowledg
proper
channel
especi
regard
blood
donat
differ
religion
race
depend
cultur
custom
hered
differ
popul
support
result
barrier
blood
donat
particip
refus
give
blood
race
religion
gener
knowledg
attitud
toward
blood
donat
good
howev
significantli
associ
translat
practic
blood
transfus
servic
must
focu
barrier
donat
blood
take
appropri
step
overcom
myth
fals
belief
regard
blood
donat
suit
multicultur
background
popul
enlighten
religi
depart
full
use
social
media
interact
could
help
correct
myth
subsequ
rais
awar
toward
blood
donat
among
popul
j
br
b
g
r
nacion
mayor
de
san
marco
peruana
cayetano
heredia
lima
peru
background
peru
voluntari
blood
donat
scarc
practic
repres
less
avail
blood
blood
bank
lack
voluntari
blood
donor
major
public
health
challeng
blood
demand
mainli
cover
replac
donor
therefor
necessari
identifi
factor
affect
voluntari
donat
blood
come
gener
popul
aim
explor
knowledg
attitud
practic
blood
donat
among
peopl
commun
method
octob
conduct
pilot
studi
among
adult
health
care
provid
health
scienc
student
elig
particip
studi
particip
select
use
nonrandom
sampl
techniqu
particip
underw
oral
inform
consent
survey
public
place
lima
peru
structur
survey
appli
collect
demograph
knowledg
attitud
practic
regard
blood
donat
assess
associ
futur
intent
donat
blood
potenti
explanatori
variabl
relat
demograph
knowledg
attitud
practic
preval
ratio
pr
estim
use
gener
linear
model
data
analysi
perform
stata
consid
p
signific
result
among
respond
male
year
old
profession
worker
knowledg
regard
blood
use
elig
criteria
relat
age
weight
minimum
interv
time
donat
blood
safeti
vari
even
inadequ
among
particip
needl
phobia
lack
inform
donat
process
distrust
steril
materi
use
blood
extract
believ
blood
subsequ
sold
frequent
reason
report
donat
blood
respond
admit
donat
blood
interestingli
highlight
import
blood
donat
howev
could
donat
futur
mainli
motiv
sick
rel
friend
nation
catastroph
year
old
significantli
associ
better
attitud
futur
blood
donat
follow
group
p
peopl
year
old
p
peopl
older
p
lower
predisposit
futur
blood
donat
compar
young
peopl
sex
work
statu
knowledg
independ
predictor
futur
blood
donat
summaryconclus
find
suggest
level
knowledg
relat
blood
donat
process
scarc
frequent
mistaken
despit
good
attitud
voluntari
blood
donat
possibl
lack
inform
fear
repres
main
barrier
prevent
voluntari
donat
young
peopl
year
old
could
repres
target
public
promot
voluntari
donat
inform
commun
requir
blood
donat
process
could
potenti
increas
voluntari
donat
e
n
e
e
region
blood
center
krasnoyarsk
region
blood
center
stavropol
nation
medic
surgic
center
moscow
russian
feder
background
toxic
effect
tobacco
smoke
influenc
rheolog
properti
blood
coagul
activ
hematolog
score
develop
inflammatori
reaction
impact
tobacco
smoke
blood
donor
organ
predon
test
donor
discuss
aim
evalu
impact
tobacco
smoke
concentr
hemoglobin
blood
donor
method
predon
blood
test
donor
studi
male
femal
mean
age
year
associ
hemoglobin
concentr
sex
height
weight
age
smoke
experi
number
cigarett
smoke
per
day
estim
result
mean
concentr
hemoglobin
men
gl
women
gl
p
associ
hemoglobin
concentr
age
reveal
howev
concentr
hemoglobin
correl
posit
growth
r
p
weight
r
p
hemoglobin
concentr
higher
group
smoke
donor
group
gl
p
increas
smoke
experi
test
h
critic
valu
p
posit
correl
concentr
hemoglobin
number
cigarett
smoke
per
day
establish
r
p
summaryconclus
hemoglobin
concentr
blood
donor
associ
age
donor
hemoglobin
concentr
higher
among
smoke
donor
increas
smoke
experi
correl
posit
growth
weight
number
cigarett
smoke
per
day
abstract
withdrawn
g
j
technician
career
depart
escuela
universitaria
de
de
facultad
de
medicina
universidad
de
la
orient
del
uruguay
montevideo
bank
transfus
medicin
technolog
hemocentro
region
maldonado
maldonado
uruguay
background
blood
donor
select
key
step
blood
safeti
donor
deferr
play
major
role
relat
blood
bank
donor
base
sinc
impact
blood
qualiti
process
keep
loyal
educ
blood
donor
base
deferr
rate
may
vari
blood
center
countri
rate
report
aim
analyz
blood
donat
center
period
assess
rate
reason
deferr
return
deferr
method
perform
retrospect
analysi
blood
center
databas
descript
statist
analysi
well
test
compar
defer
donor
subpopul
p
statist
analysi
perform
spss
result
person
concur
center
donat
blood
defer
tri
donat
voluntarili
rest
either
replac
blood
donor
enterpris
agreement
temporarili
defer
women
differ
mean
age
sex
year
women
year
men
defer
donor
point
donat
blood
center
defer
period
defer
return
defer
occas
number
adjust
higher
sinc
donor
complet
temporari
deferr
period
return
defer
donor
gener
found
differ
men
women
p
import
deferr
caus
low
hemoglobin
hypertens
relev
medic
treatment
sexual
risk
behavior
hypotens
state
recent
surgeri
other
includ
get
tatoo
less
one
year
recent
use
marijuana
low
weight
recent
vaccin
travel
endem
zone
signific
defer
donor
subpopul
behav
defer
donor
exhibit
better
return
rate
expect
gener
defer
donor
popul
differ
statist
signific
includ
hypotens
return
p
hypertens
p
state
p
recent
use
marijuana
p
lowest
return
rate
low
weight
p
bodi
pierc
p
sexual
risk
behavior
p
also
low
weight
bodi
pierc
defer
donor
repeat
lowest
rate
effect
donat
time
respect
compar
defer
donor
summaryconclus
center
defer
person
present
facil
donat
blood
defer
temporarili
defer
donor
donat
blood
either
tri
donat
voluntarili
subgroup
defer
donor
return
consist
import
defer
due
hypotens
hypertens
state
recent
use
marijuana
subgroup
almost
never
return
defer
due
low
weight
bodi
pierc
sexual
risk
behaviour
promin
age
factor
return
defer
donor
analysi
defer
donor
popul
characterist
provid
institut
opportun
plan
intervent
educ
moment
deferr
coupl
promot
effort
impact
deferr
better
understood
donor
akmeemana
de
silva
dayarathn
perera
blood
bank
provinci
gener
hospit
badulla
sri
lanka
background
accord
annual
report
nation
stdaid
control
programm
nsacp
sri
lanka
voluntari
blood
donor
confirm
hiv
infect
upward
trend
number
blood
donor
detect
hiv
year
possibl
transmit
hiv
patient
window
period
donat
discontinu
mobil
campaign
organ
main
recruit
blood
donor
sound
knowledg
hivaid
help
identifi
recruit
safe
blood
donor
aim
mobil
blood
donat
campaign
organ
uva
provinc
sri
lanka
year
assess
basic
knowledg
hivaid
identifi
high
risk
person
popul
societi
method
transmiss
hiv
treatment
option
avail
attitud
societi
toward
hiv
infect
person
knowledg
relev
blood
donat
transmiss
hiv
blood
transfus
studi
also
analyz
answer
relat
educ
qualif
mobil
organ
first
time
versu
repeat
campaign
organ
method
prospect
studi
use
structur
self
administ
questionnair
hand
mobil
organ
data
collect
statist
comparison
perform
use
test
spss
p
consid
statist
signific
result
mobil
campaign
organ
consent
particip
studi
among
studi
ordinari
level
ol
advanc
level
al
graduat
first
time
mobil
organ
regular
organ
analyz
basic
knowledg
hivaid
knew
hiv
transmit
viru
knew
hiv
infect
identifi
earli
stage
diseas
specif
symptom
awar
nsacp
facil
free
hiv
test
clinic
identifi
high
risk
popul
societi
identifi
correctli
high
risk
categori
knew
peopl
sexual
transmit
diseas
bear
higher
risk
contract
hiv
good
knowledg
method
transmiss
hiv
regard
knowledg
blood
donat
transmiss
hiv
knew
blood
unit
collect
test
hiv
transfus
thought
screen
blood
safe
unawar
risk
window
period
donat
respond
knew
one
infect
unit
transmit
diseas
sever
patient
blood
compon
organ
knew
hiv
infect
blood
donat
detect
sri
lanka
studi
also
show
posit
attitud
among
particip
toward
hiv
infect
person
regard
welfar
treatment
analyz
data
relat
organ
level
educ
ol
ol
al
graduat
high
educ
level
higher
basic
knowledg
hivaid
p
identifi
better
high
risk
popul
group
contract
hiv
p
awar
window
period
hiv
test
risk
p
signific
consid
first
time
versu
regular
organ
summaryconclus
studi
show
clearli
campaign
organ
educ
rel
sound
knowledg
subject
hivaid
better
recruit
safe
blood
donor
conduct
educ
programm
recruit
increas
qualiti
transfus
servic
n
van
r
k
b
servic
research
australian
red
cross
blood
servic
melbourn
psycholog
univers
queensland
st
lucia
australia
background
demand
plasma
product
therefor
reliabl
plasma
donat
continu
grow
australia
first
time
plasma
donor
retent
frequenc
subsequ
donat
press
issu
plasma
donor
australia
donat
everi
two
week
oppos
everi
week
whole
blood
yet
plasma
donor
return
within
four
month
first
plasma
donat
moreov
averag
plasma
donat
frequenc
time
per
year
previou
research
explor
motiv
facilit
barrier
affect
convers
plasma
donat
howev
littl
understand
initi
experi
plasmapheresi
encourag
new
plasmapheresi
donor
return
donat
regular
basi
aim
explor
prompt
donor
convert
plasmapheresi
identifi
intent
return
donat
plasma
futur
frequenc
method
telephon
interview
conduct
donor
given
first
plasma
donat
within
preced
day
donor
sampl
repres
broad
mix
age
gender
locat
prior
whole
blood
wb
donat
experi
interview
approxim
minut
length
record
transcrib
qualit
techniqu
use
code
interview
identifi
key
theme
result
studi
particip
n
littl
prior
knowledg
plasma
donat
blood
servic
staff
member
ask
consid
blood
centr
staff
also
report
primari
sourc
inform
includ
frequenc
donat
import
sourc
support
donat
process
particip
identifi
abl
donat
frequent
benefit
donat
plasma
compar
wb
frequent
donat
would
allow
help
peopl
often
easili
establish
donat
routin
express
intent
donat
plasma
indic
intend
donat
minimum
interv
australia
everi
two
week
respons
prioriti
live
donor
indic
frequenc
donat
plasma
need
often
enough
meaning
contribut
often
chore
prefer
frequenc
donat
everi
four
week
summaryconclus
find
indic
plasma
donor
posit
orient
toward
establish
donat
routin
earli
career
importantli
decis
futur
donat
made
context
want
help
mani
peopl
possibl
donat
also
activ
assess
fit
behaviour
live
meet
balanc
donor
intend
donat
often
blood
servic
allow
everi
two
week
australian
context
often
current
averag
provid
preliminari
support
introduc
initi
earli
career
assist
donor
establish
donat
frequenc
substanti
higher
typic
donat
experi
countri
j
kimera
blood
donor
recruit
depart
uganda
blood
transfus
servic
kampala
uganda
background
blood
donat
remark
safe
medic
procedur
howev
attitud
belief
level
knowledg
may
affect
rang
organiz
physiolog
psycholog
factor
may
influenc
peopl
willing
donat
blood
educ
posit
influenc
attitud
toward
blood
donat
well
blood
donor
satisfact
time
locat
donat
common
misconcept
blood
donat
risk
infect
sell
donat
blood
patient
blood
donat
believ
caus
physic
weak
aim
measur
level
knowledg
regard
blood
donationto
find
posit
neg
attitudesto
suggest
motiv
factor
method
studi
conduct
nakasero
blood
bank
particip
select
conveni
sampl
techniqu
questionnair
use
data
collect
august
novemb
result
studi
includ
individu
particip
claim
histori
blood
donat
report
caus
donat
blood
blood
donat
cross
mind
time
donat
difficulti
access
blood
donat
center
report
motiv
factor
donat
blood
one
day
mobil
blood
donat
caravan
public
area
token
gift
summaryconclus
peopl
age
group
year
male
femal
higher
educ
militari
like
donat
blood
well
peopl
show
higher
knowledg
level
posit
attitud
toward
blood
donat
anthropolog
studi
blood
donat
need
plan
effect
revis
target
blood
donat
campaign
also
focu
motiv
factor
recommend
ml
zucoloto
n
menez
b
custer
w
mcfarland
e
martinez
paulo
preto
system
research
california
san
francisco
san
francisco
unit
state
america
background
blood
bank
around
world
struggl
perman
deficit
blood
despit
effort
compris
psychosoci
factor
associ
blood
donat
far
littl
known
reason
impact
differ
barrier
blood
donat
behavior
distinct
popul
fear
anxieti
due
fear
associ
blood
donat
consid
relev
barrier
blood
donat
scientif
literatur
howev
fear
blood
inject
vasovag
reaction
never
investig
blood
donat
context
aim
investig
fear
blood
inject
vasovag
reaction
associ
blood
donat
attitud
practic
sampl
primari
healthcar
user
brazilian
municip
method
survey
stratifi
repres
sampl
interview
carri
healthcar
facil
studi
variabl
lifetim
donat
profil
frequenc
donat
never
donat
unabl
donat
attitud
regard
blood
donat
among
intent
donat
futur
never
thought
donat
current
donat
profil
current
unabl
donat
need
blood
donat
frequenc
assess
fear
blood
fbg
fear
inject
fig
fear
vasovag
reaction
ffi
use
blood
injectionfear
scale
bif
test
associ
variabl
use
regress
model
condit
infer
tree
cit
result
total
primari
healthcar
user
particip
femal
mean
year
never
donat
blood
claim
unabl
donat
donat
donat
time
donat
time
donat
time
femal
exhibit
higher
score
fig
fbg
ffi
associ
middl
socioeconom
statu
among
studi
particip
never
intend
donat
exhibit
highest
score
three
dimens
fear
accord
cit
gender
variabl
best
distinguish
donor
femal
present
high
score
fbg
characterist
associ
decreas
blood
donat
among
male
blood
donat
frequenc
low
among
age
year
summaryconclus
fear
blood
inject
vasovag
reaction
associ
blood
donat
attitud
practic
consid
import
barrier
blood
donat
decis
brazilian
sampl
primari
healthcar
user
l
z
blood
transfus
research
center
institut
blood
transfus
cam
pumc
chengdu
china
northwest
seattl
unit
state
america
background
screen
blood
donor
antibodi
hcv
hcv
nucleic
acid
test
nat
well
establish
venu
prevent
hcv
transmit
diseas
howev
current
avail
technolog
hcv
test
may
result
donor
loss
due
fals
posit
result
studi
intend
establish
donor
reentri
procedur
hcv
screen
reactiv
donor
china
aim
establish
blood
donor
reentri
strategi
hcv
nucleic
acid
test
nat
screen
reactiv
donor
method
studi
collabor
institut
blood
transfus
ibt
chines
academi
medic
scienc
blood
center
sampl
elisa
nat
screen
reactiv
collect
sent
ibt
jan
sept
confirm
track
identif
donor
hcv
antibodi
true
posit
fals
posit
result
sampl
collect
twelv
blood
center
china
donor
could
classifi
success
true
posit
fals
posit
donor
abandon
unsuccess
hcv
antibodi
posit
rate
nat
screen
reactiv
donor
summaryconclus
accord
experiment
result
blood
donor
confirm
strategi
hcvnat
screen
reactiv
donor
formul
result
elisa
reactiv
donor
determin
hcv
antibodi
posit
result
elisa
reactiv
riba
posit
donor
determin
hcv
antibodi
posit
result
reactiv
riba
neg
three
month
result
reactiv
three
month
accord
reentri
strategi
donor
determin
true
posit
donor
determin
fals
posit
reenter
safe
abstract
withdrawn
sa
ali
usama
mirza
laboratori
patel
hospit
karachi
pakistan
background
provis
safe
adequ
blood
fundament
part
blood
bank
servic
crucial
step
prevent
transfus
transmit
infect
notifi
counsel
reactiv
donor
blood
donor
post
donat
notif
counsel
blood
donor
protect
health
donor
also
prevent
secondari
transmiss
infecti
diseas
aim
aim
studi
determin
respons
rate
reactiv
blood
donor
notif
screen
statu
method
observ
studi
carri
patel
hospit
blood
bank
period
month
juli
novemb
involv
total
donor
blood
donor
inform
blood
bank
staff
abnorm
test
result
advic
report
blood
bank
counsel
referr
respect
departmentclin
hospit
manag
respons
rate
reactiv
donor
notif
abnorm
test
result
evalu
result
total
reactiv
donor
reactiv
donor
could
contact
respond
posit
notif
call
attend
counsel
blood
bank
reactiv
donor
could
contact
either
due
incorrectchang
contact
detail
pick
call
even
three
attempt
summaryconclus
respons
rate
reactiv
donor
found
respons
rate
reactiv
blood
donor
develop
countri
quit
low
suggest
insuffici
health
care
knowledg
poor
understand
screen
test
abstract
withdrawn
e
e
tetovo
strumica
skopj
macedonia
background
analysi
socio
demograph
structur
blood
donor
region
center
tetovo
achiev
signific
inform
sever
crucial
issu
plan
boost
number
voluntari
donor
well
program
gain
new
blood
donor
aim
prepar
plan
stimul
blood
donat
region
especi
young
popul
emphasi
high
school
student
univers
student
due
fact
popul
age
method
studi
cover
one
year
period
start
januari
decemb
region
center
tetovo
includ
blood
donat
depart
transfusiolog
well
mobil
team
field
outsid
depart
input
materi
use
studi
data
local
blood
donor
registri
result
analyz
period
collect
blood
unit
blood
unit
collect
depart
transfusiolog
unit
collect
field
mobil
team
major
blood
unit
voluntari
precis
unit
male
donor
domin
particip
blood
unit
femal
donor
unit
blood
donor
donat
blood
first
time
particip
unit
blood
donor
donat
blood
sever
time
greater
particip
blood
unit
employ
blood
donor
domin
particip
unit
unemploy
blood
donor
unit
unit
collect
high
school
student
collect
univers
student
retir
popul
particip
unit
unit
donat
macedonian
unit
albanian
unit
donat
nation
even
though
percentag
blood
unit
donat
albanian
higher
macedonian
nation
must
put
emphasi
fact
albanian
popul
approxim
tetovo
therefor
particip
insignificantli
higher
summaryconclus
blood
unit
region
center
tetovo
collect
two
sourc
almost
equal
import
howev
studi
conclud
unit
collect
depart
transfusiolog
prevail
analyz
unit
show
vast
major
blood
collect
voluntari
unit
donat
male
popul
major
blood
donor
donat
blood
sever
time
employ
popul
crucial
blood
donat
term
nation
albanian
donat
blood
unit
nation
futur
intent
implement
promot
activ
order
increas
blood
donat
femal
high
school
univers
student
unemploy
peopl
nation
especi
albanian
major
popul
tetovo
b
hermundstad
llohn
knutsen
mousavi
blood
bank
akershu
univers
hospit
norway
background
adequ
blood
suppli
depend
stabil
donor
corp
alway
need
recruit
new
volunt
replac
outgo
donor
due
variou
reason
age
limit
migrat
travel
deferr
everi
blood
bank
know
best
method
recruit
volunt
blood
donor
aim
aim
studi
provid
knowledg
variou
method
blood
donor
recruit
blood
bank
investig
whether
method
recruit
influenc
demograph
chang
time
method
data
collect
use
questionnair
given
donor
donor
stratifi
recruit
group
recruit
friendscolleagu
recruit
famili
recruit
method
red
cross
webpag
media
recruit
campaign
facebook
assess
chang
time
donor
group
five
period
result
compar
group
recruit
friendscolleagu
group
recruit
famili
significantli
higher
percentag
men
vs
higher
percentag
age
group
vs
higher
percentag
rhd
neg
blood
type
vs
logist
regress
model
rhd
neg
blood
type
singl
import
predictor
recruit
famili
adjust
odd
ratio
p
proport
donor
regist
http
wwwgiblodno
increas
significantli
period
mean
age
recruit
increas
year
year
summaryconclus
find
show
effect
method
blood
bank
encourag
blood
donor
recruit
famili
member
friendscolleagu
recruit
famili
member
becom
import
donor
less
common
blood
type
increas
proport
peopl
regist
http
wwwgiblodno
blood
donor
encourag
e
petkovikj
g
andonov
blagoevska
k
dimitrovski
r
grubov
useini
l
mitevska
institut
transfus
medicin
skopj
macedonia
background
improv
blood
donat
process
one
mission
goal
institut
transfus
medicin
itm
skopj
continu
provid
suffici
amount
safe
blood
aim
aim
studi
analyz
structur
donor
donat
blood
blood
donor
session
organ
itm
skopj
republ
macedonia
studi
variabl
like
gender
profess
well
first
time
donor
method
retrospect
studi
perform
use
data
offici
record
mobil
team
donat
itm
year
result
collect
blood
unit
blood
unit
total
number
male
femal
employ
unemploy
high
school
student
univers
student
retir
one
blood
donor
male
femal
employ
unemploy
high
school
student
univers
student
retir
one
blood
donor
discuss
around
blood
donor
men
increas
women
blood
donor
employ
largest
group
among
blood
donor
high
percentag
increas
vs
doubl
reduct
unemploy
blood
donor
high
school
student
vs
summaryconclus
develop
better
strategi
motiv
recruit
new
blood
donor
among
youth
especi
keep
regular
donor
need
p
research
center
high
institut
research
educ
transfus
medicin
tehran
research
center
high
institut
research
educ
transfus
medicin
shiraz
faculti
shahid
beheshti
univers
medic
scienc
tehran
faculti
ahvaz
jundishapur
univers
medic
scienc
ahvaz
iran
background
main
goal
blood
transfus
organ
provid
safe
adequ
blood
suppli
ensur
stringent
elig
blood
donor
select
criteria
must
implant
along
sensit
laboratori
screen
test
evalu
donor
deferr
reason
use
design
effici
donor
select
strategi
aim
evalu
blood
donor
select
deferr
pattern
south
iran
method
retrospect
studi
carri
volunt
admit
far
blood
transfus
organ
fbto
south
iran
year
total
deferr
rate
donor
analyz
within
demograph
characterist
donor
statu
thereaft
deferr
reason
calcul
result
overli
blood
donor
volunt
admit
studi
period
among
defer
donat
perman
temporarili
deferr
rate
male
femal
respect
moreov
rate
regular
laps
donor
respect
seventeen
percent
donor
defer
physic
examin
common
caus
donor
deferr
unsaf
sexual
contact
tattoo
acupunctur
ear
pierc
summaryconclus
find
indic
deferr
rate
countri
slightli
higher
region
may
caus
strictli
donor
select
criteria
usual
defer
blood
donor
return
donat
blood
consequ
high
donor
deferr
rate
lead
decreas
blood
donor
pool
henc
nation
guidelin
blood
donor
select
reconsid
decreas
unnecessari
deferr
abstract
withdrawn
abstract
withdrawn
abstract
withdrawn
abstract
withdrawn
bb
gorbachev
memori
institut
children
oncolog
hematolog
transplant
st
petersburg
state
medic
univers
saint
petersburg
russian
feder
scientif
blood
center
dushanb
tajikistan
background
medic
withdraw
blood
donat
remain
relev
problem
neg
affect
overal
state
donat
one
frequent
reason
decreas
hemoglobin
level
associ
iron
defici
reveal
blood
donor
determin
donor
ferritin
concentr
serum
allow
identifi
iron
reserv
aim
determin
reason
low
hemoglobin
level
regular
blood
donor
develop
method
reduc
number
medic
withdraw
blood
donat
method
assess
tissu
iron
store
blood
donor
concentr
serum
ferritin
sf
determin
immunoradiometr
assay
method
immunotech
routin
hematolog
paramet
analyz
content
sf
determin
blood
donor
male
femal
similar
paramet
examin
femal
blood
donor
regular
blood
donat
male
blood
donor
regular
blood
donat
one
year
comparison
group
consist
blood
donor
n
includ
men
women
underw
addit
treatment
bival
iron
blood
donat
mg
day
day
oral
donor
age
rang
year
result
content
sf
hemoglobin
erythrocyt
hematocrit
differ
primari
regular
blood
donor
regular
blood
donor
addit
iron
supplement
tabl
frequenc
medic
withdraw
blood
donat
primari
donor
due
low
serum
blood
paramet
men
women
donor
addit
iron
supplement
number
medic
withdraw
due
low
hemoglobin
case
case
regular
donor
take
iron
mostli
femal
summaryconclus
regular
blood
donat
hot
dri
climat
lead
deplet
iron
reserv
increas
number
medic
withdraw
blood
donat
prophylact
use
iron
prevent
develop
iron
deplet
reduc
likelihood
withdraw
blood
donat
l
n
l
transfus
research
centr
high
institut
research
educ
transfus
medicin
univers
medic
scienc
anesthesiolog
depart
shiraz
univers
medic
scienc
shiraz
iran
background
women
blood
donat
creat
blood
shortag
studi
aim
determin
factor
encourag
imped
blood
donat
women
aim
find
help
us
design
effect
recruit
strategi
could
encourag
women
donat
blood
cover
patient
need
method
studi
conduct
shiraz
iran
januari
august
women
age
year
old
demograph
characterist
particip
survey
well
reason
motiv
blood
donor
factor
deter
reason
laps
donor
also
mention
result
frequent
reason
blood
donat
altruist
reason
moral
person
oblig
feel
respons
help
peopl
awar
posit
effect
blood
donat
health
common
deterr
blood
donat
fear
develop
anemia
fear
weak
dizzi
unsuit
due
certain
medic
condit
never
situat
ask
donat
blood
summaryconclus
spite
figur
indic
altruist
reason
chief
motiv
factor
women
donat
blood
assum
blood
donat
worthi
act
overal
femal
contribut
blood
donat
remain
low
therefor
necessari
implement
measur
aim
inform
women
import
blood
donat
step
must
also
taken
allay
fear
base
misinform
confid
blood
donat
organ
must
major
consider
futur
recruit
strategi
reassur
women
safeti
blood
donat
final
measur
prevent
correct
anemia
must
implement
jalali
j
torabi
zadeh
f
treatment
affair
shahid
beheshti
univers
medic
scienc
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
hemoglobinopathi
research
center
ahvaz
jundishapur
univers
medic
scienc
transfus
research
center
high
institut
research
educ
transfus
medicin
educ
ministri
educ
ahwaz
iran
background
provid
safer
adequ
blood
suppli
main
goal
blood
transfus
organ
goal
achiev
select
appropri
blood
donor
medic
one
caus
exclus
blood
donor
due
effect
donor
andor
recipi
health
medic
affect
donat
two
mechan
show
diseas
donor
take
medic
second
mechan
drug
metabolit
exist
blood
circul
situat
mayb
teratogen
affect
health
recipi
reason
blood
organ
take
strict
strategi
guarante
safeti
blood
donor
recipi
aim
studi
deferr
rate
among
blood
donor
help
evalu
success
donor
counsel
identif
rate
donat
method
retrospect
studi
includ
blood
donor
refer
khuzestan
blood
transfus
servic
khbt
six
year
exclud
blood
donat
due
medic
donor
inform
analyz
statist
softwar
result
total
deferr
blood
donor
peopl
total
temporari
perman
deferr
rate
show
irregular
variat
first
year
studi
sixth
year
respect
exclus
rate
due
medic
show
significantli
decreas
begin
end
studi
defer
donor
male
deferr
rate
among
donat
type
show
fluctuat
studi
period
begin
among
fir
time
laps
regular
blood
donor
pattern
chang
last
year
follow
respect
summaryconclus
find
show
effect
strategi
reduc
rate
medic
deferr
high
number
medic
laps
regular
donor
need
correct
action
inform
materi
provid
avail
base
updat
list
common
drug
caus
deferr
laps
regular
blood
donor
easi
access
drug
countri
without
physician
prescript
enhanc
blood
donor
knowledg
effect
health
donor
recipi
highli
recommend
due
gener
tendenc
tradit
herbal
medicin
donor
nt
account
herbal
medicin
medic
blood
transfus
updat
deferr
caus
consid
herbal
medic
h
p
k
divis
taichung
blood
center
tbsf
tunghai
univers
process
taichung
blood
center
tbsf
taichung
blood
center
tbsf
taichung
taiwan
background
mani
studi
show
altruism
import
motiv
factor
blood
donat
studi
examin
sens
extent
altruism
motiv
blood
donat
regular
donor
univers
student
qualit
explor
aim
gener
concept
altruism
unabl
captur
divers
motiv
behind
varieti
altruist
behavior
draw
focu
group
interview
studi
tri
identifi
differ
situat
motiv
repeat
blood
donat
young
regular
donor
method
particip
recruit
data
bank
taichung
blood
center
arrang
four
focu
group
includ
three
regular
donor
one
univers
student
ask
question
concern
respect
situat
experi
blood
donat
interview
transcrib
use
content
analysi
specifi
pattern
situat
motiv
four
focu
group
conduct
april
octob
result
studi
found
gener
subcultur
play
signific
role
blood
donat
behavior
seem
quit
common
younger
peopl
mani
social
activ
includ
blood
donat
impli
altruist
motiv
may
major
motiv
factor
altruist
behavior
younger
gener
moreov
identifi
two
type
altruist
motiv
regular
blood
donor
interviewe
view
blood
donat
good
deed
benefact
belief
might
bring
retribut
return
either
famili
futur
health
statu
inspir
evolutionari
biolog
conceptu
altruist
motiv
reciproc
altruism
summaryconclus
find
show
altruist
behavior
might
motiv
concern
welfar
other
altruist
motiv
may
also
involv
reciproc
motiv
find
may
heurist
develop
effect
strategi
recruit
retent
blood
donor
among
differ
gener
abstract
withdrawn
jalali
shirmohammadi
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
hemoglobinopathi
research
center
ahvaz
jundishapur
univers
medic
scienc
ahvaz
transfus
research
center
high
institut
research
educ
transfus
medicin
shiraz
manag
resourc
develop
ministri
health
medic
educ
treatment
affair
shahid
beheshti
univers
medic
scienc
tehran
iran
background
provid
safe
blood
suppli
select
suitabl
donor
lowest
risk
critic
mani
blood
donor
defer
year
return
donat
blood
result
loss
donor
wet
cup
therapi
wct
call
hijama
common
muslim
countri
lead
mani
donor
deferr
mani
strong
report
shown
wct
significantli
increas
risk
bloodborn
infect
includ
hiv
hepat
b
hepat
c
infect
aim
evalu
cup
caus
blood
donor
deferr
method
retrospect
studi
carri
volunt
admit
year
total
deferr
rate
donor
calcul
thereaft
deferr
caus
wct
analyz
result
total
defer
blood
donat
defer
wct
histori
wct
caus
deferr
regular
laps
donor
respect
rate
donor
deferr
wct
increas
summaryconclus
spite
high
risk
bloodborn
pathogen
infect
also
absenc
evid
support
efficaci
wct
practic
increas
countri
nation
standard
design
licens
wct
practition
decreas
risk
infect
moreov
peopl
must
inform
risk
wct
thorough
mass
media
e
e
institut
transfus
medicin
republ
macedonia
strumica
transfus
medicin
republ
macedonia
tetovo
transfus
medicin
republ
macedonia
skopj
macedonia
background
today
blood
power
mean
treatment
bring
hope
back
ill
injur
imagin
modern
health
care
popul
without
enough
blood
blood
compon
reserv
depart
transfus
medicin
special
branch
medicin
serv
mediat
human
blood
donor
patient
aim
order
obtain
blood
satisfi
need
secur
minim
reserv
blood
countri
necessari
motiv
citizen
donat
blood
aim
studi
conduct
review
blood
donat
region
strumica
show
effici
depart
transfus
medicin
strumica
obtain
enough
blood
blood
compon
necessari
treatment
ill
injur
patient
strumica
time
conduct
analysi
review
profil
blood
donor
sex
age
profess
etc
method
data
obtain
depart
transfus
strumica
retrospect
studi
period
year
analyz
number
blood
donor
record
year
structur
result
number
blood
unit
last
five
year
oscil
obtain
blood
unit
total
number
blood
unit
collect
depart
transfus
medicin
strumica
period
unit
accord
profil
blood
donor
voluntari
blood
donor
rel
total
number
blood
donor
employ
unemploy
high
school
student
univers
student
accord
sex
male
donor
femal
blood
group
blood
donor
blood
group
blood
group
b
blood
group
ab
blood
donor
summaryconclus
although
patient
blood
requir
satisfi
order
achiev
keep
posit
atmospher
donat
blood
necessari
carri
regular
activ
inform
educ
motiv
peopl
donat
blood
start
youngest
popul
special
attent
target
group
show
enough
interest
donat
blood
aim
activ
increas
number
new
young
blood
donor
keep
regular
blood
donor
abstract
withdrawn
bou
patholog
blood
bank
hospit
lebanes
univers
beirut
lebanon
medicin
univers
lyon
franc
medicin
blood
bank
saint
joseph
hospit
dora
medicin
psychiatr
hospit
cross
jaledib
lebanon
nation
de
la
transfus
sanguin
pari
franc
medicin
univers
lyon
saint
etienn
lebanon
background
lebanon
decentralizedfrag
transfus
system
blood
suppli
system
mainli
base
replacementfamili
donat
around
follow
compens
voluntari
donat
current
system
nt
meet
world
health
organ
recommend
firmli
advis
countri
establish
blood
suppli
base
exclus
voluntari
non
remuner
blood
donat
vnrbd
consid
donor
safe
sustain
mode
suppli
accord
vnrbd
mode
respect
ethic
valu
blood
donat
valu
defin
intern
societi
blood
transfus
isbt
code
ethic
later
endors
includ
mainli
volunt
absenc
coercion
financi
incent
sens
respons
donor
toward
releas
inform
interview
anonym
donor
recipi
protect
respect
individu
right
confidenti
protect
donor
health
safeti
adequ
inform
regard
potenti
risk
advers
event
provid
donor
respect
intern
scientif
standard
donat
respons
suitabl
qualifi
regist
medic
practition
aim
describ
featur
replacementfamili
donor
system
lebanon
order
determin
whether
predomin
mode
donat
respect
ethic
valu
vnrbd
method
analysi
publish
work
lebanon
relat
recruit
motiv
replacementfamili
donor
initi
conduct
follow
deep
interpret
current
situat
base
person
experi
specialist
transfus
medicin
result
volunt
complet
free
sinc
donor
undergo
famili
social
friendsacquaint
coercion
thu
motiv
donat
base
pure
altruism
restrict
solidar
answer
question
interview
awar
respons
might
affect
social
coercion
even
though
donor
receiv
payment
financi
substitut
moral
profit
debt
gratitud
toward
receiv
alway
present
anonym
fulli
respect
sinc
patient
might
know
donor
despit
fact
donat
mandatorili
transfus
recipi
howev
donor
right
usual
respect
sinc
discrimin
kind
includ
gender
race
nation
religion
inform
adequ
provid
respect
intern
standard
despit
fact
blood
bank
staff
around
half
facil
alway
qualifi
avail
qualifi
regist
medic
practition
summaryconclus
despit
replacementfamili
donor
system
major
blood
suppli
lebanon
repeatedli
prove
effici
especi
emerg
situat
howev
featur
nt
fulli
respect
ethic
valu
vnrbd
place
addit
transfus
environ
form
pressur
replac
suppli
moreov
safeti
type
donat
debat
consequ
doubt
lebanon
need
transform
current
replac
base
blood
suppli
vnrbd
base
system
order
respect
ethic
valu
donat
increas
blood
safeti
level
p
kitpoka
w
thienphopirak
chanthet
chiawchan
p
phattanachak
patholog
ramathibodi
hospit
bangkok
thailand
background
new
gener
apheresi
system
enabl
multipl
unit
collect
platelet
one
elig
donor
singl
procedur
advantag
procedur
maxim
donor
resourc
minim
risk
transfus
transmit
diseas
reduc
product
cost
aim
aim
studi
evalu
perform
collect
efficaci
amicor
apheresi
system
freseniu
kabi
ag
germani
collect
doubl
dose
platelet
ddp
platelet
qualiti
characterist
donor
safeti
also
evalu
method
eighteen
repeat
donor
recruit
ddp
ddp
collect
plasma
target
donor
paramet
procedur
platelet
qualiti
characterist
measur
donor
reaction
observ
result
prior
platelet
collect
donor
ddp
collect
averag
platelet
count
none
donor
platelet
count
less
red
cell
loss
ddp
collect
averag
ml
collect
time
averag
min
ddp
collect
averag
platelet
collect
effici
produc
total
averag
platelet
yield
averag
actual
target
platelet
yield
ratio
ddp
residu
white
blood
cell
advers
event
report
donor
summaryconclus
effici
safeti
ddp
collect
amicor
apheresi
system
reveal
evalu
leukoreduc
platelet
accept
characterist
pass
intern
standard
requir
q
feng
f
kong
j
chen
j
ye
c
li
donat
zhejiang
blood
center
hangzhou
china
background
platelet
sdp
transfus
effect
prevent
treatment
bleed
patient
platelet
number
andor
function
disord
demand
sdp
grow
steadili
china
howev
due
limit
number
plateletpheresi
donor
imbal
clinic
demand
suppli
sdp
becom
increasingli
promin
allevi
shortag
suppli
plateletpheresi
interv
modifi
day
annual
donat
frequenc
accord
amend
nation
blood
donat
law
adjust
plateletpheresi
frequenc
donor
significantli
increas
center
yet
well
known
whether
adjust
affect
coagul
platelet
function
donor
aim
aim
studi
systemat
evalu
effect
plateletpheresi
frequenc
donor
coagul
platelet
function
use
thromboelastogram
teg
method
select
case
regular
plateletpheresi
donor
zhejiang
blood
center
august
juli
accord
frequenc
plateletpheresi
donor
divid
group
time
annual
also
select
case
first
time
plateletpheresi
donor
control
group
blood
sampl
collect
donat
coagul
platelet
function
test
use
teg
haemonet
compani
braintre
usa
platelet
count
test
sysmex
blood
cell
analyz
result
statist
analyz
use
spss
version
comparison
among
differ
group
analyz
use
analysi
varianc
p
set
significantli
differ
result
result
valu
r
k
plt
mpv
pdw
four
group
normal
rang
paramet
statist
signific
among
four
group
f
respect
p
also
signific
differ
two
group
correl
plateletpheresi
frequenc
r
k
plt
mpv
pdw
valu
statist
signific
r
respect
p
summaryconclus
frequenc
plateletpheresi
rang
donat
annual
affect
plt
count
function
affect
coagul
function
plateletpheresi
donor
ak
tiwari
arora
g
bhardwaj
g
sharma
g
aggarw
pabbi
ratan
setya
transfus
medicin
medic
hospit
gurgaon
india
background
institut
qualiti
assur
qa
program
requir
new
equip
facil
evalu
perform
put
routin
use
amicor
apheresi
system
new
gener
centrifug
apheresi
devic
use
use
dispos
kit
anticoagul
salin
volum
replac
platelet
sdp
platelet
ddp
initi
evalu
amicor
freseniu
kabi
ag
germani
found
platelet
yield
collect
effici
manufactur
appris
turn
made
chang
paramet
set
devic
improv
oper
perform
op
aim
aim
studi
evalu
op
devic
paramet
optim
manufactur
method
donor
healthi
met
statuari
donat
criteria
donor
given
mg
oral
calcium
prior
procedur
part
institut
standard
oper
procedur
sop
advers
reaction
note
devic
set
basic
default
set
whole
blood
anticoagul
ratio
citrat
infus
rate
mgkgmin
inlet
flow
rate
mlmin
return
flow
rate
mlmin
consecut
sdp
procedur
perform
target
yield
op
data
procedur
collect
analyz
includ
donor
platelet
count
plasma
loss
volum
whole
blood
process
collect
time
flow
rate
platelet
product
qualiti
characterist
actual
platelet
yield
swirl
ph
residu
wbc
count
primari
perform
paramet
platelet
yield
actual
vs
target
ratio
collect
effici
assess
paramet
result
manufactur
inform
result
along
data
manufactur
analyz
submit
data
well
data
download
devic
order
optim
devic
perform
made
three
chang
machin
yield
adjust
input
hematocrit
anoth
sdp
procedur
perform
target
platelet
yield
op
data
procedur
also
collect
analyz
done
earlier
procedur
result
primari
perform
devic
similar
except
platelet
yield
ratio
actual
vs
target
yield
ce
donor
vital
procedur
detail
vari
statist
signific
devic
optim
chang
platelet
yield
ratio
collect
effici
statist
signific
manner
platelet
yield
respect
percent
increas
pre
respect
percent
increas
collect
effici
respect
percent
increas
summaryconclus
studi
show
initi
oper
qualif
equip
part
qa
program
partnership
manufactur
play
import
role
success
implement
new
devic
institut
dz
de
b
e
f
j
e
h
w
de
de
van
r
van
transfus
medicin
donor
affair
blood
cell
research
red
blood
cell
diagnost
donor
studi
product
process
develop
transfus
medicin
donor
affair
sanquin
blood
bank
amsterdam
netherland
background
apheresi
increasingli
appli
collect
cell
plasma
even
allow
collect
multipl
blood
compon
one
procedur
although
qualiti
cellular
plasma
product
obtain
apheresi
extens
studi
shown
high
qualiti
impact
apheresi
red
blood
cell
rbc
return
donor
thoroughli
investig
aim
aim
blind
prospect
studi
investig
impact
plateletapheresi
rbc
return
donor
use
devic
current
use
dutch
nation
blood
bank
sanquin
mc
trima
accel
method
effect
plasma
plateletapheresi
procedur
four
differ
devic
mc
haemonet
haemonet
trima
accel
terumo
bct
freseniu
kabi
rbc
return
donor
test
blind
prospect
trial
cohort
donor
result
rheolog
analysi
donor
rbc
prior
plateletapheresi
show
differ
outcom
howev
strong
increas
hemolysi
found
sampl
trima
accel
devic
plateletapheresi
compar
machin
test
furthermor
increas
complement
deposit
rbc
seen
plasmapheresi
procedur
lastli
signific
decreas
express
complement
regul
protein
seen
post
apheresi
sampl
well
signific
decreas
adhes
molecul
summaryconclus
increas
complement
deposit
decreas
express
suggest
rbc
clearanc
might
enhanc
return
donor
possibl
effect
donor
due
increas
hemolysi
trima
accel
plateletapheresi
investig
k
van
den
u
south
african
nation
blood
servic
port
elizabeth
laboratori
servic
south
african
nation
blood
servic
constantia
kloof
south
africa
background
combin
apheresi
pool
platelet
utilis
south
african
nation
blood
servic
sanb
increas
apheresi
donat
account
almost
platelet
product
issu
collect
suffici
apheresi
product
vast
larg
rural
countri
south
africa
remain
challeng
avail
safe
suffici
product
depend
among
factor
local
elig
releas
criteria
individu
product
sanb
apheresi
donor
white
cell
count
wcc
perform
normal
wcc
requir
product
releas
addit
randomli
select
subset
apheresi
product
submit
bacteri
cultur
qualiti
control
purpos
neg
cultur
requir
product
releas
pool
platelet
product
subject
requir
aim
aim
assess
impact
wcc
releas
criterion
apheresi
platelet
associ
rais
wcc
posit
bacteri
cultur
method
apheresi
platelet
collect
use
cell
separ
may
depend
total
platelet
count
split
multipl
product
releas
criteria
apheresi
product
includ
inter
alia
normal
wcc
subset
collect
neg
bacteri
cultur
pool
platelet
produc
buffi
coat
regular
donor
subject
releas
criteria
includ
wcc
bacteri
cultur
collect
demograph
wcc
bacteri
cultur
result
apheresi
platelet
collect
sanb
januari
decemb
extract
sanb
busi
intellig
databas
summari
statist
use
describ
data
test
use
assess
signific
associ
result
total
apheresi
platelet
donat
perform
sanb
male
donor
white
donor
mean
overal
wcc
rais
wcc
note
donor
averag
wcc
group
maximum
record
wcc
unit
submit
bacteri
test
test
posit
signific
differ
proport
unit
rais
wcc
among
unit
either
posit
neg
bacteri
cultur
summaryconclus
data
indic
associ
rais
wcc
posit
bacteri
cultur
among
apheresi
platelet
donor
sanb
period
report
case
transfus
transmit
bacteri
infect
albeit
haemovigil
south
africa
hamper
use
wcc
releas
criterion
apheresi
platelet
result
loss
collect
translat
product
environ
plagu
chronic
shortag
knowledg
south
africa
one
countri
use
wcc
releas
criterion
apheresi
platelet
find
conjunct
differ
practic
pool
platelet
support
review
use
wcc
releas
criterion
apheresi
platelet
r
g
k
nilsson
b
j
j
immunolog
transfus
medicin
uppsala
univers
hospit
uppsala
develop
univers
hospit
epidemiolog
biostatist
karolinska
institutet
stockholm
genet
patholog
uppsala
univers
uppsala
sweden
red
cross
blood
servic
kelvin
grove
queensland
australia
stockholm
sweden
background
plasmapheresi
donat
increas
number
donor
collect
higher
frequenc
increas
volum
also
practic
previous
unpublish
observ
therefor
summar
level
plasma
pool
european
pharmacopoeia
requir
sourc
plasma
immunoglobulin
prepar
thu
regist
plasma
donor
offer
hepat
b
vaccin
accord
schedul
use
stockholm
vaccin
health
care
worker
aim
increas
antibodi
content
plasma
pool
immun
plasma
donor
method
antibodi
neg
plasma
donor
offer
vaccin
month
sampl
taken
donat
one
month
later
vaccin
inject
anoth
month
vaccin
blood
sampl
perform
prior
plasmapheresi
procedur
plasma
collect
perform
use
pc
hemonet
usa
quantit
antibodi
determin
perform
ausria
ii
abbot
usa
result
donor
enrol
septemb
april
altogeth
donor
complet
vaccin
scheme
complet
scheme
altogeth
donor
women
men
complet
whole
scheme
protect
antibodi
level
iul
observ
women
men
geometr
mean
titer
gmt
iul
women
iul
men
respond
donor
antibodi
level
maximum
titer
higher
titer
women
p
number
plasma
donat
prior
vaccin
period
correl
maximum
titer
donor
summaryconclus
comment
level
plasma
pool
expect
develop
protect
iul
antibodi
respons
vaccin
plasma
donor
compar
outcom
vaccin
studi
includ
seri
stockholm
gmt
lower
expect
sa
e
r
g
e
bank
instituto
nacion
de
cancerologia
nutrit
lab
instituto
nacion
de
perinatologia
mexico
citi
mexico
background
apheresi
donat
produc
sever
metabol
chang
donor
due
chelat
effect
sodium
citrat
infus
anticoagul
whole
donat
procedur
secondari
hyperparathyroid
phenomenon
conspicu
effect
metabol
chang
scarc
explor
well
potenti
prevent
measur
taken
aim
assess
oral
supplement
calcium
either
pill
plateletpheresi
donat
could
benefit
prevent
metabol
chang
dival
cation
hormon
bone
marker
method
prospect
studi
includ
plateletpheresi
donor
divid
amongst
four
differ
group
receiv
oral
supplement
calcium
carbon
vitamin
cc
supplement
calcium
carbon
miner
vitamin
cmd
receiv
diet
dt
control
group
donor
receiv
supplement
ctrl
either
way
oral
supplement
start
h
plateletpheresi
donat
follow
serolog
test
perform
calcium
ca
magnesium
mg
level
colorimetr
assay
zinc
zn
copper
cu
atom
absorpt
spectrophotometri
vitamin
parathyroid
hormon
pth
osteocalcin
oc
telopeptid
collagen
type
eia
blood
sampl
drawn
three
differ
stage
immedi
donat
well
plateletpheresi
statist
analysi
whitney
wilcoxon
test
protocol
approv
ethic
research
committe
particip
institut
result
cation
ca
mg
zn
cu
well
vitamin
level
significantli
decreas
immedi
apheresi
donat
contrast
pth
increas
compar
predon
level
chang
observ
studi
group
howev
donor
receiv
oral
supplement
belong
cc
cmd
group
trend
recov
homeostasi
follow
day
regard
metabol
bone
chang
ctrl
cc
cmd
group
increas
oc
level
respect
chang
statist
signific
final
level
increas
ctrl
group
summaryconclus
even
though
way
prevent
metabol
chang
produc
infus
sodium
citrat
apheresi
donor
found
trend
acceler
homeostasi
donor
receiv
oral
supplement
calcium
assess
pth
oc
believ
develop
new
anticoagul
chelat
cation
would
desir
meantim
suggest
increas
gap
consecut
donat
well
supplement
cmd
plateletpheresi
donor
l
bonstein
p
abu
shkara
e
goldshtain
z
malki
e
dahan
ej
dann
l
shapira
blood
bank
platelet
donat
unit
rambam
health
care
campu
haifa
israel
background
need
platelet
donat
despit
suggest
advantag
singl
donor
platelet
sdp
deriv
apheresi
platelet
concentr
pc
deriv
whole
blood
sever
donor
sdp
previous
use
second
option
institut
due
higher
cost
order
reduc
patient
exposur
multipl
donor
increas
platelet
transfus
efficaci
decreas
associ
advers
effect
establish
medic
center
plateletpheresi
donat
unit
capabl
meet
need
therapeut
unit
pltunit
annual
collect
unit
reli
donor
recruit
patient
famili
donor
borderlin
venou
access
henc
search
apheresi
collect
devic
adapt
wide
rang
donor
econom
effici
impli
abil
produc
maxim
amount
sdp
unit
within
short
time
period
recruit
donor
aim
compar
efficaci
four
plateletpheresi
devic
includ
newest
trima
uniqu
pool
donor
method
collect
effici
ce
rate
process
time
adapt
wide
rang
donor
percentag
unitsdonor
exposur
anticoagul
acda
retrospect
compar
use
four
apheresi
devic
amicu
freseniu
cobe
spectra
terumo
bct
use
collect
set
well
spectra
optia
terumo
bct
trima
terumo
bct
use
set
evalu
devic
applic
varieti
donor
categor
four
group
accord
venou
access
group
difficult
manag
smallest
venou
diamet
result
retrospect
analysi
includ
result
procedur
perform
devic
male
compris
donor
donor
averag
age
tbv
hematocrit
platelet
year
ml
respect
overal
ce
highest
trima
follow
spectra
optia
cobe
spectra
amicu
trima
also
significantli
econom
effici
collect
yield
unit
compar
cobe
spectra
spectra
optia
amicu
respect
addit
collect
rate
yielddur
trima
significantli
higher
pltmin
devic
pltmin
spectra
optia
cobe
spectra
amicu
respect
acda
volum
use
amicu
significantli
greater
assess
system
p
spectra
optia
suitabl
sole
donor
group
donor
cobe
spectra
amicu
use
set
adapt
wider
rang
donor
group
trima
although
use
singl
needl
set
could
adapt
donor
due
abil
adjust
low
high
venou
resist
summaryconclus
four
evalu
system
trima
found
effici
devic
yield
maxim
number
sdp
unit
divers
donor
popul
provid
highest
collect
rate
use
reduc
acda
volum
q
feng
zheng
f
kong
c
li
donat
zhejiang
blood
center
hangzhou
china
background
plateletpheresi
rel
safe
techniqu
commonli
use
nowaday
donat
platelet
donor
undergo
repeat
plateletpheresi
might
certain
proport
complic
includ
thrombosi
haemorrhag
disord
minor
even
fatal
complic
might
relat
abnorm
coagul
function
donor
current
plateletpheresi
donor
undergo
coagul
function
test
replac
physic
histori
platelet
count
tradit
coagul
function
test
labori
thromboelastographi
teg
rapid
dynam
method
monitor
platelet
coagul
function
wide
use
clinic
rare
plateletpheresi
donor
aim
aim
studi
evalu
proport
coagul
dysfunct
plateletpheresi
donor
thromboelastographi
teg
investig
relationship
teg
index
routin
platelet
index
method
total
plateletpheresi
donor
elig
plateletpheresi
zhejiang
blood
center
test
teg
routin
platelet
test
plateletpheresi
teg
index
r
time
k
time
routin
platelet
index
plt
mpv
pdw
test
r
min
k
min
mm
defin
hypocoagul
r
min
k
min
mm
defin
hypercoagul
result
plateletpheresi
donor
abnorm
teg
index
among
found
hypocoagul
donor
hypercoagul
ratio
hypocoagul
male
femal
donor
respect
p
ratio
hypercoagul
male
femal
donor
respect
p
plt
neg
correl
r
time
k
time
r
p
posit
correl
r
p
found
signific
correl
among
mpv
pdw
teg
index
summaryconclus
summari
studi
show
almost
quarter
plateletpheresi
donor
abnorm
teg
index
male
donor
higher
ratio
hypocoagul
femal
donor
higher
ratio
hypercoagul
plt
signific
correl
teg
index
sharifi
pourfathollah
k
sham
asanjan
ali
balazadeh
asadi
high
institut
research
educ
transfus
medicin
tehran
iran
background
advanc
transfus
medicin
method
platelet
product
gradual
shift
centrifug
method
toward
plateletpheresi
aim
plateletpheresi
mani
advantag
tradit
method
therefor
platelet
donor
care
import
donor
care
program
begun
iranian
blood
transfus
organ
method
studi
conduct
plateletpheresi
donor
apheresis
trima
hemonet
machin
year
second
half
year
firstli
guidelin
prepar
side
effect
monitor
use
monthli
form
provinci
center
perform
apheresi
result
platelet
donat
trima
hemonet
side
effect
report
side
effect
respect
case
vascular
injuri
case
vasovag
shock
follow
case
citrat
toxicityin
studi
correl
side
effect
vasovag
histori
donat
correl
type
incid
side
effect
kind
apheresi
machin
reaction
major
case
mild
moder
summaryconclus
consid
fact
hematoma
side
effect
recommend
train
phlebotomist
ja
e
e
r
l
b
de
sangr
tejido
de
navarra
de
hemoterapia
complejo
hospitalario
de
navarra
pamplona
spain
bct
zaventem
belgium
background
terumo
bct
trima
accel
softwar
version
enhanc
aspect
perform
new
version
expect
donor
spend
less
donat
time
connect
machin
encount
fewer
venou
access
pressur
alarm
collect
improv
amelior
averag
donor
experi
target
yield
split
rate
kept
constant
expect
procedur
time
reduc
compar
earlier
trima
version
improv
baselin
leukoreduct
perform
introduct
new
insight
leukoreduct
chamber
manag
procedur
reflect
decreas
leukoreduct
failur
well
reduc
number
run
flag
residu
leukocyt
verif
aim
object
evalu
evalu
impact
new
softwar
featur
introduc
compar
procedur
retrospect
trima
accel
version
method
procedur
span
period
januari
octob
compar
procedur
cover
period
octob
januari
data
extract
machin
data
logger
record
relev
procedur
paramet
individu
run
primari
outcom
number
machin
access
pressur
alert
per
procedur
statsoft
inc
statistica
data
analysi
softwar
system
version
http
wwwstatsoftcom
use
compar
data
set
result
donor
popul
vs
respect
compar
character
tbv
vs
ml
donor
platelet
count
vs
donor
hematocrit
vs
gender
distribut
femal
vs
venou
access
pressur
alert
significantli
improv
averag
alert
per
procedur
compar
p
procedur
time
reduc
min
respect
p
number
white
blood
cell
verif
flag
decreas
slightli
vs
summaryconclus
compar
donor
popul
implement
decreas
number
access
pressur
alert
significantli
compar
previou
trima
version
without
increas
procedur
time
averag
procedur
durat
also
found
slightli
significantli
reduc
improv
expect
offer
donor
comfort
overal
satisfactori
donor
experi
g
andonov
rm
grubov
rastvorceva
k
dimitrovski
blagoevska
useini
e
petkovikj
damevska
todorovska
b
todorovski
grubov
institut
transfus
medicin
rm
medic
faculti
skopj
skopj
macedonia
background
republ
macedonia
around
inhabit
least
donat
blood
accord
estim
need
treatment
sick
injur
patient
still
blood
donat
per
year
around
donat
aim
aim
studi
evalu
blood
donat
institut
transfus
medicin
rm
januari
till
januari
method
retrospect
analysi
monthli
blood
donat
registri
blood
donat
depart
institut
registri
donat
mobil
site
result
donat
institut
transfus
medicin
rm
mobil
team
collect
blood
unit
across
countri
donat
male
femal
highest
peak
mobil
team
march
donat
juli
donat
novemb
donat
blood
donat
itm
donat
male
femal
peak
march
donat
decemb
donat
first
time
blood
donor
donat
blood
mobil
site
donat
blood
itm
defer
donor
total
defer
mobil
site
defer
donor
itm
number
univers
student
donat
blood
number
high
school
student
summaryconclus
order
increas
blood
donat
rate
updat
method
motiv
introduc
especi
young
peopl
abl
overcom
gap
donat
age
due
age
popul
countri
p
tak
affair
canadian
blood
servic
ottawa
affair
canadian
blood
servic
laboratori
medicin
pathobiolog
univers
toronto
health
studi
ryerson
univers
toronto
labatt
school
nurs
western
univers
affair
canadian
blood
servic
london
canada
background
current
canadian
blood
servic
cb
donor
criteria
defer
allogen
donor
degre
coronari
arteri
diseas
cad
even
asymptomat
medic
optim
howev
autolog
donor
uncompl
stabl
cad
permit
phlebotom
clinic
donor
physician
challeng
cad
deferr
question
evid
support
decis
aim
given
age
donor
popul
threat
blood
shortag
cad
deferr
estim
per
year
intern
extern
review
perform
determin
evid
support
refut
elig
stabl
cad
allogen
donor
method
pubm
search
use
key
word
whole
blood
donor
complic
high
risk
autolog
blood
donor
perform
find
evid
complic
individu
low
high
risk
cad
undergo
blood
donat
phlebotomi
addit
cb
reaction
databas
cb
autolog
program
review
report
cad
complic
intern
blood
oper
cad
polici
also
review
result
myocardi
infarct
mi
death
rare
report
worldwid
cb
reaction
report
secondari
potenti
probabl
cad
symptom
record
period
year
yield
possibl
cardiac
symptom
report
per
annual
donat
donor
base
litig
aris
report
review
cb
autolog
program
indic
seriou
cad
complic
donor
bled
clinic
hospit
high
risk
program
mani
year
intern
literatur
four
hospit
report
follow
million
american
red
cross
arc
donat
intern
oper
hospit
autolog
high
risk
program
report
advers
event
rate
causal
relationship
demonstr
advers
complic
cad
autolog
donor
frequent
compar
allogen
donor
phlebotomi
secondari
iron
overload
high
risk
individu
demonstr
associ
cad
complic
donor
cad
complic
rate
cb
lower
predict
cad
rate
gener
popul
among
intern
blood
oper
survey
arc
determin
accept
stabl
cad
allogen
donor
australian
red
cross
unit
kingdom
nation
health
servic
german
red
cross
hema
quebec
itali
defer
allogen
donor
evid
cad
council
europ
recommend
deferr
cad
histori
yet
autolog
standard
stabl
cad
absolut
contraind
donat
may
subject
cardiologist
assess
summaryconclus
signific
evid
relat
cad
complic
blood
donor
except
rare
unproven
event
autolog
program
arc
screen
million
allogen
donor
accept
stabl
cad
donor
mani
year
without
major
event
low
risk
cad
allogen
donor
ie
asymptomat
new
treatment
physic
restrict
safe
bled
clinic
cb
plan
revis
cad
criterion
accordingli
useini
rm
grubov
rastvorceva
k
dimitrovski
g
andonov
e
petkovikj
institut
transfus
medicin
rm
medic
faculti
skopj
skopj
macedonia
background
singl
donor
platelet
concentr
deriv
plateletpheresi
prefer
term
reduc
risk
advers
reaction
platelet
transfus
compar
random
donor
platelet
concentr
aim
aim
studi
present
experi
collect
singl
donor
platelet
apheresi
method
retrospect
studi
perform
institut
transfus
medicin
republ
macedonia
till
donor
fulli
inform
donat
procedur
sign
inform
consent
donat
optim
platelet
count
want
achiev
equal
random
donor
platelet
dose
minimum
preapheresi
platelet
count
donor
request
start
apheresi
collect
platelet
collect
perform
use
flow
cell
separ
haemonet
mc
trima
accel
acid
citrat
dextros
formula
use
anticoagul
result
apheresi
platelet
collect
mention
period
median
per
year
apheresi
collect
collect
collect
collect
collect
collect
collect
collect
number
apheresi
collect
increas
year
year
almost
doubl
increas
median
precollect
platelet
count
donor
rang
male
donor
femal
singl
procedur
usual
took
min
median
platelet
count
collect
rang
median
process
blood
volum
ml
median
use
ml
mean
total
volum
collect
product
ml
advers
effect
includ
vein
perfor
numb
extrem
reaction
hypocalcemia
occur
rare
mild
summaryconclus
apheresi
collect
platelet
effect
safe
procedur
collect
platelet
count
want
optimum
platelet
count
number
apheresi
donor
increas
work
expand
voluntari
platelet
donor
registri
z
b
b
p
affair
canadian
blood
servic
labatt
school
nurs
laboratori
medicin
schulich
school
medicin
western
univers
health
scienc
centr
manag
suppli
chain
canadian
blood
servic
medicin
univers
toronto
affair
canadian
blood
servic
ottawa
affair
canadian
blood
servic
health
studi
ryerson
univers
toronto
canada
background
canadian
blood
servic
cb
assess
donor
elig
medic
enquiri
suitabl
donat
blood
determin
without
medic
evalu
donor
temporarili
defer
medic
offic
assess
elig
impact
donor
retent
compar
donor
involv
process
evalu
yet
signific
resourc
expend
enquiri
aim
studi
assess
donor
retent
donor
accept
compar
donor
never
defer
nd
temporarili
defer
td
method
retrospect
review
cb
nation
donor
base
use
busi
intellig
bi
warehous
data
analyz
whole
blood
donat
repeat
deferr
frequenc
nd
td
group
td
group
consist
donor
defer
six
month
less
group
includ
donor
accept
me
initi
resolv
octob
april
data
collect
group
april
octob
apheresi
plasma
platelet
donor
exclud
statist
differ
analyz
test
p
valu
signific
use
graphpad
softwar
confid
interv
calcul
group
result
me
initi
resolv
studi
period
ci
accept
ci
defer
abandon
donor
accept
ci
return
attempt
donat
ci
return
studi
period
td
group
ci
return
attempt
donat
ci
differ
elig
donor
return
attempt
donat
group
could
detect
p
nd
group
consist
donor
gave
donat
group
donor
gave
donat
donor
td
group
gave
donat
donor
accept
significantli
less
like
td
group
defer
second
time
n
ci
n
ci
respect
p
ci
nd
group
donat
studi
period
comparison
ci
p
td
group
ci
p
group
donat
summaryconclus
td
donor
make
small
import
sourc
regular
commit
blood
donor
major
return
deferr
donat
regularli
nd
group
differ
may
due
recruit
effort
bring
new
laps
donor
relat
motiv
differ
td
group
studi
process
effect
prevent
futur
donor
displac
evidenc
decreas
repeat
deferr
group
data
demonstr
overal
effect
process
retain
prevent
futur
donor
displac
highlight
valu
blood
center
oper
djenad
r
smiljan
v
divac
drndarev
filipov
b
tesov
jankov
depart
transfus
medicin
gener
hospit
uzic
uzic
serbia
background
transfus
irrevers
event
mean
blood
donat
pleasant
donor
safe
patient
select
blood
donor
first
step
toward
transfus
criteria
select
base
nation
legisl
transfus
medicin
recommend
european
union
aim
analysi
reason
donor
deferr
zlatibor
region
method
retrospect
analysi
reason
donor
deferr
januari
decemb
base
complet
questionnair
determin
haemoglobin
level
capillari
blood
copper
sulphat
method
haemocu
autom
haematolog
analyz
physic
examin
specialist
transfus
medicin
result
period
total
number
potenti
donat
deferr
occur
percent
case
collect
blood
depart
gener
hospit
mobil
unit
popul
male
donor
percent
femal
donor
account
percent
among
defer
donor
male
percent
femal
percent
total
number
total
number
donor
reason
perman
deferr
percent
hbv
hcv
infect
sever
health
problem
common
reason
temporari
deferr
low
haemoglobin
level
percent
low
blood
pressur
percent
sort
infect
percent
high
blood
pressur
percent
take
drug
percent
summaryconclus
deferr
rate
within
accept
percentag
deferr
accord
intern
standard
exceed
percent
donor
less
donor
temporarili
defer
need
encourag
donat
alway
necessari
safe
treat
patient
b
k
labatt
school
nurs
western
univers
affair
manag
suppli
chain
canadian
blood
servic
laboratori
medicin
schulich
school
medicin
western
univers
health
scienc
centr
london
affair
canadian
blood
servic
toronto
canada
background
tran
umbrella
term
individu
whose
gender
ident
differ
sex
assign
birth
ie
transgend
transsexu
gender
individu
tran
blood
donor
report
distress
donat
experi
may
indic
staff
difficulti
cultur
sensit
care
provis
neg
experi
harm
donor
reput
blood
agenc
discours
regard
best
practic
cultur
sensit
care
provis
tran
donor
current
absent
transfus
medicin
literatur
aim
address
knowledg
gap
systemat
scope
review
undertaken
explor
understand
extent
rang
research
relat
cultur
sensit
care
provis
tran
individu
investig
health
care
disciplin
method
electron
databas
cinah
pubm
scopu
search
octob
novemb
initi
search
term
includ
tran
healthcar
deliveri
knowledg
dispar
modifi
accord
databas
requir
english
languag
north
american
studi
publish
use
data
collect
within
last
five
year
includ
captur
recent
societ
discours
north
america
studi
regard
medic
intervent
popul
subset
exclud
result
among
elig
studi
met
inclus
criteria
studi
span
varieti
health
care
disciplin
nurs
gynecolog
psychiatri
intern
medicin
etc
vari
degre
tran
patient
exposur
themat
analysi
reveal
system
practic
gap
system
gap
includ
rigid
binari
intak
process
uncertainti
regard
tran
individu
identifi
practic
set
difficulti
know
ask
use
pronoun
defici
hinder
therapeut
relationship
also
dilut
data
institut
broad
public
health
intervent
research
evid
base
recommend
review
includ
intak
process
ask
individu
sex
assign
birth
gender
ident
ask
individu
pronoun
outset
therapeut
relationship
practic
gap
identifi
lack
educ
assist
care
tran
individu
frequent
confus
conflat
key
term
patholog
tran
patient
identifi
well
confus
regard
preval
gender
affirm
surgeri
discours
patient
requir
intervent
moreov
lack
understand
stigma
gener
health
care
system
tran
individu
stigma
elev
patient
health
risk
recommend
includ
institut
purpos
built
job
specif
train
tran
sensit
howev
consensu
optim
medium
deliv
educ
research
requir
regard
best
way
implement
intervent
summaryconclus
absenc
transfus
medicin
specif
research
scope
review
identifi
key
knowledg
gap
highlight
evid
base
recommend
literatur
across
sever
health
care
disciplin
system
practic
gap
identifi
investig
blood
agenc
could
improv
provis
cultur
sensit
care
tran
donor
review
provid
call
action
transfus
medicin
research
topic
improv
donor
relat
overal
efficaci
blood
program
x
f
j
transfus
blood
collect
guangzhou
blood
center
guangzhou
china
background
guangzhou
medic
center
southern
china
concentr
medic
resourc
attract
patient
surround
area
grow
number
medic
servic
increas
demand
blood
transfus
result
gradual
increas
pressur
blood
suppli
meet
clinic
transfus
need
increas
blood
collect
decreas
blood
discard
two
main
reason
caus
blood
discard
infecti
reason
alt
hepat
hiv
etc
noninfecti
reason
physic
examin
expir
etc
review
data
blood
collect
blood
discard
guangzhou
blood
center
analyz
reason
blood
discard
aim
obtain
caus
blood
donat
discard
trend
find
improv
minim
wastag
blood
method
data
blood
collect
blood
test
blood
prepar
blood
discard
target
year
review
analyz
discard
blood
divid
infecti
noninfecti
reason
infecti
reason
includ
alt
greater
unit
hbvhcv
hiv
qualifi
elsa
andor
nat
elsa
detect
infecti
marker
treponema
pallidum
qualifi
noninfecti
reason
physic
reason
includ
lipem
hemolysi
clot
etc
expir
confidenti
blood
abandon
statist
analysi
perform
use
softwar
result
total
unit
blood
collect
prepar
blood
unit
discard
total
blood
discard
rate
main
reason
blood
discard
infecti
reason
owe
unit
discard
alt
account
largest
proport
infecti
blood
discard
blood
discard
due
infecti
show
steadi
declin
p
total
unit
blood
discard
owe
noninfecti
reason
rate
increas
significantli
p
major
noninfecti
discard
physic
unqualifi
donat
account
among
lipem
blood
account
caus
account
includ
hemolysi
clot
nonstandard
quantiti
etc
rate
damag
packag
summaryconclus
infecti
factor
primari
reason
blood
discard
present
steadili
declin
noninfecti
reason
increas
yearli
pay
attent
process
blood
collect
especi
consult
blood
donat
exclud
diet
blood
donor
strictli
follow
standard
oper
procedur
improv
qualiti
blood
collect
thu
minim
wastag
blood
caus
noninfecti
factor
ensur
suppli
blood
b
e
h
c
h
blood
transfus
servic
copenhagen
oe
blood
transfus
servic
serum
institut
copenhagen
blood
transfus
servic
denmark
background
studi
confirm
calcium
inhibit
iron
absorpt
danish
tap
water
come
groundwat
contain
vari
amount
calcium
depend
subsoil
aim
investig
associ
calcium
drink
water
iron
level
danish
blood
donor
method
use
data
danish
blood
donor
includ
dietari
lifestyl
habit
blood
donat
histori
physiolog
characterist
includ
measur
ferritin
level
along
inform
area
resid
danish
blood
donor
studi
data
calcium
level
groundwat
water
hard
obtain
geu
geolog
survey
denmark
greenland
perform
multipl
linear
logist
regress
analys
evalu
effect
water
hard
ferritin
level
risk
iron
defici
defin
ferritin
level
ngml
stratifi
sex
result
statist
signific
neg
associ
water
hard
ferritin
level
men
women
risk
iron
defici
correspondingli
increas
men
ci
women
ci
increas
water
hard
analys
restrict
individu
receiv
supplement
iron
tablet
statist
signific
associ
groundwat
hard
ferritin
level
observ
summaryconclus
measur
ferritin
level
residenti
drink
water
calcium
content
associ
blood
donor
iron
level
risk
iron
defici
calcium
level
drink
water
may
need
consid
advis
blood
donor
popul
risk
iron
defici
van
weert
l
wirht
g
gunarso
e
bakker
nation
screen
laboratori
sanquin
sanquin
blood
suppli
amsterdam
netherland
background
regular
blood
donat
known
caus
iron
loss
detect
possibl
iron
deplet
ferritin
use
monitor
iron
store
blood
donor
wherea
clinic
set
ferritin
mostli
test
within
h
blood
donat
test
within
day
blood
collect
alway
feasibl
therefor
nation
screen
laboratori
sanquin
assess
stabil
ferritin
measur
within
workflow
central
screen
facil
aim
studi
stabil
ferritin
measur
blood
donat
sampl
dilut
seri
intern
standard
evalu
day
use
three
differ
platform
architect
coba
lumipuls
result
aim
provid
insight
effect
time
measur
ferritin
toward
determin
oper
effici
blood
donat
test
without
compromis
qualiti
method
two
dilut
seri
ngml
made
pb
serum
serum
sampl
whole
blood
donor
collect
seri
dilut
serum
measur
day
data
correct
serum
ferritin
concentr
seri
dilut
pb
donat
sampl
measur
day
donat
sampl
measur
day
blood
donat
sampl
store
measur
done
duplic
system
calibr
human
liver
architect
recombin
lumipuls
result
system
dilut
seri
pb
serum
show
valu
consist
time
point
valu
measur
lumipuls
line
valu
expect
concentr
architect
show
higher
valu
seriescompar
serum
pb
data
architect
show
constant
data
rang
ngml
lumipuls
rang
ngml
contrast
data
donat
sampl
valu
ferritin
concentr
consist
highest
intermedi
architect
lowest
lumipuls
summaryconclus
ferritin
measur
stabli
day
blood
collect
shown
measur
dilut
seri
pb
serum
measur
donat
sampl
architect
lumipuls
coba
provid
requir
flexibl
test
without
compromis
qualiti
measur
possibl
within
hour
due
logist
constraint
ferritin
concentr
vari
among
system
explain
heterogen
ferritin
differ
antibodi
use
system
system
calibr
differ
standard
q
clinic
servic
canadian
blood
servic
patholog
laboratori
medicin
univers
ottawa
surveil
canadian
blood
servic
epidemiolog
commun
medicin
univers
ottawa
surveil
canadian
blood
servic
ottawa
canada
background
iron
defici
common
whole
blood
wb
donor
donor
popul
male
borderlin
hb
level
femal
donat
high
frequenc
particularli
high
risk
partial
mitig
strategi
chang
minimum
hb
level
gl
male
increas
minimum
interdon
interv
day
femal
aim
aim
assess
impact
chang
hb
deferr
rate
perform
extra
analysi
donor
black
donor
known
fy
evalu
impact
rare
phenotyp
unit
method
predon
hb
measur
fingerstick
sampl
use
portabl
hemoglobinomet
fall
messag
femal
donor
reduc
donat
frequenc
start
follow
chang
minimum
interdon
interv
donor
appoint
book
system
dec
chang
criteria
march
minimum
hb
femal
remain
gl
male
donor
minimum
hb
increas
gl
march
minimum
interdon
interv
remain
day
compar
hb
deferr
rate
frequenc
donat
sept
period
period
donor
donor
black
avail
fix
site
donat
fy
donor
assess
hb
deferr
rate
may
march
march
dec
result
femal
hb
deferr
rate
period
period
p
number
success
wb
donationsfemal
donor
previou
month
decreas
gradual
period
period
male
hb
deferr
rate
period
period
p
number
wb
donationsmal
donor
unchang
period
vs
period
overal
hb
deferr
rate
male
femal
combin
decreas
p
hb
deferr
rate
fy
donor
increas
male
p
decreas
femal
p
result
overal
declin
hb
deferr
p
deferr
rate
black
male
vs
p
black
femal
vs
p
unchang
statist
partli
due
small
number
howev
net
trend
male
femal
combin
vs
p
similar
donor
overal
overal
wb
collect
decreas
period
period
donat
new
donor
increas
p
summaryconclus
deferr
increas
male
decreas
substant
femal
result
overal
decreas
hb
deferr
donor
black
donor
fy
donor
like
better
hb
recoveri
femal
longer
minimum
interdon
interv
seen
uk
interv
studi
donat
shortfal
address
recruit
new
donor
demonstr
import
coordin
campaign
offset
oper
impact
donor
health
initi
f
c
collect
ef
strasbourg
franc
background
prevent
anaemia
blood
donor
base
two
method
franc
haemoglobin
test
perform
photometr
measur
limit
popul
donor
new
donor
donor
two
year
last
donat
detect
quarter
anaem
donor
reveal
blood
count
systemat
sampl
begin
donat
minimum
haemoglobin
level
gl
femal
gl
male
whole
blood
donat
gl
threshold
defin
european
direct
thu
donor
allow
give
blood
despit
haemoglobin
level
close
anaemia
aim
evalu
current
method
anaemia
prevent
blood
donor
franc
method
retrospect
studi
conduct
alsac
donat
per
year
includ
donor
present
low
haemoglobin
level
character
donor
profil
medic
obstacl
return
donat
simultan
prospect
studi
conduct
femal
donor
age
histori
anaemia
month
develop
anaemia
iron
defici
investig
result
retrospect
studi
show
preval
anaemia
femal
age
year
annual
whole
blood
donat
frequenc
vs
global
donor
popul
p
half
come
back
donat
year
detect
anaemia
among
half
benefit
medic
recurr
rate
anaemia
subsequ
donat
within
year
prospect
studi
reveal
incid
anaemia
iron
defici
minimum
donat
interv
day
deduc
protect
factor
prevent
anaemia
p
summaryconclus
data
consist
intern
studi
prescrib
sever
method
prevent
anaemia
blood
donor
reduct
donat
frequenc
increas
donat
interv
ferritin
test
iron
supplement
computer
monitor
haemoglobin
concentr
kinet
help
anticip
anaemia
occurr
defin
pattern
person
counsel
donor
would
allow
increas
donat
interv
prevent
donat
much
note
valu
adopt
european
threshold
haemoglobin
level
would
rais
donor
deferr
rate
anaemia
year
implement
j
centr
pay
de
la
loir
saint
jean
de
la
ruell
franc
background
franc
establish
specif
regul
anaemia
prevent
blood
donat
lower
haemoglobin
hb
threshold
gl
women
men
target
predon
hb
measur
systemat
blood
count
sampl
donat
week
interv
whole
blood
donat
wbd
maximum
number
wbd
per
year
women
men
aim
publish
studi
regul
scarc
interest
consequ
donor
hb
regener
know
underli
individu
characterist
abl
bia
donor
return
chose
work
specif
larg
base
new
donor
method
extract
french
nation
donor
databas
donor
first
wbd
follow
everi
wbd
made
end
henc
survey
period
year
main
studi
criteria
ratio
donor
achiev
recoveri
initi
hb
level
delay
vari
mandatori
time
interv
donat
one
year
result
studi
popul
contain
women
w
men
mean
hb
first
donat
gl
nearli
half
never
made
second
donat
w
sex
made
least
wbd
studi
period
strictli
correl
hb
level
first
donat
maximum
number
donat
studi
second
donat
women
recov
hb
level
first
donat
week
proport
rise
slowli
greater
interv
never
reach
even
one
year
compar
half
men
recov
initi
level
week
ratio
remain
stabl
afterward
pattern
similar
men
came
third
fourth
donat
differ
women
acceler
hb
recoveri
reach
threshold
week
third
donat
week
fourth
women
also
recoveri
ratio
continu
rise
delay
donat
grow
non
recoveri
cumul
donat
rapidli
consecut
peculiarli
women
ratio
third
donat
occur
week
first
one
fourth
donat
done
total
delay
week
respect
men
analysi
take
account
age
donor
show
clearli
bad
recoveri
young
women
compar
oldest
one
realli
observ
men
summaryconclus
work
confirm
hb
recoveri
better
men
women
first
wbd
show
kind
adapt
occur
women
follow
donat
observ
men
besid
result
mean
result
show
signific
number
donor
includ
men
never
recov
initi
hb
person
introduct
ferritin
measur
necess
j
centr
pay
de
la
loir
saint
jean
de
la
ruell
franc
background
franc
upgrad
organis
prevent
anaem
donor
donat
predon
haemoglobin
hb
measur
pm
becam
mandatori
new
donor
donor
donat
sinc
two
year
least
donor
recent
low
hb
invas
method
chosen
perform
first
capillari
blood
venou
duplic
case
valu
threshold
gl
women
men
besid
full
blood
count
fbc
ad
mandatori
test
order
survey
regular
blood
donor
aim
studi
want
evalu
efficaci
organis
nearli
ten
year
implement
specif
focu
upon
invas
method
practic
method
data
extract
blood
donat
candidatur
august
done
french
nation
databas
fbc
hb
valu
analys
gold
standard
compar
pm
one
done
result
fbc
hb
women
men
usabl
among
respect
gl
donor
select
quit
effect
anaem
valu
found
whole
blood
donat
anaem
donor
prevent
donat
anaemia
present
donat
whole
blood
donat
done
anaem
donor
slightli
threshold
among
test
hb
pm
test
correl
fbc
capillari
pm
quit
good
far
less
fbc
venou
pm
plot
venou
pm
better
differ
mean
capillari
pm
versu
lower
standard
deviat
versu
summaryconclus
french
organis
prevent
donat
anaem
donor
quit
effect
especi
higher
anaem
state
systemat
hb
pm
would
abl
detect
two
third
failur
extens
invas
method
heavi
method
precis
enough
nowaday
failur
would
improv
venou
pm
right
away
choic
may
bind
blood
donor
van
e
screen
laboratori
sanquin
tta
sanquin
blood
suppli
amsterdam
netherland
background
blood
donor
may
develop
increas
iron
loss
due
regular
blood
donat
ferritin
test
use
monitor
iron
statu
howev
within
workflow
blood
donat
screen
ferritin
test
within
h
alway
possibl
extra
handl
test
requir
assay
insert
effect
effici
donat
screen
therefor
strategi
effici
reliabl
ferritin
test
blood
donat
sampl
develop
aim
studi
ferritin
measur
serum
plasma
edta
sampl
blood
donor
order
establish
test
strategi
ferritin
measur
routin
screen
without
conced
qualiti
effici
method
ferritin
test
valid
architect
establish
precis
dilut
seri
concentr
ngml
measur
done
two
fix
time
point
three
day
defin
test
methodolog
serum
tube
plasma
edta
tube
store
room
temperatur
centrifug
test
differ
time
point
h
blood
donat
order
mimic
time
blood
draw
test
next
plasma
edta
serum
sampl
donat
test
duplic
day
statist
analys
done
statist
comput
result
coeffici
variat
averag
ferritin
concentr
time
concentr
dilut
seri
sampl
measur
ferritin
concentr
increas
averag
edta
serum
per
day
rel
chang
respect
varianc
differ
valu
compar
first
ferritin
measur
blood
collect
h
increas
standard
deviat
plasma
serum
postpon
centrifug
well
storag
sampl
result
delay
measur
higher
ferritin
concentr
valu
time
sampl
ferritin
test
n
daili
routin
confirm
increas
measur
ferritin
valu
rel
valu
measur
within
h
ferritin
test
done
consist
even
done
h
blood
donat
summaryconclus
ferritin
measur
plasma
edta
serum
tube
h
blood
collect
reveal
higher
valu
compar
measur
within
h
blood
draw
increas
less
sampl
store
versu
room
temperatur
well
postpon
centrifug
may
explain
heterogen
ferritin
isoform
commut
take
account
time
need
transport
donat
sampl
laboratori
test
strategi
centrifug
sampl
h
blood
collect
first
complet
routin
screen
subsequ
use
tube
ferritin
test
even
though
ferritin
measur
later
h
blood
collect
effici
qualiti
maintain
verifi
implement
ferritin
test
routin
daili
practic
high
throughput
donat
screen
abstract
withdrawn
r
z
p
p
region
hospit
liberec
health
studi
technic
univers
liberec
liberec
rock
structur
mechan
academi
scienc
cr
praha
czech
republ
background
incid
undesir
delay
blood
donat
reaction
appear
leav
donat
centr
thoroughli
observ
unlik
earli
reaction
aim
aim
studi
determin
incid
delay
complic
blood
donat
use
method
electron
survey
method
studi
popul
compris
voluntari
donor
gave
whole
blood
apheresi
donor
region
hospit
liberec
last
month
donor
address
via
short
mobil
phone
text
messag
link
anonym
electron
questionnair
locat
region
hospit
liberec
websit
donor
fill
possibl
troubl
regard
last
finish
donat
result
questionnair
use
definit
analysi
address
donor
donor
averag
age
year
complic
present
donor
male
femal
p
frequent
troubl
fatigu
hematoma
donat
weak
faint
dizzi
pain
limb
blood
taken
short
breath
exert
manifest
infect
cold
elev
temperatur
muscl
joint
pain
chill
seven
day
late
venipunctur
bleed
phlebiti
nausea
vomit
collaps
unconsci
advers
reaction
occur
frequent
whole
blood
donat
plasmapheresi
p
tire
male
donor
time
higher
risk
weak
dizzi
donor
p
also
tire
women
time
higher
risk
weak
dizzi
femal
donor
p
summaryconclus
donor
major
women
report
troubl
donat
fatigu
domin
difficulti
among
studi
provid
detail
data
work
educ
materi
donor
p
v
b
health
primari
care
univers
cambridg
cambridg
unit
kingdom
mcgill
univers
montreal
canada
background
variou
stimuli
orthostat
stress
stimuli
fear
haemorrhag
etc
capabl
trigger
vasovag
respons
vvr
remain
unclear
extent
repres
ident
similar
physiolog
reaction
aim
studi
examin
specif
vvr
respons
stimuli
involv
bloodinjuri
compar
emot
stimuli
built
upon
idea
simul
blood
loss
hypothes
vvr
base
prevent
excess
blood
loss
thu
trigger
stimuli
suggest
well
produc
actual
loss
result
effect
certain
emot
stressor
interact
certain
postur
stressor
method
healthi
young
adult
complet
questionnair
assess
medic
fear
medic
fear
survey
olatunji
et
al
watch
five
stimulu
video
differ
emot
content
particip
watch
neutral
video
follow
subsequ
video
present
order
bloodinjuri
video
depict
open
heart
surgeri
three
addit
video
medic
chasefear
losssad
particip
randomli
assign
watch
video
either
stand
sit
vasovag
symptom
blood
pressur
bp
heart
rate
hr
assess
video
result
primari
analys
postur
sittingstand
x
video
x
medic
fear
treat
continu
measur
gener
linear
model
glm
sex
neutral
video
valu
covari
predict
signific
postur
x
video
interact
f
p
due
specif
enhanc
symptom
bloodinjuri
video
stand
effect
moder
fear
lead
signific
postur
x
video
x
medic
fear
interact
f
p
stand
significantli
increas
symptom
experienc
fear
particip
bloodinjuri
video
pattern
corrobor
sbp
hr
signific
postur
x
film
interact
effect
f
p
f
p
respect
expect
due
notabl
decreas
among
watch
surgeri
film
stand
summaryconclus
fear
play
key
role
elicit
vvr
orthostat
stress
enhanc
effect
find
provid
support
theori
vvr
may
develop
mean
facilit
surviv
anim
injur
experienc
signific
blood
loss
clinic
implic
includ
manag
reduct
stimuli
blood
donor
k
k
l
c
l
transfus
medicin
univers
hospit
oslo
oslo
transfus
medicin
hospit
trust
kaln
center
medic
biochemistri
innlandet
hospit
trust
innlandet
norway
background
norway
blood
donor
take
hypertens
medic
previous
perman
defer
assumpt
might
higher
risk
advers
reaction
due
reduc
respons
vascular
system
polici
chang
sever
blood
bank
norway
sinc
grow
number
blood
donor
medic
accept
donat
approv
criteria
includ
stabl
dose
medic
least
month
normal
blood
pressur
experi
side
effect
therapi
accord
lab
inform
system
approxim
donor
blood
bank
oslo
regist
take
medic
donat
blood
within
last
year
aim
qualiti
studi
want
valid
new
criteria
test
donor
experi
higher
rate
advers
effect
ae
like
dizzi
faint
compar
previou
experi
donor
safe
use
group
peopl
blood
donor
ad
number
donat
acquir
donor
medic
method
inform
blood
donor
use
drug
collect
questionnair
present
upon
arriv
blood
bank
two
blood
bank
current
particip
blood
center
oslo
blood
center
innlandet
trust
questionnair
inform
consent
form
approv
data
protect
offic
oslo
univers
hospit
plan
gather
inform
mani
donor
possibl
within
month
period
result
within
first
week
studi
period
donor
take
medic
recruit
studi
men
women
mean
age
year
rang
use
angiotensin
ii
antagonist
use
calcium
blocker
use
use
combin
therapi
none
experienc
sever
episod
outsid
blood
bank
two
experienc
weak
reaction
connect
blood
donat
eg
dizzi
short
breath
follow
recommend
drink
l
fluid
beforedur
donat
accept
blood
donor
led
welcom
extra
suppli
altogeth
unit
whole
blood
blood
center
summaryconclus
preliminari
result
studi
suggest
safe
accept
blood
donor
despit
drug
therapi
nt
experi
frequent
ae
part
explain
group
averag
higher
blood
pressur
donor
also
experi
previou
donat
exhibit
good
complianc
advic
blood
bank
personnel
sj
h
comsat
institut
inform
technolog
ciit
bank
rawalpindi
institut
cardiolog
govern
servic
hospit
post
graduat
medic
institut
islamabad
pakistan
background
blood
donat
safe
procedur
gener
involv
complic
howev
blood
donor
may
experi
variou
advers
event
ae
variabl
sever
pakistan
blood
transfus
system
reli
predominantli
famili
replac
donor
littl
contribut
voluntari
blood
donor
howev
time
emerg
crise
tremend
respons
voluntari
blood
donor
observ
advers
event
blood
donat
document
due
lack
proper
document
system
lack
awar
staff
involv
current
studi
initi
improv
safeti
standard
blood
donat
monitor
advers
event
blood
donor
section
blood
transfus
servic
rawalpindi
institut
cardiolog
rawalpindi
aim
studi
carri
estim
compar
number
type
ae
assess
practic
would
minim
ae
strengthen
donor
vigil
blood
transfus
servic
rawalpindi
institut
cardiolog
method
retrospect
singl
centr
studi
carri
januari
decemb
whole
blood
donor
attend
rawalpindi
institut
cardiolog
includ
studi
ae
occur
end
donat
note
standard
report
form
develop
conduct
studi
result
blood
donat
blood
donor
report
advers
reaction
result
event
rate
everi
donat
advers
event
mild
intens
sever
complic
medic
emerg
life
threaten
advers
reaction
observ
advers
event
includ
slow
puls
n
low
bp
n
sweat
n
faint
n
pallor
skin
n
nausea
n
drowsi
n
vomit
n
cold
extrem
n
hematoma
n
feel
warmth
n
multipl
prick
n
short
breath
n
headach
n
bruis
n
weak
n
fall
n
restless
n
anxious
n
summaryconclus
donor
haemovigil
system
allow
monitor
donor
safeti
assess
success
intervent
design
improv
donor
safeti
studi
underlin
fact
blood
donat
safe
procedur
could
made
follow
proper
physic
behavior
screen
blood
donat
appli
haemovigil
tool
collect
data
need
provid
specif
inform
card
donor
time
advers
event
detail
immedi
manag
prevent
action
relev
subsequ
donat
adequ
hydrat
proper
physic
screen
comfort
environ
donat
place
reduc
frequenc
advers
reaction
crucial
blood
bank
adopt
systemat
approach
monitor
rate
donor
advers
reaction
current
studi
need
emul
blood
bank
bring
gener
improv
function
blood
transfus
servic
pakistan
c
j
h
blood
servic
foundat
blood
center
taiwan
blood
servic
foundat
taipei
taiwan
background
insuffici
sleep
one
risk
factor
vasovag
reaction
vvr
studi
evalu
associ
sleep
qualiti
sq
vvr
aim
investig
relationship
sq
vvr
among
blood
donor
method
conduct
studi
recruit
whole
blood
wb
donor
vvr
case
group
identifi
blood
donat
wb
donor
without
vvr
control
group
frequenc
match
age
gender
donat
site
questionnair
telephon
use
collect
risk
factor
vvr
pittsburgh
sleep
qualiti
index
psqi
demograph
characterist
inform
blood
donat
result
medic
examin
obtain
bodi
mass
index
bmi
estim
blood
volum
ebv
percentag
blood
loss
defin
volum
blood
collect
divid
ebv
calcul
logist
regress
adopt
evalu
associ
sq
vvr
adjust
confound
factor
result
averag
psqi
score
case
group
control
group
respect
show
signific
differ
proport
poor
sq
two
group
case
group
vs
control
group
p
adjust
confound
factor
stratifi
gender
impact
sq
vvr
signific
male
donor
poor
sq
ci
less
hour
sleep
ci
sleep
disord
ci
femal
donor
influenc
blood
loss
import
sq
vvr
although
femal
donor
less
hour
sleep
sleep
disord
higher
risk
vvr
differ
signific
howev
signific
increas
risk
vvr
observ
femal
donor
blood
loss
ci
summaryconclus
knowledg
first
document
studi
analyz
donor
sq
develop
vvr
found
poor
sq
import
factor
vvr
male
donor
femal
donor
femal
donor
evalu
percentag
blood
loss
rather
sq
moreov
appropri
percentag
blood
loss
consid
individu
ensur
donor
safeti
p
robillard
gregoir
antar
montreal
canada
background
vasovag
reaction
vvr
common
blood
donor
donor
drink
water
eat
salt
snack
donat
recogn
prevent
measur
easi
obtain
monitor
aim
measur
effect
implement
structur
process
administ
water
salt
snack
donor
rate
vvr
method
donor
simpli
inform
registr
drink
water
donat
amount
mention
suppli
vari
empti
glass
donor
fill
juic
box
water
bottl
noth
snack
offer
donat
sugari
june
program
introduc
collect
site
leaflet
poster
pictogram
inform
donor
import
drink
water
eat
salt
snack
donor
provid
water
bottl
bag
salt
pretzel
registr
told
drink
whole
bottl
donat
eat
pretzel
three
check
point
monitor
consumpt
interview
venipunctur
recoveri
area
sever
vvr
report
standard
form
rate
vvr
vvr
without
loss
conscious
loc
per
donat
month
pre
dec
jun
post
dec
implement
compar
use
test
result
signific
reduct
number
pre
post
rate
vvr
pre
post
risk
reduct
ci
risk
reduct
ci
rate
pre
post
rate
vvr
significantli
declin
vs
experienc
donor
vs
femal
vs
male
donor
vs
risk
reduct
femal
male
donor
risk
reduct
signific
age
group
greatest
yo
although
rate
lower
apheresi
donor
risk
reduct
import
whole
blood
donor
femal
summaryconclus
structur
program
water
salt
snack
deliveri
blood
collect
site
significantli
reduc
incid
vvr
importantli
loc
improv
donor
safeti
make
donat
experi
better
make
like
donor
return
c
w
k
c
health
technolog
informat
hong
kong
polytechn
univers
anaesthesia
intens
care
chines
univers
hong
kong
collect
donor
recruit
depart
hong
kong
red
cross
transfus
servic
ha
hong
kong
hong
kong
background
vasovag
reaction
vvr
advers
effect
may
occur
blood
donat
symptom
mild
howev
seriou
consequ
result
symptom
donat
report
vvr
major
factor
account
reduct
first
time
repeat
blood
donor
even
extens
research
target
risk
factor
age
gender
weight
blood
donor
seem
definit
solut
address
issu
aim
vvr
associ
abrupt
cardiovascular
challeng
lead
haemodynam
decompens
aim
studi
investig
haemodynam
effect
differ
method
fluid
prehydr
attempt
minim
immedi
delay
vvr
among
young
healthi
blood
donor
method
blood
donor
age
recruit
particip
random
control
studi
subject
assign
one
three
group
prior
blood
donat
prehydr
control
ml
water
prehydr
placebo
ml
oral
rehydr
salt
or
haemodynam
measur
record
use
transcutan
doppler
ultrasound
five
time
point
follow
interv
start
complet
blood
donat
procedur
result
data
analys
subject
subject
alloc
control
placebo
or
group
respect
differ
incid
immedi
delay
vvr
among
group
immedi
vvr
record
subject
two
placebo
one
or
group
delay
vvr
also
report
subject
two
control
one
placebo
group
measur
reveal
significantli
higher
stroke
volum
sv
vs
ml
higher
cardiac
output
co
vs
lmin
lower
system
vascular
resist
svr
vs
mmhg
minml
or
group
control
group
p
reduct
sv
co
detect
regardless
group
alloc
blood
donat
blood
donat
or
group
show
significantli
higher
sv
vs
ml
co
vs
lmin
lower
svr
vs
mmhg
minml
control
group
blood
pressur
paramet
show
clinic
signific
chang
across
group
blood
donat
summaryconclus
preliminari
find
suggest
prehydr
or
may
provid
better
preserv
haemodynam
although
may
necessarili
reduc
incid
vvr
caus
vvr
multifactori
or
may
exert
posit
effect
one
import
contribut
factor
vvr
k
k
offic
transfus
centr
slovenia
ljubljana
slovenia
background
sever
advers
transfus
reaction
satr
advers
effect
blood
blood
compon
potenti
fatal
could
caus
long
term
ill
analysi
advers
transfus
reaction
atr
rais
awar
could
allow
earli
recognit
prevent
nation
slovenian
hemovigil
offic
collect
inform
atr
transfus
depart
suppli
blood
compon
slovenian
hospit
mandatori
law
report
sever
advers
transfus
reaction
slovenian
compet
author
end
year
produc
annual
report
submit
european
commiss
aim
aim
rais
awar
atr
especi
encourag
physician
report
often
mild
atr
method
retrospect
analyz
report
satr
slovenian
hemovigil
system
januari
decemb
result
observ
period
case
atr
satr
satr
case
period
issu
blood
compon
simplic
assum
issu
compon
high
major
actual
transfus
calcul
incid
atr
period
analys
transfus
case
satr
frequent
advers
reaction
volum
overload
taco
report
case
incid
taco
transfus
red
blood
cell
second
common
sever
allerg
reaction
case
incid
transfus
also
case
transmiss
hepat
b
viru
incid
transfus
hypotens
reaction
incid
transfus
trali
incid
case
delay
haemolysi
incid
calcul
transfus
red
blood
cell
compon
case
death
caus
transfus
case
thrombocytopen
purpura
acut
haemolysi
summaryconclus
slovenia
hemovigil
system
determin
law
strict
test
regim
combin
surveil
system
qualiti
control
safeti
blood
product
high
level
realis
atr
underreport
especi
mild
sign
transfus
reaction
physician
sure
relat
transfus
hand
believ
vast
major
satr
report
hard
overlook
report
life
treat
complic
transfus
report
atr
great
import
sinc
repres
opportun
learn
system
improv
awar
transfus
complic
recognis
faster
take
swift
action
benefit
patient
make
transfus
safer
vain
donor
vain
recipi
best
interest
respons
everyon
involv
transfus
chain
wong
k
iskhak
ho
l
li
pennefath
h
tan
l
tan
p
thant
blood
resourc
health
scienc
author
singapor
singapor
singapor
background
notic
recent
year
rise
donor
vasovag
reaction
vvr
nation
blood
bank
seriou
vvr
may
caus
injuri
fear
futur
donat
group
donor
identifi
prone
vvr
age
year
old
thu
small
studi
monitor
donor
blood
pressur
bp
post
donat
reduc
vvr
recommend
aim
determin
implement
post
donat
bp
monitor
discharg
donor
bp
could
reduc
incid
vvr
method
studi
conduct
septemb
octob
whole
blood
donor
local
univers
blood
mobil
age
rang
within
studi
group
donor
particip
studi
donor
control
group
donor
drank
least
ml
isoton
drink
half
donor
studi
group
post
donat
blood
pressur
taken
addit
prevent
measur
coupl
least
ml
isoton
drink
consum
particip
control
studi
group
equal
divid
amongst
univers
ensur
consist
variabl
group
physic
social
environ
comparison
group
done
ascertain
group
higher
number
reaction
rate
result
particip
particip
drop
studi
group
could
wait
bp
monitor
rush
back
class
anoth
donor
studi
group
termin
donat
half
way
donat
studi
donor
control
group
advers
reaction
donor
studi
group
note
develop
advers
reaction
complet
donat
result
p
valu
signific
signific
level
use
test
donor
studi
group
complet
donat
low
bp
advers
reaction
rest
donat
room
encourag
drink
fluid
allow
leav
donat
room
bp
read
reach
group
donor
could
potenti
develop
vvr
monitor
close
donat
room
summaryconclus
studi
show
higher
rate
vvr
despit
post
donat
blood
pressur
monitor
howev
p
valu
result
insignific
group
donor
lack
sleep
food
water
insuffici
higher
level
activ
could
contribut
factor
caus
vvr
therefor
monitor
blood
pressur
alon
ineffect
prevent
reaction
continu
educ
group
donor
prevent
advers
reaction
event
advers
reaction
post
blood
donat
practic
approach
conclud
take
bp
post
donat
help
reduc
vvr
abstract
withdrawn
ferdowsi
babahajian
k
khaledian
karimian
blood
transfus
research
center
tehran
iran
background
blood
donat
wide
consid
safe
low
incid
advers
reaction
ar
howev
ar
occasion
occur
end
blood
collect
hand
ar
neg
affect
donor
retent
aim
aim
studi
assess
frequenc
ar
kurdistan
blood
transfus
center
west
iran
also
determin
impact
ar
donor
return
rate
method
perform
cohort
studi
whole
blood
donat
use
data
extract
blood
servic
inform
ar
record
use
intern
agre
standard
definit
donor
observ
follow
donat
possibl
advers
event
min
addit
donor
ar
evalu
return
donat
within
month
subsequ
reaction
result
total
blood
donor
enrol
repeat
donor
first
time
donor
total
number
donor
experienc
ar
develop
vasovag
reaction
vvr
arteri
injuri
develop
hematoma
mean
age
femal
male
donor
experienc
ar
year
respect
donor
man
repeat
donat
donor
hemoglobin
less
grdl
significantli
associ
vvr
p
return
rate
within
year
repeat
door
donor
experienc
ar
first
donat
uncompl
second
donat
summaryconclus
incid
reaction
low
center
addit
result
show
donat
experi
strongli
influenc
donor
return
reduc
donor
return
seen
follow
ar
abstract
withdrawn
abstract
withdrawn
abstract
withdrawn
k
shamsasenjan
sedaghat
aminikafiabadi
maghsoodlu
b
rabbani
pourfathollah
high
institut
research
educ
transfus
medicin
iranian
blood
transfus
organ
tehran
iran
background
advers
reaction
blood
donat
main
role
improv
donor
satisfact
accordingli
increas
blood
donat
frequenc
retain
regular
blood
donor
advers
reaction
especi
sever
one
import
blood
donor
care
ethic
issu
blood
donat
well
standard
nation
donor
vigil
system
could
abl
monitor
advers
reaction
among
blood
donor
care
reduc
frequent
sever
advers
reaction
also
improv
qualiti
safeti
blood
donor
aim
improv
donor
satisfactionto
increas
donat
frequenciesto
reduc
frequenc
sever
advers
eventsto
reduc
donor
injur
method
nation
donor
vigil
system
scale
iran
strengthen
nation
donor
vigil
report
system
plan
intervent
design
implement
base
categori
follow
nation
protocol
donor
vigil
revis
updat
base
last
version
guidelin
standard
definit
donor
vigil
nation
donor
vigil
report
system
record
form
revis
updat
nation
train
manual
prevent
method
sever
reaction
develop
nation
train
workshop
conduct
qualifi
physician
donor
vigil
staff
blood
collect
center
base
experi
proport
sever
advers
donor
reaction
reduc
advers
donor
reaction
year
year
result
nation
donor
vigil
system
scale
nation
donor
vigil
report
system
show
proport
sever
advers
reaction
advers
reaction
percentag
record
year
experi
show
reduct
sever
advers
donor
reaction
index
year
scale
nation
donor
vigil
system
summaryconclus
donor
vigil
essenti
role
blood
donor
safeti
recruit
retent
blood
donor
also
ethic
issu
blood
donor
accur
system
record
report
blood
donor
advers
reaction
especi
standard
prevent
intervent
sever
reaction
could
effect
nation
experi
train
staff
import
role
reduc
donor
sever
advers
reaction
al
n
h
r
e
blood
servic
vancouv
british
columbia
servic
canadian
blood
servic
london
ontario
labatt
school
nurs
western
ontario
london
blood
servic
halifax
nova
scotia
blood
servic
toronto
ontario
canada
background
incomplet
filtrat
occur
red
blood
cell
whole
blood
wb
unit
complet
filter
due
blockag
canadian
blood
servic
cb
implement
polici
manag
donor
wb
donat
result
per
polici
donor
wb
donat
result
consecut
intermitt
medic
offic
notifi
evalu
donor
possibl
deferr
publish
literatur
show
donor
might
associ
health
issu
howev
donor
still
lost
deferr
current
polici
aim
aim
studi
retrospect
examin
data
donor
identifi
associ
factor
found
among
defer
donor
method
retrospect
review
nation
cb
donor
base
use
busi
intellig
bi
warehous
data
eprogesa
data
analyz
defer
blood
donor
due
period
januari
decemb
data
collect
includ
donor
gender
age
deferr
blood
group
total
number
donat
prior
deferr
due
product
method
unit
associ
versu
collect
bag
type
filter
use
cb
result
donor
defer
due
studi
period
among
male
femal
distribut
abo
blood
group
donor
includ
group
donor
group
donor
group
b
donor
group
ab
donor
among
defer
donor
regular
donor
variabl
total
donat
rang
associ
collect
bag
doubl
frequenc
compar
collect
bag
howev
total
collect
cb
around
whole
blood
collect
collect
note
product
method
use
differ
filter
also
filtrat
step
take
place
differ
stage
compon
product
summaryconclus
observ
appar
associ
age
gender
blood
group
number
donat
event
defer
donor
associ
method
product
method
may
manufactur
rbc
plt
plasma
method
first
rbc
filter
whole
blood
filter
separ
rbc
plasma
factor
may
includ
distanc
clinic
donor
factor
creat
robust
system
investig
donor
factor
obtain
medic
histori
result
follow
test
could
identifi
donor
relat
factor
cb
current
follow
donor
defer
implement
robust
donor
would
provid
better
line
sight
donor
causal
factor
k
garg
p
kaur
govern
medic
colleg
hospit
sector
chandigarh
chandigarh
india
background
increas
demand
platelet
transfus
shrink
donor
pool
led
shift
toward
autom
blood
collect
newer
gener
apheresi
platform
provid
high
qualiti
platelet
short
time
apheresi
procedur
associ
uniqu
complic
due
citrat
infus
citrat
induc
hypocalcaemia
hypomagnesaemia
usual
transient
lead
signific
donor
discomfort
affect
donor
retent
present
studi
conduct
analyz
chang
biochem
paramet
plateletpheresi
associ
donor
advers
reaction
aim
determin
effect
citrat
infus
biochem
paramet
plateletpheresi
healthi
donor
correl
chang
advers
donor
reaction
method
studi
conduct
septemb
januari
healthi
replac
plateletpheresi
donor
written
inform
consent
donor
approv
institut
ethic
committe
donor
includ
studi
met
elig
criteria
laid
director
gener
health
servic
india
plateletpheresi
procedur
perform
continu
flow
machin
fenwal
amicu
trima
accel
autom
blood
collect
system
depend
upon
venou
access
per
depart
standard
oper
procedur
use
close
system
apheresi
kit
blood
sampl
drawn
donor
three
occas
includ
baselin
sampl
min
start
procedur
min
complet
procedur
ml
sampl
taken
heparin
syring
occas
measur
ioniz
calcium
ml
sampl
plain
vacutain
plain
sampl
subject
measur
serum
calcium
serum
magnesium
parathyroid
hormon
total
protein
serum
albumin
use
hitachi
model
analyz
result
healthi
replac
donor
age
year
mean
weight
kg
underw
plateletpheresi
statist
signific
declin
mean
total
calcium
mgdl
mgdl
ioniz
calcium
mgdl
mgdl
p
baselin
level
minut
start
procedur
respect
use
pair
similar
signific
fall
observ
serum
magnesium
level
mgdl
mgdl
total
protein
gdl
gdl
serum
albumin
gdl
gdl
level
restor
near
baselin
level
within
minut
parathyroid
hormon
show
signific
increas
baselin
level
pgml
pgml
procedur
level
remain
elev
minut
donor
n
experienc
symptom
toxic
form
perior
tingl
numb
extrem
donor
manag
oral
calcium
supplement
summaryconclus
plateletpheresi
induc
mark
reduct
biochem
paramet
particularli
ioniz
calcium
magnesium
level
moreov
alter
parathyroid
hormon
level
could
result
signific
impact
bone
miner
metabol
regular
repeat
donor
addit
declin
total
protein
serum
albumin
may
concern
donor
also
particip
plasmapheresi
prophylact
calcium
magnesium
supplement
may
consid
prevent
donor
reaction
regular
plateletpheresi
donor
aa
navkudkar
p
desai
rajadhyaksha
transfus
medicin
tata
memori
hospit
mumbai
india
background
blood
donat
healthi
volunt
assur
avail
blood
compon
transfus
blood
donat
well
toler
donor
howev
may
experi
advers
reaction
reaction
occur
donat
site
document
occur
donor
left
donat
site
may
go
unnot
thu
unreport
henc
import
get
inform
advers
reaction
aim
analyz
frequenc
type
advers
donor
reaction
correl
contributori
factor
anyto
add
donor
hemovigil
data
better
understand
advers
donor
reaction
analyz
data
blood
centersto
develop
predict
model
donor
goal
defin
target
group
recommend
best
practic
improv
donor
care
safeti
method
prospect
observ
studi
voluntari
whole
blood
wb
donor
consent
particip
donor
contact
telephon
interview
two
occas
first
h
donat
second
week
donat
donor
ask
structur
questionnair
inform
document
accord
gender
age
weight
place
donat
donat
statu
occup
statist
analysi
done
spss
statist
packag
social
scienc
softwar
result
voluntari
wb
donor
respond
phone
call
occas
donor
experienc
advers
reaction
donor
experienc
reaction
within
h
donat
none
experienc
reaction
beyond
h
week
donor
reaction
occur
donat
site
reaction
occur
donor
left
donat
site
total
onsit
reaction
vasovag
reaction
vvr
offsit
reaction
hematoma
donor
experienc
vvr
experienc
hematoma
includ
donor
experienc
vvr
higher
low
weight
donor
femal
donor
first
time
donor
p
vvr
mild
moder
sever
donor
vvr
donor
complain
fear
anxieti
donat
first
time
donor
gave
histori
inadequ
waterfluid
intak
donor
associ
factor
report
hematoma
reaction
occur
offsit
occur
onsit
major
hematoma
took
day
recov
summaryconclus
post
donat
interview
prove
effect
tool
acquir
inform
advers
donor
reaction
hour
help
reaction
occur
within
time
period
donor
recal
reaction
better
would
otherwis
gone
unreport
donor
advis
manag
also
use
valuabl
tool
donor
hemovigil
present
mandatori
india
help
improv
donor
safeti
satisfact
posit
impact
nation
blood
suppli
improv
donor
return
rate
mi
puppo
v
cabrera
g
castelli
l
giunta
kuperman
hospit
nacion
de
pediatria
prof
dr
juan
p
garrahan
caba
argentina
background
postdon
inform
pdi
fact
report
blood
donor
anoth
person
disclos
blood
center
blood
donat
could
put
risk
safeti
blood
product
stem
donat
occur
donor
fail
report
risk
would
result
deferr
exclus
screen
process
blood
center
implement
novemb
standard
oper
procedur
homogen
process
put
practic
intern
document
regist
data
pdi
aim
studi
analyz
post
donat
inform
form
regist
sinc
investig
number
type
main
sourc
pdi
also
took
account
action
taken
result
pdi
method
descript
retrospect
studi
perform
novemb
decemb
follow
data
collect
pdi
form
kind
blood
donor
first
time
repeat
recept
time
seven
day
donat
sourc
blood
donor
third
person
type
pdi
also
analyz
decis
adopt
blood
compon
involv
donat
result
studi
period
blood
donat
ipd
regist
first
week
blood
donat
report
blood
donor
first
time
donor
type
pdi
analyz
relat
medic
reason
respiratori
infect
fever
diarrhea
associ
risk
factor
risk
sexual
contact
blood
exposit
analyz
action
taken
blood
compon
associ
ipd
detect
although
major
discard
compon
sent
blood
transfus
servic
moment
pdi
relat
risk
sexual
factor
summaryconclus
current
donor
screen
process
use
precautionari
question
guard
theoret
potenti
risk
limit
context
pdi
manag
import
term
blood
safeti
even
though
studi
commonli
report
pdi
fever
respiratori
infect
diarrhea
eighteen
percent
relat
risk
factor
commonli
sexual
risk
factor
blood
centr
discard
compon
relat
pdi
inform
discov
report
compon
distribut
blood
bank
may
attempt
retriev
meet
qualiti
standard
studi
detect
compon
relat
risk
sexual
contact
sent
transfus
servic
case
blood
center
notifi
potenti
risk
ipd
process
need
blood
donor
inform
potenti
risk
blood
transfus
achiev
voluntari
repeat
blood
donor
import
frame
ipd
qualiti
program
order
ensur
train
personnel
involv
pdi
recept
decis
make
regard
affect
blood
unit
gao
blood
donat
servic
depart
wuhan
blood
center
wuhan
china
background
nowaday
occurr
advers
reaction
still
import
problem
time
blood
donat
still
mani
blood
donor
easi
advers
reaction
especi
blood
donor
accord
research
mental
stress
main
caus
advers
reaction
psycholog
care
effect
allevi
anxieti
emot
advers
reaction
prevent
increas
amount
blood
collect
world
difficult
give
full
attent
everi
blood
donor
good
way
investig
time
characterist
associ
occurr
advers
reaction
blood
donor
aim
investig
time
characterist
associ
occurr
advers
reaction
blood
donor
explor
appropri
time
give
psycholog
care
prevent
advers
reaction
enhanc
proport
fix
blood
donor
ensur
blood
suppli
meet
clinic
use
demand
method
retrospect
analysi
conduct
data
blood
donor
accord
time
donor
came
donat
h
work
time
divid
time
period
time
occurr
advers
reaction
evalu
blood
donor
repeat
blood
donor
result
incid
advers
reaction
blood
donor
group
significantli
frequent
repeat
group
p
incid
advers
reaction
second
fourth
time
period
significantli
frequent
blood
donor
group
repeat
group
p
incid
advers
reaction
first
third
time
period
show
signific
differ
two
group
p
summaryconclus
incid
advers
reaction
frequent
therefor
blood
donor
close
monitor
care
nurs
especi
blood
donor
come
donat
blood
time
period
advers
reaction
prevent
time
psycholog
care
given
accord
time
period
donat
allevi
anxieti
emot
incid
revers
reaction
volunt
necessari
establish
scientif
effect
mode
psycholog
counsel
differ
time
period
voluntari
blood
donat
ti
mugisha
polycarp
caesar
bashir
w
fred
intern
health
scienc
univers
kampala
uganda
background
rhd
variant
clinic
import
owe
high
immunogen
potenti
caus
alloimmunis
among
rhd
neg
individu
follow
transfus
red
blood
cell
aim
determin
preval
rhd
variant
phenotyp
among
voluntari
non
remuner
blood
donor
gulu
region
blood
bank
grbb
northern
uganda
method
conduct
cross
section
studi
first
ml
ethylen
tetra
acet
acid
edta
blood
sampl
collect
voluntari
non
remuner
blood
donor
type
abo
rhd
blood
group
statu
use
iggigm
monoclon
type
antiserum
blood
sampl
test
rhd
neg
investig
rhd
variant
phenotyp
use
indirect
antihuman
globulin
techniqu
result
assay
rhd
neg
blood
sampl
obtain
voluntari
non
remuner
blood
donor
n
male
median
age
rang
year
major
particip
abo
blood
group
n
follow
n
b
n
least
ab
n
preval
rhd
variant
phenotyp
occur
among
n
ci
statist
associ
rhd
variant
phenotyp
donor
gender
tribe
abo
blood
group
summaryconclus
studi
reveal
high
preval
rhd
variant
among
blood
donor
gulu
region
blood
bank
northern
uganda
highlight
potenti
risk
alloimmunis
present
blood
type
practic
identifi
rhd
variant
phenotyp
de
blood
servic
ottawa
quebec
canada
background
canada
red
blood
cell
concentr
rbcc
manufactur
use
two
method
first
method
buffi
coat
bc
whole
blood
wb
collect
cpd
bag
unit
store
h
prior
product
rbcc
canadian
blood
servic
cb
produc
bc
rbcc
use
method
hq
manufactur
bc
rbcc
autom
atreu
wb
process
system
second
method
rbcc
product
involv
wb
collect
hq
cpd
cb
bag
unit
store
h
prior
rbcc
product
aim
compar
bacteri
growth
rbcc
manufactur
bc
method
influenc
addit
solut
donor
gender
also
evalu
method
three
cpd
wb
unit
pool
split
manufactur
three
rbcc
suspend
differ
sagm
paggsm
unit
prepar
use
bc
hq
cb
method
addit
wb
unit
use
manufactur
rbcc
suspend
use
method
hq
distribut
organ
rbcc
inocul
one
four
bacteria
klebsiella
pneumonia
staphylococcu
epidermidi
yersinia
enterocolitica
propionibacterium
acn
target
coloni
form
unit
cfuml
n
rbcc
sampl
weekli
determin
bacteri
concentr
end
storag
viabil
determin
bactalert
cultur
effect
rbcc
manufactur
donor
gender
bacteri
growth
statist
analyz
result
epidermidi
rbcc
regardless
manufactur
method
k
pneumonia
viabil
decreas
rbcc
storag
differ
relat
gender
affect
k
pneumonia
viabil
unit
prepar
method
signific
interact
storag
day
observ
bc
unit
p
p
acn
concentr
declin
faster
male
bc
unit
compar
femal
bc
rbcc
p
higher
load
observ
male
unit
compar
femal
rbcc
prepar
method
p
enterocolitica
grew
rbcc
differ
observ
depend
manufactur
method
bacterium
reach
higher
concentr
unit
prepar
method
compar
bc
unit
suspend
sagm
paggsm
p
contrast
enterocolitica
grew
similar
level
rbcc
prepar
method
independ
except
differenti
growth
observ
paggsm
unit
p
bc
unit
higher
enterocolitica
concentr
femal
donat
compar
male
unit
p
differ
observ
relat
gender
rbcc
prepar
method
summaryconclus
studi
demonstr
rbcc
manufactur
method
support
higher
prolifer
enterocolitica
compar
bc
unit
result
might
due
higher
iron
avail
andor
higher
residu
white
blood
cell
rbcc
prepar
method
merit
investig
interestingli
femal
bc
rbcc
unit
report
lower
level
hemolysi
male
unit
support
higher
level
enterocolitica
find
also
warrant
addit
studi
abstract
withdrawn
n
f
f
j
l
l
p
control
collect
red
cross
luxemburg
luxembourg
luxembourg
affair
terumo
bct
zaventem
belgium
red
cross
luxemburg
luxembourg
luxembourg
background
end
red
cross
luxembourg
rcl
implement
mirasol
prt
system
terumo
bct
treat
whole
blood
deriv
platelet
concentr
pc
one
year
later
rcl
introduc
whole
blood
autom
reveo
autom
whole
blood
process
system
terumo
bct
optim
compon
process
align
platelet
process
prt
treatment
aim
aim
studi
describ
impact
implement
reveo
technolog
mirasol
prt
process
product
qualiti
logist
aspect
method
whole
blood
collect
reveo
collect
bag
target
volum
ml
store
eutect
plate
least
h
depend
collect
time
blood
process
either
day
overnight
hold
room
temperatur
whole
blood
unit
one
red
cell
concentr
one
plasma
one
interim
platelet
unit
ipu
produc
least
four
hour
rest
agit
time
ipu
pool
unit
filter
leukoreduct
filter
sinc
august
pool
process
manag
use
select
tool
softwar
applic
sort
group
ipu
base
estim
platelet
yield
reveo
system
current
approxim
routin
process
pc
treat
mirasol
prt
system
content
pc
riboflavin
bag
transfer
illumin
bag
connect
use
tscd
bag
subsequ
illumin
platelet
count
yield
determin
beckman
coulter
devic
concentr
visual
check
swirl
complet
procedur
result
sinc
novemb
februari
rcl
produc
pc
concentr
treat
mirasol
prt
system
averag
yield
treat
pc
mirasol
treatment
per
bag
ipu
n
per
bag
ipu
n
illumin
product
conform
specif
platelet
content
period
product
discard
mainli
owe
technic
failur
aggreg
found
mirasol
treat
platelet
concentr
calcul
platelet
loss
process
transferillumin
evalu
implement
reveo
system
enabl
spare
time
illumin
process
increas
full
time
resourc
delay
avail
pc
observ
final
evid
increas
notif
transfus
reaction
pc
record
rcl
hemovigil
databas
summaryconclus
autom
upstream
whole
blood
separ
process
reveo
system
led
increas
product
concomitantli
improv
blood
compon
standardis
stay
within
product
specif
enabl
rcl
maintain
whole
blood
process
mirasol
prt
treatment
pc
without
increas
full
time
equival
fte
resourc
involv
blood
compon
product
k
j
p
j
k
f
g
medicin
univers
medicin
greifswald
greifswald
pharma
intern
gmbh
langen
germani
pharma
sa
mouvaux
franc
background
di
phthalat
dehp
plastic
blood
bag
bound
polyvinylchlorid
pvc
polym
leach
blood
product
exposur
dehp
might
induc
development
reproduct
toxic
human
aim
object
studi
evalu
altern
plastic
di
isononyl
dinch
use
system
whole
blood
wb
process
result
product
plasma
red
blood
cell
concentr
rbc
platelet
concentr
pc
method
total
wb
healthi
volunt
collect
dehp
dinch
system
maco
pharma
franc
within
h
wb
centrifug
g
min
separ
plasma
buffi
coat
rbc
plasma
unit
per
studi
arm
shock
frozen
store
day
sampl
taken
thaw
day
analyz
regard
coagul
paramet
triglycerid
protein
level
microparticl
buffi
coat
pool
pc
dehp
dinch
system
addit
ssp
addit
solut
maco
pharma
franc
studi
arm
pc
store
day
room
temperatur
rt
agit
sampl
taken
day
analyz
regard
metabol
platelet
function
hypoton
shock
respons
hsr
addit
addit
solut
rbc
studi
arm
leukoreduc
analyz
vitro
characterist
metabol
hemolysi
adenosin
triphosph
atp
glycer
level
microparticl
storag
day
result
usag
dinch
base
blood
bag
system
influenc
whole
blood
separ
process
plasma
coagul
factor
level
triglycerid
protein
level
compar
plastic
eg
factor
viii
activ
day
thaw
dehp
vs
dinch
p
pc
show
equival
outcom
regard
platelet
count
metabol
hsr
aggreg
activ
abil
plastic
differ
manufactur
time
rbc
analysi
result
compar
result
regard
metabol
rbc
count
hematocrit
hemoglobin
microparticl
hemolysi
increas
use
dinch
base
bag
short
time
wb
separ
dehp
vs
dinch
p
day
storag
wb
h
show
differ
hemolysi
dinch
dehp
bag
use
addit
solut
dehp
vs
dinch
day
atp
level
rbc
differ
plastic
manufactur
time
addit
solut
atp
concentr
highest
bag
dinch
manufactur
within
h
hb
lowest
bag
dinch
manufactur
within
h
hb
day
summaryconclus
replac
dehp
plastic
dinch
impair
manufactur
process
overal
plasma
pc
rbc
qualiti
paramet
compar
dehp
dinch
base
bag
hemolysi
rbc
increas
dinch
bag
process
within
h
day
storag
far
threshold
whole
blood
separ
plasma
rbc
pc
dinch
altern
dehp
j
affair
innov
canada
background
inventori
contain
rare
red
blood
cell
rbc
glycerol
use
meryman
manual
method
current
unit
deglycerol
use
cobe
outdat
need
replac
eventu
although
autom
cell
processor
integr
activ
glycerol
deglycerol
rbc
yet
valid
deglycerol
manual
glycerol
rbc
unit
aim
studi
aim
assess
possibl
use
autom
cell
processor
system
deglycerol
manual
glycerol
unit
moreov
sinc
unit
still
manual
glycerol
current
oper
studi
also
aim
assess
qualiti
accord
age
rbc
unit
moment
freez
method
twenti
manual
glycerol
rbc
unit
inventori
frozen
approxim
ten
year
thaw
water
bath
deglycerol
use
autom
cell
processor
system
acp
haemonet
resuspend
rbc
vitro
qualiti
assess
h
deglycerol
separ
experi
addit
rbc
unit
manual
glycerol
day
n
per
group
unit
frozen
day
unit
thaw
deglycerol
acp
rbc
vitro
qualiti
assess
h
deglycerol
result
deglycerol
unit
inventori
met
criteria
hematocrit
steril
h
storag
howev
hemolysi
still
lower
typic
obtain
unit
deglycerol
cobe
unit
met
criteria
hemolysi
hemoglobin
gunit
percent
recoveri
could
assess
sampl
sinc
data
concentr
obtain
upon
freez
age
unit
time
glycerol
influenc
hemolysi
upon
deglycerol
inde
hemolysi
significantli
higher
unit
frozen
day
collect
result
justifi
need
evalu
optim
time
unit
still
manual
glycerol
institut
second
set
experi
deglycerol
unit
respect
standard
hematocrit
hemoglobin
hemolysi
steril
long
glycerol
frozen
later
seven
day
summaryconclus
rbc
unit
manual
glycerol
deglycerol
automat
cell
resuspend
store
h
met
vitro
qualiti
standard
steril
hematocrit
difficulti
reach
standard
hemoglobin
might
relat
centrifug
volum
limit
aspect
warrant
optim
standard
hemolysi
met
everi
unit
vastli
improv
compar
routin
obtain
cobe
thu
automat
cell
processor
use
deglycerol
rbc
unit
manual
glycerol
alghisi
l
pavan
colonna
p
dragon
c
sardella
blood
transfus
medicin
depart
vicenza
hospit
vicenza
itali
background
vicenza
blood
depart
process
around
whole
blood
unit
yearli
collect
within
collect
center
provid
blood
compon
whole
depart
plasma
pharmaceut
industri
blood
process
santorso
hospit
februari
transfer
blood
collect
process
data
batch
basi
done
end
day
make
statist
qualiti
analysi
difficult
separ
program
assign
manual
oper
unit
aim
improv
fulli
autom
monitor
step
concern
blood
compon
product
donat
process
qualiti
control
order
ensur
high
qualiti
standard
traceabl
real
time
data
transfer
method
depart
reorgan
occur
februari
center
start
use
line
whole
blood
collect
kit
top
bottom
macopharma
bag
macomix
blood
mixer
macopharma
macopress
smart
revo
autom
plasma
extractor
macopharma
macopharma
softwar
hemocompon
qualiti
control
manag
blood
mixer
plasma
extractor
bidirect
connect
laboratori
inform
system
li
mixer
receiv
donor
inform
transfer
data
describ
donat
time
date
kit
number
durat
collect
volum
plasma
extractor
three
program
avail
program
product
fresh
plasma
leucodeplet
red
cell
concentr
exclud
platelet
product
process
time
exce
h
collect
program
product
fresh
frozen
plasma
leucodeplet
red
cell
concentratesprogram
product
fresh
frozen
plasma
leucodeplet
red
cell
concentr
bc
exclud
platelet
product
donat
durat
longer
clinic
reason
plasma
extractor
also
connect
automat
import
volum
data
hemocompon
produc
serial
number
separ
enabl
product
assess
addit
hemocompon
qualiti
control
surveil
result
data
export
period
analyz
blood
unit
automat
process
follow
use
program
use
program
use
program
analysi
perform
devic
show
distribut
workload
percentag
among
extractor
min
max
demonstr
optim
red
cell
unit
detect
real
time
rang
volum
accord
intern
criteria
abl
check
immedi
compon
order
verifi
complianc
term
qualiti
respect
italian
regulatori
intern
guidelin
summaryconclus
demonstr
huge
improv
achiev
due
fulli
autom
manag
system
term
blood
compon
safeti
traceabl
workflow
complianc
qualiti
compon
standard
bidirect
connect
li
mixer
plasma
extractor
reduc
oper
allow
better
qualiti
hemocompon
avoid
error
attribut
separ
program
particularli
import
depart
blood
collect
multipl
center
p
c
n
p
compon
product
control
manag
nation
blood
centr
thai
red
cross
societi
bangkok
thailand
background
process
red
blood
cell
rbc
injur
result
hemolysi
separ
whole
blood
quadrupl
top
bottom
bag
system
mostli
take
less
second
howev
short
separ
time
may
caus
higher
rate
rbc
hemolysi
aim
aim
studi
investig
whether
hemolysi
leukocyt
poor
pack
red
cell
lprc
increas
shorter
separ
time
appli
method
routin
separ
time
lprc
top
bottom
system
compar
design
separ
time
within
kawasumi
autom
separ
hemolysi
detect
day
visual
inspect
hemolyz
sampl
test
hemolysi
end
storag
day
result
visual
inspect
unit
unit
detect
hemolyz
sampl
end
storag
found
unit
unit
hemolyt
hemolysi
averag
hemolysi
respect
averag
separ
time
maximum
minimum
averag
separ
time
maximum
minimum
summaryconclus
lprc
separ
within
exhibit
higher
mean
hemolysi
separ
p
therefor
commonli
use
separ
time
suitabl
confirm
studi
lower
limit
separ
time
consid
less
ca
vaz
f
vasconcelo
lope
fernand
j
cruz
henriqu
koch
imunohemoterapia
centro
hospitalar
de
porto
portug
background
blood
bank
activ
hospit
bank
portug
blood
compon
implement
autom
whole
blood
wb
process
system
reveo
system
process
four
wb
unit
simultan
red
blood
cell
rbc
unit
interim
platelet
plt
unit
ipu
plasma
unit
residu
leukocyt
unit
also
obtain
multipl
ipu
pool
form
transfus
platelet
pool
aim
evalu
qualiti
compon
obtain
reveo
system
centr
method
wb
ml
process
use
reveo
system
accord
terumo
bct
protocol
protocol
overnight
rbc
ipu
plasma
unit
obtain
method
ad
rbc
unit
leukoreduc
use
integr
filter
platelet
pool
prepar
pool
ipu
rest
platelet
shaker
analyz
group
rbc
unit
platelet
pool
obtain
march
qualiti
paramet
studi
rbc
unit
volum
haemoglobin
hb
content
haematocrit
hct
residu
leucocyt
platelet
pool
volum
platelet
yield
residu
leucocyt
evalu
result
blood
compon
obtain
rbc
unit
plasma
unit
ipu
analyz
n
blood
compon
obtain
reveo
system
rbc
unit
platelet
pool
overal
unit
met
portugues
regul
rbc
unit
achiev
requir
paramet
platelet
pool
case
rbc
unit
legal
requir
paramet
met
hct
hg
residu
leucocyt
platelet
pool
percentag
unit
within
legal
requir
platelet
yield
residu
leucocyt
summaryconclus
blood
compon
prepar
reveo
system
use
protocol
overnight
met
qualiti
criteria
establish
portugues
regul
case
number
unit
met
requir
paramet
higher
rbc
unit
analyz
platelet
pool
sinc
implant
wb
autom
process
system
centr
method
blood
process
shown
effici
consist
p
r
pj
p
h
j
servic
research
australian
red
cross
blood
servic
perth
servic
research
australian
red
cross
blood
servic
sydney
servic
research
australian
red
cross
blood
servic
adelaid
australia
background
australian
red
cross
blood
servic
blood
servic
oper
nation
perform
leucodeplet
platelet
red
cell
sinc
filter
blockag
leucodeplet
failur
note
donor
sickl
cell
haemoglobin
hb
trait
failur
leucodeplet
increas
risk
cmv
transmiss
transfus
reaction
recipi
may
also
donor
safeti
implic
report
first
australian
studi
identifi
manag
donor
recurr
filter
blockag
red
cell
compon
filtrat
clot
issu
discard
routin
systemat
process
contact
donor
red
cell
process
issu
identifi
report
function
standardis
donor
could
repeat
donat
discard
aim
systemat
whole
blood
donor
note
issu
leucodeplet
red
cell
process
result
compon
repeatedli
discard
method
studi
approv
blood
servic
ethic
committe
initi
april
includ
data
avail
end
januari
discard
process
code
nation
standardis
within
nation
blood
manag
system
routin
report
discard
data
aggreg
use
ibm
cogno
databas
donor
consecut
total
whole
blood
donat
discard
identifi
donor
defer
record
review
letter
sent
donor
gener
practition
suggest
investig
includ
full
blood
count
reticulocyt
count
blood
film
ferritin
high
perform
liquid
chromatographi
hplc
lactic
acid
dehydrogenas
ldh
serum
electrophoresi
epg
immunofix
direct
test
cold
agglutinin
test
donor
consent
sought
analys
result
test
donor
manag
accord
find
routin
letter
sent
perman
deferr
blood
donat
hb
trait
cold
agglutinin
paraprotein
identifi
result
studi
period
total
donor
identifi
multipl
whole
blood
donat
discard
respons
receiv
donor
hb
trait
found
caus
found
donor
cold
agglutinin
identifi
paraprotein
found
chronic
lymphocyt
leukaemia
detect
donor
summaryconclus
use
standardis
report
donor
repeatedli
discard
whole
blood
donat
systemat
review
exclud
blood
donat
whole
blood
process
failur
often
aris
hb
trait
presenc
cold
antibodi
paraprotein
larg
number
implic
donor
base
current
test
known
reason
process
failur
could
warrant
investig
donor
safeti
paramount
import
implic
donor
refer
manag
includ
consider
genet
counsel
hb
trait
relev
donor
review
process
transit
becom
routin
part
donor
compon
manag
j
e
p
g
medicin
karolinska
institutet
hematolog
karolinska
univers
hospit
medic
epidemiolog
biostatist
clinic
immunolog
transfus
medicin
karolinska
institutet
cardiolog
stockholm
south
gener
hospit
stockholm
sweden
background
red
blood
cell
commonli
store
day
conflict
evid
effect
red
blood
cell
storag
durat
clinic
outcom
previou
research
focus
determin
associ
durat
storag
time
risk
advers
outcom
includ
mortal
data
support
associ
surprisingli
studi
address
associ
red
blood
cell
storag
compon
efficaci
aim
main
aim
studi
determin
effect
red
blood
cell
storag
durat
regard
hemoglobin
increment
transfus
recipi
method
transfus
data
cohort
myelodysplast
syndrom
link
hemoglobin
measur
taken
within
day
day
follow
transfus
appli
mix
effect
regress
model
studi
impact
storag
durat
categor
day
hemoglobin
yield
per
red
blood
cell
unit
result
studi
popul
consist
uniqu
patient
transfus
transfus
occas
compar
patient
receiv
unit
store
day
receipt
blood
unit
store
day
result
hemoglobin
increas
confid
interv
ci
ci
ci
gl
lower
respect
per
red
blood
cell
unit
result
consist
sensit
analyz
summaryconclus
observ
gradual
drop
mean
hemoglobin
increas
prolong
red
blood
cell
storag
although
effect
statist
signific
effect
modest
clinic
relev
subgroup
patient
must
investig
brouard
p
landri
e
duca
de
grandmont
cloutier
dioguardi
yoshida
affair
innov
quebec
health
scienc
inc
lexington
kentucki
unit
state
america
background
storag
red
blood
cell
rbc
expos
increas
oxid
stress
shown
advers
affect
biolog
properti
surviv
transfus
develop
red
cell
process
system
reduc
rbc
oxid
stress
enhanc
metabol
statu
reduc
concentr
oxygen
carbon
dioxid
rbc
refriger
storag
aim
purpos
work
evalu
two
differ
studi
perform
hemanext
product
use
leukoreduc
red
cell
concentr
rcc
store
sagm
paggsm
addit
solut
first
studi
compar
perform
two
addit
solut
util
pool
split
design
second
studi
paggsm
addit
solut
select
evalu
hemanext
rcc
store
day
method
studi
n
four
aborh
compat
leukoreduc
unit
pool
split
four
way
sagm
pagsm
addit
solut
without
hemanext
process
store
sampl
weekli
day
hemanext
process
freshli
process
rcc
steril
transfer
oxygen
reduct
bag
orb
follow
h
agit
room
temperatur
reduct
transfer
hemanext
storag
bag
hsb
refriger
storag
day
rcc
sampl
weekli
cbc
ga
panel
thb
htc
ph
na
k
glucos
lactat
free
hemoglobin
spun
hematocrit
atp
studi
n
freshli
process
rcc
paggsm
addit
underw
hemanext
process
store
day
sampl
day
studi
result
devic
reduc
level
entir
storag
period
studi
studi
level
hemanext
unit
reduc
treatment
maintain
day
control
unit
increas
day
studi
level
paggsm
unit
reduc
treatment
maintain
day
day
hemolysi
rate
day
studi
unit
day
hemolysi
paggsm
unit
hemolysi
higher
storag
condit
significantli
improv
level
rbc
unit
maximum
day
hb
paggsm
hb
sagm
vs
hb
control
summaryconclus
hemanext
devic
allow
storag
rbc
unit
signific
impact
multipl
vitro
metric
red
cell
qualiti
first
studi
demonstr
rbc
unit
store
paggsm
present
better
overal
properti
sagm
expir
second
studi
confirm
result
obtain
r
v
sharifzadeh
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
hematolog
blood
bank
faculti
medic
scienc
mashhad
univers
medic
scienc
hematolog
blood
bank
mashhad
univers
medic
scienc
mashhad
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
student
research
center
isfahan
univers
medic
scienc
isfahan
iran
background
red
blood
cell
rbc
develop
progress
structur
biochem
altern
storag
collect
call
rbc
storag
lesion
accord
mani
studi
glutathion
addit
solut
lead
long
delay
rbc
storag
lesion
magnesium
essenti
cellular
enzym
involv
glycolyt
metabol
play
control
role
cell
includ
rbc
erythrocyt
older
age
lower
concentr
magnesium
accord
studi
conduct
mice
signific
decreas
magnesium
lead
lower
surviv
well
structur
defect
cell
membran
aim
compar
vitro
qualiti
rbc
ad
magnesium
rbc
unit
ad
glutathion
control
group
rbc
storag
method
whole
blood
wb
collect
donor
iranian
blood
transfus
organ
ibto
wb
process
red
cell
concentr
rcc
addit
solut
total
rcc
pair
use
studi
two
unit
isogroup
rcc
pool
divid
three
equal
part
rcc
one
two
consid
ad
magnesium
chlorid
glutathion
respect
third
one
serv
control
rcc
sampl
day
sampl
collect
biosafeti
cabinet
steril
sampl
devic
gentl
mix
invers
approxim
min
differ
biochem
paramet
measur
includ
hemoglobin
hb
hematocrit
hemolysi
mean
corpuscular
volum
mcv
sodium
potassium
intracellular
magnesium
lactat
ldh
enzym
activ
well
rbc
microvesicl
mv
atp
level
rbc
microvesicl
mv
prepar
low
speed
centrifug
rbc
follow
filtrat
ultracentrifug
result
signific
differ
known
vitro
measur
rbc
storag
lesion
seen
among
three
group
rcc
greater
increas
extracellular
potassium
higher
hemolysi
level
seen
control
vs
magnesium
glutathion
ad
rcc
p
level
intracellular
magnesium
three
group
decreas
test
time
although
chang
signific
group
atp
level
decreas
rapidli
control
group
compar
glutathion
rcc
p
membran
vesicul
also
increas
storag
period
three
group
howev
significantli
lower
glutathion
rbc
day
p
summaryconclus
vitro
data
demonstr
attenu
rbc
storag
lesion
magnesium
glutathion
group
vs
control
one
vari
dose
combin
applic
rbc
antioxid
appli
differ
model
magnesium
increas
sampl
size
use
studi
like
provid
statist
signific
observ
rb
p
r
v
medicin
kokilaben
dhirubhai
ambani
hospit
bungalow
andheri
west
kokilaben
dhirubhai
ambani
hospit
mumbai
mumbai
india
background
crucial
evalu
valid
blood
collect
process
system
center
practis
leucodeplet
especi
light
complex
solid
organ
transplant
bone
marrow
transplant
patient
intend
recipi
aim
evalu
blood
bag
filter
suppli
two
differ
manufactur
valid
leucodeplet
process
outcom
use
two
differ
compon
separ
system
method
n
compoflow
blood
bag
freseniu
kabi
n
macopharma
bag
use
blood
compon
separ
per
manufactur
instruct
compon
volum
total
hb
content
prbc
unit
percent
recoveri
red
cell
platelet
platelet
yield
compon
separ
time
evalu
valid
leucodeplet
process
done
studi
filtrat
time
percentag
loss
red
cell
whole
blood
collect
residu
wbc
rwbc
count
use
flow
cytometri
platform
done
result
volum
ml
versu
ml
hb
content
prbc
unit
g
versu
g
platelet
yield
versu
percentag
platelet
recoveri
versu
higher
macopharma
bag
time
taken
compon
separ
macopress
smart
system
lesser
min
compon
mean
min
volum
platelet
concentr
higher
mean
ml
macopharma
bag
compar
campoflow
bag
mean
ml
compoflow
system
result
lesser
red
cell
loss
filtrat
macopharma
system
bag
type
yield
rwbc
count
unit
time
taken
filtrat
lesser
min
macopharma
bag
compar
compoflow
bag
min
summaryconclus
blood
bag
filter
advantag
limit
associ
use
howev
system
ensur
achiev
good
compon
qualiti
leucodeplet
prbc
unit
requir
fulfil
special
transfus
requir
transplant
patient
k
j
e
health
red
cross
blood
servic
univers
melbourn
australia
background
australia
red
blood
cell
rbc
storag
strictli
control
maintain
preserv
product
qualiti
integr
safeti
australian
nation
standard
nation
patholog
accredit
advisori
council
guidelin
australian
new
zealand
societi
blood
transfus
state
remov
control
storag
rbc
must
exceed
min
room
temperatur
occas
howev
permiss
number
limit
temperatur
excurs
defin
unit
store
transport
outsid
temperatur
specif
must
transfus
except
discret
laboratori
director
typic
except
circumst
howev
guidanc
exist
inform
individu
case
rule
base
histor
concern
limit
evid
base
number
recent
studi
demonstr
signific
differ
rbc
qualiti
andor
bacteri
contamin
rate
expos
ambient
temperatur
min
time
storag
grandmont
vox
sanguini
transfu
med
hemoth
aim
clinic
audit
number
rbc
discard
due
storag
transport
outsid
environ
less
equal
min
two
main
campus
centr
bed
centr
b
bed
monash
health
mh
larg
academ
hospit
metropolitan
melbourn
australia
method
mh
rbc
wastag
data
extract
nation
blood
author
bloodnet
system
januari
decemb
paediatr
rbc
unit
discard
reason
temperatur
control
inform
miss
exclud
issu
return
date
time
unit
individu
extract
mh
hospit
laboratori
inform
system
result
total
rbc
discard
four
year
unit
centr
centr
b
due
min
outsid
control
storag
centr
unit
outsid
control
storag
min
centr
b
unit
total
unit
discard
rbc
year
could
save
rule
extend
min
translat
aud
wast
averag
approxim
aud
per
annum
health
servic
summaryconclus
rule
rbc
appear
safe
increasingli
wide
adopt
intern
result
suggest
substanti
number
discard
rbc
may
salvag
current
rule
could
extend
min
australia
studi
australian
set
investig
generalis
singl
institut
experi
nation
consensu
whether
adopt
rule
australia
need
along
effort
improv
complianc
storag
handl
requir
r
zhong
z
j
liu
h
wang
institut
blood
transfus
chengdu
china
background
filtrat
leukocyt
common
method
ensur
safeti
effect
clinic
transfus
current
research
leukocyt
filtrat
materi
mostli
focu
increas
leukocyt
remov
decreas
platelet
adhes
howev
report
effect
materi
platelet
function
blood
compat
aim
immobil
polybutylen
terephthal
pbt
film
chitosan
heparin
electrostat
techniqu
evalu
effect
platelet
adhes
blood
compat
applic
prospect
techniqu
surfac
modif
membran
leukocyt
deplet
discuss
method
first
pbt
soak
polyethyleneimin
solut
aminolysi
materi
surfac
posit
electr
altern
adsorb
neg
charg
heparin
posit
charg
chitosan
heparin
form
outermost
layer
multilay
structur
platelet
adhes
platelet
function
hemolyt
rate
erythrocyt
deform
erythrocyt
osmot
fragil
polyelectrolyt
multilay
modifi
pbt
investig
result
result
show
chitosanheparin
multilay
form
gradual
water
contact
angl
zeta
potenti
atom
forc
microscopi
hemolyt
rate
multilay
film
differ
layer
less
red
cell
deform
index
increas
gradual
increas
number
assembl
layer
erythrocyt
osmot
fragil
multilay
film
differ
layer
statist
differ
control
group
result
scan
electron
microscopi
show
number
platelet
adher
origin
pbt
significantli
higher
modifi
film
surfac
increas
number
layer
adhes
platelet
surfac
decreas
platelet
function
influenc
origin
pbt
film
shown
maximum
platelet
aggreg
rate
significantli
lower
control
group
vs
hypoton
shock
rel
chang
rate
declin
vs
express
rate
increas
vs
increas
number
assembl
layer
maximum
aggreg
rate
platelet
increas
hsr
increas
express
rate
decreas
compar
unmodifi
pbt
among
ten
layer
assembl
membran
statist
signific
differ
control
group
summaryconclus
chitosanheparin
decor
pbt
hydrophil
pbt
improv
adhes
platelet
reduc
platelet
function
red
blood
cell
significantli
affect
electrostat
multilay
film
expect
new
type
biolog
pbt
surfac
show
applic
prospect
surfac
modif
leukocyt
filter
materi
l
h
immunolog
transfus
medicin
karolinska
univers
hospit
clinic
scienc
intervent
technolog
karolinska
institutet
stockholm
sweden
background
karolinska
univers
hospit
convert
product
buffi
coat
platelet
bcp
autom
orbisac
system
manual
afford
pathogen
inactiv
pi
system
intercept
implement
manual
system
biggest
challeng
higher
sensit
fluctuat
seen
differ
bcp
volum
platelet
count
compar
autom
system
aim
aim
standardis
manual
product
procedur
everi
step
current
process
optimis
method
identifi
weak
area
manual
product
remov
optimis
creat
standardis
procedur
thereaft
compar
bcp
count
volum
yearli
qualiti
control
n
optimis
result
logist
challeng
intercept
pi
system
h
window
remov
excess
chemic
compound
cad
optimis
four
staff
member
work
daili
stress
condit
bcp
product
includ
pi
meet
prolong
h
allow
workload
evenli
spread
throughout
workday
therebi
allow
reduct
three
staff
member
number
bcp
produc
even
distribut
render
less
stress
clearer
approach
even
one
less
personlong
also
allow
buffi
coat
bc
rest
two
addit
hour
process
well
introduct
pool
rest
centrifug
like
contribut
higher
overal
yield
sop
revis
present
necessari
process
step
streamlin
way
elimin
risk
shortcut
save
time
shelv
design
allow
bc
rest
confin
space
shelf
optimis
hook
pool
design
simplifi
standardis
procedur
initi
plasma
remain
top
tube
bc
bag
whole
blood
separ
make
steril
connect
long
tube
mandatori
achiev
correct
amount
plasma
pool
optimis
whole
blood
separ
program
left
plasma
bc
bag
allow
tube
length
shorten
prevent
unnecessari
loss
platelet
tube
new
way
load
centrifug
liner
invent
prevent
bcp
red
colour
low
volum
caus
littl
much
space
pool
liner
plt
content
direct
reflect
differ
pool
agit
therefor
strict
instruct
mix
implement
number
avail
centrifug
separ
product
restrict
forc
staff
work
smaller
batch
therebi
proper
condit
monitor
individu
separ
platelet
count
per
unit
ml
optimis
ml
summaryconclus
optimis
manual
process
staff
less
stress
work
uniformli
result
see
bcp
higher
yield
less
fluctuat
regard
volum
platelet
count
especi
noteworthi
standard
deviat
platelet
count
per
unit
greatli
reduc
conclud
fulli
possibl
standardis
manual
product
process
g
centrum
krwiodawstwa
krwiolecznictwa
w
olsztyni
olsztyn
bct
zaventem
belgium
background
archimed
autom
extractor
manufactur
moelca
itali
distribut
terumo
bct
use
process
blood
compon
archimed
devic
softwar
facilit
configur
sever
custom
separ
protocol
accommod
specif
need
process
requir
characterist
blood
center
separ
automat
transfer
one
blood
compon
centrifug
contain
one
satellit
bag
oper
top
top
top
bottom
blood
bag
high
degre
autom
allow
addit
flexibl
allow
one
singl
oper
manag
sever
machin
simultan
archimed
test
rckik
olsztyn
poland
aim
goal
perform
assess
consist
separ
process
archimed
devic
reflect
variabl
method
whole
blood
unit
target
volum
ml
separ
mean
top
bottom
separ
protocol
red
cell
concentr
plasma
unit
buffi
coat
volum
buffi
coat
measur
store
centrifug
follow
center
standard
oper
procedur
volum
data
furthermor
regist
compon
process
time
also
record
result
averag
process
time
min
n
volum
red
cell
concentr
obtain
addit
addit
solut
ml
plasma
volum
ml
main
paramet
studi
focus
bc
volum
consist
bc
volum
averag
ml
n
minimum
maximum
ml
confid
interv
bc
volum
ml
summaryconclus
archimed
separ
perform
plan
easi
use
repeat
bc
separ
pool
bc
satisfactori
g
medicin
gener
hospit
croatia
affair
support
terumo
bct
zaventem
belgium
background
archimed
automat
blood
compon
extractor
abc
autom
devic
manufactur
moelca
itali
distribut
terumo
bct
use
process
blood
compon
devic
provid
autom
control
manag
extract
help
ration
product
blood
compon
abc
equip
salin
adenin
glucos
mannitol
plasma
press
standard
optim
qualiti
blood
compon
well
process
flow
desir
option
omnidirect
barcod
reader
captur
barcod
blood
bag
one
singl
step
technolog
platform
furthermor
allow
bidirect
commun
well
remot
monitor
troubleshoot
oper
top
top
tat
top
bottom
tab
blood
bag
high
degre
autom
allow
addit
flexibl
one
singl
oper
manag
sever
machin
simultan
aim
goal
perform
assess
effect
whole
blood
compon
separ
process
mean
abc
method
unit
whole
blood
target
ml
collect
volunt
donor
transfer
lab
facil
process
collect
whole
blood
bag
store
overnight
h
process
blood
bag
process
fresh
tab
bag
centrifug
min
separ
perform
abc
appli
forc
kg
millilit
ml
ad
red
cell
concentr
rcc
complet
process
yield
one
unit
plasma
buffi
coat
bc
rcc
platelet
pool
combin
bc
centrifug
rpm
min
result
volum
red
cell
concentr
obtain
addit
addit
solut
ml
plasma
volum
ml
bc
volum
averag
ml
ml
ml
fresh
averag
platelet
recoveri
pool
vs
whole
blood
unit
three
pool
platelet
recoveri
one
fresh
pool
hematocrit
bc
fresh
respect
summaryconclus
repeat
bc
separ
abc
satisfactori
demonstr
narrow
standard
deviat
show
good
process
consist
likewis
platelet
recoveri
found
excel
valu
overnight
pool
challeng
fresh
pool
abc
separ
perform
plan
furthermor
easi
use
abstract
withdrawn
wp
v
c
molecular
medicin
mcmaster
univers
innov
canadian
blood
servic
hamilton
innov
canadian
blood
servic
ottawa
canada
background
canada
whole
blood
donat
may
process
either
via
buffi
coat
bc
method
transfus
plasma
platelet
red
cell
concentr
via
whole
blood
filtrat
wbf
donat
manufactur
via
bc
method
must
process
compon
within
h
phlebotomi
wbf
method
donat
store
may
process
within
h
phlebotomi
plasma
red
cell
concentr
process
take
place
h
phlebotomi
recov
plasma
rp
may
use
fraction
transfus
qualiti
transfus
plasma
made
via
either
manufactur
method
previous
assess
studi
canadian
rp
undertaken
consid
possibl
protract
hold
time
affect
qualiti
rp
aim
quantifi
activ
coagul
factor
prothrombin
fii
fv
fvii
fviii
fibrinogen
fg
von
willebrand
factor
vwf
concentr
igg
total
protein
prothrombin
time
pt
rp
process
h
h
phlebotomi
method
total
rp
unit
process
h
phlebotomi
equal
number
process
h
phlebotomi
compar
group
contain
type
type
unit
male
femal
donor
also
equal
repres
rp
unit
thaw
plasma
thawer
helmer
ml
aliquot
taken
subsequ
test
autom
coagul
analyz
sta
compact
max
diagnostica
stago
employ
determin
fii
fv
fvii
fviii
fg
activ
pt
time
wherea
assay
use
measur
vwf
activ
igg
total
protein
concentr
determin
bradford
assay
data
set
assess
use
unpair
test
welch
correct
unequ
varianc
p
indic
statist
signific
differ
result
overal
hold
time
significantli
affect
fii
fv
fvii
fg
vwf
activ
pt
valu
total
protein
concentr
valu
rp
process
time
h
vs
h
mean
sd
fii
vs
iuml
fv
vs
iuml
fvii
vs
iuml
fg
vs
gl
vwf
vs
iuml
pt
vs
total
protein
vs
mgml
rp
unit
process
h
phlebotomi
contain
significantli
fviii
activ
rp
unit
iuml
vs
iuml
p
well
higher
concentr
igg
mgml
vs
mgml
p
summaryconclus
result
show
major
assay
plasma
protein
activ
unaffect
extens
hold
time
h
h
hold
time
h
process
whole
blood
provid
oper
flexibl
transfus
servic
limit
time
h
would
increas
yield
fviii
igg
relev
concern
four
plasma
protein
product
current
produc
canadian
rp
fviiivwf
intraven
immunoglobulin
ivig
albumin
fibrinogen
concentr
altern
contribut
rp
process
h
phlebotomi
plasma
pool
destin
manufactur
fviiivwf
ivig
could
limit
loss
fviii
activ
plasma
held
storag
time
previous
note
although
bulk
loss
activ
took
place
first
h
sheffield
transfus
contrast
tempor
later
loss
whole
blood
report
l
j
h
immunolog
transfus
medicin
karolinska
univers
hospit
clinic
scienc
intervent
technolog
karolinska
institutet
stockholm
sweden
background
tube
seal
pivot
part
blood
process
import
seal
withstand
mechan
stress
sinc
expos
larg
forc
rapid
temperatur
chang
within
larg
interv
previous
studi
impact
centrifug
forc
seal
singl
sealer
combin
tube
contain
differ
amount
plastic
dehp
phthalat
want
expand
knowledg
includ
sever
sealer
differ
manufactur
extend
strength
test
aim
aim
studi
investig
seal
made
multipl
type
seal
equip
resist
mechan
stress
possibl
link
dehp
content
tube
method
blood
collect
bag
contain
teruflex
transfer
bag
terumobct
macopharma
dehp
fill
whole
blood
contain
cpd
randomli
select
donor
seal
creat
everi
cm
tube
use
follow
panel
sealer
conroy
medic
ii
compos
mobilea
freseniu
kabi
iii
sebra
model
sebra
iv
medicaldocon
seal
handl
medic
seal
perform
tube
content
room
temperatur
seal
inspect
avoid
defect
separ
cut
segment
cm
seal
end
wash
water
thereaft
two
kind
strength
test
perform
test
segment
per
tube
type
sealer
connect
air
pressur
regul
mini
reg
atla
copco
seal
tube
end
submerg
water
enabl
detect
small
leakag
air
press
segment
bar
measur
point
integ
pressur
held
test
segment
per
tube
type
sealer
fill
water
strip
manual
tube
stripper
lmb
technologi
breakag
thereaft
inspect
magnifi
glass
result
test
segment
resist
bar
pressur
without
break
sealer
b
one
segment
sealer
c
contain
dehp
broke
seal
bar
test
segment
made
sealer
c
broke
seal
segment
b
broke
similarli
except
dehp
tube
tube
broke
seal
intact
segment
dehp
dehp
tube
broke
seal
none
segment
broke
seal
summaryconclus
purpos
sealer
creat
keep
close
system
seal
gener
resist
larg
forc
howev
forc
break
sever
mechan
stress
point
breakag
ie
seal
versu
tube
depend
type
sealer
use
mean
qualiti
differ
seal
pattern
depend
equip
demonstr
seal
repres
weakest
point
close
system
breakag
seal
avoid
whether
dehp
content
tube
affect
point
breakag
inconclus
may
possibl
relat
seal
mechan
temperatur
need
investig
r
g
b
l
c
j
g
canadian
blood
servic
toronto
clinic
servic
canadian
blood
servic
edmonton
canadian
blood
servic
calgari
servic
canadian
blood
servic
winnipeg
servic
ottawa
hospit
servic
iwk
health
center
halifax
medicin
foothil
medic
center
calgari
servic
mount
sinai
hospit
toronto
servic
bc
children
health
center
vancouv
canada
background
base
recommend
canadian
nation
advisori
committe
blood
blood
product
nac
canadian
blood
servic
blood
supplier
canada
outsid
quebec
prepar
substanti
reduc
serolog
cmv
test
donor
sampl
blood
compon
intend
use
intrauterin
transfus
would
test
antibodi
cmv
indic
nac
guidelin
recommend
cmv
safe
leukoreduc
cmv
igg
seroneg
product
consid
equival
order
select
unit
appropri
phenotyp
cmv
antibodi
test
assess
number
iut
perform
usual
phenotyp
requir
red
blood
cell
rbc
use
iut
requir
aim
confirm
number
locat
hospit
perform
iutsto
determin
phenotyp
requir
rbc
unit
use
iut
method
canadian
blood
servic
conduct
survey
base
survey
result
would
test
limit
inventori
donor
rbc
phenotyp
suitabl
common
indic
iut
store
unit
day
blood
supplier
distribut
site
geograph
near
hospit
perform
iut
test
would
occur
twice
per
week
rbc
unit
maintain
stock
inventori
iut
would
group
rh
neg
c
e
k
neg
cmv
igg
seroneg
five
day
less
age
canadian
blood
servic
oper
site
serv
hospit
perform
iut
would
keep
unit
hand
survey
intend
inform
select
phenotyp
requir
stock
inventori
determin
addit
rbc
antigen
type
may
requir
result
august
determin
six
hospit
serv
canadian
blood
servic
provinc
perform
iut
rbc
antibodi
involv
period
six
hospit
summar
chart
data
number
individu
procedur
perform
summaryconclus
plan
limit
inventori
group
rh
neg
c
e
k
neg
cmv
igg
seroneg
rbc
would
meet
hospit
patient
need
need
antigen
neg
cmv
igg
seroneg
rbc
would
met
demand
cmv
serolog
test
less
turnaround
time
given
iut
schedul
procedur
advanc
transfus
servic
notic
confid
approach
could
meet
need
cmv
seroneg
product
time
fashion
date
patient
rbc
antibodi
undergo
iut
abl
meet
hospit
patient
need
recent
requir
c
neg
rbc
unit
three
patient
indic
addit
possibl
requir
stock
inventori
c
neg
well
cmv
igg
seroneg
h
c
j
e
clinic
immunologytransfus
medicin
karolinska
univers
hospit
clinic
scienc
intervent
technolog
clintec
karolinska
institutet
stockholm
sweden
background
granulocyt
transfus
possibl
treatment
patient
sever
granulocytopenia
infect
convent
treatment
success
higher
granulocyt
dose
thought
give
better
effect
granulocyt
level
recipi
current
use
granulocyt
compon
gc
apheresi
increas
granulocyt
yield
donor
treat
steroid
stimul
factor
prior
donat
drug
document
side
effect
treat
healthi
donor
debat
ethic
point
view
drug
avoid
use
gc
deriv
pool
buffi
coat
bc
whole
blood
public
gc
bc
mainli
focus
prepar
tradit
centrifug
separ
aim
want
investig
whether
possibl
produc
gc
bc
use
spectra
optia
apheresi
system
terumo
bct
commonli
use
apheresi
applic
bone
marrow
separ
novel
approach
gc
prepar
method
pool
bc
spectra
optia
bmp
accessori
set
ref
terumo
bct
connect
spectra
optia
apheresi
system
idl
set
ref
terumo
bct
granulocyt
extract
use
bone
marrow
process
program
flow
rate
mlmin
collect
rate
mlmin
collect
prefer
volum
white
blood
cell
wbc
count
hematocrit
platelet
plt
count
assess
well
gc
residu
use
scale
entri
sartoriu
lab
instrument
germani
cell
counter
sysmex
sysmex
corpor
japan
cell
surviv
annexin
gc
analyz
use
flow
cytometri
cytom
mpl
mpx
softwar
beckman
coulter
usa
result
gc
contain
wbc
plt
total
volum
ml
hematocrit
origin
contain
wbc
plt
ml
hematocrit
give
us
recoveri
wbc
plt
annexin
v
analysi
show
signific
differ
percentag
live
granulocyt
gc
summaryconclus
show
novel
method
prepar
gc
bc
use
spectra
optia
apheresi
system
recoveri
granulocyt
high
substanti
number
platelet
also
collect
final
product
contain
two
transfus
dose
platelet
deplet
red
blood
cell
substanti
prepar
method
use
spectra
optia
seem
affect
cell
viabil
investig
need
includ
analysi
function
collect
granulocyt
comparison
gc
bc
gc
apheresi
abstract
withdrawn
p
langi
van
k
van
den
technolog
assess
donor
studi
medic
affair
studi
technolog
assess
sanquin
amsterdam
netherland
background
variou
trend
becom
appar
western
blood
transfus
practic
persist
declin
red
blood
cell
retrospect
also
occur
netherland
along
decreas
fresh
frozen
plasma
although
plasma
protein
increas
platelet
steadi
could
due
driver
patient
blood
manag
new
therapeut
option
furthermor
develop
innov
blood
transfus
relat
domain
great
potenti
impact
futur
transfus
field
innov
includ
technolog
clinic
advanc
oper
blood
manag
pharmaceut
polit
eg
open
border
intern
trade
combin
aforement
trend
driver
innov
may
significantli
impact
futur
demand
blood
product
first
step
larger
project
conduct
scenario
develop
futur
demand
blood
product
netherland
topic
explor
use
combin
literatur
expert
perspect
aim
aim
explor
identifi
histor
develop
blood
usag
past
twenti
year
underli
driver
develop
variou
innov
would
impact
futur
demand
blood
product
dutch
context
method
purpos
sampl
snowbal
use
recruit
expert
blood
transfus
netherland
interview
manner
simultan
extens
literatur
review
pubm
googl
scholar
gray
literatur
perform
result
expert
variou
role
research
clinic
manag
interview
literatur
review
reveal
articl
relat
histor
trend
driver
articl
relat
innov
interview
respond
report
declin
blood
product
due
driver
rise
medicin
ebm
link
patient
blood
manag
pbm
chang
clinic
transfus
polici
safeti
cost
improv
new
surgic
techniqu
howev
increas
use
plasma
protein
come
rise
demand
medicin
product
due
increas
research
knowledg
immunoglobulin
exampl
key
innov
may
decreas
futur
blood
demand
includ
person
transfus
treatment
immunotherapygen
therapi
improv
addit
solut
red
blood
cell
storag
smart
prescript
drug
howev
innov
uncertain
effect
demand
due
diverg
opinion
includ
cultur
red
blood
cell
landscap
eu
literatur
find
compat
interview
find
term
trend
driver
innov
howev
literatur
emphas
order
innov
make
signific
impact
need
overcom
barrier
cost
safeti
logist
regul
summaryconclus
first
step
ongo
research
show
driver
past
innov
may
affect
futur
demand
blood
product
next
step
includ
quantif
histor
blood
use
netherland
use
prior
data
expert
elicit
workshop
construct
variou
medium
long
term
scenario
develop
organiz
mathemat
model
approach
expect
contribut
toward
adapt
polici
recommend
support
sanquin
dutch
nation
blood
bank
bj
j
j
medicin
patholog
univers
alberta
blood
servic
edmonton
canada
background
red
blood
cell
rbc
transfus
wide
accept
treatment
anemia
despit
success
transfus
rbc
associ
advers
outcom
transfus
patient
occurr
immunomodul
trim
role
rbc
storag
length
extracellular
vesicl
ev
rbc
concentr
trim
highli
controversi
electr
resist
teer
often
use
pharmaceut
cancer
research
involv
measur
electr
resist
across
cellular
monolay
sensit
reliabl
method
confirm
integr
permeabl
endothelium
barrier
aim
aim
develop
teer
assay
cell
analyz
rtca
new
approach
evalu
effect
ev
store
rbc
concentr
human
vein
endotheli
cell
huvec
permeabl
method
huvec
purchas
pool
primari
cell
grown
media
lonza
group
ltd
walkersvil
md
usa
confluent
huvec
monolay
trypsin
seed
concentr
cellwel
passag
fibronectin
coat
gold
microelectrod
place
xcellig
rtca
system
incub
imped
read
taken
cell
index
ci
hour
interv
day
fresh
peripher
blood
day
store
rbc
centrifug
g
min
supernat
collect
dilut
media
huvec
monolay
treat
cultur
media
neg
control
vv
triton
x
vv
posit
control
dilut
rbc
supernat
chang
teer
across
huvec
monolay
assess
h
result
averag
ci
huvec
monolay
treatment
ci
untreat
huvec
monolay
remain
high
stabl
throughout
experi
ci
h
respect
treatment
triton
x
result
immedi
drop
teer
h
ci
treatment
result
statist
signific
reduct
teer
manner
compar
neg
control
p
treatment
fresh
supernat
result
statist
signific
reduct
teer
concentr
test
time
point
assess
compar
supernat
instanc
dilut
fresh
vs
ci
h
vs
h
vs
h
respect
p
summaryconclus
analysi
advantag
measur
allow
sensit
comparison
rbc
supernat
tool
uniqu
potenti
studi
trim
would
allow
evalu
differ
blood
product
base
abil
modul
integr
endothelium
sm
p
w
molecular
medicin
mcmaster
universitycanadian
blood
servic
hamilton
laboratori
medicin
univers
british
columbiacanadian
blood
servic
vancouv
canada
background
prolong
storag
red
blood
cell
rbc
lead
biochem
morpholog
alter
enhanc
suscept
eryptosi
cell
death
character
cell
surfac
aminophospholipid
exposur
although
multipl
clinic
trial
demonstr
equival
safeti
fresher
older
rbc
recent
year
uncertainti
remain
qualiti
oldest
rbc
unit
blood
bank
particular
concern
appli
rbc
store
day
led
countri
limit
rbc
storag
day
also
unclear
whether
clinic
factor
combin
rbc
storag
age
affect
transfus
benefit
recent
evid
point
substanti
reduct
posttransfus
hemoglobin
increment
critic
ill
febril
patient
compar
patient
enhanc
eryptosi
document
wide
rang
febril
diseas
believ
diminish
lifespan
circul
rbc
caus
microcirculatori
derang
aim
examin
impact
durat
rbc
storag
blood
bank
condit
cellular
metabol
eryptosi
follow
exposur
increas
temperatur
method
rbc
unit
n
store
addit
solut
either
fresh
frbc
day
old
orbc
incub
ringer
solut
hematocrit
h
multipl
variabl
rbc
storag
lesion
microvesicul
eryptot
cell
death
analyz
comparison
baselin
valu
indic
eryptosi
directli
determin
rbc
retriev
refriger
storag
bag
result
rbc
subject
sustain
hyperthermia
display
increas
cell
membran
phosphatidylserin
ps
extern
day
storag
respect
increas
percentag
ps
rbc
hypertherm
condit
reach
statist
signific
p
follow
day
refriger
storag
comparison
ps
exposur
rbc
incub
show
increas
day
storag
respect
exposur
grade
increas
temperatur
augment
percentag
ps
rbc
effect
significantli
pronounc
orbc
compar
frbc
temperatur
examin
flow
cytometri
analysi
reveal
hyperthermia
trigger
signific
increas
intracellular
level
fluoresc
gener
reactiv
oxygen
speci
dcf
fluoresc
ceramid
abund
fluoresc
antibodi
detect
effect
significantli
accentu
orbc
judg
forward
scatter
analysi
hyperthermia
significantli
reduc
cell
volum
orbc
frbc
extent
rbc
microvesicul
follow
exposur
hyperthermia
howev
similar
frbc
orbc
variabl
rbc
storag
lesion
includ
hemolysi
cellular
ph
lactat
product
show
subtl
variat
hypertherm
condit
summaryconclus
prolong
storag
rbc
aggrav
eryptot
phenotyp
experiment
hyperthermia
potenti
contribut
reduc
recoveri
transfus
rbc
febril
patient
acceler
clearanc
vivo
futur
seek
replic
find
mice
vivo
rb
v
u
medicin
kokilaben
dhirubhai
ambani
hospit
bungalow
andheri
west
kokilaben
dhirubhai
ambani
hospit
mumbai
mumbai
india
background
platelet
high
antibodi
titer
report
caus
advers
reaction
recipi
protocol
involv
remov
plasma
platelet
unit
replac
pa
perform
igm
igg
titer
platelet
unit
pa
ensur
safeti
platelet
refer
antibodi
titer
aim
evolv
protocol
univers
use
pa
ad
platelet
across
blood
group
method
platelet
concentr
n
compris
n
pool
platelet
n
apheresi
platelet
studi
igm
igg
titer
platelet
unit
perform
prior
pa
addit
pa
addit
comparison
volum
plasma
remov
platelet
content
unit
also
studi
result
paramet
pa
addit
compar
platelet
blood
group
n
b
n
n
studi
result
mean
volum
platelet
unit
pa
addit
ml
volum
plasma
remov
prior
pa
addit
ml
platelet
content
prior
pa
addit
mean
per
unit
wherea
mean
valu
pa
addit
baselin
titer
igm
igg
reduc
igm
igg
plasma
deplet
pa
addit
baselin
titer
igm
igg
reduc
igm
igg
plasma
deplet
pa
addit
overal
tube
reduct
antibodi
filter
achiev
pa
addit
antibodi
titer
post
pa
addit
greater
permiss
level
found
case
baselin
titer
summaryconclus
platelet
addit
solut
consid
safe
transfus
recipi
blood
group
howev
caution
exercis
platelet
unit
baselin
titer
de
h
process
develop
blood
bank
sanquin
amsterdam
netherland
lexington
unit
state
america
background
support
research
improv
erythrocyt
storag
low
oxygen
tension
haemoglobin
oxygen
satur
fresh
erythrocyt
concentr
rcc
measur
wall
rcc
bag
use
reson
raman
spectroscopi
rr
surprisingli
larg
variat
fresh
day
rcc
found
pilot
studi
analysi
find
larg
number
freshli
prepar
rcc
sanquin
blood
bank
analys
rr
devic
aim
determin
relationship
observ
variat
donordon
variabl
use
extern
oxygen
satur
measur
rr
fresh
rcc
immedi
compon
prepar
method
fresh
rcc
analys
rr
devic
microvascular
oximet
pendar
medic
devic
valid
analys
rcc
comparison
measur
qualifi
blood
ga
analys
radiomet
flex
addit
investig
whether
low
high
valu
effect
shelf
life
rcc
sampl
day
blood
ga
cbc
sysmex
well
haemolysi
atp
content
result
result
measur
rr
devic
correspond
measur
blood
ga
analys
differ
data
donor
compar
donordon
data
blood
pressur
time
donat
donat
durat
well
individu
donor
characterist
weight
height
calcul
bmi
age
hb
gender
data
rcc
show
binomi
distribut
two
peak
strongli
influenc
gender
donor
men
subject
women
subject
donor
paramet
show
clear
effect
cell
count
haemolysi
day
day
atp
day
day
show
normal
expect
valu
regardless
whether
valu
high
low
summaryconclus
measur
rr
laser
devic
correspond
measur
blood
ga
analys
use
rr
devic
advers
effect
vitro
qualiti
erythrocyt
storag
small
test
group
rcc
link
vitro
qualiti
valu
immedi
collect
mean
femal
donor
lower
male
donor
explain
basi
avail
donordon
data
research
need
explain
differ
francoi
n
bertin
x
telot
j
gomez
j
gachelin
aeniti
technolog
pari
franc
background
prophylact
platelet
concentr
pc
transfus
first
line
therapi
patient
hemorrhag
syndrom
puriti
function
transfus
pc
cornerston
effici
treatment
obtain
pc
whole
blood
sampl
blood
bank
current
use
hard
spin
centrifug
g
method
lead
poor
rest
platelet
yield
prolong
storag
also
issu
blood
bank
platelet
storag
lesion
aim
order
improv
platelet
qualiti
preserv
therapeut
aim
develop
fraction
devic
isol
human
platelet
whole
blood
bag
alreadi
shown
acoust
platelet
separ
effici
method
fraction
blood
low
shear
stress
environ
puriti
yield
lead
minim
platelet
activ
preserv
platelet
respons
agonist
function
aim
studi
impact
acoust
fraction
platelet
storag
compar
qualiti
platelet
rich
plasma
prp
produc
acoustophoresi
soft
spin
centrifug
g
method
prp
obtain
soft
spin
centrifug
acoust
fraction
store
day
constant
agit
platelet
analyz
rest
condit
stimul
common
platelet
agonist
use
flow
cytometri
monitor
express
activ
marker
annexin
v
phosphatidylserin
check
morpholog
metabol
characterist
platelet
day
storag
result
prp
obtain
soft
spin
acoust
fraction
show
compar
storag
respons
surfac
express
phosphatidylserin
increas
upon
storag
type
prp
differ
surfac
level
platelet
activ
marker
two
type
prp
interestingli
platelet
prepar
acoustophoresi
retain
slightli
increas
respons
collagen
storag
compar
platelet
prepar
soft
spin
centrifug
metabolit
concentr
increas
platelet
storag
prp
ph
simultan
decreas
compar
variou
public
metabol
chang
within
standard
therapeut
transfus
summaryconclus
preliminari
result
show
compar
platelet
age
prp
prepar
soft
spin
acoust
fraction
data
suggest
side
effect
platelet
storag
acoust
fraction
platelet
storag
lesion
result
metabol
activ
platelet
shown
revers
upon
transfus
qualiti
function
platelet
obtain
acoust
fraction
appear
match
blood
bank
standard
therapeut
transfus
plan
larger
trial
collabor
ef
french
blood
bank
confirm
result
valid
devic
p
van
der
j
de
process
develop
sanquin
institut
academ
medic
centr
amsterdam
netherland
background
previous
shown
donor
could
classifi
platelet
plt
good
averag
poor
storag
properti
recent
studi
demonstr
plt
storag
perform
consist
donor
bonteko
transfus
main
differ
good
poor
storag
properti
involv
metabol
activ
result
faster
declin
ph
storag
poor
plt
concentr
pc
might
caus
mitochondri
defect
associ
age
diseas
like
metabol
syndrom
type
diabet
aim
test
hypothesi
plt
obtain
young
whole
blood
wb
donor
better
storag
properti
plt
age
donor
method
fifteen
wb
donor
year
select
select
buffi
coat
bc
plasma
ship
laboratori
overnight
hold
pc
spc
prepar
addit
spc
prepar
donor
year
spc
store
day
ml
contain
condit
flatb
shaker
sampl
day
determin
vitro
qualiti
diabet
marker
determin
red
cell
cholesterol
triglycerid
level
plasma
storag
data
analys
use
unpair
result
young
donor
age
year
age
donor
year
age
donor
higher
blood
pressur
donat
higher
vs
mmolmol
total
cholesterol
vs
vs
young
donor
young
donor
within
normal
rang
mmolmol
age
donor
mmolmol
indic
spc
group
volum
vs
ml
plt
content
vs
day
spc
young
donor
show
higher
vs
p
lower
lactat
product
young
group
contain
one
outlier
ph
wherea
age
group
contain
spc
ph
lower
limit
outlier
includ
two
donor
high
also
mani
variabl
like
swirl
effect
annexin
bind
hypoton
shock
respons
reflect
better
vitro
qualiti
young
group
age
group
howev
differ
mitochondri
membran
potenti
measur
detect
summaryconclus
pc
prepar
bc
obtain
young
wb
donor
show
better
storag
perform
age
donor
might
impact
donor
select
platelet
product
especi
apheresi
product
higher
glycolysi
rate
plt
age
donor
probabl
caus
higher
demand
pyruv
mitochondria
partial
mitochondri
dysfunct
due
age
andor
pre
diabet
n
k
h
k
k
k
hematolog
kanagawa
cancer
center
yokohama
hematolog
jichi
medic
univers
hospit
shimotsuk
blood
transfus
akita
univers
hospit
akita
laboratori
japanes
red
cross
narita
hospit
narita
transfus
servic
tokai
univers
hospit
isehara
clinic
laboratori
st
marianna
univers
school
medicin
yokohama
citi
seibu
hospit
yokohama
transfus
blood
purif
therapi
nation
defens
medic
colleg
hospit
tokorozawa
hematolog
niigata
prefectur
central
hospit
joetsu
transfus
medicin
jikei
univers
kashiwa
hospit
kashiwa
cell
therapi
unit
nagasaki
univers
hospit
nagasaki
cell
therapi
center
hakod
municip
hospit
hakod
block
blood
center
japanes
red
cross
sapporo
medicin
hachioji
medic
center
tokyo
medic
univers
tokyo
transfus
medicin
univers
tsukuba
hospit
tsukuba
blood
transfus
servic
gunma
univers
hospit
maebashi
transfus
medicin
osaka
citi
univers
hospit
osaka
transfus
medicin
toranomon
hospit
tokyo
nurs
shinko
memori
hospit
kobe
transfus
cell
therapi
hamamatsu
univers
school
medicin
hamamatsu
cell
transplant
transfus
jichi
medic
univers
hospit
shimotsuk
japan
background
manag
transfus
reaction
remain
import
issu
transfus
medicin
although
transfus
reaction
caus
platelet
concentr
pc
frequent
sever
clinic
studi
confirm
prevent
effect
replac
platelet
concentr
wash
platelet
concentr
wpc
recent
japanes
red
cross
societi
jrc
began
suppl
wpc
approv
blood
compon
ident
price
pc
surveil
studi
releas
wpc
rwpc
conduct
clinic
data
associ
product
remain
insuffici
aim
aim
studi
evalu
clinic
efficaci
safeti
rwpc
nation
multicent
studi
method
retrospect
evalu
rwpc
suppli
jrc
blood
center
septemb
januari
japan
manufactur
rwpc
leukoreduc
apheresi
pc
wash
bicarbon
ringer
solut
autom
cell
processor
result
among
institut
part
studi
actual
use
rwpc
studi
period
studi
includ
rwpc
bag
patient
cover
rwpc
suppli
jrc
blood
center
patient
hematolog
disord
median
transfus
histori
median
number
rwpc
bag
per
patient
rang
rwpc
transfus
patient
histori
transfus
reaction
could
prevent
premed
hydrocortison
antihistamin
transfus
reaction
includ
seriou
reaction
anaphylaxi
respiratori
distress
patient
median
platelet
count
rang
premed
prior
rwpc
implement
rwpc
bag
clinic
respons
transfus
reaction
rwpc
complet
respons
partial
respons
chang
progress
observ
n
n
n
n
bag
respect
subgroup
analysi
overal
respons
rate
affect
diseas
rwpc
transfus
histori
type
sever
transfus
reaction
median
correct
count
increment
cci
h
transfus
rang
rang
respect
patient
without
risk
factor
associ
platelet
transfus
refractori
bleed
infect
median
cci
h
rang
transfus
reaction
associ
rwpc
infus
rwpc
bag
pruritu
n
urticaria
n
chillsrigor
n
chest
discomfort
n
summaryconclus
retrospect
multicent
studi
first
evalu
clinic
effect
rwpc
transfus
effect
rwpc
refractori
transfus
reaction
recogn
almost
transfus
transfus
reaction
associ
rwpc
infus
mild
occur
low
frequenc
studi
need
evalu
transfus
efficaci
healthcar
cost
rwpc
prepar
guidelin
rwpc
indic
desir
bonteko
groot
sijbrand
p
van
der
meer
j
lagerberg
de
kort
product
process
develop
sanquin
amsterdam
netherland
background
buffi
coat
bc
donor
use
pain
medic
like
aspirin
diclofenac
ibuprofen
naproxen
day
prior
donat
discard
centr
known
side
effect
drug
inhibit
platelet
aggreg
drug
inhibit
enzym
revers
irrevers
manner
therebi
block
synthesi
thromboxan
arachidon
acid
aa
previous
observ
littl
deviat
singl
platelet
concentr
pc
prepar
bc
plasma
obtain
donor
use
ibuprofen
includ
aggreg
properti
adp
collagen
explain
known
fast
h
disappear
ibuprofen
blood
circul
revers
bind
plt
level
ibuprofen
pc
mgl
aim
investig
effect
differ
ibuprofen
dose
vitro
qualiti
pc
storag
particular
aggreg
properti
method
day
leukoreduc
pc
n
prepar
bc
ml
aliquot
unit
ml
unit
ml
ibuprofen
sandoz
granular
solut
ad
adjust
reach
final
concentr
mgl
control
unit
ml
nacl
ad
pc
store
flatb
shaker
ml
contain
sampl
day
vitro
qualiti
light
transmiss
aggregometri
perform
stimul
aa
also
day
min
addit
ibuprofen
repeat
measur
anova
dunnett
appli
statist
analysi
result
storag
differ
ph
lactat
product
express
annexin
bind
swirl
effect
mpv
group
observ
data
shown
aggreg
aa
revers
inhibit
lower
concentr
ibuprofen
mgl
aggreg
fulli
recov
min
mgl
aggreg
almost
fulli
recov
h
p
pc
mgl
recoveri
aggreg
observ
throughout
storag
summaryconclus
storag
properti
pc
ad
ibuprofen
compar
pc
control
confirm
former
result
aggreg
aa
show
clear
effect
rang
almost
immedi
full
recoveri
mgl
ibuprofen
full
impair
day
mgl
expect
level
bc
donor
use
ibuprofen
mgl
use
bc
obtain
donor
use
ibuprofen
consid
still
feasibl
pool
bc
due
dilut
vitro
qualiti
pc
investig
best
case
scenario
bc
obtain
donor
f
razavi
hospit
social
secur
organ
chemistri
high
institut
research
educ
transfus
medicin
tehran
iran
background
storag
platelet
undergo
numer
morpholog
biochem
function
chang
chang
platelet
storag
collect
term
platelet
storag
lesion
psl
effect
platelet
vivo
surviv
platelet
qualiti
oxid
stress
one
main
factor
caus
improv
psl
platelet
concentr
platelet
storag
aim
evalu
oxid
stress
marker
platelet
storag
platelet
concentr
method
experiment
studi
select
ten
platelet
concentr
pc
healthi
donor
prepar
iranian
blood
transfus
organ
ibto
store
gentl
agit
day
platelet
unit
sampl
day
collect
day
day
measur
total
antioxid
capac
tac
level
malondialdehyd
mda
nitratenitrit
metabolit
platelet
concentr
storag
also
measur
biochem
paramet
glucos
lactat
concentr
lactat
dehydrogenas
ldh
enzym
activ
ph
platelet
count
mean
platelet
volum
mpv
measur
autom
cell
counter
result
accord
result
observ
mda
increas
platelet
storag
nmolplt
also
result
show
tac
decreas
storag
tac
mmplt
nitritenitr
metabolit
decreas
platelet
storag
mmol
lactat
concentr
ldh
enzym
activ
increas
platelet
storag
mgdl
ldh
ldh
iul
moreov
concentr
glucos
decreas
storag
glucos
mgdl
plt
count
decreas
day
storag
plt
day
platelet
storag
summaryconclus
accord
result
oxid
stress
increas
platelet
storag
hand
result
show
platelet
metabol
impair
period
seem
chang
platelet
oxid
stress
platelet
metabol
play
import
role
improv
platelet
storag
lesion
j
n
p
k
k
transfus
centr
surgeri
pharmacolog
faculti
medicin
khon
kaen
univers
khon
kaen
thailand
background
platelet
addit
solut
pa
crystalloid
nutrient
media
use
place
plasma
platelet
storag
replac
plasma
platelet
compon
amount
storag
plasma
decreas
platelet
store
pa
demonstr
lower
risk
allerg
transfus
reaction
appear
equival
clinic
efficaci
control
bleed
compar
platelet
store
plasma
increas
storag
time
day
bacteri
detect
test
due
decreas
titer
abo
agglutinin
platelet
pa
requir
abo
compat
donor
plasma
recipi
cell
use
univers
platelet
separ
random
platelet
concentr
pc
whole
blood
base
differenti
densiti
variou
cellular
compon
blood
subject
variabl
centrifug
forc
problem
routin
work
pc
show
swirl
featur
day
aim
prepar
pc
pa
routin
work
instead
tradit
pc
method
whole
blood
wb
centrifug
separ
autom
system
platelet
concentr
pc
prepar
altern
approach
involv
pc
prepar
singl
bc
unit
ad
approxim
ml
plasmapa
centrifug
follow
transfer
pc
ml
transfer
bag
store
flat
agit
day
collect
observ
swirl
everi
day
pc
measur
volum
residu
leukocyt
platelet
content
ph
determin
day
result
random
platelet
concentr
pc
tradit
method
n
mean
volum
ml
platelet
yield
cellsunit
compar
pc
pa
n
mean
volum
ml
platelet
yield
cellsunit
pc
pa
increas
storag
time
day
mean
ph
tradit
pc
storag
time
day
mean
ph
summaryconclus
pc
pa
increas
storag
time
day
provid
reach
recommend
qualiti
council
europ
eu
american
associ
blood
bank
aabb
nation
blood
centr
thai
red
cross
societi
trc
random
platelet
concentr
pc
content
cellsunit
volum
ml
ph
p
j
medicin
max
super
special
hospit
vaishali
ghaziabad
india
background
platelet
apheresi
use
obtain
platelet
volunt
donor
patient
famili
member
donor
hla
phenotyp
design
apheresi
procedur
intend
collect
larg
number
platelet
individu
therebi
provid
potent
product
fewer
donor
exposur
patient
although
platelet
often
transfus
without
regard
abo
compat
use
mismatch
platelet
frequent
result
lower
recoveri
rate
case
immunoglobulin
g
igg
b
antibodi
blood
group
recipi
reactiv
transfus
platelet
carri
larg
amount
b
antigen
result
platelet
transfus
refractori
recoveri
transfus
platelet
also
influenc
transfus
group
platelet
group
recipi
andor
donor
plasma
might
reactiv
solubl
b
recipi
plasma
form
immun
complex
bind
transfus
platelet
decreas
surviv
transfus
platelet
clinic
trial
compar
unmatch
platelet
patient
cancer
requir
multipl
platelet
transfus
suggest
rate
refractori
significantli
higher
unmatch
compon
use
aim
main
aim
case
studi
highlight
import
platelet
addit
solut
pa
abo
incompat
singl
donor
platelet
sdp
transfus
method
studi
carri
depart
transfus
medicin
period
year
januari
decemb
total
number
sdp
procedur
done
period
abo
incompat
sdp
procedur
done
pa
ssp
ratio
plasma
use
result
transfus
reaction
mediat
plasma
includ
allerg
febril
nonhemolyt
transfus
reaction
fnhtr
abo
hemolysi
acut
lung
injuri
trali
observ
case
summaryconclus
high
titer
isoagglutinin
platelet
unit
caus
hemolysi
recipi
red
cell
may
clinic
signific
even
fatal
outcom
may
like
situat
apheresi
unit
use
plasma
come
donor
dilut
plasma
lower
isoagglutinin
titer
unit
pool
neutral
presenc
solubl
abo
antigen
unit
transfus
singl
donor
platelet
alway
possibl
due
limit
avail
donor
maintain
daili
sdp
stock
due
short
life
platelet
studi
found
replac
plasma
pa
best
approach
overcom
advers
effect
due
sdp
transfus
also
maintain
stock
product
issu
across
group
patient
especi
dengu
season
r
van
j
r
h
de
molecular
genet
univers
colorado
denver
anschutz
medic
campu
aurora
unit
state
america
cell
research
process
develop
blood
bank
sanquin
amsterdam
netherland
background
introduct
compon
therapi
long
time
sagm
europ
north
america
main
addit
solut
use
red
blood
cell
concentr
rbc
main
improv
qualiti
rbc
last
part
centuri
came
introduct
leukodeplet
paggsm
gener
two
still
storag
blood
bank
result
progress
accumul
storag
lesion
character
larg
number
vitro
chang
paramet
like
hemolysi
morpholog
adenosin
triphosph
atp
content
membran
stabil
etc
storag
lesion
least
partial
mitig
storag
novel
storag
addit
alkalin
addit
solut
sever
novel
alkalin
addit
formul
propos
metabolom
character
perform
date
aim
perform
metabolom
character
sever
novel
alkalin
addit
formul
comparison
sagm
paggsm
method
perform
metabolom
analys
red
blood
cell
store
sagm
standard
addit
europ
paggsm
alkalin
addit
solx
either
end
netherland
day
result
metabol
linkag
analysi
provid
glanc
overview
metabol
rewir
across
addit
indic
strong
effect
redox
homeostasi
carboxyl
acid
fatti
acid
purin
metabol
alkalin
addit
compar
sagm
result
indic
alkalin
addit
especi
better
preserv
atp
correl
atp
dpg
poor
addit
except
suggest
rewir
shunt
specif
addit
addit
deamin
purin
hypoxanthin
predict
hemolysi
morpholog
alter
guanosin
supplement
paggsm
fuel
atp
gener
feed
pentos
phosphat
pathway
via
phosphoribolysi
decreas
urat
hypoxanthin
ratio
observ
alkalin
addit
suggest
decreas
gener
urat
purin
degrad
consequ
less
format
hydrogen
peroxid
xanthin
oxidas
activ
despit
mani
benefit
observ
purin
redox
metabol
alkalin
addit
prevent
accumul
free
fatti
acid
oxid
byproduct
open
window
futur
alkalin
formul
includ
lipophil
antioxid
summaryconclus
alkalin
via
differ
strategi
replac
chlorid
anion
either
high
bicarbon
high
citratephosph
membran
imperm
glucon
result
differ
metabol
outcom
case
superior
current
canon
addit
result
metabol
analys
indic
superior
preserv
rbc
alkalin
addit
gener
alkalin
addit
sagm
paggsm
particular
dpg
atp
gener
mainten
well
purin
metabol
redox
homeostasi
especi
ppp
phase
byproduct
favor
alkalin
addit
comparison
sagm
paggsm
howev
observ
metabol
benefit
extend
prevent
fatti
acid
releas
lipid
oxid
result
present
studi
provid
addit
insight
metabol
benefit
alkalin
storag
addit
like
guid
formul
novel
addit
near
futur
rn
scienc
depart
technic
univers
mombasa
mombasa
scienc
depart
patholog
jomo
kenyatta
univers
agricultur
scienc
technolog
nairobi
kenya
background
blood
transfus
import
clinic
intervent
surgeri
treatment
sever
tissu
hypoxia
transfus
compon
blood
includ
rbc
platelet
plasma
directli
administ
recipi
allevi
condit
anaemia
haemostat
defici
effect
blood
transfus
posit
affect
prognosi
efficaci
red
blood
cell
unit
depend
amount
blood
deliv
qualiti
cell
life
span
given
unit
aim
studi
aim
establish
point
preval
red
blood
cell
abnorm
donat
blood
specif
screen
presenc
unstabl
haemoglobin
determin
haemoglobin
concentr
red
cell
indic
osmot
fragil
enzym
defici
haemoglobin
aa
ac
chain
variant
may
present
donor
blood
region
blood
transfus
centr
also
abl
determin
abo
rhd
type
donor
method
studi
base
region
blood
transfus
centr
mombasa
consecut
blood
sampl
analyz
red
blood
cell
paramet
haemoglobin
hgb
concentr
haematolog
analyz
melet
schloes
laboratori
haematolog
analyz
haemoglobin
electrophoresi
red
cell
lysi
use
osmot
fragil
test
isopropanol
methaemoglobin
reduct
test
result
found
percentag
donor
abo
rhd
type
b
ab
rhd
posit
rhd
neg
overal
proport
donor
show
one
anomali
specif
anomali
found
follow
area
donor
low
haematocrit
mean
corpuscular
volum
outsid
normal
rang
fl
donor
show
reduc
hgb
content
gdl
glucos
phosphat
dehydrogenas
screen
test
show
defici
activ
borderlin
activ
pearson
test
return
signific
associ
abo
type
defici
howev
ab
person
margin
like
normal
blood
type
individu
coef
se
anova
model
reveal
statu
normal
intermedi
defici
mayb
relat
certain
haemoglobin
level
howev
fit
ordin
logit
model
relationship
reflect
pairwis
comparison
find
unstabl
haemoglobin
studi
summaryconclus
donor
red
cell
exhibit
anomali
could
potenti
caus
advers
event
donat
transfus
percentag
anomali
studi
higher
previou
studi
western
kenya
donor
meet
normal
rang
valu
rajab
east
african
medic
recommend
blood
bank
employ
stricter
red
cell
assay
procedur
enhanc
blood
qualiti
assay
consid
inclus
minimum
assay
protocol
blood
bank
use
copper
sulphat
screen
method
found
necessari
replac
accur
method
l
j
e
immunolog
transfus
medicin
karolinska
univers
hospit
clinic
scienc
intervent
technolog
karolinska
institutet
stockholm
sweden
background
increas
migrat
peopl
world
gener
grow
mismatch
donor
patient
popul
caus
frequent
demand
avail
red
blood
cell
rbc
rare
blood
group
antigen
even
though
rcc
rbc
concentr
frequent
cryopreserv
prolong
storag
locat
match
rcc
acut
demand
aris
often
problemat
paediatr
patient
often
need
fraction
whole
rcc
transfus
remain
volum
gener
wast
even
though
new
match
rcc
difficult
find
aim
develop
new
method
cryopreserv
paediatr
rcc
autom
cell
processor
method
eight
leukoreduc
rcc
elimin
donor
variabl
glycerolis
haemonet
corp
day
donat
unit
kept
refer
whole
unit
wu
unit
divid
three
split
split
unit
su
freez
month
unit
thaw
deglycerolis
addit
solut
wu
store
ml
bag
directli
finish
procedur
reduc
excess
supernat
su
rest
h
rt
thereaft
centrifug
g
min
manual
extract
adjust
haematocrit
final
product
transfer
ml
paediatr
storag
bag
storag
sampl
execut
extend
haemolysi
extracellular
potassium
k
haemoglobin
hb
haematocrit
haemolysi
k
ph
atp
glucos
lactat
mcv
mean
corpuscular
volum
microvesicl
measur
median
calcul
compar
result
su
haematocrit
hb
gl
product
show
robust
product
method
wu
reduct
supernat
markedli
lower
haematocrit
hb
gl
haemolysi
k
increas
rate
lower
su
signific
differ
su
wu
p
p
haemolysi
reach
su
wu
edqm
guidelin
k
reach
su
wu
mmolmg
hb
glucos
ph
significantli
lower
p
su
explain
differ
supernat
compositionconcentr
gener
significantli
lower
atp
lactat
p
wu
atp
ph
decreas
rate
howev
slower
su
decreas
evenli
su
wu
level
undetect
mcv
significantli
higher
p
su
reflect
microvesicl
count
microvesicl
increas
throughout
storag
period
differ
su
wu
summaryconclus
split
unit
cryopreserv
rbc
success
produc
haemolysi
k
content
lower
make
suitabl
paediatr
transfus
along
higher
haematocrit
reduc
risk
hyperhydr
suggest
may
resist
storag
lesion
better
tradit
whole
unit
store
longer
time
replac
supernat
appear
favour
storag
rbc
outweigh
detriment
effect
addit
mechan
stress
product
split
unit
contribut
increas
stock
suppli
reduc
unnecessari
wast
rbc
rare
blood
group
p
van
der
meer
h
korsten
j
lagerberg
de
kort
sanquin
blood
bank
amsterdam
netherland
background
red
cell
show
declin
atp
store
blood
bank
condit
result
red
cell
higher
oxygen
affin
result
poorer
oxygen
deliveri
tissu
defect
correct
within
h
transfus
immedi
oxygen
deliveri
overal
red
cell
qualiti
atp
level
close
valu
found
fresh
whole
blood
develop
experiment
red
cell
addit
solut
ra
contain
phosphat
adenin
bicarbon
glucos
mannitol
absenc
sodium
chlorid
ph
led
optim
qualiti
red
cell
storag
key
optim
red
cell
storag
maintain
intern
ph
level
enzym
phosphoglycer
mutas
remain
activ
abl
synthes
without
decreas
atp
achiev
high
extern
ph
also
absenc
chlorid
storag
solut
addit
ra
lead
chlorid
move
red
cell
maintain
electrolyt
balanc
hydrogen
enter
cell
thu
increas
intern
ph
phenomenon
known
chlorid
shift
extra
bicarbon
ra
serv
addit
buffer
prevent
drop
intern
ph
guanosin
known
shift
red
cell
metabol
toward
pentos
phosphat
pathway
result
synthesi
nadhp
use
synthes
atp
aim
studi
effect
addit
extra
bicarbon
guanosin
ra
vitro
qualiti
store
red
cell
concentr
method
one
leukoreduc
pack
red
cell
concentr
split
equal
part
part
ml
ad
first
part
standard
composit
contain
mm
bicarbon
second
part
b
extra
mm
bicarbon
mm
total
third
part
c
mm
guanosin
fourth
part
extra
mm
bicarbon
mm
total
mm
guanosin
concentr
store
day
weekli
sampl
determin
variou
vitro
qualiti
paramet
three
replic
experi
perform
result
addit
extra
bicarbon
led
increas
extern
intern
ph
day
phextern
b
c
phintern
b
c
p
versu
howev
effect
level
day
b
mmolg
hemoglobin
hb
minor
effect
atp
content
day
b
mmolg
hb
presenc
guanosin
addit
adenin
led
signific
increas
atp
day
c
mmolg
hb
day
c
mmolg
hb
storag
addit
bicarbon
benefici
even
slightli
deleteri
effect
summaryconclus
addit
extra
bicarbon
ra
increas
ph
ultim
effect
atp
content
storag
addit
guanosin
increas
atp
level
even
day
conform
accept
criteria
store
red
cell
concentr
p
f
w
bank
american
red
cross
norfolk
develop
hemanext
lexington
unit
state
america
background
red
blood
cell
rbc
transfus
patient
correct
anemia
treat
prevent
inadequ
tissu
oxygen
refriger
storag
rbc
diphosphoglycer
concentr
decreas
less
undetect
level
day
storag
correspond
increas
oxygen
affin
decreas
storag
chang
suggest
rbc
may
less
efficaci
oxygen
deliveri
especi
medic
condit
immedi
need
adequ
tissu
oxygen
aim
main
object
present
studi
compar
concentr
convent
aerob
store
rbc
hemanext
rbc
store
hemanext
storag
bag
hsb
initi
process
hemanext
process
system
method
ten
unit
whole
blood
ml
collect
anticoagul
unit
process
plasma
red
cell
concentr
storag
solut
h
collect
store
room
temperatur
h
hemanext
treatment
prior
hemanext
process
ml
remov
unit
transfer
steril
mini
sampl
pvc
rbc
storag
bag
label
control
mini
storag
bag
configur
surfac
area
volum
ratio
standard
full
unit
regular
rbc
storag
bag
control
bag
store
within
h
blood
collect
remain
ml
process
hemanext
oxygen
manag
process
system
agit
h
transfer
hsb
storag
within
h
whole
blood
collect
sampl
taken
measur
complet
blood
count
cbc
ga
panel
hemolysi
morpholog
adenosin
triphosph
atp
storag
result
salient
result
show
signific
decreas
control
rbc
day
day
storag
correspond
decreas
mmhg
p
contrast
control
concentr
hemanext
rbc
maintain
mmhg
respect
day
although
concentr
atp
slightli
higher
less
variabl
hemanext
rbc
control
day
storag
differ
statist
signific
p
summaryconclus
result
show
level
atp
well
maintain
hemanext
compar
convent
store
rbc
sinc
paramet
import
normal
function
rbc
oxygen
deliveri
data
suggest
hemanext
rbc
may
efficaci
oxygen
deliveri
convent
store
rbc
especi
medic
condit
immedi
requir
adequ
oxygen
deliveri
tissu
vital
organ
tr
r
g
j
innov
canadian
blood
servic
edmonton
servic
canadian
blood
servic
toronto
clinic
servic
canadian
blood
servic
medicin
patholog
univers
alberta
edmonton
canada
background
canadian
blood
servic
frozen
blood
program
aim
provid
red
cell
concentr
rcc
patient
rare
blood
type
mani
unit
frozen
inventori
rare
phenotyp
involv
protein
structur
variat
may
interact
red
blood
cell
rbc
membran
sever
blood
group
epitop
multipass
protein
may
absent
rare
rbc
could
impact
stabil
cell
membran
collect
phenotyp
chang
could
affect
cryobiolog
cell
mcleod
phenotyp
result
absenc
kx
protein
kell
blood
group
system
lead
acanthocytosi
rbc
cryopreserv
method
continu
modern
adopt
new
anticoagul
addit
solut
blood
compon
manufactur
method
compat
process
cryopreserv
unit
store
extend
period
routin
evalu
aim
studi
perform
determin
unit
process
use
differ
product
freez
method
could
deglycerol
use
modern
method
meet
regulatori
standard
addit
specif
evalu
mcleod
donor
unit
determin
whether
cryopreserv
subsequ
deglycerol
success
perform
preserv
integr
rbc
method
control
group
n
select
unit
frozen
use
product
freez
method
mcleod
donor
unit
cryopreserv
four
unit
frozen
charter
medic
contain
reduc
whole
blood
collect
unit
previous
glycerol
use
high
glycerol
method
store
freezer
year
deglycerol
perform
use
autom
cell
processor
haemonet
unit
centrifug
remov
supernat
glycerol
standard
deglycerol
protocol
perform
result
rcc
unit
test
immedi
post
thaw
post
deglycerol
hemolysi
glycerol
concentr
recoveri
addit
test
h
day
includ
hemolysi
hemoglobin
potassium
mean
cell
volum
rbc
deform
osmot
fragil
atp
result
immedi
post
thaw
control
group
mcleod
unit
glycerol
concentr
respect
immedi
post
deglycerol
unit
residu
glycerol
hemolysi
control
group
immedi
h
day
post
deglycerol
mcleod
unit
increas
hemolysi
time
point
compar
control
group
mcleod
unit
also
decreas
mcv
fl
vs
fl
increas
mean
corpuscular
fragil
increas
rbc
rigid
vs
h
compar
control
group
summaryconclus
rcc
process
frozen
use
differ
method
test
studi
success
deglycerol
use
current
autom
cell
process
method
meet
canadian
standard
associ
csa
standard
cryopreserv
rbc
mcleod
unit
met
csa
standard
h
post
deglycerol
howev
unit
increas
fragil
hemolysi
potenti
due
uniqu
rbc
phenotyp
may
affect
decis
appropri
extend
storag
tr
r
j
innov
canadian
blood
servic
edmonton
chemistri
biomolecular
scienc
univers
ottawa
ottawa
laboratori
medicin
patholog
univers
alberta
edmonton
canada
background
cryopreserv
red
cell
concentr
rcc
use
long
term
storag
blood
product
support
patient
rare
blood
type
requir
antigen
neg
blood
unit
often
cryopreserv
use
high
glycerol
method
store
year
temperatur
howev
throughout
rcc
lifespan
mani
type
oper
event
may
caus
rcc
warm
transient
warm
event
twe
induc
cellular
damag
due
ice
recrystal
addit
novel
ice
recrystal
inhibitor
iri
previous
demonstr
mitig
damag
glycerol
red
blood
cell
rbc
aim
purpos
studi
determin
characterist
twe
rcc
cryopreserv
glycerol
evalu
effect
twe
without
iri
method
character
warm
profil
rcc
expos
room
temperatur
rt
rcc
glycerol
use
autom
cell
processor
haemonet
briefli
rcc
sagm
approxim
hematocrit
prior
freez
freezer
thermocoupl
insert
unit
twe
profil
record
triplic
small
scale
method
use
collect
hemolysi
data
drabkin
method
singl
multipl
twe
sampl
cryopreserv
cryovial
use
similar
method
rcc
twe
exposur
sampl
styrofoam
rack
place
rt
return
frozen
storag
desir
temperatur
reach
glycerol
rbc
expos
variou
singl
twe
test
weekli
sampl
without
iri
expos
cycl
either
result
cryopreserv
rcc
expos
rt
averag
time
core
temperatur
rise
min
min
min
rcc
return
frozen
storag
took
min
respect
return
exposur
ml
volum
singl
twe
demonstr
increas
hemolysi
compar
control
day
frozen
storag
sampl
expos
cycl
twe
increas
hemolysi
seen
glycerol
sampl
cycl
hemolysi
sampl
iri
hemolysi
p
glycerol
sampl
cycl
hemolysi
sampl
iri
hemolysi
p
summaryconclus
singl
twe
significantli
impact
hemolysi
glycerol
multipl
twe
cycl
increas
hemolysi
suggest
reduct
rcc
qualiti
extens
storag
twe
occur
howev
addit
iri
appear
reduc
effect
twe
rbc
integr
e
e
l
j
blood
transfus
militari
univers
hospit
pragu
cz
pod
petrinem
pragu
czech
republ
background
shelf
life
frozen
rbc
year
frozen
state
storag
time
vari
countri
countri
without
clear
evid
cryopreserv
costli
process
long
shelf
life
frozen
rbc
especi
rare
unit
desir
aim
present
studi
vitro
laboratori
paramet
freez
red
cell
thaw
year
reconstitut
two
addit
solut
nutricel
aim
verifi
qualiti
method
leucodeplet
rbc
doubl
apheresi
whole
blood
frozen
glycerol
store
year
month
thaw
rbc
deglycerolis
use
devic
haemonet
reconstitut
addit
solut
unit
unit
nutricel
thaw
unit
test
day
hemoglobin
loss
hematocrit
leucocyt
haemolysi
osmol
ph
k
p
atp
dpg
result
thaw
rbc
reconstitut
solut
nutricel
compar
valu
timelin
total
hgb
hct
k
atp
dpg
rbc
higher
osmol
day
display
significantli
higher
hemolysi
limit
day
correspond
increas
free
hgb
hand
rbc
nutricel
hemolysi
day
summaryconclus
thaw
rbc
reconstitut
solut
best
vital
energi
potenti
first
day
reconstitut
rbc
reconstitut
show
improv
qualiti
vital
storag
rbc
gener
state
collect
data
correspond
previous
publish
data
qualiti
frozen
rbc
storag
storag
year
effect
qualiti
c
le
van
n
w
el
p
pari
diderotinstitut
nation
de
la
transfus
sanguin
pari
diderotinstitut
nation
de
la
transfus
sanguin
pari
franc
antil
point
pitr
guadeloup
medicin
tokyo
women
medic
univers
women
medic
univers
tokyo
japan
natin
de
la
transfus
pari
diderot
naiton
de
la
transfus
pari
diderot
pari
franc
background
hypotherm
storag
therapeut
red
blood
cell
rbc
concentr
accompani
cellular
chang
refer
storag
lesion
storag
lesion
like
affect
rbc
survivalefficaci
increas
risk
advers
reaction
recipi
especi
inflammatori
context
underli
mechan
lead
rbc
membran
chang
storag
poorli
known
put
actor
lipid
peroxid
phospholipid
asymmetri
accumul
oxid
damag
band
oligomer
state
cellular
senesc
oxid
damag
induc
cascad
biochem
event
lead
detach
band
cytoskeleton
cluster
band
also
play
key
role
clearanc
alter
old
rbc
form
senesc
antigen
capabl
bind
autoantibodi
nab
besid
band
promin
substrat
tyrosin
kinas
band
phosphoryl
larg
document
sever
hematolog
disord
aim
aim
elucid
mechan
lead
irrevers
erythrocyt
alter
storag
identifi
relev
marker
transfus
yield
elucid
molecular
mechan
lead
band
modif
storag
ultim
lead
new
approach
toward
improv
rbc
storag
andor
surviv
efficaci
safeti
transfus
purpos
rbc
unit
prepar
whole
blood
donat
drawn
healthi
volunt
donor
store
day
standard
condit
sagm
solut
method
rbc
sampl
taken
day
storag
use
biochem
molecular
cellular
analys
ema
use
rbc
label
flow
cytometri
analysi
rbc
membran
prepar
western
blot
perform
use
antibodi
mous
monoclon
specif
band
antibodi
previous
describ
arashiki
et
al
microparticl
prepar
rbc
supernat
analyz
flow
cytometri
use
band
antibodi
band
activ
measur
exchang
rbc
ghost
use
spectrophotomet
result
use
ema
test
observ
progress
decreas
ema
label
storag
chang
band
oligomer
state
use
specif
antiphosphotyr
antibodi
show
oligomer
state
correl
higher
tyrosin
phosphoryl
band
uniqu
antibodi
specif
recogn
band
cluster
form
arashiki
et
al
show
increas
band
phosphoryl
associ
clusteringus
flow
cytometri
found
import
increas
level
erythroid
microparticl
storageus
observ
partial
loss
band
exchang
function
storag
summaryconclus
conclus
postul
blood
bag
storag
induc
profound
molecular
chang
band
lead
format
cluster
probabl
gener
present
neoantigen
transfus
red
blood
cell
could
subject
bind
autolog
nab
direct
neoantigen
may
lead
quick
import
sequestr
blood
stream
furthermor
demonstr
antibodi
specif
cluster
form
band
repres
simpl
relev
new
tool
monitor
rbc
storag
lesion
g
k
j
j
develop
australian
red
cross
blood
servic
care
research
group
princ
charl
hospit
clinic
medicin
univers
queensland
brisban
australia
background
possibl
associ
durat
red
blood
cell
rbc
storag
poor
clinic
outcom
intens
research
recent
randomis
clinic
trial
rct
appear
resolv
uncertainti
suggest
signific
differ
freshest
avail
standard
practic
issu
oldest
inventori
rbc
howev
ethic
consider
preclud
rct
investig
rbc
end
anim
model
play
crucial
role
complement
rct
address
limit
sheep
transfus
model
provid
excel
screen
tool
elucid
underli
mechan
store
blood
complic
aim
investig
cytokinechemokin
releas
transfus
either
fresh
date
expiri
rbc
use
sheep
model
method
anesthet
mechan
ventil
sheep
n
receiv
lipopolysaccharid
lp
mimic
bacteri
infect
follow
transfus
pool
supernat
sn
leucodeplet
human
rbc
unit
store
either
n
n
blood
collect
infus
plasma
aliquot
store
sheep
specif
elisa
use
quantifi
concentr
plasma
lung
tissu
collect
store
rnalat
total
rna
isol
use
rneasi
mini
kit
real
time
quantit
pcr
perform
use
taqman
real
time
pcr
system
sybr
green
pcr
master
mix
primer
reaction
perform
triplic
data
normal
geomean
actb
housekeep
gene
data
analys
repeat
measur
anova
bonferroni
multipl
comparison
assess
effect
transfus
unpair
test
appli
detect
differ
group
p
result
group
sheep
expos
lp
day
rbc
transfus
plasma
level
p
p
increas
throughout
experi
show
compar
baselin
plasma
increas
p
increas
p
p
also
show
plasma
increas
throughout
experi
group
sheep
expos
lp
day
rbc
transfus
plasma
level
p
p
increas
throughout
experi
indic
plasma
increas
p
p
plasma
increas
p
p
compar
baselin
level
howev
differ
cytokin
level
transfus
day
day
rbc
sn
observ
increas
lung
gene
express
observ
sheep
transfus
rbc
sn
store
day
compar
day
p
differ
express
observ
summaryconclus
model
transfus
rbc
sn
sheep
associ
increas
plasma
cytokin
level
howev
increas
rbc
storag
durat
associ
increas
level
result
complement
find
recent
rct
provid
evid
transfus
date
expiri
rbc
harm
mr
deyhim
n
mehrdadi
chemistri
high
institut
research
educ
transfus
medicin
scienc
branch
azad
univers
tehran
iran
background
oxid
stress
one
main
caus
red
blood
cell
rbc
storag
lesion
rbc
storag
blood
bank
condit
studi
evalu
effect
nac
addit
solut
rbc
oxid
stress
rbc
storag
aim
evalu
oxid
stress
marker
rbc
storag
pack
rbc
method
experiment
studi
bag
pack
rbc
randomli
assign
iranian
blood
transfus
organ
ibto
innov
center
evalu
effect
nac
mmol
rbc
metabol
paramet
includ
glucos
lactat
concentr
lactat
dehydrogenas
enzym
activ
ph
oxid
stress
biomark
malondialdehyd
mda
concentr
total
antioxid
capac
tac
also
hematolog
paramet
includ
rbc
count
hb
hct
mcv
mch
mchc
concentr
percentag
hemolysi
measur
rbc
storag
day
storag
result
compar
two
group
nac
treat
rbc
untreat
rbc
control
group
data
analyz
spss
statist
program
version
result
studi
concentr
lactat
ldh
enzym
activ
nac
treat
rbc
significantli
lower
control
group
without
nac
also
mda
concentr
decreas
nac
treat
rbc
compar
control
group
total
antioxid
capac
significantli
higher
nac
rbc
control
group
especi
day
storag
summaryconclus
result
studi
indic
use
nac
addit
solut
could
decreas
oxid
damag
via
maintain
rbc
antioxid
capac
rbc
storag
futur
nac
may
use
addit
maintain
rbc
surviv
rbc
qualiti
storag
blood
bank
condit
cg
c
k
manag
blood
center
colombo
sri
lanka
background
first
demonstr
human
red
blood
cell
rbc
could
thaw
wash
free
glycerol
transfus
normal
vivo
surviv
recov
cell
cryoprotect
agent
essenti
prevent
dehydr
mechan
trauma
rbc
freez
glycerol
penetr
group
cryoprotect
agent
use
nation
blood
center
high
concentr
glycerol
rbc
prevent
format
ice
crystal
consequ
membran
damag
cryopreserv
rbc
nbrl
naval
blood
research
laboratori
boston
univers
school
medicin
method
base
hgc
use
hemoneticacp
adopt
nation
blood
center
standard
oper
procedur
system
adopt
valid
aim
valid
procedur
glycerol
deglycerol
red
cellsto
assess
qualiti
deglycerol
rcc
unit
glycerol
within
day
collectionto
assess
qualiti
deglycerol
rcc
unit
glycerol
day
collect
method
prospect
valid
conduct
follow
system
specif
standard
oper
procedur
high
glycerol
concentr
glycerol
method
wv
glycerol
use
cryopreserv
sagm
use
preserv
solut
rcc
unit
within
day
collect
date
rcc
unit
day
date
collect
select
valid
seri
test
recommend
qc
paramet
product
assess
relat
requir
specif
per
edqm
guidelin
aabb
standard
result
compar
studi
analyz
use
independ
sampl
correl
assess
pearson
correl
regress
result
signific
differ
p
two
seri
relat
total
hb
content
start
rbc
unit
hb
level
freez
statist
significantli
low
older
rcc
unit
p
volum
end
product
significantli
high
p
older
rcc
unit
similarli
hb
gdl
end
product
significantli
low
older
unit
p
hct
end
product
prepar
older
rcc
unit
significantli
low
p
compar
freshli
frozen
rcc
signific
differ
recoveri
percentag
two
seri
ph
end
product
significantli
low
older
rcc
unit
p
comparison
freshli
frozen
rcc
unit
signific
differ
two
seri
relat
osmol
k
level
day
moder
posit
correl
decreas
ph
rise
supernat
hb
level
r
freshli
frozen
rcc
reduct
ph
rise
supernat
hb
evid
averag
day
older
rcc
unit
reduct
ph
rise
supernat
hb
evid
averag
day
day
respect
summaryconclus
qc
paramet
seri
accept
date
deglycerol
howev
post
deglycerol
shelf
life
rcc
frozen
near
expiri
date
significantli
shorter
clinic
outcom
assess
determin
efficaci
product
rcc
unit
frozen
day
collect
also
show
rapid
lower
ph
level
comparison
freshli
frozen
unit
may
indirectli
reflect
reduct
atp
level
reduct
oxygen
carri
capac
red
cell
mr
n
chemistri
high
institut
research
educ
transfus
medicin
scienc
branch
azad
univers
tehran
iran
background
red
blood
cell
rbc
metabol
impair
one
main
caus
rbc
storag
lesion
rbc
storag
blood
bank
condit
studi
evalu
effect
differ
concentr
cystein
nac
rbc
metabol
qualiti
rbc
storag
aim
optim
concentr
nac
better
maintain
pack
rbc
metabol
storag
method
experiment
studi
bag
pack
rbc
randomli
assign
iranian
blood
transfus
organ
ibto
innov
center
blood
bag
split
equal
blood
bag
three
inject
differ
concentr
nac
mmol
one
kept
control
bag
untreat
nac
effect
differ
concentr
nac
metabol
paramet
includ
glucos
lactat
concentr
lactat
dehydrogenas
enzym
activ
ph
investig
also
hematolog
paramet
includ
rbc
count
hb
hct
mcv
mch
mchc
concentr
measur
rbc
storag
day
result
studi
compar
group
nac
treat
rbc
untreat
rbc
data
analyz
spss
statist
program
version
result
studi
concentr
mmol
nac
compar
effect
maintain
concentr
lactat
glucos
p
also
concentr
effect
concentr
nac
rbc
count
hb
hct
mch
concentr
compar
untreat
rbc
storag
summaryconclus
result
studi
indic
use
concentr
mmol
nac
addit
solut
could
better
maintain
rbc
metabol
rbc
qualiti
storag
futur
nac
concentr
mmol
may
use
addit
maintain
rbc
surviv
rbc
qualiti
storag
blood
bank
condit
n
de
biologi
et
de
de
lausann
lausann
product
transfus
cr
epaling
produit
sanguin
transfus
cr
bern
switzerland
lexington
unit
state
america
background
donor
variabl
influenc
storag
red
blood
cell
rbc
one
variabl
oxygen
satur
recent
unexpectedli
report
vari
wide
reason
distribut
total
explain
wherea
role
oxygen
oxid
lesion
storag
rbc
concentr
rcc
known
aim
object
character
distribut
rcc
produc
region
blood
center
switzerland
investig
origin
wide
distribut
method
novemb
level
measur
leukoreduc
rcc
deriv
whole
blood
donat
tb
germani
compon
filter
n
tt
fqe
macopharma
franc
whole
blood
filtrat
n
kit
addit
tb
bag
analyz
process
measur
pvc
bag
prior
storag
reson
raman
spectroscopi
pendar
microvascular
oximet
pendar
technolog
cambridg
usa
gender
age
blood
type
hemoglobin
level
locat
donor
process
method
record
result
overal
exhibit
wide
distribut
mean
median
iqr
tt
process
show
higher
tb
process
mean
vs
median
vs
iqr
vs
respect
p
show
signific
differ
howev
process
n
reduc
p
also
affect
donor
characterist
rcc
male
n
exhibit
higher
femal
n
vs
p
wherea
correl
observ
function
age
hemoglobin
level
final
donor
locat
clearli
influenc
despit
absenc
correl
femal
posit
correl
minim
locat
elev
elevationmin
p
male
donor
addit
comparison
group
municip
equival
gender
age
hemoglobin
level
process
distribut
countri
side
mean
elev
citi
exhibit
vs
respect
data
indic
live
altitud
might
influenc
rcc
factor
pollut
life
style
exclud
summaryconclus
data
confirm
wide
distribut
rcc
report
recent
independ
level
hemoglobin
influenc
process
particularli
donor
characterist
gender
locat
stage
possibl
clearli
identifi
origin
differ
confound
variabl
consid
nevertheless
provid
new
hint
influenc
donor
sinc
rbc
lesion
known
increas
storag
relat
content
rcc
import
character
donor
popul
order
better
process
better
store
rbc
transfus
r
de
j
j
j
de
w
de
k
van
den
studi
sanquin
blood
suppli
foundat
biostatist
amsterdam
public
health
vu
univers
medic
center
school
commun
research
univers
amsterdam
process
develop
sanquin
blood
suppli
foundat
scienc
vrije
universiteit
amsterdam
amsterdam
netherland
background
lifestyl
behavior
physic
activ
sedentari
behavior
dietari
habit
shown
influenc
blood
lipid
level
lifestyl
blood
lipid
may
associ
hemolysi
storag
blood
product
aim
investig
whether
rel
unhealthi
lifestyl
ie
low
level
moder
vigor
physic
activ
high
level
sedentari
behaviour
high
intak
unhealthi
food
associ
higher
level
haemolysi
storag
miniatur
red
cell
concentr
dutch
blood
donor
furthermor
explor
whether
associ
lifestyl
behaviour
haemolysi
red
cell
concentr
mediat
triglycerid
level
method
analysi
perform
data
dutch
blood
donor
particip
donor
insight
di
averag
number
minut
spent
per
day
moder
vigor
physic
activ
sedentari
behaviour
measur
use
ipaq
questionnair
subset
donor
also
object
measur
use
actigraph
acceleromet
seven
consecut
day
wake
hour
intak
frequenc
amount
fish
nut
egg
meat
assess
use
food
frequenc
questionnair
blood
sampl
taken
divers
pouch
process
store
mini
red
cell
concentr
sagm
day
total
haemoglobin
measur
haematolog
analys
free
haemoglobin
determin
spectrophotomet
increas
readabl
regress
coeffici
haemolysi
express
hundredth
percent
free
haemoglobin
total
haemoglobin
present
red
blood
cell
correct
haematocrit
ie
hundredth
percentag
red
blood
cell
blood
mediat
analys
perform
studi
triglycerid
level
potenti
mediat
associ
lifestyl
behaviour
haemolysi
level
sensit
analys
conduct
subset
donor
object
measur
physic
activ
sedentari
behaviour
result
median
interquartil
rang
iqr
haemolysi
red
cell
concentr
median
iqr
mmoll
triglycerid
median
iqr
number
minut
per
day
moder
vigor
physic
activ
sedentari
behaviour
respect
sedentari
behaviour
significantli
associ
haemolysi
level
red
cell
concentr
ci
remain
ad
triglycerid
model
howev
signific
associ
found
sedentari
behaviour
triglycerid
thu
evid
mediat
found
regardless
lifestyl
behaviour
studi
triglycerid
level
significantli
associ
haemolysi
red
cell
concentr
sedentari
behaviour
model
ci
latter
find
confirm
sensit
analysi
ci
sensit
analys
show
signific
associ
sedentari
behaviour
haemolysi
summaryconclus
larg
cohort
blood
donor
lipid
level
strongli
consist
associ
haemolysi
red
cell
concentr
sedentari
behaviour
associ
haemolysi
red
cell
concentr
evid
found
triglycerid
mediat
associ
l
r
v
e
j
h
wp
innov
canadian
blood
servic
hamilton
research
centr
biomed
scienc
st
michael
hospit
toronto
molecular
medicin
mcmaster
univers
hamilton
innov
canadian
blood
servic
blood
research
univers
british
columbia
vancouv
canada
discoveri
corpor
develop
ioni
pharmaceut
carlsbad
unit
state
america
innov
canadian
blood
servic
toronto
molecular
medicin
mcmaster
univers
hamilton
canada
background
typic
goal
plasma
transfus
treat
coagulopathi
restor
hemostasi
bleed
patient
nation
regul
use
fviii
activ
monitor
transfus
plasma
qualiti
linkag
marker
hemostat
control
unclear
previous
establish
normovolem
coagulopath
mous
model
beca
demonstr
plasma
mice
defici
fviii
fibrinogen
reduc
blood
lose
transfus
beca
mice
subject
standard
injuri
transfus
assess
abil
plasma
knockout
mice
restor
hemostasi
limit
embryon
lethal
sever
coagul
protein
gene
mice
includ
prothrombin
fii
aim
obtain
murin
plasma
minim
express
fii
assess
abil
restor
hemostasi
limit
hemorrhag
beca
mice
induc
injuri
method
donor
mice
inject
subcutan
mgkg
control
antisens
oligonucleotid
aso
aso
direct
fii
mrna
twice
weekli
four
week
produc
con
plasma
pool
recipi
beca
mice
subject
sequenti
blood
exchang
reduc
plasma
protein
level
maintain
normal
blood
volum
receiv
mlkg
bodi
weight
plasma
prior
injuri
shed
blood
measur
directli
follow
tail
transect
tt
liver
lacer
platelet
deposit
time
measur
use
intravit
microscopi
intravascular
laser
injuri
ili
result
plasma
contain
prothrombin
concentr
plasma
fii
immunoassay
tt
model
mice
lost
less
blood
mice
versu
n
p
data
herein
given
mean
sem
model
mice
lost
less
blood
mice
versu
n
p
ili
model
product
platelet
mean
fluoresc
intens
mfi
time
measur
area
curv
greater
mice
mice
versu
respect
n
p
summaryconclus
plasma
contain
normal
fii
concentr
less
effect
plasma
treat
induc
murin
coagulopathi
evidenc
significantli
greater
blood
loss
follow
either
tail
liver
injuri
addit
mice
significantli
less
abl
form
durabl
arteriolar
hemostat
plug
respons
laser
injuri
counterpart
find
suggest
fii
critic
compon
transfus
plasma
must
constitu
minim
compon
plasma
altern
assum
analog
mechan
human
result
suggest
fii
would
improv
qualiti
marker
transfus
plasma
compar
fviii
hm
n
b
r
e
blood
servic
halifax
nova
scotia
blood
servic
univers
london
ontario
blood
servic
regina
saskatchewan
blood
servic
vancouv
british
columbia
blood
servic
calgari
alberta
blood
servic
toronto
ontario
canada
background
canadian
nation
advisori
committe
nac
blood
blood
product
recommend
solvent
deterg
plasma
sdp
use
follow
defin
indic
patient
thrombot
thrombocytopen
purpura
ttp
hemolyt
urem
syndrom
hu
factor
h
defici
clot
factor
defici
specif
licens
concentr
also
patient
histori
allerg
transfus
reaction
lung
disord
blood
group
compat
frozen
plasma
readili
avail
aim
aim
studi
retrospect
examin
indic
sdp
request
submit
canadian
blood
servic
cb
associ
transfus
reaction
method
electron
avail
data
sdp
request
collect
analyz
period
januari
juli
data
transfus
reaction
associ
sdp
collect
hemovigil
websit
studi
period
result
sdp
request
hospit
total
sdp
unit
issu
sdp
request
approv
cb
physician
miss
data
approv
statu
reject
among
approv
request
met
nac
criteria
miss
data
meet
nac
criteria
among
request
ttp
hu
factor
defici
allerg
transfus
reaction
lung
disord
avail
abo
compat
plasma
combin
secondari
qualifi
issu
sdp
unit
approv
request
request
miss
data
reject
request
sdp
unit
issu
approv
request
request
request
miss
data
request
meet
nac
criteria
incid
transfus
reaction
estim
per
transfus
sdp
unit
compar
publish
incid
per
transfus
frozen
plasma
fp
unit
report
transfus
reaction
sdp
sever
allerg
reaction
compar
report
incid
per
unit
fp
five
thrombot
event
document
ttp
patient
thrombot
event
report
ttp
case
fp
report
acut
lung
injuri
trali
reaction
sdp
transfus
studi
data
american
red
cross
seriou
hazard
transfus
report
demonstr
trali
incid
implement
plasma
strategi
estim
cost
issu
sdp
unit
per
liter
averag
per
unit
estim
cost
fp
transfus
studi
period
per
liter
averag
per
unit
summaryconclus
major
request
sdp
approv
major
sdp
unit
issu
approv
request
small
number
approv
classifi
meet
nac
criteria
data
miss
approxim
one
third
request
sdp
associ
reaction
allerg
possibl
thrombot
event
report
case
trali
e
j
n
k
hospit
research
institut
blood
servic
ottawa
hospitali
de
de
montreal
toronto
toronto
canada
background
intraven
immun
globulin
ivig
fraction
plasma
product
use
treat
rang
autoimmun
inflammatori
condit
well
immunodefici
demand
product
increas
despit
limit
evid
efficaci
character
use
ivig
time
impact
provinci
strategi
mitig
use
would
provid
inform
guid
futur
polici
aim
describ
trend
ivig
use
tertiari
care
centr
determin
impact
implement
polici
optim
use
method
retrospect
cohort
studi
larg
tertiari
care
hospit
ontario
canada
ottawa
hospit
data
warehous
queri
inpati
outpati
encount
involv
ivig
transfus
januari
decemb
ivig
use
studi
period
report
includ
number
hospit
encount
amount
ivig
prescrib
clinician
respons
ivig
order
interrupt
time
seri
analysi
perform
evalu
impact
provinci
initi
optim
ivig
use
ontario
ivig
util
manag
guidelin
releas
novemb
ivig
toolkit
releas
septemb
includ
standard
ivig
request
form
ivig
dose
calcul
standard
infus
guidelin
advers
event
chart
result
patient
ottawa
hospit
receiv
g
ivig
patient
encount
occur
outpati
clinic
attend
physician
divis
hematolog
neurolog
respons
ivig
hospit
encount
although
ivig
use
increas
gquarter
p
total
volum
use
lower
would
expect
provinci
polici
implement
ivig
use
decreas
implement
new
polici
gquarter
p
although
increas
gquarter
p
chang
util
vari
consider
specialti
hematolog
total
use
ivig
decreas
gquarter
p
intervent
period
remain
stabl
neurolog
chang
total
util
intervent
period
although
use
ivig
increas
gquarter
p
similar
increas
also
seen
rheumatolog
gquarter
p
summaryconclus
provinci
initi
signific
impact
ivig
administr
continu
increas
ivig
use
may
reflect
chang
demograph
lack
access
altern
therapi
neurolog
rheumatolog
condit
futur
work
assess
tempor
chang
subcutan
ig
use
diagnos
underli
ig
administr
hou
ye
f
liu
li
p
jiang
l
c
li
research
center
blood
biochemistri
molecular
biolog
institut
blood
transfus
chines
academi
medic
scienc
peke
union
medic
colleg
chengdu
china
background
intraven
immunoglobulin
ivig
prepar
main
compon
polyclon
immunoglobulin
g
igg
plasma
protein
product
prepar
healthi
human
blood
donor
sever
autoimmun
diseas
warm
autoimmun
hemolyt
anemia
waiha
immun
thrombocytopenia
itp
mediat
erythrocyt
thrombocyt
opson
igg
autoantibodi
respect
blood
cell
mainli
recogn
bound
receptor
innat
immun
cell
phagocytos
macrophag
spleen
liver
research
shown
high
dose
gkg
ivig
infus
directli
block
activ
upregul
express
inhibitori
receptor
lead
reduc
erythrocyt
thrombocyt
phagocytosi
achiev
effici
therapeut
effect
interestingli
recent
evid
suggest
sialyl
igg
play
import
role
immunomodulatori
ivig
furthermor
sialic
ivig
show
stronger
immunosuppress
activ
amelior
inflamm
current
debat
aim
investig
whether
inhibitori
effect
macrophag
phagocytosi
ivig
relat
sialyl
ivig
fulli
human
vitro
system
method
firstli
ivig
prepar
load
lectin
affin
chromatograph
column
sialic
sambucu
nigra
agglutinin
sna
three
fraction
obtain
flow
fraction
ft
elut
fraction
elut
fraction
note
highli
sialyl
ivig
fraction
level
sialyl
ft
less
untreat
ivig
addit
ivig
treat
neuraminidas
sialic
ivig
naas
ivig
use
control
prepar
secondli
system
macrophag
deriv
human
monocyt
cell
line
induc
phorbol
pma
human
erythrocyt
opson
antibodi
serum
establish
vitro
final
five
ivig
fraction
differ
level
sialyl
includ
untreat
ivig
ft
naas
ivig
separ
ad
macrophag
subsequ
incub
erythrocyt
rate
phagocytosi
measur
use
flow
cytometri
assay
result
ivig
prepar
could
abl
effect
inhibit
phagocytosi
macrophag
increas
ivig
concentr
stronger
inhibit
macrophag
phagocytosi
lower
phagocytosi
rate
howev
five
differ
sialyl
ivig
fraction
concentr
separ
ad
human
system
differ
among
rate
differ
sialyl
level
phagocytosi
summaryconclus
data
indic
five
differ
level
sialyl
ivig
prepar
show
capac
inhibit
macrophag
phagocytosi
togeth
inhibit
phagocytosi
human
macrophag
ivig
independ
igg
sialyl
n
k
medicin
govern
medic
colleg
alappuzha
alappuzha
medicin
mookambika
institut
medic
scienc
kanyakumari
india
background
use
ffp
significantli
increas
past
year
common
inappropri
use
product
despit
exist
guidelin
appropri
use
ffp
requir
understand
properti
inadequaci
well
appreci
complic
studi
tri
analyz
effect
transfus
audit
educ
intervent
reduc
inappropri
ffp
transfus
modifi
ffp
transfus
practic
govern
medic
colleg
trivandrum
kerala
india
aim
know
current
indic
usag
pattern
appropri
ffp
transfus
variou
depart
administ
educ
intervent
form
workshop
distribut
guidelin
find
differ
awar
practic
ffp
transfus
intervent
method
prospect
intervent
studi
done
medic
profession
request
ffp
variou
reason
period
one
year
first
phase
baselin
phase
prospect
monitor
request
form
ffp
done
identifi
indic
ffp
transfus
assess
appropri
usag
pattern
variou
specialti
second
phase
educ
intervent
phase
variou
educ
strategi
adopt
increas
awar
among
clinician
next
last
phase
post
educ
phase
prospect
monitor
request
form
done
assess
effect
educ
intervent
given
previou
phase
result
initi
audit
patient
studi
receiv
total
request
inappropri
appropri
maximum
number
inappropri
request
depart
gener
surgeri
follow
surgic
special
obstetr
gynaecolog
lead
caus
inappropri
use
studi
found
hypoproteinem
state
account
educ
intervent
period
month
conduct
assess
effect
identifi
ffp
request
patient
six
month
found
definit
reduct
inappropri
ffp
request
depart
wise
comparison
done
reduct
seen
specialti
statist
signific
gener
surgeri
p
summaryconclus
educ
appropri
blood
blood
product
util
concurr
qualiti
assur
audit
techniqu
safe
reduc
blood
blood
product
usag
oper
room
well
entir
hospit
thu
provid
maximum
benefit
patient
minim
risk
sustain
improv
practic
ffp
transfus
prospect
monitor
request
form
educ
intervent
must
never
end
process
resid
chang
everi
year
institut
blood
servic
toronto
toronto
canada
background
intraven
immunoglobulin
ivig
use
treat
number
autoimmuneinflammatori
diseas
side
effect
howev
high
dose
ivig
gkg
recogn
caus
hemolyt
anemia
blood
group
patient
approxim
ivig
recipi
document
suffer
hemolyt
anemia
grade
variou
report
group
higher
risk
hemolysi
heterozyg
bo
hemolysi
observ
due
isoagglutinin
contain
ivig
prepar
isoagglutinin
react
patient
red
blood
cell
rbc
result
hemolyt
anemia
destruct
patient
rbc
via
mononuclear
phagocyt
system
phagocytosi
recent
one
manufactur
produc
ivig
wherebi
titer
greatli
reduc
immunoaffin
chromatograph
approach
aim
aim
investig
whether
ivig
deplet
isoagglutinin
use
opson
group
b
rbc
induc
significantli
lower
phagocytosi
compar
ivig
whether
use
vitro
mma
equival
vivo
dosag
gkg
would
result
potenti
clinic
signific
hemolysi
method
b
rbc
opson
ivig
use
total
igg
level
indirect
antiglobulin
test
iat
perform
evalu
reactiv
isoagglutinin
two
ivig
prepar
use
titrat
monocyt
monolay
assay
mma
perform
examin
erythrophagocytosi
b
rbc
result
ivig
significantli
lower
titer
compar
ivig
iat
maxim
mgml
input
ivig
isoagglutinin
titrat
low
iat
mgml
contrast
ivig
opson
b
rbc
show
signific
reduct
iat
titrat
iat
mgml
neg
iat
mgml
use
mgml
ivig
give
approxim
ivig
would
administ
patient
kg
equival
gkg
phagocytosi
ivig
opson
b
rbc
determin
clinic
signific
use
mma
phagocyt
index
pi
respect
howev
phagocytosi
larg
absent
ivig
use
concentr
opson
b
rbc
pi
respect
pi
consid
potenti
clinic
signific
summaryconclus
shown
titer
significantli
lower
ivig
phagocytosi
observ
use
mma
ivig
equival
vivo
dose
gkg
opson
rbc
predict
event
infus
patient
group
b
contrast
ivig
use
lower
dose
total
igg
predict
caus
hemolyt
event
conclud
ivig
would
provid
fewer
hemolyt
event
patient
requir
ivig
therapi
g
v
bank
tasmc
tel
aviv
israel
background
cryoprecipit
concentr
mainli
use
replac
fibrinogen
hypofibrinogen
patient
also
import
part
therapi
massiv
transfus
protocol
besid
fibrinogen
contain
factor
f
viii
fxiii
von
willebrand
factor
vwf
small
amount
plasma
protein
american
european
guidelin
recommend
thaw
cryoprecipit
must
held
room
temperatur
use
within
h
storag
cryoprecipit
longer
period
reduc
wastag
increas
avail
product
aim
investig
stabil
coagul
factor
cryoprecipit
thaw
held
h
refrozen
thaw
method
individu
unit
cryoprecipit
n
thaw
min
pass
infus
set
sampl
time
sampl
held
either
room
temperatur
rt
sampl
test
fviii
fxiii
vwf
fibrinogen
activ
rt
h
first
thaw
h
kept
rt
thaw
twice
defrost
sampl
result
median
volum
individu
cryoprecipit
unit
test
thaw
ml
clot
factor
content
fviii
iu
fxiii
iu
vwf
ag
iu
fibrinogen
mg
content
fviii
drop
minimum
amount
iu
kept
h
thaw
twice
defrost
sampl
amount
vwf
decreas
lowest
point
iu
kept
h
fibrinogen
amount
even
higher
time
point
measur
highest
content
mg
defrost
sampl
chang
statist
signific
time
storag
condit
compar
baselin
howev
signific
decreas
p
fxiii
drop
iu
unit
kept
h
never
decreas
guidelin
specif
uunit
summaryconclus
stabil
fibrinogen
factor
thaw
cryoprecipit
store
h
refrozen
thaw
suggest
shelf
life
product
may
safe
extend
steril
maintain
c
p
r
j
pediatr
chu
intern
medicin
chum
montreal
medicin
surgeri
epidemiolog
commun
medicin
univers
ottawa
ottawa
intern
medicin
univers
manitoba
winnipeg
anesthesiolog
quebec
canada
background
use
intraven
immunoglobulin
ivig
clinic
medicin
increas
consider
past
year
current
use
threaten
capac
blood
product
supplier
fill
demand
importantli
use
ivig
adult
admit
intens
care
unit
icu
well
known
aim
describ
particip
age
blood
evalu
abl
studi
n
engl
j
med
receiv
ivig
icu
determin
advers
event
common
patient
compar
patient
receiv
ivig
icu
method
review
data
patient
enrol
abl
studi
receiv
least
one
dose
ivig
icu
abl
studi
larg
intern
random
control
trial
compar
outcom
adult
receiv
red
blood
cell
rbc
unit
store
day
versu
rbc
unit
deliv
accord
standard
polici
deliv
oldest
avail
unit
polici
use
ivig
well
clinic
data
prospect
collect
result
march
may
patient
enrol
abl
studi
ivig
administ
patient
mean
age
patient
receiv
ivig
year
male
medic
surgic
admiss
common
ivig
group
compar
control
vs
common
caus
icu
admiss
ivig
group
bacterialvir
pneumonia
vs
sepsi
vs
neuromuscular
diseas
vs
neurolog
diseas
vs
sever
ill
measur
apach
ii
score
differ
patient
receiv
ivig
respect
signific
patient
receiv
ivig
less
previou
myocardi
infarct
vs
receiv
therapi
vs
ivig
patient
receiv
plasma
andor
platelet
control
respect
outcom
patient
receiv
ivig
acut
lung
injuri
vs
cardiovascular
failur
vs
cardiac
ischemia
infarct
vs
treatment
vasopressor
vs
continu
renal
replac
therapi
vs
also
frequent
ivig
recipi
patient
ivig
group
also
greater
posit
fluid
balanc
almost
liter
icu
compar
control
vs
ml
differ
mortal
point
two
group
summaryconclus
ivig
given
abl
particip
ivig
therapi
potenti
associ
signific
morbid
fluid
overload
heart
failur
acut
lung
injuri
acut
renal
failur
attent
paid
costbenefit
ratio
ivig
therapi
critic
ill
adult
n
shurko
danysh
v
novak
state
institut
institut
blood
patholog
transfus
medicin
nam
ukrain
lviv
ukrain
background
import
altern
natur
ligand
specif
affin
chromatographi
textil
dye
offer
clear
advantag
biolog
ligand
term
economi
inexpens
eas
immobil
safeti
stabil
adsorb
capac
dye
synthet
hydrophil
molecul
bear
reactiv
usual
chlorotriazin
moieti
easili
attach
variou
polymer
support
biomimet
monocholoro
dicholoro
triazinyl
dye
abl
bind
type
protein
especi
enzym
industri
chromatograph
fraction
use
increasingli
last
year
plasma
fraction
led
emerg
new
gener
product
deriv
blood
especi
factor
coagul
commerci
concentr
factor
viii
fviii
use
treatment
haemophilia
main
method
obtain
plasma
concentr
fviii
remain
method
chromatographi
develop
method
obtain
fviii
use
affin
chromatographi
aim
investig
advantag
affin
chromatographi
technolog
fviii
purif
method
precipit
protein
affin
chromatographi
matrix
procion
blue
mxr
ligand
result
cryoprecipit
initi
raw
materi
work
work
activ
iumg
protein
resuspend
purifi
al
oh
mixtur
process
chromatographi
work
buffer
mm
mm
mm
nacl
mm
sodium
citrat
ph
collect
eluat
fviii
buffer
elut
use
buffer
increas
ionic
strength
mm
nacl
spent
next
phase
affin
chromatographi
dye
affin
chromatographi
protein
purif
procedur
base
high
affin
immobil
dye
bind
site
mani
protein
three
type
dye
affin
chromatographi
neg
posit
tandem
chromatographi
principl
neg
chromatographi
undesir
protein
retain
immobil
dye
desir
protein
flow
column
studi
found
purif
fviii
occur
principl
neg
sorption
protein
albumin
thrombin
fibrinogen
fvii
fix
et
al
purif
fviii
due
phenomenon
neg
sorption
practic
loss
activ
initi
activ
factor
yield
concentr
fviii
specif
activ
iumg
protein
receiv
research
factor
willabrand
vwf
nt
absorb
sorbent
stage
affin
chromatographi
chang
ratio
almost
ratio
fviiivwf
complex
eluat
blue
mxr
summaryconclus
establish
stage
chromatographi
loss
initi
activ
fviii
practic
absent
origin
ratio
fviiivwf
save
lope
l
vieira
alonso
j
marqu
ferreira
figueiredo
immunohemotherapi
centro
hospitalar
de
vila
nova
de
gaiaespinho
vila
nova
de
gaia
portug
background
demand
plasma
transfus
still
signific
countri
although
substanti
progress
blood
safeti
hypothet
risk
infect
still
exist
order
guarante
secur
plasma
direct
therapeut
use
besid
standard
screen
test
essenti
three
method
quarantin
pathogen
reduc
technolog
treatment
quarantin
plasma
substanti
less
expens
process
may
decis
countri
institut
anoth
advantag
come
greater
preserv
therapeut
content
plasma
assess
measur
viii
factor
method
unit
releas
donor
return
blood
center
test
repeatedli
neg
virus
assur
secur
plasma
portug
blood
bank
transfus
medicin
servic
two
use
quarantin
plasma
servic
one
aim
determin
efficaci
method
separ
storag
quarantin
plasma
hospit
compar
european
guidelin
qualiti
assur
method
base
intern
qualiti
control
sinc
construct
retrospect
data
base
regard
quarantin
plasma
use
therapeut
purpos
hospit
sampl
regist
storag
time
determin
level
viii
factor
qualiti
product
control
valid
intern
procedur
extern
entiti
data
analyz
use
statist
result
total
sampl
observ
variat
storag
time
day
sd
rang
level
viii
factor
ml
sd
detect
sampl
viii
factor
level
ml
n
poor
posit
correl
storag
time
level
viii
factor
rs
p
demonstr
associ
two
variabl
mainten
adequ
temperatur
along
process
verifi
guarante
control
method
compar
sampl
highest
viii
factor
level
sampl
accept
level
statist
signific
differ
found
time
elaps
collect
process
z
r
p
till
steadi
progress
decreas
number
sampl
ml
summaryconclus
level
therapeut
content
quarantin
plasma
separ
store
hospit
satisfactori
demonstr
effect
effici
method
must
also
emphas
proport
unit
viii
factor
accept
consist
reduc
support
improv
method
mainten
adequ
temperatur
time
elaps
collect
process
storag
time
factor
control
operatortechniqu
demonstr
relat
inadequ
viii
factor
level
z
pathologyblood
transfus
servic
div
headquart
teach
hospit
pathologytransfus
servic
div
headquart
teach
hospit
pathologytransfus
servic
div
headquart
teach
hospit
mirpur
ajk
pakistan
background
sever
shortag
blood
blood
compon
develop
countri
includ
pakistan
resourc
inadequ
term
meet
ever
grow
demand
blood
compon
blood
compon
carri
potenti
risk
advers
reaction
use
inappropri
fresh
frozen
plasma
ffp
major
sourc
coagul
factor
replac
therapi
patient
clot
factor
defici
although
ffp
readili
avail
use
clinic
practic
yet
administr
nt
without
risk
studi
use
ffp
reveal
often
overus
inappropri
use
recent
ffp
usag
neglig
howev
consist
nation
trend
ffp
usag
grow
hospit
last
year
henc
inappropri
usag
also
current
studi
plan
audit
ffp
transfus
practic
base
coagul
test
ffp
transfus
coagulopathi
aim
evalu
usag
fresh
frozen
plasma
ffp
accord
indic
assess
audit
transfus
method
studi
conduct
division
headquart
teach
hospit
mirpur
ajk
pakistan
ethic
approv
obtain
hospit
ethic
committe
patient
age
year
transfus
ffp
june
decemb
review
indic
appropri
use
patient
transfus
ffp
massiv
transfus
protocol
plasma
exchang
exclud
studi
patient
basic
demograph
data
blood
cp
coagul
paramet
pt
inr
aptt
transfus
transfus
indic
review
retrospect
patient
incomplet
data
exclud
appropri
ffp
transfus
analys
basi
guidelin
administr
blood
compon
british
committe
standard
haematolog
spss
spss
inc
chicago
il
employ
statist
analys
result
evalu
unit
ffp
transfus
patient
common
indic
ffp
usag
acut
dic
high
inr
patient
unit
follow
excess
bleed
high
inr
patient
unit
volum
deplet
patient
unit
ffp
transfus
inadequ
dosag
reason
per
guidelin
record
inappropri
inappropri
ffp
usag
seen
patient
transfus
inappropri
use
high
patient
transfus
aim
bleed
prophylaxi
reaction
also
record
allerg
reaction
report
five
patient
volum
overload
three
patient
seven
patient
valu
inr
could
establish
valu
high
measur
summaryconclus
ffp
scarc
resourc
henc
recommend
adopt
preferenti
use
ffp
patient
fulfil
guidelin
high
inr
audit
line
larger
sampl
size
requir
order
improv
util
resourc
j
n
e
center
transfus
medicin
clinic
hospit
shtip
institut
transfus
medicin
clinic
center
mother
teresa
skopj
shtip
skopj
itm
skopj
skopj
center
transfus
medicin
clinic
hospit
shtip
institut
transfus
medicin
clinic
center
mother
teresa
skopj
strumica
former
yugoslav
republ
macedonia
background
contrast
plasma
deriv
cryoprecipit
cryo
highli
concentr
coagul
factor
factor
viii
factor
xiii
von
willebrand
factor
fibrinogen
fibronectin
although
origin
develop
antihaemophil
treatment
strategi
today
cryo
present
crucial
chain
treatment
process
coagulopathi
patient
liver
failur
polytrauma
well
obstetr
cardiovascular
surgeri
nt
use
cryo
treat
patient
hemophil
diseas
last
year
sinc
product
fresh
frozen
plasma
ffp
cryo
daili
routin
region
center
rc
shtip
aim
show
number
produc
cryo
unit
potenti
factor
influenc
product
process
past
year
method
whole
blood
unit
collect
voluntari
blood
donor
terumo
tripl
bag
cryo
prepar
accord
standard
oper
protocol
review
data
record
order
extract
number
cryo
unit
produc
rc
well
addit
deliveri
divers
hospit
departmentscent
result
total
produc
cryo
bag
provid
depart
intern
medicin
dim
sent
depart
surgeri
ds
sent
institut
transfus
medicin
itm
skopj
moreov
product
increas
cryo
bag
sent
ds
suppli
dim
howev
half
produc
cryo
provid
central
itm
data
shown
year
period
depart
gynecolog
dg
alway
receiv
minimum
number
produc
cryo
ie
summaryconclus
product
cryo
rc
undoubtedli
increas
past
year
sinc
transfus
depart
integr
rc
main
institut
transfus
medicin
addit
new
machin
implement
consequ
number
cryo
suppl
itm
increas
hand
percentag
cryo
suppl
clinic
depart
region
clinic
hospit
shtip
decreas
past
year
due
fall
number
treat
patient
difficult
complex
diseas
region
hospit
concern
underli
risk
transmiss
blood
born
pathogen
transfus
relat
acut
lung
injuri
trali
cryo
withdrawn
usag
mani
european
countri
replac
altern
fibrinogen
prepar
howev
countri
cryo
routin
use
treatment
acquir
coagulopathi
mostli
due
liver
failur
emerg
advers
event
due
cryo
transfus
analyz
studi
research
need
order
determin
clinic
efficaci
cryo
transfus
countri
j
kim
j
lee
j
jeong
k
jung
blood
product
divis
nation
institut
food
drug
safeti
evalu
ministri
food
drug
safeti
korea
background
blood
product
human
plasma
protein
fraction
therapeut
biolog
drug
prepar
larg
pool
human
plasma
obtain
human
whole
blood
exampl
human
serum
albumin
immunoglobulin
coagul
factor
fibrinogen
prepar
sinc
drug
administ
intraven
confirm
pyrogen
substanc
caus
fever
administ
human
current
nation
lot
releas
finish
blood
product
absenc
pyrogen
confirm
rabbit
pyrogen
test
ensur
safeti
blood
deriv
product
howev
cost
mani
live
rabbit
line
intern
effort
minim
anim
use
life
scienc
also
repres
also
need
replac
due
imposs
quantif
pyrogen
also
sensit
condit
anim
techniqu
examin
aim
aim
studi
develop
altern
vitro
pyrogen
test
nation
lot
releas
final
blood
deriv
product
use
monocyt
activ
test
also
avoid
unnecessari
anim
sacrific
secur
reliabl
scientif
advanc
pyrogen
detect
blood
product
therebi
contribut
improv
qualiti
control
public
health
method
research
studi
monocyt
activ
test
altern
method
rabbit
pyrogen
test
use
cryopreserv
rabbit
peripher
blood
mononuclear
cell
sourc
monocyt
employ
immunosorb
assay
elisa
measur
releas
fever
induc
cytokin
conduct
rabbit
pyrogen
test
monocyt
activ
test
endotoxin
pyrogen
gram
posit
bacteria
fungi
result
result
establish
assay
protocol
vitro
altern
pyrogen
test
use
monocyt
compar
result
rabbit
pyrogen
test
monocyt
activ
test
pyrogen
investig
possibl
replac
correl
analysi
two
method
temperatur
rise
rabbit
increas
proport
pyrogen
rabbit
pyrogen
test
releas
fever
induc
cytokin
proport
increas
accord
increas
concentr
pyrogen
monocyt
activ
test
secret
pyrogen
cytokin
monocyt
activ
test
temperatur
rise
rabbit
pyrogen
test
show
similar
tendenc
summaryconclus
studi
altern
pyrogen
test
especi
monocyt
activ
test
nation
lot
releas
finish
blood
product
reduc
significantli
use
anim
also
predict
substitut
rabbit
pyrogen
test
result
research
use
baselin
data
introduct
vitro
pyrogen
test
mainli
inspect
safeti
blood
product
also
contribut
improv
qualiti
control
blood
product
studi
conduct
confirm
altern
method
appli
final
blood
product
also
use
offici
qualiti
control
test
r
asso
rungi
ivri
franc
background
french
nation
blood
agenc
ef
deliv
platelet
parisian
region
addit
solut
intercept
platelet
amotosalen
uva
ceru
netherland
implement
nationwid
sinc
novemb
decreas
risk
contamin
bacteria
emerg
pathogen
chick
dengu
wnv
etc
aim
describ
region
experi
implement
platelet
treatment
amotosalen
intercept
blood
system
organ
oper
aspect
complianc
product
standard
report
also
discuss
feedback
method
pool
platelet
concentr
ppc
obtain
buffi
coat
method
tacsi
devic
terumo
bct
usa
apheresi
platelet
apc
collect
mc
haemonet
usa
trima
separ
terumo
bct
usa
platelet
label
individu
treat
intercept
devic
entir
product
transfer
illumin
bag
amotosalen
solut
ad
product
expos
uva
min
storag
h
agit
compound
adsorpt
devic
integr
storag
contain
product
transfer
storag
bag
qualiti
control
test
perform
product
label
sent
distribut
site
result
implement
period
adjust
made
ensur
product
compli
requir
intercept
ifu
modifi
logist
organ
made
number
modif
blood
product
site
ceru
deploy
team
provid
three
day
train
per
product
site
ib
treatment
reach
unitsdaysit
illumin
technician
treatment
satisfi
requir
loss
due
process
trial
period
n
apc
n
ppc
expect
platelet
content
decreas
two
month
implement
ppc
n
apc
n
adjust
logist
organ
meet
new
releas
time
requir
anticip
routin
complic
use
kit
pediatr
prepar
inabl
separ
platelet
immedi
two
unit
howev
number
unexpect
advers
effect
also
observ
larg
volum
wast
packag
etc
time
lost
rehabilit
save
final
product
compliant
ifu
loss
swirl
score
apc
case
first
seven
day
limit
volum
ml
mc
swirl
score
loss
correl
platelet
concentr
limit
collect
target
platelet
trima
overcom
problemsproduct
loss
due
final
bag
breach
loss
seem
link
mode
storag
cart
use
platelet
agit
summaryconclus
ib
treatment
platelet
major
impact
entir
blood
transfus
chain
implement
consid
success
techniqu
satisfi
french
qualiti
requir
given
signific
differ
platelet
content
cost
associ
techniqu
devic
technician
compliant
product
etc
use
ib
platelet
major
econom
impact
use
dual
storag
ds
devic
combin
revis
ifu
reduc
cost
per
unit
obtain
pool
method
buffi
coat
combin
ds
devic
might
also
increas
h
b
c
control
ef
grand
est
strasbourg
franc
background
sinc
ef
grand
est
produc
deliv
pathogen
reduc
platelet
concentr
pc
use
photochem
treatment
pct
combin
amotosalen
ultraviolet
light
uva
blood
system
ceru
residu
amotosalen
adsorb
compound
adsorpt
devic
cad
incub
time
h
h
small
volum
set
sv
h
h
larg
volum
set
lv
requir
residu
amotosalen
less
limit
specifi
french
regulatori
author
aim
evalu
qualiti
pathogen
process
incub
time
cad
cad
time
h
h
comparison
cad
time
h
method
two
buffi
coat
platelet
concentr
bcpc
donor
pool
split
obtain
two
ident
bcpc
treat
pr
h
cad
time
control
n
treat
pr
h
h
cad
time
n
n
biolog
paramet
swirl
platelet
content
residu
leukocyt
ph
lactat
glucos
ldh
solubl
residu
amotosalen
concentr
assess
end
cad
time
day
day
kunicki
score
requir
electron
microscopi
measur
bcpc
control
n
result
mean
platelet
content
control
respect
unit
present
maximum
swirl
compliant
ph
residu
amotosalen
concentr
unit
day
mean
glucos
concentr
mm
control
mm
mm
mean
solubl
concentr
ngml
control
ngml
ngml
cad
kunicki
score
differ
control
group
group
illumin
control
day
control
cad
day
summaryconclus
qualiti
control
treat
amotosalen
uva
show
differ
cad
time
h
h
compar
cad
time
h
result
may
help
make
decis
cad
time
would
exceed
specifi
maximum
h
cad
time
h
f
b
patholog
laboratori
medicin
surgeri
king
faisal
specialist
hospit
research
center
riyad
saudi
arabia
support
terumo
bct
lakewood
unit
state
america
affair
terumo
bct
zaventem
belgium
background
blood
bank
transfus
servic
king
faisal
specialist
hospit
research
center
kfshrc
process
whole
blood
unit
apheresi
collect
decid
improv
effici
blood
process
introduc
reveo
autom
whole
blood
process
system
terumo
bct
maintain
high
level
safeti
treat
platelet
concentr
pc
mirasol
prt
system
terumo
bct
increas
number
blood
product
process
newli
ad
stem
cell
organ
transplant
site
aim
report
experi
kfshrc
introduct
whole
blood
autom
reveo
mirasol
prt
blood
bank
routin
method
whole
blood
unit
ml
collect
process
daili
technician
distribut
two
work
shift
blood
process
reveo
compon
red
blood
cell
concentr
rbcc
plasma
unit
one
interim
platelet
unit
ipu
help
select
ipu
select
pool
gener
pc
averag
platelet
yield
select
tool
softwar
applic
sort
group
ipu
base
estim
platelet
yield
reveo
system
addit
whole
blood
deriv
platelet
kfshrc
also
collect
platelet
apheresi
trima
accel
devic
terumo
bct
apheresi
allow
collect
singl
doubl
platelet
concentr
characterist
whole
pc
plasma
tpa
coincid
mirasol
product
incom
specif
prt
treatment
perform
per
manufactur
instruct
take
min
warrant
releas
fresh
pc
result
sinc
start
implement
autom
whole
blood
process
whole
blood
unit
process
three
compon
total
pc
deriv
apheresi
whole
blood
treat
mirasol
prt
process
whole
blood
reveo
system
result
rbcc
averag
hematocrit
final
pc
averag
platelet
yield
pltsunit
unit
plasma
averag
volum
ml
residu
wbc
valu
rbcc
pc
far
percent
apheresi
donor
repeat
donor
select
year
donat
platform
averag
split
rate
total
apheresi
platelet
collect
base
yield
count
target
summaryconclus
introduct
two
new
technolog
reveo
autom
whole
blood
process
system
mirasol
prt
system
perform
simultan
kfshrc
train
implement
seamless
due
eas
use
compat
moreov
kfshrc
blood
transfus
servic
abl
improv
product
effici
compon
safeti
without
addit
resourc
increas
product
releas
time
allow
escal
collect
jahanshahi
transfus
research
center
high
institut
research
educ
transfus
medicin
scienc
research
branch
islam
azad
univers
tehran
islam
republ
iran
background
antioxid
capac
decreas
rbc
storag
side
effect
blood
transfus
challeng
result
rbc
storag
lesion
due
oxid
stress
given
previou
studi
shown
antioxid
capac
diurnal
variat
blood
plasma
decreas
trend
age
elderli
possibl
donat
blood
base
donor
age
donat
time
differ
antioxid
capac
follow
differ
respons
storag
aim
studi
attempt
uncov
effect
blood
donor
age
blood
donat
time
biochem
hematolog
paramet
storag
rbc
lesion
method
twenti
pack
rbc
taken
volunt
male
donor
analyz
accord
variabl
donat
time
morn
n
even
pm
n
ii
donor
age
n
n
n
rbc
bag
studi
storag
rbc
blood
bank
regul
iranian
blood
transfus
organ
day
biochem
paramet
includ
sodium
potassium
glucos
lactat
concentr
lactat
dehydrogenas
ldh
enzym
activ
ph
oxid
stress
biomark
malondialdehyd
mda
concentr
total
antioxid
capac
tac
perform
use
commerci
avail
kit
nitratenitrit
metabolit
rbc
hemolysi
index
measur
drabkin
griess
method
respect
hematolog
paramet
measur
autom
cell
counter
result
group
shown
expect
decreas
trend
tac
glucos
sodium
ph
increas
trend
potassium
releas
lactat
ldh
mda
hemolysi
index
storag
manner
p
even
group
compar
morn
nitratenitrit
mda
ldh
hematolog
paramet
mcv
hb
hct
increas
significantli
p
age
group
nitratenitrit
mda
hematolog
paramet
mcv
mch
exhibit
significantli
increas
comparison
group
blood
donor
p
summaryconclus
studi
indic
donat
blood
even
donat
elderli
donor
potenti
peroxid
nitric
oxid
deplet
due
oxid
metabolit
storag
result
donor
age
effect
consist
effect
present
tzounaka
proteom
clin
appl
may
lead
product
highli
unequ
blood
labil
product
similar
storag
strategi
howev
genet
undiagnosedsubclin
medic
condit
lifestyl
factor
affect
rbc
characterist
baselin
ignor
addit
seem
donat
time
effect
rbc
lifespan
energi
metabol
sensit
oxid
stress
although
confirm
import
find
result
two
main
paramet
tac
hemolysi
index
disappoint
believ
small
sampl
size
possibl
reason
produc
meaning
result
regard
use
protocol
storag
donat
rbc
day
deeper
insight
sampl
size
need
donat
time
appar
complex
donor
age
effect
rbc
storag
lesion
b
k
olbromski
blood
center
poznan
poznan
poland
background
cryoprecipit
fraction
cryoglobulin
deriv
singl
unit
fresh
frozen
plasma
ffp
concentr
volum
ml
contain
major
amount
factor
viii
von
willebrand
factor
fibrinogen
factor
xiii
fibronectin
perfect
sourc
factor
case
insuffici
order
increas
safeti
recipi
cryoprecipit
produc
ffp
quarantin
inactiv
pathogen
quarantin
mean
store
plasma
least
week
subsequ
test
presenc
marker
infecti
diseas
obligatori
test
poland
involv
hbsag
dna
hbv
rna
hcv
rna
hiv
marker
treponema
pallidum
infect
poland
commonli
use
method
inactiv
pathogen
methylen
blue
theraflex
bm
plasma
system
riboflavin
mirasol
system
aim
aim
evalu
compar
content
fibrinogen
activ
factor
viii
cryoprecipit
obtain
quarantin
ffp
inactiv
ffp
method
analysi
unit
cryoprecipit
obtain
recov
plasma
use
unit
plasma
quarantin
week
unit
plasma
inactiv
pathogen
use
theraflex
bm
plasma
product
cryoprecipit
method
centrifug
use
test
concentr
fibrinogen
activ
factor
viii
perform
sampl
collect
directli
product
use
sysmex
analys
clot
method
factor
viii
caluss
method
fibrinogen
poland
qualiti
requir
cryoprecipit
follow
content
fibrinogen
mgunit
activ
factor
viii
iuquarantin
unit
iuinactiv
unit
result
cryoprecipit
obtain
quarantin
plasma
activ
factor
viii
iuunit
content
fibrinogen
mgunit
cryoprecipit
obtain
inactiv
plasma
activ
factor
viii
iuunit
content
fibrinogen
mgunit
analysi
unit
cryoprecipit
obtain
recov
plasma
use
unit
plasma
quarantin
week
product
unit
plasma
inactiv
pathogen
use
theraflex
bm
plasma
product
cryoprecipit
method
centrifug
use
test
concentr
fibrinogen
activ
factor
viii
perform
sampl
collect
directli
product
use
sysmex
analys
clot
method
factor
viii
caluss
method
fibrinogen
poland
qualiti
requir
cryoprecipit
follow
content
fibrinogen
mgunit
activ
factor
viii
iuquarantin
unit
iuinactiv
unit
summaryconclus
analysi
prove
high
content
factor
viii
fibrinogen
cryoprecipit
obtain
quarantin
plasma
well
cryoprecipit
obtain
inactiv
plasma
comparison
content
clot
factor
cryoprecipit
obtain
quarantin
inactiv
plasma
show
process
reduct
biolog
pathogen
plasma
product
cryoprecipit
caus
substanti
decreas
activ
factor
viii
fibrinogen
conclud
wide
spectrum
activ
inactiv
method
variou
pathogen
cryoprecipit
obtain
inactiv
plasma
safer
recipi
henc
common
use
haemotherapi
abstract
withdrawn
p
n
transfus
medicin
nation
medic
research
center
pediatr
hematolog
oncolog
immunolog
moscow
russia
affair
terumo
bct
zaventem
belgium
background
accumul
data
describ
effect
pathogen
wbc
inactiv
safe
toxicolog
profil
whole
blood
wb
treat
riboflavin
ultraviolet
rfuv
pathogen
reduct
technolog
trial
anim
healthi
volunt
demonstr
neoantigen
format
seriou
safeti
problem
blood
product
conduct
open
parallel
nonrandom
vitro
studi
rbc
concentr
rbcc
obtain
leukoreduc
wb
compar
standard
irradi
leukoreduc
rbcc
aim
compar
qualiti
rbcc
prepar
wb
prt
rbcc
irradi
irradi
determin
rbcc
prepar
wb
method
unit
wb
ml
obtain
healthi
donor
n
day
donat
wb
unit
leukoreduc
terumo
bct
treat
rfuv
mirasol
terumo
bct
follow
manufactur
instruct
separ
prt
rbcc
irradi
control
rbcc
n
origin
leukoreduc
wb
irradi
dose
gy
day
rbcc
store
c
sagm
solut
week
follow
paramet
studi
hematocrit
ph
total
free
hemoglobin
extracellular
potassium
glucos
lactat
atp
reduc
glutathion
gsh
phosphatidylserin
express
rbc
membran
hemolysi
osmot
resist
cell
measur
carri
wb
prior
prt
irradi
treatment
day
well
prt
irradi
rbcc
day
day
storag
steril
store
rbcc
test
result
statist
signific
differ
group
storag
time
ph
concentr
total
hemoglobin
extracellular
potassium
phosphatidylserin
express
atp
gsh
concentr
glucos
lactat
significantli
lower
prt
group
irradi
group
time
storag
except
day
case
lactat
p
osmot
resist
prt
group
statist
significantli
lower
day
storag
p
day
storag
higher
free
hemoglobin
concentr
hemolysi
detect
prt
group
rel
irradi
group
sampl
either
group
hemolysi
valu
greater
day
storag
sampl
prt
group
exceed
hemolysi
sampl
irradi
group
hemolysi
valu
less
storag
sampl
group
neg
bacteri
cultur
day
summaryconclus
laboratori
paramet
rbcc
prepar
wb
treat
rfuv
similar
rbcc
irradi
meet
qualiti
criteria
day
storag
prt
group
exhibit
higher
hemolysi
seen
lower
osmot
resist
hemolysi
level
due
fact
clinic
use
compon
day
storag
sagm
recommend
may
prolong
newer
gener
addit
solut
l
affair
manag
red
cross
blood
bank
foundat
willemstad
affair
terumo
bct
zaventem
belgium
background
red
cross
blood
bank
foundat
rcbf
serv
popul
includ
inhabit
dutch
caribbean
island
c
aruba
bonair
b
sint
maarten
maintain
safe
sustain
complet
blood
suppli
challeng
due
geograph
epidemiolog
situat
nearli
whole
blood
unit
process
three
compon
per
year
blood
donat
voluntari
basi
donor
donat
averag
time
yearli
case
emerg
threat
intens
collabor
paho
sanquin
aim
describ
system
establish
rcbf
ensur
sustain
safe
stabl
blood
suppli
region
deal
emerg
infecti
threat
natur
catastroph
method
newli
recruit
donor
undergo
first
physic
blood
screen
admit
regular
donor
blood
program
first
whole
blood
donat
collect
month
initi
test
whole
blood
collect
two
collect
site
c
process
compon
follow
gmp
standard
compon
quarantin
result
screen
test
known
donat
screen
hiv
abag
hcv
hbsag
htlv
treponema
gener
elisa
nat
hiv
hcv
hbv
five
percent
compon
undergo
qualiti
control
per
eu
aabb
sanquin
standard
red
blood
cell
store
day
platelet
concentr
pc
result
pool
buffi
coat
bc
singl
donor
plasma
sinc
januari
pc
treat
method
mirasol
prt
system
terumo
bct
per
manufactur
recommend
store
day
requir
standard
pc
test
bacteri
contamin
blood
product
releas
termin
prt
introduct
fresh
frozen
plasma
ffp
store
year
result
past
year
posit
hcv
hbv
htlv
posit
donor
applic
elimin
blood
program
initi
screen
htlv
posit
routin
donat
screen
blood
compon
compliant
intern
standard
implement
prt
technolog
real
impact
logist
rcbf
due
simplic
eas
use
proper
train
transfus
increas
rate
transfus
reaction
case
sever
advers
reaction
recipi
includ
recipi
neonat
intens
care
depart
summaryconclus
rcbf
success
cover
blood
demand
challeng
geograph
area
compos
island
logist
inventori
manag
commun
stakehold
extrem
import
direct
involv
patient
care
differ
clinic
eg
trauma
care
neonatolog
oncolog
hemodialysi
activ
consult
clinician
daili
inventori
check
requir
period
region
hit
outbreak
emerg
pathogen
like
dengu
chikungunya
zika
viru
henc
implement
mirasol
prt
system
proven
feasibl
valuabl
develop
prepared
emerg
infecti
threat
rungi
ivri
sur
sein
franc
background
french
nation
blood
agenc
ef
deliv
platelet
parisian
region
addit
solut
intercept
platelet
amotosalen
uva
ceru
netherland
implement
nationwid
sinc
novemb
decreas
risk
contamin
bacteria
emerg
pathogen
chick
dengu
wnv
etc
sinc
introduct
intercept
observ
increas
rate
prematur
swirl
score
loss
platelet
apheresi
aim
report
region
experi
prematur
loss
swirl
score
follow
implement
platelet
treatment
amotosalen
intercept
blood
system
method
platelet
concentr
collect
apheresi
apc
trima
accel
system
terumo
bct
lakewood
co
usa
mc
haemonet
braintre
usa
platelet
addit
solut
ssp
macopharma
tourco
franc
ad
aim
achiev
fix
plasma
carryov
trima
mc
vv
intercept
introduct
adjust
target
concentr
volum
apc
compli
larg
volum
bag
set
use
ib
collect
target
limit
ml
platelet
platelet
label
treat
intercept
devic
entir
product
transfer
illumin
bag
amotosalen
solut
ad
product
expos
uva
min
store
h
agit
compound
adsorpt
devic
integr
storag
contain
mean
time
h
product
transfer
storag
bag
qualiti
control
test
perform
product
label
sent
distribut
site
result
accord
french
regul
platelet
concentr
routin
undergo
swirl
test
distribut
seven
first
day
introduct
intercept
swirl
score
report
apc
collect
three
four
day
collect
mean
platelet
concentr
significantli
higher
mean
concentr
apc
deliv
mean
ph
significantli
lower
mean
ph
obtain
routin
practic
ph
day
previous
report
loss
swirl
score
correl
platelet
concentr
platelet
content
limit
collect
target
platelet
limit
platelet
concentr
final
bag
immedi
restrict
swirl
loss
apc
collect
end
glucos
glc
concentr
residu
plasma
determin
systemat
perform
n
mean
glc
concentr
mmoll
significantli
lower
normal
observ
day
mmoll
mean
residu
plasma
level
summaryconclus
prematur
loss
swirl
score
continu
occur
januari
appear
sever
caus
platelet
concentr
treatment
storag
time
adsorpt
limit
volum
treatment
adsorpt
bag
liter
plasma
carryov
close
lower
limit
platelet
content
final
bag
ceru
tri
improv
storag
condit
increas
volum
treatment
bag
cad
storag
contain
liter
chang
use
dual
storag
ds
devic
may
decreas
rate
swirl
score
loss
j
b
n
corpor
concord
ca
unit
state
america
corpor
amersfoort
netherland
background
platelet
transfus
import
support
thrombocytopenia
cancer
therapi
organ
transplant
platelet
store
day
limit
risk
bacteri
contamin
substanti
amount
platelet
compon
pc
discard
expir
storag
use
bacteri
contamin
platelet
storag
lesion
two
major
issu
continu
limit
storag
platelet
beyond
day
mani
geographi
storag
pc
allow
prolifer
bacteria
older
pc
associ
increas
incid
septic
transfus
reaction
pathogen
inactiv
treatment
blood
system
ceru
concord
ca
inactiv
pathogen
reduc
risk
bacteri
growth
pc
storag
therefor
facilit
storag
beyond
day
reduc
risk
sepsi
fda
approv
pc
storag
day
time
collect
aim
evalu
vitro
platelet
function
bacteri
contamin
treat
pool
buffi
platelet
store
day
method
eight
studi
conduct
europ
us
evalu
platelet
function
bacteri
contamin
platelet
store
day
studi
span
small
volum
sv
larg
volum
lv
dual
storag
ds
pc
process
set
configur
encompass
buffi
platelet
pc
evalu
two
differ
platelet
addit
solut
ssp
collect
platform
buffi
coat
platelet
terumo
bct
manual
pool
method
freseniu
kabi
terumo
bct
separ
evalu
collect
platform
apheresi
platelet
pc
assess
use
follow
paramet
storag
ph
volum
mean
platelet
volum
mpv
platelet
count
residu
leukocyt
content
supernat
glucos
supernat
lactat
supernat
ldh
express
swirl
score
result
irrespect
sourc
platelet
apheresi
buffi
coat
manufactur
methodolog
evalu
platelet
met
edqm
ph
requir
day
storag
secondli
treat
pc
across
approv
configur
met
edqm
minimum
transfus
dose
requir
plateletsunit
vitro
character
platelet
metabol
physic
properti
activ
qualiti
demonstr
pc
treat
sv
lv
ds
process
set
display
vitro
characterist
consist
accept
vivo
qualiti
hemostat
function
day
storag
bacteri
cultur
perform
whole
blood
deriv
buffi
coat
platelet
n
apheresi
platelet
n
end
day
storag
use
bd
incub
system
pc
analyz
presenc
bacteri
contamin
day
storag
show
neg
result
confirm
steril
sampl
summaryconclus
studi
combin
publish
clinic
trial
bacteri
spike
inactiv
studi
show
intercept
treat
platelet
viabl
provid
safeti
septic
risk
day
storag
g
b
affair
innov
affair
innov
canada
scientif
program
blood
system
inc
san
francisco
unit
state
america
background
pathogen
reduct
technolog
prt
platelet
plasma
previous
evalu
canada
one
method
prt
plasma
approv
regulatori
agenc
canada
yet
implement
process
platelet
review
updat
analysi
requir
decis
make
quebec
canada
aim
evalu
prt
platelet
plasma
quebec
base
recent
data
cost
residu
risk
medic
procedur
method
prt
compar
current
screen
use
markov
model
track
long
term
consequ
follow
advers
event
human
immunodefici
viru
hiv
hepat
b
viru
hepat
c
viru
hcv
human
viru
syphili
west
nile
viru
wnv
bacteria
chikungunya
viru
cytomegaloviru
trypanosoma
cruzi
diseas
febril
nonhemolyt
transfus
reaction
immunomodul
effect
evalu
term
qali
recipi
transfus
initi
model
use
canada
updat
reflect
current
situat
new
submodel
develop
bacteria
hcv
reflect
advanc
medic
treatment
cost
medic
procedur
adjust
inflat
cost
current
screen
prt
assess
residu
risk
transmiss
diseas
estim
lower
updat
cost
lost
product
blood
recipi
includ
percentag
platelet
updat
reflect
data
two
scenario
ad
evalu
potenti
impact
emerg
pathogen
pathogen
residu
risk
emerg
pathogen
calcul
repres
multipl
hypothet
scenario
base
histor
data
absenc
screen
test
cost
medic
procedur
pathogen
base
literatur
review
hiv
adjust
inflat
cost
save
relat
cessat
certain
screen
test
bacteri
cultur
platelet
includ
model
result
platelet
plasma
prt
estim
confid
interv
ci
approxim
compar
current
screen
base
case
model
without
emerg
pathogen
peak
risk
similar
hiv
canada
platelet
plasma
prt
estim
ci
approxim
emerg
pathogen
base
screen
result
quebec
platelet
plasma
prt
estim
ci
approxim
summaryconclus
result
analysi
found
base
case
valu
time
higher
one
report
accord
result
base
model
platelet
plasma
prt
solut
quebec
mainli
lower
residu
risk
transmiss
diseas
high
percentag
platelet
use
howev
event
introduct
emerg
pathogen
ratio
greatli
improv
n
j
h
medicin
chonbuk
nation
univers
medic
school
institut
clinic
medicin
chonbuk
nation
univers
research
institut
chonbuk
nation
univers
hospit
jeonju
korea
background
bacteri
contamin
known
major
infecti
hazard
platelet
transfus
patient
receiv
bacteri
contamin
platelet
risk
depend
bacteri
count
platelet
although
low
number
bacteria
contamin
platelet
product
initi
storag
day
allow
growth
high
bacteri
load
present
time
transfus
mani
approach
reduc
infecti
risk
tri
ever
use
blood
donor
screen
blood
product
test
elimin
product
risk
carri
infecti
microorgan
aim
evalu
abil
effect
antioxid
platelet
addit
solut
inhibit
bacteri
growth
platelet
product
method
nac
vitamin
c
vc
use
antioxid
studi
ten
speci
bacteria
use
contamin
platelet
includ
staphylococcu
aureu
staphylococcu
epidermidi
streptococcu
miti
enterococcu
faecali
enterococcu
faecium
acinetobact
baumannii
escherichia
coli
klebsiella
pneumonia
proteu
mirabili
pseudomona
aeruginosa
antioxid
variabl
concentr
mm
mix
broth
measur
minim
inhibitori
concentr
mic
maxim
bactericid
concentr
mbc
follow
clsi
guidelin
plasma
prp
prepar
small
ml
bag
whole
blood
collect
normal
healthi
donor
prp
spike
cfuml
bacteria
incub
day
small
amount
prp
collect
day
cultur
blood
agar
plate
result
mm
nac
mm
vc
identifi
respect
optim
mic
studi
differ
mic
neg
bacteria
speci
bacteri
grow
increas
significantli
prp
spike
bacteria
without
antioxid
day
growth
bacteria
inhibit
antioxid
prp
depend
platelet
count
effect
concentr
antioxid
differ
summaryconclus
nac
vc
effect
materi
inhibit
bacteri
growth
platelet
product
clinic
use
compon
platelet
addit
solut
necessari
evalu
relat
platelet
function
recoveri
h
e
p
w
p
oldenburg
spring
germani
background
treatment
apheresi
platelet
concentr
pc
uvc
may
enhanc
transfus
safeti
platelet
respect
contamin
pathogen
aim
use
clinic
trial
captur
eudract
singl
donor
apheresi
platelet
concentr
produc
routin
condit
present
qualiti
data
untreat
platelet
unit
method
pc
prepar
singl
donor
standard
oper
procedur
amicu
use
ssp
macopharma
mouvaux
franc
addit
solut
februari
februari
treat
uvc
within
h
prepar
use
theraflex
system
macopharma
minimum
gy
control
pc
left
untreat
sampl
qualiti
control
paramet
done
day
prepar
n
end
shelf
life
n
n
n
follow
paramet
examin
day
pc
volum
platelet
concentr
plasma
content
residu
erythrocyt
leucocyt
count
determin
platelet
concentr
ph
swirl
steril
test
done
end
shelf
life
result
mean
volum
ml
ml
ml
platelet
count
respect
residu
plasma
concentr
rang
residu
erythrocyt
leucocyt
count
met
standard
specif
pc
product
germani
end
shelf
life
ph
valu
compar
test
bacteri
contamin
neg
test
pc
summaryconclus
qualiti
control
data
demonstr
apheresi
pc
meet
standard
specif
pc
product
germani
differ
qualiti
control
observ
safeti
efficaci
pc
evalu
captur
trial
u
f
w
develop
red
cross
blood
servic
nstob
spring
langen
cross
blood
servic
nstob
spring
germani
background
theraflex
system
macopharma
pathogen
inactiv
system
platelet
concentr
pc
use
uvc
light
wavelength
nm
without
need
addit
photoact
compound
inactiv
effici
shown
broad
rang
virus
bacteria
protozoan
previou
studi
first
set
bacteria
speci
intern
repositori
platelet
transfus
relev
bacteri
refer
strain
high
inactiv
capac
clinic
relev
bacteria
shown
aim
aim
current
studi
investig
bacteria
inactiv
efficaci
theraflex
system
number
strain
recent
ad
intern
repositori
method
pc
produc
buffi
coat
use
addit
solut
ssp
macopharma
residu
plasma
content
inactiv
kinet
pc
n
spike
bacteria
enterobact
cloaca
morganella
morganii
proteu
mirabili
pseudomona
fluorescen
serratia
marcescen
staphylococcu
aureu
streptococcu
bovi
final
concentr
coloni
form
unit
cfu
ml
irradi
increas
dose
standard
uvc
dose
achiev
sampl
taken
bacteri
titer
determin
irradi
step
order
show
steril
uvc
treatment
two
pc
pool
inocul
bacteria
final
concentr
approxim
cfuml
bacteria
allow
grow
h
pc
agit
split
one
pc
remain
untreat
growth
control
one
storag
seven
day
sampl
taken
bag
steril
test
bactalert
biomerieux
determin
bacteri
titer
untreat
control
unit
result
inactiv
bacteria
pc
treatment
use
theraflex
system
shown
mean
reduct
factor
rang
seven
differ
investig
bacteria
speci
spike
pc
n
bacteria
speci
effici
steril
uvc
treatment
test
pc
treat
theraflex
system
remain
steril
storag
day
bacteria
grew
high
titer
cfuml
pc
summaryconclus
theraflex
system
effici
inactiv
broad
rang
differ
bacteria
speci
includ
refer
strain
pc
remain
steril
storag
period
day
result
suggest
pathogen
inactiv
technolog
significantli
improv
bacteri
safeti
platelet
transfus
p
van
der
p
n
van
r
van
j
van
der
j
blood
bank
amsterdam
hagu
univers
medic
center
leiden
netherland
background
pathogen
inactiv
pi
platelet
plt
concentr
show
good
efficaci
broad
array
virus
bacteria
parasit
moreov
anim
studi
shown
technolog
reduc
alloimmun
due
hla
alloantibodi
format
aim
bleed
consid
pivot
outcom
plt
transfus
trial
conduct
trial
compar
plt
concentr
use
mirasol
technolog
terumo
bct
lakewood
co
standard
untreat
plt
concentr
percentag
transfus
episod
grade
bleed
complic
world
health
organ
grade
occur
primari
outcom
method
prepar
studi
design
random
multicent
studi
use
parallel
arm
design
patient
age
year
older
elig
expect
requir
least
two
plt
transfus
patient
assign
control
group
receiv
standard
plt
concentr
studi
group
receiv
plt
patient
could
therebi
ad
multipl
transfus
episod
trial
transfus
episod
defin
time
random
time
patient
went
trial
plt
concentr
prepar
pool
buffi
coat
resuspend
plasma
leukoreduc
filtrat
pathogen
reduct
ml
riboflavin
ad
within
h
prepar
platelet
expos
uv
light
plt
product
store
gentl
agit
five
day
canada
maximum
seven
day
netherland
norway
intent
treat
itt
analysi
includ
bleed
episod
moment
random
per
protocol
pp
analysi
includ
bleed
episod
occur
first
platelet
transfus
patient
activ
bleed
day
first
transfus
receiv
transfus
exclud
prepar
trial
power
demonstr
itt
analysi
result
novemb
april
transfus
episod
random
control
group
studi
group
uniqu
patient
exclud
due
activ
bleed
time
random
due
gross
incompli
pp
analysi
episod
exclud
due
activ
bleed
time
first
platelet
transfus
control
studi
patient
receiv
platelet
transfus
transfus
control
studi
render
episod
evalu
itt
patient
control
group
versu
studi
group
grade
bleed
differ
percentag
point
ci
p
valu
pp
patient
control
group
versu
studi
group
bleed
differ
percentag
point
ci
p
valu
signific
differ
observ
percentag
day
grade
bleed
irrespect
type
analysi
summaryconclus
platelet
compar
untreat
platelet
bleed
primari
studi
outcom
criterion
met
itt
analysi
pp
analysi
n
patel
k
tucker
mcnalli
aguilera
p
bringmann
stassinopoulo
ceru
corpor
concord
unit
state
america
background
blood
system
platelet
develop
effici
inactiv
pathogen
leukocyt
platelet
concentr
pc
system
util
amotosalen
uva
light
avail
treatment
apheresi
whole
blood
wb
deriv
platelet
mostli
buffi
coat
pool
europ
treatment
apheresi
platelet
us
plasma
pa
intercept
treatment
platelet
pool
approv
us
major
platelet
manufactur
prp
system
report
inactiv
fast
grow
gram
neg
bacterium
k
pneumonia
commonli
found
contamin
pc
k
pneumonia
inocul
realist
titer
usual
found
healthi
volunt
prp
pool
allow
prolifer
inactiv
treatment
perform
acrodos
platelet
store
day
platelet
shaker
aim
object
studi
evalu
inactiv
k
pneumonia
rrp
platelet
steril
measur
prolong
storag
unit
use
intercept
blood
system
platelet
method
five
six
rdp
unit
pool
averag
platelet
dose
yield
approxim
ml
rdp
plasma
n
k
pneumonia
grown
lb
broth
unit
spike
cfu
coloni
form
unit
inocul
contamin
unit
store
platelet
shaker
incub
h
treat
intercept
sv
kit
sampl
taken
bacteri
inocul
h
storag
pre
leukoreduct
pre
treatment
day
storag
sampl
analyz
plate
lb
plate
ml
result
initi
titer
cfuunit
k
pneumonia
grew
cfuml
h
follow
leukoreduct
prior
intercept
treatment
titer
cfuml
follow
inactiv
treatment
live
bacteria
detect
correspond
inactiv
bacteria
detect
day
storag
correspond
inactiv
per
unit
summaryconclus
amotosalenuva
effect
inactiv
k
pneumonia
platelet
prp
pool
manufactur
acrodos
effect
steril
demonstr
detect
bacteria
day
storag
data
pathogen
reduct
whole
blood
deriv
prp
platelet
intercept
blood
system
storag
day
submit
fda
review
c
l
k
n
corpor
concord
unit
state
univers
hospit
blood
bank
izmir
turkey
compon
product
center
ao
citta
della
salut
e
della
scienza
di
torino
ospedaliera
brotzu
cagliari
itali
background
pathogen
inactiv
pi
process
use
amustalin
gsh
use
ex
vivo
prepar
red
blood
cell
rbc
compon
rbcc
transfus
reduc
risk
infect
tti
phase
clinic
trial
sparc
conduct
itali
turkey
compar
safeti
efficaci
compar
convent
rbc
transfus
support
thalassemia
major
patient
lifelong
transfus
therapi
carri
risk
transfus
transmit
infect
includ
hiv
hepat
emerg
pathogen
zika
west
nile
chikungunya
dengu
virus
pi
process
robustli
inactiv
broad
spectrum
pathogen
leukocyt
valid
pi
process
three
blood
center
support
sparc
studi
complet
prior
initi
product
rbc
studi
unit
aim
character
test
convent
rbc
control
manufactur
three
particip
blood
center
itali
turkey
sparc
studi
method
day
collect
cpd
whole
blood
process
rbcc
use
manual
autom
reveo
system
terumo
bct
methodolog
test
control
rbcc
rbcc
store
prior
pi
treatment
rbcc
ad
process
solut
contain
gsh
follow
final
nomin
concentr
mm
mm
h
hold
rbcc
centrifug
treatment
solut
express
replac
rbcc
store
prior
transfus
day
test
unit
sampl
treatment
qc
rbcc
also
sampl
day
control
rbc
unit
sampl
rbcc
result
rbcc
manufactur
sparc
studi
includ
test
rbcc
store
day
qc
test
rbcc
place
transfus
inventori
control
control
rbcc
place
transfus
inventori
mean
compon
volum
ml
test
ml
control
mean
total
hemoglobin
content
g
g
test
g
g
control
studi
unit
hematocrit
valu
within
test
control
mean
rbc
cell
volum
mcv
fl
test
fl
control
note
rbcc
mcv
fl
would
indic
donor
thalassemia
minor
iron
defici
may
includ
donor
popul
studi
day
storag
mean
hemolysi
test
qc
rbcc
qc
rbcc
exceed
summaryconclus
minim
loss
volum
hemoglobin
test
rbcc
compar
control
rbcc
rang
rbcc
characterist
test
control
show
larg
variabl
product
paramet
volum
hemoglobin
content
mcv
given
gram
hemoglobin
result
transfus
mg
fe
know
hemoglobin
dose
per
rbcc
may
improv
transfus
treatment
patient
manag
thalassemia
major
patient
intercept
blood
system
red
blood
cell
approv
use
abstract
withdrawn
f
varfaj
k
waldhau
h
evan
erickson
ceru
corpor
concord
ca
unit
state
america
background
blood
system
plasma
class
iii
medic
devic
approv
eu
us
ex
vivo
pathogen
reduct
storag
plasma
therapeut
use
system
util
amotosalen
uva
light
inactiv
pathogen
leukocyt
reduc
proport
dehp
materi
process
set
evalu
sever
materi
manufactur
set
reduc
level
dehp
addit
minor
modif
made
design
compound
adsorpt
devic
cad
hous
inlet
port
plasma
storag
contain
shape
aim
evalu
vitro
function
pathogen
inactiv
pi
prepar
use
process
set
consist
altern
plastic
materi
design
chang
test
compar
current
approv
ce
mark
set
control
method
replic
n
whole
blood
deriv
plasma
compon
pool
ml
pool
process
either
test
control
frozen
within
h
collect
vitro
plasma
function
evalu
pool
day
storag
residu
amotosalen
plasma
function
paramet
evalu
indic
statist
signific
differ
test
control
compon
result
evalu
conform
edqm
qualiti
requir
fibrinogen
factor
viii
result
cad
design
chang
result
lower
amotosalen
test
compar
control
vs
p
modif
storag
contain
reduc
thaw
time
frozen
plasma
approxim
min
day
frozen
storag
test
control
met
edqm
requir
pathogen
reduc
plasma
fibrinogen
mean
fresh
plasma
factor
viii
mean
iuml
fibrinogen
retent
test
control
rel
pool
factor
viii
activ
iuml
test
control
compon
among
plasma
function
paramet
assess
prothrombin
time
pt
ph
fibrinogen
factor
v
fv
show
statist
signific
differ
p
test
control
howev
differ
clinic
relev
mean
level
test
vs
control
pt
vs
sec
ph
vs
fibrinogen
vs
gl
fv
vs
iuml
despit
differ
thrombin
gener
pm
tissu
factor
global
coagul
function
measur
similar
test
control
vs
nm
min
addit
key
anticoagul
protein
similar
test
control
mean
protein
c
vs
iuml
protein
iuml
antithrombin
iii
vs
iuml
inhibitor
vs
iuml
summaryconclus
evalu
demonstr
plasma
treat
use
process
set
manufactur
plastic
compon
contain
reduc
level
dehp
lower
amotosalen
level
improv
thaw
time
compar
current
licens
pi
plasma
test
compon
retain
coagul
anticoagul
paramet
compar
pair
control
indic
process
set
altern
plastic
maintain
plasma
qualiti
critic
vitro
hemostat
function
indic
therapeut
efficaci
l
b
p
clinic
scienc
intervent
technolog
clintec
karolinska
institutet
immunolog
transfus
medicin
karolinska
univers
hospit
immunolog
transfus
medicin
karolinska
univers
hospit
karolinska
institutet
stockholm
sweden
background
cost
effect
approach
pathogen
inactiv
pi
buffi
coat
bc
pool
platelet
treat
doubl
dose
dd
platelet
concentr
pc
bc
split
two
therapeut
transfus
dose
pool
ipp
set
kansuk
turkey
integr
leukodeplet
filter
asahi
kasei
japan
special
design
purpos
tube
lead
larg
pool
bag
ml
temporari
storag
final
platelet
bag
doubl
storag
ds
process
set
use
pi
amotosalenuva
light
photochem
treatment
ceru
netherland
modifi
new
eva
storag
bag
larger
compound
adsorpt
devic
cad
contain
l
versu
l
amotosalen
reduct
step
aim
vitro
storag
studi
conduct
storag
period
assess
platelet
process
qualiti
improv
later
gener
dispos
set
method
dd
pc
obtain
pool
buffi
coat
addit
solut
ssp
use
either
standard
fenwal
ipp
pool
set
pi
process
set
current
l
cad
new
l
cad
plastic
platelet
treat
intercept
store
day
studi
arm
compar
standard
pool
setd
current
n
ippd
current
n
ippd
new
n
metabol
function
activ
paramet
test
day
result
test
pc
n
conform
edqm
guidelin
platelet
content
per
split
unit
ippd
new
seri
statist
differ
product
configur
test
compar
current
set
pi
treatment
set
new
plastic
effect
maintain
glucos
reserv
p
reduc
lactat
product
p
result
higher
ph
day
p
level
reduc
p
throughout
storag
cell
percent
maintain
p
day
platelet
respons
express
retain
p
day
overal
declin
atp
valu
measur
platelet
deriv
factor
pgdf
accumul
base
origin
concentr
equival
way
current
new
plastic
summaryconclus
process
dd
pc
bc
ipp
set
result
two
therapeut
unit
platelet
vitro
qualiti
improv
day
storag
ds
set
made
new
plastic
materi
shift
toward
anaerob
glycolysi
less
pronounc
accompani
better
platelet
qualiti
reduc
activ
marker
schott
b
warbington
g
villega
n
mufti
erickson
ceru
corpor
concord
ca
unit
state
america
background
pathogen
inactiv
pi
system
use
amustalin
glutathion
gsh
develop
inactiv
pathogen
leukocyt
red
blood
cell
rbc
compon
amustalin
form
adduct
nucleic
acid
prevent
replic
contamin
pathogen
leukocyt
amustalinegsh
treat
rbc
current
evalu
clinic
trial
puerto
rico
mainland
us
although
leukocyt
inactiv
pi
rbc
facil
may
irradi
ir
pi
rbc
base
exist
institut
practic
aim
character
vitro
function
pi
control
rbc
without
ir
day
post
donat
pd
throughout
day
storag
method
leukocyt
reduc
rbc
prepar
cpd
whole
blood
collect
within
h
donat
replic
n
abo
match
rbc
pool
split
prepar
test
control
c
compon
rbc
treat
mm
mm
amustalin
c
rbc
untreat
store
day
pd
c
replic
gamma
ir
use
gray
remain
c
replic
irradi
remain
storag
sampl
analysi
vitro
paramet
done
throughout
storag
result
day
c
compon
met
edqm
criteria
contain
g
hb
c
g
g
g
g
hematocrit
hct
c
day
storag
rbc
met
edqm
hemolysi
criterion
day
c
day
c
hemolysi
lower
versu
c
compon
significantli
lower
p
day
atp
valu
exceed
hb
compon
significantli
higher
c
respect
day
extracellular
k
mmoll
increas
ir
compon
compar
compon
level
similar
ir
compon
similar
day
hb
mm
hg
level
compon
day
post
rejuven
hb
c
mm
hg
c
level
summaryconclus
although
ir
expect
requir
routin
use
studi
demonstr
robust
pi
treatment
combin
irradi
irradi
pi
rbc
compon
met
edqm
guidelin
leukocyt
deplet
rbc
addit
solut
respect
hct
hb
content
hemolysi
end
storag
measur
vitro
paramet
intercept
treat
rbc
includ
atp
glucos
level
indic
suitabl
transfus
amustalinegsh
pi
system
rbc
approv
use
project
fund
whole
part
feder
fund
dhh
aspr
barda
contract
c
h
n
p
c
ef
bfc
ef
grand
est
strasbourg
control
ef
bfc
control
ef
grand
est
strasbourg
bfc
grand
est
strasbourg
franc
background
pathogen
inactiv
pi
option
reduc
microbiolog
risk
transfus
ef
adopt
novemb
pi
pc
photochem
treatment
pct
combin
amotosalen
ultraviolet
light
uva
blood
system
ceru
nation
scale
entir
product
small
volum
sv
larg
volum
lv
process
set
use
dual
storag
process
set
ds
allow
prepar
pc
transfus
bc
pool
platelet
doubl
dose
apheresi
platelet
aim
object
evalu
two
blood
centr
qualiti
doubl
dose
bc
apheresi
platelet
concentr
panel
marker
pre
post
pct
storag
day
method
bc
characterist
use
macopress
macopharma
adapt
reach
bc
pool
volum
approxim
ml
includ
ml
intersol
freseniu
kabi
hematocrit
separ
leukodeplet
pc
apheresi
trima
terumo
bct
set
adjust
doubl
dose
collect
pc
inactiv
pct
day
incub
compound
adsorpt
devic
h
h
split
two
contain
pc
store
day
assay
day
evalu
platelet
characterist
qualiti
marker
result
produc
split
two
storag
contain
edqm
ansm
requir
met
platelet
content
per
split
unit
respect
unit
studi
retain
homogen
conform
ph
averag
stabl
post
pct
storag
concentr
glucos
day
mm
mm
respect
day
detect
limit
mm
reach
residu
concentr
mm
lactat
concentr
increas
regularli
type
pc
day
mpv
remain
stabl
ldh
concentr
increas
ul
day
ul
day
ul
period
concentr
increas
ngml
day
ngml
day
ngml
period
swirl
retain
unit
throughout
storag
summaryconclus
use
ds
process
set
pi
allow
obtain
two
transfus
dose
platelet
buffi
coat
apheresi
prepar
techniqu
platelet
qualiti
storag
compar
routin
prepar
pct
pc
sv
lv
set
use
ds
reduc
consum
labor
time
l
infanti
n
plattner
buser
blood
donat
center
swiss
red
cross
basel
basel
switzerland
background
intercept
blood
system
platelet
pathogen
reduct
platelet
concentr
pc
routin
use
switzerland
suitabl
kit
treatment
tripl
dose
platelet
product
collect
apheresi
far
avail
tripl
storag
ts
set
process
apheresi
product
larg
volum
high
platelet
content
develop
meet
need
recent
updat
altern
plastic
made
eva
materi
improv
ga
transfer
properti
aim
object
studi
evalu
qualiti
paramet
pc
obtain
apheresi
collect
platelet
dose
suffici
therapeut
unit
platelet
treat
use
intercept
ts
process
set
includ
contain
made
altern
plastic
method
twelv
tripl
dose
collect
platelet
ml
perform
amicu
freseniu
kabi
trima
terumo
bct
obtain
singl
dose
pc
suspend
pa
ssp
store
day
treatment
ts
set
six
apheresi
product
treat
day
collect
addit
ml
mm
amotosalen
illumin
uva
incub
contain
doubl
compound
adsorpt
devic
cad
wafer
overnight
close
h
final
split
storag
contain
six
apheresi
product
store
overnight
treat
way
day
subsequ
short
cad
incub
slightli
h
paramet
test
day
incub
split
day
day
storag
result
mean
platelet
content
per
singl
pc
mean
volum
ml
recoveri
process
meet
edqm
requir
ph
valu
n
day
differ
significantli
day
vs
increas
mmhg
p
decreas
mmhg
p
day
day
glucos
initi
concentr
day
day
lactat
concentr
increas
day
mgdl
day
p
bicarbon
reserv
initi
day
normal
atp
concentr
initi
ldh
increas
day
ul
day
p
measur
residu
amotosalen
concentr
long
cad
incub
summaryconclus
tripl
dose
platelet
product
collect
apheresi
process
intercept
ts
set
made
altern
eva
plastic
exhibit
satisfactori
metabol
activ
storag
edqm
requir
platelet
content
volum
ph
valu
met
intercept
ts
set
allow
reduc
number
procedur
materi
labor
time
pathogen
inactiv
treatment
pc
preserv
product
qualiti
p
govindan
abdulmaje
depart
patholog
laboratori
medicin
king
faisal
specialist
hospit
research
jeddah
jeddah
saudi
arabia
background
despit
improv
last
decad
still
certain
risk
pathogen
platelet
concentr
especi
rel
high
risk
bacteri
contamin
platelet
give
rise
concern
also
threat
emerg
arbovirus
pathogen
inactiv
technolog
shown
significantli
reduc
risk
infecti
diseas
specif
reduc
elimin
pathogen
platelet
unit
keep
platelet
function
intact
evalu
technolog
introduct
blood
center
enhanc
blood
safeti
patient
aim
evalu
qualiti
amotosalenuva
platelet
plasma
well
bacteri
inactiv
efficaci
technolog
platelet
unit
method
pool
deriv
plasma
unit
respect
inactiv
intercept
blood
system
ceru
corpor
concord
usa
sampl
taken
analyz
fibrinogen
content
factor
viii
content
volum
apheresi
platelet
unit
plasma
pool
prp
platelet
unit
plasma
inactiv
intercept
blood
system
subsequ
analyz
platelet
volum
loss
rbc
wbc
content
ph
four
unit
store
day
analyz
ph
two
addit
apheresi
platelet
unit
spike
cfu
per
unit
ecoli
atcc
saureau
atcc
separ
control
unit
test
unit
h
post
spike
analyz
bacteri
growth
agar
plate
day
storag
assess
inactiv
efficaci
posit
control
treat
speci
confirm
biochem
test
spike
posit
cultur
plate
result
inactiv
plasma
unit
averag
volum
loss
averag
fibrinogen
loss
averag
content
gl
factor
viii
averag
loss
averag
content
iuml
averag
volum
loss
apheresi
unit
post
treatment
volum
loss
pool
prp
platelet
averag
platelet
loss
post
inactiv
apheresi
unit
pool
prp
unit
ph
platelet
unit
significantli
affect
treatment
never
drop
day
storag
inactiv
efficaci
saureu
cfu
per
unit
inactiv
platelet
neg
day
storag
inactiv
efficaci
ecoli
cfu
per
unit
inactiv
platelet
day
storag
control
unit
bacteri
load
cfuunit
aureau
cfuunit
ecoli
day
storag
summaryconclus
amotosalenuva
inactiv
plasma
apheresi
platelet
pool
prp
platelet
pass
qualiti
requir
averag
loss
plasma
coagul
factor
averag
platelet
loss
compar
untreat
control
respect
bacteri
inactiv
efficaci
fulli
suffici
point
toward
enhanc
safeti
regard
bacteri
contamin
wendel
r
amar
c
oliveira
v
nune
l
souza
r
achkar
p
scuracchio
brito
r
fachini
blood
bank
hospit
sirio
liban
paulo
brazil
background
intercept
blood
use
inactiv
broad
spectrum
virus
bacteria
protozoan
parasit
contamin
donor
leukocyt
platelet
product
aim
present
implement
intercept
platelet
fresh
frozen
plasma
ffp
transfus
hospit
march
januari
routin
procedur
method
apheresi
singl
low
volum
slowv
doubl
dose
dd
singl
larg
volum
slv
plateletapheresi
collect
use
devic
leukocyt
reduc
lr
two
slowv
apheresi
abo
pool
treatmentrandom
donor
platelet
rdp
total
rdp
produc
ml
whole
blood
donat
use
platelet
rich
plasma
method
pool
rdp
abo
prepar
lr
biop
plu
filter
slv
pool
rdp
treat
use
larg
volum
dispos
singl
intercept
treatment
lv
pool
slowv
dd
pool
rdp
treat
use
dual
storag
dispos
doubl
dose
treatment
ds
platelet
dose
defin
contain
averag
total
plateletsffp
total
whole
blood
deriv
plasma
prepar
ffp
accord
local
procedur
frozen
within
h
collect
treatment
unit
ffp
abo
thaw
pool
treat
follow
intercept
protocol
treatment
pool
divid
unit
immedi
platelet
ffp
product
treat
mm
amotosalen
respect
uva
result
total
intercept
treatment
platelet
ffp
total
platelet
dose
averag
platelet
ml
per
dose
ffp
averag
ml
unit
prepar
treat
platelet
dose
platelet
ph
valu
well
preserv
storag
day
storag
averag
bacteri
test
perform
non
reactiv
perform
day
storag
n
platelet
count
increment
cci
analyz
transfus
platelet
dose
cci
apheresi
n
rdp
n
statist
differ
p
cci
consid
well
satisfactori
standard
loss
ml
around
less
factor
viii
activ
less
fibrinogen
ffp
treatment
still
accord
pi
product
summaryconclus
addit
improv
microbiolog
safeti
receptor
blood
suppli
achiev
better
standard
platelet
ffp
compon
due
homogen
product
addit
also
abl
suspend
routin
bacteri
contamin
test
recent
brazilian
regulatori
agenc
approv
replac
gamma
irradi
intercept
prevent
diseas
abstract
withdrawn
tt
mustafa
transfus
medicin
nation
guard
saudi
arabia
alhasa
saudi
arabia
background
bacteri
contamin
platelet
one
major
threat
blood
safeti
approx
platelet
unit
potenti
contamin
risk
may
even
higher
sinc
evalu
conduct
cultur
base
method
known
high
fals
neg
rate
even
receiv
contamin
unit
necessarili
caus
bacteri
sepsi
recipi
platelet
transfus
often
immunocompromis
critic
ill
bacteri
contamin
may
problemat
consequ
health
statu
pathogen
inactiv
technolog
develop
reduc
risk
infect
nation
hemovigil
data
sever
franc
belgium
switzerland
well
sever
hemovigil
studi
show
effici
prevent
bacteri
sepsi
aim
evalu
amotosalenuva
pathogen
inactiv
technolog
mitig
risk
bacteri
contamin
platelet
use
organ
play
import
role
bacteri
sepsi
method
three
therapeut
apheresi
platelet
unit
plateletsunit
plasma
collect
h
post
collect
two
unit
spike
approx
cfu
per
bag
saureau
atcc
ecoli
atcc
respect
third
unit
serv
control
day
post
collect
h
post
spike
sampl
test
taken
follow
pathogen
inactiv
unit
intercept
blood
system
ceru
corpor
usa
use
larg
volum
process
kit
platelet
post
inactiv
unit
incub
day
take
sampl
analysi
day
day
bacteri
growth
detect
bactalert
autom
blood
cultur
system
biomerieux
franc
platelet
count
platelet
volum
ph
assess
day
day
day
standard
procedur
result
averag
ph
day
drop
day
day
drop
day
ph
unit
never
drop
cours
storag
platelet
count
per
bag
chang
significantli
storag
averag
volum
loss
neglig
day
day
bacteri
growth
detect
day
pathogen
inactiv
ecoli
saureau
unit
control
unit
day
storag
bacteri
growth
detect
blood
cultur
unit
show
steril
unit
formerli
spike
bacteria
summaryconclus
unit
spike
ecoli
saureu
success
inactiv
amotosalenuva
pathogen
inactiv
stay
steril
day
storag
post
inactiv
qualiti
paramet
unit
within
specif
recogn
signific
drop
ph
day
day
storag
v
h
f
p
e
red
cross
blood
donat
center
baden
wurttemberg
hessen
ggmbh
frankfurt
pharma
intern
langen
red
cross
blood
servic
nstob
spring
germani
background
pathogen
reduct
technolog
may
enhanc
microbi
safeti
platelet
transfus
reduc
bacteri
viral
contamin
establish
manufactur
buffi
coat
deriv
platelet
concentr
routin
condit
aim
object
studi
evalu
potenti
differ
product
characterist
uvc
treat
test
group
non
uvc
treat
control
group
platelet
concentr
pc
use
clinic
investig
product
captur
clinic
assess
platelet
treat
uvc
relat
establish
prepar
clinic
trial
method
studi
leukoreduc
pc
prepar
five
buffi
coat
bc
use
ml
ssp
addit
solut
macopharma
establish
prepar
test
pc
treat
theraflex
system
macopharma
within
h
pc
prepar
untreat
control
pc
store
theraflex
uv
storag
bag
vitro
paramet
volum
thrombocyt
concentr
total
protein
concentr
compar
unpair
p
valu
consid
statist
signific
result
pc
n
show
signific
differ
compar
untreat
control
pc
n
regard
thrombocyt
concentr
test
control
total
protein
concentr
test
gdl
control
uvc
treat
pc
show
small
signific
p
lower
volum
test
ml
vs
control
ml
untreat
pc
signific
differ
storag
time
transfus
test
control
pc
total
n
mean
age
time
transfus
day
versu
day
summaryconclus
differ
test
control
pc
platelet
concentr
total
protein
concentr
storag
durat
statist
signific
averag
differ
volum
test
control
pc
statist
signific
howev
differ
ml
consid
clinic
point
view
affair
terumo
bct
lakewood
unit
state
america
affair
terumo
bct
zaventem
belgium
background
cryoprecipit
first
develop
treat
congenit
clot
factor
defici
hemophilia
von
willebrand
diseas
use
declin
recombin
factor
concentr
becam
avail
today
primari
indic
control
bleed
associ
fibrinogen
defici
fibrinogen
one
first
clot
factor
becom
deplet
major
bleed
trauma
renew
interest
role
cryoprecipit
play
massiv
transfus
protocol
curri
bja
blood
product
cryoprecipit
carri
risk
diseas
technolog
system
introduc
mitig
risk
mirasol
system
use
riboflavin
vitamin
ultraviolet
light
modifi
nucleic
acid
pathogen
white
blood
cell
render
unabl
replic
kumar
photochemistri
photobiolog
marschner
transfus
pathogen
reduct
plasma
use
manufactur
cryoprecipit
improv
safeti
profil
effect
addit
process
end
product
must
consid
specif
effect
dose
procoagul
factor
must
assur
aim
feasibl
studi
evalu
protein
content
singl
unit
cryoprecipit
produc
plasma
european
director
qualiti
medicin
health
care
edqm
criteria
factor
viii
fviii
fibrinogen
method
total
whole
fresh
plasma
unit
healthi
donor
pool
split
produc
n
pair
ml
test
control
unit
control
unit
held
ice
test
unit
process
accord
mirasol
system
instruct
use
test
control
unit
simultan
within
h
collect
produc
fresh
frozen
plasma
ffp
test
unit
protect
ambient
light
otherwis
standard
oper
procedur
cryoprecipit
product
bonfil
blood
center
denver
co
follow
produc
pair
cryoprecipit
unit
briefli
ffp
unit
thaw
overnight
standard
blood
bank
refriger
cryoprecipit
harvest
centrifug
individu
cryoprecipit
unit
store
analysi
thaw
unit
analyz
fviii
fibrinogen
measur
result
fviii
level
rang
iuunit
test
control
unit
respect
fibrinogen
measur
mgunit
test
mgunit
control
test
unit
met
edqm
criterion
fviii
iuunit
met
criterion
fibrinogen
mgunit
control
unit
met
edqm
criteria
summaryconclus
although
fviii
fibrinogen
level
lower
cryoprecipit
unit
compar
pair
control
unit
met
edqm
criterion
fviii
met
criterion
fibrinogen
unit
meet
fibrinogen
criterion
short
mg
sinc
cryoprecipit
typic
pool
expect
qualiti
control
criteria
routin
met
end
product
character
optim
cryoprecipit
warrant
abstract
withdrawn
c
n
c
g
h
p
c
de
strasbourg
inserm
ef
grand
est
bpp
fmt
strasbourg
umr
inserm
franc
background
small
whole
blood
wb
plasma
import
sourc
therapeut
plasma
tp
carri
increas
risk
infect
due
multipl
donor
exposur
risk
mitig
pathogen
inactiv
howev
reduct
specif
coagul
factor
describ
known
method
pi
plasma
ramsey
sem
thromb
hemost
fviii
strongli
affect
current
test
use
routin
assess
reduct
coagul
factor
due
pi
real
impact
global
hemostasi
potenti
tp
aim
measur
thrombin
gener
tg
provid
integr
assess
hemostat
potenti
plasma
object
character
tg
prepar
wb
collect
store
h
pi
order
determin
therapeut
efficaci
abo
blood
group
type
known
affect
fviii
level
decreas
plasma
group
compar
individu
therefor
evalu
tg
group
donor
compar
donor
assess
impact
lower
fviii
level
hemostat
capac
method
wb
donat
store
overnight
process
prepar
plasma
pool
unit
ml
divid
two
batch
treat
auva
result
plasma
unit
per
pool
ml
frozen
store
within
h
wb
collect
pool
group
donor
prepar
hemostat
qualiti
evalu
pi
treatment
storag
day
month
tg
perform
low
concentr
tissu
factor
pm
increas
sensit
detect
potenti
effect
auva
treatment
particular
fviii
activ
result
point
test
pool
prepar
wb
met
french
guidelin
tp
fviii
level
lower
blood
group
compar
plasma
unit
vs
iuml
similar
decreas
approxim
auva
treatment
month
storag
observ
case
vs
iuml
total
amount
thrombin
gener
reflect
endogen
thrombin
potenti
etp
nm
thrombin
min
nevertheless
signific
etp
group
vs
auva
vs
p
auva
month
storag
vs
p
although
trend
decreas
observ
month
valu
etp
lay
within
refer
rang
etp
summaryconclus
despit
diminish
fviii
activ
group
donor
plasma
tg
capac
conserv
equal
well
donor
plasma
demonstr
signific
effect
photochem
treatment
storag
global
hemostat
properti
whatev
abo
blood
group
plasma
prepar
frozen
within
h
collect
repres
altern
supplement
apheresi
plasma
prepar
fresh
frozen
plasma
conform
criteria
french
regulatori
author
j
faber
luxembourg
haemophilia
associ
luxembourg
luxembourg
background
develop
countri
low
human
develop
index
treatment
patient
bleed
disord
inadequ
absent
critic
situat
chang
significantli
past
year
despit
sever
initi
set
differ
nation
intern
organ
past
experi
shown
industri
manufactur
clot
factor
concentr
cfc
solv
problem
use
sole
mean
treatment
bleed
patient
aim
recent
mani
resourc
limit
countri
signific
develop
occur
potenti
chang
exist
situat
therapi
deliveri
blood
system
eg
blood
servic
blood
center
mani
countri
tangibl
improv
novel
technolog
viru
inactiv
vi
blood
compon
market
use
amotosalen
riboflavin
method
countri
local
prepar
viru
inactiv
cryoprecipit
introduc
proven
safe
effect
therapeut
patient
bleed
disord
afford
cost
nevertheless
use
render
cryoprecipit
safe
remain
limit
therefor
major
coordin
action
undertaken
promot
facilit
implement
local
prepar
safe
cryo
end
global
initi
local
product
safe
haemostat
product
treat
patient
bleed
disord
countri
launch
base
collabor
intern
partner
organ
like
isbt
other
nation
stakehold
eg
author
blood
supplier
patient
associ
core
intervent
global
initi
revis
updat
standard
guidelin
treatment
give
high
prioriti
exist
blood
polici
strategi
local
prepar
viru
inactiv
cryoprecipit
develop
countri
local
organ
strong
advocaci
promot
run
pilot
project
six
pilot
site
three
contin
establish
expans
program
support
activ
implement
sustain
local
result
standard
set
organ
taken
standard
guidelin
treatment
patient
bleed
disord
updat
given
pilot
studi
start
januari
recruit
pilot
site
contin
audit
train
underway
individu
product
target
agre
recent
inform
progress
present
summaryconclus
global
initi
local
complementari
exist
relief
activ
eg
product
donat
industri
result
addit
suppli
safe
effect
haemostat
product
treat
patient
bleed
disord
resourc
limit
countri
time
contribut
significantli
lower
incid
inhibitor
format
neutral
inject
fviii
previous
untreat
patient
sever
hemophilia
global
initi
local
ongo
programm
make
stepwis
progress
updat
given
regular
interv
u
w
f
develop
red
cross
blood
servic
nstob
spring
langen
germani
background
hepat
e
viral
hepat
caus
infect
small
rna
viru
call
hepat
e
viru
hev
shown
past
hev
transfus
transmiss
although
case
hev
genotyp
infect
asymptomat
mild
sever
case
hepat
chronic
liver
diseas
report
immunosuppress
patient
aim
reliabl
infect
system
hev
yet
establish
studi
use
felin
caliciviru
fcv
rna
viru
model
inactiv
virus
order
assess
inactiv
capac
theraflex
pathogen
inactiv
system
virus
platelet
concentr
pc
method
plasma
reduc
pc
buffi
coat
plasma
addit
solut
ssp
macopharma
spike
viru
suspens
vv
pc
n
ml
macotron
uv
machin
macopharma
sampl
taken
spike
load
hold
sampl
illumin
differ
tlsb
light
dose
standard
titr
fcv
strain
atcc
determin
tissu
cultur
infect
dose
endpoint
titrat
microtitr
plate
assay
felin
kidney
cell
line
crfk
atcc
result
fcv
inactiv
platelet
system
spike
titer
receiv
pc
uvc
dose
titer
reduc
result
reduct
factor
summaryconclus
sever
virus
inactiv
current
avail
system
pc
shown
investig
platelet
system
potenti
inactiv
virus
like
fcv
u
w
f
develop
red
cross
blood
servic
nstob
spring
virolog
marburg
langen
germani
background
middl
east
respiratori
syndrom
coronaviru
first
identifi
like
zoonot
transmiss
event
camel
caus
sever
lower
respiratori
tract
infect
result
pneumonia
multiorgan
failur
particularli
patient
underli
comorbid
elderli
case
infect
arisen
middl
east
particularli
kingdom
saudi
arabia
republ
korea
two
document
case
travel
report
unit
state
thu
expect
continu
emerg
western
countri
import
travel
enter
countri
return
home
aim
studi
aim
investig
efficaci
theraflex
system
inactiv
platelet
concentr
pc
theraflex
system
macopharma
use
uvc
light
without
need
addit
photoact
compound
method
plasma
reduc
pc
bc
plasma
addit
solut
ssp
spike
viru
suspens
vv
pc
n
ml
macotron
uv
machin
macopharma
sampl
taken
spike
load
hold
sampl
illumin
differ
light
dose
standard
titr
strain
ron
fouchier
determin
tissu
cultur
infect
dose
endpoint
titrat
microtitr
plate
assay
vero
cell
atcc
result
result
infect
assay
demonstr
uvc
irradi
inactiv
spike
titer
bag
bag
receiv
pc
uvc
dose
higher
inactiv
detect
limit
system
result
reduct
factor
bag
bag
summaryconclus
result
demonstr
theraflex
procedur
effect
technolog
inactiv
contamin
pc
w
u
develop
red
cross
blood
servic
nstob
spring
virolog
marburg
langen
germani
background
middl
east
respiratori
syndrom
coronaviru
first
identifi
like
zoonot
transmiss
event
camel
caus
sever
lower
respiratori
tract
infect
result
pneumonia
multiorgan
failur
particularli
patient
underli
comorbid
elderli
case
infect
arisen
middl
east
particularli
kingdom
saudi
arabia
republ
korea
two
document
case
travel
report
unit
state
thu
expect
continu
emerg
western
countri
import
travel
enter
countri
return
home
aim
studi
aim
investig
efficaci
theraflex
mb
plasma
system
inactiv
human
plasma
theraflex
mb
plasma
system
macopharma
use
methylen
blue
mb
combin
visibl
light
reduct
pathogen
infect
plasma
method
leukodeplet
plasma
prepar
whole
blood
use
standard
blood
bank
technolog
plasma
unit
n
spike
viru
suspens
vv
mblight
treatment
done
accord
manufactur
instruct
use
macotron
illumin
devic
sampl
taken
spike
load
hold
sampl
illumin
differ
light
dose
standard
titer
strain
ron
fouchier
determin
tissu
cultur
infect
dose
endpoint
titrat
vero
cell
atcc
result
spike
titer
bag
bag
receiv
plasma
unit
alreadi
lowest
test
light
dose
inactiv
detect
limit
system
result
reduct
factor
bag
bag
summaryconclus
result
demonstr
theraflex
procedur
effect
technolog
inactiv
contamin
plasma
unit
w
u
develop
red
cross
blood
servic
nstob
spring
virolog
marburg
langen
germani
background
ebolaviru
ebov
diseas
sever
often
fatal
ill
death
rate
caus
ebov
member
filoviru
famili
recent
outbreak
ebov
diseas
west
africa
devast
guinea
liberia
sierra
leon
caus
almost
human
infect
fatal
aim
studi
aim
investig
efficaci
theraflex
mb
plasma
system
inactiv
ebov
human
plasma
theraflex
mb
plasma
system
macopharma
use
methylen
blue
mb
combin
visibl
light
reduct
pathogen
infect
plasma
method
leukodeplet
plasma
prepar
whole
blood
use
standard
blood
bank
technolog
plasma
unit
n
spike
viru
suspens
vv
mblight
treatment
done
accord
manufactur
instruct
use
macotron
illumin
devic
sampl
taken
spike
load
hold
sampl
illumin
differ
light
dose
standard
titer
zair
ebov
strain
determin
tissu
cultur
infect
dose
endpoint
titrat
vero
cell
atcc
result
spike
ebov
titer
bag
bag
receiv
plasma
unit
alreadi
light
dose
bag
bag
ebov
inactiv
detect
limit
system
result
reduct
factor
bag
summaryconclus
result
demonstr
theraflex
procedur
effect
technolog
inactiv
ebov
contamin
plasma
u
w
f
develop
red
cross
blood
servic
nstob
spring
virolog
marburg
langen
germani
background
ebolaviru
ebov
diseas
sever
often
fatal
ill
death
rate
caus
ebov
member
filoviru
famili
recent
outbreak
ebov
diseas
west
africa
devast
guinea
liberia
sierra
leon
caus
almost
human
infect
fatal
aim
studi
aim
investig
efficaci
theraflex
system
inactiv
ebov
platelet
concentr
pc
theraflex
system
macopharma
use
uvc
light
without
need
addit
photoact
compound
method
plasma
reduc
pc
bc
plasma
addit
solut
ssp
spike
viru
suspens
vv
pc
n
ml
macotron
uv
machin
macopharma
sampl
taken
spike
load
hold
sampl
illumin
differ
light
dose
standard
titr
zair
ebov
strain
determin
tissu
cultur
infect
dose
endpoint
titrat
microtitr
plate
assay
vero
cell
atcc
result
result
infect
assay
demonstr
uvc
irradi
inactiv
ebov
spike
ebov
titer
bag
bag
receiv
pc
uvc
dose
higher
ebov
inactiv
detect
limit
system
result
reduct
factor
bag
bag
summaryconclus
result
demonstr
theraflex
procedur
effect
technolog
inactiv
ebov
contamin
pc
r
v
zealand
blood
servic
auckland
new
zealand
compon
develop
laboratori
new
zealand
blood
servic
auckland
new
zealand
background
platelet
cryopreserv
use
dimethylsulphoxid
dmso
cryoprotect
use
stem
cell
cryopreserv
minimis
dmso
toxic
initi
platelet
compon
ad
dmso
centrifug
supernat
remov
leav
platelet
plug
ml
plasma
dmso
frozen
platelet
thaw
concentr
infus
requir
reconstitut
either
plasma
platelet
addit
solut
resuspend
fluid
current
method
requir
either
resuspend
fluid
steril
dock
onto
platelet
bag
bag
spike
resuspend
fluid
run
platelet
bag
implic
storag
eas
use
regulatori
complianc
aim
demonstr
cryopreserv
platelet
frozen
bag
plasma
separ
clip
equival
platelet
surfac
marker
flow
cytometri
function
clot
format
use
thromboelastographi
teg
demonstr
temperatur
differ
two
compart
thaw
compon
method
twelv
apheresi
irradi
platelet
dose
process
follow
bacteri
test
h
immedi
prior
cryopreserv
platelet
dose
sampl
test
annexinv
express
well
r
time
time
clot
maximum
amplitud
clot
strength
six
dose
process
use
standard
techniqu
use
macopharma
dri
bag
frozen
storag
without
resuspens
platelet
plug
post
centrifug
prior
freez
second
set
six
dose
process
way
use
cryostor
bag
frozen
storageth
platelet
plug
resuspend
prior
freez
ml
dmso
weloc
clip
appli
isol
resuspend
platelet
plug
bottom
half
ml
plasma
run
top
half
bag
via
steril
dock
prior
freez
first
set
six
dose
thaw
reconstitut
ffp
second
set
six
dose
thaw
reconstitut
contigu
plasma
sampl
bag
test
platelet
count
annexin
v
assay
separ
two
unit
platelet
frozen
thaw
use
bag
clip
temperatur
probe
smaller
platelet
larger
plasma
portion
bag
monitor
temperatur
thaw
result
compon
arm
met
volum
recoveri
criteria
second
arm
better
recoveri
vs
signific
differ
two
arm
annexinv
flow
cytometri
teg
two
arm
trend
toward
slightli
longer
second
set
dose
mean
min
vs
standard
arm
p
normal
min
thaw
show
differ
temperatur
two
portion
bag
separ
weloc
clip
summaryconclus
studi
shown
signific
chang
move
standard
prepar
novel
method
platelet
resuspend
prior
freez
frozen
bag
plasma
resuspens
nasiri
k
tekeh
center
high
institut
research
educ
transfus
medicin
tehran
iran
background
short
life
time
human
platelet
unit
led
chronic
shortag
fresh
platelet
blood
transfus
center
mani
approach
investig
experiment
produc
new
hemostat
activ
platelet
product
capabl
long
term
storag
infus
platelet
membran
ipm
prepar
fresh
outdat
human
platelet
develop
altern
standard
platelet
concentr
addit
advantag
long
shelf
life
aim
aim
studi
measur
presenc
platelet
receptor
platelet
factor
activ
ipm
prepar
method
pool
fresh
platelet
concentr
procedur
perform
lysi
platelet
remov
contamin
wash
step
appli
ipm
formul
sucros
human
serum
albumin
lyophil
steril
condit
flow
cytometr
analysi
assay
carri
result
flow
cytometr
analysi
found
activ
lyophil
step
ipm
contrast
start
fresh
pool
platelet
concentr
respect
activ
summaryconclus
result
show
lyophil
ipm
product
preserv
major
adhes
aggreg
platelet
receptor
may
retain
activ
accept
level
demonstr
hemostat
properti
lyophil
ipm
brief
although
much
remain
investig
success
investig
affect
patient
care
transfus
medicin
v
e
research
institut
emerg
medicin
center
hematolog
moscow
russia
background
techniqu
cryopreserv
human
platelet
develop
patent
obtain
russia
procedur
cryopreserv
platelet
concentr
includ
storag
cell
platelet
plasma
knowledg
prior
studi
plasma
qualiti
platelet
concentr
pc
cryopreserv
platelet
concentr
cpc
far
context
dictat
relev
investig
plasma
clot
factor
activ
pc
cpc
aim
sought
evalu
activ
plasma
coagul
factor
pc
cpc
method
pc
harvest
trima
accel
autom
blood
collect
system
patent
technolog
employ
cryopreserv
pc
within
close
system
use
dmso
cryoprotect
residu
plasma
factor
viii
activ
pc
cpc
measur
clot
assay
use
reagent
set
fviii
activ
test
method
appli
consist
ad
defici
substrat
plasma
dilut
test
plasma
determin
clot
time
mixtur
aptt
assay
impli
correct
clot
factor
except
factor
viii
aptt
mix
depend
factor
viii
activ
plasma
test
determin
calibr
plasma
refer
prepar
factor
viii
activ
certifi
intern
standard
fibrinogen
concentr
residu
plasma
remain
cpc
assay
aid
vitro
diagnost
kit
reagent
determin
fibrinogen
content
involv
note
clot
time
excess
thrombin
ad
specimen
plasma
dilut
system
time
take
fibrin
clot
form
depend
sole
plasma
fibrinogen
concentr
result
residu
plasma
analysi
pc
show
factor
viii
activ
decreas
throughout
pc
storag
period
lowest
factor
viii
activ
level
iu
reveal
within
h
pc
storag
activ
factor
viii
found
reach
anoth
trough
iu
h
pc
storag
howev
signific
chang
fibrinogen
concentr
seen
high
gl
cryopreserv
process
demonstr
nearli
halv
factor
viii
activ
compar
activ
origin
pc
activ
cpc
heavili
depend
origin
pc
storag
time
peak
activ
factor
viii
iu
detect
cpc
pc
store
within
h
signific
declin
activ
factor
viii
iu
note
cpc
obtain
ps
h
storag
longer
storag
origin
pc
cpc
produc
factor
viii
activ
level
fell
iu
fibrinogen
level
gl
cpc
unaffect
freez
prolong
storag
pc
plasma
addit
assay
prolong
storag
cpc
frozen
pc
exhibit
twofold
reduct
factor
viii
activ
afterward
hardli
chang
year
storag
summaryconclus
platelet
also
activ
plasma
clot
factor
factor
viii
fibrinogen
recov
pc
cpc
confer
dual
properti
blood
compon
review
high
activ
factor
viii
still
found
cpc
refriger
storag
period
set
patient
transfus
pc
cpc
platelet
dose
activ
clot
factor
influenc
haemostasi
hypercoagul
state
taken
account
l
l
j
cell
advanc
therapeut
develop
test
scottish
nation
blood
transfus
servic
edinburgh
unit
kingdom
background
room
temperatur
storag
platelet
compon
without
problem
increas
storag
lesion
metabol
ph
lead
reduc
storag
time
combin
potenti
bacteri
growth
ambient
temperatur
allow
platelet
store
day
last
decad
platelet
product
uk
increas
shot
report
contrast
wastag
rate
due
product
expir
thu
storag
cold
store
platelet
reduc
bacteri
growth
slow
metabol
potenti
allow
increas
storag
time
also
suggest
platelet
may
effici
bind
due
platelet
prime
cold
howev
circul
vivo
transfus
platelet
suggest
short
live
recent
evid
emerg
suggest
cold
induc
chang
may
howev
revers
period
warm
cold
storag
therefor
may
allow
transfus
platelet
stay
circul
longer
aim
evalu
cold
temperatur
cycl
condit
standard
practic
determin
whether
qualiti
function
maintain
method
briefli
buffi
coat
platelet
unit
ssp
day
pool
split
back
fresh
bag
store
follow
temperaturescondit
controlstandard
b
cold
c
c
temperatur
cycl
h
h
tc
sampl
analys
qualiti
function
day
result
platelet
paramet
measur
still
function
platelet
end
storag
despit
loss
swirl
cold
tc
store
platelet
although
note
cold
tc
store
platelet
ph
decreas
storag
compar
standard
platelet
sampl
measur
european
uk
guidelin
morpholog
platelet
surfac
chang
paramet
measur
time
annexin
v
level
increas
day
c
tc
end
storag
also
note
site
maintain
best
tc
platelet
end
storag
reduc
compar
c
haemostat
abil
retain
unit
measur
thromboelastographi
teg
stronger
clot
strength
observ
cold
tc
store
platelet
mm
tc
mm
c
mm
summaryconclus
data
suggest
platelet
effect
store
cold
standard
temperatur
although
swirl
disappear
cold
tc
store
compon
platelet
still
retain
haemostat
abil
due
chang
platelet
surfac
marker
surviv
time
compon
vivo
would
requir
assess
storag
cold
may
therefor
allow
longer
storag
time
reduc
platelet
wastag
f
p
j
r
research
develop
militari
blood
bank
leiden
netherland
dso
nation
laboratori
singapor
singapor
oper
medicin
defens
health
organis
utrecht
trauma
surgeri
alrijn
hospit
trauma
surgeri
leiden
univers
medic
center
leiden
netherland
background
netherland
arm
forc
shown
frozen
blood
product
safe
effect
treatment
trauma
casualti
militari
treatment
facil
surviv
improv
massiv
transfus
patient
frozen
blood
product
use
combin
red
blood
cell
plasma
platelet
massiv
transfus
polici
transfus
blood
product
may
improv
surviv
thaw
red
blood
cell
store
week
thaw
plasma
week
use
thaw
platelet
store
h
make
practic
use
product
prehospit
set
aim
primari
aim
assess
point
cold
storag
thaw
platelet
plasma
accord
european
guidelin
secondari
aim
provid
evid
prolong
storag
readili
avail
univers
donor
type
blood
compon
stock
prehospit
set
method
platelet
unit
type
concentr
dimethyl
sulfoxideplasma
ml
frozen
dtc
thaw
platelet
resuspend
thaw
plasma
ml
type
ab
first
pool
split
plasma
unit
dfp
store
separ
dtc
dfp
compar
day
storag
product
compar
fresh
buffi
coat
platelet
type
b
store
autolog
plasma
bctc
day
day
product
volum
determin
weight
platelet
concentr
measur
sysmex
ph
measur
coagul
factor
activ
iuml
fibrinogen
grl
phospholipid
activ
ppl
sec
measur
stago
coagul
analys
vitro
coagul
assess
kaolin
thromboelastographi
vitro
data
complianc
european
guidelin
evalu
result
dtc
platelet
content
remain
stabl
ph
decreas
storag
ph
ph
coagul
factor
similar
dtc
dfp
slightli
reduc
remain
stabl
storag
day
fibrinogen
factor
vii
factor
viii
protein
c
iii
dtc
factor
v
reduc
stronger
dfp
dtc
protein
decreas
stronger
storag
dfp
dtc
similarli
factor
v
protein
decreas
bctc
fv
ps
day
fv
ps
phospholipid
activ
highest
dtc
decreas
storag
ppl
sec
teg
min
ppl
activ
bctc
start
low
increas
storag
ppl
sec
teg
min
ppl
sec
sec
teg
min
activ
higher
compar
dfp
day
ppl
sec
teg
min
bctc
produc
stronger
clot
storag
teg
mm
teg
mm
compar
dtc
teg
mm
produc
stronger
clot
compar
dfp
teg
mm
throughout
storag
summaryconclus
thaw
plasma
platelet
storag
prolong
week
store
accord
european
guidelin
suggest
product
use
set
cold
store
thaw
platelet
plasma
support
vitro
coagul
stronger
compar
cold
store
thaw
plasma
may
effect
treatment
major
haemorrhag
futur
research
focu
effect
resuscit
vivo
g
l
j
develop
australian
red
cross
blood
servic
clinic
medicin
univers
queensland
care
research
group
princ
charl
hospit
brisban
health
command
australian
defenc
forc
canberra
develop
australian
red
cross
blood
servic
sydney
australia
background
cryopreserv
altern
standard
room
temperatur
storag
platelet
unit
offer
extend
provid
signific
logist
suppli
advantag
especi
rural
area
militari
set
howev
clinic
studi
yet
conclus
establish
safeti
efficaci
resuscit
therapi
ethic
constraint
limit
design
studi
use
anim
model
transfus
provid
sever
advantag
includ
capac
investig
implic
factor
respons
advers
event
sheep
valuabl
model
blood
transfus
research
size
anatomi
blood
volum
similar
human
aim
aim
research
project
investig
feasibl
cryopreserv
sheep
platelet
unit
optimis
protocol
manufactur
determin
hemostat
function
sheep
platelet
concentr
method
deriv
sheep
platelet
unit
n
prepar
ssp
addit
solut
minor
modif
standard
procedur
human
platelet
four
pool
platelet
separ
centrifug
leukodeplet
filtrat
store
associ
storag
bag
agit
overnight
sheep
platelet
concentr
spc
cryopreserv
within
h
manufactur
gradual
addit
dmso
supernat
contain
dmso
remov
centrifug
spc
store
day
thaw
resuspend
pool
sheep
plasma
thaw
reconstitut
sampl
immedi
platelet
count
determin
use
hematolog
analys
recoveri
calcul
platelet
hemostat
function
assess
rotat
thromboelastographi
rotem
haemoview
diagnost
use
extem
extrins
coagul
pathway
intem
intrins
pathway
test
decalcifi
sampl
extem
test
measur
chang
extrins
coagul
pathway
intem
test
measur
alter
intrins
coagul
pathway
provid
inform
clot
format
stabil
result
mean
recoveri
rang
cryopreserv
result
prolong
extem
clot
time
ct
vs
p
faster
clot
format
cft
vs
p
decreas
maximum
clot
firm
mcf
mm
vs
p
compar
platelet
intem
result
indic
cryopreserv
shorten
clot
time
vs
p
increas
clot
format
time
vs
p
time
overal
strength
clot
form
decreas
mm
vs
mm
p
result
line
characterist
human
cryopreserv
platelet
summaryconclus
sheep
platelet
unit
success
cryopreserv
hemostat
effect
base
upon
evid
sheep
biomed
model
abl
incorpor
transfus
provid
suitabl
model
address
knowledg
gap
regard
transfus
cryopreserv
blood
product
l
institut
biomed
materi
tissu
engin
colleg
biomed
engin
taipei
medic
univers
taipei
taiwan
republ
china
de
recherch
crsa
inserm
umr
pari
neurologi
inserm
u
lill
franc
background
increas
interest
clinic
use
variou
human
platelet
lysat
hpl
prepar
regen
medicin
includ
soft
tissu
heal
bone
augment
treatment
osteoarthr
even
neuroprotect
hpl
also
increasingli
use
supplement
growth
media
human
cell
propag
cell
therapi
scientif
rational
support
clinic
benefit
platelet
prepar
usual
thought
content
numer
growth
factor
pdgf
egf
vegf
hgf
bdnf
releas
platelet
howev
preliminari
evid
platelet
lysat
contain
vesicl
ev
includ
microvesicl
mv
collect
call
evsmv
potenti
contribut
function
activ
potent
cargo
molecul
facilit
commun
littl
known
presenc
content
mv
differ
type
hpl
use
regen
medicin
explor
need
aim
compar
content
characterist
size
size
distribut
morpholog
evsmv
variou
type
platelet
lysat
prepar
use
regen
medicin
applic
method
apheresi
platelet
concentr
pc
obtain
taipei
blood
center
upon
irb
approv
pc
aliquot
process
differ
platelet
lysat
ppl
platelet
pellet
lysat
hppl
platelet
lysat
scpl
platelet
lysat
use
calcium
chlorideglass
bead
treatment
hscpl
platelet
lysat
mean
popul
size
zeta
potenti
evsmv
platelet
lysat
fraction
qevorigin
size
exclus
chromatographi
sec
column
izon
scienc
analyz
dynam
light
scatter
dl
addit
explor
morpholog
individu
particl
size
count
done
transmiss
electron
microscopi
tem
nanoparticl
track
analysi
nta
result
hpl
found
contain
numer
evsmv
content
rang
approxim
scpl
hppl
dl
analysi
show
evsmv
crude
ppl
hppl
scpl
hscpl
mean
popul
size
nm
nm
nm
nm
respect
explor
evsmv
fraction
izon
column
reveal
mean
popul
size
ppl
nm
bigger
scpl
rang
nm
fraction
hppl
hscpl
mean
popul
size
fraction
evsmv
rang
nm
nm
respect
estim
evsmv
size
rang
hpl
confirm
tem
observ
support
nta
summaryconclus
size
number
evsmv
differ
differ
type
platelet
lysat
prepar
use
regen
medicin
applic
physiolog
implic
differ
deserv
vitro
anim
model
explor
v
molina
parreira
neme
b
rode
c
l
elhel
e
honnorat
alba
foundat
haemophilia
bueno
air
argentina
background
manag
patient
bleed
disord
haemophilia
signific
challeng
dental
provid
requir
collabor
haematologist
well
awar
local
haemostat
measur
techniqu
use
plasma
prp
associ
improv
tissu
heal
process
differ
procedur
aim
main
goal
studi
evalu
report
potenti
benefit
use
prp
dental
extract
popul
patient
haemophilia
method
autolog
prp
use
fill
socket
exodontia
specif
coagul
replac
therapi
administ
bolu
inject
follow
daili
dose
ml
blood
drawn
patient
use
ml
tube
contain
trisodium
citrat
solut
min
infus
fviiifix
tube
centrifug
rpm
min
tabl
centrifug
room
temperatur
prp
obtain
aspir
pipett
lower
third
plasma
fraction
transfer
steril
glass
petri
dish
plasma
ppp
obtain
upper
third
plasma
place
anoth
glass
petri
dish
ml
plasma
fraction
place
dish
calcium
chlorid
ad
dish
kept
water
bath
fresh
product
malleabl
readi
introduc
alveolar
socket
bleed
evalu
use
post
exodontia
alveolar
bleed
index
peabi
score
use
repres
total
absenc
bleed
heal
determin
use
heal
index
hi
score
given
associ
poor
heal
assess
inflamm
done
use
score
absenc
facial
plane
blur
affect
nasolabi
fold
eye
pain
evalu
use
face
pain
rate
scale
bone
heal
studi
use
longitudin
radiograph
assess
techniqu
perform
day
postop
result
consecut
patient
haemophilia
patient
sever
underw
exodontia
mean
age
year
old
bleed
score
peabi
patient
six
four
bleed
day
procedur
report
heal
index
one
patient
score
one
eight
twenti
patient
inflamm
score
patient
three
two
twenti
four
patient
report
pain
four
patient
use
analges
therapi
surgic
complic
trismu
dental
alveol
infect
report
radiograph
assess
show
signific
vertic
bone
mass
increas
observ
period
summaryconclus
report
potenti
benefit
prp
dental
extract
could
also
obtain
patient
haemophilia
appropri
replac
therapi
c
institut
biomed
materi
tissu
engin
colleg
biomed
engin
biomed
engin
colleg
biomed
engin
taipei
medic
univers
taipei
taiwan
republ
china
neurologi
inserm
jean
pierr
aubert
research
centr
umr
inserm
lill
franc
background
anim
model
suggest
human
platelet
lysat
hpl
emerg
effect
biotherapi
neurodegen
diseas
develop
one
particular
hpl
deplet
plasma
protein
hppl
remov
fibrinogen
avoid
thrombogen
inflammatori
proteolyt
activ
hppl
protect
dopaminerg
neuron
differenti
lund
human
mesencephal
luhm
cell
model
use
intranas
administr
anim
model
parkinson
diseas
neuroprotect
activ
hppl
may
result
content
multipl
neurotroph
growth
factor
pdgf
vegf
bdnf
etc
known
exert
benefici
impact
neuron
surviv
remov
neurotox
blood
compon
hpl
protect
cell
death
pathway
oxid
stress
induc
mechan
protect
neuron
cell
model
involv
activ
akt
mek
pathway
capac
hpl
exert
neurorestor
potenti
traumat
brain
injuri
tbi
explor
yet
aim
evalu
neurorestor
activ
hppl
vitro
model
tbi
method
hppl
prepar
fresh
platelet
concentr
formul
plasma
pc
platelet
pellet
lysat
first
obtain
centrifug
g
min
pc
platelet
pellet
surfac
wash
remov
residu
plasma
pb
subject
cycl
follow
centrifug
g
min
supernat
recov
min
hppl
total
protein
concentr
determin
growth
factor
assess
elisa
function
activ
evalu
use
vv
hppl
compar
fetal
bovin
serum
fb
impact
viabil
prolifer
apoptosi
neuroblastoma
microglia
human
endotheli
cell
assess
brdu
western
blot
respect
inflammatori
activ
investig
tumor
necrosi
releas
hppl
capac
stimul
wound
heal
protect
mechan
damag
evalu
scratch
assay
transect
model
respect
capac
stimul
neurit
extens
evalu
differenti
test
result
mean
hppl
n
protein
concentr
mgml
mean
content
neurotroph
factor
bdnf
ngml
ngml
egf
ngml
vegf
ngml
hppl
stimul
growth
without
affect
viabil
stimul
apoptosi
induc
detect
ngml
releas
compar
lp
control
ngml
mean
viabil
treat
hppl
obtain
fb
h
cultur
respect
hppl
exhibit
potent
wound
heal
efficaci
scratch
assay
wound
closur
index
h
hppl
induc
neurit
outgrowth
averag
neurit
length
transect
model
hppl
exhibit
signific
p
protect
effect
compar
untreat
cell
summaryconclus
vitro
data
confirm
hppl
toxic
neuron
cell
inflammatori
exert
neuroprotect
neurorestor
activ
warrant
evalu
vivo
model
tbi
v
v
p
c
b
medicin
ophthalmolog
gvhd
compet
center
univers
hospit
cologn
germani
background
treatment
blood
deriv
serum
eye
drop
sed
highli
effect
therapi
patient
suffer
sever
ocular
surfac
disord
prepar
patient
blood
common
procedur
sinc
year
autolog
approach
well
establish
centr
due
patient
inabl
donat
manufactur
result
allogen
sed
report
literatur
encourag
us
evalu
option
aim
aim
donor
regard
prospect
abil
donat
blood
gain
experi
allogen
serum
eye
drop
method
donor
evalu
potenti
factor
could
prevent
blood
donat
like
underli
diseas
poor
venou
access
low
haemoglobin
infect
circulatori
disturb
well
old
young
age
local
author
agre
upon
individu
heal
attempt
accord
patient
individu
set
necessari
procedur
contrast
countri
taiwan
korea
denmark
new
zealand
perform
regularli
germani
yet
male
donor
without
blood
born
diseas
never
receiv
blood
product
take
kind
medic
select
within
regular
blood
donor
addit
donor
must
pass
questionnair
exclud
form
dri
eye
syndrom
manufactur
direct
patient
accord
process
close
system
meis
germani
petrescu
v
transfusionsmedizin
therapeut
result
evalu
subject
measur
ocular
surfac
diseas
index
osdi
result
patient
patient
identifi
elig
anymor
temporarili
donat
blood
frequent
contraind
underli
diseas
pt
poor
venou
access
low
haemoglobin
pt
circulatori
disturb
pt
young
agelow
bodi
weight
pt
case
hepat
b
infect
patient
present
one
contraind
accord
medic
urgenc
patient
given
prioriti
year
old
child
suffer
neurotroph
keratopathi
eye
alreadi
receiv
twice
examin
show
distinct
shrink
lesion
eye
patient
suffer
ocular
gvhd
dri
eye
syndrom
receiv
examin
perform
quarterli
patient
provid
stock
expir
summaryconclus
consid
literatur
first
experi
treatment
allogen
sed
may
effect
even
equal
effici
altern
autolog
manufactur
donat
imposs
direct
comparison
set
versu
regard
effect
miss
yet
futur
need
explor
advantag
disadvantag
therapeut
effect
approach
desir
direct
comparison
group
patient
j
van
j
van
p
van
der
de
process
develop
blood
bank
sanquin
protein
molecular
cell
biolog
lab
cell
research
sanquin
research
amsterdam
netherland
background
human
serum
eye
drop
sed
use
treatment
dri
eye
syndrom
hypothesi
activ
compon
serum
growth
factor
activ
effect
dri
eye
adhes
cell
cell
layer
eye
strengthen
therebi
improv
barrier
function
howev
vitro
model
test
effect
sed
aim
develop
standard
vitro
system
test
heal
effect
sed
human
endothelialepitheli
cell
repres
cell
layer
eye
also
investig
concentr
serum
heal
effect
optim
method
two
serum
pool
test
cell
layer
human
umbil
vein
endotheli
cell
human
lung
epitheli
cell
measur
resist
across
cell
layer
caus
adhes
cell
carri
triplic
serum
pool
electr
imped
sens
eci
array
cell
per
well
format
cell
monolay
serum
pipet
per
well
duplic
final
concentr
serum
control
growth
medium
result
calcul
normal
time
serum
addit
measur
h
result
reproduc
result
obtain
variou
cell
line
serum
pool
endotheli
cell
highest
differ
resist
measur
serum
indic
strengthen
barrier
function
cell
layer
improv
adhes
cell
effect
variou
concentr
almost
maintain
full
h
epitheli
cell
highest
resist
differ
measur
serum
relationship
serum
long
activ
measur
lower
percentag
serum
return
level
serum
initi
effect
within
h
measur
summaryconclus
eci
reproduc
vitro
model
develop
test
serum
pool
use
endotheli
epitheli
cell
direct
reproduc
activ
measur
dilut
endotheli
cell
improv
adhes
cell
remain
concentr
full
measur
time
epitheli
cell
case
serumeci
suitabl
research
wound
appli
cell
layer
order
determin
maximum
heal
effect
sed
abstract
withdrawn
p
rebulla
scaramuzzino
g
c
biadati
forlani
n
greppi
blood
transfus
servic
foundat
ca
granda
ospedal
maggior
policlinico
milano
itali
background
allogen
cord
blood
platelet
gel
cbpg
blood
compon
rich
tissu
regen
factor
use
topic
treatment
skin
ulcer
cbpg
prepar
cb
unit
collect
hemopoiet
transplant
show
insuffici
cell
dose
use
unit
volum
ml
platelet
count
suitabl
cbpg
product
platelet
rich
plasma
prp
obtain
soft
cb
centrifug
follow
prp
hard
spin
platelet
resuspens
plasma
volum
appropri
achiev
specif
platelet
concentr
therapeut
applic
gel
form
ad
calcium
platelet
concentr
cbpc
cbpg
clinic
efficaci
studi
requir
care
product
standard
particular
platelet
concentr
cbpc
achiev
perform
platelet
count
prp
use
determin
appropri
volum
reduct
ensur
specif
platelet
concentr
cbpc
recommend
sever
pg
expert
standard
studi
chose
target
mean
platelet
concentr
cbpc
sd
aim
aim
determin
prp
volum
reduct
factor
use
platelet
count
complet
blood
count
routin
perform
cb
bank
whole
cb
unit
sampl
thu
avoid
workload
inaccuraci
cost
contamin
risk
associ
intermedi
step
prp
sampl
platelet
count
object
support
previou
evid
percent
platelet
recoveri
cb
fraction
step
show
limit
variat
method
preliminari
studi
cb
unit
studi
determin
cbpc
volum
platelet
concentr
empir
use
prp
discret
volum
reduct
factor
unit
initi
whole
cb
platelet
count
respect
perform
simul
studi
studi
impos
constant
platelet
concentr
pc
databas
obtain
studi
determin
linear
regress
initi
platelet
count
whole
cb
versu
impos
constant
valu
cbpc
simul
yield
follow
equat
cbpc
volum
ml
cb
platelet
count
final
studi
experiment
evalu
platelet
concentr
newli
prepar
cbpc
whose
volum
determin
weight
use
equat
obtain
studi
result
set
cbpc
volum
equat
studi
obtain
mean
platelet
count
sd
cbpc
studi
valu
close
standard
target
summaryconclus
procedur
report
studi
facilit
standard
platelet
count
cbpg
reduc
workload
improv
qualiti
compar
evalu
clinic
efficaci
ly
dimberg
parr
khat
r
bate
n
hovenga
n
johnson
marschner
sc
l
terumo
bct
lakewood
colorado
unit
state
america
background
traumat
injuri
lead
caus
death
person
age
unit
state
overal
fifth
lead
caus
death
hemorrhag
prevent
direct
caus
death
trauma
studi
shown
earli
administr
plasma
improv
clinic
outcom
trauma
howev
storag
requir
thaw
time
fresh
frozen
plasma
ffp
oper
challeng
prehospit
set
small
hospit
battlefield
lyophil
plasma
fdp
store
room
temperatur
reconstitut
rapidli
immedi
use
resuscit
fluid
potenti
solut
issu
fdp
product
store
rug
plastic
packag
suitabl
field
use
develop
aim
aim
present
studi
compar
vitro
qualiti
reconstitut
fdp
prototyp
ffp
method
ten
unit
liquid
plasma
deriv
whole
blood
collect
citrat
phosphat
dextros
anticoagul
aliquot
remov
unit
frozen
within
h
collect
serv
pair
ffp
control
remain
volum
unit
fdp
reconstitut
water
inject
reconstitut
fdp
pair
thaw
ffp
control
test
coagul
factor
activ
clot
properti
baselin
time
character
stabil
reconstitut
product
reconstitut
fdp
pair
ffp
control
store
retest
h
h
paramet
result
averag
reconstitut
time
fdp
min
comparison
unit
ffp
typic
thaw
min
ph
reconstitut
fdp
physiolog
averag
similar
ph
ffp
averag
time
reconstitut
signific
differ
observ
fdp
pair
ffp
control
factor
v
factor
viii
fibrinogen
ptt
pt
activ
partial
thromboplastin
time
aptt
prothrombin
time
pt
protein
protein
c
paramet
measur
rotem
thrombin
gener
assay
p
qualiti
paramet
reconstitut
fdp
remain
statist
similar
pair
ffp
control
even
storag
two
except
fdp
prothrombin
time
slightli
higher
h
fdp
protein
activ
lower
h
vs
howev
valu
remain
within
normal
plasma
refer
rang
summaryconclus
reconstitut
fdp
maintain
similar
vitro
qualiti
compar
thaw
ffp
day
data
pilot
studi
suggest
reconstitut
fdp
suffici
plasma
qualiti
serv
altern
ffp
rapid
reconstitut
time
possibl
room
temperatur
storag
provid
signific
oper
advantag
compar
ffp
certain
set
addit
studi
ongo
materi
base
upon
work
support
unit
state
govern
contract
abstract
withdrawn
j
meyer
r
ben
depart
chemistri
biomolecular
scienc
univers
ottawa
ottawa
canada
background
cryopreserv
provid
solut
storag
red
blood
cell
rbc
current
achiev
use
high
concentr
glycerol
north
america
cryoprotect
howev
glycerol
must
remov
prior
transfus
avoid
intravascular
hemolysi
lengthi
process
increas
patient
wait
time
prior
receiv
transfus
furthermor
glycerol
prevent
cryoinjuri
due
ice
recrystal
laboratori
develop
small
molecul
ice
recrystal
inhibitor
iri
capabl
cryopreserv
rbc
use
glycerol
mani
iri
issu
preclud
use
clinic
includ
hemoglobin
oxid
induc
hemolysi
deglycerol
process
indic
need
develop
new
class
iri
suitabl
rbc
cryopreserv
would
allow
rapid
deglycerol
aim
design
amino
iri
capabl
success
cryopreserv
rbc
use
reduc
glycerol
concentr
method
amino
acid
synthes
deriv
assess
iri
activ
use
modifi
assay
cytotox
cell
assess
use
convent
resazurin
assay
result
phenylalanin
tyrosin
methionin
isoleucin
identifi
proteinogen
amino
acid
exhibit
signific
iri
activ
valu
rang
mm
mm
sever
structur
modif
amino
acid
assess
order
determin
effect
iri
activ
phenylalanin
decreas
mm
mm
introduct
substitu
although
deriv
led
signific
loss
activ
oxid
methionin
mm
sulfoxid
significantli
decreas
activ
wherea
oxid
sulfon
retain
similar
activ
mm
importantli
incub
cell
h
mm
result
cell
viabil
wherea
mm
methionin
result
viabil
condit
summaryconclus
ration
design
amino
acid
deriv
increas
iri
activ
reduc
cytotox
compar
parent
compound
novel
class
iri
promis
cryopreserv
rbc
use
lower
glycerol
concentr
ultim
allow
shorter
process
time
prior
transfus
tr
j
j
r
j
innov
canadian
blood
servic
edmonton
chemistri
biomolecular
scienc
univers
ottawa
ottawa
laboratori
medicin
patholog
univers
alberta
edmonton
canada
background
red
cell
concentr
rcc
cryopreserv
use
low
glycerol
method
commonli
use
clinic
medicin
due
need
rapid
cool
thaw
system
storag
shipment
liquid
nitrogen
higher
incid
blood
bag
breakag
red
blood
cell
rbc
low
concentr
glycerol
highli
suscept
damag
induc
transient
warm
event
twe
allow
ice
recrystal
occur
novel
small
molecul
ice
recrystal
inhibitor
iri
shown
control
ice
crystal
size
growth
throughout
cryopreserv
process
afford
improv
protect
rbc
aim
purpos
studi
use
small
scale
model
mimic
freez
warm
profil
full
size
glycerol
rcc
evalu
effect
iri
protect
rbc
twe
afford
storag
method
sampl
prepar
ad
glycerol
without
iri
rbc
control
frozen
either
placement
directli
freezer
vapor
phase
liquid
nitrogen
follow
storag
liquid
nitrogen
storag
test
sampl
glycerol
iri
frozen
vapor
phase
liquid
nitrogen
mimic
freez
rate
full
size
rcc
frozen
directli
liquid
nitrogen
set
sampl
thaw
test
hemolysi
drabkin
method
h
day
post
glycerol
second
set
sampl
expos
either
fast
twe
expos
room
temperatur
slow
twe
expos
sampl
reach
exposur
sampl
return
storag
thaw
test
multipl
storag
time
point
third
set
sampl
expos
set
slow
twe
test
cycl
result
glycerol
control
sampl
without
twe
day
hemolysi
store
liquid
nitrogen
frozen
liquid
nitrogen
vapor
store
frozen
store
glycerol
control
frozen
store
hemolysi
glycerol
supplement
iri
frozen
liquid
nitrogen
vapor
store
post
thaw
hemolysi
improv
rbc
stabil
glycerol
alon
exposur
either
fast
slow
twe
glycerol
sampl
hemolysi
respect
howev
addit
iri
hemolysi
decreas
fast
slow
twe
multipl
slow
twe
hemolysi
sampl
contain
iri
stabil
remain
lower
sampl
summaryconclus
addit
iri
glycerol
process
rbc
cryopreserv
fast
freez
rate
follow
storag
demonstr
compar
result
store
liquid
nitrogen
iri
protect
rbc
damag
occur
multipl
twe
j
j
r
ottawa
ottawa
blood
servic
edmonton
canada
background
storag
time
refriger
blood
limit
day
cryopreserv
red
blood
cell
rbc
desir
method
extend
storag
time
year
rbc
cryopreserv
wv
glycerol
current
method
howev
routin
util
manag
larg
suppli
blood
prior
transfus
frozen
blood
must
thaw
deglycerol
process
requir
special
equip
result
use
frozen
blood
remain
impract
freez
thaw
signific
amount
cell
experi
cellular
damag
result
ice
format
recrystal
process
occur
larg
ice
crystal
grow
larger
expens
smaller
one
ice
recrystal
inhibitor
iri
abil
inhibit
process
protect
rbc
freez
thaw
use
iri
cryoprotect
allow
reduct
amount
glycerol
significantli
reduc
deglycerol
time
would
allow
frozen
rbc
rapidli
prepar
emerg
transfus
may
aid
manag
blood
suppli
aim
project
involv
use
small
molecul
iri
cryopreserv
rbc
use
reduc
glycerol
shown
carbohydr
deriv
exhibit
iri
activ
abil
increas
percentag
intact
rbc
presenc
glycerol
iri
yield
low
cell
recoveri
aim
project
design
new
class
iri
hydrophil
b
cryopreserv
deglycerol
rbc
use
iri
mean
improv
cell
recoveri
method
nine
small
molecul
carbohydr
deriv
synthes
use
convent
procedur
test
iri
activ
rbc
cryopreserv
use
molecul
combin
wv
glycerol
frozen
either
dri
ice
thaw
immedi
water
bath
percent
hemolysi
determin
use
drabkin
assay
prior
deglycerol
osmot
fragil
studi
perform
determin
optim
salin
wash
condit
rbc
sampl
deglycerol
manual
use
centrifug
supernat
remov
wash
remain
pack
rbc
resuspend
sagm
solut
percent
cell
recoveri
calcul
base
chang
rbc
volum
hematocrit
result
thaw
one
iri
show
increas
percentag
intact
rbc
compar
glycerol
control
vs
osmot
fragil
studi
show
rbc
suspend
cryosolut
contain
iri
high
osmot
toler
wash
could
use
deglycerol
combin
glycerol
iri
afford
rbc
recoveri
compar
glycerol
control
summaryconclus
small
molecul
iri
repres
novel
class
cryprotect
abil
success
cryopreserv
rbc
use
reduc
glycerol
concentr
significantli
improv
recoveri
work
demonstr
structur
iri
ration
modifi
specif
vitro
applic
c
ravanat
v
heim
dupui
c
gachet
de
strasbourg
inserm
ef
grand
est
bpp
fmt
strasbourg
franc
background
biotin
biot
altern
radioact
blood
cell
tracer
allow
one
concurr
track
vivo
multipl
cell
popul
label
differ
biot
densiti
far
red
blood
cell
safe
transfus
man
assess
surviv
mock
concern
platelet
biot
method
util
simultan
monitor
surviv
plt
anim
franco
alberio
howev
one
studi
man
describ
track
popul
stohlawetz
aim
aim
label
human
platelet
plt
differ
level
biot
determin
whether
biotinyl
affect
function
preliminari
studi
explor
feasibl
product
clinic
trial
method
plt
tyrod
albumin
ta
treat
wash
twice
remov
excess
biot
mixtur
tapppcit
vv
biot
densiti
control
flow
cytometri
analysi
label
plt
function
assess
paramet
secret
glycoprotein
gp
integr
aggreg
result
variou
popul
could
distinguish
flow
cytometri
biot
mfi
biot
mfi
biot
mfi
biot
mfi
popul
display
swirl
gpib
gpiibiiia
express
normal
use
trap
quantit
extern
stabl
biot
label
slightli
lower
biot
biot
biot
biot
biot
plt
aggreg
use
arachidon
acid
mm
well
preserv
biot
amplitud
biot
amplitud
biot
amplitud
biot
amplitud
wherea
biotinyl
impair
respons
adp
collagen
dose
depend
manner
aggreg
almost
abolish
adp
biot
amplitud
biot
amplitud
biot
amplitud
biot
amplitud
collagen
biot
amplitud
biot
amplitud
biot
amplitud
biot
amplitud
summaryconclus
main
plt
function
test
ie
secret
gp
integr
aggreg
respons
strong
agonist
arachidon
acid
fulli
preserv
biot
densiti
use
contrast
biot
label
affect
respons
adp
collagen
conclud
label
would
suitabl
trace
plt
clinic
trial
provid
low
biot
densiti
use
full
plt
function
critic
approach
help
evalu
new
plt
product
fulfil
need
tracer
v
carlier
ecol
de
scienc
criminel
univers
lausann
lausann
switzerland
background
blood
sampl
crime
scene
crucial
investig
step
aim
collect
set
bloodstain
help
reconstruct
past
event
mostli
dna
profil
repres
challeng
crime
scene
investig
must
balanc
number
stain
collect
without
miss
relev
sampl
reach
goal
usual
reli
experi
blood
pattern
analysi
aim
discrimin
bloodstain
differ
sourc
directli
crime
scene
would
repres
third
approach
provid
investig
valuabl
inform
minim
number
distinct
sourc
distinct
bloodstain
sampl
method
approach
base
use
antibodi
discrimin
bloodstain
reach
goal
first
necessari
determin
distribut
blood
antigen
correl
individu
blood
antigen
repres
highest
discriminatori
power
blood
antigen
identifi
literatur
sever
ethnic
group
set
fifteen
individu
mainli
caucasian
use
grifol
profil
kit
second
step
determin
select
antigen
stabl
time
avail
immunodetect
bloodstain
twelv
individu
ie
three
donor
per
blood
group
abo
model
left
five
substrat
ie
glass
tile
paper
fabric
wood
stain
dri
month
room
temperatur
laboratori
dot
blot
techniqu
carri
detect
presenc
chosen
antigen
ab
bloodstain
assess
specif
approach
use
b
bloodstain
neg
control
third
step
consist
establish
applic
protocol
compat
crime
scene
use
result
result
discriminatori
power
calcul
indic
antigen
abo
blood
group
discriminatori
antigen
among
antigen
test
correl
measur
show
antigen
distribut
among
experiment
set
correl
dot
blot
success
detect
antigen
ab
bloodstain
month
confirm
antigen
stabl
enough
time
current
approach
requir
solubil
bloodstain
could
hinder
applic
crime
scene
issu
illustr
one
difficulti
forens
investig
bloodstain
like
dri
must
process
effort
current
focus
way
local
solubil
bloodstain
use
anticoagul
thrombolyt
agent
promot
way
interact
antibodi
summaryconclus
conclud
research
aim
provid
crime
scene
investig
new
method
support
select
process
bloodstain
sampl
antigen
abo
blood
group
identifi
promis
discrimin
target
result
show
still
possibl
detect
antigen
month
dri
bloodstain
requir
consid
blood
type
crime
scene
research
also
illustr
antibodi
blood
antigen
use
forens
scienc
help
polic
investig
k
r
j
medicin
univers
medicin
greifswald
center
humor
immun
respons
cardiovascular
disord
univers
greifswald
greifswald
germani
background
platelet
concentr
pc
current
store
room
temperatur
rt
day
pc
storag
attract
option
reduc
bacteri
prolifer
reveal
differ
standard
qualiti
test
platelet
metabol
aggreg
activ
platelet
function
impair
assay
understand
contrast
analyz
detail
platelet
cytoskeleton
aggreg
behaviour
differ
surfac
cold
store
pc
deeper
insight
platelet
biomechan
properti
introduc
deform
cytometri
function
platelet
assay
base
cell
mechan
properti
measur
carri
without
sampl
prepar
base
intrins
materi
properti
highlight
potenti
cell
mechan
biomark
platelet
qualiti
control
aim
aim
studi
gain
deeper
insight
bind
aggreg
behaviour
platelet
character
biomechan
properti
method
platelet
apheresi
pc
healthi
donor
contain
addit
solut
ssp
maco
pharma
franc
store
either
rt
day
sampl
taken
day
donat
platelet
sampl
underw
fluoresc
microscopi
tubulin
stain
platelet
adhes
assess
collagen
laminin
fibronectin
fibrinogen
deform
cytometri
hydrodynam
method
mechan
cell
character
base
suspend
cell
pump
microfluid
channel
cell
deform
hydrodynam
shear
forc
without
physic
contact
cell
constrict
wall
cell
transloc
channel
camera
captur
imag
deform
allow
analysi
base
intrins
cell
properti
throughput
approxim
cellss
allow
carri
assay
within
second
without
extens
sampl
prepar
result
enabl
clear
differenti
rt
store
platelet
cold
storag
condit
deform
platelet
reduc
sem
biolog
replic
sampl
store
rt
show
elev
deform
p
platelet
size
project
area
decreas
cold
storag
platelet
vs
day
p
cytoskeleton
store
platelet
assess
rapidli
degrad
shown
tubulin
morpholog
alreadi
day
importantli
platelet
form
aggreg
test
matric
start
day
day
storag
constantli
increas
thereaft
strongli
indic
cold
store
platelet
might
increas
risk
summaryconclus
platelet
store
day
bear
risk
caus
allow
captur
underli
alter
platelet
cytoskeleton
h
base
analysi
platelet
biomechan
properti
r
e
experiment
transfus
medicin
dresden
imtek
freiburg
freiburg
germani
parasitolog
biomed
primat
research
centr
rijswijk
netherland
background
blood
pharm
use
embryon
bone
marrow
induc
stem
cell
repres
new
fascin
option
warrant
blood
suppli
futur
howev
littl
known
mechan
factor
would
allow
effici
vitro
gener
enucl
blood
cell
mention
progenitor
aim
show
overexpress
erythroid
precursor
enabl
sustain
exponenti
glycophorin
erythroblast
method
use
antibiot
induc
lentivir
vector
system
transduc
erythroid
precursor
cell
deriv
stem
cell
mobil
peripher
blood
blood
group
ab
rhd
five
differ
oncogen
larget
combin
two
h
transduct
gene
express
induc
addit
doxycyclin
absenc
doxycyclin
oncogen
express
use
singl
cell
print
technolog
singl
cell
coloni
obtain
expand
analys
express
morpholog
result
transduct
oncogen
alon
lead
immort
cell
combin
transduct
lead
immort
erythroid
precursor
cell
continu
prolifer
year
furthermor
obtain
singl
cell
coloni
cell
differ
morpholog
express
pattern
differ
surfac
marker
remov
doxycyclin
part
cell
differenti
normoblast
reticulocyt
within
day
summaryconclus
immort
erythroid
precursor
cell
provid
model
erythrocyt
biogenesi
could
potenti
contribut
stabl
suppli
erythrocyt
transfus
could
pave
way
develop
univers
blood
rhd
cf
coleman
j
jaza
machaba
vermeulen
donat
test
south
african
nation
blood
servic
roodepoort
south
africa
background
south
african
nation
blood
servic
approach
roch
clinic
oper
perform
post
european
conform
ce
mark
studi
roch
coba
instrument
new
hiv
duo
assay
ce
mark
fda
approv
novel
duo
technolog
allow
discrimin
antigen
antibodi
reactiv
ad
inform
infect
recenc
aim
evalu
specif
hiv
hcv
hbsag
tpha
assay
coba
screen
south
african
blood
donor
compar
abbott
prism
spinreact
assay
respect
marker
sensit
evalu
compar
confirm
posit
donor
across
system
method
septemb
subset
approxim
randomli
select
donor
sampl
test
daili
parallel
use
roch
elecsi
hiv
duo
hbsag
tpha
abbott
prism
hiv
plu
hbsag
spinreact
tpha
beckman
coulter
specif
calcul
test
donat
hiv
hcv
hbsag
tpha
discord
reactiv
sampl
confirm
compar
nucleic
acid
test
result
procleix
ultrio
elit
perform
confirmatori
test
biorad
geeniu
hbsag
elecsi
neutral
tpha
recomwel
treponema
igm
igg
result
approxim
donat
test
first
time
repeat
donor
specif
marker
use
coba
prism
respect
follow
hiv
ci
ci
hbsag
ci
hcv
ci
specif
tpha
significantli
differ
ci
ci
elecsi
tpha
spinreact
tpha
respect
p
four
hbsag
nine
confirm
posit
donat
detect
assay
concurr
hiv
duo
assay
detect
three
addit
antibodi
two
antigen
fals
posit
donat
hiv
antigen
posit
donat
confirm
elecsi
detect
fals
posit
donat
none
confirm
confirm
syphili
posit
donat
elecsi
tpha
detect
sensit
ci
spinreact
tpha
detect
posit
donat
give
sensit
ci
syphili
assay
fail
detect
one
tpha
igm
posit
sampl
summaryconclus
specif
coba
assay
compar
abbott
prism
assay
comparison
two
assay
may
bias
repeat
donor
use
evalu
therefor
fals
posit
abbott
prism
assay
may
screen
increas
specif
elecsi
hiv
hbsag
hcv
assay
abl
detect
confirm
posit
studi
elecsi
tpha
assay
significantli
sensit
spinreact
tpha
detect
tpha
igg
antibodi
p
specif
lower
p
detect
tpha
igg
antibodi
less
import
blood
servic
indic
resolv
infect
base
result
studi
coba
could
consid
transfus
servic
blood
screen
milet
stojic
vidov
jukic
croatian
institut
transfus
medicin
zagreb
croatia
background
croatian
institut
transfus
servic
routin
screen
regular
serolog
assay
hiv
hiv
antigenantibodi
hcv
hbv
hbsag
syphili
addit
respect
assay
method
comparison
roch
coba
e
abbott
prismarchitect
paramet
carri
octob
januari
aim
aim
studi
evalu
specif
one
key
perform
criteria
platform
roch
coba
e
abbott
prismarchitect
main
four
screen
serolog
paramet
method
follow
assay
use
hiv
duo
ii
hbsag
ii
syphili
prism
hiv
agab
combo
prism
hcv
prism
hbsag
well
architect
syphili
tp
follow
verif
method
use
decid
fals
correct
posit
result
immunoblot
ag
hiv
combin
assay
hiv
immunoblot
hcv
ag
assay
hcv
hbsag
confirmatori
test
hepat
b
serolog
profil
hbsag
immunoblot
tpha
rpr
syphili
elisa
syphili
addit
triplex
hbv
dna
hcv
rna
hiv
rna
result
specif
result
coba
e
hiv
duo
n
ii
n
hbsag
ii
n
n
syphili
abbott
prism
specif
hiv
agab
combo
hcv
hbsag
abbott
architect
syphili
tp
reveal
specif
summaryconclus
observ
specif
perform
data
roch
coba
e
elecsi
screen
assay
similar
respect
abbott
prismarchitect
assay
show
slightli
higher
specif
statist
differ
take
consider
test
blood
donor
popul
unselect
compris
approx
repeat
regular
donor
approx
donor
certain
howev
difficult
quantifi
bia
due
process
mani
year
routin
use
put
caus
slightli
differ
specif
result
new
establish
screen
assay
platform
consid
suitabl
blood
donor
screen
van
weert
l
n
teunissen
e
bakker
nation
screen
laboratori
sanquin
sanquin
blood
suppli
amsterdam
netherland
background
sanquin
blood
suppli
continu
investig
new
develop
acquir
share
knowledg
improv
qualiti
blood
suppli
toward
purpos
nation
screen
laboratori
sanquin
evalu
panel
five
assay
new
instrument
includ
recent
hiv
duo
assay
aim
studi
comparison
made
specif
new
coba
assay
establish
routin
screen
assay
test
whole
blood
donat
plasmapheresi
sampl
panel
includ
hiv
hbsag
syphili
result
demonstr
elecsi
assay
fulfil
direct
specif
method
may
june
sampl
whole
blood
repeat
donor
new
donor
fresh
plasmapheresi
donor
test
elecsi
hiv
duo
hivag
ahiv
ii
ii
hbsag
syphili
result
compar
routin
result
hiv
plu
hbcore
hcv
hbsag
olympu
discrep
posit
sampl
confirm
respect
assay
coba
mpx
except
syphili
confirmatori
assay
immunoblot
result
specif
sampl
test
elecsi
hiv
duo
hivag
ahiv
prism
next
hiv
plu
elecsi
ii
prism
next
hbcore
elecsi
ii
prism
next
hcv
elecsi
hbsag
prism
next
hbsag
elecsi
syphili
olympu
confirm
posit
sampl
detect
assay
summaryconclus
result
demonstr
routin
laboratori
environ
elecsi
assay
investig
provid
requir
regulatori
demand
specif
compar
establish
test
blood
screen
system
confirm
posit
sampl
detect
system
expect
separ
antigen
antibodi
hivag
ahiv
provid
ad
inform
depend
donat
test
strategi
blood
donat
screen
laboratori
may
potenti
shorten
clarif
reactiv
result
one
note
compar
specif
new
assay
platform
routin
assay
potenti
bias
sinc
donor
reactiv
donat
past
rule
time
therefor
donor
caus
fals
posit
result
past
assess
c
tingu
hotz
c
niederhaus
infecti
diseas
interregion
blood
transfus
servic
src
ltd
bern
switzerland
background
test
blood
donat
marker
infecti
diseas
blood
bank
play
import
role
maintain
safeti
blood
transfus
mandatori
serolog
test
perform
hiv
agab
hbsag
syphili
highli
specif
sensit
test
correspond
autom
essenti
purpos
aim
evalu
perform
elecsi
hiv
duo
ii
hbsag
ii
syphili
roch
diagnost
infecti
diseas
paramet
new
coba
e
instrument
compar
studi
carri
current
use
elisa
method
quadriga
befre
system
siemen
healthcar
diagnost
method
studi
took
place
interregion
blood
transfus
servic
bern
switzerland
specif
paramet
studi
blood
donor
sera
use
sera
first
time
repeat
donor
sampl
test
initi
quadriga
free
system
enzygnost
hbsag
enzygnost
enzygnosthiv
integr
beckman
coulter
tpha
newmarket
biomed
sampl
retest
day
coba
e
elecsi
hiv
duo
ii
hbsag
ii
syphili
initi
reactiv
sampl
repeat
duplic
discriminatori
test
carri
repeatedli
reactiv
sampl
use
altern
screen
test
neutralis
hbsag
abbott
architect
system
immunoblot
fujirebio
well
individu
donat
nucleic
acid
assay
hcv
hiv
hbv
roch
coba
system
result
base
result
test
blood
donat
observ
specif
roch
elecsi
assay
coba
e
r
siemen
enzygnost
assay
quadriga
befre
compar
specif
confid
interv
hcv
r
hiv
r
hbsag
r
syphili
r
initi
reactiv
ir
repeat
reactiv
rr
specif
ident
one
sampl
posit
elecsi
hbsag
ii
confirm
elecsi
hbsag
confirmatori
assay
neg
enzygnost
hbsag
architect
hbsag
confirmatori
architect
roch
hbv
id
nat
test
sampl
includ
repetit
hbsag
confirmatori
assay
assay
roch
diagnost
neg
indic
roch
elecsi
hbsag
result
fals
reactiv
summaryconclus
observ
perform
roch
elecsi
assay
siemen
enzygnost
assay
compar
blood
donor
screen
set
due
insuffici
number
donor
sampl
test
parallel
abl
analys
specif
data
statist
worth
note
sampl
includ
studi
deriv
repeat
donor
previous
test
enzygnost
assay
elecsi
assay
hiv
agab
hbsag
syphili
assay
system
exhibit
good
specif
highli
suitabl
practic
routin
blood
donor
screen
j
burkhart
sauer
b
herb
f
weinauer
blood
donor
servic
bavarian
red
cross
munich
germani
background
screen
blood
product
hiv
antibodi
combin
assay
hiv
antigenantibodi
hcv
hbv
hbsag
mandatori
germani
addit
respect
nat
assay
voluntari
aim
investig
specif
perform
new
roch
coba
e
platform
siemen
quadriga
befre
system
method
comparison
paramet
carri
novemb
decemb
method
specif
one
key
perform
criteria
platform
roch
coba
e
siemen
quadriga
befre
system
evalu
main
four
screen
paramet
parallel
test
approxim
blood
donat
follow
assay
use
hiv
duo
ii
hbsag
ii
ii
hiv
integr
iv
monoclon
hbsag
result
specif
result
coba
hiv
duo
n
ii
n
hbsag
ii
n
n
ii
initi
reactiv
ir
repeat
reactiv
rr
result
assay
equal
siemen
quadriga
befre
system
respect
specif
hiv
integr
iv
ir
rr
n
ir
rr
ir
rr
hbsag
n
monoclon
reveal
specif
ir
rr
n
fals
neg
sampl
observ
posit
hcv
immunoblotneg
sampl
exclud
calcul
due
inconclus
result
confirmatori
test
summaryconclus
observ
specif
perform
data
roch
coba
e
elecsi
screen
assay
similar
respect
siemen
enzygnost
assay
quadriga
befre
system
show
slightli
higher
specif
hiv
note
major
test
donat
regular
repeat
donor
repeat
donor
test
previous
siemen
enzygnost
assay
platform
consid
suitabl
blood
donor
screen
c
de
la
n
transfus
safeti
laboratori
banc
de
sang
teixit
barcelona
isciii
madrid
vall
dhebron
hospit
research
institut
barcelona
spain
background
hepat
e
viru
potenti
threat
blood
safeti
blood
tissu
bank
catalonia
spain
screen
blood
donat
fulli
autom
nat
platform
contrast
nat
method
nucleic
acid
amplif
reaction
brought
signal
satur
observ
variabl
signal
sco
valu
commerci
hev
nat
parallel
hev
viral
load
sampl
aim
object
studi
assess
whether
correl
sco
signal
tma
method
hev
viral
load
blood
donat
method
hev
rna
posit
blood
donat
sampl
sampl
respect
total
n
sampl
includ
studi
sampl
test
individu
qualit
nat
hev
method
procleix
hev
assay
panther
grifol
limit
detect
lod
iuml
accord
manufactur
insert
two
differ
lot
reagent
use
sco
valu
respect
posit
calibr
record
viral
load
hev
rna
posit
donat
assess
quantit
real
time
pcr
use
hev
rna
standard
pei
viral
load
express
iuml
result
mean
sco
valu
standard
set
final
concentr
iuml
cv
n
replic
hev
rna
posit
donat
sco
valu
rang
comparison
sco
valu
commerci
assay
estim
viral
load
sampl
show
linear
correl
low
sco
valu
correl
nice
low
viral
load
formula
could
obtain
calcul
estim
viral
load
accord
sco
valu
qualit
commerci
assay
equal
sco
valu
x
equal
estim
viral
load
express
mean
sco
valu
posit
calibr
commerci
reagent
lot
n
replic
lot
n
replic
coeffici
variat
cv
appli
formula
obtain
previous
hev
transcript
concentr
posit
calibr
commerci
system
would
equal
iuml
log
claim
lod
assay
summaryconclus
unlik
previou
experi
tma
reagent
hcvhivhbv
nat
screen
hev
nat
perform
assay
provid
rough
estim
hev
viral
load
sampl
hand
quit
high
variabl
sco
valu
observ
among
replic
even
hev
rna
concentr
well
assay
lod
may
lead
result
slightli
sco
true
posit
sampl
addit
run
extern
posit
control
set
concentr
closer
lod
advis
f
k
h
e
laboratori
medicin
aga
khan
univers
hospit
karachi
pakistan
hopkin
univers
school
medicin
baltimor
unit
state
khan
univers
hospit
karachi
pakistan
patholog
john
hopkin
univers
school
medicin
baltimor
unit
state
background
transfus
transmiss
infect
tti
remain
challeng
incom
countri
given
defici
span
donor
select
test
hemovigil
qualiti
system
publish
data
tti
pakistan
part
south
asia
lack
aim
sought
character
epidemiolog
ie
seropreval
demograph
tempor
trend
major
tti
hiv
hepat
b
hbv
c
hcv
syphili
malaria
blood
donor
major
academ
center
pakistan
method
retrospect
data
analysi
conduct
donat
blood
bank
aga
khan
univers
hospit
akuh
januari
decemb
akuh
locat
karachi
one
largest
tertiari
care
teach
hospit
pakistan
offer
comprehens
medic
surgic
servic
includ
stem
cell
transplant
karachi
also
largest
metropolitan
citi
pakistan
afford
broad
donor
represent
donat
routin
screen
hiv
third
gener
autom
chemiluminesc
immunoassay
clia
hepat
c
clia
hepat
b
hbsag
clia
syphili
vdrl
carbon
antigen
rpr
kit
malaria
ict
malaria
rapid
sd
malaria
antigen
test
reactiv
test
repeat
sampl
data
collect
use
blood
bank
inform
system
total
seropreval
infecti
marker
estim
annual
seroreact
rate
compar
replac
donor
test
result
total
blood
donat
collect
twelv
year
donor
male
percent
donor
n
replac
blood
donor
rest
n
voluntari
donor
paid
donat
report
overal
donor
seropreval
infecti
marker
n
trend
transfus
transmit
infect
remain
static
five
pathogen
studi
period
seropreval
infecti
marker
follow
hiv
n
hbv
n
hcv
n
syphili
n
malaria
n
n
seroposit
donor
resid
karachi
remain
seroposit
donor
span
follow
provinc
sindh
balochistan
punjab
khyber
pakhtunkhwa
resid
known
cumul
seropreval
replac
donor
n
versu
vnrbd
n
significantli
differ
p
donor
statu
ie
first
time
vs
repeat
vs
laps
record
therefor
avail
analysi
summaryconclus
find
indic
relianc
donor
pool
overwhelmingli
male
mostli
replac
donor
replac
donat
wide
public
portend
higher
risk
tti
compar
vnrbd
observ
rate
tti
pakistan
larg
static
hcv
hbv
preval
corrobor
studi
pakistan
howev
exclus
use
serolog
test
algorithm
limit
repeat
test
absent
molecular
evalu
pose
region
risk
transfus
transmiss
abstract
withdrawn
p
v
v
transfus
center
laiko
gener
hospit
aid
std
andrea
syggro
hospit
cutan
vener
diseas
athen
greec
background
use
revers
algorithm
syphili
screen
blood
donor
increasingli
adopt
autom
treponem
immunoassay
undoubtedli
mediat
transit
howev
grow
number
discord
result
treponem
nontreponem
test
impos
challeng
toward
manag
notif
blood
donor
aim
aim
studi
evalu
discord
result
syphili
screen
blood
donor
set
method
septemb
june
serum
sampl
blood
donor
screen
architect
syphili
tp
assay
abbott
diagnost
initi
reactiv
sampl
signal
cutoff
valu
sco
sampl
grey
zone
result
sco
test
refer
laboratori
nontreponem
test
vener
diseas
research
laboratori
test
vdrl
second
confirmatori
treponem
test
treponem
pallidum
agglutin
assay
tppa
result
vdrl
tppa
test
report
neg
posit
tppa
posit
sampl
report
end
point
titer
statist
analysi
perform
spss
includ
descript
frequenc
spearman
correl
sco
tppa
titer
roc
receiv
oper
characterist
curv
analysi
result
total
blood
donat
screen
syphili
use
revers
algorithm
via
autom
chemiluminesc
immunoassay
clia
character
initi
reactiv
sampl
sco
grey
zone
result
supplement
test
nontreponem
vdrl
test
confirm
clia
reactiv
case
tppa
use
confirmatori
test
sampl
confirm
posit
wherea
sampl
neg
among
vdrl
neg
sera
sampl
tppa
posit
could
repres
sampl
individu
earli
primari
infect
treat
syphili
defer
blood
donor
median
sco
ratio
higher
among
sampl
compar
sampl
vs
furthermor
correl
analysi
reveal
strong
posit
correl
sco
ratio
tppa
titer
spearman
correl
coeffici
r
p
roc
curv
analysi
exhibit
area
curv
auc
ci
reveal
optim
sco
cutoff
valu
predict
posit
result
summaryconclus
manag
blood
donor
posit
syphili
screen
could
complic
delic
issu
therefor
confirmatori
test
import
discord
sampl
clia
posit
vdrl
neg
corrobor
confirmatori
treponem
test
tppa
discrimin
fals
reactiv
blood
donor
either
treat
earli
primari
syphili
analysi
data
reveal
sco
valu
potenti
discrimin
sera
need
confirm
tppa
analysi
initi
screen
valu
optim
sco
valu
confirmatori
ttpa
analysi
omit
moreov
discord
treponem
result
clia
posit
tppa
neg
lower
sco
valu
optim
cutoff
like
repres
fals
posit
case
b
x
x
h
j
f
w
center
zhejiang
provinc
provinci
key
laboratori
blood
safeti
research
hangzhou
china
background
screen
blood
donor
mandatori
china
therefor
data
preval
chines
blood
donor
rare
test
preform
blood
donor
zhejiang
provinc
china
current
donat
determin
aim
aim
studi
evalu
htlv
preval
chines
blood
donor
compar
result
western
blot
pcr
method
method
donor
preform
physic
examin
accord
donat
regul
china
screen
hb
hbsag
alanin
aminotransferas
alt
donat
defer
donat
hbsag
posit
alt
level
abnorm
iuml
hb
level
lower
male
gl
femal
gl
follow
donat
sampl
preform
use
elisa
reagent
accord
manufactur
instruct
sampl
reactiv
elisa
test
western
blot
assay
wb
dna
sampl
also
detect
use
pcr
techniqu
research
support
scienc
foundat
zhejiang
health
bureau
result
total
sampl
posit
found
donat
initi
reactiv
rate
blood
donat
initi
reactiv
sampl
analyz
wb
result
show
sampl
posit
sampl
indetermin
sampl
neg
posit
individu
type
confirm
posit
rate
blood
donat
dna
initi
reactiv
sampl
analyz
individu
wb
posit
reactiv
pcr
individu
wb
indetermin
neg
reactiv
pcr
summaryconclus
htlv
preval
data
obtain
chines
blood
donor
pcr
assay
may
confirm
method
substitut
wb
x
x
l
l
x
blood
center
dalian
china
int
pari
franc
background
blood
donat
screen
plu
nucleic
acid
test
assay
grifol
requir
secondari
diagnost
step
use
separ
amplif
discriminatori
assay
identifi
origin
multiplex
reactiv
howev
reactiv
nrr
sampl
defin
multiplex
reactiv
discriminatori
assay
andor
repeat
multiplex
observ
confirm
hbv
dna
reactiv
prove
challeng
donor
occult
hbv
infect
obi
especi
test
inform
due
high
preval
also
critic
limit
blood
product
wastag
definit
deferr
potenti
safe
donor
area
experienc
donor
shortag
aim
develop
altern
hbv
dna
confirm
algorithm
use
viral
particl
concentr
procedur
coupl
optim
sensit
nest
pcr
assay
method
blood
donor
dalian
china
screen
hbsag
elig
donor
test
two
hbsag
eia
hbv
dna
use
plu
assay
individu
sampl
nat
initi
reactiv
ir
discrimin
accord
manufactur
procedur
nat
sampl
retest
twice
discrimin
use
procleix
ultrio
plu
assay
viral
particl
concentr
done
ultracentrifug
g
h
precipit
polyethylen
glycol
peg
ml
plasma
respect
nest
pcr
target
differ
region
hbv
genom
bcppc
precorecor
develop
optim
lod
iuml
use
intern
standard
repeat
dna
test
replic
perform
use
ultrio
elit
assay
result
sampl
reactiv
hbsag
base
repeat
discriminatori
test
sampl
identifi
nrr
dna
repeat
reactiv
rr
sampl
confirm
obi
carrier
ultrio
elit
repeat
test
randomli
select
nrr
rr
control
sampl
perform
nrr
sampl
consist
show
reactiv
replic
respect
replic
reactiv
rr
control
hbv
dna
detect
least
one
pcr
assay
nrr
sampl
follow
viru
concentr
peg
precipit
ultracentrifug
respect
five
ultrio
elit
sampl
pcr
irrespect
virion
concentr
procedur
hbv
dna
consist
detect
rr
sampl
least
two
pcr
assay
addit
nrr
plasma
sampl
dalian
blood
donor
ultracentrifug
hbv
dna
detect
sampl
summaryconclus
combin
highli
sensit
nat
presenc
low
level
hbv
dna
result
nrr
rate
blood
donor
dalian
china
concentr
viral
particl
larg
volum
plasma
develop
sensit
hbv
nest
pcr
confirm
presenc
hbv
dna
nrr
donor
sequenc
amplifi
product
definit
confirm
hbv
infect
peg
precipit
may
constitut
altern
method
concentr
hbv
particl
ultracentrifug
implement
technic
econom
reason
debruyn
e
de
samblanx
vanbrab
muylaert
e
lazarova
blood
servic
belgian
red
mechelen
belgium
background
countri
blood
donat
routin
screen
presenc
hiv
hbv
hcv
nucleic
acid
test
nat
previou
assay
base
simultan
detect
virus
requir
addit
step
discrimin
introduct
discriminatori
nat
assay
combin
new
gener
diagnost
platform
result
increas
throughput
amelior
user
friendli
improv
donor
manag
one
new
assay
coba
mpx
assay
roch
coba
platform
allow
discriminatori
detect
group
rna
rna
group
rna
human
plasma
serum
sampl
aim
aim
studi
diagnost
perform
coba
mpx
assay
coba
system
comparison
coba
taqscreen
mpx
assay
coba
system
method
verif
diagnost
specif
determin
test
minipool
donat
coba
taqscreen
mpx
assay
coba
mpx
assay
parallel
assess
diagnost
sensit
total
sampl
reactiv
hbv
hcv
hiv
test
coba
mpx
assay
individu
limit
detect
lod
determin
probit
analysi
use
refer
standard
equival
roch
materi
also
implement
coba
synergi
softwar
middlewar
connect
hamilton
star
pool
instrument
coba
system
laboratori
inform
system
manag
total
workflow
one
year
implement
assay
januari
total
donat
test
minipool
investig
reproduc
precis
calcul
cycl
threshold
valu
assay
control
measur
one
year
result
verif
diagnost
specif
sensit
lod
hbv
hcv
iuml
cpml
respect
sinc
implement
assay
sampl
nat
reactiv
test
individu
ten
result
confirm
serolog
test
nat
test
extern
laboratori
one
result
specif
howev
also
observ
pool
initi
reactiv
reactiv
result
test
individu
like
pool
caus
amplif
thu
lower
specif
cv
hbv
hcv
respect
sinc
first
user
synergi
softwar
frequent
encount
teeth
problem
hamper
workflow
summaryconclus
coba
mpx
assay
coba
show
high
analyt
diagnost
sensit
good
reproduc
routin
test
regularli
observ
reactiv
pool
resolv
individu
level
lower
initi
diagnost
specif
furthermor
synergi
softwar
current
deliv
ad
valu
compar
predecessor
limit
advis
improv
l
c
c
c
divis
clinic
immunolog
immunohematolog
transfus
medicin
transplant
immunolog
region
refer
laboratori
transplant
immunolog
aou
depart
intern
specialti
medicin
medic
surgic
neurolog
metabol
geriatr
scienc
degli
studi
della
campania
luigi
vanvitelli
sdn
napl
itali
background
chronic
hepat
c
viru
hcv
infect
estim
affect
million
individu
worldwid
screen
assay
hcv
detect
routin
perform
specif
antibodi
assay
order
guarante
safeti
blood
donat
hcvrna
detect
nucleic
acid
test
nat
also
perform
blood
donor
complianc
nation
law
mani
industri
countri
nat
introduct
blood
donor
screen
decreas
risk
viral
transmiss
via
blood
transfus
unfortun
hcv
transmiss
hemocompon
still
problem
develop
countri
nat
implement
high
cost
technic
skill
requir
aim
aim
studi
evalu
perform
hcv
core
antigen
assay
potenti
altern
nat
determin
clinic
util
manag
blood
donor
method
n
random
blood
donor
age
year
averag
result
reactiv
studi
serum
sampl
evalu
hcv
detect
use
architect
assay
chemiluminesc
microparticl
immunoassay
cmia
platform
abbott
diagnost
wiesbaden
germani
besid
sampl
test
also
architect
assay
sera
yield
samplecutoff
sco
ratio
score
gray
zone
gz
yield
sco
ratio
reactiv
sampl
reactiv
gz
sampl
assay
check
confirmatori
test
hcv
specif
immunoblot
assay
fujirebio
italia
srl
relationship
sco
confirm
seroposit
sampl
assess
blood
donat
screen
also
nat
taqscreen
method
coba
system
roch
molecular
system
branchburg
nj
usa
assay
perform
mini
pool
six
sampl
nomin
sensit
intern
unit
per
millilit
iuml
result
sampl
n
reactiv
sco
n
result
gz
reactiv
sampl
sco
posit
assay
result
also
nat
posit
correl
assay
nat
summaryconclus
data
highlight
assay
correl
highli
nat
especi
sampl
yield
sco
thu
reliabl
easi
serolog
marker
assay
could
support
nat
mainli
countri
nat
current
perform
high
cost
implement
serolog
assay
could
provid
new
scenario
blood
safeti
abstract
withdrawn
abstract
withdrawn
k
p
u
test
section
blood
centr
thai
red
cross
societi
bangkok
thailand
background
nation
blood
centr
nbc
thai
red
cross
societi
trc
follow
polici
thailand
blood
servic
recommend
donat
blood
screen
use
serolog
test
nucleic
acid
test
nat
blood
donat
blood
transfus
servic
manag
nbc
trc
blood
donat
throughout
countri
chemiluminesc
immunoassay
cia
serolog
suggest
hiv
agab
hbsag
syphili
detect
nat
suggest
method
chang
mini
pool
six
individu
nat
sinc
januari
annual
report
sampl
donat
blood
collect
nbc
sampl
collect
hospit
blood
bank
hbb
locat
bangkok
nearbi
hbb
donat
blood
sampl
sent
nbc
blood
group
infect
tti
screen
aim
sero
posit
nat
neg
spnn
sampl
implement
method
data
donat
blood
test
collect
januari
octob
blood
donor
nbc
could
distinguish
sex
donor
fd
repeat
donor
rd
data
analyz
excel
program
result
total
sampl
nbc
hbb
test
serolog
test
nat
hiv
hcv
hbv
infect
studi
found
total
seroposit
sampl
hbsag
hiv
agab
respect
sampl
spnn
hbsag
hiv
agab
respect
seroposit
sampl
hbb
hbsag
hiv
agab
sampl
hbsag
hiv
agab
spnn
wherea
total
seroposit
sampl
nbc
hbsag
hiv
agab
also
sampl
male
fd
rd
femal
fd
rd
sampl
separ
male
fd
rd
femal
fd
rd
furthermor
sampl
distinguish
male
fd
rd
femal
fd
rd
summaryconclus
studi
show
although
use
idnat
sampl
could
detect
serolog
test
sensit
serolog
reagent
consid
donat
blood
screen
spnn
sampl
might
fals
posit
serolog
fals
neg
nat
posit
donor
follow
diagnosi
second
test
experi
less
posit
donor
came
back
follow
test
furthermor
studi
show
total
sampl
hbsag
posit
rate
hiv
agab
hiv
rate
respect
signal
ratio
sco
spnn
hbsag
hiv
agab
except
fals
posit
sampl
spnn
sampl
increas
safeti
donat
blood
avoid
tti
recipi
verma
p
negi
j
singh
singh
khan
transfus
medicin
max
super
special
hospit
vaishali
ghaziabad
india
background
one
main
strategi
employ
requir
ensur
blood
safeti
donor
test
variou
pathogen
prevent
transfus
transmit
infect
tti
efficaci
test
depend
abil
detect
certain
marker
infect
two
gener
test
modal
first
nucleic
acid
test
nat
assay
nucleic
acid
sequenc
rna
dna
specif
infecti
agent
genom
second
assay
viral
protein
antibodi
produc
host
specif
infecti
agent
nat
test
gener
sensit
decreas
window
period
infecti
pathogen
compar
serologicprotein
test
aim
main
aim
case
studi
highlight
import
nat
effect
method
safeguard
blood
suppli
method
studi
carri
depart
transfus
medicin
period
year
januari
decemb
total
number
blood
donor
sampl
subject
screen
hiv
viru
hepat
b
viru
hbv
hepat
c
viru
hcv
use
fulli
autom
enhanc
chemiluminesc
immunoassay
assay
eci
processor
vitro
test
perform
hbv
surfac
antigen
hbsag
detect
hbv
detect
hcv
hiv
kit
detect
antigen
glycoprotein
antibodi
hiv
rapid
card
use
detect
malaria
syphili
period
nonreact
sampl
hiv
viru
hepat
b
viru
hbv
hepat
c
viru
hcv
use
fulli
autom
enhanc
chemiluminesc
immunoassay
assay
eci
processor
vitro
subject
nat
plasma
separ
test
use
multiplex
polymeras
chain
reaction
pcr
technolog
result
blood
donor
screen
hiv
hbv
hcv
use
fulli
autom
enhanc
chemiluminesc
immunoassay
assay
eci
processor
vitro
seroreact
hiv
hbv
hcv
nat
yield
seroneg
eci
nat
reactiv
hcv
hbv
sampl
test
includ
hbv
summaryconclus
blood
safeti
still
major
challeng
india
high
preval
hiv
hcv
hbv
rel
low
percentag
voluntari
blood
donor
lack
standard
screen
procedur
among
multitud
blood
collect
center
nat
yield
sampl
test
studi
highli
signific
singl
donat
use
gener
compon
use
differ
recipi
henc
effect
nat
yield
becom
time
save
recipi
tti
reduc
rate
tti
gain
momentum
countri
adopt
nat
test
releas
blood
product
nat
serv
addit
layer
safeti
provid
safe
high
qualiti
blood
blood
compon
patient
requir
blood
transfus
w
saekram
meemook
n
yuttayoth
r
kimilar
p
khamsawang
intharasongkroh
k
chaiwong
blood
test
section
nation
blood
centr
thai
red
cross
societi
bangkok
thailand
background
blood
safeti
provid
sever
process
minim
risk
infect
tti
infect
donor
exclud
donor
select
blood
screen
follow
nation
guidelin
serolog
test
major
role
import
method
blood
donor
screen
routin
laboratori
thailand
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
syphili
test
blood
sampl
provis
blood
safeti
seropreval
tti
among
blood
donor
nation
blood
centr
nbc
thailand
differ
year
studi
aim
assess
seropreval
hiv
hcv
hbv
syphili
nbc
blood
donor
ten
year
result
use
know
thailand
situat
trend
develop
nation
blood
donor
polici
futur
aim
assess
seropreval
hiv
hcv
hbv
syphili
infect
among
blood
donor
nbc
thailand
method
ten
year
retrospect
nbc
blood
donor
serolog
screen
studi
octob
septemb
report
seropreval
includ
hivagab
hcv
antibodi
hbsag
treponema
pallidum
antibodi
use
chemiluminesc
microparticl
immunoassay
cmia
review
summar
result
volunt
blood
donor
ten
year
ago
donor
infect
least
one
pathogen
infect
donor
posit
hiv
hcv
hbv
syphili
summaryconclus
data
hbv
infect
highest
nbc
blood
donor
thailand
follow
hcv
syphili
hiv
respect
seropreval
hiv
hcv
hbv
syphili
infect
continu
deceas
past
result
studi
show
efficaci
blood
donor
select
better
previou
thai
blood
donor
realiz
import
expos
risk
blood
donat
abstract
withdrawn
rezeq
rezeq
qa
palestinian
central
blood
bank
ramallh
palestinian
territori
occupi
background
blood
transfus
one
import
therapeut
procedur
condit
infect
tti
continu
rais
concern
blood
safeti
challeng
safe
blood
transfus
continu
due
new
emerg
pathogen
aim
studi
aim
determin
preval
examin
infect
hepat
b
hbv
hepat
c
hcv
among
blood
donor
palestinian
central
blood
bank
pcbb
reflect
current
statu
transfus
medicin
method
retrospect
cohort
profil
blood
unit
conduct
includ
donor
januari
octob
pcbb
donat
unit
routin
examin
hb
ag
syphili
data
analyz
hbv
hcv
result
among
donat
blood
unit
voluntari
donat
male
averag
age
year
studi
year
around
donor
year
old
anoth
year
old
blood
type
posit
posit
constitut
major
donat
sampl
respect
seropreval
hbsag
highest
preval
seen
hcv
hbv
moreov
seropreval
hbsag
higher
among
male
donor
neg
blood
group
wherea
hcv
seropreval
differ
demograph
factor
summaryconclus
studi
shed
light
high
preval
hbv
hcv
among
blood
donor
might
also
reflect
high
preval
unexamin
tti
thu
urgent
need
develop
blood
safeti
surveil
system
introduc
nucleic
acid
test
list
infect
consid
major
risk
factor
transfus
medicin
accord
intern
societi
blood
transfus
c
c
v
blood
transfus
center
blood
transfus
centr
lao
red
cross
vientian
lao
peopl
democrat
republ
pharmaci
kitasato
univers
tokyo
japan
background
everi
unit
blood
donat
screen
tti
test
transfus
hiv
hbsag
hcv
syphili
among
four
mandatori
test
hbsag
posit
shown
remain
stabl
high
preval
particular
first
time
blood
donor
high
preval
hbv
lao
govern
start
hbv
vaccin
program
newborn
recent
xeuatvongsa
et
al
report
preval
hbsag
high
lao
sinc
mother
year
infant
year
taken
randomli
select
district
whole
countri
show
posit
respect
report
tti
posit
analyz
accord
occup
age
gender
number
blood
donat
nation
blood
transfus
centr
vientian
lao
pdr
aim
investig
trend
tti
preval
among
blood
donor
lao
pdr
method
tti
posit
calcul
routin
screen
test
result
blood
donor
total
donor
volunt
blood
donor
famili
donor
nbtc
hiv
screen
hiv
agab
combo
sd
biolineal
hbsag
hcv
screen
commerci
elisa
kit
monolisa
hbsag
ultra
laboratori
inc
syphili
human
result
hiv
posit
case
signific
increas
respect
major
young
age
hbsag
posit
first
time
donor
repeat
donor
time
male
higher
femal
particular
year
old
show
higher
group
averag
posit
blood
donor
male
time
higher
femal
summaryconclus
increas
hiv
posit
case
show
alarm
statu
donor
select
screen
process
ensur
blood
transfus
safer
donor
posit
hbsag
lao
high
depend
age
gender
reason
high
posit
young
blood
donor
especi
teenag
unknown
probabl
due
horizont
infect
health
problem
normal
social
live
infect
nbtc
introduc
notif
system
donor
found
tti
posit
posit
accept
futur
blood
donor
major
blood
donor
young
gener
lao
howev
current
group
highest
tti
preval
measur
make
blood
safer
alway
consid
jutavijittum
p
et
al
southeast
asian
j
trop
med
public
health
jutavijittum
p
et
al
vox
sang
xeuatvongsa
et
al
plo
one
p
z
manag
resourc
develop
ministri
health
medic
educ
research
center
high
institut
research
educ
transfus
medicin
tehran
research
center
high
institut
research
educ
transfus
medicin
shiraz
iran
background
chief
aim
blood
transfus
organ
provid
adul
safe
blood
suppli
major
infect
tti
includ
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
syphili
consid
worldwid
health
concern
preval
tti
among
blood
donor
could
reflect
safeti
blood
suppli
aim
evalu
infect
preval
among
iranian
blood
donor
method
retrospect
studi
carri
blood
donor
admit
far
blood
transfus
organ
fbto
viral
screen
test
conduct
donat
initi
reactiv
donor
repeatedli
test
confirmatori
test
perform
repeatedli
reactiv
donor
donor
confirm
posit
infect
consid
analyz
preval
infect
calcul
per
donat
result
overal
preval
hbv
hcv
hiv
per
preval
viral
infect
posit
donat
slightli
increas
hbv
hcv
hiv
moreov
shown
tti
preval
significantli
higher
mobil
blood
collect
site
fix
site
vs
summaryconclus
find
indic
tti
preval
studi
region
consider
lower
neighbor
countri
found
preval
increas
studi
period
moreov
seen
donor
admit
mobil
blood
collect
site
carri
higher
risk
tti
fbto
reconsid
strategi
mobil
blood
collect
site
establish
la
b
p
e
g
abbott
laboratori
abbott
park
il
affair
american
red
cross
gaithersburg
md
abbott
laboratori
abbott
park
il
unit
state
america
background
histor
individu
dispos
pipettor
tip
use
altern
complex
sampl
pipettor
wash
protocol
autom
blood
screen
tip
increas
cost
per
test
due
commod
cost
storag
workflow
impact
loadunload
dispos
associ
solid
biohazard
wast
applic
induct
heat
technolog
sampl
probe
altern
individu
dispos
pipettor
tip
provid
method
enhanc
liquid
wash
metal
pipettor
probe
induct
heat
system
induc
altern
current
surfac
metal
probe
probe
electr
resist
current
result
local
highli
control
heat
probe
intern
extern
surfac
increas
temperatur
probe
surfac
activ
liquid
wash
greatli
enhanc
heat
quench
thorough
wash
oper
prior
aspir
next
sampl
prevent
temperatur
relat
impact
subsequ
sampl
aim
demonstr
effect
induct
heat
mean
effect
sampl
probe
wash
blood
screen
alin
method
effect
induct
heat
evalu
alin
new
autom
blood
screen
platform
worst
case
condit
establish
quantif
hbsag
concentr
hbsag
posit
donor
sampl
neg
donor
sampl
test
condit
posit
materi
present
protect
neg
compar
neg
donor
sampl
directli
preced
extrem
high
concentr
hbsag
posit
sampl
unprotect
neg
result
hbsag
concentr
determin
sampl
n
hbsag
posit
donor
identifi
million
donat
sampl
donor
hbsag
concentr
iuml
identifi
base
result
frequenc
find
donor
hbsag
concentr
iuml
approxim
thu
establish
iuml
appropri
worst
case
condit
studi
conduct
alin
use
induct
heat
worst
case
condit
compar
protect
neg
unprotect
neg
two
studi
perform
use
high
posit
sampl
greater
iuml
studi
protect
neg
replic
unprotect
neg
replic
gener
two
studi
mean
unprotect
neg
sco
sco
versu
assay
cutoff
sco
sco
shift
mean
protect
replic
mean
unprotect
replic
sco
sco
respect
summaryconclus
induct
heat
prevent
extrem
high
posit
sampl
impact
subsequ
unprotect
neg
sampl
result
result
indic
induct
heat
provid
accept
sampl
pipettor
wash
without
gener
solid
biohazard
wast
neg
consequ
associ
dispos
pipettor
tip
p
r
j
g
laboratori
abbott
park
laboratori
irv
unit
state
america
background
autom
blood
screen
potenti
contamin
previou
sampl
put
downstream
molecular
test
integr
risk
pipett
tip
filter
barrier
commonli
use
reduc
risk
although
strategi
greatli
increas
cost
per
test
due
addit
commod
storag
workflow
impact
loadunload
dispos
cost
biohazard
wast
aim
meet
critic
need
maintain
sampl
integr
evalu
novel
applic
induct
heat
mean
effect
wash
pipettor
handl
sampl
analyz
serolog
instrument
like
abbott
alin
instrument
nucleic
acid
test
nat
instrument
target
exponenti
amplifi
multipl
thermal
cycl
method
applic
induct
heat
metal
pipettor
warm
resist
electr
current
sweep
pipettor
induct
coil
temperatur
pipettor
elev
throughout
length
effect
induct
heater
evalu
new
autom
blood
screen
platform
alin
abbott
laboratori
extrem
high
viral
load
hbv
sampl
log
iu
dnaml
near
upper
limit
quantit
uloq
molecular
assay
uloq
log
iu
dnaml
realtim
hbv
abbott
molecular
diagnost
sampl
one
log
iu
dnaml
among
highest
hbv
dna
posit
specimen
abbott
global
surveil
program
bias
includ
mostli
ill
patient
seek
healthcar
worst
case
condit
evalu
organ
high
viral
load
hbv
sampl
immedi
known
hbv
dna
neg
sampl
neg
human
plasma
abbott
molecular
diagnost
run
alin
platform
induct
heat
wash
sampl
load
pattern
replic
time
known
neg
sampl
analyz
presenc
hbv
dna
use
abbott
realtim
hbv
assay
limit
detect
lod
iu
dnaml
abbott
instrument
nonconform
defin
known
neg
hbv
sampl
amount
detect
hbv
dna
result
neg
sampl
n
run
alin
immedi
log
iu
dnaml
hbv
sampl
induct
heat
wash
yield
detect
amount
hbv
target
iu
dnaml
summaryconclus
induct
heat
effect
maintain
integr
sampl
run
alin
instrument
downstream
molecular
test
given
higher
frequenc
hbv
sampl
viral
load
log
iuml
compar
virus
result
suggest
result
like
extend
addit
infecti
diseas
marker
hiv
hcv
la
martin
j
siregar
gawel
worobec
x
jiang
j
bryant
g
william
blood
screen
assay
new
product
develop
abbott
laboratori
abbott
park
il
unit
state
america
background
use
biotin
supplement
increas
recent
year
mani
health
care
profession
may
awar
high
dosag
intak
patient
donor
blood
product
specimen
collect
patient
take
mgday
may
concentr
biotin
ngml
base
guidanc
fda
alin
assay
test
level
nearli
three
time
greater
highest
concentr
report
ngml
high
level
biotin
sampl
led
inaccur
lab
result
assay
util
free
captur
methodolog
although
abbott
alin
assay
util
free
captur
methodolog
eight
assay
develop
blood
screen
alin
system
evalu
biotin
interfer
ensur
unknown
consequ
high
biotin
level
aim
purpos
studi
determin
eight
abbott
alin
assay
would
suscept
biotin
interfer
evalu
perform
presenc
high
concentr
biotin
method
alin
assay
evalu
chaga
cmv
igg
hbsag
hiv
agab
combo
htlv
iii
syphili
sampl
spike
concentr
biotin
ngml
test
control
unspik
sampl
prepar
determin
differ
control
biotin
contain
sampl
two
sampl
one
neg
one
posit
test
assay
except
hiv
htlv
assay
test
two
posit
sampl
antibodi
antigen
antibodi
antibodi
respect
result
neg
sampl
test
ngml
sampl
cutoff
sco
differ
biotin
spike
control
chaga
cmv
igg
hbsag
hiv
agab
combo
syphili
htlv
iii
neg
sampl
spike
ngml
mean
sco
differ
biotin
spike
control
either
eight
assay
posit
sampl
spike
ngml
percent
differ
biotin
spike
control
rang
assay
posit
sampl
spike
ngml
percent
differ
biotin
spike
control
rang
eight
assay
summaryconclus
eight
abbott
alin
assay
evalu
determin
suscept
biotin
interfer
result
indic
eight
alin
assay
show
suscept
biotin
interfer
concentr
ngml
abstract
withdrawn
b
r
g
l
j
g
abbott
lab
abbott
park
director
bloodwork
northwest
seattl
research
biobridg
global
san
antonio
director
csl
behr
king
prussia
abbott
lab
abbott
park
unit
state
america
background
blood
center
requir
high
throughput
assay
high
level
reproduc
assur
consist
result
minim
unnecessari
retest
sampl
deferr
donor
addit
continu
econom
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
aim
evalu
within
laboratori
reproduc
includ
within
run
run
day
variabl
new
autom
prototyp
chemiluminesc
immunoassay
detect
iii
cruzi
antibodi
autom
next
gener
platform
abbott
alin
method
reproduc
studi
conduct
test
reproduc
panel
consist
multipl
member
htlv
hbc
chaga
repres
differ
level
analyt
test
done
site
instrument
per
site
use
lot
assay
reagent
calibr
control
result
total
least
result
gener
panel
member
data
clinic
site
reagent
lot
use
final
analysi
reactiv
sampl
cv
across
assay
rang
cv
rang
within
laboratori
reproduc
cv
rang
neg
control
sampl
sd
rang
sd
rang
within
laboratori
reproduc
sd
rang
summaryconclus
new
autom
prototyp
alin
system
assay
demonstr
reproduc
valu
less
cv
reactiv
sampl
sd
neg
sampl
demonstr
precis
result
gener
fulli
autom
blood
screen
analyz
help
assur
consist
result
test
retest
blood
donor
specimen
b
r
g
l
j
g
abbott
lab
abbott
park
director
bloodwork
northwest
seattl
research
biobridg
global
san
antonio
director
csl
behr
king
prussia
abbott
lab
abbott
park
unit
state
america
background
blood
center
requir
high
throughput
assay
high
level
reproduc
assur
consist
result
minim
unnecessari
retest
sampl
deferr
donor
addit
continu
econom
pressur
laboratori
oper
demand
assay
perform
platform
capabl
increas
walk
away
time
enhanc
autom
area
reagent
manag
retest
option
commoditywast
manag
aim
evalu
within
laboratori
reproduc
includ
within
run
run
day
variabl
new
autom
prototyp
chemiluminesc
immunoassay
detect
hep
b
surfac
antigen
hiv
agab
combo
autom
next
gener
platform
abbott
alin
method
reproduc
studi
conduct
test
reproduc
panel
consist
multipl
member
hiv
agab
combo
hbsag
hcv
repres
differ
level
analyt
test
done
site
instrument
per
site
use
lot
assay
reagent
calibr
control
result
total
least
result
gener
panel
member
data
clinic
site
reagent
lot
use
final
analysi
reactiv
sampl
cv
across
assay
rang
cv
rang
within
laboratori
reproduc
cv
rang
neg
control
sampl
sd
rang
sd
rang
within
laboratori
reproduc
sd
rang
summaryconclus
new
autom
prototyp
alin
system
assay
demonstr
reproduc
valu
less
cv
reactiv
sampl
sd
neg
sampl
demonstr
precis
result
gener
fulli
autom
blood
screen
analyz
help
assur
consist
result
test
retest
blood
donor
specimen
w
l
e
j
r
affair
offic
american
red
cross
rockvil
affair
american
red
cross
gaithersburg
unit
state
america
background
monitor
incid
viral
infect
tti
key
blood
safeti
activ
calcul
incid
repeat
donor
use
differ
methodolog
brambilla
transfus
calcul
incid
recent
year
american
red
cross
arc
result
two
method
compar
convent
method
cm
extend
lookback
method
elm
cm
repeat
donor
includ
incid
case
contribut
least
donat
exist
within
estim
interv
ei
elm
histori
repeat
donor
within
ei
trace
back
length
time
ei
look
prior
neg
donat
ie
ei
month
requir
lookback
donat
data
must
avail
predat
ei
repeat
donor
appropri
lookback
allow
inclus
posit
neg
donor
may
introduc
bia
either
method
repeat
donor
lack
prior
donat
within
ei
cm
extend
lookback
elm
censor
aim
present
incid
rate
hiv
hbv
hcv
arc
donor
five
estim
interv
use
two
calcul
methodolog
method
incid
rate
calcul
number
incid
case
divid
total
time
risk
repeat
donor
express
per
pht
linear
regress
use
test
tempor
chang
rate
result
incid
rate
hiv
hbv
hcv
decreas
first
last
interv
studi
use
methodolog
decreas
signific
hiv
hbv
cm
f
p
f
p
respect
similar
data
exist
elm
use
cm
hiv
incid
pht
elm
pht
hiv
incid
use
cm
pht
use
elm
pht
hbv
rate
decreas
pht
cm
pht
elm
hcv
cm
highest
pht
elm
estim
pht
hcv
pht
use
cm
pht
use
elm
elm
captur
addit
donor
character
incid
use
cm
includ
discrep
donor
hiv
hbv
hcv
respect
summaryconclus
incid
three
tti
us
blood
donor
decreas
regardless
calcul
method
although
methodolog
show
tempor
pattern
cm
consist
higher
rate
compar
elm
even
though
elm
identifi
greater
number
incid
donor
elm
calcul
averag
greater
use
cm
number
incid
donor
captur
elm
two
calcul
less
greater
larger
denomin
without
balanc
equal
larger
numer
result
lower
elm
incid
comparison
incid
blood
collector
use
differ
methodolog
made
cautious
strength
limit
potenti
bias
must
evalu
determin
optim
method
k
swaib
ezra
laboratori
uganda
blood
transfus
servic
kampala
uganda
background
blood
transfus
ever
associ
zero
risk
patient
need
safe
transfus
risk
reduct
improv
infecti
diseas
screen
implement
nucleic
acid
test
nat
technolog
relat
convent
screen
assay
improv
screen
volunt
non
remuner
donor
assist
screen
safer
unit
confirm
well
introduct
malaria
among
transfus
transmiss
infect
tti
routin
screen
endem
uganda
mani
counti
world
implement
nat
purpos
blood
safeti
yet
implement
routin
screen
donor
blood
ubt
current
use
enzym
link
immunosorb
assay
elisa
chemiluminesc
microparticl
immunoassay
cmia
technolog
screen
donor
blood
may
increas
risk
diseas
transmiss
depend
viraem
window
period
analyz
tti
aim
studi
aim
determin
preval
undetect
tti
use
nat
unscreen
malaria
use
malaria
rapid
diagnost
test
method
prospect
studi
carri
ubt
period
six
month
septemb
februari
total
nonremuner
blood
donor
select
collect
site
central
region
neg
donat
screen
architect
use
total
minipool
five
unit
aliquot
analyz
use
bcim
screen
kit
ribonucl
acid
deoxyribonucl
acid
human
immunodefici
viru
hiv
hepat
c
hcv
hepat
b
hbv
also
malaria
rapid
diagnost
test
rdt
use
screen
malaria
data
analys
use
microsoft
excel
result
total
donor
blood
analyz
analys
nat
gave
mp
nat
detect
hbv
undetect
hiv
hcv
hbv
true
posit
test
tti
individu
donor
nucleic
acid
test
hbv
detect
none
undetect
hiv
hcv
total
unit
account
estim
preval
test
posit
malaria
rdt
summaryconclus
estim
figur
undetect
tti
nakasero
blood
bank
hbv
malaria
respect
much
higher
donor
develop
countri
screen
algorithm
nakasero
blood
bank
captur
signific
tti
addit
sensit
elisa
cmia
lower
compar
nat
detect
even
lower
viraem
diagnost
window
period
hbv
hiv
hcv
use
confirm
true
neg
nat
might
econom
save
reagent
small
turnov
adopt
nat
routin
procedur
screen
malaria
help
improv
blood
safeti
cost
ugandan
p
p
p
p
ramathibodi
hospit
institut
patholog
phramongkutklao
medic
center
bkk
thailand
background
prevent
transfus
transmit
infect
perform
serolog
test
nucleic
acid
test
nat
autom
chemiluminesc
immunoassay
clia
replac
enzym
immunoassay
eia
wide
use
due
increas
sensit
specif
aim
goal
studi
compar
perform
recent
electro
chemiluminesc
immunoassay
eclia
former
chemiluminesc
microparticl
immunoassay
cmia
detect
hbsag
antibodi
hiv
hcv
treponema
pallidum
tp
blood
donor
method
serum
sampl
voluntari
random
blood
donor
blood
bank
ramathibodi
hospit
armi
institut
patholog
screen
parallel
cmia
architect
abbott
wiesbaden
germani
eclia
coba
e
roch
mannheim
germani
detect
hbsag
antibodi
tp
initi
reactiv
sampl
repeat
duplic
repeatedli
reactiv
rr
discord
sampl
two
system
investig
confirmatori
assay
biorad
geeniu
hiv
confirmatori
hcv
score
line
immunoassay
euroimmun
fluoresc
treponem
igg
igg
multiplex
nat
taqscreen
mpx
test
roch
molecular
system
us
use
follow
sampl
avail
two
third
discord
sampl
also
test
test
result
concord
two
system
high
hiv
agab
hbsag
antibodi
tp
specif
elecsi
hiv
combi
pt
ii
abbott
hiv
agab
combo
respect
p
specif
ident
elecsi
ii
abbott
hbsag
specif
elecsi
hbsag
ii
specif
abbott
hbsag
qualit
ii
p
summaryconclus
perform
coba
e
architect
similar
high
concord
specif
hbsag
hiv
agab
slightli
higher
coba
e
statist
signific
observ
concord
specif
calcul
syphili
test
donor
discord
sampl
lost
follow
balanc
sensit
specif
donor
screen
assay
must
consid
donor
counsel
blood
product
manag
ssenyonga
laboratori
uganda
blood
transfus
servic
kampala
uganda
background
laboratori
diagnosi
hcv
hbsag
syphili
hiv
infect
usual
made
basi
serolog
serolog
assay
detect
antibodi
detect
antibodi
antigen
gener
classifi
either
assay
screen
assay
second
line
assay
supplement
assay
assay
provid
presumpt
identif
reactiv
specimen
thu
superior
sensit
assay
use
confirm
whether
specimen
found
reactiv
particular
assay
contain
antibodi
specif
antigen
assay
superior
specif
aim
object
document
process
result
process
paramet
obtain
test
hcv
hbsag
syphili
antibodi
antibodi
plu
antigen
use
fortress
elisa
reagent
kit
laboratori
nakasero
blood
bank
method
sampl
test
first
abbott
architect
immunochemistri
analyz
use
cmia
techniqu
identifi
statu
posit
duplic
rule
error
might
occur
first
step
neg
test
duplic
form
assess
specif
assay
valid
strongli
posit
sampl
od
hiv
hbsag
hcv
also
duplic
ass
sensit
assay
chronic
posit
hiv
sampl
obtain
patient
attend
one
referr
hospit
uganda
also
includ
valid
serv
refer
sampl
syphili
turn
posit
cmia
consid
test
run
elisa
result
overal
specif
fortress
diagnost
elisa
kit
sensit
reproduc
posit
predict
valu
neg
predict
valu
imprecis
three
assay
summaryconclus
onsit
valid
test
system
materi
laboratori
requir
prior
use
routin
test
process
blood
recommend
put
forth
document
address
establish
perform
specif
analyt
method
valid
method
perform
characterist
pathak
transfus
medicin
rajiv
gandhi
cancer
institut
research
center
new
delhi
new
delhi
india
background
syphili
sexual
transmit
major
rout
transfus
transmiss
rout
bacteri
infect
caus
spirochet
treponema
pallidum
pallidum
mandatori
serolog
test
syphili
donor
blood
sampl
serolog
test
syphili
usual
base
detect
antibodi
antigen
treponem
specif
antigen
larg
number
fals
result
low
sensit
test
led
introduct
pallidum
specif
test
syphili
screen
eg
tp
haemagglutin
tpha
test
fluoresc
treponem
antibodi
absorpt
test
aim
evalu
perform
syphili
tpa
assay
term
sensit
specif
comparison
current
non
treponem
syphili
assay
follow
treponem
test
healthi
donor
sampl
per
cdc
guidelin
screen
syphili
infect
base
revers
algorithm
protocol
method
prospect
studi
jan
dec
total
blood
donor
screen
syphili
infect
use
syphili
tpa
vstpa
assay
syphili
reactiv
sampl
vstpa
assay
test
syphili
rapid
test
asrt
strip
rapid
chromatograph
immunoassay
qualit
detect
antibodi
igg
igm
pallidum
serum
plasma
syphili
blood
sampl
reactiv
vstpa
assay
non
reactiv
asrt
sent
treponem
test
intern
refer
laboratori
result
sampl
screen
sampl
found
reactiv
use
vstpa
assay
vstpa
assay
reactiv
sampl
show
discord
result
test
asrt
discord
sampl
test
intern
refer
laboratori
show
concord
high
concord
result
syphili
tpa
assay
summaryconclus
syphili
tpa
assay
base
enhanc
chemiluminesc
technolog
excel
sensit
screen
syphili
infect
help
minim
fals
neg
result
therebi
enhanc
safeti
blood
transfus
assay
low
sensit
like
rpr
syphili
rapid
card
test
may
lead
fals
neg
result
may
impact
blood
safeti
introduct
syphili
tpa
assay
system
help
consolid
assay
transfus
transmitt
infect
viz
ahiv
hbsag
ahcv
screen
assay
chemiluminesc
platform
highli
valuabl
optim
workflow
effici
xie
g
zhou
l
zheng
meng
j
sun
cai
shanghai
blood
center
shanghai
china
background
transfus
transmit
infect
tti
screen
test
result
remain
challeng
continu
loss
donor
blood
product
addit
notifi
posit
tti
test
result
caus
psycholog
distress
blood
donor
aim
establish
donor
reentri
procedur
investig
psycholog
reaction
volunt
blood
donor
deferr
reentri
follow
posit
tti
screen
test
result
method
septemb
februari
total
volunt
blood
donor
shanghai
blood
center
enrol
studi
enrol
criteria
includ
donor
screen
reactiv
immunosorb
assay
eia
nucleic
acid
test
nat
reactiv
human
immunodefici
viru
hiv
donor
hepat
b
viru
hbv
donor
hepat
c
viru
hcv
donor
donor
took
reentri
procedur
accord
guidelin
chines
societi
blood
transfus
addit
donor
ask
fill
questionnair
form
opinion
toward
fals
blood
test
result
impact
result
respect
donor
hiv
antibodi
posit
donor
hbsag
posit
donor
hcv
antibodi
posit
whose
reentri
test
result
qualifi
abl
continu
donat
blood
among
qualifi
reentri
donor
donor
total
blood
donat
reentri
got
answer
form
questionnair
question
impact
test
result
percent
respond
said
neg
impact
percent
sever
question
mean
blood
donor
reentri
percent
respond
said
reliev
mind
burden
famili
friend
percent
respond
said
abl
donat
blood
summaryconclus
result
impli
blood
donor
reentri
necessari
minim
number
donor
maintain
posit
predisposit
toward
futur
blood
donat
result
also
emphas
import
appropri
inform
support
defer
donor
abstract
withdrawn
pourfathollah
sedaghat
aminikafiabadi
maghsoodlu
b
daneshvar
k
shamsasenjan
high
institut
research
educ
transfus
medicin
iranian
blood
transfus
organ
tehran
iran
background
mani
factor
increas
risk
donor
select
process
counsel
skill
qualifi
physician
confidenti
counsel
room
reliabl
blood
donor
riski
area
locat
blood
collect
center
main
factor
increas
risk
donor
select
process
nation
polici
donor
select
surveil
system
could
reduc
risk
transfus
transmit
infect
blood
suppli
toward
zero
risk
strategi
aim
improv
safeti
blood
blood
product
increas
qualiti
blood
donor
select
process
decreas
load
riski
donat
blood
screen
lab
method
nation
donor
select
surveil
system
introduc
iran
base
nation
protocol
donat
blood
blood
collect
center
confirm
posit
result
hiv
hcv
hbv
screen
test
monitor
retrospect
technic
committe
evalu
process
select
process
provinci
level
evalu
process
main
issu
must
evalu
follow
level
reliabl
donor
counsel
skill
qualifi
physician
safeti
level
locat
commun
blood
collect
center
program
donor
posit
confirm
result
hiv
hcv
hb
call
back
confidenti
counsel
qualifi
physician
evalu
counsel
skill
analyt
situat
posit
case
triangul
data
exempt
rate
rate
confidenti
unit
exclus
base
result
evalu
supervis
nation
headquart
decis
made
quarterli
intervent
could
commun
awar
rise
import
safe
blood
donat
conduct
train
cours
qualifi
physician
standard
confidenti
counsel
room
stop
activ
switch
locat
blood
collect
center
safer
area
result
month
launch
nation
donor
select
surveil
system
slope
preval
trend
hiv
hbv
hcv
marker
among
blood
donor
show
signific
decreas
vs
past
year
past
decad
base
ibto
common
strateg
vision
root
zero
risk
slope
preval
tti
among
blood
donor
reduc
trend
chang
degre
linear
regress
curv
hbv
show
arc
tan
arc
tan
hiv
hcv
found
result
well
chang
degre
linear
regress
curv
hcv
arc
tan
vs
arc
tan
chang
degre
linear
regress
curv
hiv
arc
tan
vs
reduct
rate
arc
tan
summaryconclus
activ
nation
surveil
system
donor
select
process
import
experi
iran
base
program
nation
blood
transfus
servic
could
abl
monitor
blood
collect
servic
continu
better
counsel
better
donor
select
better
locat
blood
collect
improv
safeti
assur
blood
suppli
toward
zero
risk
j
j
h
k
transfus
research
institut
korean
red
cross
blood
laboratori
center
korean
red
cross
busan
korea
background
perform
nucleic
acid
amplif
test
nat
human
lymphotrop
viru
htlv
donor
sampl
show
reactiv
result
htlv
antibodi
assay
indetermin
result
western
blot
assay
commerci
kit
htlv
nat
approv
fda
adopt
pcr
howev
adequ
intern
control
ic
identifi
fals
neg
result
owe
inhibit
pcr
htlv
pcr
aim
assur
result
htlv
pcr
establish
competit
noncompetit
ic
compar
effici
method
competit
ic
ad
sampl
construct
plasmid
dna
includ
primer
recognit
sequenc
px
region
htlv
gene
flank
heterolog
dna
fragment
larger
size
noncompetit
ic
construct
addit
primer
amplif
glyceraldehyd
dehydrogenas
gapdh
gene
housekeep
gene
result
ad
plasmid
dna
ic
htlv
posit
sampl
neg
sampl
bp
amplifi
product
ic
bp
htlv
gene
detect
togeth
posit
sampl
bp
ic
detect
neg
sampl
howev
ad
primer
amplif
gapdh
gene
primer
amplif
htlv
gene
htlv
posit
sampl
neg
sampl
bp
gapdh
gene
detect
one
posit
sampl
bp
htlv
gene
detect
one
posit
sampl
although
bp
amplifi
product
gapdh
gene
detect
togeth
neg
sampl
summaryconclus
accord
guidelin
intern
standard
organ
presenc
ic
recommend
monitor
fals
neg
result
pcr
develop
two
kind
ic
compar
effici
case
noncompetit
ic
applic
two
target
gene
may
amplifi
incomplet
interfer
primer
reaction
format
differ
primer
dimer
reaction
therefor
consid
adopt
plasmid
dna
ic
may
effici
construct
plasmid
dna
ic
may
good
way
appli
intern
qualiti
control
pcr
e
oh
blood
laboratori
centerjungbu
daejeon
korea
background
korean
red
cross
introduc
nucleic
acid
test
hepat
c
viru
hcv
human
immunodefici
viru
hiv
upgrad
individu
donat
nat
includ
hepat
b
viru
hbv
studi
analyz
residu
risk
transfus
transmit
infect
hepat
b
viru
human
immunodefici
viru
hepat
c
viru
sinc
introduct
nucleic
acid
test
aim
purpos
studi
investig
residu
risk
rr
transfus
transmit
infect
tti
patient
differ
type
transfus
transmit
viral
diseas
report
various
hcv
hiv
nat
test
first
introduc
hbv
nat
test
introduc
prevent
infect
aim
studi
evalu
efficaci
hbv
chemiluminesc
enzym
immunoassay
cleia
hcv
immunosorb
assay
elisa
hcv
immunoblot
assay
riba
hbv
hiv
hcv
screen
test
data
preval
incid
first
multipl
blood
donor
calcul
compar
residu
risk
transfus
infect
method
hb
ag
hcv
riba
hbv
hiv
hcv
hivaid
blood
donat
accumul
databas
korean
red
cross
blood
inform
manag
system
use
result
nat
test
preval
ir
tti
rr
divid
period
nat
period
nat
total
person
year
interv
calcul
method
ir
calcul
divid
number
posit
case
interv
total
person
year
number
posit
blood
donat
donor
blood
donor
blood
donat
within
year
import
rr
calcul
incid
rate
ir
window
wp
method
result
period
total
donat
screen
hcv
nat
yield
donat
calcul
rr
per
million
donat
hbv
significantli
reduc
hcv
decreas
rr
hiv
also
declin
trend
special
recent
rr
hbv
hcv
hiv
tti
estim
per
million
donat
summaryconclus
blood
donat
blood
screen
carri
variou
method
reagent
minim
infect
hiv
hcv
hbv
transmit
blood
transfus
assur
safeti
blood
improv
sensit
specif
screen
reagent
minim
transfus
infect
blood
discontinu
due
fals
posit
addit
korean
red
cross
lower
residu
risk
hbv
hcv
hiv
transfus
infect
significantli
introduc
nucleic
acid
amplif
test
howev
order
ensur
safeti
blood
necessari
establish
sensit
accur
screen
method
monitor
blood
product
qualiti
control
strengthen
prevent
occurr
much
possibl
mousavi
z
sharifi
r
golestani
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
iran
background
reduct
transfus
transmit
infect
tti
viral
inactiv
strategi
viral
cytopath
effect
cultur
cell
cpe
use
evalu
viral
inactiv
evalu
day
cpe
gold
standard
viral
load
time
consum
low
throughput
tediou
thu
need
sensit
fast
automat
techniqu
field
research
quantum
dot
higher
intens
stabil
emit
light
compar
organ
fluorophor
promis
medic
scienc
aim
aim
identif
comparison
infect
vero
cell
model
hepat
b
viru
use
quantum
dot
fitc
antibodi
conjug
flow
cytometri
fluoresc
microscopi
use
detect
viral
glycoprotein
cpe
light
invert
microscop
method
vero
cell
cultur
dmem
fetal
bovin
serum
antibiot
cpe
titrat
confluenc
cultur
vero
cell
day
gold
standard
express
use
invert
microscop
ten
fold
serial
dilut
titrat
sampl
infect
confluenc
cultur
vero
cell
h
use
specimen
evalu
cpe
flow
cytometri
indirect
immunofluoresc
light
invert
microscop
quantum
fitc
use
antibodi
conjug
detect
glycoprotein
result
quantum
use
indirect
immunofluoresc
microscopi
flow
cytometri
specif
sensit
log
moi
infecti
particl
per
ml
fitc
conjug
antibodi
show
sensit
log
moi
infecti
particl
per
ml
cpe
infect
cell
evalu
invert
microscop
show
sensit
log
infecti
particl
moi
summaryconclus
studi
show
quantum
dot
least
log
sensit
fitc
flow
cytometri
indirect
immunofluoresc
detect
h
infect
vero
cell
interestingli
conjug
uv
excit
show
emiss
red
light
green
light
infect
vero
cell
indirect
immunofluoresc
microscopi
respect
mean
higher
specif
fitc
conjug
f
u
molecular
virolog
lab
comsat
univers
islamabad
pakistan
blood
transfus
programm
ministri
nation
health
servic
govern
pakistan
islamabad
pakistan
background
health
care
system
develop
nation
continu
face
challeng
inadequ
suppli
safe
blood
increas
preval
transfus
associ
infect
one
major
challeng
throughout
access
safe
blood
blood
product
blood
donor
consid
healthiest
pool
popul
blood
screen
differ
diseas
includ
syphili
hbv
hcv
hiv
transfus
order
make
blood
transfus
safe
access
still
remain
major
challeng
throughout
world
transmiss
hbv
hcv
infect
via
blood
blood
product
lead
acut
chronic
hepat
aim
object
studi
figur
techniqu
sensit
specif
detect
hbv
hcv
best
suit
tertiari
care
hospit
also
help
blood
bank
decid
upon
effect
screen
techniqu
hepat
viru
method
prospect
studi
conduct
evalu
technic
perform
rapid
kit
use
screen
blood
donor
tertiari
care
hospit
rawalpindi
pakistan
blood
sampl
blood
donor
select
visit
blood
bank
septemb
decemb
taken
asept
condit
sampl
initi
test
use
immunochromatograph
techniqu
ict
respect
blood
bank
confirm
use
gener
elisa
microbiolog
laboratori
holi
famili
hospit
chemiluminesc
micro
particl
immunoassay
cmia
sampl
perform
blood
bank
pakistan
institut
medic
scienc
islamabad
use
compar
result
ict
elisa
chemiluminesc
compar
statist
evalu
done
result
donor
posit
hepat
b
viru
posit
hepat
c
viru
found
neg
sensit
analysi
test
shown
ict
low
detect
rate
posit
case
comparison
elisa
chemiluminesc
sensit
hbv
hcv
respect
specif
ict
kit
hbv
hcv
preval
hbv
hcv
summaryconclus
ict
show
inferior
result
compar
elisa
chemiluminesc
henc
recommend
transfus
centr
screen
blood
donor
result
studi
also
demonstr
cmia
highli
sensit
specif
screen
assay
laboratori
blood
bank
road
map
interpret
confirm
discrep
test
result
serv
patient
accur
standard
test
result
safe
transfus
occur
hm
h
j
e
laboratori
scienc
state
univers
owerri
owerri
nigeria
background
blood
transfus
compon
therapi
well
establish
essenti
medic
practic
therapi
howev
without
risk
may
lead
transmiss
infecti
agent
donor
recipi
common
infecti
agent
includ
human
viru
hepat
b
viru
hbv
hepat
c
viru
hcv
syphili
pursu
global
blood
safeti
world
health
organ
recommend
blood
donat
screen
evid
infect
prior
releas
blood
blood
product
clinic
use
aim
compar
effect
enzym
link
immunosorb
assay
elisa
rapid
test
screen
method
screen
transfus
transmiss
infect
blood
donor
method
compar
studi
involv
blood
sampl
collect
male
femal
age
year
voluntari
donor
owerri
enzym
link
immunosorb
assay
rapid
test
screen
method
use
screen
data
evalu
spss
statist
packag
social
scienc
version
result
result
show
differ
two
test
method
henc
indic
infect
unit
blood
would
transfus
due
fals
neg
result
rapid
test
method
summaryconclus
studi
demonstr
preval
transfus
transmiss
infect
major
problem
associ
blood
transfus
incid
found
higher
femal
male
transfus
medicin
king
georg
medic
univers
lucknow
medic
colleg
medic
colleg
lucknow
india
background
safeti
cost
effect
remain
central
goal
blood
screen
india
india
second
popul
countri
world
billion
million
hiv
million
hepat
b
hbv
million
hepat
c
hcv
infect
person
major
blood
bank
india
employ
screen
gener
elisa
chemiluminesc
test
still
fewer
nucleic
acid
test
nat
cost
play
major
role
select
technolog
aim
compar
detect
hiv
hepat
b
hepat
c
indian
popul
compar
differ
technolog
elisa
chemiluminesc
nat
method
singl
centr
studi
blood
donor
sampl
conduct
period
year
blood
unit
screen
combin
technolog
use
assess
reactiv
statu
reactiv
donor
evalu
counsel
reactiv
donor
recal
assess
true
posit
ictc
follow
art
centr
result
gener
elisa
reactiv
hiv
hbv
hcv
elisa
unit
show
nat
reactiv
yield
nat
yield
hiv
hbv
hcv
total
reactiv
unit
elisa
nat
yield
hiv
hbv
hcv
chemiluminesc
reactiv
unit
total
hiv
hbv
hcv
nat
yield
yield
chemiluminesc
hiv
hbv
hcv
total
reactiv
chemiluminesc
nat
yield
hiv
hbv
hcv
hiv
reactiv
donor
recal
found
true
posit
hbv
hcv
could
recal
found
true
posit
nat
reactiv
donor
true
posit
preval
seroreact
observ
studi
similar
blood
donor
seroreact
observ
state
studi
site
locat
viz
hiv
hbv
hcv
summaryconclus
nat
ad
safeti
donat
blood
irrespect
serolog
test
use
resourc
constrain
set
addit
nat
elisa
could
first
step
upgrad
sensit
chemiluminesc
nat
combin
possibl
immedi
b
e
j
j
c
g
e
viru
research
kenya
medic
research
institut
medic
research
institut
nairobi
kenya
health
agenc
canada
winnipeg
canada
nation
blood
transfus
servic
nairobi
nairobi
kenya
background
hepat
b
viru
hbv
infect
endem
kenya
estim
vari
differ
geograph
region
countri
hbv
preval
among
blood
donor
estim
although
recent
nation
baselin
data
yet
report
similarli
data
occult
hbv
infect
obi
given
intermedi
hbv
preval
countri
consid
potenti
threat
blood
safeti
aim
investig
distribut
hbv
genotyp
nation
repres
sampl
blood
donor
six
region
blood
transfus
centr
rbtc
determin
preval
provid
preliminari
data
residu
risk
hbv
transmiss
due
obi
method
hbsag
posit
specimen
investig
hbv
dna
posit
follow
dna
extract
pcr
amplif
use
primer
specif
hbsag
code
region
amplicon
either
bp
bp
length
sequenc
sequenc
subject
maximum
likelihood
phylogenet
analysi
togeth
genbank
refer
sequenc
determin
hbv
genotyp
elecsi
ii
use
qualit
determin
igg
igm
antibodi
hepat
b
core
antigen
posit
sampl
analys
hbv
dna
pcr
detect
three
differ
genom
region
result
studi
conduct
august
decemb
collect
sampl
hbsag
posit
blood
donor
five
administr
region
kenya
valley
eastern
central
coastal
two
hundr
hbv
dna
posit
could
sequenc
age
donor
rang
year
median
year
male
femal
ratio
hbv
genotyp
distribut
c
genotyp
e
genotyp
often
found
western
kenya
sub
genotyp
sequenc
cluster
african
asian
refer
sequenc
pilot
obi
studi
sampl
hbsag
neg
donor
randomli
select
screen
found
posit
hbv
dna
detect
among
donor
therefor
data
present
studi
although
preliminari
welcom
news
blood
safeti
kenya
compar
african
countri
frequenc
obi
african
blood
donor
estim
high
instanc
neighbour
sudan
preval
obi
blood
donor
possibl
reason
find
young
age
voluntari
blood
donor
popul
kenya
approxim
age
year
age
summaryconclus
hbv
genotyp
predomin
blood
donor
kenya
western
part
countri
geograph
closer
two
main
african
hbv
genotyp
e
distribut
similar
occult
hbv
infect
blood
donor
kenya
high
preval
compar
african
countri
n
r
research
alkmaar
netherland
african
nation
blood
servic
johannesburg
south
africa
system
research
institut
san
francisco
unit
state
america
british
colombia
victoria
canada
background
previou
public
model
efficaci
differ
test
scenario
elimin
hiv
hcv
transmiss
risk
use
individu
donat
nucleic
acid
amplif
technolog
screen
result
donat
blood
center
sinc
calcul
efficaci
hbv
complex
first
publish
rate
differ
stage
hbv
infect
first
time
laps
repeat
donor
six
geograph
region
leli
transfus
current
analysi
use
data
south
african
donat
estim
efficaci
differ
test
scenario
reduc
hbv
transmiss
risk
compar
baselin
screen
aim
estim
residu
hbv
window
period
wp
occult
hbv
infect
obi
transmiss
risk
screen
rbc
transfus
ml
plasma
six
geograph
region
calcul
efficaci
differ
test
strategi
elimin
hbv
transmiss
risk
south
africa
method
wp
transmiss
risk
estim
combin
risk
day
equival
model
weusten
transfus
wp
nat
yield
ratio
model
busch
transfus
use
minimum
infecti
dose
virion
obi
wp
transmiss
risk
calcul
recent
publish
model
weusten
transfus
use
virion
correct
observ
fold
higher
wp
obi
nat
yield
rate
introduct
ultrio
plu
assay
south
africa
base
line
transmiss
risk
estim
infect
stage
ie
transmiss
risk
rbc
wp
hbsag
concordantli
posit
donat
would
transfus
hbsag
positivenat
nonreact
unit
obi
wp
donat
obi
transmiss
risk
estim
reduc
screen
risk
analys
use
avail
analyt
sensit
data
south
african
hbv
genotyp
yield
sampl
ultrio
plu
lod
cpml
minipool
mp
nat
taqscreen
lod
cpml
test
vermeulen
transfus
result
correct
fold
higher
ultrio
plu
residu
hbv
wp
transmiss
risk
donat
estim
per
million
north
central
europ
per
million
south
africa
obi
transmiss
risk
region
vari
per
million
south
african
donat
overal
residu
hbv
transmiss
risk
per
million
percent
efficaci
elimin
risk
model
respect
hbsag
test
alon
hbsag
hbsag
hbsag
hbsag
hbsag
hbsag
summaryconclus
infect
base
risk
model
instrument
compar
efficaci
differ
screen
strategi
remov
transmiss
risk
l
c
offic
blood
center
taiwan
blood
servic
foundat
taipei
taiwan
china
background
taiwan
implement
world
first
nation
hbv
vaccin
program
juli
first
two
year
program
cover
neonat
whose
mother
hbsag
carrier
program
ultim
reduc
rate
hbsag
seroposit
children
less
howev
hbv
seropreval
among
blood
donor
well
address
aim
object
studi
assess
trend
preval
hbsag
occult
hbv
infect
obi
hbv
vaccin
second
object
compar
nat
use
studi
routin
minipool
nat
screen
inform
futur
strategi
hbv
screen
taiwanes
donor
method
collect
donor
test
consist
donor
repeat
donor
evalu
preval
hbv
infect
donor
test
hbv
yield
case
examin
hbv
antibodi
serolog
hbv
dna
quantif
use
abbott
realtim
hbv
assay
digit
pcr
dpcr
system
result
overal
preval
hbsag
among
donor
hbsag
carrier
hbv
dna
posit
seroposit
rate
hbsag
significantli
lower
born
start
univers
vaccin
seroposit
rate
follow
born
vaccin
hbsag
born
juli
june
hbsag
born
widespread
vaccin
hbsag
hbv
yield
case
observ
donor
born
vaccin
program
yield
rate
donor
born
hbv
vaccin
higher
repeat
donor
respect
yield
rate
tripl
rate
routin
repeat
donor
period
accord
test
result
hbv
yield
case
identifi
obi
among
yield
case
posit
neg
posit
viral
load
neg
posit
sampl
undetect
iuml
iuml
lower
posit
sampl
iuml
iuml
summaryconclus
preval
hbsag
obi
dramat
decreas
hbv
vaccin
yield
rate
significantli
higher
hbv
yield
case
determin
obi
major
obi
sampl
low
viral
load
necessit
use
detect
risk
hbv
transmiss
posit
neg
obi
case
investig
l
j
laboratori
wuhan
blood
center
laboratori
medicin
medic
school
wuhan
univers
offic
wuhan
blood
center
wuhan
china
background
screen
hepat
b
viru
hbv
blood
donor
mandatori
china
current
enzym
link
immunosorb
assay
elisa
practic
serolog
test
mandatorili
use
hbsag
hepat
b
surfac
antigen
screen
china
order
avoid
problem
fail
detect
weakli
posit
sampl
make
utmost
effort
guarante
blood
safeti
laboratori
set
gray
zone
rang
elisa
test
unitari
object
standard
disput
among
laboratori
set
verifi
gray
zone
rang
elisa
test
aim
evalu
verifi
ration
gray
zone
rang
set
laboratori
hbsag
screen
two
kind
hbsag
elisa
kit
method
hbsag
serum
panel
sampl
establish
distribut
blood
safeti
immunohematolog
refer
laboratori
nation
center
clinic
laboratori
china
screen
hbsag
domest
elisa
reagent
import
elisa
reagent
fame
platform
hamilton
parallel
experiment
data
compar
confirm
data
provid
blood
safeti
immunohematolog
refer
laboratori
chemiluminesc
microparticl
immunoassay
cmia
abbott
neutral
test
nt
diasorin
spss
softwar
use
analyz
data
receiv
oper
characterist
roc
curv
analysi
use
determin
optim
level
result
among
hbsag
elisa
gray
area
sampl
sco
valu
screen
import
reagent
kit
sampl
confirm
neg
sampl
uncertain
sampl
posit
cmia
nt
among
hbsag
elisa
gray
area
sampl
sco
valu
screen
domest
reagent
kit
sampl
confirm
posit
sampl
uncertain
none
neg
cmia
nt
accord
test
statist
differ
two
group
data
p
data
sampl
serum
panel
sampl
confirm
posit
sampl
confirm
neg
util
calcul
roc
curv
hbsag
sco
valu
two
kind
hbsag
elisa
kit
respect
term
import
reagent
kit
area
curv
auc
youden
index
obtain
maxim
peak
sco
valu
term
domest
reagent
kit
auc
youden
index
obtain
maxim
peak
sco
valu
summaryconclus
differ
laboratori
screen
result
influenc
factor
environ
reagent
equip
oper
procedur
laboratori
select
appropri
method
set
gray
zone
rang
accord
studi
optim
level
import
kit
domest
elisa
kit
necessari
set
gray
zone
rang
two
kind
evalu
hbsag
elisa
kit
laboratori
reduc
fals
neg
ensur
blood
safeti
abstract
withdrawn
c
e
c
transfus
servic
univers
teach
hospit
yaound
cameroon
int
pari
franc
system
research
institut
san
francisco
unit
state
america
faculti
medicin
biomed
scienc
univers
yaound
yaound
cameroon
background
cameroon
highli
endem
hbv
infect
prevent
hbv
transmiss
transfus
still
base
hbsag
screen
alon
howev
occult
hbv
infect
obi
character
absenc
detect
hbsag
low
level
viral
dna
remain
potenti
threat
blood
safeti
obi
preval
tend
higher
preval
overt
hbv
infect
high
nevertheless
limit
data
preval
obi
cameroonian
blood
donor
aim
preval
obi
investig
blood
donor
yaound
provid
recommend
improv
hbv
blood
safeti
method
blood
donor
screen
initi
hbv
hiv
hcv
infect
murex
hbsag
version
murex
hiv
agab
combin
murex
hcv
agab
combin
diasorin
addit
hbv
test
includ
monolisa
plu
hbv
dna
test
minipool
two
sampl
use
quantit
coba
taqman
hbv
assay
roch
lod
iuml
result
initi
screen
show
donat
reactiv
hbsag
hiv
hcv
hbsag
hiv
among
donor
neg
marker
reactiv
show
low
reactiv
low
reactiv
sampl
retest
remain
low
reactiv
show
sco
valu
ongo
molecular
test
show
positivehbsag
neg
sampl
carri
detect
level
hbv
dna
viral
load
rang
iuml
iuml
hiv
reactiv
sampl
confirm
posit
wb
pcr
hcv
confirm
sampl
posit
summaryconclus
hbv
confirm
highli
endem
cameroon
hbsag
posit
rate
overal
preval
blood
donor
preliminari
data
suggest
approxim
cameroonian
blood
donor
screen
hbsag
neg
carri
occult
hbv
infect
serolog
molecular
test
current
ongo
confirm
data
hbsag
alon
screen
prospect
donor
suffici
elimin
risk
hbv
cameroon
screen
appear
feasibl
without
compromis
blood
suppli
implement
hbv
nucleic
acid
test
might
consid
possibl
l
h
z
r
academi
medic
scienc
peke
union
medic
colleg
institut
blood
transfus
chengdu
central
blood
station
qinghai
china
background
well
known
hbv
seriou
hazard
blood
safeti
blood
screen
main
mean
ensur
blood
safeti
serolog
test
neg
sampl
test
chines
blood
collect
suppli
agenc
nucleic
acid
test
due
stabil
nucleic
acid
easili
affect
extern
environ
storag
temperatur
cycl
may
impact
detect
result
nucleic
acid
articl
report
stabil
hbv
dna
storag
cycl
high
load
assess
differ
storag
condit
effect
test
result
develop
technolog
detect
limit
get
lower
lower
present
roch
coba
nucleic
acid
automat
detect
system
use
wide
detect
limit
iuml
high
sensit
specif
accuraci
studi
sampl
load
near
detect
limit
iuml
chosen
behalf
hbv
posit
sampl
high
risk
fals
neg
result
assess
effect
storag
cycl
sampl
test
result
roch
coba
aim
evalu
effect
cycl
preserv
nucleic
acid
quantit
detect
result
posit
plasma
sampl
method
select
two
packag
unpaid
plasma
low
load
hbv
hbv
dna
load
iuml
aliquot
bag
sampl
two
tube
one
tube
store
h
h
h
anoth
store
cycl
time
repeat
test
hbv
dna
roch
coba
quantit
detect
two
time
one
sampl
time
result
test
result
posit
sampl
lower
load
hbv
test
result
detect
limit
store
cycl
sampl
slightli
higher
nucleic
acid
titer
result
detect
limit
result
sampl
store
descend
gradual
time
sampl
cycl
stabl
differ
statist
signific
summaryconclus
hbv
posit
sampl
store
less
cycl
less
time
littl
effect
hbv
dna
quantit
detect
result
g
b
h
j
f
w
provinci
key
laboratori
blood
safeti
research
center
zhejiang
provinc
hangzhou
china
background
preval
rate
hepat
b
viru
hbv
infect
high
chines
popul
threaten
blood
safeti
current
nucleic
acid
test
nat
perform
blood
donat
china
occult
hepat
b
viru
infect
obi
case
found
howev
characterist
hepat
b
viru
infect
individu
hbv
dnahbsag
obi
individu
hbv
rare
report
chines
blood
donor
aim
explor
hbv
infect
rate
blood
donor
high
preval
countri
compar
serolog
molecular
characterist
individu
hbvdnahbsag
individu
obi
threaten
blood
safeti
current
nucleic
acid
test
nat
perform
blood
donat
china
occult
hepat
b
viru
infect
obi
case
found
howev
characterist
hepat
b
viru
infect
individu
hbv
dnahbsag
obi
individu
hbv
rare
report
chines
blood
donor
method
donor
preform
physic
examin
accord
regul
china
rapid
screen
test
hbsag
alt
done
preclud
donor
hbsag
preliminari
test
posit
alt
level
abnorm
iuml
donat
donat
sampl
donor
detect
hbsag
twice
use
differ
elisa
reagent
hbv
dna
use
tma
techniqu
accord
manufactur
instruct
serolog
marker
hbeag
hbv
infect
test
use
chemiluminesc
assay
hbv
load
level
measur
use
taqman
techniqu
hbv
genotyp
analyz
use
method
result
individu
found
hbv
dna
posit
blood
donat
studi
includ
individu
hbvdnahbsag
individu
obi
hbvdnahbsag
group
individu
found
posit
howev
hbv
obi
group
individu
found
posit
individu
found
posit
individu
found
posit
distribut
serolog
marker
differ
two
group
total
individu
analyz
viral
load
level
obi
individu
hbvdnahbsag
individu
viral
load
level
iuml
individu
hbvdnahbsag
obi
individu
viral
load
level
iuml
hbv
b
c
genotyp
hbvdnahbsag
group
hbv
b
c
genotyp
obi
group
chemiluminesc
assay
hbv
load
level
measur
use
taqman
techniqu
hbv
genotyp
analyz
use
method
summaryconclus
differ
show
serolog
characterist
viral
load
level
individu
hbvdnahbsag
obi
chines
blood
donor
data
help
improv
blood
safeti
research
support
scienc
foundat
zhejiang
health
bureau
zawadzka
k
olbromski
blood
center
poznan
poznan
poland
background
hepat
b
infecti
diseas
caus
hepat
b
viru
hbv
transmit
contact
blood
bodi
fluid
infect
peopl
risk
factor
involv
medic
procedur
blood
transfus
treatment
blood
deriv
product
area
blood
donat
dedic
hemovigil
procedur
aim
minimis
risk
acut
reaction
recipi
blood
aim
aim
analysi
compar
two
popul
first
time
repeat
donor
age
group
legal
age
allow
donat
n
poland
first
popul
undergo
obligatori
vaccin
second
popul
underw
vaccin
accord
vaccin
schedul
method
poland
countri
highest
number
hbv
infect
europ
record
obligatori
vaccin
infant
introduc
first
exist
voivodeship
provinc
note
highest
number
hbv
infect
greater
poland
provinc
ie
area
activ
blood
centr
obligatori
vaccin
infant
introduc
rest
poland
infant
undergo
vaccin
first
h
life
accord
basic
schedul
month
accord
offici
report
infant
underw
vaccin
necessari
wait
year
evalu
effect
brought
analysi
involv
group
donor
area
activ
blood
centr
poznan
first
time
donor
year
age
underw
vaccin
accord
vaccin
schedul
donor
year
age
undergo
obligatori
vaccin
donor
year
includ
analysi
due
fact
group
consist
age
group
group
donor
year
includ
vaccin
donor
analysi
show
male
donor
domin
among
donor
consist
statist
data
poland
group
vaccin
donor
differ
accord
sex
donor
record
year
total
donor
confirm
hbv
posit
test
result
wherea
year
total
donor
result
analysi
show
big
chang
favour
group
vaccin
donor
chart
less
hbv
infect
group
donor
observ
absolut
valu
although
infant
vaccin
sever
hbv
infect
among
donor
note
unfortun
small
percentag
popul
show
respons
vaccin
acquir
resist
hbv
poland
summaryconclus
vaccin
potenti
donor
hbv
effect
method
minimis
risk
hbv
infect
mean
transfus
blood
compon
bogdanov
n
bujandr
r
jovanov
blood
transfus
institut
vojvodina
novi
sad
serbia
background
risk
acquir
infect
tti
blood
compon
today
lower
ever
continu
improv
donor
select
screen
test
inactiv
procedur
key
tool
reduc
risk
tti
screen
donat
blood
world
health
organ
recommend
test
marker
hepat
b
viru
hbv
hepat
c
viru
hcv
human
immunodefici
viru
hiv
syphili
countri
obligatori
screen
marker
hbv
hepat
b
viru
surfac
antigen
hbsag
hcv
antibodi
hcv
aim
paper
aim
present
demograph
characterist
hbv
hcv
seroposit
blood
donor
south
backa
district
vojvodina
method
retrospect
descript
studi
carri
januari
decemb
blood
transfus
institut
vojvodina
data
screen
confirm
test
hbv
hcv
studi
use
record
tti
laboratori
sex
age
number
blood
donat
review
blood
donor
confirm
posit
result
total
blood
donat
collect
ten
year
age
distribut
donor
rang
year
percent
repeat
blood
donor
decreas
time
percent
first
time
donor
stabl
trend
overal
seropreval
hbv
infect
rang
hcv
infect
rang
hbv
infect
preval
male
first
time
blood
donor
among
donor
age
year
highest
hcv
seropreval
observ
among
male
donor
first
time
blood
donor
donor
age
year
summaryconclus
result
present
studi
show
overal
seropreval
hbv
hcv
infect
low
risk
hbv
hcv
infect
decreas
time
still
blood
transfus
remain
risk
factor
spread
infect
therefor
collabor
parti
involv
transfus
chain
includ
nation
haemovigil
system
crucial
increas
blood
safeti
district
rajshahi
medic
colleg
rajshahi
bangladesh
background
viru
dna
viru
identifi
patient
hepat
g
type
patient
chronic
renal
failur
mainten
hemodialysi
higher
risk
viral
infect
preval
viru
infect
common
aim
studi
predictor
occurr
infect
blood
transfus
depend
hemodialysi
hd
patient
determin
frequenc
viru
ttv
viru
method
studi
compromis
patient
mainten
hemodialysi
therapi
nephrolog
unit
rajshahi
medic
colleg
hospit
healthi
individu
voluntari
blood
donor
test
viru
eia
enzym
immunoassay
statist
analysi
collect
data
tabul
analyz
use
spss
version
softwar
quantit
data
express
mean
standard
deviat
qualit
data
express
frequenc
percentag
student
use
compar
mean
two
group
chi
squar
test
use
compar
categor
data
regress
analysi
use
detect
predictor
occurr
viru
infect
p
consid
signific
result
mean
age
hemodialysi
hd
group
control
group
malefemal
ratio
respect
differ
variabl
statist
preval
ttv
infect
differ
two
studi
group
statist
signific
histori
blood
transfus
signific
predictor
occurr
ttv
infect
hd
patient
p
age
durat
hd
hbv
hcv
infect
elev
alt
ast
signific
predictor
ttv
infect
summaryconclus
histori
blood
transfus
signific
predictor
found
age
patient
durat
hemodialysi
hepat
b
c
infect
aspart
aminotransferas
alanin
aminotransferas
level
signific
predictor
viru
posit
hemodialysi
patient
preval
viru
among
hemodialysi
patient
significantli
higher
healthi
individu
histori
blood
transfus
signific
predictor
viru
posit
among
studi
viru
periton
dialysi
patient
transplant
patient
need
abstract
withdrawn
abstract
withdrawn
os
q
k
f
patholog
laboratori
medicin
control
secur
forc
hospit
lab
ministri
health
saudi
arabia
riyadh
saudi
arabia
background
blood
donor
screen
hepat
b
core
antibodi
test
controversi
particularli
use
addit
hepat
b
surfac
antigen
nucleic
acid
test
nat
major
reactiv
nonspecif
world
health
organ
current
recommend
use
routin
test
screen
blood
donor
especi
high
seroposit
countri
saudi
arabia
nevertheless
major
blood
bank
saudi
arabia
discard
blood
donat
donor
due
reactiv
aim
estim
seropreval
demograph
among
blood
donor
neg
nat
also
measur
increas
blood
donor
strategi
implement
follow
criteria
method
total
voluntari
replac
donor
includ
donor
center
riyadh
saudi
arabia
demograph
data
collect
donor
donor
classifi
three
age
group
younger
older
donor
screen
infecti
marker
includ
test
hepat
b
nat
donor
reactiv
neg
nat
test
addit
screen
result
blood
donor
male
femal
incid
posit
case
male
femal
posit
reactiv
donor
posit
hb
ab
donor
titer
miuml
preval
reactiv
donor
follow
femal
male
donor
less
year
femal
male
donor
year
femal
male
group
donor
year
old
respect
summaryconclus
preval
among
donat
saudi
arabia
younger
age
group
lower
preval
addit
femal
significantli
lower
preval
continu
use
current
approach
exclud
lead
discard
approxim
donat
yearli
appli
current
criteria
regard
perform
routin
result
signific
reduct
discard
rate
nil
data
present
studi
indic
need
initi
nation
polici
saudi
arabia
allow
mechan
l
shao
h
lin
liu
jiangsu
provinc
blood
center
nanj
china
background
hepat
c
liver
diseas
caus
hepat
c
viru
global
million
peopl
chronic
hepat
c
infect
signific
number
chronic
infect
develop
liver
cirrhosi
liver
cancer
main
part
hcv
replic
infect
liver
lot
research
suggest
hcv
also
infect
cell
b
cell
dendrit
cell
similarli
platelet
report
carri
hcv
aim
studi
relationship
gene
polymorph
hpa
suscept
hcv
chines
han
popul
method
studi
conduct
among
hcv
infect
blood
donor
elig
blood
donor
genom
dna
extract
blood
donor
use
commerci
genom
dna
kit
amplifi
genotyp
use
pcr
sequenc
specif
primer
kit
compar
hpa
genotyp
donor
elig
donor
analyz
associ
hpa
polymorph
hcv
infect
result
distribut
gene
polymorph
donor
addit
hpa
p
six
system
antigen
distribut
consist
hardi
weinberg
equilibrium
among
elig
donor
polymorph
hpa
accord
hardi
weinberg
equilibrium
statist
signific
differ
hcv
blood
donor
among
system
compar
elig
haplotyp
frequenc
found
elig
blood
donor
respect
common
type
haplotyp
han
popul
uygur
common
type
haplotyp
two
popul
aaaaaaa
f
aaaaaab
f
frequenc
aaaaaaa
aaaaaab
differ
significantli
two
popul
summaryconclus
research
hpa
polymorph
elig
blood
donor
analyz
distribut
data
allel
haplotyp
hpa
two
popul
obtain
result
show
hpa
genotyp
statist
differ
two
popul
suggest
hpa
gene
polymorph
associ
hcv
infect
n
leli
h
van
drimmelen
bio
qualiti
control
heiloo
netherland
background
sinc
first
profici
studi
hcv
nat
method
earli
zaaijer
lancet
establish
nativ
inactiv
viral
plasma
standard
two
decad
store
use
prepar
refer
panel
run
control
liquid
frozen
standard
extens
calibr
copiesml
iuml
directli
traceabl
first
establish
standard
late
stabil
refer
sampl
standard
nat
aim
examin
stabil
nativ
inactiv
lyophil
standard
run
control
rna
method
standard
dilut
run
control
store
differ
time
period
year
test
replic
test
differ
quantit
nat
method
recoveri
viru
inactiv
determin
hcv
hbv
hiv
lyophil
hiv
stabil
standard
liquid
phase
investig
acceler
degrad
studi
h
degrad
slope
confid
limit
differ
temperatur
examin
regress
analysi
assum
first
order
kinet
result
long
term
stabil
nativ
inactiv
viral
standard
store
firmli
establish
standard
nativ
antibodi
posit
hcv
standard
also
stabl
least
year
store
howev
signific
annual
degrad
measur
antibodi
neg
chemic
inactiv
hcv
standard
antibodi
neg
hcv
standard
nativ
tissu
cultur
deriv
hiv
standard
hiv
standard
nativ
antibodi
posit
hcv
standard
stabl
h
signific
degrad
h
calcul
h
decay
estim
inactiv
hcv
standard
hcv
standard
nativ
hiv
standard
inactiv
hiv
standard
year
compar
lod
found
hcv
hiv
standard
dilut
panel
ultrio
version
third
batch
refer
panel
prepar
standard
significantli
lower
potenc
compar
analyt
sensit
dilut
panel
replac
standard
hcv
standard
first
one
significantli
lower
potenc
n
summaryconclus
lyophil
destroy
viral
particl
guarante
stabil
viral
standard
standard
store
prove
altern
lyophil
standard
valid
nat
method
run
control
batch
consist
manufactur
year
store
maximum
year
guarante
less
degrad
viral
rna
research
center
high
institut
research
educ
transfus
medicin
faculti
shahid
beheshti
univers
medic
scienc
stem
cell
development
biolog
cell
scienc
research
center
royan
institut
stem
cell
biolog
technolog
acecr
tehran
islam
republ
iran
background
hepat
c
viru
hcv
common
caus
post
transfus
infect
major
global
health
problem
result
liver
cirrhosi
hepatocarcinoma
preval
vari
differ
part
world
also
shown
hcv
preval
patient
receiv
multipl
transfus
henc
patient
thalassemia
inherit
bleed
disord
high
risk
hcv
infect
report
show
hcv
preval
high
among
iranian
patient
underw
multipl
transfus
aim
systemat
review
studi
aim
determin
hepat
c
viru
preval
among
patient
thalassemia
inherit
bleed
disord
iran
method
comprehens
search
carri
differ
databas
pubm
embas
scientif
inform
databas
sid
iran
world
health
organ
index
medicu
eastern
mediterranean
region
imemr
januari
find
report
follow
prisma
guidelin
pool
proport
rate
calcul
use
metaprop
program
stata
version
mac
also
confid
interv
studi
calcul
use
exact
method
result
studi
compos
patient
thalassemia
patient
inherit
bleed
disord
mainli
hemophilia
fulfil
criteria
includ
year
data
collect
evalu
studi
pool
hcv
preval
estim
confid
interv
ci
preval
patient
thalassemia
inherit
bleed
disord
ci
ci
respect
consider
heterogen
studi
summaryconclus
find
indic
high
preval
hcv
among
patient
thalassemia
inherit
bleed
disord
iran
moreov
significantli
higher
patient
inherit
bleed
disord
thalassemia
result
also
show
transfus
relat
transmiss
hcv
iran
higher
develop
countri
oa
b
servic
prime
care
hospit
gwarinpa
abuja
foundat
infecti
diseas
nigeria
abuja
fct
nigeria
background
unsaf
blood
pathway
transmit
infect
preval
transfus
transmiss
infect
tti
donat
blood
indic
safe
countri
blood
suppli
also
use
apprais
system
donor
select
approach
monitor
distribut
trend
infect
among
healthi
individu
gener
popul
pauciti
data
poor
monitor
evalu
make
difficult
estim
residu
risk
tti
nigeria
date
effort
systemat
review
consolid
data
preval
tti
donat
blood
nigeria
aim
aim
studi
synthes
exist
literatur
preval
major
tti
hiv
hepat
b
hbv
hepat
c
hcv
syphili
donat
blood
nigeria
method
systemat
review
conduct
publish
data
assess
preval
tti
amongst
blood
donor
nigeria
period
sourc
data
pubm
googl
scholar
african
journal
onlin
search
strategi
combin
term
relat
tti
transfus
transmiss
infect
blood
born
infect
viral
infect
hepat
hcv
hbv
hiv
syphili
potenti
relev
paper
review
random
effect
model
use
implement
metaxl
version
result
eight
articl
met
inclus
criteria
includ
final
review
analysi
publish
articl
avail
data
major
tti
report
pool
preval
least
one
tti
ci
preval
tti
hbv
preval
ci
preval
major
tti
follow
hcv
ci
hiv
ci
syphili
ci
preval
major
tti
variabl
across
class
blood
donor
preval
hbv
hcv
hiv
syphili
among
commerci
donor
ci
ci
ci
ci
respect
among
famili
replac
donor
ci
among
voluntari
donor
ci
ci
respect
preval
major
tti
consist
higher
women
hcv
hiv
syphili
women
versu
hepat
b
hepat
c
hiv
syphili
men
higher
preval
women
spite
higher
proport
blood
donor
men
men
vs
women
summaryconclus
find
indic
preval
tti
amongst
blood
donor
nigeria
high
vari
across
differ
donor
group
urgent
need
appropri
control
measur
order
make
blood
donat
safer
nigeria
k
e
j
k
laboratori
medicin
seoul
nation
univers
colleg
medicin
seoul
laboratori
medicin
chonbuk
nation
univers
colleg
medicin
jeonju
laboratori
medicin
seoul
nation
univers
bundang
hospit
seongnam
republ
korea
background
follow
discontinu
recombin
immunoblot
assay
riba
avail
supplementari
test
detect
hepat
c
viru
hcv
infect
nucleic
acid
amplif
naa
test
howev
naa
test
adequ
detect
past
resolv
hcv
consequ
hard
distinguish
past
resolv
hcv
infect
biolog
fals
posit
aim
present
studi
aim
assess
diagnost
perform
immunoassay
ia
base
signal
sco
ratio
explor
algorithm
optim
effici
assess
result
one
two
ia
method
present
studi
riba
naa
test
posit
sampl
perform
use
two
immun
assay
architect
chemiluminesc
microparticl
immunoassay
cmia
access
hcv
ab
plu
chemiluminesc
immunoassay
cia
assess
diagnost
perform
util
optim
algorithm
determin
true
posit
result
result
total
sampl
evalu
riba
posit
posit
sampl
indetermin
neg
sampl
naa
test
posit
diagnost
sensit
specif
fals
posit
rate
posit
predict
valu
cmia
respect
follow
cia
respect
also
assess
optim
sco
valu
cmia
cia
ppv
singl
immunoassay
ia
determin
posit
cmia
cia
howev
use
two
ia
sampl
determin
posit
cmia
cia
cia
cmia
summaryconclus
hard
determin
posit
sco
ratio
alon
therefor
studi
sought
elucid
fundament
role
sco
ratio
refer
naa
test
riba
well
determin
mani
true
posit
possibl
posit
result
use
one
two
ia
n
l
virolog
research
center
hematolog
genet
engin
substanc
nf
gamaleia
nation
center
epidemiolog
microbiolog
moscow
russian
feder
background
occult
hcv
infect
oci
present
two
type
seroneg
seroposit
low
titer
andor
incomplet
pattern
antibodi
individu
viral
antigen
low
viremia
iuml
oci
lead
fals
neg
result
viral
marker
detect
insuffici
sensit
test
use
hcv
rna
accommod
liver
tissu
within
peripher
blood
leucocyt
anoth
distinct
featur
oci
uncertain
result
detect
grey
zone
result
point
new
challeng
transfus
servic
blood
bank
aim
search
close
analysi
serolog
weakli
express
form
hcv
infect
blood
donor
recipi
method
blood
donor
uncertain
result
detect
blood
recipi
sever
hemophilia
sever
hemophilia
b
differ
type
lymphoma
acut
leukemia
myeloprolifer
blood
disord
incomplet
pattern
antibodi
individu
hcv
antigen
follow
hcv
marker
close
investig
mean
age
donor
year
mf
ratio
mean
age
recipi
year
mf
ratio
examin
period
month
blood
donor
month
recipi
investig
includ
routin
sensit
iuml
sensit
iuml
hcv
rna
detect
detect
elisa
cmia
hcv
immunoblot
includ
sampl
hiv
hbv
neg
result
elisa
cmia
detect
result
provid
poor
match
donor
sampl
posit
grey
zone
cmia
neg
elisa
immunoblot
rest
sampl
gave
posit
grey
zone
result
elisa
uncertain
result
immunoblot
discord
result
contain
hcv
rna
concentr
iuml
recipi
donor
blood
show
hcv
rna
case
low
high
viremia
sampl
low
hcv
rna
concentr
show
low
titer
antibodi
singl
hcv
antigen
hcv
combin
contrari
sampl
level
hcv
genom
exceed
iuml
contain
high
titer
hcv
summaryconclus
oci
may
reveal
discord
result
detect
sampl
demand
close
investig
low
level
hcv
rna
plasma
blood
cell
sampl
discord
result
detect
prove
point
low
viremia
blood
recipi
correl
low
titer
antibodi
individu
hcv
antigen
e
e
l
n
v
john
hopkin
univers
school
medicin
baltimor
unit
state
center
diseas
control
public
health
tbilisi
georgia
system
research
institut
san
francisco
unit
state
background
respons
nation
hepat
c
hcv
epidem
govern
georgia
initi
public
health
program
elimin
hcv
program
combin
screen
treatment
goal
identifi
individu
treatment
chronic
hcv
infect
attain
cure
treat
hcv
infect
blood
transfus
identifi
signific
mode
transmiss
hcv
georgia
aim
assess
blood
transfus
oper
georgia
inform
develop
strateg
plan
target
intervent
hcv
prevent
broader
goal
improv
blood
transfus
safeti
method
blood
bank
hold
licens
produc
blood
georgia
requir
use
databas
uniqu
donor
identif
number
assign
donor
donat
provid
access
donat
inform
donor
demograph
test
record
data
extract
blood
donor
databas
summar
accord
oper
indic
eg
number
donat
donor
demograph
sex
remuner
voluntari
replac
first
time
repeat
infecti
marker
statu
preval
transfus
transmit
infect
inform
blood
bank
particip
state
safe
blood
program
also
avail
evalu
result
time
period
donat
record
sixti
percent
donat
collect
male
donor
donat
paid
donor
hcv
hiv
preval
result
base
screen
elisa
assay
report
blood
bank
laboratori
hcv
hiv
preval
respect
hcv
posit
donat
collect
predominantli
donor
hcv
posit
summaryconclus
previou
studi
georgia
shown
hcv
preval
highest
among
men
peopl
inject
drug
given
major
georgian
blood
donor
male
constitut
paid
donor
constitut
possibl
popul
hcv
acquisit
sinc
window
period
hcv
screen
elisa
take
week
longer
test
approach
use
typic
compris
serolog
antibodi
screen
alon
lack
suffici
sensit
detect
recent
infect
donor
thu
fail
interdict
transmit
hcv
goal
hcv
elimin
program
test
treat
hcv
infect
georgian
blood
transfus
remain
risk
transmiss
also
opportun
identifi
link
hcv
posit
donor
hcv
treatment
program
work
toward
transit
hcv
antigen
screen
ultim
nucleic
acid
test
blood
donat
shorten
window
period
reduc
risk
transfus
transmit
hcv
infect
improv
access
optim
hcv
screen
linkag
donor
databas
hcv
treatment
databas
improv
referr
hcv
posit
donor
care
treatment
servic
f
clinic
iranian
blood
transfus
organ
clinic
iran
medic
univers
tehran
islam
republ
iran
background
thalassemia
hereditari
anemia
chronic
transfus
treatment
may
side
effect
one
consequ
transfus
transmit
infect
tti
hepat
c
hcv
one
hcc
may
develop
consequ
hcv
infect
aim
report
case
hcc
thalassemia
major
patient
hcv
infect
consequ
iron
overload
hepat
fibrosi
method
year
old
thalassemia
major
patient
chronic
blood
transfus
sinc
first
year
life
complic
thalassemia
sever
skelet
problem
osteoporosi
vertebr
compress
fractur
necrosi
head
left
femur
patient
histori
splenectomi
cholecystectomi
also
patient
degre
iron
load
rel
high
ferritin
level
moder
iron
siderosi
liver
mri
cours
regular
treatment
develop
sever
abdomin
pain
abdomin
sonographi
coars
parenchym
liver
two
mass
porta
hepati
suggest
lymph
node
extramedullari
hematopoiesi
advis
confirm
mri
contrast
day
later
patient
abdomin
pelvic
mri
iv
gadolinium
show
ill
defin
mass
segment
vii
liver
suggest
invas
mass
metastat
malign
cholangiocarcinoma
also
metastat
para
aortic
lymph
node
result
patient
admit
hospit
liver
biopsi
done
hepatocellular
carcinoma
diagnos
patholog
report
also
patient
develop
rise
level
alphafetoprotein
cours
diseas
progress
patient
ill
asthen
unfortun
patient
die
start
chemotherapi
summaryconclus
hcc
usual
consequ
hcv
infect
thalassem
patient
nowaday
increas
qualiti
treatment
longer
life
expect
patient
grow
middl
age
beyond
increas
surviv
complic
thalassaemia
nt
short
life
time
risk
hcc
increas
cirrhot
liver
damag
iron
overload
result
chronic
transfus
regular
follow
good
treatment
iron
overload
may
prevent
high
risk
malign
thalassem
patient
abstract
withdrawn
abstract
withdrawn
tt
e
l
amorim
carneiro
l
c
c
de
almeida
p
b
blood
system
research
institut
san
francisco
unit
state
medicin
medic
school
univers
paulo
paulo
hemoriohemocentro
rio
de
janeiro
rio
de
janeiro
hemominashemocentro
de
mina
gerai
belo
horizont
school
univers
paulo
hemocentro
de
paulo
paulo
de
medicina
universidad
de
pernambuco
hemopehemocentro
de
pernambuco
recif
blood
system
research
institut
san
francisco
brazil
medicin
univers
california
san
francisco
san
francisco
unit
state
background
donor
elig
assess
conduct
use
interview
brazil
hiv
infect
blood
donor
brazil
higher
donor
compar
countri
high
human
develop
indic
monitor
risk
factor
among
blood
donor
import
tool
help
reduc
risk
recipi
aim
determin
recent
behavior
factor
put
associ
hiv
infect
among
accept
blood
donor
brazil
test
confirm
posit
method
hiv
donor
return
standard
counsel
referr
invit
particip
studi
novemb
march
donor
enrol
four
blood
center
locat
citi
recif
rio
de
janeiro
sao
paulo
belo
horizont
studi
particip
complet
confidenti
audio
comput
assist
structur
interview
acasi
motiv
risk
factor
blood
donat
also
provid
blood
sampl
molecular
surveil
analysi
primarili
focus
risk
behavior
report
donor
period
donat
result
hiv
posit
donor
enrol
recif
rio
de
janeiro
sao
paulo
belo
horizont
male
year
old
singl
never
marri
overal
straightheterosexu
femal
vs
male
particip
studi
similar
hiv
sex
age
race
commun
replac
donor
blood
center
donat
howev
particip
significantli
like
repeat
donor
hiv
risk
factor
disclos
acasi
vari
accord
sex
expect
sex
man
sex
anoth
man
last
month
common
male
femal
vs
femal
like
male
report
sex
inmat
last
month
vs
sex
hiv
partner
last
month
vs
equal
proport
male
femal
report
sex
hiv
partner
take
antiretrovir
therapi
last
month
vs
addit
male
femal
report
ever
person
inject
drug
pwid
male
femal
report
ever
needl
exposur
profession
work
behavior
disclos
time
would
made
donor
inelig
summaryconclus
blood
donor
import
undisclos
behavior
risk
factor
continu
donat
blood
center
brazil
result
indic
vital
need
understand
reason
motiv
nondisclosur
deferr
risk
donor
select
process
approach
acasi
evalu
altern
enhanc
disclosur
brazil
c
k
e
c
f
marmara
region
blood
center
turkish
red
crescent
region
blood
center
turkish
red
crescent
anatolia
region
blood
center
servic
gener
director
turkish
red
crescent
depart
univers
ankara
turkey
background
hivaid
human
immunodefici
virusacquir
immunodefici
syndrom
becom
one
studi
infecti
diseas
sinc
defin
hivaid
still
import
health
problem
worldwid
number
peopl
live
hiv
worldwid
continu
grow
last
year
first
hivaid
case
report
turkey
increas
trend
follow
year
number
case
reach
new
case
aim
studi
perform
determin
retrospect
demograph
characterist
confirm
hiv
posit
blood
donor
turkish
red
crescent
includ
gender
blood
donat
number
age
educ
occup
statu
method
among
blood
donor
attend
turkish
red
crescent
blood
donat
center
date
confirm
hiv
posit
donor
includ
studi
demograph
characterist
blood
donor
review
record
relat
blood
center
hiv
test
perform
enzym
immunoassay
method
elisa
diasorin
murex
hiv
agab
combin
uk
nucleic
acid
amplif
test
real
time
pcr
roch
coba
taqscreen
mpx
germani
anti
hiv
confirm
test
line
immunoassay
lia
fujirebio
belgium
result
studi
among
donat
blood
sampl
donor
accept
turkish
red
crescent
reactiv
found
sampl
hiv
andor
real
time
pcr
test
among
reactiv
sampl
hiv
posit
confirm
lia
test
confirm
hiv
posit
case
male
first
time
donor
complet
high
school
occup
statu
show
specif
characterist
hiv
posit
case
male
femal
among
male
case
made
two
blood
donat
among
hiv
posit
femal
case
percentag
first
time
donor
higher
percentag
first
time
donor
hiv
posit
male
case
major
hiv
case
found
age
year
major
hiv
posit
case
complet
high
school
hiv
confirm
posit
case
distribut
differ
occup
group
summaryconclus
primari
target
blood
center
safe
blood
transfus
obligatori
screen
test
appli
measur
taken
donor
inquiri
physic
examin
process
mean
prevent
transfus
transmit
infect
countri
increas
trend
infect
year
number
annual
new
hiv
posit
case
wherea
number
increas
reach
annual
new
hiv
posit
case
similar
increas
turkish
red
crescent
blood
donor
number
annual
confirm
hiv
posit
case
reach
annual
case
increas
result
found
studi
similar
nationwid
data
order
prevent
hiv
infect
import
public
health
problem
world
nationwid
well
essenti
creat
continu
flow
correct
inform
whole
commun
especi
school
curricula
media
channel
regard
etiolog
agent
hivaid
well
prevent
method
safe
behaviour
g
b
u
e
donat
test
south
african
nation
blood
servic
roodepoort
south
africa
bethesda
system
research
institut
san
francisco
unit
state
african
nation
blood
servic
roodepoort
south
africa
iii
nhlbi
unit
state
background
south
african
gener
popul
hiv
preval
among
adult
hiv
incid
estim
per
py
unaid
statist
south
africa
incid
infect
pose
greatest
risk
blood
safeti
although
first
time
ft
donor
incid
estim
use
parallel
hiv
antibodi
nucleic
acid
test
nat
day
rna
antibodi
window
limit
method
rel
nat
yield
rna
antibodi
donor
detect
per
year
aim
appli
new
antibodi
recenc
assay
detect
much
larger
number
recent
within
month
incid
infect
allow
precis
time
trend
subgroup
analys
ft
donor
method
plasma
sampl
hiv
seroposit
ft
donor
calendar
year
test
limit
antigen
avid
lag
assay
sedia
bioscienc
portland
use
cutoff
normal
optic
densiti
unit
correspond
incid
window
day
incid
calcul
py
numer
case
recent
infect
classifi
lag
assay
uninfect
donor
contribut
full
denomin
recent
infect
donor
contribut
half
use
multipl
imput
adjust
incid
miss
lag
result
confirm
donor
donor
classifi
longstand
hiv
exclud
numer
denomin
confid
interv
calcul
use
poisson
method
result
among
donat
ft
donor
test
hiv
seroposit
imput
total
classifi
recent
incid
infect
denomin
consist
approxim
py
overal
incid
per
py
ci
declin
p
trend
age
hiv
incid
age
year
older
age
sex
hiv
incid
femal
male
raceethn
incid
among
black
among
color
among
white
among
asian
donor
provinc
incid
rang
high
mpumalanga
free
state
natal
low
northwest
summaryconclus
south
africa
hiv
incid
among
ft
donor
high
threefold
lower
gener
popul
estim
declin
time
incid
highest
year
age
group
twice
high
femal
compar
male
highest
mpumalanga
provinc
follow
natal
free
state
provinc
consist
public
health
data
could
control
undisclos
antiretrovir
therapi
among
hiv
posit
donor
result
fals
recenc
lag
assay
may
caus
small
incid
use
antibodi
recenc
assay
import
new
tool
futur
research
compar
result
obtain
use
incid
method
z
v
tirana
faculti
natur
scienc
tirana
albania
background
syphili
hiv
hbv
hcv
share
common
mode
transmiss
syphili
high
preval
among
famili
replac
blood
donor
sexual
transmit
infect
presenc
syphili
sinc
year
consid
indic
toward
high
risk
behavior
consequ
toward
higher
risk
exposur
infect
like
hiv
hepat
actual
donat
come
famili
replac
donor
frd
voluntari
non
remuner
blood
donor
vnrbd
aim
aim
studi
determin
rate
syphili
transfus
transmit
virus
donor
popul
highest
rate
method
retrospect
analysi
donat
data
extract
regist
test
blood
infecti
agent
nbtc
tirana
year
test
perform
abbott
architect
donat
taken
consider
first
time
donat
result
total
number
first
time
donat
total
number
confirm
syphili
posit
donat
overal
preval
syphili
overal
seropreval
hbv
syphili
donor
popul
respect
overal
preval
hcv
syphili
respect
overal
preval
hiv
syphili
one
case
hbsag
syphili
present
also
high
level
transaminas
hiv
infect
mostli
accompani
syphili
among
hiv
infect
donor
present
syphili
rate
associ
syphili
significantli
higher
hiv
compar
hbv
hcv
infect
donor
found
rate
syphili
respect
donor
famili
replac
donor
among
frd
rate
wherea
among
vnrbd
summaryconclus
high
overal
rate
syphili
frd
high
rate
hiv
syphili
demonstr
highest
risk
exposur
toward
transfus
transmit
infect
famili
replac
donat
effort
toward
vnrbd
intensifi
safest
way
suffici
abstract
withdrawn
r
kaur
k
mittal
r
kaur
g
kaur
p
kaur
sood
depart
transfus
medicin
govern
medic
colleg
hospit
chandigarh
chandigarh
india
background
rate
transfus
transmit
human
immunodefici
viru
infect
hiv
shown
declin
trend
recent
year
india
increas
sensit
screen
test
increas
awar
gener
public
still
remain
major
public
health
issu
studi
examin
characterist
risk
factor
hiv
seroreact
blood
donor
aim
studi
done
evalu
respons
rate
blood
donor
disclosur
hiv
seroreact
statu
studi
also
examin
characterist
risk
factor
hiv
sero
reactiv
blood
donor
method
retrospect
studi
conduct
depart
transfus
medicin
tertiari
care
hospit
period
month
june
decemb
blood
donor
sampl
screen
hiv
use
fourth
gener
elisa
enzym
link
immunosorb
assay
kit
per
manufactur
instruct
kit
approv
use
blood
bank
drug
control
gener
india
seroreact
donor
notifi
telephon
letter
also
sent
respect
address
respond
call
letter
counsel
take
proper
histori
confidenti
maintain
refer
ictc
test
treatment
reactiv
donor
respond
three
telephon
call
letter
label
default
data
regard
characterist
age
sex
donor
statu
voluntaryreplac
donat
statu
first
time
repeat
histori
high
risk
behavior
histori
prolong
hospit
blood
transfus
histori
tattoo
ear
pierc
obtain
donor
record
form
post
donat
counsel
regist
result
total
blood
donat
twenti
donat
seroreact
hiv
twenti
seroreact
donor
nineteen
male
one
femal
eleven
twenti
donor
donat
first
time
nine
repeat
donor
nineteen
voluntari
one
replac
donor
twenti
donor
written
correspond
could
sent
nineteen
donor
wherea
one
donor
could
inform
address
incomplet
donor
record
card
telephon
call
could
made
seventeen
donor
two
donor
respond
call
one
donor
could
inform
phone
switch
fourteen
donor
revert
depart
refer
integr
counsel
test
centr
ictc
nine
male
donor
reveal
histori
high
risk
behavior
one
donor
awar
reactiv
statu
post
donat
counsel
three
donor
gave
histori
prolong
hospit
follow
blood
transfus
given
one
case
four
donor
histori
tattoo
ear
pierc
summaryconclus
present
studi
emphas
import
creat
awar
variou
mode
transfus
transmit
infect
tti
among
blood
donor
also
stress
need
strengthen
pre
donat
screen
counsel
confidenti
outdoor
voluntari
blood
donat
camp
repeatedli
track
seroreact
donor
elimin
safe
donor
pool
p
thunnok
intharasongkroh
r
kimilar
n
yuttayoth
k
chaiwong
blood
test
section
nation
blood
centr
thai
red
cross
societi
bangkok
thailand
background
syphili
chronic
infecti
diseas
caus
treponema
pallidum
main
rout
transmiss
otherwis
transmit
blood
transfus
asymptomat
donor
well
blood
donat
syphili
one
pathogen
import
test
give
blood
patient
treponema
pallidum
test
blood
donor
includ
blood
donor
screen
algorithm
must
test
gener
serolog
test
common
use
blood
donor
screen
treponem
test
thailand
screen
syphili
infect
use
combin
method
decreas
risk
infect
patient
aim
studi
preval
syphili
antibodi
blood
donor
nation
blood
center
thai
red
cross
societi
method
studi
perform
nation
blood
center
thai
red
cross
societi
treponem
test
use
antibodi
detect
use
chemiluminesc
microparticl
immunoassay
cmia
first
screen
step
posit
result
repeat
use
immuno
chromatograph
strip
ic
rapid
plasma
reagin
rpr
supplementari
test
result
blood
donor
screen
syphili
infect
found
sampl
posit
syphili
infect
preval
syphili
infect
male
blood
donor
higher
femal
blood
donor
significantli
differ
p
valu
donor
also
posit
result
repeat
donor
p
valu
moreov
found
hiv
hbv
hcv
well
summaryconclus
studi
show
syphili
infect
identifi
thai
blood
donor
differ
past
addit
similar
neighbor
countri
lower
african
countri
male
blood
donor
donor
higher
risk
syphili
infect
thai
blood
donor
moreov
syphili
infect
associ
hiv
infect
hepat
b
infect
hepat
c
infect
respect
howev
blood
donat
risk
group
may
requir
addit
screen
procedur
ensur
highest
qualiti
blood
product
b
p
bioanalyt
r
ceru
corpor
concord
ca
medicin
harborview
medic
center
univers
washington
seattl
wa
scientif
affair
ceru
corpor
concord
ca
unit
state
scientif
affair
research
ceru
corpor
concord
ca
unit
state
background
treponema
pallidum
tp
spirochet
bacterium
respons
syphili
symptomat
infect
result
develop
chancr
rash
organ
dissemin
via
blood
lymphat
system
produc
system
infect
without
treatment
infect
persist
decad
though
usual
asymptomat
bacteria
detect
blood
world
health
organ
report
million
new
syphili
case
year
million
infect
worldwid
center
diseas
control
prevent
estim
infecti
syphili
case
tripl
sinc
us
silent
bacteremia
infect
donor
pose
risk
blood
suppli
sever
report
case
syphili
tt
high
preval
earli
centuri
led
mandatori
serolog
test
blood
donat
us
throughout
world
last
time
document
case
tt
syphili
least
part
protect
offer
high
cold
sensit
spirochet
cold
storag
applic
pc
must
store
well
compon
transfus
within
day
donat
us
alon
million
blood
donat
screen
year
cost
million
recent
studi
us
blood
donor
reveal
seropreval
blood
donor
blood
donor
south
america
posit
tp
higher
preval
hiv
hbv
hcv
preval
trypanosoma
cruzi
schmuni
et
al
pathogen
reduct
offer
addit
protect
tt
syphili
aim
object
studi
evalu
inactiv
tp
platelet
suspend
plasma
mitig
syphili
tt
treatment
photochem
treatment
util
amotosalen
low
energi
ultraviolet
uva
light
blood
system
use
prevent
nucleic
acid
replic
transcript
translat
format
coval
adduct
crosslink
nucleic
acid
leukocyt
contamin
pathogen
method
experi
compon
spike
tp
harvest
previous
infect
new
zealand
white
nzw
rabbit
test
sampl
remov
prior
addit
amotosalen
determin
input
titer
sampl
remov
immedi
amotosalenuva
treatment
nzw
rabbit
inocul
dilut
undilut
sampl
via
intratesticular
inocul
monitor
orchiti
log
reduct
calcul
differ
mean
titer
sampl
result
robust
inactiv
tp
achiev
limit
detect
corrobor
data
previou
studi
plasma
pl
platelet
suspend
pa
inactiv
pl
summaryconclus
tp
inactiv
limit
detect
treatment
amotosalenuva
data
combin
previou
find
illustr
intercept
blood
system
may
mitig
risk
syphili
tt
endem
area
cm
l
e
f
region
blood
center
turkish
red
crescent
izmir
marmara
region
blood
center
turkish
red
crescent
istanbul
anatolian
region
blood
center
director
blood
servic
turkish
red
crescent
biochemistri
univers
ankara
turkey
background
laboratori
test
donat
blood
prior
transfus
intend
ensur
recipi
receiv
safest
possibl
blood
product
mandatori
test
donat
blood
infect
tti
hepat
b
viru
hbv
hepat
c
viru
hcv
human
immunodefici
viru
hiv
syphili
turkey
aim
studi
perform
review
screen
confirmatori
test
result
examin
seropreval
rate
syphili
turkish
red
crescent
trc
blood
donor
also
aim
contribut
epidemiolog
data
turkey
trc
rel
higher
number
blood
collect
method
total
blood
donor
trc
blood
donat
center
enrol
studi
screen
syphili
done
use
enzym
immunoassay
eia
treponema
pallidum
total
ab
kit
enzygnost
syphili
siemen
germani
diasorin
murex
ice
syphili
diasorin
uk
initi
reactiv
sampl
test
duplic
repeatedli
reactiv
sampl
test
confirmatori
assay
fluoresc
treponem
igg
igg
euroimmun
germani
statist
data
five
year
review
retrospect
seropreval
rate
defin
percentag
seroposit
donor
result
number
test
posit
seropreval
rate
syphili
year
respect
overal
seropreval
rate
signific
increas
seropreval
rate
p
ci
number
blood
donor
found
confirm
seroposit
year
respect
overal
confirm
seroposit
rate
slight
statist
signific
decreas
confirm
seroposit
rate
p
ci
summaryconclus
seropreval
syphili
demonstr
increas
trend
year
slight
fluctuat
seropreval
rate
syphili
year
tend
increas
accord
depart
communic
diseas
statist
data
turkish
ministri
health
moh
report
number
syphili
case
incid
rate
syphili
gener
popul
also
increas
recent
year
thought
increas
seropreval
blood
donor
consist
increas
syphili
preval
incid
gener
popul
although
increas
trend
seropreval
rate
confirm
seroposit
rate
show
decreas
trend
evalu
discord
seropreval
confirm
seroposit
rate
consist
higher
sensit
rel
lower
specif
eia
test
use
syphili
screen
also
conclud
continu
syphili
screen
still
import
maintain
blood
safeti
confirmatori
test
use
global
accept
assay
perform
test
inconclus
donat
essenti
prevent
unnecessari
wast
blood
unit
loss
donor
u
n
bank
district
headquart
hospit
mandi
bahauddin
mandi
bahauddin
bank
punjab
institut
cardiolog
lahor
govern
colleg
univers
faisalabad
blood
transfus
program
pakistan
safe
blood
transfus
program
pakistan
islamabad
patholog
univers
health
scienc
lahor
pakistan
background
syphili
plagu
humankind
year
first
report
outbreak
struck
europ
diseas
spread
quickli
contin
result
global
pandem
centuri
penicillin
base
treatment
becam
avail
infect
rate
start
declin
dramat
howev
strikingli
last
decad
infect
treponema
pallidum
global
million
case
report
per
annum
adult
year
prone
almost
burden
develop
region
furthermor
last
era
syphili
acquir
new
potenti
morbid
mortal
associ
human
immun
defici
viru
hiv
aim
studi
plan
evalu
trend
infecti
diseas
ttid
among
blood
donor
commun
attend
blood
bank
bb
district
headquart
hospit
mandi
bahauddin
pakistan
prevent
measur
may
arrang
accordingli
method
retrospect
studi
conduct
blood
bank
district
headquart
hospit
mandi
bahauddin
pakistan
januari
decemb
blood
donor
enrol
ml
blood
yellow
top
ml
lavend
top
ml
collect
subject
sampl
test
hepat
b
surfac
antigen
hb
ag
anti
hepat
c
viru
anti
human
immunodefici
viru
malari
parasit
syphili
rapid
immunochromatograph
ict
techniqu
result
blood
donor
male
remain
femal
mean
age
year
studi
popul
detect
posit
ttid
decreas
trend
ttid
posit
seen
total
ttid
posit
case
found
ttid
preval
hb
ag
follow
hb
ag
syphili
anti
hcv
syphili
anti
hcv
malari
parasit
hb
ag
malari
parasit
seropreval
hb
ag
anti
hcv
syphili
malari
parasit
hiv
respect
preval
hb
ag
anti
hcv
notic
go
downward
increas
trend
seen
malari
parasit
syphili
case
anti
hiv
found
period
studi
summaryconclus
resurg
syphili
alarm
situat
graph
ttid
go
attribut
hepat
malaria
aid
control
safe
blood
transfus
program
state
still
sexual
educ
common
public
awar
program
nation
intern
level
approach
hardli
need
stop
emerg
threat
initi
phase
p
j
l
univers
ihu
mediterranean
infect
research
unit
emerg
infecti
tropic
diseas
univers
french
blood
establish
marseil
franc
background
risk
bacteri
contamin
transfus
platelet
concentr
pc
remain
lead
caus
transfus
incid
variou
diagnost
method
screen
bacteri
contamin
pc
exist
method
must
implement
earli
stage
possibl
within
pc
product
site
ie
pc
transfer
hospit
unit
techniqu
current
avail
satisfactorili
meet
requir
earli
sensit
specif
detect
aim
aim
studi
evalu
perform
two
bacteri
cultur
system
trek
diagnost
system
bactec
fx
bd
microbiolog
method
seven
bacteri
speci
test
strain
inocul
five
differ
pc
initi
concentr
cfu
per
bag
aerob
bottl
two
volum
inocul
ml
systemat
test
duplic
detect
rate
two
method
compar
result
inocul
volum
ml
versatrek
method
higher
sensit
bactec
fx
method
versu
bottl
detect
p
contrast
detect
cultur
method
use
inocul
volum
ml
averag
significantli
differ
two
method
whatev
volum
test
summaryconclus
versatrek
bacteri
cultur
method
sensit
detect
pc
contamin
low
inocul
volum
could
therefor
propos
detect
pc
contamin
abstract
withdrawn
j
blood
servic
ottawa
blood
servic
vancouv
blood
servic
toronto
servic
manitoba
provinci
laboratori
blood
servic
manitoba
canada
background
contamin
platelet
concentr
pc
staphylococcu
aureu
one
signific
ongo
transfus
safeti
risk
develop
countri
present
case
two
pediatr
patient
transfus
one
split
doubl
apheresi
platelet
unit
transfus
stop
patient
develop
septic
symptom
patient
success
treat
antimicrobi
therapi
hospit
clinic
microbiolog
laboratori
isol
staphylococcu
aureu
patient
blood
cultur
platelet
split
unit
skin
nasal
swab
obtain
donor
aureu
isol
nasal
sampl
microbiolog
molecular
character
aureu
isol
carri
microbiolog
laboratori
canadian
blood
servic
winnipeg
health
scienc
centr
clinic
microbiolog
laboratori
diagnost
servic
manitoba
cadham
provinci
laboratori
result
present
report
implic
platelet
unit
screen
bacteri
contamin
bactalert
cultur
system
yield
neg
result
aim
character
aureu
isol
implic
septic
transfus
reaction
method
bacteri
concentr
determin
use
serial
dilut
residu
platelet
remain
split
unit
plate
onto
blood
agar
ident
related
aureu
isol
cultur
platelet
split
unit
blood
two
patient
confirm
use
microbiolog
method
includ
gram
stain
biochem
identif
api
staph
strip
antimicrobi
suscept
test
six
antibiot
use
etest
strip
molecular
related
isol
cultur
platelet
unit
patient
blood
sampl
assess
pcr
fingerprint
aureu
protein
gene
pfge
whole
genom
sequenc
also
perform
isol
platelet
unit
patient
blood
sampl
donor
nasal
isol
result
bacteri
concentr
platelet
unit
estim
coloni
form
unit
cfu
ml
four
isol
cultur
platelet
unit
two
isol
patient
blood
two
isol
identifi
aureu
biochem
test
demonstr
ident
antimicrobi
suscept
profil
pcr
fingerprint
four
isol
show
ident
band
pattern
repeat
protein
gene
molecular
related
confirm
pfge
whole
genom
sequenc
analys
demonstr
isol
platelet
unit
patient
ident
donor
isol
singl
nucleotid
variant
therefor
consid
match
isol
genom
analys
also
reveal
strain
aureu
spa
type
belong
mlst
clonal
cluster
summaryconclus
result
present
herein
confirm
transfus
platelet
unit
caus
septic
transfus
event
describ
case
platelet
screen
bacteri
contamin
yield
result
report
also
highlight
import
donor
follow
identifi
sourc
platelet
contamin
abstract
withdrawn
abstract
withdrawn
l
tang
n
chan
r
lo
c
chan
w
tsoi
laboratori
depart
hong
kong
red
cross
blood
transfus
servic
hong
kong
china
background
hong
kong
red
cross
blood
transfus
servic
implement
cultur
platelet
concentr
pc
bacteri
surveil
test
bst
minim
risk
platelet
sepsi
sinc
pc
neg
result
h
bacteri
cultur
releas
transfus
cultur
bottl
continu
monitor
anoth
h
posit
signal
detect
pc
associ
compon
would
recal
investig
sinc
end
bst
protocol
chang
total
bacteri
cultur
time
extend
till
expiri
pc
ie
day
aim
conduct
retrospect
analysi
compar
initi
bst
posit
rate
pc
found
bacteri
cultur
h
extend
time
expiri
pc
method
routin
bacteri
surveil
pc
bactalert
autom
blood
cultur
system
durham
nc
usa
implement
sinc
liu
hw
et
al
vox
sang
sampl
individu
pc
undertaken
h
donat
pool
maximum
platelet
sampl
bacteri
cultur
initi
posit
pool
sampl
would
subject
resolut
repeat
bacteri
cultur
sampl
taken
individu
pc
andor
blood
compon
implic
initi
posit
donat
bacteria
isol
confirm
posit
sampl
would
subject
bacteri
identif
purpos
studi
bacteri
cultur
result
pc
period
decemb
decemb
retriev
databas
initi
posit
rate
bst
cultur
h
expiri
pc
comput
statist
compar
consid
statist
signific
result
unit
pc
cultur
initi
bst
posit
rate
cultur
h
pc
expiri
pool
sampl
pool
sampl
respect
p
initi
posit
detect
cultur
h
could
confirm
consid
fals
posit
result
pc
associ
initi
posit
result
transfus
attend
physician
inform
result
transfus
transmit
sepsi
report
initi
reactiv
pool
sampl
confirm
posit
averag
time
initi
posit
signal
h
median
sd
rang
summaryconclus
statist
differ
bst
initi
posit
rate
pc
cultur
h
extend
time
pc
expiri
studi
provid
evid
major
initi
posit
confirm
posit
case
detect
within
h
bacteri
cultur
true
posit
case
found
h
extens
bacteri
cultur
pick
addit
true
posit
pc
base
data
perform
bst
h
data
collect
confirm
find
due
time
c
blood
servic
ottawa
canada
drug
administr
silver
spring
unit
state
background
safeti
platelet
concentr
pc
major
concern
transfus
medicin
due
contamin
mainli
skin
bacteria
predomin
contamin
staphylococcu
epidermidi
form
cell
aggreg
biofilm
pc
pose
high
safeti
risk
transfus
recipi
bacteri
biofilm
display
higher
resist
immun
clearanc
antimicrobi
suscept
cell
counterpart
combin
synthet
antimicrobi
peptid
amp
demonstr
bactericid
activ
bacteri
cell
pc
therefor
import
investig
whether
amp
also
display
bactericid
activ
cell
aim
studi
aim
evalu
abil
combin
synthet
amp
inhibit
biofilm
format
andor
elimin
matur
epidermidi
biofilm
method
three
synthet
amp
peptid
two
repeat
use
bactericid
experi
trypticas
soy
broth
tsbg
pc
spike
three
differ
strain
epidermidi
assay
perform
evalu
bactericid
capabl
peptid
cell
inhibit
biofilm
format
assay
seed
well
plate
approxim
coloni
form
unit
cfu
ml
epidermidi
cultur
contain
tsbg
pc
supplement
amp
combin
pb
neg
control
biofilm
erad
assay
perform
follow
treatment
matur
epidermidi
biofilm
amp
without
mechan
dislodg
mechan
dislodg
biofilm
subject
either
scrap
alon
scrap
follow
pipet
vortex
inhibit
biofilm
format
erad
biofilm
measur
use
crystal
violet
assay
viabl
cell
enumer
assay
perform
three
independ
time
two
replic
per
repetit
statist
analys
perform
determin
differ
bacteri
viabl
count
p
valu
less
consid
statist
signific
result
viabil
epidermidi
cell
gradual
decreas
reach
reduct
min
treatment
complet
elimin
h
neg
control
grew
concentr
cfuml
amp
treatment
preform
epidermidi
biofilm
bactericid
effect
howev
matur
biofilm
dislodg
scrap
viabil
decreas
approxim
tsbg
effect
pc
scrap
biofilm
homogen
pipet
vortex
amp
treatment
significantli
effici
p
reduc
bacteri
concentr
approxim
biofilm
cell
grown
tsbg
approxim
biofilm
cell
grown
pc
summaryconclus
result
present
herein
provid
promis
evid
use
synthet
amp
prevent
epidermidi
biofilm
format
pc
would
enhanc
safeti
transfus
recipi
investig
warrant
overcom
amp
resist
matur
biofilm
like
due
barrier
pose
biofilm
matrix
biochem
modif
cell
wall
cell
blood
servic
ottawa
canada
background
sinc
canadian
blood
servic
use
aerob
cultur
bottl
exclus
bactalert
system
screen
platelet
concentr
pc
bacteri
contamin
screen
procedur
modifi
includ
anaerob
cultur
bottl
extens
platelet
day
august
tube
platelet
sampl
devic
contain
approxim
ml
apheresi
pc
unit
ml
buffi
coat
pc
pool
trap
air
preced
pc
flow
sampl
effect
potenti
air
entri
anaerob
cultur
bottl
pc
sampl
bacteri
detect
unknown
aim
determin
effect
air
entri
inocul
pc
sampl
cultur
bottl
detect
anaerob
bacteria
bactalert
system
method
suspens
pseudomona
aeruginosa
aerob
bacteroid
fragili
anaerob
prepar
trypticas
soy
broth
tsb
pc
target
concentr
approxim
coloni
form
unit
cfu
bottl
n
assay
repeat
anaerob
b
fragili
propionibacterium
acn
pc
target
concentr
approxim
cfubottl
n
eight
ml
bacteri
suspens
prepar
tsb
pc
inocul
aerob
bpa
anaerob
bpn
bactalert
cultur
bottl
air
control
ml
ml
air
ad
sampl
inocul
cultur
bottl
incub
bactalert
system
per
standard
procedur
canadian
blood
servic
result
b
fragili
prepar
tsb
pc
inocul
cfu
bottl
detect
bpn
bottl
three
air
condit
test
inocul
ml
air
bottl
result
detect
time
h
tsb
h
pc
respect
similar
trend
observ
lower
concentr
cfubottl
b
fragili
prepar
pc
detect
bpn
bottl
time
h
ml
air
ad
bottl
respect
p
acn
pc
suspens
inocul
cfubottl
detect
similar
time
either
ml
h
ml
h
air
present
bpn
bottl
slightli
longer
compar
detect
time
hobserv
air
ad
differ
detect
p
aeruginosa
observ
presenc
air
bpa
bottl
tsb
suspens
p
aeruginosa
detect
bpn
bottl
air
ad
p
aeruginosa
detect
bpn
bottl
inocul
pc
suspens
even
addit
air
summaryconclus
studi
demonstr
air
entri
bpn
bottl
impair
growth
anaerob
b
fragili
p
acn
howev
air
entri
anaerob
bottl
inocul
avoid
sinc
could
result
delay
detect
anaerob
bacteria
result
inadvert
releas
contamin
product
transfus
differ
time
bacteri
detect
tsb
pc
suggest
competit
air
consumpt
platelet
bacteria
interest
observ
merit
investig
schneider
krut
langen
germani
background
bacteri
transmiss
red
blood
cell
rbc
concentr
still
remain
persist
problem
corrobor
anecdot
report
fatal
transfus
reaction
gener
applic
blood
bacteria
refer
strain
bbr
could
help
reduc
risk
futur
bbr
allow
object
valid
assess
variou
microbiolog
method
develop
new
techniqu
standard
manner
howev
alreadi
exist
refer
strain
platelet
fail
due
mandatori
cold
storag
condit
rbc
result
isbt
work
parti
infecti
diseas
subgroup
bacteria
conduct
collabor
studi
establish
rbc
transfus
relev
bacteria
refer
strain
aim
identif
character
promis
bacteri
candid
strain
assess
elig
subsequ
studi
intern
partner
method
bacteri
isol
major
actual
transfus
incid
involv
rbc
concentr
collect
worldwid
ident
strain
verifi
bacteri
suspens
known
concentr
produc
spike
experi
coloni
form
unit
cfu
bag
rbc
concentr
three
differ
donor
perform
strain
growth
monitor
routin
storag
condit
without
agit
determin
cfu
time
bag
show
growth
end
test
period
incub
subsequ
addit
viabil
strain
measur
cfu
count
ensur
storag
stabil
result
six
strain
test
demonstr
consist
growth
rbc
strain
prolifer
surviv
within
rbc
detect
incub
bag
remain
candid
show
growth
success
candid
listeria
monocytogen
serratia
marcescen
serratia
liquefacien
pseudomona
fluorescen
yersinia
enterocolitica
yersinia
enterocolitica
ii
repres
bacteria
mainli
facult
psychrophil
growth
properti
individu
growth
kinet
reveal
growth
count
excess
cfuml
p
fluorescen
day
storag
start
initi
inoculum
approxim
cfuml
initi
select
process
stabil
studi
perform
candid
strain
shown
date
stabl
storag
condit
summaryconclus
reliabl
growth
cold
storag
condit
independ
donor
variabl
observ
small
proport
test
candid
strain
outcom
studi
clearli
demonstr
necess
well
character
bacteri
refer
strain
provid
robust
consist
result
next
step
strain
challeng
intern
studi
prove
valid
abstract
withdrawn
f
r
p
bioanalyt
r
ceru
corpor
concord
allergi
infecti
diseas
univers
washington
seattl
wa
scientif
affair
research
ceru
corpor
concord
unit
state
background
trypanosoma
cruzi
tc
caus
agent
chaga
diseas
hemoflagel
parasit
transmit
peopl
triatomin
insect
vector
kiss
bug
found
throughout
america
preval
latin
america
estim
roughli
million
peopl
chaga
diseas
experienc
lifelong
asymptomat
chronic
indetermin
infect
potenti
transfus
transmiss
tt
blood
compon
parasitem
donor
threat
blood
suppli
transmiss
tc
blood
transfus
occur
frequent
endem
area
estim
roughli
tt
brazil
alon
late
tt
case
document
past
decad
endem
latin
america
platelet
also
document
unit
state
canada
spain
benjamin
et
al
bone
marrow
transplant
recipi
contract
chaga
diseas
lo
angel
lead
death
tc
capabl
surviv
room
temperatur
platelet
well
freezethaw
plasma
cryoprecipit
highlight
need
mitig
strategi
photochem
treatment
process
util
amotosalen
low
energi
ultraviolet
uva
light
develop
inactiv
pathogen
residu
leukocyt
routin
use
global
prepar
plasma
pl
pc
manufactur
either
platelet
addit
solut
plasma
aim
object
studi
evalu
inactiv
trypanosoma
cruzi
cruzi
plasma
platelet
compon
mitig
transfus
transmiss
method
tc
propag
high
titer
cell
harvest
quantifi
spike
either
pl
compon
final
concentr
trypomastigotesml
pc
pl
dose
amotosalen
control
sampl
remov
determin
treatment
parasit
titer
control
sampl
serial
dilut
appropri
dilut
inocul
quintupl
onto
cell
monolay
determin
tissu
cultur
infect
dose
unit
illumin
sampl
withdrawn
test
sampl
dilut
pl
pc
inocul
onto
cell
cultur
monitor
trypomastigot
viabil
indic
motil
score
posit
neg
surviv
replic
week
period
sampl
viabl
trypomastigot
observ
treat
compon
tc
inactiv
calcul
differ
valu
mean
sampl
sampl
limit
detect
lod
defin
total
volum
plate
result
lod
pl
pc
respect
result
robust
inactiv
tc
compon
achiev
lod
pl
n
n
n
summaryconclus
photochem
treatment
amotosalen
uva
pl
result
inactiv
tc
lod
compon
indic
approach
could
success
mitig
transfus
pc
plasma
compon
c
p
c
p
bioanalyt
r
ceru
corpor
concord
ca
unit
state
nation
dhistoir
naturel
pari
franc
york
blood
center
new
york
affair
ceru
corpor
concord
ca
unit
state
scientif
affair
research
ceru
corpor
concord
ca
unit
state
background
protozoan
parasit
plasmodium
falciparum
pf
account
nearli
malaria
mortal
africa
endem
tropic
countri
report
million
new
malaria
case
worldwid
result
death
malaria
major
caus
morbid
mortal
global
preval
highest
africa
infect
mortal
occur
speci
anophel
mosquito
serv
vector
diseas
contin
except
antarctica
due
global
warm
malaria
transmit
vector
spread
new
area
risk
malaria
transfus
tt
develop
countri
signific
due
increas
global
travel
malaria
endem
region
asymptomat
period
last
day
delay
symptom
appear
week
month
travel
take
antimalari
drug
mitig
strategi
base
deferr
symptomat
donor
optim
object
studi
evalu
inactiv
pf
blood
compon
use
nucleic
acid
target
technolog
provid
comprehens
approach
mitig
pf
tt
red
blood
cell
addit
solut
chemic
treatment
util
amustalin
glutathion
gsh
use
treatment
plasma
pl
platelet
resuspend
pa
plasma
nucleic
acid
target
photochem
treatment
util
amotosalen
low
energi
ultraviolet
uva
light
use
case
treatment
result
adduct
crosslink
nucleic
acid
na
pathogen
leukocyt
present
inhibit
replic
transcript
translat
na
result
inactiv
aim
evalu
inactiv
pf
blood
compon
use
nucleic
acid
target
technolog
provid
comprehens
approach
mitig
pf
tt
method
experi
blood
compon
spike
rbc
irbc
sampl
remov
prior
addit
amustalin
amotosalen
determin
input
titer
sampl
remov
h
immedi
amotosalenuva
treatment
plateletsplasma
sampl
serial
dilut
flask
contain
medium
fresh
rbc
dilut
sampl
use
inocul
flask
plate
monitor
parasitemia
count
irbc
blood
smear
andor
flow
cytometri
log
reduct
calcul
differ
mean
titer
sampl
result
robust
inactiv
pf
achiev
limit
detect
pl
n
n
n
n
summaryconclus
pf
inactiv
limit
detect
blood
compon
nucleic
acid
target
treatment
plasma
platelet
amotosalenuva
treatment
rbc
amustalinegsh
demonstr
intercept
blood
system
provid
approach
mitig
risk
pf
tt
endem
area
compon
collect
transfus
amustalinegsh
system
rbc
approv
use
dm
baquero
rodriguez
nation
blood
bank
colombian
red
cross
bogota
dc
colombia
background
chaga
diseas
infect
caus
trypanosoma
cruzi
endem
sever
region
colombia
apart
transmiss
transfus
relat
case
also
document
sinc
capit
citi
experienc
substanti
migrat
countrysid
part
due
intern
social
conflict
serolog
screen
blood
donor
cruzi
antibodi
mandatori
sinc
countri
sever
strategi
prevent
donor
give
blood
implement
time
impact
yet
assess
aim
studi
aim
calcul
compar
detect
rate
cruzi
confirm
posit
donor
last
year
blood
bank
place
capit
citi
method
result
screen
confirmatori
test
cruzi
retrospect
review
blood
donat
januari
decemb
group
year
detect
donor
age
follow
year
year
despit
use
variou
assay
donor
screen
year
sampl
confirm
indirect
immunofluoresc
supplement
test
algorithm
introduc
confirm
repeat
reactiv
sampl
algorithm
includ
second
screen
test
differ
method
cruzi
immunoblot
case
neg
result
chi
squar
test
use
compar
proport
result
total
donat
test
time
frame
analys
sampl
confirm
posit
proport
confirm
case
significantli
decreas
p
although
consist
reduct
year
year
howev
neg
trendlin
clearli
detect
rate
confirm
case
follow
period
respect
rate
last
four
year
largest
proport
case
detect
age
group
follow
age
group
summaryconclus
despit
continu
migrat
capit
citi
endem
area
found
sustain
low
rate
confirm
infect
last
year
could
explain
sever
factor
improv
vector
control
endem
area
impact
educ
materi
introduct
specif
question
donor
questionnair
strategi
prevent
donor
give
blood
focu
popul
older
year
age
abstract
withdrawn
e
h
j
innov
canadian
blood
servic
blood
research
patholog
laboratori
medicin
univers
british
columbia
vancouv
canada
biolog
chemistri
intern
medicin
univers
michigan
medic
school
ann
arbor
unit
state
background
function
plasma
clot
factor
known
modul
numer
viru
type
explain
link
shown
envelop
three
herpesvirus
acquir
cellular
initi
coagul
host
tissu
factor
tf
anion
phospholipid
apl
viral
tf
apl
act
cofactor
clot
factor
viia
fviia
factor
x
fx
activ
lead
clot
format
cell
signal
use
herp
simplex
viru
model
envelop
viru
viru
tf
previous
shown
enhanc
infect
encod
glycoprotein
c
gc
also
implic
fx
activ
aim
aim
current
research
dissect
role
gc
fx
activ
investig
ubiqu
viral
tf
apl
envelop
virus
method
variant
dengu
viru
denv
propag
cell
cultur
purifi
character
fx
activ
role
viral
tf
solubl
form
gc
assess
chromogen
plasma
clot
assay
protein
bind
experi
perform
use
microscal
thermophoresi
enzym
kinet
assay
immunogold
electron
microscopi
use
simultan
visual
tf
apl
marker
viru
surfac
result
plasma
denv
induc
clot
viral
tf
requir
optim
fx
activ
presenc
gc
virus
could
enhanc
fx
activ
plasma
clot
furthermor
gc
replac
tf
cofactor
function
purifi
chromogen
system
preliminari
evid
suggest
direct
bind
fviia
tf
apl
incorpor
denv
particl
summaryconclus
viru
surfac
tf
function
enhanc
gc
contribut
fx
activ
clot
format
purifi
system
gc
mimick
tf
function
identif
tf
denv
demonstr
viral
acquisit
host
constitu
suggest
ubiqu
tf
envelop
virus
combin
prior
observ
viru
tf
enhanc
infect
data
present
may
support
target
viral
tf
agent
j
r
p
f
c
u
h
develop
australian
red
cross
blood
servic
sydney
develop
australian
red
cross
blood
servic
chemistri
molecular
bioscienc
univers
queensland
brisban
australia
intern
gmbh
langen
germani
tourco
franc
red
cross
blood
servic
nstob
spring
germani
background
yellow
fever
viru
yfv
endem
tropic
subtrop
area
south
america
africa
current
major
public
health
threat
brazil
although
live
attenu
vaccin
avail
individu
resid
endem
area
mani
travel
countri
endem
yfv
affect
area
still
experi
signific
morbid
mortal
yfv
infect
asymptomat
symptom
occur
includ
fever
muscl
pain
promin
backach
headach
loss
appetit
nausea
vomit
yellow
fever
vaccin
viru
demonstr
indic
potenti
viral
australian
red
cross
blood
servic
blood
servic
restrict
donat
individu
vaccin
yfv
four
week
post
vaccin
individu
diagnos
yfv
infect
three
month
recoveri
altern
approach
manag
potenti
yfv
risk
use
pathogen
inactiv
pi
system
theraflex
theraflex
aim
investig
efficaci
theraflex
theraflex
system
inactiv
yfv
spike
plasma
buffi
platelet
concentr
pc
method
yfv
spike
plasma
pc
unit
n
per
blood
compon
spike
plasma
unit
treat
use
theraflex
system
visibl
light
dose
standard
presenc
methylen
blue
mb
approxim
spike
pc
treat
use
theraflex
system
uvc
dose
standard
sampl
taken
prior
first
illumin
dose
test
residu
viru
use
modifi
plaqu
assay
normal
plate
method
pi
system
level
viral
reduct
determin
result
treatment
plasma
theraflex
system
result
averag
reduct
yfv
infect
standard
visibl
light
dose
residu
viral
infect
reach
detect
limit
assay
similarli
pc
treat
theraflex
system
averag
reduct
yfv
infect
observ
standard
uvc
dose
residu
viral
infect
limit
detect
assay
summaryconclus
studi
suggest
theraflex
theraflex
system
effici
inactiv
yfv
plasma
pc
observ
reduct
viral
infect
treatment
pi
system
similar
arbovirus
includ
dengu
chikungunya
zika
west
nile
virus
studi
examin
threshold
concentr
elicit
diseas
need
order
determin
whether
level
reduct
viral
infect
pi
system
plasma
pc
suffici
prevent
nonetheless
given
reduct
level
observ
studi
pi
system
could
effect
option
manag
yfv
risk
plasma
pc
c
e
v
e
r
c
h
product
safeti
unit
australian
red
cross
blood
servic
perth
develop
australian
red
cross
blood
servic
brisban
australia
background
parvoviru
global
ubiquit
dna
viru
infect
result
varieti
clinic
present
includ
erythema
infectiosum
children
arthralgia
adult
asymptomat
infect
possibl
transmiss
usual
respiratori
rout
howev
vertic
transmiss
transmiss
solid
organ
haematopoiet
transplant
document
transmiss
product
liabl
fresh
compon
occur
australia
small
number
infect
investig
attribut
probabl
tt
aim
measur
current
seropreval
igg
australian
blood
donor
estim
likelihood
collect
viraem
donat
whole
blood
donor
australia
assess
whether
viru
pose
current
tt
risk
australia
method
agesexregion
stratifi
plasma
sampl
n
collect
whole
blood
donor
australian
state
territori
screen
igg
use
immunosorb
assay
separ
cohort
sampl
whole
blood
donor
n
stratifi
blood
donat
process
state
test
dna
pcr
confirmatori
test
perform
extern
viral
load
determin
dna
confirm
posit
sampl
preval
data
use
model
tt
risk
result
igg
detect
ci
donor
increas
donor
age
associ
p
igg
seropreval
differ
seroposit
sex
p
sampl
donor
dna
initi
reactiv
confirm
ci
sampl
reactiv
dna
distribut
equal
sex
process
centr
viral
load
rang
log
iuml
two
sampl
viral
load
theoret
infecti
dose
iuml
give
potenti
infecti
donat
rate
ci
risk
assess
model
overal
predict
number
tt
case
signific
complic
per
year
associ
risk
per
compon
approxim
transfus
group
risk
commun
exposur
much
higher
contribut
major
overal
risk
adult
paediatr
recipi
would
receiv
excess
compon
respect
equal
risk
infect
one
year
commun
exposur
summaryconclus
studi
demonstr
expect
clear
associ
seropreval
increas
age
half
donor
test
igg
antibodi
detect
dna
blood
donor
similar
rate
develop
countri
model
tt
risk
gener
recipi
neglig
minor
rout
infect
compar
commun
exposur
inform
inform
develop
optim
risk
manag
strategi
manag
tt
australia
base
stakehold
feedback
laboratori
hungarian
nation
blood
transfus
servic
hnbt
virolog
nation
public
health
institut
nphi
budapest
hungari
background
west
nile
viru
wnv
worldwid
distribut
member
genu
flaviviru
respons
numer
human
anim
infect
europ
sever
clinic
manifest
vari
wide
milder
form
west
nile
fever
west
nile
neuroinvas
diseas
main
transmiss
rout
via
bite
infect
mosquito
howev
infect
relat
blood
transfus
organ
transplant
also
describ
wnv
one
import
viral
zoonot
infect
hungari
biggest
part
countri
affect
figur
clinic
case
increas
sinc
howev
similarli
european
countri
season
wnv
screen
whole
blood
donor
implement
yet
aim
aim
studi
assess
wnv
rna
reactiv
seropreval
igg
antibodi
sampl
whole
blood
donor
collect
territori
activ
viru
circul
hungari
method
base
confirm
clinic
wnv
case
report
nphi
edta
sampl
donor
collect
affect
area
perform
coba
taqscreen
wnv
test
wnv
pcr
roch
diagnost
determin
igg
antibodi
develop
assay
wnv
iif
iif
screen
posit
indetermin
sampl
test
tbev
assay
exclud
enceph
viru
tbev
anoth
human
pathogen
flaviviru
endem
hungari
iif
result
confirm
hi
assay
hi
test
conduct
use
antibodi
parallelli
confirm
wnv
seroposit
sampl
also
test
presenc
igm
antibodi
use
wnv
iif
assay
commerci
wnv
igm
captur
elisa
focu
diagnost
result
none
sampl
show
reactiv
wnv
pcr
wnv
igg
iif
screen
result
reactiv
sampl
hi
test
donor
ci
found
posit
igg
antibodi
addit
sampl
igg
iif
show
similar
titer
igm
antibodi
determin
sampl
show
reactiv
iif
elisa
test
suggest
acut
recent
wnv
infect
donor
indic
reactiv
igg
reactiv
sera
summaryconclus
wnv
donor
screen
mandatori
hnbt
transfus
transmit
wnv
infect
confirm
far
wnv
clinic
case
report
year
result
deferr
whole
blood
donor
spent
least
h
wnv
expos
area
exclus
wnv
affect
hungarian
territori
blood
donat
enforc
hnbt
howev
regul
reconsid
ensur
recipi
safeti
stabl
blood
stock
level
hungari
n
b
j
z
laboratori
hungarian
nation
blood
transfus
servic
hnbt
biosafeti
laboratori
virolog
bacteriolog
nation
public
health
institut
nphi
budapest
hungari
background
haemorrhag
fever
cchf
infect
fatal
rate
among
hospit
peopl
cchf
viru
endem
africa
middl
east
western
asia
europ
balkan
region
affect
cchf
appear
spain
princip
vector
hyalomma
marginatum
viru
first
report
hungari
despit
vector
presenc
clinic
case
confirm
hungari
far
diseas
control
author
consid
cchf
potenti
transfus
transmitt
infect
howev
spread
via
blood
product
strengthen
yet
aim
aim
studi
set
pilot
serosurvey
assess
whether
hungari
could
consid
new
area
distribut
cchf
viru
viru
pose
factor
risk
assess
haemovigil
method
total
serum
sampl
obtain
healthi
blood
donor
test
antibodi
presenc
randomli
select
blood
donor
age
year
enrol
studi
proport
male
donor
slightli
higher
sampl
screen
antibodi
use
develop
contain
assay
cchf
ifa
exclud
potenti
ifa
slide
test
specif
virus
bacteria
support
result
obtain
ifa
assay
commerci
avail
elisa
test
contain
recombin
cchf
antigen
appli
cchf
ifa
slide
produc
nphi
nation
biosafeti
laboratori
condit
result
base
first
ifa
screen
sampl
indic
reactiv
toward
cchf
viru
commerci
test
gave
concord
result
sampl
neg
borderlin
posit
discord
sampl
positiveneg
negativeposit
negativeborderlin
among
ifa
reactiv
donor
averag
age
year
proport
men
among
posit
donor
significantli
higher
summaryconclus
result
support
serolog
evid
cchf
infect
hungari
princip
vector
h
marginatum
endem
mediterranean
region
appear
continent
area
may
indic
import
role
climat
chang
expand
distribut
haemovigil
complex
monitor
system
cover
entir
way
donat
blood
donor
recipi
one
import
aspect
monitor
possibl
impact
infecti
agent
blood
product
safeti
base
low
seropreval
lack
clinic
case
deferr
whole
blood
donor
tick
bite
suitabl
measur
prevent
viru
transmiss
substanti
task
public
health
determin
pathogen
circul
viru
strain
hungari
increas
awar
group
commun
risk
e
g
forest
hunter
health
care
worker
emerg
threat
cchf
viru
e
baraba
n
magyar
contribut
work
equal
c
c
c
p
blood
center
kaohsiung
blood
servic
foundat
institut
clinic
medicin
colleg
medicin
nation
taiwan
univers
taipei
taiwan
republ
china
background
dengu
viru
denv
infecti
agent
outbreak
dengu
fever
occur
affect
case
taiwan
seriou
one
recent
nearli
two
decad
sinc
denv
includ
routin
blood
screen
critic
evalu
prevent
effect
use
alanin
aminotransferas
alt
valu
surrog
marker
detect
asymptomat
dengu
infect
among
blood
donor
epidem
period
aim
studi
estim
proport
denv
infect
among
asymptomat
blood
donor
differ
alt
valu
epidem
area
differ
dengu
incid
amplif
tma
nucleic
acid
test
epidem
method
donor
serum
sampl
randomli
select
stratifi
group
alt
level
includ
alt
iul
n
alt
iul
n
judg
inelig
blood
suppli
donat
contribut
donor
live
dengu
epidem
area
week
incid
per
resid
select
sampl
test
denv
rna
procleix
dengu
viru
tma
assay
procleix
panther
system
tma
reactiv
sampl
sent
nation
denv
refer
laboratori
center
diseas
control
research
diagnost
center
conduct
denv
diagnost
test
use
revers
transcript
polymeras
chain
reaction
sequenc
denv
type
ag
test
immunosorb
assay
elisa
test
antibodi
result
among
test
sampl
dengu
epidem
area
total
sampl
denv
tma
reactiv
includ
sampl
donat
alt
iul
sampl
donat
alt
iul
among
donor
alt
iul
epidem
area
week
incid
per
resid
detect
denv
respect
among
donor
alt
iul
detect
denv
respect
denv
tma
detect
rate
gener
increas
increas
dengu
incid
statist
signific
denv
tma
detect
rate
found
donor
alt
iul
alt
iul
three
differ
incid
area
use
detect
rate
proportion
situat
face
epidem
denv
tma
reactiv
sampl
abl
discard
due
alt
iul
denv
tma
reactiv
sampl
perform
denv
test
nation
denv
refer
laboratori
found
recent
denv
infect
includ
posit
posit
elisa
antibodi
posit
sequenc
posit
sampl
identifi
epidem
caus
denv
type
summaryconclus
higher
posit
proport
observ
donor
alt
iul
differ
dengu
epidem
area
statist
signific
found
denv
tma
reactiv
sampl
prevent
risk
denv
infect
use
alt
valu
surrog
marker
jc
p
depart
univers
nairobi
nairobi
depart
nakuru
level
hospit
molo
kenya
background
west
nile
viru
wnv
arboviru
transmit
infect
mosquito
caus
incid
transmit
culex
mosquito
preval
kenya
aim
determin
compar
seropreval
wnv
among
blood
donor
nairobi
nakuru
region
blood
transfus
test
centr
kenya
method
studi
carri
two
region
blood
transfus
center
rbtc
base
nairobi
nakuru
two
center
associ
possibl
low
high
preval
respect
total
blood
sampl
randomli
select
period
one
month
blood
sampl
test
wnv
igg
use
elisa
result
major
donor
year
age
predominantli
male
wnv
igg
preval
blood
donor
ci
preval
cross
infect
tti
wnv
ci
preval
wvn
igg
highest
year
age
group
femal
though
result
statist
signific
differ
igg
posit
differ
center
summaryconclus
infect
wnv
public
health
concern
fifth
infect
wnv
develop
ill
develop
neurolog
symptom
succumb
diseas
test
recommend
posit
sampl
confirm
outsid
scope
studi
r
f
uganda
blood
transfus
servic
microbiolog
makerer
univers
kampala
uganda
hemomina
belo
horizont
brazil
background
caus
seriou
diseas
human
transmitt
blood
transfus
need
screen
virus
donat
blood
remain
concern
blood
transfus
servic
ensur
safeti
blood
recipi
preval
given
popul
must
known
aim
assess
seropreval
among
blood
donor
uganda
method
studi
cross
section
one
enrol
randomli
select
healthi
blood
donor
age
rang
year
donor
six
region
blood
bank
uganda
screen
use
chemiluminesc
micro
particl
immunoassay
techniqu
test
serum
sampl
result
antibodi
present
blood
donor
highest
seroposit
found
gulu
region
blood
bank
center
p
result
also
show
slight
variat
preval
seroposit
femal
male
donor
preval
also
vari
among
variou
type
blood
donor
highest
sero
posit
among
donor
presenc
risk
factor
associ
rel
higher
rate
htlv
associ
statist
signific
popul
test
summaryconclus
seropreval
found
blood
donor
uganda
rel
high
compar
region
endem
virus
south
america
japan
caribbean
region
point
need
screen
blood
donat
uganda
studi
necessari
understand
risk
factor
associ
htlv
countri
jarilla
madrig
g
andujar
p
p
de
de
ciudad
real
hospit
gener
universitario
de
ciudad
real
ciudad
real
de
enfermedad
infecciosa
instituto
maimonid
de
de
imib
hospit
universitario
reina
de
spain
background
spanish
hepat
e
viru
hev
guidelin
european
centr
diseas
prevent
control
establish
decis
screen
blood
donat
hev
determin
background
preval
transmiss
infect
donor
popul
suscept
recipi
aim
evalu
preval
hev
infect
blood
donor
south
center
spain
method
includ
studi
blood
donat
healthi
donor
collect
ciudad
real
south
center
spain
septemb
januari
serum
sampl
analyz
hev
use
nucleacid
test
method
pool
sampl
rna
extract
use
qiacub
qiagen
hilden
alemania
test
amplifi
viral
region
use
method
cfx
connect
real
time
pcr
system
biorad
hercul
california
posit
pool
test
quantifi
individu
use
lightcycl
roch
basel
switzerland
extern
run
standard
curv
appli
calcul
hev
viral
load
use
hev
standard
strain
suppli
code
consist
genotyp
viral
load
express
iuml
calcul
preval
hev
infect
result
total
donat
includ
studi
identifi
sampl
posit
hev
suppos
preval
one
donat
sampl
differ
donor
viral
load
million
iuml
iuml
iuml
iuml
respect
viral
isol
consist
genotyp
summaryconclus
studi
show
high
hev
infect
preval
among
blood
donor
south
center
spain
data
suggest
risk
hev
hev
could
import
set
c
e
p
c
coordin
haemovigil
centr
hellen
centr
diseas
control
prevent
athen
bank
univers
hospit
ioannina
unit
bank
gener
hospit
piraeu
athen
greec
health
refer
laboratori
blood
born
virus
public
health
refer
laboratori
blood
born
virus
london
unit
kingdom
hippokrateio
univers
hospit
athen
greec
background
hev
infect
caus
epidemiolog
clinic
concern
field
public
health
primarili
consumpt
undercook
pork
product
import
caus
acut
viral
hepat
worldwid
hev
threaten
blood
safeti
increas
incid
rais
question
need
includ
blood
screen
prevent
strategi
ffp
apheresi
platelet
may
present
greater
risk
red
cell
consequ
risk
group
thalassaemia
patient
extens
exposur
donor
rcc
rais
new
issu
clinic
manag
aim
present
result
haemovigil
investig
case
acut
hev
thalassaem
patient
examin
comorbid
exacerb
inflammatori
process
hev
clinic
outcom
contribut
greek
nation
strategi
prevent
method
report
infect
recipi
blood
establish
subsequ
haemovigil
centr
trace
recipi
potenti
infecti
blood
donat
test
archiv
new
sampl
implic
donat
hev
antibodi
case
posit
result
test
hev
genotyp
sequenc
analysi
sampl
donor
recipi
perform
result
patient
male
thalassaemia
transfus
rcc
start
month
old
end
receiv
unit
risk
factor
hev
patient
histori
splenectomi
chronic
hcv
genotyp
sustain
viral
respons
succeed
follow
treatment
effect
iron
chelat
therapi
appli
liver
iron
concentr
lic
current
mgg
dri
weight
liver
mri
analysi
serum
ferritin
ngdl
may
present
symptom
acut
hepat
hev
diagnos
serolog
test
liver
function
test
high
self
limit
recoveri
achiev
within
month
liver
biochem
test
normal
haemovigil
investig
possibl
show
patient
transfus
six
unit
rcc
within
relev
time
period
two
month
prior
occurr
hev
test
avail
archiv
sampl
detect
one
unit
posit
hev
igm
antibodi
implic
donor
male
asymptomat
time
donat
relev
travel
diet
occup
inform
reveal
liver
steatosi
diagnos
year
ago
donor
recal
mildli
rais
serum
transaminas
annual
checkup
one
week
blood
donat
ffp
implic
blood
unit
retriev
discard
pcr
test
posit
patient
donor
phylogenet
analysi
indic
sequenc
sampl
belong
genotyp
sequenc
comparison
indic
sampl
ident
across
region
result
make
highli
like
sequenc
link
summaryconclus
preval
document
incid
thalassaem
patient
transfus
unit
rcc
f
van
l
l
v
p
clinic
chemistri
microbiolog
immunolog
laboratori
liver
infecti
diseas
ghent
belgium
de
hemoterapia
valladolid
spain
cross
flander
ghent
belgium
background
hepat
e
viru
hev
worldwid
underdiagnos
viru
respons
least
million
infect
yearli
rna
viru
isol
infect
mammal
classifi
orthohepeviru
genu
hepevirida
famili
orthohepeviru
speci
subdivid
seven
major
genotyp
belong
singl
serotyp
genotyp
endem
mani
develop
countri
zoonot
genotyp
caus
sporad
infect
industri
countri
mainli
associ
infect
hev
mainli
caus
acut
infect
howev
chronic
infect
may
occur
among
immunocompromis
patient
eg
solid
organ
transplant
recipi
lead
fulmin
hepat
death
transmiss
transfus
blood
compon
alreadi
report
sever
european
countri
great
britain
germani
spain
franc
also
canada
japan
nevertheless
transmiss
via
medicin
product
pdmp
obtain
viru
inactiv
andor
remov
step
far
document
aim
want
assess
hev
preval
flemish
blood
donor
studi
import
determin
risk
hev
transmiss
blood
transfus
especi
immunosuppress
solid
organ
transplant
patient
method
total
amount
sampl
collect
red
cross
flander
period
may
june
previous
frozen
sampl
initi
pool
per
screen
presenc
hev
rna
use
hev
test
system
roch
diagnost
pleasanton
ca
usa
second
phase
rna
reactiv
pool
deconstruct
analyz
individu
use
methodolog
volum
limit
individu
sampl
dilut
equal
volum
pb
limit
detect
assay
undilut
sampl
iuml
use
specif
elisa
wantai
biolog
pharmaci
enterpris
beij
china
presenc
hev
igg
determin
hev
rna
posit
sampl
well
select
randomli
chosen
sampl
score
hev
rna
neg
test
pool
format
igm
wantai
determin
virem
sampl
well
sampl
result
initi
hev
rna
screen
valid
result
obtain
pool
react
posit
deconstruct
rna
reactiv
pool
blood
donat
confirm
hev
rna
posit
rang
iuml
serolog
screen
rna
posit
sampl
show
sampl
hev
igm
posit
donor
also
igg
posit
within
randomli
select
sampl
donat
hev
igg
posit
includ
donat
also
hev
igm
posit
summaryconclus
show
approxim
blood
donat
flander
may
origin
donor
activ
infect
hev
upon
transfus
donat
may
pose
risk
immunocompromis
patient
patient
liver
diseas
interestingli
also
identifi
one
blood
donor
hev
suggest
recent
exposur
epidemiolog
analysi
genotyp
experi
ongo
mf
c
j
j
hemocentro
region
maldonado
maldonado
eutm
de
la
republica
laboratori
atgen
montevideo
region
maldonado
maldonado
uruguay
background
hepat
global
health
problem
result
injuri
destruct
hepatocyt
lead
liver
malfunct
hepat
e
viru
hev
one
lead
caus
acut
liver
inflamm
consid
import
public
health
concern
mani
develop
countri
accord
world
health
organ
million
peopl
infect
hev
annual
hev
infect
usual
howev
may
develop
acut
fulmin
hepat
high
risk
group
patient
liver
problem
pregnant
women
acut
fulmin
hepat
could
develop
chronic
infect
may
progress
cirrhosi
even
death
hemocentro
region
maldonado
blood
bank
central
blood
donat
east
region
uruguay
includ
maldonado
rocha
lavalleja
cerro
largo
treinta
tre
east
region
repres
total
popul
uruguay
annual
hemocentro
collect
donat
distribut
blood
compon
among
east
region
montevideo
task
done
accord
high
qualiti
standard
aim
investig
preval
hev
among
blood
donor
east
region
uruguay
method
take
account
demograph
inform
plasma
sampl
blood
donor
obtain
hemocentro
plasma
librari
sampl
test
presenc
igg
igm
hev
ab
version
ultra
diapro
hev
ab
posit
sampl
test
presenc
igm
hev
igm
diapro
igm
posit
sampl
test
presenc
hev
rna
final
viral
rna
sampl
sequenc
determin
hev
genotyp
result
forti
blood
donor
hev
posit
total
antibodi
igg
igm
nineteen
igg
igm
reactiv
sampl
igm
reactiv
rna
posit
rna
posit
sampl
genotyp
summaryconclus
first
studi
hev
among
blood
donor
east
region
uruguay
obtain
result
alert
us
high
preval
patholog
suggest
includ
screen
hev
blood
donor
c
sargento
c
ferreira
e
silva
p
achando
j
tomaz
blood
depart
transfusion
medicin
centro
hospitalar
coimbra
coimbra
portug
background
hepat
e
viru
hev
discov
mikhail
balayan
genom
clone
sequenc
smith
bradley
rey
et
al
hev
member
famili
hepevirida
genu
orthohepeviru
compris
speci
orthohepeviru
orthohepeviru
contain
genotyp
hev
infect
human
infect
human
mammal
detect
anim
hev
lead
caus
acut
hepat
develop
countri
mostli
asia
africa
respons
estim
million
infect
geograph
area
hev
involv
mostli
genotyp
transmit
rout
develop
countri
hev
infect
consid
acquir
travel
endem
area
today
demonstr
major
infect
autochthon
involv
case
genotyp
eventu
genotyp
main
transmiss
relat
consumpt
uncook
pig
porcin
viral
reservoir
game
meat
transfus
rout
transmiss
worri
almost
european
countri
alreadi
routin
research
hev
blood
donat
england
germani
itali
other
select
test
transfus
patient
immunosuppress
patient
transplant
recipi
pregnant
women
clinic
situat
hev
infect
danger
even
fatal
aim
assess
accuraci
detect
kit
screen
donor
hand
determin
viral
load
studi
patient
method
kit
test
hepat
e
rna
fast
track
hev
select
sampl
sampl
blood
donat
hev
rna
posit
patient
sampl
valid
panel
known
viral
load
standard
quantifi
viral
load
neg
control
posit
control
doubt
pcr
result
use
addit
test
recomlin
hev
mikrogen
perform
nucleic
acid
biomerieux
amplif
detect
quantif
rt
pcr
perform
sampl
handl
laminar
flow
chamber
result
sampl
blood
donat
hev
rna
neg
result
ftd
clonit
hev
rna
border
line
result
clonit
neg
ftd
hev
rna
posit
patient
sampl
hev
rna
posit
result
ftd
clonit
hev
rna
posit
result
ftd
neg
clonit
hev
rna
posit
result
ftd
neg
clonit
sampl
discrep
result
one
recomlin
hev
igg
igm
neg
recomlin
hev
igg
igm
posit
ftd
kit
confirm
result
panel
hev
rna
use
standard
demonstr
good
perform
kit
summaryconclus
conclud
kit
good
perform
quantit
larger
studi
requir
make
sound
consist
assess
c
sargento
c
ferreira
e
silva
p
achando
j
tomaz
blood
depart
transfusion
medicin
centro
hospitalar
coimbra
coimbra
portug
background
parvoviru
singl
strand
dna
viru
icosahedr
famili
parvovirida
genu
erythroviru
discov
cossart
screen
normal
blood
bank
donor
sera
major
parvoviru
infect
clinic
asymptomat
symptom
acut
infect
parvoviru
may
also
resembl
rubella
especi
adult
rheumat
later
studi
confirm
close
associ
parvoviru
aplast
crisi
larg
studi
sera
sickl
cell
diseas
patient
case
nonimmun
hydrop
fetali
report
infect
woman
occur
pregnanc
evid
intrauterin
parvoviru
infect
lead
development
abnorm
childhood
transmiss
primarili
spread
infect
respiratori
droplet
householdclassroom
contact
transmiss
larg
report
vaccin
avail
human
parvoviru
aim
consid
mainli
asymptomat
infect
problem
infect
caus
sickl
cell
diseas
pregnanc
immunocompromis
patient
role
blood
transfus
transmiss
parvovirus
made
small
studi
blood
donor
sampl
evalu
risk
take
secur
measur
hand
want
valid
kit
want
introduc
laboratori
method
blood
donor
sampl
patient
sampl
patholog
show
specif
test
hcv
ab
hcv
rna
posit
hcv
ab
posit
hcv
rna
neg
hbsag
hbv
dna
posit
hbsag
posit
hbv
dna
neg
sampl
clinic
suspicion
parvoviru
infect
repeat
sampl
show
reproduc
qcmd
sampl
qualiti
control
molecular
diagnost
standard
known
concentr
posit
control
neg
control
dna
extract
test
parvo
rg
uiml
q
quiagen
result
qcmd
sampl
result
expect
posit
neg
control
show
correct
result
standard
show
consist
result
repeat
sampl
obtain
result
result
affect
patient
sampl
patholog
blood
donor
sampl
found
posit
result
dna
parvoviru
sampl
repeat
result
confirm
summaryconclus
artu
rg
pcr
kit
seem
sensit
specif
look
result
panel
sampl
good
reproduc
regard
blood
donor
sampl
found
posit
result
dna
parvoviru
indic
activ
infect
small
studi
posit
result
suggest
extens
crawl
e
borici
r
skendaj
v
doci
dallaku
nation
blood
transfus
center
tirana
albania
background
nucleic
acid
test
nat
molecular
techniqu
screen
blood
donat
reduc
risk
transfus
transmit
infect
tti
blood
blood
product
recipi
found
safer
test
method
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
highli
sensit
specif
viral
nucleic
acid
nat
detect
infect
agent
earlier
screen
method
thu
narrow
window
period
hiv
hbv
hcv
infect
modern
use
techniqu
becom
popular
mani
countri
benefit
safeti
blood
transfus
medicin
albania
nat
screen
began
protocol
procedur
sinc
blood
donat
screen
nat
procedur
hiv
hbv
hcv
syphili
aim
studi
bring
result
blood
donat
screen
nat
method
aim
see
efficaci
role
safeti
clinic
use
blood
method
undertook
retrospect
studi
analyz
blood
donat
overal
countri
januari
januari
blood
donat
screen
infect
agent
hiv
hbv
hcv
syphili
donat
screen
method
mention
infect
agent
anoth
sampl
tube
donor
nat
method
protocol
reactiv
nat
donat
test
discrimin
process
defin
reactiv
hbv
hcv
hiv
high
data
collect
archiv
electron
blood
sampl
identif
barcod
part
function
temperatur
humid
room
nat
machin
oper
monitor
result
blood
donat
exclud
transfus
blood
unit
posit
result
method
found
nat
method
blood
donat
donat
exclud
transfus
result
reactiv
immun
enzymat
test
identifi
posit
infect
agent
high
level
discrimin
reactiv
nat
found
hbv
reactiv
without
result
infect
agent
transaminas
although
reactiv
nat
donat
give
result
discrimin
test
exclud
transfus
summaryconclus
argu
nat
method
blood
analyz
infect
agent
effect
method
support
clinic
use
blood
give
big
advantag
safeti
blood
use
transfus
medicin
ms
brunori
marelli
e
vallejo
brufman
inmunohaematolog
nation
univers
rosario
rosario
argentina
background
fucosyltransferas
fut
control
secret
abh
blood
group
antigen
organ
fluid
play
import
role
infertil
recurr
abort
antigen
incompat
caucasian
popul
inherit
secretor
gene
se
express
abh
antigen
solubl
state
incid
infertil
relat
male
femal
factor
continu
rise
despit
mani
advanc
reproduct
technolog
well
known
abo
antigen
express
sperm
membran
semin
fluid
secretor
well
abo
antibodi
present
cervic
mucu
previou
studi
observ
signific
loss
progress
motil
spermatozoa
non
secretor
relat
secretor
one
caus
specif
cervic
mucu
antibodi
coupl
addit
sperm
cell
haploid
cell
heterozyg
individu
two
sperm
subpopul
express
correspond
allel
specif
antibodi
cervic
mucu
attack
complementari
sperm
aim
evalu
preval
secretor
charact
men
belong
fertil
infertil
coupl
order
investig
possibl
associ
reproduct
success
method
sampl
semen
infertil
men
fertil
control
studi
secretor
phenotyp
evalu
semin
plasma
laboratori
standard
procedur
inhibit
haemagglutin
techniqu
distinguish
abo
gene
pcr
design
two
set
oligonucleotid
allow
amplif
two
differ
region
transferas
without
use
restrict
enzym
comparison
band
pcr
product
individu
genotyp
determin
cervic
mucu
antibodi
femal
partner
titrat
correspond
red
blood
cell
result
result
analys
group
infertil
coupl
abo
incompat
frequenc
phenotyp
husband
significantli
higher
fertil
coupl
p
result
obtain
pcr
sperm
cell
correl
red
cell
phenotyp
summaryconclus
immunolog
implic
reproduct
biolog
studi
consid
caus
failur
interact
even
normal
gamet
secretor
phenotyp
male
partner
could
help
reproduct
success
block
cervic
abo
antibodi
besid
heterozyg
cervic
mucu
antibodi
affect
correspond
sperm
propos
evalu
abh
antigen
express
sperm
membran
semin
plasma
contribut
diagnosi
treatment
human
infertil
n
c
c
refer
laboratori
affair
innov
mcq
canada
background
abo
system
discov
consid
clinic
signific
blood
group
system
transfus
abo
genotyp
donor
patient
routin
perform
might
help
complementari
serolog
test
resolv
case
discrep
result
one
exampl
aim
sampl
year
old
caucasian
femal
newborn
sent
blood
bank
investig
abo
discrep
laboratori
refer
case
type
mother
ab
neg
babi
posit
tube
method
use
ortho
bioclon
reagent
method
sampl
analys
accord
manufactur
insert
tube
method
result
record
immedi
spin
incub
enhanc
antibodi
bind
detect
weak
abo
antigen
antibodi
abo
antigen
reach
detect
level
around
age
year
revers
type
perform
babi
sampl
follow
discrep
serolog
result
sampl
sent
dna
sequenc
abo
gene
exon
sequenc
revers
also
perform
mother
sampl
result
mother
red
blood
cell
rbc
gave
weak
reactiv
dbl
novaclon
ortho
bioclon
seraclon
reagent
rbc
gave
reactiv
dbl
novaclon
ortho
bioclon
seraclon
immucor
gammaclon
dbl
novaclon
ortho
bioclon
immucor
gammaclon
reagent
mix
field
observ
revers
type
reaction
obtain
immedi
spin
rbc
neg
reaction
obtain
b
rbc
test
tube
incub
result
addit
reactiv
cell
addit
posit
reactiv
observ
b
cell
cell
auto
control
identifi
mother
sera
gel
liss
tube
liss
tube
incub
sequenc
analys
identifi
b
allel
polymorph
addit
heterozyg
polymorph
alleleabo
mother
probabl
phenotyp
newborn
type
forward
type
dbl
novaclon
seraclon
sequenc
analys
show
heterozyg
polymorph
posit
allel
posit
allel
abo
probabl
phenotyp
babi
rbc
show
abo
genotyp
found
mother
abo
genotyp
probabl
inherit
father
summaryconclus
sequenc
result
confirm
mother
newborn
share
phenotyp
although
detect
serolog
test
babi
express
b
antigen
may
weaken
case
given
young
age
highlight
clinic
relev
confirm
serolog
abo
subgroup
molecular
method
whenev
appar
discrep
observ
j
laboratori
medicin
genet
samsung
medic
center
seoul
laboratori
medicin
chonnam
nation
univers
medic
school
gwangju
republ
korea
background
endogen
synthesi
develop
earli
month
age
period
serum
group
individu
peak
similar
level
howev
blood
type
patient
abo
discrep
show
remark
differ
reactiv
b
cell
respect
revers
type
aim
aim
studi
determin
incid
abo
discrep
analyz
caus
unbalanc
level
among
cell
type
patient
method
retrospect
studi
involv
patient
receiv
abo
type
juli
decemb
samsung
medic
center
record
result
retriev
analyz
caus
abo
type
discrep
unbalanc
level
serum
type
defin
grade
two
differ
tube
method
classifi
group
group
neonat
defin
infant
less
month
age
abo
genotyp
perform
patient
unresolv
abo
discrep
serolog
clinic
inform
differ
proport
caus
analyz
use
fisher
exact
test
result
total
patient
underw
abo
type
incid
abo
discrep
number
cell
type
patient
sampl
group
n
group
n
show
unbalanc
level
serum
type
group
abo
incompat
hematopoiet
stem
cell
transplant
frequent
caus
respect
singl
patient
group
due
abo
incompat
liver
transplant
neonat
classifi
group
remain
patient
due
variou
caus
patient
underw
abo
genotyp
group
group
frequenc
genotyp
significantli
higher
b
group
p
summaryconclus
except
abo
incompat
transplant
main
caus
unbalanc
low
level
subgroup
wherea
unbalanc
low
temporari
phenomenon
caus
age
underli
diseas
rather
b
subgroup
j
h
j
depart
hematolog
blood
transfus
pragu
jihlava
jihlava
czech
republ
immunolog
transfus
medicin
laboratori
medicin
region
laboratori
medicin
lund
univers
lund
sweden
background
chimera
singl
organ
compos
cell
distinct
phenotyp
andor
genotyp
acquir
seen
follow
hematopoiet
stem
cell
transplant
transient
follow
blood
transfus
may
also
inherit
commonli
blood
exchang
utero
twin
rare
type
call
chimer
occur
fertilis
two
separ
ova
two
sperm
follow
aggreg
two
blastocyst
zygot
stage
result
develop
whole
bodi
chimer
organ
intermingl
cell
line
doubl
set
genet
sign
mother
father
transfus
medicin
chimera
often
detect
mix
field
reactiv
observ
abod
type
less
commonli
phenotyp
blood
group
antigen
aim
investig
prompt
find
doubl
popul
erythrocyt
healthi
blood
donor
transfus
histori
blood
donor
donat
time
type
previous
group
rhd
posit
without
discrep
method
blood
group
chang
tube
agglutin
column
agglutin
gel
card
doubl
popul
found
column
agglutin
test
subsequ
type
c
antigen
aim
investig
chimera
determin
underli
abo
genotyp
blood
donor
method
blood
sampl
blood
donor
parent
sibl
investig
routin
blood
group
perform
column
agglutin
separ
doubl
cell
popul
perform
differenti
agglutin
igm
flow
cytometri
monoclon
perform
characteris
two
popul
initi
abo
genotyp
perform
fluogen
diagnostik
gmbh
resolut
perform
use
method
karyotyp
perform
standard
method
identif
refer
allel
perform
fragment
analysi
short
tandem
repeat
str
polymorph
result
donor
genotyp
identifi
abo
kit
howev
system
detect
abo
genotyp
exclus
subsequ
resolut
detect
allelesabo
dna
isol
peripher
blood
saliva
somat
genom
genotyp
donor
father
abo
mother
abo
abo
discrep
among
donor
sibl
blood
group
type
rbc
popul
remov
rbc
agglutin
typedo
ccee
second
popul
type
agglutin
cell
rbc
type
ccee
flow
cytometri
use
shown
doubl
popul
erythrocyt
group
group
cytogenet
demonstr
normal
xy
karyotyp
str
polymorph
polymorph
two
matern
two
patern
one
two
matern
one
patern
allel
ratio
peripher
blood
saliva
deriv
dna
summaryconclus
rare
case
chimera
observ
healthi
blood
donor
two
healthi
children
situat
caus
troubl
blood
group
discrep
blood
group
genotyp
c
medicin
medicin
tata
medic
center
kolkata
india
background
titrat
abo
antibodi
import
transfus
practic
antibodi
titer
influenc
outcom
abo
incompat
organ
hematopoiet
stem
cell
transplant
antibodi
titrat
also
determin
need
intervent
hemolyt
diseas
newborn
variat
titrat
result
variat
titer
techniqu
known
occur
although
antibodi
titrat
result
affect
patient
manag
india
standard
antibodi
titrat
protocol
conduct
studi
support
ortho
clinic
diagnost
assess
convent
tube
techniqu
ctt
column
agglutin
techniqu
cat
antibodi
titrat
aim
compar
ctt
cat
antibodi
titrationto
assess
igm
interfer
igg
antibodi
estim
determin
need
dtt
treatment
igg
estimationcompar
igm
igg
titer
amongst
group
b
method
twenti
voluntari
blood
donor
blood
group
b
assess
anti
b
titer
total
titer
assess
igm
igg
without
igm
inactiv
ctt
cat
ortho
biovu
system
dithiothreitol
dtt
treatment
use
igm
inactiv
doubl
dilut
prepar
master
dilut
method
affirmagen
cell
ortho
clinic
diagnost
use
method
standard
valid
techniqu
use
quantit
variabl
express
term
median
interquartil
rang
wilcoxon
rank
sum
test
appli
test
signific
two
median
result
igm
titer
igg
titer
dtt
treatment
group
b
p
higher
titer
obtain
cat
compar
ctt
method
igm
igg
dtt
igg
without
dtt
igg
antibodi
titer
dtt
treatment
less
igg
titer
without
dtt
treatment
cat
ctt
method
statist
signific
high
igg
titer
treat
plasma
note
even
use
monospecif
igg
ahg
card
igm
igg
titer
without
dtt
amongst
three
blood
group
ctt
cat
group
b
time
igm
titer
ctt
much
cat
method
summaryconclus
studi
reveal
higher
titer
cat
ctt
interest
observ
dtt
treatment
significantli
reduc
igg
titer
ctt
cat
method
henc
appear
igm
interfer
igg
estim
ctt
cat
variat
result
due
differ
titrat
method
whether
igm
inactiv
done
could
lead
variat
result
impact
patient
manag
henc
urgent
need
uniform
antibodi
titrat
practic
protocol
cat
titer
must
also
clinic
correl
ensur
appropri
interpret
addit
studi
provid
baselin
data
igm
igg
titer
amongst
b
group
blood
donor
tn
e
j
moh
biolog
laboratori
french
establish
blood
ile
de
franc
site
pari
franc
intern
medicin
bernard
hospit
pari
franc
background
paroxysm
cold
hemoglobinuria
pch
rare
type
autoimmun
hemolyt
anemia
aiha
commonli
observ
children
adult
follow
viral
infect
character
presenc
serum
biphas
hemolysin
igg
autoantibodi
sensit
red
blood
cell
rbc
effect
cold
caus
hemolysi
temperatur
subsequ
rais
report
case
man
histori
acut
p
falciparum
malaria
treat
artemeth
lumefantrin
automed
one
month
prior
admiss
hospit
cold
pain
numb
edema
cyanosi
extrem
evolut
ill
mark
onset
sever
immun
hemolyt
anemia
nadir
hb
gl
dark
urin
rapidli
irrevers
distal
ischemia
necrosi
lead
imput
finger
lower
extrem
cryoglobulin
cryofibrinogen
detect
patient
serum
strongli
complement
posit
direct
test
dat
initi
demonstr
patient
sampl
sent
laboratori
aiha
serolog
investig
aim
aim
studi
support
clinic
diagnosi
aiha
method
screen
cold
reactiv
antibodi
perform
test
patient
plasma
untreat
allogen
oi
oi
autolog
rbc
hemolyt
serum
screen
acidifi
patient
serum
plu
acidifi
normal
serum
sourc
complement
test
rbc
also
perform
test
realiz
use
patient
rbc
incub
melt
ice
follow
incub
control
test
parallel
maintain
result
cold
agglutinin
titer
obtain
test
untreat
group
oi
rbc
respect
hemolysi
observ
test
design
demonstr
monophas
hemolysin
test
posit
set
cell
incub
first
h
min
demonstr
hemolysi
patient
rbc
follow
phase
set
cell
maintain
throughout
show
hemolysi
biphas
hemolysin
thu
appear
show
specif
summaryconclus
describ
unusu
case
detect
antibodi
although
aiha
biphas
hemolysin
common
adult
consid
investig
case
serolog
clinic
evid
suggest
pch
especi
cold
agglutinin
syndrom
ca
exclud
patient
dat
ss
da
transfus
medicin
apollo
gleneagl
hospit
kolkata
india
background
neg
direct
antiglobulin
test
dat
rule
aiha
clinic
entiti
known
dat
neg
aiha
report
although
convent
tube
techniqu
ctt
polyspecif
coomb
reagent
gold
standard
method
investig
dat
howev
due
low
sensit
fals
neg
dat
may
result
hemolyz
patient
carri
low
number
igg
molecul
per
rbc
variou
advanc
method
describ
previous
diagnos
dat
neg
aiha
major
blood
bank
india
lack
method
except
facil
column
agglutin
techniqu
cat
addit
advanc
costli
method
author
past
describ
simpl
techniqu
yield
dat
posit
otherwis
dat
neg
aiha
blood
bank
part
referr
hospit
encount
clinic
suspect
case
aiha
otherwis
dat
neg
ctt
share
experi
diagnos
dat
neg
aiha
use
cat
simpl
method
describ
aim
blood
bank
part
referr
hospit
encount
clinic
suspect
case
aiha
otherwis
dat
neg
ctt
share
experi
diagnos
dat
neg
aiha
use
cat
simpl
method
describ
method
blood
sampl
patient
suspect
aiha
receiv
blood
bank
dat
investig
dat
perform
ctt
cat
use
polyspecif
coomb
reagent
posit
dat
result
report
immedi
neg
result
extend
dat
evalu
includ
monospecif
gel
card
dat
igg
subclass
dat
cold
acid
elut
cold
wash
dat
hemolysi
patient
document
laboratori
paramet
hb
gdl
b
reticulocyt
c
serum
bilirubin
mgdl
ldh
iuml
abnorm
hemolysi
classifi
moder
sever
basi
whether
laboratori
paramet
respect
abnorm
statist
analysi
done
use
spss
statist
softwar
version
result
patient
autoimmun
other
suffer
non
immun
hemolyt
anemia
eighteen
f
median
year
autoimmun
patient
clinic
serolog
diagnos
dat
neg
aiha
secondari
aiha
observ
patient
patient
complain
fatigu
routin
activ
present
clinic
icteru
moder
sever
vivo
hemolysi
observ
patient
respect
median
hb
reticulocyt
serum
bilirubin
ldh
gdl
mgdl
iuml
respect
polyspecif
cat
could
diagnos
case
dat
neg
aiha
diagnos
monospecif
cat
n
subclass
cat
n
cold
wash
dat
n
elut
n
method
three
patient
respond
aiha
therapi
despit
neg
dat
free
serum
antibodi
detect
patient
summaryconclus
absenc
high
end
sensit
method
develop
countri
includ
india
make
diagnosi
dat
neg
aiha
challeng
howev
major
patient
diagnos
use
simpl
rel
sensit
methodolog
n
j
duke
univers
servic
duke
univers
hospit
durham
unit
state
background
hemolysi
follow
liver
transplant
treat
calcineurin
inhibitor
may
associ
presenc
red
blood
cell
rbc
antibodi
immunohematolog
workup
case
complex
transfus
support
may
requir
incompat
rbc
maintain
adequ
hemoglobin
level
aim
character
serolog
find
transfus
strategi
develop
liver
transplant
patient
present
hemolyt
anemia
method
consecut
medic
record
adult
pediatr
year
old
liver
transplant
patient
present
tertiari
care
academ
institut
januari
januari
review
serolog
evalu
character
complex
follow
identifi
warm
autoantibodypanagglutinin
cold
antibodi
inconclus
immunohematolog
reactiv
could
resolv
date
liver
transplant
start
date
calcineurin
inhibitor
therapi
date
complex
serolog
find
identifi
collect
transfus
manag
advers
reaction
includ
result
total
liver
transplant
patient
review
transplant
occur
pediatr
patient
thirteen
patient
complex
serolog
signific
rbc
antibodi
classifi
warm
autoantibodi
case
inconclus
case
cold
autoantibodi
case
repres
overal
incid
patient
cohort
incid
pediatr
patient
versu
adult
patient
receiv
calcineurin
inhibitor
tacrolimu
immunosuppress
direct
antiglobulin
test
dat
posit
case
patient
show
presenc
immunoglobulin
igg
alon
patient
show
igg
complement
presenc
strong
interf
cold
antibodi
preclud
accur
direct
antiglobulin
test
one
patient
five
patient
develop
complex
serolog
follow
transplant
tacrolimu
initi
five
pediatr
age
group
hemolysi
confirm
patient
adult
pediatr
patient
hemolysi
seen
adult
case
milder
antibodi
one
requir
transfus
support
hemolyt
anemia
pediatr
patient
associ
signific
hemolysi
evidenc
extend
transfus
support
transfus
manag
includ
phenotyp
match
rbc
provid
pediatr
case
along
crossmatch
unit
patient
febril
transfus
reaction
one
pediatr
patient
prompt
prevent
manag
includ
wash
prbc
minim
cytokin
content
slow
infus
small
aliquot
summaryconclus
immun
mediat
hemolysi
post
solid
organ
transplant
report
patient
immunosuppress
calcineurin
inhibitor
calcineurin
cell
suppress
dysregul
b
cell
prolifer
postul
mechan
caus
hemolyt
anemia
pediatr
patient
seem
suscept
develop
signific
hemolyt
anemia
may
requir
extend
transfus
support
serolog
compat
blood
transfus
may
alway
possibl
limit
inform
avail
regard
transfus
guidanc
outcom
patient
transfus
servic
awar
challeng
scenario
case
direct
transfus
regimen
accordingli
care
evalu
clinic
laboratori
find
e
f
r
muhammadiyah
prof
hamka
medic
technolog
product
servic
central
blood
transfus
servic
central
blood
transfus
servic
indonesian
red
cross
jakarta
indonesia
background
immun
hemolyt
anemia
character
clinic
laboratori
featur
hemolyt
anemia
direct
antiglobulin
test
dat
posit
could
autoimmun
hemolyt
anemia
aiha
alloimmun
hemolysi
base
antigen
stimulu
aim
studi
occurr
rbc
autoimmun
among
multipl
transfus
aiha
patient
identifi
blood
group
antibodi
potenti
develop
induc
reaction
affect
patient
studi
carri
patient
record
aiha
regist
central
blood
transfus
servic
indonesian
red
cross
jakarta
studi
use
see
percentag
aiha
speci
found
referr
patient
cbt
irc
result
use
refer
case
incompat
irc
cbt
method
studi
carri
patient
record
aiha
regist
cbt
irc
jakarta
immun
hemolyt
anemia
character
clinic
laboratori
featur
hemolyt
anemia
direct
antiglobulin
test
dat
posit
result
central
blood
transfus
servic
indonesian
red
cross
patient
aiha
year
furthermor
base
thermal
amplitud
autoantibodi
aiha
classifi
warm
cold
aiha
cold
drug
induc
mix
type
mix
aiha
referr
patient
must
differenti
warm
aiha
clinic
insignific
cold
agglutinin
cold
hemagglutinin
diseas
treatment
differ
may
present
blood
group
discrep
incompat
lead
delay
arrang
suitabl
blood
unit
transfus
therefor
thorough
immunohematolog
workup
includ
monospecif
dat
indirect
antiglobulin
test
determin
thermal
amplitud
titer
essenti
summaryconclus
studi
show
indonesia
case
aiha
aiha
mix
cold
warm
autoantibodi
presenc
result
manag
perform
aiha
patient
see
success
therapi
aiha
patient
done
dat
examin
therapi
bel
h
n
ben
la
rabta
rue
jebel
lakhdar
hopit
la
rabta
tuni
tunisia
background
autoimmun
hemolyt
anemia
aiha
rel
uncommon
disord
diagnosi
made
demonstr
anemia
combin
reticulocytosi
hyperbilirubinemia
elev
lactat
dehydrogenas
ldh
demonstr
posit
direct
antiglobulin
test
dat
signific
subset
patient
may
present
atyp
featur
follow
case
aim
case
report
method
case
report
result
year
men
diabet
hypertens
evalu
anemia
admit
month
prior
cardiac
surgeri
cardiopulmonari
bypass
requir
unit
pack
red
blood
cell
ten
day
period
investig
show
regen
anemia
hemoglobin
gdl
mcv
fl
reticulocyt
ldh
ul
normal
direct
antiglobulin
test
posit
iga
uricemia
mgl
normal
aha
igg
iga
autoantibodi
direct
reticulocyt
suspect
prednison
mgkgday
indic
return
baselin
hemoglobin
gdl
within
week
treatment
summaryconclus
syndrom
aiha
reticulocytopenia
rare
caus
reticulocytopenia
well
establish
advis
examin
patient
hyperuricemia
w
h
n
ben
rue
jebel
lakhdar
rue
jebel
lakhdar
hopit
la
rabta
la
rabta
tuni
tunisia
background
g
antigen
rh
blood
group
system
present
either
along
andor
c
posit
red
cell
serolog
present
similar
pictur
multipl
antibodi
differenti
import
pregnanc
hemolyt
diseas
aim
case
report
highlight
rare
case
auto
without
myelodysplast
patient
report
dissemin
knowledg
identif
import
transfus
patient
method
case
report
result
three
month
femal
transfus
three
unit
red
blood
cell
rbc
result
standard
antibodi
screen
detect
incompat
cross
match
immunohematolog
investig
direct
antiglobulin
test
dat
posit
igg
alloantibodi
identif
panel
detect
serum
report
interpret
physician
evid
alloimmun
antigen
c
antigen
trigger
concern
patient
transfus
previous
c
rbc
result
error
blood
type
person
identif
differenti
adsorpt
elut
test
perform
distinguish
seem
caus
signific
vivo
hemolysi
summaryconclus
autoantibodi
mimick
specif
rare
encount
routin
practic
investig
must
done
accur
rapid
diagnosi
transfus
antigen
neg
rbc
unit
institut
research
educ
transfus
medicin
blood
bank
school
alli
medic
scienc
shahid
beheshti
univers
medic
scienc
tehran
islam
republ
iran
background
today
blood
transfus
becom
major
part
healthcar
system
alloimmun
import
advers
effect
patient
undergo
blood
transfus
test
patient
blood
screen
alloantibodi
inappropri
screen
test
one
main
reason
miss
immun
patient
therefor
perform
proper
reliabl
test
necessari
order
minim
hemolyt
reaction
relat
rbc
alloantibodi
aim
studi
set
determin
frequenc
specif
rbc
alloantibodi
detect
test
addit
risk
factor
alloimmun
hospit
popul
tehran
iran
method
retrospect
studi
characterist
type
alloantibodi
alloimmun
patient
among
hospit
patient
male
femal
age
year
year
examin
year
carri
test
includ
abo
group
type
antibodi
screen
compat
test
patient
appli
blood
transfus
perform
antibodi
screen
test
patient
plasma
reagent
red
blood
cell
albumin
use
enhanc
antigen
antibodi
reaction
sampl
posit
antibodi
screen
test
antibodi
identif
done
panel
cover
us
food
rbc
antigen
alloimmun
patient
demograph
characterist
includ
sex
age
medic
histori
transfus
histori
pregnanc
abort
histori
collect
data
analyz
use
statist
softwar
spss
version
excel
microsoft
corpor
result
total
clinic
signific
alloantibodi
found
patient
demonstr
alloantibodi
preval
percent
studi
male
femal
ratio
male
femal
among
alloimmun
patient
patient
singl
antibodi
wherea
remain
patient
multipl
alloantibodi
frequent
identifi
alloantibodi
b
alloimmun
patient
patient
histori
transfus
alloimmun
femal
patient
histori
pregnanc
abort
alloimmunis
patient
year
interestingli
preval
alloantibodi
detect
significantli
differ
variou
age
group
highest
frequenc
identifi
patient
age
year
patient
age
year
alloimmun
least
summaryconclus
studi
depend
hospit
patient
tehran
iran
alloimmun
rate
rel
low
compar
previou
studi
investig
factor
effect
alloimmun
femal
sex
age
histori
transfus
pregnanc
risk
factor
alloimmun
order
avoid
transfus
reaction
sensit
test
patient
need
blood
transfus
also
precis
document
alloimmun
patient
consid
la
r
h
laboratori
technolog
kwame
nkrumah
univers
scienc
technolog
kumasi
ghana
public
health
liverpool
school
tropic
medicin
liverpool
unit
kingdom
georg
washington
school
medicin
health
scienc
washington
dc
bank
transfus
servic
univers
michigan
health
system
ann
arbor
unit
state
health
school
medic
scienc
kwame
nkrumah
univers
scienc
technolog
ghana
kumasi
ghana
experiment
immunohematolog
sanquin
amsterdam
netherland
background
transfus
therapi
vital
manag
patient
sickl
cell
diseas
scd
alloantibodi
format
red
blood
cell
rbc
antigen
common
complic
transfus
therapi
ghana
practic
transfus
abo
compat
rbc
without
screen
rbc
antibodi
preval
rbc
alloimmun
well
frequenc
blood
group
antigen
abo
transfus
sickl
cell
patient
ghana
known
aim
therefor
studi
preval
specif
rbc
antibodi
frequenc
minor
blood
group
antigen
transfus
scd
patient
komfo
anoky
teach
hospit
kumasi
southern
ghana
method
studi
perform
involv
scd
patient
receiv
least
one
previou
rbc
transfus
particip
basic
data
demographi
transfus
medic
histori
record
ghana
patient
rbc
type
serolog
c
c
e
e
k
fya
fyb
jka
jkb
antigen
use
tube
method
serum
sampl
screen
type
rbc
antibodi
use
column
gel
techniqu
univers
michigan
refer
lab
usa
molecular
genotyp
perform
patient
made
antibodi
antigen
possess
result
total
scd
patient
male
femal
recruit
number
rbc
transfus
rang
major
patient
receiv
transfus
one
patient
receiv
transfus
antibodi
rbc
antigen
detect
ten
patient
one
patient
antibodi
low
frequenc
antigen
unknown
specif
respect
two
patient
three
patient
patient
two
patient
type
serolog
c
e
posit
respect
dna
sequenc
result
three
patient
show
patient
made
possess
partial
c
e
antigen
two
serolog
patient
lack
rhd
gene
variant
rhce
gene
encod
ceag
variant
antigen
occur
rhce
previous
observ
polymorph
exon
howev
two
patient
polymorph
occur
exon
due
limit
reagent
avail
rbc
antigen
type
perform
scd
patient
variou
antigen
antigen
frequenc
c
e
c
e
k
fya
fyb
jka
jkb
summaryconclus
preval
rbc
alloimmunis
transfus
scd
patient
ghana
antibodi
mainli
direct
rhesu
antigen
almost
rh
antibodi
made
due
alter
rh
allel
find
suggest
need
screen
rbc
antibodi
scd
patient
blood
transfus
ghana
howev
effect
avert
alloimmunis
limit
antigen
match
molecular
genotyp
rh
antigen
essenti
futur
r
serventi
b
golub
depart
transfus
medicin
transplant
biolog
intern
medicin
clinic
hospit
centr
zagreb
zagreb
croatia
background
almost
patient
treat
allogen
hematopoiet
stem
cell
transplant
hsct
certain
degre
dispar
red
blood
cell
rbc
antigen
major
minor
bidirect
abo
incompat
caus
acut
hemolysi
delay
erythropoiesi
recoveri
period
red
blood
cell
alloantibodi
may
caus
similar
complic
recipi
donor
rbc
express
specif
antigen
new
immun
allogen
hsct
although
rare
occurr
also
caus
hemolysi
aim
aim
investig
frequenc
alloimmun
follow
allogen
hsct
caus
occurr
specif
alloantibodi
method
data
patient
follow
allogen
hsct
uhc
zagreb
retrospect
review
patient
alloantibodi
alloantibodi
detect
allogen
hsct
patient
hsct
patient
patient
alloantibodi
detect
hsct
patient
develop
de
novo
immun
passiv
transfer
alloantibodi
blood
compon
suspect
rhd
immunoprophylaxi
appli
result
data
total
patient
analyz
male
femal
patient
second
hsct
perform
total
transplant
relat
unrel
accord
type
transplant
bone
marrow
bm
transplant
case
peripher
blood
stem
cell
pbsc
cord
blood
cb
select
cell
bm
pbsc
pbsc
cb
recipi
donor
abo
ident
hsct
major
incompat
appear
hsct
minor
incompat
bidirect
incompat
recipi
donor
rhd
ident
rhd
incompat
hsct
alloantibodi
detect
hsct
patient
donor
allogen
hsct
patient
develop
new
immun
none
patient
de
novo
immun
previous
immun
seven
patient
develop
one
alloantibodi
multipl
alloantibodi
total
alloantibodi
differ
specif
frequent
antibodi
rhesu
blood
group
system
averag
time
transplant
alloantibodi
detect
month
caus
new
immun
donor
lymphocyt
exposur
recipi
rbc
transfus
blood
compon
hsct
combin
first
second
caus
antibodi
possibl
gener
b
lymphocyt
recipi
patient
caus
alloimmunis
unknown
due
miss
data
summaryconclus
patient
treat
allogen
hsct
risk
develop
new
alloimmun
due
exposur
donor
lymphocyt
rbc
recipi
transfus
therapi
antigen
incompat
blood
compon
allogen
hsct
patient
develop
alloantibodi
rhesu
kell
mn
lutheran
blood
group
system
caus
signific
hemolysi
complic
cours
recoveri
sinc
patient
develop
alloantibodi
despit
intens
immunosuppress
treatment
continu
immunohematolog
monitor
requir
patient
follow
hsct
l
n
transfus
research
centr
high
institut
research
educ
transfus
medicin
shiraz
iran
blood
transfus
research
centr
high
institut
research
educ
transfus
medicin
shiraz
iran
depart
shiraz
univers
medic
scienc
shiraz
islam
republ
iran
background
develop
antibodi
alloantibodi
autoantibodi
rbc
antigen
one
signific
side
effect
chronic
blood
transfus
studi
conduct
estim
rate
immun
red
blood
cell
rbc
thalassemia
major
patient
aim
ultim
aim
studi
evalu
frequenc
caus
immun
rbc
tdt
patient
facilit
futur
develop
treatment
patient
method
cross
studi
conduct
thalassemia
major
patient
shiraz
iran
frequenc
type
antibodi
survey
coomb
test
antibodi
screen
antibodi
identif
test
result
rbc
immun
found
patient
indirect
agglutin
test
iat
posit
patient
direct
coomb
test
dat
posit
immun
patient
patient
show
posit
result
dat
iat
frequent
antibodi
kell
e
result
indic
gender
age
start
transfus
splenectomi
impact
immun
rate
summaryconclus
studi
alloimmun
rate
antibodi
rh
kell
system
found
frequent
antibodi
find
show
least
rbc
match
rh
kell
antigen
also
must
consid
prepar
blood
thalassemia
patient
pourfathollah
sedaghat
high
institut
research
educ
transfus
medicin
iranian
blood
transfus
organ
tehran
islam
republ
iran
background
sinc
iran
locat
thalassemia
belt
prevent
treatment
thalassemia
major
one
prioriti
nation
health
govern
countri
current
patient
thalassemia
major
iran
aim
provid
constant
compat
safe
adequ
blood
blood
product
thalassemia
patient
prevent
treatment
thalassemia
major
one
prioriti
nation
health
govern
countri
method
nation
thalassemia
prevent
plan
start
consid
number
new
patient
prove
one
success
plan
develop
countri
preval
alloimmun
among
iranian
thalassemia
patient
decreas
iran
howev
rate
consider
low
compar
countri
although
strategi
reduc
risk
rbc
alloimmun
find
compat
rbc
unit
patient
thalassemia
remain
big
challeng
ibto
provid
constant
compat
safe
adequ
blood
blood
product
thalassemia
patient
also
leukoreduct
appli
thalassemia
patient
refer
subsidiari
clinic
center
throughout
countri
provid
health
servic
patient
accord
protocol
set
iranian
ministri
health
result
part
mitig
strategi
manag
alloimmun
ibto
recommend
perform
match
protocol
k
antigen
kell
system
preval
rh
alloantibodi
patient
thalassemia
like
c
e
rh
system
secondli
person
medicin
give
appropri
transfus
format
alloantibodi
prevent
sever
complic
find
compat
rbc
unit
lastli
perform
screen
programm
find
donor
phenotyp
antigen
may
help
make
pool
donor
express
immunogen
rbc
antigen
kell
rh
antigen
summaryconclus
conclus
appropri
policymak
defin
sensit
test
like
molecular
type
variant
preval
alloimmun
may
reduc
dramat
iran
vashistha
arya
n
mahawar
bharti
k
purohit
mehra
raheja
k
mehra
depart
immuno
haematolog
transfus
medicin
sardar
patel
medic
colleg
associ
group
hospit
bikan
india
background
alloantibodi
red
blood
cell
rbc
antigen
significantli
complic
blood
transfus
caus
difficulti
pre
transfus
compat
test
caus
delay
avail
blood
unit
even
emerg
indic
preval
alloimmun
extrem
variabl
depend
upon
popul
studi
india
till
date
literatur
alloimmun
limit
patient
studi
healthi
blood
donor
blood
donor
sourc
kind
blood
compon
variou
transfus
therapi
must
type
screen
make
right
blood
unit
avail
needi
one
right
time
aim
studi
aim
determin
preval
specif
rbc
alloantibodi
among
healthi
blood
donor
india
method
type
antibodi
screen
identif
test
perform
sampl
collect
blood
donor
n
immucor
galileo
neo
fulli
autom
immunohematolog
analyz
period
april
octob
blood
group
perform
use
direct
hemagglutin
microstrip
reagent
provid
manufactur
screen
identif
perform
use
commerci
prepar
captur
liss
pool
cell
cell
cell
panel
base
solid
phase
red
cell
adher
sprca
technolog
result
interpret
use
antigram
suppli
appropri
statist
test
signific
appli
result
analyz
use
spss
version
primer
ms
excel
softwar
yate
correct
appli
result
donor
sampl
screen
posit
rbc
alloantibodi
case
year
age
group
case
year
age
group
case
year
age
group
develop
multipl
alloantibodi
p
posit
case
identifi
alloantibodi
preval
alloantibodi
mnss
system
antigen
observ
frequent
case
follow
rh
system
kell
system
antigen
case
common
individu
alloantibodi
identifi
anti
k
follow
anti
antibodi
anti
anti
fyb
anti
n
anti
reveal
frequenc
case
classifi
exhibit
solid
phase
phenomenon
spp
sinc
panel
cell
react
solid
phase
posit
reaction
observ
techniqu
tube
column
liquid
phase
specif
case
could
determin
cell
panel
use
method
adopt
studi
alloimmun
rate
observ
significantli
higher
among
femal
compar
among
male
p
signific
associ
observ
aborh
blood
group
type
alloimmun
summaryconclus
occurr
alloantibodi
uncommon
among
blood
donor
preval
particularli
femal
donor
mostli
child
bear
pattern
specif
alloantibodi
identifi
studi
tell
us
alloantibodi
mnss
kell
rh
blood
group
system
commonli
encount
blood
bank
sensit
import
antibodi
identif
perform
hundr
percent
donor
sampl
along
patient
sampl
make
compat
blood
unit
avail
needi
one
time
n
mladenov
b
zivot
n
strbac
b
vasiljev
jovanov
vlatkov
milutinov
r
dinic
v
lukic
g
bogdanov
blood
transfus
institut
serbia
belgrad
serbia
background
often
difficult
time
secur
adequ
rbc
unit
alloimmun
patient
especi
patient
complex
alloimmun
februari
lombardi
rare
donor
programm
defin
criteria
complex
antierythrocyt
immun
patient
antibodi
alloantibodi
autoantibodi
antibodi
high
frequenc
antigen
thu
suggest
establish
rare
blood
type
donor
regist
bank
rare
blood
type
februari
format
nation
type
donor
regist
ntdr
initi
blood
transfus
institut
serbia
bti
databas
member
aim
incid
analysi
complex
alloimmun
januari
till
decemb
patient
depart
pretransfus
test
blood
blood
product
distribut
hemovigil
bti
well
method
transfus
treatment
method
retrospect
studi
perform
januari
till
decemb
base
data
collect
regist
isbt
databas
includ
patient
pretransfus
test
perform
clinic
signific
antierythrocyt
antibodi
identifi
use
gel
method
anti
igg
rabbit
id
lisscoomb
nacl
cardsenzym
use
standard
papain
treat
id
panel
cell
antibodi
identif
room
temperatur
perform
tube
method
use
rea
cell
commerci
test
erythrocyt
blood
type
phenotyp
determin
use
differ
test
reagent
lorn
result
patient
necessari
identifi
antierythrocyt
antibodi
due
posit
antibodi
screen
posit
interreact
problem
blood
group
determin
patient
three
detect
alloantibodi
four
antibodi
one
antibodi
ie
total
patient
complex
immunis
total
number
patient
pretransfus
test
perform
frequent
combin
three
antibodi
dce
rh
neg
patient
patient
complex
immun
least
one
rh
antibodi
frequent
antibodi
e
kell
specif
complex
antibodi
common
hematolog
oncolog
polytransfus
patient
age
year
femal
patient
major
adequ
rbc
unit
provid
neg
interact
type
rbc
antigen
antibodi
produc
find
one
unit
neg
interact
mostli
requir
test
rbc
unit
one
case
even
unit
thank
ntdr
blood
provid
patient
donat
total
patient
autolog
transfus
predeposit
use
summaryconclus
alloantibodi
identifi
patient
complex
alloimmunis
establish
enlarg
ntdr
contribut
increas
type
blood
stock
facilit
shorten
adequ
blood
search
procedur
need
patient
complex
immun
especi
emerg
situat
hemmati
jalali
bank
sey
al
shohada
hospit
medic
scienc
univers
isfahan
isfahan
univers
medic
scienc
isfahan
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
research
institut
research
center
thalassemia
hemoglobinopathi
ahvaz
jundishapur
univers
medic
scienc
ahvaz
islam
republ
iran
background
sickl
cell
diseas
scd
congenit
homozygot
hemolyt
anemia
blood
transfus
sickl
cell
diseas
scd
common
therapeut
method
howev
due
blood
transfus
remain
main
complic
patient
frequent
transfus
background
similarli
delay
hemolyt
transfus
reaction
dhtr
one
reaction
trigger
undetect
titer
alloantibodi
produc
previou
transfus
frequent
scd
patient
belong
rh
kell
kidd
duffi
mn
blood
group
system
respect
aim
studi
focus
report
unpreced
case
sickl
cell
vagin
hemorrhag
repres
unexpect
reduct
hemoglobin
level
incompat
cross
match
transfus
one
red
blood
cell
unit
despit
intens
effort
isfahan
tehran
blood
transfus
organ
find
compat
red
blood
cell
among
donor
success
method
year
old
woman
scd
diagnosi
vagin
hemorrhag
refer
sey
al
shohada
hospit
special
center
cancer
hemoglobinopathi
isfahan
citi
iran
control
patient
condit
one
pack
blood
cell
unit
transfus
transfus
hemoglobin
repres
mgdl
unexpect
reduct
indirect
test
iat
direct
test
dat
perform
use
standard
blood
bank
method
salin
albumin
coomb
phase
determin
format
antibodi
order
identifi
screen
cell
set
vial
panel
cell
least
vial
per
set
panel
cell
antigen
type
also
run
conduct
patient
rbc
serolog
phenotyp
commerci
c
c
e
e
k
k
n
fya
fyb
jka
jkb
order
confirm
accuraci
antibodi
specif
result
screen
cell
panel
cell
determin
format
patient
serum
patient
rbc
phenotyp
patient
phenotyp
follow
c
e
k
k
fya
jka
n
summaryconclus
sinc
rh
system
antigen
caus
major
number
sickl
cell
patient
provid
match
red
blood
cell
rh
system
would
decreas
rate
although
regard
local
potenti
antibodi
among
sickl
cell
patient
appli
appropri
strategi
prevent
authent
data
frequent
among
sickl
cell
patient
common
antigen
indigen
donor
isfahan
citi
requir
research
regard
c
monteiro
l
leit
h
sousa
b
fortunato
ventura
j
baldaqu
f
baia
c
koch
depart
transfus
medicin
blood
bank
centro
hospitalar
epe
porto
portug
background
individu
expos
red
blood
cell
alloantigen
transfus
pregnanc
transplant
may
produc
antibodi
alloantigen
sinc
june
polici
feasibl
transfus
women
child
bear
potenti
transfus
depend
patient
rh
k
blood
aim
centro
hospitalar
epe
biggest
hospit
north
portug
highli
special
tertiari
hospit
bed
level
trauma
centr
larg
cardiothorac
surgeri
centr
depart
aim
studi
report
frequenc
specif
red
blood
cell
rbc
alloantibodi
centro
hospitalar
epe
chsj
evalu
transfus
polici
method
total
recipi
blood
product
analys
order
evalu
alloantibodi
detect
period
data
januari
decemb
retriev
blood
bank
databas
follow
inform
collect
age
gender
number
specif
alloantibodi
whether
patient
previou
alloantibodi
screen
neg
new
alloantibodi
result
recipi
posit
screen
alloantibodi
alloantibodi
admiss
recipi
new
alloantibodi
detect
follow
transfus
detect
frequenc
immunis
frequenc
group
recipi
new
alloantibodi
frequent
alloantibodi
detect
follow
signific
differ
gender
distribut
pattern
e
k
jka
c
also
monitor
complianc
polici
regard
transfus
practic
women
child
bear
potenti
summaryconclus
identif
rbc
alloantibodi
develop
transfus
hospit
allow
us
detect
error
blood
compon
select
order
increas
safeti
transfus
practic
sever
measur
appli
perform
repeat
rhk
phenotyp
blood
donor
identifi
rhd
variant
appar
rh
neg
donor
powley
b
wilson
liew
j
dali
clinic
servic
research
australian
red
cross
blood
servic
brisban
australia
background
follow
convers
routin
full
blood
count
result
donor
mention
unusu
gerbich
blood
group
blood
servic
medic
offic
aim
medic
offic
contact
red
cell
refer
laboratori
team
unabl
find
anyth
donor
record
suggest
known
histori
rare
type
donor
contact
addit
inform
assist
investig
provid
sampl
test
method
follow
number
convers
donor
establish
donor
rare
blood
group
identifi
twenti
year
earlier
donor
father
treat
uk
identifi
father
rare
gerbich
blood
type
make
blood
transfus
difficult
donor
state
mother
ten
sibl
test
uk
rare
blood
type
famili
caucasian
donor
allud
ethnic
group
ancestri
australian
red
cell
refer
laboratori
contact
intern
blood
group
laboratori
ibgrl
uk
inform
may
donor
famili
whilst
test
conduct
result
ibgrl
confirm
donor
known
test
larg
famili
studi
twenti
year
earlier
result
indic
donor
ge
due
compound
heterozygot
gpcgegpcyu
deduc
immunoblot
studi
test
perform
australian
red
cell
refer
laboratori
serolog
test
reveal
donor
rhd
posit
ge
blood
group
target
dna
sequenc
analysi
predict
ge
genotyp
confirm
ge
phenotyp
rare
yu
type
summaryconclus
donor
particularli
rare
use
phenotyp
transfus
reagent
red
cell
serolog
investig
donat
australia
year
identifi
rare
donor
routin
unrel
convers
medic
offic
blood
servic
miss
whole
blood
donat
may
otherwis
frozen
futur
transfus
unwittingli
recruit
donor
apheresi
plasma
miss
valuabl
whole
blood
donat
better
educ
rare
donor
use
card
identifi
donor
patient
rare
blood
group
may
help
rare
donor
also
import
staff
within
donor
recruit
collect
inform
necessari
ensur
donor
manag
effect
educ
key
part
ensur
miss
needl
haystack
q
zuo
blood
group
laboratori
shaanxi
blood
center
xian
china
background
diego
blood
group
antibodi
caus
hemolyt
diseas
newborn
hemolyt
transfus
reaction
european
chines
popul
high
frequenc
dia
antigen
thu
higher
probabl
antibodi
random
blood
transfus
blood
group
incompat
aim
investig
distribut
diego
blood
group
polymorph
shaanxi
popul
frequenc
antibodi
transfus
patient
method
genom
dna
extract
blood
donor
shaanxi
provinc
diego
blood
group
genotyp
touchdown
polymeras
chain
reaction
frequenc
identifi
indirect
antiglobulin
test
statist
analysi
blood
transfus
patient
irregular
antibodi
result
one
di
di
ab
di
di
detect
blood
donor
frequenc
dia
antigen
gene
respect
frequenc
dib
antigen
gene
blood
donor
identifi
patient
posit
irregular
antibodi
screen
frequenc
summaryconclus
studi
detect
analys
diego
blood
group
blood
donor
shaanxi
provinc
china
discov
diego
blood
group
polymorph
play
vital
role
geneticsforens
blood
transfus
studi
first
report
high
frequenc
antibodi
occur
clinic
specimen
irregular
antibodi
china
pay
special
attent
import
clinic
signific
antibodi
detect
irregular
antibodi
panel
cell
use
routin
work
includ
dia
antigen
avoid
fals
neg
result
antibodi
screen
k
kerdkaewngam
p
ovataga
j
tubrod
u
tingtoy
u
charoonruangrit
nation
blood
center
thai
red
cross
societi
bangkok
thailand
background
mn
variant
complex
antibodi
subsystem
found
total
antibodi
thai
patient
therefor
necessari
care
select
cell
antibodi
screen
cell
sinc
subclass
gphut
miii
gphop
miiv
fail
react
mn
variant
antibodi
aim
studi
mn
variant
phenotyp
thai
blood
donor
order
select
suitabl
donor
screen
cell
product
method
total
blood
sampl
phenotyp
use
salin
standard
tube
techniqu
column
agglutin
techniqu
mention
antibodi
kindli
suppli
block
blood
center
japanes
red
cross
tokyo
result
reveal
donor
donor
donor
donor
gphut
miii
gpmur
miiii
gphop
miiv
gpbun
mivi
respect
summaryconclus
result
show
gpmur
miiii
mn
variant
subclass
thai
gphut
miii
gphop
miiv
gpbun
mivi
rare
phenotyp
previou
studi
thai
chandanyingyong
etal
indic
common
gpmur
miiii
confirm
studi
result
use
select
suitabl
red
blood
cell
screen
cell
product
h
blood
transfus
center
high
institut
research
center
educ
transfus
medicin
blood
transfus
center
high
institut
research
center
educ
transfus
medicin
tehran
islam
republ
iran
background
follow
discoveri
abo
blood
group
system
mn
system
second
blood
group
system
recogn
peopl
lack
antigen
red
blood
cell
therefor
capabl
produc
expos
antigen
discuss
natur
occur
antibodi
usual
activ
temperatur
thu
clinic
signific
antibodi
present
individu
lead
discrep
forward
revers
abo
group
creat
diagnost
difficulti
blood
bank
staff
aim
report
case
variant
refer
immunohematolog
laboratori
blood
group
discrep
method
blood
sampl
ladi
receiv
immunohematolog
refer
laboratori
blood
group
discrep
admit
hospit
deliveri
hemoglobin
gdl
never
receiv
blood
transfus
cell
group
patient
posit
revers
serum
group
show
agglutin
antibodi
screen
done
use
low
ionic
strength
solut
liss
gel
techniqu
id
microtyp
system
convent
test
tube
method
serum
test
commerci
avail
three
cell
panel
result
show
posit
reaction
panel
iii
neg
panel
ii
antibodi
identif
panel
use
identifi
antibodi
confirm
select
cell
antibodi
id
panel
patient
sera
show
reaction
cell
reaction
mn
cell
neg
cell
subsequ
patient
phenotyp
consid
complet
titer
homozyg
cell
mn
heterozyg
cell
ahg
phase
interest
patient
blood
two
differ
compani
immundiagnostik
lot
clone
sifin
lot
clone
show
posit
reaction
despit
third
antisera
lorn
reaction
seen
remark
antisera
posit
reaction
clone
number
neg
antisera
polyclon
addit
direct
antiglobulin
test
dat
autocontrol
neg
result
import
type
specif
antibodi
accuraci
influenc
clinic
outcom
strict
warm
condit
maintain
procedur
result
read
immedi
summaryconclus
common
children
adult
uncommon
pregnant
produc
give
birth
case
report
type
clinic
consensu
manag
hdn
caus
alloantibodi
high
titer
igg
plu
igm
respons
neonat
red
cell
aplasia
caus
substanti
reduct
prolifer
erythroid
cell
cultur
antibodi
high
titer
high
affin
may
react
strongli
room
temperatur
caus
hemagglutin
carri
antiglobulin
test
phase
therefor
import
type
specif
antibodi
accuraci
influenc
clinic
outcom
strict
warm
condit
maintain
procedur
result
read
immedi
j
j
c
f
n
interna
universidad
de
la
frontera
de
temuco
chile
de
salud
universidad
santo
toma
universidad
de
la
frontera
temuco
chile
background
routin
individu
classifi
rh
posit
neg
depend
presenc
absenc
antigen
membran
red
cell
howev
antigen
might
present
qualit
quantit
alter
difficultli
detect
among
del
variant
character
extrem
weak
express
antigen
detect
convent
test
therefor
mistyp
rh
neg
molecular
analysi
del
individu
show
intact
gene
partial
del
lose
detect
epitop
phenotyp
associ
genet
variant
chilean
popul
frequenc
rhd
neg
phenotyp
previous
report
howev
frequenc
variant
includ
del
dna
alter
relat
variant
remain
unknown
aim
describ
frequenc
del
phenotyp
g
genotyp
chilean
blood
donor
method
rhd
neg
sampl
select
unrel
blood
donor
attend
blood
bank
hernan
henriquez
aravena
hospit
temuco
chile
classifi
use
rho
igmigg
monoclon
antisera
direct
agglutin
test
result
neg
sampl
analyz
indirect
antiglobulin
test
use
gel
card
addit
rh
del
phenotyp
detect
adsorptionelut
test
g
genotyp
detect
polymeras
chain
reaction
result
sampl
posit
adsorptionelut
test
confirm
del
phenotyp
molecular
analysi
perform
sampl
show
frequenc
n
n
g
variant
respect
moreov
n
analyz
sampl
show
presenc
genet
variant
summaryconclus
data
demonstr
high
frequenc
del
phenotyp
popul
studi
molecular
analysi
g
show
variant
present
high
percentag
use
use
genet
marker
rhdel
chile
replac
test
u
hamid
n
chemic
patholog
univers
health
scienc
lahor
punjab
pakistan
blood
banktransfus
medicin
punjab
institut
cardiolog
patholog
allama
iqbal
medic
colleg
lahor
lahor
blood
transfus
program
pakistan
safe
blood
transfus
program
pakistan
islamabad
laboratori
technolog
govern
colleg
univers
faisalabad
patholog
sahiw
medic
colleg
sahiw
pakistan
background
centuri
blood
transfus
procedur
unsaf
mysteri
solv
centuri
discoveri
abo
rh
blood
group
antigen
discoveri
rh
system
levin
stetson
great
break
transfus
medicin
signific
blood
group
system
abo
studi
shown
signific
proport
patient
rbc
lack
antigen
make
expos
weak
antigen
blood
transfus
therefor
determin
rhesu
rh
phenotyp
critic
rh
blood
group
system
clinic
import
causeshemolyt
transfus
reaction
htr
hemolyt
diseas
newborn
hdn
aim
studi
plan
determin
weak
antigen
highlight
import
weak
antigen
test
among
blood
donor
method
five
differ
tertiari
care
four
secondari
care
hospit
lahor
six
differ
institutesunivers
includ
individu
visit
blood
bank
determin
blood
group
includ
studi
two
ml
blood
sampl
collect
vial
analyz
determin
aborhesu
rh
type
sampl
process
weak
antigen
test
accord
standard
protocol
commerci
avail
monoclon
antibodi
result
total
particip
n
among
sampl
n
sampl
neg
even
weak
test
n
weak
posit
sampl
summaryconclus
everi
individu
process
detect
weak
antigen
weak
antigen
test
may
detect
immedi
spin
tube
method
j
grujic
z
budakov
obradov
z
gulan
b
pekov
krga
milanov
g
dimitrijev
blood
transfus
institut
vojvodina
novi
sad
serbia
background
rhesu
rh
blood
group
system
discov
year
ago
becam
second
import
abo
blood
group
transfus
medicin
due
highli
immunogen
highli
polymorph
gene
rhd
rhce
encod
rh
blood
group
antigen
antigen
rh
blood
group
system
signific
c
e
c
e
aim
establish
frequenc
major
rh
blood
group
antigen
voluntari
blood
donor
vojvodina
method
prospect
studi
conduct
blood
donor
one
year
rh
blood
group
type
perform
standard
gel
techniqu
statist
signific
analyz
test
descript
statist
categor
variabl
perform
comput
frequenc
categori
result
total
blood
sampl
phenotyp
blood
group
test
sampl
present
among
test
blood
donor
blood
group
b
ab
result
show
common
rh
e
antigen
follow
among
rh
posit
donor
common
phenotyp
dccee
least
common
phenotyp
dccee
analys
result
rh
neg
blood
donor
show
common
phenotyp
ddccee
rarest
ddccee
ddccee
summaryconclus
phenotyp
red
cell
routin
rh
blood
group
system
would
decreas
alloimmun
patient
occurr
delay
hemolyt
transfus
reaction
presenc
databas
phenotyp
blood
donor
would
help
provid
antigen
neg
blood
patient
improv
blood
safeti
hj
e
n
bank
ziv
medic
center
safe
bank
ziv
medic
center
mielya
israel
background
abo
rh
phenotyp
frequenc
local
popul
influenc
manag
blood
bank
stock
suppli
order
better
serv
patient
popul
northern
israel
druze
popul
approxim
hospit
patient
blood
bank
data
previous
present
regard
abo
rh
phenotyp
frequenc
aim
studi
examin
abo
rh
phenotyp
frequenc
druze
patient
popul
ziv
medic
center
method
abo
rhd
examin
druze
patient
retrospect
record
analysi
rh
phenotyp
kell
phenotyp
prospect
examin
druze
patient
result
within
druze
popul
frequenc
abo
blood
group
found
b
ab
antigen
frequenc
rhd
kell
c
e
c
e
cw
current
frequenc
abo
blood
group
intern
caucasian
popul
b
ab
antigen
frequenc
rhd
kell
c
e
c
e
cw
summaryconclus
overal
israel
frequenc
blood
type
differ
intern
caucasian
popul
vs
druze
popul
similar
frequenc
intern
caucasian
popul
howev
blood
bank
stock
base
upon
local
frequenc
thu
northern
area
israel
serv
druze
commun
import
increas
avail
stock
type
blood
unit
importantli
novel
find
significantli
lower
c
antigen
frequenc
druze
popul
reveal
increas
risk
develop
antibodi
may
majorli
impact
transfus
polici
hospit
serv
druze
commun
provid
blood
unit
c
neg
cd
de
u
medicin
teach
hospit
jaffna
jaffna
medicin
nation
blood
transfus
servic
colombo
medicin
district
gener
hospit
mullaithivu
mullaithivu
medicin
district
gener
hospit
kilinochchi
kilinochchi
medicin
base
hospit
point
pedro
point
pedro
sri
lanka
background
sri
lanka
countri
multipl
ethnic
popul
compris
sinhales
sri
lankan
tamil
sri
lankan
moor
indian
tamil
sri
lankan
malay
sri
lankan
tamil
second
largest
ethnic
group
countri
live
part
countri
live
northern
provinc
np
aim
studi
determin
preval
specif
red
cell
antibodi
sri
lankan
tamil
popul
mostli
inhabit
np
method
retrospect
analysi
done
antenat
mother
hospit
patient
underw
compat
test
four
major
hospit
np
januari
decemb
sampl
test
abo
rh
type
red
cell
antibodi
cell
panel
indirect
antiglobulin
test
antibodi
screen
posit
sampl
sent
immunohematolog
refer
laboratori
ihrl
nation
blood
center
nbc
identifi
specif
use
commerci
red
cell
panel
orthoclin
diagnost
diam
result
total
antibodi
screen
antenat
mother
patient
transfus
compat
test
red
cell
antibodi
detect
sampl
preval
preval
auto
antibodi
preval
result
show
frequenc
antibodi
specif
anti
anti
le
b
anti
lea
anti
lea
le
b
anti
e
anti
mur
anti
anti
le
b
anti
fy
anti
c
anti
jk
auto
antibodi
cold
anti
fy
b
anti
jk
b
anti
jk
b
auto
antibodi
anti
cold
auto
antibodi
warm
auto
antibodi
cold
warm
auto
antibodi
signific
associ
whole
sri
lankan
northern
tamil
popul
anti
p
anti
leb
p
anti
lea
leb
p
anti
e
p
summaryconclus
frequenc
antibodi
specif
found
among
sri
lankan
tamil
differ
compar
island
wide
data
accord
studi
done
ihrl
nbc
analyz
sampl
part
countri
antibodi
detect
sampl
frequenc
antibodi
specif
anti
anti
leb
anti
lea
anti
lea
leb
anti
e
anti
c
ji
acosta
centro
zonal
de
fraccionamiento
hemocentro
nacion
cruz
roja
ecuatoriana
ambato
ecuador
background
identif
irregular
antibodi
one
step
carri
safe
transfus
practic
search
identif
antibodi
carri
use
indirect
antiglobulin
techniqu
mandatori
blood
donor
know
donor
develop
alloantibodi
necessari
environ
larg
number
peopl
receiv
transfus
pregnant
main
caus
develop
irregular
antibodi
could
caus
transfus
reaction
alloantibodi
divid
two
group
antibodi
clinic
import
signific
transfus
medicin
trace
identifi
blood
donor
prelud
releas
product
transfus
step
aim
evalu
presenc
irregular
antibodi
ecuadorian
donor
method
irregular
antibodi
screen
plasma
volunt
blood
donor
central
highland
ecuador
visit
fraction
zonal
center
ambato
nation
hemocent
ecuadorian
red
cross
period
januari
decemb
screen
alloantibodi
three
reactiv
screen
use
column
agglutin
techniqu
posit
sampl
identif
antibodi
made
use
panel
cell
techniqu
result
result
total
analyz
donor
sampl
blood
volunt
correspond
male
donor
femal
donor
posit
result
obtain
detect
irregular
antibodi
sampl
correspond
male
sex
femal
sex
frequent
specif
identifi
eight
posit
result
could
identifi
antibodi
therefor
categor
indetermin
summaryconclus
antibodi
commonli
found
blood
donor
consid
littl
clinic
import
despit
report
transfus
reaction
antibodi
commonli
found
ecuadorian
blood
donor
refer
clinic
signific
one
follow
antibodi
classifi
indetermin
must
studi
deepli
order
evalu
clinic
signific
antibodi
found
identifi
femal
donor
least
one
pregnanc
prior
donat
h
k
k
laboratori
medicin
seoul
nation
univers
colleg
medicin
seoul
laboratori
medicin
myongji
hospit
goyang
laboratori
medicin
seoul
nation
univers
bundang
hospit
seongnam
laboratori
medicin
myongji
hospit
seoul
republ
korea
background
blood
group
antigen
recogn
frequenc
vari
among
commun
ethnic
group
ensur
stabl
suppli
blood
unit
predict
probabl
obtain
compat
blood
unit
import
aim
use
data
korean
nation
registri
studi
conduct
establish
korean
nation
registri
evalu
distribut
unexpect
antibodi
determin
frequenc
specif
blood
unit
method
data
ad
korean
nation
registri
juli
april
analyz
distribut
unexpect
antibodi
frequenc
specif
blood
unit
estim
result
total
case
institut
regist
common
singl
alloantibodi
common
multipl
alloantibodi
frequenc
unit
respect
summaryconclus
distribut
unexpect
antibodi
frequenc
specif
blood
unit
investig
use
data
korean
nation
registri
result
provid
use
data
predict
number
blood
unit
test
obtain
compat
blood
unit
k
h
j
h
b
v
karamat
n
e
immunohematolog
institut
hematolog
transfus
medicin
warsaw
poland
red
cell
refer
laboratori
nhsbt
filton
blood
centr
bristol
unit
kingdom
background
detect
identif
antibodi
high
frequenc
antigen
hfa
great
challeng
blood
transfus
laboratori
clinic
signific
potenti
caus
haemolyt
diseas
foetu
newborn
haemolyt
transfus
reaction
incompat
transfus
case
provid
compat
blood
transfus
challeng
inform
specif
antibodi
current
popul
import
develop
polici
blood
donor
type
rare
blood
group
aim
present
data
regard
alloantibodi
high
frequenc
antigen
identifi
year
period
investig
preval
rare
antibodi
polish
popul
method
blood
sampl
patient
includ
pregnant
women
test
antibodi
detect
sampl
react
major
panel
cell
specif
antibodi
determin
routin
appli
panel
red
blood
cell
rbc
rt
salin
test
enzym
test
diam
iat
untreat
papain
treat
dtt
treat
cell
differenti
reaction
confirm
suspect
specif
appropri
antigen
neg
sampl
rbc
serum
correspond
antibodi
phenotyp
patient
cell
obtain
scarf
serum
cell
rare
fluid
exchang
use
patient
genotyp
establish
use
rare
kronbergtaunu
germani
protocol
lwab
abstract
rhce
lu
sequenc
lan
jr
case
specif
antibodi
hfa
determin
ibgrl
uk
result
test
sampl
alloantibodi
hfa
specif
determin
mostli
confirm
patient
genotyp
antibodi
alway
regard
clinic
signific
detect
patient
oh
individu
among
detect
pregnant
women
antibodi
classifi
sometim
rare
destroy
incompat
rbc
found
patient
clinic
signific
antibodi
within
htla
specif
patient
found
case
necessari
consid
search
antigen
neg
donor
summaryconclus
data
illustr
broad
rang
antibodi
high
frequenc
antigen
present
polish
popul
data
studi
essenti
establish
suitabl
rare
donor
screen
program
tailor
rare
blood
provis
strategi
polici
develop
popul
c
n
lejon
l
j
c
h
blood
transfus
src
bern
switzerland
blood
group
refer
laboratori
nhsbt
bristol
unit
kingdom
background
indian
blood
group
glycoprotein
predomin
cell
surfac
receptor
hyaluronan
compon
extracellular
matrix
protein
encod
gene
chromosom
consist
exon
variabl
hematopoiet
isoform
compos
exon
indian
blood
group
system
consist
high
preval
antigen
inb
infi
inja
inra
one
low
preval
antigen
ina
report
case
antithet
preval
arab
iranian
indian
popul
aim
sampl
patient
sri
lankan
origin
investig
antibodi
specif
due
pan
reactiv
sampl
brother
patient
also
investig
method
serolog
investig
perform
iat
tube
column
agglutin
papain
trypsin
treat
cell
also
utilis
solubl
recombin
blood
group
protein
imusyn
germani
use
neutral
test
clinic
signific
antibodi
assess
monocyt
monolay
assay
mma
genom
dna
isol
whole
blood
sampl
character
pcr
amplif
sanger
sequenc
includ
flank
intron
region
hematopoiet
isoform
exon
result
plasma
patient
brother
react
posit
cell
test
except
iat
trypsin
iat
neg
papain
salin
test
antibodi
neutral
therebi
confirm
specif
patient
brother
found
phenotyp
monocyt
index
mi
patient
sequenc
reveal
mutat
homozyg
state
patient
brother
mutat
lead
amino
acid
chang
patient
serum
compat
cell
brother
cell
patient
brother
found
cell
found
incompat
brother
plasma
summaryconclus
report
case
patient
sri
lankan
origin
whose
cell
lack
novel
high
preval
antigen
system
plasma
contain
correspond
antibodi
lack
novel
antigen
due
homozygos
novel
mutat
exon
brother
found
genotyp
serolog
compat
patient
plasma
patient
brother
appar
transfus
presum
antibodi
natur
occur
mi
suggest
antibodi
clinic
relev
h
chen
c
chung
p
tsai
patholog
center
chi
mei
medic
center
tainan
taiwan
republ
china
background
kidd
blood
group
system
discov
consist
two
major
antigen
jka
jkb
null
phenotyp
jk
found
antibodi
recogn
jka
jkb
later
name
asian
popul
jk
rare
patient
transfus
support
quit
difficult
aim
aim
studi
analyz
preval
report
result
case
institut
method
present
studi
also
prospect
studi
januari
total
sampl
test
antibodi
screen
screen
test
posit
identif
test
would
perform
standard
serolog
principl
aabb
technic
manual
appli
present
studi
result
past
five
year
sampl
test
antibodi
screen
sampl
identifi
antibodi
rate
antibodi
among
case
case
preval
patient
dat
neg
plasma
react
panel
cell
cat
mp
manual
polybren
method
iat
grade
agglutin
reaction
cat
stronger
mp
method
red
cell
phenotyp
three
patient
show
jk
demonstr
antibodi
specif
patient
dat
posit
antibodi
panel
cell
check
transfus
histori
learn
first
time
antibodi
screen
neg
receiv
unit
rbc
day
ago
second
time
antibodi
screen
recheck
first
sampl
phenotyp
present
jk
support
antibodi
specif
dat
second
sampl
result
influenc
transfus
summaryconclus
gener
kidd
antibodi
easi
detect
posit
agglutin
reaction
weak
absent
could
use
cell
give
sensit
result
identifi
clinic
signific
antibodi
also
caus
acut
delay
hemolyt
transfus
reaction
rare
caus
hdn
react
jka
jkb
red
cell
antigen
jk
phenotyp
would
seriou
problem
transfus
frequenc
posit
kidd
antigen
quit
high
countri
henc
patient
need
transfus
rbc
product
could
ask
local
blood
center
support
offer
jk
red
cell
transfus
addit
result
show
cat
method
sensit
mp
method
detect
howev
mp
method
routin
technolog
antibodi
screen
laboratori
therefor
weak
express
neg
result
panel
cell
identifi
confirm
cat
method
need
b
v
karamat
r
n
g
n
abu
n
blood
group
refer
laboratori
nh
blood
transplant
bristol
unit
kingdom
divis
nation
blood
center
kuala
lumpur
malaysia
background
first
exampl
detect
japanes
femal
japanes
blood
servic
describ
case
individu
major
femal
histori
pregnanc
first
exampl
found
outsid
japan
describ
howev
patient
thought
japanes
origin
kanno
high
frequenc
antigen
sensit
papain
trypsin
pronas
treatment
resist
aet
dtt
treatment
characterist
high
titr
low
avid
htla
antibodi
case
individu
previous
describ
aim
describ
first
case
phenotyp
individu
origin
method
blood
sampl
year
old
male
patient
indian
origin
diagnosi
singl
ventricl
fontan
oper
investig
due
detect
unidentifi
alloantibodi
high
frequenc
antigen
serolog
test
perform
standard
liss
tube
iat
artifici
coat
cell
achiev
incub
cell
sucros
human
ab
serum
cell
treat
papain
trypsin
pronas
dtt
inhibit
studi
carri
use
follow
solubl
recombin
blood
group
yta
jmh
inb
result
patient
plasma
react
moder
strength
liss
iat
untreat
panel
cell
reactiv
observ
papain
treat
cell
patient
cell
found
posit
follow
papain
sensit
antigen
kna
yta
jmh
inb
ena
coat
cell
found
react
strength
uncoat
cell
therebi
indic
antibodi
inhibit
test
patient
plasma
solubl
recombin
yta
jmh
inb
protein
show
inhibit
patient
plasma
neg
trypsin
pronas
treat
cell
wherea
dtt
treat
cell
posit
reaction
profil
indic
possibl
cell
found
compat
patient
plasma
autolog
cell
exampl
cell
patient
cell
type
three
exampl
found
summaryconclus
describ
new
case
individu
first
report
case
rare
phenotyp
individu
serolog
present
antibodi
show
distinct
reaction
profil
enzym
treat
chemic
modifi
cell
accord
previous
report
exampl
provid
use
tool
identifi
rare
antibodi
mv
van
der
p
r
e
van
den
g
c
van
der
immunohematolog
diagnost
servic
sanquin
blood
suppli
amsterdam
netherland
background
alloimmunis
vel
blood
group
caus
blood
transfus
pregnanc
may
result
transfus
reaction
haemolyt
diseas
correct
type
vel
blood
group
therefor
crucial
patient
donor
present
type
perform
use
patient
sera
contain
antibodi
howev
sera
limit
avail
subject
donor
variabl
unabl
discrimin
donor
therefor
need
unlimit
sourc
reagent
also
reactiv
weak
vel
express
red
blood
cell
rbc
aim
product
character
monoclon
antibodi
vel
antigen
method
cell
alloimmunis
patient
month
child
birth
incub
ghost
cell
affin
ghost
singl
cell
sort
expand
feeder
cell
gener
b
cell
clone
produc
antibodi
dohmen
et
al
ji
rna
isol
clone
produc
antibodi
react
rbc
variabl
ig
region
amplifi
cdna
sequenc
variabl
heavi
vh
light
vl
domain
clone
harbour
constant
domain
heavi
light
chain
igg
igm
freestyl
cell
transfect
produc
antibodi
purifi
chromatographi
reactiv
antibodi
test
flow
cytometri
use
array
rbc
variabl
vel
antigen
express
use
cell
ectop
express
complement
activ
upon
antibodi
bind
determin
measur
deposit
flow
cytometri
result
antibodi
titr
patient
contain
predominantli
igm
antibodi
isol
cell
affin
ghost
singl
cell
sort
antibodi
produc
clone
one
clone
produc
igm
vel
specif
antibodi
somat
hypermut
detect
vh
vl
chain
clone
express
vector
recombin
igm
antibodi
igg
antibodi
specif
vel
antigen
react
direct
agglutin
flow
cytometri
panel
rbc
rbc
furthermor
antibodi
reactiv
express
cell
recombin
igm
antibodi
induc
complement
activ
differ
express
level
vel
caus
heterozyg
delet
andor
snp
intron
detect
flow
cytometri
serolog
howev
serolog
sensit
direct
agglutin
moab
identifi
one
donor
vel
weak
wherea
test
human
serum
react
cell
vel
express
donor
confirm
sera
summaryconclus
gener
recombin
igm
moab
specif
vel
antigen
antibodi
least
sensit
current
use
human
sera
use
direct
agglutin
assay
abstract
withdrawn
ponsen
phonimit
n
premprayoon
k
kerdkaewngam
u
tingtoy
u
charoonruangrit
nation
blood
center
thai
red
cross
societi
bangkok
thailand
background
reagent
nation
blood
center
thai
red
cross
societi
recent
involv
signific
cost
expens
import
supernat
aim
produc
human
hybridoma
secret
monoclon
antibodi
human
b
lymphocyt
method
first
isol
human
b
lymphocyt
produc
buffi
coat
pack
red
cell
whole
blood
use
densiti
gradient
centrifug
subsequ
transform
viru
ebv
next
fuse
transform
secret
cell
line
human
myeloma
use
polyethylen
glycol
peg
produc
hybridoma
also
investig
whether
molecul
could
aggreg
rh
e
antigen
red
blood
cell
save
secret
clone
limit
dilut
follow
expans
hybridoma
assess
supernat
detail
check
specif
panel
cell
reactiv
differ
rh
e
antigen
antibodi
titer
test
sequenti
dilut
salin
indirect
antiglobulin
iat
techniqu
result
establish
differ
cell
line
stabli
express
name
titer
antibodi
cell
respect
reagent
react
perfectli
e
posit
cell
wherea
react
e
neg
cell
result
indic
reagent
fulfil
qualiti
current
reagent
summaryconclus
although
serolog
test
requir
differ
cell
line
could
stabli
produc
reagent
substitut
supernat
oversea
import
reduc
financi
cost
medic
servic
futur
e
j
g
blood
servic
calgari
blood
servic
ottawa
blood
servic
edmonton
canada
background
canadian
blood
servic
blood
donor
select
phenotyp
test
base
abo
group
number
histor
donat
test
done
primarili
immucor
gamma
autom
neo
instrument
recent
found
donor
previous
test
neg
small
antigen
current
test
small
posit
neo
instrument
test
immucor
monoclon
antisera
use
manual
tube
method
found
donor
small
neg
aim
review
result
autom
instrument
manual
test
donor
discrep
small
antigen
incorpor
result
genet
test
resolv
discrep
demonstr
process
use
resolv
appar
antigen
phenotyp
discrep
method
immucor
gamma
neo
use
solid
phase
technolog
base
principl
indirect
antiglobulin
test
antisera
prepar
pool
human
serum
contain
polyclon
antibodi
manual
test
method
room
temperatur
incub
min
use
immucor
monoclon
antisera
immucor
monoclon
antisera
prepar
igm
antibodi
humanmurin
heterohybridoma
cell
line
genotyp
complet
use
grifolsprogenika
idcorext
kit
result
histor
small
result
manual
test
use
immucor
monoclon
antisera
neg
current
test
neo
instrument
use
immucor
polyclon
antisera
posit
small
test
neo
repeat
use
neo
instrument
four
neo
instrument
abl
reproduc
posit
result
posit
autom
neo
instrument
donor
sampl
manual
test
use
monoclon
antisera
small
neg
dat
test
complet
reagent
neg
donor
sampl
genotyp
predict
phenotyp
packag
insert
polyclon
antisera
use
autom
instrument
indic
low
preval
antigen
exclud
reagent
phenotyp
test
presenc
low
preval
antigen
may
cross
react
polyclon
antisera
perform
donor
red
cell
donor
wr
hinder
test
low
preval
antigen
mn
system
summaryconclus
advanc
technolog
blood
group
serolog
test
becom
autom
less
manual
process
autom
bring
accuraci
effici
decreas
risk
error
howev
discrep
small
phenotyp
donor
show
limit
autom
case
differ
polyclon
monoclon
antisera
like
respons
discrep
polyclon
show
cross
reactiv
low
preval
antigen
donor
posit
routin
process
resolv
appar
discrep
must
use
varieti
techniqu
reagent
standard
fashion
ensur
accur
phenotyp
inform
donor
e
v
p
c
de
v
servic
belgian
red
mechelen
belgium
immunohematolog
diagnost
sanquin
diagnost
servic
amsterdam
netherland
background
clinic
signific
produc
bombay
oh
phenotyp
defici
ah
bh
abh
phenotyp
furthermor
found
healthi
peopl
commonli
individu
express
littl
h
antigen
antibodi
gener
igm
type
reactiv
rare
room
temperatur
rt
also
report
individu
cold
agglutinin
syndrom
howev
unusu
case
transfus
reaction
due
wide
thermal
rang
antibodi
also
describ
aim
report
case
sickl
cell
diseas
scd
patient
blood
group
b
present
hemolyt
episod
transfus
pack
rbc
prbc
blood
group
method
serolog
test
perform
edta
patient
sampl
panel
studi
perform
format
tube
test
salin
method
rt
indirect
antiglobulin
test
iat
use
monospecif
reagent
reagent
cell
patient
plasma
treat
dithiothreitol
determin
immunoglobulin
class
react
agglutinin
result
case
report
patient
young
woman
homozyg
scd
blood
group
b
posit
c
e
k
fyb
jka
lan
ata
jra
p
known
follow
alloantibodi
receiv
two
neg
prbc
institut
also
transfus
one
neg
prbc
admit
may
pain
crisi
sever
anemia
hemoglobin
hb
gl
receiv
clinic
signific
antigen
neg
prbc
advers
event
hb
rais
gl
ten
day
later
readmit
pain
crisi
anemia
hb
gl
direct
antiglobulin
test
neg
plasma
show
panreact
room
temperatur
iat
enzym
treat
test
cell
test
cell
except
autolog
control
follow
h
hb
drop
gl
one
neg
prbc
transfus
emerg
transfus
ineffici
patient
continu
deterior
hb
decreas
till
gl
meantim
diagnost
strong
larg
thermal
amplitud
antibodi
igm
type
react
also
iat
establish
afterward
patient
effici
transfus
two
thaw
b
neg
prbc
deliv
sanquin
cryobank
hb
rais
gl
summaryconclus
rare
case
wide
thermal
rang
autoantibodi
behav
alloantibodi
caus
sever
hemolysi
hemolysi
appear
day
transfus
episod
neg
prbc
acceler
follow
transfus
one
neg
prbc
could
stipul
also
delay
hemolyt
transfus
reaction
complic
particular
scd
patient
case
togeth
similar
case
literatur
confirm
match
phenotyp
match
consid
scd
set
vl
g
k
b
le
j
institut
nation
de
la
transfus
sanguin
pari
de
poitier
etabliss
du
sang
poitier
danger
etabliss
du
sang
anger
franc
background
individu
harbor
gerbich
phenotyp
ge
lack
antigen
develop
orand
antibodi
common
may
natur
immun
occur
clinic
signific
regularli
discuss
literatur
regard
risk
acut
transfus
reaction
data
overal
reassur
unit
scarc
screen
routin
implement
donor
recruit
famili
studi
former
immun
patient
discov
donor
test
natur
antibodi
present
aim
report
transfus
manag
immun
gerbich
patient
hemorrhag
shock
requir
transfus
episod
day
apart
frozen
stock
group
group
fresh
unit
method
standard
haemagglutin
techniqu
biochemistri
test
perform
result
patient
group
ge
rush
hospit
overdos
vitamin
k
antagonist
massiv
hepat
bleed
diagnos
transfus
titer
techniqu
four
group
incompat
unit
transfus
protocol
intraven
immunoglobulin
ivig
steroid
hemolysi
monitor
hemoglobin
haptoglobin
lactat
dehydrogenas
ldh
bilirubin
sinc
day
highlight
hemolysi
wherea
transfus
yield
satisfi
scarciti
unit
forc
us
monitor
hemolysi
marker
antibodi
screen
antibodi
titrat
dat
elut
abo
type
titrat
perform
evalu
risk
hemolysi
due
passiv
antibodi
ivig
prophylaxi
transfus
need
day
later
dat
becam
posit
first
transfus
serum
weak
detect
abo
reaction
still
present
group
incompat
unit
select
day
patient
requir
transfus
antibodi
titer
still
weakli
detect
new
inject
ivig
alreadi
made
case
new
incompat
transfus
one
unit
thaw
transfus
fresh
unit
collect
time
last
episod
summaryconclus
hemolysi
marker
present
bia
haptoglobin
sensit
drop
rapidli
may
reduc
patient
liver
damag
might
overestim
case
acut
inflamm
ldh
present
mani
tissu
lack
specif
drop
hemoglobin
sign
hemolysi
bleed
stop
paramet
difficult
interpret
use
direct
marker
destruct
transfus
red
blood
cell
exampl
group
unit
help
evalu
intens
hemolysi
reaction
reassur
cross
match
unit
serum
eluat
monitor
titer
strength
antibodi
help
us
select
appropri
unit
case
illustr
respons
sever
transfus
reaction
clear
evid
hemolysi
observ
gupta
v
rajendran
r
nair
transfus
medicin
sree
chitra
tirun
institut
medic
scienc
technolog
thiruvananthapuram
kerala
india
thiruvananthapuram
kerala
india
background
solv
problem
immunohematolog
alway
challeng
time
interest
recent
encount
interest
case
discrep
blood
group
usual
acquir
type
igg
antibodi
like
rh
antibodi
rare
occur
natur
also
apart
also
occur
natur
among
rh
antibodi
aim
report
similar
case
deal
presenc
natur
occur
blood
elderli
male
method
male
past
histori
transfus
admit
centr
cardiopulmonari
bypass
surgeri
blood
sampl
sent
blood
centr
abo
group
rh
type
forward
group
show
rhd
posit
revers
group
weak
agglutin
observ
cell
reaction
pool
cell
strengthen
incub
reaction
obtain
pool
cell
salin
red
cell
neg
upon
test
lectin
group
suspect
compat
perform
gel
card
two
randomli
chosen
rhd
rbc
unit
neg
room
temperatur
agglutin
reaction
observ
probabl
due
insignific
cold
auto
antibodi
compat
test
patient
serum
unit
incompatiblepati
serum
unit
compat
result
red
cell
unit
found
posit
thu
possibl
rule
antibodi
screen
perform
cell
panel
reveal
possibl
patient
cell
found
rhe
neg
phenotyp
unit
found
compat
also
found
rhe
neg
unit
rhe
posit
one
donor
unit
use
prepar
pool
cell
revers
group
found
e
posit
antibodi
screen
pool
papainis
group
cell
gave
strong
posit
result
unit
rhe
neg
unit
rhe
posit
red
cell
cross
match
patient
serum
cell
agglutin
serum
room
temperatur
reaction
observ
rhe
neg
cell
specif
confirm
portion
serum
treat
dtt
titrat
parallel
untreat
serum
cell
rzrz
phenotyp
use
titrat
titr
observ
globulin
ahg
phase
untreat
serum
antibodi
undetect
dtt
treat
serum
summaryconclus
initi
thought
later
found
consid
reactiv
e
antigen
posit
cell
salin
phase
disappear
upon
treatment
dtt
like
igm
antibodi
wide
thermal
amplitud
even
though
natur
occur
clinic
signific
correspond
antigen
neg
red
cell
issu
transfus
b
j
blood
transfus
institut
fb
h
sarajevo
bosnia
herzegovina
depart
transfus
medicin
transplant
biolog
univers
hospit
center
zagreb
zagreb
croatia
background
lutheran
b
blood
antigen
high
preval
antigen
occur
popul
consequ
antibodi
format
lutheran
b
rare
describ
one
case
pregnanc
complic
lub
alloimmun
aim
lutheran
antibodi
first
describ
callend
race
paykog
serum
patient
develop
number
antibodi
respons
multipl
transfus
blood
antibodi
caus
hemolyt
reaction
adult
limit
clinic
inform
effect
fetu
newborn
main
challeng
case
like
obtain
antigen
neg
blood
possibl
matern
foetal
transfus
method
blood
sampl
screen
two
autom
system
biorad
autovu
ortho
well
tube
techniqu
result
twenti
eight
year
old
women
week
gestat
one
normal
pregnanc
seven
year
sampl
obtain
anoth
hospit
blood
center
antibodi
screen
posit
specif
remain
unknown
institut
well
univers
hospit
centr
zagreb
croatia
clinic
institut
transfus
medicin
transplant
biolog
result
identicalth
serum
pregnant
woman
gave
panagglutin
test
cell
mix
field
phenomena
antiglobulin
test
strength
reaction
use
tube
microcolumn
techniqu
well
enzym
techniqu
papain
titrat
score
autocontrol
neg
direct
antiglobulin
test
presenc
antibodi
antigen
high
frequenc
suspect
lu
phenotyp
women
found
lu
hla
antibodi
exclud
antibodi
confirm
intern
blood
group
refer
laboratori
bristol
babi
bom
term
vagin
deliveri
neg
direct
antiglobulin
test
clinic
evid
haemolyt
diseas
newborn
unfortun
could
famili
test
unavail
blood
sampl
summaryconclus
learn
lesson
could
think
high
frequenc
antigen
routin
work
howev
rare
wereit
would
recommand
review
option
maxim
perinat
postnat
outcom
case
emphas
import
perinat
surveil
transfus
medicin
specialist
import
sensit
specif
tool
antibodi
screen
identif
exist
nation
region
regist
rare
blood
donor
transfus
support
mother
child
cooper
center
collegu
desir
even
necessari
l
gynecolog
obstetr
laboratori
hematolog
transfus
gynecolog
obstetr
clinic
center
serbia
belgrad
serbia
background
cold
agglutinin
natur
occur
predominantli
igm
antibodi
react
predominantli
natur
antibodi
belong
abo
hh
ii
lewi
mn
p
blood
group
system
altern
may
associ
mycoplasma
infect
malign
diseas
complex
antibodi
commonli
benign
natur
preferenti
action
cold
temperatur
aim
aim
report
describ
clinic
signific
antibodi
wide
thermal
rang
recogn
laboratori
test
pregnanc
method
case
report
result
pregnant
woman
week
gestat
admit
clinic
monitor
pregnanc
deliveri
plan
pretransfus
test
demonstr
group
posit
forward
group
revers
group
show
agglutin
b
cell
agglutin
cell
stronger
subgroup
antigen
confirm
use
lectin
lorn
uk
ce
immunodiagnost
germani
erythrocyt
phenotyp
c
e
antibodi
identif
commerci
avail
panel
biorad
diapanel
switzerland
reveal
room
temperatur
reaction
gradual
weaken
coomb
phase
autocontrol
direct
coomb
test
neg
antibodi
titr
room
temperatur
immunolog
test
antinuclear
antibodi
antineutrophil
cytoplasm
antibodi
anticardiolipin
antibodi
rheumatoid
factor
neg
mycoplasma
antibodi
igg
igm
test
also
neg
addit
patient
sera
test
adult
blood
group
group
cord
blood
group
reaction
neg
ten
cell
posit
cell
agglutin
cord
cell
rule
patient
serum
react
adult
cell
cord
cell
adult
cell
conclud
antibodi
patient
blood
found
compat
cell
cell
group
unit
red
cell
concentr
select
test
due
obstetr
reason
decis
made
deliv
child
cesarean
section
week
gestat
healthi
boy
deliv
apgar
score
first
minut
haemoglobin
gl
direct
coomb
test
neg
unlik
antibodi
react
presenc
antigen
togeth
seen
individu
b
blood
group
reactiv
depend
amount
h
antigen
red
cell
summaryconclus
case
describ
antibodi
broad
thermal
amplitud
recogn
test
pregnanc
case
report
illustr
presenc
clinic
signific
antibodi
import
revers
group
antibodi
screen
clump
erythrocyt
due
cold
agglutinin
may
occlud
microvasculatur
base
case
report
associ
fetal
growth
restrict
moreov
draw
attent
fact
blood
group
alway
compat
blood
group
r
sood
transfus
medicin
immunohematolog
blood
bank
vp
rockland
hospit
new
delhi
india
background
rh
antigen
highli
immunogen
major
rh
antibodi
igg
type
alloantibodi
induc
hemolyt
anaemia
due
anti
e
igg
antibodi
bind
red
blood
cell
surfac
antigen
character
extrem
hemolysi
typic
extravascular
common
caus
sever
neonat
hemolyt
diseas
rh
abo
incompat
demonstr
newborn
signific
hemolyt
hyperbilirubinemia
hemolyt
diseas
strongli
consid
differenti
diagnosi
sever
form
minor
group
antibodi
hemolyt
diseas
character
anemia
sever
hyperbilirubinemia
requir
mani
exchang
transfus
may
encount
cours
diseas
aim
detect
alloantibodi
induc
hemolysi
antibodi
direct
rh
antigen
e
detect
frequent
blood
transfus
sensit
pregnanc
rare
occas
thought
natur
occurr
ie
present
without
obviou
preced
antigen
stimul
use
panel
blood
cell
known
antigen
identifi
antibodi
emphas
rh
antibodi
rare
activ
complement
major
igg
type
bind
rbc
mark
destruct
spleen
extravascular
hemolysi
typic
caus
delay
hemolyt
transfus
reaction
also
common
caus
hdn
method
femal
patient
start
develop
fever
gener
weak
loss
appetit
nausea
vomit
jaundic
anemia
progress
pancytopenia
splenomegali
continu
fall
hemoglobin
also
continu
evid
extravascular
hemolysi
spleen
sinc
last
day
rh
antibodi
bind
rbc
mark
destruct
spleen
also
hematuria
note
blood
transfus
peripher
smear
show
anisopoikilocytosi
spherocytosi
pancytopen
pictur
reticulocyt
count
lower
side
immunohematolog
test
forward
revers
blood
group
show
group
discrep
direct
antiglobulin
test
dct
perform
patient
blood
sampl
reveal
posit
agglutin
polyspecif
antihuman
globulin
ict
indirect
coomb
test
antisera
dct
ict
make
tulip
diagnost
owe
histori
multipl
transfus
occurr
hematuria
patient
serum
test
cell
panel
screen
red
cell
use
gel
technolog
card
ortho
biovu
system
ortho
clinic
diagnost
react
cell
contain
e
antigen
behav
incomplet
antibodi
identif
panel
ortho
biovu
system
ortho
clinic
diagnost
confirm
presenc
antibodi
titer
tube
method
neg
eluat
obtain
red
cell
use
commerci
acid
elut
kit
make
ortho
clinic
diagnost
confirm
specif
extend
red
cell
type
patient
show
cell
neg
e
antigen
treatment
serum
confirm
presenc
igg
type
antibodi
enzym
treatment
show
increas
reactiv
result
patient
diagnos
case
alloantibodi
anti
e
base
test
result
summaryconclus
detect
blood
antibodi
auto
allo
cold
warm
import
role
transfus
medicin
immunohematolog
laboratori
diagnosi
patient
hemolysi
anemia
emphasis
abstract
withdrawn
ms
saleh
issu
nbt
egypt
giza
egypt
background
autoimmun
cold
antibodi
clinic
interfer
test
like
antibodi
screen
mask
presenc
antibodi
may
clinic
signific
aim
aim
studi
find
preval
autoimmun
cold
antibodi
among
regularli
transfus
egyptian
patientsth
preval
mask
autoimmun
cold
antibodi
method
studi
conduct
transfus
depend
patient
patient
thalassemia
aplast
anemia
leukemia
renal
failur
anemia
chronic
diseas
present
egyptian
nbtc
blood
transfus
accord
nation
egyptian
test
strategi
patient
subject
screen
group
reagent
rbc
panel
cell
use
appropri
iat
catantibodi
identif
posit
screen
sampl
group
reagent
rbc
panel
cell
use
appropri
iat
cat
screen
room
temperatur
detect
presenc
cold
antibodi
screen
group
reagent
rbc
panel
cell
use
appropri
iat
strict
serum
reagent
case
posit
result
screen
room
temperatur
antibodi
identif
posit
screen
sampl
identifi
specif
mask
autoimmun
cold
one
group
reagent
rbc
panel
cell
use
appropri
iat
strict
serum
reagent
result
total
patient
examin
presenc
autoimmun
cold
antibodi
allo
antibodi
may
mask
total
found
patient
autoimmun
cold
antibodi
preval
mask
follow
autoimmun
cold
antibodi
patient
patient
c
patient
e
patient
patient
k
patient
fya
patient
jka
patient
patient
summaryconclus
techniqu
help
differenti
cold
ab
warm
ab
proper
test
patient
sampl
kim
hong
h
kim
e
song
k
park
j
song
k
han
depart
laboratori
medicin
seoul
nation
univers
colleg
medicin
seoul
republ
korea
background
del
weakest
rhd
variant
serolog
detect
via
test
transfus
red
cell
del
phenotyp
mistyp
potenti
elicit
alloimmun
aim
aim
studi
identifi
accuraci
test
establish
laboratori
protocol
del
identif
serolog
korean
donor
method
serolog
sampl
determin
use
indirect
globulin
test
subsequ
test
del
phenotyp
use
test
sampl
also
test
rhce
phenotyp
pcr
melt
curv
analysi
perform
identifi
hitherto
report
del
allel
korean
popul
result
serolog
case
antigen
detect
case
test
del
allel
detect
case
case
test
case
found
harbor
del
allel
del
allel
found
serolog
sampl
rhc
summaryconclus
test
combin
rhc
phenotyp
use
screen
tool
korean
del
donor
despit
high
rate
test
also
help
overcom
inher
limit
genotyp
assay
j
cote
j
morden
pigneau
c
welch
c
pambrun
blood
servic
ottawa
canada
background
cryopreserv
red
cell
liquid
nitrogen
may
use
store
aliquot
red
blood
cell
storag
red
cell
may
caus
antigen
deterior
time
especi
duffi
mn
knop
kna
mcca
blood
group
system
goodspe
bg
antigen
red
cell
aliquot
ad
rare
inventori
canadian
blood
servic
immunohematolog
refer
laboratori
sinc
use
antibodi
identif
compat
test
comprehens
inventori
well
character
rare
red
cell
essenti
immunohematolog
refer
laboratori
aim
determin
red
cell
antigen
integr
frozen
storag
greater
year
method
select
rare
red
cell
frozen
day
collect
frozen
year
rare
red
cell
frozen
per
method
describ
gibb
et
al
thaw
serolog
phenotyp
fya
fyb
use
licens
commerci
antisera
follow
manufactur
instruct
heterozyg
red
cell
use
posit
control
eg
mn
fy
ab
monospecif
use
antihuman
globulin
requir
phenotyp
compar
obtain
cell
fresh
cell
anoth
time
point
frozen
storag
result
result
obtain
concord
previous
obtain
fya
fyb
phenotyp
rare
red
cell
strength
reactiv
posit
test
result
equal
greater
strength
reactiv
observ
heterozyg
posit
control
summaryconclus
rare
red
cell
maintain
frozen
greater
year
show
serolog
evid
antigen
loss
fya
fyb
antigen
though
duffi
mn
blood
group
known
deterior
storag
freez
liquid
nitrogen
base
find
appear
protect
antigen
integr
long
period
time
c
coello
de
portug
j
garcia
rodriguez
j
palomar
r
palma
flore
c
b
eguia
pajar
region
de
transfus
toledo
spain
centro
region
de
transfus
toledo
spain
background
treatment
red
cell
rc
dithiothreitol
dtt
make
possibl
resolv
interfer
immunohematolog
test
produc
daratumumab
techniqu
improv
safeti
transfus
still
disadvantag
sinc
allow
crossmatch
antibodi
screen
one
aim
demonstr
treatment
rc
dtt
obtain
result
current
techniqu
achiev
less
equal
degre
hemolysi
better
interpret
gel
result
observ
degre
hemolysi
storag
rc
treat
dtt
compar
use
differ
method
preserv
rc
treat
dtt
allow
crossmatch
day
treatment
therefor
allow
reduct
pretransfusion
time
method
select
patient
treatment
daratumumab
known
erythrocyt
genotyp
phenotyp
unit
blood
donor
abo
rh
duffi
kidd
mnss
use
commerci
immucor
rc
irc
control
day
perform
crossmatch
unit
irc
without
dtt
treatment
check
interfer
treat
cc
rc
irc
dtt
ratio
reconstitut
pb
ph
check
erythrocyt
phenotyp
ep
rc
treat
abo
duffi
kidd
mnss
perform
crossmatch
one
patient
plasma
anoth
addit
igg
antisera
known
clinic
signific
antibodi
rh
duffi
kidd
kell
ss
immucor
grifol
store
wash
rbc
treat
cc
differ
preserv
media
day
degre
hemolysi
dh
analyz
day
dh
measur
cobasc
roch
perform
crossmatch
igg
antisera
known
clinic
signific
antibodi
rh
duffi
kidd
kell
ss
sampl
preserv
medium
result
day
sampl
equival
elimin
interfer
dtt
lower
degre
hemolysi
similar
reaction
vs
rh
ss
less
discrep
heterozyg
duffi
kidd
vs
respect
day
crossmatch
similar
vs
preserv
medium
higher
hemolysi
duffi
kidd
heterozygot
phenotyp
higher
discrep
group
dh
liss
better
group
pb
worst
day
crossmatch
remain
viabl
pb
alsev
liss
alsev
liss
greater
degre
hemolysi
vs
group
summaryconclus
treatment
dtt
rc
similar
rc
treat
less
hemolysi
group
vs
storag
rc
especi
liss
alsev
preserv
medium
less
discrep
day
rc
treat
abstract
withdrawn
abstract
withdrawn
l
soufflet
barradeau
c
betremieux
dambron
p
desmet
r
diagast
loo
franc
background
new
blood
group
serolog
techniqu
develop
base
membran
technolog
indirect
antiglobulin
techniqu
use
innov
process
autom
system
intend
detect
unexpect
antibodi
plasma
new
gener
iat
base
detect
andor
complement
reagent
immun
complex
rbc
antibodi
retent
sensit
cell
onto
spot
porou
membran
simpl
technolog
without
centrifug
step
allow
conveni
time
result
min
aim
present
work
report
result
obtain
indirect
antiglobulin
test
iat
detect
unexpect
cell
antibodi
use
assay
autom
system
compar
sensit
specif
classic
gel
test
method
red
blood
cell
panel
incub
plasma
sampl
microtit
plate
min
transfer
membran
spot
presenc
polyc
form
red
cell
spot
polyval
antiglobulin
ad
order
detect
antibodi
consolid
cell
network
wash
pan
agglutin
effect
elimin
result
red
blood
cell
elimin
white
spot
neg
sampl
retent
red
blood
cell
spot
unexpect
antibodi
fix
rbc
first
autom
studi
cohort
neg
posit
sampl
respect
select
transfus
laboratori
lill
hospit
center
franc
screen
french
blood
bank
test
sampl
also
test
gel
test
system
result
panel
posit
sampl
antibodi
rhkelduffykiddmnslewi
test
new
test
use
autom
system
gel
test
refer
test
rank
sensit
agreement
two
techniqu
near
moreov
french
nation
refer
sampl
detect
low
ngml
depend
use
red
blood
cell
panel
neg
sampl
n
found
neg
techniqu
interestingli
ttr
shorten
min
assay
compar
min
gel
test
system
summaryconclus
compar
studi
show
iat
perform
simpl
rapid
method
specif
sensit
usual
gel
filtrat
test
detect
red
blood
cell
unexpect
antibodi
conclud
new
gener
test
effici
fulli
autom
altern
gel
filtrat
test
shorten
ttr
make
assay
particularli
attract
especi
case
emerg
transfus
k
ganier
dupont
c
betremieux
barradeau
r
diagast
loo
franc
background
blood
transfus
potenti
hazard
procedur
thu
complet
blood
compat
test
prior
transfus
howev
situat
delay
test
might
jeopard
patient
urgent
requir
red
blood
cell
transfus
get
compat
test
result
may
issu
especi
due
time
need
perform
indirect
antiglobulin
test
new
fulli
autom
system
use
test
type
test
antibodi
screen
iat
provid
complet
blood
group
serolog
result
within
min
minim
risk
blood
incompat
emerg
transfus
aim
present
work
report
data
obtain
technolog
blood
type
test
antibodi
iat
autom
system
method
perform
two
studi
test
compar
standard
autom
gel
filtrat
techniqu
time
measur
load
sampl
display
result
time
result
evalu
specif
test
combin
sampl
antibodi
screen
iat
sampl
type
test
includ
revers
type
combin
test
launch
sampl
evalu
complet
blood
group
serolog
test
requir
result
antibodi
screen
test
perform
within
min
test
includ
revers
type
perform
less
min
consid
combin
test
abo
revers
type
antibodi
screen
obtain
load
sampl
display
result
less
min
thank
manag
test
perform
min
incub
red
blood
cell
panel
plasma
sampl
antibodi
screen
test
combin
test
perform
less
min
observ
concord
techniqu
gel
filtrat
techniqu
use
standard
summaryconclus
result
show
technolog
autom
system
offer
fast
secur
solut
test
blood
compat
case
emerg
transfus
mt
c
f
j
patholog
laboratori
medicin
taoyuan
arm
forc
gener
hospit
taoyuan
transfus
medicin
depart
patholog
laboratori
medicin
shin
kong
wu
memori
hospit
taipei
clinic
patholog
far
eastern
memori
hospit
new
taipei
taiwan
republ
china
background
implement
manual
blood
group
confirm
aborhd
donor
blood
group
control
blood
bag
reduc
human
error
allow
econom
high
throughput
improv
turnaround
time
aim
aim
evalu
eas
use
effici
abd
diagast
french
comparison
clinic
tube
method
three
differ
laboratori
method
abd
technolog
base
immobil
antibodi
coval
bound
porou
membran
red
blood
cell
correspond
antigen
fix
membran
reveal
immedi
reaction
step
procedur
allow
manual
blood
group
confirm
safe
standard
way
initi
train
abd
use
parallel
tube
method
follow
daili
workload
total
individu
sampl
run
abd
forward
group
sampl
patient
sampl
militari
health
examin
sampl
blood
bag
specif
case
result
abd
rapid
tube
method
need
centrifug
specif
case
two
subtyp
show
type
three
subtyp
show
b
type
respect
other
consist
two
method
regard
eas
use
abd
intuit
user
friendli
summaryconclus
abd
bring
appreci
new
featur
could
patient
bedsid
outsid
lab
purpos
mobil
blood
collect
ambul
militari
etc
thu
accommod
wide
rang
clinic
need
suggest
abd
pad
could
setup
abd
revers
group
ab
subtyp
futur
j
j
servic
research
technic
servic
australian
red
cross
blood
servic
brisban
australian
red
cross
blood
servic
sydney
australia
background
histor
australian
red
cross
blood
servic
blood
servic
perform
high
titr
antibodi
htab
test
manual
test
restrict
group
apheresi
platelet
donat
previous
report
case
haemolysi
minor
abo
incompat
involv
group
donor
blood
servic
commenc
review
follow
two
report
seriou
transfus
reaction
due
compon
contain
high
titr
andor
includ
one
group
apheresi
platelet
extrem
high
titr
transfus
group
ab
recipi
aim
identifi
evalu
altern
test
methodolog
enabl
increas
test
group
b
apheresi
donat
high
volum
clinic
plasma
compon
method
literatur
review
conduct
determin
exist
intern
practic
autom
htab
screen
use
beckman
coulter
utilis
nation
health
servic
blood
transplant
nhsbt
england
scottish
nation
blood
transfus
servic
snbt
evalu
suitabl
method
complet
blood
servic
complet
design
control
valid
modifi
autom
htab
screen
test
base
nhsbt
snbt
method
two
htab
test
use
differ
dilut
ratio
test
parallel
lower
dilut
ratio
approxim
convent
tube
salin
direct
agglutin
titr
differenti
low
high
titr
second
dilut
ratio
highest
dilut
ratio
avail
beckman
coulter
use
identifi
donat
may
except
high
titr
andor
requir
test
dilut
donor
plasma
test
separ
group
group
b
cell
beckman
coulter
pk
system
revers
group
cell
report
result
base
combin
result
individu
cell
neg
result
must
obtain
cell
overal
neg
result
report
result
evalu
valid
test
sampl
test
sampl
test
posit
pk
dilut
ratio
sampl
return
indetermin
result
default
posit
result
interpret
increas
rate
donat
high
titr
andor
total
sampl
test
posit
also
posit
higher
dilut
ratio
summaryconclus
australian
method
regist
accredit
class
ivd
australian
regulatori
bodi
apheresi
platelet
clinic
plasma
compon
test
found
neg
test
label
low
compon
releas
label
implement
new
autom
test
improv
access
low
titr
clinic
plasma
compon
apheresi
platelet
reduc
risk
transfus
reaction
intend
recipi
abo
incompat
transfus
unavoid
e
b
j
r
immucor
gmbh
dreieich
zentrum
transfusionsmedizin
und
zelltherapi
berlin
gmbh
ein
gemeinschaftsunternehmen
der
berlin
und
de
berlin
germani
background
abo
antibodi
titrat
igm
igg
antibodi
clinic
relev
sever
area
stem
cell
solid
organ
transplant
blood
group
donor
character
transfus
well
pregnanc
common
method
determin
abo
antibodi
titer
includ
convent
tube
test
column
agglutin
techniqu
time
consum
poor
accuraci
reproduc
subject
respect
interpret
titer
end
point
immucor
base
fulli
autom
igm
igg
abo
titrat
assay
valid
use
galileo
abo
titrat
assay
valid
intern
clinic
studi
immucor
newli
develop
platform
neo
aim
aim
studi
evalu
perform
fulli
autom
igm
igg
abo
titrat
assay
neo
platform
intern
clinic
set
method
neo
offer
fulli
autom
igg
full
rang
assay
dilut
neat
low
titer
assay
high
titer
assay
well
full
rang
igm
assay
neat
b
cell
method
fulli
autom
titer
result
provid
instrument
without
manual
intervent
reproduc
repeat
fulli
autom
abo
titrat
assay
donor
plasma
test
evalu
low
titer
igm
igg
well
high
titer
igg
configur
two
donor
specimen
per
assay
test
triplic
morn
afternoon
five
day
within
day
three
neo
instrument
result
titer
result
per
assay
verifi
titer
consist
studi
perform
intern
clinic
set
clinic
studi
least
patient
specimen
per
igm
per
igg
assay
low
high
titer
combin
test
util
autom
abo
titrat
rang
assay
neo
versu
galileo
result
autom
abo
titrat
assay
demonstr
high
reproduc
across
differ
neo
instrument
differ
time
point
titer
result
analyz
igm
igg
assay
averag
assay
show
titer
differ
one
doubl
dilut
differ
two
doubl
dilut
high
consist
neo
galileo
demonstr
intern
clinic
studi
confirm
high
consist
titer
result
titer
result
within
two
doubl
dilut
step
assay
evalu
summaryconclus
fulli
autom
abo
titrat
assay
offer
excel
reproduc
repeat
across
sever
neo
instrument
high
consist
demonstr
intern
clinic
studi
immucor
provid
complet
highli
consist
igm
igg
abo
titrat
assay
set
galileo
neo
may
help
overcom
current
labor
intens
less
precis
manual
techniqu
f
r
market
cressier
switzerland
pari
franc
background
deliv
right
blood
short
time
one
biggest
challeng
laboratori
request
urgent
blood
deliveri
arriv
time
throughout
day
must
handl
daili
routin
test
manag
test
urgent
blood
sampl
requir
staff
resourc
well
addit
resourc
autom
instrument
manag
stat
sampl
autom
instrument
essenti
ensur
deliveri
urgent
blood
sampl
request
without
delay
interrupt
daili
routin
sampl
test
aim
aim
evalu
determin
optim
custom
laboratori
condit
perform
immunohematolog
autom
combin
new
instrument
softwar
version
particular
manag
stat
sampl
revers
full
phenotyp
antibodi
screen
antibodi
identif
routin
test
method
perform
evalu
routin
custom
laboratori
new
instrument
softwar
use
id
gel
system
comparison
known
previous
obtain
data
routin
softwar
version
use
result
result
compliant
accord
expect
result
known
previou
test
routin
observ
full
phenotyp
stat
sampl
averag
time
result
min
compar
previou
version
improv
min
reduct
also
ab
screen
ab
identif
improv
time
result
observ
reduct
min
ab
identif
min
ab
screen
result
summaryconclus
comparison
softwar
use
routin
test
instrument
softwar
show
signific
improv
time
result
stat
routin
sampl
handl
full
blood
group
includ
phenotyp
antibodi
identif
antibodi
screen
j
lee
j
shin
h
choi
kim
shin
laboratori
medicin
chonnam
nation
univers
hwasun
hospit
hwasun
republ
korea
background
import
obtain
correct
result
patient
abo
rhd
type
success
blood
transfus
although
abo
rhd
type
tradit
perform
manual
method
use
slide
test
tube
replac
autom
immunohematolog
analyz
aim
studi
aim
test
autom
daymat
valid
abo
rhd
type
compar
manual
method
system
method
total
patient
sampl
randomli
collect
test
month
chonnam
nation
univers
hwasun
hospit
abo
rhd
type
sampl
perform
use
manual
method
daymat
system
system
respect
manual
method
done
refer
procedur
slide
tube
method
daymat
use
column
agglutin
gel
reagent
ad
empti
well
result
among
sampl
sampl
blood
type
b
ab
respect
one
type
sampl
concord
rate
abo
type
manual
method
autom
system
daymat
system
system
one
sampl
show
abo
discrep
system
follow
rbc
b
rbc
respect
sampl
obtain
patient
diagnos
plasmacytoma
compar
correl
manual
method
autom
analyz
use
pearson
correl
rho
valu
daymat
follow
rbc
b
rbc
respect
p
autom
immunohematolog
analyz
show
good
correl
manual
method
daymat
system
exhibit
slightli
better
correl
manual
method
system
respect
b
rbc
summaryconclus
daymat
autom
immunohematolog
analyz
show
appropri
concord
well
good
correl
manual
method
abo
rhd
type
daymat
suffici
use
abo
rhd
type
clinic
sampl
ruebsamen
geller
e
spigarelli
r
immucor
medizinisch
diagnostik
gmbh
dreieich
germani
background
titrat
alloantibodi
red
cell
antigen
method
measur
strength
antibodi
use
predict
fetal
risk
suffer
hemolyt
diseas
fetu
newborn
hdfn
donorpati
character
incompat
blood
transfus
organ
transplant
due
technic
human
factor
manual
titrat
antibodi
remain
highli
variabl
therefor
autom
solut
strongli
desir
immucor
previous
launch
igg
igm
specif
base
fulli
autom
abo
titrat
assay
avail
immucor
galileo
neo
platform
current
igg
specif
assay
titrat
alloantibodi
develop
aim
aim
studi
compar
igg
titer
result
obtain
differ
autom
manual
techniqu
ie
autom
solid
phase
manual
column
agglutin
techniqu
gel
manual
tube
test
iat
method
patient
pregnanc
donor
sampl
differ
known
alloantibodi
well
intern
standard
immunoglobulin
test
use
base
prototyp
assay
includ
autom
titrat
sampl
neo
base
prototyp
assay
use
manual
dilut
sampl
neo
manual
gel
card
manual
dilut
sampl
gel
card
manual
dilut
sampl
indirect
agglutin
tube
test
manual
dilut
sampl
result
titer
result
base
assay
use
autom
dilut
sampl
consist
titer
result
manual
dilut
sampl
assay
type
neo
titer
within
one
doubl
dilut
gel
titer
compar
sampl
untreat
sampl
iat
show
highest
variat
compar
gel
summaryconclus
prototyp
assay
autom
neo
alloantibodi
titrat
abl
accur
pipett
sampl
doubl
dilut
minimum
oper
time
effort
comparison
techniqu
prove
assay
specif
clinic
relev
igg
alloantibodi
os
v
qualiti
control
safeti
transfus
blood
cell
process
cryopreserv
clinic
transfusiolog
nation
medic
research
center
hematolog
russian
feder
moscow
moscow
russian
feder
background
conduct
test
individu
compat
hemotransfus
import
part
ensur
immunolog
safeti
transfus
therapi
crossmatch
method
would
reliabl
reveal
clinic
relev
antibodi
would
give
result
howev
number
case
applic
particular
crossmatch
test
method
enabl
select
compat
blood
safe
transfus
method
allow
aim
compar
gel
techniqu
techniqu
crossmatch
test
individu
select
media
hematolog
patient
method
crossmatch
test
transfus
media
conduct
analyz
galileo
neo
immucor
usa
use
method
techniqu
hematolog
patient
variou
nosolog
year
age
averag
age
similar
research
direct
coomb
test
conduct
gel
card
lisscoomb
usa
result
patient
posit
direct
coomb
test
year
age
averag
age
make
total
number
hematolog
patient
diagnos
conduct
hemotransfus
myelogen
leukemia
hemotransfus
multipl
myeloma
hemotransfus
clear
cell
carcinoma
kidney
hemotransfus
waldenstrom
macroglobulinemia
hemotransfus
crossmatch
test
gel
techniqu
posit
incompat
techniqu
test
neg
compat
case
method
demonstr
ident
result
test
select
compat
method
sampl
donor
erythrocyt
neg
compat
recipi
case
hemotransfus
recipi
without
hemolyt
incompat
blood
transfus
reaction
character
clinic
relev
hemoglobin
increas
gl
summaryconclus
patholog
state
igm
clinic
relev
caus
hemolysi
gel
techniqu
enabl
without
process
serum
differenti
igm
igg
adhes
method
solid
phase
allow
reveal
igg
case
enabl
select
compat
erythrocyt
time
one
bear
mind
possibl
presenc
pure
igm
erythrocyt
allotyp
antigen
erythrocyt
rhesu
system
system
other
hemolyt
effici
final
decis
immunolog
compat
conduct
hemotransfus
made
base
upon
compat
test
vivo
g
gryfelt
wikman
kitm
karolinska
univers
hospit
stockholm
sweden
background
adsorpt
use
determin
patient
waiha
also
underli
alloantibodi
common
method
adsorpt
use
peg
plasma
rbc
peg
mix
equal
proport
incub
min
centrifug
supernat
test
panel
rbc
indirect
antiglobulin
test
iat
either
tube
gel
techniqu
slightli
differ
approach
first
incub
centrifug
mix
supernat
rbc
liss
tube
thereaft
incub
mixtur
min
one
wash
pb
pellet
transfer
gel
card
contain
year
ago
compar
modifi
three
peg
adsorpt
method
aim
aim
identifi
adsorpt
method
best
detect
underli
irregular
erythrocyt
antibodi
method
plasma
autoantibodi
detect
patient
plasma
weak
titer
alloantibodi
patient
use
antigen
neg
rbc
method
modifi
see
background
method
differ
amount
supernat
rbc
liss
transfer
gel
card
contain
incub
min
centrifug
method
suspens
method
suspens
method
suspens
one
sampl
autoantibodi
adsorb
method
one
sampl
test
method
four
method
use
test
plasma
sampl
contain
result
autoantibodi
three
five
sampl
test
still
posit
use
method
one
gave
neg
result
method
test
fifth
sampl
due
prophylaxi
discov
method
method
method
test
alloantibodi
three
six
weak
test
detect
method
two
weak
detect
method
respect
weak
detect
either
method
method
gave
strongest
posit
reaction
method
weakest
method
difficult
interpret
probabl
larg
volum
peg
summaryconclus
method
result
strong
specif
reaction
use
laboratori
laboratori
research
blood
center
wuhan
china
background
abo
blood
group
rhd
blood
group
import
human
erythrocyt
blood
group
system
play
import
role
clinic
safeti
transfus
organ
transplant
tissu
match
forens
identif
accur
screen
abo
rhd
blood
group
prerequisit
safeti
blood
transfus
automat
blood
group
analyz
neo
wide
use
blood
station
perform
rare
compar
aim
compar
perform
automat
blood
group
analyz
neo
screen
abo
rhd
blood
group
method
sampl
determin
repeatedli
detect
time
use
automat
blood
group
analyz
neo
see
whether
result
consist
second
abo
blood
group
rhd
blood
group
detect
use
automat
blood
group
analyz
neo
automat
bold
group
analyz
cell
agglutin
rhd
neg
specimen
sent
blood
transfus
research
depart
wuhan
blood
center
identifi
result
first
result
repeat
determin
consist
time
second
blood
donor
detect
abo
blood
group
correct
rate
automat
blood
group
analyz
neo
automat
blood
group
analyz
respect
rhd
blood
group
correct
rate
respectivelyno
statist
signific
case
doubt
sampl
sent
blood
transfus
research
depart
case
antibodi
result
pattern
cell
b
cell
reaction
weakli
case
weak
case
subgroup
case
irregular
antibodi
summaryconclus
automat
blood
group
analyz
may
good
stabil
statist
differ
result
automat
blood
group
analyz
neo
automat
blood
group
analyz
result
compar
compar
neo
automat
blood
group
analyz
automat
blood
group
analyz
would
conveni
oper
faster
speed
less
reagent
clear
instrument
pictur
intuit
result
conveni
manual
check
would
reliabl
suitabl
blood
station
larg
blood
sampl
main
reason
doubt
abo
blood
group
automat
blood
group
analyz
attribut
weak
irregular
antibodi
abstract
withdrawn
g
cook
royal
alexandra
hospit
edmonton
ab
canada
background
echo
lumenatm
newli
ce
mark
immucor
immunohematolog
platform
use
blood
bank
laboratori
current
user
galileo
larg
hospit
clinic
process
evalu
new
instrument
aim
object
studi
assess
concord
group
screen
assay
use
echo
lumena
compar
galileo
echo
evalu
sensit
specif
new
platform
method
perform
new
autom
echo
lumena
compar
galileo
echo
instrument
day
use
patient
sampl
came
clinic
laboratori
specimen
run
within
h
collect
reagent
lot
number
use
platform
total
blood
group
screen
antibodi
identif
aborh
donor
unit
confirm
perform
addit
cord
blood
sampl
aborh
result
compar
result
echo
lumena
show
concord
galileo
echo
group
assay
screen
assay
echo
lumena
detect
two
addit
clinic
signific
antibodi
detect
galileo
echo
qualiti
imag
echo
lumena
improv
compar
galileo
echo
summaryconclus
echo
lumena
shown
concord
galileo
echo
improv
sensit
clinic
signific
antibodi
staff
feedback
posit
shorter
run
time
echo
lumena
chang
oper
use
echo
lumena
train
requir
e
r
e
e
w
trasfusional
fondazion
ircc
ca
granda
ospedal
maggior
policlinico
clinic
diagnost
milan
itali
clinic
diagnost
turnhout
belgium
background
increasingli
demand
routin
continu
reduct
avail
resourc
call
laboratori
better
fewer
resourc
purpos
laboratori
size
take
advantag
use
autom
choic
type
instrument
best
suit
realiti
must
take
consider
perform
effici
safeti
economi
scale
ortho
max
present
automat
tool
high
perform
volum
aim
aim
evalu
eas
use
effici
ortho
max
analys
vision
max
routin
use
transfus
laboratori
comparison
manual
method
ortho
autovu
innova
method
basic
immunohematolog
test
perform
direct
indirect
determin
abo
group
rh
type
rhk
phenotyp
dweak
erythrocyt
antibodi
screen
compat
test
addit
second
level
test
perform
identif
type
system
erythrocyt
antibodi
titrat
total
test
system
evalu
follow
time
startup
time
period
mainten
execut
intern
qualiti
control
cqi
direct
indirect
determin
abo
type
rh
detect
erythrocyt
antibodi
sampl
time
tat
group
determin
phenotyp
fulli
load
machin
manag
urgenc
stat
group
determin
antibodi
screen
fulli
load
empti
machin
system
effici
base
protocol
pb
routin
repetit
instrument
current
use
laboratori
day
advanc
protocol
pa
erythrocyt
antibodi
titrat
assess
reagent
consumpt
maximum
number
blood
sampl
possibl
instrument
complet
test
profil
direct
indirect
determin
abo
group
rh
type
rhk
phenotyp
allo
erythrocyt
antibodi
screen
result
startup
time
period
mainten
daili
weekli
monthli
cqi
tat
sampl
time
stat
fulli
load
empti
pb
test
two
day
pa
titrat
test
perform
sampl
test
perform
perform
sampl
expect
reagent
optim
dedic
cassett
punch
tool
allow
effici
use
well
test
result
agreement
obtain
method
use
summaryconclus
experiment
shown
ortho
max
excel
impact
laboratori
routin
consider
reduct
test
execut
time
especi
urgent
manag
reagent
consumpt
possibl
perform
allow
uniform
treatment
unexpect
result
optim
report
time
titrat
perform
vision
allow
better
standard
effici
time
complet
test
tube
jalali
shirmohammadi
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
islam
republ
iran
transplant
research
center
shiraz
univers
medic
scienc
shiraz
islam
republ
iran
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
islam
republ
iran
research
institut
research
center
thalassemia
hemoglobinopathi
ahvaz
jundishapur
univers
medic
scienc
ahvaz
khuzestan
ahvaz
islam
republ
iran
background
natur
laboratori
test
prone
error
everi
step
heavi
workload
import
accuraci
precis
maintain
good
laboratori
practic
blood
transfus
caus
use
autom
mani
aspect
transfus
servic
one
import
vital
part
transfus
immunohematolog
blood
group
type
abo
rh
blood
group
system
play
great
vital
role
blood
transfus
incompat
wrong
blood
group
type
may
lead
mortal
morbid
due
hemolyt
reaction
rh
system
caus
sensit
first
exposur
acut
delay
hemolyt
reaction
special
blood
depend
patient
controversi
convent
autom
blood
group
type
advantag
disadvantag
two
method
want
studi
compar
method
aim
evalu
compar
manual
standard
routin
method
autom
method
blood
group
blood
donor
method
cross
section
experiment
studi
conduct
march
april
blood
donor
admit
far
blood
transfus
servic
blood
sampl
test
autom
qwali
diagast
instrument
confirm
presenc
weak
antigen
among
sampl
rh
neg
sampl
check
standard
manual
method
use
blend
rh
antisera
iranian
blood
refin
fraction
ibrf
cinna
gen
igm
antisera
antigen
commerci
kit
parallel
sampl
check
use
three
autom
qwali
diagast
instrument
diagast
weak
kit
check
valid
perform
autom
instrument
rh
posit
confirm
sampl
randomli
select
rh
type
done
sampl
data
collect
analyz
result
total
blood
donat
test
rh
posit
show
neg
autom
procedur
use
manual
method
two
differ
iranian
commerci
kit
sampl
rh
neg
three
sampl
neg
manual
method
perform
weak
procedur
igg
cinna
gen
antisera
one
show
weak
posit
reaction
examin
rh
posit
sampl
autom
show
one
sampl
could
read
result
two
instrument
third
instrument
show
neg
rh
sampl
summaryconclus
accord
find
take
consider
import
rh
transfus
implement
autom
procedur
center
high
number
blood
donor
blood
depend
patient
highli
recommend
prevent
mani
error
mayb
happen
perform
test
variabl
red
cell
concentr
red
cell
suspens
lack
consist
read
agglutin
reaction
human
error
use
autom
method
caus
save
time
cost
time
show
highli
sensit
result
also
take
care
qualiti
blood
sampl
avoid
wrong
blood
group
type
instrument
must
valid
time
prevent
error
happen
studi
e
carrillo
e
rebagliati
essalud
lima
lima
essalud
lima
peru
background
transfus
blood
concentr
ch
emerg
center
utmost
import
allow
rapid
recoveri
oxygen
transport
capac
critic
patient
compat
test
includ
largest
major
crossmatch
pc
andor
type
screen
abbrevi
crossmatch
procedur
allow
transfus
compat
time
blood
sinc
june
implement
blood
bank
emerg
center
lima
rebagliati
healthcar
network
follow
guidelin
compat
procedur
blood
transfus
laboratori
bcsh
aim
implement
blood
bank
hospit
emerg
center
attend
compat
time
blood
method
ta
procedur
perform
echo
lumena
immucor
blood
group
aborhd
perform
igm
igg
igm
b
cell
screen
irregular
antibodi
eai
carri
captur
technolog
solid
phase
immucor
detect
antibodi
identifi
immunohematolog
laboratori
edgardo
rebagliati
martin
hospit
patient
previous
regist
alloantibodi
softwar
hemasoft
detect
alloantibodi
major
crossmatch
perform
need
blood
urgent
ch
releas
aborhd
group
abbrevi
crossmatch
procedur
continu
case
patient
posit
eai
direct
posit
coomb
without
previou
transfus
proceed
protocol
incompat
blood
ahai
result
june
februari
process
treat
patient
critic
situat
ch
unit
reserv
transfus
posit
found
sampl
neg
sampl
identifi
antibodi
patient
posit
crossmatch
transfus
ch
result
compat
test
andor
crossmatch
compat
incompat
due
emerg
situat
less
incompat
unit
transfus
process
time
min
first
applic
follow
one
min
case
great
urgenc
request
attend
without
major
crossmatch
continu
summaryconclus
implement
celim
allow
attend
red
blood
cell
concentr
singl
sampl
within
h
safe
time
manner
servic
time
min
process
pack
red
blood
cell
allow
save
major
crossmatch
g
p
c
c
b
blood
transfus
servic
zurich
swiss
red
cross
schlieren
grifol
diagnost
duedingen
blood
transfus
servic
zurich
swiss
red
cross
schlieren
switzerland
background
basic
extend
phenotyp
medion
grifol
diagnost
duedingen
ch
launch
septemb
allow
simultan
type
jka
jkb
fya
fyb
antigen
use
later
flow
techniqu
aim
order
implement
addit
analyt
platform
examin
seri
sampl
taken
patient
suffer
clinic
condit
known
hamper
serolog
red
blood
cell
rbc
antigen
type
method
sampl
n
patient
suffer
posit
direct
antiglobulin
test
dat
n
includ
warm
cold
autoimmun
hemolysi
aiha
sepsi
sickl
cell
diseas
n
paraproteinemia
due
multipl
myeloma
morbu
n
sampl
newborn
n
well
sampl
healthi
blood
donor
n
three
known
weak
fyx
assess
basic
extend
phenotyp
addit
ten
sampl
store
least
one
month
includ
studi
result
compar
find
altern
test
method
either
standard
serolog
type
gelcard
medion
grifol
duedingen
ch
biorad
cressier
ch
commerci
molecular
type
gmbh
kronberg
result
easi
handl
provid
rapid
result
averag
min
test
start
make
method
suitabl
emerg
applic
overal
result
confirm
altern
method
known
two
known
fya
neg
sampl
show
fals
posit
reaction
due
patient
strongli
posit
dat
one
sampl
deliv
weak
jkb
posit
result
although
patient
known
jkb
neg
pcr
clinic
evalu
reveal
recent
transfus
jkb
posit
rbc
concentr
two
posit
sampl
predict
phenotyp
pcr
accur
diagnos
upon
wash
patient
rbc
nacl
similar
observ
made
cord
blood
cell
anoth
sampl
patient
sever
cold
aiha
need
wash
warm
nacl
summaryconclus
allow
reliabl
rbc
type
even
dat
posit
sampl
may
appli
sampl
patient
suffer
clinic
condit
sickl
cell
diseas
aiha
paraproteinemia
impair
standard
serolog
type
patient
strongli
posit
dat
distinct
posit
reaction
allow
differenti
fals
posit
reaction
inherit
antigen
posit
rbc
emerg
situat
prove
provid
rapid
reliabl
antigen
type
allow
transfus
patient
phenotyp
compat
rbc
concentr
fontain
j
herlem
g
alluin
c
djobo
delsal
manteau
franc
ef
hfno
lill
loo
franc
background
abd
pad
diagast
innov
method
manual
abo
blood
group
determin
use
technolog
base
antibodi
coval
bound
porou
membran
correspond
antigen
red
blood
cell
fix
membran
reveal
immedi
reaction
aim
aim
studi
test
method
blood
patient
sampl
order
estim
exactitud
blood
group
determin
whatev
patholog
biolog
abnorm
method
sampl
chosen
base
clinic
inform
provid
laboratori
blood
group
abd
pad
compar
usual
method
laboratori
autoanalys
blood
group
qwali
diagast
manual
techniqu
confirm
abo
blood
type
result
evalu
impact
sampl
heterogen
abd
pad
method
differenti
characterist
sampl
red
blood
cell
patholog
autoimmun
hemolyt
anemia
thalassemia
sickl
cell
anemia
macrocyt
microcyt
mcv
schistocyt
malign
hemopathi
cold
agglutinin
leucocytosi
thrombocytosi
daratumumab
therapi
blood
protein
disord
hyperproteinemia
hypoproteinemia
monoclon
gammopathi
bridg
high
low
plasma
fibrinogen
hyperbilirubinemia
hypercholesterolemia
abnorm
sampl
chylomicron
creami
layer
test
tube
hemolysi
agglutin
transfus
weak
express
blood
group
antigen
weak
express
blood
group
antigen
red
cell
antibodi
stem
cell
transplant
result
obtain
abd
pad
accord
method
use
laboratori
reaction
sampl
cold
agglutinin
fals
posit
blood
type
obtain
warm
wash
salin
red
cell
reaction
weak
blood
group
antigen
weak
blood
group
antigen
posit
saw
particular
mix
agglutin
transfus
obtain
usual
method
recipi
antigen
alway
posit
summaryconclus
method
show
high
sensibl
weak
express
blood
group
antigen
also
benefit
fast
determin
blood
group
studi
confirm
use
new
concept
donor
recipi
villa
n
revelli
scognamiglio
manazza
prati
refer
laboratori
uoc
centro
trasfusional
fondazion
ircc
cagranda
ospedal
maggior
policlinico
milan
itali
background
abd
diagast
loo
fr
new
diagnost
devic
quick
confirm
abo
blood
group
rhesu
donor
recipi
kit
use
technolog
base
immobil
antibodi
coval
bound
porou
membran
aim
aim
studi
evalu
perform
reliabl
sensit
specif
devic
method
abd
method
compar
full
autom
microcolumn
innova
ortho
raritan
nj
micropl
neogalileo
immucor
norcross
ga
usa
method
studi
carri
train
technician
accord
manufactur
instruct
total
test
perform
blood
donor
sampl
segment
donat
bag
patient
sampl
cord
blood
patient
treat
daratumumab
patient
red
blood
cell
antibodi
patient
weak
patient
antibodi
patient
cold
auto
immun
hemolyt
anemia
aiha
select
sampl
collect
edta
store
c
test
within
day
collect
reaction
abd
plate
read
interpret
immedi
h
later
concord
method
assess
expect
histor
result
case
discrep
sampl
refer
method
discrep
resolv
test
also
perform
tube
test
result
concord
result
abd
refer
method
obtain
sampl
result
donor
sampl
segment
donat
concord
wherea
patient
sampl
posit
direct
antiglobulin
test
concord
presenc
strong
autoagglutin
summaryconclus
abd
easi
procedur
quickli
provid
confirm
aborh
type
test
certainli
faster
method
current
use
abd
plate
readi
use
method
show
compar
result
routin
refer
method
suggest
use
check
blood
group
emerg
patient
bedsid
b
g
loo
franc
univers
hospit
algier
algeria
background
confirm
aborh
blood
group
donor
patient
test
perform
differ
step
transfus
chain
blood
transfus
servic
univers
hospit
algeria
control
perform
blood
bag
tube
segment
second
patient
specimen
use
liquid
antisera
plate
aim
new
abd
devic
diagast
loo
franc
suitabl
applic
evalu
prior
commerci
launch
method
routin
method
liquid
antisera
associ
plate
compar
abd
result
evalu
carri
sampl
red
blood
cell
concentr
tube
segment
demonstr
concord
regard
expect
result
averag
satisfact
score
ergonom
summaryconclus
devic
shown
reliabl
blood
group
confirm
v
n
j
p
grifol
diagnost
duedingen
switzerland
diagnost
solut
emeryvil
unit
state
background
novel
drug
daratumumab
dara
use
treatment
multipl
myeloma
interfer
diagnost
screen
identif
unexpect
antibodi
caus
reagent
red
blood
cell
rrbc
complic
detect
underli
potenti
clinic
relev
strategi
overcom
problem
includ
pretreat
rrbc
reduc
agent
dithiothreitol
dtt
issu
phenotypegenotyp
match
rbc
unit
patient
plasma
solubl
antibodi
oostendorp
transfus
latter
approach
suffer
unavail
reagent
suffici
activ
aim
aim
studi
evalu
diagnost
use
novel
recombin
method
part
extracellular
domain
express
mammalian
cell
purifi
solubl
nomin
concentr
mgml
evalu
diagnost
function
spike
donor
plasma
contain
mix
pb
control
incub
min
antibodi
detect
perform
indirect
antiglobulin
test
iat
tube
techniqu
dg
gel
techniqu
accord
manufactur
instruct
medion
grifol
diagnost
duedingen
switzerland
diagnost
grifol
paret
del
vall
spain
altern
done
directli
incub
chamber
dg
gel
coomb
card
diagnost
grifol
follow
iat
ie
addit
rrbc
suspens
medion
grifol
diagnost
min
incub
centrifug
absenc
residu
activ
indic
neg
result
test
rrbc
provid
sampl
contain
unexpect
antibodi
result
recombin
allow
complet
inhibit
mgml
correspond
titer
donor
plasma
experiment
set
antibodi
spike
bare
detect
amount
donor
plasma
could
detect
incub
antibodi
specif
compris
summaryconclus
present
result
show
inhibit
therapeut
plasma
concentr
daratumumab
use
novel
high
concentr
data
show
interfer
step
blood
group
alloantibodi
detect
nevertheless
exclud
complet
weak
antibodi
may
escap
detect
due
small
dilut
caus
addit
liquid
neutral
plasma
screen
commerci
avail
routin
techniqu
tube
gel
techniqu
import
advantag
use
protein
blocker
fact
allow
screen
identif
antibodi
blood
group
antigen
also
neutral
plasmat
instead
denatur
cellular
reduc
workload
process
highli
concentr
present
work
may
provid
combin
iat
rapid
accur
screen
identif
method
even
weakli
react
mask
r
transfus
medicin
max
healthcar
support
immucor
india
pvt
ltd
new
delhi
india
background
multipl
myeloma
condit
neoplast
prolifer
plasma
cell
produc
monoclon
antibodi
bone
marrow
result
increas
serum
protein
concentr
unexplain
anemia
hypercalcemia
daratumumab
also
known
dara
new
medic
recent
approv
nov
us
fda
treat
multipl
myeloma
daratumumab
kappa
monoclon
antibodi
recogn
target
myeloma
cell
singl
therapi
drug
significantli
effect
heavili
treat
patient
relaps
refractori
diseas
aim
present
case
year
old
male
patient
diagnos
relaps
multipl
myeloma
given
daratumumab
immunotherapi
due
activ
dara
interfer
screen
identif
red
cell
alloantibodi
cross
match
manag
overcom
interfer
use
warm
auto
antibodi
remov
medium
routin
antibodi
screen
compat
test
patient
plasma
consist
caus
posit
reaction
ict
cell
screen
cell
panel
ahg
crossmatch
howev
nt
interfer
aborhd
type
crossmatch
method
patient
test
abo
rh
cell
antibodi
screen
solid
phase
method
fulli
autom
immunohematolog
analyz
immucor
norcross
usa
obtain
pan
reactiv
cell
panel
sampl
test
antibodi
identif
captur
readi
solid
phase
also
pan
reactiv
collect
patient
brief
clinic
therapeut
histori
test
warm
treat
panel
cell
warm
use
removedestroy
structur
contain
dithiothreitol
panel
cell
treat
warm
volum
panel
cell
mix
volum
reagent
incub
min
incub
cell
wash
four
time
pb
limit
list
antibodi
screen
would
detect
antibodi
kell
duffi
n
result
warm
treatment
panel
cell
reduc
dara
bind
denatur
cell
surfac
abo
compat
along
rh
kell
pheno
match
rbc
also
found
compat
treat
warm
reagent
summaryconclus
howev
sever
method
introduc
worldwid
resolv
dara
interfer
blood
bank
test
like
solubl
infus
patient
plasma
neutral
circul
daratumumab
drug
daratumumab
antibodi
mous
also
neutral
circul
daratumumab
drug
dtt
dithiothreitol
warm
treatment
destroy
structur
reagent
red
cell
extend
phenotyp
patient
rbc
provid
phenotyp
red
cell
trypsin
treat
reagent
rbc
cleav
prevent
antigen
destruct
compar
dtt
test
lu
rbc
rbc
low
express
surfac
method
new
introduc
requir
much
cost
skill
treat
panel
cell
blood
unit
cell
warm
reagent
robust
method
prevent
dara
interfer
enabl
blood
bank
provid
blood
patient
without
delay
much
expenditur
n
lone
h
v
l
clinic
immunolog
herlev
univers
hospit
herlev
health
technolog
metropolitan
univers
colleg
copenhagen
denmark
background
daratumumab
dara
monoclon
antibodi
direct
glycoprotein
use
treatment
patient
multipl
myeloma
dara
caus
interfer
serolog
antibodi
test
complic
detect
clinic
signific
alloantibodi
prior
blood
transfus
interfer
elimin
use
dithiothreitol
dtt
reagent
red
blood
cell
rbc
howev
disadvantag
procedur
hemolysi
observ
storag
reagent
rbc
overcom
challeng
depart
clinic
immunolog
herlev
univers
hospit
develop
modifi
protocol
dtt
treatment
improv
stabil
reagent
rbc
day
without
visual
hemolysi
ensur
detect
alloantibodi
protocol
modif
technic
manual
due
reduc
amount
dtt
use
treatment
reagent
rbcsthe
purpos
modifi
protocol
enabl
prepar
reagent
rbc
conjunct
regular
reagent
rbc
order
improv
laboratori
effici
reduc
turnaround
time
antibodi
detect
aim
aim
studi
valid
modifi
protocol
dtt
treatment
reagent
rbc
measur
reduc
time
spent
detect
alloantibodi
method
dtt
treatment
reagent
rbc
perform
dtt
suppli
manufactur
sigma
aldrich
accord
technic
manual
except
rbc
dtt
ratio
vol
vol
multipl
batch
reagent
rbc
continu
prepar
distribut
three
transfus
servic
capit
region
region
zealand
denmark
februari
februari
antibodi
screen
test
perform
three
studi
site
untreat
reagent
rbc
plasma
sampl
patient
n
plasma
sampl
n
patient
known
clinic
signific
alloantibodi
n
antibodi
screen
test
perform
use
column
agglutin
technolog
coomb
id
card
biorad
laboratori
analysi
time
measur
compar
use
immedi
advanc
prepar
reagent
rbc
result
outcom
studi
show
dara
interfer
elimin
sampl
patient
alloantibodi
detect
remain
alloantibodi
within
kell
system
neg
use
modifi
protocol
reagent
reagent
rbc
prepar
advanc
provid
antibodi
screen
test
result
within
min
compar
min
immedi
prepar
reagent
rbc
summaryconclus
valid
result
show
modifi
protocol
reagent
rbc
elimin
dara
interfer
detect
alloantibodi
examin
except
alloantibodi
within
kell
system
reagent
rbc
prepar
advanc
reduc
antibodi
detect
time
min
present
studi
show
central
prepar
reagent
rbc
distribut
transfus
servic
ensur
qualiti
improv
laboratori
effici
therefor
prevent
delay
blood
transfus
j
j
c
f
p
j
du
sang
occitani
control
chronic
infect
univ
montpelli
inserm
ef
montpelli
du
sang
blood
cell
grand
sud
du
sang
paca
cors
biologi
de
group
sanguin
marseil
univ
cnr
ef
ade
marseil
du
sang
occitani
toulous
franc
background
alloimmun
one
main
side
effect
blood
transfus
could
sever
complic
red
blood
cell
transfus
especi
patient
diseas
requir
multipl
transfus
convent
pretransfus
determin
blood
group
phenotyp
base
hemagglutin
may
fail
certain
clinic
situat
molecular
type
offer
altern
deduc
blood
group
phenotyp
genotyp
howev
current
method
requir
turnaround
time
usual
perform
hospit
limit
applic
emerg
situat
rapid
decis
need
test
perform
near
advantag
aim
work
report
develop
novel
rapid
multiplex
molecular
method
identifi
seven
allel
three
clinic
relev
blood
group
system
fy
fy
gypb
gypb
jk
jk
assay
design
carri
unitari
test
specif
clinic
situat
test
patient
serolog
method
fail
emerg
situat
method
aim
develop
straightforward
rapid
genotyp
test
purpos
chose
handl
dna
procedur
includ
multiplex
late
amplif
perform
directli
whole
blood
amplicon
migrat
nucleic
acid
dipstick
gold
nanoparticl
use
report
permit
detect
blood
group
snp
gener
red
dot
visibl
nake
eye
assay
paramet
optim
test
valid
blood
donor
sampl
known
phenotyp
result
optim
assay
includ
multiplex
paramet
primer
concentr
cycl
number
later
flow
paramet
migrationhybrid
temperatur
buffer
composit
final
protocol
enabl
determin
deduc
phenotyp
within
total
process
time
h
receiv
blood
sampl
valid
show
concord
rate
deduc
standard
serolog
phenotyp
summaryconclus
test
allow
accur
determin
deduc
phenotyp
antigen
due
simpl
handl
assay
oper
blood
bank
staff
member
propos
assay
offer
potenti
develop
other
relev
snp
panel
immunohematolog
also
new
applic
test
infecti
diseas
near
futur
h
j
c
lejon
f
ml
j
interregional
blood
transfus
src
ltd
bern
switzerland
laboratori
medicin
clinic
immunolog
transfus
medicin
offic
medic
servic
region
skane
divis
hematolog
transfus
medicin
dept
laboratori
medicin
lund
univers
lund
sweden
background
rare
bombay
oh
hw
phenotyp
partial
function
enzym
encod
two
highli
homolog
gene
h
se
enzym
encod
crucial
synthesi
h
antigen
red
blood
cell
rbc
precursor
process
form
either
b
antigen
enzym
encod
respons
synthesi
h
antigen
bodi
fluid
saliva
plasma
secretor
phenotyp
bombay
individu
neither
express
abh
antigen
rbc
secret
h
substanc
saliva
due
inact
allel
respect
phenotyp
typic
display
weaken
h
antigen
express
either
result
variant
allel
diminish
enzym
activ
secretor
aim
two
sampl
proband
caucasian
origin
investig
due
presenc
plasma
three
sampl
proband
analys
discrep
abo
blood
group
type
method
rbc
type
antibodi
identif
perform
use
standard
serolog
test
biorad
cressier
switzerland
tube
test
flow
cytometr
analysi
monoclon
antibodi
h
b
antigen
also
perform
genom
dna
isol
whole
blood
detect
common
abo
allel
perform
sequenc
abo
analys
use
publish
primer
secretor
phenotyp
either
determin
serolog
detect
snp
sampl
parent
proband
analys
confirm
result
proband
detect
b
h
antigen
serolog
flow
cytometri
plasma
proband
contain
strong
react
iat
compat
oh
rbc
proband
genotyp
abo
proband
abo
dna
sequenc
reveal
proband
homozyg
wherea
proband
show
compound
heterozygos
novel
mutat
sampl
parent
proband
show
new
allel
inherit
group
father
proband
show
reduc
express
antigen
neg
weakli
posit
abo
genotyp
predict
phenotyp
detect
serum
proband
flow
cytometr
analysi
proband
rbc
demonstr
ah
express
monoclon
nonreact
monoclon
serum
proband
show
strong
serum
proband
antibodi
neg
sequenc
reveal
homozygos
proband
proband
heterozyg
novel
mutat
proband
heterozyg
two
novel
suggest
proband
secretor
wherea
proband
summaryconclus
five
novel
mutat
gene
identifi
result
bombay
phenotyp
five
unrel
individu
base
serolog
data
five
mutat
appar
abolish
diminish
fucosyltransferas
activ
em
wagner
c
c
group
serolog
transfus
medicin
medic
univers
graz
austria
biochemistri
technic
univers
graz
graz
austria
background
two
relat
blood
donor
aberr
abo
blood
group
phenotyp
show
promin
mutat
code
sequenc
abo
gene
abo
mut
aim
defin
hereditari
charact
evalu
associ
famili
studi
conduct
method
serolog
abo
type
famili
member
perform
studi
rbc
use
monoclon
sequenc
abo
gene
carri
select
sampl
famili
member
screen
identifi
delet
pcr
abo
specif
gene
transcript
amplifi
clone
mammalian
express
vector
transform
e
coli
clone
differ
sampl
cdna
investig
sequenc
analysi
hela
cell
use
recipi
dna
transfect
experi
plasmid
dna
contain
mutat
specif
transcript
variant
transfect
harvest
analyz
antigen
express
flow
cytometri
method
result
sequenc
analysi
reveal
novel
abo
allel
delet
basepair
bp
exon
continu
delet
bp
intron
investig
famili
member
show
mutat
abo
genefamili
member
genotyp
abo
oabo
like
mut
indic
abo
blood
group
antigen
type
reactiv
present
sera
weak
agglutin
lack
isoagglutinin
found
revers
type
two
individu
carri
mutat
abo
allel
elut
studi
identifi
weak
express
rbc
contrast
eluat
prepar
rbc
individu
exhibit
specif
expos
clone
cdna
indic
least
four
differ
transcript
variant
gener
altern
splice
cdna
clone
four
differ
individu
reveal
mutat
abo
transcript
variant
show
delet
exon
andor
retent
nucleotid
intron
interestingli
cdna
clone
one
sampl
genotyp
abo
mut
show
abo
transcript
relat
wild
type
abo
allel
hela
cell
transfect
mutant
abo
cdna
neg
express
summaryconclus
sever
member
austrian
famili
carri
novel
abo
allel
variant
caus
defect
mrna
splice
realiz
retent
intron
sequenc
mutat
abo
gene
transcript
sinc
adsorpt
elut
studi
differ
famili
member
rbc
show
divers
result
concern
express
function
mutat
abo
gene
remain
unclear
transfect
hela
cell
mutat
abo
cdna
result
posit
cell
howev
one
cdna
clone
recombin
individu
encod
abo
b
abo
mut
sequenc
may
result
format
function
abo
allel
transcript
restor
abo
transferas
activ
q
j
z
w
l
w
blood
center
shenzhen
china
institut
transfus
medicin
shenzhen
blood
center
matern
child
health
hospit
shenzhen
china
background
abo
blood
type
complic
express
regul
mechan
although
abo
variat
detect
region
explain
weak
express
ab
group
antigen
molecular
mechan
underli
subgroup
still
complet
understood
addit
mani
factor
influenc
synthesi
activ
result
glycosyltransferas
exampl
usag
altern
first
exon
promot
enhanc
statu
repressor
transcript
well
methyl
statu
promot
report
loss
antigen
express
group
b
associ
cancer
caus
methyl
abo
gene
aim
base
identifi
abo
blood
group
serolog
genet
background
rare
b
weak
subgroup
invest
level
cpg
methyl
promot
abo
gene
correl
abh
antigen
express
studi
epigenet
may
partli
reveal
abo
gene
express
mechan
method
total
unrel
individu
includ
weak
phenotyp
b
weak
phenotyp
studi
paper
normal
b
antigen
express
sampl
randomli
chosen
control
sampl
detect
abo
blood
group
standard
serum
techniqu
seven
abo
exon
five
intron
promot
plu
includ
factornuclear
factor
bind
enhanc
abo
transcript
level
measur
revers
level
methyl
cpg
island
abo
gene
promot
analyz
bisulfit
sequenc
cloningpcr
amplif
perform
genom
dna
perform
bisulfit
use
follow
primer
sequenc
ttgttgggtgtattttgtatttt
pcr
product
dilut
time
use
templat
second
round
amplif
posit
clone
sampl
randomli
select
directli
sequenc
result
serolog
characterist
sampl
show
b
antigen
obvious
decreas
sampl
includ
ay
aelb
n
awb
n
bel
abx
abw
n
bw
n
phenotyp
genotyp
n
n
n
n
respect
mutat
code
sequenc
splice
receptor
sitesth
nucleotid
characterist
consist
common
allel
type
abnorm
identifi
promot
enhanc
regulatori
sequenc
region
sampl
except
sampl
ay
phenotyp
enhanc
polymorph
haploid
sequenc
four
repeat
g
posit
first
repeat
integr
cdna
transcript
abo
gene
obtain
new
splice
isoform
cpg
island
methyl
site
abo
gene
promot
region
analyz
compar
control
group
differ
methyl
level
cpg
site
abo
gene
promot
region
appear
sampl
c
residu
sampl
partial
methyl
summaryconclus
methyl
statu
cpg
island
abo
gene
promot
region
may
caus
weak
express
b
antigen
j
c
q
q
transfus
laboratori
medicin
shanghai
children
medic
center
shanghai
jiaotong
univers
school
medicin
shanghai
china
background
abo
blood
group
system
highli
import
clinic
transfus
transplant
medicin
lot
weak
express
abo
phenotyp
discov
caus
singl
nucleotid
polymorph
snp
also
relat
hybrid
format
common
allel
mutat
untransl
region
utr
indic
one
four
domain
enhanc
minisatellit
approxim
kbp
upstream
translat
start
codon
utr
abo
gene
aim
studi
aim
investig
molecular
basi
abo
gene
patient
serolog
abo
blood
group
discrep
method
patient
girl
enrol
shanghai
children
medic
center
serolog
blood
group
identif
coomb
test
antibodi
screen
detect
dg
gel
confirm
card
neutral
card
coomb
card
compact
analyz
diagnost
grifol
sa
enhanc
promot
exon
adjac
intron
region
abo
gene
amplifi
use
polymeras
chain
reaction
pcr
method
pcr
product
directli
sequenc
identifi
gene
mutat
result
patient
red
blood
cell
show
weak
agglutin
agglutin
patient
serum
show
strong
agglutin
cell
b
cell
agglutin
cell
direct
antiglobulin
test
dat
indirect
antiglobulin
test
iat
antibodi
screen
neg
abo
gene
sequenc
result
show
four
bp
short
tandem
repeat
unit
enhanc
region
bp
three
normal
allel
characterist
allel
reveal
addit
one
variat
exon
two
variat
exon
delet
one
variat
exon
g
variat
exon
abo
gene
identifi
compar
refer
sequenc
allel
summaryconclus
base
blood
group
antigen
gene
mutat
databas
patient
identifi
reason
weak
express
four
bp
tandem
repeat
unit
enhanc
region
novel
variat
enhanc
glycosyltransferas
gene
may
caus
weak
phenotyp
js
k
g
refer
laboratori
heartland
blood
center
part
versiti
aurora
il
refer
laboratori
blood
center
wisconsin
part
versiti
research
institut
milwauke
wi
unit
state
background
matern
cord
blood
sampl
refer
laboratori
investig
group
ab
obstetr
patient
deliveri
appar
group
neonat
aim
resolv
abo
inherit
discrep
use
genom
dna
sequenc
strategi
abo
gene
method
matern
neonat
red
cell
phenotyp
use
sever
exampl
commerci
b
neonat
red
cell
incub
commerci
b
min
room
temperatur
matern
plasma
test
abo
isoagglutinin
test
omit
neonat
sampl
abo
exon
polymeras
chain
reaction
pcr
genom
dna
sequenc
sanger
dideoxi
method
use
bigdy
termin
cycl
sequenc
kit
complementari
primer
result
align
abo
result
matern
rbc
dat
neg
igg
strongli
agglutin
immedi
spin
commerci
antisera
evid
matern
plasma
neonat
red
cell
dat
neg
igg
nonreact
reagent
b
immedi
spin
weakli
reactiv
min
room
temperatur
incub
microscop
mix
field
reactiv
observ
follow
incub
cord
red
cell
indic
probabl
contamin
sampl
matern
red
cell
genom
dna
matern
neonat
blood
use
sequenc
abo
due
discord
serolog
find
allel
identifi
exon
neonat
repres
common
nonfunct
group
allel
absent
matern
dna
therefor
denot
patern
allel
remain
allel
contain
singl
nucleotid
polymorph
snp
allel
close
relat
allel
repres
addit
snp
allel
also
identifi
within
matern
sampl
summaryconclus
allel
report
normal
express
antigen
howev
snp
missens
mutat
previous
report
therefor
repres
novel
group
b
allel
observ
group
allel
novel
mutat
unknown
effect
b
antigen
express
red
cell
may
show
weak
mix
field
b
antigen
express
similar
antigen
express
case
suggest
strong
express
b
antigen
possibl
express
may
weak
birth
therefor
observ
group
type
neonat
consist
combin
effect
missens
mutat
addit
fact
abo
antigen
well
develop
birth
absenc
matern
patient
plasma
indic
product
b
isoagglutinin
expect
individu
possess
novel
allel
k
r
n
develop
japanes
red
cross
central
blood
institut
tokyo
group
laboratori
japanes
red
cross
hokkaido
block
blood
center
sapporo
group
laboratori
japanes
red
cross
tohoku
block
blood
center
sendai
group
laboratori
japanes
red
cross
block
blood
center
tokyo
group
laboratori
japanes
red
cross
block
blood
center
higashimatsuyama
group
laboratori
japanes
red
cross
block
blood
center
seto
group
laboratori
japanes
red
cross
kinki
block
blood
center
osaka
group
laboratori
japanes
red
cross
block
blood
center
hiroshima
group
laboratori
japanes
red
cross
kyushu
block
blood
center
kurum
japan
background
bm
phenotyp
frequent
abo
variant
japanes
popul
b
antigen
bm
red
blood
cell
detect
adsorpt
elut
test
plasma
activ
usual
detect
half
less
level
compar
common
b
recent
b
allel
lack
erythroid
transcript
enhanc
element
intron
abo
gene
identifi
individu
bm
phenotyp
could
explain
uniqu
serolog
properti
bm
bm
allel
kb
delet
includ
element
bind
site
mutat
element
bmgaga
g
identifi
aim
investig
occurr
distribut
bm
allel
bmgaga
within
bm
subgroup
japanes
popul
method
japanes
red
cross
societi
eight
blood
center
test
blood
sampl
donor
throughout
japan
collect
blood
sampl
bm
individu
autom
blood
group
system
beckman
coulter
follow
standard
tube
test
genom
dna
extract
whole
blood
allel
type
polymeras
chain
reaction
pcr
specif
primer
ssp
type
neg
nucleotid
sequenc
perform
nucleotid
sequenc
genbank
access
use
refer
result
dna
analysi
reveal
individu
allel
three
individu
neg
result
screen
nucleotid
sequenc
reveal
one
individu
allel
two
individu
bmgaga
allel
one
individu
secretor
summaryconclus
result
clearli
demonstr
predomin
allel
account
bm
allel
japanes
individu
bm
phenotyp
allel
may
inherit
long
time
period
spread
japanes
popul
contrast
bmgaga
may
gener
recent
event
sporad
popul
wide
distribut
allel
type
convent
method
w
h
j
r
v
r
r
z
brigham
women
hospit
medic
school
boston
fisher
scientif
south
san
francisco
unit
state
background
abo
import
blood
group
system
transfus
medicin
b
immunogen
blood
group
antigen
abo
compat
donor
recipi
critic
transfus
success
abo
type
must
perform
everi
singl
transfus
two
sampl
collect
differ
time
laboratori
typic
use
serolog
method
perform
abo
type
howev
serolog
signific
limit
includ
recent
transfus
patient
may
exhibit
mix
field
agglutin
wherein
patient
recent
donor
antigen
detect
ii
forward
revers
type
must
perform
may
yield
discord
result
limit
problemat
phenotyp
involv
weakli
express
antigen
laboratori
overcom
drawback
combin
genotyp
solut
ssp
sequenc
etc
method
requir
interpret
subject
matter
expert
aim
abo
variant
caus
polymorph
snp
abo
molecular
type
current
perform
labor
intens
techniqu
method
util
post
pcr
analysi
step
sequenc
base
type
sbt
sbt
requir
substanti
financi
invest
long
turnaround
time
extens
technic
expertis
aim
studi
evalu
altern
abo
genotyp
solut
recent
introduc
thermo
fisher
scientif
method
thermo
fisher
scientif
solut
base
pcr
technolog
develop
year
ago
genotyp
complex
human
leukocyt
antigen
hla
system
abo
analyz
reaction
identifi
multipl
relev
snp
locat
within
abo
gene
evalu
solut
analyz
archiv
dna
sampl
includ
blood
blank
sampl
serotyp
fail
produc
discord
result
sampl
deceas
solid
organ
donor
result
genotyp
result
gener
concord
type
obtain
tradit
methodolog
two
case
serolog
could
nt
provid
conclus
result
type
reflex
lectin
test
sbt
overcom
major
challeng
molecular
type
provid
robust
autom
approach
increas
laboratori
product
reduc
time
less
min
oper
intervent
reagent
softwar
fulli
autom
analysi
deliv
genotyp
predict
phenotyp
result
approxim
min
summaryconclusionsw
conclud
provid
simpl
effect
robust
method
abo
type
includ
accur
subgroup
abstract
withdrawn
n
n
p
p
p
transfus
scienc
depart
medic
technolog
faculti
associ
medic
scienc
chiang
mai
univers
bank
section
maharaj
nakorn
chiang
mai
hospit
faculti
medicin
chiang
mai
univers
chiang
mai
thailand
background
b
allel
encod
transfer
sugar
h
antigen
produc
b
antigen
b
allel
locat
abo
gene
consist
code
exon
polymorph
b
allel
mostli
found
exon
caus
decreas
activ
specif
transferas
enzym
lead
b
subgroup
abo
type
serolog
test
perform
use
either
tube
test
column
agglutin
test
cat
basic
subgroup
identifi
observ
agglutin
mfa
red
cell
suspens
forward
group
bweak
weak
agglutin
observ
eg
w
advanc
molecular
technolog
implement
abo
genotyp
use
confirm
test
eight
differ
allel
report
bweak
subgroup
respect
accord
isbt
blood
group
allel
tabl
mutat
report
caucasian
asian
popul
howev
report
thai
popul
first
time
describ
mutat
posit
found
suspect
b
subgroup
within
thai
blood
donor
aim
identifi
nucleotid
sequenc
b
allel
suspect
b
subgroup
thai
blood
donor
method
routin
abo
type
use
cat
donor
blood
sampl
mfa
posit
diaclon
abod
revers
group
card
laboratori
switzerland
collect
b
allel
analysi
prepar
genom
dna
polymeras
chain
reaction
pcr
perform
use
primer
specif
exon
abo
gene
pcr
product
fraction
agaros
gel
gel
purifi
sanger
sequenc
carri
bio
basic
canada
inc
markham
canada
consensu
sequenc
analyz
mutat
posit
compar
isbt
blood
group
allel
tabl
result
total
unrel
donor
observ
red
blood
cell
agglutin
sampl
suppos
phenotyp
show
weak
b
express
b
allel
analysi
exon
locat
nucleotid
nt
differ
allel
detect
one
donor
carri
heterozyg
abo
c
allel
one
carri
abo
allel
one
carri
novel
g
variant
four
donor
show
abo
allel
summaryconclus
cat
sensit
mfa
detect
howev
observ
mfa
necessarili
indic
subgroup
direct
sequenc
prove
abo
bw
allel
encod
weak
b
antigen
express
includ
mfa
studi
found
novel
variant
b
allel
g
amino
acid
substitut
phenylalanin
f
leucin
l
posit
enzym
investig
need
determin
effect
amino
acid
chang
activ
transferas
enzym
moreov
whole
abo
gene
sequenc
need
confirm
new
variant
well
donor
sampl
show
weak
b
antigen
express
cat
assay
indic
mutat
exon
abstract
withdrawn
q
k
w
transfus
medicin
nih
bethesda
unit
state
faculti
addi
ababa
univers
addi
ababa
ethiopia
drug
administr
wheaton
unit
state
background
human
atyp
chemokin
receptor
gene
encod
glycoprotein
express
duffi
blood
group
antigen
fy
duffi
protein
act
receptor
distinct
cytokin
malaria
parasit
plasmodium
vivax
plasmodium
knowlesi
studi
systemat
analyz
gene
haplotyp
level
long
rang
haplotyp
confirm
malaria
endem
area
popul
gambela
endogen
southwestern
region
ethiopia
expos
malaria
mani
gener
aim
aim
identifi
long
rang
allel
confirm
haplotyp
variat
gene
possibl
includ
regulatori
element
without
ambigu
autochthon
popul
malaria
endem
area
method
collect
blood
sampl
healthi
volunt
ethiopia
southwestern
low
altitud
tropic
region
assay
devis
amplifi
gene
singl
amplicon
determin
genom
sequenc
haplotyp
resolv
nucleotid
cover
gene
flank
region
necessari
pcr
nucleotid
sequenc
length
polymorph
analysi
appli
result
among
chromosom
analyz
allel
confirm
without
ambigu
allel
carri
snp
found
common
fy
b
phenotyp
howev
allel
also
compat
clinic
relev
fy
allel
duffi
protein
neg
defin
gata
box
mutat
c
allel
repres
fy
allel
fy
b
fy
allel
fy
bw
phenotyp
respect
among
nucleotid
sequenc
found
singl
nucleotid
polymorph
snp
snp
novel
snp
occur
exon
region
region
intron
snp
ethiopian
sampl
substitut
remain
polymorph
site
follow
equilibrium
snp
c
indic
allel
detect
summaryconclus
describ
haplotyp
gene
autochthon
popul
found
distinct
allel
high
frequenc
fy
allel
studi
similar
studi
conduct
western
central
african
region
gambia
mozambiqu
long
rang
allel
determin
without
ambigu
use
templat
phase
analyz
next
gener
sequenc
data
thu
enhanc
reliabl
clinic
diagnost
g
j
c
et
innov
de
et
de
cellul
souch
canada
background
molecular
analys
slowli
implement
transfus
medicin
two
decad
ago
knowledg
identifi
gene
involv
blood
group
progress
technolog
permit
perform
analys
duffi
blood
group
isbt
although
simpl
five
antigen
gene
present
sever
genet
variant
fyafyb
polymorph
report
sever
group
variant
particular
specif
popul
exampl
fy
c
preval
african
descent
individu
encod
fy
phenotyp
caucasian
fy
x
often
observ
two
variant
respons
fyx
phenotyp
accur
fy
bw
fy
fy
polymorph
alon
describ
sever
sampl
without
impact
antigen
express
sinc
predict
occur
second
domain
protein
aim
first
blood
sampl
refer
immunohematolog
refer
laboratori
irl
weak
fyb
express
three
addit
sampl
later
found
similar
result
method
phenotyp
repeat
twice
two
differ
sourc
darc
fy
sequenc
perform
clone
done
confirm
allel
heterozyg
polymorph
ci
tran
result
fyb
express
weaker
posit
control
test
tube
salin
iat
sequenc
analys
show
presenc
polymorph
heterozyg
form
normal
polymorph
posit
polymorph
associ
weak
phenotyp
isbt
websit
allel
clone
confirm
presenc
ci
fyb
antigen
reagentssera
avail
test
summaryconclus
human
polyclon
reagent
pool
human
sera
use
differ
group
past
similar
use
four
case
describ
three
differ
lot
number
howev
result
show
weaker
reaction
compar
control
differ
compar
previou
public
might
caus
fact
sera
differ
immun
donor
use
prepar
differ
reagent
lot
although
fyb
weakli
express
none
four
case
report
develop
j
g
l
c
nation
de
pour
le
group
sanguin
institut
nation
de
la
transfus
sanguin
pari
du
sang
lill
dexcel
pari
diderot
pari
franc
background
duffi
fy
system
includ
three
major
antigensfya
fyb
molecular
basi
fyafyb
polymorph
correspond
g
snp
exon
fy
gene
darc
duffi
protein
found
red
blood
cell
rbc
tissu
fy
type
frequent
encount
peopl
african
origin
due
c
mutat
promot
fy
b
allel
fy
mutat
abolish
express
duffi
protein
rbc
much
rarer
mutat
open
read
frame
sequenc
missens
nonsens
insert
delet
frameshift
may
abolish
express
tissu
report
either
fy
n
fy
b
n
background
peopl
homozyg
second
kind
mutat
mostli
discov
alloimmun
whole
fy
protein
final
weaken
fy
variant
common
correspond
weaken
fyb
antigen
call
fyx
phenotyp
fy
fy
x
allel
difficult
detect
reagent
aim
patient
fy
phenotyp
origin
algeria
north
africa
subject
serolog
studi
laboratori
alloimmun
occur
transfus
recent
plasma
current
laboratori
techniqu
studi
fy
gene
perform
method
rbc
antibodi
screeningidentificationtitr
carri
indirect
antiglobulin
test
nativ
rbc
fy
genotyp
perform
beadchip
hea
immucor
fy
sequenc
carri
genom
dna
result
serolog
studi
show
presenc
confirm
high
potenc
titer
fy
ab
rbc
fy
rbc
fy
genotyp
antibodi
fy
rbc
african
origin
n
genotyp
show
homozyg
fy
b
allel
c
mutat
fy
sequenc
confirm
absenc
mutat
gene
promot
presenc
homozyg
state
novel
fy
b
allel
show
delet
one
nucleotid
posit
exon
delet
predict
caus
frameshift
gener
prematur
stop
codon
posit
summaryconclus
report
case
patient
north
africa
develop
potent
initi
discov
year
ago
abl
strongli
agglutin
rbc
weaken
express
due
african
origin
molecular
studi
conduct
far
assumpt
would
fy
fy
fy
sequenc
reveal
homozyg
delet
one
nucleotid
fy
b
allel
suppos
abolish
express
duffi
protein
rbc
tissu
suggest
new
allel
name
fy
subject
agreement
isbt
work
parti
red
cell
immunogenet
blood
group
terminolog
case
similar
except
report
literatur
complet
absenc
duffi
protein
expos
sever
immun
transfus
liu
liu
r
zhang
l
shi
f
zhao
jiangsu
provinc
blood
center
nanj
china
background
vel
one
difficult
blood
type
suppli
mani
countri
littl
studi
data
vel
blood
group
china
present
team
report
frequenc
allel
han
popul
nanj
china
significantli
lower
countri
report
perform
detail
genet
analysi
vel
blood
group
xinjiang
area
china
demonstr
strong
region
ethnic
characterist
aim
molecular
screen
blood
donor
give
detail
genet
analysi
vel
blood
group
xinjiang
area
china
method
two
pair
primer
respect
specif
name
p
allel
name
design
genom
dna
healthi
blood
donor
randomli
select
yili
blood
center
xinjiang
provinc
combin
pool
four
sampl
dna
pool
amplifi
sampl
posit
pool
individu
amplifi
p
sanger
sequenc
perform
verifi
genotyp
one
mutat
result
identifi
individu
heterozyg
allel
blood
donor
han
popul
ethnic
minor
seven
uygur
total
uygur
donor
four
kazakh
total
kazakh
donor
two
han
total
han
donor
one
mongolian
total
mongolian
say
allel
frequenc
among
donor
test
xinjiang
area
china
frequenc
allel
han
popul
xinjiang
significantli
higher
han
popul
nanj
allel
frequenc
among
uygur
kazakh
mongolian
respect
summaryconclus
allel
frequenc
xinjiang
area
significantli
higher
nanj
han
popul
xinjiang
nanj
quit
differ
allel
frequenc
allel
frequenc
differ
ethnic
minor
xinjiang
area
also
show
much
differ
togeth
distribut
vel
blood
group
show
strong
region
ethnic
characterist
c
j
c
e
b
c
le
van
nation
de
pour
le
group
sanguin
institut
nation
de
la
transfus
sanguin
pari
diderot
dexcel
pari
marseil
cnr
ef
ade
biologi
de
group
sanguin
du
sang
paca
cors
marseil
inserm
pari
diderot
institut
nation
de
la
transfus
sanguin
imagin
pari
descart
pari
franc
background
cromer
blood
group
system
consist
antigen
carri
glycoprotein
daf
antigen
report
date
cromer
antigen
absent
except
inab
phenotyp
daf
contribut
regul
complement
system
red
cell
surfac
except
one
allel
molecular
background
cromer
antigen
correspond
singl
nucleotid
mutat
gene
consensu
sequenc
aim
describ
novel
antigen
cromer
blood
group
system
method
blood
sampl
refer
laboratori
investig
antibodi
antibodi
identif
iat
perform
nativ
diagast
sigma
rbc
genom
dna
extract
peripher
blood
cell
exom
captur
carri
genom
dna
recommend
manufactur
use
sureselect
exon
kit
agil
technolog
sequenc
data
analyz
softwar
packag
polyweb
institut
imagin
pari
result
proband
femal
patient
french
corsican
origin
island
mediterranean
sea
group
one
pregnanc
posit
inconclus
antibodi
identif
hospit
anemia
sampl
sent
laboratori
investig
occur
transfus
rbc
unit
antibodi
react
nativ
reagent
rbc
neg
autocontrol
specif
could
assess
despit
workup
probabl
htla
antibodi
conclud
new
blood
sampl
refer
anemia
context
serolog
investig
remain
inconclus
decid
extract
dna
sampl
proband
son
serolog
incompat
perform
exom
sequenc
reveal
proband
presenc
homozyg
mutat
exon
gene
predict
caus
amino
acid
chang
son
found
heterozyg
mutat
mutat
report
date
previou
sequenc
project
eg
genom
cromer
specif
antibodi
confirm
find
reactiv
patient
eluat
singl
sourc
rbc
happen
becom
avail
discov
inab
phenotyp
patient
crom
genotyp
summaryconclus
next
gener
sequenc
approach
allow
us
indirectli
resolv
complex
challeng
serolog
case
character
molecular
basi
novel
antigen
cromer
blood
group
system
exom
sequenc
method
made
us
abl
find
novel
allel
also
importantli
identifi
specif
patient
antibodi
provid
possibl
transfus
strategi
suggest
novel
allel
provision
name
crom
new
antigen
call
cor
corsican
origin
patient
subject
formal
agreement
isbt
work
parti
red
cell
immunogenet
blood
group
terminolog
c
c
c
dexcel
pari
diderot
nation
de
pour
le
group
sanguin
institut
nation
de
la
transfus
sanguin
pari
franc
background
kidd
blood
group
system
compris
three
antigen
jka
jkb
molecular
basi
jkajkb
polymorph
correspond
mutat
jk
gene
exon
g
besid
jkb
antigen
associ
synonym
mutat
exon
g
antigen
absent
rare
jk
phenotyp
also
known
jknull
sever
molecular
background
report
jknull
either
jk
jk
allel
basi
homozyg
compound
heterozyg
inactiv
mutat
aim
report
serolog
molecular
investig
three
unrel
jk
patient
method
blood
sampl
refer
laboratori
rbc
antibodi
investig
confirm
rare
jk
phenotyp
antibodi
identif
iat
perform
nativ
diagast
sigma
rbc
kidd
phenotyp
determin
standard
hemagglutin
techniqu
two
commerci
reagent
monoclon
genom
dna
sequenc
jk
gene
consensu
sequenc
perform
previous
describ
horn
et
al
transfus
result
first
proband
femal
patient
bosnia
blood
sampl
refer
confirm
jknull
phenotyp
studi
antibodi
patient
serum
react
nativ
reagent
rbc
reactiv
observ
jk
rbc
consist
alloimmun
second
case
femal
patient
refer
confirm
jk
rare
type
suspicion
reactiv
antibodi
conclud
laboratori
third
individu
woman
subject
antibodi
screen
prior
gastric
surgeri
presenc
confirm
well
allogen
adsorpt
homolog
rbc
genom
dna
sequenc
reveal
first
patient
presenc
jk
allel
basi
mutat
exon
posit
expect
caus
amino
acid
chang
second
proband
mutat
found
exon
homozyg
state
jk
sequenc
reveal
last
patient
presenc
insert
one
nucleotid
exon
posit
homozyg
state
respons
frameshift
prematur
stop
codon
two
last
mutat
found
jk
allel
basi
associ
g
synonym
chang
summaryconclus
character
three
novel
silent
jk
allel
jk
jk
jk
novel
mutat
predict
deleteri
accord
respect
score
polyphen
sift
tool
furthermor
mutat
report
numer
genom
sequenc
project
observ
european
african
popul
second
mutat
describ
exac
project
found
european
howev
insert
never
report
date
jk
allel
recent
report
team
vox
sang
jk
second
case
silent
jk
allel
caus
nucleotid
insert
mechan
n
h
k
k
r
k
n
k
block
blood
center
japanes
red
cross
blood
institut
japanes
red
cross
tokyo
japan
background
low
incid
antigen
sta
mn
system
commonli
associ
variou
hybrid
molecul
glycophorin
b
gpb
glycophorin
gpa
gp
hybrid
n
antigen
known
gpsch
predomin
st
individu
st
individu
gp
hybrid
trypsin
resist
antigen
found
sta
resist
antigen
encod
gyp
gyp
zan
gyp
gyp
mar
gyp
gyp
ebh
aim
analyz
genom
dna
isol
japanes
st
individu
confirm
novel
allel
encod
sta
specif
glycophorin
antigen
method
blood
sampl
deriv
blood
donor
kanto
koshinetsu
block
blood
center
written
inform
consent
obtain
blood
donor
blood
sampl
screen
monoclon
bromelain
treat
rbc
perform
autom
blood
group
analyz
beckman
coulter
posit
reaction
observ
sta
n
antigen
examin
tube
method
use
untreat
rbc
hous
hous
hous
ortho
clinic
diagnost
japan
posit
reaction
rbc
also
confirm
tube
method
genom
dna
sampl
st
trypsin
resist
antigen
extract
white
blood
cell
peripher
blood
identifi
molecular
mechan
sta
antigen
extracellular
domain
exon
gyp
amplifi
pcr
pcr
product
subsequ
sequenc
result
confirm
novel
allel
sta
gene
antigen
one
new
molecular
mechan
bp
delet
includ
gt
motif
donor
splice
site
end
intron
gyp
donor
splice
site
essenti
mrna
process
exon
splice
exon
directli
ligat
exon
exon
skip
critic
event
sta
format
also
found
novel
gyp
hybrid
gene
contain
pseudoexon
gyp
b
proxim
breakpoint
exon
proxim
breakpoint
intron
anoth
variant
rare
hybrid
format
compris
gyp
e
gyp
identifi
proxim
breakpoint
gp
variant
intron
confirm
sequenc
data
gp
variant
match
refer
sequenc
gyp
e
intron
breakpoint
pseudoexon
gyp
e
splice
defect
donor
splice
site
exon
gyp
e
directli
ligat
exon
gyp
proxim
breakpoint
identifi
yet
sinc
gyp
e
highli
sequenc
similar
gyp
summaryconclus
analyz
japanes
individu
identifi
individu
resist
sta
antigen
base
nucleotid
sequenc
st
individu
reveal
novel
splice
site
mutat
bp
delet
includ
donor
splice
site
end
intron
gyp
five
individu
gyp
hybrid
allel
nine
novel
gp
variant
remain
individu
still
unknown
c
g
c
n
c
b
j
b
diagnost
research
develop
blood
transfus
servic
zurich
src
switzerland
research
institut
versiti
inc
milwauke
wisconsin
unit
state
servic
vienna
lower
austria
burgenland
austrian
red
cross
vienna
austria
red
cross
blood
donat
servic
west
hagen
germani
laboratori
medicin
lund
univers
hematolog
transfus
medicin
lund
sweden
clinic
molecular
biolog
christian
albrecht
univers
kiel
kiel
germani
offic
blood
transfus
servic
zurich
src
switzerland
background
u
antigen
origin
describ
character
absent
african
american
wiener
jama
associ
mn
blood
group
system
concurr
phenotyp
becam
evid
greenwalt
pna
later
postul
caus
homozyg
gypb
delet
huang
blood
howev
lack
exact
molecular
definit
delet
prohibit
unequivoc
interrog
parent
haplotyp
aim
studi
aim
exact
molecular
definit
gypb
delet
caus
recess
neg
phenotyp
black
african
ad
classic
mn
genotyp
posit
detect
delet
enabl
definit
gypb
genotyp
method
bioinformat
analysi
publicli
avail
human
genom
data
reveal
sever
hit
two
distinct
kb
one
hit
kb
kb
gypb
delet
identifi
among
black
african
sanger
sequenc
analyt
bridg
delet
predefin
sampl
reveal
delet
exact
molecular
posit
use
design
specif
diagnost
pcr
use
prime
subsequ
valid
genotyp
perform
sampl
known
phenotyp
concomit
neg
gypb
gypb
plu
sampl
coriel
human
genet
cell
repositori
show
kb
delet
result
one
kb
delet
stretch
kb
gypb
start
codon
kb
gype
start
codon
kb
delet
start
kb
gypa
stop
codon
end
kb
gypb
stop
codon
delet
encompass
whole
gypb
gene
involv
highli
paralog
intergen
sequenc
suggest
unequ
causal
molecular
origin
variat
valid
sampl
genotyp
gypb
kb
homozygot
gypb
kb
kb
heterozygot
one
gypb
kb
homozygot
three
heterozyg
gypb
kb
yet
undefin
second
parent
origin
expect
kb
delet
one
coriel
sampl
fact
gypb
kb
kb
heterozyg
display
kb
combin
absenc
gypb
sequenc
rather
uniqu
delet
suggest
kb
delet
observ
one
coriel
sampl
haplotyp
presumpt
gypb
delet
analys
total
gypb
kb
gypb
kb
remain
unresolv
overal
estim
consid
mention
phenotyp
frequenc
black
african
summaryconclus
studi
describ
character
three
causal
gypb
delet
underli
phenotyp
develop
genotyp
assay
detect
individu
thu
assay
perform
simultan
classic
genotyp
rudimentari
express
uvar
allel
allow
unequivoc
result
correct
phenotyp
predict
genotyp
involv
observ
phenotyp
frequenc
heterozyg
involv
gypb
delet
may
expect
black
american
recent
report
molecular
natur
preval
gypb
delet
haplotyp
contribut
reduc
risk
malaria
invas
support
independ
find
leffler
scienc
e
g
g
e
c
r
c
g
bank
princ
wale
hospit
new
south
wale
health
patholog
randwick
red
cross
blood
servic
brisban
south
wale
health
patholog
randwick
new
south
wale
randwick
australia
background
male
kenyan
descent
admit
princ
wale
hospit
sydney
return
africa
continu
treatment
acut
mix
phenotyp
leukaemia
transfus
unit
red
cell
transfer
blood
sampl
refer
australian
red
cross
blood
servic
red
cell
refer
laboratori
brisban
genotyp
phenotyp
possibl
wife
fy
serolog
phenotyp
two
daughter
test
fy
sampl
also
refer
genotyp
aim
elucid
molecular
basi
observ
phenotyp
explain
pattern
inherit
famili
also
discuss
problem
match
blood
type
method
red
cell
phenotyp
base
genotyp
perform
use
standard
procedur
extend
sequenc
perform
massiv
parallel
sequenc
mp
use
trusight
one
tso
sequenc
panel
illumina
copi
number
variat
analysi
perform
compar
normalis
mean
coverag
gypb
exon
refer
valu
measur
gypb
zygos
confirm
tso
result
pcr
amplicon
complet
gypb
gener
sampl
wildtyp
gypb
control
sequenc
use
nexteraxt
kit
illumina
refer
align
sequenc
read
variant
detect
perform
use
clc
genom
workbench
result
phenotyp
result
show
famili
member
homozyg
fy
allel
frequent
african
popul
result
fy
red
cell
phenotyp
also
note
genotyp
show
patient
daughter
homozyg
gypb
null
allel
either
gypb
exon
absent
gypb
exon
absent
patient
wife
carri
one
copi
gypb
null
allel
display
genotyp
pattern
famili
one
copi
wildtyp
gypb
gypb
allel
predict
phenotyp
summaryconclus
patient
fy
phenotyp
aris
mutat
may
transfus
fy
red
cell
current
protocol
extend
genotyp
show
patient
two
daughter
homozyg
variant
gene
mn
blood
group
system
result
phenotyp
precis
boundari
defin
nucleotid
sequenc
chang
occur
await
investig
case
notabl
number
reason
firstli
demonstr
benefit
extend
genotyp
clinic
set
secondli
patient
alloimmunis
red
cell
match
would
difficult
inventori
frozen
phenotyp
limit
seven
unit
australia
one
blood
donor
regist
australian
panel
time
patient
receiv
unit
red
cell
month
australia
evid
alloimmunis
final
problem
support
patient
futur
need
consider
k
c
k
r
n
k
block
blood
center
japanes
red
cross
blood
institut
japanes
red
cross
tokyo
japan
background
mn
blood
group
system
consist
antigen
carri
glycophorin
gpa
glycophorin
b
gpb
hybrid
molecul
compos
portion
gpa
gpb
miltenberg
phenotyp
express
hybrid
glycophorin
molecul
gp
gp
gp
form
genet
recombin
gyp
gyp
b
gpvw
gphut
gpnob
gpjoh
gpdane
encod
gyp
hybrid
gene
gyp
aris
gene
convers
involv
gyp
b
gyp
donor
recipi
respect
gpmur
gphop
gpbun
gphf
gpkip
encod
gyp
hybrid
gene
gphil
gpjl
encod
gyp
hybrid
gene
screen
japanes
donor
use
detect
mi
could
classifi
known
miltenberg
phenotyp
aim
report
novel
gp
glycophorin
hybrid
molecul
predict
encod
gyp
gene
method
genom
dna
isol
whole
blood
cell
deriv
japanes
donor
test
mn
blood
group
system
antigen
rbc
perform
use
standard
serolog
test
polyclon
monoclon
antibodi
immunoblot
analysi
perform
monoclon
antibodi
nucleotid
sequenc
glycophorin
gene
analyz
use
direct
sequenc
result
mn
blood
type
propositu
n
w
test
antibodi
antigen
reveal
posit
mia
mut
mur
hopnob
kip
neg
vw
hil
hop
mini
analysi
patient
red
cell
reveal
fluoresc
intens
antigen
equival
n
respect
fluoresc
intens
n
antigen
lower
n
immunoblot
monoclon
antibodi
mut
mur
n
domain
gpa
show
abnorm
band
approxim
mr
direct
sequenc
demonstr
normal
gyp
normal
gyp
bs
hybrid
gene
although
exact
breakpoint
identifi
confirm
locat
least
upstream
breakpoint
place
replac
gyp
homolog
region
gyp
b
includ
exon
intron
part
pseudoexon
gyp
b
gener
novel
gyp
gene
identifi
hybrid
nucleotid
sequenc
contain
sequenc
motif
previous
shown
requir
express
mia
mur
mut
hopnob
kip
consist
serolog
find
summaryconclus
gpmot
phenotyp
predict
produc
hybrid
gp
protein
caus
dna
insert
gyp
b
gyp
gyp
composit
hybrid
protein
gpb
r
b
n
k
program
faculti
alli
health
scienc
thammasat
univers
pathumtani
thailand
medic
technolog
faculti
pharmaci
univers
santo
toma
manila
philippin
medic
technolog
faculti
alli
health
scienc
thammasat
univers
pathumtani
blood
centr
songkhla
thai
red
cross
societi
songkhla
bank
section
faculti
medicin
chiang
mai
univers
chiang
mai
thailand
background
antigen
mn
system
clinic
import
usual
caus
delay
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
hdfn
difficulti
test
interpret
serolog
techniqu
may
found
case
patient
fetal
risk
hdfn
variou
red
cell
genotyp
establish
predict
phenotyp
solv
serolog
test
limit
aim
studi
aim
determin
gypb
gypb
genotyp
frequenc
lead
predict
phenotyp
estim
alloimmun
risk
among
central
northern
southern
thai
popul
method
altogeth
blood
sampl
thai
blood
donor
includ
sampl
test
indirect
antiglobulin
test
sampl
genotyp
gypb
gypb
allel
use
pcr
primer
addit
allel
frequenc
use
estim
alloimmun
risk
compar
popul
result
phenotyp
genotyp
result
sampl
concord
allel
frequenc
gypb
central
northern
southern
thai
gypb
respect
frequenc
among
central
thai
similar
among
northern
thai
korean
popul
p
significantli
differ
asian
caucasian
african
american
hispan
popul
p
addit
risk
alloimmun
among
southern
thai
higher
among
central
northern
thai
summaryconclus
first
studi
report
predict
phenotyp
estim
alloimmun
risk
among
thai
benefici
prevent
alloimmun
among
donor
patient
l
j
k
ml
medicin
lund
univers
immunolog
transfus
medicin
offic
medic
servic
chemistri
biolog
medic
mass
spectrometri
cebmm
lund
univers
lund
sweden
background
pk
glycosphingolipid
blood
group
system
synthes
util
paraglobosid
lactosylceramid
acceptor
substrat
respect
addit
compat
aspect
molecul
constitut
receptor
microb
toxin
statu
erythrocyt
determin
common
pk
phenotyp
transcript
level
higher
individu
singl
nucleotid
polymorph
snp
region
particularli
correl
statu
interestingli
lu
phenotyp
caus
haploinsuffici
show
decreas
level
erythrocyt
aim
despit
find
molecular
mechan
underli
express
remain
elus
aim
resolv
longstand
question
hypothes
andor
transcript
factor
tf
regul
manner
method
genom
region
surround
examin
site
use
jaspar
http
jaspargeneregnet
databas
electrophoret
assay
emsa
perform
use
nuclear
extract
hel
cell
recombin
supershift
assay
three
two
biotinyl
oligonucleotid
probe
differ
length
synthes
use
emsa
protein
experi
follow
incub
hel
nuclear
extract
complex
immobil
onto
magnet
bead
subject
western
blot
analysi
possibl
interact
candid
tf
detect
protein
bound
probe
queri
string
analysi
http
hel
cell
transfect
sirna
target
transcript
level
target
gene
determin
qpcr
normal
level
gapdh
sirna
without
human
gene
target
serv
posit
neg
control
respect
experi
perform
technic
triplic
statist
analyz
use
result
motif
around
reveal
put
bind
site
sever
hematopoiet
tf
includ
three
display
predict
decreas
bind
energi
score
variant
investig
potenti
transcript
factor
bind
implic
region
emsa
perform
intriguingli
shift
nuclear
extract
note
supershift
neither
detect
western
blot
protein
bound
probe
furthermor
effici
sirna
silenc
affect
transcript
level
instead
protein
experi
probe
identifi
multipl
peptid
correspond
hematopoiet
transcript
factor
mass
spectrometri
find
confirm
western
blot
protein
bound
probe
also
emsa
competit
assay
increas
amount
weaken
shift
band
knockdown
gave
reduct
protein
result
signific
decreas
transcript
summaryconclus
data
indic
regul
therebi
express
pk
blood
group
antigen
implic
transfus
incompat
interact
thu
molecular
mechan
determin
statu
involv
bind
vs
site
l
r
q
n
blood
group
refer
laboratori
nh
blood
transplant
bristol
unit
kingdom
institut
hematolog
blood
transfus
hanoi
viet
nam
background
red
cell
rare
p
phenotyp
lack
pk
p
lke
antigen
carri
carbohydr
residu
red
cell
glycosphingolipid
p
phenotyp
result
homozygos
compound
heterozygos
inactiv
mutat
encod
enzym
respons
convert
lactosylceramid
pk
paraglobosid
individu
p
phenotyp
antibodi
known
agglutin
haemolys
red
cell
except
p
phenotyp
caus
sever
haemolyt
transfus
reaction
also
implic
earli
spontan
abort
women
p
phenotyp
significantli
higher
incid
habitu
abort
aim
present
result
serolog
molecular
investig
case
novel
molecular
background
p
phenotyp
includ
famili
studi
method
sampl
year
old
vietnames
patient
diagnosi
thin
endometrium
histori
five
first
trimest
miscarriag
investig
due
presenc
strong
alloantibodi
react
cell
except
sister
blood
sampl
patient
brother
sister
mother
also
test
serolog
investig
perform
standard
tube
liss
iat
direct
agglutin
techniqu
genom
dna
extract
pcr
amplif
sequenc
carri
exon
gene
result
patient
sister
found
p
phenotyp
strong
present
plasma
sampl
mutual
compat
cell
mother
brother
incompat
sequenc
exon
reveal
famili
member
homozyg
associ
phenotyp
sequenc
exon
reveal
compound
heterozygos
two
differ
delet
p
individu
first
result
correspond
known
null
allel
second
appear
novel
allel
carri
delet
nucleotid
posit
result
frameshift
amino
acid
posit
truncat
amino
acid
fs
compound
heterozygos
delet
allel
predict
result
result
p
phenotyp
brother
mother
reveal
carri
novel
mutat
allel
heterozyg
state
togeth
allel
summaryconclus
identifi
novel
null
allel
found
vietnames
famili
novel
allel
carri
compound
heterozyg
state
known
null
allel
result
p
phenotyp
patient
sister
identifi
plasma
patient
histori
multipl
first
trimest
spontan
abort
known
occur
higher
rate
normal
women
p
phenotyp
ea
e
z
g
us
food
drug
administr
silver
spring
research
institut
milwauke
unit
state
background
patient
carri
rh
blood
group
variant
may
develop
clinic
signific
antibodi
requir
match
red
blood
cell
transfus
avail
serolog
reagent
rh
variant
limit
make
molecular
genotyp
assay
essenti
manag
transfus
mani
patient
howev
develop
molecular
assay
hamper
lack
refer
reagent
rh
variant
need
ensur
qualiti
perform
renew
dna
panel
cover
mani
blood
group
allel
recent
develop
valid
intern
collabor
studi
aim
develop
renew
dna
panel
rh
variant
complement
blood
group
panel
method
immort
line
gener
whole
blood
donor
rhd
rhce
gene
character
use
combin
multiplex
pcr
exon
sequenc
pcr
allel
discrimin
polymeras
chain
fragment
length
polymorph
result
analysi
rhd
rhce
reveal
sampl
carri
variant
allel
either
rhce
rhd
sampl
carri
least
one
follow
rhce
variant
allelesrhc
rhce
rhce
rhce
rhce
rhce
rhce
carri
least
one
follow
rhd
variant
allelesrhd
diva
rhd
rhd
rhd
dhmi
rhd
diiia
rhd
remain
sampl
carri
convent
rhce
allel
ce
ce
ce
along
either
convent
hemizyg
homozyg
rhd
delet
rhd
summaryconclus
comprehens
character
rh
locu
donor
sampl
result
identif
sampl
carri
rh
variant
allel
potenti
interest
includ
member
panel
rh
variant
genotyp
plan
perform
collabor
studi
character
first
rh
variant
panel
continu
screen
addit
rh
variant
includ
panel
keller
j
keller
thoma
horn
nation
molecular
laboratori
american
red
cross
philadelphia
unit
state
background
rh
alloimmun
patient
sickl
cell
diseas
lead
challeng
find
compat
blood
donor
rh
variant
antigen
express
common
individu
african
descent
patient
insuffici
decreas
sickl
hemoglobin
hb
exchang
transfus
hemolyt
transfus
reaction
andor
monocyt
monolay
assay
incompat
report
patient
may
benefit
rh
donor
transfus
rh
allel
match
describ
process
select
blood
donor
base
rhce
rhd
allel
patient
use
tier
system
keller
et
al
transfus
aim
blood
center
routin
use
rbc
genotyp
screen
blood
donor
sinc
donor
screen
sinc
recent
develop
rhce
genotyp
panel
util
multiplex
dideoxynucleotid
extens
analysi
massarray
agena
bioscienc
assay
includ
marker
allow
predict
v
vs
hrb
hr
antigen
also
stem
jal
celo
ceag
donor
chosen
base
rhce
genotyp
result
hemoid
dq
genotyp
panel
agena
bioscienc
result
test
donor
present
method
genom
dna
plate
test
hemoid
dq
use
qiagil
qiagen
donor
predict
hb
neg
neg
hr
neg
test
genotyp
panel
test
rhce
result
donor
test
hemoid
dq
select
addit
rhce
genotyp
predict
hrbvw
due
rhce
allel
predict
homozyg
rhce
donor
test
predict
hr
neg
heterozyg
rhce
cemo
rhce
cear
eighti
donor
test
one
two
copi
rhce
ceti
allel
associ
reagent
seventeen
donor
weaken
v
antigen
express
associ
rhce
cear
allel
small
number
donor
express
low
preval
antigen
stem
jal
nearli
half
donor
test
rhce
homozygot
associ
partial
e
antigen
express
summaryconclus
algorithm
develop
select
subset
donor
test
develop
rhce
genotyp
panel
rh
genotyp
donor
assign
rhce
allel
hrb
hr
v
vs
statu
definit
predict
frequenc
donor
cohort
donor
select
base
rh
variant
low
highlight
difficulti
identifi
donor
approxim
donor
test
candid
american
rare
donor
program
select
donor
base
rhce
marker
rbc
genotyp
panel
hb
statu
pair
custom
genotyp
panel
focus
e
variant
use
identifi
rare
donor
rh
allel
match
rh
alloimmun
patient
de
l
v
transfus
servic
metropolitan
area
bologna
polyclin
transfus
servic
metropolitan
area
bologna
maggior
hospit
bologna
itali
background
character
rhd
variant
essenti
blood
donor
patient
adequ
blood
suppli
appropri
use
immunoglobulin
monoclon
reagent
help
differenti
weak
partial
rhd
rare
identifi
specif
rhd
variant
molecular
techniqu
resolv
major
part
serolog
discrep
diagnos
rhd
variant
risk
immun
aim
evalu
advantag
monoclon
antisera
molecular
method
rhd
variant
investig
defin
diagnost
algorithm
guid
rhd
variant
character
method
rhd
variant
result
sampl
analys
serolog
extend
partial
rhd
type
set
diam
switzerland
advanc
partial
rhd
type
kit
quotient
alba
bioscienc
usa
molecular
weak
cde
daddon
innotrain
germani
bagen
germani
e
idrhdxt
spain
method
retrospect
review
sensit
concord
monoclon
panel
molecular
type
result
evalu
evalu
sampl
overcom
small
number
sampl
indic
rhd
variant
concord
calcul
test
name
specificgener
ratio
number
rhd
variant
specif
result
number
rhd
variant
gener
result
result
overal
extend
partial
rhd
type
set
sensit
rate
rhd
variant
partial
rhd
vs
weak
rhd
specificgener
ratio
partial
rhd
vs
weak
rhd
advanc
partial
rhd
type
kit
higher
sensit
partial
weak
rhd
variant
vs
specificgener
ratio
respect
kit
highest
sensit
rhd
variant
group
weak
rhd
partial
rhd
respect
overal
specificgener
ratio
sensit
specificgener
ratio
idrhdxt
summaryconclus
expect
monoclon
panel
better
perform
identif
rhd
variant
amino
acid
chang
outsid
membran
howev
advanc
partial
rhd
type
kit
higher
concord
molecular
result
good
sensit
weak
type
identif
molecular
type
result
conclus
congruent
serolog
result
case
except
sampl
unknown
yet
identifi
rhd
variant
even
serolog
rhd
variant
confirm
molecular
analysi
earli
phase
serolog
analysi
monoclon
antibodi
panel
allow
direct
follow
molecular
character
especi
identifi
exclud
rhd
variant
weak
type
would
treat
rhd
transfus
immunoglobulin
administr
result
use
defin
diagnost
algorithm
rhd
variant
character
serolog
molecular
method
target
clinic
context
urgent
routin
donor
patient
pregnanc
c
paccapelo
g
spaltro
f
truglio
cosco
v
iemmolo
n
revelli
villa
prati
immunohematholog
refer
laboratori
uoc
centro
trasfusional
fondazion
ircc
cagranda
ospedal
maggior
policlinico
milan
itali
background
rh
antigen
encod
two
highli
homolog
gene
rhd
rhce
antigen
clinic
signific
antigen
rh
blood
group
system
extrem
immunogen
make
one
import
antigen
transfus
medicin
pregnanc
number
rhd
allel
associ
weak
partial
del
phenotyp
identifi
among
european
subject
carri
aberr
rhd
allel
serolog
discrimin
allel
normal
antigen
mistyp
individu
may
potenti
lead
alloimmun
aim
review
rhd
allel
identifi
individu
weak
vsv
hea
kit
refer
lombardi
immunohematolog
refer
laboratori
start
method
genom
dna
isol
whole
blood
use
qiaamp
dna
blood
kit
qiagen
germani
rhd
genotyp
determin
rhd
kit
solut
warren
nj
usa
kit
weak
partial
bagen
germani
gene
cde
gene
weak
germani
result
individu
analyz
patient
blood
donor
rhd
weak
type
identifi
patient
n
donor
n
allel
cumul
other
rhd
allel
caus
weak
phenotyp
risk
alloimmun
rhd
weak
type
patient
n
donor
n
rhd
weak
type
patient
n
donor
n
repres
aberr
rhd
identifi
also
identifi
mani
allel
variant
may
caus
immun
interestingli
rhd
weak
type
caus
del
phenotyp
repres
n
patient
n
donor
n
cohort
rhd
allel
variant
aris
weak
phenotyp
rhd
weak
type
total
n
patient
n
donor
n
rhd
weak
type
total
n
patient
n
donor
n
rhd
weak
type
total
n
patient
n
donor
n
rhd
weak
type
donor
n
rhd
weak
type
total
n
patient
n
donor
dau
cluster
found
n
cohort
rhd
repres
especi
within
african
donor
popul
total
n
patient
n
donor
n
rhd
partial
allel
cumul
concur
n
within
total
popul
rhd
diiia
rhd
diva
rhd
div
rhd
dv
rhd
db
rhd
dvi
rhd
dvii
rhd
dhmi
rhd
dnb
rhd
dfr
summaryconclus
rhd
genotyp
show
rhd
weak
type
frequent
allel
popul
accord
result
frequenc
weak
antigen
european
countri
accord
transfus
clinic
practic
subject
carri
weak
type
risk
alloimmun
patient
popul
repres
n
howev
patient
carri
aberr
rhd
allel
manag
care
transfus
pregnanc
cl
l
b
e
c
paulo
brazil
system
research
institut
san
francisco
unit
state
hemorio
rio
de
janeiro
hemomina
belo
horizont
hemop
recif
system
research
institut
san
francisco
tropic
medicin
univers
paulo
paulo
brazil
york
blood
center
new
york
unit
state
background
rh
system
complex
divers
rhd
rhce
allel
describ
primarili
popul
african
descent
includ
patient
sickl
cell
diseas
scd
africa
europ
america
studi
evalu
rh
variat
scd
patient
racial
divers
popul
well
incid
unexplain
rh
antibodi
incomplet
aim
describ
rh
variat
among
scd
patient
mix
race
unexpect
enrol
recipi
evalu
donor
studi
red
brazil
scd
cohort
method
larg
scd
cohort
establish
six
brazilian
citi
paulo
rio
de
janeiro
recif
belo
horizont
juiz
de
fora
mont
claro
patient
unexplain
rh
antibodi
rbc
type
antigen
posit
patient
correspond
antibodi
identifi
follow
transfus
rhd
rhce
genotyp
target
next
gener
sequenc
ng
use
ion
torrent
platform
result
scd
patient
enrol
includ
mix
race
black
white
unknownoth
time
enrol
alloimmun
unexplain
rh
antibodi
subject
rh
ng
sequenc
identifi
variant
rhd
variant
rhce
frequent
alter
rhd
rhd
n
rhd
n
encod
phenotyp
rhd
dar
n
diiia
n
encod
phenotyp
less
frequent
detect
rhd
allel
includ
rhd
rhd
diva
rhd
rhd
dvii
rhd
rhd
case
rhce
encod
weak
e
rhce
encod
partial
c
e
rhd
ce
encod
partial
c
partial
e
preval
variant
rhce
allel
n
respect
addit
detect
rhce
n
rhce
cear
n
rhce
ceag
n
rhce
ceti
n
rhce
n
rhce
cemo
n
rhce
n
rhce
n
rhce
allel
distribut
homogen
among
differ
center
specif
rhd
variant
allel
differ
throughout
countri
rhd
dar
concentr
northeast
compris
rhd
variant
detect
variant
dau
cluster
common
african
cohort
patient
scd
observ
rio
de
janeiro
mont
claro
one
novel
allel
identifi
rhd
tran
rhd
high
percentag
convent
rhce
ce
encod
convent
c
phenotyp
found
overal
allel
frequenc
highest
frequenc
dce
haplotyp
observ
northeast
frequenc
summaryconclus
rhd
dar
rhd
diiia
rhce
rhce
rhce
ce
preval
rh
allel
encod
variant
antigen
among
scd
patient
divers
brazilian
popul
whose
rbc
type
serolog
e
exhibit
rh
antibodi
specif
contrast
patient
dau
cluster
underrepres
frequenc
dce
haplotyp
higher
brazil
versu
other
differ
like
reflect
signific
popul
admixtur
brazil
may
account
lower
report
alloimmun
rate
signific
antigen
match
patient
g
w
k
j
refer
laboratori
research
institut
versitiblood
center
wisconsin
milwauke
transfus
medicin
nih
clinic
center
bethesda
unit
state
blood
servic
edmonton
edmonton
canada
background
rh
antigen
statu
routin
perform
select
appropri
blood
product
transfus
recipi
provid
rh
immun
globulin
appropri
pregnanc
current
approach
rh
antigen
phenotyp
base
data
origin
inform
peopl
european
ancestri
data
collect
person
african
ancestri
data
begin
collat
ethnic
group
littl
known
rhd
divers
indigen
peopl
northern
canada
repres
distinct
popul
compris
canadian
evalu
rhd
allel
present
among
indigen
peopl
northern
canada
would
valid
phenotyp
reagent
use
determin
transfus
practic
administr
rh
immun
globulin
patient
popul
aim
purpos
studi
character
rhd
allel
present
among
indigen
peopl
northern
canada
method
studi
approv
aurora
research
institut
nwt
canadian
blood
servic
research
ethic
board
pregnant
women
northern
canada
indigen
person
provid
inform
consent
particip
studi
rh
c
e
c
e
phenotyp
collect
manual
test
residu
blood
edta
anticoagul
sampl
use
obtain
genom
dna
sequenc
rhd
exon
sanger
dideoxi
method
use
bigdy
termin
cycl
sequenc
kit
complementari
primer
result
align
use
seqscap
softwar
result
total
sampl
rhd
submit
studi
complet
rhd
exon
sequenc
data
obtain
sampl
rhd
exon
amplifi
rh
sampl
sampl
fail
amplifi
rhd
exon
none
consist
known
hybrid
rhdrhce
allel
exon
flank
intron
nucleotid
polymorph
posit
confirm
copi
rhd
sampl
three
differ
weak
type
allel
observ
one
weak
type
cdecd
weak
type
cdecd
weak
type
cdecd
combin
nucleotid
polymorph
detect
allel
rhd
consensu
rhd
rhd
rhd
rhd
rhd
rhd
rhd
rhd
rhd
summaryconclus
least
allel
present
among
sampl
submit
analysi
rhd
allel
among
indigen
peopl
northern
canada
reflect
weak
type
observ
ethnic
notabl
pauciti
partial
allel
although
fail
exon
amplif
may
indic
hybrid
rhdrhce
allel
addit
intron
nucleotid
polymorph
affect
pcr
amplif
l
k
u
laboratori
servic
south
african
nation
blood
servic
durban
laboratori
servic
south
african
nation
blood
servic
constantia
kloof
south
africa
background
identif
gene
code
red
cell
antigen
use
molecular
genotyp
method
first
introduc
south
african
nation
blood
servic
sanb
late
prior
limit
red
cell
genotyp
data
exist
sanb
blood
donor
studi
first
describ
rh
genet
variabl
base
red
cell
genotyp
amongst
subset
sanb
blood
donor
assist
sourc
antigen
neg
rare
blood
unit
transfus
thu
prevent
case
haemolyt
diseas
newborn
hdn
transfus
reaction
aim
describ
uniqu
genet
variabl
rh
blood
group
system
subset
south
african
blood
donor
method
red
cell
genotyp
randomli
select
donor
perform
use
idcorext
assay
luminex
instrument
januari
august
retrospect
compar
data
analysi
rh
system
complet
valid
red
cell
genotyp
result
indian
colour
donor
exclud
due
inadequ
represent
demograph
inform
serolog
phenotyp
red
cell
genotyp
result
collat
busi
intellig
databas
report
result
donor
male
major
white
donor
n
rh
posit
donor
n
rh
neg
donor
n
amongst
rh
posit
genotyp
distribut
black
b
white
w
donor
follow
rhce
cece
ro
rhce
ce
ce
rhce
ce
ce
rhce
ce
ce
rhce
ce
ce
rhce
ce
ce
rare
rhce
cear
rhce
ce
rhce
ce
rhd
ce
hrb
rh
genotyp
found
ro
black
donor
respect
comparison
rh
neg
genotyp
preval
amongst
white
donor
n
distribut
follow
rhce
ce
ce
rr
rhce
ce
ce
r
r
rhce
cece
r
r
rhce
ce
ce
r
r
rhce
cece
r
r
rh
neg
black
donor
rare
genotyp
rhce
ce
rhd
ce
rr
phenotyp
summaryconclus
due
high
cost
red
cell
genotyp
assay
compar
serolog
data
donor
avail
howev
genotyp
base
molecular
method
critic
overcom
limit
serolog
method
analysi
show
main
rh
genotyp
variabl
white
black
donor
higher
preval
rhce
ce
ce
genotyp
rh
posit
black
donor
rh
neg
genotyp
preval
amongst
white
donor
black
donor
display
r
haplotyp
associ
rhce
cear
associ
clear
associ
rare
blood
type
specif
rh
subgroup
base
outcom
studi
focus
screen
molecular
method
implement
search
specif
rare
blood
type
rh
system
rare
blood
type
similar
found
amongst
countri
intern
rare
donor
programm
irdp
south
africa
larger
pool
donor
first
discov
amongst
black
south
african
l
wlosinski
transfus
medicin
henri
ford
health
system
detroit
michigan
unit
state
america
background
rh
system
complex
follow
abo
system
immunogen
rhd
protein
multifacet
depend
person
genet
way
rhd
antigen
express
red
blood
cell
rbc
membran
vari
variat
patient
classifi
weak
express
antigen
formal
du
serolog
test
weak
reaction
also
caus
variant
part
antigen
miss
rhd
serolog
test
mostli
autom
avail
help
detect
potenti
rhd
discrep
patient
autom
test
use
two
differ
clone
monoclon
reagent
provid
abil
detect
discrep
rhd
patient
sampl
howev
molecular
test
differenti
rhd
gene
fulli
express
variant
express
serolog
detect
rhd
discrep
pose
concern
women
child
bear
age
year
old
depend
rhd
variant
identifi
women
potenti
develop
expos
rhd
antigen
pregnanc
facil
develop
pilot
program
identifi
genet
rhd
statu
qualifi
rhd
discrep
patient
determin
rhd
statu
women
year
old
aid
accur
conserv
rbc
allow
proper
administr
rhig
prophylaxi
patient
popul
aim
identifi
women
child
bear
age
risk
develop
due
present
variant
rhd
gene
method
begin
januari
patient
sampl
show
inconclus
result
autom
test
subject
manual
serolog
investig
via
tube
test
patient
qualifi
manual
analysi
rbc
test
monoclon
reagent
valid
tube
test
women
year
old
manual
reaction
sampl
sent
molecular
rhd
determin
result
known
patient
classifi
receiv
rbc
candid
rhig
prophylaxi
evalu
b
women
year
old
men
manual
reaction
classifi
receiv
rbc
c
patient
manual
reaction
classifi
receiv
rbc
molecular
test
result
interpret
patient
support
per
molecular
laboratori
recommend
result
februari
femal
patient
child
bear
age
evalu
rhd
test
discrep
seven
patient
classifi
manual
serolog
test
molecular
test
perform
patient
patient
identifi
variant
variant
rhd
identifi
patient
variant
rhd
identifi
qualifi
patient
sampl
summaryconclus
serolog
rhd
discrep
via
autom
method
good
predictor
presenc
variant
rhd
recommend
confirm
molecular
test
h
el
el
z
f
n
k
n
hematolog
cellular
genet
engin
faculti
medicin
pharmaci
hassan
ii
univers
blood
transfus
center
casablanca
blood
transfus
center
rabat
morocco
background
antigen
immunogen
antigen
rh
system
determin
variant
critic
import
field
transfus
obstetr
medicin
transfus
neg
patient
rbc
carri
variant
may
develop
alloantibodi
antigen
frequenc
variant
vari
significantli
among
differ
ethnic
popul
howev
variant
frequent
among
subject
neg
rhc
andor
rhe
posit
aim
aim
studi
evalu
frequenc
variant
morocco
compar
data
ethnic
group
method
blood
sampl
edta
anticoagul
collect
blood
donor
phenotyp
rhd
neg
use
autom
analyz
olympu
pk
japan
region
blood
transfus
center
casablanca
collect
blood
sampl
rephenotyp
laboratori
rhesu
antigen
c
e
c
e
determin
use
standard
tube
method
monoclon
accord
manufactur
instruct
diagast
franc
blood
donor
type
rhc
andor
rhe
posit
test
weak
use
papain
test
indirect
antiglobulin
test
adsorpt
elut
techniqu
blend
igg
igm
fortress
diagnost
uk
dna
sampl
posit
weak
test
test
multiplex
pcr
cover
exon
result
result
sensit
serolog
test
show
blood
donor
rhd
type
del
pcr
multiplex
reveal
partial
variant
determin
frequenc
rhd
vari
one
ethnic
group
anoth
low
europ
similar
within
germani
denmark
higher
tunisian
popul
summaryconclus
distribut
variant
among
differ
race
show
differ
find
clinic
signific
transfus
medicin
hemolyt
diseas
fetu
newborn
hdfn
abstract
withdrawn
v
v
c
h
el
transfus
chu
brugmann
brussel
belgium
nation
de
la
transfus
sanguin
int
centr
nation
de
pour
le
group
sanguin
cnrg
pari
franc
transfus
erasm
obstetr
gynaecolog
erasm
brussel
belgium
background
rhce
ceek
allel
rhce
defin
singl
nucleotid
substitut
g
c
g
g
present
homozyg
state
encod
rare
blood
group
rh
allel
mostli
encount
peopl
african
descent
three
rhce
allel
also
associ
phenotyp
rhce
cear
rhce
cebi
rhce
cesm
homozyg
compound
heterozyg
individu
could
develop
respons
hemolyt
transfus
reaction
hemolyt
diseas
fetu
newborn
rhce
ceek
allel
report
segreg
either
rhd
rhd
rhd
rhd
aim
report
new
rhce
ceek
allel
without
g
c
link
rhd
allel
method
abo
rh
kell
type
perform
monoclon
reagent
two
techniqu
solid
phase
immucor
antibodi
identif
done
use
untreat
papain
treat
trypsin
treat
rbc
hr
phenotyp
determin
reagent
rhd
rhce
genotyp
run
rhd
rhce
beadchip
kit
bioarray
solut
immucor
hous
pcr
techniqu
result
phenotyp
patient
tutsi
pregnant
woman
group
b
weaken
reaction
antibodi
identif
show
complex
mixtur
genom
test
found
patient
homozyg
hemizyg
rhd
homozyg
rhce
ceek
g
homozyg
g
c
heterozyg
patient
phenotyp
birth
newborn
phenotyp
group
b
signal
obtain
rhd
beadchip
kit
conclud
genotyp
rhd
molecular
analysi
rhce
gene
consist
rhce
ceek
allel
heterozyg
state
g
heterozyg
without
g
c
nucleotid
chang
summaryconclus
accord
rhce
genotyp
mother
like
harbor
convent
rhce
ceek
new
rhce
ceek
allel
lack
g
c
nucleotid
chang
molecular
work
perform
newborn
proof
new
allel
linkag
rhd
allel
point
also
interest
vast
major
rhce
ceek
defin
haplotyp
one
follow
allel
rhd
rhd
famili
investig
detail
result
mother
also
suggest
linkag
rhce
ceek
normal
rhd
gene
situat
never
describ
j
k
r
laboratori
immunohaematolog
institut
haematolog
blood
transfus
pragu
czech
republ
laboratori
grifol
immunohematolog
center
san
marco
texa
unit
state
america
diagnostik
gmbh
kronberg
germani
depart
institut
haematolog
blood
transfus
pragu
czech
republ
background
clinic
import
antigen
rh
system
encod
rhd
gene
one
polymorph
blood
group
gene
human
still
increas
number
known
allel
variat
date
around
allel
encod
amino
acid
sequenc
primari
structur
fold
organ
secondari
tertiari
structur
final
rhd
protein
gene
variat
point
mutat
gene
convers
influenc
rhd
protein
incorpor
rh
complex
red
blood
cell
rbc
membran
normal
alter
exofaci
express
monoclon
antibodi
recogn
multipl
epitop
surfac
antigen
individu
lack
one
epitop
refer
partial
antigen
produc
amino
acid
chang
partial
antigen
usual
locat
six
exofaci
loop
polypeptid
chain
extracellular
part
rhd
protein
vestibul
sever
except
critic
amino
acid
residu
locat
one
twelv
transmembran
segment
influenc
gener
protein
conform
express
exofaci
epitop
aim
investig
prompt
find
rbc
suspect
partial
antigen
two
czech
pregnant
women
serolog
test
reveal
clearcut
signific
loss
epitop
explanatori
result
convent
genotyp
assay
rhd
sequenc
determin
genom
dna
epitop
pattern
studi
commerci
workshop
panel
compar
mutat
region
method
serolog
test
done
column
agglutin
biorad
neutraligm
coom
igg
use
monoclon
antibodi
partial
kit
biorad
dscreen
kit
diagast
nant
pari
moab
workshop
routin
partial
weak
genotyp
perform
fluogen
sequenc
grifol
ih
center
homolog
model
perform
model
use
crystal
structur
human
rhesu
glycoprotein
rhcg
templat
best
model
chosen
accord
stereochem
properti
determin
procheck
result
routin
rhd
type
show
weaken
express
convent
abo
rhd
gel
card
phenotyp
case
commerci
partial
kit
reveal
pattern
fit
known
variant
reaction
vs
one
neg
first
three
neg
second
case
commerci
kit
partial
weak
provid
normal
result
variant
detect
sequenc
found
far
report
mutat
predict
amino
acid
chang
rhd
protein
vestibul
one
case
c
code
substitut
propos
name
rhd
deep
twelfth
transmembran
helix
code
substitut
propos
name
rhd
epitop
map
found
lack
lack
summaryconclus
two
novel
mutat
caus
partial
phenotyp
interest
point
view
impact
known
epitop
amino
acid
substitut
rhd
locat
protein
vestibular
part
allow
compar
effect
neighbour
amino
acid
substitut
epitop
express
variant
rhd
predict
substitut
last
transmembran
part
protein
affect
substanti
exofaci
epitop
express
abstract
withdrawn
h
medicin
chonnam
nation
univers
medic
school
gwangju
medicin
samsung
medic
center
seoul
pusan
nation
univers
children
hospit
yangsan
samsung
medic
center
sungkyunkwan
univers
school
medicin
seoul
korea
background
report
new
rhd
variant
allel
rhd
discov
korean
male
hepatocellular
carcinoma
patient
perform
epitop
map
analyz
expect
effect
variat
comparison
two
express
variant
amino
acid
chang
posit
aim
identifi
novel
rhd
variant
effect
express
includ
epitop
express
method
serolog
test
antigen
done
ten
rhd
exon
sequenc
full
length
epitop
map
studi
site
antigen
epitop
express
examin
result
rhd
observ
reaction
routin
test
weak
test
evalu
multipl
clone
reagent
totem
diagast
loo
franc
show
posit
fraction
test
reagent
silico
analysi
method
provid
sdm
server
predict
effect
mutat
protein
stabil
malfunct
done
comparison
variant
result
amino
acid
chang
posit
weak
type
weak
type
suspect
intens
antigen
new
allel
found
report
weakest
follow
type
type
although
antigen
strength
type
type
compar
parallel
report
weak
observ
case
show
trace
reactiv
weak
test
suggest
silico
analysi
concord
actual
phenotyp
result
summaryconclus
discov
novel
variat
amino
acid
chang
within
transmembran
region
identif
locat
singl
nucleotid
variat
predict
intens
antigen
express
silico
analysi
help
predict
characterist
chang
abstract
withdrawn
h
medicin
chonnam
nation
univers
medic
school
gwangju
medicin
samsung
medic
center
seoul
pusan
nation
univers
children
hospit
yangsan
samsung
medic
center
sungkyunkwan
univers
school
medicin
seoul
korea
background
recent
experienc
case
coexist
weak
type
rhd
allel
asia
type
del
rhd
allel
reveal
express
individu
suggest
possibl
blood
transfus
individu
aim
identifi
effect
coexist
asia
type
del
allel
weak
allel
serolog
studi
target
variou
epitop
antigen
method
serolog
test
antigen
done
ten
rhd
exon
sequenc
full
length
epitop
map
studi
site
antigen
epitop
express
examin
result
blood
group
done
manual
tube
method
two
reagent
routin
test
show
neg
weak
test
indirect
antiglobulin
test
iat
show
posit
reaction
extend
rh
phenotyp
ceee
full
sequenc
exon
adjac
intron
rhd
gene
done
observ
heterozyg
g
nucleotid
posit
weak
type
rhd
asia
type
del
indic
presenc
two
rhd
allel
investig
epitop
done
iat
addit
adsorpt
elut
studi
iat
result
neg
reagent
evalu
epitop
done
reagent
kit
diagast
loo
franc
iat
result
posit
reagent
target
epitop
ident
typic
weak
type
reagent
neg
iat
adsorpt
elut
test
show
posit
remain
epitop
summaryconclus
serolog
investig
studi
reminisc
epitop
map
guo
et
al
done
asia
type
del
case
suggest
rhd
genotyp
extend
case
asian
popul
detect
presenc
asia
type
allel
result
subject
omit
rho
immun
globulin
administr
candid
blood
transfus
n
c
n
boto
salgado
c
canal
e
immunohematolog
banc
de
sang
teixit
barcelona
spain
background
mani
studi
conduct
differ
popul
aim
identifi
rhd
variant
associ
alter
antigen
express
expect
due
similar
rhd
rhce
gene
increas
number
rhce
variant
also
identifi
investig
weak
alter
express
rhce
antigen
howev
clinic
import
rhce
variant
less
well
known
studi
focus
popul
african
ancestri
aim
aim
present
studi
character
rhce
variant
present
collect
sampl
refer
immunohematolog
refer
laboratori
weak
andor
discrep
result
routin
rh
type
method
year
period
sampl
suspect
rhce
variant
comprehens
analyz
serolog
molecular
level
moab
use
express
analysi
rhd
gene
exon
scan
rhce
genotyp
perform
rhce
exon
amplifi
primer
sequenc
result
total
sampl
correspond
blood
donor
n
patient
n
studi
among
three
sampl
discrep
result
rhe
type
identifi
carri
rhce
allel
rhce
ceiv
two
case
rhce
rhce
ceew
one
case
four
addit
sampl
studi
discrep
result
rhc
type
three
identifi
carri
rhce
rhce
cejal
variant
rhce
ce
allel
detect
remain
sampl
carri
c
g
chang
addit
g
chang
exon
allel
appar
describ
yet
associ
alter
rhc
express
besid
two
sampl
weak
rhc
rhe
express
found
carri
rhce
rhce
variant
one
case
novel
rhce
variant
exon
case
novel
rhce
allel
carri
microdelet
affect
atg
start
codon
also
identifi
sampl
weak
rhc
rhe
express
apart
three
sampl
carri
rare
phenotyp
also
analyz
molecular
level
hybrid
allel
rhce
identifi
two
sampl
third
one
though
heterozyg
carri
silent
rhce
rhce
allel
togeth
appar
normal
rhce
ce
allel
despit
pursu
analysi
sampl
abl
identifi
alter
silenc
express
allel
sampl
studi
includ
blood
donor
n
abnorm
result
rhd
type
end
identifi
rhce
cesl
carrier
two
clinic
sampl
carri
hybrid
dhar
allel
rhce
cecf
variant
respect
known
express
epitop
rhce
protein
summaryconclus
comprehens
analysi
sampl
includ
studi
allow
us
gain
insight
rhce
variant
present
popul
despit
encount
rhce
variant
alreadi
describ
novel
rhce
allel
also
identifi
overal
molecular
alter
detect
rhce
allel
correl
well
weak
partial
null
express
encod
rhce
antigen
howev
one
sampl
phenotyp
could
find
alter
unexpress
rhce
allel
indic
mechan
involv
rhce
gene
silenc
identifi
current
methodolog
h
el
el
z
f
n
k
c
n
hematolog
cellular
genet
engin
faculti
medicin
pharmaci
hassan
ii
univers
casablanca
morocco
du
sang
bretagn
franc
blood
transfus
center
casablanca
blood
transfus
center
rabat
morocco
background
variant
weak
partial
rhd
allel
current
known
similar
heterogen
rhce
allel
may
anticip
individu
carri
variant
risk
develop
alloantibodi
respons
mismatch
pregnanc
transfus
preval
rhce
variant
morocco
remain
unknown
aim
aim
studi
determin
variant
rhce
allel
blood
donor
region
blood
transfus
center
casablanca
method
total
sampl
blood
donor
routin
analyz
rhce
phenotyp
use
qwali
analyz
monoclon
reagent
sampl
weaken
andor
discrep
serolog
reaction
pattern
c
c
e
e
antigen
autom
test
andor
tube
column
agglutin
techniqu
analyz
qmpsf
rhce
exon
sequenc
result
identifi
sampl
weak
express
one
two
major
rhce
antigen
serolog
test
molecular
analysi
sampl
reveal
differ
rhce
allel
one
publish
novel
allel
rhce
ce
ce
ce
two
hybrid
allel
summaryconclus
result
show
import
rhce
molecular
analysi
sampl
show
aberr
phenotyp
discrep
weak
unclear
result
antigen
ccee
order
allow
better
donor
recipi
match
base
phenotyp
match
red
blood
cell
unit
also
unit
genet
match
c
c
nation
de
pour
le
group
sanguin
institut
nation
de
la
transfus
sanguin
pari
diderot
dexcel
pari
du
sang
nord
de
franc
lill
franc
background
rh
complex
blood
group
system
encod
paralog
rhd
rhce
gene
current
includ
antigen
offici
recogn
intern
societi
blood
transfus
isbt
rhce
gene
encod
four
allel
ce
ce
ce
ce
decreas
express
c
e
rare
caucasian
popul
wherea
weaken
express
e
c
quit
uncommon
aim
describ
novel
rhce
ce
allel
delet
start
codon
code
decreas
express
e
c
antigen
method
blood
sampl
unrel
patient
caucasian
origin
refer
refer
laboratori
follow
reason
weak
e
andor
c
reactiv
ii
reagent
vigil
procedur
phenotyp
investig
carri
standard
hemagglutin
techniqu
genom
dna
isol
wbc
fulli
autom
method
follow
rhce
exon
flank
intron
region
sequenc
consensu
sequenc
result
among
blood
sampl
refer
nation
immunohematolog
refer
laboratori
refer
suspicion
c
e
variant
eight
weak
e
antigen
express
confirm
weakli
reactiv
two
routin
techniqu
ortho
biovu
systemmonoclon
panel
monoclon
antibodi
show
neg
reaction
clone
posit
test
reagent
rhce
sequenc
reveal
presenc
delet
heterozyg
state
partli
cover
begin
exon
delet
four
nucleotid
caus
loss
convent
start
codon
gene
summaryconclus
report
novel
mutat
rhce
ce
allel
could
expect
critic
local
delet
could
fulli
abolish
rhce
protein
express
howev
e
c
antigen
unambigu
detect
rbc
membran
common
monoclon
reagent
specul
anoth
aug
sequenc
utr
posit
may
use
replac
initi
codon
encod
protein
would
case
amino
acid
longer
global
preserv
rhce
quaternari
structur
weaken
antigen
express
could
either
due
alter
traffick
plasma
membran
defici
anchor
rbc
surfac
hypothesi
would
need
confirm
protein
analysi
techniqu
precaut
consid
individu
express
allel
partial
e
partial
c
recommend
rbc
unit
especi
women
age
transfus
propos
novel
rhce
ce
allel
variant
assign
refer
number
isbt
work
parti
red
cell
immunogenet
blood
group
terminolog
offici
list
allel
rh
blood
group
system
c
r
f
l
paulo
campina
brazil
background
rh
gene
highli
polymorph
variant
rhce
allel
alreadi
describ
rhce
allel
consid
clinic
signific
almost
exclus
found
peopl
african
descent
code
partial
rh
antigen
time
protein
lack
antigen
easi
find
compat
donor
fulfil
need
patient
rhce
variant
special
alloimmun
patient
sickl
cell
diseas
scd
aim
order
provid
better
transfus
support
scd
patient
present
rhce
variant
aim
defin
strategi
facilit
select
donor
common
rhce
variant
countri
increas
miscegen
method
select
three
group
blood
donor
african
brazilian
donor
abd
character
genet
marker
self
declar
african
descend
donor
sda
donor
type
sampl
abd
sda
submit
molecular
test
analys
g
g
g
polymorph
accord
result
perform
anoth
analysi
use
flowchart
previous
describ
arnoni
et
al
immunohematolog
rbc
sampl
neg
result
specif
pcr
rhd
intron
exon
also
submit
specif
pcr
rhd
exon
posit
result
genotyp
rhce
g
polymorph
confirm
multiplex
pcr
hybrid
exon
character
presenc
c
ce
haplotyp
result
frequenc
rhce
variant
allel
abd
group
sda
group
rhce
rhce
frequent
allel
found
respect
sda
group
also
found
sampl
homozyg
rhce
variant
allel
lead
partial
c
partial
e
phenotyp
abd
group
variant
allel
associ
convent
ce
ce
allel
form
addit
sampl
group
studi
exon
rhd
present
least
one
hybrid
haplotyp
four
homozyg
c
ce
haplotyp
compound
heterozyg
rhce
variant
allel
summaryconclus
result
suggest
admix
popul
brazilian
easier
find
rhce
variant
allel
donor
african
descend
donor
african
ancestri
defin
molecular
marker
addit
strategi
identifi
c
ce
haplotyp
donor
type
also
help
find
donor
rare
rhce
phenotyp
k
g
c
w
refer
laboratori
research
institut
versitibloodcent
wisconsin
patholog
medic
colleg
wisconsin
milwauke
wisconsin
unit
state
america
background
bloodcent
wisconsin
donor
ethnic
genotyp
sinc
singl
nucleotid
polymorph
snp
routin
detect
presenc
partial
rhd
allel
marker
ensur
accuraci
high
throughput
genotyp
verifi
presenc
absenc
rhd
allel
serolog
blood
donor
respect
rare
discrep
genotyp
serolog
occur
must
investig
aim
purpos
studi
investig
presenc
determin
frequenc
rhd
allel
serolog
blood
donor
method
autom
rhd
phenotyp
perform
use
blood
rhce
phenotyp
perform
use
reagent
red
cell
genotyp
perform
use
taqman
primerprob
endpoint
assay
weak
partial
analysi
perform
use
singl
specif
primer
polymeras
chain
reaction
rhd
exon
polymeras
chain
reaction
pcr
genom
dna
use
flank
intron
primer
contain
senseantisens
sequenc
fragment
sequenc
sanger
dideoxi
method
use
bigdy
termin
cycl
sequenc
kit
complementari
primer
result
align
use
seqscap
softwar
donor
rhd
rhd
pseudogen
rhd
rhd
allel
exclud
analysi
result
blood
donor
rhd
phenotypegenotyp
discrep
investig
presenc
variant
rhd
allel
caucasian
ca
asian
hispan
hi
african
american
aa
ot
rhce
phenotyp
perform
sampl
reveal
c
e
ce
result
obtain
donor
divid
categori
weak
n
rhd
ca
rhce
ce
rhd
ca
rhce
ce
rhd
ca
rhce
ce
partial
n
rhd
ca
ot
rhce
ce
rhd
ca
link
rhce
ce
rhce
ce
nonfunct
n
rhd
ca
rhce
ce
rhd
ca
relat
rhce
ce
rhd
ca
rhce
ce
rhd
ca
rhce
ce
rhd
variant
rhd
exon
delet
hi
rhce
ce
rhd
ca
rhce
ce
novel
rhd
aa
hi
rhce
ce
del
n
rhd
rhce
cerhc
ce
rhce
ce
rhd
ca
rhce
ce
rhd
ca
relat
rhce
ce
four
donor
inconclus
result
show
presenc
rhd
exon
analysi
perform
miss
least
rhd
exon
use
sanger
sequenc
suggest
presenc
intron
polymorph
nonfunct
allel
summaryconclus
although
small
fraction
popul
presenc
rhd
allel
serolog
blood
donor
may
signific
find
term
transfus
alloimmun
rhd
sequenc
reveal
variant
previous
describ
presenc
snp
along
rhce
ce
rhce
ce
indic
variant
rhd
allel
blood
donor
abstract
withdrawn
r
h
b
w
c
van
der
h
research
center
surinam
pediatr
academ
hospit
paramaribo
medic
scienc
anton
kom
univers
surinam
parimaribo
surinam
obstetr
leiden
univers
medic
center
leiden
holland
immunohematolog
sanquin
research
amsterdam
medicin
radboud
univers
nijmegen
blood
transfus
leiden
univers
medic
center
leiden
netherland
pediatr
diakonessen
hospit
parimaribo
surinam
background
antigen
highli
polymorph
rhd
variant
describ
next
normal
express
three
type
variant
express
exist
weak
del
partial
individu
partial
variant
express
antigen
lack
one
sever
effect
antigen
express
hamper
detect
routin
serolog
character
rhd
allel
especi
ethnic
group
limit
access
prevent
measur
practic
clinic
import
surinam
phenotyp
transfus
recipi
pregnant
women
newborn
serolog
determin
prophylaxi
women
risk
immun
routin
popul
surinam
mixtur
differ
ethnic
group
hindustani
maroon
creol
javanes
repres
four
common
previou
studi
reveal
serolog
neg
multigravida
women
surinam
zonneveld
transfus
aim
determin
frequenc
character
rhd
variant
allel
surinames
serolog
pregnant
women
differ
ethnic
group
method
studi
pregnant
women
visit
one
four
hospit
academ
hospit
paramaribo
diakonessen
hospit
land
hospit
sint
vincentiu
hospit
paramaribo
surinam
routin
pregnanc
care
perform
surinam
pregnant
women
routin
test
blood
group
use
convent
serolog
slide
direct
agglutin
test
singl
monoclon
antibodi
women
particip
rhesun
studi
residu
blood
separ
plasma
remaind
cell
dna
ship
netherland
rhd
variant
allel
test
use
qpcr
target
rhd
exon
probe
amplif
dna
extract
sampl
either
exon
present
discrep
molecular
serolog
analyz
singl
sampl
remaind
ie
exon
absent
test
batch
dna
sampl
result
total
pregnant
women
includ
rhesun
studi
sampl
avail
rhd
variant
allel
test
sampl
either
exon
present
exon
absent
reveal
rhd
delet
rhd
total
variant
allel
detect
rhd
rhd
rhd
pseudogen
rhd
two
rhd
rhd
two
rhd
rhd
one
rhd
rhd
one
del
rhd
two
allel
variant
current
unknown
six
sampl
show
despit
serolog
appar
normal
rhd
allel
also
investig
found
eleven
women
neg
variant
rhd
gene
rhd
delet
rhd
rhd
pseudogen
summaryconclus
frequenc
variant
rh
allel
cohort
surinames
serolog
pregnant
women
rhd
rhd
repres
variant
allel
antibodi
present
women
genotyp
commonli
known
risk
behalf
rhesu
surinames
neonat
rhesun
studi
group
abstract
withdrawn
ji
z
wang
jia
j
chen
r
zhang
j
wen
l
wei
g
luo
institut
clinic
blood
transfus
guangzhou
blood
center
guangzhou
china
background
del
weak
form
antigen
rare
caucasian
black
ethic
group
common
east
asian
popul
del
individu
commonli
mistyp
phenotyp
low
densiti
antigen
express
surfac
red
cell
test
way
del
test
serolog
routin
perform
clinic
laboratori
far
allel
report
account
del
phenotyp
rhd
rhd
preval
east
asian
del
individu
call
asia
type
del
aim
conduct
phenotyp
genotyp
analysi
del
chines
southern
han
pregnant
women
primari
phenotyp
method
octob
januari
peripher
blood
sampl
chines
pregnant
women
primari
phenotyp
test
antigen
firstli
test
use
anoth
blend
reagent
clone
igmigg
test
del
phenotyp
conduct
sampl
primari
phenotyp
melt
hrm
method
develop
asia
type
del
genotyp
use
one
pair
rhd
specif
primer
amplifi
exon
rhd
gene
cover
synonym
mutat
zygos
rhd
gene
predict
hrm
analysi
confirm
hybrid
rhesu
box
pcr
psti
digest
sampl
inconsist
rhd
genotyp
analyz
mlpa
genotyp
andor
rhd
gene
sequenc
meanwhil
serolog
rhce
type
antibodi
screen
perform
result
pregnant
women
identifi
variant
phenotyp
rest
sampl
primari
phenotyp
total
pregnant
women
identifi
del
phenotyp
eight
differ
kind
genotyp
identifi
includ
rhd
n
involv
ccee
phenotyp
n
ccee
n
ccee
n
rhd
n
ccee
phenotyp
rhd
n
ccee
phenotyp
rhd
n
ccee
rhd
n
ccee
rhd
type
n
ccee
rhd
n
ccee
one
novel
rhd
genotyp
n
ccee
among
pregnant
women
except
pregnant
women
receiv
prophylaxi
prior
del
test
pregnant
women
identifi
asia
type
del
phenotyp
one
detect
produc
rest
pregnant
women
true
phenotyp
detect
produc
titer
guidanc
need
receiv
prophylaxi
provid
asia
type
del
pregnant
women
summaryconclus
asia
type
del
pregnant
women
produc
exposur
blood
fetu
develop
hrm
genotyp
method
fit
routin
test
asia
type
del
realli
relev
avoid
unnecessari
prophylaxi
asia
type
del
pregnant
women
phenotyp
common
chines
popul
immunoglobulin
also
still
avail
mainland
china
j
j
r
w
develop
australian
red
cross
blood
servic
alexandria
medic
school
univers
sydney
camperdown
servic
australian
red
cross
blood
servic
alexandria
australia
background
case
haemolyt
diseas
foetu
newborn
declin
significantli
sinc
introduct
success
routin
administr
prophylact
immunoglobulin
ig
suscept
pregnant
women
blood
servic
conduct
program
activ
immunis
select
blood
donor
small
volum
red
blood
cell
rbc
stimul
ig
product
approxim
primarili
immunis
donor
develop
serum
ig
concentr
iuml
assign
respond
profil
previous
sought
examin
donor
genet
factor
associ
donor
respond
profil
tan
molecular
immunolog
aim
hypothesis
rbc
phenotyp
could
also
influenc
donor
respond
profil
method
immunis
record
donor
collect
analys
examin
subset
donor
immunis
rbc
belong
one
haplotyp
either
dce
dce
dce
rz
dce
result
determin
n
femal
donor
n
male
donor
respond
donor
p
valu
found
donor
unlik
develop
antibodi
addit
booster
inject
found
donor
immunis
donor
immunis
rbc
develop
ig
oppos
donor
immunis
rz
rbc
respond
donor
also
develop
antibodi
rbc
antigen
match
select
rbc
immunis
summaryconclus
data
collect
analysi
allow
us
determin
red
blood
cell
phenotyp
influenc
donor
abil
develop
antibodi
abstract
withdrawn
c
j
nation
de
pour
le
group
sanguin
institut
nation
de
la
transfus
sanguin
pari
diderot
dexcel
nation
de
la
transfus
sanguin
pari
franc
background
glycoprotein
rhag
formerli
known
glycoprotein
human
blood
group
system
known
form
complex
red
blood
cell
surfac
rhd
rhce
protein
essenti
express
rh
antigen
gene
encod
rhag
chromosom
similar
rhd
rhce
chromosom
molecular
alter
rhag
gene
may
caus
global
decreas
express
rh
protein
induc
rhmod
phenotyp
lead
except
rhnull
regul
type
rhag
mutat
deleteri
first
case
nonfunct
rhag
allel
variant
describ
et
al
natur
genet
five
rhnull
peopl
genom
dna
cdna
studi
delet
nucleotid
rhag
detect
one
rhnull
patient
name
tb
howev
delet
surprisingli
found
heterozyg
state
attempt
amplifi
product
second
rhag
allel
unsuccess
allel
subsequ
refer
rhag
isbt
allel
databas
sinc
discoveri
except
blood
type
tb
becam
repeat
blood
donor
french
nation
rare
blood
bank
aim
describ
complementari
investig
tb
proband
current
avail
genom
tool
order
find
full
molecular
basi
rhnull
phenotyp
method
genom
dna
extract
peripher
blood
cell
fulli
autom
devic
whole
exom
sequenc
perform
illumina
technolog
eurofin
genom
rhag
exon
amplifi
specif
primer
sequenc
result
tb
male
donor
known
blood
group
rhnull
transfus
histori
make
exom
studi
confirm
presenc
previous
character
mutat
rhag
gene
predict
caus
frameshift
reveal
presenc
exon
anoth
delet
heterozyg
state
mutat
predict
result
frameshift
codon
encod
phenylalanin
posit
mutat
confirm
convent
sanger
sequenc
rhag
gene
summaryconclus
tb
belong
except
individu
rhnull
regul
type
initi
report
unexpectedli
demonstr
one
inactiv
mutat
rhag
gene
tb
sampl
readili
avail
cryobank
prompt
us
investig
case
genom
dna
sequenc
two
differ
approach
allow
us
find
novel
silent
rhag
allel
mutat
definit
explain
time
rhnull
phenotyp
proband
suggest
updat
current
databas
newli
report
silent
rhag
allel
could
name
rhag
subject
agreement
isbt
work
parti
red
cell
immunogenet
blood
group
terminolog
case
highlight
fact
reinvestig
unexplain
former
immunohematolog
case
may
relev
success
current
avail
molecular
techniqu
n
transfus
medicin
robert
tomsich
patholog
laboratori
medicin
institut
cleveland
clinic
transfus
medicin
robert
tomsich
patholog
laboratori
medicin
institut
cleveland
clinic
cleveland
ohio
unit
state
america
background
approxim
patient
primari
myelofibrosi
pmf
carri
somat
activ
mpl
mutat
may
aris
copi
neutral
cn
loss
heterozygos
loh
chromosom
loh
may
involv
neighbor
rhdrhce
gene
loci
result
phenotyp
chang
express
rh
antigen
rh
type
discrep
may
impact
transfus
support
patient
aim
describ
immunohematolog
featur
molecular
find
clinic
progress
patient
pmf
method
literatur
review
describ
clonal
chang
patient
progress
myeloid
malign
base
case
review
patient
pmf
result
femal
longstand
histori
myeloprolif
diseas
manag
conserv
prior
transfus
schedul
elect
red
cell
transfus
symptomat
anemia
type
gel
hemagglutin
show
reaction
type
contrast
histor
type
posit
recent
month
prior
discrep
attribut
pmf
progress
bone
marrow
exam
previous
hypocellular
slightli
fibrot
marrow
show
promin
osteosclerosi
amidst
increas
fibrosi
stain
posit
bone
marrow
cytogenet
g
band
demonstr
normal
karyotyp
mutat
neg
chromosom
snp
microarray
detect
copi
number
loss
long
arm
chromosom
includ
tumor
suppressor
gene
cell
count
approxim
cell
contain
larg
short
arm
chromosom
involv
includ
rhdrhce
loci
next
gener
sequenc
confirm
presenc
pathogen
mpl
mutat
chromosom
patient
receiv
infrequ
rbc
transfus
next
two
year
although
make
develop
b
correspond
rh
kidd
blood
group
system
antigen
respect
summaryconclus
incid
rh
discrep
myeloprolif
neoplasm
mpn
probabl
underreport
consid
frequenc
chromosom
aberr
disord
report
patient
acquir
rh
antigen
mosaic
secondari
clonal
mpn
somat
loss
tumor
suppressor
gene
follow
chromosom
underscor
divers
molecular
pathway
multistep
pathogenesi
involv
evolut
phenotyp
mutat
event
describ
suggest
initi
mutat
follow
mutat
detect
hematolog
phenotyp
phenotyp
evid
clonal
evolut
may
impact
transfus
patient
mpn
w
tounsi
madgett
n
avent
school
biomed
healthcar
scienc
plymouth
univers
plymouth
unit
kingdom
background
rh
blood
group
system
second
import
blood
group
abo
two
close
relat
gene
rhd
rhce
encod
differ
antigen
recombin
delet
point
mutat
two
gene
gener
rh
allel
divers
gener
eight
common
rh
haplotyp
includ
dce
dce
dce
rz
dce
r
dce
ry
dce
r
dce
r
dce
blood
group
genotyp
could
decreas
rh
mistyp
eventu
minimis
advers
reaction
follow
blood
transfus
especi
blood
transfus
depend
patient
previou
studi
use
exom
sequenc
identifi
rh
variat
high
homolog
rhd
rhce
gene
could
make
challeng
analys
data
especi
exon
amino
acid
differ
two
gene
aim
aim
use
amplifi
rh
gene
get
full
sequenc
includ
promot
intron
exon
focus
establish
refer
allel
rhd
rhce
gene
studi
intron
snp
gene
relationship
specif
rh
haplotyp
method
genom
dna
sampl
n
blood
donor
isbt
workshop
differ
phenotyp
sequenc
use
ion
person
genom
rhd
gene
sequenc
sampl
rhce
gene
sequenc
blood
donor
sampl
data
map
refer
sequenc
analyz
use
clc
workbench
result
multipl
exon
snp
detect
encod
rhd
allel
includ
rhd
rhd
rhd
rhd
rhd
rhd
rhd
rhd
rhd
rhd
rhd
one
novel
allel
identifi
one
rhd
hemizyg
sampl
show
snp
encod
rhd
encod
rhd
mean
rhd
allel
hybrid
two
variant
rhd
allel
due
rhd
rhd
refer
sequenc
rhd
gene
homozyg
snp
detect
sampl
thought
specif
refer
allel
compar
refer
sequenc
multipl
intron
snp
detect
suspect
haplotyp
specif
snp
homozyg
snp
sampl
haplotyp
snp
homozyg
sampl
haplotyp
intron
snp
analysi
rhce
gene
reveal
intron
snp
intron
confirm
presenc
bp
insert
intron
sampl
haplotyp
intron
snp
detect
r
sampl
summaryconclus
research
sampl
sequenc
rhd
gene
rhce
gene
studi
differ
allel
present
popul
establish
refer
allel
sequenc
utilis
analysi
intron
snp
correl
specif
rh
haplotyp
intron
snp
suspect
relat
specif
haplotyp
may
repres
novel
diagnost
approach
investig
known
novel
variant
gene
e
madgett
w
tounsi
g
farnham
n
avent
school
biomed
healthcar
scienc
univers
plymouth
plymouth
unit
kingdom
background
high
homolog
rhd
rhce
gene
rh
blood
group
system
high
allel
divers
rh
allel
dna
sequenc
offer
huge
opportun
complet
blood
group
genotyp
previou
studi
use
second
gener
method
sequenc
ion
person
genom
complex
rh
system
make
prime
singl
molecul
sequenc
aim
aim
compar
sequenc
minion
sequenc
rhd
gene
focus
establish
whether
minion
sequenc
could
use
achiev
allel
phase
accur
variant
call
method
genom
dna
sampl
n
blood
donor
sequenc
use
minion
rhd
gene
product
kb
sequenc
use
kit
spoton
flow
cell
minion
run
h
follow
base
call
ont
albacor
softwar
read
extract
poretool
map
refer
sequenc
analysi
use
ont
set
variant
phase
allel
call
use
nanopolish
softwar
data
compar
sequenc
data
sampl
ion
result
minion
gener
read
two
hour
sequenc
run
gave
coverag
rang
abl
call
variant
phase
differ
allel
compar
result
minion
ion
one
sampl
sequenc
rhd
ion
amino
acid
chang
detect
despit
sampl
serolog
phenotyp
weak
zygos
test
sampl
show
discrep
hemizyg
rhd
exon
homozyg
rhd
exon
indic
delet
exon
one
rhd
allel
ion
unabl
detect
absenc
rhd
exon
one
allel
due
presenc
wild
type
allel
intron
snp
detect
sampl
sequenc
minion
intron
snp
shown
correl
specif
haplotyp
ion
amplicon
sequenc
platform
fragment
necessari
ion
challeng
map
short
read
refer
sequenc
due
shorter
read
sometim
align
differ
region
gene
contrast
minion
produc
read
cover
entir
amplicon
kb
allel
phase
use
ion
data
feasibl
unlik
minion
longer
read
gener
summaryconclus
research
shown
potenti
use
minion
singl
molecul
sequenc
platform
blood
group
genotyp
advantag
allel
phase
complic
genet
structur
exist
rhdrhce
gene
exampl
hybrid
easili
assess
platform
straightforward
use
work
ongo
optimis
barcod
sequenc
minion
allow
sequenc
multipl
sampl
run
rhd
gene
work
open
possibl
studi
variat
blood
group
gene
use
minion
f
g
r
g
de
c
k
l
l
medicin
unit
san
camillo
forlanini
hospit
rome
immucor
italia
spa
milan
itali
solut
immucor
warren
new
jersi
unit
state
america
ospedal
sanna
turin
gbgrassi
ostia
rm
spaziani
frosinon
itali
background
introduct
rhd
genotyp
routin
transfus
laboratori
allow
resolut
rhd
discrep
found
serolog
standard
method
nevertheless
diagnost
platform
still
show
larg
limit
detect
rhd
variant
use
rhd
gene
sequenc
sometim
crucial
clearli
defin
rhd
statu
patient
donor
especi
molecular
serolog
techniqu
present
type
ambigu
due
lack
specif
marker
rhd
variant
commerci
avail
kit
aim
present
studi
aim
evalu
frequent
determin
turn
rhd
sequenc
analys
order
took
exampl
amount
rhd
genotyp
assay
perform
method
rhd
serolog
type
carri
micropl
direct
agglutin
test
neo
immucor
use
differ
igm
clone
clone
dvi
clone
differ
igg
clone
clone
clone
sampl
found
discrep
approach
therefor
address
rhd
genotyp
rhd
beadchip
kit
immucor
sampl
still
show
inconclus
result
due
gene
result
conjunct
weak
agglutin
score
higher
andor
discord
score
sampl
analyz
bidirect
sequenc
analysi
whole
rhd
code
region
result
sampl
analyz
rhd
sequenc
male
femal
median
age
year
year
weak
variant
weak
type
weak
type
weak
type
weak
type
weak
type
partial
weak
type
dnu
show
weak
type
categor
del
variant
subject
weak
type
african
descent
other
caucasian
patient
bear
dnu
variant
also
show
presenc
alloantibodi
serum
summaryconclus
contribut
rhd
sequenc
pivot
resolv
rhd
type
ambigu
experi
although
consid
rel
short
period
time
year
sequenc
analys
allow
us
identifi
case
weak
type
women
childbear
age
weak
type
blood
donor
respect
group
partial
del
categori
isbt
committe
import
implic
practic
immunoprophylaxi
transfus
therapi
keller
j
keller
horn
molecular
laboratori
american
red
cross
philadelphia
pennsylvania
unit
state
america
background
red
blood
cell
rbc
genotyp
effici
mean
identifi
donor
lack
high
preval
antigen
multipl
common
blood
group
antigen
unit
donor
use
transfus
patient
alloantibodi
case
patient
sickl
cell
diseas
prophylact
phenotyp
match
avoid
alloimmun
aim
blood
center
routin
use
rbc
genotyp
screen
blood
donor
sinc
screen
predominantli
african
american
donor
sinc
recent
transit
immucor
precisetyp
hea
molecular
beadchip
agena
bioscienc
hemoid
dq
describ
result
genotyp
mostli
ethnic
divers
donor
use
hemoid
dq
includ
antigen
blood
group
system
well
hba
c
method
donor
select
base
aa
ethnic
base
histor
serolog
type
blood
tube
red
cell
donor
transport
region
site
central
molecular
test
laboratori
genom
dna
extract
whole
blood
use
autom
extractor
dna
subject
multiplex
pcr
reaction
follow
dephosphoryl
unincorpor
dntp
assay
probe
extend
polymorph
site
singl
nucleotid
extens
termin
analyz
laser
desorptionion
spectrometri
massarray
agena
bioscienc
rarefind
script
agena
bioscienc
use
talli
specif
predict
phenotyp
result
genom
dna
sampl
yield
result
one
well
genotyp
assay
sampl
complet
predict
phenotyp
js
jo
lu
co
donor
identifi
di
sc
lw
enrich
aa
cohort
includ
donor
donor
donor
predict
cf
donor
fybw
sickl
trait
identifi
donor
test
rhce
singl
nucleotid
polymorph
use
identifi
donor
predict
donor
predict
though
heterozyg
rhce
donor
predict
base
homozygos
marker
summaryconclus
rbc
genotyp
effici
mean
identifi
antigen
neg
blood
donor
addit
rbc
genotyp
identifi
donor
carri
variant
associ
antigen
type
discrep
includ
fyb
frequenc
donor
predict
phenotyp
combin
result
close
report
black
reid
et
al
blood
group
antigen
factsbook
failur
identifi
donor
homozyg
rhce
nearli
predominantli
african
american
donor
highlight
rariti
phenotyp
us
c
le
c
inserm
ef
ubo
ibsam
inserm
ef
ubo
ibsam
chu
brest
brest
franc
background
convent
sequenc
sequenc
proven
effici
power
sequenc
blood
group
gene
phase
still
remain
challeng
issu
due
short
read
sequenc
data
andor
absenc
polymorph
marker
past
year
sequenc
includ
pacbio
technolog
emerg
potent
tool
investig
sever
kilobas
kb
singl
read
aim
thought
test
pacbio
sequenc
technolog
investig
full
locu
gene
involv
express
blood
group
antigen
ie
rhd
involv
respect
duffi
rh
blood
group
system
method
primer
set
design
gener
larg
amplicon
product
kb
rhd
overlap
product
kb
gene
pcr
amplif
two
differ
pool
made
first
ten
genom
dna
gdna
sampl
extern
qualiti
control
known
genotyp
use
amplifi
target
purifi
product
barcod
mix
togeth
equimolar
ratio
second
three
rhd
product
gener
use
gdna
extract
cell
line
pool
togeth
librari
sequenc
individu
sequel
system
pacif
bioscienc
ca
usa
use
singl
molecul
smrt
sequenc
technolog
result
gene
allel
identifi
genotyp
full
accord
obtain
altern
mean
ie
microarray
sanger
sequenc
rhd
gene
full
sequenc
gene
locu
ie
approxim
kb
could
reconstitut
success
summaryconclus
first
time
knowledg
genom
sequenc
blood
group
gene
specif
gener
pacbio
technolog
current
process
extend
studi
blood
group
gene
includ
rhce
rh
blood
group
gypagypb
mn
kel
kell
kidd
dombrock
although
routin
diagnost
mean
recommend
due
cost
determin
refer
geneallel
sequenc
insuffici
document
field
research
typic
applic
technolog
result
product
valuabl
dataset
blood
group
genotyp
anoth
conveni
applic
resolut
complex
genom
rearrang
hybrid
gene
commonli
observ
blood
group
gene
specif
encod
rh
mn
antigen
overal
preliminari
result
pave
way
use
sequenc
field
blood
group
genom
n
k
g
c
p
l
progenika
biopharma
grifol
compani
derio
depart
develop
support
progenika
biopharma
grifol
compani
derio
spain
laboratori
progenika
inc
grifol
compani
san
marco
texa
american
red
cross
philadelphia
pennsylvania
lifeshar
blood
center
shreveport
louisiana
bloodwork
northwest
seattl
washington
children
nation
health
system
washington
dc
new
york
blood
center
long
island
new
york
affair
grifol
diagnost
solut
emeryvil
california
unit
state
america
background
molecular
technolog
increasingli
implement
immunohematolog
laboratori
improv
extend
blood
group
antigen
match
transfus
medicin
id
core
xt
qualit
pcr
genotyp
test
luminex
xmap
technolog
simultan
identif
multipl
allel
encod
red
blood
cell
antigen
genom
dna
test
use
genotyp
polymorph
target
allel
predict
antigen
ten
blood
group
system
rh
cw
c
c
e
e
v
vs
hrb
hr
kell
k
k
kpa
kpb
jsa
jsb
kidd
jka
jkb
duffi
fya
fyb
mn
n
u
mia
diego
dia
dib
dombrock
doa
dob
hy
joa
colton
coa
cob
cartwright
yta
ytb
lutheran
lua
lub
aim
object
clinic
studi
evalu
perform
id
core
xt
comparison
refer
method
clinic
determin
blood
group
antigen
method
whole
blood
sampl
collect
edta
tube
blood
donor
three
refer
blood
center
unit
state
genom
dna
sampl
extract
test
id
core
xt
immucor
hea
molecular
beadchip
bd
commerci
test
perform
accord
manufactur
instruct
id
core
xt
predict
phenotyp
compar
precisetyp
hea
serolog
test
antigen
test
precisetyp
hea
serolog
avail
cw
hr
hrb
mia
yta
ytb
compar
bd
result
sinc
polymorph
predict
allel
genotyp
interrog
id
core
xt
report
precisetyp
hea
genotyp
compar
bd
method
result
total
blood
donor
includ
evalu
valid
run
valid
test
rate
id
core
xt
obtain
studi
due
protocol
deviat
respect
discrep
resolv
referr
refer
laboratori
comparison
precisetyp
hea
five
sampl
show
discrep
predict
phenotyp
four
sampl
rhce
c
v
vs
due
limit
precisetyp
hea
one
fals
neg
result
id
core
xt
ii
comparison
serolog
one
sampl
gave
fals
neg
lub
antigen
serolog
iii
comparison
bd
four
sampl
gave
discrep
genotyp
id
core
xt
three
discrep
resolv
dna
sampl
bd
one
discrep
due
bd
concord
id
core
xt
refer
method
except
gypa
c
genotyp
correspond
antigen
lower
bound
ci
concord
greater
polymorph
allel
genotyp
antigen
summaryconclus
id
core
xt
accur
test
system
predict
red
blood
cell
antigen
determin
polymorph
genotyp
associ
predict
allel
ten
blood
group
system
clinic
trial
result
id
core
xt
implement
genotyp
routin
immunohematolog
laboratori
b
p
j
r
r
van
den
de
c
de
c
van
der
immunohematolog
immunohematolog
sanquin
amsterdam
leiden
univers
medic
center
leiden
netherland
background
blood
group
type
patient
donor
perform
prevent
transfus
reaction
case
pregnant
women
prevent
hemolyt
diseas
fetu
newborn
genotyp
method
use
serolog
method
possibl
conclus
guid
prophylaxi
abl
reliabl
predict
phenotyp
genotyp
import
refer
laboratori
report
rare
blood
group
allel
encount
daili
practic
refer
laboratori
sanquin
total
individu
genotyp
determin
blood
group
antigen
variant
blood
group
antigen
chimer
rhd
zygos
report
phenotyp
genotyp
characteris
rare
allel
observ
among
sampl
aim
characteris
rare
blood
group
allel
molecular
type
need
serolog
could
provid
conclus
result
method
diagnost
set
use
three
differ
genotyp
assay
allel
discrimin
assay
use
type
common
blood
group
antigen
multiplex
probe
amplif
mlpa
assay
determin
antigen
differ
blood
group
system
includ
zygos
final
sanger
sequenc
determin
variant
could
determin
mlpa
dna
extract
edta
blood
use
either
qiasymphoni
chemag
instrument
result
eight
novel
allel
rh
kel
jk
blood
group
system
detect
new
allel
dau
cluster
g
extrem
weak
express
use
sever
reagent
lack
epitop
anoth
novel
allel
g
lack
epitop
two
patient
neg
epitop
allel
addit
mutat
similar
weak
type
c
g
novel
mutat
exon
rhd
caus
weak
express
rhd
rhce
variant
found
contain
rhd
exon
part
exon
serolog
compar
rhce
cern
variant
two
novel
mutat
kel
gene
g
g
caus
loss
express
kel
final
mutat
exon
gene
caus
loss
jk
express
summaryconclus
eight
novel
rare
blood
group
allel
detect
genotyp
donor
patient
serolog
could
provid
conclus
result
expand
databas
blood
group
allel
correspond
serolog
support
predict
blood
group
phenotyp
genotyp
abstract
withdrawn
abstract
withdrawn
k
p
j
w
j
b
e
immunohematolog
institut
hematolog
transfus
medicin
blood
transfus
centr
warsaw
blood
transfus
centr
radom
blood
transfus
centr
blood
transfus
centr
blood
transfus
centr
szczecin
blood
transfus
centr
blood
transfus
centr
poland
background
patient
immun
high
preval
erythrocyt
antigen
requir
compat
transfus
donor
antigen
identif
donor
rare
blood
group
low
cost
possibl
use
high
throughput
genotyp
method
aim
identif
ytab
kpab
doab
diab
coab
lwab
luab
knab
vel
lan
polymorph
encod
rare
antigen
determin
frequenc
allel
group
polish
blood
donor
method
dna
blood
donor
region
blood
transfus
centr
isol
automat
use
chemag
dna
blood
kit
lh
chemagen
janu
pipettor
allel
discrimin
polymorph
perform
automat
format
pcr
lightcycl
roch
accord
standard
protocol
result
among
blood
donor
six
donor
yt
bb
genotyp
one
homozyg
lan
genotyp
identifi
estim
frequenc
test
rare
allel
polish
popul
follow
yt
b
kp
b
b
di
b
co
b
lw
b
lu
b
kn
b
vel
lan
summaryconclus
donor
identifi
uniqu
rare
antigen
extend
polish
rare
blood
donor
registri
valuabl
diagnost
purpos
transfus
patient
antibodi
estim
frequenc
allel
indic
identif
homozyg
donor
remain
rare
antigen
requir
test
least
donor
l
castilho
menegati
delfino
macedo
gilli
hemocentro
unicamp
campina
brazil
background
red
cell
alloimmun
seriou
problem
chronic
transfus
patient
routin
phenotyp
blood
recipi
use
blood
unit
transfus
use
lower
occurr
red
cell
alloantibodi
patient
extens
phenotyp
expens
labori
perform
certain
situat
molecular
understand
blood
group
enabl
design
assay
use
better
guid
match
red
blood
cell
transfus
maintain
inventori
unit
dna
type
aim
base
aim
evalu
impact
molecular
match
incid
red
cell
alloimmun
transfus
patient
sickl
cell
diseas
scd
thalassemia
myelodysplast
syndrom
md
method
blood
group
genotyp
determin
dna
sampl
chronic
transfus
patient
scd
patient
thalassemia
patient
md
dna
sampl
blood
donor
laboratori
develop
test
ldt
hea
rhd
rhce
sequenc
use
determin
genotyp
among
patient
donor
molecular
match
perform
level
rh
k
match
extend
match
extend
match
includ
rh
variant
consid
total
red
blood
cell
unit
request
patient
number
donat
per
year
compat
donor
result
accord
patient
need
perform
molecular
match
md
patient
thalassem
patient
level
scd
patient
patient
thalassemia
level
patient
scd
level
patient
transfus
median
rbc
unit
five
year
molecular
match
overal
incid
rbc
alloimmun
decreas
patient
md
patient
thalassemia
patient
scd
summaryconclus
molecular
match
shown
clinic
benefit
patient
contribut
significantli
reduc
rate
alloimmun
rh
k
match
md
thalassem
patient
extend
match
scd
patient
improv
clinic
outcom
patient
scd
receiv
extend
molecular
match
blood
includ
rh
variant
also
observ
shown
increas
hb
level
reduct
hb
better
vivo
rbc
surviv
diminish
frequenc
transfus
ying
x
xu
x
hong
k
j
f
zhu
w
hu
zhejiang
provinci
key
laboratori
blood
safeti
research
blood
center
zhejiang
provinc
binjiang
hangzhou
zhejiang
china
background
genotyp
common
red
blood
cell
rbc
antigen
success
appli
routin
test
discrepantli
serolog
result
lack
commerci
antibodi
screen
rare
blood
group
donor
effect
accur
method
tradit
serolog
assay
mani
molecular
techniqu
pcr
etc
develop
base
singl
nucleotid
polymorph
snp
antithet
allel
detect
singl
blood
group
system
one
test
thu
almost
limit
routin
test
aim
overcom
limit
convent
serolog
establish
low
cost
assay
genotyp
assay
base
multiplex
probe
amplif
mlpa
technolog
appli
chines
popul
method
three
differ
probe
combin
includ
site
use
detect
sampl
mlpa
reaction
perform
thermocycl
abi
appli
biosystem
accord
manufactur
instruct
mlpa
probe
hybrid
ligat
dna
ligat
product
pcr
amplifi
use
univers
primer
pcr
product
electrophoret
analyz
polym
dna
analyz
abi
appli
biosystem
comput
program
coffalys
mrc
holland
use
analyz
raw
data
also
copi
number
allel
rhd
determin
mlpa
result
three
multiplex
pcr
system
abl
simultan
analysi
site
includ
red
blood
cell
group
rh
colton
cromer
diego
dombrock
duffi
gerbich
indian
kell
kidd
knop
lw
lutheran
lewi
mn
ok
scianna
yt
two
platelet
antigen
system
clear
typic
peak
posit
fluoresc
peak
amplifi
fragment
clearli
discern
eighteen
blood
group
two
platelet
antigen
system
genotyp
sampl
obtain
analysi
softwar
posit
peak
relat
length
amplifi
fragment
posit
mutat
blood
group
antigen
determin
accord
posit
peak
height
fluoresc
peak
relat
amount
amplifi
product
copi
number
templat
quantit
determin
accord
peak
fluoresc
result
found
concord
direct
dna
sequenc
complet
addit
experi
hybrid
rhesu
box
test
summaryconclus
assay
could
easili
simultan
identifi
common
allel
correctli
predict
phenotyp
chines
popul
provid
simpl
tool
dna
genotyp
chines
donor
screen
work
support
scienc
research
foundat
zhejiang
provinc
medic
scienc
research
foundat
zhejiang
provinc
abstract
withdrawn
c
l
e
l
j
e
cell
therapi
patholog
hospit
israelita
albert
einstein
paulo
bank
univers
campina
campina
brazil
background
blood
group
chimer
rare
phenomenon
occur
either
congenit
acquir
case
describ
literatur
sinc
case
present
major
clinic
manifest
usual
recogn
time
blood
group
type
agglutin
discrep
cell
type
serum
type
requir
evalu
aim
herein
describ
case
femal
twin
abo
rh
antigen
perman
chimer
detect
routin
abo
rh
type
method
abo
rh
type
perform
hemagglutin
gel
card
abo
genotyp
perform
saliv
studi
perform
inhibit
hemagglutin
tube
short
tandem
repeat
str
loci
powerplex
fusion
pcr
amplif
kit
promega
corpor
usa
chimermark
softwar
softgenet
use
verifi
presenc
chimer
result
old
femal
donor
found
reaction
abo
forward
type
rhc
type
reaction
gel
test
reagent
rang
found
donor
type
routin
revers
abo
group
donor
plasma
nonreact
group
b
rbc
donor
ask
new
blood
collect
togeth
rel
father
mother
twin
sister
rbc
saliv
sampl
collect
father
sampl
type
b
mother
sampl
type
without
discrep
abo
type
twin
sampl
reproduc
result
initi
detect
abo
type
saliv
studi
show
secret
b
substanc
mother
father
twin
type
howev
reaction
observ
c
antigen
type
twin
abo
genotyp
analysi
perform
demonstr
appar
abo
genotyp
twenti
one
short
tandem
repeat
str
loci
perform
genom
dna
extract
peripher
blood
show
one
two
addit
peak
besid
main
tall
str
peak
least
six
loci
vwa
tpox
consist
presenc
chimer
summaryconclus
rare
case
abo
rh
discrep
found
routin
donor
type
donor
twin
sister
although
uncommon
occurr
perman
chimer
involv
twin
two
blood
group
system
presenc
ab
c
c
phenotyp
despit
rare
phenomenon
diagnost
suspicion
presenc
chimera
necessari
order
resolv
type
discrep
provid
compat
blood
transfus
r
tobita
matsumoto
uchikawa
n
tsuno
k
nakajima
block
blood
center
japanes
red
cross
tokyo
japan
background
erythrocyt
agglutin
reaction
salin
test
depend
abil
antibodi
form
bridg
across
adjac
erythrocyt
except
igg
antibodi
blood
group
antigen
igg
antibodi
abl
induc
erythrocyt
agglutin
salin
test
report
abil
igg
antibodi
induc
hemagglutin
depend
differ
length
hing
region
antibodi
aim
aim
produc
igg
antibodi
abil
induc
direct
hemagglutin
salin
test
chang
length
linker
scfvd
hg
method
variabl
region
heavi
vh
light
vl
chain
monoclon
antibodi
synthes
produc
hybridoma
cell
amplifi
pcr
use
extract
cdna
side
vh
side
vl
ligat
linker
make
scfvd
flexibl
linker
fl
compos
n
one
unit
prepar
joint
scfvd
human
igg
h
chain
constant
region
hg
adjust
copi
number
n
length
fl
suitabl
induct
hemagglutin
examin
result
obtain
antibodi
show
abil
induc
direct
agglutin
red
blood
cell
salin
test
antibodi
titer
requir
induc
hemagglutin
cell
salin
test
room
temperatur
agglutin
score
scfvd
scfvd
scfvd
scfvd
scfvd
summaryconclus
produc
antibodi
abl
induc
hemagglutin
red
cell
salin
test
although
molecular
size
produc
monoclon
similar
igg
molecul
scfvd
particular
abl
induc
strong
direct
hemagglutin
salin
test
elimin
constant
region
light
chain
may
improv
flexibl
igg
molecul
result
abil
form
bridg
across
adjac
erythrocyt
addit
experi
yield
highest
antibodi
titer
conclud
suitabl
length
flexibl
crosslink
erythrocyt
genet
engin
monoclon
antibodi
may
use
applic
laboratori
test
red
cell
especi
tube
test
gel
column
test
without
need
addit
reagent
j
g
p
medic
school
univers
sydney
camperdown
develop
australian
red
cross
blood
servic
alexandria
haematolog
princ
wale
hospit
randwick
servic
australian
red
cross
blood
servic
alexandria
australia
background
collect
singl
nucleotid
polymorph
snp
within
immunolog
gene
signal
pathway
deriv
gene
chip
screen
prove
use
predict
immunoglobulin
product
healthi
blood
donor
tan
molecular
immunolog
uncertain
whether
snp
could
predict
valu
patient
may
receiv
blood
transfus
aim
hypothesis
identifi
genet
factor
could
use
predict
alloantibodi
format
patient
opportun
conduct
studi
limit
patient
deliber
transfus
antigen
howev
cours
transfus
support
patient
requir
red
cell
may
receiv
phenotyp
mismatch
unit
method
regular
transfus
patient
n
sydney
metropolitan
hospit
assign
either
respond
profil
base
alloantibodyautoantibodi
statu
dna
extract
thalassaemia
patient
blood
sampl
n
genotyp
target
snp
predict
respond
profil
gener
use
predict
model
result
twenti
nine
percent
thalassaemia
patient
sickl
cell
diseas
patient
form
antibodi
older
thalassaemia
patient
like
develop
antibodi
younger
counterpart
p
valu
respond
thalassaemia
patient
significantli
associ
two
snp
blnk
p
valu
tslp
p
valu
predict
model
predict
thalassaemia
patient
current
assign
base
alloantibodyautoantibodi
statu
like
respond
summaryconclus
find
predict
model
indic
thalassaemia
patient
classifi
respond
may
higher
propens
develop
alloantibodi
continu
receiv
fulli
match
phenotyp
red
blood
cell
transfus
longitudin
follow
patient
requir
determin
predict
model
accur
x
wang
zhao
q
zhou
l
zhan
beij
peke
china
background
complex
array
physicochem
chang
happen
red
blood
cell
rbc
storag
lead
enhanc
clearanc
dendrit
cell
dc
play
crucial
role
engulf
age
rbc
howev
still
lack
evid
store
rbc
srbc
modul
respons
inflammatori
stimuli
home
antigen
present
abil
aim
studi
interact
store
rbc
dc
inflamm
respons
initi
store
rbc
migrat
antigen
present
abil
dc
monitor
indic
shed
light
specif
correl
method
use
mice
fresh
rbc
store
rbc
pb
separ
stimul
imdc
deriv
mous
bone
marrow
h
low
dose
lp
ex
vivo
supernat
collect
batch
analysi
cytokin
chemokin
secret
elisa
dc
collect
phenotyp
analysi
fac
vivo
distribut
migrat
dynam
bioluminesc
imag
adopt
transfus
prolifer
activ
cell
elicit
dc
also
detect
result
srbc
intern
dc
compar
fresh
one
block
interact
significantli
decreas
engraft
accumul
srbc
significantli
promot
express
allostimulatori
molecul
well
secret
type
cytokin
presenc
lpsin
particular
home
abil
transfus
dc
treat
srbc
also
significantli
higher
fresh
counterpart
elev
cytoskeleton
measur
srbc
treat
dc
rhorock
pathway
involv
contrari
prolifer
activ
secret
cell
store
rbc
group
demonstr
opposit
regulatori
effect
dc
abil
prime
suppress
lymphocyt
store
rbc
inhibit
antigen
present
store
rbc
treat
dc
mediat
alter
antigen
engulf
mhcipeptid
tcr
interact
probabl
associ
intracellular
level
immunoproteasom
respons
antigen
process
dc
summaryconclus
although
store
rbc
capabl
promot
dc
home
cell
abund
region
mean
srbc
threw
increas
dc
abil
initi
downstream
immun
respons
mayb
partli
respons
immunosuppress
effect
store
rbc
transfus
b
j
j
b
p
j
h
medicin
pathobiolog
univers
toronto
medicin
keenan
research
centr
biomed
scienc
st
michael
hospit
platelet
immunobiolog
group
st
michael
hospit
hospit
sick
children
innov
canadian
blood
servic
medicin
keenan
research
centr
biomed
scienc
st
michael
hospit
toronto
canada
perelman
school
medicin
univers
pennsylvania
pediatr
children
hospit
philadelphia
philadelphia
pennsylvania
unit
state
america
univers
toronto
toronto
canada
background
fetal
neonat
alloimmun
thrombocytopenia
fnait
disord
caus
matern
immun
respons
patern
inherit
platelet
antigen
character
sever
bleed
includ
intracrani
hemorrhag
ich
intrauterin
growth
restrict
death
fnait
occur
liveborn
neonat
howev
may
underestim
due
miscarriag
integrin
commonli
target
protein
although
number
polymorph
subunit
similar
report
incid
fnait
greater
previous
demonstr
subunit
endotheli
cell
target
fnait
lead
ich
placent
vascular
patholog
journal
clinic
investig
natur
commun
although
mainli
express
platelet
known
one
earliest
marker
hematopoiet
commit
express
popul
hematopoiet
stem
cell
hsc
hsc
gener
yolk
sac
region
migrat
placenta
fetal
liver
final
bone
marrow
aim
test
hypothesi
miscarriag
preval
mediat
fnait
matern
antibodi
target
hsc
result
decreas
blood
cell
count
increas
bleed
fetal
death
method
activ
fnait
model
establish
immun
femal
mice
wt
platelet
breed
wt
male
femal
bred
wt
male
control
sera
collect
prior
breed
ultrasound
loss
gday
deliveri
dead
pup
use
detect
miscarriag
mice
sacrif
fetus
placenta
fetal
liver
weigh
tissu
bone
marrow
blood
prepar
singl
cell
suspens
analyz
flow
cytometri
fluoresc
marker
use
identifi
hsc
cell
b
cell
cell
myeloid
lineag
cell
megakaryocyt
result
immun
mice
gener
signific
immun
respons
fnait
fetus
reduc
bodi
liver
weight
bleed
diathesi
post
natal
day
neonat
low
platelet
count
ultrasound
reveal
miscarriag
mainli
occur
fnait
pregnanc
rate
miscarriag
significantli
higher
model
sera
immun
mice
abl
bind
fetal
liver
hsc
vitro
suggest
matern
antibodi
target
fetal
hsc
vivo
fnait
fetus
reduc
overal
hsc
hsc
placenta
liver
yolk
sac
blood
analysi
show
reduc
cell
megakaryocyt
popul
summaryconclus
establish
mous
model
fnait
reveal
high
rate
miscarriag
may
explain
pauciti
report
human
case
experi
progress
elucid
mechan
result
current
indic
matern
antibodi
bind
may
target
fetal
hsc
embryon
develop
contribut
significantli
impair
placent
fetal
liver
develop
miscarriag
studi
destruct
earli
hsc
progenitor
may
explain
decreas
total
hsc
account
cytopenia
fnait
fetus
well
enrich
gener
knowledg
hsc
develop
migrat
differenti
g
l
r
blood
servic
medicin
patholog
univers
alberta
edmonton
blood
servic
winnipeg
fetal
medicin
bc
women
hospit
blood
servic
british
columbia
vancouv
canada
background
old
patient
present
perinat
care
found
fetal
hemorrhag
ich
serolog
investig
hla
hpa
antibodi
neg
genet
studi
includ
whole
genom
sequenc
identifi
definit
etiolog
ich
matern
patern
human
platelet
antigen
hpa
mismatch
note
matern
genotyp
patern
type
pregnanc
end
fetal
demis
definit
caus
ich
identifi
second
pregnanc
fetal
ich
occur
aim
identifi
emerg
anti
platelet
antibodi
may
explain
ich
determin
treatment
fetalneonat
thrombocytopenia
fnait
warrant
method
earli
fetal
ultrasound
clinic
monitor
institut
ich
detect
week
gestat
matern
patern
hpa
genotyp
perform
use
beadchip
bioarray
immucor
antibodi
investig
perform
luminex
method
matern
plasma
sampl
follow
test
elisa
maipa
matern
plasmapatern
platelet
crossmatch
confirm
find
repeat
test
sampl
confirm
reproduc
result
addit
test
method
new
matern
plasma
sampl
follow
one
month
later
result
matern
patern
hpa
genotyp
confirm
singl
hpa
mismatch
matern
genotyp
patern
genotyp
review
whole
genom
sequenc
data
fetu
first
pregnanc
reveal
genotyp
initi
luminex
antibodi
screen
neg
antibodi
posit
hla
antibodi
retest
serum
first
pregnanc
perform
antibodi
detect
initi
elisa
maipa
reveal
posit
result
howev
contain
test
well
matern
plasmapatern
platelet
crossmatch
show
higher
od
read
well
contain
platelet
addit
maipa
test
perform
initi
sampl
reveal
weak
antibodi
elisa
maipa
weak
reactiv
patern
crossmatch
repeat
sampl
sent
month
first
collect
grown
stronger
screen
elisa
maipa
method
crossmatch
summaryconclus
ivig
therapi
gkg
per
week
start
continu
week
deliveri
hpa
match
platelet
donor
identifi
one
book
peripartum
donat
ich
remain
stabl
remaind
pregnanc
babi
deliv
elect
cs
week
neonat
scan
confirm
ich
cord
platelet
count
higher
expect
treat
fnait
platelet
transfus
neonat
platelet
genotyp
confirm
repeat
test
time
may
necessari
identifi
weak
clinic
signific
antibodi
presenc
maternalpatern
hpa
mismatch
set
bleed
may
enough
institut
therapi
context
otherwis
un
explain
ich
given
unexpectedli
high
cord
blood
platelet
count
possibl
ich
due
altern
un
identifi
caus
must
consid
h
brouk
bennouar
amirech
h
ouelaa
servic
hemobiolog
blood
transfus
univers
hospit
center
faculti
medicin
univers
badji
mokhtar
annaba
algeria
background
fetal
neonat
alloimmun
thrombocytopenia
fnait
one
frequent
caus
sever
thrombocytopenia
intracrani
hemorrhag
ich
fetus
term
neonat
diagnosi
establish
demonstr
antibodi
human
platelet
antigen
hpa
discord
platelet
antigen
type
parent
mother
neonat
fnait
tend
sever
infant
born
subsequ
mother
previous
gave
birth
infant
condit
aim
report
manag
subsequ
pregnanc
previou
sever
nait
due
max
antibodi
addit
risk
alloimmun
antigen
method
noninvas
method
estim
sever
fnait
pregnanc
use
platelet
antigen
monoclon
antibodi
immobil
test
maipa
perform
everi
four
six
week
pregnanc
test
mother
serum
strength
antibodi
serolog
crossmatch
patern
platelet
detect
rare
hpa
specif
platelet
genotyp
hpa
readi
gene
plu
diagnostik
gmbh
hpa
hla
gene
dr
diagnostik
gmbh
perform
detect
hpa
incompat
studi
immun
antigen
biolog
investig
carri
hemobiolog
blood
transfus
servic
univers
hospit
center
annaba
algeria
result
platelet
genotyp
reveal
four
incompat
parent
system
father
heterozyg
system
futur
infant
chanc
possess
implic
antigen
hla
antigen
found
could
correl
lack
immun
antigen
detect
matern
observ
maipa
test
low
posit
note
crossmatch
gpiibiiia
patern
platelet
favor
alloimmun
although
increas
crossmatch
densiti
ivig
treatment
indic
prevent
measur
week
gestat
posolog
gkgweek
summaryconclus
matern
immun
import
caus
fnait
consid
case
appar
fnait
resolv
basi
incompat
common
platelet
antigen
close
monitor
pregnanc
provid
proper
medic
support
condit
reduc
incid
neurolog
sequela
fetu
newborn
x
xu
chen
ying
liu
x
hong
j
f
zhu
w
hu
blood
center
zhejiang
provinc
hangzhou
china
background
platelet
antigen
antibodi
play
import
role
immun
thrombocytopenia
import
antibodi
form
besid
hla
antibodi
caucasian
howev
chines
phenotyp
rare
clear
antibodi
clinic
signific
chines
aim
aim
studi
deduc
preval
antibodi
evalu
import
chines
popul
method
antigen
frequenc
hpa
analyz
compar
accord
data
immuno
polymorph
databas
site
previou
report
antigen
mismatch
possibl
mmp
hpa
calcul
use
correspond
antigen
frequenc
chines
caucasian
preval
constitu
ratio
antibodi
hpa
caucasian
review
statist
analyz
accord
previou
report
preval
constitu
ratio
antibodi
chines
estim
use
equat
ab
chines
ab
caucasian
mmp
chines
mmp
caucasian
antibodi
preval
clinic
signific
compar
hpa
chines
caucasian
work
support
nation
natur
scienc
foundat
china
zhejiang
innov
health
talent
result
frequenc
allel
antigen
caucasian
respect
correspond
frequenc
chines
mmp
antigen
chines
time
caucasian
vs
howev
mmp
chines
caucasian
vs
caucasian
antibodi
highest
preval
ie
preval
constitu
ratio
follow
preval
antibodi
antibodi
antibodi
preval
chines
deriv
equat
complet
differ
caucasian
antibodi
highest
preval
chines
antibodi
ie
preval
constitu
ratio
follow
calcul
preval
along
chines
almost
lowest
among
common
platelet
antibodi
summaryconclus
profil
platelet
antibodi
chines
caucasian
complet
differ
due
ethnic
genet
divers
major
platelet
immun
antigen
caucasian
rel
minor
role
contrari
rather
may
clinic
signific
platelet
antigen
chines
therefor
primari
task
china
develop
sensit
specif
techniqu
identifi
antibodi
establish
donor
databas
zhou
g
wu
f
lu
z
zhong
j
lin
nan
institut
transfus
medicin
nan
china
background
broadli
express
platelet
monocyt
endotheli
cell
etc
incid
defici
guangxi
china
antibodi
develop
defici
peopl
frequent
report
case
fetalneonat
alloimmun
thrombocytopenia
fnait
platelet
transfus
refractori
ptr
asian
popul
role
program
platelet
death
apoptosi
thrombocytopenia
caus
antibodi
rel
therefor
detail
get
attent
aim
investig
impact
antibodi
platelet
apoptosi
contribut
platelet
dysfunct
compar
antibodi
method
platelet
sampl
twenti
healthi
blood
donor
incub
antisera
monoclon
antibodi
mab
clone
gpiv
antisera
mab
clone
gpiib
respect
meanwhil
platelet
incub
ab
sera
pb
control
group
apoptot
event
platelet
detect
annexin
v
stain
analyz
mitochondri
transmembran
potenti
depolar
phosphatidylserin
ps
exposur
respect
result
compar
percentag
apoptosi
control
group
shown
mean
standard
deviat
antisera
antisera
markedli
induc
apoptosi
platelet
healthi
blood
donor
role
antisera
weaker
antisera
result
mab
consist
antisera
demonstr
greater
platelet
apoptosi
depolar
well
ps
exposur
summaryconclus
find
show
normal
platelet
incur
apoptosi
antisera
thrombocytopenia
patient
antisera
mab
induc
apoptosi
platelet
healthi
blood
donor
effect
weaker
hpa
compar
antibodi
might
relat
less
sever
clinic
manifest
newborn
fnait
caus
antibodi
c
chenet
j
quesn
f
bianchi
philipp
n
ferr
c
casal
mammass
v
jallu
c
martageix
r
petermann
platelet
immunolog
int
pari
franc
background
human
platelet
antigen
hpa
caus
allel
polymorph
locat
gene
encod
main
platelet
membran
glycoprotein
complex
gpiaiia
gpiibiiia
gpibix
platelet
genotyp
routin
perform
platelet
immunolog
laboratori
differ
techniqu
ssp
rflp
rt
beadchip
technolog
ng
panel
antigen
use
vari
lab
lab
countri
depend
allel
frequenc
accord
ethnic
popul
analysi
aim
goal
studi
determin
whether
panel
antigen
use
lab
platelet
genotyp
adequ
accord
activ
focus
fetal
neonat
alloimmun
thrombocytopenia
fnait
allo
immunis
inde
peopl
studi
caucasian
howev
mix
ethnic
popul
pari
differ
origin
sampl
french
oversea
depart
territori
relev
use
larg
panel
antigen
platelet
genotyp
method
studi
platelet
genotyp
perform
routin
hpa
beadchip
genotyp
kit
bioarray
solut
immucor
warren
nj
kit
diagnostik
gmbh
germani
hous
rare
privat
hpa
system
data
collect
use
laboratori
inform
manag
system
institut
result
analyz
result
obtain
last
year
hpa
genotyp
done
context
nait
highlight
involv
rare
hpa
system
peopl
n
n
n
bw
n
detect
follow
context
one
nait
ii
one
miscarriag
prenat
diagnosi
done
background
known
anti
alloantibodi
iii
found
chanc
thrombocytopenia
prospect
iv
intracrani
hemorrhag
explor
nait
studi
includ
one
case
discoveri
anti
alloantibodi
moreov
platelet
genotyp
analysi
less
frequent
privat
hpa
system
respect
perform
one
one
also
identifi
found
nait
context
absenc
detect
antibodi
matern
sera
fnait
also
found
three
individu
famili
father
plu
children
genotyp
first
hpa
antigen
system
locat
gpix
summaryconclus
context
fnait
nait
use
larg
panel
antigen
platelet
genotyp
includ
rare
privat
hpa
make
sens
regard
ethnic
mixtur
popul
particularli
situat
hpa
incompat
identifi
despit
evoc
clinic
context
strategi
increas
possibl
identifi
hpa
incompat
might
guid
serolog
investig
identifi
potenti
alloantibodi
c
r
abu
pmc
ramallah
palestinian
territori
medicin
gothenburg
univers
gothenburg
sweden
lab
scienc
univers
ramallah
palestinian
territori
background
receptor
play
central
role
platelet
aggreg
thrombu
format
recent
variat
platelet
respons
healthi
untreat
individu
establish
explain
genet
variat
receptor
gene
sever
singl
nucleotid
polymorph
snp
receptor
associ
increas
platelet
reactiv
risk
cardiovascular
diseas
aim
studi
aim
evalu
patholog
haplotyp
use
polymorph
three
differ
ethnic
group
palestinian
swedish
congoles
method
haplotyp
snp
determin
conveni
select
healthi
individu
differ
ethnic
group
n
whole
sequenc
analyz
use
abi
prism
genet
analyz
major
minor
allel
frequenc
snp
determin
studi
popul
genet
differ
ethnic
group
elucid
addit
frequenc
genotyp
calcul
among
ethnic
group
result
studi
five
benign
singl
nucleotid
polymorph
snp
genotyp
identifi
g
overal
frequenc
snp
studi
popul
n
respect
frequenc
haplotyp
among
swedish
n
congoles
n
palestinian
n
respect
frequenc
respect
signific
differ
frequenc
haplotyp
among
ethnic
group
p
regard
patholog
snp
studi
particip
neg
summaryconclus
signific
differ
frequenc
genet
variant
studi
ethnic
group
studi
perform
studi
effect
genet
variat
adp
induc
platelet
aggreg
chen
x
hong
k
q
wu
c
chen
j
f
zhu
w
hu
blood
centr
zhejiang
provinc
hangzhou
china
background
human
platelet
antigen
system
hpa
associ
fetalneonat
alloimmun
thrombocytopenia
fnait
platelet
transfus
refractori
hpa
genotyp
dna
method
help
confirm
specif
hpa
antibodi
prenat
type
fetus
suspect
case
fnait
polymorph
hpa
found
system
chines
popul
mani
polymeras
chain
reaction
type
method
hpa
multiplex
rare
report
aim
aim
studi
establish
multiplex
simpl
quick
accur
genotyp
system
estim
distribut
chines
han
popul
method
blood
sampl
collect
random
platelet
donor
inform
consent
genom
dna
extract
genotyp
system
sixteen
specif
amplif
primer
eight
primer
pair
design
primer
v
softwar
base
polymorph
site
obtain
immuno
polymorph
databas
end
primer
ad
differ
specif
adaptor
eight
primer
pair
divid
two
group
one
group
contain
primer
group
consist
amplif
paramet
optim
primer
pair
group
amplifi
one
tube
amplicon
analyz
electrophoresi
sequenc
bidirect
four
univers
sequenc
primer
pair
design
accord
differ
specif
adaptor
amplif
primer
work
sponsor
nation
scienc
foundat
china
medic
scienc
research
foundat
zhejiang
provinc
result
obvious
specif
band
observ
electrophoresi
amplif
product
length
consist
expect
valu
sequenc
chromatogram
clear
genotyp
ten
sampl
platelet
immunolog
workshop
isbt
concord
refer
result
b
allel
frequenc
platelet
donor
respect
summaryconclus
multiplex
genotyp
system
two
amplif
reaction
establish
distribut
system
analyz
chines
han
popul
abstract
withdrawn
g
c
v
immunolog
depart
french
blood
servic
brittani
ef
renn
laboratori
univers
hospit
nanci
franc
background
fetalneonat
alloimmun
thrombocytopenia
fnait
result
matern
alloimmun
fetal
platelet
antigen
due
scarciti
phenotyp
reagent
platelet
immunolog
laboratori
perform
genotyp
number
uncharacter
mutat
singl
nucleotid
polymorph
locat
near
hpa
report
caus
fals
genotyp
result
aim
report
case
woman
angola
gave
birth
sever
thrombocytopen
boy
platelet
immunolog
investig
perform
identifi
caus
neonat
thrombocytopenia
method
platelet
genotyp
perform
sequenc
antibodi
detect
use
maipa
method
result
identifi
addit
mother
newborn
also
carri
rare
polymorph
correspond
allel
mutat
close
within
sequenc
primer
use
amplifi
allel
detect
newborn
summaryconclus
rare
platelet
antigen
investig
absenc
etiolog
fetalneonat
thrombocytopenia
coupl
absenc
evid
incompat
among
common
antigen
case
also
point
import
local
pcr
primer
use
hpa
genotyp
abstract
withdrawn
j
g
j
p
k
j
j
h
medicin
pathobiolog
univers
toronto
medicin
keenan
research
centr
biomed
scienc
st
michael
hospit
toronto
canada
transfus
research
institut
shanghai
blood
center
shanghai
china
platelet
immunobiolog
group
hospit
sick
children
st
michael
hospit
medicin
keenan
research
centr
st
michael
hospit
platelet
immunobiolog
group
hospit
sick
children
innov
canadian
blood
servic
univers
toronto
toronto
canada
background
platelet
receptor
von
willebrand
factor
play
critic
role
thrombosi
hemostasi
defici
human
known
bernard
soulier
syndrom
bss
bleed
disord
previou
studi
demonstr
adapt
respons
mice
significantli
lower
compar
integrin
defici
mice
immun
antigen
respect
thromb
haemost
suggest
defici
may
alter
immun
homeostasi
lead
impair
gener
immun
respons
howev
role
immun
system
consequ
immun
respons
never
explor
aim
examin
whether
differ
cell
subtyp
mice
compar
mice
mice
method
subtyp
cell
treg
treg
peripher
blood
lymphocyt
mice
phenotyp
assess
week
fluoresc
analyz
flow
cytometri
result
observ
signific
differ
percentag
cell
treg
cell
mice
week
old
mice
interestingli
mice
higher
percentag
treg
compar
mice
vs
p
vs
p
vs
p
mean
sem
howev
percentag
cell
lower
vs
p
cell
exhibit
signific
differ
moreov
week
old
mice
still
higher
percentag
treg
cell
compar
within
cell
total
percentag
cell
subtyp
cell
includ
lower
compar
mice
vs
p
respons
vs
p
respons
vs
p
howev
signific
differ
percentag
treg
observ
within
cell
significantli
increas
compar
mice
summaryconclus
preliminari
data
demonstr
percentag
cell
treg
mice
significantli
higher
mice
polar
cell
decreas
increas
treg
mice
may
partial
explain
difficult
stimul
immun
respons
eg
antibodi
gener
mice
thu
data
uncov
potenti
novel
role
shape
immun
repertoir
may
significantli
impact
immun
system
immun
respons
character
investig
immun
respons
progress
b
r
k
c
h
patholog
blood
bank
clinic
patholog
depart
patholog
gener
hospit
institut
medic
scienc
institut
life
scienc
nation
defens
medic
center
taipei
taiwan
china
background
plasma
prp
autolog
product
deriv
patient
whole
blood
util
process
gradient
densiti
centrifug
multipl
studi
demonstr
role
prp
acceler
facilit
improv
respons
injuri
medic
potenti
prp
larg
due
growth
factor
cytokin
deriv
platelet
recent
report
disclos
influenc
cycl
activ
growth
factor
cytokin
concentr
studi
focu
variat
temperatur
effect
prepar
prp
aim
purpos
studi
standard
prepar
prp
activ
platelet
differ
temperatur
set
requir
addit
substrat
thu
alter
content
sampl
analyz
effect
differ
temperatur
set
storag
quantif
variou
growth
factor
cytokin
method
prp
sampl
collect
healthi
donor
half
volum
underw
incub
platelet
activ
egf
detect
day
incub
differ
temperatur
set
two
pattern
set
includ
consist
pattern
incub
liquid
nitrogen
ln
temperatur
control
high
temperatur
min
altern
pattern
cycl
min
cycl
cycl
result
growth
factor
cytokin
concentr
prp
differ
temperatur
set
analyz
compar
use
immunosorb
assay
elisa
prepar
prp
store
analyz
long
term
effect
month
month
result
concentr
egf
prp
prepar
high
temperatur
set
lower
prepar
ln
set
concentr
differ
five
set
level
prp
prepar
liquid
nitrogen
higher
compar
temperatur
set
prp
h
h
group
kept
month
level
growth
factor
increas
level
egf
prp
increas
approxim
two
fold
egf
month
storag
howev
level
prp
decreas
lower
fresh
prp
summaryconclus
method
use
vitro
laboratori
experi
use
physic
chemic
mechan
platelet
activ
despit
wide
variat
concentr
growth
factor
cytokin
altern
system
still
conveni
method
prp
prepar
growth
factor
level
month
suggest
autolog
prp
store
without
preserv
agent
although
vivo
studi
requir
order
evalu
clinic
efficaci
measur
growth
factor
level
goodarzi
f
yari
mohammadipour
deyhim
research
center
high
institut
research
educ
transfus
medicin
tehran
islam
republ
iran
background
platelet
factor
homotetram
protein
kda
molecular
weight
cxc
chemokin
store
alpha
granul
releas
follow
upon
mani
agonist
high
affin
heparin
main
function
tumor
angiostasi
may
lead
prevent
tumor
metastasi
featur
mainli
mediat
endotheli
cell
howev
also
particip
pathophysiolog
diseas
evalu
valuabl
biomark
aim
evalu
apoptot
effect
recombin
cell
line
express
compar
daudi
cell
line
method
extract
human
platelet
concentr
pc
immunoaffin
chromatographi
purifi
concentr
tube
quantiti
obtain
measur
immunosorb
assay
elisa
molecular
weight
specif
determin
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
cell
line
treat
h
recombin
apoptosi
assay
use
activ
lactat
dehydrogenas
ldh
cell
count
pair
wilcoxon
test
use
statist
analysi
p
consid
signific
result
act
weakli
induc
apoptosi
cell
line
data
show
cell
count
signific
differ
control
experi
group
p
ldh
activ
p
likewis
recombin
could
show
consider
apoptot
effect
marker
p
summaryconclus
observ
releas
platelet
weak
potenc
induc
apoptosi
cancer
cell
line
vitro
factor
may
contribut
process
appli
dose
purif
method
cell
line
type
proteoglycan
carrier
moreov
data
clearli
demonstr
nativ
recombin
form
function
similarli
apoptosi
pathway
r
x
c
f
z
c
blood
transfus
chines
academi
medic
scienc
chengdu
transfus
depart
peopl
hospit
aba
maerkang
china
background
although
hypoxia
report
caus
signific
chang
red
blood
cell
rbc
increas
risk
thrombot
diseas
peopl
resid
high
altitud
relationship
rbc
factor
contribut
clot
strength
remain
larg
unclear
aim
explor
relationship
rbc
count
hemoglobin
hgb
content
haematocrit
hct
factor
contribut
clot
strength
high
altitud
popul
method
total
volunt
elig
studi
divid
three
group
accord
rbc
count
hgb
content
hct
respect
pt
aptt
tt
fbg
measur
clot
assay
rbc
count
hgb
content
hct
platelet
count
assess
use
autom
hematolog
analys
result
pt
aptt
show
signific
posit
correl
rbc
count
hct
hgb
content
r
resp
pt
r
resp
aptt
p
wherea
neg
relationship
observ
plt
count
r
resp
p
small
correl
found
fbg
hct
r
p
tt
fbg
show
correl
rbc
count
hgb
content
hct
mean
pt
level
significantli
higher
high
rbc
hct
hgb
group
medium
normal
group
p
comparison
mean
aptt
level
significantli
higher
high
rbc
hct
group
medium
group
p
comparison
mean
plt
count
significantli
lower
high
hct
hgb
group
medium
normal
group
p
comparison
summaryconclus
rbc
count
hgb
content
hct
show
differ
effect
factor
contribut
clot
strength
platelet
count
fbg
pt
aptt
tt
new
data
high
altitud
popul
quit
help
studi
format
mechan
altitud
thrombot
diseas
j
j
l
l
hospit
de
de
porto
alegr
porto
alegr
brazil
background
recent
implement
flow
cytometri
platelet
center
analys
paramet
would
influenc
platelet
count
increment
especi
mean
channel
shift
variabl
convent
evalu
dichotom
littl
still
known
platelet
refer
valu
reproduct
solid
organ
transplant
experi
aim
evalu
mean
channel
shift
continu
predictor
platelet
correct
count
increment
pci
control
relev
factor
method
prospect
enrol
platelet
transfus
refractori
ptr
patient
platelet
protocol
guid
flow
cytometri
screen
data
collect
regard
h
pci
base
correct
count
increment
cci
formula
abo
compat
number
transfus
platelet
flow
cytometri
deriv
mean
channel
shift
mc
perform
sensit
platelet
donor
patient
serum
follow
stain
acquir
fac
canto
ii
consid
posit
mc
equal
greater
channel
sd
neg
control
result
march
januari
group
patient
enrol
patient
receiv
total
crossmatch
platelet
transfus
cpt
consid
compat
base
describ
criteria
major
transfus
median
platelet
count
previous
transfus
afterward
compat
cpt
median
platelet
count
pci
higher
incompat
cpt
pci
p
correl
coeffici
pci
mc
p
pci
number
transfus
platelet
p
abo
incompat
associ
pci
p
mc
p
although
dichotom
evalu
positiveneg
inde
prove
import
predictor
pci
mean
differ
ci
p
linear
associ
mc
pci
could
also
identifi
progress
decreas
pci
observ
increment
point
mc
median
pci
per
strata
mc
se
se
se
se
se
p
summaryconclus
observ
immunolog
ptr
patient
abo
incompat
number
transfus
patient
may
influenc
final
pci
much
compat
flow
cytometri
moreov
mc
present
linear
correl
final
pci
stratifi
msc
valu
observ
even
mc
valu
would
consid
incompat
dichotom
standpoint
eventu
render
adequ
pci
valu
overlook
especi
critic
situat
howev
compat
must
still
sought
prevent
alloimmun
abstract
withdrawn
rn
makroo
fadadu
agraw
chowdhri
p
karna
depart
transfus
medicin
indraprastha
apollo
hospit
new
delhi
india
background
platelet
refractori
repres
signific
clinic
problem
complic
provis
platelet
transfus
associ
advers
clinic
outcom
increas
health
care
cost
platelet
use
manag
thrombocytopen
patient
refractori
transfus
randomli
select
platelet
solid
phase
red
cell
adher
assay
sprca
technolog
allow
platelet
antibodi
screen
platelet
cross
match
aim
aim
studi
determin
effect
platelet
group
oncolog
patient
refractori
platelet
method
random
abo
compat
singl
donor
platelet
sdp
random
donor
platelet
rdp
transfus
given
refractori
patient
studi
patient
defin
refractori
correct
count
increment
cci
follow
two
consecut
platelet
transfus
platelet
sprca
cci
determin
monitor
effect
platelet
transfus
result
four
hundr
three
compat
platelet
sdp
rdp
unit
incompat
platelet
cross
match
compar
platelet
incompat
platelet
statist
signific
improv
found
mean
correct
count
increment
p
compat
platelet
transfus
associ
good
respons
case
incompat
platelet
associ
good
respons
transfus
event
p
cci
mean
sd
significantli
higher
platelet
incompat
one
p
summaryconclus
cross
match
compat
platelet
lead
higher
cci
platelet
refractori
patient
platelet
use
sprca
technolog
effect
rapid
approach
select
compat
platelet
treatment
thrombocytopen
cancer
patient
e
f
e
n
immunohematolog
institut
feder
state
institut
scienc
kirov
research
institut
hematolog
blood
transfus
feder
medic
biolog
agenc
russia
kirov
russian
feder
background
platelet
refractori
aris
seriou
complic
transfus
therapi
transfus
platelet
requir
reduc
risk
bleed
refractori
patient
aim
studi
frequenc
detect
alloantibodi
hematolog
patient
method
result
determin
hla
antibodi
patient
hematolog
clinic
analyz
screen
identif
antibodi
perform
cytotox
assay
flow
cytometri
bd
facscanto
ii
usa
result
detect
hematolog
patient
men
women
children
antibodi
establish
patient
myelodysplast
syndrom
acut
leukemia
aplast
anemia
hematolog
diseas
indic
criterion
assess
degre
panel
reactiv
antibodi
pra
calcul
percentag
posit
reaction
patient
blood
serum
lymphocyt
differ
donor
pra
record
patient
pra
pra
pra
detect
patient
refractori
platelet
transfus
summaryconclus
thu
despit
use
blood
compon
level
remain
high
women
patient
myelodysplast
syndrom
acut
leukemia
hla
antibodi
one
main
reason
poor
posttransfus
platelet
increment
l
z
j
center
zhejiang
provinc
zhejiang
provinci
key
laboratori
blood
safeti
research
run
run
shaw
hospit
hangzhou
china
background
antibodi
direct
hla
hpa
present
platelet
surfac
frequent
associ
platelet
alloimmun
clinic
refractori
lot
clinic
studi
describ
detail
phenomenon
platelet
antigen
alloimmun
littl
report
focus
persist
antibodi
especi
china
aim
studi
perform
investig
persist
antibodi
transfus
patient
period
year
evalu
transfus
histori
pregnanc
histori
method
retrospect
examin
perform
record
antibodi
blood
bank
comput
databas
record
patient
underw
least
one
antibodi
investig
antibodi
detect
studi
antibodi
regard
persist
previou
detect
screen
becam
neg
antibodi
studi
patient
switch
transfus
exclud
antibodi
detect
adher
sprca
techniqu
test
use
compar
incid
antibodi
undetect
group
result
analysi
perform
record
fulfil
criteria
median
antibodi
week
rang
median
age
patient
year
old
includ
male
women
previous
pregnant
patient
patient
becam
undetect
within
week
antibodi
becam
undetect
cours
time
initi
neg
screen
investig
antibodi
patient
reform
differ
durat
antibodi
posit
base
patient
previou
transfus
number
gender
p
summaryconclus
clinic
signific
platelet
reactiv
antibodi
format
probabl
common
previous
realiz
percent
antibodi
becam
undetect
within
initi
week
differ
persist
rate
antibodi
base
patient
previou
transfus
number
gender
j
l
j
l
hospit
de
de
porto
alegr
porto
alegr
brazil
background
clinic
platelet
transfus
refractori
ptr
caus
immun
mechan
immun
ptr
mainli
associ
human
leukocyt
antigen
hla
class
alloimmun
center
ptr
manag
includ
flow
cytometri
platelet
fcpxm
singl
antigen
bind
hla
antibodi
detect
aim
evalu
influenc
hla
class
ci
antibodi
dsa
parallel
effect
abo
compat
median
channel
shift
mc
fcpxm
method
retrospect
evalu
fcpxm
involv
hla
type
donor
concern
one
hla
alloimmun
myelodysplast
syndrom
patient
ci
panel
reactiv
antibodi
pra
june
august
inform
mc
abo
compat
dsa
compil
medic
data
posit
fcpxm
defin
presenc
dsa
least
one
andor
antibodi
mean
fluoresc
intens
mfi
stratifi
result
dsa
observ
mfi
level
higher
result
posit
fcpxm
mc
valu
median
differ
among
dsa
strata
dsa
x
intermedi
dsa
p
dsa
x
high
dsa
p
low
dsa
x
high
dsa
p
differ
dsa
x
low
dsa
intermedi
dsa
x
high
dsa
b
correl
coeffici
p
observ
progress
concentr
dsa
mc
abo
group
compat
also
seem
influenc
result
mc
mean
standard
error
even
control
presenc
dsa
follow
abo
compat
x
major
incompat
p
abo
compat
x
bidirect
incompat
p
minor
x
major
incompat
p
minor
x
bidirect
incompat
p
signific
differ
mc
found
abo
compat
minor
incompat
major
bidirect
incompat
summaryconclus
three
preval
allel
brazilian
southernmost
region
found
enrol
donor
patient
pra
present
mfi
antigen
could
explain
posit
fcpxm
moreov
high
proport
high
dsa
could
result
pra
observ
patient
result
dsa
strata
allow
us
defin
major
compat
group
dsalow
dsa
median
mc
intermedi
dsahigh
dsa
median
mc
conclud
dsa
level
may
necessarili
result
incompat
fcpxm
hand
mfi
valu
exceed
systemat
associ
posit
fcpxm
find
reinforc
import
dsa
quantit
rather
exclus
qualit
evalu
manag
alloimmun
ptr
patient
also
abo
compat
influenc
result
mc
even
dsa
control
support
import
abo
group
guid
platelet
select
even
patient
requir
fcpxm
mediat
support
j
f
w
center
zhejiang
provinc
provinci
key
laboratori
blood
safeti
research
hangzhou
china
background
platelet
antibodi
close
relat
platelet
transfus
refractori
ptr
ptr
patient
detect
antibodi
human
leucocyt
antigen
hla
antibodi
human
platelet
antigen
hpa
therefor
detect
antibodi
hla
hpa
crucial
platelet
transfus
therapi
howev
reliabl
method
simultan
detect
hla
hpa
antibodi
yet
describ
china
aim
detect
hla
antibodi
simultan
luminex
bead
coupl
antibodi
platelet
glycoprotein
gp
ibix
hla
compar
monoclon
antibodi
immobil
platelet
antigen
maipa
assay
method
antibodi
specif
gpibix
clone
hla
clone
separ
coupl
luminex
xmap
bead
mous
igg
coupl
luminex
xmap
bead
posit
control
coupl
bead
valid
rabbit
igg
eight
serum
sampl
contain
hla
hpa
antibodi
confirm
monoclon
immobil
platelet
antigen
maipa
test
studi
eight
sera
without
hpa
hla
antibodi
prepar
ab
type
blood
donor
neg
control
platelet
collect
four
individu
known
hpa
genotyp
react
sera
respect
reaction
complex
lyse
incub
luminex
bead
mix
subject
flow
cytometr
analysi
valu
calcul
valu
identifi
posit
result
significantli
higher
mfi
valu
valu
vs
hla
vs
vs
igg
observ
bead
coupl
confirm
experi
suggest
antibodi
gpibix
hla
success
coupl
luminex
bead
result
show
mfi
valu
significantli
higher
valu
vs
impli
serum
sampl
posit
mfi
valu
higher
valu
vs
react
lower
valu
react
illumin
posit
antibodi
depend
specif
hpa
genotyp
platelet
donor
sampl
posit
exhibit
neg
result
luminex
bead
technolog
illumin
technolog
could
affect
hpa
antibodi
seven
sampl
test
luminex
bead
technolog
consist
maipa
result
illustr
luminex
bead
technolog
capabl
detect
hla
hpa
antibodi
summaryconclus
luminex
bead
coupl
gpibix
hpa
antibodi
could
success
use
detect
hla
antibodi
simultan
work
sponsor
nation
natur
scienc
foundat
china
scienc
research
foundat
zhejiang
healthi
bureau
abstract
withdrawn
k
yan
c
chan
leung
c
lam
divis
haematolog
queen
mari
hospit
pokfulam
hong
kong
background
high
demand
platelet
immunolog
servic
queen
mari
hospit
hong
kong
acut
region
hospit
tertiari
quaternari
care
includ
solid
organ
haematopoiet
stem
cell
transplant
hsct
wide
rang
adult
paediatr
surgic
servic
total
request
platelet
immunolog
test
suspect
autoimmun
thrombocytopenia
aitp
platelet
transfus
refractori
ptr
neonat
alloimmun
thrombocytopenia
nait
studi
record
past
year
aim
accredit
platelet
immunolog
servic
establish
support
time
diagnosi
manag
unexplain
thrombocytopenia
platelet
transfus
refractori
method
platelet
antibodi
detect
monoclon
immobil
platelet
antigen
maipa
luminex
elisa
platelet
immunofluoresc
test
pift
regard
maipa
panel
monoclon
antibodi
select
target
hla
class
antigen
human
platelet
antigen
hpa
type
perform
polymeras
chain
specif
primer
method
cover
system
phenotyp
done
platelet
monocyt
flow
cytometri
monoclon
antibodi
hpa
type
platelet
panel
establish
among
group
staff
fresh
platelet
labil
antigen
readili
avail
result
januari
decemb
case
receiv
platelet
autoantibodi
studi
mostli
compat
clinic
diagnosi
aitp
other
includ
unexplain
scenario
isol
thrombocytopenia
hsct
peripher
consumpt
thrombocytopenia
refractori
steroid
ivig
treatment
thrombocytopenia
associ
haematolog
malign
autoimmun
diseas
etc
among
posit
case
platelet
glycoprotein
antibodi
detect
ptr
case
class
class
class
antibodi
detect
regard
case
suspect
nait
class
luminex
without
defin
hpa
specif
detect
mother
carri
luminex
thrombocytopen
gave
neg
reaction
direct
maipa
pift
test
thrombocytopen
babi
gave
posit
reaction
direct
pift
test
natur
specif
luminex
antibodi
remain
unresolv
summaryconclus
substanti
need
platelet
immunolog
servic
shown
current
studi
acut
region
hospit
hong
kong
request
age
group
across
differ
clinic
specialti
diagnos
compris
aitp
ptr
nait
studi
follow
constitut
major
platelet
autoantibodi
respect
found
case
class
frequent
detect
platelet
glycoprotein
antibodi
found
alloimmun
thrombocytopen
case
still
servic
gap
identif
novel
rare
hpa
antigen
hereditari
platelet
disord
l
amini
l
transfus
research
center
high
institut
research
educ
transfus
microbiolog
depart
shiraz
iran
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
iran
background
differ
method
isol
microparticl
one
differ
efficaci
puriti
function
isol
microparticl
popul
centrifug
flow
cytometri
mac
mac
technolog
suitabl
method
isol
viabl
function
activ
cell
aim
current
studi
use
mac
techniqu
platelet
microparticl
pmp
need
function
activ
pmp
activ
assay
method
first
microparticl
prepar
low
high
speed
centrifug
platelet
concentr
pc
day
furthermor
pmp
isol
via
streptavidin
kit
pmp
immunophenotyp
done
via
flowcytometri
method
pmp
activ
assay
perform
zymuphen
data
analyz
comparison
test
via
med
calc
softwar
less
consid
signific
result
pmp
puriti
increas
mac
applic
activ
marker
also
express
pmp
use
mac
techniqu
furthermor
result
activ
assay
show
isol
pmp
function
activ
vs
neg
control
summaryconclus
conclus
seem
mac
applic
pmp
isol
effect
method
improv
puriti
pmp
without
effect
pmp
activ
agraw
transfus
medicin
forti
escort
heart
institut
new
delhi
india
background
india
among
medium
develop
countri
popul
billion
area
difficult
terrain
landslid
season
outbreak
dengu
benefit
apheresi
platelet
sdp
vs
random
donor
platelet
rdp
well
document
challeng
come
requir
group
specif
donor
arrang
group
specif
donor
realli
challeng
especi
case
intern
patient
outstat
patient
patient
requir
numer
platelet
transfus
case
like
dengu
etc
especi
corpor
hospit
limit
voluntari
apheresi
blood
donor
registri
advantag
associ
use
pa
greater
remov
plasma
thu
reduc
risk
hemolysi
product
issu
across
group
patient
lesser
allerg
reaction
patient
lesser
vasovag
reaction
donor
smooth
inventori
wastag
prevent
aim
demonstr
clinic
equival
group
specif
sdp
method
studi
conduct
multispecialti
tertiari
health
care
corpor
hospit
delhincr
major
patient
client
age
intern
patient
use
pa
platelet
addit
solut
approv
dcgi
india
central
hospit
transfus
committe
group
hospit
use
pa
implement
apheresi
prepar
use
storag
solut
platelet
use
apheresi
platformpa
ad
later
collect
hyperconcentr
plt
unit
contamin
white
blood
cell
remov
unit
leukoreduct
system
cell
separ
studi
durat
month
donor
particip
studi
met
guidelin
select
blood
donor
platelet
collect
store
constant
agit
undergo
qualiti
control
check
day
till
day
platelet
pouch
even
product
issu
studi
marker
volum
final
product
platelet
count
mean
platelet
volum
mpv
ph
swirl
movement
visual
inspect
patient
platelet
count
pretransfus
patient
platelet
count
next
day
transfus
day
fresh
transfus
result
total
apheresi
unit
prepar
pa
studi
unit
issu
patient
four
unit
discard
date
expir
donor
studi
male
age
group
year
blood
group
posit
final
platelet
volum
prepar
mlmpv
within
normal
rang
fl
swirl
fulli
maintain
studi
grade
visual
inspect
unit
product
ph
rang
platelet
count
patient
platelet
count
assess
apheresi
transfus
h
transfus
mean
percentag
increment
mpi
rang
mean
calcul
advers
transfus
reaction
note
case
summaryconclus
use
pa
apheresi
platelet
elimin
need
platelet
convert
sdp
univers
platelet
therebi
help
better
manag
avail
group
without
compromis
patient
compar
normal
sdp
term
platelet
count
blood
bag
platelet
increment
obtain
patient
therebi
demonstr
clinic
equival
advers
reaction
report
group
indic
safeti
paper
subject
especi
indian
subcontin
larger
studi
need
becom
norm
f
p
g
r
j
develop
australian
red
cross
blood
servic
kelvin
grove
medicin
univers
queensland
queensland
critic
care
research
group
princ
charl
hospit
chermsid
health
queensland
univers
technolog
brisban
neutrophil
refer
laboratori
australian
red
cross
blood
servic
kelvin
grove
health
command
australian
defenc
forc
canberra
australia
background
despit
implement
risk
reduct
strategi
acut
lung
injuri
trali
continu
lead
caus
mortal
morbid
trali
hypothesis
develop
via
threshold
mechan
first
insult
patient
morbid
second
insult
transfus
caus
cellular
activ
contribut
trali
develop
antibodi
target
human
neutrophil
antigen
hna
human
leucocyt
antigen
hla
blood
product
caus
trali
anim
laboratori
model
sought
defin
mechan
trali
develop
neutrophil
initi
consid
primari
cell
respons
caus
trali
subsequ
studi
identifi
pathway
depend
presenc
monocyt
complement
potenti
multipl
pathway
contribut
clinic
trali
role
monocyt
complement
remain
unclear
vitro
model
human
lung
microvascular
endotheli
cell
hlmvec
damag
develop
understand
characteris
pathway
involv
trali
develop
aim
investig
pathway
trali
develop
hlmvec
damag
model
use
serum
donor
implic
report
case
trali
method
granulocyt
immunofluoresc
granulocyt
agglutin
test
confirm
presenc
antibodi
serum
donor
implic
report
case
trali
hlmvec
endotheli
cell
growth
medium
lipopolysaccharid
lp
e
coli
h
model
underli
infect
monocyt
neutrophil
isol
direct
monocyt
direct
neutrophil
isol
kit
freshli
collect
whole
blood
monocyt
neutrophil
ad
hlmvec
min
serum
final
dilut
plasma
complement
sourc
final
dilut
ad
min
viabl
hlmvec
determin
via
trypan
blue
stain
two
independ
observ
statist
differ
determin
p
analysi
varianc
use
tukey
result
absenc
lp
stimul
serum
donor
implic
report
case
trali
induc
hlmvec
damag
addit
complement
sourc
monocyt
hlmvec
mediat
enhanc
damag
donor
serum
induc
hlmvec
damag
hlmvec
first
stimul
lp
hlmvec
damag
evid
hlmvec
lp
donor
serum
complement
sourc
ad
summaryconclus
result
highlight
critic
role
lp
hlmvec
damag
demonstr
role
patient
underli
patholog
predispos
trali
develop
togeth
data
provid
preliminari
evid
trali
develop
via
neutrophil
monocyt
complement
depend
pathway
donor
serum
contain
antibodi
pathway
antibodi
induc
hlmvec
damag
remain
elucid
precis
understand
cell
degre
caus
trali
human
could
provid
avenu
potenti
prophylact
therapeut
target
p
g
k
u
centr
research
develop
medic
diagnost
laboratori
faculti
associ
medic
scienc
khon
kaen
univers
khon
kaen
thailand
clinic
immunolog
transfus
medicin
justu
liebig
univers
giessen
giessen
germani
transfus
center
faculti
medicin
khon
kaen
univers
khon
kaen
thailand
chemistri
biolog
freseniu
univers
appli
scienc
idstein
univers
appli
scienc
kite
centr
excel
inform
technolog
giessen
germani
serum
institut
copenhagen
medic
parasitolog
depart
intern
health
immunolog
microbiolog
depart
infecti
diseas
univers
copenhagen
denmark
background
receptor
iiib
glycoprotein
play
signific
role
phagocytosi
clearanc
immun
complex
polymorph
express
alloantigen
determin
known
human
neutrophil
antigen
hna
sever
studi
report
role
hna
pathomechan
alloimmun
mediat
neutropenia
acut
lung
injuri
well
infect
immun
complex
diseas
meanwhil
four
alloform
discov
howev
littl
known
role
rare
alloform
recent
evid
indic
inherit
rare
alloform
protect
malaria
howev
exact
mechan
known
aim
studi
character
bind
properti
differ
alloform
toward
igg
prove
relev
protect
malaria
method
use
stabl
transfect
cell
recombin
protein
express
character
bind
properti
alloform
toward
igg
prove
relev
efficaci
malaria
clearanc
result
analysi
transfect
recombin
protein
show
higher
affin
toward
igg
alloform
accordingli
neutrophil
deriv
individu
bound
significantli
stronger
igg
antibodi
plasmodium
falciparum
glutam
rich
protein
glurp
compar
donor
presenc
p
falciparum
merozoit
summaryconclus
result
indic
amino
acid
substitut
respons
format
result
high
affin
consequ
bind
antibodi
caus
enhanc
neutrophil
activ
lead
effect
clearanc
malaria
intracellular
ro
n
e
c
moreno
n
boto
c
canal
e
immunohematolog
banc
de
sang
teixit
barcelona
spain
background
swann
antigen
swa
identifi
serum
patient
autoimmun
hemolyt
anemia
aiha
assign
diego
system
incid
less
popul
usual
identifi
patient
ahai
multispecif
sera
due
rariti
clinic
import
establish
present
case
incompat
antibodi
specif
identifi
pregnant
woman
induc
haemolyt
diseas
newborn
hdn
aim
character
clinic
case
involv
rare
blood
group
specif
method
clinic
case
woman
nativ
morocco
transfus
patholog
histori
interest
gave
birth
third
child
present
posit
direct
antiglobulin
test
dat
birth
incompat
studi
show
mother
child
share
blood
group
rhd
posit
antibodi
detect
matern
plasma
begin
howev
clearli
posit
result
dat
confirm
two
previou
pregnanc
complic
although
second
child
also
present
posit
dat
test
whose
caus
establish
result
sampl
father
request
blood
group
rhd
posit
test
pregnant
woman
plasma
partner
red
cell
strongli
posit
result
indic
mother
carri
antibodi
antigen
express
father
red
cell
like
newborn
antibodi
igg
class
titer
father
red
blood
cell
investig
antibodi
low
incid
matern
plasma
exclud
presenc
common
antibodi
identifi
antibodi
specif
father
phenotyp
confirm
sw
studi
complement
amplif
sequenc
region
correspond
exon
gene
encod
band
chang
identifi
heterozygos
result
appear
tryptophan
residu
band
protein
allel
variant
associ
sw
phenotyp
sult
appear
tryptophan
residu
band
protein
allel
variant
associ
sw
phenotyp
summaryconclus
report
case
inform
sever
aspect
worth
remark
new
case
rare
specif
find
specif
present
serum
sampl
context
incompat
antibodi
induc
posit
dat
without
clinic
sign
symptom
newborn
molecular
studi
confirm
serolog
find
sw
phenotyp
father
maric
k
zeleznik
immunohaematolog
blood
transfus
centr
slovenia
ljubljana
slovenia
background
present
case
year
old
pregnant
woman
bodi
mass
index
bmi
vagin
bleed
week
prematur
ruptur
amniot
sac
membran
prolaps
umbil
cord
week
pregnanc
inject
three
dose
immunoglobulin
ig
intramuscularli
gluteal
area
first
one
week
second
one
week
third
one
four
day
second
one
indirect
antiglobulin
test
iat
test
column
agglutin
technolog
borderlin
posit
slovenia
three
differ
ig
product
two
differ
manufactur
accord
first
manufactur
instruct
rout
administr
either
intramuscular
intraven
bmi
consid
bmi
intraven
rout
recommend
increas
risk
lack
effect
sinc
peak
concentr
ig
may
lower
accord
second
manufactur
instruct
rout
administr
either
intramuscular
subcutan
intramuscular
applic
contraind
exact
place
intramuscular
inject
defin
neither
manufactur
ig
intramuscular
administr
slowli
absorb
recipi
circul
reach
maximum
delay
day
aim
tri
clarifi
reason
iat
neg
two
intramuscular
inject
ig
method
serolog
test
genotyp
flow
cytometri
fc
test
kbt
result
genotyp
confirm
patient
realli
exclud
weak
partial
antigen
might
absorb
inject
ig
rbc
lead
almost
neg
iat
direct
antiglobulin
test
dat
also
neg
also
exclud
larg
fetomatern
haemorrhag
fmh
kbt
fc
use
monoclon
antibodi
mab
fc
use
mab
exclud
possibl
patient
rbc
chimer
presenc
small
proport
rbc
apart
rbc
could
nt
seen
serolog
also
fmh
fetu
blood
group
fetu
unknown
assum
gluteal
applic
ig
inject
fat
tissu
slow
minim
absorpt
bloodstream
recommend
addit
dose
via
intraven
rout
four
hour
intraven
applic
ig
control
iat
perform
strongli
posit
confirm
right
applic
drug
exclud
reason
neg
iat
summaryconclus
exclud
possibl
situat
could
neutralis
inject
ig
patient
variant
rbc
chimer
larg
fmh
high
bmi
thick
subcutan
tissu
greater
needl
inject
drug
need
longer
administr
drug
muscl
otherwis
drug
stay
subcutan
fat
tissu
slow
absorpt
probabl
reason
postadministr
low
level
ig
case
opinion
higher
bmi
taken
consider
inject
ig
pigneau
j
cote
c
pambrun
canadian
blood
servic
ottawa
canada
background
prenat
patient
new
guinea
gravida
para
present
week
gestat
panreact
ab
patient
group
rhd
dat
neg
red
cell
genotyp
identifi
variant
polymorph
human
erythrocyt
antigen
ag
aim
determin
antibodi
specif
panreact
prenat
patient
method
standard
serolog
indirect
antiglobulin
iat
piat
test
method
execut
panreact
investig
test
perform
util
commerci
reagent
red
blood
cell
rbc
panel
rbc
frozen
rare
rbc
neg
high
preval
antigen
hpa
advanc
serolog
method
includ
fixat
use
untreat
rbc
elut
studi
eg
gamma
ii
perform
determin
ab
hpa
present
serolog
phenotyp
patient
rbc
assess
use
licens
antisera
accord
manufactur
instruct
erythrocyt
antigen
interrog
qualit
genotyp
test
bloodchip
idcorext
util
luminex
xmap
technolog
sanger
sequenc
result
initi
test
reveal
iat
piat
rbc
test
except
autocontrol
pattern
autoallo
suspect
immedi
spin
andor
autoallo
phenotyp
similar
rbc
react
decdec
rbc
react
weak
iat
suggest
ab
hpa
rh
blood
group
system
rhnull
iat
piat
indic
presenc
ab
hpa
rh
blood
group
system
fixationelut
studi
use
dcedc
phenotyp
similar
untreat
rbc
result
remov
ab
specif
hpa
fixationelut
studi
use
dcedc
result
remov
ab
hpa
identif
elut
rhnull
rbc
indic
presenc
ab
hpa
patient
red
cell
phenotyp
genotyp
confirm
dcedc
patient
dna
refer
sanger
sequenc
rhce
gene
molecular
sequenc
determin
prenat
patient
homozyg
rhce
cern
associ
partial
c
partial
e
predict
phenotyp
summaryconclus
serolog
investig
conjunct
molecular
test
allow
final
ab
identif
ab
produc
hpa
individu
genotyp
homozyg
rhce
cern
express
partial
c
partial
e
ag
also
lack
e
c
antigen
transfus
purpos
compat
rbc
rh
rhnull
newborn
mildli
affect
requir
phototherapi
transfus
support
futur
pregnanc
may
clinic
implic
therefor
requir
monitor
hemolyt
diseas
fetu
newborn
e
p
g
r
l
patholog
laboratori
medicin
univers
ottawa
ottawa
hospit
eastern
ontario
region
laboratori
associ
ottawa
blood
servic
halifax
blood
servic
ottawa
blood
servic
edmonton
blood
servic
toronto
canada
background
alloantibodi
produc
antigen
neg
individu
follow
exposur
foreign
red
blood
cell
rbc
transfus
pregnanc
u
antigen
part
mn
system
present
almost
caucasian
black
popul
individu
alway
neg
alloantibodi
although
extrem
uncommon
cross
placenta
coat
u
posit
fetal
rbc
caus
hemolyt
diseas
fetu
newborn
hdfn
hdfn
commonli
caus
lesser
extent
alloantibodi
aim
case
present
report
case
pregnant
woman
alloantibodi
deliv
healthi
babi
hemolyt
anemia
year
old
woman
gravida
para
present
week
group
neg
posit
antibodi
screen
antibodi
investig
reveal
titr
weak
titr
extend
red
cell
phenotyp
show
jk
fy
previou
pregnanc
unev
neonat
complic
compat
unit
local
avail
canadian
blood
servic
cb
notifi
request
rbc
phenotyp
match
c
u
k
jk
fy
avail
frozen
unit
match
patient
phenotyp
cb
identifi
match
volunt
abl
provid
urgent
donat
day
patient
deliv
full
term
healthi
male
babi
patient
need
blood
transfus
deliveri
bay
apgar
score
min
babi
cord
blood
group
group
neg
evid
hemolysi
hgb
gl
total
bilirubin
direct
antiglobulin
test
dat
posit
acid
eluat
red
cell
phenotyp
demonstr
phenotyp
despit
posit
dat
close
neonat
bloodwork
show
evid
hemolysi
discuss
report
illustr
rare
case
pregnant
woman
alloantibodi
case
emphas
import
protocol
deal
rare
unusu
circumst
earli
notif
hematopathologist
call
ensur
accur
character
immun
antibodi
extrem
import
presenc
antibodi
possibl
kept
mind
g
antigen
part
rh
system
appear
plu
activ
differenti
antibodi
necessari
routin
blood
transfus
patient
receiv
rhd
c
antigen
neg
blood
howev
import
distinguish
antibodi
pregnanc
determin
need
prophylact
rhig
also
import
realis
challeng
find
compat
red
cell
unit
patient
alloantibodi
antigen
earli
notif
cb
crucial
allow
initi
search
compat
unit
extend
genotyp
could
consid
patient
uncommon
andor
multipl
antibodi
final
vigil
perinat
follow
necessari
monitor
possibl
onset
hdfn
k
veal
j
white
r
hagga
rowley
uk
nation
extern
qualiti
assess
servic
uk
neqa
btlp
watford
unit
kingdom
background
practic
estim
haemorrhag
fmh
immunoglobulin
ig
dose
vari
accord
local
polici
nation
guidelin
ig
manufactur
variabl
fmh
includ
techniqu
use
acid
elut
ae
flow
cytometri
fc
calcul
variabl
includ
matern
blood
volum
matbv
correct
factor
size
fetal
cell
cf
percentag
fetal
cell
stain
fc
error
may
lead
sensitis
antigen
potenti
haemolyt
diseas
fetu
newborn
uk
british
societi
haematolog
bsh
guidelin
follow
ae
fc
assum
matern
red
cell
volum
ml
cf
ae
fc
uk
neqa
btlp
provid
eqa
scheme
fmh
estim
result
submit
ml
pack
cell
pc
use
bsh
guidelin
calcul
aim
aim
gather
inform
laboratori
calcul
estim
fmh
impact
eqa
scheme
particip
use
altern
guidelin
method
onlin
questionnair
design
determin
calcul
use
ae
fc
test
sent
ireland
particip
countri
also
fc
user
countri
uk
neqa
result
filter
remov
duplic
incomplet
respons
respond
measur
fmh
result
full
set
result
analys
countri
countri
ae
countri
fc
respond
current
particip
fmh
eqa
six
differ
guidelin
list
fmh
estim
state
guidelin
test
two
report
unit
list
whole
blood
wb
pc
three
cf
state
three
fcss
respond
report
use
fix
matbv
patient
five
differ
volum
use
ml
ml
ml
ml
ml
summaryconclus
case
respond
indic
report
result
wb
pc
overal
calcul
contradict
signific
question
provid
dose
perform
use
correct
report
unit
comparison
overal
calcul
show
result
similar
bleed
volum
bsh
calcul
give
lowest
indic
oversea
calcul
would
result
suffici
ig
administ
compar
bsh
guidanc
two
laboratori
state
differ
guidelin
use
clinic
practic
bsh
guidelin
use
report
eqa
result
report
fmh
eqa
result
calcul
use
formula
affect
accuraci
score
particip
potenti
skew
overal
data
use
calcul
score
respons
fmh
exercis
instruct
updat
specifi
bsh
calcul
use
ensur
compar
result
robust
data
studi
allow
us
understand
address
limit
intern
eqa
scheme
gain
knowledg
oversea
practic
use
inform
uk
guidelin
review
zadsar
shaiegan
g
ahmad
zadeh
shad
samie
high
institut
educ
research
transfus
medicin
tehran
iran
background
miss
carriag
pregnanc
loss
import
issu
marri
life
mani
direct
indirect
factor
might
play
role
encount
eg
hematolog
immunolog
disord
likewis
hpa
genotyp
also
might
attribut
pregnanc
outcom
defin
discord
genotyp
coupl
histori
recurr
abort
present
research
design
aim
investig
allel
frequenc
discord
antigen
coupl
medic
histori
recurr
pregnanc
loss
compar
iranian
blood
donor
method
total
coupl
histori
recurr
abort
without
appar
caus
week
gestat
age
detect
method
spss
chicago
use
report
frequenc
test
comparison
two
group
hardi
weinberg
equat
appli
find
allel
frequenc
result
mean
age
particip
year
mean
abort
histori
gestat
age
respect
found
person
discord
coupl
found
compar
frequenc
among
iranian
blood
donor
subtl
differ
p
summaryconclus
controversi
concept
correl
mutat
recurr
abort
present
studi
could
support
associ
howev
shown
previou
studi
preval
hpa
vari
differ
ethnic
group
could
suggest
investig
role
hpa
iranian
patient
histori
pregnanc
loss
g
l
v
immunolog
depart
french
blood
servic
brittani
ef
la
sagess
laboratori
french
blood
servic
brittani
ef
renn
franc
background
fetal
neonat
alloimmun
thrombocytopenia
fnait
result
form
matern
alloimmun
fetal
platelet
antigen
aim
present
case
year
old
french
woman
gave
birth
first
babi
week
gestat
investig
perform
due
suspicion
maternofet
infect
h
life
infect
detect
howev
moder
thrombocytopenia
observ
second
day
life
nadir
platelet
count
third
day
neonat
anemia
appear
day
deliveri
hb
method
hpa
genotyp
perform
sanger
sequenc
antibodi
detect
perform
use
maipa
method
immunohematolog
investig
carri
antigen
test
abo
rh
kell
antibodi
detect
direct
indirect
antiglobulin
test
result
direct
coomb
newborn
red
blood
cell
rbc
intens
rbc
elut
antibodi
identif
reveal
presenc
matern
group
antibodi
mother
blood
group
father
newborn
blood
group
group
antibodi
titer
matern
serum
quantifi
test
donor
rbc
investig
platelet
immunolog
reveal
platelet
incompat
antibodi
detect
matern
serum
test
donor
platelet
use
maipa
matern
serum
father
platelet
posit
maipa
due
matern
anti
blood
group
antibodi
adsorpt
matern
serum
father
rbc
maipa
matern
serum
father
platelet
neg
thu
demonstr
antibodi
respons
posit
summaryconclus
case
neonat
thrombocytopenia
sever
without
sign
bleed
therapi
need
newborn
recov
spontan
day
birth
demonstr
thrombocytopenia
due
matern
alloantibodi
cross
placenta
barrier
affect
rbc
platelet
count
k
j
p
e
immunohematolog
institut
hematolog
transfus
medicin
health
care
centr
obstetr
gynecolog
medic
centr
postgradu
educ
warsaw
poland
background
obligatori
postnat
immunoprophylaxi
alloimmunis
rhd
antigen
rhig
perform
poland
sinc
earli
antenat
administr
recommend
sinc
nation
system
prenat
diagnost
fetal
rhd
rhd
nipd
rhig
current
given
rhd
neg
pregnant
women
literatur
report
state
women
receiv
rhig
unnecessarili
sinc
babi
rhd
neg
addit
immunoprophylaxi
unwarr
women
weak
rhd
type
decis
obstetrician
recommend
rhd
nipt
procedur
free
access
institut
hematolog
transfus
medicin
ihtm
warsaw
aim
determin
criteria
qualif
antenat
immunoprophylaxi
base
preliminari
result
rhd
nipt
method
dna
isol
easymag
biomerieux
plasma
pregnant
women
determin
standard
serolog
week
gestat
use
nipt
perform
pcr
roch
primer
specif
exon
rhd
two
women
whole
blood
dna
isol
use
prepito
dna
blood
kit
chemagen
baesweil
germani
chemag
prepito
chemagen
germani
test
identif
rhd
variant
use
rbc
fluogen
kronbergtaunu
germani
result
case
rhd
nipd
result
indic
rhig
recommend
delta
ct
due
rhd
posit
fetu
case
rhig
recommend
rhd
gene
detect
matern
cfdna
case
similar
rhd
indic
matern
variant
delta
ct
fetal
rhd
predict
imposs
case
perform
identifi
rhd
rhig
recommend
rhd
rhig
recommend
summaryconclus
ihtm
test
pregnanc
fetal
genotyp
rhd
neg
therefor
rhig
immunoprophylaxi
unnecessari
implement
follow
procedur
weak
rhd
variant
identif
help
elimin
rhig
immunoprophylaxi
case
mother
rhd
allel
mammass
c
chenet
c
martageix
r
petermann
platelet
immunolog
int
pari
franc
background
fetal
neonat
alloimmun
thrombocytopenia
fnait
caus
develop
alloantibodi
main
platelet
membran
glycoprotein
gpiaiia
gpiibiiia
gpibix
caucasian
estim
frequenc
live
birth
fnait
may
devast
consequ
intracrani
hemorrhag
ich
fnait
case
system
involv
fetal
platelet
genotyp
usual
form
use
invas
procedur
risk
bleed
miscarriag
therefor
differ
method
non
invas
prenat
test
nipt
develop
still
evalu
routin
use
aim
former
analysi
refer
laboratori
highlight
refer
fnait
case
relat
fetomatern
incompat
therefor
implement
nipt
main
platelet
antigen
system
implic
fnait
goal
studi
determin
whether
develop
strategi
adequ
precis
diagnos
fnait
patient
sampl
sent
laboratori
method
fetal
platelet
genotyp
perform
use
droplet
digit
pcr
ddpcr
case
nipt
result
confirm
blood
newborn
sampl
amniot
liquid
pregnanc
data
extract
collect
mother
andor
babi
discharg
hospit
letter
confront
inform
fetal
hpa
genotyp
result
result
nipt
pregnant
women
perform
result
confirm
hpa
genotyp
blood
newborn
sampl
amniot
liquid
receiv
hospit
discharg
letter
complet
inform
result
show
pregnant
women
compat
fetu
incompat
one
hpa
system
includ
case
incompat
two
three
combin
hpa
system
found
fnait
histori
babi
n
due
coupl
twin
male
femal
born
aliv
except
due
medic
abort
one
ventricular
dilat
wg
platelet
count
result
incompat
antibodi
test
ii
one
ich
wg
platelet
count
gl
incompat
antibodi
test
summaryconclus
result
confirm
non
invas
fetal
platelet
genotyp
system
essenti
sinc
repres
nipt
probabl
due
lab
expertis
difficult
fnait
case
develop
strategi
focus
simultan
adequ
patient
sampl
sent
lab
howev
studi
also
show
difficulti
special
laboratori
collect
data
hospit
discharg
letter
mani
miss
data
platelet
count
babi
weight
exampl
whatev
fetal
hpa
genotyp
use
ddpcr
allow
diagnosi
platelet
incompat
implement
routin
clinic
test
e
castro
c
c
v
de
transfus
medicin
azienda
sanitaria
universitaria
integrata
di
udin
udin
prenat
diagnosi
institut
matern
child
health
ircc
burlo
garofolo
triest
itali
background
recent
introduct
noninvas
fetal
rhd
test
repres
import
tool
manag
neg
pregnant
women
first
trimest
screen
allow
earli
classif
pregnanc
term
risk
target
immunoprophylaxi
aim
aim
studi
introduc
first
trimest
fetal
rhd
screen
region
level
valid
optim
use
commerci
kit
method
recruit
rhd
neg
pregnant
women
perform
gestat
week
fetal
dna
extract
robot
use
qiasymphoni
dsp
circul
dna
kit
ml
matern
plasma
amplifi
pcr
use
free
dna
fetal
kit
pcr
fresh
frozen
dna
sampl
evalu
stabil
extract
fetal
dna
assay
accuraci
precis
evalu
term
sensit
specif
repeat
reproduc
compar
fetal
rhd
genotyp
result
versu
cord
blood
rhd
serolog
determin
perform
test
duplic
within
run
differ
run
result
total
sampl
use
process
valid
fetal
rhd
genotyp
result
consist
serolog
rhd
test
cord
blood
sampl
rhd
posit
rhd
neg
sensit
specif
differ
observ
fresh
frozen
extract
fetal
dna
give
concord
precis
paramet
summaryconclus
preliminari
find
confirm
feasibl
fetal
rhd
genotyp
first
trimest
sampl
benefit
process
frozen
dna
sampl
thu
optim
laboratori
routin
organ
larger
scale
studi
progress
routin
implement
test
genic
friuli
venezia
giulia
region
grant
project
data
encourag
realiz
region
screen
program
differ
gestat
age
mh
ahmadi
n
amirizadeh
blood
group
genotyp
central
lab
high
institut
research
educ
transfus
medicin
tehran
iran
background
discoveri
cffdna
matern
plasma
denni
lo
possibl
fetal
rhd
genotyp
done
use
noninvas
method
rh
genotyp
fetu
pregnant
women
immun
could
import
case
turn
babi
rh
posit
time
treatment
appropri
measur
taken
account
fetal
rh
neg
unnecessari
invas
procedur
serial
amniocentesi
cordocentesi
avoid
confirm
presenc
fetal
dna
matern
plasma
specif
marker
use
specif
fetal
present
matern
plasma
sri
gene
wide
use
marker
issu
exist
chromosom
presenc
dna
extract
matern
plasma
prove
exist
fetal
dna
mother
circul
use
male
fetu
genotyp
test
aim
aim
studi
evalu
sri
confirm
presenc
fetal
dna
fetal
rhd
genotyp
use
cffdna
method
experi
plasma
sampl
collect
pregnant
women
gestat
period
week
age
year
mean
dna
extract
sinaclon
dna
extract
kit
pcr
reaction
done
triplic
specif
primer
sri
actb
gene
result
compar
neonat
sex
determin
birth
time
result
analyz
spss
version
use
independ
test
cohen
kappa
p
consid
statist
signific
result
matern
plasma
sampl
consid
sri
genotyp
reveal
presenc
sri
gene
neg
gene
concord
fetal
sex
genotyp
pcr
newborn
sex
result
sensit
specif
precis
calcul
sri
gene
detect
p
k
actin
gene
detect
sampl
summaryconclus
sri
good
marker
confirm
presenc
fetal
dna
plasma
use
marker
applic
pregnant
women
carri
male
fetu
case
fetus
femal
fetal
rhd
genotyp
result
neg
sri
prove
presenc
fetal
dna
case
epigenet
marker
use
k
p
e
immunohematolog
institut
hematolog
transfus
medicin
obstetr
gynecolog
medic
centr
postgradu
educ
hematolog
transfus
medicin
warsaw
poland
background
fetal
antigen
genotyp
nipt
base
fetal
dna
matern
plasma
routin
use
predict
antigen
statu
child
purpos
establish
precis
manag
immun
pregnanc
stabil
fetalmatern
materi
crucial
accuraci
nipt
especi
encod
singl
nucleotid
polymorph
high
background
matern
allel
lead
unspecif
result
aim
compar
nipt
tube
routin
use
institut
stabil
matern
blood
cell
method
ml
blood
pregnant
women
collect
parallel
edta
vacutain
tube
gel
barrier
bd
vacutain
ppt
usa
dna
collect
tube
roch
dna
isol
fresh
frozen
plasma
use
easymag
biomerieux
examin
pcr
roch
presenc
fetal
marker
exon
rhd
sri
insdel
polymorph
matern
marker
result
fetal
matern
marker
materi
collect
bd
tube
test
within
h
compar
result
materi
collect
roch
tube
test
within
h
n
b
storag
day
ambient
temperatur
n
c
plasma
freez
n
result
materi
collect
roch
tube
test
within
h
compar
result
materi
roch
tube
test
day
n
e
plasma
freez
n
result
compar
group
differ
fetal
fraction
statist
signific
mean
ct
valu
fetal
marker
compar
group
sd
versu
sd
p
sd
versu
sd
p
sd
versu
sd
p
sd
versu
sd
p
sd
versu
sd
p
matern
fraction
significantli
lower
blood
collect
roch
test
within
h
blood
bd
tube
mean
ct
group
sd
versu
sd
p
also
matern
fraction
significantli
lower
dna
isol
fresh
plasma
test
within
h
frozen
plasma
mean
ct
compar
group
sd
versu
sd
p
group
differ
matern
fraction
mean
ct
group
sd
versu
sd
p
sd
versu
sd
p
sd
versu
sd
p
summaryconclus
collect
matern
blood
roch
tube
well
plasma
prepar
affect
fetal
dna
fraction
addit
stabil
matern
dna
fraction
provid
store
roomambi
temperatur
process
within
h
venipunctur
condit
fulfil
nipt
fetal
antigen
materi
collect
roch
tube
whole
territori
poland
suffici
accur
abstract
withdrawn
maric
k
zeleznik
bricl
dovc
drnovsek
immunohaematolog
blood
transfus
centr
slovenia
ljubljana
slovenia
background
slovenian
prenat
care
law
defin
prenat
care
test
includ
prophylaxi
immunoglobulin
ig
pregnant
women
everi
pregnant
woman
done
blood
group
indirect
antiglobulin
test
iat
end
week
gestat
everi
pregnant
woman
iat
repeat
week
gestat
receiv
ig
woman
give
birth
child
receiv
addit
dose
ig
within
h
give
birth
adjust
dose
ig
evalu
fetomatern
haemorrhag
fmh
necessari
ig
given
also
everi
pregnant
woman
case
event
could
caus
immunis
vagin
bleed
abdomin
trauma
therapeut
termin
pregnanc
miscarriag
intrauterin
procedur
ectop
pregnanc
intrauterin
fetal
death
extern
cephal
version
base
percentag
women
ratio
homozygos
dd
heterozygos
dd
gen
slovenian
popul
calcul
pregnant
women
give
birth
child
henc
administr
ig
case
unnecessari
discov
presenc
fetal
dna
matern
blood
possibl
genotyp
fetal
gen
method
inject
ig
pregnant
women
bear
fetu
implement
new
protocol
prophylaxi
ig
week
gestat
determin
presenc
fetal
gen
matern
blood
prophylaxi
ig
base
presenc
fetal
gen
matern
blood
aim
start
pregnant
women
bear
fetu
accord
genotyp
receiv
ig
week
gestat
method
use
real
time
pcr
hous
method
reagent
appli
biosystem
determin
presenc
fetal
gen
matern
peripher
blood
result
around
birth
annual
slovenia
around
birth
given
women
base
slovenian
gen
popul
studi
perform
conclud
around
pregnant
women
give
birth
child
conclus
calcul
expens
old
prophylaxi
program
compar
new
target
prophylaxi
program
annual
cost
old
program
averag
cost
new
program
estim
net
differ
summaryconclus
discoveri
matern
peripher
blood
enabl
noninvas
obtain
fetal
genet
materi
progress
molecular
technolog
made
fetal
genotyp
access
thu
make
implement
target
prophylaxi
ig
realiti
estim
cost
differ
old
new
program
rel
small
especi
compar
unnecessari
administr
ig
women
nt
need
h
k
h
medicin
pusan
nation
univers
yangsan
hospit
yangsan
medicin
pusan
nation
univers
hospit
medicin
inj
univers
colleg
medicin
busan
korea
background
frequenc
irregular
antibodi
pregnant
women
caus
hemolyt
diseas
fetu
newborn
hdfn
vari
differ
studi
popul
clinic
manifest
hdfn
differ
accord
specif
degre
irregular
antibodi
therefor
awar
preval
matern
alloantibodi
import
manag
health
fetu
neonat
aim
aim
studi
provid
data
preval
natur
matern
rbc
alloimmun
neonat
outcom
compar
fetal
neonat
outcom
pregnanc
without
rbc
antibodi
method
pregnant
women
underw
irregular
antibodi
screen
prenat
test
obstetr
clinic
singl
center
enrol
pregnant
women
screen
posit
irregular
antibodi
select
test
group
obstetr
pregnant
women
select
control
group
evalu
pregnanc
outcom
accord
irregular
antibodi
aborh
type
irregular
antibodi
screen
age
obstetr
histori
pregnant
women
direct
antiglobulin
test
bilirubin
aborh
type
phototherapi
histori
mortal
gestat
age
birth
pregnant
women
babi
record
result
total
sampl
pregnant
women
test
within
studi
period
median
age
pregnant
women
total
sampl
show
posit
result
antibodi
screen
test
exclus
duplic
sampl
patient
preval
irregular
antibodi
among
women
irregular
antibodi
women
test
identifi
specif
irregular
antibodi
thu
women
identifi
specif
irregular
antibodi
frequent
identifi
antibodi
follow
except
unidentifi
test
case
rh
pregnant
women
prophylact
immun
common
alloantibodi
belong
rhesu
system
two
group
obstetr
histori
includ
gravida
para
age
abo
blood
type
differ
statist
surviv
rate
current
pregnanc
statist
differ
p
transfus
histori
prior
current
pregnanc
four
pregnant
women
transfus
pack
rbc
differ
test
group
control
group
p
eight
pregnant
women
one
woman
stillborn
four
live
neonat
develop
hyperbilirubinemia
six
pregnant
women
alon
alloantibodi
three
spontan
abort
stillborn
present
pregnanc
among
six
newborn
matern
jka
neonat
show
hyperbilirubinemia
spontan
abort
stillborn
summaryconclus
conclus
found
preval
irregular
antibodi
among
korean
pregnant
women
common
signific
antibodi
belong
rhesu
blood
group
name
combin
death
rate
fetus
higher
pregnant
women
irregular
antibodi
without
irregular
antibodi
monitor
pregnant
women
irregular
antibodi
rhesu
blood
group
evalu
hdfn
neonat
matern
irregular
antibodi
rhesu
kidd
lewi
blood
group
perform
perinat
mortal
rate
could
decreas
n
c
j
et
innov
de
et
de
cellul
souch
de
linform
canada
background
sole
blood
bank
provid
provinc
servic
popul
million
annual
immunohematolog
refer
laboratori
irl
receiv
request
hospit
blood
bank
investig
antibodi
identif
case
pregnanc
weaker
antigen
express
transfus
reaction
variou
discrep
among
servic
provid
within
irl
pregnanc
repres
third
activ
softwar
haemonet
implement
manag
clinic
case
receiv
sampl
report
result
request
hospit
serv
electron
databas
aim
present
studi
survey
antibodi
found
specif
pregnanc
identifi
one
frequent
also
provid
valuabl
inform
titer
frequenc
workup
method
data
extract
databas
use
pregnanc
specif
code
june
implement
januari
result
excel
file
manual
analys
result
pregnanc
case
receiv
close
consid
unev
case
lack
antibodi
refer
weaker
antigen
express
case
reaction
cold
agglutinin
antibodi
red
blood
cell
media
autoantibodi
without
clinic
signific
underli
antibodi
case
show
blood
group
antigen
specif
without
clinic
signific
bg
htla
le
yt
b
knop
rhig
autoantibodi
total
remain
case
show
blood
group
antigen
specif
clinic
signific
except
made
numer
studi
consid
clinic
signific
even
igm
form
among
case
request
averag
requestscas
show
uniqu
antibodi
rh
specif
antibodi
found
case
case
least
one
case
antibodi
case
least
one
overal
frequent
case
follow
case
case
combin
observ
case
antibodi
identifi
case
term
titer
antibodi
weak
titer
highest
case
summaryconclus
studi
summar
last
year
prenat
irl
clearli
show
remain
major
burden
pregnanc
manag
rare
case
also
unravel
work
exampl
three
case
bombay
women
one
case
one
day
day
work
done
antibodi
identifi
howev
whole
pictur
lost
workload
urgenc
behind
request
studi
show
import
pregnanc
order
prevent
hemolyt
diseas
fetu
newborn
favor
success
neonat
outcom
c
h
e
j
fonctionnel
dexpertis
en
centr
nation
de
en
cnrhp
de
biologi
et
pathologi
st
antoin
de
foetal
trousseau
fonctionnel
de
soin
et
dexpertis
de
et
de
centr
nation
de
en
cnrhp
trousseau
assist
publiqu
de
de
pari
pari
franc
background
fetal
anemia
could
induc
red
blood
cell
incompat
antibodi
well
known
caus
sever
fetal
anemia
specif
red
blood
cell
antibodi
may
involv
aim
aim
work
identifi
specif
red
blood
cell
antibodi
could
respons
fetal
anemia
besid
larg
number
pregnanc
follow
french
nation
refer
center
perinat
hemobiolog
cnrhp
method
perform
retrospect
extract
laboratori
comput
system
synergi
technidata
phenotyp
direct
antiglobulin
test
perform
fetal
blood
fetal
transfus
januari
decemb
look
caus
fetal
anemia
case
anemia
link
incompat
look
specif
antibodi
involv
matern
antibodi
titer
hemoglobin
bilirubin
cord
blood
level
well
fetal
reticulocyt
count
collect
result
throughout
period
fetus
receiv
least
one
transfus
case
fetal
anemia
caus
red
blood
cell
incompat
unsurprisingli
involv
case
incompat
n
follow
n
antibodi
involv
n
n
n
twin
n
n
antibodi
c
e
antigen
alreadi
known
abil
caus
sever
hemolyt
diseas
fetu
newborn
hdfn
fetal
anemia
occur
mostli
last
trimest
pregnanc
sever
case
sever
fetal
anemia
presenc
high
titer
antibodi
alreadi
describ
literatur
respect
fetus
concern
incompat
studi
matern
antibodi
titer
also
high
equal
case
sever
fetal
anemia
due
high
titer
antibodi
seem
rare
knowledg
case
describ
literatur
antibodi
fetal
anemia
occur
week
gestat
case
anemia
associ
poor
hemolyt
process
neg
weak
posit
direct
antiglobulin
test
low
total
bilirubin
level
low
moder
reticulocyt
count
cord
blood
suggest
antibodi
may
act
least
partli
suppress
erythropoiesi
describ
antibodi
summaryconclus
close
monitor
fetu
reserv
pregnanc
complic
antibodi
presenc
high
titer
antibodi
also
lead
sever
hdfn
sinc
antibodi
direct
high
preval
antigen
monitor
immun
women
requir
close
cooper
nation
rare
blood
suppli
abstract
withdrawn
n
bujandr
bogdanov
blood
transfus
institut
vojvodina
novi
sad
serbia
background
red
blood
cell
rbc
antibodi
screen
perform
pregnanc
detect
unexpect
alloantibodi
present
matern
blood
mother
may
rbc
antibodi
expos
blood
transfus
pregnanc
rbc
rbc
antibodi
pass
placenta
fetal
circul
caus
hemolyt
diseas
newborn
hdn
defin
neonat
anemia
hyperbilirubinemia
aim
aim
studi
analyz
frequenc
type
clinic
signific
unexpect
rbc
antibodi
pregnant
women
popul
south
backa
district
vojvodina
serbia
period
method
data
obtain
inform
system
protocol
blood
transfus
institut
vojvodina
use
retrospect
analysi
antibodi
screen
result
pregnant
women
transfus
histori
rbc
alloimmun
previou
pregnanc
antibodi
detect
use
indirect
antiglobulin
test
iat
gel
base
technolog
test
perform
use
commerci
screen
reagent
rbc
diam
gmbh
autom
immunohematolog
system
laboratori
switzerland
antibodi
specif
determin
gel
techniqu
commerci
reagent
rbc
panel
diam
gmbh
switzerland
result
cohort
analyz
pregnant
women
antibodi
found
singl
antibodi
multipl
antibodi
distribut
antibodi
among
sensit
pregnant
women
antibodi
undetermin
specif
b
antibodi
singl
c
clinic
signific
antibodi
usual
clinic
signific
antibodi
summaryconclus
despit
rhd
prophylaxi
perform
serbia
sinc
antibodi
detect
major
pregnant
women
south
backa
district
vojvodina
specif
howev
antibodi
analys
period
decreas
percentag
compar
period
last
studi
n
gunasekara
transfus
depart
nation
blood
transfus
servic
colombo
sri
lanka
background
red
cell
alloimmun
caus
haemolyt
diseas
fetu
newborn
hdfn
signific
caus
fetal
neonat
morbid
mortal
develop
countri
henc
time
detect
alloantibodi
antenat
women
essenti
earli
manag
hdfn
univers
screen
antenat
women
mandatori
per
bcsh
guidelin
practic
develop
countri
howev
sri
lanka
screen
alloantibodi
antenat
period
primarili
done
rh
women
aim
make
certain
frequenc
red
cell
alloimmunis
antenat
women
attend
tertiari
care
hospit
method
retrospect
studi
carri
pregnant
women
attend
antenat
clinic
tertiari
care
hospit
colombo
period
two
year
women
group
abo
rh
antigen
screen
identif
done
alloantibodi
convent
tube
method
detail
obstetr
histori
women
review
result
total
pregnant
femal
femal
rh
posit
rh
neg
regard
major
blood
group
system
posit
common
phenotyp
follow
b
posit
femal
found
posit
antibodi
screen
either
week
gestat
total
antibodi
detect
women
said
period
conclud
overal
preval
alloimmun
posit
antibodi
screen
seen
rh
posit
pregnant
women
rh
neg
pregnant
women
statist
signific
differ
alloimmun
rate
rh
antigen
neg
rh
posit
group
versu
p
alloimmun
women
found
possess
singl
multipl
clinic
signific
alloantibodi
c
e
jkb
antibodi
known
caus
hdfn
leb
henc
risk
matern
alloimmun
clinic
signific
antibodi
implic
caus
hdfn
found
clinic
signific
antibodi
commonli
occasion
associ
hdfn
rh
neg
rh
posit
summaryconclus
red
cell
alloimmun
frequenc
pregnanc
antibodi
clinic
signific
pose
risk
hdfn
evid
studi
rh
posit
women
like
rh
neg
women
form
clinic
signific
alloantibodi
therefor
recommend
pregnant
women
prefer
screen
unexpect
antibodi
irrespect
rh
type
antenat
period
line
guidelin
howev
develop
countri
financi
burden
routin
screen
irregular
antibodi
antenat
women
weigh
benefit
h
h
k
medicin
pusan
nation
univers
yangsan
hospit
yangsan
medicin
pusan
nation
univers
hospit
busan
korea
background
hemolyt
diseas
newborn
hdn
diseas
matern
immunoglobulin
g
ig
g
antibodi
fetal
red
blood
cell
rbc
antibodi
cross
placenta
bind
fetal
rbc
antigen
lead
hemolysi
clinic
spectrum
diseas
vari
includ
mild
hemolyt
anemia
hyperbilirubinemia
hepatomegali
sever
anemia
hydrop
even
death
fetu
diagnos
hdn
evalu
caus
hdn
direct
antiglobulin
test
dat
rbc
newborn
indirect
antiglobulin
test
serum
mother
done
aim
aim
studi
provid
data
preval
neonat
hyperbilirubinemia
etiolog
analyz
data
neonat
test
dat
method
infant
patient
underw
direct
antiglobulin
test
perinat
test
neonat
clinic
pusan
nation
univers
yansan
hospit
august
juli
enrol
dat
total
bilirubin
aborh
type
phototherapi
histori
mortal
gestat
age
bodyweight
birth
infant
record
aborh
type
irregular
antibodi
screen
obstetr
histori
infant
mother
record
statist
analys
perform
use
comput
softwar
spss
spss
inc
chicago
il
usa
result
consid
statist
signific
p
valu
result
total
neonat
test
within
studi
period
total
sampl
show
posit
result
dat
test
rate
get
phototherapi
dat
posit
group
dat
neg
group
differ
statist
howev
newborn
show
posit
dat
test
longer
phototherapi
median
initi
serum
total
bilirubin
level
mgdl
dat
neg
newborn
posit
newborn
rang
rang
p
median
initi
serum
total
bilirubin
level
rh
incompat
abo
incompat
other
rang
rang
rang
respect
among
total
neonat
age
day
initi
test
differ
day
day
initi
serum
total
bilirubin
level
dat
posit
group
dat
neg
day
old
neonat
day
old
neonat
significantli
differ
initi
serum
total
bilirubin
level
rh
incompat
abo
incompat
other
day
old
neonat
significantli
differ
median
level
rang
rang
rang
respect
p
total
neonat
got
phototherapi
serum
total
bilirubin
level
peak
one
admiss
analyz
peak
level
significantli
differ
day
peak
significantli
differ
mean
durat
phototherapi
rhesu
incompat
day
sd
day
sd
abo
incompat
neonat
p
mother
c
tendenc
bore
babi
mother
p
mother
show
p
neonat
matern
c
got
phototherapi
gestat
age
significantli
differ
neonat
matern
abo
incompat
p
summaryconclus
studi
suspect
rh
incompat
neonat
shortli
reach
peak
level
bilirubin
abo
incompat
neonat
posit
rate
dat
abo
incompat
rh
incompat
detect
hdn
earlier
sensit
eluat
screen
care
matern
screen
requir
f
clinic
serolog
iranian
blood
transfus
organ
research
center
gyn
tehran
medic
univers
tehran
iran
background
introduct
alloimmun
occur
transfus
patient
hemoglobinopathi
high
preval
alloantibodi
product
note
thalassemia
patient
alloantibodi
rbc
subgroup
may
occur
femal
thalassem
patient
husband
antigen
fetu
may
inherit
antigen
may
risk
hdn
fetu
therefor
complet
histori
prior
alloimmun
elicit
pregnant
patient
thalassemia
consider
given
alloantibodi
screen
earli
pregnanc
certif
exist
titer
also
check
rbc
subgroup
husband
import
describ
case
thalassemia
success
pregnanc
cours
aim
describ
case
thalassemia
success
pregnanc
cours
method
year
old
case
thalassemia
intermedia
hydroxi
urea
transfus
marri
stop
hu
plan
pregnanc
month
later
got
pregnant
week
pregnanc
develop
sever
anemia
hgb
gdl
receiv
blood
transfus
two
day
transfus
hgb
drop
gdl
nt
get
better
transfus
advis
termin
pregnanc
result
refer
us
hgb
gdl
admiss
huge
splenomegali
low
hgb
level
antibodi
screen
antibodi
identif
gp
anti
c
anti
fya
low
platelet
count
huge
splenomegali
fortun
husband
rbc
phenotyp
c
neg
fya
neg
fear
reduc
risk
hdn
fetu
patient
receiv
leukoreduc
match
c
neg
fya
neg
blood
without
immunosuppress
ivigg
spleen
size
reduc
littl
bit
week
pregnanc
accept
good
fetal
growth
spleen
interfer
cours
pregnanc
hope
termin
pregnanc
without
need
splenectomi
deliveri
summaryconclus
improv
life
expect
hemoglobinopathi
mani
women
thalassemia
choos
becom
pregnant
increas
chanc
success
pregnanc
patient
care
hematologist
obstetrician
begin
patient
heavili
alloimmun
requir
rbc
transfus
receiv
extend
phenotyp
match
product
also
check
patern
rbc
phenotyp
find
risk
hdn
fetu
control
matern
hgb
risk
hdn
two
point
care
alloimmun
femal
thalassem
patient
b
blood
transfus
lago
state
health
servic
commiss
lago
blood
transfus
gynaecolog
univers
benin
teach
hospit
benin
citi
blood
transfus
univers
benin
teach
hospit
benin
citi
nigeria
background
matern
associ
advers
outcom
haemolyt
diseas
foetu
newborn
also
major
sourc
morbid
among
pregnant
women
expos
multipl
blood
transfus
patient
sickl
cell
diseas
major
placenta
previa
magnitudepattern
patholog
consequ
among
nigerian
pregnant
women
mani
part
countri
poorli
defin
larg
relat
absenc
routin
screen
poor
qualiti
data
aim
studi
therefor
aim
determin
proport
specif
atyp
matern
among
antenat
attende
univers
benin
teach
hospit
ubth
benin
citi
nigeria
possibl
attend
risk
factor
associ
pregnanc
childbirth
studi
popul
also
assess
method
studi
hospit
base
survey
conduct
among
pregnant
women
attend
antenat
clinic
ubth
may
august
one
hundr
fifti
particip
interview
structur
questionnair
obtain
data
pariti
transfus
histori
clinic
detail
aborh
blood
group
haemoglobin
phenotyp
retriev
hospit
antenat
record
screen
serolog
test
subsequ
perform
screen
cell
panel
cell
albacyt
reagent
red
cell
detect
identif
unexpect
procur
lorn
laboratori
uk
lot
number
respect
descript
data
present
mean
proport
signific
associ
alloimmunis
variabl
test
use
chi
squar
fisher
exact
test
ethic
approv
protocol
number
obtain
institut
review
board
prior
studi
result
mean
matern
age
particip
year
mean
gestat
age
time
studi
year
particip
third
trimest
first
trimest
pregnanc
particip
test
posit
rh
antigen
preval
haemoglobin
phenotyp
aa
follow
ss
sc
nineti
one
percent
particip
blood
transfus
seven
particip
posit
screen
two
clinic
signific
matern
statist
signific
associ
p
valu
observ
alloimmunis
variabl
gestat
age
pariti
haemoglobin
phenotyp
previou
blood
transfus
rh
neg
studi
summaryconclus
matern
alloimmunis
affect
pregnanc
benin
citi
nigeria
atyp
alloantibodi
lub
found
two
particip
total
antibodi
screen
clinic
signific
potenti
advers
pregnanc
perinat
outcom
rh
isoimmunis
still
occur
among
pregnant
women
benin
citi
nigeria
signific
relationship
observ
unexpect
matern
factor
pariti
haemoglobin
phenotyp
previou
blood
transfus
g
g
j
laboratori
medicin
patholog
univers
alberta
blood
servic
edmonton
canada
background
manag
potenti
hemolyt
diseas
fetu
newborn
hdfn
reli
monitor
matern
antibodi
concentr
way
antibodi
titrat
individu
multipl
antibodi
separ
titrat
antibodi
gener
perform
assess
antibodi
concentr
separ
ignor
vivo
condit
may
repres
combin
effect
multipl
antibodi
fetu
aim
aim
studi
examin
differ
combin
separ
titr
level
multipl
antibodi
present
result
help
determin
combin
titrat
reach
critic
titr
signal
need
direct
fetal
monitor
earlier
tradit
singl
antibodi
titrat
method
method
sampl
contain
variou
combin
differ
antibodi
examin
sampl
titrat
perform
titrat
standard
method
separ
titr
level
antibodi
determin
singl
combin
titrat
method
detect
titr
antibodi
togeth
separ
method
achiev
titter
individu
antibodi
separ
reagent
cell
express
one
antigen
combin
antibodi
combin
titr
method
perform
use
reagent
cell
express
antigen
antibodi
direct
separ
combin
titrat
everi
sampl
test
parallel
use
indirect
antiglobulin
test
salin
tube
method
differ
separ
combin
method
whether
reagent
cell
express
one
antigen
toward
antibodi
present
direct
result
overal
sampl
show
increas
titr
level
combin
titrat
method
sampl
show
increas
contain
separ
titr
either
one
antibodi
sampl
antibodi
separ
titr
show
increas
titr
level
combin
titrat
method
increas
also
observ
sampl
one
separ
antibodi
titr
addit
sampl
titr
separ
antibodi
show
increas
level
combin
method
titr
increas
rang
method
furthermor
comparison
separ
titrat
method
decreas
titr
level
observ
use
combin
method
summaryconclus
studi
demonstr
case
two
antibodi
present
titrat
perform
combin
method
produc
titr
level
equal
higher
standard
separ
antibodi
titrat
method
base
result
combin
titrat
reach
critic
titr
level
earli
earlier
gestat
antibodi
monitor
singl
titrat
method
monitor
hdfn
patient
multipl
antibodi
use
combin
titrat
method
could
potenti
alert
physician
need
addit
test
direct
fetal
monitor
earlier
tradit
singl
antibodi
titrat
approach
j
white
r
hagga
k
veal
c
whitham
rowley
uk
neqa
btlp
watford
unit
kingdom
background
uk
neqa
abo
titrat
abot
exercis
demonstr
wide
variat
titrat
result
within
technolog
uk
titrat
quantit
clinic
signific
red
cell
antibodi
use
inform
clinic
manag
pregnanc
british
societi
haematolog
bsh
guidelin
blood
group
antibodi
test
pregnanc
provid
algorithm
test
referr
pregnant
women
kell
system
antibodi
unless
partner
confirm
antigen
neg
refer
fetal
medicin
unit
fmu
antibodi
first
identifi
titrat
undertaken
interv
week
thereaft
referr
made
test
use
cell
free
fetal
dna
cffdna
gestat
recommend
refer
laboratori
aim
investig
uk
practic
antenat
titrat
referr
requir
eqa
method
uk
neqa
btlp
offer
option
assess
titrat
eqa
sampl
contain
present
antenat
book
sampl
laboratori
use
titrat
method
local
select
reagent
red
cell
answer
questionnair
practic
result
uk
roi
laboratori
return
iat
titrat
result
use
biorad
ortho
immucor
tube
answer
accompani
question
rang
result
within
one
dilut
median
endpoint
determin
last
weak
reaction
use
one
median
result
vari
endpoint
technolog
bioradortho
select
reagent
red
cell
heterozyg
express
relev
antigen
possibl
titrat
parallel
nibsc
standard
patient
previou
sampl
avail
clinic
sampl
would
request
patern
sampl
refer
fmu
book
repeat
titrat
within
week
refer
cffdna
test
summaryconclus
pattern
variat
iat
titrat
result
technolog
seen
abot
data
observ
possibl
due
lower
igm
compon
compar
abo
antibodi
variabl
technolog
detect
igm
iat
howev
number
exercis
low
investig
would
requir
confirm
hypothesi
low
referr
rate
hypothet
sampl
molecular
test
may
reflect
laboratori
wait
patern
k
type
result
cffdna
k
kel
gener
offer
week
gestat
due
increas
risk
fals
neg
result
time
titrat
result
use
make
decis
test
strategi
referr
fmu
howev
point
use
make
decis
consist
antibodi
titr
wide
use
trigger
action
result
necessarili
repres
concentr
antibodi
laboratori
eqa
pilot
introduc
monitor
antenat
titrat
result
rais
awar
guidelin
test
referr
abstract
withdrawn
adiogo
h
delabi
mailloux
c
fonctionnel
dexpertis
en
centr
nation
de
en
cnrhp
de
biologi
et
pathologi
st
antoin
assist
publiqu
de
de
pari
pari
franc
background
antibodi
titrat
tube
method
still
main
method
use
worldwid
quantifi
blood
cell
antibodi
situat
incompat
base
titrat
result
threshold
trigger
fetal
specif
ultrasonographi
doppler
determin
nevertheless
titrat
tube
method
associ
substanti
variabl
within
laboratori
aim
aim
studi
determin
factor
could
caus
titer
score
valu
variabl
within
laboratori
order
limit
investig
role
differ
paramet
titrat
result
method
perform
tube
titrat
score
unilater
variat
one
paramet
sampl
time
studi
follow
paramet
manual
autom
dilut
sampl
concentr
red
cell
red
blood
cell
phenotyp
use
singl
pool
red
blood
cell
concentr
antiglobulin
pure
dilut
incub
time
min
centrifug
speed
g
read
delay
centrifug
immedi
min
later
read
differ
oper
use
end
point
procedur
statist
analysi
perform
graphpad
prism
wilcoxon
test
differ
p
interpret
statist
signific
differ
dilut
titer
valu
consid
clinic
signific
result
titer
andor
score
valu
significantli
impact
antiglobulin
red
blood
cell
concentr
use
ii
red
blood
cell
phenotyp
iii
reader
oper
impact
paramet
weak
differ
often
dilut
non
clinic
signific
use
pool
red
blood
cell
manual
autom
dilut
incub
time
read
delay
centrifug
nt
seem
influenc
result
summaryconclus
sever
paramet
slight
impact
titrat
result
howev
addit
paramet
may
result
clinic
signific
variat
use
standard
detail
procedur
harmon
read
stape
may
reduc
variabl
within
laboratori
j
l
c
j
n
medicin
servic
mount
sinai
hospit
medicin
sunnybrook
health
scienc
centr
toronto
canada
background
titrat
alloantibodi
red
cell
antigen
screen
tool
detect
increas
product
matern
antibodi
pregnanc
current
standard
care
titr
contribut
clinic
decis
whether
investig
fetal
anemia
two
common
methodolog
tube
techniqu
microcolumn
gel
techniqu
antibodi
titr
differ
accord
sensit
techniqu
util
tube
techniqu
use
standard
techniqu
therefor
critic
titr
valu
base
fetalneonat
outcom
obtain
sever
center
use
gel
techniqu
titr
correspond
valu
tube
techniqu
definit
determin
aim
aim
studi
correl
alloantibodi
titr
red
cell
antigen
c
k
determin
tube
gel
techniqu
prenat
patient
method
titrat
perform
use
serial
dilut
plasma
prenat
sampl
titr
perform
parallel
tube
gel
techniqu
use
prepar
dilut
titr
express
reciproc
highest
dilut
show
reaction
tube
techniqu
reaction
gel
techniqu
result
forti
patient
studi
total
titrat
perform
rang
undetect
antibodi
overal
titrat
two
method
gener
result
within
one
dilut
titr
within
one
dilut
ie
chang
increas
dilut
titr
detect
gel
techniqu
titrat
gel
method
result
titr
time
higher
gel
tube
time
higher
c
k
respect
gel
techniqu
infrequ
result
titr
lower
detect
tube
techniqu
summaryconclus
antibodi
titrat
microcolumn
gel
techniqu
show
higher
titr
convent
tube
techniqu
titrat
may
possibl
use
mean
standard
valu
correl
two
methodolog
prenat
alloantibodi
titrat
prospect
data
need
valid
find
abstract
withdrawn
n
british
columbia
hematopatholog
bc
children
hospit
bc
women
hospit
patholog
laboratori
medicin
univers
british
columbia
vancouv
canada
background
irradi
red
cell
known
caus
membran
damag
result
increas
supernat
potassium
hemoglobin
level
current
standard
canada
state
red
cell
may
store
day
unit
origin
expiri
date
whichev
come
first
howev
near
futur
canada
expect
adopt
stricter
approach
base
council
europ
coe
standard
dictat
irradi
cell
must
transfus
later
day
irradi
later
day
aim
aim
studi
assess
potenti
impact
shorter
red
cell
storag
red
cell
util
tertiari
care
pediatr
hospit
irradi
util
dedic
donor
unit
system
nicu
patient
method
data
irradi
red
cell
transfus
retrospect
obtain
one
year
period
transfus
laboratori
comput
system
data
element
includ
donor
unit
number
collect
date
irradi
datetim
transfus
datetim
patient
medic
record
number
data
analyz
determin
age
red
cell
irradi
age
red
cell
transfus
interv
irradi
transfus
number
donor
exposur
nicu
patient
number
transfus
would
consid
unaccept
accord
coe
standard
chang
donor
exposur
coe
standard
appli
due
variabl
red
cell
age
time
receipt
blood
supplier
donor
exposur
rang
calcul
base
red
cell
unit
either
day
old
day
old
time
design
patient
addit
unit
requir
result
transfus
administ
patient
overal
transfus
administ
nicu
patient
transfus
nicu
transfus
would
accept
accord
coe
standard
overal
unaccept
transfus
includ
red
cell
day
age
time
irradi
n
b
red
cell
transfus
day
age
n
c
red
cell
transfus
day
irradi
n
nicu
patient
unaccept
transfus
would
due
irradi
red
cell
day
age
n
nicu
patient
receiv
one
transfus
donor
exposur
rang
increas
donor
exposur
would
occur
patient
nicu
patient
coe
guidelin
appli
would
increas
one
donor
exposur
patient
patient
summaryconclus
major
current
irradi
red
cell
transfus
would
accept
accord
coe
guidelin
red
cell
util
may
increas
would
like
insubstanti
approxim
nicu
patient
may
experi
increas
donor
exposur
case
would
one
addit
donor
exposur
benefit
administ
less
extracellular
potassium
hemoglobin
like
outweigh
risk
one
addit
donor
exposur
donor
popul
care
screen
known
transmiss
diseas
j
j
patholog
laboratori
medicin
neonatolog
haematologyoncolog
servic
kk
women
children
hospit
singapor
singapor
background
transfus
red
cell
crucial
compon
neonat
intens
care
low
birth
weight
vlbw
neonat
anaemia
prematur
develop
first
week
life
due
multipl
factor
includ
ineffect
erythropoiesi
incomplet
placent
iron
transfer
iatrogen
blood
loss
frequent
blood
sampl
major
contributori
factor
multipl
blood
transfus
often
requir
maintain
optim
haemoglobin
level
tailor
neonat
clinic
condit
aim
minim
blood
sampl
vlbw
neonat
review
institut
neonat
transfus
guidelin
allow
transfus
red
cell
neonat
less
month
without
full
compat
test
donor
blood
blood
specimen
method
protocol
term
neonat
omiss
crossmatch
neoxm
introduc
novemb
prospect
review
decemb
februari
protocol
applic
vlbw
neonat
weigh
less
kg
chronolog
age
less
month
test
perform
specimen
mother
neonat
prior
transfus
matern
sampl
abo
rh
group
antibodi
screen
neonat
sampl
abo
rh
group
direct
antiglobulin
test
dat
pretransfus
matern
antibodi
screen
neonat
dat
neg
need
provid
neonat
blood
specimen
subsequ
blood
transfus
request
month
age
anoth
requir
avail
histor
neonat
abo
rh
group
cord
blood
sampl
full
compat
test
would
requir
deviat
elig
criteria
group
red
cell
select
transfus
data
review
includ
evalu
resourc
test
time
save
time
taken
physician
request
blood
administr
also
monitor
studi
effect
direct
blood
product
issu
advers
reaction
transfus
also
record
result
review
neonat
enrol
neoxm
protocol
neonat
inelig
due
unavail
matern
pretransfus
sampl
case
absenc
histor
abo
rh
group
record
elig
case
neonat
subject
blood
sampl
twice
initi
blood
drawn
meet
pretransfus
test
guidelin
total
unit
blood
transfus
neonat
subject
compat
test
blood
process
avoid
due
neoxm
protocol
cost
abo
rh
group
compat
test
unit
respect
total
cost
save
patient
without
need
test
compat
process
time
blood
unit
patient
shorten
min
min
transfus
advers
reaction
observ
uncrossmatch
transfus
summaryconclus
neoxm
protocol
result
cost
save
patient
also
enabl
faster
time
blood
administr
blood
order
c
h
n
chu
montreal
canada
background
current
american
canadian
guidelin
recommend
delay
measl
mump
rubella
mmr
varicella
immun
month
follow
transfus
unwash
red
blood
cell
rbc
due
potenti
interfer
serum
antibodi
thu
patient
chronic
transfus
rbc
commonli
suffer
delay
absenc
mmrvaricella
vaccin
pauciti
data
concern
true
effect
transfus
live
attenu
vaccin
immun
recommend
may
thu
unfound
prevent
valuabl
vaccin
opportun
children
frequent
blood
transfus
aim
primari
aim
project
determin
mmr
vaccin
immunogen
patient
chronic
transfus
rbc
secondari
aim
quantifi
amount
antibodi
pack
rbc
method
igg
antibodi
quantifi
pediatr
patient
receiv
dose
mmr
vaccin
less
month
chronic
rbc
transfus
program
sickl
cell
diseas
major
anemia
pyruv
kinas
defici
antibodi
also
quantifi
sampl
pack
rbc
supernat
result
divid
among
blood
donor
born
versu
like
mmr
antibodi
natur
infect
versu
vaccin
result
immun
mmr
vaccin
compon
found
formal
control
group
immun
rate
literatur
mmr
compon
receiv
rbc
transfus
less
month
prior
serolog
sampl
higher
antibodi
titer
transfus
month
ago
supernat
pack
rbc
blood
donat
donor
found
igg
antibodi
either
measl
mump
rubella
born
like
mmr
vaccin
versu
donor
born
like
natur
immun
summaryconclus
first
studi
effect
rbc
transfus
mmr
vaccin
immunogen
although
lower
rate
report
literatur
result
suggest
high
rate
immunogen
compon
mmr
vaccin
patient
immun
less
month
amount
antibodi
mmr
found
significantli
lower
blood
donor
born
like
vaccin
mmr
rather
natur
infect
either
virus
argu
favor
natur
infect
provid
quantifi
higher
level
antibodi
compar
vaccin
infer
antibodi
level
vaccin
compon
becom
lower
futur
blood
donat
blood
donor
vaccin
weigh
risk
benefit
diseas
prevent
highli
vulner
popul
immun
delay
post
rbc
transfus
call
technologist
pmc
cbb
ramallah
palestinian
territori
background
hemolyt
diseas
fetu
newborn
hdfn
caus
destruct
fetalneon
red
blood
cell
due
red
cell
antibodi
produc
mother
result
fetal
hydrop
pregnanc
neonat
anaemia
jaundic
occur
birth
howev
introduct
routin
postnat
prophylact
immunoglobulin
rh
neg
women
obvious
reduc
form
hdfn
direct
antiglobulin
test
dat
cornerston
detect
antibodi
bound
red
cell
valuabl
test
aid
diagnosi
hdfn
aim
studi
aim
determin
caus
consequ
posit
dat
newborn
central
blood
bank
palestin
period
month
method
retrospect
cohort
studi
conduct
central
blood
bank
palestin
year
total
newborn
analyz
data
includ
dat
blood
group
antibodi
statu
mother
child
indirect
coomb
test
result
studi
period
total
newborn
analyz
number
newborn
posit
dat
case
case
underli
caus
hdnb
abo
blood
group
mismatch
mother
infant
case
mother
red
cell
factor
present
among
posit
dat
newborn
group
newborn
b
newborn
newborn
regard
mother
blood
group
newborn
posit
dat
mother
group
follow
respect
among
mother
posit
indirect
coomb
test
n
mother
neg
indirect
coomb
test
newborn
neonat
jaundic
requir
treatment
requir
singl
phototherapi
treatment
n
requir
phototherapi
n
newborn
requir
intens
follow
doubl
singl
phototherapi
treatment
n
regard
neonat
eight
requir
phototherapi
treatment
data
regard
phototherapi
treatment
neonat
found
none
newborn
requir
exchang
transfus
summaryconclus
common
caus
posit
dat
neonat
palestin
year
abo
blood
group
incompat
mother
child
despit
caus
eg
alloimmun
drug
also
explor
sz
r
j
medicin
kk
woman
children
hospit
medicin
kk
woman
children
hospit
singapor
singapor
background
benefit
prophylact
platelet
transfus
reduc
bleed
complic
chemotherapi
induc
thrombocytopaenia
base
robust
evid
recent
publish
intern
guidelin
recommend
much
lower
threshold
compar
convent
transfus
practic
qualiti
improv
project
conduct
review
exist
platelet
transfus
practic
paediatr
oncolog
depart
kk
hospit
chang
platelet
transfus
practic
made
effect
studi
aim
primari
aim
studi
examin
increas
incid
clinic
bleed
revis
prophylact
platelet
transfus
threshold
secondari
aim
examin
revis
prophylact
platelet
transfus
threshold
led
reduct
platelet
transfus
administ
method
retrospect
studi
conduct
may
juli
prior
revis
platelet
transfus
guidelin
thirti
two
patient
receiv
one
hundr
nineti
six
platelet
transfus
inpati
oncolog
ward
respect
platelet
count
indic
transfus
bleed
sever
transfus
studi
restrict
platelet
transfus
guidelin
subsequ
implement
april
revis
prophylact
platelet
transfus
threshold
stabl
afebril
patient
patient
fever
sepsi
prospect
studi
conduct
april
june
review
effect
restrict
transfus
strategi
includ
patient
oncolog
ward
oncolog
day
therapi
unit
oncolog
outpati
clinic
studi
includ
patient
receiv
platelet
transfus
met
criteria
platelet
transfus
previou
guidelin
revis
guidelin
therefor
given
transfus
clinic
bleed
total
twenti
seven
patient
receiv
eighti
four
platelet
transfus
review
world
health
organ
scale
bleed
miller
cancer
use
assess
sever
bleed
chi
squar
test
independ
use
explor
relationship
type
transfus
protocol
incid
sever
bleed
result
statist
signific
increas
rate
bleed
restrict
transfus
strategi
group
compar
liber
transfus
strategi
p
breakdown
clinic
signific
bleed
grade
show
restrict
transfus
strategi
group
grade
bleed
increas
number
patient
grade
bleed
patient
reduc
incid
grade
bleed
compar
liber
strategi
group
addit
data
collect
three
month
show
seventeen
platelet
transfus
avoid
accord
decreas
threshold
revis
guidelin
result
reduct
number
prophylact
platelet
transfus
result
estim
amount
annualis
cost
save
approxim
usd
summaryconclus
conclud
lower
prophylact
platelet
transfus
threshold
adopt
new
guidelin
safe
increas
incid
sever
bleed
addit
reduct
number
platelet
transfus
translat
reduc
cost
less
demand
preciou
platelet
unit
improv
patient
safeti
avoid
transfus
relat
risk
abstract
withdrawn
r
joshi
ganu
women
children
hospit
adelaid
australia
background
histor
convent
coagul
test
like
pt
inr
aptt
platelet
count
fibrinogen
level
use
manag
coagulopathi
viscoelast
coagul
test
rotem
gain
renew
interest
safe
manag
coagulopathi
adult
paediatr
patient
howev
correl
convent
coagul
test
rotem
investig
paediatr
popul
conclud
whether
reciproc
replac
aim
studi
correl
standard
coagul
test
rotem
infant
undergo
craniofaci
surgeri
method
local
human
ethic
committe
approv
obtain
prospect
studi
studi
conduct
year
time
women
children
hospit
data
collect
children
age
month
year
undergo
craniofaci
surgeri
women
children
hospit
rotem
test
result
rotem
done
along
convent
coagul
test
time
collect
analysi
result
children
boy
girl
includ
studi
underw
craniofaci
surgeri
women
children
hospit
adelaid
age
rang
month
year
spearman
coeffici
correl
test
perform
see
correl
convent
coagul
test
rotem
result
pt
inr
show
statist
signific
correl
fibrinogen
level
show
statist
signific
correl
summaryconclus
amount
fibrinogen
need
correct
coagulopathi
determin
monitor
clot
strength
fibtem
mcf
decis
taken
quickli
point
care
rotem
test
correl
inr
use
clinic
set
like
warfarin
revers
howev
studi
higher
number
patient
need
draw
definit
clinic
conclus
j
n
e
l
g
j
c
j
h
g
h
michael
hospit
hospit
sick
children
medicin
obstetr
medicin
mount
sinai
hospit
canadian
blood
servic
toronto
canada
blood
transplant
oxford
univers
hospit
univers
oxford
oxford
unit
kingdom
immunolog
transfus
medicin
univers
hospit
greifswald
greifswald
hospit
greifswald
univers
tuebingen
tuebingen
germani
therapeut
servic
nh
blood
transplant
bristol
unit
kingdom
health
network
univers
toronto
toronto
blood
servic
ottawa
blood
servic
toronto
hematolog
thromboembol
mcmaster
univers
hamilton
canada
red
cross
blood
servic
brisban
australia
immunolog
depart
french
blood
servic
brittani
ef
renn
franc
cornel
medicin
new
york
new
york
unit
state
america
hospit
north
norway
finnmark
hospit
trust
hammerfest
norway
formerli
institut
nation
de
la
transfus
sanguin
pari
franc
clinic
immunolog
transfus
medicin
region
univers
laboratori
lund
sweden
obstetr
leiden
univers
medic
center
leiden
netherland
children
hospit
melbourn
australia
medicin
unit
mount
sinai
hospit
toronto
haematologyoncolog
chu
univers
montreal
montreal
canada
background
fetal
neonat
alloimmun
thrombocytopenia
fnait
may
result
bleed
aim
systemat
review
postnat
manag
fnait
examin
transfus
human
platelet
antigen
hpa
unselect
platelet
alon
combin
ivig
platelet
increment
hemorrhag
mortal
method
medlin
embas
cochran
databas
search
conduct
well
bibliograph
review
januari
select
origin
research
publish
english
five
newborn
diagnos
fnait
least
one
intervent
one
outcom
interest
studi
two
individu
extract
data
independ
grade
recommend
assess
develop
evalu
grade
approach
use
assess
overal
studi
qualiti
categor
outcom
result
could
combin
due
heterogen
treatment
outcom
limit
qualiti
result
thirteen
studi
fulfil
inclus
criteria
three
prospect
studi
random
control
studi
studi
low
qualiti
accord
grade
unabl
determin
whether
transfus
affect
ich
mortal
time
ich
predomin
caus
death
could
ascertain
predomin
caus
fnait
studi
rang
neonat
neonat
treat
receiv
platelet
transfus
increas
platelet
count
platelet
transfus
either
select
unselect
platelet
without
ivig
durat
thrombocytopenia
describ
one
studi
rang
day
patient
treat
hpa
select
platelet
day
six
patient
treat
hpa
unselect
platelet
three
neonat
treat
hpa
select
unselect
neonat
platelet
count
transfus
howev
none
studi
determin
optim
platelet
transfus
threshold
platelet
transfus
tend
result
higher
platelet
increment
longer
respons
hpa
platelet
avail
studi
clearli
demonstr
benefit
ad
ivig
platelet
transfus
alon
summaryconclus
literatur
spars
limit
descript
studi
rare
address
specif
outcom
platelet
count
platelet
transfus
commonli
use
increas
platelet
count
patient
fnait
sever
thrombocytopenia
andor
bleed
platelet
prefer
immedi
avail
unavail
unselect
platelet
may
use
hpa
select
platelet
avail
rais
platelet
count
evid
ad
ivig
platelet
transfus
lack
r
e
trasfusional
intens
care
unit
fondazion
ircc
ca
granda
ospedal
maggior
policlinico
milan
itali
background
polici
intrauterin
fetal
iuft
neonat
transfus
involv
use
concentr
blood
cell
ec
prefer
group
rh
neg
cdecd
fresh
day
period
donor
compat
mother
andor
newborn
plasma
hematocrit
iuft
newborn
aim
efficaci
safeti
ec
transfus
fulli
compliant
polici
manag
particular
case
pregnant
women
phenotyp
antibodi
method
iuft
mother
sampl
perform
group
determin
complet
rh
phenotyp
indirect
direct
antiglobulin
test
iat
dat
cross
match
automat
method
innova
ortho
clinic
diagnost
extend
type
molecular
biolog
neonat
transfus
perform
group
determin
direct
rh
phenotyp
iat
dat
cross
match
automat
method
innova
result
mother
group
rh
posit
phenotyp
alloantibodi
rare
bank
unit
servic
found
donor
avail
region
phenotyp
unit
donat
divid
two
aliquot
ml
first
concentr
hematocrit
irradi
compat
mother
plasma
transfus
utero
day
donat
second
work
first
transfus
utero
day
donat
fetal
hb
increas
gdl
day
last
iuft
elect
caesarean
section
perform
week
gestat
delay
clamp
min
newborn
weigh
g
hb
gdl
reticulocyt
tot
bilirubin
mgdl
assist
respiratori
support
ncpap
h
spontan
breath
h
life
subject
phototherapi
h
bilirubin
remain
stabl
throughout
hospit
need
phototherapi
day
gkg
immunoglobulin
infus
day
therapi
erythropoietin
iron
folic
acid
start
hb
remain
stabl
hospit
need
transfus
dimiss
day
life
hb
gdl
reticulocyt
tot
group
phenotyp
perform
birth
unreli
previou
iuft
presenc
antibodi
neg
dat
next
hospit
day
life
anemia
hb
gdl
bilirubin
mdl
mlkg
ec
group
rh
transfus
use
aliquot
taken
deglycerol
ec
donor
compat
avail
follow
failur
increas
hb
gdl
bilirubin
mgdl
day
life
mlkg
unit
deglycerol
ec
transfus
increas
hb
gdl
bilirubin
mgdl
dat
remain
neg
birth
child
discharg
follow
day
summaryconclus
procedur
iuft
neonat
transfus
compli
recommend
blood
transfus
standard
polici
due
rariti
need
ec
good
clinic
result
absenc
advers
reaction
observ
l
f
transfus
imperi
colleg
healthcar
nh
trust
nh
blood
transplant
london
unit
kingdom
background
bone
marrow
transplant
recipi
usual
transfus
depend
mani
month
provid
blood
product
recipi
complex
major
minor
compat
problemat
nh
trust
support
paediatr
bmt
centr
special
haemoglobinopathi
disord
essenti
blood
compon
order
appropri
maximis
cross
patient
abo
rhd
compat
line
nation
guidelin
howev
equal
import
meet
individu
patient
requir
without
delay
minimis
compon
wastag
facilit
best
cross
patient
compat
review
upcom
bmt
protocol
aim
implement
inclus
compat
abo
rhd
group
red
cell
ffp
cyro
platelet
compon
protocol
prior
transplant
aim
maximis
cross
compat
blood
compon
bmt
patient
minim
delay
product
wastag
whilst
meet
individu
patient
requir
method
review
patient
bmt
protocol
line
compat
compon
group
prior
transplant
engag
clinic
team
servic
lead
highlight
potenti
benefit
patient
care
well
patient
blood
manag
pbm
provid
train
across
transplant
team
major
minor
group
blood
product
compat
result
compar
stock
hold
bmt
patient
week
implement
chang
show
reduct
rbc
unit
platelet
unit
stock
also
abl
reduc
stock
hold
group
b
plasma
product
approxim
unit
total
chang
polici
also
result
fewer
patient
possibl
compat
miss
bmt
protocol
patient
review
chang
miss
rbc
group
miss
platelet
plasma
group
follow
chang
patient
miss
rbc
group
platelet
group
plasma
group
also
patient
major
minor
incompat
miss
compat
product
group
number
larg
save
equat
signific
improv
potenti
decreas
delay
provid
compat
product
result
reduc
need
await
deliveri
stock
nhsbt
summaryconclus
sinc
chang
implement
cost
save
reduct
miss
rbc
compat
group
reduct
miss
platelet
compat
group
reduct
miss
group
plasma
product
chang
practic
led
potenti
reduct
delay
bmt
patient
transfus
v
bakhru
r
dara
j
bakhru
choudhari
pediatr
neonatolog
prakash
hospit
jaipur
india
background
normal
newborn
present
jaundic
first
two
week
life
make
neonat
jaundic
common
diagnosi
period
gener
bilirubin
level
rise
soon
birth
risk
factor
acceler
bilirubin
level
lead
sever
hyperbilirubinemia
defin
bilirubin
level
greater
mgdl
necessit
need
exchang
transfus
sever
bilirubin
cross
blood
brain
barrier
result
potenti
neurolog
squeal
kernicteru
associ
high
mortal
acut
encephalopathi
cerebr
palsi
hear
loss
neonat
jaundic
recogn
major
problem
asian
countri
data
incid
avail
vast
major
birth
still
occur
home
prevent
sever
hyperbilirubinemia
primari
aim
adequ
feed
secondari
prevent
includ
vigil
monitor
neonat
jaundic
recommend
american
academi
pediatr
aap
guidelin
newborn
bilirubin
measur
done
discharg
hospit
center
start
univers
bilirubin
screen
program
aim
aim
studi
assess
impact
univers
bilirubin
screen
incid
sever
hyperbilirubinemia
use
phototherapi
need
exchang
transfus
method
retrospect
cohort
studi
direct
neonat
week
gestat
protocol
follow
measur
total
serum
bilirubin
tsb
h
day
visit
clinic
risk
factor
identifi
systemat
data
collect
patient
demograph
bilirubin
level
phototherapi
use
exchang
transfus
length
stay
lo
emerg
depart
visit
readmiss
result
total
neonat
enrol
studi
period
januari
decemb
matern
age
year
birth
weight
kg
mean
sd
twenti
two
neonat
exclud
studi
shift
neonat
intens
care
unit
infant
consent
refus
infant
neonat
complet
includ
final
analysi
visibl
jaundic
observ
studi
neonat
first
week
life
phototherapi
requir
infant
treat
birth
hospit
treat
discharg
fifteen
neonat
tsb
level
mgdl
birth
hospit
treat
phototherapi
none
neonat
requir
exchang
transfus
median
length
stay
h
two
neonat
admit
jaundic
relat
emerg
requir
exchang
transfus
initi
lost
follow
summaryconclus
vigil
monitor
neonat
jaundic
via
univers
bilirubin
screen
use
tool
prevent
complic
sever
hyperbilirubinemia
univers
implement
screen
consid
effect
protocol
develop
countri
though
increas
cost
involv
screen
visit
howev
increas
cost
balanc
reduc
cost
fewer
emerg
visit
hospit
readmiss
need
exchang
transfus
r
z
z
f
c
c
blood
transfus
chines
academi
medic
scienc
peke
union
medic
colleg
academi
medic
scienc
sichuan
provinci
peopl
hospit
chengdu
china
background
children
special
patient
group
clinic
transfus
receiv
attent
howev
china
till
transfus
guidelin
neonat
older
children
issu
practic
pediatr
patient
popul
report
aim
concis
review
blood
transfus
practic
among
pediatr
patient
popul
carri
get
full
knowledg
current
statu
blood
transfus
practic
among
children
sichuan
china
method
survey
deal
issu
regard
children
blood
transfus
perform
use
questionnair
sent
hospit
sichuan
china
result
hospit
return
questionnair
hospit
transfus
guidelin
pediatr
popul
children
transfus
reli
larg
expert
opinion
rather
experiment
data
less
hospit
small
packag
blood
product
use
children
hospit
granulocyt
concentr
neonat
patient
transfus
percentag
hospit
offer
detect
neonat
hemolyt
diseas
identif
difficult
blood
type
hospit
carri
plasmapheresi
children
summaryconclus
china
mani
aspect
children
blood
transfus
process
improv
studi
children
transfus
practic
need
taken
transfus
guidelin
neonat
older
children
need
guid
pediatrician
transfus
children
f
health
astana
medic
univers
scientif
centr
astana
kazakhstan
background
studi
clinic
efficaci
transfus
apheresi
platelet
aim
studi
clinic
efficaci
transfus
apheresi
platelet
method
studi
correct
platelet
gain
transfus
apheresi
platelet
children
oncohematolog
diseas
n
transfus
effici
indic
correct
platelet
gain
estim
h
transfus
use
absolut
platelet
count
bodi
surfac
area
number
transfus
platelet
typolog
random
sampl
children
hematolog
diseas
age
month
year
research
period
januari
januari
clinic
base
nation
scienc
center
matern
childhood
astana
studi
design
retrospect
analysi
result
structur
boy
n
girl
n
children
month
n
year
n
year
n
year
n
year
n
year
n
nosolog
structur
solid
tumor
n
acut
lymphoblast
leukemia
n
acut
myeloblast
leukemia
n
acquir
aplast
anemia
n
myelodysplast
syndrom
n
cours
analysi
averag
correct
platelet
gain
l
median
l
clinic
efficaci
note
n
children
transfus
apheresi
platelet
n
effect
one
case
child
myelodysplast
syndrom
low
level
adjust
platelet
gain
l
massiv
splenomegali
observ
case
child
osteogen
sarcoma
l
clinic
factor
contribut
posttransfus
thrombocytopenia
fact
develop
refractori
transfus
apheresi
platelet
possibl
summaryconclus
purpos
earli
detect
refractori
platelet
transfus
monitor
correct
platelet
gain
consid
routin
practic
order
prevent
refractori
produc
alloimmun
advis
solv
problem
determin
compat
donor
recipi
f
h
b
transfus
imperi
colleg
healthcar
nh
trust
london
unit
kingdom
background
mix
field
mf
reaction
refer
presenc
two
distinct
popul
red
cell
agglutin
cell
cell
mf
reaction
commonli
seen
recent
abo
incompat
transfus
patient
undergo
stem
cell
transplant
ident
donor
publish
data
soon
mf
reaction
seen
abo
incompat
transplant
patient
aim
analys
transfus
data
stem
cell
transplant
see
mix
field
mf
reaction
first
seen
major
abo
incompat
transplant
method
review
paediatr
stem
cell
transplant
protocol
ascertain
undertaken
identifi
major
abo
mismatch
transplant
list
review
blood
transfus
record
identifi
rbc
group
blood
given
patient
phase
transplant
abo
test
perform
edta
blood
sampl
use
gel
column
agglutin
biorad
repeat
test
perform
second
sampl
patient
rbc
evalu
reactiv
b
transfus
record
ascertain
patient
first
present
mix
field
pattern
ie
begin
recipi
chang
blood
group
result
stem
cell
transplant
undertaken
year
period
major
abo
incompat
transplant
data
obtain
abo
mismatch
minor
mismatch
transplant
major
abo
incompat
transplant
earliest
mix
field
seen
day
longest
took
day
averag
mf
visibl
day
post
transplant
transplant
recipi
data
earliest
mf
seen
day
longest
took
day
averag
day
summaryconclus
major
major
abo
incompat
transplant
recipi
develop
mix
field
pattern
approxim
month
date
transplant
studi
would
need
see
patient
earlier
present
mf
requir
less
transfus
support
better
outcom
abstract
withdrawn
j
ilunga
l
health
equilibr
intern
medicin
good
shepherd
hospit
tshikaji
kananga
congo
background
treatment
transfus
also
perform
case
anemia
less
ml
retrospect
work
present
take
account
transfus
made
sickl
cell
children
anemia
reason
transfus
aim
work
address
problem
inher
transfus
without
great
rigor
method
hardwar
work
involv
sickl
cell
children
regularli
follow
b
method
studi
hemoglobin
carri
electrophoresi
cellulos
acet
alkalin
acid
ph
follow
quantif
fraction
hemoglobin
studi
perform
two
month
transfus
parent
result
type
hb
patientsth
group
studi
compos
boy
girl
distribut
differ
electrophoret
phenotyp
frequent
encount
complic
osteoarticular
pain
frequent
found
patient
anemia
found
homozyg
sickl
cell
patient
contrast
sickl
cell
patient
never
seriou
complic
discuss
major
children
first
sickl
cell
crisi
year
old
first
sign
discoveri
common
ill
osteoarticular
pain
anemia
rel
unknown
sign
parent
reason
consult
case
transfus
made
accord
hb
level
less
g
ml
sickl
cell
patient
transfus
total
one
sc
summaryconclus
retrospect
work
show
lack
rigor
sickl
cell
children
transfus
consult
sickl
cell
diseas
hospit
good
shepherd
period
mainli
use
whole
blood
risk
allo
could
occur
transfus
isoform
search
irregular
agglutinin
perform
prior
transfus
hiv
hbv
serolog
also
perform
sickl
cell
patient
l
de
c
c
divis
clinic
immunolog
immunohematolog
transfus
medicin
transplant
immunolog
region
refer
laboratori
transplant
immunolog
aou
depart
intern
specialti
medicin
mental
health
prevent
medicin
woman
child
gener
specialist
surgeri
medic
surgic
neurolog
metabol
geriatr
scienc
degli
studi
della
campania
luigi
vanvitelli
sdn
napl
itali
background
children
incid
advers
transfus
reaction
higher
adult
patient
respect
blood
collect
blood
prepar
continu
improv
reduc
risk
transfus
relat
advers
event
especi
patient
aim
aim
studi
assess
occurr
advers
transfus
reaction
hemocompon
whole
blood
apheresi
pediatr
patient
method
n
pediatr
patient
transfus
hemocompon
obtain
whole
blood
apheresi
collect
uoc
divis
clinic
immunolog
immunohaematolog
transfus
medicin
della
campania
luigi
vanvitelli
advers
event
describ
minor
allerg
reaction
febril
episod
vomit
presenc
dyspnea
bronchospasm
comparison
transfus
compon
presenceabs
advers
event
assess
use
pearson
test
result
data
pediatr
patient
n
n
thalassem
patient
analyz
male
gender
respect
thalassem
patient
mean
age
year
respect
thalassem
patient
median
time
observ
year
interquartil
rang
iqr
patient
year
iqr
thalassem
patient
period
unit
hemocompon
transfus
thalassem
patient
differ
proport
advers
event
whole
blood
apheresi
observ
whole
blood
apheresi
result
found
consid
separ
whole
blood
apheresi
thalassem
patient
whole
blood
aphaeresi
summaryconclus
differ
advers
event
relat
whole
blood
apheresi
thalassem
pediatr
patient
observ
blood
compon
shown
transfus
safeti
pediatr
patient
c
k
medicin
liver
diseas
transplant
gleneagl
global
health
citi
chennai
india
background
accident
suicid
consumpt
rat
killer
poison
contain
yellow
phosphoru
yp
compon
could
lead
death
yp
could
caus
acut
liver
failur
alf
cardiac
arrhythmia
bone
marrow
depress
renal
failur
liver
transplant
lt
success
treatment
option
alf
patient
develop
acut
liver
failur
follow
consumpt
yp
therapeut
plasma
exchang
tpe
provid
potenti
therapeut
option
support
liver
function
provid
scope
regener
alf
howev
literatur
regard
role
tpe
yp
poison
aim
identifi
tpe
reduc
mortal
increas
transplant
free
surviv
patient
yp
poison
method
prospect
studi
approv
institut
ethic
committe
adult
consum
yp
receiv
standard
medic
therapi
tpe
indic
inr
alt
ast
elev
encephalopathi
signific
chang
liver
biopsi
tpe
perform
use
optia
spectra
centrifug
apheresi
terumo
bct
consecut
day
plasma
volum
exchang
perform
fresh
frozen
plasma
albumin
replac
fluid
patient
monitor
transfus
procedur
relat
advers
event
given
calcium
prophylaxi
patient
monitor
liver
function
test
renal
function
test
arteri
ammonia
abg
inr
liver
biopsi
patient
also
monitor
chang
pre
post
tpe
h
cytokin
level
result
studi
period
dec
januari
patient
f
mean
age
rang
admit
yp
poison
induc
alf
averag
time
yp
intak
admiss
rang
day
averag
day
baselin
investig
show
elev
inr
rais
liver
enzym
ast
alt
total
procedur
perform
averag
procedur
procedur
perform
consecut
day
averag
ml
blood
volum
process
averag
ml
plasma
exchang
minor
allerg
reaction
major
advers
reaction
tpe
procedur
cytokin
analysi
show
signific
increas
inflammatori
cytokin
il
il
plasmapheresi
proinflammatori
cytokin
il
p
fibrogen
cytokin
tgf
p
show
signific
decreas
patient
show
signific
improv
serum
alt
ast
level
coagul
statu
patient
improv
without
need
liver
transplant
discharg
averag
day
day
patient
requir
urgent
liver
transplant
day
respect
poison
intak
post
lt
patient
develop
graft
dysfunct
postop
period
improv
post
lt
tpe
cycl
post
tpe
liver
biopsi
show
histolog
improv
form
reduct
hepatocyt
necrosi
compar
pre
tpe
patient
expir
due
multi
organ
failur
summaryconclus
first
studi
highlight
role
tpe
effect
treatment
intervent
patient
yellow
phosphoru
poison
along
standard
medic
therapi
initi
experi
provid
strong
recommend
tpe
reduc
mortal
improv
surviv
nativ
liver
patient
yp
poison
v
v
sechenov
first
moscow
state
medic
univers
transplantolog
artifici
organ
clinic
institut
pediatr
moscow
russian
feder
background
elimin
antibodi
detect
patient
arrhythmia
due
myocard
improv
cardiac
function
antiarrhythm
drug
effect
aim
investig
clinic
effici
plasma
exchang
pe
patient
arrhythmia
due
myocard
comparison
control
group
without
pe
method
patient
arrhythmia
resist
antiarrhythm
drug
aad
mean
age
year
prematur
atrial
contract
pac
n
prematur
ventricular
contract
pvc
n
per
day
atrial
fibril
af
n
treatment
group
patient
mean
age
year
pac
n
pvc
n
af
n
follow
without
pe
patient
two
fold
increas
least
two
antibodi
aha
level
cardiac
nuclear
antigen
endotheli
cardiomyocyt
conduct
smooth
muscl
cell
antigen
patient
treatment
group
underw
singl
volum
therapeut
pe
studi
group
patient
underw
endomyocardi
biopsi
emb
n
cardiac
ct
n
mri
n
myocardi
perfus
scan
n
coronari
angiographi
n
diagnos
myocard
patient
treat
either
immunosuppress
drug
without
group
patient
underw
clinic
evalu
includ
aha
level
detect
holter
monitor
baselin
fu
visit
month
result
aha
cardiomyocyt
level
significantli
decreas
p
control
group
arrhythmia
thirteen
treatment
group
patient
arrhythmia
patient
control
group
classifi
respond
achiev
decreas
pav
pvc
af
frequenc
rel
baselin
aad
elimin
treatment
group
patient
control
group
patient
treatment
group
respond
character
higher
level
aha
cardiac
nuclear
antigen
baselin
p
nine
treatment
group
patient
arrhythmia
nineteen
control
group
patient
got
methylprednisolon
respect
p
mean
dose
mg
per
day
p
summaryconclus
pe
improv
aad
effect
patient
immun
mediat
arrhythmia
treatment
group
respond
patient
arrhythmia
initi
high
aha
level
cardiac
nuclear
antigen
good
outcom
predictor
patient
arrhythmia
pe
help
avoid
use
immunosuppress
medic
reduc
high
dose
n
g
j
e
c
transfus
medicin
dermatolog
paracelsu
medic
univers
hospit
cord
injuri
tissu
regener
center
salzburg
austria
background
atop
dermat
ad
also
known
atop
eczema
chronic
inflammatori
condit
skin
affect
children
adult
industri
countri
patient
sever
ad
tend
high
total
serum
ige
level
treatment
antibodi
omalizumab
howev
abandon
ineffect
reduc
highli
elev
ige
serum
level
signific
clinic
improv
ad
seen
recent
publish
data
show
promis
result
treatment
ad
patient
ige
immunoadsorpt
ia
still
carri
mind
also
complex
immun
dysregul
ige
might
crucial
mechan
ad
aim
aim
current
studi
determin
safeti
efficaci
ige
ia
newli
develop
ige
immunoadsorb
column
freseniusmed
care
bad
homburg
germani
method
pilot
studi
enrol
four
patient
sever
ad
scorad
elev
ige
level
kul
patient
receiv
three
cycl
ia
igenio
freseniusmed
care
bad
homburg
germani
first
cycl
consist
three
consecut
treatment
follow
two
cycl
two
consecut
treatment
cycl
perform
monthli
regimen
twofold
plasma
volum
patient
separ
centrifug
apheresi
devic
spectra
optia
terumo
bct
lakewood
co
usa
anticoagul
treatment
maintain
continu
citrat
dosag
volumecitr
ratio
sodium
heparin
iukg
bodi
weight
efficaci
ia
determin
immunoglobulin
level
ige
igg
igm
iga
week
termin
treatment
clinic
improv
dispassion
evalu
scorad
index
two
experienc
dermatologist
week
last
treatment
cycl
result
ia
well
toler
patient
total
procedur
mild
advers
event
record
cycl
ia
result
signific
decreas
ige
level
although
rebound
ige
level
saw
tooth
manner
ia
cycl
seen
studi
patient
total
ia
select
deplet
ige
end
treatment
cycl
averag
reduct
scorad
index
patient
end
studi
period
summaryconclus
studi
provid
first
evid
ige
ia
newli
develop
column
safe
therapi
patient
sever
ad
despit
fact
ige
level
rose
initi
valu
cycl
could
observ
signific
averag
reduct
scorad
index
end
studi
period
long
time
patient
assess
impact
novel
therapeut
strategi
h
k
h
medicin
pusan
nation
univers
yangsan
hospit
yangsan
medicin
pusan
nation
univers
hospit
medicin
pusan
nation
univers
hospit
busan
korea
background
reject
amr
occur
patient
donor
specif
antibodi
dsa
patient
wait
heart
lung
transplant
often
lot
preform
hla
antibodi
result
presenc
dsa
patient
arrang
design
organ
candid
possibl
receiv
organ
transplant
low
desensit
dsa
import
aim
analyz
dsa
characterist
protocol
desensit
dsa
recipi
heart
lung
amount
blood
transfus
period
aim
aim
analyz
dsa
characterist
protocol
desensit
dsa
recipi
heart
lung
amount
blood
transfus
period
method
may
june
patient
underw
heart
transplant
patient
got
lung
transplant
dsa
classifi
preform
found
prior
transplant
wherea
found
transplant
classifi
de
novo
patient
group
categor
accord
presenc
dsa
patient
type
dsa
classifi
dsa
group
patient
without
dsa
group
among
dsa
group
reclassifi
perform
pcpf
pcpf
accord
treatment
plasmapheresi
periop
hemoglobin
platelet
record
transfus
day
oper
day
oper
analyz
result
among
patient
total
patient
dsa
among
eight
patient
preform
dsa
four
patient
de
novo
dsa
two
patient
type
dsa
overal
patient
dsa
patient
preform
dsa
accord
type
strength
dsa
patient
preform
dsa
underw
addit
treatment
pcpf
maintain
immunosuppress
therapi
two
patient
strong
preform
dsa
accord
guidelin
antibodi
incompat
transplant
hard
get
transplant
tri
desensit
desensit
pcpf
immunosuppress
patient
show
amr
episod
also
infect
two
patient
underw
pcpf
despit
dsa
low
mfi
valu
physician
decid
need
pcpf
oper
transplant
unit
prbc
transfus
heart
recipi
unit
lung
recipi
p
also
unit
ffp
transfus
heart
recipi
unit
lung
transplant
p
amount
platelet
transfus
significantli
differ
heart
lung
respect
p
mean
pt
inr
right
transplant
significantli
differ
heart
recipi
lung
recipi
p
mean
aptt
significantli
differ
heart
recipi
lung
recipi
p
mean
hb
gdl
plt
k
heart
recipi
lung
recipi
significantli
differ
summaryconclus
case
multipl
strong
dsa
desensit
cocktail
protocol
immunosuppress
plasmapheresi
especi
pcpf
maintain
effect
immunosuppress
pcpf
adjuv
administr
immunosuppress
effect
prevent
amr
infect
periop
hb
plt
differ
heart
lung
transplant
blood
transfus
lung
transplant
done
intens
transfus
support
need
lung
transplant
g
g
transfus
medicin
diseas
renal
transplant
medanta
medic
gurgaon
gurgaon
india
background
therapeut
apheresi
ta
serv
rescu
therapi
mani
patient
kidney
diseas
indic
expand
dramat
past
year
rapid
remov
undesir
antibodi
immun
complex
remain
prime
rational
adopt
plasmapheresi
therapi
howev
limit
data
avail
regard
indic
efficaci
safeti
ta
nephrolog
patient
aim
assess
efficaci
safeti
ta
differ
nephrolog
indic
method
retrospect
analysi
ta
perform
adult
pediatr
nephrolog
patient
tertiari
healthcar
centr
januari
decemb
ta
includ
convent
plasma
exchang
cascad
plasmapheresi
immunoadsorpt
procedur
demograph
clinic
condit
asfa
categori
procedur
paramet
like
blood
plasma
volum
process
anticoagul
use
volum
type
replac
fluid
administ
advers
reaction
event
clinic
respons
note
result
total
patient
femal
male
underw
session
ta
differ
indic
procedur
perform
pediatr
adult
patient
respect
mean
age
present
pediatr
age
group
year
adult
year
procedur
convent
plasma
exchang
cascad
plasmapheresi
immunoadsorpt
mean
blood
urea
serum
creatinin
prior
initi
plasmapheresi
indic
except
desensit
mgdl
mgdl
time
termin
mgdl
mgdl
respect
replac
fluid
plasma
procedur
albumin
combin
plasma
albumin
procedur
acid
citrat
dextros
remain
prefer
anticoagul
per
department
standard
oper
procedur
patient
bodi
weight
kg
ie
procedur
requir
prime
kit
albumin
red
cell
patient
outcom
term
surviv
pediatr
adult
age
group
procedur
pediatr
adult
associ
advers
event
form
shiver
urticaria
cathet
relat
complic
summaryconclus
find
studi
highlight
efficaci
safeti
ta
pediatr
adult
nephrolog
patient
nayak
bajpai
transfus
medicin
institut
liver
biliari
scienc
new
delhi
new
delhi
india
background
hemophagocyt
lymphohistiocytosi
hlh
disord
fulmin
immun
respons
therapeut
plasma
exchang
tpe
document
produc
optim
respons
patient
howev
diseas
yet
find
place
variou
categori
indic
tpe
asfa
classif
aim
summar
six
case
hlh
children
success
treat
therapeut
plasma
exchang
method
data
pediatr
patient
diagnos
hlh
treat
tpe
institut
studi
period
juli
decemb
compil
diagnosi
treatment
hlh
base
hlh
protocol
data
collect
includ
demograph
age
weight
clinic
histori
complain
admiss
sign
symptom
factor
necessit
tpe
clinic
statu
session
drug
administ
laboratori
paramet
blood
count
ferritin
triglycerid
fibrinogen
bone
marrow
aspir
report
cours
hospit
stay
tpe
procedur
done
spectra
optia
terumo
bct
use
anticoagul
fresh
frozen
plasma
replac
fluid
patient
vital
continu
monitor
throughout
procedur
plasma
volum
exchang
volum
rate
mlmin
plasma
extract
dialysi
cathet
appropri
calib
place
intern
jugular
femor
vein
tpe
done
till
symptomat
resolut
fever
hepatosplenomegali
andor
laboratori
paramet
increas
blood
count
decreas
ferritin
level
improv
result
total
procedur
tpe
done
patient
age
year
secondari
hlh
primari
etiolog
dengu
hepat
evb
ie
epstein
barr
viru
patient
high
grade
fever
transient
respond
antipyret
moder
sever
cytopenia
hemoglobin
gdl
platelet
tlc
present
averag
ferritin
ngml
ngml
triglycerid
mgdl
fibrinogen
mgdl
bone
marrow
aspir
done
four
six
patient
show
hemophagocyt
three
six
patient
receiv
tpe
patient
requir
tpe
one
patient
receiv
session
tpe
five
six
patient
improv
tpe
ivig
gkg
methyl
prednisolon
mgkg
time
diagnosi
initi
tpe
session
along
medic
effect
howev
one
patient
hlh
secondari
ebv
receiv
session
tpe
chemotherapi
viral
infect
succumb
spite
effort
summaryconclus
respons
secondari
hlh
tpe
ivig
steroid
found
satisfactori
patient
pk
n
v
medicin
transplant
immunolog
transplant
kidney
transplant
jaype
hospit
noida
india
background
antibodi
mediat
reject
amr
remain
major
caus
graft
failur
kidney
transplant
presenc
donor
specif
leukocyt
antigen
hla
increas
risk
amr
kidney
transplant
patient
develop
anti
hla
antibodi
result
previou
exposur
prior
transplant
blood
transfus
pregnanc
howev
desensit
protocol
enabl
renal
transplant
high
risk
patient
patient
nt
donor
aim
aim
present
studi
find
effect
plasmapheresi
hla
sensit
kidney
transplant
case
method
singl
center
retrospect
observ
case
kidney
transplant
done
hla
sensit
patient
june
dec
patient
desensit
plasmapheresi
low
dose
ivig
rituximab
tpe
done
use
com
tec
freseniu
kabi
germani
volum
tpe
done
use
albumin
replac
fluid
luminex
cross
match
donor
lysat
dsa
use
luminex
immucor
usa
done
plasmapheresi
monitor
effect
tpe
ahg
lymphocytotox
crossmatch
assay
flowcytometri
cross
match
fcxm
bd
fac
canto
done
start
tpe
transplant
procedur
done
use
department
sop
manufactur
instruct
interpret
report
per
ashi
guidelin
fcxm
median
channel
shift
mfi
mfi
consid
posit
dsa
class
class
ii
mfi
consid
posit
target
luminex
dsa
mean
fluoresc
index
mfi
along
neg
neg
fcxm
effect
tpe
measur
use
dsa
result
total
case
requir
desensit
mean
age
recipi
donor
year
year
respect
recipi
mf
ratio
one
total
retranspl
second
case
pre
tpe
mean
serum
creatinin
mgdl
patient
histori
previou
blood
transfus
femal
recipi
multipar
two
case
abo
incompat
along
hla
sensit
dsa
class
posit
two
patient
mean
class
ii
posit
five
mean
remain
five
posit
class
mean
class
ii
mean
fcxm
posit
case
mean
number
pretranspl
tpe
procedur
requir
procedur
requir
patient
regular
till
compil
data
protocol
biopsi
reveal
evid
tissu
injuri
deposit
mean
serum
creatinin
concentr
last
mgdl
summaryconclus
plasmapheresi
effect
modal
reduc
antibodi
load
prevent
amr
though
role
tpe
well
acknowledg
asfa
guidelin
categori
recommend
still
high
risk
transplant
done
center
india
j
trejo
e
issst
hrlalm
citi
mexico
citi
mexico
background
thrombot
microangiopathi
tma
set
process
lead
alter
vascular
endothelium
present
characterist
find
peripher
blood
smear
microangiopath
hemolyt
anemia
schistocyt
characterist
laboratori
data
elev
reticulocyt
lactat
dehydrogenas
ldh
creatinin
thrombocytopenia
variabl
intens
last
year
differ
physiopatholog
mechan
describ
determin
appear
tma
differ
situat
allow
differ
therapeut
approach
fundament
test
diagnosi
tma
adamt
inhibitor
activ
inaccess
time
initi
assess
mexico
aim
know
prognost
impact
serum
marker
initi
respons
plasma
exchang
pe
tma
method
observ
studi
retrospect
retrolect
longitudin
mean
multivari
analysi
linear
regress
obtain
impact
variabl
know
respons
diseas
pe
patient
diagnosi
tma
entri
includ
receiv
initi
treatment
intraven
steroid
pe
fresh
frozen
plasma
compat
volum
exclud
patient
salin
solut
replac
albumin
replac
volum
differ
time
present
transfus
reaction
well
use
anoth
immunosuppress
therapi
differ
intraven
steroid
result
patient
includ
women
mean
age
year
year
patient
blood
group
seven
one
b
ten
patient
respond
respons
platelet
without
transfus
absenc
clinic
data
tma
pe
mean
pe
number
obtain
respons
pe
group
mean
biomark
time
diagnosi
tma
prior
start
pe
hb
g
dl
platelet
ml
schistocyt
ldh
l
creatinin
mg
dl
versu
hb
g
dl
platelet
ml
schistocyt
ldh
l
creatinin
mg
dl
group
patient
respond
pe
achiev
statist
signific
level
creatinin
platelet
p
summaryconclus
center
serum
level
time
diagnosi
platelet
creatinin
level
serv
initi
prognost
marker
respons
tma
pe
h
j
j
k
k
laboratori
medicin
seoul
nation
univers
colleg
medicin
seoul
laboratori
medicin
hallym
univers
colleg
medicin
hwaseong
korea
background
nationwid
apheresi
registri
give
us
inform
current
statu
trend
regard
apheresi
procedur
data
compar
countri
find
understand
differ
perspect
indic
technolog
clinic
practic
korean
societi
apheresi
ksfa
launch
onlin
web
base
registri
system
apheresi
procedur
sinc
aim
report
registri
data
fiscal
year
method
inform
apheresi
procedur
instrument
use
report
onlin
registri
system
voluntarili
particip
hospit
korea
inform
blood
center
also
collect
email
result
total
apheresi
procedur
perform
blood
center
plasmapheresi
platelet
plasma
plateletpheresi
number
instrument
use
blood
center
mc
amicu
trima
among
platelet
unit
suppli
apheresi
platelet
count
random
donor
platelet
apheresi
platelet
hospit
report
case
apheresi
procedur
cobe
spectra
amicu
wide
use
instrument
therapeut
plasmapheresi
frequent
procedur
follow
autolog
peripher
blood
stem
cell
pbsc
collect
allogen
pbsc
collect
donor
leukapheresi
therapeut
leukapheresi
centrifug
domin
techniqu
therapeut
plasmapheresi
follow
primari
membran
filtrat
plasma
filtrat
summaryconclus
apheresi
registri
well
run
year
major
revis
updat
registri
plan
year
help
us
achiev
better
understand
apheresi
statu
region
abstract
withdrawn
r
ciotola
mottola
mottola
c
bruno
c
arcopinto
n
adinolfi
de
cenzo
b
zuccarelli
immunohematolog
servic
aorndei
colli
napoli
itali
background
cardiac
transplant
current
consid
treatment
gold
standard
therapi
termin
heart
failur
despit
introduct
power
immunosuppress
drug
acut
reject
transplant
organ
repres
seriou
complic
cardiac
transplant
cardiac
allograft
reject
hyperacut
acut
cellular
acr
acut
amr
chronic
cav
chronic
allograft
vasculopathi
well
classif
ishlt
intern
societi
heart
lung
transplant
pathophysiolog
amr
suggest
prime
role
antibodi
b
cell
plasma
cell
complement
system
factor
like
involv
appear
camr
event
associ
antibodi
present
either
transplant
appear
subsequ
even
mani
year
aim
benefit
treatment
immunoadsorpt
techniqu
cardiac
allograft
reject
method
treat
two
patient
underw
orthotop
heart
transplant
ten
year
ago
year
develop
cav
occurr
sign
congest
heart
failur
first
patient
ef
eject
fraction
second
patient
ef
hospit
novemb
depart
cardiac
surgeri
patient
underw
endomyocardi
biopsi
emb
determin
hla
antibodi
pra
diagnos
amr
therefor
servic
contact
introduc
therapeut
treatment
immunoadsorpt
ia
addit
immunosuppress
therapi
treatment
perform
cell
separ
comtec
plasma
apheresi
guid
adsorb
globaffin
devic
day
follow
follow
week
altern
day
monitor
antibodi
total
treatment
result
end
treatment
dosag
antibodi
first
patient
significantli
reduc
simultan
improv
clinic
echocardiograph
ef
condit
second
patient
despit
remain
unchang
antibodi
titer
clinic
improv
accompani
increas
cardiac
function
ef
summaryconclus
two
case
treat
procedur
ia
prove
effect
strategi
treatment
amr
first
case
evid
laboratori
investig
reset
hla
antibodi
second
case
signific
clinic
improv
impli
effect
treatment
depend
remov
hla
antibodi
circul
inflammatori
mediat
involv
nellamr
p
p
j
hemotherapi
de
sangr
tejido
de
navarra
complejo
hospitalario
de
navarra
pamplona
spain
centr
segment
terumobct
zaventem
belgium
background
accord
guidelin
acquir
idiopath
thrombot
thrombocytopen
purpura
ttp
treat
therapeut
plasma
exchang
tpe
earli
possibl
circul
von
willebrand
factor
molecul
adamt
proteas
remov
circul
newli
infus
plasma
restor
adamt
level
fresh
frozen
plasma
ffp
treat
pathogen
reduct
technolog
prt
use
riboflavin
uv
light
ffprb
commerci
europ
sinc
use
sinc
blood
centr
qualiti
ffprb
compli
specif
coe
guidelin
accord
literatur
moreov
hemovigil
data
attest
safeti
blood
product
aim
report
treatment
four
patient
diagnos
primari
idiopath
ttp
therapeut
plasma
exchang
remiss
use
ffprb
method
four
patient
femal
male
diagnos
primari
idiopath
ttp
treat
therapeut
plasma
exchang
volum
per
day
use
ffprb
combin
corticosteroid
prednison
mgkgday
remiss
tpe
perform
spectra
optia
system
terumo
bct
four
patient
show
treatment
start
detect
adamt
activ
three
detect
level
one
neurolog
symptom
result
serum
lactat
dehydrogenas
ldh
level
increas
four
patient
averag
ul
rang
creatinin
level
remain
stabl
mgdl
begin
treatment
mgdl
remiss
averag
platelet
count
begin
treatment
rang
remiss
attain
averag
pe
session
rang
platelet
count
reach
averag
rang
ldh
level
ul
rang
sever
advers
event
observ
despit
high
volum
transfus
plasma
two
mild
cutan
reaction
observ
good
respons
treatment
histor
data
depart
previou
treatment
ttp
patient
n
tpe
use
standard
ffp
quarantin
plasma
show
averag
number
session
till
remiss
summaryconclus
plasma
treat
riboflavin
uv
light
adequ
safe
treatment
ttp
four
patient
standard
regimen
vol
plasma
per
day
accompani
corticosteroid
therapi
abstract
withdrawn
n
garcia
ortega
sanchez
r
ramoneda
nova
garcia
miguel
moral
casal
villan
mora
gonzalez
medina
apheresi
transfus
blood
tissu
bank
barcelona
spain
background
sever
plasmodium
falciparum
malaria
signific
health
problem
worldwid
especi
develop
countri
aim
report
use
autom
erythrocytapheresi
adjunct
artesun
manag
sever
plasmodium
falciparum
malaria
hyperparasitaemia
three
patient
method
treat
three
patient
affect
sever
plasmodium
falciparum
malaria
combin
anti
malari
measur
devic
use
cobe
spectra
system
case
one
two
optia
spectra
third
one
result
patient
one
spanish
man
idiopath
dilat
cardiomyopathi
receiv
heart
allograft
day
post
ht
present
fever
chill
hypotens
requir
noradrenalin
bilirubin
elev
hemoglobin
drop
gdl
gdl
peripher
blood
smear
show
intracellular
parasit
compat
pfalciparum
parasitaemia
rate
quinin
doxycyclin
administr
hyperparasitaemia
immunosuppress
due
ht
sever
consid
adjunct
therapi
order
rapid
remov
alter
red
cell
circul
rate
parasitemia
decreas
point
artesun
given
one
day
pharmacolog
treatment
rate
becam
neg
patient
two
spanish
man
travel
ghana
take
prophylaxi
one
week
later
arriv
start
fever
consult
medic
institut
sinc
one
week
sever
clinic
condit
patient
transfer
hospit
hypotens
renal
failur
dissemin
intravascular
coagulopathi
requir
noradrenalin
develop
peripher
blood
smear
show
intracellular
parasit
compat
pfalciparum
parasitaemia
rate
ad
quinin
previou
doxycyclin
perform
autom
erythropheresi
treatment
support
care
also
patient
receiv
artesun
patient
three
french
woman
travel
papua
new
guinea
also
take
prophylaxi
present
fever
seizur
flight
back
countri
pilot
decid
land
barcelona
airport
due
sever
symptom
arriv
hospit
patient
develop
progress
delirium
coma
manifest
cerebr
malaria
peripher
blood
smear
show
intracellular
parasit
compat
pfalciparum
hyperparasitaemia
emerg
servic
decid
treatment
artesun
control
parasitaemia
next
h
case
adjunct
treatment
autom
erythrocytapheresi
consid
first
place
notic
still
proper
protocol
situat
control
rate
parasitaemia
decreas
autom
erythrocytapheresi
perform
unfortun
patient
die
h
later
summaryconclus
measur
reduc
parasit
burden
sever
malaria
must
consid
except
case
adjunct
strategi
solv
emerg
autom
erythrocytapheresi
safe
procedur
perform
sever
situat
easili
avail
howev
delay
eventu
emphas
need
establish
consensu
procedur
e
e
van
medicin
sanquin
blood
bank
amsterdam
affair
sanquin
blood
bank
maastricht
netherland
background
sinc
sanquin
blood
bank
appli
therapeut
erythrocytapheresi
te
mostli
treatment
hereditari
hemochromatosi
sinc
number
patient
procedur
indic
excess
grown
conform
guidelin
accept
patient
reduct
red
blood
cell
rbc
treatment
except
patient
recent
myocardi
infarct
seriou
arrhythmia
recent
neurovascular
event
histori
epilepsi
grand
mal
last
month
aim
aim
studi
observ
review
consecut
patient
treat
te
sanquin
blood
bank
method
perform
retrospect
analysi
te
procedur
emphasi
patient
characterist
advers
event
occur
procedur
result
total
patient
treat
male
femal
total
te
procedur
major
patient
n
total
patient
treat
hereditari
hemochromatosi
total
procedur
second
largest
group
patient
polycythemia
vera
total
patient
procedur
patient
treatment
appli
hyperferritinemia
unknown
diagnosi
total
procedur
patient
secondari
hemochromatosi
caus
multipl
transfus
histori
also
success
treat
group
total
procedur
perform
number
patient
treat
secondari
polyglobulia
caus
heart
lung
diseas
total
procedur
total
patient
chronic
steatohepat
alcohol
hepat
treat
procedur
two
patient
diagnos
porphyria
cutanea
tarda
need
treatment
two
patient
aceruloplasminemia
treat
procedur
one
patient
diagnosi
hereditari
erythrocytosi
treat
treatment
seriou
advers
event
report
mild
mild
complic
occur
procedur
patient
experienc
least
one
complic
cours
treatment
patient
advers
event
femal
male
half
reaction
patient
citrat
reaction
muscl
cramp
paresthesia
nausea
respond
simpl
measur
reduc
flow
rate
andor
oral
administr
calcium
tablet
milk
dizzi
shortli
procedur
notic
time
patient
near
vasovag
collaps
occur
procedur
patient
patient
pain
arm
experienc
shortli
procedur
furthermor
arrhythmia
normal
blood
pressur
experi
itch
place
venesect
occurr
hypoglycemia
report
individu
patient
summaryconclus
varieti
patient
n
either
iron
overload
high
red
blood
cell
mass
treat
te
blood
bank
set
procedur
mild
mild
complic
occur
seriou
advers
event
report
confirm
te
safe
appli
blood
bank
set
pk
n
e
medicin
transplant
immunolog
bone
marrow
transplant
care
medicin
jaype
hospit
noida
india
background
hlh
syndrom
patholog
hyperact
inflamm
due
uncheck
immun
activ
hlh
clinic
syndrom
occur
age
group
primarili
recogn
pediatr
age
group
patient
develop
countri
remain
rel
diagnosi
hlh
base
hlh
diagnost
criteria
propos
hlh
societi
criterion
requir
fulfil
five
eight
clinic
tool
though
tpe
approv
definit
treatment
modal
manag
secondari
hlh
case
report
shown
benefici
effect
calm
cytokin
storm
aim
observ
effect
tpe
hlh
method
observ
done
tertiari
healthcar
center
nation
capit
region
india
complet
blood
count
like
hemoglobin
hb
platelet
count
pc
total
differenti
leukocyt
count
done
use
xn
sysmex
usa
biochem
paramet
like
serum
ferritin
fibrinogen
triglycerid
lactat
dehydrogenas
ldh
liver
function
test
lft
kidney
function
test
kft
done
vitro
ocd
coagul
paramet
pt
aptt
measur
destini
plu
tcoag
stago
bone
marrow
biopsi
done
detect
hemophagocytosi
rule
lymphoid
malign
aplasia
diagnosi
made
base
hlh
criteria
result
patient
year
absolut
well
one
week
ago
present
hospit
chief
complaint
persist
fever
bodyach
throat
pain
decreas
oral
intak
one
week
vital
persist
low
systolicdiastol
mm
hg
even
infus
ml
normal
salin
patient
shift
medic
icu
treatment
broad
spectrum
antibiot
ionotrop
support
noradrenalin
start
hematolog
consult
taken
view
pancytopenia
derang
coagul
gdl
sec
sec
paramet
relev
hlh
investig
show
convinc
result
favour
hlh
iul
mgdl
ngml
fast
mgdl
lft
kft
coagul
profil
grossli
derang
bone
marrow
biopsi
done
demonstr
featur
characterist
hlh
due
progress
deterior
clinic
condit
intub
start
iv
methylprednisolon
puls
tpe
three
session
tpe
clinic
condit
improv
remark
switch
iv
dexamethason
mainten
treatment
tpe
done
use
comtec
freseniu
kabi
germani
one
standard
tpe
procedur
plasma
volum
exchang
use
fresh
frozen
plasma
replac
fluid
slowli
organ
function
improv
extub
hospit
stay
patient
requir
transfus
unit
pack
red
cell
unit
ffp
unit
singl
donor
platelet
concentr
unit
cryoprecipit
discharg
day
hospit
admiss
time
discharg
hematolog
biochem
coagul
paramet
within
normal
rang
summaryconclus
develop
countri
like
india
infect
still
prime
concern
physician
make
accur
diagnosi
hlh
great
concern
high
suspicion
time
diagnosi
earli
start
tpe
life
save
patient
sk
jefferson
univers
medicin
hematolog
oncolog
univers
pennsylvania
philadelphia
pennsylvania
unit
state
america
background
pulmonari
hypertens
ph
controversi
complic
controversari
center
diagnosi
accur
type
ph
manag
describ
patient
pulmonari
arteri
hypertens
pah
diagnos
right
heart
catheter
success
treat
whole
blood
exchang
wbe
aim
demonstr
safeti
efficaci
wbe
transfus
treatment
sever
pah
patient
intermedia
method
man
greek
ancestri
present
progress
dyspnea
acut
cor
pulmonal
secondari
ph
past
medic
histori
remark
histori
intermedia
extramedullari
hematopoiesi
iron
overload
splenectomi
chelat
therapi
deferoxamin
find
physic
exam
includ
respiratori
distress
respiratori
rate
puls
puls
oximetri
two
liter
oxygen
blood
pressur
temperatur
lung
exam
clear
auscult
heart
exam
reveal
split
hematolog
biochem
imag
studi
done
routin
method
non
synthet
ratio
determin
column
chromatographi
carboxymethyl
cellulos
urea
radioact
globin
prepar
peripher
blood
incub
mutat
determin
polymeras
chain
reaction
pcr
revers
dot
blot
hybrid
deform
index
rbc
determin
osmot
gradient
ektacytometri
whole
blood
viscos
determin
viscometri
right
heart
catheter
whole
blood
exchang
done
establish
method
result
hemoglobin
hb
level
gl
mean
corpuscular
volum
mcv
fl
white
blood
cell
wbc
platelet
arteri
blood
ga
ph
hb
electrophoresi
show
hb
af
hb
f
hb
molecular
diagnost
show
delet
one
gene
non
synthet
ratio
mutat
show
mutat
one
c
g
mutat
second
iv
g
thu
hb
genotyp
specif
mutat
c
iv
g
deform
index
rbc
normal
control
whole
blood
viscos
increas
normal
cardiac
catheter
reveal
sever
pah
mean
pulmonari
arteri
pressur
mpap
mmhg
normal
pulmonari
capillari
wedg
pressur
mmhg
possibl
decreas
deform
rbc
increas
whole
blood
viscos
worsen
pah
wbe
perform
result
dramat
prompt
clinic
improv
whole
blood
exchang
repeat
everi
week
within
month
evid
pulmonari
hypertens
echocardiographi
unfortun
develop
multipl
rbc
alloantibodi
associ
difficulti
find
compat
rbc
chronic
wbe
transfus
interrupt
perform
less
frequent
depend
avail
compat
rbc
also
maintain
therapi
calcium
channel
blocker
time
gradual
worsen
pah
lead
death
year
later
age
year
due
cardiopulmonari
complic
summaryconclus
whole
blood
exchang
safe
method
treat
sever
pah
complic
intermedia
possibl
type
z
kirov
depart
clinic
transfus
blood
transfus
institut
ni
ni
serbia
background
therapeut
plasma
exchang
tpe
nonselect
nonspecif
method
use
separ
circul
agent
autom
apheresi
procedur
extracorpor
circul
aim
reduc
concentr
elimin
pathogen
blood
plasma
reimburs
remov
volum
suitabl
liquid
tpe
use
number
indic
current
classifi
four
separ
categori
categori
includ
diseas
tpe
standard
primari
treatment
option
disord
categori
ii
tpe
addit
support
therapi
usual
combin
treatment
modal
categori
iii
patholog
condit
exact
role
apheresi
still
safe
defin
valid
tpe
applic
well
achiev
effect
individu
categori
iv
includ
diseas
perform
tpe
proven
effect
aim
continu
introduct
new
effect
immunomodulatori
medic
indic
perform
tpe
achiev
effect
requir
continu
critic
reason
aim
work
analysi
feasibl
type
treatment
categor
indic
essenti
understand
place
role
tpe
treatment
patient
group
method
retrospect
analysi
indic
total
tpe
period
well
categor
accord
criteria
aabb
blood
transfus
institut
ni
serbia
done
tpe
perform
use
blood
cell
separ
haemonet
mc
accord
applic
standard
recommend
number
frequenc
procedur
optim
time
applic
amount
extract
plasma
result
tpe
procedur
analys
categor
follow
result
obtain
categori
repres
categori
ii
categori
ii
categori
iii
categori
iv
repres
common
indic
myasthenia
gravi
mg
tpe
follow
guillain
barr
syndrom
tpe
multipl
sclerosi
patient
tpe
hiperbilirubinemia
patient
tpe
cidp
patient
tpe
thrombot
thrombocytopen
purpura
ttp
repres
patient
tpe
ii
iii
categori
summaryconclus
result
suggest
indic
tpe
predominantli
belong
categori
ii
disord
categori
iv
present
interpret
ration
optim
tpe
applic
special
formmod
treatment
posit
therapeut
effect
tpe
treatment
patient
depend
upon
natur
basic
diseas
stage
gener
condit
volum
plasma
remov
addit
therapi
g
blood
transfus
dayanand
medic
colleg
hospit
ludhiana
punjab
india
blood
transfus
dayanand
medic
colleg
hospit
ludhiana
india
background
neuromyel
optica
spectrum
disord
recent
propos
unifi
term
nmo
also
call
devic
diseas
relat
syndrom
character
longitudin
extens
transvers
myeliti
associ
serum
immunoglobulin
g
antibodi
leav
one
quit
debilit
present
unilater
bilater
optic
neuriti
treat
appropri
patient
lose
function
vision
least
one
eye
unabl
walk
high
dose
steroid
usual
given
first
line
treatment
acut
attack
non
respond
steroid
treat
plasma
exchang
rescu
therapi
aim
studi
therapeut
effect
plasma
exchang
patient
acut
attack
method
year
old
femal
housewif
profess
present
right
side
weak
day
start
numb
right
upper
lower
limb
progress
weak
cours
follow
day
left
side
bodi
left
lower
limb
involv
associ
band
like
sensat
waist
rise
upward
till
nippl
admiss
patient
hospit
muscl
power
right
left
upper
limb
respect
right
left
lower
limb
respect
lhermitt
sign
posit
mri
spine
show
long
segment
myeliti
abnorm
detect
csf
analysi
antibodi
detect
came
posit
work
diagnosi
made
solumedrol
puls
therapi
initi
weak
increas
next
day
plasma
exchang
plan
commenc
procedur
follow
investig
analyz
mgdl
aspart
alanin
total
serum
gdl
gdl
serum
electrolyt
within
normal
rang
plasma
exchang
perform
hemonet
mc
singl
arm
procedur
procedur
perform
everi
altern
day
exchang
plasma
volum
replac
fluid
use
normal
salin
fresh
frozen
plasma
ratio
approxim
percent
last
procedur
addit
transfus
fresh
frozen
plasma
done
fibrinogen
level
declin
initi
procedur
patient
monitor
throughout
puls
blood
pressur
respiratori
rate
temperatur
session
went
unev
except
third
patient
experienc
shiver
manag
appropri
result
patient
show
minim
improv
first
procedur
third
power
seen
improv
right
lower
limb
left
upper
limb
abl
lift
arm
flex
elbow
knee
cycl
power
upper
lower
limb
respect
neck
muscl
truncal
weak
also
improv
patient
discharg
day
last
plasma
exchang
follow
day
show
increas
rang
motion
limb
improv
sensat
affect
region
summaryconclus
plasma
exchang
perform
time
manner
adjunct
steroid
therapi
caus
mark
improv
acut
episod
help
success
outcom
abstract
withdrawn
r
e
p
von
dem
j
k
de
j
j
j
van
der
clinic
transfus
research
sanquin
research
immunohematolog
blood
transfus
clinic
epidemiolog
leiden
univers
medic
center
leiden
hematolog
maastricht
univers
medic
center
maastricht
hematolog
leiden
univers
medic
center
leiden
hematolog
clinic
chemistri
hematolog
univers
medic
center
utrecht
utrecht
hematolog
haga
hospit
den
haag
netherland
background
intracrani
hemorrhag
one
seriou
bleed
complic
thrombocytopen
patient
prevent
bleed
complic
patient
frequent
receiv
prophylact
platelet
transfus
base
platelet
count
howev
evid
low
platelet
count
independ
risk
factor
inconclus
clinic
risk
factor
thought
also
modifi
bleed
risk
aim
describ
associ
platelet
count
transfus
clinic
risk
factor
like
age
sex
infect
medic
previou
seven
day
risk
intracrani
hemorrhag
patient
acut
leukemia
method
nest
case
control
studi
cohort
leukemia
patient
four
hospit
case
intracrani
hemorrhag
identifi
regress
model
previous
design
identifi
patient
major
hemorrhag
control
match
diagnosi
therapi
time
case
exclud
case
inabl
identifi
suitabl
control
uncertain
date
intracrani
hemorrhag
irretriev
clinic
data
clinic
risk
factor
record
medic
record
seven
day
preced
bleed
case
correspond
index
period
control
univari
condit
logist
regress
perform
explor
associ
bleed
platelet
count
potenti
risk
factor
result
identifi
case
four
hospit
exclud
one
exclus
criteria
fourteen
case
control
includ
case
control
analysi
patient
acut
myeloid
leukemia
case
receiv
remiss
induct
new
relaps
leukemia
receiv
consolid
therapi
allogen
stem
cell
transplant
admit
diseas
treatment
relat
complic
morn
platelet
count
associ
increas
bleed
risk
ci
age
associ
increas
bleed
risk
ci
sex
show
relev
associ
women
ci
compar
none
receiv
one
two
platelet
transfus
one
week
associ
intracrani
hemorrhag
ci
three
platelet
transfus
risk
increas
ci
furthermor
presenc
infect
proven
posit
cultur
posit
polymeras
chain
reaction
ci
usag
antihypertens
medic
ci
associ
increas
risk
intracrani
hemorrhag
summaryconclus
age
usag
antihypertens
medic
presenc
cultur
polymeras
chain
reaction
proven
infect
associ
increas
risk
intracrani
hemorrhag
also
need
platelet
transfus
associ
increas
risk
intracrani
hemorrhag
although
impli
causal
conclus
could
relev
platelet
transfus
decis
make
c
j
p
f
b
k
e
j
p
f
b
matern
blood
manag
improv
servic
research
australian
red
cross
blood
servic
melbourn
hospit
health
servic
canberra
children
health
network
adelaid
down
hospit
health
servic
toowoomba
servic
research
australian
red
cross
blood
servic
adelaid
servic
research
australian
red
cross
blood
servic
brisban
red
cross
blood
servic
adelaid
australia
background
iron
defici
id
common
pregnanc
increas
iron
demand
often
lead
iron
defici
anaemia
ida
impact
babi
eg
increas
risk
low
birth
weight
prematur
mother
eg
antenat
depress
increas
risk
postpartum
haemorrhag
antenat
id
go
unnot
haemoglobin
hb
alon
measur
result
miss
opportun
optimis
woman
iron
statu
haemoglobin
deliveri
blood
servic
partner
three
hospit
align
current
practic
nation
patient
blood
manag
pbm
guidelin
modul
obstetr
matern
aim
implement
system
improv
antenat
detect
manag
id
ferritin
ida
method
partnership
span
march
march
use
clinic
practic
improv
cpi
methodolog
initi
data
identifi
variat
ida
manag
across
site
tool
develop
includ
matern
ida
assess
manag
flowchart
includ
routin
trimest
ferritin
screen
iron
therapi
recommend
women
id
ida
address
patient
educ
matern
patient
handout
recommend
oral
iron
prepar
introduc
educ
provid
staff
involv
implement
initi
patient
hb
ferritin
phone
base
patient
satisfact
survey
measur
staff
feedback
activ
pursu
collect
result
prior
cpi
antenat
idida
assess
manag
vari
three
hospit
previou
obstetr
guidelin
local
protocol
recommend
hb
screen
accord
matern
staff
flowchart
help
becom
confid
blood
test
interpret
manag
id
ida
provid
long
need
guidanc
consist
approach
hb
ferritin
request
increas
trimest
hospit
overal
women
screen
ferritin
test
iron
defici
hospit
data
across
site
show
anaem
matern
patient
deliveri
hb
gl
higher
chanc
transfus
compar
patient
follow
introduct
cpi
tool
rate
anaemia
intrapartum
fell
first
hospit
second
hospit
prior
partnership
minim
patient
educ
iron
poor
complianc
oral
iron
therapi
across
hospit
feedback
women
receiv
iron
prescript
matern
handout
indic
use
report
complianc
oral
iron
therapi
consist
posit
feedback
receiv
women
across
hospit
summaryconclus
better
system
identifi
manag
idida
pregnant
women
signific
benefit
mother
babi
blood
servic
hospit
partnership
provid
practic
improv
matern
blood
manag
align
pbm
guidelin
embed
practic
routin
ferritin
screen
reliabl
detect
id
pregnanc
allow
earli
provis
iron
therapi
result
improv
hb
deliveri
success
result
matern
blood
manag
practic
improv
toolkit
develop
may
translat
readili
institut
l
j
j
r
c
n
j
health
network
health
scienc
center
toronto
canada
background
hemolyt
diseas
fetu
newborn
hdfn
occur
matern
alloantibodi
cross
placenta
mark
fetu
red
blood
cell
rbc
destruct
neonat
present
rang
mild
jaundic
anemia
rare
hydrop
fetali
death
pregnanc
treatment
includ
observ
andor
intrauterin
transfus
iut
neonat
treatment
includ
observ
phototherapi
intraven
immunoglobulin
ivig
neonat
transfus
aim
object
studi
determin
preval
rbc
antibodi
singl
center
evalu
fetal
neonat
outcom
pregnanc
method
retrospect
audit
alloimmun
pregnanc
conduct
singl
center
perform
deliveri
annual
data
collect
includ
matern
neonat
demograph
data
clinic
data
pregnanc
deliveri
laboratori
result
diagnosi
hdfn
defin
one
follow
matern
receipt
intrauterin
blood
transfus
neonat
receipt
intens
phototherapi
grade
neonat
receipt
simpl
rbc
transfus
exchang
transfus
result
mother
neonat
alloimmun
n
c
n
n
k
n
frequent
clinic
signific
antibodi
identifi
prenat
patient
follow
bloodwork
alon
follow
doppler
surveil
abnorm
ultrasound
result
requir
iut
neonat
requir
treatment
requir
phototherapi
mild
intens
receiv
least
one
blood
product
ivig
rbc
transfus
thirteen
percent
neonat
fulfil
hdfn
criteria
major
rh
kell
antibodi
summaryconclus
although
recent
scientif
literatur
postul
case
hdfn
caus
declin
result
suggest
rh
antibodi
remain
main
culprit
sever
case
hdfn
futur
prospect
studi
requir
better
valid
result
p
b
e
f
canberra
hospit
woden
school
curtin
school
medic
research
australian
nation
univers
canberra
hospit
canberra
canberra
hospit
woden
australia
background
guidelin
recommend
screen
anaemia
pregnanc
haemoglobin
specif
ferritin
despit
preval
iron
defici
young
women
may
part
due
uncertainti
interpret
context
physiolog
chang
pregnanc
anaemia
time
deliveri
major
risk
factor
transfus
aim
determin
valu
ferritin
screen
differ
stage
pregnanc
order
guid
patient
blood
manag
strategi
method
data
extract
antenat
patholog
databas
women
pregnanc
australian
tertiari
referr
hospit
haemoglobin
ferritin
level
retriev
avail
result
stratifi
trimest
multipl
pregnanc
prematur
deliveri
exclud
valu
test
stage
pregnanc
predict
anaemia
present
within
two
day
deliveri
determin
rate
compar
fisher
exact
test
data
analysi
repeat
follow
patient
blood
manag
intervent
target
iron
replac
pregnanc
result
women
ferritin
first
trimest
haemoglobin
record
ferritin
anaemia
ferritin
first
trimest
associ
increas
risk
anaemia
prior
deliveri
p
fisher
exact
test
receiv
oper
characterist
curv
ferritin
first
trimest
predict
anaemia
deliveri
area
curv
ci
ferritin
sensit
sensit
women
haemoglobin
trimest
one
low
haemoglobin
first
trimest
predict
anaemia
time
deliveri
p
haemoglobin
gl
sensit
specif
women
low
ferritin
first
trimest
three
anaem
time
sampl
women
iron
store
assess
trimest
two
haemoglobin
anaemia
deliveri
ferritin
predict
later
anaemia
p
fisher
exact
test
receiv
oper
curv
identifi
significantli
better
ferritin
anaemia
hb
gl
second
trimest
predict
anaemia
prior
deliveri
iron
replac
intervent
women
ferritin
first
trimest
ferritin
three
one
low
ferritin
anaem
time
test
taken
two
prior
deliveri
ferritin
first
trimest
associ
anaemia
period
activ
iron
replac
summaryconclus
screen
women
iron
defici
first
second
trimest
pregnanc
identifi
women
risk
anaemia
deliveri
associ
lost
follow
implement
activ
iron
replac
patient
blood
manag
strategi
result
support
screen
iron
defici
first
trimest
serum
ferritin
even
within
low
risk
popul
c
j
n
c
e
l
c
h
royal
london
hospit
london
uk
whipp
cross
hospit
newham
univers
hospit
blood
transplant
king
colleg
hospit
royal
free
hospit
london
nh
blood
transplant
birmingham
unit
kingdom
background
anaemia
pregnanc
associ
advers
outcom
mother
babi
may
lead
increas
risk
requir
blood
transfus
perinat
iron
defici
commonest
caus
uk
guidelin
royal
colleg
gynaecolog
rcog
british
societi
haematolog
nation
institut
health
care
excel
recommend
screen
anaemia
book
week
start
empir
oral
iron
replac
haemoglobin
hb
normal
rang
gestat
gl
trimest
gl
trimest
measur
ferritin
recommend
unless
inadequ
respons
iron
approach
fail
detect
women
iron
defici
anaem
risk
develop
anaemia
later
pregnanc
measur
ferritin
treatment
iron
defici
could
prevent
anaemia
bart
health
nh
trust
serv
popul
million
east
london
high
preval
iron
defici
due
dietari
ethnic
factor
approxim
women
deliv
year
across
three
hospit
royal
london
hospit
rlh
routin
ferritin
test
antenat
blood
sampl
introduc
iron
tablet
given
woman
ferritin
less
newham
nuh
whipp
cross
wxh
hospit
follow
standard
rcog
guidelin
aim
retrospect
observ
studi
aim
assess
impact
proactiv
detect
treatment
iron
defici
haemoglobin
anaemia
rate
pregnanc
compar
hospit
method
data
collect
retrospect
women
deliv
rlh
nuh
wxh
octob
hb
ferritin
level
record
book
week
labour
postnat
compar
use
analysi
varianc
number
women
requir
red
cell
transfus
record
rlh
prescript
oral
iron
iron
defici
women
assess
result
deliveri
anaemia
common
rise
book
week
rlh
iron
defici
book
week
though
less
women
anaem
iron
defici
book
week
given
iron
deliveri
mean
hb
significantli
higher
rlh
gl
compar
wxh
gl
nuh
gl
p
fewer
women
anaem
versu
respect
women
receiv
red
cell
transfus
follow
major
obstetr
haemorrhag
anaem
labour
postnat
signific
differ
mean
hb
level
site
summaryconclus
isol
iron
defici
without
anaemia
common
pregnanc
treatment
oral
iron
associ
higher
hb
time
deliveri
correl
reduc
transfus
rate
higher
postnat
hb
blood
loss
labour
unpredict
transfus
uncommon
unless
major
obstetr
haemorrhag
howev
improv
iron
store
hb
may
addit
benefit
matern
foetal
health
wellb
focu
futur
studi
r
p
r
n
medicin
medicin
medicin
pgimer
chandigarh
india
background
import
determin
optim
platelet
dose
thrombocytopen
patient
judici
use
scarc
resourc
achiev
transfus
platelet
differ
dose
compar
post
transfus
respons
indictor
aim
prospect
studi
perform
compar
efficaci
low
high
dose
standard
dose
singl
donor
apheresi
platelet
sdap
transfus
term
platelet
transfus
respons
indic
correct
count
increment
cci
percent
platelet
recoveri
ppr
correl
patient
clinic
profil
method
total
stabl
patient
enrol
studi
fulfil
inclus
criteria
studi
approv
institut
ethic
committe
patient
receiv
apheresi
platelet
low
dose
unit
medium
dose
plateletsunit
high
dose
differ
time
point
sequenc
standard
low
high
dose
request
receiv
base
hisher
pre
transfus
platelet
count
clinic
profil
post
transfus
count
assess
h
transfus
post
transfus
respons
indic
calcul
term
platelet
increment
correct
count
increment
cci
percent
platelet
recoveri
ppr
transfus
free
interv
bleed
event
also
record
differ
dose
result
post
transfus
respons
indic
cci
ppr
compar
standard
dose
low
dose
post
transfus
increment
compar
standard
high
dose
howev
cci
p
ppr
p
better
standard
dose
statist
signific
higher
post
transfus
increment
observ
high
dose
compar
low
dose
howev
cci
p
ppr
p
better
low
dose
statist
signific
transfus
free
interv
standard
dose
low
dose
high
dose
day
day
day
respect
howev
differ
statist
signific
donor
exposur
patient
significantli
p
reduc
owe
split
platelet
product
form
custom
dose
transfus
summaryconclus
standard
dose
apheresi
platelet
best
choic
adequ
post
transfus
respons
patient
howev
possibl
low
dose
altern
standard
consid
stabl
thrombocytopen
patient
owe
compar
post
transfus
respons
indic
cci
ppr
two
group
e
khalaf
ade
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
iran
tehran
iran
background
cardiopulmonari
bypass
cpb
induc
multifactori
coagulopathi
due
extens
consumpt
coagul
factor
especi
fibrinogen
contradictori
report
effect
preoper
supplement
fibrinogen
patient
without
hypofibrinogenemia
aim
aim
studi
investig
effect
supplement
fibrinogen
concentr
bleed
transfus
requir
cardiac
surgeri
method
total
patient
schedul
elect
cabg
valvular
surgeri
includ
clinic
trial
studi
march
novemb
patient
randomli
assign
fibrinogen
control
group
fibrinogen
group
patient
receiv
gram
fibrinogen
dissolv
ml
normal
salin
min
period
min
induct
anesthesia
control
group
patient
receiv
volum
normal
salin
period
time
bleed
record
overal
mediastin
drainag
drain
surgic
site
h
surgeri
amount
transfus
pack
red
blood
cell
fresh
frozen
plasma
platelet
first
day
also
document
result
mean
volum
bleed
significantli
lower
fibrinogen
group
compar
control
group
ml
vs
ml
p
furthermor
mean
volum
ffp
platelet
concentr
use
fibrinogen
group
significantli
lower
fibrinogen
group
compar
control
group
p
howev
nt
found
signific
differ
rbc
consumpt
group
summaryconclus
preoper
supplement
fibrinogen
result
reduct
postop
blood
loss
transfus
requir
cardiac
surgeri
h
p
intern
medicin
allegheni
health
network
hematolog
cellular
therapi
allegheni
health
network
cancer
institut
pittsburgh
pennsylvania
unit
state
america
background
despit
widespread
use
fresh
frozen
plasma
ffp
interest
random
control
trial
establish
indic
ffp
transfus
base
guidelin
ash
aabb
expert
opinion
indic
plasma
transfus
agre
upon
activ
bleed
trauma
patient
set
multipl
coagul
factor
defici
massiv
transfus
dissemin
intravascular
anticoagul
etc
emerg
revers
warfarin
activ
intracrani
bleed
plasma
exchang
howev
consensu
dose
ffp
observ
mlkg
recipi
weight
aim
object
studi
evalu
consist
appropri
dose
correl
coagul
test
common
set
ffp
transfus
method
retrospect
review
conduct
tertiari
care
facil
includ
patient
receiv
ffp
januari
june
transfus
order
place
state
time
period
base
studi
publish
ffp
meet
statistician
decid
sampl
size
event
randomli
select
analyz
age
weight
number
unit
order
transfus
indic
transfus
inr
multipl
order
transfus
place
day
dose
plasma
calcul
mlkg
bodi
weight
unit
plasma
ml
result
among
event
unit
ffp
transfus
median
age
recipi
year
rang
common
indic
inr
bleed
n
follow
massiv
transfus
n
plasma
exchang
n
unknown
n
total
transfus
adequ
dose
base
weight
among
transfus
inr
correct
inr
one
order
transfus
day
inr
summaryconclus
commonplac
transfus
ffp
base
coagul
studi
eg
inr
data
establish
correl
two
fact
major
transfus
inadequ
dose
explain
half
case
correct
inr
around
one
third
requir
multipl
transfus
moreov
ffp
transfus
come
without
risk
commonli
circulatori
overload
allerg
reaction
acut
lung
injuri
develop
antibodi
therefor
strongli
recommend
medic
staff
educ
indic
well
appropri
dose
ffp
also
highlight
need
clear
guidelin
ffp
transfus
abbrevi
ash
american
societi
hematolog
aabb
american
associ
blood
bank
n
medicin
oncolog
tata
memori
navi
mumbai
medicin
tata
memori
hospit
mumbai
india
background
despit
usag
broad
spectrum
antibiot
antifung
drug
bacteri
fungal
infect
continu
caus
life
threaten
sever
neutropenia
patient
hematopoiet
stem
cell
transplant
hsct
neutrophil
play
integr
role
host
defens
bacteri
opportunist
fungal
pathogen
neutrophil
product
marrow
adequ
number
blood
tissu
neutrophil
key
predictor
recoveri
infect
henc
granulocyt
transfus
therapi
possibl
way
bridg
gap
marrow
suppress
neutrophil
recoveri
unrespons
appropri
antimicrobi
therapi
aim
determin
safeti
efficaci
granulocyt
transfus
therapi
allogen
hsct
patient
neutropenia
relat
infect
method
retrospect
analysi
done
determin
safeti
efficaci
granulocyt
transfus
hsct
patient
sever
neutropenia
relat
infect
unrespons
appropri
antimicrobi
agent
granulocyt
donat
healthi
donor
stimul
subcutan
plu
mg
dexamethason
oral
cobe
spectra
cell
separ
machin
respons
analyz
term
clinic
respons
surviv
patient
day
first
granulocyt
transfus
particular
neutropenia
episod
transfus
includ
subject
transfus
arm
receiv
mean
dose
per
transfus
equival
averag
kg
patient
rest
includ
transfus
arm
receiv
mean
dose
per
transfus
h
h
absolut
neutrophil
count
anc
increment
patient
receiv
high
dose
low
dose
granulocyt
transfus
compar
test
p
consid
signific
result
patient
receiv
mean
granulocyt
transfus
rang
mean
dose
granulocyt
rang
total
transfus
episod
granulocyt
transfus
granulocyt
transfus
h
h
post
transfus
anc
increment
significantli
higher
transfus
arm
patient
respond
favor
granulocyt
transfus
patient
surviv
day
first
granulocyt
transfus
granulocyt
transfus
well
toler
advers
reaction
seen
patient
summaryconclus
granulocyt
transfus
therapi
effect
adjuv
therapeut
method
hsct
patient
neutropenia
relat
infect
resist
appropri
antimicrobi
agent
howev
heterogen
patient
popul
type
infect
antimicrobi
therapi
dosag
granulocyt
concentr
includ
outcom
paramet
make
difficult
propos
accur
recommend
j
j
laboratori
medicin
royal
univers
hospit
saskatoon
laboratori
servic
calgari
canada
background
recent
studi
acut
ill
hospit
patient
demonstr
red
blood
cell
rbc
age
impact
mortal
howev
advers
patient
outcom
known
increas
cumul
number
transfus
receiv
rise
chronic
transfus
medic
outpati
compris
signific
proport
transfus
recipi
annual
popul
larg
underrepres
literatur
aim
goal
prospect
evalu
impact
rbc
age
product
utilis
cohort
chronic
transfus
medic
outpati
random
receiv
fresh
day
old
age
day
old
rbc
primari
outcom
evalu
overal
rbc
transfus
rate
fresh
versu
age
blood
recipi
hypothes
use
fresh
rbc
chronic
transfus
patient
would
lead
decreas
overal
rbc
transfus
method
institut
ethic
approv
obtain
enrol
random
control
feasibl
studi
invit
inclus
criteria
includ
adult
patient
year
age
receiv
outpati
chronic
red
cell
transfus
red
cell
unit
per
month
least
consecut
month
ambulatori
care
clinic
within
calgari
zone
patient
establish
fresh
irradi
rbc
chronic
hemodialysi
acut
decompens
chronic
diseas
exclud
paramet
usual
bloodwork
follow
total
durat
enrol
year
unpair
use
statist
calcul
base
principl
result
total
particip
enrol
n
fresh
n
age
rbc
group
underli
particip
diagnos
includ
myelodysplast
syndrom
myelofibrosi
palli
acut
myeloid
leukemia
mean
durat
enrol
day
rang
day
particip
complet
full
year
n
fresh
n
age
total
rbc
unit
given
transfus
event
fresh
rbc
group
compar
rbc
unit
transfus
event
age
rbc
group
calcul
mean
number
rbc
unit
transfus
per
day
particip
enrol
fresh
rbc
versu
age
rbc
group
p
signific
differ
mean
number
day
transfus
receiv
among
group
day
versu
day
fresh
versu
age
rbc
group
p
hemoglobin
gl
gl
fresh
age
rbc
group
p
summaryconclus
demonstr
statist
signific
decreas
rbc
unit
transfus
chronic
transfus
particip
receiv
fresh
rbc
averag
reduct
utilis
rbc
unit
per
particip
per
month
limit
studi
includ
small
sampl
size
variabl
particip
underli
clinic
profil
greater
overal
proport
irradi
rbc
transfus
age
blood
group
due
site
inventori
manag
requir
larger
studi
complet
design
requir
confirm
find
abstract
withdrawn
az
b
h
sultan
qaboo
univers
hospit
research
oman
medic
specialti
board
sultan
qaboo
univers
hospit
medic
specialti
board
muscat
oman
background
last
year
sever
investig
describ
anemia
associ
advers
outcom
risk
anemia
patient
undergo
heart
surgeri
describ
precis
report
need
studi
field
express
studi
region
assess
incid
outcom
anemia
patient
undergo
cardiac
surgeri
aim
studi
aim
investig
incid
anemia
patient
undergo
cardiac
surgeri
institut
studi
associ
patient
outcom
method
retrospect
review
clinic
laboratori
transfus
data
patient
underw
cardiac
surgeri
sultan
qaboo
univers
hospit
perform
patient
divid
anem
group
base
hb
level
anemia
defin
base
definit
hemoglobin
hb
gdl
male
gdl
femal
patient
demograph
clinic
variabl
compar
anem
patient
use
test
independ
factor
influenc
preoper
mortal
analyz
use
multivari
binari
logist
regress
method
consid
statist
signific
result
total
patient
femal
male
oper
studi
period
major
patient
underw
coronari
arteri
bypass
surgeri
anemia
found
male
femal
patient
respect
rate
red
blood
cell
rbc
transfus
higher
among
anem
patient
compar
patient
vr
respect
p
anem
patient
higher
risk
mortal
compar
patient
vr
p
patient
anemia
though
wors
risk
profil
surgeri
compar
patient
higher
incid
diabet
mellitu
vr
p
heart
failur
vr
p
arrhythmia
vr
p
cerebrovascular
diseas
vr
p
cardiogen
shock
present
vr
p
howev
take
risk
account
logist
regress
analysi
anemia
remain
risk
factor
mortal
p
odd
ratio
ci
moreov
anemia
found
risk
factor
earli
odd
ratio
ci
summaryconclus
anemia
patient
undergo
cardiac
surgeri
independ
associ
increas
risk
mortal
higher
rate
rbc
transfus
earli
rate
r
k
van
den
sanb
roodepoort
sanb
port
elizabeth
south
africa
background
although
allogen
red
blood
cell
rbc
transfus
often
intervent
also
come
certain
risk
search
appropri
transfus
protocol
optimis
patient
outcom
sever
studi
assess
transfus
practis
base
inter
alia
use
haemoglobin
hb
trigger
medic
indic
restrict
transfus
strategi
hb
gdl
associ
reduc
infect
risk
without
compromis
patient
outcom
south
africa
deliv
health
care
servic
system
public
privat
facil
underli
percept
higher
utilis
better
resourc
privat
facil
compar
lower
resourc
public
facil
sinc
june
sanb
captur
hb
inform
blood
product
request
enabl
us
benchmark
transfus
practis
recommend
transfus
strategi
aim
evalu
transfus
practic
hb
trigger
among
sanb
blood
recipi
method
rbc
requisit
receiv
blood
bank
record
sanb
oper
system
hb
level
demograph
clinic
inform
request
juli
decemb
extract
sanb
busi
intellig
system
summari
statist
test
use
describ
patient
popul
blood
usag
assess
signific
find
blood
usag
express
number
unit
per
transfus
event
transfus
event
includ
transfus
activ
within
h
receiv
specimen
result
studi
period
patient
receiv
red
cell
product
per
cent
patient
treat
public
facil
receiv
red
cell
product
public
patient
older
year
receiv
rbc
per
transfus
event
compar
rbc
privat
patient
similar
age
p
per
transfus
event
male
receiv
rbc
compar
rbc
femal
older
recipi
receiv
unit
younger
recipi
unit
recipi
year
increas
recipi
older
hb
level
avail
requisit
hb
level
gdl
averag
hb
gdl
differ
significantli
public
privat
sector
vs
gdl
p
public
privat
facil
unit
given
lower
hb
level
decreas
steadili
hb
increas
overal
privat
facil
order
unit
similar
hb
level
public
facil
disciplin
trauma
depart
issu
unit
per
event
follow
surgeri
medic
depart
use
blood
unit
per
transfus
event
summaryconclus
overal
transfus
trigger
south
africa
fall
within
guidelin
restrict
transfus
practic
transfus
practic
public
sector
seem
align
restrict
protocol
privat
sector
sector
follow
scale
approach
request
fewer
unit
higher
hb
level
except
high
hb
level
probabl
relat
patient
specif
risk
factor
patient
hb
inform
avail
sanb
enabl
us
develop
target
strategi
first
attempt
gain
understand
patient
blood
manag
south
africa
l
c
j
c
alfr
health
melbourn
australia
background
patient
blood
manag
import
part
patient
care
intent
improv
patient
outcom
alfr
hospit
major
tertiari
referr
hospit
metropolitan
melbourn
one
australia
busiest
emerg
trauma
centr
varieti
specialti
servic
retrospect
audit
transfus
elect
primari
hip
knee
arthroplasti
perform
provid
baselin
audit
aim
implement
patient
blood
manag
strategi
elect
orthopaed
surgic
patient
improv
patient
care
optimis
haemoglobin
minimis
blood
loss
reduc
unnecessari
transfus
method
transfus
team
work
orthopaed
anaesthet
group
develop
haemoglobin
optimis
algorithm
optimis
patient
haemoglobin
prior
surgeri
mainli
regard
correct
iron
defici
algorithm
introduc
ongo
transfus
nurs
collect
month
data
march
month
data
time
frame
algorithm
review
modifi
respons
result
audit
chang
avail
guidelin
improv
outcom
exampl
ferritin
test
routin
ad
patient
ensur
miss
patient
iron
defici
yet
anaem
team
also
provid
inform
anaesthet
depart
enhanc
recoveri
surgeri
era
pathway
regard
use
tranexam
acid
singl
unit
transfus
polici
result
baselin
audit
data
primari
hip
primari
knee
replac
show
transfus
rate
post
introduct
algorithm
transfus
rate
remain
post
refin
includ
addit
era
univers
ferritin
test
transfus
rate
drop
rate
reduc
time
use
tranexam
acid
increas
singl
unit
transfus
rate
remain
similar
follow
patient
iron
replac
prior
surgeri
current
optim
patient
retest
howev
major
patient
requir
transfus
anaemia
associ
chronic
diseas
rather
iron
defici
summaryconclus
patient
blood
manag
strategi
associ
increas
recognit
correct
anaemia
iron
defici
orthopaed
surgeri
group
also
note
increas
use
tranexam
acid
along
significantli
reduc
transfus
rate
year
limit
data
includ
retrospect
natur
incomplet
complianc
algorithm
inabl
attribut
reduct
transfus
rate
particular
blood
manag
strategi
result
posit
find
approach
also
introduc
major
surgic
group
ongo
audit
review
requir
order
continu
improv
patient
blood
manag
lj
j
j
blood
transplant
depart
medicin
univers
oxford
oxford
blood
transplant
leed
ltd
congleton
blood
servic
cardiff
unit
kingdom
background
red
cell
platelet
transfus
essenti
manag
peopl
haematolog
malign
bone
marrow
failur
disord
platelet
compon
red
cell
compon
issu
given
haematolog
patient
use
elderli
uk
popul
age
predict
doubl
peopl
age
year
use
red
cell
platelet
transfus
like
benefit
imper
minimis
side
effect
limit
cost
maintain
blood
suppli
aim
aim
nation
audit
identifi
area
practic
improv
compar
audit
identifi
area
requir
improv
method
hospit
uk
invit
particip
audit
red
cell
platelet
transfus
adult
year
haematolog
malign
myeloid
failur
disord
initi
audit
undertaken
januari
assess
use
platelet
red
cell
nation
agre
standard
follow
feedback
result
particip
hospit
repeat
audit
perform
juli
patient
chronic
anaemia
exclud
red
blood
cell
rbc
transfus
standard
use
haemoglobin
threshold
alon
group
may
requir
individualis
transfus
threshold
result
total
hospit
uk
particip
audit
provid
inform
platelet
transfus
rbc
transfus
hospit
also
particip
audit
major
patient
includ
audit
sixti
year
age
median
year
myelodysplasia
larg
diseas
older
peopl
commonest
haematolog
diagnosi
chronic
anaemia
commonest
reason
rbc
transfus
platelet
transfus
prophylact
within
group
given
patient
chronic
bone
marrow
failur
addit
given
prevent
bleed
prior
procedur
compar
practic
hospit
particip
audit
round
improv
use
restrict
red
cell
transfus
polici
hb
gl
addit
risk
factor
p
increas
use
singl
unit
rbc
transfus
approach
inpati
p
outpati
p
despit
inpati
hb
measur
receiv
rbc
unit
prophylact
platelet
transfus
consid
appropri
revers
bone
marrow
failur
compar
p
prophylact
platelet
transfus
singl
unit
transfus
compar
summaryconclus
overal
improv
practic
sinc
particularli
evid
area
chang
practic
achiev
readili
nation
campaign
improv
practic
singl
unit
transfus
polici
e
st
georg
univers
hospit
nh
foundat
trust
london
unit
kingdom
univers
health
alli
scienc
ho
ghana
leed
teach
hospit
trust
cancer
patholog
univers
leed
leed
public
health
liverpool
school
tropic
medicin
liverpool
unit
kingdom
background
whilst
blood
transfus
remain
treatment
africa
difficulti
blood
suppli
safeti
persist
mani
countri
includ
ghana
reach
target
donat
per
popul
background
preval
infect
higher
develop
countri
context
appropri
clinic
use
blood
compon
support
nation
guidelin
vital
aim
undertook
studi
assess
complianc
clinician
nation
blood
servic
ghana
nbsg
guidelin
clinic
use
blood
compon
tertiari
referr
hospit
ghana
assess
clinician
knowledg
percept
transfus
order
identifi
potenti
area
intervent
improv
clinic
use
blood
compon
method
retrospect
data
collect
patient
volta
region
hospit
transfus
sept
nov
blood
bank
patient
folder
electron
record
use
guidelin
checklist
assess
appropri
transfus
devis
collabor
nbsg
base
interview
clinician
questionnair
devis
assess
clinician
knowledg
percept
transfus
result
data
gather
transfus
patient
transfus
appropri
appropri
episod
appropri
unknown
transfus
whole
blood
pack
cell
appropri
appropri
episod
appropri
unknown
ffp
transfus
appropri
use
unrecognis
indic
includ
hypoalbuminaemia
questionnair
respons
respons
rate
receiv
respond
indic
felt
knowledg
indic
complic
transfus
felt
confid
make
transfus
decis
howev
signific
gap
knowledg
identifi
respond
provid
haemoglobin
threshold
transfus
differ
nbsg
guidelin
larg
rang
individu
variat
respond
list
incorrect
indic
ffp
respond
familiar
nbsg
guidelin
summaryconclus
conclus
transfus
within
period
appropri
whilst
confid
clinic
use
transfus
clinician
unawar
nation
guidelin
gap
knowledg
rel
nation
guidelin
identifi
effort
optimis
appropri
use
blood
compon
one
compon
nation
strategi
improv
safeti
avail
blood
transfus
ghana
increas
develop
transfus
committe
target
educ
clinician
may
role
support
effort
p
j
canberra
hospit
woden
curtin
school
medic
research
school
australian
nation
univers
canberra
australia
background
store
blood
deterior
age
recent
studi
verifi
safeti
blood
store
longer
period
compar
fresh
blood
older
blood
known
reduc
post
transfus
red
cell
recoveri
follow
transfus
aim
assess
effect
red
cell
storag
durat
post
transfus
haemoglobin
increment
transfus
interv
myelodysplast
syndrom
md
method
patient
md
transfus
identifi
hospit
patholog
databas
data
transfus
haemoglobin
level
prior
subsequ
transfus
collat
transfus
episod
consid
unit
transfus
consecut
day
haemoglobin
defin
lowest
read
day
day
prior
transfus
post
transfus
haemoglobin
first
haemoglobin
read
transfus
provid
within
one
week
interv
defin
time
start
two
consecut
transfus
interv
blood
consid
old
unit
transfus
transfus
episod
day
collect
sensit
analysi
conduct
evalu
transfus
fresh
day
less
storag
old
red
cell
unit
effect
age
post
transfus
haemoglobin
transfus
interv
analys
use
linear
mix
model
spss
ibm
anova
use
subset
fix
interv
result
consid
statist
signific
p
result
md
patient
evalu
receiv
transfus
mean
age
year
male
red
cell
mean
day
rang
old
time
transfus
post
transfus
haemoglobin
increment
gl
per
unit
differ
fresh
gl
old
gl
blood
p
interv
day
day
fresh
old
blood
respect
p
differ
secondari
analysi
transfus
episod
old
fresh
unit
compar
haemoglobin
increment
per
unit
red
cell
interv
summaryconclus
red
cell
store
longer
day
prior
transfus
compar
term
haemoglobin
respons
interv
transfus
fresh
red
cell
tm
de
luca
l
lopez
szelagowski
yantorno
j
napal
j
milon
hospit
italiano
de
la
plata
la
plata
argentina
background
allogen
bone
marrow
transplant
use
altern
mani
patient
pt
hematolog
diseas
associ
high
morbid
mortal
differ
risk
factor
involv
age
comorbid
hla
dispar
diseas
statu
condit
intens
high
risk
malign
anemia
etc
addit
patient
poor
evolut
usual
fall
high
consumpt
transfus
import
know
indic
relat
consumpt
blood
compon
period
aim
analyz
blood
transfus
consumpt
relat
differ
risk
indic
method
analyz
medic
record
transplant
pt
divid
accord
hemoglobin
pthb
mgdl
vs
mgdl
diseas
statu
cr
vs
nocr
score
low
vs
intermediatehigh
condit
mac
vs
ric
kind
donor
histoident
vs
haploident
vs
unrel
abo
incompat
major
vs
major
age
vs
accord
diseas
risk
index
dri
lowintermedi
vs
highveri
high
blood
transfus
requir
analyz
consecut
period
day
global
compar
differ
group
multivari
analysi
use
multipl
regress
test
result
evalu
pt
mean
age
year
women
accord
patholog
pt
aml
md
nhl
hl
mcl
mf
aa
multivari
analysi
show
differ
pt
divid
accord
pthb
signific
analyz
transfus
requir
period
global
mean
transfus
blood
unit
pt
mgdl
period
global
pt
mgdl
global
p
p
p
p
addit
age
also
signific
period
mean
transfus
pt
p
variabl
signific
period
summaryconclus
variabl
associ
allogen
transplant
set
known
howev
seem
relat
blood
transfus
requir
experi
pthb
independ
risk
factor
blood
transfus
requir
period
month
mgdl
point
age
impact
first
month
abstract
withdrawn
j
l
periop
care
vancouv
gener
hospit
vancouv
bc
medicin
vancouv
gener
hospit
blood
servic
bci
vancouv
canada
background
bleed
manag
cardiac
surgeri
remain
challeng
rotat
thromboelastometri
whole
blood
coagul
test
introduc
mani
cardiac
surgeri
program
attempt
improv
blood
product
util
aim
undertook
retrospect
review
blood
util
two
distinct
time
period
rotem
use
institut
cardiac
surgeri
hypothes
use
rotem
would
associ
fewer
red
cell
plasma
transfus
method
blood
product
util
retrospect
analyz
time
period
nov
nov
one
year
time
frame
prior
rotem
test
oper
room
n
nov
may
month
trial
rotem
test
point
care
poc
platelet
function
test
n
may
nov
month
period
poc
test
avail
n
nov
nov
one
year
period
rotem
n
patient
manag
accord
publish
transfus
algorithm
bleed
manag
guidelin
provid
treatment
discret
treat
anesthesiologist
purpos
analysi
patient
alloc
high
risk
cardiac
combin
cabg
valv
multipl
valv
aortic
redo
surgeri
n
low
risk
cardiac
cabg
singl
valv
minim
invas
surgeri
n
result
high
risk
low
risk
cardiac
surgeri
time
frame
rotem
use
associ
significantli
less
frozen
plasma
fp
use
intraop
fp
use
vs
unit
p
summaryconclus
institut
time
frame
includ
rotem
use
associ
signific
increas
fibrinogen
replac
decreas
use
fp
low
high
risk
cardiac
surgeri
red
cell
use
decreas
low
risk
cardiac
surgeri
group
rotem
use
associ
fewer
larg
volum
intraop
resuscit
red
cell
potenti
reflect
decreas
factor
viia
use
supplier
perspect
clear
rotem
guid
transfus
result
signific
practic
chang
toward
use
fibrinogen
replac
remain
unclear
whether
chang
practic
posit
impact
patient
b
kakkar
bajpai
transfus
medicin
institut
liver
biliari
scienc
new
delhi
india
background
patient
chronic
liver
diseas
cld
high
risk
bleed
due
underli
coagulopathi
thrombocytopenia
patient
requir
transfus
support
variou
therapeut
prophylact
indic
aim
aim
studi
perform
clinic
audit
platelet
transfus
practic
chronic
liver
diseas
cld
patient
admit
hospit
compar
current
platelet
transfus
practic
british
societi
haematolog
bsh
guidelin
platelet
transfus
method
retrospect
audit
platelet
transfus
practic
conduct
juli
septemb
cld
patient
platelet
transfus
request
receiv
studi
period
retriev
review
record
evalu
determin
total
number
transfus
request
receiv
indic
transfus
transfus
trigger
follow
comparison
standard
guidelin
result
studi
period
total
platelet
transfus
request
receiv
patient
male
femal
age
rang
month
year
patient
patient
receiv
repeat
transfus
maximum
number
request
receiv
liver
intens
care
unit
follow
emerg
servic
high
depend
unit
around
request
receiv
prophylact
transfus
mean
platelet
count
therapeut
transfus
mean
platelet
count
common
indic
transfus
thrombocytopenia
follow
activ
bleed
correct
coagulopathi
base
thromboelastographi
compar
transfus
trigger
bsh
guidelin
percentag
inappropri
transfus
patient
thrombocytopenia
activ
bleed
correct
coagulopathi
respect
summaryconclus
chronic
liver
diseas
patient
known
thrombocytopenia
well
platelet
function
defect
high
rate
seen
platelet
transfus
given
patient
due
lack
standard
guidelin
platelet
transfus
cld
patient
current
guidelin
transfus
threshold
may
suitabl
therefor
wide
scope
research
develop
guidelin
appropri
use
platelet
transfus
patient
k
j
blood
transplant
health
nh
trust
london
blood
transplant
manchest
colleg
hospit
london
blood
transplant
oxford
ltd
hospit
neurolog
neurosurgeri
london
leed
teach
hospit
nh
trust
leed
unit
kingdom
background
patient
blood
manag
pbm
evid
base
patient
centr
approach
transfus
practic
emphasi
activ
anaemia
manag
minimis
blood
loss
appropri
blood
use
aim
repeat
larg
nation
compar
audit
assess
improv
pbm
practic
previou
audit
method
initi
audit
undertaken
period
feb
april
assess
practic
applic
pbm
measur
rang
surgic
patient
like
need
transfus
follow
feedback
result
particip
hospit
repeat
audit
undertaken
period
sep
nov
result
data
case
avail
analysi
submit
site
across
uk
site
also
took
part
audit
case
round
case
round
commonest
type
surgeri
audit
elect
orthopaed
surgeri
follow
surgeri
fractur
neck
femur
cardiac
surgeri
overal
improv
pbm
practic
sinc
particularli
evid
area
chang
practic
achiev
readili
compar
practic
site
particip
round
improv
use
restrict
approach
postop
transfus
p
increas
use
singl
unit
transfus
approach
p
tranexam
acid
use
increas
p
contrast
smaller
although
still
signific
p
improv
manag
anaemia
rel
proport
manag
appropri
improv
compar
overal
patient
receiv
transfus
found
appropri
pbm
measur
attempt
compar
p
summaryconclus
key
barrier
need
overcom
includ
adequ
resourc
support
infrastructur
deliv
effect
manag
restructur
pathway
allow
time
investig
manag
also
difficulti
resolv
role
primari
secondari
care
optimis
anaemia
within
secondari
care
set
servic
manag
patient
effect
encourag
see
progress
implement
pbm
sinc
particularli
area
highlight
nice
clinic
transfus
guidelin
qualiti
standard
work
requir
deliv
time
anaemia
manag
particular
ensur
consist
implement
appropri
pbm
measur
n
e
b
l
j
singapor
gener
hospit
servic
group
health
scienc
author
khoo
teck
puat
hospit
medicin
nation
univers
hospit
kk
women
children
hospit
ng
teng
fong
gener
hospit
changi
gener
hospit
tan
tock
seng
hospit
singapor
singapor
background
blood
servic
group
bsg
serv
singapor
nation
blood
servic
activ
promot
patient
blood
manag
pbm
implement
public
hospit
sinc
endors
hospit
senior
manag
transfus
committe
htc
seri
measur
undertaken
nationwid
facilit
pbm
implement
includ
distribut
recommend
conduct
educ
talk
increas
awar
via
lectur
discuss
held
intern
pbm
expert
also
agre
onward
public
hospit
would
particip
annual
nation
audit
coordin
bsg
benchmark
effort
implement
pbm
purpos
encourag
improv
share
good
practic
aim
first
nation
pbm
audit
carri
pilot
find
present
method
earli
consensu
reach
among
bsg
public
hospit
select
pbm
perform
measur
nation
audit
percentag
complianc
document
clinic
indic
rbc
prior
transfus
percentag
complianc
anaemia
screen
day
elect
surgeri
perform
measur
select
encourag
appropri
rbc
transfus
perform
measur
chosen
promot
improv
anaemia
screen
manag
pilot
audit
conduct
retrospect
cover
period
oct
data
hospit
bsg
analys
data
survey
hospit
relev
pbm
initi
share
audit
outcom
good
practic
hospit
senior
manag
htc
result
public
acut
care
hospit
bed
includ
tertiari
specialti
hospit
particip
pilot
audit
complianc
perform
measur
rang
wide
median
hospit
submit
data
unabl
retriev
data
audit
hospit
incorpor
mandatori
indic
electron
transfus
order
better
complianc
variat
like
also
due
differ
data
collect
method
document
case
note
might
captur
hospit
encourag
incorpor
indic
mandatori
field
electron
transfus
order
includ
system
guid
appropri
transfus
complianc
perform
measur
also
rang
wide
median
hospit
submit
altern
metric
patient
receiv
periop
transfus
proper
preoper
anaemia
screen
manag
hospit
establish
preoper
anaemia
screen
manag
workflow
better
complianc
good
practic
one
hospit
share
rest
hospit
advis
establish
workflow
postpon
surgeri
proper
evalu
treatment
revers
caus
anaem
patient
summaryconclus
feasibl
conduct
nation
pbm
audit
use
nationwid
promot
benchmark
effort
pbm
implement
continu
nation
audit
annual
includ
periop
rbc
transfus
rate
select
major
surgeri
futur
audit
blood
centr
colombo
sri
lanka
blood
transfus
servic
nation
blood
centr
colombo
sri
lanka
background
patient
blood
manag
becom
one
wide
discuss
topic
transfus
medicin
establish
patient
blood
manag
minim
unnecessari
transfus
relat
complic
ensur
good
clinic
practic
transfus
practition
highlight
import
patient
blood
manag
depend
clinician
activ
implement
concept
patient
blood
manag
clinic
aim
aim
assess
level
knowledg
attitud
practic
surgic
obstetr
medic
offic
patient
blood
manag
method
cross
section
descript
studi
conduct
nation
hospit
de
soysa
matern
hospit
colombo
sri
lanka
among
medic
offic
work
surgic
obstetr
ward
data
collect
self
administ
structur
questionnair
statist
analyz
spss
softwar
microsoft
excel
result
among
particip
appreci
correl
anemia
diagnos
preoper
relat
periop
morbid
mortal
clinician
consid
blood
transfus
option
treat
preoper
anemia
elect
surgeri
analyz
knowledg
treat
defici
anemia
suggest
blood
transfus
treatment
modal
suggest
blood
transfus
necessari
treat
defici
anemia
detect
day
surgeri
analyz
trigger
red
cell
transfus
suggest
transfus
patient
undergo
elect
surgeri
hemoglobin
level
gdl
question
transfus
patient
hemoglobin
level
gdl
appreci
singl
unit
transfus
reassess
hemoglobin
level
transfus
anoth
unit
among
whole
studi
popul
agre
adequ
knowledg
patient
blood
manag
like
learn
patient
blood
manag
summaryconclus
patient
blood
manag
seem
rel
new
topic
medic
offic
major
agre
inadequaci
knowledg
subject
import
implement
method
educ
clinician
patient
blood
manag
order
improv
transfus
practic
patient
outcom
ms
k
r
j
j
j
care
research
group
faculti
medicin
univers
queensland
develop
australian
red
cross
blood
servic
berghof
medic
research
institut
brisban
australia
clinic
transfus
research
sanquin
research
leiden
netherland
background
chang
fresh
frozen
plasma
ffp
posit
lead
decreas
transfus
efficaci
safeti
date
effect
ffp
storag
durat
mortal
investig
one
studi
cardiac
surgeri
patient
van
straten
j
thorac
cardiovasc
surg
aim
studi
aim
determin
relationship
ffp
storag
durat
mortal
method
secondari
analys
conduct
patient
level
data
previous
collect
individu
studi
effect
pack
red
blood
cell
storag
durat
studi
report
ffp
storag
durat
includ
analysi
perform
deriv
pool
effect
estim
ffp
storag
durat
mortal
mix
effect
logist
regress
model
also
fit
model
adjust
age
gender
volum
ffp
transfus
result
ffp
storag
durat
analysi
includ
patient
across
studi
conduct
orthopaed
surgeri
acut
medicin
intens
care
cardiac
surgeri
patient
addit
month
ffp
storag
associ
small
enhanc
risk
mortal
ci
p
effect
estim
mix
effect
model
consist
remain
signific
level
ci
p
summaryconclus
studi
updat
exist
inform
clinic
ffp
storag
durat
effect
includ
wide
rang
patient
subtyp
increas
risk
mortal
longer
storag
ffp
consid
ffp
shelf
life
alter
investig
warrant
address
potenti
confound
factor
patient
subgroup
countri
recruit
year
acknowledg
australian
govern
fund
australian
red
cross
blood
servic
provis
blood
blood
product
servic
australian
commun
project
partial
fund
princ
charl
hospit
foundat
zolfaghari
j
hendri
j
mccarthi
depart
patholog
laboratori
medicin
calgari
laboratori
servicesunivers
calgari
calgari
canada
background
scig
administr
increasingli
becom
popular
among
chronic
ivig
user
therefor
import
ensur
altern
rout
effect
ivig
therapi
especi
patient
receiv
higher
dose
product
immunomodulatori
therapeut
modal
although
ivig
scig
therapi
approv
treatment
primari
secondari
immunodefici
pid
sid
respect
use
scig
altern
rout
instead
ivig
debat
neuromuscular
disord
aim
goal
assess
clinic
outcom
patient
satisfact
cost
effect
scig
among
patient
requir
immun
globulin
therapi
replac
immunomodulatori
treatment
method
studi
observ
retrospect
studi
conduct
calgari
zone
cz
cl
scig
program
adult
chronic
ivig
user
patient
interest
scig
program
refer
program
attend
physician
follow
criteria
approv
cz
ivig
advisori
group
patient
also
review
cl
medic
team
inform
consent
medic
physic
elig
patient
pid
sid
accept
scig
program
complet
immun
defici
complet
immun
defici
expert
defici
patient
medic
reason
referr
scig
program
loss
iv
access
histori
sever
headachesasept
mening
continu
hemolysi
ivig
patient
clinic
inform
enter
ivigscig
databas
use
analysi
survey
develop
tm
team
assess
patient
satisfact
program
month
cost
advantag
calcul
base
daym
clinic
encount
patient
get
ivig
result
scig
clinic
receiv
referr
septemb
decemb
elig
case
n
includ
pid
sid
neuromuscular
patient
pid
patient
mainli
includ
common
variabl
immunodefici
patient
cvid
n
patient
sid
scig
patient
includ
one
develop
humor
immun
defici
due
treatment
underli
lymphomaleukemia
multipl
myeloma
sct
stem
cell
transplant
major
neuromuscular
scig
patient
total
pt
includ
chronic
inflammatori
demyelin
polyneuropathi
cidp
multifoc
motor
neuropathi
mmn
myasthenia
gravi
mg
seven
drop
patient
neuromuscular
group
patient
survey
reveal
satisfact
rate
express
posit
impact
qualiti
patient
life
addit
shift
patient
daym
ivig
clinic
toward
scig
program
came
estim
annual
cost
save
well
open
outpati
spot
other
requir
care
summaryconclus
studi
confirm
patient
pid
sid
benefit
scig
therapi
allow
patient
better
medic
manag
provid
steadi
igg
level
signific
improv
life
qualiti
job
secur
moreov
scig
seem
reason
altern
neuromuscular
patient
suffer
ivig
medic
complic
econom
save
could
easili
compens
justifi
oper
expens
program
p
transfus
medicin
tata
memori
hospit
transfus
medicin
tata
memori
centr
mumbai
india
background
despit
million
blood
donat
india
blood
still
short
suppli
blood
transfus
servic
challeng
maintain
fine
balanc
suppli
limit
resourc
demand
blood
order
surgeri
clearli
excess
import
polici
reduc
order
type
screen
wherebi
unit
cross
match
actual
need
transfus
occur
anoth
polici
msbo
list
commonli
perform
surgic
procedur
suggest
extent
test
perform
case
begin
mani
intern
nation
guidelin
avail
msbo
pauciti
data
oncolog
patient
therefor
revis
msbo
requir
exclus
oncolog
patient
aim
primari
aim
revis
msbo
institut
secondari
aim
predict
transfus
requir
respect
surgic
disciplin
evalu
crossmatch
transfus
ratio
ct
ratio
method
retrospect
data
retriev
analyz
assess
transfus
requir
blood
requisit
surgic
patient
data
evalu
patient
less
year
age
exclud
surgic
procedur
group
differ
procedur
categori
determin
surgic
subspecialti
relev
anatom
oper
site
detail
data
collect
respect
age
gender
organ
type
surgeri
blood
order
hb
prior
surgeri
requir
rbc
transfus
ffp
fresh
frozen
plasma
platelet
transfus
result
total
surgic
event
studi
surgeri
got
postpon
cancel
leav
surgic
event
analysi
total
rbc
unit
surgeri
rbc
unit
transfus
give
high
ct
ratio
nearli
surgeri
studi
respect
ct
ratio
transfus
probabl
transfus
index
variou
paramet
revis
msbo
propos
optimum
util
blood
servic
summaryconclus
algorithm
formul
guid
preoper
blood
order
oncolog
surgic
procedur
implement
updat
msbo
substanti
advantag
includ
decreas
number
blood
order
consid
unnecessari
reduc
ct
ratio
decreas
overal
cost
without
evid
impact
patient
safeti
implement
recommend
msbo
safe
effect
financi
benefici
strategi
c
f
clinic
patholog
far
eastern
memori
hospit
societi
blood
transfus
new
taipei
citi
taiwan
china
background
despit
accumul
investig
conduct
premed
transfus
remain
controversi
prevent
advers
transfus
reaction
atr
lack
evid
concern
efficaci
steroid
premed
prevent
atr
aim
investig
whether
premed
use
steroid
prevent
outpati
atr
method
may
decemb
outpati
transfus
regist
clinic
data
retrospect
obtain
test
multivari
regress
analysi
includ
diseas
categor
premed
presenc
atr
p
valu
less
statist
signific
result
studi
interv
total
blood
unit
transfus
outpati
transfus
event
transfus
mostli
prescrib
follow
nephrologist
gynecologist
overal
premed
rate
includ
use
antipyret
antihistamin
steroid
common
use
regimen
premed
diphenhydramin
follow
steroid
acetaminophen
plu
diphenhydramin
eleven
atr
report
includ
febril
transfus
reaction
fnhtr
minor
allerg
reaction
univari
multivari
regress
analys
reveal
statist
signific
concern
premed
acetaminophen
p
diphenhydramin
p
prevent
atr
outpati
furthermor
premed
hydrocortison
may
decreas
risk
develop
atr
outpati
statist
signific
ci
p
summaryconclus
seem
steroid
premed
significantli
efficaci
prevent
atr
outpati
prospect
studi
warrant
research
establish
transfus
strategi
futur
j
k
laboratori
medicin
hematolog
oncolog
research
taichung
hospit
buddhist
tzu
chi
medic
foundat
medic
laboratori
scienc
biotechnolog
central
taiwan
univers
scienc
technolog
taichung
taiwan
china
background
platelet
transfus
one
major
therapeut
support
thrombocytopenia
everi
year
approxim
platelet
concentr
apheresi
platelet
apheresi
platelet
lrp
product
transfus
taiwan
transfus
number
rise
past
sever
year
aim
accord
aabb
guidelin
recommend
suggest
prophylact
platelet
transfus
platelet
count
less
cellsl
major
elect
neuraxi
surgeri
less
cellsl
reduc
risk
spontan
bleed
research
focus
clinic
platelet
transfus
provid
evid
appropri
use
platelet
hospit
method
retrospect
review
patient
transfus
platelet
compon
report
taichung
hospit
total
patient
includ
total
platelet
apheresi
lrp
also
platelet
concentr
transfus
hospit
physician
requir
document
reason
blood
transfus
group
characterist
compar
use
test
multivari
logist
regress
model
appli
estim
odd
ratio
ci
incid
transfus
reaction
result
total
patient
transfus
platelet
product
individu
hematolog
diseas
follow
chest
diseas
patient
result
patient
platelet
count
cellsl
transfus
within
unit
platelet
count
cellsl
transfus
within
unit
howev
patient
platelet
count
cellsl
patient
also
transfus
platelet
product
within
unit
without
activ
bleed
patient
may
necessari
platelet
transfus
may
consid
overus
platelet
summaryconclus
earli
studi
spontan
bleed
increas
bleed
risk
significantli
platelet
count
high
proport
platelet
unit
transfus
prophylact
reduc
risk
bleed
howev
platelet
transfus
also
associ
risk
transfus
reaction
thrombocytopenia
patient
although
good
proport
platelet
transfus
consid
appropri
still
misus
overus
justifi
result
may
help
reduc
platelet
inappropri
use
also
improv
transfus
qualiti
n
bint
r
g
r
g
b
l
laboratori
medicin
oncolog
nurs
orthopaed
surgeri
surgeri
anaesthesia
nation
univers
hospit
singapor
singapor
background
patient
blood
manag
pbm
multidisciplinari
approach
optim
care
patient
might
need
blood
transfus
nation
recommend
institut
last
sever
year
hospit
encourag
adopt
aim
studi
aim
examin
impact
pbm
implement
red
cell
rbc
transfus
rate
surgeri
perform
tertiari
hospit
method
periop
rbc
transfus
rate
number
case
transfusedtot
number
case
x
occur
day
day
six
surgeri
coronari
arteri
bypass
graft
cabg
total
knee
arthroplasti
tka
total
hip
arthroplasti
tha
nephrectomi
colectomi
hysterectomi
studi
baselin
transfus
rate
intens
implement
pbm
measur
june
transfus
rate
measur
randomli
select
period
pbm
plan
phase
occur
measur
intens
implement
juli
onward
earli
screen
anemia
rapid
access
anemia
manag
clinic
use
tranexam
acid
indic
use
intraop
cell
salvag
high
blood
loss
surgeri
introduc
remind
transfus
guidelin
electron
order
system
time
rbc
order
audit
appropri
rbc
transfus
extens
engag
surgeon
anaesthetist
occur
talk
meet
rais
awar
pbm
measur
take
rate
pbm
two
indic
record
proport
patient
whose
anemia
manag
ii
mean
hemoglobin
transfus
surrog
adopt
transfus
threshold
result
number
surgeri
period
cabg
tka
tha
nephrectomi
colectomi
hysterectomi
transfus
rate
cabg
tha
significantli
lower
compar
baselin
cabg
vs
ci
differ
p
tha
vs
ci
differ
p
tka
nephrectomi
hysterectomi
show
trend
toward
lower
transfus
rate
compar
baselin
ie
vs
vs
vs
transfus
rate
colectomi
increas
sampl
size
small
surgeri
combin
proport
whose
anemia
manag
increas
baselin
ci
differ
p
mean
hemoglobin
decreas
baselin
gdl
gdl
ci
differ
p
cabg
differ
remain
signific
proport
whose
anemia
manag
increas
vs
p
mean
hemoglobin
decreas
gdl
vs
gdl
p
mean
number
rbc
unit
transfus
per
transfus
patient
decreas
vs
summaryconclus
implement
multifacet
pbm
abl
reduc
transfus
rate
across
differ
type
surgeri
proport
anemia
manag
increas
mean
hemoglobin
decreas
reflect
adopt
pbm
measur
next
phase
would
focu
ensur
mani
patient
possibl
manag
accordingli
studi
outcom
infect
rate
resourc
util
l
lopez
de
luca
f
cillero
j
napal
j
milon
hematologia
hospit
italiano
la
plata
la
plata
argentina
background
bone
marrow
allogen
transplant
treatment
wide
varieti
hematolog
diseas
period
patient
gener
receiv
support
transfus
blood
compon
risk
factor
associ
greater
consumpt
presenc
incompat
abo
donor
recipi
addit
studi
relat
increas
risk
diseas
gvhd
lower
surviv
transplant
type
abo
incompat
one
associ
differ
complic
occur
period
addit
alreadi
mention
major
abo
incompat
prevail
hemolyt
anemia
pure
red
cell
aplasia
delay
engraft
red
blood
cell
neutrophil
platelet
minor
abo
incompat
hemolyt
anemia
passeng
lymphocyt
syndrom
bidirect
abo
incompat
combin
aim
establish
associ
presenc
abo
incompat
blood
transfus
requir
red
blood
cell
neutrophil
engraft
platelet
chang
abo
group
incid
gvhd
global
surviv
well
report
occurr
immunohematolog
complic
method
total
clinic
histori
patient
undergo
allogen
transplant
analyz
divid
group
accord
abo
incompat
isogroup
minor
abo
majorbidirect
abo
incompat
blood
transfus
requir
analyz
consecut
period
day
group
compar
use
analysi
varianc
anova
method
use
evalu
chang
abo
group
engraft
neutrophil
platelet
preval
acut
chronic
gvhd
analyz
test
global
surviv
evalu
use
kaplan
meier
curv
compar
group
test
result
patient
evalu
averag
age
year
women
patient
accord
patholog
aml
mcl
md
nhl
hl
patient
majorbidirect
abo
incompat
patient
minor
abo
incompat
median
number
day
neutrophil
engraft
isogroup
minor
abo
major
abo
platelet
isogroup
minor
abo
major
abo
abo
group
chang
detect
median
day
minor
abo
major
abo
median
transfus
period
isogroup
minor
abo
major
abo
period
isogroup
minor
abo
major
abo
period
isogroup
minor
abo
major
abo
global
surviv
month
isogroup
minor
abo
major
abo
median
month
patient
aml
receiv
transplant
major
abo
incompat
diagnos
pure
red
cell
aplasia
summaryconclus
experi
presenc
abo
incompat
factor
impact
transfus
requir
engraft
neutrophil
platelet
surviv
seri
patient
observ
higher
preval
acut
chronic
gvhd
patient
transplant
abo
incompat
p
ns
abstract
withdrawn
p
k
provinci
blood
coordin
offic
children
women
hospit
st
paul
hospit
vancouv
canada
background
immunoglobulin
ig
expens
blood
product
made
pool
human
plasma
ig
global
short
suppli
canada
one
highest
user
ig
world
util
data
bc
provinci
blood
coordin
offic
pbco
central
transfus
registri
ctr
show
ig
use
bc
increas
fiscal
year
immunolog
compris
largest
special
account
provinci
ig
use
condit
primari
immun
defici
diseas
pidd
account
ig
use
immunolog
patient
growth
util
year
year
signific
address
increas
support
optim
care
pbco
establish
pidd
work
group
wg
wg
consist
immunologist
hematopathologist
data
analyst
technologist
healthcar
profession
aim
develop
pidd
toolkit
provid
standard
tool
resourc
support
physician
manag
care
pidd
patient
tool
includ
diagnost
treatment
algorithm
proven
key
compon
success
current
bc
rheumatolog
neuromuscular
program
method
comprehens
review
literatur
ctr
data
ig
use
pidd
done
collabor
wg
wg
identifi
gap
opportun
current
process
form
basi
content
pidd
toolkit
data
analysi
show
variat
across
region
institut
physician
level
term
amount
ig
prescrib
patient
despit
provinci
ig
guidelin
prompt
need
treatment
diagnost
algorithm
support
gener
physician
determin
refer
suspect
pidd
patient
immunologist
wg
highlight
import
ensur
care
earli
establish
goal
outcom
treatment
process
need
access
diphtheria
tetanu
pneumococc
antibodi
test
accur
diagnosi
also
identifi
wg
collabor
bc
centr
diseas
control
bccdc
expedit
approv
process
diphtheria
tetanu
test
work
bc
clinic
support
servic
bccss
streamlin
process
pneumococc
antibodi
test
result
develop
pidd
toolkit
diagnost
algorithm
treatment
algorithm
dosag
calcul
adjust
dose
calcul
updat
provinci
ig
util
recommend
easili
access
date
refer
collabor
bccdc
obtain
preapprov
diphtheria
tetanu
test
bc
immunologist
collabor
bccss
establish
expedit
process
pneumococc
antibodi
test
summaryconclus
pidd
toolkit
dissemin
pidd
work
group
bc
societi
allergi
immunolog
transfus
medicin
servic
hematopathologist
technic
coordin
receiv
toolkit
bc
stakehold
committe
toolkit
use
ensur
accur
diagnosi
pidd
appropri
treatment
ig
ongo
adopt
use
current
algorithm
order
physician
regular
review
ctr
data
use
patient
outcom
evalu
provid
time
easili
access
access
pbco
develop
pidd
toolkit
app
expect
launch
date
may
e
e
epidemiolog
ottawa
hospit
research
institut
ottawa
hospit
ottawa
canada
background
patient
care
blood
product
alloc
within
hospit
optim
better
understand
preval
patient
receiv
multipl
blood
product
well
characterist
outcom
recipi
howev
lack
literatur
describ
epidemiolog
studi
concentr
particular
blood
product
util
aim
purpos
systemat
review
describ
preval
secondari
object
determin
patient
characterist
outcom
associ
method
databas
medlin
embas
cochran
librari
systemat
review
search
observ
cohort
studi
adult
pediatr
hospit
patient
report
incid
preval
patient
characterist
outcom
associ
includ
descript
synthesi
studi
perform
result
total
studi
identifi
includ
report
preval
found
preval
vari
greatli
patient
popul
specif
combin
blood
product
given
chang
littl
time
patient
includ
burn
cardiac
surgeri
liver
transplant
cancer
infecti
diseas
trauma
patient
requir
massiv
blood
transfus
icu
patient
five
studi
found
associ
advers
health
outcom
cardiac
surgeri
liver
transplant
patient
howev
find
like
confound
indic
overal
qualiti
evid
low
given
individu
studi
qualiti
inconsist
estim
signific
confound
indic
summaryconclus
knowledg
trend
recipi
need
help
improv
patient
care
patient
blood
manag
physician
awar
risk
benefit
help
optim
transfus
lead
appropri
transfus
practic
avoid
unnecessari
transfus
research
show
certain
patient
group
mani
patient
yet
littl
realli
known
patient
research
need
sever
area
gain
better
understand
epidemiolog
includ
studi
hematolog
cancer
patient
studi
look
patient
characterist
better
predict
need
abstract
withdrawn
bb
g
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
st
petersburg
state
medic
univers
saint
petersburg
russian
feder
citi
matern
hospit
dushanb
tajikistan
background
disord
hemostasi
system
clinic
practic
lead
bleed
menac
life
major
bleed
obstetr
practic
among
women
caus
hemostasi
disord
form
dissemin
intravascular
coagul
syndrom
dic
case
destini
patient
depend
time
diagnost
patholog
hemostasi
system
effect
treatment
use
modern
program
medicament
therapi
itt
aim
identifi
treat
complic
relat
hemostasi
system
acut
massiv
bleed
identifi
way
improv
itt
program
perform
method
analyz
treatment
result
pregnant
women
acut
massiv
bleed
connect
disturb
hemostasi
system
durat
bleed
rang
h
patient
seriou
post
hemorrhag
anemia
hemoglobin
gl
initi
indic
gl
erythrocyt
hematocrit
number
thrombocyt
made
observ
elong
blood
coagul
min
full
coagul
time
plasma
recalcif
activ
partial
thromboplastin
time
depress
prothrombin
thrombotest
degre
fibrinogen
mainten
gl
rise
retract
bloodi
clot
fibrinolyt
activ
meant
patient
dissemin
intravascular
coagul
syndrom
presenc
dic
identifi
observ
principl
itt
meant
restor
blood
volum
organ
blood
flow
restor
defici
plasma
procoagul
transfus
fresh
frozen
plasma
ffp
dose
mlkg
combin
salin
solut
pariti
cryoprecipit
dose
transfus
ffp
carri
great
speed
ml
within
min
necessari
repeat
transfus
ffp
h
dose
mlkg
achiev
hemostat
effect
presenc
clinic
sign
hemic
hypoxia
transfus
wash
pack
red
blood
cup
clinic
sign
hypoxia
irrespect
hemoglobin
hematocrit
level
decreas
fibrinolyt
blood
activ
reach
intraven
introduct
contric
unit
unit
min
prior
transfus
ffp
presenc
thrombocytopenia
carri
transfus
medic
dose
thrombocyt
concentr
also
use
prednisolonum
dose
mgkg
correl
acidosi
detect
hypercoagul
phase
acut
dic
transfus
drop
heparin
introduct
dose
weight
rheolog
natur
lethal
case
result
acut
massiv
bleed
obstetr
practic
connect
dic
possibl
achiev
posit
treatment
result
transfus
suffici
volum
ffp
combin
salin
solut
transfus
eritro
contain
compon
carri
achiev
hemostat
effect
presenc
clinic
implic
anemia
summaryconclus
acut
massiv
bleed
obstetr
practic
connect
dic
possibl
achiev
posit
result
treatment
transfus
suffici
volum
ffp
combin
salin
solut
transfus
eritro
contain
compon
carri
achiev
hemostat
effect
presenc
clinic
implic
anemia
abstract
withdrawn
n
adinolfi
mottola
b
federico
de
cenzo
r
ciotola
v
mininni
b
zuccarelli
immunohematolog
servic
aorndei
colli
napoli
itali
background
sever
sepsi
defin
presenc
infect
organ
dysfunct
one
main
factor
morbid
hospit
mortal
incid
steadili
increas
annual
help
trigger
dic
acquir
syndrom
character
activ
intravascular
coagul
format
intravascular
fibrin
definit
clinic
consequ
character
syndrom
organ
damag
due
process
hemorrhag
diathesi
patient
sepsi
manag
dic
problemat
may
requir
infus
larg
amount
blood
product
result
overload
circl
increas
fluid
loss
tran
capillari
worsen
pulmonari
complianc
ga
exchang
aim
aim
studi
assess
impact
rate
infus
ffp
surviv
resolut
shorter
time
dicsepsi
method
use
ffp
evalu
prospect
cohort
patient
affect
dic
relat
sepsi
admit
type
intens
care
januari
decemb
patient
diagnosi
acut
dic
laboratori
investig
show
lengthen
clot
time
platelet
count
presenc
fdp
abnorm
plasma
level
coagul
inhibitor
patient
diagnosi
acut
dic
laboratori
investig
show
lengthen
clot
time
thrombocytopenia
presenc
fdp
abnorm
plasma
level
coagul
inhibitor
patient
receiv
plasma
slow
infus
continu
mlmin
remain
transfus
slowli
first
mlmin
monitor
appear
reaction
subsequ
infus
rate
increas
mlkgh
result
patient
treat
slow
continu
infus
averag
stay
assess
gg
surviv
patient
averag
stay
gg
gg
surviv
summaryconclus
one
hand
studi
highlight
inadequ
use
ffp
like
due
habit
person
convict
resuscit
led
need
enact
new
corpor
guidelin
order
allow
oper
surgeon
resuscit
immunohematologist
act
synergi
second
heterogen
rel
small
size
popul
studi
togeth
methodolog
limit
spur
us
formul
prospect
studi
resuscit
order
improv
diagnosi
treatment
dic
creat
project
manag
sever
sepsi
septic
shock
joshi
bakdash
p
figueroa
sapatnekar
section
transfus
medicin
cleveland
clinic
cleveland
unit
state
america
background
passeng
lymphocyt
syndrom
pl
alloimmun
phenomenon
classic
occur
abo
stem
cell
organ
transplant
may
occur
involv
blood
group
system
antibodi
recipi
antigen
deriv
plasma
cell
lymphocyt
may
caus
sever
hemolysi
recipi
pl
consid
disord
last
durat
surviv
lymphocyt
aim
describ
clinic
serolog
featur
case
prolong
hemolysi
due
pl
set
liver
transplant
method
clinic
case
manag
chart
literatur
review
result
hepat
c
liver
diseas
diabet
underw
orthotop
liver
transplant
deceas
donor
patient
record
red
cell
antibodi
requir
allogen
transfus
within
preced
month
transplant
surgeri
postop
day
routin
type
screen
reveal
new
posit
direct
antiglobulin
test
dat
new
plasma
eluat
new
plasma
alon
patient
red
cell
type
transfus
medicin
staff
review
find
deem
suspici
antibodi
enquiri
initi
transfus
servic
organ
procur
agenc
confirm
donor
histori
concurr
patient
hemoglobin
drop
gdl
laboratori
featur
hemolysi
evid
hemorrhag
context
immunohematolog
find
clinic
present
found
consist
pl
patient
receiv
corticosteroid
intraven
immunoglobulin
rituximab
pl
addit
immunosuppress
eventu
prolong
cours
mainten
corticosteroid
measur
fail
control
symptom
hemolysi
requir
frequent
transfus
approxim
unit
rbc
everi
day
next
month
red
cell
antibodi
persist
plasma
eluat
seven
month
transplant
result
poor
glycem
control
develop
transfusion
siderosi
splenectomi
perform
splenectomi
dramat
reduct
transfus
requir
transfus
next
week
none
thereaft
howev
plasma
antibodi
present
least
four
month
dat
remain
posit
least
month
four
year
later
patient
remain
hemoglobin
consist
gd
howev
continu
demonstr
evid
compens
hemolysi
like
multifactori
etiolog
graft
function
robust
show
evid
lymphoprolif
disord
summaryconclus
set
organ
transplant
pl
potenti
prolong
hemolysi
patient
new
red
cell
antibodi
follow
transplant
must
evalu
condit
inclus
donor
antibodi
statu
part
donor
blood
type
report
would
facilit
earli
recognit
complic
medic
laboratori
scienc
univers
medic
research
nephrolog
depart
intern
medicin
laboratori
medicin
hospit
kaohsiung
taiwan
china
background
blood
transfus
frequent
use
manag
patient
anemia
accord
retrospect
studi
overal
preval
alloimmun
blood
transfus
hospit
howev
significantli
higher
rbc
alloimmun
rate
found
hemodialysi
patient
p
well
known
develop
erythrocyt
alloantibodi
complic
transfus
therapi
chronic
transfus
patient
result
difficulti
delay
obtain
compat
blood
induc
hemolyt
transfus
reaction
hemodialysi
patient
alloantibodi
aim
strategi
could
provid
rbc
transfus
hemodialysi
patient
reduc
alloimmun
method
retrospect
studi
first
conduct
review
blood
request
record
blood
transfus
unit
hospit
hemodialysi
patient
extend
rbc
protocol
appli
hemodialysi
patient
extend
rbc
protocol
patient
donor
phenotyp
mia
e
antigen
use
inform
select
rbc
unit
lack
antigen
express
recipi
result
mia
antibodi
demonstr
common
alloantibodi
encount
follow
antibodi
hemodialysi
patient
rbc
antibodi
commonli
associ
alloimmun
popul
direct
agath
rbc
antibodi
commonli
associ
alloimmun
popul
direct
miiii
e
antigen
implement
extend
rbc
protocol
mia
antibodi
demonstr
common
alloantibodi
encount
follow
antibodi
hemodialysi
patient
studi
preval
miiii
e
antigen
among
hemodialysi
patient
respect
extend
blood
match
mia
e
antigen
hemodialysi
patient
singl
patient
produc
alloantibodi
receiv
blood
transfusioninst
miiii
e
antigen
studi
perform
immunohematolog
studi
mia
e
antigen
hemodialysi
patient
preval
miiii
e
recommend
administ
blood
extend
blood
match
mia
e
antigen
hemodialysi
patient
demonstr
patient
produc
alloantibodi
receiv
blood
transfus
summaryconclus
extend
blood
type
match
beyond
abo
long
propos
strategi
reduc
alloimmun
found
extend
match
strategi
mia
e
antigen
hemodialysi
patient
could
significantli
decreas
alloimmun
ratio
compar
implement
transfus
protocol
conclud
chronic
transfus
patient
could
highli
benefit
extend
blood
type
strategi
common
associ
antigen
r
u
e
chief
doctor
bank
bashkortostan
ufa
nation
medic
surgic
center
moscow
russian
feder
background
platelet
transfus
import
tool
prevent
treatment
bleed
thrombocytopenia
andor
thrombocytopathi
current
nation
guidelin
platelet
transfus
recommend
therapeut
dose
platelet
per
recipi
bodi
surfac
specif
indic
transfus
platelet
determin
attend
physician
basi
clinic
pictur
caus
thrombocytopenia
degre
express
local
bleed
volum
sever
forthcom
procedur
one
unit
platelet
must
contain
accordingli
two
therapeut
unit
platelet
transfus
simultan
adult
patient
appropri
minim
risk
pathogen
transmiss
particularli
bacteri
contamin
pathogen
inactiv
platelet
unit
implement
center
aim
compar
clinic
efficaci
singl
simultan
doubl
transfus
platelet
method
data
regard
clinic
efficaci
transfus
collect
hospit
bashkortostan
republ
cover
transfus
platelet
intercept
blood
system
ceru
corpor
concord
usa
case
one
patient
simultan
transfus
two
therapeut
unit
platelet
result
process
use
descript
statist
signific
level
result
friday
simultan
doubl
transfus
occur
time
often
singl
dose
p
wednesday
time
less
often
p
stop
bleed
transfus
perform
case
platelet
use
prevent
bleed
recipi
singl
doubl
transfus
show
differ
follow
indic
surfac
area
bodi
averag
number
transfus
histori
proport
first
transfus
platelet
frequenc
prevent
therapeut
transfus
effect
stop
bleed
correct
platelet
gain
platelet
count
transfus
doubl
unit
lower
p
group
singl
transfus
ratio
level
concentr
platelet
transfus
correct
platelet
increment
h
cci
studi
group
differ
number
platelet
platelet
contain
correl
cci
singl
doubl
transfus
cci
directli
correl
concentr
platelet
transfus
singl
dual
transfus
p
direct
correl
cci
baselin
platelet
concentr
suggest
increas
consumpt
transfus
platelet
lowest
initi
cell
concentr
accordingli
necessari
search
boundari
valu
initi
concentr
platelet
prophylact
transfus
excess
summaryconclus
evid
differ
efficaci
dual
singl
transfus
pathogen
inactiv
amotosalenuva
platelet
concentr
direct
correl
cci
initi
concentr
platelet
indic
limit
diagnost
signific
cci
indic
effect
platelet
transfus
wwwtransfusionru
medicin
haematolog
tata
medic
center
kolkata
india
background
granulocyt
transfus
use
patient
often
prove
life
save
patient
profound
neutropenia
granulocyt
apheresi
expens
requir
suitabl
donor
centr
granulocyt
indic
often
use
buffi
coat
granulocyt
bcg
altern
apheresi
granulocyt
ag
studi
retrospect
review
bcg
transfus
undertaken
centr
twenti
month
period
aim
studi
qualiti
bcg
product
assess
outcom
bcg
transfus
method
period
patient
receiv
total
bcg
transfus
buffi
coat
granulocyt
prepar
use
quadrupl
bag
tace
ii
machin
group
specif
cross
match
compat
donor
donor
met
criteria
blood
donat
infect
marker
hbv
hcv
hiv
malaria
syphili
unit
process
compon
platelet
pack
red
cell
plasma
buffi
coat
bag
group
specif
buffi
coat
bag
cross
match
compat
patient
identifi
depend
avail
donor
total
buffi
coat
bag
use
prepar
bcg
product
product
irradi
transfus
within
h
prepar
indic
anc
drug
resist
invas
bacterialfung
infect
result
gender
distribut
male
femal
age
rang
year
patient
five
patient
receiv
bcg
transfus
consecut
day
four
patient
receiv
bcg
transfus
consecut
day
three
patient
receiv
bcg
transfus
day
granulocyt
content
pool
bcg
product
rang
rbc
contamin
rang
ml
post
transfus
count
h
perform
assess
absolut
neutrophil
count
anc
summaryconclus
buffi
coat
granulocyt
transfus
use
manag
drug
resist
neutropen
patient
rel
inexpens
easili
prepar
viabl
option
granulocyt
apheresi
donor
avail
patel
lab
medicin
global
hospit
research
centr
mumbai
india
background
critic
shortag
platelet
dengu
epidem
lead
preferenti
transfus
platelet
aim
overcom
platelet
shortag
denguemalaria
epidem
india
method
six
hundr
patient
high
grade
fever
test
posit
denguemalaria
admit
screen
malaria
dengu
ns
igm
igg
cbc
atyp
lymphocyt
atl
platelet
count
mean
platelet
volum
mpv
platelet
function
test
result
three
hundr
patient
low
platelet
count
show
atyp
lymphocyt
alt
high
mean
platelet
volum
mpv
normal
mpv
cbc
sampl
test
everi
ten
hour
reveal
patient
high
mpv
increas
platelet
count
period
next
h
also
smear
show
reduct
atl
howev
patient
thrombocytopenia
associ
atl
normal
platelet
volum
worsen
start
develop
petechia
requir
immedi
platelet
transfus
thrombocytopenia
patient
normal
platelet
volum
associ
atl
also
dengu
ns
igm
posit
indic
activ
recent
dengu
infect
summaryconclus
dengu
malaria
case
low
platelet
need
transfus
patient
posit
igg
igm
atl
thrombocytopenia
platelet
respond
product
larg
platelet
given
immedi
platelet
transfus
patient
constitut
seen
studi
therebi
releas
remain
platelet
ration
use
requir
needi
f
colleg
medicin
univers
ibadan
ibadan
nigeria
background
variat
transfus
practic
among
surgeon
differ
procedur
procedur
variat
may
due
differ
opinion
threshold
level
hemoglobin
patient
need
blood
transfus
differ
surgic
anesthet
techniqu
differ
case
gradat
preoper
anemia
despit
shortag
blood
larg
number
blood
unit
tie
surgic
procedur
may
requir
may
reflect
percept
uncertainti
surgeon
relationship
blood
loss
subsequ
transfus
aim
studi
carri
evalu
transfus
practic
thyroidectomi
tertiari
hospit
nigeria
method
year
retrospect
analysi
patient
underw
thyroidectomi
hospit
conduct
inform
follow
retriev
demograph
characterist
pre
post
oper
haematocrit
number
blood
crossmatch
blood
transfus
indic
use
determin
effici
blood
order
util
system
includ
crossmatch
transfus
ratio
ct
ratio
probabl
transfus
transfus
index
ti
number
unit
crossmatch
thyroidectomi
determin
use
maxim
surgic
blood
order
schedul
msbo
ti
result
exist
data
two
hundr
patient
elect
thyroidectomi
collect
use
studi
patient
femal
mean
age
patient
year
commonest
clinic
diagnosi
observ
among
patient
simpl
multinodular
follow
simpl
solitari
nodular
patient
blood
crossmatch
blood
transfus
oper
haematocrit
patient
haematocrit
indic
use
determin
effici
blood
order
util
show
transfus
ratio
c
ratio
transfus
probabl
transfus
index
ti
maxim
surgic
blood
order
schedul
msbo
estim
amount
blood
need
procedur
associ
blood
transfus
type
oper
statist
signific
summaryconclus
studi
show
excess
blood
arrang
thyroid
surgeri
suggest
ct
ratio
less
ti
would
led
avoid
burden
blood
bank
staff
resourc
need
blood
transfus
patient
surgeri
thyroid
function
type
thyroidectomi
perform
besid
msbo
suggest
group
patient
save
group
compat
blood
without
crossmatch
like
detriment
effect
qualiti
care
patient
thyroid
surgeri
anaemia
uncommon
among
patient
preoper
postop
corrobor
need
chang
transfus
practic
surgeon
haysom
r
sparrow
tacey
z
mcquilten
e
wood
depart
public
health
prevent
medicin
monash
univers
melbourn
australia
background
emerg
admiss
requir
massiv
transfus
mt
guidelin
recommend
transfus
blood
group
oneg
red
blood
cell
rbc
patient
blood
group
known
due
low
frequenc
oneg
blood
group
suppli
may
exhaust
limit
data
exist
use
oneg
rbc
emerg
admiss
includ
frequent
unit
given
particularli
emerg
transfus
manag
femal
childbear
potenti
australian
new
zealand
massiv
transfus
registri
captur
clinic
laboratori
data
patient
mt
rbc
h
period
type
critic
bleed
hospit
admiss
aim
describ
use
oneg
rbc
mt
occur
within
h
hospit
admiss
proport
femal
year
receiv
rbc
method
patient
receiv
mt
within
h
hospit
admiss
particip
hospit
includ
variabl
includ
patient
sex
age
time
issu
first
blood
compon
bleed
context
number
blood
group
rbc
transfus
compar
patient
blood
group
data
analys
use
statist
softwar
stata
result
mt
case
met
inclus
criteria
metropolitan
hospit
admit
ie
weekend
andor
pm
common
bleed
context
trauma
gastrointestin
vascular
obstetr
oneg
patient
male
femal
receiv
exclus
oneg
rbc
male
femal
receiv
oneg
rbc
male
receiv
rbc
median
rang
iqr
rbc
transfus
within
h
three
group
respect
patient
receiv
least
one
unit
oneg
rbc
receiv
exclus
oneg
rbc
patient
receiv
exclus
oneg
rbc
mt
durat
h
receiv
median
iqr
rbc
male
examin
femal
age
year
mean
age
trauma
admiss
obstetr
femal
oneg
receiv
exclus
oneg
rbc
femal
receiv
exclus
rbc
one
femal
receiv
rbc
trauma
patient
age
transfus
rbc
h
die
within
h
summaryconclus
cohort
massiv
transfus
patient
receiv
least
one
oneg
rbc
small
import
proport
transfus
exclus
oneg
rbc
transfus
rbc
achiev
oneg
patient
patient
one
case
emerg
admiss
femal
year
receiv
rbc
unit
find
suggest
transfus
laboratori
inventori
larg
met
rbc
requir
emerg
admiss
requir
massiv
transfus
v
c
k
b
j
health
scienc
centr
region
blood
coordin
network
toronto
michael
hospit
toronto
canada
background
massiv
hemorrhag
protocol
mhp
key
ensur
patient
receiv
standard
coordin
care
achiev
best
possibl
outcom
previou
survey
shown
variabl
protocol
includ
activ
criteria
transfus
ratio
laboratori
test
addit
retrospect
review
found
poor
protocol
complianc
associ
inferior
outcom
aim
aim
survey
determin
proport
hospit
across
ontario
formal
mhp
implement
underli
compon
protocol
hypothes
mhp
still
lack
mani
ontario
hospit
present
protocol
would
highli
variabl
survey
perform
prepar
launch
provinci
wide
standard
mhp
method
survey
sent
hospit
n
transfus
servic
hospit
fail
respond
deadlin
email
encourag
complet
hospit
fail
respond
email
contact
phone
encourag
report
provid
neg
affirm
mhp
survey
includ
question
regard
activ
criteria
commun
laboratori
test
transfus
pack
configur
hemostat
adjunct
temperatur
blood
transport
contain
anticoagul
revers
qualiti
improv
metric
result
overal
survey
complet
rate
hospit
remain
provid
neg
affirm
protocol
mhp
place
hospit
protocol
commonli
term
massiv
transfus
protocol
activ
criteria
present
commonli
activ
base
volum
blood
loss
number
unit
transfus
activ
trigger
commonli
call
transfus
laboratori
andor
locat
blood
work
commonli
drawn
discret
physician
predefin
interv
major
everi
min
common
routin
laboratori
test
perform
cbc
inr
aptt
fibrinogen
fibrinogen
test
avail
report
hospit
median
target
hemostat
resuscit
platelet
inr
fibrinogen
gl
hemoglobin
gl
protocol
requir
patient
temperatur
monitor
specifi
revers
plan
patient
anticoagul
site
patient
initi
manag
neg
blood
site
issu
blood
predefin
pack
vs
base
physician
order
hemostat
agent
protocol
includ
tranexam
acid
pcc
fibrinogen
rviia
qualiti
metric
track
hospit
commonli
proport
activ
wastag
appropri
activ
summaryconclus
mhp
still
lack
least
hospit
ontario
mark
variabl
aspect
report
mhp
across
ontario
variabl
may
due
differ
capac
report
hospit
lack
support
literatur
allow
uniform
practic
knowledg
gap
lack
tranexam
acid
part
protocol
hospit
lack
consist
laboratori
test
suggest
consider
gain
made
uniform
provinc
wide
protocol
lim
laboratori
medicin
ajou
univers
school
medicin
suwon
korea
background
massiv
blood
transfus
mt
requir
signific
effort
blood
bank
prepar
differ
blood
product
use
mt
ajou
univers
hospit
auh
bed
tertiari
care
hospit
blood
product
provid
blood
bank
follow
open
trauma
surgeri
center
tsc
octob
four
unit
dedic
emerg
rh
posit
red
cell
emerg
rbc
avail
blood
bank
emerg
use
sinc
march
emerg
rbc
held
releas
directli
tsc
emerg
patient
abo
rh
blood
type
determin
aim
analyz
blood
product
use
mt
sinc
march
emerg
rbc
avail
directli
tsc
method
mt
defin
transfus
rbc
within
h
case
patient
continu
transfus
blood
product
h
number
product
transfus
first
h
includ
medic
transfus
record
mt
case
extract
hospit
inform
system
review
total
rbc
fresh
frozen
plasma
ffp
platelet
plt
donor
platelet
sdp
random
platelet
concentr
pc
issu
auh
blood
bank
march
novemb
review
sdp
consid
equival
unit
pc
percentag
product
transfus
mt
compar
overal
percent
product
transfus
also
percentag
emerg
rbc
transfus
compar
total
unit
transfus
per
patient
defin
use
emerg
rbc
result
mt
month
survey
period
casesmonth
total
rbc
transfus
period
rbc
use
mt
routin
rbc
transfus
group
group
b
group
ab
mt
rbc
transfus
group
b
ab
period
ffp
cryoprecipit
plt
use
mt
ratio
rbc
ffp
plt
use
mt
total
transfus
emerg
rbc
use
mt
case
total
emerg
rbc
use
case
total
rbc
rbc
mt
averag
number
emerg
rbc
unit
transfus
per
patient
vari
use
emerg
rbc
vari
mean
sd
summaryconclus
ongo
educ
clinician
minimis
use
emerg
rbc
mt
requir
although
emerg
rbc
quickli
avail
procedur
thaw
plasma
readili
avail
mt
appear
import
avail
rbc
ffp
use
frequent
mt
compar
total
transfus
blood
centr
gynecolog
de
soysa
matern
hospit
colombo
sri
lanka
background
hemorrhag
pph
identifi
lead
caus
matern
death
worldwid
guidelin
recogn
institut
state
blood
transfus
initi
clinic
judgment
fix
criteria
initi
blood
transfus
aim
aim
analyz
clinic
biochem
paramet
trigger
consid
obstetr
specialist
commenc
blood
transfus
clinic
practic
method
descript
studi
conduct
among
consult
obstetrician
practic
sri
lanka
data
collect
administ
questionnair
analyz
microsoft
excel
spss
result
mean
year
experi
particip
practic
clinic
consult
year
among
particip
agre
consid
initi
blood
transfus
depend
rate
bleed
irrespect
estim
total
loss
evid
hypovolemia
use
increas
puls
rate
rise
puls
rate
base
line
indic
agre
consid
blood
transfus
rate
bleed
irrespect
estim
total
blood
loss
clinic
paramet
regard
total
blood
loss
patient
ongo
bleed
consid
transfus
total
blood
loss
ml
irrespect
clinic
paramet
consid
transfus
increas
puls
rate
drop
blood
pressur
even
total
loss
less
ml
particip
agre
visual
assess
total
blood
loss
inaccur
method
defin
pph
agre
combin
clinic
paramet
reliabl
effect
method
assess
need
transfus
singl
paramet
particip
agre
puls
rate
reliabl
paramet
follow
blood
pressur
respiratori
rate
suggest
chang
respiratori
rate
follow
puls
rate
blood
pressur
would
reliabl
none
suggest
consid
blood
transfus
basi
clinic
pallor
patient
conscious
statu
alon
unless
defin
blood
loss
evid
hypovolemia
agre
wait
hemoglobin
assess
patient
pale
without
consid
ongo
blood
loss
normal
clinic
paramet
particip
agre
involv
hematologist
transfus
physician
would
benefici
make
decis
blood
compon
therapi
hematologist
avail
agre
initi
compon
transfus
unit
unit
red
cell
coagul
profil
avail
patient
facil
point
care
test
agre
could
benefici
necessari
manag
obstetr
hemorrhag
wherea
never
facil
manag
patient
test
summaryconclus
specialist
agre
clinic
judgment
import
determin
specif
paramet
use
initi
blood
transfus
van
den
c
k
j
j
van
der
clinic
transfus
research
sanquin
research
clinic
epidemiolog
obstetr
leiden
univers
medic
center
leiden
obstetr
univers
medic
center
utrecht
utrecht
thrombosi
hemostasi
leiden
univers
medic
center
leiden
netherland
background
order
achiev
volum
expans
prevent
hypovolem
shock
administr
clear
fluid
becom
essenti
part
manag
postpartum
haemorrhag
time
larg
amount
fluid
may
induc
dilut
coagulopathi
describ
chang
coagul
paramet
increas
volum
given
cours
postpartum
haemorrhag
aim
aim
studi
evalu
associ
restrict
liber
volum
resuscit
manag
strategi
develop
dilut
coagulopathi
postpartum
haemorrhag
method
nationwid
retrospect
cohort
studi
women
experienc
postpartum
haemorrhag
receiv
least
four
unit
red
cell
fresh
frozen
plasma
platelet
addit
red
cell
women
data
avail
coagul
paramet
amount
time
clear
fluid
amount
blood
loss
time
blood
sampl
categoris
group
ml
ml
ml
ml
ml
ml
ml
ml
refer
categori
coagul
paramet
alloc
categori
repres
amount
blood
loss
sampl
subsequ
amount
clear
fluid
administ
time
blood
sampl
calcul
classifi
three
fluid
administr
strategi
base
rcog
guidelin
ml
ml
ml
thu
coagul
paramet
first
group
base
amount
blood
loss
sampl
subdivid
three
fluid
administr
strategi
analys
outcom
includ
haemoglobin
haematocrit
platelet
count
fibrinogen
aptt
pt
level
result
lowest
highest
categori
fluid
administr
median
haemoglobin
level
decreas
gdl
iqr
gdl
iqr
median
platelet
count
iqr
iqr
aptt
prolong
iqr
iqr
although
sampl
amount
blood
loss
fibrinogen
largest
chang
display
measur
refer
categori
blood
loss
ml
gl
iqr
gl
iqr
gl
iqr
three
fluid
manag
categori
transfus
blood
product
observ
differ
diminish
summaryconclus
larg
cohort
women
postpartum
haemorrhag
administr
larg
volum
clear
fluid
associ
chang
coagul
paramet
correspond
dilut
coagulopathi
c
k
l
medicin
nci
nation
univers
hospit
loo
lin
school
medicin
nation
univers
singapor
singapor
singapor
background
massiv
transfus
protocol
mtp
structur
mechan
earli
blood
product
deliveri
critic
bleed
transfus
practic
increasingli
use
across
differ
hospit
specialti
earli
resuscit
maintain
perfus
correct
consumpt
coagulopathi
prior
definit
hemostat
measur
despit
benefit
mtp
may
also
result
wastag
costli
blood
product
aim
review
blood
product
usag
mortal
patient
receiv
mtp
nation
univers
hospit
nuh
method
nuh
mtp
consist
packag
includ
consist
pack
red
cell
prbc
unit
fresh
frozen
plasma
ffp
unit
platelet
pool
bag
pplt
addit
unit
cryoprecipit
ad
packag
issu
attend
physician
decid
requir
assess
blood
consumpt
abc
score
trauma
patient
use
guid
mtp
activ
review
indic
massiv
transfus
patient
demograph
clinic
data
mtp
initi
result
total
mtp
activ
male
median
age
patient
year
year
trauma
case
gastrointestin
hemorrhag
hemorrhag
ruptur
aortic
aneurysm
aaa
peripartum
hemorrhag
massiv
bleed
due
caus
overal
activ
case
requir
total
blood
product
issu
period
account
total
blood
product
issu
hospit
blood
product
issu
emerg
depart
oper
theatr
intens
care
unit
gener
ward
blood
product
return
unus
includ
unit
prbc
unit
pplt
unit
ffp
unit
cryoprecipit
mtp
activ
blood
product
return
due
patient
death
account
blood
product
return
patient
surviv
day
mtp
activ
trauma
bgit
ruptur
aaa
other
patient
surviv
activ
expir
within
month
summaryconclus
blood
product
activ
mtp
return
unus
blood
bank
less
half
due
patient
death
overal
blood
product
wastag
much
lower
compar
dunbar
et
al
balver
et
al
lower
ffp
wastag
return
provid
meet
stringent
storag
requir
polici
hospit
wherea
may
wast
due
improp
storag
limit
shelf
life
limit
clinic
predict
score
aid
decis
activ
mtp
mtp
activ
base
clinic
judgment
senior
physician
attend
inconsist
educ
clinician
prompt
return
blood
product
blood
bank
mtp
ceas
crucial
reduc
wastag
pandey
j
chay
blood
servic
group
health
scienc
author
hsa
singapor
singapor
background
background
massiv
transfus
protocol
mtp
use
maintain
adequ
circul
haemostasi
critic
bleed
especi
trauma
bleed
use
standard
earli
deliveri
blood
product
trauma
bleed
mtp
recommend
use
valid
massiv
transfus
predict
score
system
specif
abc
score
initi
mtp
bleed
activ
mtp
base
clinic
assess
medic
judgement
medic
team
attend
patient
recent
concern
rais
use
mtp
especi
case
might
ineffici
due
protocol
activ
may
lead
transfus
reaction
blood
wastag
also
fear
high
ratio
plasma
platelet
transfus
may
lead
poorer
outcom
bleed
patient
requir
mtp
support
aim
aim
investig
rate
mtp
activ
year
report
would
arous
awar
regard
inappropri
activ
mtp
harm
patient
method
activ
mtp
case
differ
restructur
hospit
singapor
period
year
decemb
decemb
analys
use
modifi
definit
massiv
transfus
unit
red
cell
reach
mtp
pack
transfus
within
h
adult
patient
mtp
case
categor
trauma
surgic
medic
obstetr
base
type
haemorrhag
mtp
decid
medic
surgic
team
result
decemb
case
mtp
initi
identifi
trauma
trauma
common
diagnosi
includ
obstetr
medic
mostli
gastrointestin
bleed
surgic
mostli
cardiac
op
mtp
found
case
gener
trauma
non
reach
pack
use
less
unit
red
cell
summaryconclus
result
indic
major
mtp
activ
case
meet
definit
massiv
transfus
reduc
wastag
recommend
improv
triag
mtp
case
especi
mtp
triag
b
consid
viscoelast
hemostat
test
poct
guid
mtp
blood
product
transfus
eg
rotem
possibl
mtp
vital
sign
normal
godamunn
nation
blood
transfus
servic
narahenpita
colombo
sri
lanka
background
road
traffic
accid
rta
lead
caus
death
global
well
sri
lanka
result
larg
proport
disabl
especi
among
young
peopl
world
road
traffic
death
occur
countri
gross
dispar
injuri
outcom
relat
immedi
hospit
manag
blood
transfus
procedur
manag
rta
victim
thu
import
provid
safe
blood
right
time
right
patient
right
quantiti
aim
main
object
research
assess
proport
rta
victim
receiv
blood
transfus
calcul
proport
blood
transfus
injuri
pattern
method
studi
conduct
descript
studi
consecut
rta
victim
admit
surgic
ward
district
gener
hospit
matal
sri
lanka
period
three
month
includ
studi
result
data
road
traffic
accid
victim
analyz
major
year
age
group
seventi
six
percent
patient
male
motorcycl
trishaw
affect
given
patient
limb
head
affect
area
bodi
blood
transfus
rta
victim
male
patient
sustain
grievou
injuri
blood
transfus
victim
blood
transfus
victim
categor
fatal
ordinari
caus
natur
necessarili
fatal
patient
howev
none
victim
sustain
injuri
transfus
seventeen
red
cell
concentr
pack
issu
patient
none
gone
massiv
transfus
protocol
summaryconclus
per
studi
blood
transfus
road
traffic
accid
victim
patient
sustain
grievou
injuri
blood
transfus
victim
among
victim
sustain
fatal
ordinari
caus
natur
necessarili
fatal
injuri
respect
f
n
j
transfus
depart
imperi
colleg
healthcar
nh
trust
london
unit
kingdom
background
st
mari
hospit
becam
major
trauma
centr
sinc
go
live
date
need
satellit
blood
fridg
care
monitor
agre
blood
fridg
requir
remot
blood
fridg
went
live
januari
agre
stock
group
rh
posit
group
rh
neg
unit
howev
group
neg
rbc
usag
remain
constantli
higher
avail
maintain
adequ
suppli
group
rh
neg
unit
emerg
patient
unknown
blood
group
remain
challeng
blood
servic
tri
save
group
rh
neg
unit
review
code
red
demograph
six
month
period
assess
could
reduc
stock
group
neg
unit
satellit
fridg
aim
ensur
appropri
blood
stock
avail
emerg
depart
code
red
trauma
call
method
base
st
mari
major
trauma
registri
data
code
red
call
period
review
identifi
demograph
trauma
victim
cross
examin
data
blood
transfus
laboratori
system
identifi
number
male
femal
trauma
victim
rh
statu
result
sixti
three
code
red
call
code
red
call
male
femal
femal
child
bear
age
femal
subsequ
identifi
rh
posit
major
male
trauma
victim
ie
subsequ
identifi
rh
posit
summaryconclus
risk
give
femal
male
trauma
patient
rh
incompat
unit
low
therefor
plan
reduc
stock
group
rh
neg
unit
unit
increas
group
rh
posit
emerg
stock
unit
bohonek
kutac
markovina
hematolog
blood
transfus
militari
univers
hospit
pragu
pragu
czech
republ
background
massiv
bleed
second
common
caus
death
trauma
patient
main
caus
death
wartim
injuri
death
occur
within
h
treatment
inadequ
fatal
outcom
larg
avoid
appli
damag
control
resuscit
dcr
procedur
reduc
bleed
optim
coagul
includ
surgic
approach
essenti
part
strategi
hemostat
resuscit
implement
transfus
protocol
transfus
whole
blood
activ
care
includ
combat
situat
fire
dcr
concept
modifi
remot
dcr
procedur
rdcr
integr
part
acceler
haemostat
resuscit
blood
far
forward
train
medic
personnel
appli
blood
product
blood
deriv
includ
fresh
whole
blood
collect
walk
blood
bank
name
aim
safe
blood
collect
transfus
walk
blood
bank
necessari
robust
usabl
assay
determin
verifi
blood
group
least
system
particip
member
special
forc
czech
armi
conduct
check
select
blood
group
test
assess
usabl
care
combat
deploy
method
evalu
test
kit
grifol
spain
abtest
diagast
franc
one
man
kit
eldon
card
eldon
denmark
abo
set
mp
exbio
czech
republ
three
cl
specialist
select
train
perform
blood
group
type
use
evalu
examin
examin
blood
sampl
individu
evalu
paramet
test
prepar
time
sec
test
time
sec
total
test
time
sec
readabl
point
worst
best
eas
test
practic
test
point
view
field
use
influenc
environ
perform
read
test
robust
durabl
result
examin
conduct
ground
valu
arithmet
averag
use
compar
individu
experi
result
test
prepar
time
grifol
diagast
eldoncard
exbio
time
type
grifol
diagast
eldoncard
exbio
total
time
grifol
diagast
eldoncard
exbio
readabl
grifol
diagast
eldoncard
exbio
eas
test
grifol
diagast
eldoncard
exbio
practic
grifol
diagast
eldoncard
exbio
influenc
environ
grifol
diagast
eldoncard
exbio
robust
grifol
diagast
eldoncard
exbio
durabl
result
grifol
diagast
eldoncard
exbio
summaryconclus
abtest
diagast
appear
appropri
test
test
best
rate
virtual
paramet
examin
appreci
featur
surprisingli
eldon
card
diagnost
kit
current
widespread
field
trial
nato
coelho
hospit
santa
maria
lisbon
portug
background
pph
lead
caus
death
worldwid
rapid
diagnosi
earli
treatment
critic
pph
defin
blood
loss
ml
within
h
vagin
deliveri
ml
caesarean
deliveri
uterin
atoni
major
caus
pph
caus
includ
surgic
incis
lacer
presenc
coagulopathi
unfortun
although
sever
risk
factor
exist
often
pph
occur
without
warn
aim
control
massiv
post
partum
haemorrhag
use
medic
surgic
strategi
method
woman
year
old
obes
imc
diabet
mellitu
type
week
pregnanc
macrosom
fetu
present
hb
gdl
gdl
pre
caesarean
deliveri
respect
given
oxytocin
bolu
continu
perfus
plu
mg
misoprostol
rectal
two
hour
deliveri
patient
becam
hemodynam
instabl
sever
pph
hb
submit
urgent
treatment
stop
bleed
stepwis
progress
bimanu
uterin
compress
loos
cc
bloodcompress
tranexam
acid
g
min
follow
g
h
replac
blood
compon
rbc
platelet
concentr
unit
fresh
frozen
plasma
clot
factor
g
fibrinogen
prothrombin
complex
concentr
accord
point
care
poc
rotem
result
pph
algorithm
result
surgeri
intervent
need
control
massiv
bleed
hysterectomi
plu
right
adnexectomi
puerpera
transfer
intens
care
unit
next
day
surgic
hemostasi
control
need
g
fc
given
clinic
diagnosi
pph
effect
multidisciplinari
team
manag
involv
commun
resuscit
investig
clinic
laboratori
monitor
treatment
mechan
pharmacolog
transfusion
surgic
measur
use
stop
bleed
summaryconclus
fibrinogen
level
play
main
role
obstetr
bleed
manag
coagulopathi
associ
pph
crucial
transfusion
medicin
base
poc
laboratori
test
ca
coagul
multidisciplinari
team
must
involv
sinc
begin
pph
provid
earli
recognit
correct
diagnosi
treatment
base
pph
algorithm
accord
european
societi
escal
pph
manag
protocol
must
includ
uteroton
drug
surgic
andor
endovascular
intervent
procoagul
drug
k
e
laboratori
medicin
st
michael
hospit
laboratori
medicin
univers
toronto
toronto
canada
medicin
st
michael
hospit
toronto
medicin
st
michael
hospit
toronto
canada
background
cryoprecipit
cryo
transfus
use
treat
bleed
patient
fibrinogen
defici
cryo
indic
bleed
patient
fibrinogen
level
less
gl
unit
cryo
contain
minimum
mg
fibrinogen
unit
cryo
expect
increas
fibrinogen
gl
bleed
adult
aim
cryo
util
increas
year
year
canada
institut
want
assess
use
method
retrospect
review
patient
transfus
cryo
novemb
singl
tertiari
centr
perform
determin
cryo
use
cryo
dose
prepar
thaw
pool
unit
cryo
one
bag
pool
cryo
expir
h
room
temperatur
collect
data
patient
demograph
diagnos
bleed
statu
blood
compon
use
pre
post
fibrinogen
level
result
month
dose
cryo
order
transfus
cryo
dose
use
discard
fibrinogen
gl
cryo
dose
transfus
patient
patient
receiv
cryo
male
femal
male
median
age
yr
femal
median
age
yr
patient
undergo
cardiovascular
surgeri
account
patient
receiv
cryo
trauma
miscellan
diagnos
reason
cryo
transfus
coagulopathi
bleed
transfus
transfus
administ
part
massiv
hemorrhag
protocol
cryo
transfus
pre
transfus
fibrinogen
level
less
gl
patient
receiv
cryo
also
receiv
blood
compon
summaryconclus
cryo
commonli
use
cardiovascular
surgeri
patient
cryo
use
patient
coagulopathi
bleed
appropri
wastag
rate
low
soleimani
amini
control
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
iran
background
clinic
hemostasi
laboratori
complex
test
employ
numer
coagul
assay
span
sever
differ
test
methodolog
activ
factor
coagul
protein
measur
three
method
one
clot
assay
chromogen
assay
ad
complex
test
result
express
wide
varieti
uniqu
unit
time
percentag
aim
factor
viii
activ
individu
mild
hemophilia
regardless
method
employ
howev
approxim
patient
show
mark
discrep
factor
viii
activ
measur
differ
method
method
object
studi
investig
incid
assay
discrep
center
assess
impact
altern
reagent
factor
viii
activ
assay
determin
use
global
assay
hemostasi
mild
hemophilia
citrat
plasma
sampl
vacutain
becton
dickinson
usa
male
seven
femal
carrier
hemophilia
fviii
c
level
iudl
least
one
method
obtain
follow
inform
consent
assay
discrep
defin
greater
differ
result
clot
assay
rotat
thromboelastometri
calibr
autom
thrombographi
perform
result
assay
discrep
observ
individu
lower
activ
assay
lower
activ
assay
current
intern
guidelin
defin
type
assay
use
diagnosi
mild
hemophilia
patient
could
misclassifi
normal
studi
patient
would
diagnos
basi
factor
viii
assay
summaryconclus
intern
standard
avail
hemostasi
unfortun
mani
analyt
await
develop
standard
valu
analyt
deriv
local
manufactur
standard
method
introduc
clinic
use
analyt
clinic
perform
must
verifi
standard
oper
paramet
laboratori
laboratori
use
one
stage
chromogen
assay
diagnosi
patient
possibl
hemophilia
use
standard
valid
protocol
refer
interv
determin
help
object
evalu
method
perform
abstract
withdrawn
bb
n
n
mukhiddinov
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
pavlov
first
state
medic
univers
saint
petersburg
russian
feder
postgradu
educ
health
care
republ
tajikistan
institut
postgradu
educ
health
care
dushanb
tajikistan
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
st
petersburg
state
medic
univers
saint
petersburg
russian
feder
background
gastrointestin
gi
bleed
common
caus
emerg
hospit
surgic
depart
reach
overal
hospit
mortal
therapi
acut
massiv
bleed
addit
time
surgic
correct
also
requir
implement
adequ
therapi
itt
pre
postop
period
issu
optim
volum
quantit
qualit
composit
itt
acut
massiv
blood
loss
still
remain
debat
aim
analysi
itt
effect
massiv
gi
bleed
treatment
method
compar
retrospect
analysi
itt
effect
complex
gi
bleed
treatment
perform
patient
admit
surgic
inpati
depart
group
patient
receiv
addit
treatment
conduct
special
intens
care
transfus
team
blood
center
group
ii
age
patient
year
male
femal
determin
blood
loss
amount
perform
ryabov
ga
method
moor
shock
index
statist
process
perform
use
variat
statist
stat
soft
statistica
result
total
volum
blood
loss
patient
group
liter
group
ii
liter
tabl
tabl
compar
characterist
therapi
total
amount
itt
group
ml
blood
loss
volum
group
ii
ml
respect
analysi
qualit
composit
transfus
agent
show
group
ii
patient
receiv
significantli
red
blood
cell
ffp
crystalloid
solut
albumin
share
synthet
colloid
includ
solut
group
total
itt
volum
group
ii
especi
gelatin
deriv
ffp
use
group
group
ii
crystalloid
solut
respect
studi
hemostasi
system
show
develop
hypocoagul
phase
dissemin
intravascular
coagul
syndrom
hemodilut
coagulopathi
mainli
patient
group
group
patient
group
ii
requir
surgic
treatment
patient
die
group
patient
group
ii
summaryconclus
qualit
composit
itt
signific
impact
outcom
treatment
massiv
gi
bleed
itt
includ
predominantli
crystalloid
solut
combin
high
dose
ffp
natur
colloid
solut
ration
effect
compar
scheme
base
use
synthet
colloid
bb
g
gorbacheva
memori
institut
children
oncolog
hematolog
transplant
st
petersburg
state
medic
univers
saint
petersburg
russian
feder
citi
matern
hospit
citi
matern
hospit
dushanb
tajikistan
background
obstetr
bleed
continu
remain
lead
reason
matern
mortal
account
lethal
pregnanc
outcom
hemorrhag
aggrav
coagulopathi
bleed
one
reason
matern
mortal
aim
goal
research
specifi
pathogenet
mechan
hemostasi
disord
infusion
hemodilut
also
provid
characterist
hemocoagul
disturb
method
conduct
retrospect
analysi
investig
data
women
childbirth
bleed
whose
age
rang
year
analyz
condit
hemostasi
system
help
develop
hemostasiogramm
includ
test
character
coagul
link
hemostasi
system
also
anticoagul
fibrinolyt
activ
depend
charact
volem
anomali
parturi
woman
divid
two
group
first
group
includ
parturi
women
indic
defici
circul
blood
volum
mlkg
hb
gl
ht
erythrocyt
gener
fiber
gl
second
group
includ
parturi
women
defici
circul
blood
volum
mlkg
hb
gl
ht
erythrocyt
l
gener
fiber
gl
parturi
women
first
group
subject
therapi
itt
volum
colloid
crystalloid
solut
dextros
fresh
frozen
plasma
ffp
concentr
erythrocyt
total
volum
itt
hemorrhag
volum
parturi
women
second
group
subject
itt
volum
defici
circul
blood
volum
defici
compens
colloid
crystalloid
concentr
erythrocyt
ffp
result
comparison
result
indic
healthi
parturi
women
control
group
n
illustr
decreas
ht
group
accordingli
time
decreas
thrombocyt
time
quantiti
fibrinogen
time
decreas
retract
clot
time
elong
activ
partial
thromboplastin
time
time
augment
mho
irn
declin
quantiti
activ
factor
prothrombin
complex
augment
fibrinolyt
activ
blood
presenc
product
degrad
fibrin
fibrinogen
reveal
result
confirm
connect
decreas
hemostat
potenti
blood
volum
hemorrhag
conduct
itt
promot
develop
hemodilut
hemorrhag
women
group
itt
less
adequ
volum
though
possibl
fulli
correct
hypovolemia
henc
volum
itt
time
volum
volum
circul
blood
defici
qualit
composit
structur
includ
fresh
frozen
plasma
carrier
plasma
procoagul
summaryconclus
volum
itt
parturi
women
group
transfus
without
take
account
defici
circul
blood
volum
also
promot
depress
concentr
activ
plasma
procoagul
number
thrombocyt
promot
develop
hemodilut
coagulopathi
result
bleed
turn
contribut
hemorrhag
k
f
h
r
j
j
p
r
develop
australian
red
cross
blood
servic
kelvin
grove
health
queensland
univers
technolog
care
research
group
princ
charl
hospit
medicin
univers
queensland
servic
intens
care
servic
princ
charl
hospit
brisban
australia
background
transfus
potenti
modul
recipi
immun
profil
contribut
advers
outcom
collect
refer
immunomodul
trim
develop
panel
assay
prospect
assess
impact
transfus
recipi
immun
profil
use
small
blood
volum
align
principl
patient
blood
manag
coronari
arteri
bypass
graft
cabg
patient
select
studi
popul
investig
potenti
mechan
associ
trim
dendrit
cell
dc
monocyt
key
immunoregul
dysfunct
may
contribut
advers
outcom
thu
number
assay
focus
cell
understand
underli
mechan
trim
impact
dc
monocyt
dysfunct
mediat
patient
outcom
follow
limit
aim
develop
panel
assay
prospect
investig
immun
modul
use
ml
blood
assess
immun
profil
admiss
icu
day
day
cabg
patient
investig
advers
patient
outcom
patient
receiv
blood
product
transfus
method
optim
suit
assay
assess
immun
modul
use
ml
blood
quantif
immun
cell
subset
trucount
tube
ii
quantif
dc
activationadhes
marker
trucount
tube
iii
quantif
cytokineschemokin
patient
plasma
cytometr
bead
array
iv
assess
gene
express
total
leucocyt
popul
rna
extract
whole
blood
v
assess
gene
express
isol
myeloid
cell
vi
character
dc
monocyt
activ
inflammatori
respons
use
whole
blood
cultur
model
parallel
lipopolysaccharid
lp
model
bacteri
complic
associ
inflammatori
respons
advers
outcom
prolong
intens
care
unit
icu
length
stay
lo
hr
prolong
ventil
time
vt
hr
overal
patient
cohort
assess
p
impact
dc
monocyt
immun
respons
potenti
advers
outcom
transfus
patient
assess
result
cabg
result
signific
modul
dc
monocyt
immun
respons
evid
immunoparalysi
dc
monocyt
cytokin
dysfunct
associ
prolong
icu
lo
vt
patient
receiv
blood
product
transfus
ie
red
cell
platelet
preliminari
analys
indic
transfus
recipi
like
develop
advers
outcom
prolong
icu
lo
vs
patient
prolong
vt
vs
patient
addit
evid
differenti
immun
respons
day
day
transfus
patient
summaryconclus
success
develop
panel
assay
prospect
investig
impact
transfus
patient
immun
respons
preliminari
data
suggest
transfus
associ
poor
outcom
cabg
patient
saw
evid
modul
dc
monocyt
respons
panel
develop
prospect
assess
chang
immun
profil
cabg
patient
use
clinic
set
character
chang
cellular
level
facilit
improv
understand
process
associ
trim
j
c
c
l
n
r
j
medicin
program
univers
health
network
toronto
medicin
research
institut
clinic
patholog
sunnybrook
health
scienc
centr
health
network
blood
servic
toronto
canada
background
circulatori
overload
taco
increasingli
recogn
caus
signific
morbid
mortal
amongst
particularli
histori
cardiac
renal
diseas
diuret
standard
care
treatment
congest
heart
failur
unclear
whether
safe
effect
prevent
taco
urgent
need
random
control
trial
rct
address
question
aim
determin
whether
rct
furosemid
prevent
taco
patient
feasibl
method
pilot
rct
mg
iv
furosemid
perform
adult
inpati
year
older
schedul
receiv
singl
unit
rbc
regular
work
hour
primari
outcom
time
requir
patient
complet
studi
protocol
secondari
feasibl
outcom
includ
proport
rbc
transfus
meet
elig
criteria
target
proport
elig
patient
enrol
target
proport
elig
patient
compli
studi
protocol
goal
clinic
outcom
measur
includ
incid
taco
use
standard
definit
criteria
relat
cardiac
respiratori
complic
incid
hyponatremia
hypokalemia
hypotens
acut
renal
injuri
result
nearli
month
enrol
requir
patient
complet
studi
protocol
result
fewer
transfus
expect
meet
elig
criteria
analyz
elig
patient
consent
particip
protocol
complianc
achiev
target
primarili
due
miss
chart
document
caregiv
blind
maintain
studi
data
analysi
enrol
patient
admit
hematolog
malign
enrolle
histori
cardiac
diseas
renal
impair
prescrib
chronic
diuret
treatment
arm
regard
patient
characterist
transfus
therapi
singl
case
taco
occur
arm
studi
overal
incid
ci
although
volum
statu
chest
imag
consist
perform
patient
differ
observ
chang
vital
sign
peptid
differ
cardiac
respiratori
complic
observ
trend
toward
decreas
mortal
patient
random
furosemid
v
p
achiev
statist
signific
extend
hospit
vs
p
differ
treatment
arm
observ
regard
hyponatremia
hypokalemia
hypotens
renal
injuri
summaryconclus
pilot
protocol
diuresi
prevent
taco
requir
modif
achiev
target
feasibl
outcom
larger
rct
perform
dose
furosemid
studi
appear
safe
may
associ
improv
clinic
outcom
p
r
n
n
medicin
univers
hamilton
canada
background
acquir
red
cell
alloantibodi
abil
caus
sever
hemolyt
diseas
fetu
newborn
hdfn
fetal
death
previou
studi
report
antibodi
detect
pregnanc
may
relat
red
blood
cell
rbc
transfus
thu
provis
k
neg
unit
women
current
futur
child
bear
potenti
standard
care
mani
european
countri
howev
practic
mandat
canada
unit
state
multin
retrospect
studi
evalu
women
neonat
suffer
sever
hdfn
report
alloantibodi
attribut
transfus
delaney
et
al
find
rais
question
around
impact
transfus
caus
k
alloimmun
furthermor
previou
studi
limit
obstetr
popul
incid
alloimmun
pediatr
popul
remain
unknown
aim
establish
frequenc
rbc
transfus
femal
current
futur
child
bear
potenti
antibodi
method
retrospect
cohort
studi
span
jan
jun
hamilton
ontario
canada
blood
provid
patient
institut
except
includ
patient
histori
k
alloimmun
sickl
cell
patient
femal
current
futur
child
bear
potenti
age
studi
period
antibodi
document
studi
period
review
data
obtain
via
transfus
registri
util
surveil
track
trust
databas
comprehens
databas
contain
blood
product
inform
transfus
patient
demograph
clinic
inform
hospit
patient
result
jan
jun
total
unit
rbc
transfus
institut
rbc
transfus
unit
transfus
femal
age
median
unit
iqr
per
patient
unit
transfus
pediatr
patient
age
transfus
adult
patient
age
group
screen
avail
follow
rbc
unit
transfus
femal
age
studi
period
total
femal
detect
previous
detect
antibodi
median
age
time
antibodi
detect
iqr
patient
younger
age
time
initi
antibodi
detect
alloimmun
patient
least
one
iqr
rbc
transfus
preced
antibodi
detect
summaryconclus
rbc
transfus
preced
k
alloimmun
femal
antibodi
chart
review
patient
underway
transfus
servic
without
polici
provid
unit
femal
childbear
potenti
consid
clinic
impact
practic
monitor
k
alloimmun
post
transfus
v
h
el
brugmann
brussel
belgium
pari
franc
background
mta
antigen
mn
system
rare
case
haemolyt
diseas
foetu
newborn
hdfn
caus
report
literatur
antibodi
never
associ
haemolyt
transfus
reaction
htr
acut
htr
suspect
patient
congoles
origin
sickl
cell
diseas
hbss
undergo
exchang
transfus
four
red
blood
cell
rbc
unit
prior
surgeri
aim
report
first
htr
caus
method
pretransfus
test
includ
abo
rh
kell
type
well
antibodi
screen
test
indirect
antiglobulin
test
iat
column
agglutin
techniqu
posttransfus
sampl
collect
test
use
direct
antiglobulin
test
dat
transfus
rbc
unit
crossmatch
patient
plasma
reagent
use
antibodi
identif
test
mta
wra
phenotyp
result
shortli
start
transfus
third
pack
rbc
unit
patient
develop
shiver
nausea
dyspnea
pain
lower
limb
laboratori
paramet
show
sign
increas
haemolysi
posit
crossmatch
one
pack
rbc
unit
spite
neg
pretransfus
antibodi
screen
test
suggest
presenc
antibodi
antigen
posttransfus
dat
neg
antibodi
identif
show
patient
rbc
phenotyp
wr
mt
donor
rbc
found
wr
mt
summaryconclus
like
caus
transfus
reaction
experienc
patient
neg
dat
might
explain
rapid
destruct
transfus
mt
rbc
case
hdfn
caus
publish
earlier
first
report
htr
case
highlight
inabl
antibodi
screen
test
detect
antibodi
antigen
like
routin
perform
full
crossmatch
test
patient
sickl
cell
diseas
receiv
multipl
transfus
even
presenc
neg
antibodi
screen
test
might
add
safeti
transfus
manag
patient
p
w
g
research
institut
versitibloodcent
wisconsin
patholog
medic
colleg
wisconsin
refer
laboratori
versitibloodcent
wisconsin
milwauke
unit
state
america
background
transfus
low
titer
group
whole
blood
emerg
situat
plasmaapheresi
platelet
product
becom
accept
clinic
practic
despit
provis
appar
low
isohemagglutinin
titer
product
unforeseen
advers
hemolyt
event
observ
transfus
recipi
vitro
monocyt
monolay
assay
establish
test
method
predict
clinic
signific
red
blood
cell
rbc
antibodi
measur
monocyt
mediat
phagocytosi
rbc
monocyt
phagocytos
sensit
rbc
via
complement
receptor
develop
monocyt
suspens
assay
msa
assess
abo
antibodi
aim
evalu
abil
msa
detect
signific
monocyt
phagocytosi
evalu
monocyt
phagocytosi
rbc
sensit
igg
hemolysin
activ
alon
combin
fresh
serum
sourc
complement
method
monocyt
isol
acd
blood
healthi
donor
densiti
gradient
centrifug
purifi
use
posit
select
suspens
rhd
rbc
label
label
rbc
sensit
follow
sensit
rbc
ii
plu
murin
monoclon
igm
titer
fresh
individu
group
serum
n
sourc
complement
iii
group
serum
sampl
n
hemolysin
titer
use
sensit
rbc
titer
without
fresh
pool
sera
sourc
complement
phagocytosi
perform
sensit
rbc
monocyt
min
rbc
lyse
use
cold
flow
cytometri
perform
fluoresc
channel
nm
record
phagocytosi
confirm
inhibit
ivig
result
phagocytosi
proport
densiti
rhd
rbc
singl
sourc
monocyt
maximum
phagocytosi
independ
experi
inhibit
phagocytosi
ivig
achiev
n
rbc
complement
activ
use
igm
alon
show
phagocytosi
n
increas
phagocytosi
observ
plu
igm
complement
sensit
vs
alon
complement
hemagglutin
correl
percent
increas
phagocytosi
igg
hemolysin
sera
show
signific
phagocytosi
absenc
complement
activ
fold
increas
phagocytosi
upon
complement
activ
observ
igg
hemolysin
sera
summaryconclus
valid
monocyt
phagocytosi
assay
use
monocyt
suspens
msa
msa
detect
mediat
phagocytosi
manner
msa
could
use
assess
biolog
signific
whole
blood
plasmaapheresi
platelet
product
use
incompat
transfus
jl
r
r
c
j
l
r
h
c
medicin
pathobiolog
univers
toronto
lab
med
molecular
diagnost
sunnybrook
health
scienc
centr
medicin
univers
toronto
health
network
critic
care
sunnybrook
health
scienc
centr
blood
servic
roger
centr
excel
heart
function
univers
health
network
toronto
canada
background
circulatori
overload
taco
lead
caus
seriou
reaction
littl
known
regard
valu
cardiac
biomark
predictor
taco
differenti
taco
dyspneic
reaction
optim
timingthreshold
although
elev
level
cardiac
biomark
includ
diagnost
criteria
taco
guidanc
time
measur
threshold
provid
aim
prospect
evalu
kinet
cardiac
biomark
h
method
prospect
observ
studi
inpati
higher
risk
taco
receiv
red
cell
unit
cardiac
biomark
brain
natriuret
peptid
bnp
high
sensit
troponin
measur
baselin
h
except
troponin
h
primari
outcom
critic
rise
biomark
rise
exceed
threshold
h
result
patient
analyz
cardiovascular
diseas
cardiac
risk
factor
took
cardiacantihypertens
therapi
reaction
met
guidelin
observ
develop
rise
systol
pressur
mmhg
report
dyspneacough
baselin
bnp
level
ngl
pgml
critic
rise
biomark
common
h
overal
least
one
bnp
concord
highest
biomark
yield
fold
rise
pgml
h
critic
rise
h
associ
elev
systol
blood
pressur
transfus
patient
elev
bnp
vs
patient
without
elev
rise
blood
pressur
summaryconclus
higher
risk
patient
taco
baselin
elev
biomark
common
critic
rise
occur
third
optim
measur
interv
surrog
marker
taco
h
larger
studi
need
clarifi
risk
taco
given
biomark
profil
correl
taco
rise
biomark
r
h
z
b
r
j
silver
spring
llc
burlingam
baltimor
unit
state
america
background
circulatori
overload
taco
seriou
complic
account
signific
transfus
morbid
mortal
us
aim
assess
taco
occurr
potenti
risk
factor
us
elderli
transfus
inpati
set
studi
period
method
retrospect
studi
util
larg
medicar
databas
januari
april
blood
transfus
identifi
record
procedur
revenu
center
code
taco
ascertain
record
diagnosi
code
diagnosi
code
studi
evalu
taco
rate
per
inpati
transfus
stay
among
elderli
overal
calendar
year
age
sex
race
blood
compon
number
unit
transfus
fisher
exact
test
perform
compar
taco
rate
test
use
ascertain
trend
calendar
year
age
transfus
volum
result
inpati
transfus
stay
elderli
medicar
beneficiari
taco
record
overal
rate
per
stay
annual
taco
rate
studi
period
respect
p
taco
rate
number
unit
transfus
unit
unit
unit
unit
p
taco
rate
blood
compon
group
rbc
plasma
platelet
platelet
plasma
rbc
plasma
rbc
platelet
rbc
plasma
platelet
rate
age
categori
respect
p
femal
male
taco
rate
p
white
rate
p
summaryconclus
studi
taco
occurr
among
us
elderli
medicar
beneficiari
show
significantli
increas
taco
occurr
trend
time
greater
number
unit
transfus
advanc
age
studi
suggest
higher
taco
risk
stay
rbc
transfus
either
alon
combin
platelet
andor
plasma
find
also
suggest
significantli
increas
taco
risk
femal
white
need
confirm
studi
base
claim
data
thu
limit
includ
potenti
transfus
procedur
number
unit
well
lack
clinic
detail
valid
record
taco
diagnosi
r
jug
comb
n
bandarenko
j
poisson
patholog
duke
health
durham
unit
state
america
background
femal
neg
red
cell
antibodi
screen
absc
develop
new
red
cell
antibodi
post
compat
cadaver
liver
transplant
steatohepat
receiv
unit
red
blood
cell
rbc
unit
rbc
day
pod
issu
hemoglobin
hgb
level
drop
gdl
pod
gdl
pod
prompt
transfus
rbc
unit
crossmatch
xm
compat
recent
type
screen
sampl
blood
infus
new
receiv
reveal
posit
absc
new
result
transfus
discontinu
immedi
patient
asymptomat
pre
direct
antiglobulin
test
dat
posit
pod
aim
determin
clinic
signific
sourc
new
method
patient
dat
hemolysi
marker
eg
total
bilirubin
tb
lactat
dehydrogenas
ldh
test
antibodi
elut
rbc
perform
use
hemobiosci
eluclear
elut
kit
eluat
test
peg
indirect
antiglobulin
test
patient
predict
phenotyp
determin
use
molecular
microarray
human
erythrocyt
antigen
beadchiptm
bioarray
solut
lymphoid
microchimer
assay
conduct
use
polymeras
chain
reaction
mediat
amplif
subsequ
size
analysi
short
tandem
repeat
determin
peripher
blood
recipi
andor
donor
cell
composit
result
dat
neg
pod
dat
polyspecif
rang
igg
rbc
elut
demonstr
blood
sampl
recipi
demonstr
jk
phenotyp
detect
organ
donor
plasma
urinalysi
show
bilirubin
serum
tb
mgdl
n
mgdl
ldh
elev
ul
n
ul
lymphoid
microchimer
perform
pod
detect
peripher
whole
blood
fraction
two
month
later
dat
remain
posit
polyspecif
igg
w
w
w
weak
rbc
elut
demonstr
ldh
remain
elev
ul
hgb
gdl
tb
normal
mgdl
summaryconclus
serolog
evid
hemolysi
along
patient
clinic
cours
consist
hemolyt
transfus
reaction
due
passeng
lymphocyt
syndrom
pl
mediat
donor
lymphocyt
deriv
first
report
pl
liver
transplant
recipi
involv
kidd
blood
group
system
presenc
organ
donor
follow
detect
jk
antigen
posit
recipi
suggest
donor
deriv
lymphocyt
antibodi
product
lymphoid
pcr
microchimer
analysi
howev
detect
donor
lymphocyt
circul
patient
blood
poor
insuffici
dna
qualityquant
may
relat
delay
sampl
collect
follow
multipl
transfus
two
month
patient
hgb
remain
stabl
gdl
despit
persist
donor
deriv
elut
g
g
rutledg
laboratori
medicin
medicin
royal
univers
hospit
saskatoon
blood
servic
edmonton
canada
background
administr
polyclon
product
rh
immun
globulin
rhig
part
routin
care
perinat
set
prevent
matern
rh
alloimmun
signific
advers
reaction
rhig
rare
aim
report
case
repeat
grade
allerg
reaction
follow
perinat
administr
rhig
group
rh
neg
caucasian
woman
second
pregnanc
allergi
histori
unev
transfus
histori
includ
routin
rhig
prophylaxi
via
intramuscular
inject
first
pregnanc
one
unit
red
blood
cell
follow
hemorrhag
method
retrospect
chart
review
undertaken
rhig
product
administ
aptevo
biotherapeut
llc
usa
differ
lot
number
product
administ
exposur
result
woman
present
hospit
dehydr
sever
gastroenter
week
gestat
age
follow
clinic
stabilis
intraven
iv
fluid
support
note
yet
receiv
rhig
pregnanc
normal
vital
sign
record
standard
dose
iu
administ
iv
push
within
second
patient
describ
symptom
chest
constrict
dyspnea
flush
lightheaded
vital
sign
abnorm
record
two
minut
administr
includ
mark
tachypnea
hypoxemia
room
air
blood
pressur
heart
rate
normal
fetal
bradycardia
document
event
stabil
within
minut
appli
oxygen
administr
antihistamin
steroid
medic
epinephrin
requir
result
investig
done
eight
week
follow
acut
allerg
reaction
includ
normal
serum
iga
haptoglobin
level
allergi
prick
test
undilut
intraderm
test
yield
reaction
neonat
cord
blood
test
confirm
rh
posit
babi
accord
plan
protocol
receiv
antihistamin
follow
iv
infus
iu
h
observ
infus
period
unev
howev
min
infus
end
patient
develop
throat
scratchi
promin
swell
face
hand
iv
steroid
administ
immedi
caus
symptom
resolv
within
hour
associ
hypotens
hypoxemia
document
summaryconclus
knowledg
first
case
repeat
rhig
reaction
publish
grade
allerg
reaction
report
manufactur
ultim
conclud
identifi
caus
reaction
potenti
explan
repeat
reactiv
may
includ
idiosyncrat
reaction
unknown
etiolog
recipi
presenc
rare
protein
defici
complimentari
antibodi
yet
identifi
unexplain
reaction
compon
addit
within
strategi
minim
futur
rhig
reaction
includ
use
product
differ
manufactur
antihistamin
steroid
medic
plu
applic
iv
infus
protocol
close
observ
hospit
set
final
confirm
rh
neg
fetal
statu
method
antenat
may
elimin
need
rhig
administr
altogeth
e
j
r
welsh
blood
servic
pontyclun
cwm
taf
univers
health
board
llantris
welsh
blood
servic
pontyclun
unit
kingdom
background
post
transfus
purpura
ptp
rare
complic
blood
transfus
characteris
sever
thrombocytopenia
refractori
platelet
transfus
ptp
usual
occur
day
blood
transfus
due
presenc
alloantibodi
human
platelet
antigen
hpa
immun
thrombocytopen
purpura
itp
common
autoimmun
condit
irrelev
blood
transfus
due
abnorm
autoantibodi
specif
platelet
membran
glycoprotein
aim
present
new
case
ptp
patient
background
chronic
thrombocytopenia
due
itp
awar
publish
report
ptp
diagnos
patient
itp
furthermor
review
anoth
ptp
case
new
diagnosi
itp
made
week
treatment
ptp
method
multipar
femal
admit
abdomin
pain
acut
rectal
bleed
clopidogrel
urgent
endoscopi
confirm
duoden
ulcer
oesophag
admiss
gl
transfus
two
unit
red
cell
two
unit
platelet
poor
increment
platelet
transfus
consid
histori
chronic
mild
thrombocytopenia
deem
due
itp
patient
day
discharg
episod
abdomin
pain
dark
stool
purpura
leg
fbc
day
post
transfus
blood
product
first
stay
hospit
confirm
platelet
result
admiss
differenti
diagnosi
ptp
acut
chronic
itp
made
consid
possibl
gi
bleed
transfus
anoth
two
unit
platelet
also
receiv
ivig
respons
therefor
offer
methyl
prednisolon
x
bone
marrow
examin
show
dysplasia
primari
bone
marrow
chang
keep
consumpt
thrombocytopenia
also
ct
scan
rule
splenomegali
serolog
investig
confirm
presenc
alloantibodi
diagnosi
ptp
receiv
two
unit
platelet
good
increment
also
receiv
anoth
dose
ivig
despit
drop
platelet
count
discharg
gradual
increas
platelet
count
four
week
last
treatment
summaryconclus
base
literatur
review
case
confirm
ptp
case
prior
histori
itp
awar
anoth
case
itp
diagnos
week
diagnosi
ptp
femal
multipl
injuri
follow
road
traffic
accid
receiv
sever
blood
compon
normal
platelet
count
admiss
drop
day
post
transfus
extens
mucocutan
bleed
symptom
increment
platelet
transfus
also
receiv
ivig
littl
clinic
benefit
serolog
investig
confirm
alloantibodi
treat
plasma
exchang
x
three
day
dose
ivig
platelet
count
rose
one
month
later
howev
platelet
count
investig
confirm
diagnosi
itp
report
associ
hpa
polymorph
chronic
itp
addit
least
one
publish
report
concomit
diagnosi
ptp
heparin
induc
thrombocytopenia
hit
anoth
immun
thrombocytopenia
possibl
common
immunolog
suscept
among
patient
acquir
immun
thrombocytopenia
r
h
z
r
b
j
silver
spring
llc
burlingam
baltimor
unit
state
america
background
acut
lung
injuri
trali
seriou
complic
account
signific
transfus
morbid
mortal
us
aim
assess
trali
occurr
potenti
risk
factor
us
elderli
transfus
inpati
set
studi
period
method
retrospect
studi
util
larg
medicar
databas
januari
studi
period
blood
transfus
identifi
record
procedur
revenu
center
code
wherea
trali
ascertain
via
diagnosi
code
diagnosi
code
studi
evalu
trali
rate
per
inpati
transfus
stay
among
elderli
overal
calendar
year
age
sex
race
blood
compon
number
unit
transfus
fisher
exact
test
perform
compar
trali
rate
test
use
detect
trend
calendar
year
age
transfus
volum
result
inpati
transfus
stay
elderli
medicar
beneficiari
trali
record
overal
rate
per
stay
annual
trali
rate
respect
p
trali
rate
number
unit
transfus
unit
unit
unit
unit
p
trali
rate
blood
compon
group
rbc
plasma
platelet
platelet
plasma
rbc
plasma
rbc
platelet
rbc
plasma
platelet
rate
age
categori
respect
p
femal
male
trali
rate
white
rate
p
respect
summaryconclus
studi
trali
occurr
among
us
elderli
show
significantli
increas
trali
occurr
trend
time
greater
number
unit
transfus
contrast
signific
declin
trali
risk
identifi
older
age
studi
also
suggest
increas
trali
risk
platelet
transfus
especi
combin
rbc
andor
plasma
well
possibl
effect
sex
race
need
investig
studi
base
claim
data
thu
limit
includ
potenti
transfus
procedur
number
unit
well
lack
clinic
detail
valid
record
trali
abstract
withdrawn
h
b
z
r
j
r
silver
spring
llc
burlingam
baltimor
unit
state
america
background
blood
transfus
may
increas
risk
seriou
thrombot
event
te
result
death
knowledg
recent
publish
studi
evalu
potenti
te
among
us
elderli
aim
object
studi
assess
te
occurr
potenti
risk
factor
among
elderli
medicar
beneficiari
age
older
transfus
inpati
set
method
retrospect
evalu
util
larg
medicar
administr
databas
januari
septemb
period
coordin
center
medicar
medicaid
servic
inpati
blood
transfus
stay
identifi
procedur
revenu
center
code
te
present
hospit
admiss
ascertain
via
diagnosi
code
record
inpati
transfus
stay
studi
evalu
te
rate
per
inpati
transfus
stay
among
elderli
medicar
beneficiari
overal
age
gender
race
blood
compon
number
unit
transfus
studi
use
test
compar
te
rate
test
assess
te
occurr
trend
calendar
year
age
number
unit
transfus
result
among
inpati
transfus
stay
elderli
beneficiari
te
diagnosi
code
record
overal
rate
per
stay
arteri
te
rate
venou
te
rate
type
te
record
rate
overal
mortal
annual
te
rate
per
p
te
rate
blood
compon
group
rbc
plasma
platelet
platelet
plasma
rbc
plasma
rbc
platelet
rbc
plasma
platelet
te
rate
age
categori
respect
p
femal
male
te
rate
p
white
te
rate
p
respect
te
rate
number
unit
transfus
unit
unit
unit
unit
p
summaryconclus
overal
larg
investig
show
among
transfus
inpati
elderli
te
rate
vari
calendar
year
demograph
blood
compon
number
unit
transfus
studi
suggest
potenti
increas
te
occurr
trend
time
greater
number
unit
transfus
find
also
suggest
higher
te
rate
stay
platelet
transfus
combin
plasma
andor
rbc
well
higher
te
risk
male
vs
femal
vs
white
te
rate
also
significantli
chang
advanc
age
need
investig
studi
limit
includ
potenti
misrecord
transfus
procedur
unit
diagnosi
code
well
lack
clinic
detail
valid
te
futur
investig
need
evalu
underli
risk
factor
te
occurr
j
k
j
g
e
j
r
p
g
k
c
n
n
biolog
evalu
research
offic
biostatist
epidemiolog
us
food
drug
administr
silver
spring
univers
stanford
institut
indianapoli
univers
health
data
scienc
informat
new
york
data
servic
cambridg
durham
unit
state
america
background
us
fda
center
biolog
evalu
research
cber
regul
whole
blood
blood
compon
use
transfus
among
biolog
one
cber
goal
protect
blood
recipi
monitor
advers
event
ae
lead
need
build
nation
hemovigil
system
cber
recent
establish
biolog
effect
safeti
best
initi
compon
cber
sentinel
program
best
initi
distribut
network
data
provid
appli
common
data
model
cdm
util
claim
electron
health
record
ehr
data
sourc
captur
health
care
exposur
treatment
outcom
data
detail
blood
product
data
includ
inform
standard
blood
transplant
isbt
code
system
code
add
specif
granular
surveil
blood
product
code
system
lack
aim
aim
studi
build
infrastructur
nation
hemovigil
system
use
ehr
data
sourc
monitor
ae
incorpor
code
system
observ
medic
outcom
partnership
omop
common
data
model
cdm
observ
health
data
scienc
informat
ohdsi
consortium
method
explor
three
best
ehr
databas
cover
approxim
million
patient
record
geograph
divers
area
us
ad
librari
code
omop
cdm
determin
type
frequenc
code
use
patient
record
within
blood
bank
particip
independ
ehr
data
provid
particip
best
initi
identifi
addit
blood
blood
compon
also
explor
map
standard
term
use
blood
bank
prior
code
result
f
three
ehr
data
provid
two
complet
review
databas
site
b
code
two
site
consist
use
approxim
code
among
million
databas
million
databas
b
patient
record
frequenc
util
code
respect
commonli
use
code
red
blood
cell
leukocyt
reduc
irradi
red
blood
cell
leukocyt
reduc
within
ehr
databas
account
code
compar
less
within
ehr
databas
b
frequent
code
use
within
ehr
databas
b
account
code
compar
within
ehr
databas
red
blood
cell
account
blood
compon
use
databas
b
respect
follow
plasma
platelet
summaryconclus
incorpor
code
omop
cdm
further
cber
capabl
monitor
frequenc
transfus
ae
demonstr
code
captur
within
best
ehr
databas
addit
code
critic
part
hemovigil
infrastructur
afford
fda
abil
conduct
activ
monitor
ae
gr
safeti
jeevan
jyoti
blood
bank
compon
nagpur
medicin
max
super
special
hospit
new
delhi
india
background
transfus
multistep
multidisciplinari
process
often
subject
human
error
wrong
blood
tube
wbit
failur
identifi
recipi
transfus
lead
devast
consequ
abo
incompat
transfus
latest
seriou
hazard
transfus
shot
report
mention
wbit
frequent
error
near
miss
caus
three
incorrect
blood
transfus
ibct
even
without
patient
harm
time
effort
requir
investig
issu
patient
inconvenienc
sampl
delay
transfus
aim
use
novel
intervent
haemovigil
softwar
electron
driven
system
prevent
wbitissu
incorrect
componentsincorrectno
patient
identif
bedsid
method
haemovigil
compris
haemovigil
wristband
recipi
consist
uniqu
number
label
encrypt
alphabet
code
affix
specimen
tube
phlebotomi
haemovigil
softwar
blood
bank
decrypt
alphabet
code
label
specimen
tube
gener
number
haemovigil
wristband
digit
transport
insul
box
digit
lock
lockabl
enter
number
gener
softwar
open
number
present
recipi
haemovigil
wristband
analys
data
one
year
assess
number
transfus
error
preventeddetect
haemovigil
result
patient
provid
wristband
compon
transfus
patient
four
error
detectedprev
haemovigil
one
case
wbit
sampl
collect
patient
nt
intend
recipi
time
transfus
digit
transport
open
haemovigil
system
confirm
sampl
drawn
wrong
patient
one
case
wrong
requisitionord
form
sampl
collect
correct
patient
requisit
form
anoth
patient
error
note
sampl
receiv
window
blood
bank
even
overlook
haemovigil
system
would
prevent
access
blood
compon
bedsid
sinc
unit
would
gone
recipi
whose
form
sent
digit
lock
would
patient
whose
sampl
sent
one
instanc
haemovigil
wristband
remov
final
bedsid
identif
could
nt
done
compon
access
one
case
wrong
compon
requisit
patient
reserv
requisit
plasma
issu
form
platelet
sinc
haemovigil
softwar
store
reserv
compon
data
nt
allow
issu
blood
compon
summaryconclus
shot
identifi
nine
critic
step
transfus
process
sampl
collect
patient
identif
crucial
haemovigil
cover
step
deviat
lead
inabl
access
blood
compon
line
flow
transfus
process
haemovigil
ensur
necessari
label
patient
specimen
bedsid
blood
bank
correct
compon
issu
final
bedsid
haemovigil
reinforc
final
patient
identif
access
blood
compon
haemovigil
cost
effect
simpl
intervent
prevent
wbit
incorrect
blood
compon
issu
patient
prior
transfus
g
kaur
g
kaur
p
kaur
transfus
medicin
govern
medic
colleg
hospit
chandigarh
india
background
transfus
servic
aim
provid
facil
minimum
risk
recipi
howev
wide
rang
error
rang
event
error
lead
patient
injuri
even
mortal
may
occur
variou
step
transfus
process
aim
identifi
natur
caus
error
process
blood
transfus
method
prospect
analyt
studi
conduct
depart
transfus
medicin
tertiari
care
hospit
north
india
period
month
error
occur
blood
transfus
process
donor
phlebotomi
till
transfus
blood
compon
patient
ie
vein
vein
report
analyz
event
caus
calcul
percentag
frequenc
proport
risk
assess
index
rai
calcul
error
multipl
quantifi
estim
sever
actual
potenti
harm
patient
quantifi
estim
probabl
event
recur
root
caus
analysi
done
error
rai
result
total
error
report
studi
period
incid
error
occurr
found
blood
compon
issu
maximum
number
error
found
associ
prbc
compon
major
error
found
error
advers
event
respect
phase
associ
major
error
laboratori
found
area
among
transfus
servic
maximum
error
occur
serolog
laboratori
among
ward
major
error
occur
emerg
ward
maximum
error
report
occur
even
shift
personnel
involv
blood
transfus
chain
doctor
involv
major
error
incorrect
unit
issu
case
administr
incorrect
unit
surpass
check
implement
blood
transfus
process
ensur
patient
safeti
detect
case
wherea
plan
unplan
recoveri
occur
point
rest
case
total
error
high
error
low
risk
error
rai
maximum
error
discov
laboratori
major
error
discov
morn
shift
doctor
involv
discoveri
utmost
number
error
blood
bag
label
error
found
overal
common
error
categor
classif
well
common
type
amongst
error
due
transfus
servic
patient
request
patient
sampl
collect
found
second
third
common
error
collect
form
common
type
amongst
bedsid
error
blood
bag
label
incorrect
unit
issuanc
commonli
occur
error
phase
respect
summaryconclus
human
error
indispens
part
process
found
occur
whenev
whomsoev
potenti
occurr
strict
adher
department
standard
oper
procedur
sop
mandatori
clinic
staff
need
undergo
formal
train
phlebotomi
procedur
function
hospit
transfus
committe
address
error
prone
area
suggest
remedi
measur
prevent
occurr
advers
event
c
h
g
l
p
e
b
c
c
e
r
g
c
l
j
matter
stir
expert
group
depart
health
human
servic
australian
red
cross
blood
servic
melbourn
servic
research
australian
red
cross
blood
servic
queensland
australia
background
seriou
transfus
incid
report
stir
program
victoria
australia
collect
inform
transfus
associ
circulatori
overload
taco
sinc
incept
current
stir
receiv
report
four
state
territori
health
servic
regist
initi
taco
report
acut
transfus
reaction
atr
investig
form
implement
electron
report
taco
acut
lung
injuri
trali
separ
onto
new
form
stir
identifi
area
practic
improv
regard
taco
staff
awar
use
risk
assess
tool
use
singl
unit
transfus
polici
aim
describ
stir
work
increas
awar
taco
among
clinic
staff
method
due
concern
recognit
risk
underreport
taco
stir
develop
educ
campaign
regard
taco
risk
factor
prevent
measur
treatment
health
servic
implement
septemb
campaign
resourc
includ
poster
clinic
area
swing
tag
attach
blood
bag
inform
sheet
blood
fridg
inform
base
taco
checklist
uk
seriou
hazard
transfus
annual
report
tag
sent
health
servic
along
poster
inform
use
tag
sent
directli
patholog
provid
transfus
nurs
tn
equival
inform
support
campaign
result
taco
notif
stir
alway
low
averag
per
year
rang
howev
sever
rate
high
sever
rate
event
result
temporari
loss
function
unrel
natur
cours
patient
ill
differ
expect
outcom
care
although
death
describ
increas
report
taco
correl
increas
number
health
servic
regist
rather
move
report
gener
atr
form
specif
tralitaco
form
regular
recommend
annual
report
period
prior
campaign
notif
period
follow
campaign
notif
chang
regist
health
servic
feedback
educ
campaign
posit
sever
health
servic
request
addit
tag
survey
tn
demonstr
major
particip
would
campaign
use
rais
awar
taco
health
servic
outsid
campaign
area
request
tag
use
support
materi
made
avail
blood
matter
websit
summaryconclus
time
allow
full
evalu
campaign
impact
slight
increas
report
howev
difficult
determin
due
campaign
normal
fluctuat
addit
chang
report
may
reflect
increas
recognit
taco
increas
report
improv
clinic
care
risk
decreas
report
awar
campaign
describ
help
educ
clinic
staff
assist
improv
care
requir
transfus
risk
volum
overload
k
j
j
g
e
j
r
p
g
k
e
c
n
n
biolog
evalu
research
food
drug
administr
silver
spring
univers
stanford
institut
indianapoli
univers
also
observ
health
data
scienc
informat
ohdsi
new
york
data
servic
inc
cambridg
durham
unit
state
america
background
blood
transfus
associ
immunolog
eg
alloimmun
eg
bacteri
sepsi
circulatori
overload
complic
health
insur
claim
administr
bill
electron
health
record
ehr
data
may
provid
rich
data
sourc
support
safeti
monitor
blood
transfus
unit
state
us
multipl
code
system
util
mainli
medic
bill
reimburs
includ
intern
classif
diseas
current
procedur
terminolog
cpt
healthcar
common
procedur
code
system
hcpc
revenu
code
code
system
often
lack
specif
respect
blood
compon
time
administr
howev
rel
new
code
system
use
blood
bank
inform
standard
blood
transplant
isbt
contain
comprehens
granular
blood
blood
compon
data
potenti
use
blood
transfus
hemovigil
aim
describ
abil
variou
code
system
healthcar
data
sourc
captur
blood
transfus
event
complet
specif
compon
type
process
storag
data
associ
transfus
compon
method
data
provid
observ
health
data
scienc
informat
ohdsi
network
enlist
particip
studi
frequenc
cpt
hcpc
code
blood
transfus
specif
inform
relat
transfus
compon
assess
distinct
ohdsi
databas
compris
claim
million
hospit
bill
million
ambulatori
care
million
ehr
million
claim
ehr
million
patient
record
ident
queri
distribut
particip
site
identifi
frequenc
associ
transfus
event
avail
inform
collect
type
blood
compon
eg
red
blood
cell
platelet
plasma
collect
method
whole
blood
donat
apheresi
process
leukocyt
reduc
irradi
wash
deglycerol
storag
thaw
fresh
addit
temperatur
special
test
hla
type
cytomegaloviru
featur
unit
pool
autolog
result
transfus
event
detail
transfus
blood
compon
vari
significantli
across
code
system
hospit
bill
data
sourc
predominantli
captur
blood
transfus
use
code
system
identifi
blood
compon
whole
blood
red
blood
cell
plasma
platelet
attribut
donat
storag
fresh
frozen
red
blood
cell
well
plasma
claim
data
captur
blood
transfus
use
mainli
hcpc
seri
code
includ
inform
relat
blood
compon
collect
process
thaw
fresh
attribut
storag
special
test
cpt
code
least
util
system
record
transfus
event
lack
granular
transfus
blood
product
ehr
data
sourc
util
code
system
along
hcpc
code
claim
hospit
bill
data
sourc
contain
code
summaryconclus
variou
code
system
current
util
us
healthcar
data
sourc
identifi
detail
transfus
event
differ
degre
code
system
better
specif
sensit
use
would
improv
abil
conduct
hemovigil
activ
use
real
world
data
e
klausa
k
smolarczyk
laboratori
depart
region
centr
transfus
medicin
blood
bank
wroclaw
poland
background
red
blood
cell
concentr
rbcc
store
standard
condit
temperatur
day
blood
collect
subject
progress
metabol
biochem
structur
function
chang
may
neg
impact
rbc
viabil
function
transfus
numer
research
paper
publish
cours
last
sever
year
suggest
advers
reaction
short
period
transfus
occur
statist
often
case
rbcc
store
long
period
time
undergon
leucodeplet
research
view
differ
regard
length
period
blood
collect
within
rbc
consid
fresh
argu
day
other
day
rbc
consid
old
day
aim
analyz
number
type
regist
advers
reaction
patient
transfus
rbcc
leucodeplet
rbcc
answer
question
rbc
storag
period
impact
occurr
advers
reaction
method
reaction
regist
amount
circa
rbcc
transfus
analysi
number
reaction
type
depend
rbcc
storag
period
undertaken
four
group
storag
day
number
advers
reaction
transfus
rbcc
vs
leucodeplet
rbcc
compar
result
transfus
rbc
store
day
reaction
allergiesanaphylax
person
fnhtr
taco
tad
unclassifi
pain
nausea
vomit
hypertens
occur
person
includ
rbcc
transfus
day
reaction
allergiesanaphylax
fnhtr
taco
tad
trali
unclassifi
occur
person
includ
rbcc
transfus
day
reaction
allergi
fnhtr
taco
tad
trali
unclassifi
occur
person
includ
rbcc
transfus
day
reaction
allergi
fnhtr
taco
tad
unclassifi
occur
total
person
includ
rbcc
transfus
summaryconclus
analysi
clinic
data
show
number
reaction
twice
higher
case
rbcc
leucodeplet
rbcc
correl
occurr
advers
reaction
rbc
storag
period
base
analyz
data
possibl
conclud
transfus
rbc
store
longer
two
week
describ
old
creat
risk
morbid
mortal
patient
haemovigil
system
qualiti
control
examin
confirm
rbcc
storag
period
safe
extens
storag
period
make
possibl
secur
blood
larger
number
patient
b
g
k
b
u
e
manag
german
red
cross
frankfurt
german
red
cross
manag
german
red
cross
plauen
manag
german
red
cross
ulm
manag
german
red
cross
mannheim
manag
german
red
cross
berlin
manag
german
red
cross
german
red
cross
frankfurt
germani
background
german
red
cross
blood
transfus
servic
respons
blood
product
germani
addit
blood
product
produc
govern
institut
univers
privat
compani
reaction
report
haemovigil
report
transmit
annual
paul
ehrlich
institut
paul
ehrlich
institut
publish
overal
data
germani
haemovigil
report
categor
base
guidelin
intern
hemovigil
network
inh
transfus
reaction
divid
categori
aim
present
studi
hemovigil
data
blood
transfus
servic
hess
blood
transfus
servic
systemat
analyz
year
compar
hemovigil
data
whole
germani
report
paul
ehrlich
institut
method
data
electron
hemovigil
system
german
red
cross
hess
well
german
red
cross
analyz
transfus
reaction
normal
reaction
per
million
blood
transfus
data
compar
hemovigil
data
publish
institut
whole
germani
result
total
blood
transfus
perform
northeast
observ
transfus
reaction
normal
per
million
transfus
fewer
acut
transfus
reaction
blood
transfus
servic
whole
germani
per
million
versu
per
million
contrast
observ
delay
haemolyt
transfus
reaction
whole
germani
per
million
versu
per
million
bacteri
viral
transmiss
occasion
observ
blood
transfus
servic
well
whole
germani
number
sever
transfus
reaction
blood
transfus
servic
compar
number
germani
per
million
versu
per
million
transfus
wrong
blood
compon
observ
haemovigil
system
summaryconclus
hemovigil
data
focus
acut
transfus
reaction
circulatori
overload
taco
sever
transfus
reaction
essenc
result
blood
transfus
servic
compar
german
haemovigil
data
report
pei
thu
data
blood
transfus
servic
interpret
repres
valu
germani
basic
might
bia
seriou
transfus
reaction
report
frequent
minor
transfus
reaction
might
outweigh
haemovigil
report
low
proport
bacteri
viral
transmiss
repres
high
safeti
standard
blood
transfus
servic
caus
transfus
wrong
blood
compon
report
also
explain
fact
test
mandat
germani
addit
electron
patient
identif
system
patient
blood
product
current
undergo
clinic
trial
j
j
assur
viral
marker
director
rckik
w
krakowi
poland
background
requir
system
ensur
effect
commun
center
blood
donat
treatment
hospit
plasma
fraction
look
back
procedur
follow
found
retrospect
donat
exclud
transfus
use
process
unit
collect
donor
subsequ
reject
due
reactiv
viral
marker
risk
behavior
exposur
risk
relat
infecti
diseas
look
back
procedur
reactiv
viral
marker
consist
trace
previou
donat
within
time
period
least
month
prior
last
donat
neg
test
result
aim
studi
perform
evalu
traceabl
relev
suppli
blood
compon
look
back
procedur
year
method
blood
donor
test
donat
antibodi
antibodi
anti
hcv
hb
antigen
nat
nucleic
acid
amplif
technolog
test
hiv
hcv
hbv
test
conduct
tma
cmia
method
depart
viral
marker
transmit
blood
region
center
blood
donat
treatment
cracow
confirmatori
test
made
refer
laboratori
institut
hematolog
blood
transfus
warsaw
look
back
procedur
compon
blood
taken
within
month
back
last
donat
neg
result
conduct
notif
clinic
recipi
blood
compon
sent
order
confirm
rule
infect
recipi
factori
plasma
suppli
notifi
result
number
detect
infect
repeat
regular
donor
year
type
number
blood
compon
procedur
red
blood
cell
fresh
frozen
platelet
use
blood
compon
design
patient
screen
infecti
diseas
hbv
hcv
hiv
respect
result
neg
patient
screen
death
answer
result
hospit
patient
exampl
possibl
contact
patient
summaryconclus
transmiss
viral
infect
recipi
diagnost
window
studi
case
l
l
n
transfus
research
centr
high
institut
research
educ
transfus
medicin
univers
medic
scienc
anesthesiolog
depart
shiraz
medic
univers
shiraz
iran
background
role
blood
transfus
fulli
recogn
howev
may
associ
advers
reaction
hemovigil
program
systemat
surveil
advers
transfus
reaction
improv
qualiti
safeti
blood
transfus
evalu
frequenc
acut
advers
transfus
reaction
atr
blood
recipi
help
us
understand
magnitud
atr
evalu
current
report
system
prevent
recurr
atr
recogn
caus
aim
studi
aim
estim
advers
transfus
reaction
atr
blood
recipi
plan
effect
hemovigil
program
reduc
incid
recurr
rate
atr
make
blood
transfus
process
safe
possibl
method
cross
studi
conduct
hospit
shiraz
iran
march
sep
hemovigil
system
launch
gradual
everi
transfus
reaction
must
report
even
mild
one
via
standard
form
complet
deliv
blood
transfus
servic
accord
iran
hemovigil
guidelin
advers
transfus
reaction
must
report
mandatori
even
mild
one
via
standard
form
complet
deliv
blood
transfus
servic
demograph
characterist
clinic
sign
symptom
type
atr
survey
frequenc
atr
thalassemia
patient
also
thereaft
incid
atr
calcul
result
incid
atr
studi
period
respect
incid
rate
atr
seen
increas
establish
hemovigil
system
frequent
atr
allerg
febril
non
hemolyt
reaction
fnhtr
frequent
symptom
chill
fever
itch
rash
urticaria
type
blood
product
result
transfus
reaction
pack
red
blood
cell
platelet
fresh
frozen
plasma
incid
rate
atr
thalassemia
patient
frequent
atr
among
patient
fnhtr
allerg
reaction
wherea
thalassemia
patient
allerg
reaction
fnthr
summaryconclus
incid
atr
increas
gradual
establish
hemovigil
system
hemovigil
establish
could
enabl
blood
transfus
servic
introduc
measur
would
lead
improv
diagnosi
report
atr
identifi
correct
caus
atr
prevent
futur
recurr
atr
ultim
improv
blood
safeti
abstract
withdrawn
bou
f
p
patholog
blood
bank
hospit
lebanes
univers
beirut
lebanon
faculti
medicin
univers
lyon
franc
medicin
psychiatr
hospit
cross
jaledib
medicin
blood
bank
saint
joseph
hospit
dora
medicin
medic
scienc
lebanes
univers
beirut
lebanon
nation
de
la
transfus
sanguin
pari
franc
background
univers
leukoreduct
ulr
nation
implement
follow
recommend
lebanes
nation
committe
blood
transfus
order
improv
safeti
transfus
medicin
wide
known
remov
leukocyt
minim
among
other
febril
transfus
reaction
hla
alloimmun
platelet
refractori
multitransfus
patient
prevent
transmiss
leukotrop
virus
ebv
cmv
despit
fact
strategi
current
intern
standard
recommend
sever
western
intern
scientif
societi
institut
occasion
debat
regard
especi
low
middl
incom
countri
aim
describ
clinic
impact
implement
ulr
incid
acut
transfus
reaction
atr
major
tertiari
healthcar
facil
lebanon
hemovigil
report
system
well
organ
sinc
two
decad
method
acut
transfus
reaction
immunolog
report
depart
clinic
patholog
blood
bank
hospit
implement
ulr
follow
transfus
blood
product
compil
compar
occur
result
total
blood
product
pack
red
blood
cell
fresh
frozen
plasma
transfus
first
studi
period
compar
second
one
overal
incid
atr
slightli
decreas
follow
implement
ulr
per
blood
product
howev
differ
statist
signific
immunolog
atr
frequent
reaction
studi
period
around
around
febril
transfus
reaction
follow
allergi
transfus
associ
circulatori
overload
respect
summaryconclus
experi
singl
major
tertiari
healthcar
facil
lebanon
contradict
wide
recogn
notion
implement
ulr
significantli
decreas
incid
atr
henc
need
compil
data
nation
level
urgent
need
order
confirm
refut
find
report
delay
transfus
reaction
also
includ
final
find
question
cost
effect
thu
relev
appli
ulr
versu
select
reduct
strategi
abstract
withdrawn
c
vaz
c
monteiro
f
vasconcelo
lope
ventura
j
baldaqu
leit
koch
imunohemoterapia
centro
hospitalar
de
porto
portug
background
portug
institut
transfus
patient
report
seriou
advers
event
blood
compon
instituto
sangu
e
respons
ensur
nation
haemovigil
system
nh
cooper
european
haemovigil
network
portugues
advers
reaction
notif
rate
blood
compon
per
unit
transfus
centr
creat
transfus
committe
respons
manag
hospit
haemovigil
system
report
incid
relat
transfus
nh
train
profession
annual
provid
transfus
medicin
manual
onlin
aim
describ
incid
type
advers
event
blood
product
centr
method
centro
hospitalar
de
univers
hospit
tertiari
care
centr
bed
close
patient
blood
compon
annual
transfus
perform
retrospect
analysi
error
near
miss
error
transfus
reaction
tr
blood
compon
report
centr
nh
data
collect
onlin
wwwhemovigilancianet
institut
perform
transfus
blood
compon
regist
platform
report
data
annual
result
tr
error
near
miss
error
report
tr
occur
associ
transfus
erythrocyt
compon
occur
women
mean
age
patient
year
tr
report
oncolog
patient
surgic
patient
gastrointestin
bleed
patient
past
transfus
report
tr
late
serolog
transfus
reaction
allergicurticari
reaction
febril
reaction
dyspnea
associ
transfus
anaphylaxi
tr
consid
seriou
reaction
notifi
tr
occur
medic
servic
surgic
servic
intens
care
unit
oncolog
day
hospit
consid
late
event
patient
present
clinic
manifest
receiv
treatment
tr
event
consid
predict
probabl
error
occur
head
patient
laboratori
error
led
administr
wrong
blood
compon
near
miss
error
occur
clinic
set
caus
wrong
identif
patient
report
per
year
error
near
miss
error
tr
studi
period
summaryconclus
report
pattern
irregular
requir
greater
particip
profession
major
tr
occur
patient
past
transfus
recurr
transfus
need
report
tr
accord
literatur
near
miss
error
occur
request
blood
product
result
incorrect
identif
patient
incid
mostli
late
seriou
without
clinic
risk
patient
report
error
occur
mostli
head
patient
administ
blood
product
incorrectli
identifi
patient
abstract
withdrawn
b
l
k
blood
transfus
centr
slovenia
ljubljana
transfus
medicin
maribor
slovenia
background
sever
advers
event
transfus
defin
slovenian
legisl
base
eu
legisl
event
could
caus
death
patient
long
term
complic
ill
prolong
hospitalis
legisl
mandatori
analys
everi
sever
advers
event
necessari
implement
correct
measur
report
slovenian
compet
author
report
european
commiss
hemovigil
law
written
bit
outdat
sinc
mani
chang
taken
consider
classif
advers
event
outdat
sinc
start
use
new
classif
still
chang
law
purpos
report
competit
author
use
classif
purpos
public
inform
report
use
advers
event
classif
divid
eight
categori
event
happen
collect
whole
blood
apheresi
test
donor
whole
blood
process
storag
distribut
materi
other
event
four
categori
whose
fault
error
product
error
equip
human
error
classif
divid
four
categori
type
event
transfus
wrong
blood
compon
transfus
blood
compon
meet
standard
requir
wrong
handl
blood
compon
outsid
transfus
depart
near
miss
subcategori
happen
aim
implement
classif
law
would
updat
report
system
countri
time
would
reduc
amount
unnecessari
work
nation
hemovigil
offic
method
review
analys
sever
advers
event
use
classif
result
sinc
advers
event
transfus
classifi
sever
make
less
classif
event
human
error
error
distribut
event
collect
whole
blood
event
whole
blood
process
event
storag
event
materi
event
classif
event
transfus
wrong
blood
compon
event
meet
standard
near
miss
none
event
classifi
summaryconclus
classif
tell
us
event
happen
event
major
event
classifi
event
help
us
analys
sourc
event
implement
correct
measur
consequ
make
safer
transfus
practic
sole
purpos
work
use
new
classif
simplifi
report
make
transpar
easier
compar
us
countri
could
evalu
work
nation
hemovigil
offic
e
research
depart
process
cryopreserv
blood
cell
chemotherapi
hematolog
diseas
hematopoiesi
depress
qualiti
control
safeti
transfus
nation
medic
research
center
hematolog
russian
feder
moscow
moscow
russian
feder
background
platelet
concentr
pc
transfus
major
treatment
thrombocytopenia
hematolog
patient
bone
marrow
aplasia
immunosuppress
therapi
well
period
agranulocytosi
cytostat
therapi
howev
multipl
transfus
treatment
may
risk
factor
allosensit
recipi
donor
blood
cell
human
leukocyt
antigen
hla
human
platelet
antigen
hpa
subsequ
lead
immunolog
refractori
develop
reaction
lack
clinic
effect
pc
transfus
individu
hlahpa
match
donor
recipi
may
mitig
risk
aim
comparison
reaction
refractori
patient
individu
match
without
individu
match
receiv
pc
transfus
support
method
august
till
decemb
observ
patient
receiv
pc
transfus
patient
develop
refractori
pc
transfus
receiv
pc
select
individu
immucor
analyz
statist
process
perform
use
test
yate
correct
result
total
patient
total
number
recipi
donor
platelet
develop
refractori
pc
transfus
subsequ
receiv
transfus
individu
select
unit
individu
select
unit
transfus
total
number
transfus
reaction
ptr
individu
select
record
episod
patient
refractori
pc
transfus
among
aplast
anemia
aa
febril
reaction
nhfr
myelodysplast
syndrom
md
acut
myeloid
leukemia
aml
acut
lymphoblast
leukemia
background
individu
select
refractori
patient
record
episod
ptr
nhfr
bronchospasm
nhfr
combin
thu
refractori
patient
without
select
perform
pc
transfus
episod
reaction
record
total
number
pc
transfus
refractori
patient
select
perform
pc
transfus
episod
reaction
record
total
number
pc
transfus
summaryconclus
conduct
individu
select
allow
reduc
frequenc
reaction
allow
increas
immunolog
safeti
transfus
differ
group
refractori
patient
without
select
select
ptr
frequenc
statist
signific
signific
level
p
highest
risk
allosensit
develop
immunolog
reaction
observ
patient
acut
myeloid
leukemia
pt
episod
reduc
risk
reaction
adequ
complex
therapi
refractori
patient
requir
pc
transfus
individu
select
pair
mi
bermudez
p
gardeazab
j
soto
garcia
bank
transfus
servic
network
nation
institut
health
physiolog
medicin
school
universidad
del
rosario
dc
colombia
background
colombia
countri
mix
financ
health
system
public
privat
particip
popul
million
inhabit
blood
bank
transfus
servic
network
public
privat
particip
although
effort
made
move
toward
central
current
blood
bank
regist
distribut
citi
suppli
clinic
hospit
aim
improv
process
donor
select
verif
donat
histori
strengthen
blood
transfus
safeti
integr
inform
blood
bank
hospit
institut
allow
trace
origin
process
final
destin
blood
compon
obtain
countri
identifi
advers
event
relat
donor
transfus
event
associ
blood
compon
method
sihevi
softwar
design
nation
institut
health
colombia
inform
suppli
blood
bank
hospit
institut
nomin
data
donor
attend
result
serolog
immunohematolog
test
fraction
final
destin
blood
compon
donor
select
modul
creat
blood
bank
consult
histori
donat
made
person
blood
bank
countri
addit
modul
creat
allow
consult
hemocompon
transfus
patient
well
advers
transfus
event
per
patient
gener
individu
report
consult
hospit
institut
countri
result
implement
phase
sihevi
seven
donor
identifi
posit
infecti
marker
persist
donat
blood
bank
differ
one
confirm
dramat
case
posit
donor
hiv
three
attempt
donat
first
detect
likewis
two
donor
identifi
approach
donat
whole
blood
one
bank
interv
less
day
donat
defer
temporarili
order
mitig
risk
infect
tti
nation
list
perman
defer
donor
n
peopl
construct
base
inform
prior
implement
sihevi
interoper
sourc
epidemiolog
inform
countri
sivigila
one
month
hospit
institut
report
transfus
blood
compon
patient
demand
satisfact
estim
red
blood
cell
advers
transfus
event
ate
notifi
hospit
institut
locat
differ
area
countri
sever
attribut
transfus
summaryconclus
implement
sihevi
allow
improv
transfus
safeti
identifi
potenti
donor
whose
motiv
laboratori
test
result
infecti
marker
hiv
therebi
reduc
risk
tti
type
inform
real
time
reduc
risk
associ
donat
transfus
allow
ate
identifi
quickli
avail
blood
compon
throughout
countri
interoper
sourc
inform
impact
public
health
gener
improv
access
infect
patient
control
program
j
j
j
e
hospit
research
institut
ottawa
hospit
ottawa
canada
background
efficaci
tranexam
acid
txa
reduct
periop
bleed
proven
numer
studi
previou
studi
indic
increas
rate
vte
patient
treat
periop
txa
compar
placebo
therapi
aim
aim
assess
whether
use
postop
vte
prophylaxi
type
therapi
select
factor
determin
risk
postop
vte
patient
treat
periop
txa
method
search
electron
databas
medlin
embas
central
clinicaltrialsgov
incept
septemb
random
control
trial
periop
txa
involv
compar
group
report
postop
vte
event
includ
studi
characterist
result
outcom
vte
prophylact
regimen
abstract
use
der
simonian
laird
random
effect
model
result
trial
identifi
use
postop
vte
prophylaxi
measur
show
txa
associ
increas
risk
postop
vte
surgeri
type
orthoped
surgeri
specif
p
regardless
whether
vte
prophylaxi
provid
patient
studi
use
vte
prophylaxi
risk
vte
patient
treat
periop
txa
significantli
p
differ
variou
pharmaceut
physic
vte
prophylaxi
method
employ
summaryconclus
vte
uncommon
patient
treat
txa
periop
especi
proper
postop
prophylact
method
employ
addit
type
vte
prophylaxi
seem
impact
alreadi
low
risk
vte
patient
popul
futur
studi
requir
assess
use
vte
prophylaxi
patient
prior
histori
vte
treat
periop
txa
howev
patient
risk
vte
consid
barrier
use
txa
minim
blood
loss
transfus
need
j
j
j
e
ottawa
hospit
ottawa
hospit
research
institut
ottawa
canada
background
cardiac
surgeri
often
associ
substanti
blood
loss
put
patient
increas
risk
blood
transfus
use
tranexam
acid
txa
agent
blood
conserv
strategi
gain
popular
mani
surgic
specialti
shown
effect
safe
therapi
howev
txa
remain
underutil
larg
due
fear
potenti
thromboembol
event
concern
cardiac
surgeri
anoth
possibl
contribut
factor
txa
lack
guidelin
outlin
patient
group
receiv
txa
due
risk
outweigh
benefit
aim
conduct
systemat
review
determin
patient
exclud
clinic
trial
txa
cardiac
surgeri
help
determin
patient
group
risk
txa
therapi
estim
secondari
object
assess
safeti
system
txa
hope
find
review
enabl
develop
exclus
criteria
txa
use
patient
undergo
cardiac
surgeri
method
databas
medlin
embas
cochran
central
regist
control
trial
search
incept
septemb
elig
studi
random
control
trial
rct
administ
system
txa
patient
undergo
cardiac
surgeri
compar
group
placebo
intervent
activ
compar
accept
primari
outcom
descript
exclus
criteria
rct
secondari
endpoint
assess
rate
advers
event
associ
txa
use
descript
synthesi
perform
synthes
studi
characterist
analyz
exclus
criteria
txa
safeti
assess
use
random
effect
model
result
elig
rct
includ
systemat
review
varieti
cardiac
surgeri
includ
common
one
coronari
arteri
bypass
graft
surgeri
studi
two
common
reason
exclud
patient
txa
trial
cardiac
surgeri
major
hepat
renal
cardiac
comorbid
studi
use
medic
affect
coagul
studi
patient
group
frequent
exclud
trial
coagulopathi
studi
known
allergi
txa
abnorm
coagul
profil
studi
previou
histori
arteri
venou
thromboembol
event
studi
anemia
studi
show
system
txa
increas
risk
advers
event
compar
placebo
intervent
rr
ci
summaryconclus
system
txa
safe
use
cardiac
surgeri
guidelin
use
surgeri
develop
mani
patient
popul
regard
patient
group
commonli
exclud
txa
trial
cardiac
surgeri
exclus
may
warrant
base
current
evid
howev
due
frequent
exclus
rct
may
limit
efficaci
safeti
data
txa
popul
research
txa
patient
group
may
warrant
p
r
n
liu
medicin
centr
transfus
research
mcmaster
univers
hamilton
ontario
blood
servic
ancast
ontario
canada
background
red
blood
cell
rbc
often
transfus
inappropri
iron
defici
anem
patient
common
method
identifi
iron
defici
id
biochem
hematolog
indic
serum
ferritin
access
popular
biochem
test
high
specif
low
sensit
increas
set
inflamm
make
imperfect
test
iron
statu
addit
biochem
indic
use
limit
measur
reticulocyt
hemoglobin
content
emerg
potenti
surrog
test
identifi
patient
id
reflect
iron
avail
format
new
red
blood
cell
access
measur
expand
reticulocyt
hemoglobin
equival
use
sysmex
analyz
perform
tube
collect
complet
blood
count
short
turnaround
time
could
allow
rapid
identif
id
caus
anemia
optim
manag
iron
replet
instead
rbc
transfus
possibl
test
alreadi
incorpor
iron
replet
algorithm
patient
chronic
renal
diseas
wide
valid
popul
aim
studi
evalu
diagnost
accuraci
surrog
marker
identif
id
compar
ferritin
transferrin
satur
outpati
popul
method
conduct
retrospect
studi
outpati
three
hospit
ferritin
measur
day
patient
sever
chronic
renal
diseas
treat
differ
hospit
exclud
studi
data
obtain
via
larg
comprehens
databas
contain
demograph
laboratori
inform
patient
hamilton
hospit
diagnost
accuraci
evalu
roc
curv
analysi
two
definit
id
absolut
id
ferritin
ngml
transferrin
satur
function
absolut
id
ferritin
ngml
transferrin
satur
ferritin
associ
marker
id
assess
use
pearson
correl
test
result
data
extract
juli
decemb
identifi
outpati
ferritin
result
absolut
id
identifi
patient
patient
identifi
includ
function
id
absolut
id
area
curv
auc
optim
pg
sensit
specif
includ
subject
function
id
auc
optim
pg
sensit
specif
absolut
id
correl
posit
ferritin
ci
transferrin
satur
ci
hemoglobin
ci
mcv
ci
p
similar
result
obtain
includ
function
id
summaryconclus
good
accuraci
identif
id
outpati
popul
accuraci
though
decreas
fair
includ
patient
function
id
pg
sensit
better
specif
suggest
higher
rate
fals
posit
correl
moder
ferritin
strongli
transferrin
satur
less
perform
cohort
publish
studi
auc
approxim
analysi
requir
identifi
popul
use
accur
measur
id
c
f
k
medicin
scottish
nation
blood
transfus
servic
nh
lothian
edinburgh
unit
kingdom
background
jehovah
wit
jw
repres
minor
signific
challeng
cohort
patient
seek
obstetr
surgic
procedur
within
royal
infirmari
edinburgh
scottish
blood
transfus
snbt
consult
patient
accept
refus
blood
product
includ
autolog
procedur
take
necessari
step
minimis
bleed
risk
aim
undertak
retrospect
review
jw
patient
refer
obstetr
surgeri
anaesthet
within
singl
nh
lothian
hospit
regard
characterist
manag
describ
evolv
servic
transfus
medicin
doctor
snbt
purpos
evalu
benefit
servic
patient
clinic
colleagu
method
retrospect
audit
referr
letter
blood
result
jw
refer
rie
clinic
team
carri
patient
note
suppli
inform
demograph
diagnosi
surgic
procedur
postop
blood
complic
exclus
paediatr
patient
patient
refus
descript
statist
systemat
questionnair
use
studi
target
popul
fulli
repres
statist
comparison
health
board
made
inform
analys
accord
complianc
local
nation
guidelin
avail
result
total
patient
femal
surgic
obstetr
includ
ethnic
white
scottish
polish
african
white
english
indian
eastern
european
caribbean
black
scottish
ethnic
refus
primari
blood
compon
addit
reject
secondari
blood
compon
refus
recombin
factor
viia
refus
fibrin
sealant
accept
tranexam
acid
erythropoietin
refus
contain
anim
plasma
accept
continu
cell
salvag
agre
transfus
blood
compon
altern
certain
death
due
famili
accept
form
medic
treatment
except
blood
transfus
surgic
patient
surgic
patient
two
male
seven
femal
mean
age
year
rang
underw
total
procedur
patient
consent
continu
cell
salvag
arrang
howev
two
patient
requir
transfus
one
cardiothorac
patient
develop
anaemia
death
obstetr
patient
patient
refer
second
trimest
patient
baselin
fbc
show
anaem
accord
rang
post
referr
blood
includ
serum
ferritin
folat
coagul
screen
reticulocyt
count
anaemia
due
iron
defici
patient
iron
supplement
throughout
pregnanc
receiv
iron
infus
receiv
erythropoietin
major
underw
normal
vagin
deliveri
caesarean
section
cell
salvag
avail
section
utilis
summaryconclus
sinc
jw
patient
seen
transfus
expert
discuss
blood
product
transfus
altern
optimis
haematolog
paramet
practic
improv
anaemia
monitor
snbt
liais
clinician
jw
hospit
liaison
committe
studi
identifi
need
improv
document
staff
educ
guidelin
adher
separ
polici
obstetr
surgic
patient
creat
h
j
laboratori
medicin
ewha
woman
univers
colleg
medicin
oral
maxillofaci
surgeri
ewha
woman
univers
medic
center
seoul
korea
background
preoper
autolog
blood
donat
pabd
process
collect
store
patient
blood
plan
oper
purpos
person
store
case
patient
develop
postop
anemia
pabd
use
patient
undergo
elect
main
indic
pabd
patient
rare
blood
group
patient
multipl
alloantibodi
patient
refus
consent
allogen
blood
transfus
person
reason
orthognath
surgeri
wide
perform
correct
dentofaci
deform
improv
function
physic
appear
associ
signific
risk
blood
loss
blood
transfus
pabd
commonli
use
orthognath
surgeri
much
known
current
state
pabd
blood
transfus
practic
number
studi
issu
limit
aim
studi
design
investig
current
state
pabd
orthognath
surgeri
tertiari
univers
hospit
import
safe
appropri
transfus
patient
also
ration
manag
proper
servic
hospit
blood
center
method
record
patient
request
pabd
undergo
orthognath
surgeri
period
januari
decemb
retrospect
review
one
two
unit
autolog
blood
collect
one
unit
time
interv
collect
last
unit
collect
h
preoper
blood
volum
collect
ml
result
total
unit
patient
collect
unit
patient
pabd
unit
patient
pabd
patient
pabd
patient
mean
hb
pabd
gdl
pabd
patient
mean
hb
pabd
pabd
gdl
gdl
respect
seriou
side
effect
observ
blood
collect
total
unit
pabd
transfus
patient
among
patient
receiv
blood
transfus
patient
could
avoid
allogen
blood
transfus
incid
addit
allogen
blood
transfus
pabd
patient
pabd
patient
mean
postop
hb
patient
receiv
transfus
gdl
mean
wastag
rate
pabd
significantli
higher
allogen
blood
period
less
pabd
pabd
summaryconclus
pabd
reduc
incid
allogen
blood
transfus
patient
undergo
orthognath
surgeri
risk
associ
allogen
blood
transfus
howev
high
wastag
rate
pabd
indic
inappropri
indic
pabd
pabd
play
import
role
patient
blood
manag
pbm
achiev
pbm
necessari
indic
pabd
appropri
use
adequ
without
discard
abstract
withdrawn
lukic
rao
f
plenkov
b
golub
cepul
transfus
medicin
transplant
biolog
clinic
hospit
center
zagreb
zagreb
croatia
background
polyval
immunoglobulin
ig
intraven
ivig
subcutan
scig
use
replac
therapi
primari
immunodefici
immunomodul
treatment
autoimmun
diseas
neuroimmunolog
disord
last
decad
indic
extend
secondari
immunodefici
especi
haematolog
diseas
lymphoprolif
diseas
lpd
multipl
myeloma
mm
furthermor
ig
use
iatrogen
hypogammaglobulinemia
due
immunotherapi
eg
rituximab
immunosuppress
therapi
steroid
sulfasalazin
mycophenol
mofetil
bone
marrow
bmt
solid
organ
transplant
clinic
usag
lack
scientif
proven
benefit
ig
therapi
appli
aim
aim
studi
retrospect
analyz
usag
ig
accord
indic
method
retrospect
analyz
data
type
quantiti
ig
issu
patient
data
collect
transfus
hospit
inform
system
examin
patient
treat
indic
ig
applic
determin
accord
clinic
guidelin
immunoglobulin
use
nh
scotland
modifi
result
patient
treat
ig
male
femal
children
adult
median
age
rang
total
treat
accord
medic
indic
children
adult
treatment
receiv
children
adult
patient
total
patient
receiv
ivig
patient
receiv
scig
patient
receiv
ivig
scig
total
g
ig
use
patient
treat
averag
g
rang
g
g
ivig
g
scig
analysi
consumpt
ig
adult
children
divid
three
categori
firstli
patient
total
g
mostli
bmt
patient
allogen
autolog
stem
cell
g
secondli
patient
autoimmun
diseas
consumpt
g
highest
number
patient
primari
immunodefici
pid
g
third
categori
compris
neurolog
patient
consumpt
g
mostli
adult
patient
chronic
inflammatori
demyelin
polyneuropathi
cidp
g
children
syndrom
g
summaryconclus
total
patient
children
adult
treat
polyval
immunoglobulin
due
constant
increas
ig
consumpt
expans
clinic
indic
necess
compos
nation
guidelin
treatment
would
help
ration
consumpt
preciou
resourc
eg
human
plasma
abstract
withdrawn
mm
menzi
wojtowicz
maccallum
stern
haematolog
seal
patholog
princ
wale
hospit
sydney
australia
background
fresh
frozen
plasma
preciou
resourc
often
use
inappropri
despit
evid
avail
guid
use
well
establish
definit
caus
harm
frequent
much
emphasi
place
abnorm
coagul
studi
rather
consid
entireti
clinic
context
particular
set
ffp
use
inappropri
includ
correct
mildli
derang
coagul
studi
prior
invas
procedur
veera
et
al
blood
liver
dysfunct
absenc
bleed
normal
coagul
studi
nice
nh
blood
transplant
conserv
approach
plasma
transfus
therefor
warrant
particularli
patient
aim
examin
primarili
mani
adult
ffp
transfus
appropri
inappropri
accord
current
evid
particular
nation
blood
author
nba
patient
blood
manag
pbm
guidelin
qualit
quantit
data
analys
reach
conclus
method
retrospect
local
audit
conduct
data
collat
audit
templat
record
demograph
detail
pbm
categori
whether
patient
bleed
ffp
dose
whether
therapeut
mlkg
nba
pbm
guidelin
propos
indic
rotem
involv
pre
post
ffp
transfus
coagul
studi
prescrib
anticoagul
use
prothrombinex
warfarinis
patient
vitamin
k
use
advers
event
attribut
ffp
use
translat
inform
appropri
transfus
abnorm
coagul
studi
defin
greater
upper
limit
report
rang
data
use
deriv
recommend
improv
transfus
practic
aabb
technic
manual
decreas
futur
inappropri
transfus
tinmouth
transfus
result
ffp
transfus
found
appropri
inappropri
unsurprisingli
ffp
administ
acut
area
hospit
commonli
surgic
upper
gastrointestin
cardiothorac
obstetr
patient
coagul
studi
tend
normalis
administr
ffp
mani
patient
receiv
therapeut
dose
bleed
patient
like
receiv
appropri
transfus
third
receiv
therapeut
dose
bleed
reduct
poorli
document
episod
involv
patient
anticoagul
ffp
necessarili
given
revers
effect
episod
warfarinis
patient
inappropri
prothrombinex
underutilis
rotem
use
bleed
episod
within
cardiothorac
surgeri
vitamin
k
use
bleed
patient
none
ffp
transfus
audit
period
document
lead
harm
sever
interest
case
vignett
illustr
interest
scenario
ffp
use
institut
includ
context
renal
transplant
massiv
bleed
associ
warfarin
therapi
catastroph
surgic
bleed
summaryconclus
audit
use
educ
clinician
supplement
new
restrict
local
guidelin
appropri
inappropri
ffp
use
improv
futur
transfus
practic
ultim
reduc
inappropri
ffp
transfus
rb
r
v
medicin
marrow
transplant
unit
kokilaben
dhirubhai
ambani
hospit
mumbai
india
background
patient
receiv
bmt
like
receiv
platelet
transfus
prophylact
well
therapeut
bmt
report
major
factor
independ
associ
poor
respons
platelet
transfus
aim
studi
efficaci
platelet
transfus
patient
receiv
bmt
hospit
set
method
prospect
studi
done
determin
effect
platelet
transfus
bmt
patient
determin
h
correct
count
increment
platelet
transfus
event
bmt
patient
autolog
bmt
allogen
bmt
studi
h
cci
consid
indic
refractori
platelet
transfus
patient
receiv
either
abo
ident
pool
leucodeplet
random
donor
platelet
abo
compat
apheresi
platelet
transfus
associ
reduc
cci
clinic
factor
patient
record
result
mean
threshold
platelet
transfus
bmt
patient
platelet
count
platelet
transfus
mean
day
storag
mean
platelet
dose
per
unit
transfus
overal
mean
cci
wherea
autolog
bmt
patient
allogen
bmt
patient
cci
platelet
transfus
episod
nine
patient
allogen
bmt
autolog
bmt
found
refractori
platelet
transfus
base
cci
valu
sever
mucos
increas
bilirubin
increas
level
found
associ
reduc
cci
patient
mean
cci
adult
patient
receiv
platelet
transfus
pediatr
patient
receiv
transfus
platelet
unit
mean
cci
advers
reaction
clinic
bleed
report
studi
period
none
patient
investig
antibodi
summaryconclus
h
cci
found
reliabl
indic
evalu
clinic
effect
platelet
transfus
efficaci
platelet
transfus
bmt
patient
found
better
paediatr
patient
patient
undergo
autolog
bmt
clinic
factor
also
affect
efficaci
platelet
transfus
significantli
abstract
withdrawn
p
c
r
l
e
b
system
research
institut
san
francisco
unit
state
america
hemomina
juiz
de
fora
da
da
da
faculdad
de
medicina
da
universidad
de
paulo
sao
paulo
hemomina
belo
horizont
de
hemop
recif
hemorio
rio
de
janeiro
hemomina
mont
claro
brazil
rockvil
unit
state
america
de
medicina
instituto
de
medicina
tropic
da
universidad
de
paulo
sao
paulo
brazil
background
red
blood
cell
transfus
use
scd
patient
treat
acut
complic
ctt
prevent
sever
diseas
manifest
aim
describ
util
indic
advers
event
ae
associ
transfus
scd
compar
outcom
patient
treat
ctt
method
brazilian
scd
cohort
establish
investig
transfus
outcom
patient
encount
prior
year
randomli
select
elig
brazilian
center
sao
paulo
rio
de
janeiro
belo
horizont
juiz
de
fora
mont
claro
recif
medic
blood
bank
record
abstract
clinic
histori
detail
inform
transfus
year
prior
enrol
ctt
defin
schedul
transfus
period
prevent
scd
complic
two
control
treat
ctt
select
ctt
case
match
center
scd
genotyp
gender
age
clinic
outcom
compar
two
group
use
standard
statist
method
result
patient
enrol
cohort
children
year
hemoglobin
hb
ss
common
scd
genotyp
follow
hbsc
cohort
children
adult
transfus
least
children
adult
transfus
prior
year
common
indic
transfus
ctt
transfus
children
transfus
adult
next
three
common
indic
children
acut
chest
syndrom
ac
acut
symptomat
anemia
pain
episod
voe
acut
symptomat
anemia
follow
voe
ac
adult
ae
report
transfus
episod
febril
bacteri
acut
ae
report
acut
transfus
transfus
ctt
transfus
children
adult
treat
ctt
commonli
histori
clinic
stroke
children
adult
follow
abnorm
transcrani
doppler
children
frequent
voe
adult
major
transfus
ctt
administ
manual
exchang
compar
simpl
transfus
children
treat
ctt
like
voe
ac
hospit
prior
year
treat
vs
vs
respect
adult
treat
differ
acut
event
approxim
half
children
adult
treat
ctt
iron
overload
defin
ferritin
ngdl
alloimmun
common
ctt
case
compar
control
vs
p
children
vs
adult
respect
summaryconclus
transfus
common
scd
cohort
major
administ
part
ctt
transfus
reaction
common
alloimmun
iron
overload
highlight
need
novel
clinic
strategi
mitig
risk
ctt
scd
f
yousef
p
j
tehran
heart
center
tehran
univers
medic
scienc
outcom
research
educ
core
univers
scientif
educ
research
network
usern
tehran
univers
medic
scienc
tehran
iran
background
practic
transfus
medicin
cardiac
set
encount
signific
chang
recent
due
substanti
prescript
anticoagul
differ
mechan
action
regard
overwhelm
cost
transfus
mandatori
know
effect
anticoagul
need
transfus
cardiac
surgeri
even
though
unavoid
continu
form
anticoagul
oper
aim
studi
aim
determin
administr
anticoagul
affect
need
transfus
cardiac
surgeri
candid
tertiari
hospit
method
recruit
patient
correl
studi
follow
admiss
discharg
hospit
candid
cardiac
surgeri
tehran
heart
center
enrol
studi
addit
demographi
anthropometr
measur
lab
data
detail
periop
consumpt
blood
blood
product
well
complet
histori
anticoagul
includ
type
dosag
time
usag
assess
studi
oper
room
postop
event
includ
bleed
volum
record
result
men
women
studi
patient
receiv
blood
blood
product
includ
warm
whole
blood
unit
unit
pack
rbc
unit
ffp
unit
platelet
unit
cryoprecipit
regard
anticoagul
consumpt
aspirin
rank
first
follow
heparin
clopidogrel
warfarin
enoxaparin
multivari
analysi
predictor
pack
rbc
consumpt
show
gender
age
year
bodi
surfac
area
bsa
preoper
hemoglobin
import
predictor
transfus
coronari
patient
odd
ratio
respect
aspirin
usag
surgeri
among
predictor
massiv
postop
transfus
four
unit
coronari
patient
confid
interv
ci
respect
heparin
associ
fresh
frozen
plasma
usag
valvular
patient
ci
moreov
patient
stop
clopidogrel
least
three
day
surgeri
significantli
less
bleed
compar
other
summaryconclus
import
predictor
periop
transfus
pack
rbc
coronari
arteri
surgeri
gender
age
bsa
preoper
hemoglobin
though
anticoagul
rank
among
import
predictor
transfus
dosag
time
discontinu
care
monitor
due
risk
massiv
bleed
patient
group
medic
ti
withanawasam
nation
blood
transfus
servic
colombo
sri
lanka
background
sri
lankan
nation
blood
transfus
servic
depend
voluntari
blood
donor
blood
prescrib
clinician
awar
blood
stock
manag
order
blood
common
practic
absenc
explicit
maximum
surgic
blood
order
schedul
request
clinician
assess
aim
studi
done
object
evalu
current
practic
blood
order
util
elect
surgic
procedur
aim
formul
msbo
streamlin
blood
usag
stock
manag
reduc
unnecessari
blood
wastag
method
retrospect
hospit
base
studi
conduct
durat
six
month
cross
match
request
relat
elect
gener
orthoped
otorhinolaryngolog
surgeri
renal
biopsi
analyz
number
blood
unit
request
transfus
first
six
month
cross
match
transfus
c
ratio
number
unit
cross
match
divid
number
unit
transfus
transfus
index
ti
number
unit
transfus
divid
number
patient
cross
match
transfus
probabl
number
patient
transfus
divid
number
patient
cross
match
x
calcul
procedur
result
total
number
procedur
request
blood
transfus
patient
highest
number
request
elect
lower
segment
caesarian
section
laparotomi
dynam
hip
screw
total
abdomin
hysterectomi
surgeri
total
blood
transfus
n
studi
period
elect
surgic
procedur
procedur
util
cross
match
blood
immedi
period
uncompl
requir
blood
transfus
cross
match
transfus
c
ratio
higher
standard
surgeri
except
open
reduct
intern
fixat
surgeri
highest
ratio
saphenofemor
ligat
procedur
transfus
index
ti
total
knee
hip
replac
surgeri
three
orthoped
surgeri
close
reduct
intern
fixat
open
reduct
intern
fixat
total
knee
hip
replac
summaryconclus
analyz
data
present
hospit
transfus
committe
meet
indic
use
determin
effici
blood
order
util
c
ratio
ti
c
ratio
andor
ti
indic
effici
blood
usag
consid
indic
signific
blood
usag
accord
studi
major
surgeri
could
manag
group
save
method
without
cross
match
blood
procedur
requir
msbo
agre
unanim
clinician
blood
bank
msbo
guid
optim
blood
usag
surgeri
decreas
order
blood
therebi
reduc
blood
wastag
laboratori
workload
without
compromis
standard
patient
care
c
seneviratn
blood
bank
nation
hospit
sri
lanka
colombo
sri
lanka
background
appropri
goal
transfus
therapi
optim
safeti
transfus
blood
key
concept
protocol
routin
administr
red
blood
cell
patient
repeat
transfus
sustain
live
famili
patient
compromis
priorit
need
patient
bring
neg
social
impact
famili
order
find
practic
necessari
carri
situat
analysi
aim
describ
transfus
practic
repeatedli
transfus
patient
ladi
ridgeway
hospit
children
sri
lanka
method
prospect
descript
cross
section
studi
carri
ladi
ridgeway
hospit
children
sri
lanka
three
month
period
present
complaint
repeatedli
transfus
patient
medic
ward
admiss
pre
post
transfus
haemoglobin
level
current
transfus
practic
relat
type
blood
use
volum
frequenc
transfus
advers
event
outcom
social
impact
transfus
analyz
result
total
episod
analyz
patient
male
thalassaem
patient
extend
phenotyp
done
prior
initi
transfus
admiss
routin
transfus
transfus
hb
level
lower
gdl
post
transfus
hb
done
achiev
hb
level
gdl
buffi
coat
remov
rbc
special
blood
product
given
patient
approxim
patient
get
rh
kell
match
product
prior
alloantibodi
format
use
two
unit
blood
per
episod
transfus
frequenc
day
advers
reaction
transfus
urticari
allerg
reaction
febril
reaction
haemolyt
reaction
clinic
signific
alloantibodi
posit
patient
signific
alloantibodi
thalassaem
patient
year
age
studi
popul
anti
antibodi
patient
one
day
admiss
per
episod
kept
away
home
parentguardian
miss
one
school
day
per
episod
summaryconclus
patient
studi
popul
predominantli
compris
male
rel
older
children
develop
alloantibodi
repeatedli
transfus
patient
alway
receiv
abo
rh
match
buffi
coat
remov
rcc
social
problem
famili
patient
vari
accord
distanc
home
transfus
centr
signific
amount
money
spent
episod
famili
emphas
develop
plan
provid
facil
servic
peripher
hospit
distanc
travel
minim
therebi
minim
expenditur
loss
school
day
also
plan
build
faith
servic
given
peripher
hospit
children
parent
improv
outcom
k
iwaki
kyoritsu
medic
center
servic
iwaki
blood
center
servic
iwaki
kyoritsu
medic
center
iwaki
japan
background
surgic
procedur
much
improv
decad
contribut
save
blood
oper
total
amount
blood
product
howev
seem
significantli
reduc
aim
clarifi
relat
surgeri
full
year
data
blood
transfus
btf
patient
collect
method
patient
oper
procedur
four
surgic
clinic
consum
surgeri
sg
orthoped
ort
cardiovascular
surgeri
cav
gynecolog
gne
select
analysi
total
gastrectomi
mean
age
year
colectomi
rectal
resect
hepatectomi
pancrea
resect
sg
replac
hip
joint
non
hip
joint
ort
open
repair
aortic
aneurysm
repair
valv
aortic
stent
cav
total
hysterectomi
elect
caesarian
section
gne
time
blood
transfus
btf
patient
count
period
tmb
b
c
e
indic
month
b
within
day
c
oper
day
within
day
e
month
number
product
per
btf
patient
express
rfpaa
rbc
ffp
pc
alb
alb
result
time
btf
tmb
period
btf
sg
patient
total
gastrectomi
receiv
btf
tmb
oper
rfpaa
colectomi
tmb
rfpaa
rectal
resect
tmb
rfpaa
hepatectomi
tmb
rfpaa
pancrea
resect
tmb
rfpaa
b
btf
ort
replac
artifici
hip
tmb
rfpaa
blood
non
hip
tmb
rfpaa
blood
c
btf
cav
open
repair
aneurysm
tmb
rfpaa
aneurysm
stent
tmb
rfpaa
valv
tmb
rfpaa
btf
gne
total
hysterectomi
tmb
rfpaa
elect
caesarean
section
tmb
rfpaa
summaryconclus
tmb
time
btf
rfpaa
type
product
show
distinct
featur
oper
procedur
use
rbc
sg
gne
excess
use
postop
alb
sg
autolog
rbc
limit
ort
postop
use
compar
intraop
use
procedur
product
rbc
ffp
pc
equal
use
cav
thu
tmb
rfpaa
analys
may
contribut
forecast
demand
ration
use
blood
product
l
wijesekara
nation
blood
transfus
servic
sri
lanka
nation
hospit
sri
lanka
colombo
sri
lanka
background
despit
presenc
guidelin
appropri
use
product
literatur
report
high
percentag
inappropri
transfus
ffp
stake
overal
patient
wellb
articl
present
result
descript
studi
use
ffp
medic
gener
surgic
ward
nation
hospit
sri
lanka
aim
studi
analys
practic
effect
ffp
transfus
major
tertiari
care
hospit
sri
lanka
studi
analys
practic
effect
ffp
transfus
major
tertiari
care
hospit
sri
lanka
method
studi
carri
period
week
examin
request
form
ffp
medic
gener
surgic
ward
nation
hospit
sri
lanka
clinic
data
obtain
bed
head
ticket
transfus
patient
manual
indic
identifi
evalu
demograph
data
patient
complet
request
form
appropri
indic
dose
transfus
episod
avail
pre
post
transfus
test
coagul
advers
event
efficaci
treatment
evalu
improv
pt
aptt
ratio
wilcoxon
test
guidelin
use
plasma
cryoprecipit
cryosupernat
british
committe
standard
haematolog
taken
benchmark
result
six
hundr
forti
five
transfus
episod
util
unit
ffp
inward
patient
relat
clinic
record
scrutin
request
satisfactori
complet
request
form
indic
transfus
appropri
accord
guidelin
transfus
episod
evalu
high
inr
undocu
aetiolog
activ
bleed
high
risk
bleed
found
commonest
indic
ffp
transfus
appropri
commonest
inappropri
indic
liver
diseas
prolong
pt
andor
aptt
absenc
bleed
risk
bleed
dose
appropri
request
comparison
pt
aptt
ratio
show
signific
correct
ffp
transfus
p
summaryconclus
despit
clinic
justif
may
warrant
use
ffp
clinician
resourc
poor
set
larg
proport
ffp
transfus
carri
indic
deem
inappropri
guidelin
util
coagul
test
guid
compon
therapi
still
routin
practic
attent
drawn
complet
request
form
clinic
staff
well
blood
bank
staff
blood
centr
gynecolog
de
soysa
matern
hospit
colombo
sri
lanka
background
obstetr
hemorrhag
one
common
indic
blood
transfus
recommend
obtain
consent
blood
transfus
may
possibl
critic
emerg
antenat
manag
guidelin
recommend
routin
educ
blood
transfus
aim
aim
analyz
knowledg
attitud
regard
blood
transfus
among
antenat
mother
need
routin
educ
regard
blood
transfus
among
antenat
popul
method
descript
studi
conduct
among
transfus
naiv
antenat
women
trimest
attend
antenat
clinic
de
soysa
matern
hospit
colombo
sri
lanka
data
collect
questionnair
analyz
spss
microsoft
excel
result
studi
popul
includ
primi
multi
gravida
analyz
religion
buddhist
hindu
christian
muslim
respect
none
jehovah
wit
none
mother
counsel
blood
transfus
antenat
visit
health
care
worker
total
popul
awar
least
one
indic
blood
transfus
bleed
anemia
indic
known
mother
respect
mother
knew
least
one
side
effect
blood
transfus
transfus
transmit
infect
allerg
reaction
complic
known
mother
respect
among
studi
popul
agre
would
agre
blood
transfus
irrespect
indic
suggest
health
staff
wherea
particip
mention
would
agre
blood
transfus
acut
life
threaten
situat
none
mention
would
refus
transfus
even
life
threaten
situat
among
mother
agre
situat
decid
sinc
consid
blood
transfus
danger
wherea
due
needl
fear
mother
scare
see
blood
religi
reason
mention
restrict
factor
transfus
among
studi
popul
mother
suggest
pregnant
mother
routin
counsel
blood
transfus
antenat
care
summaryconclus
although
knowledg
blood
transfus
inadequ
mother
accept
blood
transfus
import
clinic
manag
major
studi
popul
favor
inclus
educ
counsel
blood
transfus
antenat
period
abstract
withdrawn
f
n
ben
la
rabta
depart
depart
hopit
la
rabta
depart
la
rabta
hopit
la
rabta
tuni
tunisia
background
cardiac
surgeri
current
one
consumpt
specialti
blood
product
great
heterogen
servic
identif
preoper
bleed
risk
factor
earli
diagnosi
hemostat
disord
essenti
ration
consumpt
blood
product
aim
studi
aim
studi
hematolog
variat
induc
extracorpor
circul
cardiac
surgeri
evalu
transfusion
practic
surgeri
method
data
consecut
adult
patient
underw
first
cardiac
surgeri
januari
april
collect
variabl
includ
standard
bleed
histori
prothrombin
time
pt
activ
partial
thromboplastin
time
fibrinogen
level
hemoglobin
hb
platelet
count
patient
blood
sampl
taken
heparinis
per
surgeri
min
protamin
administr
h
post
oper
blood
loss
measur
amount
transfus
product
record
result
thirti
patient
enrol
averag
age
year
hemodilut
extracorpor
circuit
induc
hemoglobin
drop
platelet
count
fibrinogen
level
mean
rate
fall
hemoglobin
gdl
evalu
transfus
practic
shown
patient
transfus
least
labil
blood
product
lbp
wherea
patient
excess
transfus
summaryconclus
studi
show
signific
variat
hemostat
paramet
cardiac
surgeri
transfus
rate
around
implement
transfus
save
strategi
necessari
reduc
number
transfus
patient
c
j
c
n
f
health
nh
trust
blood
transplant
london
blood
transplant
cambridg
unit
kingdom
background
royal
colleg
pathologist
uk
organis
annual
nation
patholog
week
highlight
import
contribut
pathologist
make
healthcar
mani
event
rang
peopl
age
aim
improv
awar
engag
school
polit
figur
health
care
profession
public
method
nation
patholog
week
novemb
key
theme
patholog
commun
rcpath
host
free
scienc
fair
entitl
adventur
health
secret
lab
invit
school
student
famili
mile
end
ecolog
pavilion
attende
join
team
doctor
scientist
go
behind
scene
hospit
laboratori
varieti
fun
activ
demonstr
display
school
student
age
member
public
attend
scienc
fair
result
hospit
transfus
practition
haematologist
bart
health
nh
trust
collabor
patient
blood
manag
donor
market
team
nh
blood
transplant
nhsbt
nation
blood
servic
england
organis
highli
success
display
blood
transfus
sever
interact
tabl
show
journey
safe
blood
transfus
includ
patient
inform
sampl
take
blood
compon
blood
group
antibodi
test
safeti
check
need
prior
administr
display
highlight
special
requir
patient
group
sickl
cell
diseas
need
recruit
donor
black
asian
minor
ethnic
bame
group
discuss
indic
also
organ
donat
engag
mani
visitor
also
took
away
inform
join
nation
organ
donor
regist
make
take
stand
allow
particip
make
model
red
cell
add
abo
type
model
antibodi
demonstr
fundament
blood
group
serolog
consequ
abo
mismatch
stand
highli
popular
well
attend
student
young
old
leav
proud
owner
abo
type
model
red
cell
preced
nation
patholog
week
initi
team
bart
health
nh
trust
nhsbt
organis
specif
event
entitl
patient
voic
ask
patient
sickl
cell
diseas
scd
thalassaemia
share
perspect
impact
transfus
live
healthcar
profession
work
behind
scene
within
hospit
laboratori
blood
servic
turn
spoke
safe
journey
blood
step
improv
blood
suppli
follow
activ
joint
discuss
better
reach
differ
ethnic
minor
encourag
donat
rare
blood
unit
essenti
patient
develop
red
cell
antibodi
summaryconclus
abl
mani
member
public
particular
school
children
age
famili
rais
awar
around
safe
blood
transfus
also
rais
interest
blood
organ
donat
patient
voic
event
help
share
experi
patient
hospit
laboratori
blood
servic
team
j
lin
chen
divis
transfus
medicin
depart
medicin
taipei
veteran
gener
hospit
taipei
taiwan
china
background
pack
red
blood
cell
prbc
transfus
may
associ
develop
venou
thromboembol
phenomena
amount
prbc
transfus
incid
venou
thromboembol
vte
taiwan
patient
gastric
cancer
determin
aim
queri
taiwan
health
insur
databas
studi
transfus
requir
incid
vte
gastric
cancer
patient
method
conduct
nationwid
studi
use
data
retriev
taiwan
longitudin
health
insur
databas
contain
claim
data
beneficiari
randomli
select
registri
beneficiari
nhird
analyz
data
patient
gastric
cancer
code
diagnos
period
vte
includ
deep
vein
thrombosi
dvt
code
pulmonari
embol
pe
code
includ
iatrogen
pe
code
result
patient
gastric
cancer
randomli
select
median
age
year
rang
year
male
prbc
transfus
prescrib
patient
amount
prbc
transfus
follow
unit
patient
unit
patient
unit
patient
unit
patient
unit
patient
higher
unit
patient
number
transfus
transfus
patient
transfus
patient
transfus
twice
patient
transfus
time
patient
transfus
time
patient
seventeen
patient
develop
vte
dvt
alon
patient
pe
alon
patient
dvt
pe
patient
seven
patient
vte
receiv
prbc
transfus
vte
occurr
none
receiv
prbc
transfus
vte
episod
summaryconclus
requir
prbc
transfus
incid
vte
low
gastric
cancer
patient
taiwan
prbc
transfus
identifi
risk
factor
vte
patient
h
g
h
c
k
sn
medicin
patholog
alberta
health
servicesunivers
alberta
medicin
patholog
univers
alberta
edmonton
canada
background
although
transfus
consider
safer
past
risk
persist
sinc
risk
typic
per
unit
high
concern
chronic
transfus
patient
addit
inventori
challeng
cost
associ
support
patient
manag
patient
workload
impact
databas
chronic
transfus
patient
edmonton
zone
ez
compli
contain
transfus
frequenc
phenotyp
advers
event
transfus
indic
underli
diagnosi
inform
system
chronic
transfus
patient
defin
transfus
least
everi
two
month
six
month
longer
aim
highlight
databas
assist
manag
inventori
workload
chronic
transfus
recipi
method
sinc
blood
bank
lab
inform
system
sunquest
relev
clinic
inform
use
annual
popul
databas
data
store
secur
institut
share
drive
allow
retrospect
analysi
databas
result
total
patient
enter
databas
rang
per
year
frequenc
gender
blood
group
remain
consist
studi
period
averag
male
femal
b
ab
hematolog
diseas
account
patient
proport
hemoglobinopathi
patient
increas
time
decreas
trend
chronic
transfus
renal
failur
chronic
gi
bleed
anemia
iron
defici
anemia
anemia
chronic
diseas
patient
note
alloimmun
highest
drop
stabl
data
show
increas
phenotyp
match
patient
receiv
full
phenotyp
increas
patient
phenotyp
rh
kell
full
phenotyp
match
restrict
rh
kell
match
full
phenotyp
match
overal
alloimmun
rate
decreas
increas
use
phenotyp
match
antibodi
patient
versu
antibodi
patient
transfus
occur
patient
patient
develop
antibodi
result
summaryconclus
signific
drop
number
chronic
transfus
patient
note
compar
previou
year
may
due
alter
treatment
plan
sever
disord
chang
transfus
guidelin
use
iv
iron
therapi
erythropoietin
stimul
agent
bone
marrow
spare
therapi
due
proport
hematolog
disord
ongo
discuss
clinic
hematolog
allow
increas
awar
factor
initi
drop
alloimmun
rate
like
due
increas
phenotyp
increas
steadili
studi
period
preval
full
phenotyp
databas
allow
us
predict
phenotyp
requir
inventori
blood
group
impact
workload
blood
bank
l
lopez
r
p
p
cardiac
critic
care
la
fe
hospit
transfus
de
la
comunidad
valenciana
critic
care
la
fe
hospit
valencia
spain
background
blood
transfus
acquir
special
relev
cardiac
surgeri
set
sinc
one
surgic
specialti
greater
haemorrhag
risk
surgic
procedur
character
high
requir
pack
red
blood
cell
rbc
larg
number
adult
cardiac
surgeri
patient
receiv
periop
transfus
howev
rang
broad
rbc
transfus
rate
rang
variabl
may
due
part
differ
preoper
assess
manag
differ
bleed
risk
absenc
intern
accept
standard
periop
transfus
manag
type
patient
reduc
variabl
variou
strategi
tri
includ
studi
develop
descript
sever
transfus
risk
score
may
identifi
target
popul
highest
probabl
transfus
aim
definit
preoper
variabl
independ
affect
rbc
transfus
rate
cardiac
surgeri
order
develop
transfus
risk
score
set
method
data
consecut
patient
older
year
hospit
underw
elect
cardiac
surgeri
taken
two
period
decemb
juli
blood
save
protocol
prep
group
octob
may
protocol
alreadi
implement
postp
group
clinic
demograph
characterist
haematolog
paramet
biochem
haemostat
analyt
data
transfus
inform
evalu
primari
outcom
exposur
rbc
transfus
oper
first
postop
day
multivari
logist
regress
techniqu
use
determin
relationship
independ
variabl
exposur
rbc
transfus
result
overal
transfus
rate
entir
group
rbc
ffp
platelet
protocol
implement
decreas
overal
transfus
rate
rbc
ffp
platelet
differ
signific
hemoglobin
level
hospit
discharg
similar
group
grdl
multivari
analysi
show
variabl
posit
influenc
reduct
rbc
transfus
rate
protocol
implement
higher
preoper
hb
valu
preoper
congenit
cardiac
condit
interatri
commun
contrari
previou
cardiac
surgeri
mix
cardiac
condit
chronic
renal
failur
unfavour
summaryconclus
implement
blood
save
protocol
manag
decreas
transfus
rate
without
lower
haemoglobin
level
discharg
set
preoper
variabl
constitut
transfus
risk
factor
absenc
blood
save
protocol
lower
preoper
hb
lower
minimum
hb
cpb
interatri
commun
previou
cardiac
surgeri
mix
cardiac
condit
chronic
renal
failur
abstract
withdrawn
abstract
withdrawn
p
r
j
centrum
krwiodawstwa
krwiolecznictwa
w
hematolog
copernicu
memori
hospit
bct
polska
sp
z
oo
katowic
poland
background
platelet
concentr
pc
use
worldwid
prevent
treat
bleed
due
thrombocytopenia
oncolog
haematolog
patient
frequent
receiv
pc
institut
patient
receiv
bone
marrow
stem
cell
transplant
undergo
immunosuppress
treatment
preferenti
receiv
pc
collect
apheresi
singl
donor
reduc
risk
pathogen
transmiss
pc
transfus
pathogen
reduct
technolog
prt
implement
mirasol
prt
system
terumo
bct
use
riboflavin
uv
light
use
region
centr
blood
donat
haemotherapi
rckik
sinc
pc
collect
apheresi
platelet
suspend
platelet
addit
solut
plasma
unit
pc
pc
treat
mirasol
technolog
plasma
aim
aim
studi
compar
transfus
perform
platelet
concentr
pc
treat
mirasol
prt
system
untreat
pc
method
clinic
result
singl
pc
transfus
administ
patient
thrombocytopenia
analys
retrospect
transfus
pc
treat
mirasol
prt
call
treat
group
transfus
pc
prt
call
control
group
number
patient
present
increas
platelet
count
hr
post
transfus
determin
group
patient
present
increas
platelet
count
increment
platelet
count
h
post
transfus
h
correct
count
increment
h
calcul
h
platelet
count
platelet
count
h
h
transfus
platelet
dose
bsa
bsa
height
weight
result
averag
h
treat
control
group
respect
p
h
treat
control
group
respect
p
patient
refractori
platelet
transfus
h
group
treat
group
control
reason
might
relat
administ
medic
fever
antibodi
summaryconclus
preliminari
data
present
abstract
suggest
platelet
treat
system
show
similar
perform
untreat
platelet
concentr
collect
apheresi
success
transfus
rate
patient
treat
control
group
concord
previou
report
experi
prospect
randomis
analysi
would
need
exclud
possibl
bia
dc
dame
univers
hati
societi
haitian
red
cross
port
au
princ
haiti
background
haiti
separ
blood
compon
improv
fresh
frozen
plasma
platelet
concentr
cryoprecipit
introduc
nation
servic
blood
transfus
haitian
red
cross
unfortun
major
haitian
healthcar
provid
accustom
use
blood
product
transfus
educ
includ
medic
curriculum
appropri
use
blood
fundament
blood
transfus
safeti
healthcar
provid
need
continu
train
updat
improv
system
aim
describ
transfus
practic
healthcar
provid
identifi
constraint
encount
integr
fraction
blood
compon
patient
manag
univers
hospit
haiti
method
conduct
survey
septemb
januari
questionnair
intend
nurs
doctor
resid
assign
intern
medicin
pediatr
anesthesiolog
surgeri
orthoped
obstetr
gynecolog
depart
univers
hospit
haiti
questionnair
includ
inform
consent
blood
recipi
blood
product
prescript
util
blood
product
infus
practic
advers
reaction
monitor
post
transfus
comment
particip
also
list
result
questionnair
deliv
resid
nurs
hospit
low
respons
rate
healthcar
profession
agre
complet
return
questionnair
good
transfus
practic
notifi
regard
inform
consent
patient
transfus
nevertheless
effort
need
appropri
util
blood
compon
platelet
concentr
report
sever
thrombocytopenia
caregiv
declar
use
fresh
frozen
plasma
mostli
dissemin
intravascular
coagul
hypoproteinemia
cryoprecipit
unknown
although
haitian
red
cross
promot
prescript
fraction
blood
compon
caregiv
state
use
whole
blood
massiv
bleed
indic
furthermor
good
blood
product
infus
monitor
practic
report
mani
constraint
disclos
post
transfus
caregiv
state
face
low
financi
resourc
patient
recur
unavail
laboratori
test
delay
blood
product
order
issuanc
blood
receiv
also
emphas
need
addit
educ
transfus
medicin
summaryconclus
despit
low
respons
rate
questionnair
notic
insuffici
knowledg
util
limit
post
transfus
blood
product
strongli
recommend
research
clinic
transfus
transfus
medic
educ
program
healthcar
provid
protocol
patient
reinforc
hospit
blood
bank
j
marqu
f
g
vera
cruz
hospit
cellular
hemotherapi
center
medicin
campina
brazil
background
transfus
vital
therapi
achiev
improv
patient
outcom
avoid
unnecessari
exposur
blood
product
effect
conserv
manag
patient
blood
patient
blood
manag
pbm
program
creat
program
aim
promot
medic
educ
associ
blood
transfus
altern
patient
care
rational
blood
util
aim
optim
task
studi
red
blood
cell
adequaci
index
sinc
report
demonstr
valu
provid
use
tool
pbm
program
method
institut
transfus
request
audit
classifi
proper
base
guidelin
request
adapt
suit
protocol
april
octob
request
red
blood
cell
rbc
identifi
hemoglobin
higher
gdl
absenc
inform
hemoglobin
level
associ
higher
likelihood
indic
two
characterist
use
calcul
rbc
transfus
adequaci
index
rai
repres
proport
rbc
transfus
two
characterist
present
rai
monitor
prospect
six
differ
health
care
institut
campina
brazil
tool
pbm
program
provid
inform
promot
intervent
institut
practic
result
first
part
studi
transfus
request
analyz
classifi
second
part
studi
januari
decemb
blood
unit
transfus
rai
monitor
data
show
overal
global
rai
assess
whole
six
unit
posit
correl
regress
valu
unit
individu
evalu
differ
realiti
shown
differ
pattern
tendenc
exampl
unit
e
show
improv
annual
rai
sd
unlik
unit
wors
result
last
two
year
accept
rai
vari
significantli
servic
servic
accord
institut
focu
local
pattern
rbc
transfus
real
valu
tool
enabl
follow
progress
institut
time
measur
efficaci
pbm
program
anoth
contribut
tool
make
possibl
measur
index
hierarch
level
eg
hospit
suppli
blood
bank
hospit
unit
surgeri
specialti
even
specif
physician
therefor
continu
monitor
rai
allow
one
identifi
deviat
establish
standard
identifi
focu
deviat
provid
inform
accur
intervent
ultim
improv
transfus
safeti
summaryconclus
optim
manag
blood
transfus
patient
relat
risk
cours
task
rai
part
pbm
program
help
tool
process
abstract
withdrawn
j
c
r
r
hospit
servic
shanghai
blood
center
dongfang
hospit
huadong
hospit
zhongshan
hospit
blood
center
shanghai
china
background
patient
blood
manag
pbm
multidisciplinari
approach
optim
care
patient
might
need
transfus
encompass
aspect
patient
evalu
clinic
manag
surround
transfus
process
patient
blood
manag
propos
world
health
organ
concept
blood
transfus
comprehens
chang
clinic
practic
patient
blood
manag
made
develop
countri
howev
pbm
still
studi
stage
clinic
studi
practic
china
aim
want
investig
clinic
applic
pbm
shanghai
china
method
patient
blood
transfus
shanghai
investig
collect
clinic
case
pbm
intervent
includ
preoper
use
iron
erythropoietin
surgeri
preoper
use
hemostat
agent
control
hypotens
technolog
surgeri
result
two
depart
given
iron
supplement
correct
anemia
nine
use
hemostat
drug
tranexam
acid
ten
depart
use
least
one
intervent
surgeri
wide
use
cardiac
surgeri
gener
surgeri
depart
took
intervent
none
depart
preoper
epo
boost
hemoglobin
summaryconclus
studi
demonstr
pbm
still
earli
stage
attract
enough
attent
shanghai
china
z
transfus
institut
cardiac
surgeri
clinic
center
ni
ni
serbia
background
although
establish
unambigu
role
aspirin
primari
secondari
prevent
cardiovascular
cerebrovascular
advers
event
case
suboptim
respons
asa
call
resist
associ
advers
outcom
therapi
aim
aim
studi
identifi
factor
influenc
variabl
respons
aspirin
platelet
function
measur
platelet
aggreg
method
imped
aggregometri
method
examin
includ
patient
treat
one
three
differ
aspirin
prepar
acut
myocardi
infarct
singl
therapi
clopidogrel
platelet
function
measur
use
imped
aggregomet
multipl
multipl
platelet
function
analyz
roch
blood
sampl
heparin
aspi
trap
test
investig
impact
follow
factor
valu
trap
aspi
gender
age
type
asa
prepar
presenc
diabet
mellitu
smoke
use
drug
agent
proton
pump
inhibitor
result
age
use
anticoagul
reduc
basic
platelet
function
proton
pump
inhibitor
increas
diabet
risk
factor
reduc
effici
asa
p
well
smoke
p
use
proton
pump
inhibitor
p
hand
use
anticoagul
enhanc
effect
asa
p
also
use
aspirin
protect
p
summaryconclus
smoke
diabet
use
proton
pump
inhibitor
anticoagul
well
type
appli
aspirin
prepar
stand
import
factor
affect
effici
aspirin
platelet
function
measur
method
imped
aggregometri
n
r
h
innov
blood
bank
stem
cell
manufactur
canadian
blood
servic
ottawa
canada
background
cord
blood
cb
bank
must
understand
relationship
qualiti
potenc
attach
segment
main
cord
blood
unit
cbu
bag
relationship
may
vari
bank
due
differ
bag
equip
process
thaw
test
procedur
moreov
low
cell
viabil
frequent
issu
experienc
cb
bank
result
osmot
shock
thaw
dilut
red
blood
cell
rbc
lysi
treatment
ammonium
chlorid
solut
altogeth
also
contribut
high
variabl
test
result
bank
aim
establish
relationship
viabil
cb
cell
segment
bag
cbu
process
canadian
blood
servic
cb
optim
cytometri
stain
protocol
minim
toxic
cb
cell
method
cbu
store
ml
buffi
coat
final
product
attach
segment
cbu
obtain
inform
consent
red
cell
plasma
reduct
carri
hespan
cell
separ
cbu
frozen
bioarchiv
cbu
thaw
water
bath
dilut
minsstep
equilibrium
phase
dilut
protocol
human
albumin
solut
cell
viabil
cell
count
measur
use
stem
kit
beckman
coulter
includ
min
rbc
lysi
step
viabil
cell
count
monitor
bag
outermost
segment
cbu
cbu
segment
closest
bag
also
analyz
potenc
monitor
use
coloni
form
unit
cfu
assay
result
analys
cbu
reveal
viabil
cb
cell
gener
lower
outermost
segment
mean
viabil
cell
compar
bag
p
viabil
slightli
lower
well
differ
vs
bag
signific
six
cbu
analyz
detail
viabil
cell
segment
closest
bag
found
similar
bag
higher
p
recoveri
viabl
cell
also
lowest
bag
vs
p
similarli
recoveri
cfu
also
lowest
p
wherea
cfu
recoveri
similar
bag
cell
viabil
fell
standard
threshold
measur
cbu
test
henc
optim
stain
protocol
minim
cell
loss
like
due
necrosi
rbc
lysi
found
import
caus
toxic
p
reduc
length
rbc
lysi
treatment
min
partial
restor
high
cell
viabil
furthermor
reduc
time
sampl
dilut
start
cell
stain
min
also
improv
viabil
p
henc
rbc
lysi
stain
provid
highest
cell
viabil
follow
sampl
stain
min
min
rbc
lysi
step
wherea
control
sampl
lowest
viabil
summaryconclus
cb
cell
viabil
potenc
significantli
underestim
outermost
segment
safe
assum
qualiti
cbu
superior
main
bag
low
cb
cell
viabil
result
high
sensit
matur
myeloid
cell
osmot
physic
stress
lead
necrosi
partial
overcom
minim
rbc
lysi
treatment
schleck
de
mo
monfort
chu
belgium
background
daratumumab
dara
human
monoclon
antibodi
bind
myeloma
cell
use
promis
new
therapi
multipl
myeloma
nevertheless
also
weakli
express
red
blood
cell
rbc
drug
interfer
routin
laboratori
test
caus
fals
posit
antibodi
screen
test
therefor
significantli
delay
distribut
compat
rbc
unit
order
elimin
interfer
dithiothreitol
dtt
screen
cell
use
deplet
express
rbc
howev
method
cumbersom
poorli
reproduc
moreov
dtt
known
destroy
erythrocyt
antigen
among
hamper
detect
correspond
antibodi
aim
cord
blood
cell
cbc
antigen
develop
protocol
use
panel
phenotyp
group
cbc
altern
rapid
antibodi
screen
method
patient
dara
treatment
method
prepar
panel
extens
phenotyp
rh
kel
fy
jk
mn
system
group
cbc
twenti
differ
cord
blood
sampl
order
detect
clinic
signific
alloantibodi
valid
method
patient
dara
treatment
previous
immun
antibodi
develop
transfus
pregnanc
ad
equal
volum
plasma
patient
dara
treatment
sever
plasma
sampl
contain
clinic
signific
low
titer
alloantibodi
spike
plasma
test
correspond
antigen
posit
antigen
neg
cbc
result
total
patient
dara
treatment
screen
antibodi
cbc
result
neg
wherea
alloantibodi
use
mixtur
plasma
dara
patient
detect
cbc
preserv
stabil
solut
remain
stabl
week
summaryconclus
order
avoid
interfer
antibodi
screen
test
patient
dara
treatment
develop
protocol
use
panel
phenotyp
group
cbc
altern
method
cell
clinic
signific
alloantibodi
test
detect
among
normal
destroy
dtt
although
achiev
extend
phenotyp
take
time
cbc
commerci
avail
requir
test
mani
cord
blood
sampl
select
suitabl
cell
eg
homozyg
cell
screen
method
rapid
reproduc
cbc
remain
stabl
time
compar
cell
week
versu
h
respect
techniqu
easili
implement
blood
bank
provid
safe
rbc
unit
emerg
case
patient
dara
treatment
z
asadpoor
dezaki
kheirandish
immunolog
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
iran
background
multipl
sclerosi
ms
demyelin
diseas
associ
progress
disabl
hypoxia
precondit
mesenchym
stem
cell
msc
prior
use
therapi
adapt
way
prepar
surviv
threaten
environ
enhanc
regulatori
function
local
immun
respons
eae
model
aim
present
investig
hypothes
whether
hypox
precondit
umbil
cord
blood
mesenchym
stem
cell
could
promot
remyelin
recoveri
experiment
autoimmun
encephalomyel
eae
mous
model
ms
effect
comparison
method
present
studi
msc
human
umbil
cord
blood
expos
hypoxia
min
reoxygen
min
subsequ
hypoxia
precondit
hucb
expos
hypoxia
h
cell
cultur
hypothes
could
promot
remyelin
recoveri
experiment
autoimmun
encephalomyel
eae
mous
model
ms
effect
comparison
cultur
normoxia
condit
h
result
hypoxia
precondit
cell
viabil
expans
rate
umbil
cord
blood
mesenchym
stem
cell
significantli
increas
without
alter
cell
surfac
marker
express
result
show
transplant
lead
consider
function
improv
patholog
test
outcom
eae
model
summaryconclus
hypoxia
precondit
provid
power
cultur
condit
promot
effici
transplant
umbil
cord
blood
mesenchym
stem
cell
eae
model
hope
translat
knowledg
gain
murin
model
may
ultim
help
find
way
increas
therapeut
efficaci
ms
patient
l
j
rojo
j
de
bank
centro
nacion
de
la
director
centro
nacion
de
la
transfus
blood
bank
centro
nacion
de
la
mexico
mexico
background
umbil
cord
blood
ucb
wide
use
rich
sourc
hematopoiet
progenitorstem
cell
hpchsc
treatment
malign
diseas
ucb
cell
lower
probabl
immun
reject
toler
differ
human
leukocyt
antigen
hla
hpchsc
character
abl
higher
prolifer
expans
potenti
support
blood
cell
format
vivo
transplant
ucb
collect
process
cryopreserv
biobank
futur
transplant
step
process
freez
thaw
damag
hpchsc
therefor
care
taken
everi
process
cell
count
cell
viabil
cfu
content
commonli
analyz
qualiti
control
ass
maintain
high
viabil
pluripot
ucb
transplant
vitro
vivo
studi
suggest
durat
storag
affect
hpchsc
ucb
howev
cryopreserv
practic
cord
blood
biobank
impact
hpchsc
function
partial
studi
aim
evalu
qualiti
control
cryopreserv
ucb
differ
thaw
method
method
select
cryopreserv
ucb
period
nation
center
blood
transfus
biobank
mexico
inclus
criteria
ucb
rang
cell
prior
cryopreserv
ucb
fragment
avail
cbu
qualiti
control
achiev
ml
volum
leukocyt
neg
microbiolog
cultur
hiv
hbv
hcv
treponema
pallidum
trypanosoma
cruzi
reactiv
use
thaw
method
cbu
fragment
rapidli
thaw
hand
cbu
fragment
fast
thaw
water
bath
cbu
fragment
dilut
solut
vv
rheomacrodex
glucos
solut
human
albumin
solut
immedi
thaw
ucb
fragment
analyz
hematopoiet
stem
cell
viabl
marker
flow
cytometri
moreov
ucb
fragment
human
unit
cfu
assay
perform
cultur
medium
duplic
determin
pluripot
hpchsc
result
method
averag
viabl
cell
cfu
cell
viabil
method
viabl
cell
cfu
cell
viabil
method
viabl
cell
cfu
cell
viabil
summaryconclus
result
suggest
three
thaw
method
ubc
analyz
affect
number
cell
cfu
cell
viabil
furthermor
cryopreserv
time
ucb
biobank
neither
affect
variabl
qualiti
control
f
amiri
movah
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
iran
background
mesenchym
stem
cell
msc
isol
differ
tissu
includ
wj
shown
paracrin
abil
support
hematopoiet
stem
cell
hsc
expans
vitro
howev
msc
heterogen
limit
capac
secret
cytokin
involv
hematopoiesi
henc
improv
cultur
condit
might
promot
secret
capac
aim
herein
set
simpl
cultur
method
promot
cytokin
secret
method
separ
wharton
jelli
isol
cell
ad
methocult
medium
dilut
seed
plate
condit
medium
harvest
concentr
serum
free
media
express
cytokin
includ
factor
evalu
western
blot
techniqu
result
cultiv
suspens
condit
express
comparison
cultur
adher
condit
p
p
signific
differ
secret
amount
suspend
adher
summaryconclus
suspens
cultiv
enhanc
abil
produc
import
hematopoiet
cytokin
suspend
could
use
effect
low
cost
vitro
expans
hsc
k
n
h
innov
blood
bank
canadian
blood
servic
ottawa
canada
background
biomed
research
cord
blood
increas
knowledg
current
blood
stem
cell
transplant
practic
well
current
process
collect
manufactur
store
cord
blood
addit
stem
cell
obtain
cord
blood
investig
develop
new
treatment
mani
diseas
stem
cell
research
provid
hope
safe
effect
medic
therapi
futur
aim
canadian
blood
servic
cord
blood
bank
cbb
support
research
cord
blood
two
mechan
cord
blood
research
program
cbrp
process
return
cord
blood
unit
collect
hospit
research
commun
method
august
canadian
blood
servic
cbb
partnership
ottawa
hospit
launch
cbrp
implement
process
distribut
cord
blood
unit
suitabl
storag
transplant
canadian
scientif
commun
fresh
unprocess
cord
blood
unit
frozen
process
cord
blood
unit
made
avail
cbrp
research
distribut
approv
biomed
research
project
cbrp
consent
research
obtain
canadian
blood
servic
cbb
part
collect
process
start
cbb
develop
process
return
cord
blood
unit
design
collect
hospit
process
hospit
manag
matern
consent
requir
distribut
unit
research
commun
accord
local
process
result
retrospect
data
analysi
cbrp
go
live
aug
jan
perform
total
project
approv
research
distribut
total
cbu
collect
ottawa
hospit
total
mother
consent
donat
cbu
cbrp
consent
rate
total
cbu
avail
research
distribut
cbu
qualifi
cbb
bank
cbu
distribut
research
project
avail
research
inventori
distribut
cbu
averag
volum
ml
ml
averag
tnc
addit
cryopreserv
cbu
ad
inventori
research
distribut
cryopreserv
cbu
averag
tnc
total
total
viabil
may
jan
total
cord
blood
unit
collect
cbb
return
collect
hospit
ottawa
hospit
made
avail
research
summaryconclus
implement
formal
process
develop
partnership
hospit
canadian
blood
servic
cbb
facilit
stem
cell
research
canada
ultim
benefit
canadian
patient
h
medicin
sanquin
blood
suppli
amsterdam
netherland
az
delta
roeselar
belgium
background
factjaci
standard
ed
given
procedur
polici
must
design
amongst
other
reduc
risk
hpc
donor
long
mani
collect
procedur
includ
mobil
hpc
peripher
circul
increas
risk
donor
hpc
mathemat
section
edit
asfa
principl
apheresi
technolog
give
formula
calcul
donor
blood
volum
process
collect
request
number
hpc
bvprocess
need
donor
x
collect
effici
aim
valid
formula
bvprocess
need
donor
x
collect
effici
method
hpc
collect
procedur
autolog
patient
calcul
collect
effici
blood
volum
process
collect
request
number
posit
cell
base
count
day
independ
formula
collect
perform
process
volum
outcom
collect
effici
regist
result
hpc
apheresi
collect
procedur
spectra
optia
terumo
bct
request
number
posit
cell
collect
one
procedur
averag
liter
patient
blood
volum
tbv
process
collect
averag
cell
per
kilogram
recipi
bodyweight
collect
effici
spectra
optia
standard
deviat
regress
model
calcul
versu
real
process
blood
volum
show
accuraci
predict
number
posit
cell
collect
formula
summaryconclus
formula
accuraci
predict
number
posit
cell
collect
process
calcul
blood
volum
autolog
donor
known
collect
effici
vari
diseas
background
probabl
data
per
diseas
andor
per
gender
need
better
predict
model
hand
reason
certainti
known
procedur
prolong
procedur
addit
process
ml
blood
could
avoid
addit
collect
procedur
subsequ
day
avoid
addit
mobil
therapi
donor
shorten
central
venou
cathet
insert
formula
therefor
risk
donor
reduc
k
haematolog
blood
transfus
colleg
medicin
univers
lago
obstetr
gynaecolog
colleg
medicin
univers
lago
clinic
patholog
colleg
medicin
univers
lago
lago
nigeria
background
approxim
patient
need
unrel
blood
stem
cell
transplant
unabl
find
time
suitabl
match
due
divers
human
leucocyt
antigen
hla
allel
antigen
particularli
true
nigerian
patient
uniqu
stem
cell
match
need
reflect
nigeria
extens
ethnic
divers
address
problem
bone
marrow
registri
nigeria
launch
februari
donor
futur
plan
construct
cord
blood
bank
cbb
unfortun
awar
level
remain
substanti
limit
har
benefit
umbil
cord
blood
ucb
especi
among
pregnant
women
whose
support
crucial
success
cord
blood
transplant
program
aim
examin
knowledg
percept
pregnant
women
regard
collect
bank
umbil
cord
blood
stem
cell
method
studi
questionnair
administ
pregnant
women
attend
antenat
clinic
lago
univers
teach
hospit
part
assess
issu
awar
knowledg
ucb
part
assess
percept
attitud
toward
ucb
donat
data
analys
use
spss
version
statist
packag
window
manufactur
ibm
corp
armonk
ny
unit
state
result
one
hundr
survey
far
analys
studi
mean
age
respond
awar
ucb
use
treat
diseas
though
level
awar
ucb
high
respond
confid
knowledg
ucb
would
like
healthcar
provid
provid
inform
purpos
use
umbil
cord
blood
respond
agre
cord
blood
donat
cbb
avail
countri
respond
agre
cord
blood
donat
said
religion
influenc
decis
respond
said
would
prefer
public
cbb
privat
one
respond
disagre
donat
cord
blood
use
famili
member
summaryconclus
nigeria
larg
popul
uniqu
place
set
largest
cord
blood
bank
cater
nigerian
ultim
whole
africa
howev
well
understood
blood
donat
without
priorit
donor
educ
find
studi
exemplifi
fact
half
studi
popul
express
willing
donat
cord
blood
cord
blood
bank
avail
countri
major
respond
agre
cord
blood
donat
cbd
also
choos
donat
cord
blood
public
blood
bank
iron
posit
attitud
toward
cbd
despit
poorli
inform
uneduc
lack
knowledg
regard
ucb
also
surprisingli
deepli
religi
countri
women
open
cbd
admit
religion
influenc
decis
ucb
donat
result
far
provid
insight
infer
conclus
studi
data
gather
meaning
incorpor
govern
cord
blood
bank
polici
j
g
transfus
medicin
oslo
univers
hospit
medicin
transfus
medicin
clinic
medicin
univers
oslo
oslo
norway
background
water
extract
prepar
medicin
basidiomycet
mushroom
mainli
agaricu
blazei
muril
also
contain
hericeum
erinaceu
grifola
frondosa
recent
year
mani
studi
report
differ
extract
agaricu
blazei
muril
variou
anticanc
effect
rang
improv
immunomodulatori
activ
inhibit
tumor
growth
via
direct
inhibit
angiogenesi
mice
aim
present
studi
carri
investig
effect
myeloma
cell
line
vitro
method
myeloma
cell
line
peripher
blood
mononuclear
cell
pbmc
expos
variou
concentr
maintain
humidifi
atmospher
h
plate
total
number
percent
viabl
cell
count
nucleocount
use
nucleocassett
kit
chemometec
denmark
accord
manufactur
manual
cell
cycl
analysi
flow
cytometri
cell
control
treat
myeloma
cell
wash
pb
fix
slow
addit
ml
ice
cold
methanol
mixer
store
analysi
cell
cycl
analysi
perform
accord
vindelov
et
al
vindelov
cytometri
analys
fac
aria
cell
sorter
becton
dickenson
san
jose
ca
result
induc
inhibitori
effect
myeloma
cell
line
pbmc
furthermor
cell
cycl
studi
percentag
cell
higher
phase
phase
cell
cultur
vs
control
suggest
cell
cycl
arrest
phase
summaryconclus
data
suggest
reduc
myeloma
cell
line
viabil
via
induct
arrest
without
harm
normal
peripher
blood
mononuclear
cell
k
mousavi
hosseini
navidroian
biotechnolog
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
iran
background
gener
apheresi
involv
remov
whole
blood
patient
donor
medic
procedur
separ
blood
individu
compon
way
one
particular
compon
remov
rest
remain
blood
compon
return
back
blood
stream
donor
patient
aim
aim
collect
patient
stem
cell
prior
high
dose
chemotherapi
method
patient
may
receiv
inject
growth
factor
order
increas
number
peripher
stem
cell
blood
day
blood
cell
count
reach
suffici
level
blood
remov
needl
cathet
circul
blood
cell
separ
machin
blood
separ
mononuclear
white
blood
cell
peripher
blood
stem
cell
transfer
collect
bag
save
frozen
blood
compon
plasma
red
blood
cell
platelet
circul
back
patient
return
needl
result
hematopoiet
stem
cell
harvest
apheresi
found
primari
method
obtain
cell
transplant
procedur
call
bone
marrow
transplant
use
treatment
variou
type
leukemia
lymphoma
cancer
occasion
certain
genet
diseas
lead
anemia
immun
defici
summaryconclus
origin
bone
marrow
transplant
requir
place
needl
interior
bone
obtain
cell
nowaday
case
equival
cell
collect
bloodstream
hematopoiet
stem
cell
harvest
apheresi
avoid
pain
complex
procedur
bone
marrow
aspir
jl
b
k
h
blood
stem
cell
manufactur
canadian
blood
servic
medicin
patholog
univers
alberta
edmonton
blood
stem
cell
manufactur
canadian
blood
servic
ottawa
canada
background
autolog
hematopoiet
progenitor
cell
hpc
transplant
follow
myeloabl
therapi
remain
standard
intervent
treatment
mani
hematolog
malign
hpc
typic
collect
peripher
blood
apheresi
cryopreserv
addit
cryoprotect
agent
dimethyl
sulfoxid
dmso
follow
storag
liquid
nitrogen
prior
patient
undergo
chemotherapi
infus
thaw
cell
suspens
dmso
may
induc
side
effect
mani
hpc
manufactur
centr
employ
manual
volum
reduct
freez
hpc
unit
reduc
volum
dmso
infus
autom
volum
reduct
process
provid
hpc
compon
centrifug
separ
transfer
evalu
canadian
blood
servic
edmonton
stem
cell
manufactur
facil
aim
studi
describ
effect
outcom
first
canadian
experi
implement
autom
close
volum
reduct
system
biosaf
sepax
pericel
process
hpc
autolog
transplant
method
leukapheresi
autolog
stem
cell
transplant
patient
perform
use
spectra
optia
apheresi
system
collect
procedur
mononuclear
harvest
hpc
unit
patient
volum
reduc
use
autom
system
prior
freez
effect
monitor
includ
unit
volum
reduct
recoveri
nucleat
cell
sysmex
autom
cell
counter
cell
recoveri
total
cell
viabil
flow
cytometri
overal
clonogen
capac
coloni
form
unit
assay
steril
bacteri
fungal
cultur
hematolog
platelet
anc
engraft
monitor
patient
receiv
autolog
volum
reduc
hpc
unit
transplant
result
initi
volum
hpc
unit
ml
reduc
autom
centrifug
process
ml
result
estim
reduct
dmso
ml
per
hpc
unit
recoveri
nucleat
cell
respect
white
blood
cell
viabil
remain
high
microbiolog
cultur
hpc
unit
neg
twenti
eight
patient
underw
stem
cell
autolog
transplant
mean
dose
cfu
infusedkg
recipi
bodi
weight
result
advers
reaction
median
time
neutrophil
platelet
engraft
day
summaryconclus
effect
outcom
first
canadian
experi
implement
biosaf
sepax
volum
reduct
system
process
hpc
autolog
transplant
met
predetermin
accept
criteria
support
use
autom
close
system
stem
cell
manufactur
laboratori
compliant
good
manufactur
practic
regul
fh
swaneveld
j
drent
smienk
h
vrielink
sanquin
blood
suppli
amsterdam
netherland
background
chemotherapi
autolog
hematopoiet
cell
transplant
prefer
therapi
patient
multipl
myeloma
mm
stem
cell
collect
apheresi
yield
stem
cell
vari
consider
amongst
patient
wonder
collect
effici
ce
vari
gender
age
type
procedur
mononuclear
cell
collect
mnc
vs
continu
mononuclear
cell
collect
cmnc
aim
evalu
influenc
gender
age
type
procedur
ce
mm
patient
method
retrospect
studi
data
mm
patient
underw
stem
cell
collect
facil
compar
mean
ce
group
use
independ
sampl
use
independ
sampl
median
test
compar
median
ce
patient
stratifi
compar
median
patient
stratifi
age
group
result
patient
underw
apheresi
procedur
procedur
patient
avail
patient
male
median
age
year
rang
year
year
men
rang
year
year
women
rang
year
mean
ce
rang
sd
sd
male
sd
femal
differ
signific
ci
howev
stratifi
signific
differ
male
femal
observ
stratifi
signific
differ
mean
ce
patient
distribut
year
age
respect
ci
year
age
respect
ci
year
age
ci
year
age
ci
also
compar
patient
younger
year
patient
older
year
patient
age
year
patient
age
year
signific
differ
mean
ce
stratifi
gender
also
nt
find
signific
differ
mean
ce
differ
age
group
median
nt
differ
significantli
age
group
signific
differ
median
ce
patient
stratifi
explain
differ
seen
mean
ce
men
women
women
significantli
higher
men
vs
ci
final
compar
mean
ce
type
procedur
mnc
cmnc
yet
signific
disappear
stratif
indic
confound
mean
significantli
lower
mnc
cmnc
vs
ci
summaryconclus
popul
influenc
ce
lower
seem
relat
higher
ce
wherea
gender
age
type
collect
procedur
relat
ce
lee
kim
depart
laboratori
medicin
daegu
cathol
univers
school
medicin
daegu
korea
background
multipl
myeloma
mm
neoplast
plasma
cell
disord
character
clonal
prolifer
malign
monoclon
plasma
cell
bone
marrow
andor
extramedullari
site
chemotherapi
follow
autolog
peripher
blood
transplant
pbsct
standard
therapi
select
patient
diagnos
mm
relaps
may
due
insuffici
erad
malign
plasma
cell
chemotherapi
reinfus
residu
malign
plasma
cell
pbsct
ex
vivo
manipul
autograft
prior
infus
remov
contamin
residu
myeloma
cell
process
call
purg
could
improv
patient
outcom
aim
studi
purg
method
human
multipl
myeloma
cell
peripher
blood
mononuclear
cell
develop
use
chemotherapeut
drug
treatment
efficaci
myeloma
cell
remov
evalu
method
human
myeloma
cell
line
seoul
korea
treat
bortezomib
selleck
chemic
usa
lenalidomid
sigma
aldrich
usa
cell
viabil
assay
perform
use
cell
count
assay
determin
proper
concentr
drug
mixtur
human
peripher
blood
mononuclear
cell
line
treat
bortezomib
lenalidomid
h
efficaci
purg
myeloma
cell
evalu
flow
cytometr
analysi
result
cytotox
bortezomib
nmoll
lenalidomid
nmoll
investig
myeloma
cell
line
incub
bortezomib
nmoll
induc
growth
inhibit
cell
respect
incub
lenalidomid
nmoll
induc
growth
inhibit
cell
respect
bortezomib
nmoll
h
lenalidomid
nmoll
h
effect
remov
cell
peripher
mononuclear
cell
cell
show
aberr
phenotyp
summaryconclus
result
present
studi
demonstr
bortezomib
lenalidomid
treatment
multipl
myeloma
cell
effect
remov
contamin
plasma
cell
n
n
k
e
k
h
h
k
transfus
servic
juntendo
univers
urayasu
hospit
urayasu
transfus
servic
juntendo
univers
hospit
tokyo
laboratori
medicin
hematolog
juntendo
univers
urayasu
hospit
urayasu
transfus
medicin
stem
cell
regul
juntendo
univers
school
medicin
tokyo
japan
background
plerixafor
mozobil
use
mobil
hematopoiet
stem
cell
hsc
combin
granulocyt
factor
sinc
plerixafor
commerci
avail
japan
mobil
hsc
patient
multipl
myeloma
mm
malign
lymphoma
ml
howev
literatur
base
patient
advis
plerixafor
treatment
limit
present
report
differ
mobil
effici
patient
treat
plerixafor
previous
treat
without
plerixafor
aim
studi
aim
evalu
mobil
effici
hsc
plerixafor
japanes
patient
mm
ml
addit
attempt
determin
patient
show
better
mobil
effici
plerixafor
method
retrospect
analyz
clinic
data
patient
underw
hsc
harvest
without
plerixafor
januari
januari
juntendo
univers
urayasu
hospit
urayasu
japan
data
consist
clinic
diagnosi
number
harvest
cell
count
target
cell
count
patient
mm
ml
within
two
harvest
day
within
four
harvest
day
respect
studi
approv
institut
review
board
ethic
committe
result
total
patient
mm
ml
underw
harvest
respect
among
four
patient
mm
treat
plerixafor
mm
eight
patient
mm
treat
without
plerixafor
mm
seven
patient
ml
treat
plerixafor
ml
seven
patient
ml
treat
without
plerixafor
ml
patient
mean
cell
count
day
harvest
follow
mm
mm
ml
ml
mm
ml
patient
cell
increas
time
time
respect
mean
cell
count
harvest
bag
follow
mm
mm
ml
ml
among
patient
mm
mm
ml
ml
achiev
target
cell
count
plerixafor
administr
increas
success
rate
stem
cell
collect
patient
mm
suffici
stem
cell
harvest
possibl
one
mm
one
ml
patient
cell
count
day
harvest
less
mean
number
harvest
day
follow
mm
day
mm
day
ml
day
ml
day
patient
mm
number
harvest
day
shorten
plerixafor
administr
summaryconclus
mobil
collect
effici
greatli
improv
patient
mm
administ
plerixafor
though
cell
count
increas
plerixafor
administr
patient
ml
stem
cell
collect
effici
less
patient
mm
although
necessari
verifi
suffici
number
cell
mobil
peripher
blood
alon
patient
mm
advis
plerixafor
administr
along
stem
cell
collect
h
e
j
laboratori
medicin
nation
medic
center
laboratori
medicin
seoul
nation
univers
colleg
medicin
laboratori
medicin
borama
hospit
metropolitan
govern
public
cord
blood
bank
allcord
seoul
korea
background
seoul
metropolitan
govern
public
cord
blood
bank
allcord
found
may
releas
cb
unit
cb
transplant
cbt
start
juli
cbt
candid
cb
unit
select
base
hla
match
patient
hla
type
total
nucleat
cell
tnc
count
cell
count
cell
viabil
analyz
cb
segment
evalu
qualiti
cb
unit
clinician
choos
cb
unit
cbt
accord
tnc
cell
count
cryopreserv
period
cb
unit
exce
year
wonder
whether
clinician
would
prefer
cb
unit
shorter
cryopreserv
period
longer
cb
unit
aim
investig
chang
qualiti
cb
unit
cryopreserv
period
identifi
whether
cryopreserv
period
impact
clinician
choic
cb
unit
cbt
method
octob
cb
unit
select
among
unit
use
cbt
tnc
count
cell
count
cell
viabil
analyz
cb
unit
conduct
compar
analysi
identifi
presenc
differ
recoveri
rate
tnc
cell
count
cell
viabil
cryopreserv
period
investig
whether
differ
cryopreserv
period
tnc
cell
count
cb
unit
accord
cbt
year
result
mean
cryopreserv
period
cb
unit
day
rang
recoveri
rate
tnc
cell
count
increas
accord
increas
cryopreserv
period
tnc
p
cell
p
differ
cell
viabil
freez
cell
viabil
thaw
increas
accord
increas
cryopreserv
period
cb
unit
mean
cell
viabil
percentag
freez
thaw
respect
accord
cbt
year
number
cb
unit
use
cbt
follow
mean
cryopreserv
period
short
cb
unit
use
day
day
respect
mean
cryopreserv
period
show
increas
tendenc
longest
day
cb
unit
use
signific
differ
tnc
count
accord
cbt
year
mean
tnc
count
cb
unit
cell
count
differ
sinc
cbt
year
mean
cell
count
cb
unit
summaryconclus
signific
decreas
tnc
cell
count
signific
chang
cell
viabil
cryopreserv
year
presum
cryopreserv
period
cb
unit
signific
effect
clinician
choic
rm
grubov
rastvorceva
useini
k
dimitrovski
e
petkovikj
g
andonov
grubov
institut
transfus
medicin
rm
medic
faculti
skopj
skopj
macedonia
background
allogen
hematopoiet
stem
cell
transplant
establish
therapi
mani
benign
malign
hematolog
diseas
sinc
discoveri
potenti
peripher
blood
stem
cell
pbsc
hematopoiet
reconstitut
mid
earli
pbsc
gradual
replac
bone
marrow
prefer
sourc
stem
cell
introduct
hematopoiet
cytokin
mobil
larg
number
progenitor
circul
acceler
pbsc
usag
aim
aim
studi
present
experi
year
apheresi
collect
pbsc
healthi
donor
method
retrospect
studi
perform
institut
transfus
medicin
republ
macedonia
univers
hematolog
hospit
period
till
donor
hla
type
match
fulli
inform
donat
procedur
sign
inform
consent
donat
minimum
dose
requir
ensur
success
sustain
engraft
cell
mononuclear
cell
mnc
pbsc
harvest
perform
continu
flow
cell
separ
baxter
cobe
spectra
use
apheresi
process
total
blood
volum
per
apheresi
femor
cathet
use
harvest
acid
citrat
dextros
formula
use
anticoagul
recombin
human
granulocyt
factor
use
mobil
pbpc
collect
harvest
pbsc
usual
perform
day
subcutan
administr
dose
bodi
weight
result
apheresi
procedur
perform
healthi
donor
apheresi
per
donor
nineti
four
sibl
donor
one
unrel
donor
recruit
bone
marrow
donor
worldwid
registri
donat
pbsc
unknown
donor
usa
first
unrel
donat
institut
male
femal
age
one
two
apheresi
procedur
requir
collect
adequ
graft
singl
procedur
usual
took
h
volum
collect
stem
cell
ml
need
number
mnc
cell
success
collect
apheresi
abo
incompat
donor
procedur
mobil
collect
pbpc
healthi
donor
gener
well
toler
advers
effect
apheresi
procedur
bone
pain
reaction
numb
extrem
reaction
hypocalcemia
occur
rare
mild
collect
pbsc
use
allogen
stem
cell
transplant
patient
acut
myeloid
leukemia
patient
acut
lymphoblast
leukemia
patient
chronic
myeloid
leukemia
patient
lymphoma
patient
myelofibrosi
patient
sever
aplast
anemia
patient
myelodysplast
syndrom
chronic
lymphoblast
leukemia
patient
hodgkin
diseas
patient
multipl
myeloma
patient
summaryconclus
apheresi
collect
mobil
pbsc
healthi
donor
effect
safe
procedur
develop
nation
stem
cell
donor
registri
part
bone
marrow
donor
worldwid
way
hope
help
widen
world
network
stem
cell
donor
enlarg
possibl
patient
find
right
match
h
k
k
h
center
hematolog
medipol
univers
istanbul
turkey
background
extracorpor
photopheresi
ecp
continu
controversi
treatment
probabl
due
mechan
action
identifi
vari
photopheresi
procedur
treatment
schedul
aim
studi
investig
outcom
ecp
children
stem
cell
transplant
develop
gvhd
method
ecp
perform
pediatr
transplant
center
patient
mean
age
year
diagnos
pt
thalassemia
pt
aplast
anemia
blackfan
diamond
refractori
hodgkin
diseas
follow
intern
protocol
ecp
session
five
patient
mud
hla
id
sibl
transplant
chronic
gvhd
diagnos
patient
acut
gvhd
skin
involv
patient
liver
patient
lung
gut
mucou
membran
patient
ecp
treatment
consist
essenti
three
step
collect
mnc
patient
process
mnc
buffi
coat
return
mnc
patient
collect
perform
use
cell
separ
haemonet
mc
plu
process
two
blood
volum
protocol
provid
maximum
final
mnc
volum
collect
ml
hematocrit
hct
valu
maximum
procedur
time
set
min
mnc
collect
adjust
constant
volum
ml
addit
salin
ml
aqueou
solut
alway
obtain
final
concentr
drug
ngml
dilut
buffi
coat
transfer
special
bag
medtech
solut
radiat
perform
irradi
photoactiv
mnc
return
patient
within
min
use
blood
transfus
set
ecp
procedur
patient
vital
sign
monitor
anticoagul
consist
acid
formula
set
variabl
ratio
accord
patient
characterist
clinic
condit
bodi
weight
coagul
valu
platelet
plt
count
prophylaxi
hypocalcemia
consist
administr
calcium
glucon
ml
dilut
ml
salin
everi
min
procedur
relat
side
effect
record
reinfus
postreinfus
phase
patient
monitor
fever
chill
headach
rash
erythema
urticaria
itch
edema
result
patient
also
steroid
concurr
mesenchym
stem
cell
ecp
appli
consecut
day
everi
week
continu
approxim
month
follow
mainten
schedul
taper
everi
mean
session
cycl
februari
novemb
commonli
involv
organ
skin
demonstr
respons
rate
follow
liver
lung
gut
mucou
membran
concurr
immunosuppress
could
reduc
ecp
therapi
increas
opportunist
infect
detect
patient
die
relaps
aliv
chronic
mild
gvhd
seriou
complic
detect
summaryconclus
howev
despit
good
respons
rate
understand
ecp
remain
limit
patient
suffer
acut
chronic
gvhd
limit
treatment
option
ecp
remain
import
therapeut
option
futur
basic
translat
clinic
research
studi
provid
better
understand
mechan
action
optim
therapeut
potenti
rm
grubov
rastvorceva
institut
transfus
medicin
rm
medic
faculti
skopj
skopj
macedonia
background
peripher
blood
hematopoiet
stem
cell
pbsc
larg
replac
bone
marrow
deriv
stem
cell
autolog
transplant
becom
prefer
sourc
stem
cell
major
allogen
transplant
suffici
number
mobil
collect
hematopoiet
stem
cell
hsc
need
success
hematopoiet
stem
cell
transplant
aim
aim
studi
analyz
possibl
predict
factor
could
influenc
hematopoiet
stem
cell
yield
method
studi
perform
institut
transfus
medicin
rm
univers
hematolog
hospit
till
allogen
autolog
donor
underw
mobil
collect
pbsc
associ
number
collect
pbsc
possibl
predict
factor
demograph
characterist
laboratori
paramet
collect
paramet
group
mobil
strategi
clinic
characterist
autolog
donor
analyz
use
spearman
rank
order
correl
result
apheresi
autolog
donor
mean
rang
apheresi
allogen
donor
mean
rang
mean
number
collect
mnc
autolog
donor
cell
mnc
cell
allogen
donor
significantli
larger
number
mnc
cell
collect
wbc
set
statist
signific
correl
total
number
collect
mnc
autolog
donor
platelet
count
mobil
number
cycl
one
apheresi
procedur
quantiti
collect
graft
number
collect
mnc
cell
first
day
apheresi
statist
signific
correl
total
number
collect
mnc
allogen
donor
platelet
count
mobil
number
cycl
one
apheresi
procedur
quantiti
collect
graft
number
mnc
first
day
apheresi
strong
correl
number
collect
mnc
cell
first
harvest
total
number
collect
mnc
cell
poor
mobil
invers
correl
number
apheresi
procedur
donor
donat
mnc
andor
cell
first
harvest
strong
predictor
poor
mobil
summaryconclus
determin
proper
level
baselin
preapheresi
laboratori
paramet
initi
mobil
apheresi
procedur
safe
donor
greatli
effici
collect
pbsc
need
optim
procedur
well
earli
intervent
poor
mobil
abstract
withdrawn
khetarp
v
gupta
u
kotwal
transfus
medicin
artemi
hospit
gurgaon
india
background
qualiti
peripher
hematopoiet
stem
cell
hsc
product
determin
content
hsc
also
contamin
cell
leucocyt
rbc
platelet
number
viabil
hsc
import
factor
predict
success
engraft
howev
cell
like
granulocyt
rbc
platelet
along
cryoprotect
known
affect
viabil
stem
cell
also
mani
advers
event
recipi
report
differ
studi
attribut
infus
damag
cellular
product
complement
activ
larg
volum
dmso
rbc
reduc
viabil
invas
cfu
capac
progenitor
cell
dose
depend
manner
hemolysi
rbc
result
high
level
free
heme
caus
cellular
injuri
lead
proxim
renal
tubul
endotheli
cell
damag
similarli
leucocyt
breakdown
debri
implic
play
direct
causal
role
advers
event
report
mani
author
previous
centr
also
notic
high
rbc
contamin
rel
high
volum
stem
cell
product
collect
comtec
apheresi
system
associ
advers
event
high
hematocrit
volum
prompt
us
modifi
exist
program
better
product
qualiti
aim
aim
studi
reduc
rbc
contamin
volum
stem
cell
product
modif
stem
cell
collect
protocol
program
freseniu
comtec
apheresi
system
version
collect
autolog
hsc
adult
patient
analyz
effect
variabl
method
retrospect
studi
compris
autolog
stem
cell
collect
procedur
mobil
patient
multipl
sclerosi
divid
two
group
program
set
b
modifi
program
product
qualiti
engraft
data
collect
analyz
result
mean
volum
harvest
product
reduc
ml
group
ml
group
b
cell
product
hematocrit
group
group
b
thu
mean
dose
rbc
decreas
ml
ml
per
infus
mnc
platelet
count
group
group
b
respect
harvest
dose
cell
millionkg
bodi
weight
group
millionkg
bodi
weight
group
b
engraft
data
show
neutrophil
ne
platelet
engraft
pe
within
normal
rang
group
mean
ne
pe
day
group
b
mean
ne
pe
day
summaryconclus
new
protocol
result
mark
reduct
product
hematocrit
volum
margin
decreas
leucocyt
concentr
without
compromis
stem
cell
dose
thu
product
becom
econom
effici
volum
reduct
cryopreserv
better
qualiti
abstract
withdrawn
abstract
withdrawn
abstract
withdrawn
mk
j
n
r
biomolecular
scienc
microbiolog
immunolog
univers
ottawa
innov
canadian
blood
servic
ottawa
canada
background
isol
hematopoiet
stem
progenitor
cell
hspc
umbil
cord
blood
ucb
offer
sourc
stem
cell
therapi
hematopoiet
stem
cell
transplant
hsct
hspc
clinic
cryopreserv
dimethyl
sulfoxid
dmso
toxic
cryoprotect
fail
mitig
cellular
injuri
result
ice
recrystal
unabl
preserv
function
hspc
reduc
hsct
complic
associ
delay
fail
engraft
involv
improv
hematolog
potenc
increas
function
achiev
vitro
class
ice
recrystal
inhibitor
use
cryoprotect
conjunct
dmso
cryopreserv
importantli
use
promis
cryoprotect
hspc
yet
investig
vivo
aim
object
studi
examin
use
cryopreserv
affect
engraft
activ
cryopreserv
hspc
human
umbil
cord
blood
method
human
hspc
ucb
cryopreserv
base
total
nucleat
cell
tnc
count
presenc
dmso
conjunct
dmso
use
cool
rate
thaw
dilut
method
implement
prior
transplant
thaw
hspc
immunocompromis
nsg
mice
follow
serial
transplant
protocol
allow
determin
platelet
leukocyt
engraft
hspc
differenti
activ
hspc
capabl
analysi
time
point
well
bone
marrow
primari
secondari
recipi
achiev
use
cell
sort
fac
clonogen
coloni
form
cell
cfc
assay
result
viabil
hspc
cryopreserv
dmso
compar
dmso
condit
base
result
clonogen
assay
hspc
cryopreserv
differenti
prolifer
cryopreserv
dmso
alon
increas
platelet
progenitor
b
cell
level
observ
mice
transplant
hspc
cryopreserv
ice
recrystal
inhibit
cryoprotect
first
transplant
experi
addit
higher
leukocyt
level
observ
secondari
recipi
condit
summaryconclus
use
ice
recrystal
inhibitor
hspc
cryopreserv
appear
increas
engraft
activ
hspc
e
z
l
g
l
g
g
e
h
p
p
serolog
hungarian
nation
blood
transfus
servic
hematolog
hsct
st
istvan
st
laszlo
hospit
depart
intern
medicin
semmelwei
univers
budapest
hungari
stem
cell
transplant
immunolog
univers
hospit
frankfurtmain
frankfurt
germani
background
steroid
refractori
diseas
gvhd
seriou
complic
allogen
hematopoiet
stem
cell
transplant
hsct
experi
accumul
immunomodulatori
effect
mesenchym
stem
cell
msc
infus
numer
immunopatholog
disord
gvhd
signal
aim
evalu
efficaci
novel
msc
product
exclus
use
licens
deriv
bone
marrow
kuci
et
al
haematologica
submit
basi
case
gvhd
refractori
convent
immunosuppress
treatment
method
patient
gvhd
treat
time
per
case
weekli
dose
million
cellskg
novel
msc
product
gener
mnc
volunt
donor
gener
univers
frankfurt
main
germani
clinic
respons
assess
day
administ
first
dose
complet
remiss
defin
complet
disappear
symptom
partial
remiss
assess
signific
relief
symptom
gener
improv
patient
condit
evalu
red
blood
cell
platelet
concentr
need
patient
treatment
result
patient
receiv
total
cycl
dose
per
cycl
median
age
year
malefemal
ratio
distribut
underli
malign
n
acut
myeloid
leukemia
acut
lymphoblast
leukemia
myelofibrosi
myelodysplast
syndrom
multipl
myeloma
lymphoma
twelv
patient
undergon
allogen
hsct
match
unrel
donor
five
stem
cell
deriv
rel
first
episod
gvhd
hsct
observ
median
day
involv
organ
skin
gut
skin
gut
combin
lung
case
appli
averag
line
treatment
vari
line
start
treatment
median
time
first
infus
day
stem
cell
transplant
hsct
day
first
episod
gvhd
six
patient
treat
show
complet
remiss
result
partial
remiss
patient
gvhd
nih
stage
score
infus
decreas
median
treatment
overal
surviv
day
first
gvhd
summaryconclus
accord
observ
effect
treatment
gvhd
major
observ
case
applic
offer
promis
altern
therapi
gvhd
complic
hsct
research
requir
warrant
optim
start
dosag
treatment
along
issu
safeti
abstract
withdrawn
abstract
withdrawn
e
j
j
h
p
z
red
cross
societi
tokyo
japan
excel
safer
transfus
collabor
lebanon
utah
salt
lake
citi
institut
health
bethesda
maryland
school
medicin
baltimor
unit
state
america
blood
transplant
john
radcliff
hospit
oxford
unit
kingdom
hospit
braunschweig
ggmbh
institut
surfac
engin
thin
film
ist
braunschweig
germani
univers
nashvil
minnesota
saint
paul
medic
center
lebanon
unit
state
america
hematolog
transfus
medicin
warsaw
poland
background
viabil
test
common
practic
laboratori
cord
blood
transplant
cryopreserv
cord
blood
bank
requir
valid
procedur
cryopreserv
thaw
measur
viabl
cell
recoveri
sinc
process
cord
blood
unit
typic
involv
concentr
buffi
coat
fraction
mean
total
nucleat
cellular
fraction
consist
larg
neutrophil
variou
method
use
viabil
test
method
use
may
affect
test
result
lead
data
inconsist
among
laboratori
aim
goal
studi
ascertain
current
laboratori
practic
intern
perform
viabil
test
cryopreserv
cord
blood
product
glean
inform
standard
method
improv
reproduc
method
survey
evalu
current
laboratori
practic
viabil
test
design
distribut
intern
question
topic
includ
sampl
test
method
respons
unexpect
result
rate
reliabl
cord
blood
qualiti
test
togeth
expect
standard
result
respond
survey
respond
detail
questionnair
viabil
method
particip
ten
cord
blood
bank
transplant
centr
four
overal
respons
indic
variou
stain
use
among
laboratori
multipl
site
use
viabil
stain
method
differ
longest
time
allow
thaw
viabil
test
vari
one
minut
min
laboratori
definit
time
limit
accept
limit
viabil
assay
result
also
vari
popul
popul
flow
cytometri
trypan
blue
among
cord
blood
assay
tnc
count
data
regard
import
particip
viabil
cfu
data
consid
less
valuabl
viabil
data
regard
import
seven
ten
particip
cord
blood
bank
four
particip
transplant
centr
major
respond
favour
standard
viabil
test
method
wide
varieti
prefer
commun
standard
method
major
advoc
use
flow
cytometri
summaryconclus
survey
result
reveal
varieti
test
inconsist
practic
perform
viabil
assay
flow
cytometri
dye
suggest
first
step
toward
standard
e
v
e
n
blood
transfus
center
hospit
villa
maria
tirana
albania
background
cutan
ulcer
commonli
seen
peopl
diabet
renal
failur
hypertens
lupu
diseas
impair
circul
improp
heal
follow
accid
trauma
skin
disord
affect
blood
clot
arteriolosclerosi
caus
skin
ulcer
non
infect
skin
ulcer
difficult
treat
especi
caus
possibl
correct
wound
diabet
ulcer
avascular
necrosi
vascul
difficult
get
close
treatment
challeng
use
platelet
rich
plasma
prp
gel
becom
good
option
treatment
skin
ulcer
aim
studi
bring
experi
treat
skin
ulcer
prp
gel
aim
prove
effect
role
wound
closur
method
period
time
januari
januari
treat
patient
cutan
ulcer
male
femal
includ
studi
pass
criteria
treatment
exclud
infect
wound
wound
bone
tendon
expos
pregnant
women
patient
suffer
cancer
diseas
mean
age
patient
yo
patient
patholog
caus
ulcer
diabet
vascul
avascular
necrosi
trauma
prepar
prp
gel
homolog
blood
donat
deriv
platelet
plasma
plasma
provid
cryoprecipit
mix
platelet
activ
thrombin
calcium
chlorid
form
prp
gel
measur
photograph
wound
treatment
week
wound
medic
session
perform
clean
wound
betadin
necrotomi
necessari
prp
gel
appli
onto
wound
surfac
dress
correctli
result
saw
everi
wound
granul
form
medic
session
wound
closur
session
session
one
patient
acquir
infect
treatment
period
oblig
us
exclud
studi
diabet
foot
patient
toe
necrot
amput
base
necessari
wound
close
session
patient
wound
closur
without
perform
type
treatment
summaryconclus
conclud
prp
gel
good
option
treat
skin
ulcer
treatment
wound
method
give
satisfi
outcom
patient
feel
comfort
use
medic
therapi
kheirandish
h
rafieemehr
z
asadpoor
dezaki
immunolog
blood
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
iran
background
multipl
sclerosi
ms
autoimmun
inflammatori
demyelin
diseas
central
nervou
system
aim
aim
studi
investig
neuroprotect
effect
transplant
human
umbil
cord
blood
mesenchym
stromal
cell
deriv
neural
progenitor
cell
mdnpc
eae
experiment
model
ms
method
initi
neuron
differenti
medium
remov
replac
induct
media
contain
retino
acid
b
fgf
h
egf
ngf
ibmx
ascorb
acid
one
week
express
neural
gene
examin
comparison
control
group
pcr
assay
experiment
autoimmun
enceph
eae
induc
use
myelin
oligodendrocyt
glycoprotein
mog
peptid
mice
induct
mice
divid
four
group
follow
healthi
pb
mdnpc
respect
end
studi
diseas
statu
group
analyz
use
h
e
stain
brain
section
result
found
exhibit
neuron
differenti
potenti
vitro
transplant
mdnpc
lower
clinic
score
reduc
cn
leukocyt
infiltr
compar
untreat
mice
summaryconclus
result
show
mdnpc
ucb
may
proper
candid
regen
therapi
ms
neurodegen
diseas
abstract
withdrawn
abstract
withdrawn
abstract
withdrawn
abstract
withdrawn
f
habibi
transfus
research
center
high
institut
research
educ
transfus
medicin
tehran
iran
tehran
biotechnolog
research
center
paramedicin
faculti
research
center
guilan
univers
medic
scienc
rasht
iran
background
hemolyt
anemia
associ
intravascular
heme
releas
oxid
stress
lead
endotheli
dysfunct
hemopexin
hpx
plasma
play
pivot
role
heme
transfer
hepatocyt
iron
recycl
recent
hpx
administr
hemolyt
patient
attenu
oxid
damag
endotheli
disord
led
rise
strategi
hpx
therapi
human
hpx
product
use
recombin
dna
technolog
could
provid
real
altern
hpx
aim
purpos
studi
gener
stabl
chines
hamster
ovari
cho
cell
line
express
human
rhpx
method
total
rna
extract
cell
hpx
gene
amplifi
real
chain
reaction
hpx
gene
clone
shuttl
vector
recombin
transform
e
coli
strain
gene
clone
verifi
coloni
pcr
restrict
digest
dna
sequenc
cho
cell
chemic
transfect
screen
perform
sulfat
effect
concentr
develop
stabl
singl
cell
clone
rhpx
express
verifi
western
blot
result
clone
confirm
analys
show
hpx
gene
success
clone
vector
screen
transfect
cell
sulfat
enrich
popul
singl
cell
clone
express
human
rhpx
western
blot
analys
confirm
rhpx
express
cho
cell
line
transcript
translat
level
summaryconclus
human
rhpx
protein
stabli
express
cho
cell
studi
pioneer
work
futur
product
therapeut
rhpx
e
v
e
n
r
van
care
academ
medic
center
cell
research
sanquin
amsterdam
netherland
medicin
david
geffen
school
medicin
univers
california
lo
angel
lo
angel
unit
state
america
background
anemia
inflamm
ai
occur
patient
system
inflamm
caus
infect
cancer
disord
ai
high
level
hepcidin
caus
iron
sequestr
macrophag
thu
low
serum
iron
avail
haemoglobin
synthesi
iron
therapi
ai
test
sever
random
clinic
trial
studi
show
increas
haemoglobin
level
respons
iron
therapi
anoth
factor
limit
iron
avail
erythropoiesi
ai
decreas
serum
transferrin
tf
level
condit
therefor
combin
iron
tf
therapi
may
effect
support
erythropoiesi
individu
suffer
ai
aim
studi
potenti
combin
iron
tf
therapi
anim
model
ai
support
erythropoiesi
correct
anemia
method
mous
model
ai
induc
inject
brucella
abortu
ba
use
mice
receiv
intraperiton
inject
salin
iron
dextran
apotf
iron
dextran
apotf
inject
given
everi
day
start
first
day
ba
inject
mice
sacrif
day
ba
inject
result
tf
plu
iron
therapi
correct
anemia
ai
tf
therapi
alon
aggrav
anemia
compar
salin
control
contrast
iron
therapi
alon
increas
haemoglobin
level
accord
haemoglobin
level
reticulocyt
lower
tf
treat
anim
compar
salin
treat
mice
iron
therapi
decreas
iron
restrict
erythropoiesi
compar
salin
treat
anim
shown
decreas
zinc
protoporphyrin
level
iron
plu
tf
therapi
decreas
iron
restrict
erythropoiesi
serum
iron
level
decreas
day
group
compar
healthi
control
serum
iron
level
increas
day
mice
treat
tf
iron
compar
salin
treat
anim
summaryconclus
tf
therapi
either
alon
combin
iron
therapi
correct
anemia
anim
model
ai
contrast
tf
without
iron
aggrav
anemia
model
howev
iron
therapi
correct
anemia
model
result
suggest
correct
ai
depend
tf
satur
total
serum
iron
given
amount
iron
administ
equal
iron
iron
tf
group
hypothes
tf
therapi
caus
lower
tf
satur
therebi
increas
amount
monoferr
tf
monoferr
tf
lower
affin
transferrin
receptor
diferr
tf
consequ
transport
less
iron
bone
marrow
erythropoiesi
iron
consumpt
may
lower
tf
treat
group
caus
higher
serum
iron
level
group
result
suggest
decreas
tf
inflamm
caus
anemia
rather
may
protect
g
w
hospit
balamand
beirut
lebanon
background
spectra
optia
apheresi
system
perform
wide
rang
therapeut
procedur
includ
peripher
blood
stem
cell
pbsc
collect
mobil
donor
patient
pt
aim
devic
studi
evalu
cellular
composit
pbsc
harvest
pt
multipl
myeloma
mm
lymphoma
nhl
hodgkin
lymphoma
hl
plane
autolog
peripher
stem
cell
transplant
apbsct
optim
collect
pbsc
use
precount
collect
effici
apheresi
devic
method
studi
enrol
pt
undergo
pbsc
mobil
plane
apbsct
evalu
system
mononuclear
cell
mnc
collect
perform
respect
cell
mnc
collect
effici
platelet
reduct
pre
post
apheresi
product
puriti
view
use
predict
algorithm
optim
procedur
predict
yield
blood
volum
process
platelet
loss
also
evalu
neutrophil
platelet
recoveri
pt
underw
apbsct
result
pt
underw
pbsc
harvest
devic
median
age
femal
male
diagnosi
mm
pt
hl
pt
nhl
pt
number
apheres
procedur
mobil
consist
alon
pt
chemotherapi
pt
inhibitor
one
patient
median
count
cell
median
total
blood
volum
process
median
count
cell
collect
median
mnc
collect
efficaci
median
cell
collect
efficaci
median
platelet
reduct
pre
post
apheresi
median
product
hematocrit
granulocyt
product
respect
pt
underw
myeloabl
high
dose
chemotherapi
follow
apbsct
perform
mm
pt
hl
pt
nhl
pt
median
count
cell
infus
pt
receiv
neutrophil
recoveri
median
day
neutrophil
recoveri
median
durat
sever
neutropenia
anc
day
median
day
platelet
recoveri
median
durat
sever
thrombocytopenia
platelet
day
summaryconclus
studi
result
confirm
apheresi
system
mnc
collect
protocol
safe
effect
neutrophil
platelet
recoveri
pt
inferior
compar
histor
control
addit
system
help
use
predict
algorithm
whole
blood
process
achiev
desir
optim
yield
base
precount
apheresi
devic
ej
l
health
care
campu
rappaport
faculti
medicin
technion
haifa
israel
background
current
stem
cell
collect
could
perform
apheresi
devic
use
one
two
follow
program
mononuclear
cell
collect
mnc
procedur
fulli
autom
requir
intervent
case
technic
problem
clamp
incorrect
interphas
unlik
mnc
continu
mononuclear
cell
collect
cmnc
interfac
need
frequent
check
verifi
correct
cell
layer
collect
rambam
health
care
campu
tertiari
care
center
provid
servic
northern
israel
mnc
use
point
cmnc
introduc
patient
white
blood
cell
wbc
count
mnc
program
employ
patient
lower
wbc
count
collect
day
aim
comparison
peripher
blood
stem
cell
pbsc
yield
obtain
healthi
donor
hematolog
patient
undergo
cmnc
procedur
evalu
impact
pb
count
total
pbsc
collect
method
data
retrospect
retriev
patient
pbsc
collect
report
consecut
cmnc
procedur
includ
autolog
healthi
donor
compar
result
patient
pb
count
result
healthi
donor
result
cmnc
follow
paramet
statist
differ
autolog
healthi
donor
mean
collect
time
min
respect
total
blood
volum
process
respect
pb
wbc
count
median
respect
differ
mean
collect
defin
total
amount
collect
bag
divid
amount
cell
pb
process
collect
apparatu
respect
reach
statist
signific
either
follow
valu
significantli
differ
autolog
healthi
donor
percentag
pb
cell
median
rang
rang
respect
percentag
cell
collect
bag
respect
well
total
cell
amount
respect
notabl
result
patient
pb
cell
count
analyz
found
ident
obtain
healthi
donor
summaryconclus
cmnc
highli
effect
term
cell
yield
healthi
autolog
donor
pb
count
similar
observ
donor
group
total
amount
cell
collect
found
directli
correl
pb
count
l
f
phd
program
biomed
engin
colleg
biomed
engin
cell
therapi
regener
medicin
taipei
medic
univers
taipei
taiwan
china
immunolog
transfus
medicin
igp
uppsala
univers
uppsala
sweden
institut
biomed
materi
tissu
engin
colleg
biomed
engin
taipei
medic
univers
taipei
taiwan
china
background
experiment
studi
convincingli
show
human
platelet
lysat
hpl
use
place
fetal
bovin
serum
fb
supplement
growth
media
need
expand
mesenchym
stromal
cell
msc
reach
number
transplant
recent
work
demonstr
possibl
use
expir
platelet
concentr
pc
well
pc
subject
pathogen
inactiv
treatment
sourc
materi
product
hpl
need
hpl
cell
therapi
applic
expect
develop
sharpli
product
scale
may
also
increas
meet
demand
increas
hpl
pool
size
one
mean
improv
product
rais
concomitantli
issu
viru
safeti
case
plasma
fraction
industri
implement
doubl
viru
reduct
treatment
may
becom
mandatori
provid
suffici
margin
safeti
hpl
aim
evalu
possibl
expand
deriv
msc
ex
vivo
use
growth
medium
supplement
hpl
prepar
expir
pc
psoralenuv
treatment
viral
inactiv
solventdeterg
sd
method
expir
psoralenuv
intercept
pc
n
formul
pasplasma
prepar
uppsala
univers
blood
bank
frozen
pc
thaw
pool
prepar
cycl
centrifug
obtain
addit
incub
vv
tnbp
vv
triton
h
follow
vv
soybean
oil
extract
hydrophob
interact
chromatographi
steril
filtrat
hpl
total
protein
concentr
protein
profil
content
growth
factor
gf
elisa
determin
capac
vv
supplement
expand
compar
use
fb
control
morpholog
cell
viabil
cumul
popul
doubl
cpd
differenti
capac
evalu
result
mean
total
protein
content
mgml
lower
fb
mgml
content
five
gf
bdnf
egf
fgf
significantli
lower
hgf
essenti
unchang
present
elong
morpholog
supplement
fb
cell
larger
expand
cell
viabil
higher
use
fb
cpd
four
passag
higher
use
better
p
fb
differenti
capac
chondrocyt
osteocyt
lineag
effect
less
pronounc
toward
adipocyt
lineag
use
summaryconclus
promot
expans
better
fb
data
support
possibl
develop
inactiv
hpl
substitut
fb
supplement
sd
treatment
result
chang
content
gf
impact
cell
morpholog
cpd
compar
hpl
treat
psoralenuv
studi
investig
immunophenotyp
immunomodul
properti
n
ali
u
shaikh
adil
aga
khan
univers
karachi
pakistan
background
prophylact
platelet
transfus
consid
standard
practic
patient
undergo
haematopoiet
stem
cell
transplant
platelet
concentr
frequent
util
blood
product
institut
develop
countri
like
platelet
limit
resourc
repres
signific
cost
patient
hospit
aim
retrospect
analyz
platelet
transfus
trigger
patient
undergo
stem
cell
transplant
method
consecut
adult
pediatr
patient
admit
aga
khan
univers
hospit
bone
marrow
transplant
unit
includ
studi
transfus
monitor
time
admiss
bmt
unit
till
discharg
variabl
analyz
includ
age
gender
type
transplant
underli
diagnosi
engraft
bleed
diathesi
outcom
transplant
follow
institut
guidelin
prophylact
platelet
transfus
threshold
count
less
result
studi
period
perform
transplant
allogen
transplant
autolog
transplant
male
femal
ratio
frequent
diagnosi
aplast
anaemia
thalassemia
major
leukemia
median
rang
year
mean
durat
stay
day
rang
day
eighti
percent
patient
engraft
patient
achiev
institut
benchmark
prophylact
platelet
transfus
level
less
prophylact
platelet
transfus
done
level
indic
approach
sepsi
bleed
diathesi
intracrani
bleed
graft
failur
autolog
transplant
patient
threshold
decreas
mainli
due
delay
engraft
overal
surviv
rate
summaryconclus
achiev
requir
benchmark
patient
way
forward
evalu
safeti
efficaci
lower
platelet
transfus
threshold
ie
ensur
judici
use
product
stem
cell
transplant
patient
basendwah
h
aljedani
greenshield
w
hasegawa
r
liwski
couban
c
campbel
faculti
medicin
dalhousi
univers
halifax
canada
background
platelet
refractori
pr
refer
persist
inadequ
respons
platelet
transfus
patient
hypoprolif
thrombocytopenia
ht
pr
associ
inferior
clinic
outcom
signific
cost
healthcar
system
major
pr
case
due
caus
fever
infect
drug
minor
case
less
caus
alloimmun
foreign
human
leucocyt
antigen
hla
induc
sensit
via
pregnanc
transfus
solid
organ
transplant
calcul
panel
reactiv
antibodi
cpra
score
use
solid
organ
transplant
indic
patient
hla
alloreact
gener
donor
popul
cpra
platelet
recipi
similarli
calcul
includ
antibodi
target
antigen
patient
high
cpra
multipl
antibodi
target
common
hla
antigen
predict
incompat
larg
proport
platelet
donor
current
standard
care
provid
platelet
patient
administr
pool
apheresi
unit
would
like
result
immunolog
pr
aim
studi
aim
review
correl
clinic
laboratori
factor
suspect
alloimmun
pr
case
institut
includ
gender
cpra
potenti
sensit
event
method
retrospect
review
clinic
laboratori
chart
conduct
hematolog
patient
investig
alloimmun
pr
januari
juli
class
hla
antibodi
test
perform
canadian
blood
servic
platelet
laboratori
use
labscreen
singl
antigen
bead
assay
one
lambda
cpra
determin
base
b
locu
antibodi
use
canadian
cpra
calcul
result
review
identifi
patient
pr
femal
male
hla
antibodi
data
avail
analysi
femal
patient
either
mildli
sensit
patient
highli
sensit
cpra
male
patient
mildli
moder
sensit
patient
highli
sensit
cpra
overal
degre
hla
sensit
significantli
greater
femal
vs
male
mean
vs
p
mean
number
rbc
unit
transfus
similar
femal
vs
male
patient
vs
mean
number
transfus
platelet
unit
femal
vs
male
mean
number
pregnanc
highli
sensit
femal
patient
vs
mildli
sensit
femal
summaryconclus
vast
major
patient
immunolog
pr
highli
sensit
cpra
femal
histori
pregnanc
differ
number
rbc
platelet
transfus
receiv
femal
vs
male
patient
find
suggest
pregnanc
transfus
main
caus
antibodi
subsequ
alloimmun
pr
femal
patient
pr
would
therefor
see
benefit
use
platelet
b
g
transfus
medicin
oslo
univers
hospit
transfus
medicin
institut
clinic
medicin
univers
oslo
oslo
norway
background
antibodi
foreign
hla
class
molecul
form
patient
expos
allogen
cell
exampl
blood
transfus
addit
around
pregnant
women
hla
antibodi
plasma
platelet
transfus
class
antibodi
bind
transfus
platelet
mediat
destruct
thu
lead
platelet
refractori
patient
need
provid
platelet
requir
expens
type
donor
altern
deplet
platelet
hla
class
use
brief
incub
citric
acid
ice
low
ph
meink
transfus
treatment
result
reduct
hla
class
express
platelet
membran
loss
reactiv
hla
class
antibodi
aim
present
studi
carri
investig
whether
hla
class
express
reduct
acid
treatment
might
affect
platelet
storag
method
platelet
plt
concentr
pool
buffi
coat
pellet
h
process
g
min
cool
ice
resuspend
pltsml
citric
acid
buffer
equal
volum
mmoll
citric
acid
mmoll
result
ph
min
acid
neutral
dilut
excess
volum
platelet
addit
solut
macopharma
plt
centrifug
dilut
acid
remov
plt
resuspend
origin
supernat
plasma
plt
count
abx
pentra
horiba
medic
surfac
express
hla
class
analyz
gallio
flowcytomet
beckman
coulter
use
mous
b
c
biolegend
clone
immunotech
killi
transfus
apheresi
scienc
spontan
activ
residu
activ
potenti
assess
day
acid
treatment
use
bd
bioscienc
thrombin
receptor
activ
peptid
trap
result
hla
class
surfac
express
reduc
treat
plt
compar
untreat
one
day
day
acid
treatment
induc
signific
chang
express
analysi
residu
plt
activ
potenti
express
trap
stimul
show
signific
differ
plt
control
run
parallel
day
acid
treatment
residu
plt
activ
potenti
significantli
decreas
plt
day
compar
control
summaryconclus
data
suggest
acid
treatment
induc
reduct
hla
class
express
plt
without
chang
residu
activ
potenti
least
day
subsequ
routin
plt
storag
h
f
l
clinic
patholog
far
eastern
memori
hospit
new
taipei
medic
refer
laboratori
taipei
taiwan
china
background
donor
specif
hla
antibodi
play
import
role
allotranspl
reject
allograft
loss
sensit
statu
hla
dramat
influenc
wait
time
organ
transplant
therefor
precis
identif
antibodi
essenti
current
hla
laboratori
practic
transplant
detect
hla
antibodi
test
use
purifi
hla
antigen
increasingli
use
aim
studi
aim
investig
perform
differ
method
detect
pra
identif
antibodi
specif
method
total
sera
collect
includ
sera
multipar
taiwanes
femal
blood
donor
develop
hla
antibodi
pregnanc
sera
first
screen
detect
hla
antibodi
one
lambda
elisa
flow
cytometri
fc
lifescreen
delux
kit
immucor
fc
lifecod
hla
class
iii
id
kit
one
lambda
elisa
kit
use
determin
pra
valu
antibodi
identif
perform
util
labscreen
singl
antigen
hla
class
iii
one
lambda
one
lambda
elisa
lifecod
hla
class
iii
id
kit
immucor
result
hla
class
class
ii
antibodi
screen
test
show
concord
neg
specimen
posit
specimen
fc
luminex
method
elisa
method
show
concord
compar
two
method
screen
hla
class
antibodi
detect
pra
mean
valu
pra
class
posit
class
ii
posit
sampl
util
three
method
luminex
method
exhibit
highest
sensit
mean
class
elisa
mean
fc
mean
method
detect
class
class
ii
pra
consensu
assign
sampl
detect
three
differ
method
term
discord
result
detect
immucor
praid
elisa
method
except
elisa
method
luminex
immucor
praid
one
lambda
singl
antigen
identifi
besid
detect
one
lambda
singl
antigen
elisa
method
summaryconclus
immucor
one
lambda
assay
similar
abil
detect
antibodi
although
correl
assay
present
signific
differ
detect
specif
antibodi
exist
may
caus
test
interfer
andor
loss
nativ
epitop
investig
need
clarifi
possibl
reason
phenomena
p
arcot
r
h
medicin
chandigarh
chandigarh
india
background
variou
studi
west
implic
plasma
caus
trali
femal
becom
alloimmun
pregnanc
frequenc
sensit
hla
found
correl
pariti
score
studi
preval
antibodi
parou
femal
blood
donor
india
done
till
date
henc
cross
section
studi
frequenc
hla
alloimmun
parou
femal
blood
donor
done
aim
studi
frequenc
hla
alloimmun
parou
femal
blood
donor
shall
help
us
decid
also
adopt
male
plasma
strategi
decreas
occurr
trali
select
divert
femal
donor
plasma
manufactur
plasma
deriv
method
total
consent
voluntari
blood
donor
blood
donat
camp
enrol
studi
test
group
consist
parou
femal
donor
control
group
consist
nullipar
femal
donor
male
donor
hla
alloimmun
test
lifecod
life
screen
delux
lmx
screen
assay
detect
igg
antibodi
hla
class
class
ii
molecul
human
origin
mfi
consid
posit
reaction
luminex
bead
assay
high
sensit
give
overestim
hla
antibodi
otherwis
healthi
popul
result
donor
test
posit
anti
hla
antibodi
three
donor
control
group
donor
test
group
test
posit
anti
hla
antibodi
rate
alloimmun
time
higher
test
compar
control
group
donor
gender
base
comparison
male
donor
femal
donor
test
posit
hla
antibodi
hla
alloimmun
significantli
higher
femal
donor
compar
male
donor
although
frequenc
hla
alloimmun
higher
nullipar
femal
donor
male
donor
differ
signific
base
increas
pariti
score
frequenc
hla
alloimmun
found
significantli
correl
compar
frequenc
hla
alloimmun
base
durat
sinc
last
pregnanc
frequenc
alloimmun
higher
pariti
group
greater
equal
pariti
score
less
statist
signific
higher
frequenc
hla
alloimmun
observ
femal
donor
histori
transfus
bad
obstetr
histori
compar
femal
histori
transfus
bad
obstetr
histori
respect
differ
signific
summaryconclus
henc
present
studi
substanti
plasma
parou
femal
donor
higher
chanc
contain
anti
hla
antibodi
henc
order
prevent
transfus
relat
advers
event
due
hla
antibodi
better
use
plasma
donor
fraction
rather
clinic
use
n
z
w
w
f
w
laboratori
blood
safeti
research
zhejiang
provinc
center
zhejiang
provinc
hangzhou
china
background
human
leucocyt
antigen
hla
match
critic
success
hematopoiet
stem
cell
transplant
hsct
hla
allel
haplotyp
frequenc
import
especi
unrel
hsct
known
distribut
hla
allel
haplotyp
vari
among
differ
ethnic
popul
although
data
hla
allel
haplotyp
report
popul
data
loci
high
resolut
level
zhejiang
han
popul
limit
aim
analyz
hla
allel
haplotyp
frequenc
base
volunt
zhejiang
branch
china
bone
marrow
donor
registri
program
method
loci
type
secor
sequenc
commerci
kit
high
resolut
level
polymeras
chain
reaction
type
nucleotid
sequenc
exon
exon
exon
amplifi
use
locu
specif
primer
sequenc
reaction
process
abi
dna
analyz
genotyp
hla
loci
sampl
assign
hla
sbt
utyp
softwar
allel
frequenc
deviat
equilibrium
hwe
determin
arlequin
softwar
haplotyp
frequenc
linkag
disequilibrium
ld
allel
pair
also
analyz
base
em
algorithm
arlequin
softwar
level
signific
ld
set
p
result
frequenc
allel
haplotyp
estim
among
volunt
bone
marrow
donor
zhejiang
han
popul
china
total
number
allel
respect
top
three
frequent
allel
allel
respect
c
c
c
b
b
b
total
haplotyp
frequenc
present
common
haplotyp
frequenc
greater
three
haplotyp
overlap
three
frequent
haplotyp
frequenc
greater
frequent
haplotyp
follow
likelihood
ratio
test
ld
reveal
major
pairwis
associ
statist
signific
three
frequent
haplotyp
frequent
haplotyp
c
follow
c
c
three
frequent
haplotyp
summaryconclus
data
present
studi
use
select
unrel
donor
plan
donor
registri
anthropolog
studi
abstract
withdrawn
z
e
center
transfusiolog
ministri
healthcar
republ
kazakhstan
astana
kazakhstan
medic
surgic
center
name
ni
pirogov
moscow
russian
feder
background
acut
lymphoblast
leukemia
hereinaft
refer
common
tumor
hematopoiet
tissu
children
account
malign
tumor
childhood
patient
younger
year
diagnos
al
case
peak
incid
fall
age
year
frequenc
decreas
geograph
variat
averag
case
per
million
peopl
year
result
numer
studi
signific
number
evid
obtain
relationship
liabil
number
human
diseas
antigen
main
histocompat
system
often
associ
hla
diseas
appear
form
associ
hla
antigen
associ
diseas
consid
suscept
antigen
diseas
marker
locu
link
true
antigen
determin
liabil
diseas
allow
earli
diagnosi
oncohematolog
diseas
thu
import
studi
hla
phenotyp
peculiar
patient
acut
lymphoblast
leukemia
kazakhstan
search
link
develop
patholog
hla
system
antigen
aim
studi
peculiar
hla
antigen
patient
acut
lymphoblast
leukosi
kazakhstan
method
studi
incid
hla
antigen
patient
live
kazakhstan
total
peopl
examin
healthi
blood
donor
patient
diagnosi
genom
dna
type
hla
antigen
isol
peripher
blood
leukocyt
proteinas
method
use
column
silica
gel
membran
studi
carri
use
set
protran
dna
box
reagent
protran
germani
type
patient
b
c
blood
donor
b
c
perform
polymeras
chain
reaction
commerci
set
protran
reagent
protran
b
cyclerpl
system
protran
cyclerpl
system
protran
cyclerpl
system
use
averag
age
donor
control
group
year
rang
year
mean
age
patient
trial
group
year
rang
year
distribut
sex
among
patient
follow
men
women
male
patient
prevail
femal
respect
result
evalu
use
descript
statist
nonparametr
odd
ratio
confid
interv
ci
result
studi
hla
antigen
distribut
patient
let
assum
exist
associ
link
presenc
ci
p
b
ci
p
c
ci
p
ci
p
ci
p
patholog
behavior
presum
resist
diseas
person
ci
p
c
ci
p
p
phenotyp
establish
summaryconclus
data
obtain
use
develop
immunogenet
criteria
predict
develop
studi
variou
diseas
associ
hla
antigen
abstract
withdrawn
turganbekova
z
burkitbayev
abdrakhmanova
ramilyeva
scientif
product
center
transfusiolog
ministri
health
republ
kazakhstan
astana
kazakhstan
background
provid
immunolog
safeti
blood
transfus
remain
import
problem
transfusiolog
solut
main
sens
belong
measur
aim
prevent
allosensitis
recipi
precaut
posttransfus
reaction
complic
aim
studi
sensit
patient
receiv
blood
platelet
transfus
kazakhstan
method
scientif
product
center
transfusiolog
citi
astana
patient
hematolog
diseas
receiv
blood
platelet
transfus
examin
establish
level
sensit
blood
sampl
carri
three
time
first
day
patient
enter
depart
twice
interv
week
sampl
patient
seros
examin
presenc
leukocyt
aim
antigen
first
class
hla
system
ductal
cytofluorometri
method
use
labscan
analyz
one
lambda
usa
result
screen
seros
obtain
platelet
transfus
show
presenc
leukocyt
antibodi
class
hla
patient
patient
without
leukocyt
antibodi
detect
antibodi
monitor
among
patient
neg
statu
show
patient
antibodi
detect
seros
obtain
week
begin
blood
transfus
therapi
patient
posit
result
obtain
week
two
monitor
antibodi
among
patient
posit
statu
determin
increas
level
sensit
summaryconclus
studi
monitor
leukocyt
antibodi
sensit
hla
class
antigen
found
multipl
platelet
transfus
lead
increas
percentag
patient
sensit
given
necessari
transfus
platelet
individu
select
take
account
hla
antigen
donor
cell
patient
pei
j
lin
h
huang
l
li
j
chen
h
li
nan
institut
transfus
medicin
nan
china
background
hla
found
critic
infect
resist
autoimmun
diseas
suscept
tumour
resist
immun
respons
allograft
solid
organ
haematopoiet
stem
cell
transplant
hsct
aim
investig
allel
haplotyp
frequenc
loci
nan
han
popul
live
guangxi
provinc
china
doubt
better
accur
character
hla
genotyp
improv
cmdp
benefit
transplant
recipi
patient
method
genotyp
perform
sequenc
kit
life
brown
deer
wi
usa
nucleotid
sequenc
exon
exon
amplifi
use
locu
specif
primer
accord
manufactur
instruct
result
total
allel
identifi
nan
individu
han
ethnic
group
type
method
three
common
allel
loci
respect
b
b
b
departur
expect
observ
popul
total
haplotyp
frequenc
present
five
common
haplotyp
summaryconclus
phylogenet
tree
princip
compon
analysi
suggest
nan
han
popul
rel
close
genet
relationship
chines
zhuang
popul
rel
distant
genet
relationship
northern
han
chines
inform
use
anthropolog
studi
hla
match
transplant
diseas
associ
studi
chines
popul
j
f
w
provinci
key
laboratori
blood
safeti
research
transfus
medicin
blood
center
zhejiang
provinc
hangzhou
china
background
killer
cell
immunoglobulin
receptor
kir
belong
immunoglobulin
superfamili
mainli
express
surfac
nk
cell
cell
kir
molecul
surfac
target
cell
regul
nk
cell
cell
activ
transfer
activ
inhibit
signal
conduct
report
differ
kir
molecul
differ
bind
characterist
ligand
lead
differ
effect
nk
cell
aim
order
construct
baculoviru
express
system
kir
obtain
recombin
kir
protein
use
analyz
bind
characterist
kir
ligand
method
cdna
fragment
consist
complet
code
sequenc
obtain
specif
primer
forward
primer
ctataaatacggatccatgtcgctcttggtcgtcag
revers
primer
ggccgcccgggaattctcaatgatgatgatgatgatgtgggcaggagacaactttgg
doubl
restrict
enzym
site
bamh
iecor
ad
end
primer
tail
ad
stop
codon
cdna
fragment
ligat
vector
recombin
plasmid
extract
sequenc
construct
plasmid
correct
sequenc
viru
produc
use
bacpak
baculoviru
express
system
clontech
code
monoclon
cell
strain
select
cell
infect
express
small
amount
target
protein
target
express
protein
detect
western
blot
antibodi
result
baculoviru
express
vector
two
common
kir
allel
construct
recombin
protein
obtain
cell
day
infect
high
titer
viru
result
western
blot
show
target
protein
correct
summaryconclus
baculoviru
express
system
kir
gene
success
establish
protein
two
common
kir
allel
obtain
studi
recombin
kir
protein
could
use
research
interact
kir
ligand
would
help
explain
modul
nk
cell
work
sponsor
nation
scienc
foundat
china
zhejiang
provinci
program
cultiv
innov
health
talent
scienc
research
foundat
zhejiang
provinc
abstract
withdrawn
j
j
n
k
k
n
h
transfus
medicin
univers
tokyo
tokyo
health
scienc
saitama
prefectur
univers
saitama
surgeri
divis
depart
surgeri
graduat
school
medicin
univers
tokyo
cardiac
surgeri
graduat
school
medicin
univers
tokyo
cardiac
surgeri
graduat
school
medicin
univers
tokyo
depart
japanes
red
cross
block
blood
center
tokyo
japan
background
antibodi
dsa
detect
import
predict
factor
humor
reject
reaction
solid
organ
transplant
desensit
treatment
plasmapheresi
appli
howev
differ
result
report
effect
effect
plasmapheresi
clinic
efficaci
remain
elucid
aim
present
studi
aim
investig
effect
plasmapheresi
reduc
dsa
titer
purpos
evalu
antibodi
titer
patient
receiv
organ
transplant
method
among
patient
admit
univers
hospit
period
march
june
intent
receiv
liver
heart
transplant
analyz
patient
receiv
plasmapheresi
remov
dsa
labscreen
singl
antigen
one
lambda
use
measur
dsa
antibodi
titer
express
mean
fluoresc
intens
mfi
compar
result
one
patient
receiv
plasmapheresi
sinc
reduct
antibodi
titer
achiev
transplant
cancel
among
case
receiv
organ
transplant
one
case
liver
transplant
receiv
plasmapheresi
day
pod
antibodi
titer
decreas
respect
antibodi
case
heart
transplant
recipi
start
mmf
administr
plasmapheresi
start
dsa
igg
titer
case
decreas
respect
antibodi
case
respect
antibodi
rel
high
titer
antibodi
high
frequenc
hla
type
japanes
identifi
neither
case
develop
clinic
evid
episod
reject
reaction
addit
igm
antibodi
test
detect
time
point
case
summaryconclus
antibodi
titer
reduc
effect
plasmapheresi
vari
accord
case
dsa
present
undetect
level
hand
antibodi
still
persist
high
titer
especi
high
frequenc
antigen
japanes
discrep
dsa
suggest
among
may
true
antibodi
also
known
kidney
transplant
plasmapheresi
remov
igm
type
antibodi
effici
igg
type
one
howev
case
igm
antibodi
almost
detect
could
confirm
plasmapheresi
also
superior
remov
antibodi
igm
igg
type
differ
remov
rate
accord
antibodi
specif
possibl
mechan
caus
differ
desensit
treatment
discuss
sm
c
l
c
f
c
transfus
medicin
blood
bank
centro
hospitalar
epe
transfus
medicin
blood
bank
centro
hospitalar
vila
nova
de
gaiaespinho
center
north
portugues
institut
blood
transplant
porto
portug
background
hla
antibodi
graft
antigen
may
lead
acut
chronic
transplant
reject
therefor
current
practic
studi
receptor
potenti
antibodi
may
lead
organ
reject
xmap
technolog
sensit
play
major
role
studi
kidney
transplant
kt
candid
aim
aim
evalu
frequent
antibodi
found
kidney
transplant
candid
regist
transplant
center
respons
northern
region
portug
method
studi
result
kt
candid
sampl
subject
luminex
singl
antigen
lsa
bead
ii
order
calcul
frequent
antibodi
found
patient
previou
kt
exclud
test
consid
posit
standard
medium
fluoresc
intens
mfi
also
evalu
patient
previou
transfus
pregnanc
histori
result
total
patient
male
mean
age
year
femal
patient
histori
pregnanc
patient
histori
transfus
total
lsa
lsa
ii
assay
analyz
lsa
frequent
antibodi
found
lsa
ii
summaryconclus
hla
antibodi
frequenc
found
repres
hla
antigen
frequenc
portugues
popul
illustr
hla
antibodi
assign
base
sab
assay
mfi
mislead
emphas
technic
limit
associ
methodolog
even
though
import
number
fals
posit
test
hla
antibodi
remain
essenti
transplant
risk
assess
allow
perform
virtual
improv
technolog
seem
utmost
import
due
key
role
patient
evalu
gs
manchanayak
blood
bank
nation
hospit
sri
lanka
colombo
sri
lanka
background
end
stage
renal
diseas
esrd
becom
major
public
health
problem
worldwid
chronic
debilit
diseas
requir
renal
transplant
perman
therapi
chronic
kidney
diseas
unknown
aetiolog
major
health
problem
north
central
provinc
sri
lanka
mani
studi
perform
variou
popul
assess
associ
hla
allel
haplotyp
develop
esrd
aim
determin
associ
hla
antigen
develop
end
stage
renal
failur
among
patient
await
renal
transplant
test
nation
blood
centr
sri
lanka
method
descript
studi
carri
histocompat
laboratori
nation
blood
centr
iso
approv
hla
laboratori
countri
period
one
year
june
may
time
studi
hla
type
perform
serolog
method
complement
depend
cytotox
test
use
commerci
avail
type
plate
hla
type
result
collect
sri
lankan
patient
renal
failur
await
transplant
hla
type
data
kidney
donor
sri
lankan
origin
taken
healthi
group
hla
class
class
ii
type
result
consid
studi
hla
antigen
frequenc
loci
assess
patient
donor
group
relat
ethnic
sinhales
tamil
moor
result
total
data
collect
patient
esrd
renal
donor
five
frequent
antigen
locu
patient
donor
categori
three
race
group
sinhales
moor
commonest
tamil
among
renal
patient
equal
frequenc
among
donor
commonest
frequent
occur
antigen
patient
donor
highest
frequenc
donor
three
race
patient
sinhala
tamil
origin
patient
moor
origin
commonest
locu
locu
locu
commonest
categori
three
race
frequent
hla
antigen
combin
detect
renal
patient
combin
commonest
among
renal
donor
combin
commonli
detect
three
race
among
patient
donor
sinhales
tamil
associ
posit
esrd
neg
associ
develop
esrd
moor
summaryconclus
signific
posit
well
neg
associ
occurr
hla
antigen
develop
esrd
molecular
hla
type
technolog
avail
similar
well
design
studi
conduct
larg
studi
popul
mn
le
h
thu
thi
b
van
hoang
truong
ray
blood
transfus
centr
cho
ray
hospit
biotechnolog
intern
univers
ho
chi
minh
citi
vietnam
background
today
renal
transplant
wide
consid
best
treatment
patient
renal
diseas
esrd
significantli
improv
surviv
life
qualiti
success
kidney
graft
vietnam
kidney
donat
relat
donor
rather
unrel
one
result
numer
patient
wait
list
therefor
kidney
donat
unrel
donor
includ
deceas
best
solut
high
demand
transplant
howev
lack
understand
characterist
hla
antibodi
kidney
donor
recipi
vietnam
caus
lot
difficulti
find
match
donor
due
time
aim
studi
hla
antibodi
profil
pair
kidney
donor
recipi
investig
transplant
screen
cho
ray
blood
transfus
center
cho
ray
btc
cho
ray
hospit
ho
chi
minh
citi
vietnam
method
pair
kidney
donor
recipi
includ
male
femal
averag
age
donor
recipi
rang
year
old
respect
donor
recipi
test
b
type
use
labtyp
luminex
technolog
antibodi
recipi
test
use
onelambda
labscreen
panel
reactiv
antibodi
pra
class
class
ii
luminex
labscan
analyz
system
test
donor
recipi
perform
use
complement
depend
cytotox
cdc
assay
result
among
pair
consanguin
pair
neg
result
test
pair
posit
test
rate
allel
mismatch
pair
major
common
b
type
b
b
b
recipi
record
neg
antibodi
posit
antibodi
common
antibodi
found
b
b
summaryconclus
first
studi
vietnam
provid
hla
antibodi
profil
pair
kidney
donor
recipi
obtain
data
particularli
help
find
match
unrel
donor
futur
transplant
also
gener
first
vietnames
databas
hla
antibodi
help
immunolog
epidemiolog
research
applic
bukowska
bogacz
bukowska
k
olbromski
h
skalisz
blood
center
poznan
poznan
poland
background
immunogenet
compat
donor
recipi
import
issu
transplant
condit
amino
acid
sequenc
hla
human
leukocyt
antigen
molecul
reflect
donor
recipi
genotyp
dna
level
incompat
hla
amino
acid
sequenc
within
peptid
present
context
hla
molecul
promot
occurr
seriou
immun
infecti
complic
transplant
worsen
surviv
recipi
order
detect
hla
antigen
genet
method
polymeras
chain
reaction
pcr
dna
analysi
use
use
modern
molecular
biolog
techniqu
hla
type
recipi
donor
result
signific
improv
result
allogen
transplant
new
gener
technolog
allow
provid
highest
possibl
resolut
obtain
unambigu
result
hla
genotyp
due
high
degre
complex
hla
system
aim
aim
studi
determin
frequenc
polymorph
variant
hla
loci
patient
base
high
resolut
use
sequenc
method
use
miseq
system
illumina
method
studi
includ
group
patient
sex
age
year
genet
studi
determin
preval
polymorph
variant
hla
loci
made
basi
high
resolut
use
sequenc
method
dna
isol
peripher
blood
use
commerci
column
kit
prepar
sequenc
librari
carri
use
trusight
hla
sequenc
panel
test
illumina
analysi
hla
type
result
perform
use
conexio
softwar
statist
analysi
perform
use
pl
program
result
analysi
high
resolut
hla
type
use
sequenc
ng
show
common
hla
class
variant
among
studi
group
patient
case
hla
genotyp
class
ii
common
variant
summaryconclus
preliminari
result
confirm
legitimaci
use
dna
sequenc
method
obtain
unambigu
genotyp
result
hla
system
use
sequenc
widen
hla
type
panel
addit
loci
suggest
possibl
extend
surviv
time
patient
transplant
j
g
rivera
arrazola
r
fuent
v
g
benitez
laboratori
imss
bank
bank
imss
cdmx
mexico
background
renal
transplant
shown
best
treatment
final
stage
chronic
kidney
diseas
sinc
allow
restor
renal
function
whole
one
caus
loss
graft
immunolog
origin
acut
reject
may
cellular
humor
origin
despit
advanc
understand
mechan
respons
cellular
immun
renal
reject
develop
new
immunosuppress
drug
reject
mediat
humor
immun
antibodi
appear
danger
graft
surviv
short
long
term
perform
transplant
highli
sensit
patient
result
recogn
higher
risk
reject
graft
loss
lower
graft
surviv
howev
risk
associ
presenc
hla
antibodi
dsa
rather
degre
sensit
per
se
desensit
protocol
effect
chang
crossmatch
posit
neg
enabl
transplant
highli
sensit
patient
howev
achiev
success
transplant
prioriti
know
magnitud
alloimmun
respons
inform
help
make
therapeut
decis
surviv
graft
situat
probabl
vast
major
case
howev
surviv
still
uncertain
aim
establish
relationship
posit
singl
antigen
assay
sa
without
presenc
dsa
neg
cytotox
cdc
crossmatch
reject
renal
graft
method
studi
record
patient
present
posit
singl
antigen
assay
use
without
presenc
dsa
antigen
andor
hla
system
neg
cdc
crossmatch
result
total
patient
includ
studi
present
dsa
present
reject
renal
graft
total
reject
patient
present
humor
type
reject
cellular
reject
present
type
patient
reject
due
caus
thrombosi
graft
hyperacut
reject
due
anastomosi
lymphocel
opportunist
infect
cytomegaloviru
polyomaviru
pneumonia
one
patient
show
humor
reject
conjunct
viral
infect
episod
reject
determin
analyz
biopsi
accord
banff
classif
summaryconclus
end
present
work
conclud
cdc
crossmatch
singl
antigen
assay
mutual
complementari
decis
transplant
cdc
crossmatch
decis
result
posit
sinc
contraind
transplant
could
demonstr
work
singl
antigen
assay
provid
use
tool
decis
transplant
treatment
cours
success
graft
result
measur
mean
fluoresc
intens
presenc
dsa
qualifi
prognosi
success
transplant
sinc
indic
antibodi
titer
translat
immunolog
statu
patient
ideal
scenario
transplant
protocol
neg
cdc
crossmatch
valu
hla
antibodi
howev
know
type
patient
possibl
avoid
alloimmun
event
expos
pregnanc
transfus
previou
transplant
